In defects of BC6ENTG , BC6OTHER is transformed to BC6ENTC , resulting in high levels of BC6OTHER in the body. CPR:falsenewlineIn defects of BC6ENTG , BC6OTHER is transformed to BC6OTHER , resulting in high levels of BC6ENTC in the body. CPR:falsenewlineOnce formed, the molecule can be converted to BC6ENTC by BC6ENTG ( BC6OTHER ). CPR:9newlineOnce formed, the molecule can be converted to BC6ENTC by BC6OTHER - BC6OTHER aminotransferase ( BC6ENTG ). CPR:9newlineOnce formed, the molecule can be converted to BC6OTHER by BC6ENTC - BC6OTHER aminotransferase ( BC6ENTG ). CPR:falsenewlineOnce formed, the molecule can be converted to BC6OTHER by BC6OTHER - BC6ENTC aminotransferase ( BC6ENTG ). CPR:falsenewlineIn defects of BC6ENTG , BC6ENTC is transformed to BC6OTHER , resulting in high levels of BC6OTHER in the body. CPR:falsenewlineBC6ENTC kinase inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTG of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6ENTC kinase inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6ENTG , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6ENTC kinase inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6ENTG , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6ENTC kinase inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6OTHER , and BC6ENTG , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6ENTC kinase inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6ENTG signaling. CPR:falsenewlineBC6ENTG inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6OTHER inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTG of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6OTHER inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6ENTG , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6OTHER inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6ENTG , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6OTHER inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6OTHER , and BC6ENTG , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6OTHER inhibitors are BC6ENTC - derived, low molecular weight synthetic molecules that can block the intracellular BC6OTHER of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6ENTG signaling. CPR:falsenewlineBC6ENTG inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTC kinase domain of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6OTHER inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTC kinase domain of several receptors, including BC6ENTG , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6OTHER inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTC kinase domain of several receptors, including BC6OTHER , BC6ENTG , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6OTHER inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTC kinase domain of several receptors, including BC6OTHER , BC6OTHER , and BC6ENTG , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6OTHER signaling. CPR:falsenewlineBC6OTHER inhibitors are BC6OTHER - derived, low molecular weight synthetic molecules that can block the intracellular BC6ENTC kinase domain of several receptors, including BC6OTHER , BC6OTHER , and BC6OTHER , and thereby inhibit ligand - induced receptor phosphorylation and abrogate the biologic effect of BC6ENTG signaling. CPR:falsenewlinePreincubation with 1 microM of the BC6ENTG ( BC6OTHER ) activator BC6OTHER ( BC6ENTC ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization. CPR:falsenewlinePreincubation with 1 microM of the BC6OTHER ( BC6ENTG ) activator BC6OTHER ( BC6ENTC ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization. CPR:falsenewlinePreincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6OTHER ( BC6ENTC ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6ENTG - mediated heterologous BC6OTHER desensitization. CPR:falsenewlinePreincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6OTHER ( BC6ENTC ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6ENTG desensitization. CPR:falsenewlinePreincubation with 1 microM of the BC6ENTG ( BC6OTHER ) activator BC6OTHER ( BC6OTHER ) caused a small but significant decrease in BC6ENTC - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization. CPR:falsenewlinePreincubation with 1 microM of the BC6OTHER ( BC6ENTG ) activator BC6OTHER ( BC6OTHER ) caused a small but significant decrease in BC6ENTC - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization. CPR:falsenewlinePreincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6OTHER ( BC6OTHER ) caused a small but significant decrease in BC6ENTC - induced E(max), indicating activated BC6ENTG - mediated heterologous BC6OTHER desensitization. CPR:falsenewlinePreincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6OTHER ( BC6OTHER ) caused a small but significant decrease in BC6ENTC - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6ENTG desensitization. CPR:falsenewlineTo investigate the capacity of activated BC6ENTG to regulate homologous desensitization, we incubated the smooth muscle strips with the combination of both 1 microM PMA and 1 microM BC6ENTC . CPR:falsenewlineMoreover, the specific BC6ENTG - inhibitor BC6ENTC ( BC6OTHER ) markedly increased the potency and E(max) of BC6OTHER for all conditions used, including control conditions, and the synergistic effects of BC6OTHER and BC6OTHER were completely prevented. CPR:falsenewlinePreincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of BC6ENTC decreased BC6OTHER - induced maximal relaxation (E(max)) of BC6OTHER - contracted preparations in a concentration dependent fashion, indicating desensitization of the BC6ENTG . CPR:falsenewlineMoreover, the specific BC6ENTG - inhibitor BC6OTHER ( BC6ENTC ) markedly increased the potency and E(max) of BC6OTHER for all conditions used, including control conditions, and the synergistic effects of BC6OTHER and BC6OTHER were completely prevented. CPR:falsenewlineMoreover, the specific BC6ENTG - inhibitor BC6OTHER ( BC6OTHER ) markedly increased the potency and E(max) of BC6ENTC for all conditions used, including control conditions, and the synergistic effects of BC6OTHER and BC6OTHER were completely prevented. CPR:falsenewlineMoreover, the specific BC6ENTG - inhibitor BC6OTHER ( BC6OTHER ) markedly increased the potency and E(max) of BC6OTHER for all conditions used, including control conditions, and the synergistic effects of BC6ENTC and BC6OTHER were completely prevented. CPR:falsenewlineMoreover, the specific BC6ENTG - inhibitor BC6OTHER ( BC6OTHER ) markedly increased the potency and E(max) of BC6OTHER for all conditions used, including control conditions, and the synergistic effects of BC6OTHER and BC6ENTC were completely prevented. CPR:falsenewlinePreincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of BC6OTHER decreased BC6ENTC - induced maximal relaxation (E(max)) of BC6OTHER - contracted preparations in a concentration dependent fashion, indicating desensitization of the BC6ENTG . CPR:falsenewlinePreincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of BC6OTHER decreased BC6OTHER - induced maximal relaxation (E(max)) of BC6ENTC - contracted preparations in a concentration dependent fashion, indicating desensitization of the BC6ENTG . CPR:falsenewlinePreincubation with 1 microM of the BC6ENTG ( BC6OTHER ) activator BC6ENTC ( BC6OTHER ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization. CPR:falsenewlinePreincubation with 1 microM of the BC6OTHER ( BC6ENTG ) activator BC6ENTC ( BC6OTHER ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6OTHER desensitization. CPR:falsenewlinePreincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6ENTC ( BC6OTHER ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6ENTG - mediated heterologous BC6OTHER desensitization. CPR:falsenewlinePreincubation with 1 microM of the BC6OTHER ( BC6OTHER ) activator BC6ENTC ( BC6OTHER ) caused a small but significant decrease in BC6OTHER - induced E(max), indicating activated BC6OTHER - mediated heterologous BC6ENTG desensitization. CPR:falsenewlineUNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineUNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineUNLABELLED: Apparent muscarinic BC6ENTC (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineUNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ). CPR:falsenewlineUNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ). CPR:falsenewlineUNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ). CPR:falsenewlineUNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ). CPR:falsenewlineBoth radioligands labeled BC6ENTG in these brain regions, and the relative regional distributions of the specific binding of BC6ENTC in vivo paralleled the distribution of BC6OTHER . CPR:falsenewlineBoth radioligands labeled BC6OTHER in these brain regions, and the relative regional distributions of the specific binding of BC6ENTC in vivo paralleled the distribution of BC6ENTG . CPR:falsenewlineA similar discrepancy in sensitivity to competitors between BC6ENTC and BC6OTHER was also observed when BC6OTHER was used as a competitor, indicating that binding to different subtypes of the BC6ENTG could not account for the observed differences in sensitivity to competition. CPR:falsenewlineA similar discrepancy in sensitivity to competitors between BC6OTHER and BC6ENTC was also observed when BC6OTHER was used as a competitor, indicating that binding to different subtypes of the BC6ENTG could not account for the observed differences in sensitivity to competition. CPR:falsenewlineA similar discrepancy in sensitivity to competitors between BC6OTHER and BC6OTHER was also observed when BC6ENTC was used as a competitor, indicating that binding to different subtypes of the BC6ENTG could not account for the observed differences in sensitivity to competition. CPR:falsenewlineUNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6ENTC , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineUNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6ENTC , an antagonist, and BC6OTHER , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineThis finding, together with the more favorable accumulation of BC6ENTC in cerebral cortex, hippocampus, and striatum, leads us to conclude that BC6OTHER , or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of BC6ENTG occupancy by cholinergic drugs in the brain. CPR:falsenewlineThis finding, together with the more favorable accumulation of BC6OTHER in cerebral cortex, hippocampus, and striatum, leads us to conclude that BC6ENTC , or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of BC6ENTG occupancy by cholinergic drugs in the brain. CPR:falsenewlineUNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6ENTC , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineUNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6ENTC , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineKEYWORDS: BC6ENTG , BC6ENTC , BC6OTHER , in vivo, mouse. CPR:falsenewlineKEYWORDS: BC6ENTG , BC6OTHER , BC6ENTC , in vivo, mouse. CPR:falsenewlineUNLABELLED: Apparent muscarinic BC6OTHER (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6ENTG antagonist, was estimated with competitive binding studies using two different radioligands: BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineUNLABELLED: Apparent BC6ENTG occupancy in mouse cerebral cortex, hippocampus, and striatum by BC6OTHER , an antagonist, and BC6OTHER , a relatively selective BC6OTHER antagonist, was estimated with competitive binding studies using two different radioligands: BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER is an BC6OTHER which is metabolised to BC6ENTC and which binds selectively to the BC6ENTG BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER is an BC6OTHER which is metabolised to BC6ENTC and which binds selectively to the BC6OTHER receptors BC6ENTG and BC6OTHER . CPR:falsenewlineBC6OTHER is an BC6OTHER which is metabolised to BC6ENTC and which binds selectively to the BC6OTHER receptors BC6OTHER and BC6ENTG . CPR:falsenewlineBC6ENTC is an BC6OTHER which is metabolised to BC6OTHER and which binds selectively to the BC6ENTG BC6OTHER and BC6OTHER . CPR:falsenewlineBC6ENTC is an BC6OTHER which is metabolised to BC6OTHER and which binds selectively to the BC6OTHER receptors BC6ENTG and BC6OTHER . CPR:falsenewlineBC6ENTC is an BC6OTHER which is metabolised to BC6OTHER and which binds selectively to the BC6OTHER receptors BC6OTHER and BC6ENTG . CPR:falsenewlineBC6OTHER is an BC6OTHER which is metabolised to BC6OTHER and which binds selectively to the BC6ENTC receptors BC6ENTG and BC6OTHER . CPR:falsenewlineBC6OTHER is an BC6OTHER which is metabolised to BC6OTHER and which binds selectively to the BC6ENTC receptors BC6OTHER and BC6ENTG . CPR:falsenewlineBC6OTHER is an BC6ENTC which is metabolised to BC6OTHER and which binds selectively to the BC6ENTG BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER is an BC6ENTC which is metabolised to BC6OTHER and which binds selectively to the BC6OTHER receptors BC6ENTG and BC6OTHER . CPR:falsenewlineBC6OTHER is an BC6ENTC which is metabolised to BC6OTHER and which binds selectively to the BC6OTHER receptors BC6OTHER and BC6ENTG . CPR:falsenewlinePotency switch between BC6OTHER and BC6ENTG : Discovery of BC6ENTC - and BC6OTHER - based BC6OTHER inhibitors. CPR:falsenewlinePotency switch between BC6OTHER and BC6OTHER : Discovery of BC6ENTC - and BC6OTHER - based BC6ENTG inhibitors. CPR:falsenewlinePotency switch between BC6ENTG and BC6OTHER : Discovery of BC6ENTC - and BC6OTHER - based BC6OTHER inhibitors. CPR:falsenewlinePotency switch between BC6OTHER and BC6ENTG : Discovery of BC6OTHER - and BC6ENTC - based BC6OTHER inhibitors. CPR:falsenewlinePotency switch between BC6OTHER and BC6OTHER : Discovery of BC6OTHER - and BC6ENTC - based BC6ENTG inhibitors. CPR:falsenewlinePotency switch between BC6ENTG and BC6OTHER : Discovery of BC6OTHER - and BC6ENTC - based BC6OTHER inhibitors. CPR:falsenewlineBoth BC6ENTC and BC6ENTG attenuated the parameters increased by acid - induced lung injury in rats. CPR:falsenewlineWe examined the effects of the high dose of BC6ENTG ( BC6OTHER ), which is capable of increasing peripheral neutrophils, and a specific BC6OTHER inhibitor ( BC6ENTC ) on acid lung injury in rats. CPR:falsenewlineWe examined the effects of the high dose of BC6OTHER ( BC6ENTG ), which is capable of increasing peripheral neutrophils, and a specific BC6OTHER inhibitor ( BC6ENTC ) on acid lung injury in rats. CPR:falsenewlineWe examined the effects of the high dose of BC6OTHER ( BC6OTHER ), which is capable of increasing peripheral neutrophils, and a specific BC6ENTG inhibitor ( BC6ENTC ) on acid lung injury in rats. CPR:falsenewlineThirty minutes before BC6ENTC instillation, BC6ENTG (150 microg kg( - 1)) was injected subcutaneously or BC6OTHER (10 mg kg( - 1) h( - 1)) was infused continuously into the right jugular vein. CPR:falsenewlineThirty minutes before BC6OTHER instillation, BC6ENTG (150 microg kg( - 1)) was injected subcutaneously or BC6ENTC (10 mg kg( - 1) h( - 1)) was infused continuously into the right jugular vein. CPR:falsenewlineEffects of BC6ENTG ( BC6OTHER ) and BC6OTHER inhibitor ( BC6ENTC ) on acid - induced lung injury in rats. CPR:falsenewlineEffects of BC6OTHER ( BC6ENTG ) and BC6OTHER inhibitor ( BC6ENTC ) on acid - induced lung injury in rats. CPR:falsenewlineEffects of BC6OTHER ( BC6OTHER ) and BC6ENTG inhibitor ( BC6ENTC ) on acid - induced lung injury in rats. CPR:4newlineComplexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods. CPR:falsenewlineComplexes of BC6ENTG with a range of anions ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods. CPR:falsenewlineComplexes of BC6ENTG with a range of anions ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods. CPR:falsenewlineComplexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods. CPR:falsenewlineStructure and energetics of gas phase BC6ENTC - bonding in BC6ENTG as studied by BIRD. CPR:falsenewlineComplexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods. CPR:falsenewlineComplexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods. CPR:falsenewlineComplexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ( BC6OTHER )) have been studied in the gas phase by both experimental and theoretical methods. CPR:falsenewlineComplexes of BC6ENTG with a range of anions ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTC )) have been studied in the gas phase by both experimental and theoretical methods. CPR:falsenewlineAn increase in the energy required to remove the same anion from the BC6ENTG when compared to the BC6OTHER is explained as being due to the increase in BC6ENTC bonding interactions. CPR:falsenewlineAn increase in the energy required to remove the same anion from the BC6OTHER when compared to the BC6ENTG is explained as being due to the increase in BC6ENTC bonding interactions. CPR:falsenewlineThe present study was initiated to evaluate the safety and efficacy of Haemate - P (Humate - P in North America) (anti - hemophilic BC6ENTG / BC6OTHER complex [human] dried, pasteurized) dosed in BC6ENTC cofactor units (VWF:RCo) in the treatment of von Willebrand disease (VWD) patients in Canada. CPR:falsenewlineThe present study was initiated to evaluate the safety and efficacy of Haemate - P (Humate - P in North America) (anti - hemophilic BC6OTHER / BC6ENTG complex [human] dried, pasteurized) dosed in BC6ENTC cofactor units (VWF:RCo) in the treatment of von Willebrand disease (VWD) patients in Canada. CPR:falsenewlineEfficacy and safety of the BC6OTHER / BC6ENTG concentrate, haemate - P / humate - P: BC6ENTC cofactor unit dosing in patients with von Willebrand disease. CPR:falsenewlineEfficacy and safety of the BC6ENTG / BC6OTHER concentrate, haemate - P / humate - P: BC6ENTC cofactor unit dosing in patients with von Willebrand disease. CPR:falsenewlineNeonatal epileptic encephalopathy caused by mutations in the BC6ENTG gene encoding BC6ENTC oxidase. CPR:falsenewlineCerebrospinal fluid and urine analyses indicated reduced activity of BC6ENTG and other BC6ENTC - dependent enzymes. CPR:falsenewlineSeizures ceased with the administration of BC6ENTC , having been resistant to treatment with CHEM, suggesting a defect of BC6ENTG ( BC6OTHER ). CPR:falsenewlineSeizures ceased with the administration of BC6ENTC , having been resistant to treatment with CHEM, suggesting a defect of BC6OTHER oxidase ( BC6ENTG ). CPR:falsenewlineSeizures ceased with the administration of BC6OTHER , having been resistant to treatment with CHEM, suggesting a defect of BC6ENTC oxidase ( BC6ENTG ). CPR:falsenewlineExpression studies in Chinese hamster ovary cells showed that the splice site (IVS3 - 1 BC6ENTG ) and stop codon (X262Q) mutations were null activity mutations and that the missense mutation ( BC6OTHER ) markedly reduced BC6ENTC oxidase activity. CPR:falsenewlineExpression studies in Chinese hamster ovary cells showed that the splice site (IVS3 - 1 BC6OTHER ) and stop codon (X262Q) mutations were null activity mutations and that the missense mutation ( BC6ENTG ) markedly reduced BC6ENTC oxidase activity. CPR:falsenewlineBC6ENTG - induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of BC6ENTC by driving BC6OTHER - dependent BC6OTHER expression, which, in turn, drives fibroblast proliferation. - Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. BC6OTHER - induced cytoskeleton reorganization drives fibrosis through BC6OTHER - dependent fibroblast proliferation. CPR:falsenewlineBC6OTHER - induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of BC6ENTC by driving BC6ENTG - dependent BC6OTHER expression, which, in turn, drives fibroblast proliferation. - Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. BC6OTHER - induced cytoskeleton reorganization drives fibrosis through BC6OTHER - dependent fibroblast proliferation. CPR:falsenewlineBC6OTHER - induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of BC6ENTC by driving BC6OTHER - dependent BC6ENTG expression, which, in turn, drives fibroblast proliferation. - Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. BC6OTHER - induced cytoskeleton reorganization drives fibrosis through BC6OTHER - dependent fibroblast proliferation. CPR:falsenewlineBC6OTHER - induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of BC6ENTC by driving BC6OTHER - dependent BC6OTHER expression, which, in turn, drives fibroblast proliferation. - Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. BC6ENTG - induced cytoskeleton reorganization drives fibrosis through BC6OTHER - dependent fibroblast proliferation. CPR:falsenewlineBC6OTHER - induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of BC6ENTC by driving BC6OTHER - dependent BC6OTHER expression, which, in turn, drives fibroblast proliferation. - Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. BC6OTHER - induced cytoskeleton reorganization drives fibrosis through BC6ENTG - dependent fibroblast proliferation. CPR:falsenewlineThere has been much recent interest in BC6OTHER ( BC6OTHER ) signaling through one of its receptors, BC6OTHER , in fibrotic diseases, but the mechanisms by which BC6ENTC - BC6ENTG signaling promotes pathological fibrosis remain to be fully elucidated. CPR:falsenewlineThere has been much recent interest in BC6OTHER ( BC6OTHER ) signaling through one of its receptors, BC6ENTG , in fibrotic diseases, but the mechanisms by which BC6ENTC - BC6OTHER signaling promotes pathological fibrosis remain to be fully elucidated. CPR:falsenewlineUsing a mouse peritoneal fibrosis model, we demonstrate central roles for BC6ENTC and BC6ENTG in fibroblast proliferation. CPR:falsenewlineThere has been much recent interest in BC6ENTC ( BC6OTHER ) signaling through one of its receptors, BC6OTHER , in fibrotic diseases, but the mechanisms by which BC6OTHER - BC6ENTG signaling promotes pathological fibrosis remain to be fully elucidated. CPR:falsenewlineThere has been much recent interest in BC6ENTC ( BC6OTHER ) signaling through one of its receptors, BC6ENTG , in fibrotic diseases, but the mechanisms by which BC6OTHER - BC6OTHER signaling promotes pathological fibrosis remain to be fully elucidated. CPR:falsenewlineThere has been much recent interest in BC6OTHER ( BC6ENTC ) signaling through one of its receptors, BC6OTHER , in fibrotic diseases, but the mechanisms by which BC6OTHER - BC6ENTG signaling promotes pathological fibrosis remain to be fully elucidated. CPR:falsenewlineThere has been much recent interest in BC6OTHER ( BC6ENTC ) signaling through one of its receptors, BC6ENTG , in fibrotic diseases, but the mechanisms by which BC6OTHER - BC6OTHER signaling promotes pathological fibrosis remain to be fully elucidated. CPR:falsenewlineBC6ENTG of the BC6OTHER ( BC6ENTC - ) subtype are tetrameric allosteric and BC6OTHER . CPR:falsenewlineBC6OTHER receptors of the BC6OTHER ( BC6ENTC - ) subtype are tetrameric allosteric and BC6ENTG . CPR:falsenewline BC6ENTC receptors are not alone: dynamic regulation of BC6OTHER structure and function by BC6OTHER and BC6ENTG leads to disease - specific nuances of BC6OTHER - signalling. CPR:falsenewline BC6ENTC receptors are not alone: dynamic regulation of BC6ENTG structure and function by BC6OTHER and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling. CPR:falsenewline BC6ENTC receptors are not alone: dynamic regulation of BC6OTHER structure and function by BC6ENTG and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling. CPR:falsenewline BC6ENTG are not alone: dynamic regulation of BC6OTHER structure and function by BC6OTHER and transient BC6ENTC - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling. CPR:falsenewline BC6OTHER are not alone: dynamic regulation of BC6ENTG structure and function by BC6OTHER and transient BC6ENTC - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling. CPR:falsenewline BC6OTHER are not alone: dynamic regulation of BC6OTHER structure and function by BC6ENTG and transient BC6ENTC - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling. CPR:falsenewline BC6ENTG are not alone: dynamic regulation of BC6OTHER structure and function by BC6OTHER and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6ENTC - signalling. CPR:falsenewline BC6OTHER are not alone: dynamic regulation of BC6OTHER structure and function by BC6OTHER and BC6ENTG leads to disease - specific nuances of BC6ENTC - signalling. CPR:falsenewline BC6OTHER are not alone: dynamic regulation of BC6ENTG structure and function by BC6OTHER and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6ENTC - signalling. CPR:falsenewline BC6OTHER are not alone: dynamic regulation of BC6OTHER structure and function by BC6ENTG and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6ENTC - signalling. CPR:falsenewline BC6ENTG are not alone: dynamic regulation of BC6ENTC receptor structure and function by BC6OTHER and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling. CPR:falsenewline BC6OTHER are not alone: dynamic regulation of BC6ENTC receptor structure and function by BC6OTHER and BC6ENTG leads to disease - specific nuances of BC6OTHER - signalling. CPR:falsenewline BC6OTHER are not alone: dynamic regulation of BC6ENTC receptor structure and function by BC6ENTG and transient BC6OTHER - rich membrane domains leads to disease - specific nuances of BC6OTHER - signalling. CPR:falsenewlineBC6ENTC receptors of the BC6OTHER ( BC6OTHER - ) subtype are tetrameric allosteric and BC6ENTG . CPR:falsenewlineThis fundamental significance of BC6ENTG - related excitotoxicity is discussed in the context of the developing clinical success of BC6ENTC , but moreover set into relation to various proteomic and genetic markers of said diseases. CPR:falsenewlineThe very complex localisational and functional regulation of BC6ENTC receptors appears to be dependent on BC6ENTG and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6ENTC receptors appears to be dependent on BC6OTHER and BC6ENTG in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6ENTC receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6ENTC receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6ENTG appears to be dependent on BC6OTHER and receptor BC6ENTC kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6ENTG and receptor BC6ENTC kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6ENTC kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6ENTC kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6ENTG appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6ENTC - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6ENTG and receptor BC6OTHER kinases in BC6ENTC - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and BC6ENTG in BC6ENTC - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6ENTC - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6ENTC - rich membrane domains (lipid rafts), BC6OTHER - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6ENTG appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6ENTC - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6ENTG and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6ENTC - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and BC6ENTG in BC6OTHER - rich membrane domains (lipid rafts), BC6ENTC - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6ENTC - related mitochondrial feedback - loops and subsynaptic structural elements like BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe very complex localisational and functional regulation of BC6OTHER receptors appears to be dependent on BC6OTHER and receptor BC6OTHER kinases in BC6OTHER - rich membrane domains (lipid rafts), BC6ENTC - related mitochondrial feedback - loops and subsynaptic structural elements like BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6ENTG of the BC6ENTC ( BC6OTHER - ) subtype are tetrameric allosteric and BC6OTHER . CPR:falsenewlineBC6OTHER receptors of the BC6ENTC ( BC6OTHER - ) subtype are tetrameric allosteric and BC6ENTG . CPR:falsenewlineOn the structural level BC6ENTC receptors have an enormous flexibility due to seven genes ( BC6ENTG , BC6OTHER and BC6OTHER ), alternative splicing, RNA - editing and extensive posttranslational modifications, like phosphorylation and glycosylation. CPR:falsenewlineOn the structural level BC6ENTC receptors have an enormous flexibility due to seven genes ( BC6OTHER , BC6ENTG and BC6OTHER ), alternative splicing, RNA - editing and extensive posttranslational modifications, like phosphorylation and glycosylation. CPR:falsenewlineOn the structural level BC6ENTC receptors have an enormous flexibility due to seven genes ( BC6OTHER , BC6OTHER and BC6ENTG ), alternative splicing, RNA - editing and extensive posttranslational modifications, like phosphorylation and glycosylation. CPR:falsenewlineThe availability of the BC6OTHER prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that BC6ENTG , the activating enzyme for BC6ENTC , is expressed at a higher level in tumor tissue compared with normal tissue counterparts. CPR:falsenewlineBC6ENTC synthase ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6ENTG ( BC6OTHER ) continues to be a critical target for BC6ENTC ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6OTHER ( BC6ENTG ) continues to be a critical target for BC6ENTC ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6ENTC ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6ENTC ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6ENTC / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6ENTC / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineWhile BC6ENTC antimetabolites have other sites of action, antifolates BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) are more specific and potent BC6ENTG inhibitors. CPR:falsenewlineBC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC , primarily because this enzyme is essential for the synthesis of BC6OTHER , a precursor for DNA synthesis. CPR:falsenewlineBC6ENTG ( BC6OTHER ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6ENTC , a precursor for DNA synthesis. CPR:falsenewlineBC6OTHER ( BC6ENTG ) continues to be a critical target for BC6OTHER ( BC6OTHER ) and its prodrugs, BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER , primarily because this enzyme is essential for the synthesis of BC6ENTC , a precursor for DNA synthesis. CPR:falsenewlineWhile BC6OTHER antimetabolites have other sites of action, antifolates BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) are more specific and potent BC6ENTG inhibitors. CPR:falsenewlineWhile BC6OTHER antimetabolites have other sites of action, antifolates BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) are more specific and potent BC6ENTG inhibitors. CPR:falsenewlineWhile BC6OTHER antimetabolites have other sites of action, antifolates BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) are more specific and potent BC6ENTG inhibitors. CPR:falsenewlineWhile BC6OTHER antimetabolites have other sites of action, antifolates BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER ) are more specific and potent BC6ENTG inhibitors. CPR:falsenewlineWhile BC6OTHER antimetabolites have other sites of action, antifolates BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) are more specific and potent BC6ENTG inhibitors. CPR:falsenewlineThe availability of the BC6ENTC prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that BC6ENTG , the activating enzyme for BC6OTHER , is expressed at a higher level in tumor tissue compared with normal tissue counterparts. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6ENTG receptor agonists BC6OTHER , BC6OTHER and BC6ENTC in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6OTHER receptors. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6OTHER and BC6ENTC in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6ENTG , BC6OTHER and BC6OTHER receptors. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6OTHER and BC6ENTC in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6ENTG and BC6OTHER receptors. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6OTHER and BC6ENTC in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6ENTG receptors. CPR:falsenewlineIn vitro studies showed that all three BC6ENTC are high affinity, full agonists at BC6ENTG receptors, but that BC6OTHER is functionally less potent as a BC6OTHER agonist than BC6OTHER and BC6OTHER . CPR:falsenewlineIn vitro studies showed that all three BC6ENTC are high affinity, full agonists at BC6OTHER receptors, but that BC6OTHER is functionally less potent as a BC6ENTG agonist than BC6OTHER and BC6OTHER . CPR:falsenewlineIn vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6ENTG receptors, but that BC6ENTC is functionally less potent as a BC6OTHER agonist than BC6OTHER and BC6OTHER . CPR:falsenewlineIn vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6OTHER receptors, but that BC6ENTC is functionally less potent as a BC6ENTG agonist than BC6OTHER and BC6OTHER . CPR:falsenewlineIn vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6ENTG receptors, but that BC6OTHER is functionally less potent as a BC6OTHER agonist than BC6ENTC and BC6OTHER . CPR:falsenewlineIn vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6OTHER receptors, but that BC6OTHER is functionally less potent as a BC6ENTG agonist than BC6ENTC and BC6OTHER . CPR:falsenewlineIn vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6ENTG receptors, but that BC6OTHER is functionally less potent as a BC6OTHER agonist than BC6OTHER and BC6ENTC . CPR:falsenewlineIn vitro studies showed that all three BC6OTHER are high affinity, full agonists at BC6OTHER receptors, but that BC6OTHER is functionally less potent as a BC6ENTG agonist than BC6OTHER and BC6ENTC . CPR:falsenewline The observation that BC6ENTC and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6ENTG receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6OTHER receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration. CPR:falsenewline The observation that BC6ENTC and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6OTHER receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6ENTG receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration. CPR:falsenewline The observation that BC6OTHER and BC6ENTC produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6ENTG receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6OTHER receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration. CPR:falsenewline The observation that BC6OTHER and BC6ENTC produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6OTHER receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6ENTG receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6ENTG receptor agonists BC6ENTC , BC6OTHER and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6OTHER receptors. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6ENTC , BC6OTHER and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6ENTG , BC6OTHER and BC6OTHER receptors. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6ENTC , BC6OTHER and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6ENTG and BC6OTHER receptors. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6ENTC , BC6OTHER and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6ENTG receptors. CPR:falsenewline The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6ENTG receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6ENTC is likely due to its weaker functional BC6OTHER receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration. CPR:falsenewline The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6OTHER receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6ENTC is likely due to its weaker functional BC6ENTG receptor agonist potency than BC6OTHER and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6ENTG receptor agonists BC6OTHER , BC6ENTC and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6OTHER receptors. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6ENTC and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6ENTG , BC6OTHER and BC6OTHER receptors. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6ENTC and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6ENTG and BC6OTHER receptors. CPR:falsenewlineIn vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the BC6OTHER receptor agonists BC6OTHER , BC6ENTC and BC6OTHER in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at BC6OTHER , BC6OTHER and BC6ENTG receptors. CPR:falsenewline The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6ENTG receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6OTHER receptor agonist potency than BC6ENTC and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration. CPR:falsenewline The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6OTHER receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6ENTG receptor agonist potency than BC6ENTC and BC6OTHER , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration. CPR:falsenewline The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6ENTG receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6OTHER receptor agonist potency than BC6OTHER and BC6ENTC , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration. CPR:falsenewline The observation that BC6OTHER and BC6OTHER produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional BC6OTHER receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg / kg i.v. On the other hand, the lack of central serotonergic effects of 3.2 mg / kg i.v. BC6OTHER is likely due to its weaker functional BC6ENTG receptor agonist potency than BC6OTHER and BC6ENTC , rather than lower brain levels, consistent with CHEM's fivefold lower potency after intracerebral administration. CPR:falsenewlineIn addition, we examined the ability of BC6OTHER ; a BC6ENTC antidepressant that is devoid of BC6OTHER reuptake inhibitory properties on BC6ENTG production. CPR:falsenewlineIn addition, we examined the ability of BC6OTHER ; a BC6OTHER antidepressant that is devoid of BC6ENTC reuptake inhibitory properties on BC6ENTG production. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6ENTC transporter ( BC6OTHER and BC6OTHER ), or the BC6ENTG ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6ENTC transporter ( BC6OTHER and BC6OTHER ), or the BC6OTHER transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood. CPR:falsenewlineAll of the antidepressants suppressed BC6ENTG production in the 10 - 50 microM concentration range, irrespective of their preference for BC6ENTC or BC6OTHER transporters. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6OTHER ( BC6ENTC and BC6OTHER ), or the BC6ENTG ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6OTHER ( BC6ENTC and BC6OTHER ), or the BC6OTHER transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6ENTG ( BC6ENTC and BC6OTHER ), or the BC6OTHER transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood. CPR:falsenewlineAll of the antidepressants suppressed BC6ENTG production in the 10 - 50 microM concentration range, irrespective of their preference for CHEM or BC6ENTC transporters. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6ENTC ), or the BC6ENTG ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6ENTC ), or the BC6OTHER transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6ENTG ( BC6OTHER and BC6ENTC ), or the BC6OTHER transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood. CPR:falsenewlineAntidepressants suppress production of the Th1 BC6ENTG BC6OTHER , independent of BC6ENTC transporter blockade. CPR:falsenewlineAntidepressants suppress production of the Th1 BC6OTHER BC6ENTG , independent of BC6ENTC transporter blockade. CPR:falsenewlineThe fact that BC6ENTC also suppressed BC6ENTG production and T - cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of BC6OTHER reuptake. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6OTHER ), or the BC6ENTC transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6ENTG ( BC6OTHER and BC6OTHER ), or the BC6ENTC transporter ( BC6OTHER and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood. CPR:falsenewlineThe fact that BC6OTHER also suppressed BC6ENTG production and T - cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of BC6ENTC reuptake. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6OTHER ), or the BC6ENTG ( BC6ENTC and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6OTHER ), or the BC6OTHER transporter ( BC6ENTC and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6ENTG ( BC6OTHER and BC6OTHER ), or the BC6OTHER transporter ( BC6ENTC and BC6OTHER ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood. CPR:falsenewlineInterestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T - cell - derived BC6ENTG production, with significant effects elicited by the BC6ENTC reuptake inhibitors BC6OTHER and BC6OTHER . CPR:falsenewlineInterestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T - cell - derived BC6ENTG production, with significant effects elicited by the BC6OTHER reuptake inhibitors BC6ENTC and BC6OTHER . CPR:falsenewlineInterestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T - cell - derived BC6ENTG production, with significant effects elicited by the BC6OTHER reuptake inhibitors BC6OTHER and BC6ENTC . CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6OTHER ), or the BC6ENTG ( BC6OTHER and BC6ENTC ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6OTHER ( BC6OTHER and BC6OTHER ), or the BC6OTHER transporter ( BC6OTHER and BC6ENTC ) were examined in terms of their ability to promote an anti - inflammatory BC6ENTG phenotype in human blood. CPR:falsenewlineIn this study, antidepressants with selectivity for the BC6ENTG ( BC6OTHER and BC6OTHER ), or the BC6OTHER transporter ( BC6OTHER and BC6ENTC ) were examined in terms of their ability to promote an anti - inflammatory BC6OTHER phenotype in human blood. CPR:falsenewlineIn addition, we examined the ability of BC6ENTC ; a BC6OTHER antidepressant that is devoid of BC6OTHER reuptake inhibitory properties on BC6ENTG production. CPR:falsenewlineCONCLUSION: Our results did not lend strong support to the view that the genetic variation of the BC6ENTG gene plays a major role in the individually variable adverse effect induced by BC6ENTC , at least in Chinese patients with schizophrenia. CPR:falsenewlineIn this study, we evaluate the role BC6ENTG plays in BC6ENTC - induced EPS in schizophrenic patients. CPR:falsenewlineMETHODS: We identified seven SNP(single BC6ENTC polymorphism) ( - 141Cins>del, CHEM, TaqID, BC6ENTG , rs6275, rs6277 and TaqIA) in the BC6OTHER gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson - Angus Scale) treated with BC6OTHER after 8 weeks. CPR:falsenewlineMETHODS: We identified seven SNP(single BC6ENTC polymorphism) ( - 141Cins>del, CHEM, TaqID, BC6OTHER , rs6275, rs6277 and TaqIA) in the BC6ENTG gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson - Angus Scale) treated with BC6OTHER after 8 weeks. CPR:falsenewlineMETHODS: We identified seven SNP(single BC6OTHER polymorphism) ( - 141Cins>del, CHEM, TaqID, BC6ENTG , rs6275, rs6277 and TaqIA) in the BC6OTHER gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson - Angus Scale) treated with BC6ENTC after 8 weeks. CPR:falsenewlineMETHODS: We identified seven SNP(single BC6OTHER polymorphism) ( - 141Cins>del, CHEM, TaqID, BC6OTHER , rs6275, rs6277 and TaqIA) in the BC6ENTG gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson - Angus Scale) treated with BC6ENTC after 8 weeks. CPR:falsenewlineAssociation of BC6ENTG polymorphisms and BC6ENTC - induced extrapyramidal syndrome in Chinese schizophrenic patients. CPR:falsenewlineBC6ENTG level in plasma and mesenteric arteries in BC6ENTC group was significantly lower than that in BC6OTHER group (P<0.05). CPR:falsenewlineBC6ENTG level in plasma and mesenteric arteries in BC6OTHER group was significantly lower than that in BC6ENTC group (P<0.05). CPR:falsenewlineThe BC6ENTG absorbed light value / BC6OTHER absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6ENTC , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6OTHER group (P<0.05). CPR:falsenewlineThe BC6OTHER absorbed light value / BC6ENTG absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6ENTC , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6OTHER group (P<0.05). CPR:falsenewlineThe BC6ENTG absorbed light value / BC6OTHER absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6ENTC groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6OTHER group (P<0.05). CPR:falsenewlineThe BC6OTHER absorbed light value / BC6ENTG absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6ENTC groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6OTHER group (P<0.05). CPR:falsenewlineThe BC6ENTG absorbed light value / BC6OTHER absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6ENTC group than in BC6OTHER group (P<0.05). CPR:falsenewlineThe BC6OTHER absorbed light value / BC6ENTG absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6ENTC group than in BC6OTHER group (P<0.05). CPR:falsenewlineThe BC6ENTG absorbed light value / BC6OTHER absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6ENTC group (P<0.05). CPR:falsenewlineThe BC6OTHER absorbed light value / BC6ENTG absorbed light value of mesenteric arteries in the SHR group was 0.850+ / - 0.015, which was significantly higher than that in the WKY, BC6OTHER , and BC6OTHER groups (0.582+ / - 0.013, 0.743+ / - 0.012, and 0.789+ / - 0.013, respectively, P<0.01), and was significantly lower in BC6OTHER group than in BC6ENTC group (P<0.05). CPR:falsenewlineCONCLUSION: BC6ENTC and BC6OTHER can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of BC6ENTG , BC6OTHER in SHR. CPR:falsenewlineCONCLUSION: BC6ENTC and BC6OTHER can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of BC6OTHER , BC6ENTG in SHR. CPR:falsenewlineCONCLUSION: BC6OTHER and BC6ENTC can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of BC6ENTG , BC6OTHER in SHR. CPR:falsenewlineCONCLUSION: BC6OTHER and BC6ENTC can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of BC6OTHER , BC6ENTG in SHR. CPR:falsenewlineBC6ENTC ( BC6ENTG ) level in plasma and mesenteric arteries was measured by radioimmunoassay. CPR:falsenewlineBC6ENTG ( BC6ENTC ) level in plasma and mesenteric arteries was measured by radioimmunoassay. CPR:falsenewlineAIM: To investigate the remodeling of mesenteric artery and the expression of BC6ENTG , BC6OTHER in mesenteric artery and effects of BC6ENTC and BC6OTHER on the remodeling in spontaneously hypertensive rats (SHR). CPR:falsenewlineAIM: To investigate the remodeling of mesenteric artery and the expression of BC6OTHER , BC6ENTG in mesenteric artery and effects of BC6ENTC and BC6OTHER on the remodeling in spontaneously hypertensive rats (SHR). CPR:falsenewlineBC6ENTG level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in BC6ENTC group and lower in BC6OTHER group. CPR:falsenewlineBC6ENTG level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in BC6OTHER group and lower in BC6ENTC group. CPR:falsenewlineAIM: To investigate the remodeling of mesenteric artery and the expression of BC6ENTG , BC6OTHER in mesenteric artery and effects of BC6OTHER and BC6ENTC on the remodeling in spontaneously hypertensive rats (SHR). CPR:falsenewlineAIM: To investigate the remodeling of mesenteric artery and the expression of BC6OTHER , BC6ENTG in mesenteric artery and effects of BC6OTHER and BC6ENTC on the remodeling in spontaneously hypertensive rats (SHR). CPR:falsenewlineThe ratio of BC6ENTG absorbed light value to BC6OTHER absorbed light value in the SHR group was 0.887+ / - 0.019, which was significantly higher than that in WKY group, BC6ENTC group, and BC6OTHER group with the ratios of 0.780+ / - 0.018, 0.803+ / - 0.005, and 0.847+ / - 0.017, respectively (P<0.01). CPR:falsenewlineThe ratio of BC6OTHER absorbed light value to BC6ENTG absorbed light value in the SHR group was 0.887+ / - 0.019, which was significantly higher than that in WKY group, BC6ENTC group, and BC6OTHER group with the ratios of 0.780+ / - 0.018, 0.803+ / - 0.005, and 0.847+ / - 0.017, respectively (P<0.01). CPR:falsenewlineThe ratio of BC6ENTG absorbed light value to BC6OTHER absorbed light value in the SHR group was 0.887+ / - 0.019, which was significantly higher than that in WKY group, BC6OTHER group, and BC6ENTC group with the ratios of 0.780+ / - 0.018, 0.803+ / - 0.005, and 0.847+ / - 0.017, respectively (P<0.01). CPR:falsenewlineThe ratio of BC6OTHER absorbed light value to BC6ENTG absorbed light value in the SHR group was 0.887+ / - 0.019, which was significantly higher than that in WKY group, BC6OTHER group, and BC6ENTC group with the ratios of 0.780+ / - 0.018, 0.803+ / - 0.005, and 0.847+ / - 0.017, respectively (P<0.01). CPR:falsenewlineIn overexpressing cell lines, BC6ENTG - and BC6OTHER - mediated BC6ENTC uptake and BC6OTHER - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6OTHER investigated. CPR:falsenewlineIn overexpressing cell lines, BC6OTHER - and BC6ENTG - mediated BC6ENTC uptake and BC6OTHER - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6OTHER investigated. CPR:falsenewlineIn overexpressing cell lines, BC6OTHER - and BC6OTHER - mediated BC6ENTC uptake and BC6ENTG - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6OTHER investigated. CPR:falsenewlineIn overexpressing cell lines, BC6ENTG - and BC6OTHER - mediated BC6OTHER uptake and BC6OTHER - mediated BC6ENTC uptake were inhibited by most of the CHEM BC6OTHER investigated. CPR:falsenewlineIn overexpressing cell lines, BC6OTHER - and BC6ENTG - mediated BC6OTHER uptake and BC6OTHER - mediated BC6ENTC uptake were inhibited by most of the CHEM BC6OTHER investigated. CPR:falsenewlineIn overexpressing cell lines, BC6OTHER - and BC6OTHER - mediated BC6OTHER uptake and BC6ENTG - mediated BC6ENTC uptake were inhibited by most of the CHEM BC6OTHER investigated. CPR:falsenewlineIn overexpressing cell lines, BC6ENTG - and BC6OTHER - mediated BC6OTHER uptake and BC6OTHER - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6ENTC investigated. CPR:falsenewlineIn overexpressing cell lines, BC6OTHER - and BC6ENTG - mediated BC6OTHER uptake and BC6OTHER - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6ENTC investigated. CPR:falsenewlineIn overexpressing cell lines, BC6OTHER - and BC6OTHER - mediated BC6OTHER uptake and BC6ENTG - mediated BC6OTHER uptake were inhibited by most of the CHEM BC6ENTC investigated. CPR:falsenewlineBC6ENTG - , BC6OTHER - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6ENTC (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively). CPR:falsenewlineBC6OTHER - , BC6ENTG - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6ENTC (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively). CPR:falsenewlineBC6OTHER - , BC6OTHER - , and BC6ENTG - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6ENTC (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively). CPR:falsenewlineInteraction of CHEM BC6ENTC with BC6ENTG . CPR:falsenewlineBC6ENTG - , BC6OTHER - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6ENTC (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively). CPR:falsenewlineBC6OTHER - , BC6ENTG - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6ENTC (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively). CPR:falsenewlineBC6OTHER - , BC6OTHER - , and BC6ENTG - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6ENTC (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6OTHER (IC50 values of 9.0, 36.4, and 3.6 µM, respectively). CPR:falsenewlineBC6ENTG - , BC6OTHER - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6ENTC (IC50 values of 9.0, 36.4, and 3.6 µM, respectively). CPR:falsenewlineBC6OTHER - , BC6ENTG - , and BC6OTHER - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6ENTC (IC50 values of 9.0, 36.4, and 3.6 µM, respectively). CPR:falsenewlineBC6OTHER - , BC6OTHER - , and BC6ENTG - mediated substrate transport was inhibited efficiently by CHEM (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), BC6OTHER (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), BC6OTHER (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and BC6ENTC (IC50 values of 9.0, 36.4, and 3.6 µM, respectively). CPR:falsenewlineFurthermore, CHEM, BC6ENTC , and BC6OTHER (100 µM) significantly inhibited BC6ENTG - mediated BC6OTHER and BC6OTHER uptake into human hepatocytes. CPR:9newlineFurthermore, CHEM, BC6OTHER , and BC6ENTC (100 µM) significantly inhibited BC6ENTG - mediated BC6OTHER and BC6OTHER uptake into human hepatocytes. CPR:9newlineFurthermore, CHEM, BC6OTHER , and BC6OTHER (100 µM) significantly inhibited BC6ENTG - mediated BC6ENTC and BC6OTHER uptake into human hepatocytes. CPR:9newlineFurthermore, CHEM, BC6OTHER , and BC6OTHER (100 µM) significantly inhibited BC6ENTG - mediated BC6OTHER and BC6ENTC uptake into human hepatocytes. CPR:9newlineThe extent of CHEM - drug interactions depends on BC6ENTG isoform specificity and concentrations of BC6ENTC at the site of drug transport. CPR:falsenewlineHigher than customary doses of CHEM, or formulations with improved bioavailability, may increase the risk of BC6ENTC interactions with BC6ENTG substrates in patients. CPR:falsenewlineThe present study examined the effect of CHEM BC6ENTC on BC6ENTG - , BC6OTHER - , and BC6OTHER - mediated transport in cell lines stably expressing these transporters and in human hepatocytes. CPR:falsenewlineThe present study examined the effect of CHEM BC6ENTC on BC6OTHER - , BC6ENTG - , and BC6OTHER - mediated transport in cell lines stably expressing these transporters and in human hepatocytes. CPR:falsenewlineThe present study examined the effect of CHEM BC6ENTC on BC6OTHER - , BC6OTHER - , and BC6ENTG - mediated transport in cell lines stably expressing these transporters and in human hepatocytes. CPR:falsenewlineAn inhibitor of BC6ENTG ( BC6OTHER ), BC6ENTC ( BC6OTHER ), was reported to have neuroprotective activity, but clinical trials failed to confirm it. CPR:4newlineAn inhibitor of type B BC6OTHER oxidase ( BC6ENTG ), BC6ENTC ( BC6OTHER ), was reported to have neuroprotective activity, but clinical trials failed to confirm it. CPR:falsenewlineAn inhibitor of BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6ENTC ), was reported to have neuroprotective activity, but clinical trials failed to confirm it. CPR:4newlineAn inhibitor of type B BC6OTHER oxidase ( BC6ENTG ), BC6OTHER ( BC6ENTC ), was reported to have neuroprotective activity, but clinical trials failed to confirm it. CPR:falsenewlineBC6ENTC prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic BC6ENTG and a BC6OTHER , BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6ENTC prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic BC6OTHER and a BC6ENTG , BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6ENTC prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic BC6OTHER and a BC6OTHER , BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6ENTC prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic BC6OTHER and a BC6OTHER , BC6OTHER ( BC6ENTG ). CPR:falsenewlineLong - term administration of BC6ENTC to rats increased the activities of antioxidative enzymes BC6ENTG ( BC6OTHER ) and BC6OTHER in the brain regions containing BC6OTHER neurons. CPR:falsenewlineLong - term administration of BC6ENTC to rats increased the activities of antioxidative enzymes BC6OTHER dismutase ( BC6ENTG ) and BC6OTHER in the brain regions containing BC6OTHER neurons. CPR:falsenewlineLong - term administration of BC6ENTC to rats increased the activities of antioxidative enzymes BC6OTHER dismutase ( BC6OTHER ) and BC6ENTG in the brain regions containing BC6OTHER neurons. CPR:falsenewlineLong - term administration of BC6OTHER to rats increased the activities of antioxidative enzymes BC6ENTC dismutase ( BC6ENTG ) and BC6OTHER in the brain regions containing BC6OTHER neurons. CPR:falsenewlineLong - term administration of BC6OTHER to rats increased the activities of antioxidative enzymes BC6ENTC dismutase ( BC6OTHER ) and BC6ENTG in the brain regions containing BC6OTHER neurons. CPR:falsenewlineLong - term administration of BC6OTHER to rats increased the activities of antioxidative enzymes BC6ENTG ( BC6OTHER ) and BC6OTHER in the brain regions containing BC6ENTC neurons. CPR:falsenewlineLong - term administration of BC6OTHER to rats increased the activities of antioxidative enzymes BC6OTHER dismutase ( BC6ENTG ) and BC6OTHER in the brain regions containing BC6ENTC neurons. CPR:falsenewlineLong - term administration of BC6OTHER to rats increased the activities of antioxidative enzymes BC6OTHER dismutase ( BC6OTHER ) and BC6ENTG in the brain regions containing BC6ENTC neurons. CPR:falsenewlineAn inhibitor of type B BC6ENTC oxidase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), was reported to have neuroprotective activity, but clinical trials failed to confirm it. CPR:falsenewlineThe induction of BC6ENTG by CHEM was inhibited by BC6ENTC but not by BC6OTHER , BC6OTHER , nor BC6OTHER . CPR:falsenewlineThe induction of BC6ENTG by CHEM was inhibited by BC6OTHER but not by BC6ENTC , BC6OTHER , nor BC6OTHER . CPR:falsenewlineThe induction of BC6ENTG by CHEM was inhibited by BC6OTHER but not by BC6OTHER , BC6ENTC , nor BC6OTHER . CPR:falsenewlineThe induction of BC6ENTG by CHEM was inhibited by BC6OTHER but not by BC6OTHER , BC6OTHER , nor BC6ENTC . CPR:falsenewlineMost importantly, administration of EIH significantly reduced not only increase in blood BC6ENTG , BC6OTHER BC6OTHER , BUN, BC6ENTC levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by CHEM, a BC6OTHER inhibitor. CPR:falsenewlineMost importantly, administration of EIH significantly reduced not only increase in blood BC6OTHER , BC6ENTG BC6OTHER , BUN, BC6ENTC levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by CHEM, a BC6OTHER inhibitor. CPR:falsenewlineMost importantly, administration of EIH significantly reduced not only increase in blood BC6OTHER , BC6OTHER BC6ENTG , BUN, BC6ENTC levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by CHEM, a BC6OTHER inhibitor. CPR:falsenewlineMost importantly, administration of EIH significantly reduced not only increase in blood BC6OTHER , BC6OTHER BC6OTHER , BUN, BC6ENTC levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by CHEM, a BC6ENTG inhibitor. CPR:falsenewlineWe recently proposed that BC6ENTC oxygenase - 1 ( BC6ENTG ) negatively regulates BC6OTHER in inflammatory conditions. CPR:falsenewlineWe recently proposed that BC6ENTC oxygenase - 1 ( BC6OTHER ) negatively regulates BC6ENTG in inflammatory conditions. CPR:falsenewlineWe investigated whether BC6ENTC extract of Inula helenium L. (EIH) activates BC6ENTG BC6OTHER / BC6OTHER / BC6OTHER pathways in RAW264.7 cells and reduces inflammation in CLP - induced septic mice. CPR:falsenewlineWe investigated whether BC6ENTC extract of Inula helenium L. (EIH) activates BC6OTHER BC6ENTG / BC6OTHER / BC6OTHER pathways in RAW264.7 cells and reduces inflammation in CLP - induced septic mice. CPR:falsenewlineWe investigated whether BC6ENTC extract of Inula helenium L. (EIH) activates BC6OTHER BC6OTHER / BC6ENTG / BC6OTHER pathways in RAW264.7 cells and reduces inflammation in CLP - induced septic mice. CPR:falsenewlineWe investigated whether BC6ENTC extract of Inula helenium L. (EIH) activates BC6OTHER BC6OTHER / BC6OTHER / BC6ENTG pathways in RAW264.7 cells and reduces inflammation in CLP - induced septic mice. CPR:falsenewlineInduction of BC6ENTG through BC6OTHER BC6OTHER / BC6OTHER signaling pathway by BC6ENTC extract of Inula helenium L. reduces inflammation in LPS - activated RAW 264.7 cells and CLP - induced septic mice. CPR:falsenewlineInduction of BC6OTHER through BC6ENTG BC6OTHER / BC6OTHER signaling pathway by BC6ENTC extract of Inula helenium L. reduces inflammation in LPS - activated RAW 264.7 cells and CLP - induced septic mice. CPR:falsenewlineInduction of BC6OTHER through BC6OTHER BC6ENTG / BC6OTHER signaling pathway by BC6ENTC extract of Inula helenium L. reduces inflammation in LPS - activated RAW 264.7 cells and CLP - induced septic mice. CPR:falsenewlineInduction of BC6OTHER through BC6OTHER BC6OTHER / BC6ENTG signaling pathway by BC6ENTC extract of Inula helenium L. reduces inflammation in LPS - activated RAW 264.7 cells and CLP - induced septic mice. CPR:falsenewlineA novel missense mutation, BC6ENTG , in exon 5 of the erythroid - specific BC6OTHER synthase gene ( BC6OTHER ) was identified in a Japanese male with BC6ENTC - responsive sideroblastic anemia. CPR:falsenewlineA novel missense mutation, BC6OTHER , in exon 5 of the BC6ENTG gene ( BC6OTHER ) was identified in a Japanese male with BC6ENTC - responsive sideroblastic anemia. CPR:falsenewlineA novel missense mutation, BC6OTHER , in exon 5 of the erythroid - specific BC6OTHER synthase gene ( BC6ENTG ) was identified in a Japanese male with BC6ENTC - responsive sideroblastic anemia. CPR:falsenewlineActivity of the mutant BC6ENTG protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of BC6ENTC , consistent with the clinical response of the patient to BC6OTHER treatment. CPR:falsenewlineActivity of the mutant BC6ENTG protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of BC6OTHER , consistent with the clinical response of the patient to BC6ENTC treatment. CPR:falsenewlineA novel missense mutation, BC6ENTG , in exon 5 of the erythroid - specific BC6ENTC synthase gene ( BC6OTHER ) was identified in a Japanese male with BC6OTHER - responsive sideroblastic anemia. CPR:falsenewlineA novel missense mutation, BC6OTHER , in exon 5 of the erythroid - specific BC6ENTC synthase gene ( BC6ENTG ) was identified in a Japanese male with BC6OTHER - responsive sideroblastic anemia. CPR:falsenewlineA novel mutation of the BC6ENTG gene in a patient with non - inherited BC6ENTC - responsive sideroblastic anemia. CPR:falsenewlineBC6ENTC receptor ( BC6OTHER ) antagonists are valuable in the treatment of BC6ENTG - positive human breast cancer. CPR:falsenewlineBC6ENTC receptor ( BC6ENTG ) antagonists are valuable in the treatment of BC6OTHER - positive human breast cancer. CPR:falsenewlineIn this study, we designed and synthesized nine new derivatives of BC6ENTC (E2) with a bulky side chain attached to its C - 7α position, and determined their BC6ENTG antagonistic activity using in vitro bioassays. CPR:6newlineComputational docking analysis was conducted to model the interaction of these antagonists with the BC6ENTG and showed that they could tightly bind to the BC6OTHER in a manner similar to that of BC6ENTC , a pure BC6OTHER antagonist. CPR:falsenewlineComputational docking analysis was conducted to model the interaction of these antagonists with the BC6OTHER and showed that they could tightly bind to the BC6ENTG in a manner similar to that of BC6ENTC , a pure BC6OTHER antagonist. CPR:falsenewlineComputational docking analysis was conducted to model the interaction of these antagonists with the BC6OTHER and showed that they could tightly bind to the BC6OTHER in a manner similar to that of BC6ENTC , a pure BC6ENTG antagonist. CPR:falsenewlineThese results provide an example that attachment of a bulky side chain to the CHEM position of E2 can produce BC6ENTG antagonists with BC6OTHER affinity comparable to that of BC6ENTC . CPR:falsenewlineThese results provide an example that attachment of a bulky side chain to the CHEM position of E2 can produce BC6OTHER antagonists with BC6ENTG affinity comparable to that of BC6ENTC . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6ENTG release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6ENTG , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6ENTC and more than 45% with HMW core BC6OTHER . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6ENTG release rate is much greater than that of BC6OTHER , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC . CPR:falsenewlineWhen dual angiogenic growth factors (GFs), such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), are encapsulated separately in the core and shell domains, respectively, the BC6OTHER release rate is much greater than that of BC6ENTG , and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core BC6OTHER and more than 45% with HMW core BC6ENTC . CPR:falsenewlineCSF production in wildtype mice was (in microl / min) 0.37 + / - 0.04 microl / min (control), 0.16 + / - 0.03 microl / min ( BC6ENTC - treated) and 1.14 + / - 0.15 microl / min ( BC6OTHER - treated), and reduced by up to 25% in BC6ENTG null mice. CPR:falsenewlineCSF production in wildtype mice was (in microl / min) 0.37 + / - 0.04 microl / min (control), 0.16 + / - 0.03 microl / min ( BC6OTHER - treated) and 1.14 + / - 0.15 microl / min ( BC6ENTC - treated), and reduced by up to 25% in BC6ENTG null mice. CPR:falsenewlineBACKGROUND & AIMS: Sensitization of Kupffer cells (KCs) to lipopolysaccharide (LPS) and overproduction of BC6ENTG are critical for progression of BC6ENTC liver injury. CPR:falsenewlineCONCLUSIONS: These results collectively indicate that BC6ENTC prevents alcoholic liver injury through suppression of BC6ENTG production and abolishment of KC sensitization. CPR:4newlineBC6ENTC has been shown to suppress BC6ENTG production from macrophages. CPR:falsenewlineKCs were isolated after 4 weeks of BC6ENTC treatment and intracellular BC6OTHER ([ BC6OTHER ]i) was measured using fura - 2, whereas BC6ENTG was evaluated by reverse - transcription polymerase chain reaction and enzyme - linked immunosorbent assay. CPR:falsenewlineKCs were isolated after 4 weeks of BC6OTHER treatment and intracellular BC6ENTC ([ BC6OTHER ]i) was measured using fura - 2, whereas BC6ENTG was evaluated by reverse - transcription polymerase chain reaction and enzyme - linked immunosorbent assay. CPR:falsenewlineKCs were isolated after 4 weeks of BC6OTHER treatment and intracellular BC6OTHER ([ BC6ENTC ]i) was measured using fura - 2, whereas BC6ENTG was evaluated by reverse - transcription polymerase chain reaction and enzyme - linked immunosorbent assay. CPR:falsenewline BC6ENTC prevents BC6OTHER liver injury in rats through suppression of Kupffer cell sensitization and BC6ENTG production. CPR:falsenewline BC6OTHER prevents BC6ENTC liver injury in rats through suppression of Kupffer cell sensitization and BC6ENTG production. CPR:falsenewlineFurthermore, BC6ENTC abolished the LPS - induced increase in BC6ENTG expression and [ BC6OTHER ]i elevation in KCs. CPR:falsenewlineFurthermore, BC6OTHER abolished the LPS - induced increase in BC6ENTG expression and [ BC6ENTC ]i elevation in KCs. CPR:falsenewlineMoreover, BC6ENTC reduced the LPS - induced BC6ENTG production by KCs by decreasing BC6OTHER messenger RNA. CPR:falsenewlineMoreover, BC6ENTC reduced the LPS - induced BC6OTHER production by KCs by decreasing BC6ENTG messenger RNA. CPR:falsenewlineBC6ENTC between CHEM(183) and CHEM(191) are necessary for proper BC6ENTG activation, but additional sequence between CHEM(195) and CHEM(197) or between CHEM(260) and CHEM(265) is required for complete restoration of activation. CPR:falsenewlineTo identify key BC6ENTC involved in BC6ENTG activation, recombinant BC6OTHER proteins containing BC6OTHER substitutions for wild - type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay. CPR:falsenewlineTo identify key BC6ENTC involved in BC6OTHER activation, recombinant BC6ENTG proteins containing BC6OTHER substitutions for wild - type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay. CPR:falsenewlineTo identify key BC6OTHER involved in BC6ENTG activation, recombinant BC6OTHER proteins containing BC6ENTC substitutions for wild - type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay. CPR:falsenewlineTo identify key BC6OTHER involved in BC6OTHER activation, recombinant BC6ENTG proteins containing BC6ENTC substitutions for wild - type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay. CPR:falsenewlineSubstitutions for CHEM and CHEM at the BC6ENTC terminus and for CHEM at the BC6OTHER terminus of the BC6ENTG markedly decreased BC6OTHER coagulant activity. CPR:falsenewlineSubstitutions for CHEM and CHEM at the BC6ENTC terminus and for CHEM at the BC6OTHER terminus of the BC6OTHER markedly decreased BC6ENTG coagulant activity. CPR:falsenewlineSubstitutions for CHEM and CHEM at the BC6OTHER terminus and for CHEM at the BC6ENTC terminus of the BC6ENTG markedly decreased BC6OTHER coagulant activity. CPR:falsenewlineSubstitutions for CHEM and CHEM at the BC6OTHER terminus and for CHEM at the BC6ENTC terminus of the BC6OTHER markedly decreased BC6ENTG coagulant activity. CPR:falsenewlineIdentification of BC6ENTC in the BC6ENTG required for activation of BC6OTHER . CPR:falsenewlineIdentification of BC6ENTC in the BC6OTHER required for activation of BC6ENTG . CPR:falsenewlineThe current comprehensive BC6OTHER clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6OTHER compared to standard therapy: 1) The BC6OTHER Heart Failure Survival Study - ELITE II, 2) The BC6OTHER Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6ENTC Hypertension Survival Study - LIFE and 4) The BC6OTHER Renal Protection Study - RENAAL. CPR:falsenewlineThe current comprehensive BC6OTHER clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6OTHER compared to standard therapy: 1) The BC6OTHER Heart Failure Survival Study - ELITE II, 2) The BC6OTHER Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6OTHER Hypertension Survival Study - LIFE and 4) The BC6ENTC Renal Protection Study - RENAAL. CPR:falsenewlineSince all of the BC6ENTC antagonists are selective for the BC6ENTG , these drugs should exhibit similar cardiovascular effects. CPR:falsenewlineBC6ENTC (parent compound), has moderate affinity for the BC6ENTG (competitive inhibition). CPR:falsenewlineBC6ENTC is well - absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20 - to 30 - times greater for the BC6ENTG (non - competitive inhibition). CPR:falsenewline BC6ENTC : a selective BC6ENTG antagonist for the treatment of heart failure. CPR:6newlineBC6ENTC ( BC6OTHER ) is the prototype of a new class of potent and selective BC6ENTG antagonists with the largest published preclinical and clinical data base. CPR:6newlineBC6OTHER ( BC6ENTC ) is the prototype of a new class of potent and selective BC6ENTG antagonists with the largest published preclinical and clinical data base. CPR:6newlineClinical experience in heart failure is growing, and recent data suggest an improved survival with BC6ENTC versus BC6OTHER , a drug from the BC6ENTG inhibitor class with proven benefit in this population. CPR:falsenewlineClinical experience in heart failure is growing, and recent data suggest an improved survival with BC6OTHER versus BC6ENTC , a drug from the BC6ENTG inhibitor class with proven benefit in this population. CPR:falsenewlineThe current comprehensive BC6ENTC clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6OTHER compared to standard therapy: 1) The BC6OTHER Heart Failure Survival Study - ELITE II, 2) The BC6OTHER Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6OTHER Hypertension Survival Study - LIFE and 4) The BC6OTHER Renal Protection Study - RENAAL. CPR:falsenewlineThe current comprehensive BC6OTHER clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6ENTC compared to standard therapy: 1) The BC6OTHER Heart Failure Survival Study - ELITE II, 2) The BC6OTHER Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6OTHER Hypertension Survival Study - LIFE and 4) The BC6OTHER Renal Protection Study - RENAAL. CPR:falsenewlineThe current comprehensive BC6OTHER clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6OTHER compared to standard therapy: 1) The BC6ENTC Heart Failure Survival Study - ELITE II, 2) The BC6OTHER Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6OTHER Hypertension Survival Study - LIFE and 4) The BC6OTHER Renal Protection Study - RENAAL. CPR:falsenewlineThe current comprehensive BC6OTHER clinical end - point programme (4 large scale morbidity / mortality trials) should provide evidence regarding the efficacy of direct blockade of the BC6ENTG with BC6OTHER compared to standard therapy: 1) The BC6OTHER Heart Failure Survival Study - ELITE II, 2) The BC6ENTC Post - Myocardial Infarction Survival Study - OPTIMAAL, 3) The BC6OTHER Hypertension Survival Study - LIFE and 4) The BC6OTHER Renal Protection Study - RENAAL. CPR:falsenewlineSince 10( - 3)M BC6OTHER oxidises BC6OTHER and BC6OTHER residues in proteins, we examined BC6ENTC binding to BC6ENTG in the presence and absence of BC6OTHER utilising (45) BC6OTHER . CPR:falsenewlineSince 10( - 3)M BC6OTHER oxidises BC6OTHER and BC6OTHER residues in proteins, we examined BC6OTHER binding to BC6ENTG in the presence and absence of BC6ENTC utilising (45) BC6OTHER . CPR:falsenewlineSince 10( - 3)M BC6OTHER oxidises BC6OTHER and BC6OTHER residues in proteins, we examined BC6OTHER binding to BC6ENTG in the presence and absence of BC6OTHER utilising (45) BC6ENTC . CPR:falsenewlineThe results showed that all four BC6ENTC atoms exchanged per molecule of BC6ENTG . CPR:falsenewlineSince oxidised BC6ENTG looses its ability to activate BC6ENTC ATPase, enzyme activities were followed in full skin biopsies from lesional skin of patients with acute vitiligo (n=6) and healthy controls (n=6). CPR:falsenewlineComputer simulation of native and oxidised BC6ENTG confirmed the loss of all four BC6ENTC ions from their specific BC6OTHER . CPR:falsenewlineComputer simulation of native and oxidised BC6OTHER confirmed the loss of all four BC6ENTC ions from their specific BC6ENTG . CPR:falsenewline BC6ENTC - mediated oxidative stress disrupts BC6OTHER binding on BC6ENTG : more evidence for oxidative stress in vitiligo. CPR:falsenewline BC6OTHER - mediated oxidative stress disrupts BC6ENTC binding on BC6ENTG : more evidence for oxidative stress in vitiligo. CPR:falsenewlineTaken together BC6ENTC - mediated oxidation affects BC6OTHER binding in BC6ENTG leading to perturbed BC6OTHER homeostasis and perturbed BC6OTHER - uptake in the epidermis of acute vitiligo. CPR:falsenewlinePatients with acute vitiligo have low epidermal BC6ENTG expression / activities and accumulate 10( - 3) M BC6ENTC . CPR:falsenewlineTaken together BC6OTHER - mediated oxidation affects BC6ENTC binding in BC6ENTG leading to perturbed BC6OTHER homeostasis and perturbed BC6OTHER - uptake in the epidermis of acute vitiligo. CPR:falsenewlineTaken together BC6OTHER - mediated oxidation affects BC6OTHER binding in BC6ENTG leading to perturbed BC6ENTC homeostasis and perturbed BC6OTHER - uptake in the epidermis of acute vitiligo. CPR:falsenewlineTaken together BC6OTHER - mediated oxidation affects BC6OTHER binding in BC6ENTG leading to perturbed BC6OTHER homeostasis and perturbed BC6ENTC - uptake in the epidermis of acute vitiligo. CPR:falsenewlineSince 10( - 3)M BC6ENTC oxidises BC6OTHER and BC6OTHER residues in proteins, we examined BC6OTHER binding to BC6ENTG in the presence and absence of BC6OTHER utilising (45) BC6OTHER . CPR:falsenewlineSince 10( - 3)M BC6OTHER oxidises BC6ENTC and BC6OTHER residues in proteins, we examined BC6OTHER binding to BC6ENTG in the presence and absence of BC6OTHER utilising (45) BC6OTHER . CPR:falsenewlineSince 10( - 3)M BC6OTHER oxidises BC6OTHER and BC6ENTC residues in proteins, we examined BC6OTHER binding to BC6ENTG in the presence and absence of BC6OTHER utilising (45) BC6OTHER . CPR:falsenewlineThe transport BC6ENTC - sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to BC6OTHER - BC6OTHER exchange ( BC6ENTG isoform). CPR:falsenewlineThe transport BC6OTHER - sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to BC6ENTC - BC6OTHER exchange ( BC6ENTG isoform). CPR:falsenewlineThe transport BC6OTHER - sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to BC6OTHER - BC6ENTC exchange ( BC6ENTG isoform). CPR:falsenewlineThe synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective BC6ENTG inhibitor 15b ( BC6ENTC ) are described. CPR:4newlineIn this initial report, preliminary structure - activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation BC6ENTG inhibitor 4 ( BC6ENTC ). CPR:4newlineSynthesis, structure - activity relationships, and in vivo efficacy of the novel potent and selective BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC ( BC6OTHER ) currently in phase 1 and phase 2 clinical trials. CPR:4newlineSynthesis, structure - activity relationships, and in vivo efficacy of the novel potent and selective BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC ( BC6OTHER ) currently in phase 1 and phase 2 clinical trials. CPR:4newlineSynthesis, structure - activity relationships, and in vivo efficacy of the novel potent and selective BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER ( BC6ENTC ) currently in phase 1 and phase 2 clinical trials. CPR:4newlineSynthesis, structure - activity relationships, and in vivo efficacy of the novel potent and selective BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER ( BC6ENTC ) currently in phase 1 and phase 2 clinical trials. CPR:4newlineThis process was reduced by a protonophore, BC6ENTC , and a typical BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER . CPR:falsenewlineThis process was reduced by a protonophore, BC6ENTC , and a typical BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER . CPR:falsenewlineThis process was reduced by a protonophore, BC6ENTC , and a typical BC6OTHER ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTG . CPR:falsenewlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTC transporter ( BC6ENTG ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER . CPR:falsenewlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTC transporter ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTG . CPR:falsenewlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTG ( BC6OTHER ) inhibitor, BC6ENTC , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER . CPR:falsenewlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6ENTG ) inhibitor, BC6ENTC , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER . CPR:falsenewlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6OTHER ) inhibitor, BC6ENTC , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTG . CPR:9newlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6ENTC uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER . CPR:9newlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER , suggesting that BC6ENTC uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6OTHER . CPR:9newlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6ENTC uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTG . CPR:9newlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6ENTC - coupled BC6OTHER . CPR:falsenewlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6ENTC - coupled BC6OTHER . CPR:falsenewlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6ENTC - coupled BC6ENTG . CPR:falsenewlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTC transport system. CPR:falsenewlineThis process was reduced by a protonophore, BC6OTHER , and a typical BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER , suggesting that BC6OTHER uptake by rat astrocytes is mediated by BC6OTHER - coupled BC6ENTC transport system. CPR:falsenewlineBecause BC6ENTC reduced to 67% of the BC6OTHER uptake even at 10mM, it is unlikely that BC6OTHER uptake in rat astrocytes is mediated by BC6ENTG and / or BC6OTHER . CPR:falsenewlineBecause BC6ENTC reduced to 67% of the BC6OTHER uptake even at 10mM, it is unlikely that BC6OTHER uptake in rat astrocytes is mediated by BC6OTHER and / or BC6ENTG . CPR:falsenewlineBecause BC6OTHER reduced to 67% of the BC6ENTC uptake even at 10mM, it is unlikely that BC6OTHER uptake in rat astrocytes is mediated by BC6ENTG and / or BC6OTHER . CPR:falsenewlineBecause BC6OTHER reduced to 67% of the BC6ENTC uptake even at 10mM, it is unlikely that BC6OTHER uptake in rat astrocytes is mediated by BC6OTHER and / or BC6ENTG . CPR:falsenewlineBecause BC6OTHER reduced to 67% of the BC6OTHER uptake even at 10mM, it is unlikely that BC6ENTC uptake in rat astrocytes is mediated by BC6ENTG and / or BC6OTHER . CPR:9newlineBecause BC6OTHER reduced to 67% of the BC6OTHER uptake even at 10mM, it is unlikely that BC6ENTC uptake in rat astrocytes is mediated by BC6OTHER and / or BC6ENTG . CPR:9newlineThese results provide biochemical evidence of a BC6ENTC - coupled and saturable transport system, presumed to be a BC6ENTG BC6OTHER or other unknown BC6OTHER - coupled BC6OTHER transport system, for BC6OTHER in rat cerebrocortical astrocytes. CPR:9newlineThese results provide biochemical evidence of a BC6ENTC - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6ENTG or other unknown BC6OTHER - coupled BC6OTHER transport system, for BC6OTHER in rat cerebrocortical astrocytes. CPR:falsenewlineThese results provide biochemical evidence of a BC6ENTC - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6OTHER or other unknown BC6ENTG , for BC6OTHER in rat cerebrocortical astrocytes. CPR:falsenewlineThese results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6ENTC transporter BC6ENTG or other unknown BC6OTHER - coupled BC6OTHER transport system, for BC6OTHER in rat cerebrocortical astrocytes. CPR:9newlineThese results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6ENTC transporter BC6OTHER or other unknown BC6ENTG , for BC6OTHER in rat cerebrocortical astrocytes. CPR:9newlineThese results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a BC6ENTG BC6OTHER or other unknown BC6ENTC - coupled BC6OTHER transport system, for BC6OTHER in rat cerebrocortical astrocytes. CPR:9newlineThese results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6ENTG or other unknown BC6ENTC - coupled BC6OTHER transport system, for BC6OTHER in rat cerebrocortical astrocytes. CPR:falsenewlineThese results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a BC6ENTG BC6OTHER or other unknown BC6OTHER - coupled BC6ENTC transport system, for BC6OTHER in rat cerebrocortical astrocytes. CPR:9newlineThese results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6ENTG or other unknown BC6OTHER - coupled BC6ENTC transport system, for BC6OTHER in rat cerebrocortical astrocytes. CPR:9newlineThese results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a BC6ENTG BC6OTHER or other unknown BC6OTHER - coupled BC6OTHER transport system, for BC6ENTC in rat cerebrocortical astrocytes. CPR:9newlineThese results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6ENTG or other unknown BC6OTHER - coupled BC6OTHER transport system, for BC6ENTC in rat cerebrocortical astrocytes. CPR:9newlineThese results provide biochemical evidence of a BC6OTHER - coupled and saturable transport system, presumed to be a low - affinity BC6OTHER transporter BC6OTHER or other unknown BC6ENTG , for BC6ENTC in rat cerebrocortical astrocytes. CPR:9newline BC6ENTC , the first prostate - selective BC6ENTG antagonist. CPR:falsenewlineTreatment options for DUB are: combined oral contraceptives (COCs), BC6ENTC , non CHEM anti inflammatory drugs (NSAIDs), BC6OTHER (anti - fibrinolytic), BC6ENTG analogues, BC6OTHER and BC6OTHER releasing intra uterine system (LNG IUS). CPR:falsenewlineTreatment options for DUB are: combined oral contraceptives (COCs), BC6OTHER , non CHEM anti inflammatory drugs (NSAIDs), BC6ENTC (anti - fibrinolytic), BC6ENTG analogues, BC6OTHER and BC6OTHER releasing intra uterine system (LNG IUS). CPR:falsenewlineTreatment options for DUB are: combined oral contraceptives (COCs), BC6OTHER , non CHEM anti inflammatory drugs (NSAIDs), BC6OTHER (anti - fibrinolytic), BC6ENTG analogues, BC6ENTC and BC6OTHER releasing intra uterine system (LNG IUS). CPR:falsenewlineTreatment options for DUB are: combined oral contraceptives (COCs), BC6OTHER , non CHEM anti inflammatory drugs (NSAIDs), BC6OTHER (anti - fibrinolytic), BC6ENTG analogues, BC6OTHER and BC6ENTC releasing intra uterine system (LNG IUS). CPR:falsenewlineThe phosphorylations of BC6ENTG and endothelial BC6OTHER synthase ( BC6OTHER ) as well as the level of BC6ENTC were measured to confirm the effect of BC6OTHER on BC6OTHER signaling pathway. CPR:falsenewlineThe phosphorylations of BC6OTHER and BC6ENTG ( BC6OTHER ) as well as the level of BC6ENTC were measured to confirm the effect of BC6OTHER on BC6OTHER signaling pathway. CPR:falsenewlineThe phosphorylations of BC6OTHER and endothelial BC6OTHER synthase ( BC6ENTG ) as well as the level of BC6ENTC were measured to confirm the effect of BC6OTHER on BC6OTHER signaling pathway. CPR:falsenewlineThe phosphorylations of BC6OTHER and endothelial BC6OTHER synthase ( BC6OTHER ) as well as the level of BC6ENTC were measured to confirm the effect of BC6ENTG on BC6OTHER signaling pathway. CPR:falsenewlineThe phosphorylations of BC6OTHER and endothelial BC6OTHER synthase ( BC6OTHER ) as well as the level of BC6ENTC were measured to confirm the effect of BC6OTHER on BC6ENTG signaling pathway. CPR:falsenewlineThe preventive effect of uncarboxylated BC6OTHER against BC6OTHER - induced endothelial apoptosis through the activation of BC6ENTC 3 - kinase / BC6ENTG signaling pathway: BC6OTHER and endothelial apoptosis. CPR:falsenewlineThe preventive effect of uncarboxylated BC6OTHER against BC6OTHER - induced endothelial apoptosis through the activation of BC6ENTC 3 - kinase / BC6OTHER signaling pathway: BC6ENTG and endothelial apoptosis. CPR:falsenewlineThe preventive effect of uncarboxylated BC6ENTG against BC6OTHER - induced endothelial apoptosis through the activation of BC6ENTC 3 - kinase / BC6OTHER signaling pathway: BC6OTHER and endothelial apoptosis. CPR:falsenewlineThe preventive effect of uncarboxylated BC6OTHER against BC6ENTC - induced endothelial apoptosis through the activation of BC6ENTG / BC6OTHER signaling pathway: BC6OTHER and endothelial apoptosis. CPR:falsenewlineThe preventive effect of uncarboxylated BC6OTHER against BC6ENTC - induced endothelial apoptosis through the activation of BC6OTHER / BC6ENTG signaling pathway: BC6OTHER and endothelial apoptosis. CPR:falsenewlineThe preventive effect of uncarboxylated BC6OTHER against BC6ENTC - induced endothelial apoptosis through the activation of BC6OTHER / BC6OTHER signaling pathway: BC6ENTG and endothelial apoptosis. CPR:falsenewlineThe preventive effect of uncarboxylated BC6ENTG against BC6ENTC - induced endothelial apoptosis through the activation of BC6OTHER / BC6OTHER signaling pathway: BC6OTHER and endothelial apoptosis. CPR:falsenewlineRESULTS: Pretreatment of BC6ENTG (30ng / ml) prevented LA - induced apoptosis in BC6OTHER - stimulated endothelial cells; effects were abolished by pretreatment with the BC6ENTC 3 - kinase ( BC6OTHER ) inhibitor, BC6OTHER . CPR:falsenewlineRESULTS: Pretreatment of BC6OTHER (30ng / ml) prevented LA - induced apoptosis in BC6ENTG - stimulated endothelial cells; effects were abolished by pretreatment with the BC6ENTC 3 - kinase ( BC6OTHER ) inhibitor, BC6OTHER . CPR:falsenewlineRESULTS: Pretreatment of BC6OTHER (30ng / ml) prevented LA - induced apoptosis in BC6OTHER - stimulated endothelial cells; effects were abolished by pretreatment with the BC6ENTC 3 - kinase ( BC6ENTG ) inhibitor, BC6OTHER . CPR:falsenewlineRESULTS: Pretreatment of BC6ENTG (30ng / ml) prevented LA - induced apoptosis in BC6OTHER - stimulated endothelial cells; effects were abolished by pretreatment with the BC6OTHER 3 - kinase ( BC6OTHER ) inhibitor, BC6ENTC . CPR:falsenewlineRESULTS: Pretreatment of BC6OTHER (30ng / ml) prevented LA - induced apoptosis in BC6ENTG - stimulated endothelial cells; effects were abolished by pretreatment with the BC6OTHER 3 - kinase ( BC6OTHER ) inhibitor, BC6ENTC . CPR:falsenewlineRESULTS: Pretreatment of BC6OTHER (30ng / ml) prevented LA - induced apoptosis in BC6OTHER - stimulated endothelial cells; effects were abolished by pretreatment with the BC6ENTG ( BC6OTHER ) inhibitor, BC6ENTC . CPR:falsenewlineRESULTS: Pretreatment of BC6OTHER (30ng / ml) prevented LA - induced apoptosis in BC6OTHER - stimulated endothelial cells; effects were abolished by pretreatment with the BC6OTHER 3 - kinase ( BC6ENTG ) inhibitor, BC6ENTC . CPR:falsenewlineTreatment of BC6ENTG (ranged from 0.3 to 30ng / ml) significantly increased the phosphorylation of BC6OTHER and BC6OTHER and BC6ENTC secretion from endothelial cells in a BC6OTHER dependent manner. CPR:falsenewlineTreatment of BC6OTHER (ranged from 0.3 to 30ng / ml) significantly increased the phosphorylation of BC6ENTG and BC6OTHER and BC6ENTC secretion from endothelial cells in a BC6OTHER dependent manner. CPR:falsenewlineTreatment of BC6OTHER (ranged from 0.3 to 30ng / ml) significantly increased the phosphorylation of BC6OTHER and BC6ENTG and BC6ENTC secretion from endothelial cells in a BC6OTHER dependent manner. CPR:falsenewlineTreatment of BC6OTHER (ranged from 0.3 to 30ng / ml) significantly increased the phosphorylation of BC6OTHER and BC6OTHER and BC6ENTC secretion from endothelial cells in a BC6ENTG dependent manner. CPR:falsenewlineApoptosis was evaluated using various methods including a terminal BC6ENTC transferase - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6ENTG , cleaved BC6OTHER polymerase and BC6OTHER . CPR:falsenewlineApoptosis was evaluated using various methods including a terminal BC6ENTC transferase - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6ENTG and BC6OTHER . CPR:falsenewlineApoptosis was evaluated using various methods including a terminal BC6ENTC transferase - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6OTHER polymerase and BC6ENTG . CPR:falsenewlineApoptosis was evaluated using various methods including a terminal BC6ENTG - mediated BC6ENTC nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6OTHER polymerase and BC6OTHER . CPR:falsenewlineApoptosis was evaluated using various methods including a terminal BC6OTHER transferase - mediated BC6ENTC nick - end labeling analysis kit and Western blotting for cleaved BC6ENTG , cleaved BC6OTHER polymerase and BC6OTHER . CPR:falsenewlineApoptosis was evaluated using various methods including a terminal BC6OTHER transferase - mediated BC6ENTC nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6ENTG and BC6OTHER . CPR:falsenewlineApoptosis was evaluated using various methods including a terminal BC6OTHER transferase - mediated BC6ENTC nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6OTHER polymerase and BC6ENTG . CPR:falsenewlineApoptosis was evaluated using various methods including a terminal BC6ENTG - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6ENTC polymerase and BC6OTHER . CPR:falsenewlineApoptosis was evaluated using various methods including a terminal BC6OTHER transferase - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6ENTG , cleaved BC6ENTC polymerase and BC6OTHER . CPR:falsenewlineApoptosis was evaluated using various methods including a terminal BC6OTHER transferase - mediated BC6OTHER nick - end labeling analysis kit and Western blotting for cleaved BC6OTHER , cleaved BC6ENTC polymerase and BC6ENTG . CPR:falsenewlineThe phosphorylations of BC6ENTG and endothelial BC6ENTC synthase ( BC6OTHER ) as well as the level of BC6OTHER were measured to confirm the effect of BC6OTHER on BC6OTHER signaling pathway. CPR:falsenewlineThe phosphorylations of BC6OTHER and endothelial BC6ENTC synthase ( BC6ENTG ) as well as the level of BC6OTHER were measured to confirm the effect of BC6OTHER on BC6OTHER signaling pathway. CPR:falsenewlineThe phosphorylations of BC6OTHER and endothelial BC6ENTC synthase ( BC6OTHER ) as well as the level of BC6OTHER were measured to confirm the effect of BC6ENTG on BC6OTHER signaling pathway. CPR:falsenewlineThe phosphorylations of BC6OTHER and endothelial BC6ENTC synthase ( BC6OTHER ) as well as the level of BC6OTHER were measured to confirm the effect of BC6OTHER on BC6ENTG signaling pathway. CPR:falsenewlineIn the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6OTHER kinase ( BC6ENTG ) and BC6ENTC oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6OTHER kinase ( BC6OTHER ) and BC6ENTC oxidase ( BC6ENTG ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6ENTG ( BC6OTHER ) and BC6ENTC oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineTherefore, decreases of BC6ENTG and BC6OTHER in the hippocampal CA1 region of aged brains may be involved in aging processes related with BC6ENTC ( BC6OTHER ) function. CPR:falsenewlineTherefore, decreases of BC6OTHER and BC6ENTG in the hippocampal CA1 region of aged brains may be involved in aging processes related with BC6ENTC ( BC6OTHER ) function. CPR:falsenewlineTherefore, decreases of BC6ENTG and BC6OTHER in the hippocampal CA1 region of aged brains may be involved in aging processes related with BC6OTHER ( BC6ENTC ) function. CPR:falsenewlineTherefore, decreases of BC6OTHER and BC6ENTG in the hippocampal CA1 region of aged brains may be involved in aging processes related with BC6OTHER ( BC6ENTC ) function. CPR:falsenewlineIn the present study, age - related changes of BC6ENTC ( BC6OTHER ) synthesizing enzymes, BC6OTHER kinase ( BC6ENTG ) and BC6OTHER oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6ENTC ( BC6OTHER ) synthesizing enzymes, BC6OTHER kinase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6ENTC ( BC6OTHER ) synthesizing enzymes, BC6OTHER kinase ( BC6OTHER ) and BC6OTHER oxidase ( BC6ENTG ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6ENTC ( BC6OTHER ) synthesizing enzymes, BC6ENTG ( BC6OTHER ) and BC6OTHER oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6OTHER ( BC6ENTC ) synthesizing enzymes, BC6OTHER kinase ( BC6ENTG ) and BC6OTHER oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6OTHER ( BC6ENTC ) synthesizing enzymes, BC6OTHER kinase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6OTHER ( BC6ENTC ) synthesizing enzymes, BC6OTHER kinase ( BC6OTHER ) and BC6OTHER oxidase ( BC6ENTG ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6OTHER ( BC6ENTC ) synthesizing enzymes, BC6ENTG ( BC6OTHER ) and BC6OTHER oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6ENTC kinase ( BC6ENTG ) and BC6OTHER oxidase ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6ENTC kinase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineIn the present study, age - related changes of BC6OTHER ( BC6OTHER ) synthesizing enzymes, BC6ENTC kinase ( BC6OTHER ) and BC6OTHER oxidase ( BC6ENTG ), their protein contents and activities were examined in the gerbil hippocampus proper. CPR:falsenewlineBC6OTHER ( BC6OTHER ) enzymes or BC6OTHER are a family of BC6ENTG BC6ENTC ) deacetylases. CPR:falsenewlineBC6ENTG ( BC6OTHER ) enzymes or BC6OTHER are a family of BC6OTHER - dependent protein BC6OTHER ( BC6ENTC ) deacetylases. CPR:falsenewlineBC6OTHER ( BC6ENTG ) enzymes or BC6OTHER are a family of BC6OTHER - dependent protein BC6OTHER ( BC6ENTC ) deacetylases. CPR:falsenewlineBC6OTHER ( BC6OTHER ) enzymes or BC6ENTG are a family of BC6OTHER - dependent protein BC6OTHER ( BC6ENTC ) deacetylases. CPR:falsenewlineBC6ENTG ( BC6OTHER ) enzymes or BC6OTHER are a family of BC6ENTC - dependent protein BC6OTHER ( BC6OTHER ) deacetylases. CPR:falsenewlineBC6OTHER ( BC6ENTG ) enzymes or BC6OTHER are a family of BC6ENTC - dependent protein BC6OTHER ( BC6OTHER ) deacetylases. CPR:falsenewlineBC6OTHER ( BC6OTHER ) enzymes or BC6ENTG are a family of BC6ENTC - dependent protein BC6OTHER ( BC6OTHER ) deacetylases. CPR:falsenewlineBC6ENTG ( BC6OTHER ) enzymes or BC6OTHER are a family of BC6OTHER - dependent protein BC6ENTC ( BC6OTHER ) deacetylases. CPR:falsenewlineBC6OTHER ( BC6ENTG ) enzymes or BC6OTHER are a family of BC6OTHER - dependent protein BC6ENTC ( BC6OTHER ) deacetylases. CPR:falsenewlineBC6OTHER ( BC6OTHER ) enzymes or BC6ENTG are a family of BC6OTHER - dependent protein BC6ENTC ( BC6OTHER ) deacetylases. CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6ENTC , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6ENTG - activated modulation of BC6OTHER transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6ENTC , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6ENTG transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6ENTG antagonist BC6ENTC , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6OTHER transcription factors. CPR:falsenewlineBC6ENTC pre - treatment also attenuated the BC6OTHER - induced increases in BC6ENTG / BC6OTHER expression, BC6OTHER DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus. CPR:falsenewlineBC6ENTC pre - treatment also attenuated the BC6OTHER - induced increases in BC6OTHER / BC6ENTG expression, BC6OTHER DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus. CPR:falsenewlineBC6ENTC pre - treatment also attenuated the BC6OTHER - induced increases in BC6OTHER / BC6OTHER expression, BC6ENTG DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus. CPR:falsenewlineBC6OTHER pre - treatment also attenuated the BC6ENTC - induced increases in BC6ENTG / BC6OTHER expression, BC6OTHER DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus. CPR:falsenewlineBC6OTHER pre - treatment also attenuated the BC6ENTC - induced increases in BC6OTHER / BC6ENTG expression, BC6OTHER DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus. CPR:falsenewlineBC6OTHER pre - treatment also attenuated the BC6ENTC - induced increases in BC6OTHER / BC6OTHER expression, BC6ENTG DNA - binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus. CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6ENTC or BC6OTHER is, at least in part, related to BC6ENTG - activated modulation of BC6OTHER transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6ENTC or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6ENTG transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6ENTG antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6ENTC or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6OTHER transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6ENTC or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6ENTG - activated modulation of BC6OTHER transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6ENTC or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6ENTG transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6ENTC or BC6OTHER was significantly counteracted by a selective BC6ENTG antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6OTHER transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6ENTC was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6ENTG - activated modulation of BC6OTHER transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6ENTC was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6ENTG transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6ENTC was significantly counteracted by a selective BC6ENTG antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6OTHER is, at least in part, related to BC6OTHER - activated modulation of BC6OTHER transcription factors. CPR:falsenewlineThe BC6OTHER analog BC6OTHER attenuates CHEM - induced seizures via BC6ENTG activation: comparison with the effects of BC6ENTC . CPR:falsenewlineThe BC6OTHER analog BC6ENTC attenuates CHEM - induced seizures via BC6ENTG activation: comparison with the effects of BC6OTHER . CPR:falsenewlineThe BC6ENTC analog BC6OTHER attenuates CHEM - induced seizures via BC6ENTG activation: comparison with the effects of BC6OTHER . CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6ENTC is, at least in part, related to BC6ENTG - activated modulation of BC6OTHER transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6OTHER antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6ENTC is, at least in part, related to BC6OTHER - activated modulation of BC6ENTG transcription factors. CPR:falsenewlineThe anticonvulsant action of BC6OTHER or BC6OTHER was significantly counteracted by a selective BC6ENTG antagonist BC6OTHER , suggesting that the anticonvulsant action of BC6OTHER or BC6ENTC is, at least in part, related to BC6OTHER - activated modulation of BC6OTHER transcription factors. CPR:falsenewlineBC6ENTC and BC6OTHER are high - affinity ligands at BC6ENTG . CPR:falsenewlineBC6OTHER and BC6ENTC are high - affinity ligands at BC6ENTG . CPR:falsenewlineThe expression of key genes important in BC6OTHER metabolism, such as BC6ENTG , BC6OTHER - BC6OTHER methyltransferase and BC6ENTC BC6OTHER - methyltransferase, were suppressed. CPR:falsenewlineThe expression of key genes important in BC6OTHER metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6ENTG and BC6ENTC BC6OTHER - methyltransferase, were suppressed. CPR:falsenewlineThe expression of key genes important in BC6OTHER metabolism, such as BC6ENTG , BC6OTHER - BC6OTHER methyltransferase and CHEM BC6ENTC - methyltransferase, were suppressed. CPR:falsenewlineThe expression of key genes important in BC6OTHER metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6ENTG and CHEM BC6ENTC - methyltransferase, were suppressed. CPR:falsenewlineSeveral genes involved with BC6ENTC metabolism also showed remarkable expression changes, including increased expression of BC6ENTG ( BC6OTHER ; involved in BC6OTHER production) and decreased expression of BC6OTHER (involved in BC6OTHER production). CPR:falsenewlineSeveral genes involved with BC6ENTC metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6ENTG ; involved in BC6OTHER production) and decreased expression of BC6OTHER (involved in BC6OTHER production). CPR:falsenewlineSeveral genes involved with BC6ENTC metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6OTHER ; involved in BC6OTHER production) and decreased expression of BC6ENTG (involved in BC6OTHER production). CPR:falsenewlineVarious genes controlled by BC6ENTC , including BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and small BC6OTHER - rich protein - 2A, were dramatically over - expressed. CPR:falsenewlineVarious genes controlled by BC6ENTC , including BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and small BC6OTHER - rich protein - 2A, were dramatically over - expressed. CPR:falsenewlineVarious genes controlled by BC6ENTC , including BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and small BC6OTHER - rich protein - 2A, were dramatically over - expressed. CPR:falsenewlineVarious genes controlled by BC6ENTC , including BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and small BC6OTHER - rich protein - 2A, were dramatically over - expressed. CPR:falsenewlineVarious genes controlled by BC6ENTC , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and small BC6OTHER - rich protein - 2A, were dramatically over - expressed. CPR:falsenewlineVarious genes controlled by BC6ENTC , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , were dramatically over - expressed. CPR:falsenewlineVarious genes controlled by BC6OTHER , including BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and small BC6ENTC - rich protein - 2A, were dramatically over - expressed. CPR:falsenewlineVarious genes controlled by BC6OTHER , including BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and small BC6ENTC - rich protein - 2A, were dramatically over - expressed. CPR:falsenewlineVarious genes controlled by BC6OTHER , including BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and small BC6ENTC - rich protein - 2A, were dramatically over - expressed. CPR:falsenewlineVarious genes controlled by BC6OTHER , including BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and small BC6ENTC - rich protein - 2A, were dramatically over - expressed. CPR:falsenewlineVarious genes controlled by BC6OTHER , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and small BC6ENTC - rich protein - 2A, were dramatically over - expressed. CPR:falsenewlineBC6ENTC - regulated genes including BC6OTHER and BC6ENTG were over - expressed, although BC6OTHER was suppressed. CPR:falsenewlineBC6ENTC - regulated genes including BC6OTHER and BC6OTHER were over - expressed, although BC6ENTG was suppressed. CPR:falsenewlineBC6ENTC - regulated genes including BC6ENTG and BC6OTHER were over - expressed, although BC6OTHER was suppressed. CPR:falsenewlineSeveral genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6ENTC dehydrogenase - 7 ( BC6ENTG ; involved in BC6OTHER production) and decreased expression of BC6OTHER (involved in BC6OTHER production). CPR:falsenewlineSeveral genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6ENTC dehydrogenase - 7 ( BC6OTHER ; involved in BC6OTHER production) and decreased expression of BC6ENTG (involved in BC6OTHER production). CPR:falsenewlineSeveral genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6ENTG ( BC6OTHER ; involved in BC6ENTC production) and decreased expression of BC6OTHER (involved in BC6OTHER production). CPR:falsenewlineSeveral genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6ENTG ; involved in BC6ENTC production) and decreased expression of BC6OTHER (involved in BC6OTHER production). CPR:falsenewlineSeveral genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6OTHER ; involved in BC6ENTC production) and decreased expression of BC6ENTG (involved in BC6OTHER production). CPR:falsenewlineSeveral genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6ENTG ( BC6OTHER ; involved in BC6OTHER production) and decreased expression of BC6OTHER (involved in BC6ENTC production). CPR:falsenewlineSeveral genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6ENTG ; involved in BC6OTHER production) and decreased expression of BC6OTHER (involved in BC6ENTC production). CPR:falsenewlineSeveral genes involved with BC6OTHER metabolism also showed remarkable expression changes, including increased expression of BC6OTHER ( BC6OTHER ; involved in BC6OTHER production) and decreased expression of BC6ENTG (involved in BC6ENTC production). CPR:falsenewlineThe expression of key genes important in BC6ENTC metabolism, such as BC6ENTG , BC6OTHER - BC6OTHER methyltransferase and CHEM BC6OTHER - methyltransferase, were suppressed. CPR:9newlineThe expression of key genes important in BC6ENTC metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6ENTG and CHEM BC6OTHER - methyltransferase, were suppressed. CPR:9newlineThe expression of key genes important in BC6ENTC metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6OTHER - BC6OTHER methyltransferase and BC6ENTG , were suppressed. CPR:9newlineThe expression of key genes important in BC6OTHER metabolism, such as BC6ENTC adenosyltransferase - 1a, BC6ENTG and CHEM BC6OTHER - methyltransferase, were suppressed. CPR:falsenewlineThe expression of key genes important in BC6OTHER metabolism, such as BC6ENTC adenosyltransferase - 1a, BC6OTHER - BC6OTHER methyltransferase and BC6ENTG , were suppressed. CPR:falsenewlineThe expression of key genes important in BC6OTHER metabolism, such as BC6ENTG , BC6ENTC - BC6OTHER methyltransferase and CHEM BC6OTHER - methyltransferase, were suppressed. CPR:falsenewlineThe expression of key genes important in BC6OTHER metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6ENTC - BC6OTHER methyltransferase and BC6ENTG , were suppressed. CPR:falsenewlineThe expression of key genes important in BC6OTHER metabolism, such as BC6ENTG , BC6OTHER - BC6ENTC methyltransferase and CHEM BC6OTHER - methyltransferase, were suppressed. CPR:falsenewlineThe expression of key genes important in BC6OTHER metabolism, such as BC6OTHER adenosyltransferase - 1a, BC6OTHER - BC6ENTC methyltransferase and BC6ENTG , were suppressed. CPR:falsenewline The BC6OTHER BC6OTHER kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6ENTG ( BC6OTHER ) stimulation. CPR:falsenewline The BC6OTHER BC6OTHER kinase is important for BC6ENTG - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation. CPR:falsenewline The BC6ENTG BC6OTHER kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation. CPR:falsenewline The BC6OTHER BC6ENTG is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation. CPR:falsenewline The BC6OTHER BC6OTHER kinase is important for BC6OTHER - induced BC6ENTG phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation. CPR:falsenewline The BC6OTHER BC6OTHER kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6ENTG is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation. CPR:falsenewline The BC6OTHER BC6OTHER kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTC kinase that is activated in response to BC6OTHER ( BC6ENTG ) stimulation. CPR:falsenewline In the present report, we show that BC6ENTG associates with the activated BC6OTHER ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6ENTC 579, BC6OTHER 581, BC6OTHER 740 and BC6OTHER 1021. CPR:falsenewline In the present report, we show that BC6OTHER associates with the activated BC6ENTG ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6ENTC 579, BC6OTHER 581, BC6OTHER 740 and BC6OTHER 1021. CPR:falsenewline In the present report, we show that BC6OTHER associates with the activated BC6OTHER ( BC6ENTG ) through multiple autophosphorylation sites, i.e. BC6ENTC 579, BC6OTHER 581, BC6OTHER 740 and BC6OTHER 1021. CPR:falsenewline In the present report, we show that BC6ENTG associates with the activated BC6OTHER ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6ENTC 581, BC6OTHER 740 and BC6OTHER 1021. CPR:falsenewline In the present report, we show that BC6OTHER associates with the activated BC6ENTG ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6ENTC 581, BC6OTHER 740 and BC6OTHER 1021. CPR:falsenewline In the present report, we show that BC6OTHER associates with the activated BC6OTHER ( BC6ENTG ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6ENTC 581, BC6OTHER 740 and BC6OTHER 1021. CPR:falsenewline In the present report, we show that BC6ENTG associates with the activated BC6OTHER ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6ENTC 740 and BC6OTHER 1021. CPR:falsenewline In the present report, we show that BC6OTHER associates with the activated BC6ENTG ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6ENTC 740 and BC6OTHER 1021. CPR:falsenewline In the present report, we show that BC6OTHER associates with the activated BC6OTHER ( BC6ENTG ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6ENTC 740 and BC6OTHER 1021. CPR:falsenewline In the present report, we show that BC6ENTG associates with the activated BC6OTHER ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6OTHER 740 and BC6ENTC 1021. CPR:falsenewline In the present report, we show that BC6OTHER associates with the activated BC6ENTG ( BC6OTHER ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6OTHER 740 and BC6ENTC 1021. CPR:falsenewline In the present report, we show that BC6OTHER associates with the activated BC6OTHER ( BC6ENTG ) through multiple autophosphorylation sites, i.e. BC6OTHER 579, BC6OTHER 581, BC6OTHER 740 and BC6ENTC 1021. CPR:falsenewline The BC6OTHER BC6ENTC kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6ENTG that is activated in response to BC6OTHER ( BC6OTHER ) stimulation. CPR:falsenewline The BC6OTHER BC6ENTC kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6OTHER kinase that is activated in response to BC6ENTG ( BC6OTHER ) stimulation. CPR:falsenewline The BC6OTHER BC6ENTC kinase is important for BC6ENTG - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6OTHER kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation. CPR:falsenewline The BC6ENTG BC6ENTC kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6OTHER kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation. CPR:falsenewline The BC6OTHER BC6ENTC kinase is important for BC6OTHER - induced BC6ENTG phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6OTHER kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation. CPR:falsenewline The BC6OTHER BC6ENTC kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6ENTG is a cytoplasmic BC6OTHER kinase that is activated in response to BC6OTHER ( BC6OTHER ) stimulation. CPR:falsenewline The BC6OTHER BC6ENTC kinase is important for BC6OTHER - induced BC6OTHER phosphorylation, colony formation in soft agar and tumor growth in vivo. BC6OTHER is a cytoplasmic BC6OTHER kinase that is activated in response to BC6OTHER ( BC6ENTG ) stimulation. CPR:falsenewline Other ligands (e.g. BC6OTHER for BC6ENTG ; BC6OTHER , BC6OTHER , BC6ENTC for BC6OTHER ) were found to have subtype - selective intrinsic efficacy. CPR:falsenewline Other ligands (e.g. BC6OTHER for BC6OTHER ; BC6OTHER , BC6OTHER , BC6ENTC for BC6ENTG ) were found to have subtype - selective intrinsic efficacy. CPR:falsenewlineEXPERIMENTAL APPROACH: Stable clonal CHO - K1 cell lines, transfected with either the BC6ENTG , were used, and whole - cell BC6ENTC radioligand binding and BC6OTHER accumulation were measured. CPR:falsenewlineEXPERIMENTAL APPROACH: Stable clonal CHO - K1 cell lines, transfected with either the BC6ENTG , were used, and whole - cell BC6OTHER radioligand binding and BC6ENTC accumulation were measured. CPR:falsenewline KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6ENTC and BC6OTHER , for the BC6ENTG over the BC6OTHER or BC6OTHER ), while others (e.g. BC6OTHER ) had little affinity - selectivity. CPR:falsenewline KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6ENTC and BC6OTHER , for the BC6OTHER over the BC6ENTG or BC6OTHER ), while others (e.g. BC6OTHER ) had little affinity - selectivity. CPR:falsenewline KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6ENTC and BC6OTHER , for the BC6OTHER over the BC6OTHER or BC6ENTG ), while others (e.g. BC6OTHER ) had little affinity - selectivity. CPR:falsenewline KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6ENTC , for the BC6ENTG over the BC6OTHER or BC6OTHER ), while others (e.g. BC6OTHER ) had little affinity - selectivity. CPR:falsenewline KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6ENTC , for the BC6OTHER over the BC6ENTG or BC6OTHER ), while others (e.g. BC6OTHER ) had little affinity - selectivity. CPR:falsenewline KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6ENTC , for the BC6OTHER over the BC6OTHER or BC6ENTG ), while others (e.g. BC6OTHER ) had little affinity - selectivity. CPR:falsenewline KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6OTHER , for the BC6ENTG over the BC6OTHER or BC6OTHER ), while others (e.g. BC6ENTC ) had little affinity - selectivity. CPR:falsenewline KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6OTHER , for the BC6OTHER over the BC6ENTG or BC6OTHER ), while others (e.g. BC6ENTC ) had little affinity - selectivity. CPR:falsenewline KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. BC6OTHER and BC6OTHER , for the BC6OTHER over the BC6OTHER or BC6ENTG ), while others (e.g. BC6ENTC ) had little affinity - selectivity. CPR:falsenewline Other ligands (e.g. BC6ENTC for BC6ENTG ; BC6OTHER , BC6OTHER , BC6OTHER for BC6OTHER ) were found to have subtype - selective intrinsic efficacy. CPR:falsenewline Other ligands (e.g. BC6ENTC for BC6OTHER ; BC6OTHER , BC6OTHER , BC6OTHER for BC6ENTG ) were found to have subtype - selective intrinsic efficacy. CPR:falsenewline Other ligands (e.g. BC6OTHER for BC6ENTG ; BC6ENTC , BC6OTHER , BC6OTHER for BC6OTHER ) were found to have subtype - selective intrinsic efficacy. CPR:falsenewline Other ligands (e.g. BC6OTHER for BC6OTHER ; BC6ENTC , BC6OTHER , BC6OTHER for BC6ENTG ) were found to have subtype - selective intrinsic efficacy. CPR:falsenewline Other ligands (e.g. BC6OTHER for BC6ENTG ; BC6OTHER , BC6ENTC , BC6OTHER for BC6OTHER ) were found to have subtype - selective intrinsic efficacy. CPR:falsenewline Other ligands (e.g. BC6OTHER for BC6OTHER ; BC6OTHER , BC6ENTC , BC6OTHER for BC6ENTG ) were found to have subtype - selective intrinsic efficacy. CPR:falsenewlineBC6OTHER was crystallized with the ligand - binding domain of BC6ENTG , and the structure revealed a complex containing BC6ENTC at the CHEM binding site. CPR:falsenewlineBC6ENTC locks the BC6ENTG in an open form, consistent with a pharmacological action as competitive antagonist of BC6OTHER . CPR:falsenewlineBC6ENTC locks the BC6OTHER in an open form, consistent with a pharmacological action as competitive antagonist of BC6ENTG . CPR:falsenewlineStudies on an BC6OTHER BC6ENTG antagonist BC6ENTC : asymmetric synthesis, neuroactivity, and structural characterization. CPR:6newlineStudies on an BC6ENTC BC6ENTG antagonist BC6OTHER : asymmetric synthesis, neuroactivity, and structural characterization. CPR:falsenewlineBC6ENTC was developed and identified as a member of a new class of heterotricyclic BC6OTHER analogues that act as BC6ENTG - selective antagonists. CPR:6newlineBC6ENTC was crystallized with the ligand - binding domain of BC6ENTG , and the structure revealed a complex containing BC6OTHER at the CHEM binding site. CPR:falsenewlineBC6OTHER was developed and identified as a member of a new class of heterotricyclic BC6ENTC analogues that act as BC6ENTG - selective antagonists. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6ENTC and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and BC6ENTG [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6ENTC and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6ENTC and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTG , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6ENTC and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6ENTC or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and BC6ENTG [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6ENTC or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6ENTC or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTG , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6ENTC or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6ENTC BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and BC6ENTG [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6ENTC BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6ENTC BC6OTHER - methyltransferase, BC6ENTG , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6ENTC BC6OTHER - methyltransferase, BC6OTHER , BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6ENTC - methyltransferase, BC6OTHER , BC6OTHER , and BC6ENTG [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6ENTC - methyltransferase, BC6OTHER , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6ENTC - methyltransferase, BC6ENTG , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6ENTC - methyltransferase, BC6OTHER , BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTC binding protein beta polypeptide 3, BC6OTHER , and BC6ENTG [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTC binding protein beta polypeptide 3, BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTC binding protein beta polypeptide 3, BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6OTHER ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6ENTC ] member 4 [homo sapiens] [ BC6ENTG ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6ENTG , BC6OTHER , and solute carrier family 6 [neurotransmitter transporter, BC6ENTC ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe influence of candidate gene polymorphisms involved in BC6OTHER and BC6OTHER or receptor function ( BC6OTHER BC6OTHER - methyltransferase, BC6OTHER , BC6ENTG , and solute carrier family 6 [neurotransmitter transporter, BC6ENTC ] member 4 [homo sapiens] [ BC6OTHER ]) on weight loss and gastric functions was evaluated. CPR:falsenewlineThe BC6ENTC group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial BC6ENTG compared with the placebo group. CPR:falsenewlineThe LS / SS genotype of the promoter for BC6ENTG was associated with enhanced weight loss with BC6ENTC . CPR:falsenewlineCONCLUSIONS: Weight reduction with BC6ENTC is associated with altered gastric functions and increased BC6ENTG and is significantly associated with BC6OTHER genotype. CPR:3newlineCONCLUSIONS: Weight reduction with BC6ENTC is associated with altered gastric functions and increased BC6OTHER and is significantly associated with BC6ENTG genotype. CPR:falsenewlineThe role of genetic variation in BC6ENTG on weight loss in response to BC6ENTC deserves further study. CPR:falsenewlineBC6ENTG treatment of complex IV prevented trimer formation in the absence of BC6ENTC . CPR:falsenewlineWe have examined the effectiveness of two novel BC6ENTG selective inhibitors, BC6ENTC and BC6OTHER , in a panel of melanoma cell lines and normal cell types. CPR:4newlineWe have examined the effectiveness of two novel BC6ENTG selective inhibitors, BC6OTHER and BC6ENTC , in a panel of melanoma cell lines and normal cell types. CPR:4newlineCONTEXT: BC6ENTC is a novel BC6ENTG and BC6OTHER selective agonist recently approved for insomnia treatment. CPR:5newlineCONTEXT: BC6ENTC is a novel BC6OTHER and BC6ENTG selective agonist recently approved for insomnia treatment. CPR:5newlineBACKGROUND: A mutation in the cardiac BC6ENTC channel gene ( BC6ENTG ) has been described in patients with the syndrome of right bundle branch block, ST - segment elevation in leads V1 to V3, and sudden death (Brugada syndrome). CPR:falsenewlineMETHODS AND RESULTS: The effect of intravenous BC6ENTC (1 mg / kg), BC6OTHER (10 mg / kg), or BC6OTHER (2 mg / kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a BC6ENTG mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C). CPR:falsenewlineMETHODS AND RESULTS: The effect of intravenous BC6OTHER (1 mg / kg), BC6ENTC (10 mg / kg), or BC6OTHER (2 mg / kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a BC6ENTG mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C). CPR:falsenewlineMETHODS AND RESULTS: The effect of intravenous BC6OTHER (1 mg / kg), BC6OTHER (10 mg / kg), or BC6ENTC (2 mg / kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a BC6ENTG mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C). CPR:falsenewlineBC6ENTC is a potent and selective BC6ENTG antagonist. CPR:6newlinerespectively) for the BC6ENTG in receptor binding and in functional studies (42 - and 29 - fold, respectively) measuring BC6ENTC changes using a cell - based luciferase reporter gene assay. CPR:falsenewlineThese findings demonstrate that the addition of spacer linkages to bivalent BC6ENTC molecules provides a successful approach to the development of ligands that are potent and highly selective for the BC6ENTG . CPR:falsenewlineInitial studies showed that BC6ENTC was about 4 - and 15 - fold more selective for the BC6ENTG in comparison with the BC6OTHER , respectively. CPR:falsenewlineInitial studies showed that BC6ENTC was about 4 - and 15 - fold more selective for the BC6OTHER in comparison with the BC6ENTG , respectively. CPR:falsenewlineTo improve on this BC6ENTG subtype selectivity, a series of BC6ENTC dimers (varying from n = 2 to 24 spacer atoms) were prepared and evaluated for receptor binding on BC6OTHER subtypes expressed in Chinese hamster ovary cells. CPR:falsenewlineTo improve on this BC6OTHER subtype selectivity, a series of BC6ENTC dimers (varying from n = 2 to 24 spacer atoms) were prepared and evaluated for receptor binding on BC6ENTG subtypes expressed in Chinese hamster ovary cells. CPR:falsenewlineEach dimeric analog showed higher affinities for BC6ENTG versus the BC6OTHER ; and BC6ENTC dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the BC6OTHER . CPR:falsenewlineEach dimeric analog showed higher affinities for BC6OTHER versus the BC6ENTG ; and BC6ENTC dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the BC6OTHER . CPR:falsenewlineEach dimeric analog showed higher affinities for BC6OTHER versus the BC6OTHER ; and BC6ENTC dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the BC6ENTG . CPR:falsenewline BC6ENTC dimers exhibiting selectivity for the BC6ENTG subtype. CPR:falsenewlineStriatal BC6ENTG protein ( - 25 to - 46%) and BC6OTHER ( - 17 to - 22%) were reduced, whereas BC6OTHER determined by BC6ENTC binding was normal. CPR:falsenewlineStriatal BC6OTHER protein ( - 25 to - 46%) and BC6ENTG ( - 17 to - 22%) were reduced, whereas BC6OTHER determined by BC6ENTC binding was normal. CPR:falsenewlineStriatal BC6OTHER protein ( - 25 to - 46%) and BC6OTHER ( - 17 to - 22%) were reduced, whereas BC6ENTG determined by BC6ENTC binding was normal. CPR:falsenewlineIn conclusion, our data suggest that chronic BC6ENTC use is associated with modestly reduced levels of striatal BC6OTHER and the BC6ENTG in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug. CPR:falsenewlineIn conclusion, our data suggest that chronic BC6OTHER use is associated with modestly reduced levels of striatal BC6ENTC and the BC6ENTG in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug. CPR:falsenewlineStriatal BC6OTHER , BC6ENTC transporter, and BC6ENTG in chronic BC6OTHER users. CPR:falsenewlineStriatal BC6OTHER , BC6ENTG , and vesicular BC6ENTC transporter in chronic BC6OTHER users. CPR:falsenewlineStriatal BC6OTHER , BC6ENTG , and vesicular BC6OTHER transporter in chronic BC6ENTC users. CPR:falsenewlineStriatal BC6OTHER , BC6OTHER , and BC6ENTG in chronic BC6ENTC users. CPR:falsenewlineStriatal BC6ENTC , BC6ENTG , and vesicular BC6OTHER transporter in chronic BC6OTHER users. CPR:falsenewlineStriatal BC6ENTC , BC6OTHER , and BC6ENTG in chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6ENTC , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTG ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6ENTC , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6ENTG ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6ENTC , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the BC6ENTG ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6ENTC , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6ENTG ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6ENTC nerve terminal indices, namely, the BC6ENTG ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6ENTC nerve terminal indices, namely, the BC6OTHER transporter ( BC6ENTG ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6ENTC nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the BC6ENTG ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6ENTC nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6ENTG ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTC transporter ( BC6ENTG ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTC transporter ( BC6OTHER ) and the BC6ENTG ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTC transporter ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6ENTG ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTG ( BC6OTHER ) and the vesicular BC6ENTC transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6ENTG ) and the vesicular BC6ENTC transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the vesicular BC6ENTC transporter ( BC6ENTG ) in autopsied brain of 12 chronic BC6OTHER users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6ENTG ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6ENTC users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6ENTG ) and the vesicular BC6OTHER transporter ( BC6OTHER ) in autopsied brain of 12 chronic BC6ENTC users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the BC6ENTG ( BC6OTHER ) in autopsied brain of 12 chronic BC6ENTC users. CPR:falsenewlineWe measured levels of BC6OTHER , as well as two BC6OTHER nerve terminal indices, namely, the BC6OTHER transporter ( BC6OTHER ) and the vesicular BC6OTHER transporter ( BC6ENTG ) in autopsied brain of 12 chronic BC6ENTC users. CPR:falsenewlineThe expression of BC6ENTG and BC6OTHER was induced by BC6OTHER , as well as BC6OTHER and BC6ENTC , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6ENTG was induced by BC6OTHER , as well as BC6OTHER and BC6ENTC , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6OTHER and BC6ENTC , which are ligands of the BC6ENTG BC6OTHER / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6OTHER and BC6ENTC , which are ligands of the BC6OTHER BC6ENTG / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6OTHER and BC6ENTC , which are ligands of the BC6OTHER BC6OTHER / BC6ENTG . CPR:falsenewlineWhen the expression of BC6ENTG and BC6OTHER was induced, BC6ENTC efflux was stimulated in the presence of BC6OTHER ( BC6OTHER ), whereas BC6OTHER was not an efficient acceptor. CPR:9newlineWhen the expression of BC6OTHER and BC6ENTG was induced, BC6ENTC efflux was stimulated in the presence of BC6OTHER ( BC6OTHER ), whereas BC6OTHER was not an efficient acceptor. CPR:9newlineWhen the expression of BC6OTHER and BC6OTHER was induced, BC6ENTC efflux was stimulated in the presence of BC6ENTG ( BC6OTHER ), whereas BC6OTHER was not an efficient acceptor. CPR:9newlineWhen the expression of BC6OTHER and BC6OTHER was induced, BC6ENTC efflux was stimulated in the presence of BC6OTHER ( BC6ENTG ), whereas BC6OTHER was not an efficient acceptor. CPR:9newlineWhen the expression of BC6OTHER and BC6OTHER was induced, BC6ENTC efflux was stimulated in the presence of BC6OTHER ( BC6OTHER ), whereas BC6ENTG was not an efficient acceptor. CPR:9newlineTo confirm the role of each transporter, we analyzed HEK293 cells stably expressing BC6OTHER or BC6OTHER ; we clearly observed BC6ENTC efflux in the presence of BC6ENTG , whereas efflux in the presence of BC6OTHER was marginal. CPR:falsenewlineTo confirm the role of each transporter, we analyzed HEK293 cells stably expressing BC6OTHER or BC6OTHER ; we clearly observed BC6ENTC efflux in the presence of BC6OTHER , whereas efflux in the presence of BC6ENTG was marginal. CPR:falsenewlineTo confirm the role of each transporter, we analyzed HEK293 cells stably expressing BC6ENTG or BC6OTHER ; we clearly observed BC6ENTC efflux in the presence of BC6OTHER , whereas efflux in the presence of BC6OTHER was marginal. CPR:falsenewlineTo confirm the role of each transporter, we analyzed HEK293 cells stably expressing BC6OTHER or BC6ENTG ; we clearly observed BC6ENTC efflux in the presence of BC6OTHER , whereas efflux in the presence of BC6OTHER was marginal. CPR:falsenewline BC6ENTC is actively eliminated from neuronal cells by BC6ENTG . CPR:9newlineFurthermore, the treatment of primary cerebral neurons with BC6ENTG / BC6OTHER ligands suppressed the toxicity of BC6ENTC . CPR:falsenewlineFurthermore, the treatment of primary cerebral neurons with BC6OTHER / BC6ENTG ligands suppressed the toxicity of BC6ENTC . CPR:falsenewlineThese results suggest that BC6ENTG actively eliminates BC6ENTC in the presence of BC6OTHER as a lipid acceptor and protects neuronal cells. CPR:falsenewlineThese results suggest that BC6OTHER actively eliminates BC6ENTC in the presence of BC6ENTG as a lipid acceptor and protects neuronal cells. CPR:falsenewlineBecause BC6ENTC ( BC6OTHER ), produced by BC6ENTG , induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells. CPR:falsenewlineBecause BC6OTHER ( BC6ENTC ), produced by BC6ENTG , induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells. CPR:falsenewlineHere, using differentiated SH - SY5Y neuron - like cells as a model, we examined whether BC6ENTC is actively eliminated via BC6ENTG induced by its accumulation. CPR:9newlineThe expression of BC6ENTG and BC6OTHER was induced by BC6ENTC , as well as BC6OTHER and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6ENTG was induced by BC6ENTC , as well as BC6OTHER and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6OTHER was induced by BC6ENTC , as well as BC6OTHER and BC6OTHER , which are ligands of the BC6ENTG BC6OTHER / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6OTHER was induced by BC6ENTC , as well as BC6OTHER and BC6OTHER , which are ligands of the BC6OTHER BC6ENTG / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6OTHER was induced by BC6ENTC , as well as BC6OTHER and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6ENTG . CPR:falsenewlineThe expression of BC6ENTG and BC6OTHER was induced by BC6OTHER , as well as BC6ENTC and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6ENTG was induced by BC6OTHER , as well as BC6ENTC and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6ENTC and BC6OTHER , which are ligands of the BC6ENTG BC6OTHER / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6ENTC and BC6OTHER , which are ligands of the BC6OTHER BC6ENTG / BC6OTHER . CPR:falsenewlineThe expression of BC6OTHER and BC6OTHER was induced by BC6OTHER , as well as BC6ENTC and BC6OTHER , which are ligands of the BC6OTHER BC6OTHER / BC6ENTG . CPR:falsenewlineHigh BC6ENTC turnover catalyzed by BC6ENTG is essential for neural functions, especially learning. CPR:9newlineBC6ENTG conjugated with BC6OTHER ( BC6OTHER - HIS) has been used for the demonstration of BC6ENTC receptors on human platelets. CPR:falsenewlineBC6OTHER conjugated with BC6OTHER ( BC6ENTG - HIS) has been used for the demonstration of BC6ENTC receptors on human platelets. CPR:falsenewlineThe binding of BC6ENTG - HIS was inhibited on 35 - 79% of the platelets by the BC6ENTC H1 receptor antagonists BC6OTHER and BC6OTHER . CPR:falsenewlineThe binding of BC6ENTG - HIS was inhibited on 35 - 79% of the platelets by the BC6OTHER H1 receptor antagonists BC6ENTC and BC6OTHER . CPR:falsenewlineThe binding of BC6OTHER - HIS was inhibited on 35 - 79% of the platelets by the BC6ENTG antagonists BC6ENTC and BC6OTHER . CPR:falsenewlineThe binding of BC6ENTG - HIS was inhibited on 35 - 79% of the platelets by the BC6OTHER H1 receptor antagonists BC6OTHER and BC6ENTC . CPR:falsenewlineThe binding of BC6OTHER - HIS was inhibited on 35 - 79% of the platelets by the BC6ENTG antagonists BC6OTHER and BC6ENTC . CPR:falsenewlineThe BC6ENTC H2 receptor antagonist BC6OTHER blocked the BC6ENTG - HIS binding on 14 - 37% of the platelets. CPR:falsenewlineThe BC6ENTG antagonist BC6ENTC blocked the BC6OTHER - HIS binding on 14 - 37% of the platelets. CPR:falsenewlineThe BC6OTHER H2 receptor antagonist BC6ENTC blocked the BC6ENTG - HIS binding on 14 - 37% of the platelets. CPR:falsenewlineBC6ENTG conjugated with BC6ENTC ( BC6OTHER - HIS) has been used for the demonstration of BC6OTHER receptors on human platelets. CPR:falsenewlineBC6OTHER conjugated with BC6ENTC ( BC6OTHER - HIS) has been used for the demonstration of BC6ENTG on human platelets. CPR:falsenewlineBC6OTHER conjugated with BC6ENTC ( BC6ENTG - HIS) has been used for the demonstration of BC6OTHER receptors on human platelets. CPR:falsenewlineIt is concluded that BC6ENTC H1 as well as BC6ENTG occur on human platelets but the receptors are not equally distributed in the platelet population. CPR:falsenewlineBlood pressure was increased in rats exposed to IH, and treatment with the BC6ENTG inhibitor BC6ENTC [ BC6OTHER ] (33 mg / day) lowered blood pressure in IH but not sham group rats. CPR:4newlineBlood pressure was increased in rats exposed to IH, and treatment with the BC6ENTG inhibitor BC6OTHER [ BC6ENTC ] (33 mg / day) lowered blood pressure in IH but not sham group rats. CPR:4newlinemRNA levels for BC6ENTG , BC6OTHER and BC6OTHER , the BC6OTHER for BC6ENTC , decreased during activation of freshly isolated HSC even with BC6OTHER supplementation. CPR:falsenewlinemRNA levels for BC6OTHER , BC6ENTG and BC6OTHER , the BC6OTHER for BC6ENTC , decreased during activation of freshly isolated HSC even with BC6OTHER supplementation. CPR:falsenewlinemRNA levels for BC6OTHER , BC6OTHER and BC6ENTG , the BC6OTHER for BC6ENTC , decreased during activation of freshly isolated HSC even with BC6OTHER supplementation. CPR:falsenewlinemRNA levels for BC6OTHER , BC6OTHER and BC6OTHER , the BC6ENTG for BC6ENTC , decreased during activation of freshly isolated HSC even with BC6OTHER supplementation. CPR:falsenewlinemRNA levels for BC6ENTG , BC6OTHER and BC6OTHER , the BC6OTHER for BC6OTHER , decreased during activation of freshly isolated HSC even with BC6ENTC supplementation. CPR:falsenewlinemRNA levels for BC6OTHER , BC6ENTG and BC6OTHER , the BC6OTHER for BC6OTHER , decreased during activation of freshly isolated HSC even with BC6ENTC supplementation. CPR:falsenewlinemRNA levels for BC6OTHER , BC6OTHER and BC6ENTG , the BC6OTHER for BC6OTHER , decreased during activation of freshly isolated HSC even with BC6ENTC supplementation. CPR:falsenewlinemRNA levels for BC6OTHER , BC6OTHER and BC6OTHER , the BC6ENTG for BC6OTHER , decreased during activation of freshly isolated HSC even with BC6ENTC supplementation. CPR:falsenewlineBC6OTHER , BC6OTHER and BC6ENTG mRNA and BC6OTHER protein was undetectable in chronically activated HSC and remained absent after BC6ENTC supplementation. CPR:falsenewlineBC6OTHER , BC6OTHER and BC6OTHER mRNA and BC6ENTG protein was undetectable in chronically activated HSC and remained absent after BC6ENTC supplementation. CPR:falsenewlineBC6ENTG , BC6OTHER and BC6OTHER mRNA and BC6OTHER protein was undetectable in chronically activated HSC and remained absent after BC6ENTC supplementation. CPR:falsenewlineBC6OTHER , BC6ENTG and BC6OTHER mRNA and BC6OTHER protein was undetectable in chronically activated HSC and remained absent after BC6ENTC supplementation. CPR:falsenewlineMany stimuli cause HSC to activate, lose their BC6ENTC and produce BC6ENTG . CPR:falsenewlineWe also determine if BC6ENTC : (1) reverse HSC activation; (2) maintain / restore HSC intracellular BC6OTHER levels; (3) maintain expression of HSC BC6ENTG ( BC6OTHER ) in HSC that are becoming activated or are chronically activated. CPR:falsenewlineWe also determine if BC6ENTC : (1) reverse HSC activation; (2) maintain / restore HSC intracellular BC6OTHER levels; (3) maintain expression of HSC nuclear receptors for BC6OTHER ( BC6ENTG ) in HSC that are becoming activated or are chronically activated. CPR:falsenewlineWe also determine if BC6OTHER : (1) reverse HSC activation; (2) maintain / restore HSC intracellular BC6ENTC levels; (3) maintain expression of HSC BC6ENTG ( BC6OTHER ) in HSC that are becoming activated or are chronically activated. CPR:falsenewlineWe also determine if BC6OTHER : (1) reverse HSC activation; (2) maintain / restore HSC intracellular BC6ENTC levels; (3) maintain expression of HSC nuclear receptors for BC6OTHER ( BC6ENTG ) in HSC that are becoming activated or are chronically activated. CPR:falsenewlineWe also determine if BC6OTHER : (1) reverse HSC activation; (2) maintain / restore HSC intracellular BC6OTHER levels; (3) maintain expression of HSC nuclear receptors for BC6ENTC ( BC6ENTG ) in HSC that are becoming activated or are chronically activated. CPR:falsenewlineUsing computer analysis, we recently identified nuclear BC6ENTG ( BC6OTHER ) binding sites termed " BC6ENTC response elements" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No. CPR:falsenewlineUsing computer analysis, we recently identified nuclear BC6OTHER receptor ( BC6ENTG ) binding sites termed " BC6ENTC response elements" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No. CPR:falsenewlineUsing computer analysis, we recently identified nuclear BC6OTHER receptor ( BC6OTHER ) binding sites termed " BC6ENTC response elements" ( BC6ENTG ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No. CPR:falsenewlineUsing computer analysis, we recently identified nuclear BC6OTHER receptor ( BC6OTHER ) binding sites termed " BC6ENTC response elements" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6ENTG BC6OTHER (Accession No. CPR:falsenewlineUsing computer analysis, we recently identified nuclear BC6OTHER receptor ( BC6OTHER ) binding sites termed " BC6ENTC response elements" ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6ENTG (Accession No. CPR:falsenewlineAs these regulatory motifs mediate regulation of target genes by BC6ENTG agonists including BC6ENTC and BC6OTHER , we have systematically investigated the effect of both contaminants on functional BC6OTHER transport activity in primary bovine mammary epithelial cells. CPR:falsenewlineAs these regulatory motifs mediate regulation of target genes by BC6OTHER agonists including BC6ENTC and BC6OTHER , we have systematically investigated the effect of both contaminants on functional BC6ENTG transport activity in primary bovine mammary epithelial cells. CPR:9newlineAs these regulatory motifs mediate regulation of target genes by BC6ENTG agonists including BC6OTHER and BC6ENTC , we have systematically investigated the effect of both contaminants on functional BC6OTHER transport activity in primary bovine mammary epithelial cells. CPR:falsenewlineAs these regulatory motifs mediate regulation of target genes by BC6OTHER agonists including BC6OTHER and BC6ENTC , we have systematically investigated the effect of both contaminants on functional BC6ENTG transport activity in primary bovine mammary epithelial cells. CPR:9newlineBC6ENTC or BC6OTHER doubled BC6ENTG - mediated BC6OTHER secretion. CPR:falsenewlineBC6OTHER or BC6ENTC doubled BC6ENTG - mediated BC6OTHER secretion. CPR:falsenewlineBC6OTHER or BC6OTHER doubled BC6ENTG - mediated BC6ENTC secretion. CPR:9newlineThis effect was almost completely reversed by specific BC6ENTG inhibitor BC6ENTC . CPR:falsenewlineFungicide BC6ENTC and environmental pollutant BC6OTHER induce the BC6OTHER transporter in bovine mammary epithelial cells by the BC6ENTG signaling pathway. CPR:falsenewlineFungicide BC6ENTC and environmental pollutant BC6OTHER induce the BC6ENTG transporter in bovine mammary epithelial cells by the BC6OTHER signaling pathway. CPR:falsenewlineFungicide BC6OTHER and environmental pollutant BC6OTHER induce the BC6ENTG transporter in bovine mammary epithelial cells by the BC6ENTC receptor signaling pathway. CPR:falsenewlineFungicide BC6OTHER and environmental pollutant BC6ENTC induce the BC6OTHER transporter in bovine mammary epithelial cells by the BC6ENTG signaling pathway. CPR:falsenewlineFungicide BC6OTHER and environmental pollutant BC6ENTC induce the BC6ENTG transporter in bovine mammary epithelial cells by the BC6OTHER signaling pathway. CPR:falsenewlineReceptor binding was significantly reduced by specific BC6ENTG antagonist BC6ENTC . CPR:falsenewlineInduction of BC6ENTG by BC6ENTC and BC6OTHER resulted in a time - and dose - dependent increase of BC6OTHER gene expression and transporter protein levels. CPR:9newlineInduction of BC6OTHER by BC6ENTC and BC6OTHER resulted in a time - and dose - dependent increase of BC6ENTG gene expression and transporter protein levels. CPR:9newlineInduction of BC6ENTG by BC6OTHER and BC6ENTC resulted in a time - and dose - dependent increase of BC6OTHER gene expression and transporter protein levels. CPR:9newlineInduction of BC6OTHER by BC6OTHER and BC6ENTC resulted in a time - and dose - dependent increase of BC6ENTG gene expression and transporter protein levels. CPR:9newlineThrough identification of mammary BC6ENTG as a novel target gene of pesticide BC6ENTC and BC6OTHER , our results may therefore help to improve the protection of breast - feeding infants and the consumer of dairy products. CPR:falsenewlineThrough identification of mammary BC6ENTG as a novel target gene of pesticide BC6OTHER and BC6ENTC , our results may therefore help to improve the protection of breast - feeding infants and the consumer of dairy products. CPR:falsenewlineUsing computer analysis, we recently identified nuclear BC6ENTC receptor ( BC6ENTG ) binding sites termed " BC6OTHER " ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No. CPR:falsenewlineUsing computer analysis, we recently identified nuclear BC6ENTC receptor ( BC6OTHER ) binding sites termed " BC6ENTG " ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No. CPR:falsenewlineUsing computer analysis, we recently identified nuclear BC6ENTC receptor ( BC6OTHER ) binding sites termed " BC6OTHER " ( BC6ENTG ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6OTHER (Accession No. CPR:falsenewlineUsing computer analysis, we recently identified nuclear BC6ENTC receptor ( BC6OTHER ) binding sites termed " BC6OTHER " ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6ENTG BC6OTHER (Accession No. CPR:falsenewlineUsing computer analysis, we recently identified nuclear BC6ENTC receptor ( BC6OTHER ) binding sites termed " BC6OTHER " ( BC6OTHER ) in the 5' - untranslated region (5' - UTR) of BC6OTHER BC6ENTG (Accession No. CPR:falsenewlinePhysicians should consider using low - dose BC6ENTC and BC6ENTG activated in the treatment of patients who have vasopressor - dependent septic shock with persistent signs of hypoperfusion, organ dysfunction, or hypotension. CPR:falsenewlineThis article summarizes the current knowledge on the benefit / risk profile from the use of low - dose BC6ENTC and BC6ENTG in treating septic shock. CPR:falsenewline BC6ENTC and BC6ENTG for septic shock. CPR:falsenewlineMATERIALS AND METHODS: Methylation of BC6ENTC sulfotransferase pi ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) genes was studied using methylation sensitive PCR (MS - PCR). CPR:falsenewlineMATERIALS AND METHODS: Methylation of BC6ENTC sulfotransferase pi ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) genes was studied using methylation sensitive PCR (MS - PCR). CPR:falsenewlineMATERIALS AND METHODS: Methylation of BC6ENTC sulfotransferase pi ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) genes was studied using methylation sensitive PCR (MS - PCR). CPR:falsenewlineWe postulate that this conserved BC6ENTC residue provides a flexible hinge within the BC6ENTG catalytic pocket to facilitate linker dynamics and the structural alterations that accompany drug binding of the covalent enzyme - DNA intermediate. CPR:falsenewlineBC6ENTG is the cellular target of the anti - cancer drug BC6ENTC ( BC6OTHER ), which reversibly stabilizes a covalent enzyme - DNA intermediate. CPR:falsenewlineBC6ENTG is the cellular target of the anti - cancer drug BC6OTHER ( BC6ENTC ), which reversibly stabilizes a covalent enzyme - DNA intermediate. CPR:falsenewlineBC6ENTG clamps around duplex DNA, wherein the core and BC6ENTC - terminal domains are connected by extended BC6OTHER ( BC6OTHER ), which position the active site BC6OTHER of the BC6OTHER - terminal domain within the catalytic pocket. CPR:falsenewlineBC6OTHER clamps around duplex DNA, wherein the core and BC6ENTC - terminal domains are connected by extended BC6ENTG ( BC6OTHER ), which position the active site BC6OTHER of the BC6OTHER - terminal domain within the catalytic pocket. CPR:falsenewlineBC6OTHER clamps around duplex DNA, wherein the core and BC6ENTC - terminal domains are connected by extended BC6OTHER ( BC6ENTG ), which position the active site BC6OTHER of the BC6OTHER - terminal domain within the catalytic pocket. CPR:falsenewlineWe report that mutation of this conserved BC6ENTC in BC6ENTG alters enzyme sensitivity to BC6OTHER . CPR:falsenewlineBC6ENTG clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6OTHER ( BC6OTHER ), which position the active site BC6ENTC of the BC6OTHER - terminal domain within the catalytic pocket. CPR:falsenewlineBC6OTHER clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6ENTG ( BC6OTHER ), which position the active site BC6ENTC of the BC6OTHER - terminal domain within the catalytic pocket. CPR:falsenewlineBC6OTHER clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6OTHER ( BC6ENTG ), which position the active site BC6ENTC of the BC6OTHER - terminal domain within the catalytic pocket. CPR:falsenewlineBC6ENTG clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6OTHER ( BC6OTHER ), which position the active site BC6OTHER of the BC6ENTC - terminal domain within the catalytic pocket. CPR:falsenewlineBC6OTHER clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6ENTG ( BC6OTHER ), which position the active site BC6OTHER of the BC6ENTC - terminal domain within the catalytic pocket. CPR:falsenewlineBC6OTHER clamps around duplex DNA, wherein the core and BC6OTHER - terminal domains are connected by extended BC6OTHER ( BC6ENTG ), which position the active site BC6OTHER of the BC6ENTC - terminal domain within the catalytic pocket. CPR:falsenewlineThe physical connection of the linker with the BC6ENTG clamp as well as linker flexibility affect enzyme sensitivity to BC6ENTC . CPR:falsenewlineCrystallographic data reveal that a conserved BC6ENTC residue (located at the juncture between the linker and BC6OTHER - terminal domains) is at one end of a short BC6ENTG , which extends to the active site BC6OTHER covalently linked to the DNA. CPR:falsenewlineCrystallographic data reveal that a conserved BC6OTHER residue (located at the juncture between the linker and BC6ENTC - terminal domains) is at one end of a short BC6ENTG , which extends to the active site BC6OTHER covalently linked to the DNA. CPR:falsenewlineCrystallographic data reveal that a conserved BC6OTHER residue (located at the juncture between the linker and BC6OTHER - terminal domains) is at one end of a short BC6ENTG , which extends to the active site BC6ENTC covalently linked to the DNA. CPR:falsenewlineIn the presence of drug, the linker is rigid and this BC6ENTG extends to include BC6ENTC and the preceding BC6OTHER . CPR:falsenewlineIn the presence of drug, the linker is rigid and this BC6ENTG extends to include BC6OTHER and the preceding BC6ENTC . CPR:falsenewlineMutation of CHEM721 alters BC6ENTG active site architecture and sensitivity to BC6ENTC . CPR:falsenewlineWe report that mutation of this conserved BC6OTHER in BC6ENTG alters enzyme sensitivity to BC6ENTC . CPR:falsenewlineOf the antihypertensive agents, CHEM is now rarely prescribed and adverse effects are reported infrequently, whereas cases of liver injury associated with the BC6ENTC receptor and BC6ENTG inhibitors are increasingly reported. CPR:falsenewlineOf the antidiabetic agents, BC6ENTC , BC6OTHER , BC6OTHER , and BC6ENTG have been implicated in causing liver injury. CPR:falsenewlineOf the antidiabetic agents, BC6OTHER , BC6ENTC , BC6OTHER , and BC6ENTG have been implicated in causing liver injury. CPR:falsenewlineOf the antidiabetic agents, BC6OTHER , BC6OTHER , BC6ENTC , and BC6ENTG have been implicated in causing liver injury. CPR:falsenewlineRice with high BC6ENTC content in seed endosperm has been developed by insertion of BC6ENTG gene under the control of the endosperm specific BC6OTHER into the genome of indica rice line IR68144. CPR:falsenewlineRice with high BC6ENTC content in seed endosperm has been developed by insertion of BC6OTHER gene under the control of the endosperm specific BC6ENTG into the genome of indica rice line IR68144. CPR:falsenewline BC6ENTC prevents cardiac hypertrophy and overexpression of BC6ENTG and BC6OTHER in pressure - overloaded rat heart. CPR:falsenewline BC6ENTC prevents cardiac hypertrophy and overexpression of BC6OTHER and BC6ENTG in pressure - overloaded rat heart. CPR:falsenewlineTreatment with BC6ENTC , BC6OTHER , or BC6OTHER did not significantly affect BC6ENTG and BC6OTHER proteins expression in the banding groups. CPR:falsenewlineTreatment with BC6ENTC , BC6OTHER , or BC6OTHER did not significantly affect BC6OTHER and BC6ENTG proteins expression in the banding groups. CPR:falsenewlineTreatment with BC6OTHER , BC6ENTC , or BC6OTHER did not significantly affect BC6ENTG and BC6OTHER proteins expression in the banding groups. CPR:falsenewlineTreatment with BC6OTHER , BC6ENTC , or BC6OTHER did not significantly affect BC6OTHER and BC6ENTG proteins expression in the banding groups. CPR:falsenewlineTreatment with BC6OTHER , BC6OTHER , or BC6ENTC did not significantly affect BC6ENTG and BC6OTHER proteins expression in the banding groups. CPR:falsenewlineTreatment with BC6OTHER , BC6OTHER , or BC6ENTC did not significantly affect BC6OTHER and BC6ENTG proteins expression in the banding groups. CPR:falsenewlineTreatment with BC6ENTC reversed both protein and mRNA of BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER to the baseline values. CPR:falsenewlineTreatment with BC6ENTC reversed both protein and mRNA of BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER to the baseline values. CPR:falsenewlineTreatment with BC6ENTC reversed both protein and mRNA of BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER to the baseline values. CPR:falsenewlineTreatment with BC6ENTC reversed both protein and mRNA of BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG to the baseline values. CPR:falsenewlineIncreased immunohistochemical labeling of BC6ENTG , BC6OTHER , and BC6OTHER in the ventricular myocardium was observed in the banding group and BC6ENTC again normalized the labeling. CPR:falsenewlineIncreased immunohistochemical labeling of BC6OTHER , BC6ENTG , and BC6OTHER in the ventricular myocardium was observed in the banding group and BC6ENTC again normalized the labeling. CPR:falsenewlineIncreased immunohistochemical labeling of BC6OTHER , BC6OTHER , and BC6ENTG in the ventricular myocardium was observed in the banding group and BC6ENTC again normalized the labeling. CPR:falsenewlineTreatment with BC6ENTC is associated with a reversal of abnormal regulation of BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER in the hypertrophic myocardium. CPR:falsenewlineTreatment with BC6ENTC is associated with a reversal of abnormal regulation of BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER in the hypertrophic myocardium. CPR:falsenewlineTreatment with BC6ENTC is associated with a reversal of abnormal regulation of BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER in the hypertrophic myocardium. CPR:falsenewlineTreatment with BC6ENTC is associated with a reversal of abnormal regulation of BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG in the hypertrophic myocardium. CPR:falsenewlineTo evaluate the effect of BC6ENTC on both myocardial BC6ENTG expression and cardiac hypertrophy, infra - renal aortic banding was performed for 4 weeks in adult Sprague - Dawley rats to induce cardiac hypertrophy. CPR:falsenewlineFurthermore, the activation of the FRET biosensor also confirms the endothelial cell apoptosis induced by the abnormal pulsatile shear stress and high BC6ENTC concentration is through BC6ENTG pathway. CPR:falsenewlineA double - labeling fluorescent technique ( BC6ENTC and BC6OTHER ) was used to validate the findings revealed by the FRET - based BC6ENTG sensor. CPR:falsenewlineA double - labeling fluorescent technique ( BC6OTHER and BC6ENTC ) was used to validate the findings revealed by the FRET - based BC6ENTG sensor. CPR:falsenewlineBC6ENTG ( BC6OTHER ) salvages BC6ENTC by releasing BC6OTHER from BC6OTHER and is often deleted in mesothelioma. CPR:falsenewlineBC6OTHER phosphorylase ( BC6ENTG ) salvages BC6ENTC by releasing BC6OTHER from BC6OTHER and is often deleted in mesothelioma. CPR:falsenewlineBC6ENTG ( BC6OTHER ) salvages BC6OTHER by releasing BC6ENTC from BC6OTHER and is often deleted in mesothelioma. CPR:falsenewlineBC6OTHER phosphorylase ( BC6ENTG ) salvages BC6OTHER by releasing BC6ENTC from BC6OTHER and is often deleted in mesothelioma. CPR:falsenewlineBC6ENTG ( BC6OTHER ) salvages BC6OTHER by releasing BC6OTHER from BC6ENTC and is often deleted in mesothelioma. CPR:falsenewlineBC6OTHER phosphorylase ( BC6ENTG ) salvages BC6OTHER by releasing BC6OTHER from BC6ENTC and is often deleted in mesothelioma. CPR:falsenewlineThe current study addresses the effect of BC6ENTG on BC6ENTC activity using a highly potent transition state inhibitor of BC6OTHER , MT - DADMe - Immucillin A (ImmA; K(i) = 86 pmol / L) in the BC6OTHER (+) NCI - H28 and BC6OTHER ( - ) NCI - H2052 mesothelioma cell lines. CPR:falsenewlineThe current study addresses the effect of BC6OTHER on BC6ENTC activity using a highly potent transition state inhibitor of BC6ENTG , MT - DADMe - Immucillin A (ImmA; K(i) = 86 pmol / L) in the BC6OTHER (+) NCI - H28 and BC6OTHER ( - ) NCI - H2052 mesothelioma cell lines. CPR:falsenewlineThe current study addresses the effect of BC6OTHER on BC6ENTC activity using a highly potent transition state inhibitor of BC6OTHER , MT - DADMe - Immucillin A (ImmA; K(i) = 86 pmol / L) in the BC6ENTG (+) NCI - H28 and BC6OTHER ( - ) NCI - H2052 mesothelioma cell lines. CPR:falsenewlineThe current study addresses the effect of BC6OTHER on BC6ENTC activity using a highly potent transition state inhibitor of BC6OTHER , MT - DADMe - Immucillin A (ImmA; K(i) = 86 pmol / L) in the BC6OTHER (+) NCI - H28 and BC6ENTG ( - ) NCI - H2052 mesothelioma cell lines. CPR:falsenewlineCHEM is a new - generation antifolate inhibitor of BC6ENTC synthase ( BC6OTHER ) and a weaker inhibitor of BC6ENTG ( BC6OTHER ) required for de novo BC6OTHER synthesis. CPR:falsenewlineCHEM is a new - generation antifolate inhibitor of BC6ENTC synthase ( BC6OTHER ) and a weaker inhibitor of BC6OTHER transformylase ( BC6ENTG ) required for de novo BC6OTHER synthesis. CPR:falsenewlineCHEM is a new - generation antifolate inhibitor of BC6ENTC synthase ( BC6ENTG ) and a weaker inhibitor of BC6OTHER transformylase ( BC6OTHER ) required for de novo BC6OTHER synthesis. CPR:falsenewlineBased on selective CHEM protection, BC6ENTG was found to be the primary BC6ENTC target in both cell lines with BC6OTHER inhibition requiring 20 - to 30 - fold higher BC6OTHER concentrations. CPR:falsenewlineBased on selective CHEM protection, BC6OTHER was found to be the primary BC6ENTC target in both cell lines with BC6ENTG inhibition requiring 20 - to 30 - fold higher BC6OTHER concentrations. CPR:falsenewlineBased on selective CHEM protection, BC6ENTG was found to be the primary BC6OTHER target in both cell lines with BC6OTHER inhibition requiring 20 - to 30 - fold higher BC6ENTC concentrations. CPR:falsenewlineBased on selective CHEM protection, BC6OTHER was found to be the primary BC6OTHER target in both cell lines with BC6ENTG inhibition requiring 20 - to 30 - fold higher BC6ENTC concentrations. CPR:falsenewlineImmA had no effect on BC6ENTC activity but, when BC6OTHER was added, the BC6OTHER IC(50) decreased by a factor of approximately 3 in BC6ENTG (+) H28 cells with no effect in BC6OTHER ( - ) H2052 cells. CPR:falsenewlineImmA had no effect on BC6ENTC activity but, when BC6OTHER was added, the BC6OTHER IC(50) decreased by a factor of approximately 3 in BC6OTHER (+) H28 cells with no effect in BC6ENTG ( - ) H2052 cells. CPR:falsenewlineImmA had no effect on BC6OTHER activity but, when BC6ENTC was added, the BC6OTHER IC(50) decreased by a factor of approximately 3 in BC6ENTG (+) H28 cells with no effect in BC6OTHER ( - ) H2052 cells. CPR:falsenewlineImmA had no effect on BC6OTHER activity but, when BC6ENTC was added, the BC6OTHER IC(50) decreased by a factor of approximately 3 in BC6OTHER (+) H28 cells with no effect in BC6ENTG ( - ) H2052 cells. CPR:falsenewlineImmA had no effect on BC6OTHER activity but, when BC6OTHER was added, the BC6ENTC IC(50) decreased by a factor of approximately 3 in BC6ENTG (+) H28 cells with no effect in BC6OTHER ( - ) H2052 cells. CPR:falsenewlineImmA had no effect on BC6OTHER activity but, when BC6OTHER was added, the BC6ENTC IC(50) decreased by a factor of approximately 3 in BC6OTHER (+) H28 cells with no effect in BC6ENTG ( - ) H2052 cells. CPR:falsenewlineConversely, the transfection of BC6ENTG into H2052 cells increased the BC6ENTC IC(50) by nearly 3 - fold but only in the presence of BC6OTHER ; this was reversed by ImmA. CPR:falsenewlineThe effect of a novel transition state inhibitor of BC6ENTG on BC6ENTC activity. CPR:falsenewlineCHEM is a new - generation antifolate inhibitor of BC6OTHER ( BC6OTHER ) and a weaker inhibitor of BC6ENTC transformylase ( BC6ENTG ) required for de novo BC6OTHER synthesis. CPR:falsenewlineCHEM is a new - generation antifolate inhibitor of BC6ENTG ( BC6OTHER ) and a weaker inhibitor of BC6ENTC transformylase ( BC6OTHER ) required for de novo BC6OTHER synthesis. CPR:falsenewlineCHEM is a new - generation antifolate inhibitor of BC6OTHER ( BC6ENTG ) and a weaker inhibitor of BC6ENTC transformylase ( BC6OTHER ) required for de novo BC6OTHER synthesis. CPR:falsenewlineConversely, the transfection of BC6ENTG into H2052 cells increased the BC6OTHER IC(50) by nearly 3 - fold but only in the presence of BC6ENTC ; this was reversed by ImmA. CPR:falsenewlineAn BC6ENTG - specific short interfering RNA produced a 2 - fold decrease in BC6ENTC IC(50) in BC6OTHER (+) HeLa cells in the presence of BC6OTHER . CPR:falsenewlineAn BC6OTHER - specific short interfering RNA produced a 2 - fold decrease in BC6ENTC IC(50) in BC6ENTG (+) HeLa cells in the presence of BC6OTHER . CPR:falsenewlineAn BC6ENTG - specific short interfering RNA produced a 2 - fold decrease in BC6OTHER IC(50) in BC6OTHER (+) HeLa cells in the presence of BC6ENTC . CPR:falsenewlineAn BC6OTHER - specific short interfering RNA produced a 2 - fold decrease in BC6OTHER IC(50) in BC6ENTG (+) HeLa cells in the presence of BC6ENTC . CPR:falsenewlineThese data indicate that suppression of constitutive BC6ENTG has no effect on BC6ENTC activity when the primary target is BC6OTHER . CPR:falsenewlineThese data indicate that suppression of constitutive BC6OTHER has no effect on BC6ENTC activity when the primary target is BC6ENTG . CPR:falsenewlineThere is a modest salutary effect when the BC6ENTC target is BC6ENTG alone. CPR:falsenewlineCHEM is a new - generation antifolate inhibitor of BC6OTHER ( BC6OTHER ) and a weaker inhibitor of BC6ENTG ( BC6OTHER ) required for de novo BC6ENTC synthesis. CPR:falsenewlineCHEM is a new - generation antifolate inhibitor of BC6OTHER ( BC6OTHER ) and a weaker inhibitor of BC6OTHER transformylase ( BC6ENTG ) required for de novo BC6ENTC synthesis. CPR:falsenewlineCHEM is a new - generation antifolate inhibitor of BC6ENTG ( BC6OTHER ) and a weaker inhibitor of BC6OTHER transformylase ( BC6OTHER ) required for de novo BC6ENTC synthesis. CPR:falsenewlineCHEM is a new - generation antifolate inhibitor of BC6OTHER ( BC6ENTG ) and a weaker inhibitor of BC6OTHER transformylase ( BC6OTHER ) required for de novo BC6ENTC synthesis. CPR:falsenewlineBC6ENTC phosphorylase ( BC6ENTG ) salvages BC6OTHER by releasing BC6OTHER from BC6OTHER and is often deleted in mesothelioma. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTC dehydrogenase ( BC6ENTG ), BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTC dehydrogenase ( BC6OTHER ), BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6ENTG , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTG ( BC6OTHER ), BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6ENTG ), BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6OTHER ), BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6ENTG , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTG ( BC6OTHER ), BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6ENTG ), BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6ENTG , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTG ( BC6OTHER ), BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6ENTG ), BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6ENTG , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6ENTG ( BC6OTHER ), BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6ENTG ), BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6OTHER , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineThe purpose of this study was to compare viability assessments determined with the CHEM, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC assays in sandwich - cultured rat hepatocytes following exposure to xenobiotics known to inhibit BC6ENTG , and to define the LOAEL for these xenobiotics in this system. CPR:falsenewlineBC6ENTC also decreased viability as measured by the BC6ENTG , BC6OTHER and BC6OTHER assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the BC6OTHER assay. CPR:falsenewlineBC6OTHER , BC6OTHER and BC6OTHER inhibit the BC6ENTG ( BC6OTHER ) which transports BC6ENTC into bile. CPR:4newlineBC6OTHER , BC6OTHER and BC6OTHER inhibit the BC6OTHER ( BC6ENTG ) which transports BC6ENTC into bile. CPR:4newlineBC6ENTC , BC6OTHER and BC6OTHER inhibit the BC6ENTG ( BC6OTHER ) which transports BC6OTHER into bile. CPR:4newlineBC6ENTC , BC6OTHER and BC6OTHER inhibit the BC6OTHER ( BC6ENTG ) which transports BC6OTHER into bile. CPR:4newlineBC6OTHER also decreased viability as measured by the BC6ENTG , BC6ENTC and BC6OTHER assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the BC6OTHER assay. CPR:falsenewlineBC6OTHER also decreased viability as measured by the BC6ENTG , BC6OTHER and BC6ENTC assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the BC6OTHER assay. CPR:falsenewlineBC6OTHER also decreased viability as measured by the BC6ENTG , BC6OTHER and BC6OTHER assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the BC6ENTC assay. CPR:falsenewlineBased on the results of this study, the BC6ENTG or BC6ENTC assays would be the methods of choice to assess viability in sandwich - cultured rat hepatocytes after xenobiotic exposure. CPR:falsenewlineBC6OTHER , BC6ENTC and BC6OTHER inhibit the BC6ENTG ( BC6OTHER ) which transports BC6OTHER into bile. CPR:4newlineBC6OTHER , BC6ENTC and BC6OTHER inhibit the BC6OTHER ( BC6ENTG ) which transports BC6OTHER into bile. CPR:4newlineSandwich - cultured rat hepatocytes maintain functional BC6ENTC co - transporting polypeptide and BC6ENTG transport proteins, and may be useful to study inhibition of transport by xenobiotics at concentrations below the lowest observable adverse effect level (LOAEL). CPR:falsenewlineBC6OTHER , BC6OTHER and BC6ENTC inhibit the BC6ENTG ( BC6OTHER ) which transports BC6OTHER into bile. CPR:4newlineBC6OTHER , BC6OTHER and BC6ENTC inhibit the BC6OTHER ( BC6ENTG ) which transports BC6OTHER into bile. CPR:4newlineFor the BC6ENTG antagonist BC6OTHER , none of the receptor constructs were able to provide a binding with higher affinity than the starting BC6ENTC V2 receptor. CPR:falsenewlineIn contrast, the binding of BC6ENTC was significantly improved when the transmembrane domains 1 and 2 were transferred from the BC6OTHER receptor to the BC6ENTG . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTC V1A / CHEM receptor antagonist BC6OTHER and the agonists BC6ENTG and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6ENTG for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTC V1A / CHEM receptor antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTG antagonist, in comparison to the combined BC6ENTC V1A / CHEM receptor antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineIn contrast, the binding of BC6OTHER was significantly improved when the transmembrane domains 1 and 2 were transferred from the BC6ENTC receptor to the BC6ENTG . CPR:falsenewlineThe binding domain of BC6ENTC differs from the binding domain of the agonists and the nonselective BC6ENTG antagonist CHEM BC6OTHER that has been used in previous studies. CPR:falsenewlineThe binding domain of BC6ENTC differs from the binding domain of the agonists and the nonselective BC6OTHER antagonist CHEM BC6ENTG that has been used in previous studies. CPR:falsenewlineThe binding domain of BC6OTHER differs from the binding domain of the agonists and the nonselective BC6ENTC receptor antagonist CHEM BC6ENTG that has been used in previous studies. CPR:falsenewlineThe binding domain of BC6OTHER differs from the binding domain of the agonists and the nonselective BC6ENTG antagonist BC6ENTC that has been used in previous studies. CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTG antagonist BC6ENTC and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6ENTC and the agonists BC6ENTG and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6ENTG for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6ENTC and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTG antagonist, in comparison to the combined BC6OTHER antagonist BC6ENTC and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineIn displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6OTHER , [Arg8] BC6ENTG , BC6ENTC , and BC6OTHER . CPR:falsenewlineIn displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6ENTG , [Arg8] BC6OTHER , BC6ENTC , and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTG antagonist BC6OTHER and the agonists BC6ENTC and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6ENTG for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTC and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTG antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTC and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTG antagonist BC6OTHER and the agonists BC6OTHER and BC6ENTC . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTG and BC6ENTC . CPR:falsenewlineWe have analyzed binding domains of the BC6ENTG for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6ENTC . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTG antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6ENTC . CPR:falsenewlineWe have analyzed binding domains of the BC6ENTC receptor for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTG antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6ENTC receptor for BC6OTHER , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTG and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6ENTC receptor for BC6OTHER , a highly selective BC6ENTG antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineThese recombinant receptors have been produced by transfer of domains from the BC6ENTC receptor into the related BC6ENTG and have already been successfully employed for the identification of ligand binding domains at the BC6OTHER (Postina, R., Kojro, E., Fahrenholz, F., 1996. CPR:falsenewlineThese recombinant receptors have been produced by transfer of domains from the BC6ENTC receptor into the related BC6OTHER and have already been successfully employed for the identification of ligand binding domains at the BC6ENTG (Postina, R., Kojro, E., Fahrenholz, F., 1996. CPR:falsenewlineThese recombinant receptors have been produced by transfer of domains from the BC6ENTG into the related BC6ENTC V2 receptor and have already been successfully employed for the identification of ligand binding domains at the BC6OTHER (Postina, R., Kojro, E., Fahrenholz, F., 1996. CPR:falsenewlineThese recombinant receptors have been produced by transfer of domains from the BC6OTHER into the related BC6ENTC V2 receptor and have already been successfully employed for the identification of ligand binding domains at the BC6ENTG (Postina, R., Kojro, E., Fahrenholz, F., 1996. CPR:falsenewlineThese recombinant receptors have been produced by transfer of domains from the BC6ENTG into the related BC6OTHER and have already been successfully employed for the identification of ligand binding domains at the BC6ENTC receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996. CPR:falsenewlineThese recombinant receptors have been produced by transfer of domains from the BC6OTHER into the related BC6ENTG and have already been successfully employed for the identification of ligand binding domains at the BC6ENTC receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996. CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6ENTC , a highly selective BC6OTHER antagonist, in comparison to the combined BC6ENTG antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6ENTC , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTG and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6ENTG for BC6ENTC , a highly selective BC6OTHER antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6ENTC , a highly selective BC6ENTG antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineSeparate agonist and peptide antagonist binding sites of the BC6ENTC receptor defined by their transfer into the BC6ENTG . CPR:falsenewlineIn displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6OTHER , [Arg8] BC6ENTG , BC6OTHER , and BC6ENTC . CPR:falsenewlineIn displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6ENTG , [Arg8] BC6OTHER , BC6OTHER , and BC6ENTC . CPR:falsenewlineSeparate agonist and peptide antagonist binding sites of the BC6ENTG defined by their transfer into the V2 BC6ENTC receptor. CPR:falsenewlineIn displacement studies with 10 chimeric receptor constructs, the binding profile of BC6ENTC was compared with the binding profiles of the ligands BC6OTHER , [Arg8] BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineIn displacement studies with 10 chimeric receptor constructs, the binding profile of BC6ENTC was compared with the binding profiles of the ligands BC6ENTG , [Arg8] BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTC receptor antagonist, in comparison to the combined BC6ENTG antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6OTHER for BC6OTHER , a highly selective BC6ENTC receptor antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6ENTG and BC6OTHER . CPR:falsenewlineWe have analyzed binding domains of the BC6ENTG for BC6OTHER , a highly selective BC6ENTC receptor antagonist, in comparison to the combined BC6OTHER antagonist BC6OTHER and the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineIn displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6ENTC , [Arg8] BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineIn displacement studies with 10 chimeric receptor constructs, the binding profile of BC6OTHER was compared with the binding profiles of the ligands BC6ENTG , BC6ENTC , BC6OTHER , and BC6OTHER . CPR:falsenewlineBinding domains of the BC6ENTG for the selective BC6OTHER antagonist BC6OTHER in comparison to the agonists BC6ENTC and BC6OTHER . CPR:falsenewlineBinding domains of the BC6OTHER for the selective BC6ENTG antagonist BC6OTHER in comparison to the agonists BC6ENTC and BC6OTHER . CPR:falsenewlineBinding domains of the BC6OTHER for the selective BC6OTHER antagonist BC6OTHER in comparison to the agonists BC6ENTG and BC6ENTC . CPR:falsenewlineBinding domains of the BC6ENTG for the selective BC6OTHER antagonist BC6OTHER in comparison to the agonists BC6OTHER and BC6ENTC . CPR:falsenewlineBinding domains of the BC6OTHER for the selective BC6ENTG antagonist BC6OTHER in comparison to the agonists BC6OTHER and BC6ENTC . CPR:falsenewlineBinding domains of the BC6ENTC receptor for the selective BC6OTHER antagonist BC6OTHER in comparison to the agonists BC6ENTG and BC6OTHER . CPR:falsenewlineBinding domains of the BC6ENTC receptor for the selective BC6ENTG antagonist BC6OTHER in comparison to the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineBinding domains of the BC6OTHER for the selective BC6ENTC receptor antagonist BC6OTHER in comparison to the agonists BC6ENTG and BC6OTHER . CPR:falsenewlineBinding domains of the BC6ENTG for the selective BC6ENTC receptor antagonist BC6OTHER in comparison to the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineBinding domains of the BC6OTHER for the selective BC6OTHER antagonist BC6ENTC in comparison to the agonists BC6ENTG and BC6OTHER . CPR:falsenewlineBinding domains of the BC6ENTG for the selective BC6OTHER antagonist BC6ENTC in comparison to the agonists BC6OTHER and BC6OTHER . CPR:falsenewlineBinding domains of the BC6OTHER for the selective BC6ENTG antagonist BC6ENTC in comparison to the agonists BC6OTHER and BC6OTHER . CPR:6newlineThe binding profiles for the agonists BC6ENTG and BC6ENTC were found to be similar. CPR:falsenewlineFor both agonists, important binding domains were the extracellular BC6ENTC - terminus (=E1) and the extracellular loops E2 and E3 from the BC6ENTG . CPR:falsenewlineFor the BC6ENTC V1A / BC6OTHER receptor antagonist BC6OTHER , none of the receptor constructs were able to provide a binding with higher affinity than the starting BC6ENTG . CPR:falsenewlineFor the BC6OTHER V1A / BC6ENTC receptor antagonist BC6OTHER , none of the receptor constructs were able to provide a binding with higher affinity than the starting BC6ENTG . CPR:falsenewlineFor the BC6ENTG antagonist BC6ENTC , none of the receptor constructs were able to provide a binding with higher affinity than the starting BC6OTHER . CPR:falsenewlineFor the BC6OTHER V1A / BC6OTHER receptor antagonist BC6ENTC , none of the receptor constructs were able to provide a binding with higher affinity than the starting BC6ENTG . CPR:falsenewlineBlock of BC6ENTG with BC6ENTC after channel activation was voltage dependent. CPR:4newlineAt - 20 mV, 10 nM BC6ENTC reduced BC6ENTG tail - current amplitude by 5%, whereas, at + 20 mV, the tail - current amplitude was reduced by 45% (n = 4 cells). CPR:falsenewlineBlockage of the BC6ENTG by the gastrointestinal prokinetic agent BC6ENTC . CPR:4newlineWe conclude that BC6ENTC is a potent blocker of BC6ENTG channels expressed in HEK293 cells. CPR:4newlineThe BC6ENTG ( BC6OTHER ), which encodes the rapidly activating delayed rectifier BC6ENTC current and is important in cardiac repolarization, may serve as a target for the action of BC6OTHER . CPR:falsenewlineThe BC6OTHER ( BC6ENTG ), which encodes the rapidly activating delayed rectifier BC6ENTC current and is important in cardiac repolarization, may serve as a target for the action of BC6OTHER . CPR:falsenewlineThe BC6ENTG ( BC6OTHER ), which encodes the rapidly activating delayed rectifier BC6OTHER current and is important in cardiac repolarization, may serve as a target for the action of BC6ENTC . CPR:falsenewlineThe BC6OTHER ( BC6ENTG ), which encodes the rapidly activating delayed rectifier BC6OTHER current and is important in cardiac repolarization, may serve as a target for the action of BC6ENTC . CPR:falsenewlineWe tested the hypothesis that BC6ENTC blocks BC6ENTG . CPR:falsenewlineUnder voltage - clamp conditions, BC6ENTC block of BC6ENTG is dose dependent with a half - maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells). CPR:4newlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6ENTC ) transporter ( BC6ENTG ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6OTHER reuptake process. CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6ENTC ) transporter ( BC6OTHER ) function, we chronically antagonized BC6ENTG by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6OTHER reuptake process. CPR:falsenewlineCONCLUSIONS: These findings suggest that the degree of BC6ENTG blockade can be assessed with the plasma or urine BC6ENTC / BC6OTHER ratio and the pressor effect of CHEM. CPR:falsenewlineCONCLUSIONS: These findings suggest that the degree of BC6ENTG blockade can be assessed with the plasma or urine BC6OTHER / BC6ENTC ratio and the pressor effect of CHEM. CPR:falsenewlineAlso, the BC6ENTC / BC6OTHER ratio is more sensitive at the lower end of BC6ENTG inhibition, whereas CHEM exhibits a linear relation, with BC6OTHER inhibition commencing at a higher dose. CPR:falsenewlineAlso, the BC6ENTC / BC6OTHER ratio is more sensitive at the lower end of BC6OTHER inhibition, whereas CHEM exhibits a linear relation, with BC6ENTG inhibition commencing at a higher dose. CPR:falsenewlineAlso, the BC6OTHER / BC6ENTC ratio is more sensitive at the lower end of BC6ENTG inhibition, whereas CHEM exhibits a linear relation, with BC6OTHER inhibition commencing at a higher dose. CPR:falsenewlineAlso, the BC6OTHER / BC6ENTC ratio is more sensitive at the lower end of BC6OTHER inhibition, whereas CHEM exhibits a linear relation, with BC6ENTG inhibition commencing at a higher dose. CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6ENTG ( BC6OTHER ) function, we chronically antagonized BC6OTHER by a range of doses of BC6ENTC [ BC6OTHER ], which blocks the BC6OTHER reuptake process. CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6ENTG ) function, we chronically antagonized BC6OTHER by a range of doses of BC6ENTC [ BC6OTHER ], which blocks the BC6OTHER reuptake process. CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6OTHER ) function, we chronically antagonized BC6ENTG by a range of doses of BC6ENTC [ BC6OTHER ], which blocks the BC6OTHER reuptake process. CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6ENTG ( BC6OTHER ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6ENTC ], which blocks the BC6OTHER reuptake process. CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6ENTG ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6ENTC ], which blocks the BC6OTHER reuptake process. CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6OTHER ) function, we chronically antagonized BC6ENTG by a range of doses of BC6OTHER [ BC6ENTC ], which blocks the BC6OTHER reuptake process. CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6ENTG ( BC6OTHER ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6ENTC reuptake process. CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6ENTG ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6ENTC reuptake process. CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6OTHER ( BC6OTHER ) transporter ( BC6OTHER ) function, we chronically antagonized BC6ENTG by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6ENTC reuptake process. CPR:falsenewlinePlasma from BC6ENTC - treated subjects (ex vivo effect) dose - dependently decreased radioligand binding to BC6ENTG (maximum inhibition was 60%) (P=0.02). CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6ENTC ( BC6OTHER ) transporter ( BC6ENTG ) function, we chronically antagonized BC6OTHER by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6OTHER reuptake process. CPR:falsenewlineBACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral BC6ENTC ( BC6OTHER ) transporter ( BC6OTHER ) function, we chronically antagonized BC6ENTG by a range of doses of BC6OTHER [ BC6OTHER ], which blocks the BC6OTHER reuptake process. CPR:falsenewlineMoreover, activation of transfected cells and porcine PBMC by BC6ENTG ligands was inhibited by BC6ENTC indicating the requirement of endosomal / lysosomal acidification for activation of the receptors. CPR:falsenewlineBoth BC6ENTG and BC6OTHER proteins were expressed in cell lines and were BC6ENTC - glycosylated. CPR:falsenewlineBoth BC6OTHER and BC6ENTG proteins were expressed in cell lines and were BC6ENTC - glycosylated. CPR:falsenewlineTwo BC6ENTC molecules, BC6OTHER and BC6OTHER , markedly activated both BC6ENTG and BC6OTHER whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands. CPR:falsenewlineTwo BC6ENTC molecules, BC6OTHER and BC6OTHER , markedly activated both BC6OTHER and BC6ENTG whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands. CPR:falsenewlineTwo BC6ENTC molecules, BC6OTHER and BC6OTHER , markedly activated both BC6OTHER and BC6OTHER whereas only BC6ENTG , but not BC6OTHER , was activated by the ligands. CPR:falsenewlineTwo BC6ENTC molecules, BC6OTHER and BC6OTHER , markedly activated both BC6OTHER and BC6OTHER whereas only BC6OTHER , but not BC6ENTG , was activated by the ligands. CPR:falsenewlineTwo BC6OTHER molecules, BC6ENTC and BC6OTHER , markedly activated both BC6ENTG and BC6OTHER whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands. CPR:falsenewlineTwo BC6OTHER molecules, BC6ENTC and BC6OTHER , markedly activated both BC6OTHER and BC6ENTG whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands. CPR:falsenewlineTwo BC6OTHER molecules, BC6ENTC and BC6OTHER , markedly activated both BC6OTHER and BC6OTHER whereas only BC6ENTG , but not BC6OTHER , was activated by the ligands. CPR:falsenewlineTwo BC6OTHER molecules, BC6ENTC and BC6OTHER , markedly activated both BC6OTHER and BC6OTHER whereas only BC6OTHER , but not BC6ENTG , was activated by the ligands. CPR:falsenewlineTwo BC6OTHER molecules, BC6OTHER and BC6ENTC , markedly activated both BC6ENTG and BC6OTHER whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands. CPR:falsenewlineTwo BC6OTHER molecules, BC6OTHER and BC6ENTC , markedly activated both BC6OTHER and BC6ENTG whereas only BC6OTHER , but not BC6OTHER , was activated by the ligands. CPR:falsenewlineTwo BC6OTHER molecules, BC6OTHER and BC6ENTC , markedly activated both BC6OTHER and BC6OTHER whereas only BC6ENTG , but not BC6OTHER , was activated by the ligands. CPR:falsenewlineTwo BC6OTHER molecules, BC6OTHER and BC6ENTC , markedly activated both BC6OTHER and BC6OTHER whereas only BC6OTHER , but not BC6ENTG , was activated by the ligands. CPR:falsenewlinePorcine BC6OTHER and BC6ENTG are both activated by a selective BC6OTHER ligand, BC6ENTC . CPR:falsenewlinePorcine BC6OTHER and BC6OTHER are both activated by a selective BC6ENTG ligand, BC6ENTC . CPR:falsenewlinePorcine BC6ENTG and BC6OTHER are both activated by a selective BC6OTHER ligand, BC6ENTC . CPR:falsenewlineThe BC6ENTC lipase ( BC6ENTG ) inhibitor BC6OTHER produces antinociceptive and anti - inflammatory effects. CPR:falsenewlineThe BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC produces antinociceptive and anti - inflammatory effects. CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC produces antinociceptive and anti - inflammatory effects. CPR:falsenewlineMice given daily injections of high dose BC6ENTC (≥16 mg / kg) for six days displayed decreased BC6ENTG receptor density and function in brain, as assessed in BC6OTHER binding and BC6OTHER - stimulated [ BC6OTHER ]GTPγS binding assays, respectively. CPR:falsenewlineMice given daily injections of high dose BC6OTHER (≥16 mg / kg) for six days displayed decreased BC6ENTG receptor density and function in brain, as assessed in BC6ENTC binding and BC6OTHER - stimulated [ BC6OTHER ]GTPγS binding assays, respectively. CPR:falsenewlineMice given daily injections of high dose BC6OTHER (≥16 mg / kg) for six days displayed decreased BC6ENTG receptor density and function in brain, as assessed in BC6OTHER binding and BC6ENTC - stimulated [ BC6OTHER ]GTPγS binding assays, respectively. CPR:falsenewlineMice given daily injections of high dose BC6OTHER (≥16 mg / kg) for six days displayed decreased BC6ENTG receptor density and function in brain, as assessed in BC6OTHER binding and BC6OTHER - stimulated [ BC6ENTC ]GTPγS binding assays, respectively. CPR:falsenewlineRepeated Low Dose Administration of the BC6ENTC Lipase Inhibitor BC6OTHER Retains BC6ENTG Receptor Mediated Antinociceptive and Gastroprotective Effects. CPR:falsenewlineRepeated Low Dose Administration of the BC6ENTG Inhibitor BC6ENTC Retains BC6OTHER Receptor Mediated Antinociceptive and Gastroprotective Effects. CPR:4newlineRepeated Low Dose Administration of the BC6OTHER Inhibitor BC6ENTC Retains BC6ENTG Receptor Mediated Antinociceptive and Gastroprotective Effects. CPR:falsenewlineIn contrast, normal BC6ENTG receptor expression and function were maintained following repeated administration of low dose BC6ENTC (≤8 mg / kg). CPR:falsenewlineHowever, repeated administration of high dose BC6ENTC (40 mg / kg) causes dependence, antinociceptive tolerance, cross - tolerance to the pharmacological effects of BC6ENTG agonists, and BC6OTHER receptor downregulation and desensitization. CPR:falsenewlineHowever, repeated administration of high dose BC6ENTC (40 mg / kg) causes dependence, antinociceptive tolerance, cross - tolerance to the pharmacological effects of BC6OTHER agonists, and BC6ENTG receptor downregulation and desensitization. CPR:falsenewlineBC6ENTC crystals stimulate monocytes and macrophages to release BC6OTHER through the BC6ENTG component of the inflammasome. CPR:falsenewlineBC6ENTC crystals stimulate monocytes and macrophages to release BC6ENTG through the BC6OTHER component of the inflammasome. CPR:falsenewlineThe effectiveness of BC6ENTG inhibition was first evaluated in a mouse model of BC6ENTC crystal - induced inflammation. CPR:falsenewlineEffect of BC6ENTC on lipid peroxidation, BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6ENTC on lipid peroxidation, BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6ENTC on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6ENTC on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6ENTC on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6ENTC on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6ENTC oxygenase 1( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6ENTC oxygenase 1( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6ENTC oxygenase 1( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6ENTC oxygenase 1( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6ENTC oxygenase 1( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC ( BC6OTHER ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineEffect of BC6OTHER on lipid peroxidation, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6ENTC ) and expression of cell adhesion molecules (CAM) is summarized stepwise. CPR:falsenewlineIn vitro metabolism of the BC6ENTG receptor antagonist BC6ENTC . CPR:falsenewlineBC6ENTG has shown to be an essential component in BC6OTHER catalyzed BC6ENTC formation and provides insights on the disconnect between human liver microsomes data and that of BC6OTHER . CPR:falsenewlineBC6OTHER has shown to be an essential component in BC6ENTG catalyzed BC6ENTC formation and provides insights on the disconnect between human liver microsomes data and that of BC6OTHER . CPR:9newlineBC6OTHER has shown to be an essential component in BC6OTHER catalyzed BC6ENTC formation and provides insights on the disconnect between human liver microsomes data and that of BC6ENTG . CPR:falsenewlineThe metabolism of BC6ENTC has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe metabolism of BC6ENTC has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe BC6ENTG data was normalized relative to the levels of each BC6OTHER form in native human liver microsomes to better assess the contribution of each BC6OTHER in the metabolism of BC6ENTC . CPR:falsenewlineThe BC6OTHER data was normalized relative to the levels of each BC6ENTG form in native human liver microsomes to better assess the contribution of each BC6OTHER in the metabolism of BC6ENTC . CPR:falsenewlineThe BC6OTHER data was normalized relative to the levels of each BC6OTHER form in native human liver microsomes to better assess the contribution of each BC6ENTG in the metabolism of BC6ENTC . CPR:9newline BC6ENTG regulates BC6ENTC - induced BC6OTHER gene expression. CPR:falsenewline BC6OTHER regulates BC6ENTC - induced BC6ENTG gene expression. CPR:falsenewlineHowever, none of the BC6ENTG in that region were required for promoter activation by BC6ENTC . CPR:falsenewlineFurthermore, knockdown of BC6ENTG significantly attenuated BC6ENTC - induced BC6OTHER expression. CPR:falsenewlineFurthermore, knockdown of BC6OTHER significantly attenuated BC6ENTC - induced BC6ENTG expression. CPR:falsenewlineThus, our findings indicate that the expression of BC6ENTG depends on BC6OTHER activity and contributes to BC6OTHER induction by BC6ENTC . CPR:falsenewlineThus, our findings indicate that the expression of BC6OTHER depends on BC6ENTG activity and contributes to BC6OTHER induction by BC6ENTC . CPR:falsenewlineThus, our findings indicate that the expression of BC6OTHER depends on BC6OTHER activity and contributes to BC6ENTG induction by BC6ENTC . CPR:falsenewlineFor example, involvement of BC6ENTG in LHβ induction by BC6ENTC has been discovered. CPR:falsenewlineBC6ENTC caused a sustained increase in nuclear BC6ENTG levels, which was significantly reduced CHEM BC6OTHER - terminal kinase ( BC6OTHER ) inhibition. CPR:falsenewlineBC6ENTC caused a sustained increase in nuclear BC6OTHER levels, which was significantly reduced by BC6ENTG ( BC6OTHER ) inhibition. CPR:falsenewlineBC6ENTC caused a sustained increase in nuclear BC6OTHER levels, which was significantly reduced CHEM BC6OTHER - terminal kinase ( BC6ENTG ) inhibition. CPR:falsenewlineThe regulation of BC6ENTG synthesis by BC6ENTC plays an essential role in the neuroendocrine control of reproduction. CPR:9newlineBC6ENTG caused a sustained increase in nuclear BC6OTHER levels, which was significantly reduced by c - Jun BC6ENTC - terminal kinase ( BC6OTHER ) inhibition. CPR:falsenewlineBC6OTHER caused a sustained increase in nuclear BC6ENTG levels, which was significantly reduced by c - Jun BC6ENTC - terminal kinase ( BC6OTHER ) inhibition. CPR:falsenewlineBC6OTHER caused a sustained increase in nuclear BC6OTHER levels, which was significantly reduced by c - Jun BC6ENTC - terminal kinase ( BC6ENTG ) inhibition. CPR:falsenewlineSmall interfering RNA - mediated knockdown of BC6ENTG mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6OTHER by BC6OTHER occurred independently of the BC6OTHER - BC6OTHER pathway. CPR:falsenewlineSmall interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6ENTG mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6OTHER by BC6OTHER occurred independently of the BC6OTHER - BC6OTHER pathway. CPR:falsenewlineSmall interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6ENTG and that regulation of BC6OTHER by BC6OTHER occurred independently of the BC6OTHER - BC6OTHER pathway. CPR:falsenewlineSmall interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6ENTG by BC6OTHER occurred independently of the BC6OTHER - BC6OTHER pathway. CPR:falsenewlineSmall interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6OTHER by BC6ENTG occurred independently of the BC6OTHER - BC6OTHER pathway. CPR:falsenewlineSmall interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6OTHER by BC6OTHER occurred independently of the BC6ENTG - BC6OTHER pathway. CPR:falsenewlineSmall interfering RNA - mediated knockdown of BC6OTHER mRNA demonstrated that induction of BC6OTHER mRNA by BC6ENTC depended on BC6OTHER and that regulation of BC6OTHER by BC6OTHER occurred independently of the BC6OTHER - BC6ENTG pathway. CPR:falsenewlineIn LβT2 cells transfected with BC6ENTG luciferase fusion constructs, BC6ENTC responsiveness was conferred by the proximal promoter ( - 944 / - 1) and was markedly decreased by BC6OTHER knockdown. CPR:falsenewlineIn LβT2 cells transfected with BC6OTHER luciferase fusion constructs, BC6ENTC responsiveness was conferred by the proximal promoter ( - 944 / - 1) and was markedly decreased by BC6ENTG knockdown. CPR:falsenewlineOf the compounds active in the present assay system, the most potent compound 7, BC6ENTC , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6ENTG ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6OTHER , a BC6OTHER agonist. CPR:4newlineOf the compounds active in the present assay system, the most potent compound 7, BC6ENTC , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6OTHER ( BC6ENTG ) protein expression, and inhibited adipocyte differentiation induced by BC6OTHER , a BC6OTHER agonist. CPR:4newlineOf the compounds active in the present assay system, the most potent compound 7, BC6ENTC , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6OTHER , a BC6ENTG agonist. CPR:falsenewlineOf the compounds active in the present assay system, the most potent compound 7, BC6ENTC , significantly suppressed the induction of BC6ENTG ( BC6OTHER and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6OTHER , a BC6OTHER agonist. CPR:4newlineOf the compounds active in the present assay system, the most potent compound 7, BC6ENTC , significantly suppressed the induction of BC6OTHER ( BC6ENTG and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6OTHER , a BC6OTHER agonist. CPR:4newlineOf the compounds active in the present assay system, the most potent compound 7, BC6OTHER , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6ENTG ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6ENTC , a BC6OTHER agonist. CPR:falsenewlineOf the compounds active in the present assay system, the most potent compound 7, BC6OTHER , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6OTHER ( BC6ENTG ) protein expression, and inhibited adipocyte differentiation induced by BC6ENTC , a BC6OTHER agonist. CPR:falsenewlineOf the compounds active in the present assay system, the most potent compound 7, BC6OTHER , significantly suppressed the induction of BC6OTHER ( BC6OTHER and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6ENTC , a BC6ENTG agonist. CPR:falsenewlineOf the compounds active in the present assay system, the most potent compound 7, BC6OTHER , significantly suppressed the induction of BC6ENTG ( BC6OTHER and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6ENTC , a BC6OTHER agonist. CPR:falsenewlineOf the compounds active in the present assay system, the most potent compound 7, BC6OTHER , significantly suppressed the induction of BC6OTHER ( BC6ENTG and BC6OTHER ( BC6OTHER ) protein expression, and inhibited adipocyte differentiation induced by BC6ENTC , a BC6OTHER agonist. CPR:falsenewlineA selective BC6ENTG agonist BC6ENTC ( BC6OTHER , BC6OTHER ) inhibits angiogenesis and metastasis in solid tumours. CPR:5newlineA selective BC6ENTG agonist BC6OTHER ( BC6ENTC , BC6OTHER ) inhibits angiogenesis and metastasis in solid tumours. CPR:falsenewlineA selective BC6ENTG agonist BC6OTHER ( BC6OTHER , BC6ENTC ) inhibits angiogenesis and metastasis in solid tumours. CPR:falsenewlineAnalysis of tumour - conditioned medium indicated that BC6ENTC decreased the secretion of angiogenic factors and BC6ENTG and increased the tissue inhibitor of BC6OTHER . CPR:4newlineAnalysis of tumour - conditioned medium indicated that BC6ENTC decreased the secretion of angiogenic factors and BC6OTHER and increased the tissue inhibitor of BC6ENTG . CPR:falsenewlineThe ability of BC6ENTC to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner BC6ENTG . CPR:falsenewlineIn vivo angiogenesis assay utilising CHEM sponges, BC6ENTC reduced angiogenesis in sponges containing BC6ENTG , BC6OTHER and basic BC6OTHER to various extent. CPR:falsenewlineIn vivo angiogenesis assay utilising CHEM sponges, BC6ENTC reduced angiogenesis in sponges containing BC6OTHER , BC6ENTG and basic BC6OTHER to various extent. CPR:falsenewlineIn vivo angiogenesis assay utilising CHEM sponges, BC6ENTC reduced angiogenesis in sponges containing BC6OTHER , BC6OTHER and basic BC6ENTG to various extent. CPR:falsenewlineThe present study determined the influence of a BC6ENTG agonist BC6ENTC on angiogenesis and metastasis in solid tumours. CPR:falsenewlineBC6ENTC acting on BC6ENTG at the central nervous system appears to have an important role in these modulatory processes. CPR:falsenewlineBC6ENTG acting on BC6ENTC AT1 receptors at the central nervous system appears to have an important role in these modulatory processes. CPR:falsenewlineWe investigated the effect of BC6ENTG blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent BC6ENTC . CPR:falsenewline BC6ENTG antagonist BC6ENTC and the defence reaction in the anaesthetised rat. CPR:falsenewlineThis review will try to enlighten on the BC6ENTG as a molecular link between dietary BC6ENTC and reproductive diseases in women. CPR:falsenewlineBC6ENTG and BC6OTHER are nuclear receptors activated by BC6ENTC , oxidized derivatives of BC6OTHER . CPR:falsenewlineBC6OTHER and BC6ENTG are nuclear receptors activated by BC6ENTC , oxidized derivatives of BC6OTHER . CPR:falsenewlineBC6ENTG and BC6OTHER are nuclear receptors activated by BC6OTHER , oxidized derivatives of BC6ENTC . CPR:falsenewlineBC6OTHER and BC6ENTG are nuclear receptors activated by BC6OTHER , oxidized derivatives of BC6ENTC . CPR:falsenewlineSince their discovery, the role of BC6ENTG in the control of BC6ENTC homeostasis has been widely described. CPR:falsenewlineINTRODUCTION: BC6OTHER ( BC6ENTC ) induces BC6OTHER ( BC6OTHER ) - positive and BC6OTHER ( BC6ENTG ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineINTRODUCTION: BC6OTHER ( BC6ENTC ) induces BC6ENTG ( BC6OTHER ) - positive and BC6OTHER ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineINTRODUCTION: BC6OTHER ( BC6ENTC ) induces BC6OTHER ( BC6ENTG ) - positive and BC6OTHER ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineINTRODUCTION: BC6OTHER ( BC6ENTC ) induces BC6OTHER ( BC6OTHER ) - positive and BC6ENTG ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineWithin this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6ENTC and BC6OTHER , and the levels of BC6ENTG and BC6OTHER expression in BC6OTHER - treated and BC6OTHER - treated mammary glands. CPR:falsenewlineWithin this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6ENTC and BC6OTHER , and the levels of BC6OTHER and BC6ENTG expression in BC6OTHER - treated and BC6OTHER - treated mammary glands. CPR:falsenewlineWithin this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6ENTC , and the levels of BC6ENTG and BC6OTHER expression in BC6OTHER - treated and BC6OTHER - treated mammary glands. CPR:falsenewlineWithin this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6ENTC , and the levels of BC6OTHER and BC6ENTG expression in BC6OTHER - treated and BC6OTHER - treated mammary glands. CPR:falsenewlineWithin this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6ENTG and BC6OTHER expression in BC6ENTC - treated and BC6OTHER - treated mammary glands. CPR:falsenewlineWithin this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6OTHER and BC6ENTG expression in BC6ENTC - treated and BC6OTHER - treated mammary glands. CPR:falsenewlineWithin this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6ENTG and BC6OTHER expression in BC6OTHER - treated and BC6ENTC - treated mammary glands. CPR:falsenewlineWithin this experimental setting, we studied the carcinogenic effects of BC6OTHER , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6OTHER and BC6ENTG expression in BC6OTHER - treated and BC6ENTC - treated mammary glands. CPR:falsenewlineINTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6ENTC receptor ( BC6OTHER ) - positive and BC6OTHER ( BC6ENTG ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineINTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6ENTC receptor ( BC6ENTG ) - positive and BC6OTHER ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineINTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6ENTC receptor ( BC6OTHER ) - positive and BC6ENTG ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineIn addition, BALB / c and C57BL / 6 females were treated with BC6ENTC or BC6OTHER for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of BC6ENTG and BC6OTHER . CPR:falsenewlineIn addition, BALB / c and C57BL / 6 females were treated with BC6ENTC or BC6OTHER for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of BC6OTHER and BC6ENTG . CPR:falsenewlineIn addition, BALB / c and C57BL / 6 females were treated with BC6OTHER or BC6ENTC for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of BC6ENTG and BC6OTHER . CPR:falsenewlineIn addition, BALB / c and C57BL / 6 females were treated with BC6OTHER or BC6ENTC for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of BC6OTHER and BC6ENTG . CPR:falsenewlineINTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6OTHER ( BC6OTHER ) - positive and BC6ENTC receptor ( BC6ENTG ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineINTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6ENTG ( BC6OTHER ) - positive and BC6ENTC receptor ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineINTRODUCTION: BC6OTHER ( BC6OTHER ) induces BC6OTHER ( BC6ENTG ) - positive and BC6ENTC receptor ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineAssociation of BC6ENTC receptor - alpha and BC6ENTG A expression with hormonal mammary carcinogenesis: role of the host microenvironment. CPR:falsenewlineAssociation of BC6ENTG and BC6ENTC receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. CPR:falsenewlineINTRODUCTION: BC6ENTC ( BC6OTHER ) induces BC6OTHER ( BC6OTHER ) - positive and BC6OTHER ( BC6ENTG ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineINTRODUCTION: BC6ENTC ( BC6OTHER ) induces BC6ENTG ( BC6OTHER ) - positive and BC6OTHER ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineINTRODUCTION: BC6ENTC ( BC6OTHER ) induces BC6OTHER ( BC6ENTG ) - positive and BC6OTHER ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineINTRODUCTION: BC6ENTC ( BC6OTHER ) induces BC6OTHER ( BC6OTHER ) - positive and BC6ENTG ( BC6OTHER ) - positive ductal invasive mammary carcinomas in BALB / c mice. CPR:falsenewlineThe expression of BC6ENTG and BC6OTHER in virgin mice was surprisingly much higher in BALB / c than in C57BL / 6 mammary glands, and both receptors were downregulated in BC6ENTC - treated BALB / c mice (P < 0.05). CPR:falsenewlineThe expression of BC6OTHER and BC6ENTG in virgin mice was surprisingly much higher in BALB / c than in C57BL / 6 mammary glands, and both receptors were downregulated in BC6ENTC - treated BALB / c mice (P < 0.05). CPR:falsenewlineBC6ENTG levels were low in virgin control mice and increased after BC6ENTC treatment in both strains. CPR:falsenewlineWithin this experimental setting, we studied the carcinogenic effects of BC6ENTC , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6ENTG and BC6OTHER expression in BC6OTHER - treated and BC6OTHER - treated mammary glands. CPR:falsenewlineWithin this experimental setting, we studied the carcinogenic effects of BC6ENTC , the morphologic changes in mammary glands that are induced by BC6OTHER and BC6OTHER , and the levels of BC6OTHER and BC6ENTG expression in BC6OTHER - treated and BC6OTHER - treated mammary glands. CPR:falsenewlineThe radioactivity was rapidly and widely distributed throughout the body, and remained detectable in all tissues investigated at later time points (24 and 48 hours for [ BC6ENTC ] - BC6ENTG and [ BC6OTHER ] - SSB siRNA, respectively). CPR:falsenewlineThe radioactivity was rapidly and widely distributed throughout the body, and remained detectable in all tissues investigated at later time points (24 and 48 hours for [ BC6OTHER ] - BC6ENTG and [ BC6ENTC ] - SSB siRNA, respectively). CPR:falsenewlineInstead, radiolabeled BC6ENTC resulting from BC6ENTG hydrolysis were observed. CPR:falsenewlineExpression of pituitary BC6ENTG and BC6OTHER , under the control of pulsatile BC6ENTC , is essential for fertility. CPR:falsenewlineExpression of pituitary BC6OTHER and BC6ENTG , under the control of pulsatile BC6ENTC , is essential for fertility. CPR:falsenewlineA BC6ENTG ( BC6OTHER ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6OTHER stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6ENTG ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6OTHER stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6OTHER ) reduced BC6ENTC - stimulated BC6ENTG and markedly decreased BC6OTHER stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6OTHER ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6ENTG stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6OTHER ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6OTHER stimulation of BC6ENTG mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6OTHER ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6OTHER stimulation of BC6OTHER mRNA and BC6ENTG LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6OTHER ) reduced BC6ENTC - stimulated BC6OTHER and markedly decreased BC6OTHER stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6ENTG LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6ENTG ( BC6OTHER ) reduced BC6OTHER - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6ENTG ) reduced BC6OTHER - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6OTHER ) reduced BC6ENTG - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6OTHER ) reduced BC6OTHER - stimulated BC6ENTG and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6OTHER ) reduced BC6OTHER - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6ENTG mRNA and BC6OTHER LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6OTHER ) reduced BC6OTHER - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6ENTG LUC activity, but had little effect on BC6OTHER LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineA BC6OTHER ( BC6OTHER ) reduced BC6OTHER - stimulated BC6OTHER and markedly decreased BC6ENTC stimulation of BC6OTHER mRNA and BC6OTHER LUC activity, but had little effect on BC6ENTG LUC activity, indicating relative specificity of this pathway. CPR:falsenewlineIn perifusion studies, BC6ENTG mRNA levels and BC6OTHER LUC activities were increased by pulsatile BC6ENTC , with significantly greater increases at low compared with high pulse frequencies. CPR:3newlineIn perifusion studies, BC6OTHER mRNA levels and BC6ENTG LUC activities were increased by pulsatile BC6ENTC , with significantly greater increases at low compared with high pulse frequencies. CPR:3newline BC6ENTC pulse frequency - dependent stimulation of BC6OTHER transcription is mediated via activation of BC6OTHER and BC6ENTG . CPR:falsenewline BC6ENTC pulse frequency - dependent stimulation of BC6ENTG transcription is mediated via activation of BC6OTHER and BC6OTHER . CPR:falsenewline BC6ENTC pulse frequency - dependent stimulation of BC6OTHER transcription is mediated via activation of BC6ENTG and BC6OTHER . CPR:falsenewlineBC6ENTC response element - binding protein ( BC6ENTG ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6OTHER regulates BC6OTHER activation remain poorly understood. CPR:falsenewlineBC6ENTC response element - binding protein ( BC6OTHER ) has been implicated in the regulation of BC6ENTG gene expression, but the molecular mechanisms by which pulsatile BC6OTHER regulates BC6OTHER activation remain poorly understood. CPR:falsenewlineBC6ENTC response element - binding protein ( BC6OTHER ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6ENTG regulates BC6OTHER activation remain poorly understood. CPR:falsenewlineBC6ENTC response element - binding protein ( BC6OTHER ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6OTHER regulates BC6ENTG activation remain poorly understood. CPR:falsenewlineBC6ENTG markedly reduced these BC6ENTC - stimulated BC6OTHER responses at both low and high pulse frequencies. CPR:falsenewlineBC6OTHER markedly reduced these BC6ENTC - stimulated BC6ENTG responses at both low and high pulse frequencies. CPR:falsenewlineCorrelating with BC6ENTG activation, both BC6OTHER activity and levels of BC6OTHER were increased to a greater extent by low compared with high BC6ENTC pulse frequencies, and the induction of BC6OTHER was also attenuated by overexpression of BC6OTHER at both low and high pulse frequencies. CPR:falsenewlineCorrelating with BC6OTHER activation, both BC6ENTG activity and levels of BC6OTHER were increased to a greater extent by low compared with high BC6ENTC pulse frequencies, and the induction of BC6OTHER was also attenuated by overexpression of BC6OTHER at both low and high pulse frequencies. CPR:falsenewlineCorrelating with BC6OTHER activation, both BC6OTHER activity and levels of BC6ENTG were increased to a greater extent by low compared with high BC6ENTC pulse frequencies, and the induction of BC6OTHER was also attenuated by overexpression of BC6OTHER at both low and high pulse frequencies. CPR:falsenewlineCorrelating with BC6OTHER activation, both BC6OTHER activity and levels of BC6OTHER were increased to a greater extent by low compared with high BC6ENTC pulse frequencies, and the induction of BC6ENTG was also attenuated by overexpression of BC6OTHER at both low and high pulse frequencies. CPR:falsenewlineCorrelating with BC6OTHER activation, both BC6OTHER activity and levels of BC6OTHER were increased to a greater extent by low compared with high BC6ENTC pulse frequencies, and the induction of BC6OTHER was also attenuated by overexpression of BC6ENTG at both low and high pulse frequencies. CPR:falsenewlineTaken together, these data indicate that a BC6ENTG - mediated signaling pathway mediates BC6ENTC activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6OTHER signal to result in frequency - dependent BC6OTHER activation. CPR:falsenewlineTaken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6ENTC activation of BC6ENTG at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6OTHER signal to result in frequency - dependent BC6OTHER activation. CPR:falsenewlineTaken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6ENTC activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6ENTG signal to result in frequency - dependent BC6OTHER activation. CPR:falsenewlineTaken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6ENTC activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6OTHER signal to result in frequency - dependent BC6ENTG activation. CPR:falsenewlineTaken together, these data indicate that a BC6ENTG - mediated signaling pathway mediates BC6OTHER activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6ENTC signal to result in frequency - dependent BC6OTHER activation. CPR:falsenewlineTaken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6ENTG activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6ENTC signal to result in frequency - dependent BC6OTHER activation. CPR:falsenewlineTaken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6OTHER activation of BC6ENTG at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6ENTC signal to result in frequency - dependent BC6OTHER activation. CPR:falsenewlineTaken together, these data indicate that a BC6OTHER - mediated signaling pathway mediates BC6OTHER activation of BC6OTHER at low - pulse frequencies, playing a significant role in the decoding of the hypothalamic BC6ENTC signal to result in frequency - dependent BC6ENTG activation. CPR:falsenewlineBC6ENTG ( BC6OTHER ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6ENTC regulates BC6OTHER activation remain poorly understood. CPR:falsenewlineBC6OTHER response element - binding protein ( BC6ENTG ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6ENTC regulates BC6OTHER activation remain poorly understood. CPR:falsenewlineBC6OTHER response element - binding protein ( BC6OTHER ) has been implicated in the regulation of BC6ENTG gene expression, but the molecular mechanisms by which pulsatile BC6ENTC regulates BC6OTHER activation remain poorly understood. CPR:falsenewlineBC6OTHER response element - binding protein ( BC6OTHER ) has been implicated in the regulation of BC6OTHER gene expression, but the molecular mechanisms by which pulsatile BC6ENTC regulates BC6ENTG activation remain poorly understood. CPR:falsenewlineWe hypothesized that BC6ENTG is activated by a distinct signaling pathway in response to pulsatile BC6ENTC in a frequency - dependent manner to dictate the BC6OTHER transcriptional response. CPR:falsenewlineWe hypothesized that BC6OTHER is activated by a distinct signaling pathway in response to pulsatile BC6ENTC in a frequency - dependent manner to dictate the BC6ENTG transcriptional response. CPR:falsenewlineBC6ENTC stimulation of BC6ENTG phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6OTHER ) inhibitor, BC6OTHER . CPR:falsenewlineBC6ENTC stimulation of BC6OTHER phosphorylation ( BC6ENTG ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6OTHER ) inhibitor, BC6OTHER . CPR:falsenewlineBC6ENTC stimulation of BC6OTHER phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER . CPR:falsenewlineBC6ENTC stimulation of BC6OTHER phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER . CPR:falsenewlineBC6ENTG stimulation of BC6OTHER phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6OTHER ) inhibitor, BC6ENTC . CPR:falsenewlineBC6OTHER stimulation of BC6ENTG phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6OTHER ) inhibitor, BC6ENTC . CPR:falsenewlineBC6OTHER stimulation of BC6OTHER phosphorylation ( BC6ENTG ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6OTHER ) inhibitor, BC6ENTC . CPR:falsenewlineBC6OTHER stimulation of BC6OTHER phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6ENTG ( BC6OTHER ) inhibitor, BC6ENTC . CPR:falsenewlineBC6OTHER stimulation of BC6OTHER phosphorylation ( BC6OTHER ) in the gonadotrope - derived LβT2 cell line was attenuated by a BC6OTHER ( BC6ENTG ) inhibitor, BC6ENTC . CPR:falsenewlineIn humans, BC6ENTG deficiency results in the accumulation of BC6ENTC at the expense of BC6OTHER derivatives required for BC6OTHER and BC6OTHER biosynthesis. CPR:falsenewlineIn humans, BC6ENTG deficiency results in the accumulation of BC6OTHER at the expense of BC6ENTC derivatives required for BC6OTHER and BC6OTHER biosynthesis. CPR:falsenewlineIn humans, BC6ENTG deficiency results in the accumulation of BC6OTHER at the expense of BC6OTHER derivatives required for BC6ENTC and BC6OTHER biosynthesis. CPR:falsenewlineIn humans, BC6ENTG deficiency results in the accumulation of BC6OTHER at the expense of BC6OTHER derivatives required for BC6OTHER and BC6ENTC biosynthesis. CPR:falsenewlineThis model is a hypomorph, with reduced BC6ENTG activity, thus avoiding the lethality associated with the absence of BC6ENTC synthase activity. CPR:falsenewlineWe have constructed a mouse model with a gene trap insertion in the BC6ENTG gene specifying BC6ENTC synthase reductase, an enzyme essential for the activity of BC6OTHER . CPR:falsenewlineWe have constructed a mouse model with a gene trap insertion in the BC6OTHER gene specifying BC6ENTC synthase reductase, an enzyme essential for the activity of BC6ENTG . CPR:falsenewlineWe have constructed a mouse model with a gene trap insertion in the BC6ENTG gene specifying BC6OTHER , an enzyme essential for the activity of BC6ENTC synthase. CPR:falsenewlineWe have constructed a mouse model with a gene trap insertion in the BC6OTHER gene specifying BC6ENTG , an enzyme essential for the activity of BC6ENTC synthase. CPR:falsenewlineThis model is a hypomorph, with reduced BC6ENTC synthase reductase activity, thus avoiding the lethality associated with the absence of BC6ENTG activity. CPR:falsenewlineMetabolic derangement of BC6ENTC and BC6OTHER metabolism in mice deficient in BC6ENTG . CPR:falsenewlineMetabolic derangement of BC6OTHER and BC6ENTC metabolism in mice deficient in BC6ENTG . CPR:falsenewlineBC6ENTG (gt / gt) mice have increased plasma BC6ENTC , decreased plasma BC6OTHER , and increased tissue BC6OTHER . CPR:falsenewlineBC6ENTG (gt / gt) mice have increased plasma BC6OTHER , decreased plasma BC6ENTC , and increased tissue BC6OTHER . CPR:falsenewlineBC6ENTG (gt / gt) mice have increased plasma BC6OTHER , decreased plasma BC6OTHER , and increased tissue BC6ENTC . CPR:falsenewlineUnexpectedly, BC6ENTG (gt / gt) mice do not show decreases in the BC6ENTC / BC6OTHER ratio in most tissues. CPR:falsenewlineUnexpectedly, BC6ENTG (gt / gt) mice do not show decreases in the BC6OTHER / BC6ENTC ratio in most tissues. CPR:falsenewlineBC6ENTC had no effect on resting intracellular [ BC6OTHER ] or BC6ENTG - induced increase in BC6OTHER mobilization. CPR:falsenewlineBC6OTHER had no effect on resting intracellular [ BC6ENTC ] or BC6ENTG - induced increase in BC6OTHER mobilization. CPR:falsenewlineBC6OTHER had no effect on resting intracellular [ BC6OTHER ] or BC6ENTG - induced increase in BC6ENTC mobilization. CPR:falsenewlineAddition of the inhibitors of endothelial BC6ENTC synthase or BC6ENTG did not alter the protective effect of BC6OTHER . CPR:falsenewlineAddition of the inhibitors of BC6ENTG or BC6ENTC receptor did not alter the protective effect of BC6OTHER . CPR:falsenewlineAddition of the inhibitors of BC6ENTG or BC6OTHER did not alter the protective effect of BC6ENTC . CPR:falsenewlineAddition of the inhibitors of endothelial BC6OTHER synthase or BC6ENTG did not alter the protective effect of BC6ENTC . CPR:falsenewlineBC6ENTG inhibitor blocked the protective effect of BC6ENTC on endothelial permeability and also ablated BC6OTHER - induced BC6OTHER - phosphorylation in ECs. CPR:falsenewlineBC6OTHER inhibitor blocked the protective effect of BC6ENTC on endothelial permeability and also ablated BC6ENTG - induced BC6OTHER - phosphorylation in ECs. CPR:falsenewlineBC6OTHER inhibitor blocked the protective effect of BC6ENTC on endothelial permeability and also ablated BC6OTHER - induced BC6ENTG - phosphorylation in ECs. CPR:falsenewlineCHEM BC6ENTC protects against endothelial barrier dysfunction in vascular endothelial cells through BC6ENTG - mediated suppression of BC6OTHER signaling. CPR:falsenewlineCHEM BC6ENTC protects against endothelial barrier dysfunction in vascular endothelial cells through BC6OTHER - mediated suppression of BC6ENTG signaling. CPR:falsenewlineInhibition of BC6ENTG significantly attenuated the effect of BC6ENTC on BC6OTHER - induced EC permeability, BC6OTHER phosphorylation, and BC6OTHER membrane translocation in ECs. CPR:falsenewlineInhibition of BC6OTHER significantly attenuated the effect of BC6ENTC on BC6ENTG - induced EC permeability, BC6OTHER phosphorylation, and BC6OTHER membrane translocation in ECs. CPR:falsenewlineInhibition of BC6OTHER significantly attenuated the effect of BC6ENTC on BC6OTHER - induced EC permeability, BC6ENTG phosphorylation, and BC6OTHER membrane translocation in ECs. CPR:falsenewlineInhibition of BC6OTHER significantly attenuated the effect of BC6ENTC on BC6OTHER - induced EC permeability, BC6OTHER phosphorylation, and BC6ENTG membrane translocation in ECs. CPR:falsenewlineFurthermore, BC6ENTG diminished BC6ENTC production in ECs, which were prevented by treatment with BC6OTHER . CPR:falsenewlineFurthermore, BC6ENTG diminished BC6OTHER production in ECs, which were prevented by treatment with BC6ENTC . CPR:falsenewlineThese findings demonstrated that BC6ENTC improves BC6ENTG - induced endothelial barrier dysfunction in ECs through BC6OTHER - mediated suppression of BC6OTHER signaling. CPR:falsenewlineThese findings demonstrated that BC6ENTC improves BC6OTHER - induced endothelial barrier dysfunction in ECs through BC6ENTG - mediated suppression of BC6OTHER signaling. CPR:falsenewlineThese findings demonstrated that BC6ENTC improves BC6OTHER - induced endothelial barrier dysfunction in ECs through BC6OTHER - mediated suppression of BC6ENTG signaling. CPR:falsenewlineHere, we report that BC6ENTC at physiologically relevant concentrations (0.1 - 10 μM) significantly inhibited BC6ENTG - induced increase in endothelial monolayer permeability. CPR:falsenewlineBC6ENTC also reduced the formation of stress fibers by BC6ENTG and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6OTHER (19) / BC6OTHER (18) in endothelial cells (ECs). CPR:falsenewlineBC6ENTC also reduced the formation of stress fibers by BC6OTHER and suppressed BC6ENTG - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6OTHER (19) / BC6OTHER (18) in endothelial cells (ECs). CPR:falsenewlineBC6ENTC also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6ENTG ( BC6OTHER ) on BC6OTHER (19) / BC6OTHER (18) in endothelial cells (ECs). CPR:falsenewlineBC6ENTC also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6ENTG ) on BC6OTHER (19) / BC6OTHER (18) in endothelial cells (ECs). CPR:falsenewlineBC6OTHER also reduced the formation of stress fibers by BC6ENTG and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6ENTC (19) / BC6OTHER (18) in endothelial cells (ECs). CPR:falsenewlineBC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6ENTG - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6ENTC (19) / BC6OTHER (18) in endothelial cells (ECs). CPR:falsenewlineBC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6ENTG ( BC6OTHER ) on BC6ENTC (19) / BC6OTHER (18) in endothelial cells (ECs). CPR:falsenewlineBC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6ENTG ) on BC6ENTC (19) / BC6OTHER (18) in endothelial cells (ECs). CPR:falsenewlineBC6OTHER also reduced the formation of stress fibers by BC6ENTG and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6OTHER (19) / BC6ENTC (18) in endothelial cells (ECs). CPR:falsenewlineBC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6ENTG - induced phosphorylation of BC6OTHER ( BC6OTHER ) on BC6OTHER (19) / BC6ENTC (18) in endothelial cells (ECs). CPR:falsenewlineBC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6ENTG ( BC6OTHER ) on BC6OTHER (19) / BC6ENTC (18) in endothelial cells (ECs). CPR:falsenewlineBC6OTHER also reduced the formation of stress fibers by BC6OTHER and suppressed BC6OTHER - induced phosphorylation of BC6OTHER ( BC6ENTG ) on BC6OTHER (19) / BC6ENTC (18) in endothelial cells (ECs). CPR:falsenewlineIn the absence of BC6ENTG (in BC6OTHER Δ mutant strain) sensitivity to the essential oil and BC6OTHER increased indicating that this oil and BC6ENTC are generating reactive BC6OTHER species (ROS). CPR:falsenewlineIn the absence of BC6OTHER dismutase (in BC6ENTG Δ mutant strain) sensitivity to the essential oil and BC6OTHER increased indicating that this oil and BC6ENTC are generating reactive BC6OTHER species (ROS). CPR:falsenewlineIn the absence of BC6ENTG (in BC6OTHER Δ mutant strain) sensitivity to the essential oil and BC6OTHER increased indicating that this oil and BC6OTHER are generating reactive BC6ENTC species (ROS). CPR:falsenewlineIn the absence of BC6OTHER dismutase (in BC6ENTG Δ mutant strain) sensitivity to the essential oil and BC6OTHER increased indicating that this oil and BC6OTHER are generating reactive BC6ENTC species (ROS). CPR:falsenewlineThe ROS production was confirmed by BC6ENTC probing assay in BC6ENTG - deficient strains. CPR:falsenewlineOur results revealed an important role of base excision repair (BER) as the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER mutants showed pronounced sensitivity to essential oil and BC6ENTC . CPR:falsenewlineOur results revealed an important role of base excision repair (BER) as the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER mutants showed pronounced sensitivity to essential oil and BC6ENTC . CPR:falsenewlineOur results revealed an important role of base excision repair (BER) as the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER mutants showed pronounced sensitivity to essential oil and BC6ENTC . CPR:falsenewlineOur results revealed an important role of base excision repair (BER) as the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG mutants showed pronounced sensitivity to essential oil and BC6ENTC . CPR:falsenewlineIn the absence of BC6ENTC dismutase (in BC6ENTG Δ mutant strain) sensitivity to the essential oil and BC6OTHER increased indicating that this oil and BC6OTHER are generating reactive BC6OTHER species (ROS). CPR:falsenewlineIn the absence of BC6ENTG (in BC6OTHER Δ mutant strain) sensitivity to the essential oil and BC6ENTC increased indicating that this oil and BC6OTHER are generating reactive BC6OTHER species (ROS). CPR:falsenewlineIn the absence of BC6OTHER dismutase (in BC6ENTG Δ mutant strain) sensitivity to the essential oil and BC6ENTC increased indicating that this oil and BC6OTHER are generating reactive BC6OTHER species (ROS). CPR:falsenewlineThe suppression of BC6ENTG activation by inhibition of the BC6OTHER contributes to the well - known anti - inflammatory and immunosuppressive effects of BC6ENTC . CPR:falsenewlineThe suppression of BC6OTHER activation by inhibition of the BC6ENTG contributes to the well - known anti - inflammatory and immunosuppressive effects of BC6ENTC . CPR:falsenewlineVarious drugs used in the treatment of IBD, such as glucocorticoids, BC6ENTC , and BC6OTHER , interfere with BC6ENTG / BC6OTHER signaling. CPR:falsenewlineVarious drugs used in the treatment of IBD, such as glucocorticoids, BC6ENTC , and BC6OTHER , interfere with BC6OTHER / BC6ENTG signaling. CPR:falsenewlineVarious drugs used in the treatment of IBD, such as glucocorticoids, BC6OTHER , and BC6ENTC , interfere with BC6ENTG / BC6OTHER signaling. CPR:falsenewlineVarious drugs used in the treatment of IBD, such as glucocorticoids, BC6OTHER , and BC6ENTC , interfere with BC6OTHER / BC6ENTG signaling. CPR:falsenewlineThe aim of this study was to define the molecular mechanism by which BC6ENTC inhibits BC6ENTG activation. CPR:falsenewlineMETHODS: The effects of BC6ENTC and its moieties on BC6ENTG signaling were evaluated using electromobility shift, transfection, and immune complex kinase assays. CPR:falsenewlineThe direct effect of BC6ENTC on BC6ENTG ( BC6OTHER ) activity was investigated using purified recombinant BC6OTHER proteins. CPR:falsenewlineThe direct effect of BC6ENTC on BC6OTHER ( BC6ENTG ) activity was investigated using purified recombinant BC6OTHER proteins. CPR:falsenewlineThe direct effect of BC6ENTC on BC6OTHER ( BC6OTHER ) activity was investigated using purified recombinant BC6ENTG proteins. CPR:falsenewlineRESULTS: BC6ENTG / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER / BC6ENTG activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6ENTG , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6ENTG , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6ENTG , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6ENTG , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6ENTG and BC6OTHER mutants was inhibited dose dependently by BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6ENTC , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6ENTG mutants was inhibited dose dependently by BC6OTHER . CPR:falsenewlineRESULTS: BC6ENTG / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC . CPR:falsenewlineRESULTS: BC6OTHER / BC6ENTG activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6ENTG , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6ENTG , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6ENTG , BC6OTHER , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6ENTG , or constitutively active BC6OTHER and BC6OTHER mutants was inhibited dose dependently by BC6ENTC . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6ENTG and BC6OTHER mutants was inhibited dose dependently by BC6ENTC . CPR:falsenewlineRESULTS: BC6OTHER / BC6OTHER activity induced by BC6OTHER , BC6OTHER , or overexpression of BC6OTHER , BC6OTHER , BC6OTHER , or constitutively active BC6OTHER and BC6ENTG mutants was inhibited dose dependently by BC6ENTC . CPR:falsenewlineBC6ENTC inhibited BC6ENTG - induced activation of endogenous BC6OTHER in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified BC6OTHER and BC6OTHER in vitro. CPR:falsenewlineBC6ENTC inhibited BC6OTHER - induced activation of endogenous BC6ENTG in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified BC6OTHER and BC6OTHER in vitro. CPR:falsenewlineBC6ENTC inhibited BC6OTHER - induced activation of endogenous BC6OTHER in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified BC6ENTG and BC6OTHER in vitro. CPR:falsenewlineBC6ENTC inhibited BC6OTHER - induced activation of endogenous BC6OTHER in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified BC6OTHER and BC6ENTG in vitro. CPR:falsenewlineSuppression of BC6ENTG activity by BC6ENTC is mediated by direct inhibition of BC6OTHER . CPR:4newlineSuppression of BC6OTHER activity by BC6ENTC is mediated by direct inhibition of BC6ENTG . CPR:4newlineActivation of BC6ENTG , c - Jun - BC6ENTC - terminal kinase (JNK) 1, and BC6OTHER was unaffected by BC6OTHER . CPR:falsenewlineActivation of BC6OTHER , c - Jun - BC6ENTC - terminal kinase (JNK) 1, and BC6ENTG was unaffected by BC6OTHER . CPR:falsenewlineActivation of BC6ENTG , c - Jun - BC6OTHER - terminal kinase (JNK) 1, and BC6OTHER was unaffected by BC6ENTC . CPR:falsenewlineActivation of BC6OTHER , BC6ENTG , and BC6OTHER was unaffected by BC6ENTC . CPR:falsenewlineActivation of BC6OTHER , c - Jun - BC6OTHER - terminal kinase (JNK) 1, and BC6ENTG was unaffected by BC6ENTC . CPR:falsenewlineThe decrease in substrate phosphorylation by BC6ENTG is associated with a decrease in autophosphorylation of BC6OTHER and can be antagonized by excess BC6ENTC . CPR:falsenewlineThe decrease in substrate phosphorylation by BC6OTHER is associated with a decrease in autophosphorylation of BC6ENTG and can be antagonized by excess BC6ENTC . CPR:falsenewlineCONCLUSIONS: These data identify BC6ENTC as a direct inhibitor of BC6ENTG by antagonizing BC6OTHER binding. CPR:4newlineCONCLUSIONS: These data identify BC6OTHER as a direct inhibitor of BC6ENTG by antagonizing BC6ENTC binding. CPR:falsenewlineInhibition of the BC6ENTG BC6ENTC channel by BC6OTHER : affinity for open and inactivated states. CPR:falsenewlineInhibition of the BC6ENTG BC6OTHER channel by BC6ENTC : affinity for open and inactivated states. CPR:4newline6 In conclusion, BC6ENTG channel inhibition by BC6ENTC exhibits features consistent with open and inactivated state binding and is sensitive to external BC6OTHER concentration. CPR:4newline6 In conclusion, BC6ENTG channel inhibition by BC6OTHER exhibits features consistent with open and inactivated state binding and is sensitive to external BC6ENTC concentration. CPR:4newline2 In a chronic transfection model using CHO - K1 cells, BC6ENTC inhibited BC6ENTG tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16. CPR:4newlineWhen combined, BC6OTHER antagonized the effects of the full BC6ENTG agonists in BC6ENTC assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6OTHER phosphorylation by BC6OTHER . CPR:falsenewlineWhen combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6ENTC assays and reduced the stimulation of BC6ENTG BC6OTHER and BC6OTHER phosphorylation by BC6OTHER . CPR:falsenewlineWhen combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6ENTC assays and reduced the stimulation of BC6OTHER BC6ENTG and BC6OTHER phosphorylation by BC6OTHER . CPR:falsenewlineWhen combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6ENTC assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6ENTG phosphorylation by BC6OTHER . CPR:falsenewlineWhen combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6ENTC assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6OTHER phosphorylation by BC6ENTG . CPR:falsenewlineWe previously reported that BC6ENTC antidepressants act as agonists at distinct BC6ENTG . CPR:falsenewlineWhen combined, BC6OTHER antagonized the effects of the full BC6ENTG agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6OTHER phosphorylation by BC6ENTC . CPR:falsenewlineWhen combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6ENTG BC6OTHER and BC6OTHER phosphorylation by BC6ENTC . CPR:falsenewlineWhen combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6ENTG and BC6OTHER phosphorylation by BC6ENTC . CPR:falsenewlineWhen combined, BC6OTHER antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6ENTG phosphorylation by BC6ENTC . CPR:falsenewlineCONCLUSIONS AND IMPLICATIONS: In different cell systems, BC6ENTC directly activates BC6ENTG , displaying partial agonist activity at brain receptors. CPR:5newlineHere, we investigated the effect of the atypical antidepressant BC6ENTC at cloned and native BC6ENTG . CPR:falsenewlineEXPERIMENTAL APPROACH: Effects of BC6ENTC were examined in CHO cells transfected with BC6ENTG , C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of BC6OTHER binding and BC6OTHER phosphorylation. CPR:falsenewlineEXPERIMENTAL APPROACH: Effects of BC6ENTC were examined in CHO cells transfected with BC6OTHER , C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of BC6OTHER binding and BC6ENTG phosphorylation. CPR:falsenewlineEXPERIMENTAL APPROACH: Effects of BC6OTHER were examined in CHO cells transfected with BC6ENTG , C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of BC6ENTC binding and BC6OTHER phosphorylation. CPR:falsenewlineEXPERIMENTAL APPROACH: Effects of BC6OTHER were examined in CHO cells transfected with BC6OTHER , C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of BC6ENTC binding and BC6ENTG phosphorylation. CPR:falsenewlineKEY RESULTS: BC6ENTC displayed 12 - and 18 - fold higher affinity for BC6ENTG respectively. CPR:falsenewlineIn BC6ENTC assays, BC6OTHER selectively activated BC6ENTG . CPR:falsenewlineIn BC6OTHER assays, BC6ENTC selectively activated BC6ENTG . CPR:3newlineBC6ENTC and BC6OTHER increased BC6ENTG phosphorylation in CHO cells expressing BC6OTHER and C6 cells, and these effects were antagonized by BC6OTHER . CPR:falsenewlineBC6ENTC and BC6OTHER increased BC6OTHER phosphorylation in CHO cells expressing BC6ENTG and C6 cells, and these effects were antagonized by BC6OTHER . CPR:falsenewlineThe agonist activity was antagonized by the selective BC6ENTG blocker BC6ENTC ( BC6OTHER ). CPR:4newlineThe agonist activity was antagonized by the selective BC6ENTG blocker BC6OTHER ( BC6ENTC ). CPR:falsenewlineThe BC6ENTC analogue BC6OTHER also displayed BC6ENTG agonist activity. CPR:falsenewlineThe BC6OTHER analogue BC6ENTC also displayed BC6ENTG agonist activity. CPR:5newlineThe atypical antidepressant BC6ENTC exhibits agonist activity at BC6ENTG . CPR:5newlineBC6OTHER and BC6ENTC increased BC6ENTG phosphorylation in CHO cells expressing BC6OTHER and C6 cells, and these effects were antagonized by BC6OTHER . CPR:falsenewlineBC6OTHER and BC6ENTC increased BC6OTHER phosphorylation in CHO cells expressing BC6ENTG and C6 cells, and these effects were antagonized by BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER increased BC6ENTG phosphorylation in CHO cells expressing BC6OTHER and C6 cells, and these effects were antagonized by BC6ENTC . CPR:falsenewlineBC6OTHER and BC6OTHER increased BC6OTHER phosphorylation in CHO cells expressing BC6ENTG and C6 cells, and these effects were antagonized by BC6ENTC . CPR:falsenewlineIn rat striatum and nucleus accumbens, BC6ENTC stimulated BC6OTHER binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6ENTG agonists BC6OTHER and BC6OTHER . CPR:falsenewlineIn rat striatum and nucleus accumbens, BC6ENTC stimulated BC6OTHER binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6OTHER agonists BC6OTHER and BC6ENTG . CPR:falsenewlineIn rat striatum and nucleus accumbens, BC6OTHER stimulated BC6ENTC binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6ENTG agonists BC6OTHER and BC6OTHER . CPR:falsenewlineIn rat striatum and nucleus accumbens, BC6OTHER stimulated BC6ENTC binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6OTHER agonists BC6OTHER and BC6ENTG . CPR:falsenewlineIn rat striatum and nucleus accumbens, BC6OTHER stimulated BC6OTHER binding in a BC6ENTC - sensitive manner with maximal effects lower than those of the full BC6ENTG agonists BC6OTHER and BC6OTHER . CPR:falsenewlineIn rat striatum and nucleus accumbens, BC6OTHER stimulated BC6OTHER binding in a BC6ENTC - sensitive manner with maximal effects lower than those of the full BC6OTHER agonists BC6OTHER and BC6ENTG . CPR:falsenewlineIn rat striatum and nucleus accumbens, BC6OTHER stimulated BC6OTHER binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6ENTG agonists BC6ENTC and BC6OTHER . CPR:falsenewlineIn rat striatum and nucleus accumbens, BC6OTHER stimulated BC6OTHER binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6OTHER agonists BC6ENTC and BC6ENTG . CPR:falsenewlineIn rat striatum and nucleus accumbens, BC6OTHER stimulated BC6OTHER binding in a BC6OTHER - sensitive manner with maximal effects lower than those of the full BC6ENTG agonists BC6OTHER and BC6ENTC . CPR:falsenewlineWhen combined, BC6ENTC antagonized the effects of the full BC6ENTG agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6OTHER phosphorylation by BC6OTHER . CPR:falsenewlineWhen combined, BC6ENTC antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6ENTG BC6OTHER and BC6OTHER phosphorylation by BC6OTHER . CPR:falsenewlineWhen combined, BC6ENTC antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6ENTG and BC6OTHER phosphorylation by BC6OTHER . CPR:falsenewlineWhen combined, BC6ENTC antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6ENTG phosphorylation by BC6OTHER . CPR:falsenewlineWhen combined, BC6ENTC antagonized the effects of the full BC6OTHER agonists in BC6OTHER assays and reduced the stimulation of BC6OTHER BC6OTHER and BC6OTHER phosphorylation by BC6ENTG . CPR:falsenewlineFluorescence of the reporter dye is turned on by rapid removal of the BC6OTHER quencher, an event that immediately occurs only after highly selective, two - electron reduction of the sterically and conformationally restricted BC6ENTC substrate by the cancer - associated BC6ENTG ( BC6OTHER ). CPR:falsenewlineFluorescence of the reporter dye is turned on by rapid removal of the BC6OTHER quencher, an event that immediately occurs only after highly selective, two - electron reduction of the sterically and conformationally restricted BC6ENTC substrate by the cancer - associated human CHEM: BC6OTHER oxidoreductase isozyme 1 ( BC6ENTG ). CPR:falsenewlineFluorescence of the reporter dye is turned on by rapid removal of the BC6OTHER quencher, an event that immediately occurs only after highly selective, two - electron reduction of the sterically and conformationally restricted BC6OTHER substrate by the cancer - associated human CHEM: BC6ENTC oxidoreductase isozyme 1 ( BC6ENTG ). CPR:falsenewlineFluorescence of the reporter dye is turned on by rapid removal of the BC6ENTC quencher, an event that immediately occurs only after highly selective, two - electron reduction of the sterically and conformationally restricted BC6OTHER substrate by the cancer - associated BC6ENTG ( BC6OTHER ). CPR:falsenewlineFluorescence of the reporter dye is turned on by rapid removal of the BC6ENTC quencher, an event that immediately occurs only after highly selective, two - electron reduction of the sterically and conformationally restricted BC6OTHER substrate by the cancer - associated human CHEM: BC6OTHER oxidoreductase isozyme 1 ( BC6ENTG ). CPR:falsenewlineBC6ENTG required BC6OTHER and BC6ENTC - tRNA([Ser]Sec) as substrates to generate BC6OTHER - tRNA([Ser]Sec). CPR:9newlineBC6ENTG required BC6OTHER and BC6OTHER - tRNA([Ser]Sec) as substrates to generate BC6ENTC - tRNA([Ser]Sec). CPR:9newlineMoreover, it was found that BC6ENTC was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6ENTC was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6ENTC was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6ENTC was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineMoreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6ENTC , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6ENTC , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6ENTC , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6ENTC , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6ENTC , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineMoreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6OTHER , BC6ENTC , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6ENTC , and BC6OTHER using tRNA([Ser]Sec), BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6ENTC , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6ENTC , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6ENTC , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineMoreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6ENTC using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6ENTC using tRNA([Ser]Sec), BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6ENTC using tRNA([Ser]Sec), BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6ENTC using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6ENTC using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineMoreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTC - tRNA synthetase, BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTC - tRNA synthetase, BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTC - tRNA synthetase, BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTC - tRNA synthetase, BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineMoreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTC - tRNA([Ser]Sec) kinase, BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTG , BC6ENTC - tRNA([Ser]Sec) kinase, BC6OTHER , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTC - tRNA([Ser]Sec) kinase, BC6ENTG , and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTC - tRNA([Ser]Sec) kinase, BC6OTHER , and BC6ENTG . CPR:falsenewlineMoreover, it was found that BC6ENTG was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTC synthetase, and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6ENTG , BC6OTHER , BC6ENTC synthetase, and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6ENTG , BC6ENTC synthetase, and BC6OTHER . CPR:falsenewlineMoreover, it was found that BC6OTHER was synthesized on the tRNA scaffold from BC6OTHER , BC6OTHER , and BC6OTHER using tRNA([Ser]Sec), BC6OTHER , BC6OTHER , BC6ENTC synthetase, and BC6ENTG . CPR:falsenewlineBy identifying the pathway of BC6ENTC biosynthesis in mammals, this study not only functionally characterized BC6ENTG but also assigned the function of the BC6OTHER . CPR:falsenewlineBy identifying the pathway of BC6ENTC biosynthesis in mammals, this study not only functionally characterized BC6OTHER but also assigned the function of the BC6ENTG . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is cotranslationally inserted into protein in response to BC6ENTG codons and is the 21st BC6OTHER in the genetic code. CPR:falsenewlineBy identifying the pathway of BC6OTHER biosynthesis in mammals, this study not only functionally characterized BC6ENTG but also assigned the function of the BC6ENTC - tRNA([Ser]Sec) kinase. CPR:falsenewlineIn addition, we found that BC6ENTC synthetase 2 could synthesize BC6OTHER in vitro but BC6ENTG could not. CPR:falsenewlineIn addition, we found that BC6OTHER could synthesize BC6ENTC in vitro but BC6ENTG could not. CPR:falsenewlineIn addition, we found that BC6ENTG could synthesize BC6ENTC in vitro but BC6OTHER synthetase 1 could not. CPR:9newlineIn addition, we found that BC6ENTG could synthesize BC6OTHER in vitro but BC6ENTC synthetase 1 could not. CPR:falsenewlineBC6OTHER ( BC6OTHER ) is cotranslationally inserted into protein in response to BC6ENTG codons and is the 21st BC6ENTC in the genetic code. CPR:falsenewlineBC6OTHER ( BC6ENTC ) is cotranslationally inserted into protein in response to BC6ENTG codons and is the 21st BC6OTHER in the genetic code. CPR:falsenewlineHerein, comparative genomics and experimental analyses revealed that the mammalian BC6ENTC synthase ( BC6ENTG ) is the previously identified BC6OTHER - containing protein known as the BC6OTHER . CPR:falsenewlineHerein, comparative genomics and experimental analyses revealed that the mammalian BC6ENTC synthase ( BC6OTHER ) is the previously identified BC6OTHER - containing protein known as the BC6ENTG . CPR:falsenewlineHerein, comparative genomics and experimental analyses revealed that the BC6ENTG ( BC6OTHER ) is the previously identified BC6ENTC - containing protein known as the BC6OTHER . CPR:falsenewlineHerein, comparative genomics and experimental analyses revealed that the mammalian BC6OTHER synthase ( BC6ENTG ) is the previously identified BC6ENTC - containing protein known as the BC6OTHER . CPR:falsenewlineHerein, comparative genomics and experimental analyses revealed that the mammalian BC6OTHER synthase ( BC6OTHER ) is the previously identified BC6ENTC - containing protein known as the BC6ENTG . CPR:falsenewlineBC6ENTG required BC6ENTC and BC6OTHER - tRNA([Ser]Sec) as substrates to generate BC6OTHER - tRNA([Ser]Sec). CPR:9newlineAmong 12 BC6OTHER with linear BC6OTHER chains ranging in length from C1 to C12, BC6ENTC (C7) and BC6OTHER (C5) showed the most potent BC6ENTG and BC6OTHER agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12. CPR:falsenewlineAmong 12 BC6OTHER with linear BC6OTHER chains ranging in length from C1 to C12, BC6ENTC (C7) and BC6OTHER (C5) showed the most potent BC6OTHER and BC6ENTG agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12. CPR:falsenewlineAmong 12 BC6OTHER with linear BC6OTHER chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6ENTC (C5) showed the most potent BC6ENTG and BC6OTHER agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12. CPR:falsenewlineAmong 12 BC6OTHER with linear BC6OTHER chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6ENTC (C5) showed the most potent BC6OTHER and BC6ENTG agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12. CPR:5newlineMost BC6ENTC showing estrogenic activity exhibited BC6ENTG - agonistic activity at lower concentrations than those inducing BC6OTHER - agonistic activity. CPR:falsenewlineMost BC6ENTC showing estrogenic activity exhibited BC6OTHER - agonistic activity at lower concentrations than those inducing BC6ENTG - agonistic activity. CPR:falsenewlineThe estrogenic activity of BC6ENTC was markedly decreased by incubation with rat liver microsomes, and the decrease of activity was blocked by a BC6ENTG inhibitor. CPR:falsenewlineComparative study on transcriptional activity of 17 BC6OTHER mediated by BC6ENTG and BC6ENTC receptor. CPR:falsenewlineComparative study on transcriptional activity of 17 BC6ENTC mediated by BC6OTHER and BC6ENTG . CPR:falsenewlineComparative study on transcriptional activity of 17 BC6ENTC mediated by BC6ENTG and BC6OTHER . CPR:falsenewlineComparative study on transcriptional activity of 17 BC6OTHER mediated by BC6ENTC receptor α and β and BC6ENTG . CPR:falsenewlineThese results indicate that BC6ENTC are selective agonists for BC6ENTG over BC6OTHER ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6OTHER groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity. CPR:falsenewlineThese results indicate that BC6ENTC are selective agonists for BC6OTHER over BC6ENTG ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6OTHER groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity. CPR:falsenewlineThese results indicate that BC6ENTC are selective agonists for BC6OTHER over BC6OTHER ; their interactions with BC6ENTG are dependent on the size and bulkiness of the BC6OTHER groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity. CPR:falsenewlineThese results indicate that BC6ENTC are selective agonists for BC6OTHER over BC6OTHER ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6OTHER groups; and they are metabolized by BC6ENTG , leading to attenuation of their estrogenic activity. CPR:falsenewlineThese results indicate that BC6OTHER are selective agonists for BC6ENTG over BC6OTHER ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6ENTC groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity. CPR:falsenewlineThese results indicate that BC6OTHER are selective agonists for BC6OTHER over BC6ENTG ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6ENTC groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity. CPR:falsenewlineThese results indicate that BC6OTHER are selective agonists for BC6OTHER over BC6OTHER ; their interactions with BC6ENTG are dependent on the size and bulkiness of the BC6ENTC groups; and they are metabolized by BC6OTHER , leading to attenuation of their estrogenic activity. CPR:falsenewlineThese results indicate that BC6OTHER are selective agonists for BC6OTHER over BC6OTHER ; their interactions with BC6OTHER are dependent on the size and bulkiness of the BC6ENTC groups; and they are metabolized by BC6ENTG , leading to attenuation of their estrogenic activity. CPR:falsenewlineThe structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6ENTC receptor α ( BC6ENTG ), BC6OTHER and BC6OTHER receptor ( BC6OTHER ) were investigated. CPR:falsenewlineThe structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6ENTC receptor α ( BC6OTHER ), BC6ENTG and BC6OTHER receptor ( BC6OTHER ) were investigated. CPR:falsenewlineThe structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6ENTC receptor α ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ) were investigated. CPR:falsenewlineThe structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6ENTC receptor α ( BC6OTHER ), BC6OTHER and BC6OTHER receptor ( BC6ENTG ) were investigated. CPR:falsenewlineThe structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by BC6ENTG ( BC6OTHER ), BC6OTHER and BC6ENTC receptor ( BC6OTHER ) were investigated. CPR:falsenewlineThe structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6ENTG ), BC6OTHER and BC6ENTC receptor ( BC6OTHER ) were investigated. CPR:falsenewlineThe structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6OTHER ), BC6ENTG and BC6ENTC receptor ( BC6OTHER ) were investigated. CPR:falsenewlineThe structure - activity relationships of BC6OTHER which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6OTHER ), BC6OTHER and BC6ENTC receptor ( BC6ENTG ) were investigated. CPR:falsenewlineFourteen of 17 BC6ENTC exhibited BC6ENTG and / or BC6OTHER agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6OTHER showed BC6OTHER agonistic or antagonistic activity. CPR:falsenewlineFourteen of 17 BC6ENTC exhibited BC6OTHER and / or BC6ENTG agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6OTHER showed BC6OTHER agonistic or antagonistic activity. CPR:falsenewlineFourteen of 17 BC6ENTC exhibited BC6OTHER and / or BC6OTHER agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6OTHER showed BC6ENTG agonistic or antagonistic activity. CPR:falsenewlineFourteen of 17 BC6OTHER exhibited BC6ENTG and / or BC6OTHER agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6ENTC showed BC6OTHER agonistic or antagonistic activity. CPR:falsenewlineFourteen of 17 BC6OTHER exhibited BC6OTHER and / or BC6ENTG agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6ENTC showed BC6OTHER agonistic or antagonistic activity. CPR:falsenewlineFourteen of 17 BC6OTHER exhibited BC6OTHER and / or BC6OTHER agonistic activity at concentrations of ⩽1×10( - 5)M, whereas none of the 17 BC6ENTC showed BC6ENTG agonistic or antagonistic activity. CPR:falsenewlineThe structure - activity relationships of BC6ENTC which are widely used as preservatives for transcriptional activities mediated by BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER receptor ( BC6OTHER ) were investigated. CPR:falsenewlineThe structure - activity relationships of BC6ENTC which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6ENTG ), BC6OTHER and BC6OTHER receptor ( BC6OTHER ) were investigated. CPR:falsenewlineThe structure - activity relationships of BC6ENTC which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6OTHER ), BC6ENTG and BC6OTHER receptor ( BC6OTHER ) were investigated. CPR:falsenewlineThe structure - activity relationships of BC6ENTC which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ) were investigated. CPR:falsenewlineThe structure - activity relationships of BC6ENTC which are widely used as preservatives for transcriptional activities mediated by human BC6OTHER receptor α ( BC6OTHER ), BC6OTHER and BC6OTHER receptor ( BC6ENTG ) were investigated. CPR:falsenewlineAmong 12 BC6ENTC with linear BC6OTHER chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6OTHER (C5) showed the most potent BC6ENTG and BC6OTHER agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12. CPR:falsenewlineAmong 12 BC6ENTC with linear BC6OTHER chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6OTHER (C5) showed the most potent BC6OTHER and BC6ENTG agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12. CPR:falsenewlineAmong 12 BC6OTHER with linear BC6ENTC chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6OTHER (C5) showed the most potent BC6ENTG and BC6OTHER agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12. CPR:falsenewlineAmong 12 BC6OTHER with linear BC6ENTC chains ranging in length from C1 to C12, BC6OTHER (C7) and BC6OTHER (C5) showed the most potent BC6OTHER and BC6ENTG agonistic activity in the order of 10CHEM, respectively, and the activities decreased in a stepwise manner as the CHEM chain was shortened to C1 or lengthened to C12. CPR:falsenewlineA novel membrane sensor for BC6ENTG antagonist " BC6ENTC ". CPR:6newlineThe relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6ENTC > BC6OTHER . CPR:falsenewlineThe relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTC . CPR:falsenewlineThis cDNA clone, designated BC6ENTG , shares a 90% BC6ENTC identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6OTHER in the BC6OTHER and BC6OTHER terminal regions. CPR:falsenewlineThis cDNA clone, designated BC6OTHER , shares a 90% BC6ENTC identity with the previously reported BC6ENTG cDNA splice variant and differed from BC6OTHER in the BC6OTHER and BC6OTHER terminal regions. CPR:falsenewlineThis cDNA clone, designated BC6OTHER , shares a 90% BC6ENTC identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6ENTG in the BC6OTHER and BC6OTHER terminal regions. CPR:falsenewlineThis cDNA clone, designated BC6ENTG , shares a 90% BC6OTHER identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6OTHER in the BC6ENTC and BC6OTHER terminal regions. CPR:falsenewlineThis cDNA clone, designated BC6OTHER , shares a 90% BC6OTHER identity with the previously reported BC6ENTG cDNA splice variant and differed from BC6OTHER in the BC6ENTC and BC6OTHER terminal regions. CPR:falsenewlineThis cDNA clone, designated BC6OTHER , shares a 90% BC6OTHER identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6ENTG in the BC6ENTC and BC6OTHER terminal regions. CPR:falsenewlineThis cDNA clone, designated BC6ENTG , shares a 90% BC6OTHER identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6OTHER in the BC6OTHER and BC6ENTC terminal regions. CPR:falsenewlineThis cDNA clone, designated BC6OTHER , shares a 90% BC6OTHER identity with the previously reported BC6ENTG cDNA splice variant and differed from BC6OTHER in the BC6OTHER and BC6ENTC terminal regions. CPR:falsenewlineThis cDNA clone, designated BC6OTHER , shares a 90% BC6OTHER identity with the previously reported BC6OTHER cDNA splice variant and differed from BC6ENTG in the BC6OTHER and BC6ENTC terminal regions. CPR:falsenewlineCell lines stably expressing BC6ENTG protein formed homomeric BC6OTHER responsive, in order of decreasing affinity to domoate, BC6ENTC , BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCell lines stably expressing BC6OTHER protein formed homomeric BC6ENTG responsive, in order of decreasing affinity to domoate, BC6ENTC , BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCell lines stably expressing BC6ENTG protein formed homomeric BC6OTHER responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6ENTC and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCell lines stably expressing BC6OTHER protein formed homomeric BC6ENTG responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6ENTC and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCell lines stably expressing BC6ENTG protein formed homomeric BC6OTHER responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6OTHER and BC6ENTC ( BC6OTHER ). CPR:falsenewlineCell lines stably expressing BC6OTHER protein formed homomeric BC6ENTG responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6OTHER and BC6ENTC ( BC6OTHER ). CPR:falsenewlineCell lines stably expressing BC6ENTG protein formed homomeric BC6OTHER responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC ). CPR:falsenewlineCell lines stably expressing BC6OTHER protein formed homomeric BC6ENTG responsive, in order of decreasing affinity to domoate, BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC ). CPR:falsenewlineLigand binding studies with the recombinant BC6ENTG receptor expressed in mammalian cells indicated a high affinity BC6ENTC binding site (Kd = 120 + / - 15.0 nM). CPR:falsenewlineBC6ENTC - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6ENTC - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6ENTC - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6OTHER ) but not BC6OTHER and were attenuated by the non - BC6ENTG antagonist BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6ENTC and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6ENTC and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6OTHER ) but not BC6ENTC and were attenuated by the non - BC6ENTG antagonist BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6OTHER and were attenuated by the BC6ENTC (CHEM) receptor antagonist BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6OTHER and were attenuated by the BC6ENTC (CHEM) receptor antagonist BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6OTHER and were attenuated by the non CHEM ( BC6ENTC ) receptor antagonist BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6OTHER and were attenuated by the non CHEM ( BC6ENTC ) receptor antagonist BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6ENTC ( BC6OTHER ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6ENTC ( BC6OTHER ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6OTHER ) but not BC6OTHER and were attenuated by the non - BC6ENTG antagonist BC6ENTC ( BC6OTHER ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6ENTG ( BC6OTHER ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6ENTC ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6ENTG ) but not BC6OTHER and were attenuated by the non CHEM ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6ENTC ). CPR:falsenewlineBC6OTHER - evoked currents showed partial desensitization that was reduced on incubation with BC6OTHER ( BC6OTHER ) but not BC6OTHER and were attenuated by the non - BC6ENTG antagonist BC6OTHER ( BC6ENTC ). CPR:falsenewlineBC6ENTC and BC6OTHER activated the heteromeric channel with significantly higher affinities than observed for BC6ENTG alone. CPR:falsenewlineBC6OTHER and BC6ENTC activated the heteromeric channel with significantly higher affinities than observed for BC6ENTG alone. CPR:falsenewlinecDNA cloning and functional properties of human BC6ENTC receptor BC6ENTG ( BC6OTHER ) in homomeric and heteromeric configuration. CPR:falsenewlinecDNA cloning and functional properties of human BC6ENTC receptor BC6OTHER ( BC6ENTG ) in homomeric and heteromeric configuration. CPR:falsenewlineThe relative potency of compounds in displacing BC6ENTC binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER . CPR:falsenewlineThe relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6ENTC > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER . CPR:falsenewlineThe relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6ENTC = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER . CPR:falsenewlineThe relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6ENTC > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER . CPR:falsenewlineThe relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6ENTC ( BC6OTHER ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER . CPR:falsenewlineThe relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6ENTC ) = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER . CPR:falsenewlineThe relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6ENTC > BC6OTHER > BC6OTHER > BC6OTHER . CPR:falsenewlineThe relative potency of compounds in displacing BC6OTHER binding to BC6ENTG receptor was: domoate > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ( BC6OTHER ) = BC6OTHER > BC6ENTC > BC6OTHER > BC6OTHER . CPR:falsenewlineTo investigate the recognition sites of BC6OTHER tRNA for BC6ENTG from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed BC6ENTC - tRNA synthetase and various BC6OTHER tRNA transcripts that were prepared by in vitro transcription system. CPR:falsenewlineTo investigate the recognition sites of BC6OTHER tRNA for BC6OTHER from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed BC6ENTG and various BC6ENTC tRNA transcripts that were prepared by in vitro transcription system. CPR:falsenewlineTo investigate the recognition sites of BC6OTHER tRNA for BC6ENTG from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed BC6OTHER and various BC6ENTC tRNA transcripts that were prepared by in vitro transcription system. CPR:falsenewlineTo investigate the recognition sites of BC6ENTC tRNA for BC6OTHER from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed BC6ENTG and various BC6OTHER tRNA transcripts that were prepared by in vitro transcription system. CPR:falsenewlineTo investigate the recognition sites of BC6ENTC tRNA for BC6ENTG from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed BC6OTHER and various BC6OTHER tRNA transcripts that were prepared by in vitro transcription system. CPR:falsenewlineResults indicated that anticodon was not recognized by the BC6ENTG similar to that of Escherichia coli BC6ENTC tRNA recognition system. CPR:falsenewlineMolecular recognition of BC6ENTC tRNA by BC6ENTG from hyperthermophilic archaeon, Aeropyrum pernix K1. CPR:falsenewlineIn this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6ENTC (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01). CPR:falsenewlineIn this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6ENTC 0.36+ / - 0.03+blocker 0.03+ / - 0.01). CPR:falsenewlineThese data indicate that BC6ENTC , BC6OTHER and BC6OTHER interact with an allosteric site on the BC6ENTG (located on the heart) and this may explain some of their cardiac side effects. CPR:falsenewlineThese data indicate that BC6OTHER , BC6ENTC and BC6OTHER interact with an allosteric site on the BC6ENTG (located on the heart) and this may explain some of their cardiac side effects. CPR:falsenewlineThese data indicate that BC6OTHER , BC6OTHER and BC6ENTC interact with an allosteric site on the BC6ENTG (located on the heart) and this may explain some of their cardiac side effects. CPR:falsenewlineAllosteric interaction of the neuromuscular blockers BC6ENTC and BC6OTHER with recombinant BC6ENTG . CPR:falsenewlineAllosteric interaction of the neuromuscular blockers BC6OTHER and BC6ENTC with recombinant BC6ENTG . CPR:falsenewlineIn this study the neuromuscular blocking drug BC6ENTC and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01). CPR:falsenewlineIn this study the neuromuscular blocking drug BC6OTHER and the controls BC6ENTC and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01). CPR:falsenewlineIn this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6ENTC slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01). CPR:falsenewlineIn this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6ENTC induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01). CPR:falsenewlineIn this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6ENTC dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01). CPR:falsenewlineIn this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6ENTC (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01). CPR:falsenewlineIn this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6ENTC 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01). CPR:falsenewlineIn this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6ENTC (21 nM), BC6OTHER 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01). CPR:falsenewlineIn this study the neuromuscular blocking drug BC6OTHER and the controls BC6OTHER and BC6OTHER slowed the rate of BC6OTHER induced BC6OTHER dissociation from Chinese hamster ovary cells expressing recombinant BC6ENTG K(off) values min( - 1); BC6OTHER (125 nM), BC6OTHER 0.45+ / - 0.07+blocker 0.04+ / - 0.02; BC6OTHER (21 nM), BC6ENTC 0.42+ / - 0.05+blocker 0.15+ / - 0.04; BC6OTHER (21 nM), BC6OTHER 0.36+ / - 0.03+blocker 0.03+ / - 0.01). CPR:falsenewlineThe smooth muscle relaxant, BC6OTHER , which is believed relatively specific in inhibiting the BC6ENTC - BC6ENTG interaction, depressed hyposmolarity - induced BC6OTHER secretion in a dose - dependent manner (r = - 0.991, p less than 0.01). CPR:falsenewlineThe smooth muscle relaxant, BC6OTHER , which is believed relatively specific in inhibiting the BC6ENTC - BC6OTHER interaction, depressed hyposmolarity - induced BC6ENTG secretion in a dose - dependent manner (r = - 0.991, p less than 0.01). CPR:falsenewlineThe above drugs also blocked or decreased high BC6ENTC - induced secretion, but had much less effect on BC6ENTG - induced secretion. CPR:falsenewlineSecretion induced by BC6ENTG , hyposmolarity, or high BC6ENTC was optimal at pH 7.3 - 7.65 and was significantly depressed at pH 6.0 or 8.0, indicating that release of hormone induced by all 3 stimuli is due to an active cell process requiring a physiologic extracellular pH and is not produced by nonspecific cell toxicity. CPR:falsenewlineRole of extracellular BC6OTHER and BC6ENTG in BC6OTHER secretion induced by hyposmolarity, BC6OTHER , and high BC6ENTC in GH4C1 cells. CPR:falsenewlineRole of extracellular BC6OTHER and BC6OTHER in BC6ENTG secretion induced by hyposmolarity, BC6OTHER , and high BC6ENTC in GH4C1 cells. CPR:falsenewlineRole of extracellular BC6OTHER and BC6OTHER in BC6OTHER secretion induced by hyposmolarity, BC6ENTG , and high BC6ENTC in GH4C1 cells. CPR:falsenewlineRole of extracellular BC6ENTC and BC6ENTG in BC6OTHER secretion induced by hyposmolarity, BC6OTHER , and high BC6OTHER in GH4C1 cells. CPR:falsenewlineRole of extracellular BC6ENTC and BC6OTHER in BC6ENTG secretion induced by hyposmolarity, BC6OTHER , and high BC6OTHER in GH4C1 cells. CPR:falsenewlineRole of extracellular BC6ENTC and BC6OTHER in BC6OTHER secretion induced by hyposmolarity, BC6ENTG , and high BC6OTHER in GH4C1 cells. CPR:falsenewlineThe data suggest hyposmolarity and high BC6ENTC may share some similarities in their mechanism of stimulating secretion, which is different from that of BC6ENTG . CPR:falsenewlineThe mechanism by which 30% medium hyposmolarity induces BC6OTHER secretion by GH4C1 cells was compared with that induced by 100 nmol / l BC6ENTG or 30 mmol / l BC6ENTC . CPR:falsenewlineThe mechanism by which 30% medium hyposmolarity induces BC6ENTG secretion by GH4C1 cells was compared with that induced by 100 nmol / l BC6OTHER or 30 mmol / l BC6ENTC . CPR:falsenewlineRemoving medium BC6ENTC , blocking BC6ENTG with 50 mumol / l BC6OTHER , or inhibiting BC6OTHER activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion. CPR:falsenewlineRemoving medium BC6ENTC , blocking BC6OTHER channels with 50 mumol / l BC6OTHER , or inhibiting BC6ENTG activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion. CPR:falsenewlineRemoving medium BC6OTHER , blocking BC6ENTC channels with 50 mumol / l BC6OTHER , or inhibiting BC6ENTG activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion. CPR:falsenewlineRemoving medium BC6OTHER , blocking BC6ENTG with 50 mumol / l BC6ENTC , or inhibiting BC6OTHER activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion. CPR:falsenewlineRemoving medium BC6OTHER , blocking BC6OTHER channels with 50 mumol / l BC6ENTC , or inhibiting BC6ENTG activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion. CPR:falsenewlineRemoving medium BC6OTHER , blocking BC6ENTG with 50 mumol / l BC6OTHER , or inhibiting BC6OTHER activation with 20 mumol / l BC6ENTC , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion. CPR:falsenewlineRemoving medium BC6OTHER , blocking BC6OTHER channels with 50 mumol / l BC6OTHER , or inhibiting BC6ENTG activation with 20 mumol / l BC6ENTC , 10 mumol / l BC6OTHER or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion. CPR:falsenewlineRemoving medium BC6OTHER , blocking BC6ENTG with 50 mumol / l BC6OTHER , or inhibiting BC6OTHER activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6ENTC or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion. CPR:falsenewlineRemoving medium BC6OTHER , blocking BC6OTHER channels with 50 mumol / l BC6OTHER , or inhibiting BC6ENTG activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6ENTC or 10 mumol / l BC6OTHER almost completely blocked hyposmolarity - induced secretion. CPR:falsenewlineRemoving medium BC6OTHER , blocking BC6ENTG with 50 mumol / l BC6OTHER , or inhibiting BC6OTHER activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6ENTC almost completely blocked hyposmolarity - induced secretion. CPR:falsenewlineRemoving medium BC6OTHER , blocking BC6OTHER channels with 50 mumol / l BC6OTHER , or inhibiting BC6ENTG activation with 20 mumol / l BC6OTHER , 10 mumol / l BC6OTHER or 10 mumol / l BC6ENTC almost completely blocked hyposmolarity - induced secretion. CPR:falsenewlineThe smooth muscle relaxant, BC6ENTC , which is believed relatively specific in inhibiting the BC6OTHER - BC6ENTG interaction, depressed hyposmolarity - induced BC6OTHER secretion in a dose - dependent manner (r = - 0.991, p less than 0.01). CPR:falsenewlineThe smooth muscle relaxant, BC6ENTC , which is believed relatively specific in inhibiting the BC6OTHER - BC6OTHER interaction, depressed hyposmolarity - induced BC6ENTG secretion in a dose - dependent manner (r = - 0.991, p less than 0.01). CPR:falsenewlineBC6ENTC has an advantage over the indirect BC6ENTG inhibitors, unfractionated heparin and low - molecular - weight heparin, in that it inhibits free and BC6OTHER - bound BC6OTHER . CPR:falsenewlineBC6ENTC has an advantage over the indirect BC6OTHER inhibitors, unfractionated heparin and low - molecular - weight heparin, in that it inhibits free and BC6ENTG - bound BC6OTHER . CPR:4newlineBC6ENTC has an advantage over the indirect BC6OTHER inhibitors, unfractionated heparin and low - molecular - weight heparin, in that it inhibits free and BC6OTHER - bound BC6ENTG . CPR:4newline The reversible binding of BC6ENTC may provide safer and more predictable anticoagulant treatment than seen with irreversible, non - covalent BC6ENTG inhibitors, e.g. hirudin. CPR:falsenewline BC6ENTG inhibitors, e.g. BC6ENTC and BC6OTHER , are potent, oral direct inhibitors of BC6OTHER - bound, clot - associated or free BC6OTHER . CPR:4newline BC6OTHER inhibitors, e.g. BC6ENTC and BC6OTHER , are potent, oral direct inhibitors of BC6ENTG - bound, clot - associated or free BC6OTHER . CPR:4newline BC6OTHER inhibitors, e.g. BC6ENTC and BC6OTHER , are potent, oral direct inhibitors of BC6OTHER - bound, clot - associated or free BC6ENTG . CPR:4newline BC6ENTG inhibitors, e.g. BC6OTHER and BC6ENTC , are potent, oral direct inhibitors of BC6OTHER - bound, clot - associated or free BC6OTHER . CPR:4newline BC6OTHER inhibitors, e.g. BC6OTHER and BC6ENTC , are potent, oral direct inhibitors of BC6ENTG - bound, clot - associated or free BC6OTHER . CPR:4newline BC6OTHER inhibitors, e.g. BC6OTHER and BC6ENTC , are potent, oral direct inhibitors of BC6OTHER - bound, clot - associated or free BC6ENTG . CPR:4newlineSince both are substrates, co - administration of BC6ENTC and BC6OTHER with strong BC6ENTG and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers. CPR:falsenewlineSince both are substrates, co - administration of BC6ENTC and BC6OTHER with strong BC6OTHER and BC6ENTG ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers. CPR:falsenewlineSince both are substrates, co - administration of BC6ENTC and BC6OTHER with strong BC6OTHER and BC6OTHER ( BC6ENTG ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers. CPR:falsenewlineSince both are substrates, co - administration of BC6ENTC and BC6OTHER with strong BC6OTHER and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6ENTG and BC6OTHER inducers. CPR:falsenewlineSince both are substrates, co - administration of BC6ENTC and BC6OTHER with strong BC6OTHER and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6ENTG inducers. CPR:falsenewlineSince both are substrates, co - administration of BC6OTHER and BC6ENTC with strong BC6ENTG and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers. CPR:falsenewlineSince both are substrates, co - administration of BC6OTHER and BC6ENTC with strong BC6OTHER and BC6ENTG ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers. CPR:falsenewlineSince both are substrates, co - administration of BC6OTHER and BC6ENTC with strong BC6OTHER and BC6OTHER ( BC6ENTG ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6OTHER inducers. CPR:falsenewlineSince both are substrates, co - administration of BC6OTHER and BC6ENTC with strong BC6OTHER and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6ENTG and BC6OTHER inducers. CPR:falsenewlineSince both are substrates, co - administration of BC6OTHER and BC6ENTC with strong BC6OTHER and BC6OTHER ( BC6OTHER ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong BC6OTHER and BC6ENTG inducers. CPR:falsenewlineAlthough parenteral oral direct BC6ENTG inhibitors (DTIs), such as BC6ENTC and CHEM, have been on the market for years, DTIs such as BC6OTHER are novel synthetic BC6OTHER antagonists. CPR:falsenewlineAlthough parenteral oral direct BC6OTHER inhibitors (DTIs), such as BC6ENTC and CHEM, have been on the market for years, DTIs such as BC6OTHER are novel synthetic BC6ENTG antagonists. CPR:falsenewlineAlthough parenteral oral direct BC6ENTG inhibitors (DTIs), such as BC6OTHER and CHEM, have been on the market for years, DTIs such as BC6ENTC are novel synthetic BC6OTHER antagonists. CPR:falsenewlineAlthough parenteral oral direct BC6OTHER inhibitors (DTIs), such as BC6OTHER and CHEM, have been on the market for years, DTIs such as BC6ENTC are novel synthetic BC6ENTG antagonists. CPR:falsenewlineOne is that the binding of BC6ENTC to nuclear BC6ENTG ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6ENTC to nuclear BC6OTHER receptors ( BC6ENTG ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6ENTC to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6ENTG , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6ENTC to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6ENTG in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6ENTC to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6ENTG . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6ENTC receptors ( BC6ENTG ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6ENTC receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6ENTG , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6ENTC receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6ENTG in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6ENTC receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6ENTG . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6ENTG ( BC6OTHER ) does not match their therapeutic efficacy: BC6ENTC activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6ENTG ) does not match their therapeutic efficacy: BC6ENTC activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6ENTC activates the three receptor subtypes, BC6ENTG , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6ENTC activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6ENTG in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6ENTC activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6OTHER preferentially binds to and activates BC6OTHER in preference to BC6ENTG . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6ENTG ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6ENTC preferentially binds to and activates BC6OTHER in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6ENTG ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6ENTC preferentially binds to and activates BC6OTHER in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6ENTG , without measurable receptor binding, whereas BC6ENTC preferentially binds to and activates BC6OTHER in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6ENTC preferentially binds to and activates BC6ENTG in preference to BC6OTHER . CPR:falsenewlineOne is that the binding of BC6OTHER to nuclear BC6OTHER receptors ( BC6OTHER ) does not match their therapeutic efficacy: BC6OTHER activates the three receptor subtypes, BC6OTHER , without measurable receptor binding, whereas BC6ENTC preferentially binds to and activates BC6OTHER in preference to BC6ENTG . CPR:falsenewlineThe octanoylation of BC6OTHER is critical for its orexigenic functions and is dependent upon ghrelin BC6ENTC - acyltransferase ( BC6ENTG ) catalyzation. CPR:falsenewlineThe octanoylation of BC6ENTG is critical for its orexigenic functions and is dependent upon ghrelin BC6ENTC - acyltransferase ( BC6OTHER ) catalyzation. CPR:falsenewlineProtein BC6ENTC phosphatase 1B ( BC6OTHER ) is an important factor in non - BC6ENTG - dependent diabetes mellitus (type - 2 diabetes), and a promising target for treatment of diabetes and obesity. CPR:falsenewlineProtein BC6ENTC phosphatase 1B ( BC6ENTG ) is an important factor in non - BC6OTHER - dependent diabetes mellitus (type - 2 diabetes), and a promising target for treatment of diabetes and obesity. CPR:falsenewline BC6ENTG inhibitory effect by BC6OTHER - type BC6OTHER from hydrolyzate of total Gynostemma pentaphyllum BC6ENTC . CPR:4newline BC6ENTG inhibitory effect by BC6ENTC - type BC6OTHER from hydrolyzate of total Gynostemma pentaphyllum BC6OTHER . CPR:falsenewline BC6ENTG inhibitory effect by BC6OTHER - type BC6ENTC from hydrolyzate of total Gynostemma pentaphyllum BC6OTHER . CPR:falsenewlineBC6ENTC blocks BC6ENTG activation without modifying BC6OTHER synthesis. CPR:falsenewlineBC6OTHER blocks BC6ENTG activation without modifying BC6ENTC synthesis. CPR:falsenewlineThey include BC6ENTC antagonists, dopaminergic agonists, BC6OTHER , BC6OTHER , BC6ENTG analogs and BC6OTHER . CPR:falsenewlineThey include BC6OTHER antagonists, dopaminergic agonists, BC6ENTC , BC6OTHER , BC6ENTG analogs and BC6OTHER . CPR:falsenewlineThey include BC6OTHER antagonists, dopaminergic agonists, BC6OTHER , BC6ENTC , BC6ENTG analogs and BC6OTHER . CPR:falsenewlineThey include BC6OTHER antagonists, dopaminergic agonists, BC6OTHER , BC6OTHER , BC6ENTG analogs and BC6ENTC . CPR:falsenewlineBC6ENTC markedly increased postprandial plasma BC6OTHER release (P<0.001) while distinctly reducing postprandial BC6ENTG levels (P<0.01) as compared to placebo. CPR:falsenewlineBC6ENTC markedly increased postprandial plasma BC6ENTG release (P<0.001) while distinctly reducing postprandial BC6OTHER levels (P<0.01) as compared to placebo. CPR:falsenewlineThe study demonstrates for the first time the marked gastrokinetic properties of the new BC6ENTG antagonist BC6ENTC in humans. CPR:6newlineWe studied the role of endogenous BC6ENTG in the emptying of a solid / liquid meal administering the new, highly specific and potent BC6OTHER antagonist BC6ENTC . CPR:falsenewlineWe studied the role of endogenous BC6OTHER in the emptying of a solid / liquid meal administering the new, highly specific and potent BC6ENTG antagonist BC6ENTC . CPR:6newlineEffect of BC6ENTC , a new BC6ENTG antagonist, on gastric emptying of a solid - liquid meal in humans. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6ENTC ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6ENTC ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6ENTC ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6ENTC ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineInterestingly, the inhibitory effect of BC6OTHER on BC6ENTG activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6ENTC ( BC6OTHER ), an end product of BC6OTHER . CPR:falsenewlineInterestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6ENTG siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6ENTC ( BC6OTHER ), an end product of BC6OTHER . CPR:falsenewlineInterestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6ENTG gene transfection or treatment with BC6ENTC ( BC6OTHER ), an end product of BC6OTHER . CPR:falsenewlineInterestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6ENTC ( BC6OTHER ), an end product of BC6ENTG . CPR:falsenewlineInterestingly, the inhibitory effect of BC6OTHER on BC6ENTG activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6ENTC ), an end product of BC6OTHER . CPR:falsenewlineInterestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6ENTG siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6ENTC ), an end product of BC6OTHER . CPR:falsenewlineInterestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6ENTG gene transfection or treatment with BC6OTHER ( BC6ENTC ), an end product of BC6OTHER . CPR:falsenewlineInterestingly, the inhibitory effect of BC6OTHER on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6ENTC ), an end product of BC6ENTG . CPR:falsenewlineBC6ENTC treatment also inhibited LPS - induced BC6OTHER production and BC6ENTG expression via its inactivation of BC6OTHER . CPR:4newlineBC6ENTC treatment also inhibited LPS - induced BC6OTHER production and BC6OTHER expression via its inactivation of BC6ENTG . CPR:4newlineBC6OTHER treatment also inhibited LPS - induced BC6ENTC production and BC6ENTG expression via its inactivation of BC6OTHER . CPR:falsenewlineBC6OTHER treatment also inhibited LPS - induced BC6ENTC production and BC6OTHER expression via its inactivation of BC6ENTG . CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6ENTC ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6ENTC ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6ENTC ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6ENTC ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6ENTC ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6ENTC ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6ENTC ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6ENTC ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineCollectively, our results suggest that BC6ENTC can inhibit BC6OTHER production and BC6ENTG activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6OTHER / BC6OTHER . CPR:4newlineCollectively, our results suggest that BC6ENTC can inhibit BC6OTHER production and BC6OTHER activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6ENTG / BC6OTHER . CPR:falsenewlineCollectively, our results suggest that BC6OTHER can inhibit BC6ENTC production and BC6ENTG activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6OTHER / BC6OTHER . CPR:falsenewlineCollectively, our results suggest that BC6OTHER can inhibit BC6ENTC production and BC6OTHER activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6ENTG / BC6OTHER . CPR:falsenewlineCollectively, our results suggest that BC6OTHER can inhibit BC6OTHER production and BC6ENTG activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6OTHER / BC6ENTC . CPR:falsenewlineCollectively, our results suggest that BC6OTHER can inhibit BC6OTHER production and BC6OTHER activation in LPS - stimulated macrophages through a mechanism that involves the action of BC6ENTG / BC6ENTC . CPR:falsenewlineBC6ENTC ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6ENTC ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6ENTC ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6ENTC ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6ENTC ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6ENTC ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6ENTC ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6ENTC ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6ENTC ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6ENTC ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6ENTC ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6ENTC ) production is unexplored. CPR:falsenewlineHere, we show that at noncytotoxic concentrations, BC6ENTC was able to inhibit BC6OTHER production and BC6ENTG ( BC6OTHER ) expression via BC6OTHER ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). CPR:4newlineHere, we show that at noncytotoxic concentrations, BC6ENTC was able to inhibit BC6OTHER production and inducible BC6OTHER synthase ( BC6ENTG ) expression via BC6OTHER ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). CPR:4newlineHere, we show that at noncytotoxic concentrations, BC6ENTC was able to inhibit BC6OTHER production and inducible BC6OTHER synthase ( BC6OTHER ) expression via BC6ENTG ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). CPR:falsenewlineHere, we show that at noncytotoxic concentrations, BC6ENTC was able to inhibit BC6OTHER production and inducible BC6OTHER synthase ( BC6OTHER ) expression via BC6OTHER ( BC6ENTG ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). CPR:falsenewlineHere, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6ENTC production and BC6ENTG ( BC6OTHER ) expression via BC6OTHER ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). CPR:falsenewlineHere, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6ENTC production and inducible BC6OTHER synthase ( BC6ENTG ) expression via BC6OTHER ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). CPR:falsenewlineHere, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6ENTC production and inducible BC6OTHER synthase ( BC6OTHER ) expression via BC6ENTG ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). CPR:falsenewlineHere, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6ENTC production and inducible BC6OTHER synthase ( BC6OTHER ) expression via BC6OTHER ( BC6ENTG ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). CPR:falsenewlineHere, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6OTHER production and inducible BC6ENTC synthase ( BC6ENTG ) expression via BC6OTHER ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). CPR:falsenewlineHere, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6OTHER production and inducible BC6ENTC synthase ( BC6OTHER ) expression via BC6ENTG ( BC6OTHER ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). CPR:4newlineHere, we show that at noncytotoxic concentrations, BC6OTHER was able to inhibit BC6OTHER production and inducible BC6ENTC synthase ( BC6OTHER ) expression via BC6OTHER ( BC6ENTG ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). CPR:4newlineBoth BC6ENTC solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6ENTG expression through the activation of the BC6OTHER ( BC6OTHER ). CPR:falsenewlineBoth BC6ENTC solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6ENTG ( BC6OTHER ). CPR:falsenewlineBoth BC6ENTC solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6OTHER ( BC6ENTG ). CPR:falsenewlineBoth BC6OTHER solution prepared by bubbling pure BC6ENTC gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6ENTG expression through the activation of the BC6OTHER ( BC6OTHER ). CPR:falsenewlineBoth BC6OTHER solution prepared by bubbling pure BC6ENTC gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6ENTG ( BC6OTHER ). CPR:falsenewlineBoth BC6OTHER solution prepared by bubbling pure BC6ENTC gas and BC6OTHER , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6OTHER ( BC6ENTG ). CPR:falsenewlineBoth BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6ENTC , a BC6OTHER donor, dose dependently induced BC6ENTG expression through the activation of the BC6OTHER ( BC6OTHER ). CPR:falsenewlineBoth BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6ENTC , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6ENTG ( BC6OTHER ). CPR:falsenewlineBoth BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6ENTC , a BC6OTHER donor, dose dependently induced BC6OTHER expression through the activation of the BC6OTHER ( BC6ENTG ). CPR:falsenewlineBoth BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6ENTC donor, dose dependently induced BC6ENTG expression through the activation of the BC6OTHER ( BC6OTHER ). CPR:falsenewlineBoth BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6ENTC donor, dose dependently induced BC6OTHER expression through the activation of the BC6ENTG ( BC6OTHER ). CPR:falsenewlineBoth BC6OTHER solution prepared by bubbling pure BC6OTHER gas and BC6OTHER , a BC6ENTC donor, dose dependently induced BC6OTHER expression through the activation of the BC6OTHER ( BC6ENTG ). CPR:falsenewlinePretreatment with BC6ENTC or BC6OTHER significantly inhibited LPS - induced BC6ENTG expression and BC6OTHER production. CPR:4newlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6ENTG inhibitor BC6ENTC but not by the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6ENTC but not by the BC6ENTG inhibitor BC6OTHER . CPR:falsenewlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6ENTG mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6ENTC but not by the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlinePretreatment with BC6OTHER or BC6ENTC significantly inhibited LPS - induced BC6ENTG expression and BC6OTHER production. CPR:falsenewlinePretreatment with BC6OTHER or BC6OTHER significantly inhibited LPS - induced BC6ENTG expression and BC6ENTC production. CPR:falsenewlineMoreover, BC6ENTC production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6ENTG inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineMoreover, BC6ENTC production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6ENTG inhibitor BC6OTHER . CPR:falsenewlineMoreover, BC6ENTC production in LPS - stimulated macrophages that are expressing BC6ENTG mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTC gamma - lyase ( BC6ENTG ) and / or BC6OTHER beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTC gamma - lyase ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTC gamma - lyase ( BC6OTHER ) and / or BC6OTHER beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6ENTC , a substrate for BC6OTHER , but enhanced by the selective BC6ENTG inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6ENTC , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6ENTG inhibitor BC6OTHER . CPR:falsenewlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6ENTG mRNA was significantly reduced by the addition of BC6ENTC , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6ENTC , but enhanced by the selective BC6ENTG inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6ENTC , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6ENTG inhibitor BC6OTHER . CPR:falsenewlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6ENTG mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6ENTC , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6OTHER . CPR:falsenewline BC6ENTC inhibits BC6OTHER production and BC6ENTG via BC6OTHER expression in RAW264.7 macrophages stimulated with lipopolysaccharide. CPR:4newline BC6ENTC inhibits BC6OTHER production and BC6OTHER via BC6ENTG expression in RAW264.7 macrophages stimulated with lipopolysaccharide. CPR:4newline BC6OTHER inhibits BC6ENTC production and BC6ENTG via BC6OTHER expression in RAW264.7 macrophages stimulated with lipopolysaccharide. CPR:falsenewline BC6OTHER inhibits BC6ENTC production and BC6OTHER via BC6ENTG expression in RAW264.7 macrophages stimulated with lipopolysaccharide. CPR:falsenewlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6ENTG inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6ENTC . CPR:falsenewlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6OTHER mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6ENTG inhibitor BC6ENTC . CPR:falsenewlineMoreover, BC6OTHER production in LPS - stimulated macrophages that are expressing BC6ENTG mRNA was significantly reduced by the addition of BC6OTHER , a substrate for BC6OTHER , but enhanced by the selective BC6OTHER inhibitor BC6OTHER but not by the BC6OTHER inhibitor BC6ENTC . CPR:falsenewlineWhile either blockage of BC6ENTG activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6ENTG inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6ENTG expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6ENTG small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6ENTG expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6ENTC on BC6OTHER expression and BC6OTHER production, BC6ENTG overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6ENTG ) and / or BC6ENTC beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6OTHER ( BC6OTHER ) and / or BC6ENTC beta - synthase ( BC6ENTG ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a regulatory gaseous molecule that is endogenously synthesized by BC6ENTG ( BC6OTHER ) and / or BC6ENTC beta - synthase ( BC6OTHER ) from BC6OTHER ( BC6OTHER ) metabolism, is a putative vasodilator, and its role in BC6OTHER ( BC6OTHER ) production is unexplored. CPR:falsenewlineWhile either blockage of BC6ENTG activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6ENTC production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6ENTG inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6ENTC production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6ENTG expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6ENTC production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6ENTG small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6ENTC production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6ENTG expression and BC6ENTC production, BC6OTHER overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6ENTC production, BC6ENTG overexpression produced the same inhibitory effects of BC6OTHER . CPR:falsenewlineWhile either blockage of BC6ENTG activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6ENTC . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6ENTG inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6ENTC . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6ENTG expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6ENTC . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6ENTG small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6ENTC . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6ENTG expression and BC6OTHER production, BC6OTHER overexpression produced the same inhibitory effects of BC6ENTC . CPR:falsenewlineWhile either blockage of BC6OTHER activity by the BC6OTHER inhibitor, CHEM, or down - regulation of BC6OTHER expression by BC6OTHER small interfering RNA (siRNA) reversed the inhibitory effects of BC6OTHER on BC6OTHER expression and BC6OTHER production, BC6ENTG overexpression produced the same inhibitory effects of BC6ENTC . CPR:falsenewlineIn addition, LPS - induced nuclear factor BC6ENTG activation was diminished in RAW264.7 macrophages preincubated with BC6ENTC . CPR:4newlineInterestingly, the inhibitory effect of BC6ENTC on BC6ENTG activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6OTHER ), an end product of BC6OTHER . CPR:falsenewlineInterestingly, the inhibitory effect of BC6ENTC on BC6OTHER activation was reversed by the transient transfection with BC6ENTG siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6OTHER ), an end product of BC6OTHER . CPR:falsenewlineInterestingly, the inhibitory effect of BC6ENTC on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6ENTG gene transfection or treatment with BC6OTHER ( BC6OTHER ), an end product of BC6OTHER . CPR:falsenewlineInterestingly, the inhibitory effect of BC6ENTC on BC6OTHER activation was reversed by the transient transfection with BC6OTHER siRNA, but was mimicked by either BC6OTHER gene transfection or treatment with BC6OTHER ( BC6OTHER ), an end product of BC6ENTG . CPR:falsenewlineBC6ENTG is expressed in differentiating osteoclast - like cells and the BC6OTHER mutation selectively impairs the BC6OTHER - BC6OTHER interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6OTHER - BC6OTHER complex. CPR:falsenewlineBC6OTHER is expressed in differentiating osteoclast - like cells and the BC6ENTG mutation selectively impairs the BC6OTHER - BC6OTHER interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6OTHER - BC6OTHER complex. CPR:falsenewlineBC6OTHER is expressed in differentiating osteoclast - like cells and the BC6OTHER mutation selectively impairs the BC6ENTG - BC6OTHER interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6OTHER - BC6OTHER complex. CPR:falsenewlineBC6OTHER is expressed in differentiating osteoclast - like cells and the BC6OTHER mutation selectively impairs the BC6OTHER - BC6ENTG interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6OTHER - BC6OTHER complex. CPR:falsenewlineBC6OTHER is expressed in differentiating osteoclast - like cells and the BC6OTHER mutation selectively impairs the BC6OTHER - BC6OTHER interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6ENTG - BC6OTHER complex. CPR:falsenewlineBC6OTHER is expressed in differentiating osteoclast - like cells and the BC6OTHER mutation selectively impairs the BC6OTHER - BC6OTHER interaction in co - immunoprecipitations, which molecular modelling indicates results from effects on critical BC6ENTC bonds required to stabilise the BC6OTHER - BC6ENTG complex. CPR:falsenewlineEspecially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme BC6ENTG , as compared to the standard tyrosinase inhibitors BC6ENTC (IC50=16.67 microM) and BC6OTHER (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes. CPR:falsenewlineEspecially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme BC6ENTG , as compared to the standard tyrosinase inhibitors BC6OTHER (IC50=16.67 microM) and BC6ENTC (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes. CPR:falsenewlinePatients treated with BC6ENTC - based chemotherapy, carrying the BC6ENTG BC6OTHER genotype had significantly decreased time - to - tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16 - 5.29; P=0.019). CPR:falsenewlinePatients treated with BC6ENTC - based chemotherapy, carrying the BC6OTHER BC6ENTG genotype had significantly decreased time - to - tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16 - 5.29; P=0.019). CPR:falsenewlineThe BC6OTHER ( BC6ENTG ) BC6OTHER polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant BC6ENTC - based chemotherapy. CPR:falsenewlineThe BC6OTHER ( BC6OTHER ) BC6ENTG polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant BC6ENTC - based chemotherapy. CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) BC6OTHER polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant BC6ENTC - based chemotherapy. CPR:falsenewlineFiltering and analysis of data identified three oncogenic pathways interfered by BC6ENTC : BC6ENTG / BC6OTHER pathway, cell adhesion and BC6OTHER / BC6OTHER signaling. CPR:falsenewlineFiltering and analysis of data identified three oncogenic pathways interfered by BC6ENTC : BC6OTHER / BC6ENTG pathway, cell adhesion and BC6OTHER / BC6OTHER signaling. CPR:falsenewlineFiltering and analysis of data identified three oncogenic pathways interfered by BC6ENTC : BC6OTHER / BC6OTHER pathway, cell adhesion and BC6ENTG / BC6OTHER signaling. CPR:falsenewlineFiltering and analysis of data identified three oncogenic pathways interfered by BC6ENTC : BC6OTHER / BC6OTHER pathway, cell adhesion and BC6OTHER / BC6ENTG signaling. CPR:falsenewlineBC6ENTG emerged as a consensus target of BC6ENTC , orchestrating these pathways. CPR:falsenewlineMoreover, BC6ENTC treatment restored membranous expression of adhesion molecules BC6ENTG and BC6OTHER . CPR:falsenewlineMoreover, BC6ENTC treatment restored membranous expression of adhesion molecules BC6OTHER and BC6ENTG . CPR:falsenewline BC6ENTC modulates intercellular adhesion through inhibition of BC6ENTG . CPR:4newlineBC6ENTG expression was elevated in APC(min) polyps and BC6ENTC treatment reduced its expression. CPR:falsenewlineOur data demonstrates novel pharmacological mechanism of BC6ENTC in modulation of cell adhesion and role of BC6ENTG in APC(min) polyposis. CPR:falsenewlineWe propose that inhibition of BC6ENTG expression by BC6ENTC can impede with neoplastic progression in colorectal carcinogenesis. CPR:4newlineThe mechanism of BC6ENTG inhibition and induction of membranous translocation of adhesion proteins by BC6ENTC might be independent of its known anti - inflammatory action. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:9newlineStrain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:9newlineStrain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:9newlineStrain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:9newlineStrain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:9newlineStrain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:9newlineStrain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:9newlineStrain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ), was observed. CPR:9newlineStrain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), was observed. CPR:9newlineStrain - dependent down - regulation of several key one - BC6ENTC metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ), was observed. CPR:9newlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTC adenosyltransferase 1α ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTG ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6ENTG ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTC - β - synthase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - homocysteinase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6ENTC dehydrogenase 1 ( BC6OTHER ), was observed. CPR:falsenewlineStrain - dependent down - regulation of several key one - BC6OTHER metabolism genes, including BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC dehydrogenase 1 ( BC6ENTG ), was observed. CPR:falsenewlineIn contrast, the BC6ENTG sequence showed well - defined structure only near its BC6ENTC - terminal residues. CPR:falsenewlineThe BC6ENTG of the BC6ENTC (1) receptor have not yet been conclusively resolved, and bear limited sequence identity to known structures. CPR:falsenewlineThis study involved development of a peptide to characterize the intrinsic structure of the BC6ENTC (1) BC6ENTG second BC6OTHER . CPR:falsenewlineThis study involved development of a peptide to characterize the intrinsic structure of the BC6ENTC (1) BC6OTHER second BC6ENTG . CPR:falsenewlineThe loop was embedded between two helices that assemble into a BC6ENTG , which served as a receptor - mimetic folding constraint ( BC6ENTC (1) - CC - BC6OTHER peptide). CPR:falsenewlineThe loop was embedded between two helices that assemble into a BC6OTHER , which served as a receptor - mimetic folding constraint ( BC6ENTC (1) - CC - BC6ENTG peptide). CPR:falsenewlineAcute and chronic BC6OTHER administration increase brain BC6OTHER levels, an effect due, at least in part, to an inhibition of the activity of the BC6OTHER metabolizing enzyme, BC6ENTC transaminase ( BC6ENTG ). CPR:falsenewlineAs with BC6ENTC , the metabolism of BC6OTHER involves a BC6ENTG . CPR:9newlineAs with BC6OTHER , the metabolism of BC6ENTC involves a BC6ENTG . CPR:9newlineIn the study reported here, the effects of acute BC6ENTC treatment on the levels of various BC6OTHER , some of which are also metabolized by BC6ENTG were compared in rat whole brain. CPR:falsenewlineIn the study reported here, the effects of acute BC6OTHER treatment on the levels of various BC6ENTC , some of which are also metabolized by BC6ENTG were compared in rat whole brain. CPR:falsenewlineIn addition, we also showed that the elevation in BC6ENTC levels and the inhibition of BC6ENTG in the brain are retained after 14 days of BC6OTHER treatment, and that BC6OTHER produces a marked increase in extracellular levels of BC6OTHER . CPR:falsenewlineThe elevation in brain BC6ENTC levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6ENTG ( BC6OTHER ), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced. CPR:falsenewlineThe elevation in brain BC6ENTC levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6OTHER ( BC6ENTG ), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced. CPR:falsenewlineAcute and chronic BC6ENTC administration increase brain BC6OTHER levels, an effect due, at least in part, to an inhibition of the activity of the BC6OTHER metabolizing enzyme, BC6ENTG ( BC6OTHER ). CPR:falsenewlineAcute and chronic BC6ENTC administration increase brain BC6OTHER levels, an effect due, at least in part, to an inhibition of the activity of the BC6OTHER metabolizing enzyme, BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6ENTC on BC6ENTG ( BC6OTHER ), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced. CPR:falsenewlineThe elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6ENTC on BC6OTHER ( BC6ENTG ), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced. CPR:falsenewlineThe elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6ENTC transaminase ( BC6ENTG ), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced. CPR:falsenewlineThe elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6ENTG ( BC6ENTC - T), although as with BC6OTHER the increases are higher than expected from the degree of enzyme inhibition produced. CPR:falsenewlineThe elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6ENTG ( BC6OTHER ), although as with BC6ENTC the increases are higher than expected from the degree of enzyme inhibition produced. CPR:falsenewlineThe elevation in brain BC6OTHER levels could be explained, at least in part, by a time - and dose - dependent inhibitory effect of BC6OTHER on BC6OTHER ( BC6ENTG ), although as with BC6ENTC the increases are higher than expected from the degree of enzyme inhibition produced. CPR:falsenewlineEffects of the antidepressant / antipanic drug BC6ENTC on BC6OTHER and BC6ENTG in rat brain. CPR:falsenewlineEffects of the antidepressant / antipanic drug BC6OTHER on BC6ENTC and BC6ENTG in rat brain. CPR:falsenewlineAcute and chronic BC6OTHER administration increase brain BC6ENTC levels, an effect due, at least in part, to an inhibition of the activity of the BC6OTHER metabolizing enzyme, BC6ENTG ( BC6OTHER ). CPR:falsenewlineAcute and chronic BC6OTHER administration increase brain BC6ENTC levels, an effect due, at least in part, to an inhibition of the activity of the BC6OTHER metabolizing enzyme, BC6OTHER ( BC6ENTG ). CPR:falsenewlineIn addition, we also showed that the elevation in BC6OTHER levels and the inhibition of BC6ENTG in the brain are retained after 14 days of BC6ENTC treatment, and that BC6OTHER produces a marked increase in extracellular levels of BC6OTHER . CPR:falsenewlineIn addition, we also showed that the elevation in BC6OTHER levels and the inhibition of BC6ENTG in the brain are retained after 14 days of BC6OTHER treatment, and that BC6ENTC produces a marked increase in extracellular levels of BC6OTHER . CPR:falsenewlineIn addition, we also showed that the elevation in BC6OTHER levels and the inhibition of BC6ENTG in the brain are retained after 14 days of BC6OTHER treatment, and that BC6OTHER produces a marked increase in extracellular levels of BC6ENTC . CPR:falsenewlineAcute and chronic BC6OTHER administration increase brain BC6OTHER levels, an effect due, at least in part, to an inhibition of the activity of the BC6ENTC metabolizing enzyme, BC6ENTG ( BC6OTHER ). CPR:falsenewlineAcute and chronic BC6OTHER administration increase brain BC6OTHER levels, an effect due, at least in part, to an inhibition of the activity of the BC6ENTC metabolizing enzyme, BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6ENTC 11 ( BC6OTHER ) was synthesized and evaluated as BC6OTHER (also known as BC6ENTG or BC6OTHER ) inhibitor. CPR:4newlineBC6ENTC 11 ( BC6OTHER ) was synthesized and evaluated as BC6OTHER (also known as BC6OTHER or BC6ENTG ) inhibitor. CPR:4newlineBC6ENTC 11 ( BC6OTHER ) was synthesized and evaluated as BC6ENTG (also known as BC6OTHER or BC6OTHER ) inhibitor. CPR:4newlineBC6OTHER 11 ( BC6ENTC ) was synthesized and evaluated as BC6OTHER (also known as BC6ENTG or BC6OTHER ) inhibitor. CPR:4newlineBC6OTHER 11 ( BC6ENTC ) was synthesized and evaluated as BC6OTHER (also known as BC6OTHER or BC6ENTG ) inhibitor. CPR:4newlineBC6OTHER 11 ( BC6ENTC ) was synthesized and evaluated as BC6ENTG (also known as BC6OTHER or BC6OTHER ) inhibitor. CPR:4newlineDiscovery of BC6ENTC ( BC6OTHER ): a potent and selective BC6ENTG inhibitor as a topical drug for alopecia. CPR:4newlineDiscovery of BC6OTHER ( BC6ENTC ): a potent and selective BC6ENTG inhibitor as a topical drug for alopecia. CPR:4newlineBC6OTHER ( BC6ENTC ), a widely used drug to lower elevated plasma lipid levels, induced BC6ENTG enzyme activity in white adipose tissue of mice. CPR:falsenewlineBC6ENTG ( BC6OTHER ) catalyses the conversion of BC6OTHER to BC6ENTC and plays an important role in hepatic detoxification reactions. CPR:9newlineBC6OTHER BC6OTHER - methyltransferase ( BC6ENTG ) catalyses the conversion of BC6OTHER to BC6ENTC and plays an important role in hepatic detoxification reactions. CPR:falsenewlineAdipose tissue as a source of BC6ENTG and BC6ENTC . CPR:falsenewlineBC6ENTC BC6OTHER - methyltransferase ( BC6ENTG ) catalyses the conversion of BC6OTHER to BC6OTHER and plays an important role in hepatic detoxification reactions. CPR:falsenewlineThese data support the concept that adipose tissue BC6ENTG contributes to the increased plasma BC6ENTC levels in patients treated with BC6OTHER . CPR:falsenewlineThese data support the concept that adipose tissue BC6ENTG contributes to the increased plasma BC6OTHER levels in patients treated with BC6ENTC . CPR:falsenewlineBC6OTHER BC6ENTC - methyltransferase ( BC6ENTG ) catalyses the conversion of BC6OTHER to BC6OTHER and plays an important role in hepatic detoxification reactions. CPR:falsenewlineBC6ENTC , the atherogenic product of the BC6ENTG - catalyzed reaction, was secreted from 3T3 - L1 cells or adipose tissue cultures. CPR:9newlineBC6ENTC release increased during 3T3 - L1 differentiation and was reduced when adipose tissue was treated with the BC6ENTG inhibitor BC6OTHER . CPR:falsenewlineBC6ENTG ( BC6OTHER ) catalyses the conversion of BC6ENTC to BC6OTHER and plays an important role in hepatic detoxification reactions. CPR:9newlineBC6OTHER BC6OTHER - methyltransferase ( BC6ENTG ) catalyses the conversion of BC6ENTC to BC6OTHER and plays an important role in hepatic detoxification reactions. CPR:falsenewlineBC6OTHER release increased during 3T3 - L1 differentiation and was reduced when adipose tissue was treated with the BC6ENTG inhibitor BC6ENTC . CPR:falsenewlineBC6ENTC ( BC6OTHER ), a widely used drug to lower elevated plasma lipid levels, induced BC6ENTG enzyme activity in white adipose tissue of mice. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6ENTC and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6ENTC and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6ENTC and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6ENTC and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6ENTC , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6ENTC , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6ENTC , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6ENTC , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6ENTC and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6ENTC and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:9newlineDuring BC6OTHER catabolism, BC6ENTC and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6ENTC and BC6OTHER are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn attempting to clone the BC6ENTG involved in this back - conversion pathway, we encountered an BC6OTHER that preferentially cleaves BC6ENTC in the absence of prior acetylation by BC6OTHER . CPR:falsenewlineIn attempting to clone the BC6OTHER involved in this back - conversion pathway, we encountered an BC6ENTG that preferentially cleaves BC6ENTC in the absence of prior acetylation by BC6OTHER . CPR:9newlineIn attempting to clone the BC6OTHER involved in this back - conversion pathway, we encountered an BC6OTHER that preferentially cleaves BC6ENTC in the absence of prior acetylation by BC6ENTG . CPR:9newlineDuring BC6OTHER catabolism, BC6OTHER and BC6ENTC are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6ENTC are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:9newlineDuring BC6OTHER catabolism, BC6OTHER and BC6ENTC are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6ENTC are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineA BLAST search using BC6ENTG sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20 BC6ENTC . CPR:falsenewlineSubstrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6ENTC , BC6OTHER or the preferred BC6ENTG substrate, BC6OTHER . CPR:falsenewlineSubstrate specificity using lysates of BC6ENTG - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6ENTC , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER . CPR:falsenewlineSubstrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6ENTG strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6ENTC , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER . CPR:falsenewlineDuring BC6ENTC catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:9newlineDuring BC6ENTC catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6ENTC catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6ENTC catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTC / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTC / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTC / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6ENTC BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6ENTC BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6ENTC BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6ENTC (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6ENTC (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTG ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6ENTC (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTG BC6ENTC (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6OTHER oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineSubstrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6ENTC over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6ENTG substrate, BC6OTHER . CPR:falsenewlineSubstrate specificity using lysates of BC6ENTG - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6ENTC over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER . CPR:falsenewlineSubstrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6ENTG strongly favoured BC6ENTC over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER . CPR:falsenewlineSubstrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6ENTC and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6ENTG substrate, BC6OTHER . CPR:falsenewlineSubstrate specificity using lysates of BC6ENTG - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6ENTC and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER . CPR:falsenewlineSubstrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6ENTG strongly favoured BC6OTHER over BC6ENTC and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6OTHER . CPR:falsenewlineIdentification and characterization of a novel BC6ENTC - containing BC6ENTG of mammalian cell origin. CPR:falsenewlineSubstrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6ENTC or the preferred BC6ENTG substrate, BC6OTHER . CPR:falsenewlineSubstrate specificity using lysates of BC6ENTG - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6ENTC or the preferred BC6OTHER substrate, BC6OTHER . CPR:falsenewlineSubstrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6ENTG strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6ENTC or the preferred BC6OTHER substrate, BC6OTHER . CPR:falsenewlineSubstrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6ENTG substrate, BC6ENTC . CPR:falsenewlineSubstrate specificity using lysates of BC6ENTG - transfected HEK - 293 cells revealed that the newly identified BC6OTHER strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6ENTC . CPR:falsenewlineSubstrate specificity using lysates of BC6OTHER - transfected HEK - 293 cells revealed that the newly identified BC6ENTG strongly favoured BC6OTHER over BC6OTHER and that it failed to act on BC6OTHER , BC6OTHER or the preferred BC6OTHER substrate, BC6ENTC . CPR:falsenewlineThe BC6ENTG inhibitor, BC6ENTC , only partially blocked oxidation of BC6OTHER while a previously reported BC6OTHER substrate, BC6OTHER , potently inhibited the reaction. CPR:falsenewlineThe BC6OTHER inhibitor, BC6ENTC , only partially blocked oxidation of BC6OTHER while a previously reported BC6ENTG substrate, BC6OTHER , potently inhibited the reaction. CPR:9newlineThe BC6ENTG inhibitor, BC6OTHER , only partially blocked oxidation of BC6ENTC while a previously reported BC6OTHER substrate, BC6OTHER , potently inhibited the reaction. CPR:falsenewlineThe BC6OTHER inhibitor, BC6OTHER , only partially blocked oxidation of BC6ENTC while a previously reported BC6ENTG substrate, BC6OTHER , potently inhibited the reaction. CPR:9newlineThe BC6ENTG inhibitor, BC6OTHER , only partially blocked oxidation of BC6OTHER while a previously reported BC6OTHER substrate, BC6ENTC , potently inhibited the reaction. CPR:falsenewlineThe BC6OTHER inhibitor, BC6OTHER , only partially blocked oxidation of BC6OTHER while a previously reported BC6ENTG substrate, BC6ENTC , potently inhibited the reaction. CPR:9newlineOverall, the data indicate that the enzyme represents a novel BC6ENTG which, on the basis of substrate specificity, we have designated BC6ENTC oxidase in order to distinguish it from the BC6OTHER involved in BC6OTHER back - conversion. CPR:falsenewlineOverall, the data indicate that the enzyme represents a novel BC6OTHER which, on the basis of substrate specificity, we have designated BC6ENTC oxidase in order to distinguish it from the BC6ENTG involved in BC6OTHER back - conversion. CPR:falsenewlineOverall, the data indicate that the enzyme represents a novel BC6ENTG which, on the basis of substrate specificity, we have designated BC6OTHER oxidase in order to distinguish it from the BC6OTHER involved in BC6ENTC back - conversion. CPR:falsenewlineOverall, the data indicate that the enzyme represents a novel BC6OTHER which, on the basis of substrate specificity, we have designated BC6ENTG in order to distinguish it from the BC6OTHER involved in BC6ENTC back - conversion. CPR:falsenewlineOverall, the data indicate that the enzyme represents a novel BC6OTHER which, on the basis of substrate specificity, we have designated BC6OTHER oxidase in order to distinguish it from the BC6ENTG involved in BC6ENTC back - conversion. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6ENTG ) and subsequently oxidized by BC6ENTC oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by CHEM / BC6OTHER BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTC oxidase ( BC6ENTG ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineDuring BC6OTHER catabolism, BC6OTHER and BC6OTHER are first acetylated by BC6ENTG BC6OTHER (1) - acetyltransferase ( BC6OTHER ) and subsequently oxidized by BC6ENTC oxidase ( BC6OTHER ) to produce BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn BC6OTHER - treated situation, cell viability was not different before and after administration of either BC6ENTG siRNA or BC6ENTC whereas it was lessened after co - administration of BC6OTHER siRNA and BC6OTHER . CPR:falsenewlineIn BC6OTHER - treated situation, cell viability was not different before and after administration of either BC6OTHER siRNA or BC6ENTC whereas it was lessened after co - administration of BC6ENTG siRNA and BC6OTHER . CPR:falsenewlineIn BC6OTHER - treated situation, cell viability was not different before and after administration of either BC6ENTG siRNA or BC6OTHER whereas it was lessened after co - administration of BC6OTHER siRNA and BC6ENTC . CPR:falsenewlineIn BC6OTHER - treated situation, cell viability was not different before and after administration of either BC6OTHER siRNA or BC6OTHER whereas it was lessened after co - administration of BC6ENTG siRNA and BC6ENTC . CPR:falsenewlineCompared to BC6ENTC treatment alone, cell viability was reduced with BC6ENTG plasmid but it was unchanged with BC6OTHER siRNA. CPR:falsenewlineCompared to BC6ENTC treatment alone, cell viability was reduced with BC6OTHER plasmid but it was unchanged with BC6ENTG siRNA. CPR:falsenewline BC6ENTG sensitizes to BC6ENTC by modulating BC6OTHER and BC6OTHER / BC6OTHER signal pathway in FRO anaplastic thyroid carcinoma cells. CPR:falsenewline BC6OTHER sensitizes to BC6ENTC by modulating BC6ENTG and BC6OTHER / BC6OTHER signal pathway in FRO anaplastic thyroid carcinoma cells. CPR:falsenewline BC6OTHER sensitizes to BC6ENTC by modulating BC6OTHER and BC6ENTG / BC6OTHER signal pathway in FRO anaplastic thyroid carcinoma cells. CPR:falsenewline BC6OTHER sensitizes to BC6ENTC by modulating BC6OTHER and BC6OTHER / BC6ENTG signal pathway in FRO anaplastic thyroid carcinoma cells. CPR:falsenewlineWhile BC6ENTG plasmid transfection diminished BC6OTHER and BC6ENTC - Akt protein levels, BC6OTHER siRNA transfection did not alter the protein levels. CPR:falsenewlineWhile BC6OTHER plasmid transfection diminished BC6ENTG and BC6ENTC - Akt protein levels, BC6OTHER siRNA transfection did not alter the protein levels. CPR:falsenewlineWhile BC6OTHER plasmid transfection diminished BC6OTHER and BC6ENTC - Akt protein levels, BC6ENTG siRNA transfection did not alter the protein levels. CPR:falsenewlineIn conclusion, these results suggest that BC6ENTG may sensitize FRO ATC cells to BC6ENTC thereby inhibiting cell survival by modulating BC6OTHER and BC6OTHER / BC6OTHER signal pathway. CPR:falsenewlineIn conclusion, these results suggest that BC6OTHER may sensitize FRO ATC cells to BC6ENTC thereby inhibiting cell survival by modulating BC6ENTG and BC6OTHER / BC6OTHER signal pathway. CPR:falsenewlineIn conclusion, these results suggest that BC6OTHER may sensitize FRO ATC cells to BC6ENTC thereby inhibiting cell survival by modulating BC6OTHER and BC6ENTG / BC6OTHER signal pathway. CPR:falsenewlineIn conclusion, these results suggest that BC6OTHER may sensitize FRO ATC cells to BC6ENTC thereby inhibiting cell survival by modulating BC6OTHER and BC6OTHER / BC6ENTG signal pathway. CPR:falsenewlineFurthermore, these findings imply that BC6ENTG may be a possible candidate as the chemosensitizing factor for induction of cytotoxicity in ATC cells exposed to BC6ENTC . CPR:falsenewlineIn the present study, we evaluated the effects of BC6ENTC on cell survival, BC6ENTG , and BC6OTHER / BC6OTHER signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells. CPR:falsenewlineIn the present study, we evaluated the effects of BC6ENTC on cell survival, BC6OTHER , and BC6ENTG / BC6OTHER signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells. CPR:falsenewlineIn the present study, we evaluated the effects of BC6ENTC on cell survival, BC6OTHER , and BC6OTHER / BC6ENTG signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells. CPR:falsenewlineMoreover, we investigated the roles of BC6ENTG in cell survival under condition of BC6ENTC treatment in FRO ATC cells. CPR:falsenewlineAfter BC6ENTC treatment, cell viability, BC6ENTG , and BC6OTHER protein levels were not changed. CPR:falsenewlineAfter BC6ENTC treatment, cell viability, BC6OTHER , and BC6ENTG protein levels were not changed. CPR:falsenewlineIn BC6ENTC - treated situation, cell viability was not different before and after administration of either BC6ENTG siRNA or BC6OTHER whereas it was lessened after co - administration of BC6OTHER siRNA and BC6OTHER . CPR:falsenewlineIn BC6ENTC - treated situation, cell viability was not different before and after administration of either BC6OTHER siRNA or BC6OTHER whereas it was lessened after co - administration of BC6ENTG siRNA and BC6OTHER . CPR:falsenewlineRESULTS: In the BC6ENTC - injured brain, the BC6ENTG mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes. CPR:falsenewlineBC6ENTC , BC6OTHER and BC6OTHER decreased BC6OTHER - induced injury; BC6OTHER (0.1 mg / kg) and BC6OTHER inhibited the upregulated expression of the BC6ENTG . CPR:falsenewlineBC6OTHER , BC6ENTC and BC6OTHER decreased BC6OTHER - induced injury; BC6OTHER (0.1 mg / kg) and BC6OTHER inhibited the upregulated expression of the BC6ENTG . CPR:falsenewlineBC6OTHER , BC6OTHER and BC6ENTC decreased BC6OTHER - induced injury; BC6OTHER (0.1 mg / kg) and BC6OTHER inhibited the upregulated expression of the BC6ENTG . CPR:falsenewlineBC6OTHER , BC6OTHER and BC6OTHER decreased BC6ENTC - induced injury; BC6OTHER (0.1 mg / kg) and BC6OTHER inhibited the upregulated expression of the BC6ENTG . CPR:falsenewlineBC6OTHER , BC6OTHER and BC6OTHER decreased BC6OTHER - induced injury; BC6ENTC (0.1 mg / kg) and BC6OTHER inhibited the upregulated expression of the BC6ENTG . CPR:falsenewlineBC6OTHER , BC6OTHER and BC6OTHER decreased BC6OTHER - induced injury; BC6OTHER (0.1 mg / kg) and BC6ENTC inhibited the upregulated expression of the BC6ENTG . CPR:falsenewlineAIM: To determine whether BC6ENTG ( BC6OTHER ) is involved in BC6ENTC ( BC6OTHER ) - induced excitotoxic injury in the mouse brain. CPR:falsenewlineAIM: To determine whether BC6OTHER receptor 1 ( BC6ENTG ) is involved in BC6ENTC ( BC6OTHER ) - induced excitotoxic injury in the mouse brain. CPR:falsenewlineCONCLUSION: BC6OTHER expression in neurons is upregulated after BC6ENTC injection, and BC6OTHER - induced responses are inhibited by BC6ENTG antagonists, indicating that the increased BC6OTHER is involved in BC6OTHER excitotoxicity. CPR:falsenewlineCONCLUSION: BC6OTHER expression in neurons is upregulated after BC6ENTC injection, and BC6OTHER - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6ENTG is involved in BC6OTHER excitotoxicity. CPR:falsenewlineCONCLUSION: BC6ENTG expression in neurons is upregulated after BC6ENTC injection, and BC6OTHER - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6OTHER is involved in BC6OTHER excitotoxicity. CPR:falsenewlineCONCLUSION: BC6OTHER expression in neurons is upregulated after BC6OTHER injection, and BC6ENTC - induced responses are inhibited by BC6ENTG antagonists, indicating that the increased BC6OTHER is involved in BC6OTHER excitotoxicity. CPR:falsenewlineCONCLUSION: BC6OTHER expression in neurons is upregulated after BC6OTHER injection, and BC6ENTC - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6ENTG is involved in BC6OTHER excitotoxicity. CPR:falsenewlineCONCLUSION: BC6ENTG expression in neurons is upregulated after BC6OTHER injection, and BC6ENTC - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6OTHER is involved in BC6OTHER excitotoxicity. CPR:falsenewlineCONCLUSION: BC6OTHER expression in neurons is upregulated after BC6OTHER injection, and BC6OTHER - induced responses are inhibited by BC6ENTG antagonists, indicating that the increased BC6OTHER is involved in BC6ENTC excitotoxicity. CPR:falsenewlineCONCLUSION: BC6OTHER expression in neurons is upregulated after BC6OTHER injection, and BC6OTHER - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6ENTG is involved in BC6ENTC excitotoxicity. CPR:falsenewlineCONCLUSION: BC6ENTG expression in neurons is upregulated after BC6OTHER injection, and BC6OTHER - induced responses are inhibited by BC6OTHER antagonists, indicating that the increased BC6OTHER is involved in BC6ENTC excitotoxicity. CPR:falsenewline BC6ENTG is involved in BC6ENTC - mediated neuronal injury in mice. CPR:falsenewlineAIM: To determine whether BC6ENTG ( BC6OTHER ) is involved in BC6OTHER ( BC6ENTC ) - induced excitotoxic injury in the mouse brain. CPR:falsenewlineAIM: To determine whether BC6OTHER receptor 1 ( BC6ENTG ) is involved in BC6OTHER ( BC6ENTC ) - induced excitotoxic injury in the mouse brain. CPR:falsenewlineAIM: To determine whether BC6ENTC receptor 1 ( BC6ENTG ) is involved in BC6OTHER ( BC6OTHER ) - induced excitotoxic injury in the mouse brain. CPR:falsenewlineThe changes in BC6ENTG expression 24 h after BC6ENTC injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6OTHER expression 24 h after BC6ENTC injection and the effects of a BC6ENTG antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6OTHER expression 24 h after BC6ENTC injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6ENTG antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6ENTG expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6ENTC (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6ENTG antagonist, BC6ENTC (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6ENTC (0.01 and 0.1 mg / kg), an BC6ENTG antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6ENTG expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6ENTC receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6ENTG antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6ENTC receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6ENTG expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6ENTC (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6ENTG antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6ENTC (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6ENTG antagonist, BC6ENTC (30 mg / kg), and an antioxidant, BC6OTHER (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6ENTG expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6ENTC (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6ENTG antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6OTHER receptor antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6ENTC (9 mg / kg) were observed. CPR:falsenewlineThe changes in BC6OTHER expression 24 h after BC6OTHER injection and the effects of a BC6OTHER antagonist, BC6OTHER (0.01 and 0.1 mg / kg), an BC6ENTG antagonist, BC6OTHER (30 mg / kg), and an antioxidant, BC6ENTC (9 mg / kg) were observed. CPR:falsenewlineBC6ENTC treatment for 4weeks led to marked liver fibrosis as assessed by serum biochemistry, histopathological examination, and hepatic lipid peroxidation and BC6ENTG content. CPR:falsenewlineCK significantly inhibited BC6ENTC - induced increases in serum BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6ENTC - induced increases in serum BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6ENTC - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6ENTC - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6ENTC - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6ENTG content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6ENTC aminotransferase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6ENTC aminotransferase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6ENTC aminotransferase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6ENTC aminotransferase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6ENTG content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6ENTG ( BC6OTHER ) and BC6ENTC aminotransferase ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6ENTG ) and BC6ENTC aminotransferase ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6ENTC aminotransferase ( BC6ENTG ) activities, fibrosis score, and hepatic BC6OTHER and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6ENTC aminotransferase ( BC6OTHER ) activities, fibrosis score, and hepatic BC6OTHER and BC6ENTG content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6ENTC and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6ENTC and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, fibrosis score, and hepatic BC6ENTC and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, fibrosis score, and hepatic BC6ENTC and BC6OTHER content. CPR:falsenewlineCK significantly inhibited BC6OTHER - induced increases in serum BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, fibrosis score, and hepatic BC6ENTC and BC6ENTG content. CPR:falsenewlineReverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6OTHER and BC6OTHER protein. CPR:falsenewlineReverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6OTHER and BC6OTHER protein. CPR:falsenewlineReverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6OTHER and BC6OTHER protein. CPR:falsenewlineReverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6OTHER and BC6OTHER protein. CPR:falsenewlineReverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) mRNA, and BC6OTHER and BC6OTHER protein. CPR:falsenewlineReverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ) mRNA, and BC6OTHER and BC6OTHER protein. CPR:falsenewlineReverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6ENTG and BC6OTHER protein. CPR:falsenewlineReverse transcription polymerase chain reaction (RT - PCR) and western blot analyses revealed that CK inhibited BC6ENTC - induced increases in BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) mRNA, and BC6OTHER and BC6ENTG protein. CPR:falsenewlineBC6ENTC - induced BC6OTHER ( BC6OTHER ) expression and BC6ENTG ( BC6OTHER ) activation was reduced by CK treatment. CPR:falsenewlineBC6ENTC - induced BC6OTHER ( BC6OTHER ) expression and BC6OTHER ( BC6ENTG ) activation was reduced by CK treatment. CPR:falsenewlineBC6ENTC - induced BC6ENTG ( BC6OTHER ) expression and BC6OTHER ( BC6OTHER ) activation was reduced by CK treatment. CPR:falsenewlineBC6ENTC - induced BC6OTHER ( BC6ENTG ) expression and BC6OTHER ( BC6OTHER ) activation was reduced by CK treatment. CPR:falsenewlinePlatycodi Radix attenuates BC6ENTC - induced liver fibrosis in rats by inducing BC6ENTG - mediated antioxidant enzymes. CPR:falsenewlineFurthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6ENTG ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6ENTG ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6ENTG ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTC synthetase ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6ENTG ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTG ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6ENTG ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6ENTG ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6ENTG ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTC oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6ENTG ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTG ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6ENTG ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6ENTG ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6ENTG ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTC BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6ENTG ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTG ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6ENTG ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6ENTG ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6ENTG ), and BC6OTHER - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6ENTC oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6OTHER - transferase ( BC6ENTG ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTG ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6ENTG ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6ENTG ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6ENTG ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6ENTG ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6ENTG ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6ENTG ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6ENTG ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6ENTG ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6ENTG ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6ENTG ), and BC6OTHER - BC6ENTC - transferase ( BC6OTHER ) in HepG2 cells. CPR:falsenewlineFurthermore, CK induced activation of BC6OTHER ( BC6OTHER ) - mediated antioxidant enzymes such as BC6OTHER ( BC6OTHER ), BC6OTHER oxygenase - 1 ( BC6OTHER ), BC6OTHER BC6OTHER oxidoreductase 1 ( BC6OTHER ), and BC6OTHER - BC6ENTC - transferase ( BC6ENTG ) in HepG2 cells. CPR:falsenewlineThese results demonstrated that CK attenuates BC6ENTC - induced liver fibrosis through the activation of BC6ENTG - mediated antioxidant enzymes. CPR:falsenewlineMETHODS: The effect of BC6OTHER and the BC6ENTC receptor antagonist, BC6OTHER ( BC6OTHER ) on the regulation of BC6ENTG gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells. CPR:falsenewlineMETHODS: The effect of BC6OTHER and the BC6ENTC receptor antagonist, BC6OTHER ( BC6OTHER ) on the regulation of BC6OTHER gene expression and BC6ENTG secretion were observed in human airway NCI - H292 epithelial cells. CPR:falsenewlineMETHODS: The effect of BC6OTHER and the BC6ENTG antagonist, BC6ENTC ( BC6OTHER ) on the regulation of BC6OTHER gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells. CPR:falsenewlineMETHODS: The effect of BC6OTHER and the BC6OTHER antagonist, BC6ENTC ( BC6OTHER ) on the regulation of BC6ENTG gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells. CPR:falsenewlineMETHODS: The effect of BC6OTHER and the BC6OTHER antagonist, BC6ENTC ( BC6OTHER ) on the regulation of BC6OTHER gene expression and BC6ENTG secretion were observed in human airway NCI - H292 epithelial cells. CPR:falsenewlineMETHODS: The effect of BC6OTHER and the BC6ENTG antagonist, BC6OTHER ( BC6ENTC ) on the regulation of BC6OTHER gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells. CPR:falsenewlineMETHODS: The effect of BC6OTHER and the BC6OTHER antagonist, BC6OTHER ( BC6ENTC ) on the regulation of BC6ENTG gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells. CPR:falsenewlineMETHODS: The effect of BC6OTHER and the BC6OTHER antagonist, BC6OTHER ( BC6ENTC ) on the regulation of BC6OTHER gene expression and BC6ENTG secretion were observed in human airway NCI - H292 epithelial cells. CPR:falsenewlineRESULTS: BC6ENTC upregulated BC6ENTG gene expression and BC6OTHER secretion in a dose dependent pattern. CPR:3newlineRESULTS: BC6ENTC upregulated BC6OTHER gene expression and BC6ENTG secretion in a dose dependent pattern. CPR:3newlineThe inhibitory effect of the BC6ENTC receptor antagonist on BC6OTHER - induced BC6OTHER gene expression and BC6ENTG secretion in human airway epithelial cells. CPR:falsenewlineThe inhibitory effect of the BC6ENTC receptor antagonist on BC6OTHER - induced BC6ENTG gene expression and BC6OTHER secretion in human airway epithelial cells. CPR:falsenewlineThe inhibitory effect of the BC6OTHER antagonist on BC6ENTC - induced BC6OTHER gene expression and BC6ENTG secretion in human airway epithelial cells. CPR:falsenewlineThe inhibitory effect of the BC6ENTG antagonist on BC6ENTC - induced BC6OTHER gene expression and BC6OTHER secretion in human airway epithelial cells. CPR:falsenewlineThe inhibitory effect of the BC6OTHER antagonist on BC6ENTC - induced BC6ENTG gene expression and BC6OTHER secretion in human airway epithelial cells. CPR:falsenewlineBC6ENTC ( BC6OTHER , 100 microM) downregulated the BC6OTHER - induced BC6ENTG gene expression and BC6OTHER secretion. CPR:falsenewlineBC6ENTC ( BC6OTHER , 100 microM) downregulated the BC6OTHER - induced BC6OTHER gene expression and BC6ENTG secretion. CPR:falsenewlineBC6OTHER ( BC6ENTC , 100 microM) downregulated the BC6OTHER - induced BC6ENTG gene expression and BC6OTHER secretion. CPR:falsenewlineBC6OTHER ( BC6ENTC , 100 microM) downregulated the BC6OTHER - induced BC6OTHER gene expression and BC6ENTG secretion. CPR:falsenewlineBC6OTHER ( BC6OTHER , 100 microM) downregulated the BC6ENTC - induced BC6ENTG gene expression and BC6OTHER secretion. CPR:falsenewlineBC6OTHER ( BC6OTHER , 100 microM) downregulated the BC6ENTC - induced BC6OTHER gene expression and BC6ENTG secretion. CPR:falsenewlineCONCLUSION: These results suggest that the BC6ENTC receptor system is one of the mechanisms related to BC6ENTG gene expression and BC6OTHER secretion in the human airway epithelium. CPR:falsenewlineCONCLUSION: These results suggest that the BC6ENTC receptor system is one of the mechanisms related to BC6OTHER gene expression and BC6ENTG secretion in the human airway epithelium. CPR:falsenewlineBC6ENTG , lipopolysaccharides and other inflammatory mediators such as BC6ENTC and BC6OTHER are related to the secretion and production of BC6OTHER . CPR:9newlineBC6OTHER , lipopolysaccharides and other inflammatory mediators such as BC6ENTC and BC6OTHER are related to the secretion and production of BC6ENTG . CPR:falsenewlineBC6ENTG , lipopolysaccharides and other inflammatory mediators such as BC6OTHER and BC6ENTC are related to the secretion and production of BC6OTHER . CPR:falsenewlineBC6OTHER , lipopolysaccharides and other inflammatory mediators such as BC6OTHER and BC6ENTC are related to the secretion and production of BC6ENTG . CPR:falsenewlineHowever, the relationship of BC6ENTC with BC6ENTG genes expression is not clear. CPR:falsenewlineThe aim of this study is to evaluate BC6ENTG gene expression and BC6OTHER secretion by the BC6ENTC receptor in human airway epithelial cells. CPR:falsenewlineThe aim of this study is to evaluate BC6OTHER gene expression and BC6ENTG secretion by the BC6ENTC receptor in human airway epithelial cells. CPR:falsenewlineMETHODS: The effect of BC6ENTC and the BC6ENTG antagonist, BC6OTHER ( BC6OTHER ) on the regulation of BC6OTHER gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells. CPR:falsenewlineMETHODS: The effect of BC6ENTC and the BC6OTHER antagonist, BC6OTHER ( BC6OTHER ) on the regulation of BC6ENTG gene expression and BC6OTHER secretion were observed in human airway NCI - H292 epithelial cells. CPR:falsenewlineMETHODS: The effect of BC6ENTC and the BC6OTHER antagonist, BC6OTHER ( BC6OTHER ) on the regulation of BC6OTHER gene expression and BC6ENTG secretion were observed in human airway NCI - H292 epithelial cells. CPR:falsenewlineThe pleiotropic effects of BC6ENTC are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6ENTC are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6ENTC are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6ENTC are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6ENTC are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ), BC6ENTG and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6ENTC ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6ENTC ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6ENTC ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6ENTC ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6ENTC ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ), BC6ENTG and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6ENTC ), which regulates the expression of a battery of target genes through several families of BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6ENTC ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6ENTC ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6ENTC ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ), polymorphic BC6OTHER (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6ENTC ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ), BC6ENTG and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ), polymorphic BC6ENTC (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ), polymorphic BC6ENTC (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ), polymorphic BC6ENTC (RA) response elements and multiple coregulators. CPR:falsenewlineThe pleiotropic effects of BC6OTHER are exerted mainly by one active metabolite, BC6OTHER ( BC6OTHER ), which regulates the expression of a battery of target genes through several families of BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ), polymorphic BC6ENTC (RA) response elements and multiple coregulators. CPR:falsenewlineHowever, BC6ENTC itself proved recently to be active and BC6ENTG to be present in the cytosol to regulate translation and cell plasticity. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineBC6ENTC , a putative BC6ENTG agonist, and BC6OTHER , a putative BC6OTHER / BC6OTHER agonist, also bound to this receptor with Ki values of 120 nM. CPR:falsenewlineBC6ENTC , a putative BC6OTHER agonist, and BC6OTHER , a putative BC6ENTG / BC6OTHER agonist, also bound to this receptor with Ki values of 120 nM. CPR:falsenewlineBC6ENTC , a putative BC6OTHER agonist, and BC6OTHER , a putative BC6OTHER / BC6ENTG agonist, also bound to this receptor with Ki values of 120 nM. CPR:falsenewlineBC6OTHER , a putative BC6ENTG agonist, and BC6ENTC , a putative BC6OTHER / BC6OTHER agonist, also bound to this receptor with Ki values of 120 nM. CPR:falsenewlineBC6OTHER , a putative BC6OTHER agonist, and BC6ENTC , a putative BC6ENTG / BC6OTHER agonist, also bound to this receptor with Ki values of 120 nM. CPR:falsenewlineBC6OTHER , a putative BC6OTHER agonist, and BC6ENTC , a putative BC6OTHER / BC6ENTG agonist, also bound to this receptor with Ki values of 120 nM. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineThe two receptors were discriminated by BC6ENTC , BC6OTHER and BC6OTHER that bound to the BC6ENTG receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6ENTC , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6ENTG receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6ENTC , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6ENTG but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6ENTC , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6ENTG receptor. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6ENTC and BC6OTHER that bound to the BC6ENTG receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6ENTC and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6ENTG receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6ENTC and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6ENTG but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6ENTC and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6ENTG receptor. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6OTHER and BC6ENTC that bound to the BC6ENTG receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6OTHER and BC6ENTC that bound to the BC6OTHER receptor but not to the BC6ENTG receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6OTHER and BC6ENTC that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6ENTG but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6OTHER and BC6ENTC that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6OTHER that bound to the BC6OTHER but not to the BC6ENTG receptor. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6OTHER and BC6OTHER that bound to the BC6ENTG receptor but not to the BC6OTHER receptor, and by BC6ENTC that bound to the BC6OTHER but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6ENTG receptor, and by BC6ENTC that bound to the BC6OTHER but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6ENTC that bound to the BC6ENTG but not to the BC6OTHER receptor. CPR:falsenewlineThe two receptors were discriminated by BC6OTHER , BC6OTHER and BC6OTHER that bound to the BC6OTHER receptor but not to the BC6OTHER receptor, and by BC6ENTC that bound to the BC6OTHER but not to the BC6ENTG receptor. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTC ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineThe BC6ENTG receptor showed the broadest binding profile, and bound BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM. CPR:falsenewlineThe BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM. CPR:falsenewlineThe BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM. CPR:falsenewlineThe BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM. CPR:falsenewlineThe BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM. CPR:falsenewlineThe BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , in addition to BC6OTHER and BC6OTHER , with Ki values of 0.6 - 3.7 nM. CPR:falsenewlineThe BC6ENTG receptor bound BC6ENTC , BC6OTHER and BC6OTHER in addition to BC6OTHER and BC6OTHER , with Ki values of 14 - 36 nM. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6ENTC ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineThe BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , in addition to BC6ENTC and BC6OTHER , with Ki values of 0.6 - 3.7 nM. CPR:falsenewlineThe BC6ENTG receptor showed the broadest binding profile, and bound BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , in addition to BC6OTHER and BC6ENTC , with Ki values of 0.6 - 3.7 nM. CPR:falsenewlineIn addition, three BC6ENTC ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6ENTC ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6ENTC ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively. CPR:falsenewlineIn addition, three BC6ENTG ligands, BC6ENTC , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6ENTC , BC6OTHER and BC6OTHER , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6ENTC , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6ENTC , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively. CPR:falsenewlineIn addition, three BC6ENTG ligands, BC6OTHER , BC6ENTC and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6ENTC and BC6OTHER , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6ENTC and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6ENTC and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively. CPR:falsenewlineIn addition, three BC6ENTG ligands, BC6OTHER , BC6OTHER and BC6ENTC , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6ENTC , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6ENTC , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6ENTC , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively. CPR:falsenewlineIn addition, three BC6ENTG ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTC ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTC ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTC ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively. CPR:falsenewlineIn addition, three BC6ENTG ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6ENTC , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTG ligand, BC6ENTC , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6ENTC , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6ENTC , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTG , respectively. CPR:falsenewlineIn addition, three BC6ENTG ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTC and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTC and BC6OTHER , respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTC and BC6ENTG , respectively. CPR:falsenewlineThe BC6ENTG receptor bound BC6OTHER , BC6ENTC and BC6OTHER in addition to BC6OTHER and BC6OTHER , with Ki values of 14 - 36 nM. CPR:falsenewlineIn addition, three BC6ENTG ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTC receptors, respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6ENTG ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6OTHER and BC6ENTC receptors, respectively. CPR:falsenewlineIn addition, three BC6OTHER ligands, BC6OTHER , BC6OTHER and BC6OTHER , and one BC6OTHER ligand, BC6OTHER , bound to this receptor with Ki values comparable to the Ki values of these compounds for the BC6ENTG and BC6ENTC receptors, respectively. CPR:falsenewlineBC6ENTC alpha showed only weak binding to the BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG receptor at 10 microM concentration. CPR:falsenewlineBC6ENTC alpha showed only weak binding to the BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6ENTC alpha showed only weak binding to the BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6ENTC alpha showed only weak binding to the BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6ENTC alpha showed only weak binding to the BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6ENTC , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6ENTG receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6ENTG , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6ENTG receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineBC6OTHER alpha showed only weak binding to the BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG and BC6OTHER receptor at 10 microM concentration. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6ENTC receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6ENTC receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6ENTC receptor, the BC6OTHER ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineThe BC6ENTC , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6ENTC , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6ENTC , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6ENTC , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6ENTC , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG , BC6ENTC and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTC and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTC and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTC and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTC and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG receptor bound BC6OTHER , BC6OTHER and BC6ENTC in addition to BC6OTHER and BC6OTHER , with Ki values of 14 - 36 nM. CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6ENTC receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6ENTC receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTC receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTC receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTC receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the BC6ENTG , the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6ENTC ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , and BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG receptor bound BC6OTHER , BC6OTHER and BC6OTHER in addition to BC6ENTC and BC6OTHER , with Ki values of 14 - 36 nM. CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6ENTC , BC6OTHER and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6ENTC , BC6OTHER and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6ENTC and BC6OTHER for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6ENTC and BC6OTHER for BC6ENTG . CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6ENTC for BC6OTHER . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6ENTC for BC6ENTG . CPR:falsenewlineThe BC6ENTG , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC . CPR:falsenewlineThe BC6OTHER , BC6ENTG and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTG showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC . CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6OTHER receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as BC6OTHER , BC6OTHER and BC6OTHER for BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTG , and BC6OTHER , BC6OTHER and BC6OTHER for BC6ENTC . CPR:falsenewlineThe BC6ENTG bound BC6ENTC alpha and BC6OTHER with Ki values of 3 - 4 nM. CPR:falsenewlineThe BC6ENTG bound BC6OTHER alpha and BC6ENTC with Ki values of 3 - 4 nM. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6ENTG , were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the BC6ENTG , the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG , the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the BC6ENTG and the BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineEight types and subtypes of the mouse BC6OTHER receptor, the BC6OTHER ( BC6ENTC ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor, the CHEM ( BC6OTHER ) receptor and the BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER subtypes of the BC6OTHER receptor, were stably expressed in Chinese hamster ovary cells. CPR:falsenewlineThe BC6ENTG receptor bound BC6OTHER , BC6OTHER and BC6OTHER in addition to BC6OTHER and BC6ENTC , with Ki values of 14 - 36 nM. CPR:falsenewlineBC6ENTC and two putative BC6ENTG antagonists, BC6OTHER and BC6OTHER , did not show any significant binding to this receptor. CPR:falsenewlineBC6OTHER and two putative BC6ENTG antagonists, BC6ENTC and BC6OTHER , did not show any significant binding to this receptor. CPR:falsenewlineBC6OTHER and two putative BC6ENTG antagonists, BC6OTHER and BC6ENTC , did not show any significant binding to this receptor. CPR:falsenewlineThese data indicate that a BC6ENTC binding assay using BC6ENTG membranes may help identify compounds that prolong the QT interval. CPR:falsenewline BC6ENTC binding to BC6ENTG transfected membranes: a potential high throughput preclinical screen. CPR:falsenewlineThe pharmacological characteristics of BC6OTHER binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing BC6ENTG BC6ENTC channels. CPR:falsenewlineThe pharmacological characteristics of BC6ENTC binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing BC6ENTG BC6OTHER channels. CPR:falsenewlineExploring the effect of BC6OTHER - substitution in BC6ENTC on the interaction with BC6ENTG : discovery of a potential clinical candidate for treatment of BC6OTHER abuse. CPR:falsenewlineA series of BC6ENTC - substituted BC6OTHER analogues was synthesized and evaluated for their BC6OTHER binding affinity at the BC6ENTG and for their inhibition of vesicular BC6OTHER uptake. CPR:falsenewlineA series of BC6OTHER - substituted BC6OTHER analogues was synthesized and evaluated for their BC6OTHER binding affinity at the BC6ENTG and for their inhibition of vesicular BC6ENTC uptake. CPR:falsenewlineA series of BC6OTHER - substituted BC6ENTC analogues was synthesized and evaluated for their BC6OTHER binding affinity at the BC6ENTG and for their inhibition of vesicular BC6OTHER uptake. CPR:falsenewlineA series of BC6OTHER - substituted BC6OTHER analogues was synthesized and evaluated for their BC6ENTC binding affinity at the BC6ENTG and for their inhibition of vesicular BC6OTHER uptake. CPR:falsenewlineExploring the effect of BC6OTHER - substitution in BC6OTHER on the interaction with BC6ENTG : discovery of a potential clinical candidate for treatment of BC6ENTC abuse. CPR:falsenewlineExploring the effect of BC6ENTC - substitution in BC6OTHER on the interaction with BC6ENTG : discovery of a potential clinical candidate for treatment of BC6OTHER abuse. CPR:falsenewlineThe tocolytic agent BC6ENTC acts on the BC6ENTG and is an effective treatment option for preterm labor. CPR:falsenewlineImportantly, expression of the acute - phase reactant BC6ENTG ( BC6OTHER ) significantly increased after BC6ENTC injection, with values indicating the largest fold - change. CPR:3newlineImportantly, expression of the acute - phase reactant BC6OTHER ( BC6ENTG ) significantly increased after BC6ENTC injection, with values indicating the largest fold - change. CPR:3newlineThis large increase in blood BC6OTHER levels serves as a more sensitive biomarker than conventional liver enzymes, such as BC6ENTC aminotransferase and BC6ENTG . CPR:falsenewlineThis large increase in blood BC6ENTG levels serves as a more sensitive biomarker than conventional liver enzymes, such as BC6ENTC aminotransferase and BC6OTHER aminotransferase. CPR:falsenewline BC6ENTG upsurge precedes standard biomarkers of hepatotoxicity in BC6ENTC - injected mice. CPR:falsenewlineThis large increase in blood BC6OTHER levels serves as a more sensitive biomarker than conventional liver enzymes, such as BC6ENTG and BC6ENTC aminotransferase. CPR:falsenewlineThis large increase in blood BC6ENTG levels serves as a more sensitive biomarker than conventional liver enzymes, such as BC6OTHER and BC6ENTC aminotransferase. CPR:falsenewlineThe increase in BC6ENTG expression is specific to BC6ENTC - induced liver damage, because BC6OTHER expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6OTHER , or BC6OTHER . CPR:falsenewlineThe increase in BC6OTHER expression is specific to BC6ENTC - induced liver damage, because BC6ENTG expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6OTHER , or BC6OTHER . CPR:falsenewlineThe increase in BC6ENTG expression is specific to BC6OTHER - induced liver damage, because BC6OTHER expression was not induced by other hepatotoxic drugs such as BC6ENTC , BC6OTHER , or BC6OTHER . CPR:falsenewlineThe increase in BC6OTHER expression is specific to BC6OTHER - induced liver damage, because BC6ENTG expression was not induced by other hepatotoxic drugs such as BC6ENTC , BC6OTHER , or BC6OTHER . CPR:falsenewlineThe increase in BC6ENTG expression is specific to BC6OTHER - induced liver damage, because BC6OTHER expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6ENTC , or BC6OTHER . CPR:falsenewlineThe increase in BC6OTHER expression is specific to BC6OTHER - induced liver damage, because BC6ENTG expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6ENTC , or BC6OTHER . CPR:falsenewlineThe increase in BC6ENTG expression is specific to BC6OTHER - induced liver damage, because BC6OTHER expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6OTHER , or BC6ENTC . CPR:falsenewlineThe increase in BC6OTHER expression is specific to BC6OTHER - induced liver damage, because BC6ENTG expression was not induced by other hepatotoxic drugs such as BC6OTHER , BC6OTHER , or BC6ENTC . CPR:falsenewlineOur in vitro studies showed that BC6ENTC ( BC6OTHER ) accumulation was not a primary cause of the BC6OTHER - induced BC6ENTG increase. CPR:falsenewlineOur in vitro studies showed that BC6OTHER ( BC6ENTC ) accumulation was not a primary cause of the BC6OTHER - induced BC6ENTG increase. CPR:falsenewlineOur in vitro studies showed that BC6OTHER ( BC6OTHER ) accumulation was not a primary cause of the BC6ENTC - induced BC6ENTG increase. CPR:falsenewlinePostoperative concentrations of BC6ENTG were decreased significantly in the BC6ENTC group (P < 0.001). CPR:4newlineThe altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold). CPR:falsenewlineThe altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold). CPR:falsenewlineThe altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold). CPR:falsenewlineThe altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold). CPR:falsenewlineThe altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold). CPR:falsenewlineThe altered genes associated with BC6ENTC - induced cleft palate included BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG but the magnitude of the change was relatively small (1.5 - to 2 - fold). CPR:falsenewlineThe altered genes associated with BC6ENTC - induced cleft palate included BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER but the magnitude of the change was relatively small (1.5 - to 2 - fold). CPR:falsenewlineBACKGROUND: The effects of BC6ENTG antagonist BC6ENTC on rat palate development were characterized following in utero exposure. CPR:falsenewlineEffects of the BC6ENTG antagonist BC6ENTC on rat fetal palate development. CPR:falsenewlineWe found that this interaction is highly specific, requires the BC6ENTC - UBP domain of BC6ENTG , and is disrupted by the inactivating BC6OTHER mutation within BC6OTHER . CPR:falsenewlineWe found that this interaction is highly specific, requires the BC6ENTC - UBP domain of BC6OTHER , and is disrupted by the inactivating BC6ENTG mutation within BC6OTHER . CPR:falsenewlineWe found that this interaction is highly specific, requires the BC6ENTC - UBP domain of BC6OTHER , and is disrupted by the inactivating BC6OTHER mutation within BC6ENTG . CPR:falsenewlineMoreover, we show that BC6ENTG is acetylated on multiple BC6ENTC residues and that alteration of a single BC6OTHER (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6OTHER complex. CPR:falsenewlineMoreover, we show that BC6OTHER is acetylated on multiple BC6ENTC residues and that alteration of a single BC6OTHER (K129) within the BC6ENTG is sufficient to alter interaction of the BC6OTHER with the core BC6OTHER complex. CPR:falsenewlineMoreover, we show that BC6OTHER is acetylated on multiple BC6ENTC residues and that alteration of a single BC6OTHER (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6ENTG with the core BC6OTHER complex. CPR:falsenewlineMoreover, we show that BC6OTHER is acetylated on multiple BC6ENTC residues and that alteration of a single BC6OTHER (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6ENTG complex. CPR:falsenewlineMoreover, we show that BC6ENTG is acetylated on multiple BC6OTHER residues and that alteration of a single BC6ENTC (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6OTHER complex. CPR:falsenewlineMoreover, we show that BC6OTHER is acetylated on multiple BC6OTHER residues and that alteration of a single BC6ENTC (K129) within the BC6ENTG is sufficient to alter interaction of the BC6OTHER with the core BC6OTHER complex. CPR:falsenewlineMoreover, we show that BC6OTHER is acetylated on multiple BC6OTHER residues and that alteration of a single BC6ENTC (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6ENTG with the core BC6OTHER complex. CPR:falsenewlineMoreover, we show that BC6OTHER is acetylated on multiple BC6OTHER residues and that alteration of a single BC6ENTC (K129) within the BC6OTHER - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6ENTG complex. CPR:falsenewlineMoreover, we show that BC6ENTG is acetylated on multiple BC6OTHER residues and that alteration of a single BC6OTHER (K129) within the BC6ENTC - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6OTHER complex. CPR:falsenewlineMoreover, we show that BC6OTHER is acetylated on multiple BC6OTHER residues and that alteration of a single BC6OTHER (K129) within the BC6ENTC - UBP domain is sufficient to alter interaction of the BC6ENTG with the core BC6OTHER complex. CPR:falsenewlineMoreover, we show that BC6OTHER is acetylated on multiple BC6OTHER residues and that alteration of a single BC6OTHER (K129) within the BC6ENTC - UBP domain is sufficient to alter interaction of the BC6OTHER with the core BC6ENTG complex. CPR:falsenewlineThese findings suggest that the mechanism of antiproliferative toxicity of BC6OTHER is at least partly due to BC6ENTG inhibitory activity of its active metabolite BC6OTHER ( BC6ENTC ). CPR:4newlineMonitoring of plasma BC6ENTC concentrations have the potential to help clinicians to guide scheduling of BC6OTHER or other BC6ENTG inhibitors in clinical trials. CPR:falsenewlineMonitoring of plasma BC6OTHER concentrations have the potential to help clinicians to guide scheduling of BC6ENTC or other BC6ENTG inhibitors in clinical trials. CPR:falsenewlineClinical studies in cancer patients treated with the new BC6ENTC analogue BC6OTHER ( BC6OTHER ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6ENTG ( BC6OTHER ). CPR:falsenewlineClinical studies in cancer patients treated with the new BC6ENTC analogue BC6OTHER ( BC6OTHER ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6OTHER synthase ( BC6ENTG ). CPR:falsenewlineClinical studies in cancer patients treated with the new BC6OTHER analogue BC6ENTC ( BC6OTHER ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6ENTG ( BC6OTHER ). CPR:falsenewlineClinical studies in cancer patients treated with the new BC6OTHER analogue BC6ENTC ( BC6OTHER ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6OTHER synthase ( BC6ENTG ). CPR:falsenewlineClinical studies in cancer patients treated with the new BC6OTHER analogue BC6OTHER ( BC6ENTC ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6ENTG ( BC6OTHER ). CPR:falsenewlineClinical studies in cancer patients treated with the new BC6OTHER analogue BC6OTHER ( BC6ENTC ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6OTHER synthase ( BC6ENTG ). CPR:falsenewlineClinical studies in cancer patients treated with the new BC6OTHER analogue BC6OTHER ( BC6OTHER ) have shown that plasma BC6ENTC was significantly elevated after 1 week of treatment, consistent with inhibition of BC6ENTG ( BC6OTHER ). CPR:falsenewlineClinical studies in cancer patients treated with the new BC6OTHER analogue BC6OTHER ( BC6OTHER ) have shown that plasma BC6ENTC was significantly elevated after 1 week of treatment, consistent with inhibition of BC6OTHER synthase ( BC6ENTG ). CPR:falsenewlineClinical studies in cancer patients treated with the new BC6OTHER analogue BC6OTHER ( BC6OTHER ) have shown that plasma BC6OTHER was significantly elevated after 1 week of treatment, consistent with inhibition of BC6ENTC synthase ( BC6ENTG ). CPR:falsenewlineThese findings suggest that the mechanism of antiproliferative toxicity of BC6ENTC is at least partly due to BC6ENTG inhibitory activity of its active metabolite BC6OTHER ( BC6OTHER ). CPR:4newlineThese findings suggest that the mechanism of antiproliferative toxicity of BC6OTHER is at least partly due to BC6ENTG inhibitory activity of its active metabolite BC6ENTC ( BC6OTHER ). CPR:4newlineUsing surface biotinylation, we observed that treatment of CHEM - 38 neurons with BC6OTHER or with a membrane impermeant BC6ENTC elevated plasma membrane BC6ENTG protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane. CPR:falsenewlineInsertion of BC6ENTG was blocked by the BC6OTHER antagonist BC6ENTC or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6OTHER ). CPR:falsenewlineInsertion of BC6OTHER was blocked by the BC6ENTG antagonist BC6ENTC or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6OTHER ). CPR:falsenewlineInsertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6ENTC or with the BC6ENTG ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6OTHER ). CPR:falsenewlineInsertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6ENTC or with the BC6OTHER ( BC6ENTG ) pathway inhibitor BC6OTHER ( BC6OTHER ). CPR:falsenewlineInsertion of BC6ENTG was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6ENTC ( BC6OTHER ). CPR:falsenewlineInsertion of BC6OTHER was blocked by the BC6ENTG antagonist BC6OTHER or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6ENTC ( BC6OTHER ). CPR:falsenewlineInsertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6ENTG ( BC6OTHER ) pathway inhibitor BC6ENTC ( BC6OTHER ). CPR:falsenewlineInsertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6OTHER ( BC6ENTG ) pathway inhibitor BC6ENTC ( BC6OTHER ). CPR:falsenewlineInsertion of BC6ENTG was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6ENTC ). CPR:falsenewlineInsertion of BC6OTHER was blocked by the BC6ENTG antagonist BC6OTHER or with the BC6OTHER ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6ENTC ). CPR:falsenewlineInsertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6ENTG ( BC6OTHER ) pathway inhibitor BC6OTHER ( BC6ENTC ). CPR:falsenewlineInsertion of BC6OTHER was blocked by the BC6OTHER antagonist BC6OTHER or with the BC6OTHER ( BC6ENTG ) pathway inhibitor BC6OTHER ( BC6ENTC ). CPR:falsenewlineDownstream membrane - initiated signaling was confirmed by BC6ENTC activation of BC6ENTG ( BC6OTHER ) and the release of intracellular CHEM. CPR:falsenewlineDownstream membrane - initiated signaling was confirmed by BC6ENTC activation of BC6OTHER ( BC6ENTG ) and the release of intracellular CHEM. CPR:falsenewlineThese results indicate that membrane BC6ENTG levels in N - 38 neurons are dynamically autoregulated by BC6ENTC . CPR:falsenewlineRegulation of sexual reproduction by BC6ENTC involves the activation of BC6ENTG ( BC6OTHER ) in the hypothalamus. CPR:falsenewlineRegulation of sexual reproduction by BC6ENTC involves the activation of BC6OTHER receptors ( BC6ENTG ) in the hypothalamus. CPR:falsenewlineRegulation of sexual reproduction by BC6OTHER involves the activation of BC6ENTC receptors ( BC6ENTG ) in the hypothalamus. CPR:falsenewlineUsing surface biotinylation, we observed that treatment of CHEM - 38 neurons with BC6ENTC or with a membrane impermeant BC6OTHER elevated plasma membrane BC6ENTG protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane. CPR:falsenewlineBC6ENTC inhibited BC6OTHER activity stimulated by this specific heptapeptide but did not block BC6OTHER binding or induce BC6ENTG expression. CPR:falsenewlineBC6ENTC inhibited BC6ENTG activity stimulated by this specific heptapeptide but did not block BC6OTHER binding or induce BC6OTHER expression. CPR:falsenewline BC6ENTC and BC6OTHER bind to BC6ENTG ( BC6OTHER ) and inhibit its BC6OTHER activity in human fibroblasts. CPR:falsenewline BC6ENTC and BC6OTHER bind to BC6OTHER ( BC6ENTG ) and inhibit its BC6OTHER activity in human fibroblasts. CPR:falsenewline BC6ENTC and BC6OTHER bind to BC6OTHER ( BC6OTHER ) and inhibit its BC6ENTG activity in human fibroblasts. CPR:falsenewline BC6OTHER and BC6ENTC bind to BC6ENTG ( BC6OTHER ) and inhibit its BC6OTHER activity in human fibroblasts. CPR:falsenewline BC6OTHER and BC6ENTC bind to BC6OTHER ( BC6ENTG ) and inhibit its BC6OTHER activity in human fibroblasts. CPR:falsenewline BC6OTHER and BC6ENTC bind to BC6OTHER ( BC6OTHER ) and inhibit its BC6ENTG activity in human fibroblasts. CPR:falsenewlineBC6OTHER inhibited BC6OTHER activity stimulated by this specific heptapeptide but did not block BC6ENTC binding or induce BC6ENTG expression. CPR:falsenewlineBC6OTHER inhibited BC6ENTG activity stimulated by this specific heptapeptide but did not block BC6ENTC binding or induce BC6OTHER expression. CPR:falsenewlineThese results indicate that BC6ENTC bind specifically to the polypeptide binding site of BC6ENTG in human cells that may interfere with folding and transport of proteins important in inflammation. CPR:falsenewlineThe Kd values of BC6ENTC binding to crude extract and to recombinant BC6ENTG were 45.2 and 54.6 microM, respectively. CPR:falsenewlineBC6ENTG is a BC6OTHER containing a polypeptide binding site recognizing specific BC6OTHER and an BC6ENTC binding site. CPR:falsenewlineBC6OTHER is a BC6ENTG containing a polypeptide binding site recognizing specific BC6OTHER and an BC6ENTC binding site. CPR:falsenewlineBC6OTHER is a BC6OTHER containing a polypeptide binding site recognizing specific BC6ENTG and an BC6ENTC binding site. CPR:falsenewlineAlthough BC6ENTC exerts local antioxidant activity with beneficial effects on lung tissue, this BC6ENTG inhibitor intensifies the blast overpressure caused hemodynamic insufficiency. CPR:falsenewline One group of experimental animals was treated with BC6ENTG ( BC6OTHER ) inhibitor, BC6ENTC ( BC6OTHER , Sigma, St. Louis, Missouri) (50 mg / kg, i.v.), immediately before blast. CPR:4newline One group of experimental animals was treated with BC6OTHER ( BC6ENTG ) inhibitor, BC6ENTC ( BC6OTHER , Sigma, St. Louis, Missouri) (50 mg / kg, i.v.), immediately before blast. CPR:4newline One group of experimental animals was treated with BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER ( BC6ENTC , Sigma, St. Louis, Missouri) (50 mg / kg, i.v.), immediately before blast. CPR:falsenewline One group of experimental animals was treated with BC6OTHER ( BC6ENTG ) inhibitor, BC6OTHER ( BC6ENTC , Sigma, St. Louis, Missouri) (50 mg / kg, i.v.), immediately before blast. CPR:falsenewlineBC6ENTC is a reversible, competitive BC6OTHER ( BC6OTHER ) inhibitor and allosteric potentiating ligand of BC6ENTG ( BC6OTHER - APL) that shares many common structural elements with BC6OTHER - based opioids. CPR:falsenewlineBC6ENTC is a reversible, competitive BC6OTHER ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6ENTG - APL) that shares many common structural elements with BC6OTHER - based opioids. CPR:falsenewlineBC6ENTC is a reversible, competitive BC6ENTG ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6OTHER - APL) that shares many common structural elements with BC6OTHER - based opioids. CPR:4newlineBC6ENTC is a reversible, competitive BC6OTHER ( BC6ENTG ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6OTHER - APL) that shares many common structural elements with BC6OTHER - based opioids. CPR:falsenewlineBC6OTHER is a reversible, competitive BC6OTHER ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6ENTC receptors ( BC6ENTG - APL) that shares many common structural elements with BC6OTHER - based opioids. CPR:falsenewlineBC6OTHER is a reversible, competitive BC6ENTG ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6ENTC receptors ( BC6OTHER - APL) that shares many common structural elements with BC6OTHER - based opioids. CPR:falsenewlineBC6OTHER is a reversible, competitive BC6OTHER ( BC6ENTG ) inhibitor and allosteric potentiating ligand of nicotinic BC6ENTC receptors ( BC6OTHER - APL) that shares many common structural elements with BC6OTHER - based opioids. CPR:falsenewlineBC6OTHER is a reversible, competitive BC6OTHER ( BC6OTHER ) inhibitor and allosteric potentiating ligand of BC6ENTG ( BC6OTHER - APL) that shares many common structural elements with BC6ENTC - based opioids. CPR:falsenewlineBC6OTHER is a reversible, competitive BC6OTHER ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6ENTG - APL) that shares many common structural elements with BC6ENTC - based opioids. CPR:falsenewlineBC6OTHER is a reversible, competitive BC6ENTG ( BC6OTHER ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6OTHER - APL) that shares many common structural elements with BC6ENTC - based opioids. CPR:falsenewlineBC6OTHER is a reversible, competitive BC6OTHER ( BC6ENTG ) inhibitor and allosteric potentiating ligand of nicotinic BC6OTHER receptors ( BC6OTHER - APL) that shares many common structural elements with BC6ENTC - based opioids. CPR:falsenewlineThe structurally diverse opioids BC6ENTC and BC6OTHER , like BC6OTHER , are also BC6ENTG - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6OTHER - APL development. CPR:falsenewlineThe structurally diverse opioids BC6ENTC and BC6OTHER , like BC6OTHER , are also BC6OTHER - APL that have greatly diminished affinity for BC6ENTG , representing potential lead compounds for selective BC6OTHER - APL development. CPR:falsenewlineThe structurally diverse opioids BC6ENTC and BC6OTHER , like BC6OTHER , are also BC6OTHER - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6ENTG - APL development. CPR:falsenewlineThe structurally diverse opioids BC6OTHER and BC6ENTC , like BC6OTHER , are also BC6ENTG - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6OTHER - APL development. CPR:falsenewlineThe structurally diverse opioids BC6OTHER and BC6ENTC , like BC6OTHER , are also BC6OTHER - APL that have greatly diminished affinity for BC6ENTG , representing potential lead compounds for selective BC6OTHER - APL development. CPR:falsenewlineThe structurally diverse opioids BC6OTHER and BC6ENTC , like BC6OTHER , are also BC6OTHER - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6ENTG - APL development. CPR:falsenewlineThe structurally diverse opioids BC6OTHER and BC6OTHER , like BC6ENTC , are also BC6ENTG - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6OTHER - APL development. CPR:falsenewlineThe structurally diverse opioids BC6OTHER and BC6OTHER , like BC6ENTC , are also BC6OTHER - APL that have greatly diminished affinity for BC6ENTG , representing potential lead compounds for selective BC6OTHER - APL development. CPR:falsenewlineThe structurally diverse opioids BC6OTHER and BC6OTHER , like BC6ENTC , are also BC6OTHER - APL that have greatly diminished affinity for BC6OTHER , representing potential lead compounds for selective BC6ENTG - APL development. CPR:falsenewlineThe Schild plots for the competitive antagonists BC6OTHER and BC6OTHER against BC6ENTG - selective agonist BC6ENTC - induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 + / - 0.07 (n = 5) for BC6OTHER and 9.09 + / - 0.05 (n = 3) for BC6OTHER . CPR:falsenewlineThe Schild plots for the competitive antagonists BC6OTHER and BC6OTHER against BC6ENTG - selective agonist BC6OTHER - induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 + / - 0.07 (n = 5) for BC6ENTC and 9.09 + / - 0.05 (n = 3) for BC6OTHER . CPR:falsenewlineThe Schild plots for the competitive antagonists BC6OTHER and BC6OTHER against BC6ENTG - selective agonist BC6OTHER - induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 + / - 0.07 (n = 5) for BC6OTHER and 9.09 + / - 0.05 (n = 3) for BC6ENTC . CPR:falsenewlineComputer - assisted analysis of these curvilinear Schild plots in a two - receptor system indicated that BC6ENTG populations responsible for the constrictive response are predominantly (approximately 80 - 90%) low affinity sites for the two antagonists (pKd approximately 8.1 for BC6ENTC and pKd approximately 7.1 for BC6OTHER ) and a small population (approximately 10 - 20%) are high affinity sites (pKd approximately 9.1 for both BC6OTHER and BC6OTHER ), which was in good agreement with radioligand binding studies. CPR:falsenewlineComputer - assisted analysis of these curvilinear Schild plots in a two - receptor system indicated that BC6ENTG populations responsible for the constrictive response are predominantly (approximately 80 - 90%) low affinity sites for the two antagonists (pKd approximately 8.1 for BC6OTHER and pKd approximately 7.1 for BC6ENTC ) and a small population (approximately 10 - 20%) are high affinity sites (pKd approximately 9.1 for both BC6OTHER and BC6OTHER ), which was in good agreement with radioligand binding studies. CPR:falsenewlineComputer - assisted analysis of these curvilinear Schild plots in a two - receptor system indicated that BC6ENTG populations responsible for the constrictive response are predominantly (approximately 80 - 90%) low affinity sites for the two antagonists (pKd approximately 8.1 for BC6OTHER and pKd approximately 7.1 for BC6OTHER ) and a small population (approximately 10 - 20%) are high affinity sites (pKd approximately 9.1 for both BC6ENTC and BC6OTHER ), which was in good agreement with radioligand binding studies. CPR:falsenewlineComputer - assisted analysis of these curvilinear Schild plots in a two - receptor system indicated that BC6ENTG populations responsible for the constrictive response are predominantly (approximately 80 - 90%) low affinity sites for the two antagonists (pKd approximately 8.1 for BC6OTHER and pKd approximately 7.1 for BC6OTHER ) and a small population (approximately 10 - 20%) are high affinity sites (pKd approximately 9.1 for both BC6OTHER and BC6ENTC ), which was in good agreement with radioligand binding studies. CPR:falsenewlineThe BC6ENTG alkylating agent CEC selectively inhibited the phasic component of the BC6ENTC - induced contractile response, with little effect on the tonic component. CPR:falsenewlineThe BC6ENTG occupancy - response relationship defined by the BC6ENTC inactivation method was rectangular hyperbolic for the tonic response, whereas that for the phasic response was linear, indicating the different degree of receptor reserve for the two responses. CPR:falsenewlineUsing the BC6ENTG subtype - selective antagonists BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6ENTC , we have examined the possible heterogeneity in the BC6OTHER populations in rabbit aorta. CPR:falsenewlineUsing the BC6OTHER subtype - selective antagonists BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6ENTC , we have examined the possible heterogeneity in the BC6ENTG populations in rabbit aorta. CPR:falsenewlineUsing the BC6ENTG subtype - selective antagonists BC6ENTC ( BC6OTHER ), BC6OTHER , and BC6OTHER , we have examined the possible heterogeneity in the BC6OTHER populations in rabbit aorta. CPR:falsenewlineUsing the BC6OTHER subtype - selective antagonists BC6ENTC ( BC6OTHER ), BC6OTHER , and BC6OTHER , we have examined the possible heterogeneity in the BC6ENTG populations in rabbit aorta. CPR:falsenewlineRadioligand binding studies with the nonselective BC6ENTG antagonist radioligand BC6ENTC showed that 73 - 87% of the binding sites in rabbit aorta are BC6OTHER sensitive and they are predominantly low affinity sites both for BC6OTHER (pKd = 8.1) and for BC6OTHER (pKd = 7.1). CPR:falsenewlineUsing the BC6ENTG subtype - selective antagonists BC6OTHER ( BC6ENTC ), BC6OTHER , and BC6OTHER , we have examined the possible heterogeneity in the BC6OTHER populations in rabbit aorta. CPR:falsenewlineUsing the BC6OTHER subtype - selective antagonists BC6OTHER ( BC6ENTC ), BC6OTHER , and BC6OTHER , we have examined the possible heterogeneity in the BC6ENTG populations in rabbit aorta. CPR:falsenewlineRadioligand binding studies with the nonselective BC6ENTG antagonist radioligand BC6OTHER showed that 73 - 87% of the binding sites in rabbit aorta are BC6ENTC sensitive and they are predominantly low affinity sites both for BC6OTHER (pKd = 8.1) and for BC6OTHER (pKd = 7.1). CPR:falsenewlineUsing the BC6ENTG subtype - selective antagonists BC6OTHER ( BC6OTHER ), BC6ENTC , and BC6OTHER , we have examined the possible heterogeneity in the BC6OTHER populations in rabbit aorta. CPR:falsenewlineUsing the BC6OTHER subtype - selective antagonists BC6OTHER ( BC6OTHER ), BC6ENTC , and BC6OTHER , we have examined the possible heterogeneity in the BC6ENTG populations in rabbit aorta. CPR:falsenewlineRadioligand binding studies with the nonselective BC6ENTG antagonist radioligand BC6OTHER showed that 73 - 87% of the binding sites in rabbit aorta are BC6OTHER sensitive and they are predominantly low affinity sites both for BC6ENTC (pKd = 8.1) and for BC6OTHER (pKd = 7.1). CPR:falsenewlineRadioligand binding studies with the nonselective BC6ENTG antagonist radioligand BC6OTHER showed that 73 - 87% of the binding sites in rabbit aorta are BC6OTHER sensitive and they are predominantly low affinity sites both for BC6OTHER (pKd = 8.1) and for BC6ENTC (pKd = 7.1). CPR:falsenewlineTwo pharmacologically distinct BC6ENTG subtypes in the contraction of rabbit aorta: each subtype couples with a different BC6ENTC signalling mechanism and plays a different physiological role. CPR:falsenewlineMoreover, BC6OTHER - mediated BC6ENTC ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6ENTG with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites. CPR:falsenewlineMoreover, BC6ENTG - mediated BC6ENTC ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6OTHER with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites. CPR:falsenewlineMoreover, BC6OTHER - mediated BC6OTHER ( BC6ENTC ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6ENTG with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites. CPR:falsenewlineMoreover, BC6ENTG - mediated BC6OTHER ( BC6ENTC ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6OTHER with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites. CPR:falsenewlineMoreover, BC6OTHER - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6ENTC sensitive, and fractional inactivation of BC6ENTG with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites. CPR:falsenewlineMoreover, BC6ENTG - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6ENTC sensitive, and fractional inactivation of BC6OTHER with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites. CPR:falsenewlineMoreover, BC6OTHER - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6ENTG with BC6ENTC showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites. CPR:falsenewlineMoreover, BC6ENTG - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6OTHER with BC6ENTC showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites. CPR:falsenewlineMoreover, BC6OTHER - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6ENTG with BC6OTHER showed equivalent increments in the reduction of BC6ENTC hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites. CPR:falsenewlineMoreover, BC6ENTG - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6OTHER with BC6OTHER showed equivalent increments in the reduction of BC6ENTC hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6OTHER - sensitive receptor sites. CPR:falsenewlineMoreover, BC6OTHER - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6ENTG with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6ENTC - sensitive receptor sites. CPR:falsenewlineMoreover, BC6ENTG - mediated BC6OTHER ( BC6OTHER ) hydrolysis was BC6OTHER sensitive, and fractional inactivation of BC6OTHER with BC6OTHER showed equivalent increments in the reduction of BC6OTHER hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the BC6ENTC - sensitive receptor sites. CPR:falsenewlineThe Schild plots for the competitive antagonists BC6ENTC and BC6OTHER against BC6ENTG - selective agonist BC6OTHER - induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 + / - 0.07 (n = 5) for BC6OTHER and 9.09 + / - 0.05 (n = 3) for BC6OTHER . CPR:falsenewlineThe Schild plots for the competitive antagonists BC6OTHER and BC6ENTC against BC6ENTG - selective agonist BC6OTHER - induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 + / - 0.07 (n = 5) for BC6OTHER and 9.09 + / - 0.05 (n = 3) for BC6OTHER . CPR:falsenewlineIn a search for less flexible analogues of BC6OTHER (1), a BC6OTHER BC6ENTC endowed with an interesting BC6ENTG affinity profile, we discovered compound 2, in which the terminal BC6OTHER groups of 1 have been incorporated into a BC6OTHER system. CPR:falsenewline BC6ENTC derivatives as BC6ENTG inhibitors. CPR:falsenewlineIn a search for less flexible analogues of BC6OTHER (1), a BC6OTHER BC6OTHER endowed with an interesting BC6ENTG affinity profile, we discovered compound 2, in which the terminal BC6ENTC groups of 1 have been incorporated into a BC6OTHER system. CPR:falsenewlineIn a search for less flexible analogues of BC6OTHER (1), a BC6OTHER BC6OTHER endowed with an interesting BC6ENTG affinity profile, we discovered compound 2, in which the terminal BC6OTHER groups of 1 have been incorporated into a BC6ENTC system. CPR:falsenewlineSince this compound retains good BC6ENTG inhibitory activity and its BC6ENTC moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6OTHER . CPR:falsenewlineSince this compound retains good BC6OTHER inhibitory activity and its BC6ENTC moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6ENTG and BC6OTHER . CPR:falsenewlineSince this compound retains good BC6OTHER inhibitory activity and its BC6ENTC moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6ENTG . CPR:falsenewlineSince this compound retains good BC6ENTG inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6ENTC (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6OTHER . CPR:falsenewlineSince this compound retains good BC6OTHER inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6ENTC (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6ENTG and BC6OTHER . CPR:falsenewlineSince this compound retains good BC6OTHER inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6ENTC (3), we have designed and synthesized BC6OTHER 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6ENTG . CPR:falsenewlineIn a search for less flexible analogues of BC6ENTC (1), a BC6OTHER BC6OTHER endowed with an interesting BC6ENTG affinity profile, we discovered compound 2, in which the terminal BC6OTHER groups of 1 have been incorporated into a BC6OTHER system. CPR:falsenewlineSince this compound retains good BC6ENTG inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6ENTC 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6OTHER . CPR:falsenewlineSince this compound retains good BC6OTHER inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6ENTC 4 - 6, and their biological evaluation has been assessed in vitro against BC6ENTG and BC6OTHER . CPR:falsenewlineSince this compound retains good BC6OTHER inhibitory activity and its BC6OTHER moiety is reminiscent of the BC6OTHER (3), we have designed and synthesized BC6ENTC 4 - 6, and their biological evaluation has been assessed in vitro against BC6OTHER and BC6ENTG . CPR:falsenewlineIn a search for less flexible analogues of BC6OTHER (1), a BC6ENTC BC6OTHER endowed with an interesting BC6ENTG affinity profile, we discovered compound 2, in which the terminal BC6OTHER groups of 1 have been incorporated into a BC6OTHER system. CPR:falsenewlineBC6ENTC was found to be a time - dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for BC6ENTG . CPR:falsenewlineAnother inhibitor, BC6ENTC was previously reported to be a slow - binding inhibitor of the BC6ENTG [W. Knecht, M. Loffler, Species - related inhibition of human and rat BC6OTHER dehydrogenase by immunosuppressive BC6OTHER and BC6OTHER derivatives, Biochem. CPR:falsenewlineAnother inhibitor, BC6ENTC was previously reported to be a slow - binding inhibitor of the human BC6OTHER dehydrogenase [W. Knecht, M. Loffler, Species - related inhibition of BC6ENTG by immunosuppressive BC6OTHER and BC6OTHER derivatives, Biochem. CPR:4newlineAnother inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the human BC6ENTC dehydrogenase [W. Knecht, M. Loffler, Species - related inhibition of BC6ENTG by immunosuppressive BC6OTHER and BC6OTHER derivatives, Biochem. CPR:falsenewlineAnother inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the BC6ENTG [W. Knecht, M. Loffler, Species - related inhibition of human and rat BC6ENTC dehydrogenase by immunosuppressive BC6OTHER and BC6OTHER derivatives, Biochem. CPR:falsenewlineAnother inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the BC6ENTG [W. Knecht, M. Loffler, Species - related inhibition of human and rat BC6OTHER dehydrogenase by immunosuppressive BC6ENTC and BC6OTHER derivatives, Biochem. CPR:falsenewlineAnother inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the human BC6OTHER dehydrogenase [W. Knecht, M. Loffler, Species - related inhibition of BC6ENTG by immunosuppressive BC6ENTC and BC6OTHER derivatives, Biochem. CPR:falsenewlineAnother inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the BC6ENTG [W. Knecht, M. Loffler, Species - related inhibition of human and rat BC6OTHER dehydrogenase by immunosuppressive BC6OTHER and BC6ENTC derivatives, Biochem. CPR:falsenewlineAnother inhibitor, BC6OTHER was previously reported to be a slow - binding inhibitor of the human BC6OTHER dehydrogenase [W. Knecht, M. Loffler, Species - related inhibition of BC6ENTG by immunosuppressive BC6OTHER and BC6ENTC derivatives, Biochem. CPR:falsenewlineMitochondrially - bound BC6ENTC dehydrogenase ( BC6ENTG ) catalyzes the fourth sequential step in the de novo synthesis of BC6OTHER . CPR:falsenewlineWith respect to the substrate BC6ENTC , BC6OTHER was an uncompetitive inhibitor of BC6ENTG (Kiu = 11.6 microM) and a non - competitive inhibitor of the rat enzyme (Kiu = 905 / Kic = 1,012 nM). CPR:9newlineWith respect to the substrate BC6OTHER , BC6ENTC was an uncompetitive inhibitor of BC6ENTG (Kiu = 11.6 microM) and a non - competitive inhibitor of the rat enzyme (Kiu = 905 / Kic = 1,012 nM). CPR:4newlineKinetics of inhibition of BC6ENTG by BC6OTHER , BC6OTHER derivatives, BC6ENTC and BC6OTHER . CPR:4newlineKinetics of inhibition of BC6ENTG by BC6OTHER , BC6OTHER derivatives, BC6OTHER and BC6ENTC . CPR:4newlineKinetics of inhibition of BC6ENTG by BC6ENTC , BC6OTHER derivatives, BC6OTHER and BC6OTHER . CPR:4newlineKinetics of inhibition of BC6ENTG by BC6OTHER , BC6ENTC derivatives, BC6OTHER and BC6OTHER . CPR:4newlineWith respect to the BC6ENTC co - substrate of the BC6ENTG , BC6OTHER (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of human BC6OTHER dehydrogenase. CPR:9newlineWith respect to the BC6ENTC co - substrate of the BC6OTHER dehydrogenase, BC6OTHER (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of BC6ENTG . CPR:9newlineWith respect to the BC6OTHER co - substrate of the BC6ENTC dehydrogenase, BC6OTHER (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of BC6ENTG . CPR:falsenewlineWith respect to the BC6OTHER co - substrate of the BC6ENTG , BC6ENTC (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of human BC6OTHER dehydrogenase. CPR:9newlineWith respect to the BC6OTHER co - substrate of the BC6OTHER dehydrogenase, BC6ENTC (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of BC6ENTG . CPR:4newlineWith respect to the BC6OTHER co - substrate of the BC6ENTG , BC6OTHER (Kic = 2.7 microM) and BC6ENTC (Kic = 9.8 nM) were shown to be competitive inhibitors of human BC6OTHER dehydrogenase. CPR:9newlineWith respect to the BC6OTHER co - substrate of the BC6OTHER dehydrogenase, BC6OTHER (Kic = 2.7 microM) and BC6ENTC (Kic = 9.8 nM) were shown to be competitive inhibitors of BC6ENTG . CPR:4newlineMitochondrially - bound BC6ENTG ( BC6OTHER ) catalyzes the fourth sequential step in the de novo synthesis of BC6ENTC . CPR:9newlineMitochondrially - bound BC6OTHER ( BC6ENTG ) catalyzes the fourth sequential step in the de novo synthesis of BC6ENTC . CPR:falsenewlineWith respect to the BC6OTHER co - substrate of the BC6ENTG , BC6OTHER (Kic = 2.7 microM) and BC6OTHER (Kic = 9.8 nM) were shown to be competitive inhibitors of human BC6ENTC dehydrogenase. CPR:falsenewlineSynthesis and in - silico studies of some BC6ENTC derivatives as potential BC6ENTG inhibitors. CPR:4newlineSince pathologies are often related to inflammation, an inflammatory HUVEC culture condition with BC6ENTG stimulation has been introduced and suggested to be widely applied for studying nanocarriers, since cellular uptake in this assay was clearly increased for BC6ENTC contents ⩾20mol.%. CPR:falsenewlineTransgenic expression of the human BC6ENTC receptor ( BC6ENTG ) in the duodenum of BC6OTHER - null mice attenuates the age - dependent decline in BC6OTHER absorption. CPR:falsenewlineTransgenic expression of the human BC6ENTC receptor ( BC6OTHER ) in the duodenum of BC6ENTG - null mice attenuates the age - dependent decline in BC6OTHER absorption. CPR:falsenewlineIn conclusion, transgenic BC6OTHER in the proximal small intestine of BC6ENTG + / BC6OTHER - null mice was transcriptionally active and regulated BC6ENTC absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6OTHER homeostasis. CPR:falsenewlineIn conclusion, transgenic BC6OTHER in the proximal small intestine of BC6OTHER + / BC6ENTG - null mice was transcriptionally active and regulated BC6ENTC absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6OTHER homeostasis. CPR:falsenewlineIn conclusion, transgenic BC6OTHER in the proximal small intestine of BC6OTHER + / BC6OTHER - null mice was transcriptionally active and regulated BC6ENTC absorption, but BC6ENTG actions elsewhere in the intestine are probably necessary to support adequate BC6OTHER homeostasis. CPR:falsenewlineIn conclusion, transgenic BC6ENTG in the proximal small intestine of BC6OTHER + / BC6OTHER - null mice was transcriptionally active and regulated BC6ENTC absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6OTHER homeostasis. CPR:9newlineIn conclusion, transgenic BC6OTHER in the proximal small intestine of BC6ENTG + / BC6OTHER - null mice was transcriptionally active and regulated BC6OTHER absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6ENTC homeostasis. CPR:falsenewlineIn conclusion, transgenic BC6OTHER in the proximal small intestine of BC6OTHER + / BC6ENTG - null mice was transcriptionally active and regulated BC6OTHER absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6ENTC homeostasis. CPR:falsenewlineIn conclusion, transgenic BC6OTHER in the proximal small intestine of BC6OTHER + / BC6OTHER - null mice was transcriptionally active and regulated BC6OTHER absorption, but BC6ENTG actions elsewhere in the intestine are probably necessary to support adequate BC6ENTC homeostasis. CPR:falsenewlineIn conclusion, transgenic BC6ENTG in the proximal small intestine of BC6OTHER + / BC6OTHER - null mice was transcriptionally active and regulated BC6OTHER absorption, but BC6OTHER actions elsewhere in the intestine are probably necessary to support adequate BC6ENTC homeostasis. CPR:falsenewlineIn addition, BC6ENTG + / BC6OTHER - null mice responded better to the late rescue diet suggesting that expression of BC6OTHER in the proximal small intestine protected the BC6ENTC absorbing machinery from age - dependent decline. CPR:falsenewlineIn addition, BC6OTHER + / BC6ENTG - null mice responded better to the late rescue diet suggesting that expression of BC6OTHER in the proximal small intestine protected the BC6ENTC absorbing machinery from age - dependent decline. CPR:falsenewlineIn addition, BC6OTHER + / BC6OTHER - null mice responded better to the late rescue diet suggesting that expression of BC6ENTG in the proximal small intestine protected the BC6ENTC absorbing machinery from age - dependent decline. CPR:falsenewlineTo determine if BC6ENTG 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6OTHER deaminase enhancer ( BC6OTHER + / BC6OTHER - null). CPR:falsenewlineTo determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6ENTG exclusively in the duodenum of BC6OTHER - null mice by using the BC6OTHER deaminase enhancer ( BC6OTHER + / BC6OTHER - null). CPR:falsenewlineTo determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6ENTG - null mice by using the BC6OTHER deaminase enhancer ( BC6OTHER + / BC6OTHER - null). CPR:falsenewlineTo determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6ENTG ( BC6OTHER + / BC6OTHER - null). CPR:falsenewlineTo determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6OTHER deaminase enhancer ( BC6ENTG + / BC6OTHER - null). CPR:falsenewlineTo determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6ENTC homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6OTHER deaminase enhancer ( BC6OTHER + / BC6ENTG - null). CPR:falsenewlineTo determine if BC6ENTG 's actions in the proximal small intestine can sufficiently restore BC6OTHER homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6ENTC deaminase enhancer ( BC6OTHER + / BC6OTHER - null). CPR:falsenewlineTo determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6OTHER homeostasis, we generated transgenic mice expressing BC6ENTG exclusively in the duodenum of BC6OTHER - null mice by using the BC6ENTC deaminase enhancer ( BC6OTHER + / BC6OTHER - null). CPR:falsenewlineTo determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6OTHER homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6ENTG - null mice by using the BC6ENTC deaminase enhancer ( BC6OTHER + / BC6OTHER - null). CPR:falsenewlineTo determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6OTHER homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6ENTC deaminase enhancer ( BC6ENTG + / BC6OTHER - null). CPR:falsenewlineTo determine if BC6OTHER 's actions in the proximal small intestine can sufficiently restore BC6OTHER homeostasis, we generated transgenic mice expressing BC6OTHER exclusively in the duodenum of BC6OTHER - null mice by using the BC6ENTC deaminase enhancer ( BC6OTHER + / BC6ENTG - null). CPR:falsenewlineHowever, when 90 - day - old rachitic mice were fed a rescue diet, serum BC6ENTC improved in BC6ENTG + / BC6OTHER - null mice, but not in BC6OTHER - null mice. CPR:falsenewlineHowever, when 90 - day - old rachitic mice were fed a rescue diet, serum BC6ENTC improved in BC6OTHER + / BC6ENTG - null mice, but not in BC6OTHER - null mice. CPR:falsenewlineHowever, when 90 - day - old rachitic mice were fed a rescue diet, serum BC6ENTC improved in BC6OTHER + / BC6OTHER - null mice, but not in BC6ENTG - null mice. CPR:falsenewlineTransgenic expression of the BC6ENTG ( BC6OTHER ) in the duodenum of BC6OTHER - null mice attenuates the age - dependent decline in BC6ENTC absorption. CPR:falsenewlineTransgenic expression of the human BC6OTHER receptor ( BC6ENTG ) in the duodenum of BC6OTHER - null mice attenuates the age - dependent decline in BC6ENTC absorption. CPR:falsenewlineTransgenic expression of the human BC6OTHER receptor ( BC6OTHER ) in the duodenum of BC6ENTG - null mice attenuates the age - dependent decline in BC6ENTC absorption. CPR:falsenewlineIn general, the rats treated with BC6ENTC alone did not exhibit any pronounced alteration in memory compared with controls in the MWM, and in many cases BC6ENTG did not induce any alteration. CPR:falsenewlineIn conclusion, BC6ENTG improves spatial memory in intact rats and can reverse certain effects induced by anabolic androgenic BC6ENTC . CPR:falsenewlineIn this study we report the effects of BC6ENTG on learning and memory in intact rats pretreated with the anabolic androgenic BC6ENTC BC6OTHER . CPR:falsenewlineIn this study we report the effects of BC6ENTG on learning and memory in intact rats pretreated with the anabolic androgenic BC6OTHER BC6ENTC . CPR:falsenewlineMale Wistar rats received BC6ENTC (15 mg / kg) or peanut oil every third day for 3 weeks and were subsequently treated with recombinant BC6ENTG (1.0 IU / kg) or saline for 10 consecutive days. CPR:falsenewlineIn addition, BC6ENTG was demonstrated to increase the body weight gain and was able to attenuate the reduced body weight seen in BC6ENTC - treated animals. CPR:falsenewlineSimilar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6ENTC . CPR:falsenewlineA correlation analysis of selective BC6ENTG compounds comparing the pKD for displacement of BC6ENTC vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6OTHER site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineA correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6ENTC vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTG and the BC6OTHER site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineA correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6ENTC vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6ENTG site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineThe aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6ENTG defined by BC6ENTC BC6OTHER binding and the BC6OTHER defined by inhibition of BC6OTHER release. CPR:falsenewlineThe aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6OTHER defined by BC6ENTC BC6OTHER binding and the BC6ENTG defined by inhibition of BC6OTHER release. CPR:falsenewlineA correlation analysis of selective BC6ENTG compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6ENTC release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6OTHER site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineA correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6ENTC release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTG and the BC6OTHER site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineA correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6ENTC release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6ENTG site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineA correlation analysis of selective BC6ENTG compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTC autoreceptor and the BC6OTHER site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineA correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTC autoreceptor and the BC6ENTG site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineA correlation analysis of selective BC6ENTG compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6ENTC receptor site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineA correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTG and the BC6ENTC receptor site defined by BC6OTHER binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineA correlation analysis of selective BC6ENTG compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6OTHER site defined by BC6ENTC binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineA correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6ENTG and the BC6OTHER site defined by BC6ENTC binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineA correlation analysis of selective BC6OTHER compounds comparing the pKD for displacement of BC6OTHER vs. the IC50 for inhibition of BC6OTHER release demonstrated the pharmacological similarity of the presynaptic inhibitory BC6OTHER and the BC6ENTG site defined by BC6ENTC binding in spinal cord synaptosomes (r = 0.791, P = .0193). CPR:falsenewlineThe aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6ENTG defined by BC6OTHER BC6ENTC binding and the BC6OTHER defined by inhibition of BC6OTHER release. CPR:falsenewlineThe aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6OTHER defined by BC6OTHER BC6ENTC binding and the BC6ENTG defined by inhibition of BC6OTHER release. CPR:falsenewlineSimilar to the pharmacological characteristics of the BC6ENTG site defined by BC6ENTC , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6OTHER . CPR:falsenewlineThe aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6ENTG defined by BC6OTHER BC6OTHER binding and the BC6ENTC autoreceptor defined by inhibition of BC6OTHER release. CPR:falsenewlineThe aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6ENTC (5 - HT)1B receptor defined by BC6OTHER BC6OTHER binding and the BC6ENTG defined by inhibition of BC6OTHER release. CPR:falsenewlineThese results point out that BC6ENTC identifies the BC6ENTG receptor, and affinity of compounds for this site predicts action at the BC6OTHER autoreceptor. CPR:falsenewlineThese results point out that BC6ENTC identifies the BC6OTHER receptor, and affinity of compounds for this site predicts action at the BC6ENTG autoreceptor. CPR:falsenewlineThe aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6ENTG defined by BC6OTHER BC6OTHER binding and the BC6OTHER defined by inhibition of BC6ENTC release. CPR:falsenewlineThe aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the BC6OTHER defined by BC6OTHER BC6OTHER binding and the BC6ENTG defined by inhibition of BC6ENTC release. CPR:falsenewlineSimilar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6ENTC - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6OTHER . CPR:falsenewlineBC6ENTC binding was not altered by compounds with activity at BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER or alpha - 2 receptor sites. CPR:falsenewlineBC6ENTC binding was not altered by compounds with activity at BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER or alpha - 2 receptor sites. CPR:falsenewlineBC6ENTC binding was not altered by compounds with activity at BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER or alpha - 2 receptor sites. CPR:falsenewlineBC6ENTC binding was not altered by compounds with activity at BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG or alpha - 2 receptor sites. CPR:falsenewlineCharacterization of BC6ENTG receptors in rat spinal cord via BC6OTHER binding and inhibition of BC6ENTC release. CPR:falsenewlineCharacterization of BC6ENTG receptors in rat spinal cord via BC6ENTC binding and inhibition of BC6OTHER release. CPR:falsenewlineSimilar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6ENTC were BC6OTHER = BC6OTHER BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6OTHER . CPR:falsenewlineSimilar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6ENTC = BC6OTHER BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6OTHER . CPR:falsenewlineSimilar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6ENTC BC6OTHER = BC6OTHER greater than BC6OTHER greater than BC6OTHER . CPR:falsenewlineSimilar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6ENTC = BC6OTHER greater than BC6OTHER greater than BC6OTHER . CPR:falsenewlineSimilar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6OTHER = BC6ENTC greater than BC6OTHER greater than BC6OTHER . CPR:falsenewlineSimilar to the pharmacological characteristics of the BC6ENTG site defined by BC6OTHER , compounds most active at inhibiting 15 mM BC6OTHER - stimulated release of BC6OTHER were BC6OTHER = BC6OTHER BC6OTHER = BC6OTHER greater than BC6ENTC greater than BC6OTHER . CPR:falsenewlineReductions in striatal BC6ENTC and BC6ENTG content were also less pronounced with BC6OTHER treatment. CPR:falsenewlineReductions in striatal BC6OTHER and BC6ENTG content were also less pronounced with BC6ENTC treatment. CPR:4newlineThe neuroinflammatory response to BC6ENTC was markedly attenuated, and indices of oxidative stress and BC6ENTG activation were significantly prevented with BC6OTHER . CPR:falsenewlineThe neuroinflammatory response to BC6OTHER was markedly attenuated, and indices of oxidative stress and BC6ENTG activation were significantly prevented with BC6ENTC . CPR:falsenewlineIn cultured primary microglia and astrocytes, BC6ENTC had a direct anti - inflammatory effect demonstrated by repression of lipopolysaccharide - induced BC6ENTG activation, BC6OTHER induction, and BC6OTHER production. CPR:4newlineIn cultured primary microglia and astrocytes, BC6ENTC had a direct anti - inflammatory effect demonstrated by repression of lipopolysaccharide - induced BC6OTHER activation, BC6ENTG induction, and BC6OTHER production. CPR:falsenewlineIn cultured primary microglia and astrocytes, BC6OTHER had a direct anti - inflammatory effect demonstrated by repression of lipopolysaccharide - induced BC6ENTG activation, BC6OTHER induction, and BC6ENTC production. CPR:falsenewlineIn cultured primary microglia and astrocytes, BC6OTHER had a direct anti - inflammatory effect demonstrated by repression of lipopolysaccharide - induced BC6OTHER activation, BC6ENTG induction, and BC6ENTC production. CPR:4newlineAdditionally, in SH - SY5Y cells, BC6ENTC - induced demethylation of BC6ENTG ( BC6OTHER ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by BC6OTHER . CPR:falsenewlineAdditionally, in SH - SY5Y cells, BC6ENTC - induced demethylation of BC6OTHER ( BC6ENTG ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by BC6OTHER . CPR:falsenewlineAdditionally, in SH - SY5Y cells, BC6OTHER - induced demethylation of BC6ENTG ( BC6OTHER ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by BC6ENTC . CPR:falsenewlineAdditionally, in SH - SY5Y cells, BC6OTHER - induced demethylation of BC6OTHER ( BC6ENTG ), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by BC6ENTC . CPR:falsenewlineThese findings indicate that the neuroprotective effect of BC6ENTC against BC6OTHER is through several mechanisms including its anti - inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of BC6ENTG . CPR:falsenewlineThese findings indicate that the neuroprotective effect of BC6OTHER against BC6ENTC is through several mechanisms including its anti - inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of BC6ENTG . CPR:falsenewlineOne of these compounds is BC6ENTC ( BC6OTHER ), which ameliorates the phenotype of BC6ENTG transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation. CPR:falsenewlineOne of these compounds is BC6OTHER ( BC6ENTC ), which ameliorates the phenotype of BC6ENTG transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation. CPR:falsenewlineIn a genome - wide meta - analysis of a population - based discovery cohort (n = 33 533), rs838133 in BC6ENTG (19q13.33), rs197273 near BC6OTHER ( BC6OTHER ) (2p24.2), and rs10163409 in BC6OTHER (16q12.2) were among the top associations (P < 10( - 5)) for percentage of total caloric intake from protein and BC6ENTC . CPR:falsenewlineIn a genome - wide meta - analysis of a population - based discovery cohort (n = 33 533), rs838133 in BC6OTHER (19q13.33), rs197273 near BC6ENTG ( BC6OTHER ) (2p24.2), and rs10163409 in BC6OTHER (16q12.2) were among the top associations (P < 10( - 5)) for percentage of total caloric intake from protein and BC6ENTC . CPR:falsenewlineIn a genome - wide meta - analysis of a population - based discovery cohort (n = 33 533), rs838133 in BC6OTHER (19q13.33), rs197273 near BC6OTHER ( BC6ENTG ) (2p24.2), and rs10163409 in BC6OTHER (16q12.2) were among the top associations (P < 10( - 5)) for percentage of total caloric intake from protein and BC6ENTC . CPR:falsenewlineIn a genome - wide meta - analysis of a population - based discovery cohort (n = 33 533), rs838133 in BC6OTHER (19q13.33), rs197273 near BC6OTHER ( BC6OTHER ) (2p24.2), and rs10163409 in BC6ENTG (16q12.2) were among the top associations (P < 10( - 5)) for percentage of total caloric intake from protein and BC6ENTC . CPR:falsenewlineTo examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6ENTG KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6ENTG - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6ENTG - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6ENTG ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6ENTG KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6ENTC effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6ENTG ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6ENTC or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6ENTG KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6ENTG - selective agonist BC6ENTC or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6ENTC or the BC6ENTG - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6ENTC or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6ENTG ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6ENTC or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6ENTG KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6ENTC or the BC6OTHER - selective agonist BC6OTHER were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6ENTG ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6ENTG KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6ENTG - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6ENTG - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6ENTG ( BC6OTHER KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6OTHER ( BC6ENTG KO) or BC6OTHER ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewlineTo examine receptor mediation of BC6OTHER effects, Ovx mice replaced for 2 days with either the BC6OTHER - selective agonist BC6OTHER or the BC6OTHER - selective agonist BC6ENTC were compared to Sham mice, and mice lacking either BC6OTHER ( BC6OTHER KO) or BC6ENTG ( BC6OTHER KO) were compared to WT littermates. CPR:falsenewline BC6ENTC replacement enhances BC6OTHER - stimulated locomotion in female C57BL / 6 mice through BC6ENTG . CPR:falsenewline BC6OTHER replacement enhances BC6ENTC - stimulated locomotion in female C57BL / 6 mice through BC6ENTG . CPR:falsenewlineBC6ENTG KO mice displayed modestly attenuated behavioral responses to novelty and BC6ENTC compared to αWT littermates, but no behavioral differences were found between BC6OTHER KO and βWT mice. CPR:falsenewlineBC6OTHER KO mice displayed modestly attenuated behavioral responses to novelty and BC6ENTC compared to αWT littermates, but no behavioral differences were found between BC6ENTG KO and βWT mice. CPR:falsenewlineThese results suggest that E2 enhances BC6ENTC - stimulated locomotion in mice predominantly through BC6ENTG . CPR:falsenewlineBC6ENTC - induced changes were blocked with the BC6ENTG antagonist cetuximab, which suggested direct involvement of BC6OTHER in this process. CPR:falsenewlineBC6ENTC - induced changes were blocked with the BC6OTHER antagonist cetuximab, which suggested direct involvement of BC6ENTG in this process. CPR:falsenewlineWestern blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6ENTG and downstream signaling that was reduced by inhibition of BC6OTHER ( BC6OTHER ) and BC6OTHER , but not BC6OTHER / BC6OTHER . CPR:falsenewlineWestern blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6OTHER and downstream signaling that was reduced by inhibition of BC6ENTG ( BC6OTHER ) and BC6OTHER , but not BC6OTHER / BC6OTHER . CPR:falsenewlineWestern blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6OTHER and downstream signaling that was reduced by inhibition of BC6OTHER ( BC6ENTG ) and BC6OTHER , but not BC6OTHER / BC6OTHER . CPR:falsenewlineWestern blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6OTHER and downstream signaling that was reduced by inhibition of BC6OTHER ( BC6OTHER ) and BC6ENTG , but not BC6OTHER / BC6OTHER . CPR:falsenewlineWestern blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6OTHER and downstream signaling that was reduced by inhibition of BC6OTHER ( BC6OTHER ) and BC6OTHER , but not BC6ENTG / BC6OTHER . CPR:falsenewlineWestern blot analysis of cells incubated with BC6ENTC demonstrated activation of BC6OTHER and downstream signaling that was reduced by inhibition of BC6OTHER ( BC6OTHER ) and BC6OTHER , but not BC6OTHER / BC6ENTG . CPR:falsenewlineAn in vitro BC6OTHER assay showed that BC6ENTC did not directly affect BC6OTHER BC6ENTG activity, suggesting involvement of BC6OTHER - activating molecules. CPR:falsenewlineAn in vitro BC6OTHER assay showed that BC6ENTC did not directly affect BC6OTHER BC6OTHER activity, suggesting involvement of BC6ENTG - activating molecules. CPR:falsenewlineAn in vitro BC6ENTG assay showed that BC6ENTC did not directly affect BC6OTHER BC6OTHER activity, suggesting involvement of BC6OTHER - activating molecules. CPR:falsenewlineAn in vitro BC6OTHER assay showed that BC6ENTC did not directly affect BC6ENTG BC6OTHER activity, suggesting involvement of BC6OTHER - activating molecules. CPR:falsenewlineInduction of BC6ENTG and activation of BC6OTHER in BC6ENTC - treated squamous carcinoma cells. CPR:falsenewlineInduction of BC6OTHER and activation of BC6ENTG in BC6ENTC - treated squamous carcinoma cells. CPR:falsenewlineBC6ENTC is a BC6OTHER kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER BC6OTHER . CPR:falsenewlineBC6ENTC is a BC6OTHER kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG BC6OTHER . CPR:falsenewlineBC6ENTC is a BC6OTHER kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER BC6ENTG . CPR:falsenewlineBC6ENTC is a BC6ENTG inhibitor of the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER BC6OTHER . CPR:4newlineBC6ENTC is a BC6OTHER kinase inhibitor of the BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER BC6OTHER . CPR:falsenewlineBC6ENTC is a BC6OTHER kinase inhibitor of the BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER BC6OTHER . CPR:falsenewlineInhibitors and neutralizing antibodies against BC6ENTG ( BC6OTHER ), and to a lesser extent BC6OTHER , reduced BC6ENTC - mediated BC6OTHER ( BC6OTHER ) activation. CPR:falsenewlineInhibitors and neutralizing antibodies against BC6OTHER ( BC6ENTG ), and to a lesser extent BC6OTHER , reduced BC6ENTC - mediated BC6OTHER ( BC6OTHER ) activation. CPR:falsenewlineInhibitors and neutralizing antibodies against BC6OTHER ( BC6OTHER ), and to a lesser extent BC6ENTG , reduced BC6ENTC - mediated BC6OTHER ( BC6OTHER ) activation. CPR:falsenewlineInhibitors and neutralizing antibodies against BC6OTHER ( BC6OTHER ), and to a lesser extent BC6OTHER , reduced BC6ENTC - mediated BC6ENTG ( BC6OTHER ) activation. CPR:falsenewlineInhibitors and neutralizing antibodies against BC6OTHER ( BC6OTHER ), and to a lesser extent BC6OTHER , reduced BC6ENTC - mediated BC6OTHER ( BC6ENTG ) activation. CPR:falsenewlineBC6ENTC stimulated the rapid release of soluble BC6ENTG and the subsequent induction of membrane - bound BC6OTHER , which correlated with biphasic BC6OTHER activation. CPR:falsenewlineBC6ENTC stimulated the rapid release of soluble BC6OTHER and the subsequent induction of membrane - bound BC6ENTG , which correlated with biphasic BC6OTHER activation. CPR:falsenewlineBC6ENTC stimulated the rapid release of soluble BC6OTHER and the subsequent induction of membrane - bound BC6OTHER , which correlated with biphasic BC6ENTG activation. CPR:3newlineTogether, these results suggested that BC6ENTC affects BC6ENTG activation and signaling pathways through rapid release and increased expression of endogenous BC6OTHER - activating ligands. CPR:falsenewlineTogether, these results suggested that BC6ENTC affects BC6OTHER activation and signaling pathways through rapid release and increased expression of endogenous BC6ENTG - activating ligands. CPR:falsenewlineAlthough, BC6ENTC primarily inhibits BC6ENTG , it also stimulates the activity of BC6OTHER BC6OTHER kinase in head and neck squamous tumors. CPR:4newlineAlthough, BC6ENTC primarily inhibits BC6OTHER , it also stimulates the activity of BC6ENTG BC6OTHER kinase in head and neck squamous tumors. CPR:falsenewlineAlthough, BC6ENTC primarily inhibits BC6OTHER , it also stimulates the activity of BC6OTHER BC6ENTG in head and neck squamous tumors. CPR:3newlineAlthough, BC6OTHER primarily inhibits BC6ENTG , it also stimulates the activity of BC6OTHER BC6ENTC kinase in head and neck squamous tumors. CPR:falsenewlineAlthough, BC6OTHER primarily inhibits BC6OTHER , it also stimulates the activity of BC6ENTG BC6ENTC kinase in head and neck squamous tumors. CPR:falsenewlineBC6OTHER is a BC6ENTC kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER BC6OTHER . CPR:falsenewlineBC6OTHER is a BC6ENTC kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG BC6OTHER . CPR:falsenewlineBC6OTHER is a BC6ENTC kinase inhibitor of the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER BC6ENTG . CPR:falsenewlineBC6OTHER is a BC6ENTC kinase inhibitor of the BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER BC6OTHER . CPR:falsenewlineBC6OTHER is a BC6ENTC kinase inhibitor of the BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER BC6OTHER . CPR:falsenewlineTreatment of head and neck squamous carcinoma cells with clinically relevant concentrations of BC6ENTC - induced changes in cell morphology and growth similar to changes associated with BC6ENTG ( BC6OTHER ) activation. CPR:falsenewlineTreatment of head and neck squamous carcinoma cells with clinically relevant concentrations of BC6ENTC - induced changes in cell morphology and growth similar to changes associated with BC6OTHER ( BC6ENTG ) activation. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6ENTC for BC6ENTG , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6ENTG inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6OTHER inhibitors for BC6ENTG , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6ENTG / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6ENTG , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for BC6ENTG , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6ENTC for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6ENTG or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6ENTG , BC6OTHER inhibitors for BC6OTHER , BC6ENTC for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6ENTG inhibitors for BC6OTHER , BC6ENTC for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6ENTG , BC6ENTC for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6ENTC for BC6ENTG / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6ENTC for BC6OTHER / BC6ENTG , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6ENTC for BC6OTHER / BC6OTHER , BC6OTHER analogues for BC6ENTG , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6ENTC for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6ENTG or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6ENTG , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6ENTG inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6ENTG , BC6OTHER for BC6OTHER / BC6OTHER , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6ENTG / BC6OTHER , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6ENTG , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6ENTC analogues for BC6ENTG , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6ENTC analogues for mammalian target of BC6OTHER , and agents that inhibit either BC6ENTG or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6ENTG , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6ENTG inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6ENTG , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6ENTG / BC6OTHER , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6ENTG , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6OTHER or its receptors. CPR:falsenewlineFor some, pharmacologic inhibitors are available, including BC6OTHER for BC6OTHER , BC6OTHER inhibitors for BC6OTHER , BC6OTHER for BC6OTHER / BC6OTHER , BC6OTHER analogues for mammalian target of BC6ENTC , and agents that inhibit either BC6ENTG or its receptors. CPR:falsenewlineIn this study, we compared the effects of BC6OTHER and BC6ENTC on regulating serum BC6OTHER and BC6ENTG , and also the expression of BC6OTHER , BC6OTHER , and BC6OTHER mRNA. CPR:falsenewlineIn this study, we compared the effects of BC6OTHER and BC6ENTC on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6ENTG , BC6OTHER , and BC6OTHER mRNA. CPR:falsenewlineIn this study, we compared the effects of BC6OTHER and BC6ENTC on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6OTHER , BC6ENTG , and BC6OTHER mRNA. CPR:falsenewlineIn this study, we compared the effects of BC6OTHER and BC6ENTC on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6OTHER , BC6OTHER , and BC6ENTG mRNA. CPR:falsenewlineIn this study, we compared the effects of BC6OTHER and BC6OTHER on regulating serum BC6ENTC and BC6ENTG , and also the expression of BC6OTHER , BC6OTHER , and BC6OTHER mRNA. CPR:falsenewlineIn this study, we compared the effects of BC6OTHER and BC6OTHER on regulating serum BC6ENTC and BC6OTHER , and also the expression of BC6ENTG , BC6OTHER , and BC6OTHER mRNA. CPR:falsenewlineIn this study, we compared the effects of BC6OTHER and BC6OTHER on regulating serum BC6ENTC and BC6OTHER , and also the expression of BC6OTHER , BC6ENTG , and BC6OTHER mRNA. CPR:falsenewlineIn this study, we compared the effects of BC6OTHER and BC6OTHER on regulating serum BC6ENTC and BC6OTHER , and also the expression of BC6OTHER , BC6OTHER , and BC6ENTG mRNA. CPR:falsenewlineBoth drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6ENTG mRNA expression and serum BC6OTHER effectively in the 5 / 6 NX rats, but BC6ENTC was less potent in raising serum BC6OTHER than BC6OTHER . CPR:falsenewlineBoth drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6OTHER mRNA expression and serum BC6ENTG effectively in the 5 / 6 NX rats, but BC6ENTC was less potent in raising serum BC6OTHER than BC6OTHER . CPR:falsenewlineBoth drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6ENTG mRNA expression and serum BC6OTHER effectively in the 5 / 6 NX rats, but BC6OTHER was less potent in raising serum BC6ENTC than BC6OTHER . CPR:falsenewlineBoth drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6OTHER mRNA expression and serum BC6ENTG effectively in the 5 / 6 NX rats, but BC6OTHER was less potent in raising serum BC6ENTC than BC6OTHER . CPR:falsenewlineBoth drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6ENTG mRNA expression and serum BC6OTHER effectively in the 5 / 6 NX rats, but BC6OTHER was less potent in raising serum BC6OTHER than BC6ENTC . CPR:falsenewlineBoth drugs at the tested doses (0.042 - 0.33 mug / kg) suppressed BC6OTHER mRNA expression and serum BC6ENTG effectively in the 5 / 6 NX rats, but BC6OTHER was less potent in raising serum BC6OTHER than BC6ENTC . CPR:falsenewlineIn pig parathyroid cells, BC6ENTC and the active form of BC6OTHER induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6ENTG mRNA more effectively. CPR:falsenewlineIn pig parathyroid cells, BC6ENTC and the active form of BC6OTHER induced BC6ENTG translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6OTHER mRNA more effectively. CPR:falsenewlineIn pig parathyroid cells, BC6ENTC and the active form of BC6OTHER induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6ENTG mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6OTHER mRNA more effectively. CPR:falsenewlineIn pig parathyroid cells, BC6OTHER and the active form of BC6ENTC induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6ENTG mRNA more effectively. CPR:falsenewlineIn pig parathyroid cells, BC6OTHER and the active form of BC6ENTC induced BC6ENTG translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6OTHER mRNA more effectively. CPR:falsenewlineIn pig parathyroid cells, BC6OTHER and the active form of BC6ENTC induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6ENTG mRNA expression and inhibited cell proliferation in a similar manner, although BC6OTHER induced the expression of BC6OTHER mRNA more effectively. CPR:falsenewlineBC6ENTC receptor agonists (VDRAs) directly suppress BC6ENTG ( BC6OTHER ) mRNA expression. CPR:falsenewlineBC6ENTC receptor agonists (VDRAs) directly suppress BC6OTHER ( BC6ENTG ) mRNA expression. CPR:falsenewlineIn pig parathyroid cells, BC6OTHER and the active form of BC6OTHER induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6ENTC induced the expression of BC6ENTG mRNA more effectively. CPR:falsenewlineIn pig parathyroid cells, BC6OTHER and the active form of BC6OTHER induced BC6ENTG translocation from the cytoplasm into the nucleus, suppressed BC6OTHER mRNA expression and inhibited cell proliferation in a similar manner, although BC6ENTC induced the expression of BC6OTHER mRNA more effectively. CPR:falsenewlineIn pig parathyroid cells, BC6OTHER and the active form of BC6OTHER induced BC6OTHER translocation from the cytoplasm into the nucleus, suppressed BC6ENTG mRNA expression and inhibited cell proliferation in a similar manner, although BC6ENTC induced the expression of BC6OTHER mRNA more effectively. CPR:falsenewlineThe multiple effects of VDRAs on modulating serum BC6ENTC , parathyroid cell proliferation, and the expression of BC6ENTG and BC6OTHER mRNA reflect the complex involvement of the BC6OTHER axis in regulating the mineral homeostasis system. CPR:falsenewlineThe multiple effects of VDRAs on modulating serum BC6ENTC , parathyroid cell proliferation, and the expression of BC6OTHER and BC6ENTG mRNA reflect the complex involvement of the BC6OTHER axis in regulating the mineral homeostasis system. CPR:falsenewlineThe multiple effects of VDRAs on modulating serum BC6OTHER , parathyroid cell proliferation, and the expression of BC6ENTG and BC6OTHER mRNA reflect the complex involvement of the BC6ENTC axis in regulating the mineral homeostasis system. CPR:falsenewlineThe multiple effects of VDRAs on modulating serum BC6OTHER , parathyroid cell proliferation, and the expression of BC6OTHER and BC6ENTG mRNA reflect the complex involvement of the BC6ENTC axis in regulating the mineral homeostasis system. CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6ENTC ( BC6OTHER ), which may also affect serum BC6ENTG levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6ENTC ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6ENTG secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6ENTC ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6ENTG ( BC6OTHER ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6ENTC ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6ENTG ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6OTHER ( BC6ENTC ), which may also affect serum BC6ENTG levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6OTHER ( BC6ENTC ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6ENTG secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6OTHER ( BC6ENTC ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6ENTG ( BC6OTHER ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6OTHER ( BC6ENTC ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6ENTG ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6ENTG levels since serum BC6ENTC regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6ENTC regulates BC6ENTG secretion mediated by the BC6OTHER - sensing receptor ( BC6OTHER ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6ENTC regulates BC6OTHER secretion mediated by the BC6ENTG ( BC6OTHER ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6ENTC regulates BC6OTHER secretion mediated by the BC6OTHER - sensing receptor ( BC6ENTG ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6ENTG levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6ENTC - sensing receptor ( BC6OTHER ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6ENTG secretion mediated by the BC6ENTC - sensing receptor ( BC6OTHER ). CPR:falsenewlineDifferent VDRAs are known to have differential effects on serum BC6OTHER ( BC6OTHER ), which may also affect serum BC6OTHER levels since serum BC6OTHER regulates BC6OTHER secretion mediated by the BC6ENTC - sensing receptor ( BC6ENTG ). CPR:falsenewlineIn this study, we compared the effects of BC6ENTC and BC6OTHER on regulating serum BC6OTHER and BC6ENTG , and also the expression of BC6OTHER , BC6OTHER , and BC6OTHER mRNA. CPR:falsenewlineIn this study, we compared the effects of BC6ENTC and BC6OTHER on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6ENTG , BC6OTHER , and BC6OTHER mRNA. CPR:falsenewlineIn this study, we compared the effects of BC6ENTC and BC6OTHER on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6OTHER , BC6ENTG , and BC6OTHER mRNA. CPR:falsenewlineIn this study, we compared the effects of BC6ENTC and BC6OTHER on regulating serum BC6OTHER and BC6OTHER , and also the expression of BC6OTHER , BC6OTHER , and BC6ENTG mRNA. CPR:falsenewlineThe existence of multiple affinity states for the opiate receptor in neuroblastoma x glioma NG108 - 15 hybrid cells has been demonstrated by competition binding studies with BC6OTHER and [D - Ala2, D - Leu5] BC6ENTG ( BC6ENTC ). CPR:falsenewlineHowever, in the presence of 100 mM BC6ENTC , which is required for opiate inhibition of BC6ENTG activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 + / - 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 + / - 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 + / - 110 nM. CPR:falsenewlineThese multiple affinity states of receptor in the hybrid cells are agonist - specific, and the percentage of total BC6ENTG in high affinity state is relatively constant in various concentrations of BC6ENTC . CPR:falsenewlineMultiple affinity states of BC6ENTG can be demonstrated further by Scatchard analysis of saturation binding studies with BC6ENTC . CPR:falsenewlineThe existence of multiple affinity states for the opiate receptor in neuroblastoma x glioma NG108 - 15 hybrid cells has been demonstrated by competition binding studies with BC6ENTC and [D - Ala2, D - Leu5] BC6ENTG ( BC6OTHER ). CPR:falsenewlinePURPOSE: BC6ENTC has (R) - and CHEM, which exhibit different pharmacokinetics (PK) among patients with BC6ENTG genotype groups. CPR:falsenewlineThe BC6ENTC hydroxylation index reflects BC6ENTG activity in healthy Japanese volunteers. CPR:falsenewlineAdditionally, there was a significant difference in plasma concentrations of BC6ENTC among BC6ENTG genotype groups, whereas no significant differences were observed in that of BC6OTHER . CPR:falsenewlineAdditionally, there was a significant difference in plasma concentrations of BC6OTHER among BC6ENTG genotype groups, whereas no significant differences were observed in that of BC6ENTC . CPR:falsenewlineCONCLUSION: Our findings demonstrate that BC6ENTC HI correlated better with BC6ENTG genotype groups than BC6OTHER HI, and these results may be useful for classification among patients in BC6OTHER genotype groups prior to CHEM treatment. CPR:falsenewlineCONCLUSION: Our findings demonstrate that BC6ENTC HI correlated better with BC6OTHER genotype groups than BC6OTHER HI, and these results may be useful for classification among patients in BC6ENTG genotype groups prior to CHEM treatment. CPR:falsenewlineCONCLUSION: Our findings demonstrate that BC6OTHER HI correlated better with BC6ENTG genotype groups than BC6ENTC HI, and these results may be useful for classification among patients in BC6OTHER genotype groups prior to CHEM treatment. CPR:falsenewlineCONCLUSION: Our findings demonstrate that BC6OTHER HI correlated better with BC6OTHER genotype groups than BC6ENTC HI, and these results may be useful for classification among patients in BC6ENTG genotype groups prior to CHEM treatment. CPR:falsenewlineThe aim of this study was to investigate whether the 1 - point, 4 - h postdose BC6ENTC hydroxylation index (HI) of BC6OTHER reflects the three BC6ENTG genotype groups in Japanese individuals. CPR:falsenewlineThe aim of this study was to investigate whether the 1 - point, 4 - h postdose BC6OTHER hydroxylation index (HI) of BC6ENTC reflects the three BC6ENTG genotype groups in Japanese individuals. CPR:falsenewlineCompounds 16 and 19 were more active than the positive control BC6ENTC , a known inhibitor of the BC6ENTG signaling pathway. CPR:falsenewlineThe cytosolic fraction obtained from pancreatic islets obtained from BC6ENTC - treated rats had an increased BC6ENTG level compared to the levels obtained from the pancreatic islets of control rats. CPR:falsenewlineTo investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6ENTC ( BC6OTHER ), we focused on the role of BC6ENTG ( BC6OTHER ) in islet BC6OTHER synthesis. CPR:falsenewlineTo investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6ENTC ( BC6OTHER ), we focused on the role of BC6OTHER ( BC6ENTG ) in islet BC6OTHER synthesis. CPR:falsenewlineTo investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6ENTC ( BC6OTHER ), we focused on the role of BC6OTHER ( BC6OTHER ) in islet BC6ENTG synthesis. CPR:falsenewlineTo investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6OTHER ( BC6ENTC ), we focused on the role of BC6ENTG ( BC6OTHER ) in islet BC6OTHER synthesis. CPR:falsenewlineTo investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6OTHER ( BC6ENTC ), we focused on the role of BC6OTHER ( BC6ENTG ) in islet BC6OTHER synthesis. CPR:falsenewlineTo investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of BC6OTHER ( BC6ENTC ), we focused on the role of BC6OTHER ( BC6OTHER ) in islet BC6ENTG synthesis. CPR:falsenewlineIn the present study, BC6ENTC - stimulated BC6ENTG secretion was significantly increased in BC6OTHER - treated rats compared to controls. CPR:falsenewlineIn the present study, BC6OTHER - stimulated BC6ENTG secretion was significantly increased in BC6ENTC - treated rats compared to controls. CPR:3newlineLevels of mRNA encoding BC6ENTG , BC6OTHER , and BC6OTHER were increased in the pancreatic islets of BC6ENTC - treated rats. CPR:falsenewlineLevels of mRNA encoding BC6OTHER , BC6ENTG , and BC6OTHER were increased in the pancreatic islets of BC6ENTC - treated rats. CPR:falsenewlineLevels of mRNA encoding BC6OTHER , BC6OTHER , and BC6ENTG were increased in the pancreatic islets of BC6ENTC - treated rats. CPR:falsenewlineWhen the BC6ENTG in BC6OTHER mRNA was incubated with the islet cytosolic fraction, the RNA - protein complex level was increased in the cytosolic fraction obtained from BC6ENTC - treated rats compared to the level in control rats. CPR:falsenewlineWhen the BC6OTHER in BC6ENTG mRNA was incubated with the islet cytosolic fraction, the RNA - protein complex level was increased in the cytosolic fraction obtained from BC6ENTC - treated rats compared to the level in control rats. CPR:falsenewlineBC6ENTC , a BC6ENTG inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6OTHER ) - induced BC6OTHER reporter gene activity. CPR:falsenewlineBC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6ENTG - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6OTHER ) - induced BC6OTHER reporter gene activity. CPR:falsenewlineBC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6ENTG and BC6OTHER , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6OTHER ) - induced BC6OTHER reporter gene activity. CPR:falsenewlineBC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6ENTG , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6OTHER ) - induced BC6OTHER reporter gene activity. CPR:falsenewlineBC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6ENTG - and BC6OTHER ( BC6OTHER ) - induced BC6OTHER reporter gene activity. CPR:falsenewlineBC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6OTHER - and BC6ENTG ( BC6OTHER ) - induced BC6OTHER reporter gene activity. CPR:falsenewlineBC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6ENTG ) - induced BC6OTHER reporter gene activity. CPR:falsenewlineBC6ENTC , a BC6OTHER inhibitor and anti - inflammatory compound used in traditional Chinese medicine, also decreased BC6OTHER - induced phosphorylation of BC6OTHER and BC6OTHER , and suppressed basal, BC6OTHER - and BC6OTHER ( BC6OTHER ) - induced BC6ENTG reporter gene activity. CPR:falsenewlineBC6ENTC also inhibited cell proliferation, while increasing sub - G0 DNA fragmentation and BC6ENTG markers of apoptosis. CPR:falsenewlineBC6ENTC highlights the therapeutic potential of agents targeting BC6ENTG as a key node in this pro - oncogenic BC6OTHER - BC6OTHER signal pathway. CPR:falsenewlineBC6ENTC highlights the therapeutic potential of agents targeting BC6OTHER as a key node in this pro - oncogenic BC6ENTG - BC6OTHER signal pathway. CPR:falsenewlineBC6ENTC highlights the therapeutic potential of agents targeting BC6OTHER as a key node in this pro - oncogenic BC6OTHER - BC6ENTG signal pathway. CPR:falsenewlineBC6ENTC and BC6OTHER , but not BC6OTHER , caused a dose - dependent reduction in plasma BC6ENTG , an effect that correlated with BC6OTHER - induced bone effects. CPR:falsenewlineBC6OTHER and BC6ENTC , but not BC6OTHER , caused a dose - dependent reduction in plasma BC6ENTG , an effect that correlated with BC6OTHER - induced bone effects. CPR:falsenewlineBC6OTHER and BC6OTHER , but not BC6ENTC , caused a dose - dependent reduction in plasma BC6ENTG , an effect that correlated with BC6OTHER - induced bone effects. CPR:falsenewlineBC6OTHER and BC6OTHER , but not BC6OTHER , caused a dose - dependent reduction in plasma BC6ENTG , an effect that correlated with BC6ENTC - induced bone effects. CPR:falsenewlineIn contrast, serum BC6ENTG was elevated in animals dosed with BC6ENTC or BC6OTHER but not in those dose with BC6OTHER . CPR:falsenewlineIn contrast, serum BC6ENTG was elevated in animals dosed with BC6OTHER or BC6ENTC but not in those dose with BC6OTHER . CPR:falsenewlineIn contrast, serum BC6ENTG was elevated in animals dosed with BC6OTHER or BC6OTHER but not in those dose with BC6ENTC . CPR:falsenewlineHence, plasma BC6ENTG is a better predictor of BC6ENTC - induced bone effects than serum BC6OTHER . CPR:falsenewlineHence, plasma BC6OTHER is a better predictor of BC6ENTC - induced bone effects than serum BC6ENTG . CPR:falsenewlineThe BC6ENTC had no effect on BC6ENTG times of animals fed the supplemented diet. CPR:falsenewlineWhen BC6ENTC was omitted from the diet, however, BC6OTHER - dosed animals had elevated BC6ENTG times. CPR:falsenewlineWhen BC6OTHER was omitted from the diet, however, BC6ENTC - dosed animals had elevated BC6ENTG times. CPR:falsenewlineBC6ENTC - dosed animals showed no change in BC6ENTG times. CPR:falsenewlineIn the high - dose BC6ENTC group, there was a twofold increase in BC6ENTG times but only after prolonged dosing. CPR:falsenewlineFor all BC6ENTC - dosed groups maintained on the purified diet, changes in BC6ENTG times occured as early as 1 week. CPR:falsenewlineThe order of effect was BC6ENTC greater than BC6OTHER greater than BC6OTHER , with increases in BC6ENTG times correlating with increases in hemorrhagic deaths. CPR:falsenewlineThe order of effect was BC6OTHER greater than BC6ENTC greater than BC6OTHER , with increases in BC6ENTG times correlating with increases in hemorrhagic deaths. CPR:falsenewlineThe order of effect was BC6OTHER greater than BC6OTHER greater than BC6ENTC , with increases in BC6ENTG times correlating with increases in hemorrhagic deaths. CPR:falsenewlineThis effect was reverted in the presence of BC6ENTC ( BC6OTHER ; 0.1 microM), which blocks the pre - synaptic BC6ENTG . CPR:falsenewlineThis effect was reverted in the presence of BC6OTHER ( BC6ENTC ; 0.1 microM), which blocks the pre - synaptic BC6ENTG . CPR:falsenewlineAfter that, a wide range of concentrations of drugs, concomitantly with BC6ENTC (0.1 microM), was studied in the presence of BC6OTHER ( BC6OTHER ; 0.01 microM), a BC6ENTG antagonist. CPR:falsenewlineAfter that, a wide range of concentrations of drugs, concomitantly with BC6OTHER (0.1 microM), was studied in the presence of BC6ENTC ( BC6OTHER ; 0.01 microM), a BC6ENTG antagonist. CPR:falsenewlineAfter that, a wide range of concentrations of drugs, concomitantly with BC6OTHER (0.1 microM), was studied in the presence of BC6OTHER ( BC6ENTC ; 0.01 microM), a BC6ENTG antagonist. CPR:falsenewline BC6ENTG potentiator drugs, huprine X and BC6ENTC , increase BC6OTHER release by blocking BC6OTHER activity but not acting on BC6OTHER . CPR:falsenewline BC6OTHER potentiator drugs, huprine X and BC6ENTC , increase BC6OTHER release by blocking BC6OTHER activity but not acting on BC6ENTG . CPR:falsenewline BC6OTHER potentiator drugs, huprine X and BC6ENTC , increase BC6OTHER release by blocking BC6ENTG activity but not acting on BC6OTHER . CPR:falsenewline BC6ENTG potentiator drugs, huprine X and BC6OTHER , increase BC6ENTC release by blocking BC6OTHER activity but not acting on BC6OTHER . CPR:falsenewline BC6OTHER potentiator drugs, huprine X and BC6OTHER , increase BC6ENTC release by blocking BC6OTHER activity but not acting on BC6ENTG . CPR:falsenewline BC6OTHER potentiator drugs, huprine X and BC6OTHER , increase BC6ENTC release by blocking BC6ENTG activity but not acting on BC6OTHER . CPR:falsenewlineTo test the role of BC6ENTG in the drugs' effects on BC6ENTC release, BC6OTHER ( BC6OTHER ) 100 microM was used to block such receptors. CPR:falsenewlineTo test the role of BC6ENTG in the drugs' effects on BC6OTHER release, BC6ENTC ( BC6OTHER ) 100 microM was used to block such receptors. CPR:falsenewlineTo test the role of BC6ENTG in the drugs' effects on BC6OTHER release, BC6OTHER ( BC6ENTC ) 100 microM was used to block such receptors. CPR:falsenewlineThe main goal of the present study was to analyse the effects of (+ / - ) - huprine X ((+ / - ) - HX) and CHEM (CHEM), with potentiating action on BC6ENTG , and CHEM (CHEM), devoid of nicotinic activity, on BC6ENTC ( BC6OTHER ) release in striatal slices of rat brain. CPR:falsenewlineThe main goal of the present study was to analyse the effects of (+ / - ) - huprine X ((+ / - ) - HX) and CHEM (CHEM), with potentiating action on BC6ENTG , and CHEM (CHEM), devoid of nicotinic activity, on BC6OTHER ( BC6ENTC ) release in striatal slices of rat brain. CPR:falsenewlineResults showed that BC6ENTC increased nuclear levels of BC6ENTG , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6ENTG (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6ENTG ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6ENTG expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6ENTC increased nuclear levels of BC6OTHER , and both BC6OTHER and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6ENTG - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6OTHER increased nuclear levels of BC6ENTG , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6ENTG (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6ENTG ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG and BC6OTHER expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6ENTG expression in BC6OTHER - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineResults showed that BC6OTHER increased nuclear levels of BC6OTHER , and both BC6ENTC and adenovirus - mediated overexpression of BC6OTHER (Ad - BC6OTHER ) decreased BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER expression in BC6ENTG - treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK - 49F). CPR:falsenewlineAdditionally, BC6ENTC and Ad - BC6ENTG repressed BC6OTHER - stimulated BC6OTHER activity by inhibiting BC6OTHER phosphorylation, which was restored by siRNA - mediated knockdown of BC6OTHER expression. CPR:falsenewlineAdditionally, BC6ENTC and Ad - BC6OTHER repressed BC6ENTG - stimulated BC6OTHER activity by inhibiting BC6OTHER phosphorylation, which was restored by siRNA - mediated knockdown of BC6OTHER expression. CPR:falsenewlineAdditionally, BC6ENTC and Ad - BC6OTHER repressed BC6OTHER - stimulated BC6ENTG activity by inhibiting BC6OTHER phosphorylation, which was restored by siRNA - mediated knockdown of BC6OTHER expression. CPR:falsenewlineAdditionally, BC6ENTC and Ad - BC6OTHER repressed BC6OTHER - stimulated BC6OTHER activity by inhibiting BC6ENTG phosphorylation, which was restored by siRNA - mediated knockdown of BC6OTHER expression. CPR:falsenewlineAdditionally, BC6ENTC and Ad - BC6OTHER repressed BC6OTHER - stimulated BC6OTHER activity by inhibiting BC6OTHER phosphorylation, which was restored by siRNA - mediated knockdown of BC6ENTG expression. CPR:falsenewline BC6ENTC attenuates renal fibrosis via BC6OTHER - mediated inhibition of BC6OTHER / BC6ENTG signaling. CPR:falsenewline BC6ENTC attenuates renal fibrosis via BC6ENTG - mediated inhibition of BC6OTHER / BC6OTHER signaling. CPR:falsenewline BC6ENTC attenuates renal fibrosis via BC6OTHER - mediated inhibition of BC6ENTG / BC6OTHER signaling. CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6ENTG , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6ENTG and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6ENTG ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6ENTG - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6ENTG - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6ENTG ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6ENTG ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6ENTG target genes such as BC6OTHER , BC6OTHER and BC6ENTC BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6ENTG , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6ENTG and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6ENTG ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6ENTG - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6ENTG - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6ENTG ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6ENTG ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6ENTG target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6ENTC - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6ENTG , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6ENTG and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6ENTG ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6ENTG - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6ENTG - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6ENTG ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6ENTG ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6ENTG target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6ENTC on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6OTHER . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6ENTG , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6ENTG and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6ENTG ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6ENTG - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6ENTG - independent anti - fibrotic activity of BC6ENTC . CPR:falsenewlineHowever, downregulation of the BC6ENTG ( BC6OTHER ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6ENTG ) - driven BC6OTHER target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC . CPR:falsenewlineHowever, downregulation of the BC6OTHER ( BC6OTHER ) - driven BC6ENTG target genes such as BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER - transferase ( BC6OTHER ) did not reverse the inhibitory effect of BC6OTHER on BC6OTHER - induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an BC6OTHER - independent anti - fibrotic activity of BC6ENTC . CPR:falsenewlineFinally, BC6ENTC suppressed unilateral ureteral obstruction (UUO) - induced renal fibrosis and BC6ENTG , BC6OTHER and BC6OTHER expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineFinally, BC6ENTC suppressed unilateral ureteral obstruction (UUO) - induced renal fibrosis and BC6OTHER , BC6ENTG and BC6OTHER expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineFinally, BC6ENTC suppressed unilateral ureteral obstruction (UUO) - induced renal fibrosis and BC6OTHER , BC6OTHER and BC6ENTG expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineFinally, BC6ENTC suppressed unilateral ureteral obstruction (UUO) - induced renal fibrosis and BC6OTHER , BC6OTHER and BC6OTHER expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of BC6ENTG and BC6OTHER , respectively. CPR:falsenewlineFinally, BC6ENTC suppressed unilateral ureteral obstruction (UUO) - induced renal fibrosis and BC6OTHER , BC6OTHER and BC6OTHER expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of BC6OTHER and BC6ENTG , respectively. CPR:falsenewlineIn summary, BC6ENTC attenuated renal fibrosis via the BC6ENTG - mediated inhibition of BC6OTHER / BC6OTHER signaling in an BC6OTHER - independent manner, suggesting that BC6OTHER could be used to treat renal fibrosis. CPR:falsenewlineIn summary, BC6ENTC attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6ENTG / BC6OTHER signaling in an BC6OTHER - independent manner, suggesting that BC6OTHER could be used to treat renal fibrosis. CPR:falsenewlineIn summary, BC6ENTC attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6OTHER / BC6ENTG signaling in an BC6OTHER - independent manner, suggesting that BC6OTHER could be used to treat renal fibrosis. CPR:falsenewlineIn summary, BC6ENTC attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6OTHER / BC6OTHER signaling in an BC6ENTG - independent manner, suggesting that BC6OTHER could be used to treat renal fibrosis. CPR:falsenewlineIn summary, BC6OTHER attenuated renal fibrosis via the BC6ENTG - mediated inhibition of BC6OTHER / BC6OTHER signaling in an BC6OTHER - independent manner, suggesting that BC6ENTC could be used to treat renal fibrosis. CPR:falsenewlineIn summary, BC6OTHER attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6ENTG / BC6OTHER signaling in an BC6OTHER - independent manner, suggesting that BC6ENTC could be used to treat renal fibrosis. CPR:falsenewlineIn summary, BC6OTHER attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6OTHER / BC6ENTG signaling in an BC6OTHER - independent manner, suggesting that BC6ENTC could be used to treat renal fibrosis. CPR:falsenewlineIn summary, BC6OTHER attenuated renal fibrosis via the BC6OTHER - mediated inhibition of BC6OTHER / BC6OTHER signaling in an BC6ENTG - independent manner, suggesting that BC6ENTC could be used to treat renal fibrosis. CPR:falsenewlineThis study examines whether BC6ENTC ( BC6OTHER ), which stimulates BC6ENTG , prevents renal fibrosis via the BC6OTHER - mediated suppression of BC6OTHER signaling. CPR:falsenewlineThis study examines whether BC6ENTC ( BC6OTHER ), which stimulates BC6OTHER , prevents renal fibrosis via the BC6ENTG - mediated suppression of BC6OTHER signaling. CPR:falsenewlineThis study examines whether BC6ENTC ( BC6OTHER ), which stimulates BC6OTHER , prevents renal fibrosis via the BC6OTHER - mediated suppression of BC6ENTG signaling. CPR:falsenewlineThis study examines whether BC6OTHER ( BC6ENTC ), which stimulates BC6ENTG , prevents renal fibrosis via the BC6OTHER - mediated suppression of BC6OTHER signaling. CPR:falsenewlineThis study examines whether BC6OTHER ( BC6ENTC ), which stimulates BC6OTHER , prevents renal fibrosis via the BC6ENTG - mediated suppression of BC6OTHER signaling. CPR:falsenewlineThis study examines whether BC6OTHER ( BC6ENTC ), which stimulates BC6OTHER , prevents renal fibrosis via the BC6OTHER - mediated suppression of BC6ENTG signaling. CPR:falsenewlineSAR beyond protein - ligand interactions: By combining structure - affinity relationships, protein - ligand modeling studies, and quantum mechanical calculations, we show that ligand conformational energies and basicity play critical roles in ligand binding to the BC6ENTC H4 receptor, a BC6ENTG that plays a key role in inflammation. CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6ENTC analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6ENTC analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6ENTC ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6ENTC ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6ENTC ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6ENTC ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6ENTC , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6ENTC , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a recently introduced antagonist of the human BC6ENTC and BC6OTHER transporters ( BC6ENTG and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a recently introduced antagonist of the human BC6ENTC and BC6OTHER transporters ( BC6OTHER and BC6ENTG , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6ENTC analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6ENTC analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6ENTC ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6ENTC ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6ENTC ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6ENTC ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6ENTC , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6ENTC , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6ENTC , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6ENTC , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a recently introduced antagonist of the human BC6OTHER and BC6OTHER transporters ( BC6ENTG and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a recently introduced antagonist of the human BC6OTHER and BC6OTHER transporters ( BC6OTHER and BC6ENTG , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a recently introduced antagonist of the BC6ENTG BC6OTHER transporters ( BC6OTHER and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6ENTC antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6ENTC antidepressants, and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a recently introduced antagonist of the human BC6OTHER and BC6ENTC transporters ( BC6ENTG and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a recently introduced antagonist of the human BC6OTHER and BC6ENTC transporters ( BC6OTHER and BC6ENTG , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a recently introduced antagonist of the BC6ENTG BC6ENTC transporters ( BC6OTHER and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6ENTC . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6ENTC . CPR:falsenewline BC6ENTC identifies novel antagonist binding determinants in the BC6ENTG . CPR:falsenewlineIn an initial search for molecular features that differentially define antagonist binding determinants, we document that CHEM148 in BC6ENTG selectively disrupts BC6ENTC binding but not that of DVS. CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a recently introduced antagonist of the human BC6OTHER and BC6OTHER transporters ( BC6ENTG and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a recently introduced antagonist of the human BC6OTHER and BC6OTHER transporters ( BC6OTHER and BC6ENTG , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a recently introduced antagonist of the BC6ENTG BC6OTHER transporters ( BC6OTHER and BC6OTHER , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause. CPR:falsenewlineInitial evaluation of the pharmacological properties of BC6ENTC (J Pharmacol Exp CHEM 318:657 - 665, 2006) revealed significantly reduced potency for the BC6ENTG expressed in membranes compared with whole cells when competing for BC6OTHER ( BC6OTHER ) binding. CPR:falsenewlineInitial evaluation of the pharmacological properties of BC6OTHER (J Pharmacol Exp CHEM 318:657 - 665, 2006) revealed significantly reduced potency for the BC6ENTG expressed in membranes compared with whole cells when competing for BC6ENTC ( BC6OTHER ) binding. CPR:falsenewlineInitial evaluation of the pharmacological properties of BC6OTHER (J Pharmacol Exp CHEM 318:657 - 665, 2006) revealed significantly reduced potency for the BC6ENTG expressed in membranes compared with whole cells when competing for BC6OTHER ( BC6ENTC ) binding. CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6ENTC at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6ENTC at sites labeled by BC6OTHER was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6ENTC was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6ENTC was found to distinguish BC6OTHER , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6ENTG in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6ENTC , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6OTHER antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineUsing BC6OTHER in transfected human embryonic kidney - 293 cells, this difference in potency for BC6OTHER at sites labeled by BC6OTHER was found to distinguish BC6ENTC , the BC6OTHER analog BC6OTHER ( BC6OTHER ), BC6OTHER , and the BC6OTHER analog BC6OTHER ( BC6OTHER ) from other BC6ENTG antagonists, such as BC6OTHER , BC6OTHER , BC6OTHER antidepressants, and BC6OTHER . CPR:falsenewlineParenteral administration of selective agonists of the BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6ENTC ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6ENTC ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6ENTG ( BC6ENTC ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6ENTC - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6ENTC - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6ENTG ( BC6OTHER ) produced dose - related inhibition of BC6ENTC - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewline The nonselective BC6ENTG antagonist, BC6ENTC (3 mg / kg, i.m.), attenuated the antitussive effects of BC6OTHER or BC6OTHER , indicating that the antitussive activity of both compounds is BC6OTHER - mediated. CPR:falsenewline The nonselective BC6OTHER antagonist, BC6ENTC (3 mg / kg, i.m.), attenuated the antitussive effects of BC6OTHER or BC6OTHER , indicating that the antitussive activity of both compounds is BC6ENTG - mediated. CPR:falsenewline The nonselective BC6ENTG antagonist, BC6OTHER (3 mg / kg, i.m.), attenuated the antitussive effects of BC6ENTC or BC6OTHER , indicating that the antitussive activity of both compounds is BC6OTHER - mediated. CPR:falsenewline The nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, i.m.), attenuated the antitussive effects of BC6ENTC or BC6OTHER , indicating that the antitussive activity of both compounds is BC6ENTG - mediated. CPR:falsenewline The nonselective BC6ENTG antagonist, BC6OTHER (3 mg / kg, i.m.), attenuated the antitussive effects of BC6OTHER or BC6ENTC , indicating that the antitussive activity of both compounds is BC6OTHER - mediated. CPR:falsenewline The nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, i.m.), attenuated the antitussive effects of BC6OTHER or BC6ENTC , indicating that the antitussive activity of both compounds is BC6ENTG - mediated. CPR:falsenewlineThe BC6ENTG antagonist, BC6ENTC (10 mg / kg, i.p. CPR:falsenewlineIn contrast, combined pretreatment with BC6ENTC ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6ENTG agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.). CPR:falsenewlineIn contrast, combined pretreatment with BC6ENTC ( BC6ENTG antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.). CPR:falsenewlineIn contrast, combined pretreatment with BC6ENTC ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6ENTG antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.). CPR:falsenewlineIn this study, the activity of the BC6ENTG subtype - selective agonist, BC6ENTC , was investigated in a guinea pig model of BC6OTHER - induced cough. CPR:5newlineIn contrast, combined pretreatment with BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6ENTC ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6ENTG agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.). CPR:falsenewlineIn contrast, combined pretreatment with BC6OTHER ( BC6ENTG antagonist; 20 mg / kg, s.c.) and BC6ENTC ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.). CPR:falsenewlineIn contrast, combined pretreatment with BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6ENTC ( BC6ENTG antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6OTHER (20 mg / kg, i.p.). CPR:falsenewlineIn contrast, combined pretreatment with BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6ENTG agonists, respectively, was without effect on the antitussive response of BC6ENTC (20 mg / kg, i.p.). CPR:falsenewlineIn contrast, combined pretreatment with BC6OTHER ( BC6ENTG antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6ENTC (20 mg / kg, i.p.). CPR:falsenewlineIn contrast, combined pretreatment with BC6OTHER ( BC6OTHER antagonist; 20 mg / kg, s.c.) and BC6OTHER ( BC6ENTG antagonist; 20 mg / kg, s.c.), at doses that inhibited the antitussive activity of BC6OTHER agonists, respectively, was without effect on the antitussive response of BC6ENTC (20 mg / kg, i.p.). CPR:falsenewlineThe BC6ENTG antagonist BC6ENTC (3 mg / kg, i.p.) CPR:6newlineIn this study, the activity of the BC6ENTG subtype - selective agonist, BC6OTHER , was investigated in a guinea pig model of BC6ENTC - induced cough. CPR:falsenewlineThese studies provide compelling evidence that the antitussive effects of BC6ENTC in this guinea pig cough model are mediated by agonist activity at the BC6ENTG . CPR:5newlineParenteral administration of selective agonists of the BC6ENTG ( BC6ENTC ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6OTHER ( BC6ENTC ), BC6ENTG ( BC6OTHER and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER and BC6OTHER ), and BC6ENTG ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6ENTC and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6ENTC and BC6OTHER ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC and BC6OTHER ), and BC6ENTG ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6ENTC ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER and BC6ENTC ), and BC6OTHER ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineParenteral administration of selective agonists of the BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER and BC6ENTC ), and BC6ENTG ( BC6OTHER ) produced dose - related inhibition of BC6OTHER - induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg / kg, respectively. CPR:falsenewlineFinally, the involvement of BC6ENTG and BC6OTHER was also studied, and we showed that both play a role in the antinociceptive mechanism of BC6ENTC . CPR:falsenewlineFinally, the involvement of BC6OTHER and BC6ENTG was also studied, and we showed that both play a role in the antinociceptive mechanism of BC6ENTC . CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6ENTC on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG participate in BC6OTHER 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC receptors, BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC receptors, BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC receptors, BC6OTHER and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC receptors, BC6ENTG and BC6OTHER participate in BC6OTHER 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC receptors, BC6OTHER and BC6ENTG participate in BC6OTHER 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6ENTC 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6ENTC 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER participate in BC6ENTC 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER participate in BC6ENTC 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER participate in BC6ENTC 's antinociceptive mechanism. CPR:falsenewlineConclusion The results of this work contribute information regarding the antinociceptive properties of BC6OTHER on acute pain and show that, at least in part, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG participate in BC6ENTC 's antinociceptive mechanism. CPR:falsenewlineMethods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6ENTC - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6ENTC and BC6OTHER , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6ENTC , were performed to evaluate the antinociceptive action of BC6OTHER and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER in its antinociceptive mechanism. CPR:falsenewlineMethods The BC6OTHER - induced writhing test and the paw - licking test, in which paw licking was induced by BC6OTHER and BC6OTHER , were performed to evaluate the antinociceptive action of BC6ENTC and to determine the involvement of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG in its antinociceptive mechanism. CPR:falsenewline BC6ENTG mediate the antinociceptive effect of BC6ENTC . CPR:falsenewlineIn an investigation into the participation of BC6ENTG and BC6OTHER in BC6ENTC 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98). CPR:falsenewlineIn an investigation into the participation of BC6OTHER and BC6ENTG in BC6ENTC 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98). CPR:falsenewlineIn an investigation into the participation of BC6ENTG and BC6OTHER in BC6OTHER 's antinociceptive mechanism, we used BC6ENTC (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98). CPR:falsenewlineIn an investigation into the participation of BC6OTHER and BC6ENTG in BC6OTHER 's antinociceptive mechanism, we used BC6ENTC (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98). CPR:falsenewlineIn an investigation into the participation of BC6ENTG and BC6OTHER in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6ENTC (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98). CPR:falsenewlineIn an investigation into the participation of BC6OTHER and BC6ENTG in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6ENTC (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98). CPR:falsenewlineIn an investigation into the participation of BC6ENTG and BC6OTHER in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6ENTC (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98). CPR:falsenewlineIn an investigation into the participation of BC6OTHER and BC6ENTG in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6ENTC (1.2mmol / paw) and acidified saline (2% BC6OTHER , pH 1.98). CPR:falsenewlineIn an investigation into the participation of BC6ENTG and BC6OTHER in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6ENTC , pH 1.98). CPR:falsenewlineIn an investigation into the participation of BC6OTHER and BC6ENTG in BC6OTHER 's antinociceptive mechanism, we used BC6OTHER (2.2μg / paw), BC6OTHER (10mmol / paw), BC6OTHER (1.2mmol / paw) and acidified saline (2% BC6ENTC , pH 1.98). CPR:falsenewlineBC6ENTC promotes dissociation of BC6OTHER - BC6ENTG BC6OTHER complexes both in the absence and the presence of unlabeled BC6OTHER . CPR:falsenewlineBC6ENTC promotes dissociation of BC6OTHER - BC6OTHER BC6ENTG complexes both in the absence and the presence of unlabeled BC6OTHER . CPR:falsenewlineBC6ENTC promotes dissociation of BC6OTHER - BC6OTHER BC6OTHER complexes both in the absence and the presence of unlabeled BC6ENTG . CPR:falsenewlineBC6OTHER promotes dissociation of BC6ENTC - BC6ENTG BC6OTHER complexes both in the absence and the presence of unlabeled BC6OTHER . CPR:falsenewlineBC6OTHER promotes dissociation of BC6ENTC - BC6OTHER BC6ENTG complexes both in the absence and the presence of unlabeled BC6OTHER . CPR:falsenewlineBC6OTHER promotes dissociation of BC6ENTC - BC6OTHER BC6OTHER complexes both in the absence and the presence of unlabeled BC6ENTG . CPR:falsenewlineIt has no influence on the rate of association of BC6ENTC - BC6ENTG to BC6OTHER . CPR:falsenewlineIt has no influence on the rate of association of BC6ENTC - BC6OTHER to BC6ENTG . CPR:falsenewlineBC6ENTC do not promote dissociation of BC6OTHER - BC6ENTG BC6OTHER complexes. CPR:falsenewlineBC6ENTC do not promote dissociation of BC6OTHER - BC6OTHER BC6ENTG complexes. CPR:falsenewlineBC6OTHER do not promote dissociation of BC6ENTC - BC6ENTG BC6OTHER complexes. CPR:falsenewlineBC6OTHER do not promote dissociation of BC6ENTC - BC6OTHER BC6ENTG complexes. CPR:falsenewline BC6ENTC and BC6OTHER inhibit endothelin BC6ENTG by an allosteric type of mechanism. CPR:4newline BC6OTHER and BC6ENTC inhibit endothelin BC6ENTG by an allosteric type of mechanism. CPR:4newlineIt is concluded that BC6ENTC are allosteric inhibitors of BC6ENTG . CPR:falsenewlineThe results also suggest that: 1) irreversible BC6ENTG binding probably limits actions of receptor antagonists in vivo, and 2) an association of BC6ENTC and BC6OTHER antagonists should be used to evaluate the physiopathological role of BC6OTHER and may be of therapeutic interest in the treatment of ischemic heart disease. CPR:falsenewlineThe results also suggest that: 1) irreversible BC6OTHER binding probably limits actions of receptor antagonists in vivo, and 2) an association of BC6ENTC and BC6ENTG antagonists should be used to evaluate the physiopathological role of BC6OTHER and may be of therapeutic interest in the treatment of ischemic heart disease. CPR:falsenewlineThe results also suggest that: 1) irreversible BC6OTHER binding probably limits actions of receptor antagonists in vivo, and 2) an association of BC6ENTC and BC6OTHER antagonists should be used to evaluate the physiopathological role of BC6ENTG and may be of therapeutic interest in the treatment of ischemic heart disease. CPR:falsenewlineThis study shows that BC6ENTC and BC6OTHER , its major blood metabolite, reverse contractile actions of BC6ENTG ( BC6OTHER ) in isolated rat aorta and human mammary arteries. CPR:falsenewlineThis study shows that BC6ENTC and BC6OTHER , its major blood metabolite, reverse contractile actions of BC6OTHER ( BC6ENTG ) in isolated rat aorta and human mammary arteries. CPR:falsenewlineThis study shows that BC6OTHER and BC6ENTC , its major blood metabolite, reverse contractile actions of BC6ENTG ( BC6OTHER ) in isolated rat aorta and human mammary arteries. CPR:falsenewlineThis study shows that BC6OTHER and BC6ENTC , its major blood metabolite, reverse contractile actions of BC6OTHER ( BC6ENTG ) in isolated rat aorta and human mammary arteries. CPR:falsenewlineThey also prevent the intracellular BC6ENTC mobilizing action of BC6ENTG in cultured endothelial cells but not those of BC6OTHER or CHEM. CPR:falsenewlineThey also prevent the intracellular BC6ENTC mobilizing action of BC6OTHER in cultured endothelial cells but not those of BC6ENTG or CHEM. CPR:falsenewlineInhibition of the actions of BC6ENTG by BC6ENTC is apparently competitive. CPR:falsenewlineBC6ENTC inhibit BC6OTHER - BC6ENTG binding to recombinant BC6OTHER . CPR:falsenewlineBC6ENTC inhibit BC6OTHER - BC6OTHER binding to recombinant BC6ENTG . CPR:falsenewlineBC6OTHER inhibit BC6ENTC - BC6ENTG binding to recombinant BC6OTHER . CPR:falsenewlineBC6OTHER inhibit BC6ENTC - BC6OTHER binding to recombinant BC6ENTG . CPR:falsenewlineChanges in BC6ENTG mRNA occur in parallel with modifications in the levels of free BC6ENTC , which are reduced in lactation and are upregulated due to weaning or fasting. CPR:falsenewlineConversely, when mice are fed a high - fat diet after parturition, the downregulation of BC6ENTG mRNA and BC6OTHER protein levels due to lactation is partially reversed, as is the reduction in serum free BC6ENTC levels. CPR:falsenewlineConversely, when mice are fed a high - fat diet after parturition, the downregulation of BC6OTHER mRNA and BC6ENTG protein levels due to lactation is partially reversed, as is the reduction in serum free BC6ENTC levels. CPR:falsenewlineImpaired expression of the BC6OTHER gene in skeletal muscle during lactation: CHEM and BC6ENTC reverse lactation - induced downregulation of the BC6ENTG gene. CPR:falsenewlineImpaired expression of the BC6ENTG gene in skeletal muscle during lactation: CHEM and BC6ENTC reverse lactation - induced downregulation of the BC6OTHER gene. CPR:falsenewlineTreatment of lactating mice with a single injection of BC6ENTC , an activator of the BC6ENTG ( BC6OTHER ), raises BC6OTHER mRNA in skeletal muscle to levels similar to those in virgin mice. CPR:3newlineTreatment of lactating mice with a single injection of BC6ENTC , an activator of the BC6OTHER ( BC6ENTG ), raises BC6OTHER mRNA in skeletal muscle to levels similar to those in virgin mice. CPR:3newlineTreatment of lactating mice with a single injection of BC6ENTC , an activator of the BC6OTHER ( BC6OTHER ), raises BC6ENTG mRNA in skeletal muscle to levels similar to those in virgin mice. CPR:3newlineBC6ENTC ( BC6OTHER ), a specific ligand of the BC6ENTG subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineBC6ENTC ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6ENTG mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineBC6ENTC ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6ENTG , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineBC6ENTC ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6ENTG mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineBC6OTHER ( BC6ENTC ), a specific ligand of the BC6ENTG subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineBC6OTHER ( BC6ENTC ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6ENTG mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineBC6OTHER ( BC6ENTC ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6ENTG , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineBC6OTHER ( BC6ENTC ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6OTHER , a specific activator of BC6OTHER , also significantly increases BC6ENTG mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a specific ligand of the BC6ENTG subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6ENTC , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6ENTG mRNA, whereas BC6ENTC , a specific activator of BC6OTHER , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6ENTC , a specific activator of BC6ENTG , also significantly increases BC6OTHER mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineBC6OTHER ( BC6OTHER ), a specific ligand of the BC6OTHER subtype, causes the most dramatic increase in BC6OTHER mRNA, whereas BC6ENTC , a specific activator of BC6OTHER , also significantly increases BC6ENTG mRNA abundance in skeletal muscle of lactating mice. CPR:falsenewlineHowever, in virgin mice, BC6ENTC and BC6OTHER do not significantly affect BC6ENTG mRNA expression, whereas BC6OTHER is at least as effective as it is in lactating dams. CPR:falsenewlineHowever, in virgin mice, BC6OTHER and BC6ENTC do not significantly affect BC6ENTG mRNA expression, whereas BC6OTHER is at least as effective as it is in lactating dams. CPR:falsenewlineHowever, in virgin mice, BC6OTHER and BC6OTHER do not significantly affect BC6ENTG mRNA expression, whereas BC6ENTC is at least as effective as it is in lactating dams. CPR:falsenewlineIt is proposed that the BC6ENTG gene is regulated in skeletal muscle during lactation in response to changes in circulating free BC6ENTC by mechanisms involving activation of BC6OTHER . CPR:falsenewlineIt is proposed that the BC6OTHER gene is regulated in skeletal muscle during lactation in response to changes in circulating free BC6ENTC by mechanisms involving activation of BC6ENTG . CPR:falsenewlineThe impaired expression of the BC6ENTG gene is consistent with the involvement of BC6OTHER gene regulation in the reduction of the use of BC6ENTC as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation. CPR:falsenewlineThe impaired expression of the BC6OTHER gene is consistent with the involvement of BC6ENTG gene regulation in the reduction of the use of BC6ENTC as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation. CPR:falsenewlineOligomeric BC6OTHER - (POG - ) peptides, wherein the BC6ENTG is supported by BC6ENTC - terminal capping, exhibit BC6OTHER precipitation properties (CHEM, BC6OTHER = BC6OTHER ). CPR:falsenewlineHence, BC6ENTC - enclosed BC6ENTG have promising perspectives as composite materials. CPR:falsenewlineOligomeric BC6ENTC - (POG - ) peptides, wherein the BC6ENTG is supported by BC6OTHER - terminal capping, exhibit BC6OTHER precipitation properties (CHEM, BC6OTHER = BC6OTHER ). CPR:falsenewlineOligomeric BC6OTHER - (POG - ) peptides, wherein the BC6ENTG is supported by BC6OTHER - terminal capping, exhibit BC6ENTC precipitation properties (CHEM, BC6OTHER = BC6OTHER ). CPR:falsenewlineOligomeric BC6OTHER - (POG - ) peptides, wherein the BC6ENTG is supported by BC6OTHER - terminal capping, exhibit BC6OTHER precipitation properties (CHEM, BC6ENTC = BC6OTHER ). CPR:falsenewlineOligomeric BC6OTHER - (POG - ) peptides, wherein the BC6ENTG is supported by BC6OTHER - terminal capping, exhibit BC6OTHER precipitation properties (CHEM, BC6OTHER = BC6ENTC ). CPR:falsenewlineAs quantified by a molybdate assay, the length of the covalently tethered BC6ENTG (number of POG units) determines the amount of amorphous BC6ENTC obtained from BC6OTHER solution. CPR:falsenewlineAs quantified by a molybdate assay, the length of the covalently tethered BC6ENTG (number of POG units) determines the amount of amorphous BC6OTHER obtained from BC6ENTC solution. CPR:falsenewlineAlthough lacking charged side chains, the synthetic BC6ENTG precipitate large quantities of BC6ENTC resulting in micrometer - sized spheres of varying surface morphologies as analyzed by scanning electron microscopy. CPR:9newlineThe selective BC6ENTG inhibitor BC6ENTC ( BC6OTHER ) inhibits B cell signaling and function in vitro and in vivo and augments the activity of BC6OTHER in chronic lymphocytic leukemia. CPR:4newlineThe selective BC6ENTG inhibitor BC6OTHER ( BC6ENTC ) inhibits B cell signaling and function in vitro and in vivo and augments the activity of BC6OTHER in chronic lymphocytic leukemia. CPR:4newlineBC6ENTC (also known as BC6OTHER ) is a novel, highly selective, and orally bioavailable small molecule BC6ENTG inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6OTHER . CPR:4newlineBC6ENTC (also known as BC6OTHER ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6ENTG IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6OTHER . CPR:falsenewlineBC6ENTC (also known as BC6OTHER ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6ENTG activity that is at least 80 - fold greater than its affinity for other BC6OTHER . CPR:falsenewlineBC6ENTC (also known as BC6OTHER ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6ENTG . CPR:falsenewlineBC6OTHER (also known as BC6ENTC ) is a novel, highly selective, and orally bioavailable small molecule BC6ENTG inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6OTHER . CPR:falsenewlineBC6OTHER (also known as BC6ENTC ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6ENTG IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6OTHER . CPR:falsenewlineBC6OTHER (also known as BC6ENTC ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6ENTG activity that is at least 80 - fold greater than its affinity for other BC6OTHER . CPR:falsenewlineBC6OTHER (also known as BC6ENTC ) is a novel, highly selective, and orally bioavailable small molecule BC6OTHER inhibitor ( BC6OTHER IC(50) = 1 nM) with anti - BC6OTHER activity that is at least 80 - fold greater than its affinity for other BC6ENTG . CPR:falsenewlineBC6ENTG ( BC6OTHER ) associated BC6OTHER including spleen BC6ENTC kinase ( BC6OTHER ) contribute to the pathogenesis of B - cell malignancies. CPR:falsenewlineBC6OTHER ( BC6ENTG ) associated BC6OTHER including spleen BC6ENTC kinase ( BC6OTHER ) contribute to the pathogenesis of B - cell malignancies. CPR:falsenewlineBC6OTHER ( BC6OTHER ) associated BC6ENTG including spleen BC6ENTC kinase ( BC6OTHER ) contribute to the pathogenesis of B - cell malignancies. CPR:falsenewlineBC6OTHER ( BC6OTHER ) associated BC6OTHER including spleen BC6ENTC kinase ( BC6ENTG ) contribute to the pathogenesis of B - cell malignancies. CPR:falsenewlineBC6ENTC successfully inhibited BC6ENTG - mediated BC6OTHER signaling and decreased cell viability in NHL and CLL. CPR:4newlineBC6ENTC successfully inhibited BC6OTHER - mediated BC6ENTG signaling and decreased cell viability in NHL and CLL. CPR:4newlineThe selective BC6ENTG inhibitor BC6OTHER ( BC6OTHER ) inhibits B cell signaling and function in vitro and in vivo and augments the activity of BC6ENTC in chronic lymphocytic leukemia. CPR:4newlineRecent studies have demonstrated the importance of the BC6ENTC / BC6OTHER / BC6OTHER ( BC6ENTG ) pathway to the process of learning and memory. CPR:falsenewlineRecent studies have demonstrated the importance of the BC6ENTC / BC6OTHER / BC6ENTG ( BC6OTHER ) pathway to the process of learning and memory. CPR:falsenewlineRecent studies have demonstrated the importance of the BC6OTHER / BC6ENTC / BC6OTHER ( BC6ENTG ) pathway to the process of learning and memory. CPR:falsenewlineRecent studies have demonstrated the importance of the BC6OTHER / BC6ENTC / BC6ENTG ( BC6OTHER ) pathway to the process of learning and memory. CPR:falsenewlineRecent studies have demonstrated the importance of the BC6OTHER / BC6OTHER / BC6ENTC - responsive element - binding protein ( BC6ENTG ) pathway to the process of learning and memory. CPR:falsenewlineBC6OTHER ( BC6ENTG ) mediates the degradation of BC6ENTC in a variety of tissues including brain. CPR:falsenewlineBC6ENTG ( BC6OTHER ) mediates the degradation of BC6ENTC in a variety of tissues including brain. CPR:9newlineSynthesis of BC6ENTC derivatives: discovery of a potent and selective BC6ENTG inhibitor for the treatment of Alzheimer's disease. CPR:4newlineWithin the BC6ENTC scaffold, either electronic or steric perturbations to the central BC6OTHER ring led to a loss of selective M(1) allosteric agonism and afforded pan - BC6ENTG antagonism, which was demonstrated to be mediated via the orthosteric site. CPR:falsenewlineWithin the BC6OTHER scaffold, either electronic or steric perturbations to the central BC6ENTC ring led to a loss of selective M(1) allosteric agonism and afforded pan - BC6ENTG antagonism, which was demonstrated to be mediated via the orthosteric site. CPR:falsenewlineAdditional SAR around a related M(1) allosteric agonist family ( BC6ENTC ) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan - BC6ENTG orthosteric antagonism. CPR:falsenewlineUnlike BC6ENTC , BC6ENTG activates BC6OTHER pathways, and BC6OTHER pathways can substitute for BC6OTHER signaling for BC6OTHER generation. CPR:falsenewlineUnlike BC6ENTC , BC6OTHER activates BC6ENTG pathways, and BC6OTHER pathways can substitute for BC6OTHER signaling for BC6OTHER generation. CPR:falsenewlineUnlike BC6ENTC , BC6OTHER activates BC6OTHER pathways, and BC6ENTG pathways can substitute for BC6OTHER signaling for BC6OTHER generation. CPR:falsenewlineUnlike BC6ENTC , BC6OTHER activates BC6OTHER pathways, and BC6OTHER pathways can substitute for BC6ENTG signaling for BC6OTHER generation. CPR:falsenewlineUnlike BC6OTHER , BC6ENTG activates BC6OTHER pathways, and BC6OTHER pathways can substitute for BC6OTHER signaling for BC6ENTC generation. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER activates BC6ENTG pathways, and BC6OTHER pathways can substitute for BC6OTHER signaling for BC6ENTC generation. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER activates BC6OTHER pathways, and BC6ENTG pathways can substitute for BC6OTHER signaling for BC6ENTC generation. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER activates BC6OTHER pathways, and BC6OTHER pathways can substitute for BC6ENTG signaling for BC6ENTC generation. CPR:falsenewlineWe found that BC6ENTG was activated downstream of both BC6OTHER and BC6OTHER - mediated pathways, and both BC6ENTC - and AYPGKF - induced BC6OTHER generation was significantly diminished in BC6OTHER - deficient platelets. CPR:falsenewlineWe found that BC6OTHER was activated downstream of both BC6ENTG and BC6OTHER - mediated pathways, and both BC6ENTC - and AYPGKF - induced BC6OTHER generation was significantly diminished in BC6OTHER - deficient platelets. CPR:falsenewlineWe found that BC6OTHER was activated downstream of both BC6OTHER and BC6ENTG - mediated pathways, and both BC6ENTC - and AYPGKF - induced BC6OTHER generation was significantly diminished in BC6OTHER - deficient platelets. CPR:falsenewlineWe found that BC6OTHER was activated downstream of both BC6OTHER and BC6OTHER - mediated pathways, and both BC6ENTC - and AYPGKF - induced BC6OTHER generation was significantly diminished in BC6ENTG - deficient platelets. CPR:falsenewlineWe found that BC6ENTG was activated downstream of both BC6OTHER and BC6OTHER - mediated pathways, and both BC6OTHER - and AYPGKF - induced BC6ENTC generation was significantly diminished in BC6OTHER - deficient platelets. CPR:falsenewlineWe found that BC6OTHER was activated downstream of both BC6ENTG and BC6OTHER - mediated pathways, and both BC6OTHER - and AYPGKF - induced BC6ENTC generation was significantly diminished in BC6OTHER - deficient platelets. CPR:falsenewlineWe found that BC6OTHER was activated downstream of both BC6OTHER and BC6ENTG - mediated pathways, and both BC6OTHER - and AYPGKF - induced BC6ENTC generation was significantly diminished in BC6OTHER - deficient platelets. CPR:falsenewlineWe found that BC6OTHER was activated downstream of both BC6OTHER and BC6OTHER - mediated pathways, and both BC6OTHER - and AYPGKF - induced BC6ENTC generation was significantly diminished in BC6ENTG - deficient platelets. CPR:falsenewlineIn addition, BC6ENTC generation induced by co - stimulation of BC6OTHER and BC6ENTG pathways, which is dependent on BC6OTHER signaling, was inhibited by blocking BC6OTHER . CPR:falsenewlineIn addition, BC6ENTC generation induced by co - stimulation of BC6OTHER and BC6OTHER pathways, which is dependent on BC6ENTG signaling, was inhibited by blocking BC6OTHER . CPR:falsenewlineIn addition, BC6ENTC generation induced by co - stimulation of BC6OTHER and BC6OTHER pathways, which is dependent on BC6OTHER signaling, was inhibited by blocking BC6ENTG . CPR:falsenewlineIn addition, BC6ENTC generation induced by co - stimulation of BC6ENTG and BC6OTHER pathways, which is dependent on BC6OTHER signaling, was inhibited by blocking BC6OTHER . CPR:falsenewlineDistinct role of BC6ENTG in mediating BC6ENTC generation downstream of both BC6OTHER and BC6OTHER in platelets. CPR:falsenewlineDistinct role of BC6OTHER in mediating BC6ENTC generation downstream of both BC6ENTG and BC6OTHER in platelets. CPR:falsenewlineDistinct role of BC6OTHER in mediating BC6ENTC generation downstream of both BC6OTHER and BC6ENTG in platelets. CPR:falsenewlineBC6ENTC - rich BC6OTHER kinase 2 ( BC6ENTG ) is activated by various agonists in platelets. CPR:falsenewlineFurthermore, inhibition of BC6ENTC - induced BC6OTHER generation by BC6ENTG antagonist was not rescued by co - stimulation of BC6OTHER pathways in the presence of BC6OTHER inhibitor. CPR:falsenewlineFurthermore, inhibition of BC6ENTC - induced BC6OTHER generation by BC6OTHER antagonist was not rescued by co - stimulation of BC6ENTG pathways in the presence of BC6OTHER inhibitor. CPR:falsenewlineFurthermore, inhibition of BC6ENTC - induced BC6OTHER generation by BC6OTHER antagonist was not rescued by co - stimulation of BC6OTHER pathways in the presence of BC6ENTG inhibitor. CPR:falsenewlineFurthermore, inhibition of BC6OTHER - induced BC6ENTC generation by BC6ENTG antagonist was not rescued by co - stimulation of BC6OTHER pathways in the presence of BC6OTHER inhibitor. CPR:falsenewlineFurthermore, inhibition of BC6OTHER - induced BC6ENTC generation by BC6OTHER antagonist was not rescued by co - stimulation of BC6ENTG pathways in the presence of BC6OTHER inhibitor. CPR:falsenewlineFurthermore, inhibition of BC6OTHER - induced BC6ENTC generation by BC6OTHER antagonist was not rescued by co - stimulation of BC6OTHER pathways in the presence of BC6ENTG inhibitor. CPR:falsenewlineBC6OTHER - rich BC6ENTC kinase 2 ( BC6ENTG ) is activated by various agonists in platelets. CPR:falsenewlineWe conclude that BC6ENTG is a common signaling effector downstream of both BC6OTHER and BC6OTHER signaling which contributes to BC6ENTC generation. CPR:falsenewlineWe conclude that BC6OTHER is a common signaling effector downstream of both BC6ENTG and BC6OTHER signaling which contributes to BC6ENTC generation. CPR:falsenewlineWe conclude that BC6OTHER is a common signaling effector downstream of both BC6OTHER and BC6ENTG signaling which contributes to BC6ENTC generation. CPR:falsenewlineWe found that platelet aggregation and secretion in response to BC6ENTC and AYPGKF were diminished in the presence of BC6ENTG inhibitors or in BC6OTHER - deficient platelets, suggesting that BC6OTHER plays a positive regulatory role in platelet functional responses. CPR:falsenewlineWe found that platelet aggregation and secretion in response to BC6ENTC and AYPGKF were diminished in the presence of BC6OTHER inhibitors or in BC6ENTG - deficient platelets, suggesting that BC6OTHER plays a positive regulatory role in platelet functional responses. CPR:falsenewlineWe found that platelet aggregation and secretion in response to BC6ENTC and AYPGKF were diminished in the presence of BC6OTHER inhibitors or in BC6OTHER - deficient platelets, suggesting that BC6ENTG plays a positive regulatory role in platelet functional responses. CPR:falsenewlineIt has been shown that BC6ENTC - , but not BC6ENTG - , induced BC6OTHER ( BC6OTHER ) generation depends on BC6OTHER signaling. CPR:falsenewlineIt has been shown that BC6ENTC - , but not BC6OTHER - , induced BC6OTHER ( BC6OTHER ) generation depends on BC6ENTG signaling. CPR:falsenewlineIt has been shown that BC6OTHER - , but not BC6ENTG - , induced BC6ENTC ( BC6OTHER ) generation depends on BC6OTHER signaling. CPR:falsenewlineIt has been shown that BC6OTHER - , but not BC6OTHER - , induced BC6ENTC ( BC6OTHER ) generation depends on BC6ENTG signaling. CPR:falsenewlineIt has been shown that BC6OTHER - , but not BC6ENTG - , induced BC6OTHER ( BC6ENTC ) generation depends on BC6OTHER signaling. CPR:falsenewlineIt has been shown that BC6OTHER - , but not BC6OTHER - , induced BC6OTHER ( BC6ENTC ) generation depends on BC6ENTG signaling. CPR:falsenewlineA series of structurally novel BC6OTHER was derived from optimization of the HTS lead as selective BC6ENTC H3 receptor ( BC6ENTG ) antagonists. CPR:falsenewlineA series of structurally novel BC6ENTC was derived from optimization of the HTS lead as selective BC6ENTG ( BC6OTHER ) antagonists. CPR:falsenewlineA series of structurally novel BC6ENTC was derived from optimization of the HTS lead as selective BC6OTHER ( BC6ENTG ) antagonists. CPR:6newlineDiscovery of BC6ENTC and BC6OTHER as potent and selective BC6ENTG antagonists for the treatment of obesity (Part I). CPR:6newlineDiscovery of BC6OTHER and BC6ENTC as potent and selective BC6ENTG antagonists for the treatment of obesity (Part I). CPR:6newlineThe objective of this study was to determine the influence of BC6ENTC administration (15 mg / kg intraperitoneally twice daily for 8 days) on liver expression of BC6ENTG , transporters, and DMEs in rats. CPR:falsenewlineInduction of BC6ENTG , transporters, and drug metabolizing enzymes by BC6ENTC . CPR:falsenewlineTherefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6ENTG , BC6OTHER , or BC6OTHER by BC6ENTC or its major metabolites ( BC6OTHER and BC6OTHER ). CPR:9newlineTherefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6ENTG , or BC6OTHER by BC6ENTC or its major metabolites ( BC6OTHER and BC6OTHER ). CPR:9newlineTherefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6OTHER , or BC6ENTG by BC6ENTC or its major metabolites ( BC6OTHER and BC6OTHER ). CPR:9newlineTherefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6ENTG , BC6OTHER , or BC6OTHER by BC6OTHER or its major metabolites ( BC6ENTC and BC6OTHER ). CPR:9newlineTherefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6ENTG , or BC6OTHER by BC6OTHER or its major metabolites ( BC6ENTC and BC6OTHER ). CPR:9newlineTherefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6OTHER , or BC6ENTG by BC6OTHER or its major metabolites ( BC6ENTC and BC6OTHER ). CPR:9newlineTherefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6ENTG , BC6OTHER , or BC6OTHER by BC6OTHER or its major metabolites ( BC6OTHER and BC6ENTC ). CPR:9newlineTherefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6ENTG , or BC6OTHER by BC6OTHER or its major metabolites ( BC6OTHER and BC6ENTC ). CPR:9newlineTherefore, a series of transactivation / translocation assays were conducted to determine whether the observed changes of transporters / DMEs are mediated by direct activation of BC6OTHER , BC6OTHER , or BC6ENTG by BC6OTHER or its major metabolites ( BC6OTHER and BC6ENTC ). CPR:9newlineNeither BC6ENTC nor its metabolites activated BC6ENTG , BC6OTHER , or BC6OTHER . CPR:falsenewlineNeither BC6ENTC nor its metabolites activated BC6OTHER , BC6ENTG , or BC6OTHER . CPR:falsenewlineNeither BC6ENTC nor its metabolites activated BC6OTHER , BC6OTHER , or BC6ENTG . CPR:falsenewlineTaken together, these findings identify a signature hepatic gene - network associated with repeated BC6ENTC administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6ENTG , BC6OTHER , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER . CPR:falsenewlineTaken together, these findings identify a signature hepatic gene - network associated with repeated BC6ENTC administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6ENTG , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER . CPR:falsenewlineTaken together, these findings identify a signature hepatic gene - network associated with repeated BC6ENTC administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6OTHER , and BC6ENTG ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER . CPR:falsenewlineTaken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6ENTC alters the expression of many transporters and DMEs (without direct activation of BC6ENTG , BC6OTHER , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER . CPR:falsenewlineTaken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6ENTC alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6ENTG , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER . CPR:falsenewlineTaken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6ENTC alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6OTHER , and BC6ENTG ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6OTHER . CPR:falsenewlineTaken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6ENTG , BC6OTHER , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6ENTC . CPR:falsenewlineTaken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6ENTG , and BC6OTHER ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6ENTC . CPR:falsenewlineTaken together, these findings identify a signature hepatic gene - network associated with repeated BC6OTHER administration in rats and demonstrate that BC6OTHER alters the expression of many transporters and DMEs (without direct activation of BC6OTHER , BC6OTHER , and BC6ENTG ), which could lead to undesirable DDIs after coadministration of substrates of these transporters / DMEs with BC6ENTC . CPR:falsenewlineMany transporters and DMEs are regulated by BC6ENTG [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6ENTG ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6ENTG ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6ENTG ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6ENTG ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6ENTG ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6ENTG )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6ENTC receptor ( BC6OTHER ), and BC6OTHER receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6ENTG . CPR:falsenewlineMany transporters and DMEs are regulated by BC6ENTG [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6ENTG ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6ENTG ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6ENTG ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6ENTG ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6ENTG )]; however, there is a paucity of information regarding the influence of opioids on BC6OTHER . CPR:falsenewlineMany transporters and DMEs are regulated by BC6OTHER [ BC6OTHER ; e.g., BC6OTHER ( BC6OTHER ), constitutive BC6OTHER receptor ( BC6OTHER ), and BC6ENTC receptor ( BC6OTHER )]; however, there is a paucity of information regarding the influence of opioids on BC6ENTG . CPR:falsenewlineCHEM BC6ENTC (PPS) has been shown to exert antitumor activity by antagonizing the binding of BC6ENTG to cell surface receptors. CPR:falsenewlineIn summary, BC6ENTC and BC6OTHER increase BC6ENTG activity and phosphorylation in the isolated heart. CPR:3newlineIn summary, BC6OTHER and BC6ENTC increase BC6ENTG activity and phosphorylation in the isolated heart. CPR:falsenewlineBC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6ENTC - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6ENTC - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6ENTC ratio ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6ENTC ratio ( BC6OTHER / BC6OTHER ). CPR:falsenewlineThe increase in BC6ENTG activity was always preceded by and correlated with increased cytosolic [ BC6ENTC ]. CPR:falsenewlineBC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6ENTC / BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6ENTC / BC6OTHER ). CPR:falsenewlineBC6ENTC - activated protein kinase ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6ENTC ). CPR:falsenewlineBC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6ENTC ). CPR:falsenewlineCytosolic [ BC6ENTC ] reported metabolically active BC6OTHER , which triggered increased BC6ENTG activity, but measures of total BC6OTHER did not. CPR:falsenewlineCytosolic [ BC6OTHER ] reported metabolically active BC6ENTC , which triggered increased BC6ENTG activity, but measures of total BC6OTHER did not. CPR:falsenewlineBC6ENTC and BC6OTHER , which are BC6OTHER , have been reported to increase BC6ENTG activity without increasing BC6OTHER / BC6OTHER . CPR:3newlineCytosolic [ BC6OTHER ] reported metabolically active BC6OTHER , which triggered increased BC6ENTG activity, but measures of total BC6ENTC did not. CPR:falsenewlineBC6OTHER and BC6ENTC , which are BC6OTHER , have been reported to increase BC6ENTG activity without increasing BC6OTHER / BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER , which are BC6ENTC , have been reported to increase BC6ENTG activity without increasing BC6OTHER / BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER , which are BC6OTHER , have been reported to increase BC6ENTG activity without increasing BC6ENTC / BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER , which are BC6OTHER , have been reported to increase BC6ENTG activity without increasing BC6OTHER / BC6ENTC . CPR:falsenewlineThis study tests the hypothesis that these BC6ENTC increase BC6ENTG activity in the heart by increasing cytosolic [ BC6OTHER ]. CPR:falsenewlineBC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6ENTC concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6ENTC concentration ([ BC6OTHER ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ). CPR:falsenewlineThis study tests the hypothesis that these BC6OTHER increase BC6ENTG activity in the heart by increasing cytosolic [ BC6ENTC ]. CPR:falsenewlineAt various times, hearts were freeze - clamped and assayed for BC6ENTG activity, phosphorylation of CHEM(172) on BC6OTHER , and phosphorylation of CHEM(79) on BC6ENTC carboxylase, an BC6OTHER target. CPR:falsenewlineAt various times, hearts were freeze - clamped and assayed for BC6OTHER activity, phosphorylation of CHEM(172) on BC6ENTG , and phosphorylation of CHEM(79) on BC6ENTC carboxylase, an BC6OTHER target. CPR:falsenewlineAt various times, hearts were freeze - clamped and assayed for BC6OTHER activity, phosphorylation of CHEM(172) on BC6OTHER , and phosphorylation of CHEM(79) on BC6ENTC carboxylase, an BC6ENTG target. CPR:falsenewlineIn hearts treated with BC6ENTC for 18 min and then perfused for 20 min with Krebs - Henseleit buffer, [ BC6OTHER ] began to increase at 26 min and BC6ENTG activity was elevated at 36 min. CPR:falsenewlineIn hearts treated with BC6OTHER for 18 min and then perfused for 20 min with Krebs - Henseleit buffer, [ BC6ENTC ] began to increase at 26 min and BC6ENTG activity was elevated at 36 min. CPR:falsenewlineIn hearts treated with BC6ENTC , [ BC6OTHER ] was increased at 50 min and BC6ENTG activity, phosphorylated BC6OTHER , and phosphorylated BC6OTHER carboxylase were elevated at 61 min. CPR:falsenewlineIn hearts treated with BC6ENTC , [ BC6OTHER ] was increased at 50 min and BC6OTHER activity, phosphorylated BC6ENTG , and phosphorylated BC6OTHER carboxylase were elevated at 61 min. CPR:falsenewlineIn hearts treated with BC6ENTC , [ BC6OTHER ] was increased at 50 min and BC6OTHER activity, phosphorylated BC6OTHER , and BC6ENTG were elevated at 61 min. CPR:falsenewline BC6ENTC and BC6OTHER activate BC6ENTG in the heart by increasing cytosolic BC6OTHER concentration. CPR:falsenewline BC6OTHER and BC6OTHER activate BC6ENTG in the heart by increasing cytosolic BC6ENTC concentration. CPR:falsenewline BC6OTHER and BC6ENTC activate BC6ENTG in the heart by increasing cytosolic BC6OTHER concentration. CPR:falsenewlineIn hearts treated with BC6OTHER , [ BC6ENTC ] was increased at 50 min and BC6ENTG activity, phosphorylated BC6OTHER , and phosphorylated BC6OTHER carboxylase were elevated at 61 min. CPR:falsenewlineIn hearts treated with BC6OTHER , [ BC6ENTC ] was increased at 50 min and BC6OTHER activity, phosphorylated BC6ENTG , and phosphorylated BC6OTHER carboxylase were elevated at 61 min. CPR:falsenewlineIn hearts treated with BC6OTHER , [ BC6ENTC ] was increased at 50 min and BC6OTHER activity, phosphorylated BC6OTHER , and BC6ENTG were elevated at 61 min. CPR:falsenewlineIn hearts treated with BC6OTHER , [ BC6OTHER ] was increased at 50 min and BC6ENTG activity, phosphorylated BC6OTHER , and phosphorylated BC6ENTC carboxylase were elevated at 61 min. CPR:falsenewlineIn hearts treated with BC6OTHER , [ BC6OTHER ] was increased at 50 min and BC6OTHER activity, phosphorylated BC6ENTG , and phosphorylated BC6ENTC carboxylase were elevated at 61 min. CPR:falsenewlineBC6ENTG ( BC6OTHER ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6ENTC ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTG ) acts as a cellular energy sensor: it responds to an increase in BC6OTHER concentration ([ BC6ENTC ]) or the BC6OTHER - to - BC6OTHER ratio ( BC6OTHER / BC6OTHER ). CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6ENTC - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6ENTC - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6ENTC - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6ENTC - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6ENTC - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG . CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6ENTC and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6ENTC and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6ENTC and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6ENTC and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6ENTC and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG . CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6ENTC in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6ENTC in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6ENTC in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6ENTC in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6ENTC in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG . CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6ENTC biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6ENTC biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6ENTC biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6ENTC biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6ENTC biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG . CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6ENTC synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTC synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTC synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTC synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG . CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6ENTC synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6ENTC synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTC synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTC synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG . CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6ENTC biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6ENTC biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6ENTC biosynthetic enzymes, BC6OTHER synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6ENTC biosynthetic enzymes, BC6ENTG and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6ENTC biosynthetic enzymes, BC6OTHER synthase II and BC6ENTG . CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTC synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTC synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTC synthase II and BC6OTHER synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTC synthase II and BC6ENTG . CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6ENTG , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTC synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6ENTG , and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTC synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6ENTG , to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6OTHER synthase II and BC6ENTC synthase. CPR:falsenewlineAt 6 h after injection of the compound (400 mg / kg) into rats bearing hepatoma 3924A, the pools of BC6OTHER and BC6OTHER in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of BC6OTHER - requiring enzymes of BC6OTHER biosynthesis, BC6OTHER , BC6OTHER synthase, and BC6OTHER synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of BC6OTHER biosynthetic enzymes, BC6ENTG and BC6ENTC synthase. CPR:falsenewlineBC6ENTC dismutase 1 ( BC6OTHER ) maturation within the cell is mainly accomplished with the BC6OTHER , BC6ENTG , a dimeric protein with three distinct domains in each monomer. CPR:falsenewlineBC6ENTC dismutase 1 ( BC6ENTG ) maturation within the cell is mainly accomplished with the BC6OTHER , BC6OTHER , a dimeric protein with three distinct domains in each monomer. CPR:falsenewlineBC6ENTC dismutase 1 ( BC6OTHER ) maturation within the cell is mainly accomplished with the BC6ENTG , BC6OTHER , a dimeric protein with three distinct domains in each monomer. CPR:falsenewlineWe recently showed that the first domain of BC6ENTG ( BC6OTHER ) is responsible for BC6ENTC transfer to its protein partner, BC6OTHER ( BC6OTHER ). CPR:falsenewlineWe recently showed that the first domain of BC6OTHER ( BC6ENTG ) is responsible for BC6ENTC transfer to its protein partner, BC6OTHER ( BC6OTHER ). CPR:falsenewlineWe recently showed that the first domain of BC6OTHER ( BC6OTHER ) is responsible for BC6ENTC transfer to its protein partner, BC6ENTG ( BC6OTHER ). CPR:falsenewlineWe recently showed that the first domain of BC6OTHER ( BC6OTHER ) is responsible for BC6ENTC transfer to its protein partner, BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe NMR solution structure of the BC6ENTC - loaded form of BC6ENTG reported here contributes further to characterization of the CHEM - transfer mechanism to BC6OTHER . CPR:falsenewlineThe NMR solution structure of the BC6ENTC - loaded form of BC6OTHER reported here contributes further to characterization of the CHEM - transfer mechanism to BC6ENTG . CPR:falsenewlineNMR spectroscopy was also used to examine the BC6ENTG mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6ENTG , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6ENTG , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6ENTG / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6ENTG , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6ENTG , in order to investigate the role of these BC6OTHER during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6ENTC bond in BC6OTHER , in order to investigate the role of these BC6OTHER during BC6ENTG CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6ENTG mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6ENTG , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6ENTG , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6ENTG / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6ENTG , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6ENTG , in order to investigate the role of these BC6ENTC during BC6OTHER CHEM acquisition. CPR:falsenewlineNMR spectroscopy was also used to examine the BC6OTHER mutants BC6OTHER , BC6OTHER , and BC6OTHER / BC6OTHER , which are unable to form the structurally conserved BC6OTHER bond in BC6OTHER , in order to investigate the role of these BC6ENTC during BC6ENTG CHEM acquisition. CPR:falsenewlineTogether, the information on both BC6ENTG and BC6OTHER , along with a sequence analysis of eukaryotic BC6OTHER , allows us to propose important mechanistic aspects regarding the BC6ENTC - transfer process from BC6OTHER to BC6OTHER . CPR:falsenewlineTogether, the information on both BC6OTHER and BC6ENTG , along with a sequence analysis of eukaryotic BC6OTHER , allows us to propose important mechanistic aspects regarding the BC6ENTC - transfer process from BC6OTHER to BC6OTHER . CPR:falsenewlineTogether, the information on both BC6OTHER and BC6OTHER , along with a sequence analysis of eukaryotic BC6ENTG , allows us to propose important mechanistic aspects regarding the BC6ENTC - transfer process from BC6OTHER to BC6OTHER . CPR:falsenewlineTogether, the information on both BC6OTHER and BC6OTHER , along with a sequence analysis of eukaryotic BC6OTHER , allows us to propose important mechanistic aspects regarding the BC6ENTC - transfer process from BC6ENTG to BC6OTHER . CPR:falsenewlineTogether, the information on both BC6OTHER and BC6OTHER , along with a sequence analysis of eukaryotic BC6OTHER , allows us to propose important mechanistic aspects regarding the BC6ENTC - transfer process from BC6OTHER to BC6ENTG . CPR:falsenewlineMechanistic Aspects of BC6OTHER Maturation from the Solution Structure of BC6OTHER - Loaded BC6OTHER and Analysis of BC6ENTC - Free BC6ENTG Mutants. CPR:falsenewlineMechanistic Aspects of BC6ENTG Maturation from the Solution Structure of BC6OTHER - Loaded BC6OTHER and Analysis of BC6ENTC - Free BC6OTHER Mutants. CPR:falsenewlineMechanistic Aspects of BC6OTHER Maturation from the Solution Structure of BC6OTHER - Loaded BC6ENTG and Analysis of BC6ENTC - Free BC6OTHER Mutants. CPR:falsenewlineMechanistic Aspects of BC6OTHER Maturation from the Solution Structure of BC6ENTC - Loaded BC6OTHER and Analysis of BC6OTHER - Free BC6ENTG Mutants. CPR:falsenewlineMechanistic Aspects of BC6ENTG Maturation from the Solution Structure of BC6ENTC - Loaded BC6OTHER and Analysis of BC6OTHER - Free BC6OTHER Mutants. CPR:falsenewlineMechanistic Aspects of BC6OTHER Maturation from the Solution Structure of BC6ENTC - Loaded BC6ENTG and Analysis of BC6OTHER - Free BC6OTHER Mutants. CPR:falsenewlineThe mRNA expression of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was not reduced by BC6ENTC . CPR:falsenewlineThe mRNA expression of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) was not reduced by BC6ENTC . CPR:falsenewlineThe mRNA expression of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) was not reduced by BC6ENTC . CPR:falsenewlineThe mRNA expression of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) was not reduced by BC6ENTC . CPR:falsenewlineSimilarly, the BC6ENTG enzyme level did not change after BC6ENTC exposure but BC6OTHER could not be probed with the antibody available currently. CPR:falsenewlineSimilarly, the BC6OTHER enzyme level did not change after BC6ENTC exposure but BC6ENTG could not be probed with the antibody available currently. CPR:falsenewlineBC6OTHER ( BC6OTHER ) ( BC6OTHER ) and BC6ENTC are competitive inhibitors of BC6OTHER by binding to the BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) ( BC6OTHER ) and BC6ENTC are competitive inhibitors of BC6OTHER by binding to the BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6ENTC by binding to the BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6ENTC by binding to the BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6ENTC receptor ( BC6ENTG ). CPR:falsenewlineBC6ENTC and BC6OTHER are the most potent pure antiestrogens and BC6OTHER has the highest affinity of all antiestrogens to BC6ENTG . CPR:falsenewlineBC6OTHER and BC6ENTC are the most potent pure antiestrogens and BC6OTHER has the highest affinity of all antiestrogens to BC6ENTG . CPR:falsenewlineBC6OTHER and BC6OTHER are the most potent pure antiestrogens and BC6ENTC has the highest affinity of all antiestrogens to BC6ENTG . CPR:falsenewlineBC6ENTC ( BC6OTHER ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6ENTC ( BC6OTHER ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6OTHER ( BC6ENTC ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTC ) ( BC6OTHER ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) ( BC6ENTC ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) ( BC6ENTC ) and BC6OTHER are competitive inhibitors of BC6OTHER by binding to the BC6OTHER ( BC6ENTG ). CPR:falsenewlineWe used the patch - clamp technique and BC6ENTC flux assays to determine the role of these drugs in BC6ENTG (K( BC6OTHER )) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6ENTC flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel ( BC6ENTG ) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6ENTC flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel (K( BC6OTHER )) regulation in cell lines expressing the cloned components of BC6ENTG and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTC - sensitive BC6OTHER channel ( BC6ENTG ) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTC - sensitive BC6OTHER channel (K( BC6OTHER )) regulation in cell lines expressing the cloned components of BC6ENTG and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6ENTC channel ( BC6ENTG ) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6ENTC channel (K( BC6OTHER )) regulation in cell lines expressing the cloned components of BC6ENTG and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTG ( BC6ENTC ( BC6OTHER )) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel ( BC6ENTC ( BC6OTHER )) regulation in cell lines expressing the cloned components of BC6ENTG and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTG (K( BC6ENTC )) regulation in cell lines expressing the cloned components of K( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel (K( BC6ENTC )) regulation in cell lines expressing the cloned components of BC6ENTG and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineThe BC6OTHER , BC6OTHER and BC6ENTC , are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating BC6ENTG activity. CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTG (K( BC6OTHER )) regulation in cell lines expressing the cloned components of BC6ENTC ( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel ( BC6ENTG ) regulation in cell lines expressing the cloned components of BC6ENTC ( BC6OTHER ) and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in BC6ENTG (K( BC6OTHER )) regulation in cell lines expressing the cloned components of K( BC6ENTC ) and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineWe used the patch - clamp technique and BC6OTHER flux assays to determine the role of these drugs in CHEM - sensitive BC6OTHER channel ( BC6ENTG ) regulation in cell lines expressing the cloned components of K( BC6ENTC ) and the current natively expressed in vascular smooth muscle cells (VSMCs). CPR:falsenewlineThe BC6ENTC , BC6OTHER and BC6OTHER , are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating BC6ENTG activity. CPR:falsenewlineBC6ENTC but not BC6OTHER inhibits a number of variants of BC6ENTG including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6ENTG / BC6OTHER ). CPR:falsenewlineBC6ENTC but not BC6OTHER inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6ENTG ). CPR:falsenewlineBC6OTHER but not BC6ENTC inhibits a number of variants of BC6ENTG including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6ENTG / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6ENTC inhibits a number of variants of K( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6ENTG ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6ENTG / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of BC6ENTC ( BC6OTHER ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6ENTG ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG ) and pancreatic beta - cells ( BC6OTHER / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6ENTG / BC6OTHER ). CPR:falsenewlineBC6OTHER but not BC6OTHER inhibits a number of variants of K( BC6ENTC ) including the cloned equivalents of currents present in vascular and non - vascular smooth muscle ( BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER ) and pancreatic beta - cells ( BC6OTHER / BC6ENTG ). CPR:falsenewline BC6ENTC has a direct inhibitory effect on the BC6ENTG . CPR:falsenewlineThe extent and rate of inhibition are similar to that seen with the known BC6ENTG blocker BC6ENTC . CPR:4newlineAdditionally, BC6ENTC inhibited the current elicited through the BC6ENTG (functional without BC6OTHER ) channel with an IC50 of 1.78 mM. CPR:falsenewlineAdditionally, BC6ENTC inhibited the current elicited through the BC6OTHER (functional without BC6ENTG ) channel with an IC50 of 1.78 mM. CPR:falsenewlineBC6ENTC reduced the open probability of BC6ENTG / BC6OTHER channels by approximately 90% in inside - out patches. CPR:falsenewlineBC6ENTC reduced the open probability of BC6OTHER / BC6ENTG channels by approximately 90% in inside - out patches. CPR:falsenewlineThese findings suggest that BC6ENTC interacts directly with the pore - forming BC6ENTG subunit however the BC6OTHER receptor is able to significantly modulate the affinity. CPR:falsenewlineThese findings suggest that BC6ENTC interacts directly with the pore - forming BC6OTHER subunit however the BC6ENTG is able to significantly modulate the affinity. CPR:falsenewlineThese findings suggest that BC6OTHER interacts directly with the pore - forming BC6ENTG subunit however the BC6ENTC receptor is able to significantly modulate the affinity. CPR:falsenewlineThe BC6OTHER , BC6ENTC and BC6OTHER , are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating BC6ENTG activity. CPR:falsenewlineWe have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6OTHER ( BC6OTHER ), and characterized BC6OTHER as a strong agonist of BC6OTHER , BC6OTHER , and to a lower extent BC6ENTG . CPR:falsenewlineWe have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6ENTG ( BC6OTHER ), and characterized BC6OTHER as a strong agonist of BC6OTHER , BC6OTHER , and to a lower extent BC6OTHER . CPR:falsenewlineWe have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6OTHER ( BC6ENTG ), and characterized BC6OTHER as a strong agonist of BC6OTHER , BC6OTHER , and to a lower extent BC6OTHER . CPR:falsenewlineWe have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6OTHER ( BC6OTHER ), and characterized BC6ENTG as a strong agonist of BC6OTHER , BC6OTHER , and to a lower extent BC6OTHER . CPR:falsenewlineWe have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6OTHER ( BC6OTHER ), and characterized BC6OTHER as a strong agonist of BC6ENTG , BC6OTHER , and to a lower extent BC6OTHER . CPR:falsenewlineWe have previously isolated from human hemofiltrate an BC6ENTC - terminally truncated form of the BC6OTHER ( BC6OTHER ), and characterized BC6OTHER as a strong agonist of BC6OTHER , BC6ENTG , and to a lower extent BC6OTHER . CPR:falsenewlineBC6ENTC (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6ENTC (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6OTHER (1) reduced the pro - inflammatory factor such as BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER (1) reduced the pro - inflammatory factor such as BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER (1) reduced the pro - inflammatory factor such as BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineAn BC6ENTC dehydrogenase ( BC6ENTG ) activity has been localized in the rat kidney by a histochemical technique which links BC6OTHER metabolism with the production of a color reaction. CPR:falsenewlineThese results demonstrate the presence of a BC6ENTG activity separate from the BC6ENTC ( BC6OTHER ) - dependent BC6OTHER recently purified and cloned from rat liver. CPR:falsenewlineThese results demonstrate the presence of a BC6OTHER activity separate from the BC6ENTC ( BC6OTHER ) - dependent BC6ENTG recently purified and cloned from rat liver. CPR:falsenewlineThese results demonstrate the presence of a BC6ENTG activity separate from the BC6OTHER ( BC6ENTC ) - dependent BC6OTHER recently purified and cloned from rat liver. CPR:falsenewlineThese results demonstrate the presence of a BC6OTHER activity separate from the BC6OTHER ( BC6ENTC ) - dependent BC6ENTG recently purified and cloned from rat liver. CPR:falsenewlineThese results demonstrate the presence of a BC6ENTG activity separate from the BC6OTHER ( BC6OTHER ) - dependent BC6ENTC dehydrogenase recently purified and cloned from rat liver. CPR:falsenewlineWe have named this activity BC6ENTG to distinguish it from the BC6ENTC - dependent BC6OTHER . CPR:falsenewlineWe have named this activity BC6OTHER to distinguish it from the BC6ENTC - dependent BC6ENTG . CPR:falsenewlineAn BC6ENTG ( BC6OTHER ) activity has been localized in the rat kidney by a histochemical technique which links BC6ENTC metabolism with the production of a color reaction. CPR:falsenewlineAn BC6OTHER ( BC6ENTG ) activity has been localized in the rat kidney by a histochemical technique which links BC6ENTC metabolism with the production of a color reaction. CPR:falsenewlinePossible BC6ENTG involvement in BC6ENTC metabolism in insects was evaluated using BC6OTHER - expressing and BC6OTHER - deficient Drosophila, but no differences were found in BC6OTHER nitroreduction or sensitivity between the two strains. CPR:9newlinePossible BC6OTHER involvement in BC6ENTC metabolism in insects was evaluated using BC6ENTG - expressing and BC6OTHER - deficient Drosophila, but no differences were found in BC6OTHER nitroreduction or sensitivity between the two strains. CPR:falsenewlinePossible BC6OTHER involvement in BC6ENTC metabolism in insects was evaluated using BC6OTHER - expressing and BC6ENTG - deficient Drosophila, but no differences were found in BC6OTHER nitroreduction or sensitivity between the two strains. CPR:falsenewlinePossible BC6ENTG involvement in BC6OTHER metabolism in insects was evaluated using BC6OTHER - expressing and BC6OTHER - deficient Drosophila, but no differences were found in BC6ENTC nitroreduction or sensitivity between the two strains. CPR:falsenewlinePossible BC6OTHER involvement in BC6OTHER metabolism in insects was evaluated using BC6ENTG - expressing and BC6OTHER - deficient Drosophila, but no differences were found in BC6ENTC nitroreduction or sensitivity between the two strains. CPR:falsenewlinePossible BC6OTHER involvement in BC6OTHER metabolism in insects was evaluated using BC6OTHER - expressing and BC6ENTG - deficient Drosophila, but no differences were found in BC6ENTC nitroreduction or sensitivity between the two strains. CPR:falsenewlineThis is the first study to establish the in vivo relevance of BC6ENTG in BC6ENTC metabolism in mammals and one of the first for xenobiotics in general. CPR:9newlineCurrently, the most important insecticides are BC6ENTC , which are metabolized in vitro by BC6ENTG on reduction of the BC6OTHER group and by BC6OTHER via oxidation reactions. CPR:9newlineCurrently, the most important insecticides are BC6ENTC , which are metabolized in vitro by BC6OTHER on reduction of the BC6OTHER group and by BC6ENTG via oxidation reactions. CPR:9newlineCurrently, the most important insecticides are BC6OTHER , which are metabolized in vitro by BC6ENTG on reduction of the BC6ENTC group and by BC6OTHER via oxidation reactions. CPR:9newlineCurrently, the most important insecticides are BC6OTHER , which are metabolized in vitro by BC6OTHER on reduction of the BC6ENTC group and by BC6ENTG via oxidation reactions. CPR:9newlineThe procedure was to reduce liver BC6ENTG activity by providing BC6ENTC or BC6OTHER in the drinking water or to use the BC6OTHER - deficient DBA / 2 mouse strain. CPR:falsenewlineThe procedure was to reduce liver BC6OTHER activity by providing BC6ENTC or BC6OTHER in the drinking water or to use the BC6ENTG - deficient DBA / 2 mouse strain. CPR:falsenewlineThe procedure was to reduce liver BC6ENTG activity by providing BC6OTHER or BC6ENTC in the drinking water or to use the BC6OTHER - deficient DBA / 2 mouse strain. CPR:falsenewlineThe procedure was to reduce liver BC6OTHER activity by providing BC6OTHER or BC6ENTC in the drinking water or to use the BC6ENTG - deficient DBA / 2 mouse strain. CPR:falsenewlineLiver BC6ENTG activity was reduced by 45% with BC6ENTC and 61% with BC6OTHER and 81% in BC6OTHER - deficient mice relative to controls. CPR:4newlineLiver BC6OTHER activity was reduced by 45% with BC6ENTC and 61% with BC6OTHER and 81% in BC6ENTG - deficient mice relative to controls. CPR:falsenewlineLiver BC6ENTG activity was reduced by 45% with BC6OTHER and 61% with BC6ENTC and 81% in BC6OTHER - deficient mice relative to controls. CPR:falsenewlineLiver BC6OTHER activity was reduced by 45% with BC6OTHER and 61% with BC6ENTC and 81% in BC6ENTG - deficient mice relative to controls. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6ENTC ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6ENTG - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6ENTC ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6ENTG - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6ENTC ( BC6OTHER ), metabolism by BC6ENTG oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice. CPR:falsenewlineBC6ENTC oxidase ( BC6OTHER ) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to BC6ENTG ( BC6OTHER ) and other detoxification systems. CPR:falsenewlineBC6ENTC oxidase ( BC6OTHER ) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to BC6OTHER ( BC6ENTG ) and other detoxification systems. CPR:falsenewlineBC6ENTC oxidase ( BC6ENTG ) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to BC6OTHER ( BC6OTHER ) and other detoxification systems. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6ENTC ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6ENTG - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6ENTC ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6ENTG - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6ENTC ), metabolism by BC6ENTG oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice. CPR:falsenewline BC6ENTG importance in vivo in xenobiotic metabolism: BC6ENTC nitroreduction in mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6ENTG - generated BC6ENTC metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6ENTC metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6ENTG - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6ENTG oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6ENTC metabolite was decreased by 30% with BC6OTHER and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6ENTG - generated BC6OTHER metabolite was decreased by 30% with BC6ENTC and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6ENTC and 56% with BC6OTHER and 86% in the BC6ENTG - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6ENTG oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6ENTC and 56% with BC6OTHER and 86% in the BC6OTHER - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6ENTG - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6ENTC and 86% in the BC6OTHER - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6OTHER oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6ENTC and 86% in the BC6ENTG - deficient mice. CPR:falsenewlineWhen mice were treated ip with the major neonicotinoid BC6OTHER ( BC6OTHER ), metabolism by BC6ENTG oxidation reactions was not appreciably affected, whereas the BC6OTHER - generated BC6OTHER metabolite was decreased by 30% with BC6OTHER and 56% with BC6ENTC and 86% in the BC6OTHER - deficient mice. CPR:falsenewlineThe other BC6ENTC nitroreduction metabolite, desnitro - BC6OTHER , was decreased by 55%, 65%, and 81% with BC6OTHER , BC6OTHER , and in the BC6ENTG - deficient mice, respectively. CPR:falsenewlineThe other BC6OTHER nitroreduction metabolite, desnitro - BC6ENTC , was decreased by 55%, 65%, and 81% with BC6OTHER , BC6OTHER , and in the BC6ENTG - deficient mice, respectively. CPR:falsenewlineThe other BC6OTHER nitroreduction metabolite, desnitro - BC6OTHER , was decreased by 55%, 65%, and 81% with BC6ENTC , BC6OTHER , and in the BC6ENTG - deficient mice, respectively. CPR:falsenewlineThe other BC6OTHER nitroreduction metabolite, desnitro - BC6OTHER , was decreased by 55%, 65%, and 81% with BC6OTHER , BC6ENTC , and in the BC6ENTG - deficient mice, respectively. CPR:falsenewlineThus, decreasing liver BC6ENTG activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of BC6ENTC - treated mice. CPR:falsenewlineHere we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in BC6ENTC (34%), BC6OTHER , BC6OTHER , BC6OTHER and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, BC6ENTG ( - / - ) mice. CPR:falsenewlineHere we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in BC6OTHER (34%), BC6ENTC , BC6OTHER , BC6OTHER and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, BC6ENTG ( - / - ) mice. CPR:falsenewlineHere we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in BC6OTHER (34%), BC6OTHER , BC6ENTC , BC6OTHER and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, BC6ENTG ( - / - ) mice. CPR:falsenewlineHere we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in BC6OTHER (34%), BC6OTHER , BC6OTHER , BC6ENTC and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, BC6ENTG ( - / - ) mice. CPR:falsenewlineIn vitro binding affinities of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and some of their metabolites for BC6ENTG , BC6OTHER in rat brain were previously reported from our laboratories. CPR:falsenewlineIn vitro binding affinities of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and some of their metabolites for BC6OTHER D2 receptors, BC6ENTG in rat brain were previously reported from our laboratories. CPR:falsenewlineBC6OTHER , BC6ENTC , and their metabolites had 5 - 30 times higher binding affinities for BC6ENTG than BC6OTHER , BC6OTHER and their metabolites. CPR:falsenewlineBC6OTHER , BC6OTHER , and their metabolites had 5 - 30 times higher binding affinities for BC6ENTG than BC6ENTC , BC6OTHER and their metabolites. CPR:falsenewlineIn vitro binding affinities of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and some of their metabolites for BC6ENTG , BC6OTHER in rat brain were previously reported from our laboratories. CPR:falsenewlineIn vitro binding affinities of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and some of their metabolites for BC6OTHER D2 receptors, BC6ENTG in rat brain were previously reported from our laboratories. CPR:falsenewlineBC6OTHER , BC6OTHER , and their metabolites had 5 - 30 times higher binding affinities for BC6ENTG than BC6OTHER , BC6ENTC and their metabolites. CPR:falsenewlineBC6ENTC was the most potent and BC6OTHER the least potent of the four drugs in BC6ENTG binding. CPR:falsenewlineBC6OTHER was the most potent and BC6ENTC the least potent of the four drugs in BC6ENTG binding. CPR:falsenewlineBC6ENTC , BC6OTHER and BC6OTHER had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6OTHER - metabolites of BC6OTHER and BC6OTHER had about 75% of the potency of the parent drug in this binding system. CPR:falsenewlineIn vitro binding affinities of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and some of their metabolites for BC6ENTG , BC6OTHER in rat brain were previously reported from our laboratories. CPR:falsenewlineIn vitro binding affinities of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and some of their metabolites for BC6OTHER D2 receptors, BC6ENTG in rat brain were previously reported from our laboratories. CPR:falsenewlineBC6OTHER , BC6ENTC and BC6OTHER had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6OTHER - metabolites of BC6OTHER and BC6OTHER had about 75% of the potency of the parent drug in this binding system. CPR:falsenewlineBC6OTHER , BC6OTHER and BC6ENTC had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6OTHER - metabolites of BC6OTHER and BC6OTHER had about 75% of the potency of the parent drug in this binding system. CPR:falsenewlineBC6OTHER , BC6OTHER and BC6OTHER had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6ENTC - metabolites of BC6OTHER and BC6OTHER had about 75% of the potency of the parent drug in this binding system. CPR:falsenewlineBC6OTHER , BC6OTHER and BC6OTHER had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6OTHER - metabolites of BC6ENTC and BC6OTHER had about 75% of the potency of the parent drug in this binding system. CPR:falsenewlineBC6OTHER , BC6OTHER and BC6OTHER had only 10% of the potency of the parent drug in BC6ENTG binding, while the BC6OTHER - metabolites of BC6OTHER and BC6ENTC had about 75% of the potency of the parent drug in this binding system. CPR:falsenewlineMuscarinic cholinergic and BC6ENTG binding of BC6ENTC drug metabolites. CPR:falsenewlineTheir BC6ENTG binding affinities indicate that metabolites may contribute to the sedative effects of BC6ENTC and BC6OTHER . CPR:falsenewlineTheir BC6ENTG binding affinities indicate that metabolites may contribute to the sedative effects of BC6OTHER and BC6ENTC . CPR:falsenewlineIn vitro binding affinities of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and some of their metabolites for BC6ENTC D2 receptors, BC6ENTG in rat brain were previously reported from our laboratories. CPR:falsenewlineIn vitro binding affinities of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and some of their metabolites for BC6ENTG , BC6OTHER in rat brain were previously reported from our laboratories. CPR:falsenewlineIn vitro binding affinities of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and some of their metabolites for BC6OTHER D2 receptors, BC6ENTG in rat brain were previously reported from our laboratories. CPR:falsenewlineThe present study reports the in vitro binding affinities of the same compounds for BC6ENTG and for BC6ENTC H1 receptors in rat brain, using BC6OTHER and BC6OTHER as radioligands. CPR:falsenewlineThe present study reports the in vitro binding affinities of the same compounds for BC6ENTG and for BC6OTHER H1 receptors in rat brain, using BC6ENTC and BC6OTHER as radioligands. CPR:falsenewlineThe present study reports the in vitro binding affinities of the same compounds for BC6OTHER and for BC6ENTG in rat brain, using BC6ENTC and BC6OTHER as radioligands. CPR:falsenewlineThe present study reports the in vitro binding affinities of the same compounds for BC6ENTG and for BC6OTHER H1 receptors in rat brain, using BC6OTHER and BC6ENTC as radioligands. CPR:falsenewlineThe present study reports the in vitro binding affinities of the same compounds for BC6OTHER and for BC6ENTG in rat brain, using BC6OTHER and BC6ENTC as radioligands. CPR:falsenewlineBC6ENTC , BC6OTHER , and their metabolites had 5 - 30 times higher binding affinities for BC6ENTG than BC6OTHER , BC6OTHER and their metabolites. CPR:falsenewlineBC6ENTG activates platelets through 2 pathways: one is through BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC - mediated induction of aggregation; the other is through BC6OTHER - mediated aggregation and agglutination. CPR:falsenewlineBC6OTHER activates platelets through 2 pathways: one is through BC6ENTG , BC6OTHER ( BC6OTHER ), BC6ENTC - mediated induction of aggregation; the other is through BC6OTHER - mediated aggregation and agglutination. CPR:falsenewlineBC6OTHER activates platelets through 2 pathways: one is through BC6OTHER , BC6ENTG ( BC6OTHER ), BC6ENTC - mediated induction of aggregation; the other is through BC6OTHER - mediated aggregation and agglutination. CPR:falsenewlineBC6OTHER activates platelets through 2 pathways: one is through BC6OTHER , BC6OTHER ( BC6ENTG ), BC6ENTC - mediated induction of aggregation; the other is through BC6OTHER - mediated aggregation and agglutination. CPR:falsenewlineBC6OTHER activates platelets through 2 pathways: one is through BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC - mediated induction of aggregation; the other is through BC6ENTG - mediated aggregation and agglutination. CPR:falsenewlineBC6ENTG - induced platelet aggregation was independent of BC6ENTC formation and BC6OTHER secretion but enhanced by feedback stimulation through these pathways. CPR:falsenewlineBC6ENTG - induced platelet aggregation was independent of BC6OTHER formation and BC6ENTC secretion but enhanced by feedback stimulation through these pathways. CPR:falsenewlineTreatments that raised BC6ENTC ( BC6OTHER ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6ENTG - platelet interaction (sRAGE, BC6OTHER [ BC6OTHER ]) induced almost complete inhibition. CPR:falsenewlineTreatments that raised BC6ENTC ( BC6OTHER ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6ENTG [ BC6OTHER ]) induced almost complete inhibition. CPR:falsenewlineTreatments that raised BC6ENTC ( BC6OTHER ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6OTHER [ BC6ENTG ]) induced almost complete inhibition. CPR:falsenewlineTreatments that raised BC6OTHER ( BC6ENTC ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6ENTG - platelet interaction (sRAGE, BC6OTHER [ BC6OTHER ]) induced almost complete inhibition. CPR:falsenewlineTreatments that raised BC6OTHER ( BC6ENTC ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6ENTG [ BC6OTHER ]) induced almost complete inhibition. CPR:falsenewlineTreatments that raised BC6OTHER ( BC6ENTC ), sequestered BC6OTHER ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6OTHER [ BC6ENTG ]) induced almost complete inhibition. CPR:falsenewlineTreatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6ENTC ( BC6OTHER ) or prevented BC6ENTG - platelet interaction (sRAGE, BC6OTHER [ BC6OTHER ]) induced almost complete inhibition. CPR:falsenewlineTreatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6ENTC ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6ENTG [ BC6OTHER ]) induced almost complete inhibition. CPR:falsenewlineTreatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6ENTC ( BC6OTHER ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6OTHER [ BC6ENTG ]) induced almost complete inhibition. CPR:falsenewlineTreatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6OTHER ( BC6ENTC ) or prevented BC6ENTG - platelet interaction (sRAGE, BC6OTHER [ BC6OTHER ]) induced almost complete inhibition. CPR:falsenewlineTreatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6OTHER ( BC6ENTC ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6ENTG [ BC6OTHER ]) induced almost complete inhibition. CPR:falsenewlineTreatments that raised BC6OTHER ( BC6OTHER ), sequestered BC6OTHER ( BC6ENTC ) or prevented BC6OTHER - platelet interaction (sRAGE, BC6OTHER [ BC6ENTG ]) induced almost complete inhibition. CPR:falsenewlineModulation of the function of BC6ENTG (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineModulation of the function of BC6OTHER (CD36 - / - mice), BC6ENTG ( BC6OTHER ) ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineModulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6ENTG ) ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineModulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6ENTC ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineModulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineModulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineModulation of the function of BC6ENTG (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineModulation of the function of BC6OTHER (CD36 - / - mice), BC6ENTG ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineModulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6ENTG ) ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineModulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6ENTG ( BC6ENTC ), and BC6OTHER ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineModulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6ENTG ( BC6OTHER , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineModulation of the function of BC6OTHER (CD36 - / - mice), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6ENTG , 6D1 antibody) induced approximately 50% inhibition. CPR:falsenewlineWe identified BC6ENTC as a compound that binds to BC6ENTG and showed that it inhibits SIRT5 BC6OTHER - dependent deacetylase activity with an IC(50) value of 22 microM. CPR:falsenewlineWe identified BC6ENTC as a compound that binds to BC6OTHER and showed that it inhibits BC6ENTG activity with an IC(50) value of 22 microM. CPR:4newlineWe identified BC6OTHER as a compound that binds to BC6ENTG and showed that it inhibits SIRT5 BC6ENTC - dependent deacetylase activity with an IC(50) value of 22 microM. CPR:falsenewlineTo provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of BC6ENTG , one in complex with BC6ENTC - CHEM, the other bound to BC6OTHER . CPR:falsenewlineTo provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of BC6ENTG , one in complex with BC6OTHER - CHEM, the other bound to BC6ENTC . CPR:falsenewlineOur structural studies provide a view of a synthetic inhibitory compound in a BC6ENTG active site revealing that BC6ENTC binds into the BC6OTHER , the product, and the substrate - binding site. CPR:falsenewlineOur structural studies provide a view of a synthetic inhibitory compound in a BC6ENTG active site revealing that BC6OTHER binds into the BC6ENTC , the product, and the substrate - binding site. CPR:falsenewlineStructural basis of inhibition of the BC6ENTG by BC6ENTC . CPR:4newlineInhibition of BC6ENTG pathway of BC6OTHER metabolism in human neutrophils by BC6OTHER and BC6ENTC . CPR:4newlineInhibition of BC6ENTG pathway of BC6ENTC metabolism in human neutrophils by BC6OTHER and BC6OTHER . CPR:9newlineInhibition of BC6ENTG pathway of BC6OTHER metabolism in human neutrophils by BC6ENTC and BC6OTHER . CPR:4newlineInterference with BC6ENTG enzymes, rather than a BC6ENTC - like inhibition of BC6OTHER release from intracellular CHEM, seems to be the mode of action. CPR:falsenewlineInterference with BC6ENTG enzymes, rather than a BC6OTHER - like inhibition of BC6ENTC release from intracellular CHEM, seems to be the mode of action. CPR:falsenewlineRESULTS: In contrast to immune stimulatory sequence ISS 1018, BCG DNA spontaneously formed nanoparticulate structures and induced BC6ENTG polymerization as did synthetic BC6ENTC nanoparticles. CPR:falsenewlineCHEM - incubation with BC6ENTC nanoparticles amplified the responsiveness of macrophages toward the BC6ENTG ligand ISS 1018. CPR:falsenewlineThe activation of BC6ENTG was induced by BC6ENTC nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation. CPR:falsenewlineBC6ENTG polymerization was measured by BC6ENTC - BC6OTHER staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6OTHER BC6OTHER ). CPR:falsenewlineBC6OTHER polymerization was measured by BC6ENTC - BC6OTHER staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6ENTG induction), and pull - down assays ( BC6OTHER BC6OTHER ). CPR:falsenewlineBC6OTHER polymerization was measured by BC6ENTC - BC6OTHER staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6ENTG BC6OTHER ). CPR:falsenewlineBC6OTHER polymerization was measured by BC6ENTC - BC6OTHER staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6OTHER BC6ENTG ). CPR:falsenewlineBC6ENTG polymerization was measured by BC6OTHER - BC6ENTC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6OTHER BC6OTHER ). CPR:falsenewlineBC6OTHER polymerization was measured by BC6OTHER - BC6ENTC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6ENTG induction), and pull - down assays ( BC6OTHER BC6OTHER ). CPR:falsenewlineBC6OTHER polymerization was measured by BC6OTHER - BC6ENTC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6ENTG BC6OTHER ). CPR:falsenewlineBC6OTHER polymerization was measured by BC6OTHER - BC6ENTC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay ( BC6OTHER induction), and pull - down assays ( BC6OTHER BC6ENTG ). CPR:falsenewlineCirculating levels of BC6OTHER and BC6ENTG reflect the nutritional state of animals and elicit regulatory responses in the liver that maintain BC6ENTC and lipid homeostasis. CPR:falsenewlineCirculating levels of BC6ENTG and BC6OTHER reflect the nutritional state of animals and elicit regulatory responses in the liver that maintain BC6ENTC and lipid homeostasis. CPR:falsenewlineIntroduction of the acetylation - mimicking ( BC6ENTG ) or - deficient ( BC6OTHER ) mutations promotes or inhibits BC6OTHER activity, respectively, and adenoviral expression of BC6OTHER - BC6OTHER augments expression of genes involved in BC6ENTC oxidation and ketogenesis. CPR:falsenewlineIntroduction of the acetylation - mimicking ( BC6OTHER ) or - deficient ( BC6ENTG ) mutations promotes or inhibits BC6OTHER activity, respectively, and adenoviral expression of BC6OTHER - BC6OTHER augments expression of genes involved in BC6ENTC oxidation and ketogenesis. CPR:falsenewlineIntroduction of the acetylation - mimicking ( BC6OTHER ) or - deficient ( BC6OTHER ) mutations promotes or inhibits BC6ENTG activity, respectively, and adenoviral expression of BC6OTHER - BC6OTHER augments expression of genes involved in BC6ENTC oxidation and ketogenesis. CPR:falsenewlineIntroduction of the acetylation - mimicking ( BC6OTHER ) or - deficient ( BC6OTHER ) mutations promotes or inhibits BC6OTHER activity, respectively, and adenoviral expression of BC6ENTG - BC6OTHER augments expression of genes involved in BC6ENTC oxidation and ketogenesis. CPR:falsenewlineIntroduction of the acetylation - mimicking ( BC6OTHER ) or - deficient ( BC6OTHER ) mutations promotes or inhibits BC6OTHER activity, respectively, and adenoviral expression of BC6OTHER - BC6ENTG augments expression of genes involved in BC6ENTC oxidation and ketogenesis. CPR:falsenewlineFemale precocious puberty may require hyperactivity of both BC6ENTG axes because of the "two - cell' arrangement required for ovarian BC6ENTC production. CPR:falsenewline BC6ENTC ( BC6OTHER ), an activator of BC6OTHER ( BC6OTHER ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6ENTG - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose. CPR:falsenewline BC6ENTC ( BC6OTHER ), an activator of BC6ENTG ( BC6OTHER ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6OTHER - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose. CPR:falsenewline BC6ENTC ( BC6OTHER ), an activator of BC6OTHER ( BC6ENTG ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6OTHER - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose. CPR:falsenewlineBC6ENTG release from peripheral blood CTLs after CHEM / CHEM - stimulation was not influenced significantly by BC6ENTC . CPR:falsenewlineThus, the biological activity of BC6ENTC appears to exceed its previously known functions, inasmuch as it boosts up significantly the BC6ENTG - granule system. CPR:falsenewline BC6OTHER ( BC6ENTC ), an activator of BC6OTHER ( BC6OTHER ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6ENTG - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose. CPR:falsenewline BC6OTHER ( BC6ENTC ), an activator of BC6ENTG ( BC6OTHER ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6OTHER - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose. CPR:falsenewline BC6OTHER ( BC6ENTC ), an activator of BC6OTHER ( BC6ENTG ), induces by several routes a profound anti - viral and anti - tumor effect in vivo. Physiologically, the immune system is using BC6OTHER - containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose. CPR:falsenewlineThis functional synergism prompted our current experiments addressing the question whether BC6ENTC may influence BC6ENTG - release and / or induce BC6OTHER in CTLs in vitro. CPR:falsenewlineThis functional synergism prompted our current experiments addressing the question whether BC6ENTC may influence BC6OTHER - release and / or induce BC6ENTG in CTLs in vitro. CPR:falsenewlineIn peripheral lymphocytes of healthy and diseased subjects, BC6ENTC induced a significant increase of BC6ENTG (+) CTLs within 12h in all experiments performed. CPR:falsenewlineThis effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal BC6ENTG expression: as compared to BC6OTHER (+) CTLs detected at time point zero (100%), up to 270% of BC6OTHER (+) CTLs were induced by 2.5 microg / ml [corrected] BC6ENTC . CPR:falsenewlineThis effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal BC6OTHER expression: as compared to BC6ENTG (+) CTLs detected at time point zero (100%), up to 270% of BC6OTHER (+) CTLs were induced by 2.5 microg / ml [corrected] BC6ENTC . CPR:falsenewlineThis effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal BC6OTHER expression: as compared to BC6OTHER (+) CTLs detected at time point zero (100%), up to 270% of BC6ENTG (+) CTLs were induced by 2.5 microg / ml [corrected] BC6ENTC . CPR:falsenewline BC6ENTC , a BC6ENTG agonist, induces BC6OTHER in cytotoxic T lymphocytes in vitro. CPR:falsenewline BC6ENTC , a BC6OTHER agonist, induces BC6ENTG in cytotoxic T lymphocytes in vitro. CPR:falsenewlineBlockade of the BC6ENTG - BC6OTHER system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by BC6ENTC throughout the cardiovascular and renal continua. CPR:falsenewlineBlockade of the BC6OTHER - BC6ENTG system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by BC6ENTC throughout the cardiovascular and renal continua. CPR:falsenewlineBlockade of the BC6ENTG - BC6ENTC system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by BC6OTHER throughout the cardiovascular and renal continua. CPR:falsenewlineBlockade of the BC6OTHER - BC6ENTC system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by BC6ENTG throughout the cardiovascular and renal continua. CPR:falsenewlineBC6ENTC is an BC6ENTG blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure. CPR:falsenewlineBC6OTHER triggered strong induction of BC6ENTG , which was prevented by 1 micro g / mL BC6ENTC ( BC6OTHER ). CPR:falsenewlineBC6OTHER triggered strong induction of BC6ENTG , which was prevented by 1 micro g / mL BC6OTHER ( BC6ENTC ). CPR:falsenewline BC6ENTC caused cell loss and increased cell death with features of apoptosis, i.e. CHEM - mediated CHEM nick - end labelling (TUNEL) reaction and BC6ENTG activation. CPR:falsenewlineInduction of BC6ENTG ( BC6OTHER ) by BC6ENTC in cultured astrocytes and reduction of BC6OTHER - induced cell death. CPR:3newlineInduction of BC6OTHER ( BC6ENTG ) by BC6ENTC in cultured astrocytes and reduction of BC6OTHER - induced cell death. CPR:3newlineInduction of BC6ENTG ( BC6OTHER ) by BC6OTHER in cultured astrocytes and reduction of BC6ENTC - induced cell death. CPR:falsenewlineInduction of BC6OTHER ( BC6ENTG ) by BC6OTHER in cultured astrocytes and reduction of BC6ENTC - induced cell death. CPR:falsenewlinePre - treatment with CHEM increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) phosphorylation after BC6ENTC . CPR:falsenewlinePre - treatment with CHEM increased BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) phosphorylation after BC6ENTC . CPR:falsenewlinePre - treatment with CHEM increased BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) phosphorylation after BC6ENTC . CPR:falsenewlinePre - treatment with CHEM increased BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) phosphorylation after BC6ENTC . CPR:falsenewlineHowever, while BC6ENTG phosphorylation was prevented by CHX, BC6OTHER phosphorylation was further enhanced by BC6ENTC . CPR:falsenewlineHowever, while BC6OTHER phosphorylation was prevented by CHX, BC6ENTG phosphorylation was further enhanced by BC6ENTC . CPR:falsenewlineThe results show that transient BC6ENTC pre - treatment induces BC6ENTG , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER . CPR:falsenewlineThe results show that transient BC6ENTC pre - treatment induces BC6OTHER , BC6ENTG and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER . CPR:falsenewlineThe results show that transient BC6ENTC pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6ENTG ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER . CPR:falsenewlineThe results show that transient BC6ENTC pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6ENTG following BC6OTHER . CPR:falsenewlineThe results show that transient BC6OTHER pre - treatment induces BC6ENTG , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6ENTC - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER . CPR:falsenewlineThe results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6ENTG and, to a lesser extent, BC6OTHER ; it reduces BC6ENTC - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER . CPR:falsenewlineThe results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6ENTG ; it reduces BC6ENTC - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6OTHER . CPR:falsenewlineThe results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6ENTC - induced astrocyte death; and it causes selective activation of BC6ENTG following BC6OTHER . CPR:falsenewlineThe results show that transient BC6OTHER pre - treatment induces BC6ENTG , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6ENTC . CPR:falsenewlineThe results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6ENTG and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6ENTC . CPR:falsenewlineThe results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6ENTG ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6OTHER following BC6ENTC . CPR:falsenewlineThe results show that transient BC6OTHER pre - treatment induces BC6OTHER , BC6OTHER and, to a lesser extent, BC6OTHER ; it reduces BC6OTHER - induced astrocyte death; and it causes selective activation of BC6ENTG following BC6ENTC . CPR:falsenewlineIt is suggested that BC6ENTG expression at the time of BC6ENTC exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro - survival BC6OTHER . CPR:falsenewlineIt is suggested that BC6OTHER expression at the time of BC6ENTC exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro - survival BC6ENTG . CPR:falsenewlineBC6ENTC triggered strong induction of BC6ENTG , which was prevented by 1 micro g / mL BC6OTHER ( BC6OTHER ). CPR:falsenewlineA novel potent compound, BC6ENTC (12c), which binds BC6ENTG with an IC(50) value of 54 nM was obtained. CPR:falsenewlineWe have previously reported a nanomolar inhibitor of antiapoptotic BC6ENTG protein, BC6ENTC (S1). CPR:falsenewlineFragment - based design, synthesis, and biological evaluation of BC6ENTC derivatives as novel BC6ENTG inhibitors. CPR:4newline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6ENTG ( BC6OTHER ) and of the inducible form ( BC6OTHER ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6ENTG ) and of the inducible form ( BC6OTHER ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6OTHER ) and of the inducible form ( BC6ENTG ). CPR:falsenewlineActivation of cytoprotective BC6ENTG by BC6ENTC as a possible explanation for its hair growth - stimulating effect. CPR:3newline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6ENTG ( BC6OTHER ) and of the inducible form ( BC6OTHER ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6ENTG ) and of the inducible form ( BC6OTHER ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6OTHER ) and of the inducible form ( BC6ENTG ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6ENTG ( BC6OTHER ) and of the inducible form ( BC6OTHER ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6ENTG ) and of the inducible form ( BC6OTHER ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6OTHER ) and of the inducible form ( BC6ENTG ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6ENTG ( BC6OTHER ) and of the inducible form ( BC6OTHER ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6ENTG ) and of the inducible form ( BC6OTHER ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of BC6OTHER CHEM synthase - 1 ( BC6OTHER ) and of the inducible form ( BC6ENTG ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of CHEM synthase - 1 ( BC6ENTG ) and of the inducible form ( BC6OTHER ). CPR:falsenewline Data from the literature indicate that nonsteroidal anti - inflammatory drugs (NSAIDs), such as BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER , induce hair loss in vivo. These NSAIDs are well - known inhibitors of both the cytoprotective isoform of CHEM synthase - 1 ( BC6OTHER ) and of the inducible form ( BC6ENTG ). CPR:falsenewline We thus speculated that activation of BC6ENTG might be a mechanism by which BC6ENTC ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6OTHER (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production. CPR:falsenewline We thus speculated that activation of BC6OTHER might be a mechanism by which BC6ENTC ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6ENTG (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production. CPR:falsenewline We thus speculated that activation of BC6ENTG might be a mechanism by which BC6OTHER ( BC6ENTC ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6OTHER (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production. CPR:falsenewline We thus speculated that activation of BC6OTHER might be a mechanism by which BC6OTHER ( BC6ENTC ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6ENTG (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production. CPR:falsenewline We thus speculated that activation of BC6ENTG might be a mechanism by which BC6OTHER ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6ENTC is a potent activator of purified BC6OTHER (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production. CPR:falsenewline We thus speculated that activation of BC6OTHER might be a mechanism by which BC6OTHER ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6ENTC is a potent activator of purified BC6ENTG (AC50 = 80 microM), as assayed by BC6OTHER consumption and CHEM production. CPR:3newline We thus speculated that activation of BC6ENTG might be a mechanism by which BC6OTHER ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6OTHER (AC50 = 80 microM), as assayed by BC6ENTC consumption and CHEM production. CPR:falsenewline We thus speculated that activation of BC6OTHER might be a mechanism by which BC6OTHER ( BC6OTHER ) stimulates hair growth in vivo. We demonstrate here that BC6OTHER is a potent activator of purified BC6ENTG (AC50 = 80 microM), as assayed by BC6ENTC consumption and CHEM production. CPR:falsenewlineIn rat kidney the "secretory" isoform of the BC6ENTC - BC6OTHER - BC6OTHER cotransporter ( BC6ENTG ) localizes to the basolateral membrane of the alpha - intercalated cell. CPR:falsenewlineIn rat kidney the "secretory" isoform of the CHEM - BC6ENTC - BC6OTHER cotransporter ( BC6ENTG ) localizes to the basolateral membrane of the alpha - intercalated cell. CPR:falsenewlineIn rat kidney the "secretory" isoform of the BC6ENTG BC6ENTC cotransporter ( BC6OTHER ) localizes to the basolateral membrane of the alpha - intercalated cell. CPR:falsenewlineIn rat kidney the "secretory" isoform of the CHEM - BC6OTHER - BC6ENTC cotransporter ( BC6ENTG ) localizes to the basolateral membrane of the alpha - intercalated cell. CPR:falsenewlineBC6ENTC - sensitive BC6OTHER secretion was dependent on extracellular BC6OTHER and either BC6OTHER or BC6OTHER , consistent with the ion dependency of BC6ENTG - mediated BC6OTHER transport. CPR:falsenewlineIn conclusion, OMCD tubules from BC6ENTC - treated rats secrete BC6OTHER into the luminal fluid through BC6ENTG - mediated BC6OTHER uptake across the basolateral membrane in series with BC6OTHER efflux across the apical membrane. CPR:falsenewlineBC6OTHER - sensitive BC6ENTC secretion was dependent on extracellular BC6OTHER and either BC6OTHER or BC6OTHER , consistent with the ion dependency of BC6ENTG - mediated BC6OTHER transport. CPR:9newlineBC6OTHER - sensitive BC6OTHER secretion was dependent on extracellular BC6ENTC and either BC6OTHER or BC6OTHER , consistent with the ion dependency of BC6ENTG - mediated BC6OTHER transport. CPR:falsenewlineBC6OTHER - sensitive BC6OTHER secretion was dependent on extracellular BC6OTHER and either BC6ENTC or BC6OTHER , consistent with the ion dependency of BC6ENTG - mediated BC6OTHER transport. CPR:falsenewlineBC6OTHER - sensitive BC6OTHER secretion was dependent on extracellular BC6OTHER and either BC6OTHER or BC6ENTC , consistent with the ion dependency of BC6ENTG - mediated BC6OTHER transport. CPR:falsenewlineBC6OTHER - sensitive BC6OTHER secretion was dependent on extracellular BC6OTHER and either BC6OTHER or BC6OTHER , consistent with the ion dependency of BC6ENTG - mediated BC6ENTC transport. CPR:falsenewlineContribution of the BC6ENTC - BC6OTHER - BC6OTHER cotransporter BC6ENTG to BC6OTHER secretion in rat OMCD. CPR:falsenewlineContribution of the CHEM - BC6ENTC - BC6OTHER cotransporter BC6ENTG to BC6OTHER secretion in rat OMCD. CPR:falsenewlineContribution of the BC6ENTG BC6ENTC cotransporter BC6OTHER to BC6OTHER secretion in rat OMCD. CPR:falsenewlineContribution of the CHEM - BC6OTHER - BC6ENTC cotransporter BC6ENTG to BC6OTHER secretion in rat OMCD. CPR:falsenewlineContribution of the BC6ENTG BC6OTHER cotransporter BC6OTHER to BC6ENTC secretion in rat OMCD. CPR:9newlineContribution of the CHEM - BC6OTHER - BC6OTHER cotransporter BC6ENTG to BC6ENTC secretion in rat OMCD. CPR:9newlineIn conclusion, OMCD tubules from BC6OTHER - treated rats secrete BC6ENTC into the luminal fluid through BC6ENTG - mediated BC6OTHER uptake across the basolateral membrane in series with BC6OTHER efflux across the apical membrane. CPR:9newlineIn conclusion, OMCD tubules from BC6OTHER - treated rats secrete BC6OTHER into the luminal fluid through BC6ENTG - mediated BC6ENTC uptake across the basolateral membrane in series with BC6OTHER efflux across the apical membrane. CPR:9newlineIn conclusion, OMCD tubules from BC6OTHER - treated rats secrete BC6OTHER into the luminal fluid through BC6ENTG - mediated BC6OTHER uptake across the basolateral membrane in series with BC6ENTC efflux across the apical membrane. CPR:falsenewlineThe physiological role of BC6ENTG - mediated BC6ENTC uptake remains to be determined. CPR:9newlineThe purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes BC6ENTC and whether transepithelial BC6OTHER transport occurs, in part, through BC6OTHER uptake across the basolateral membrane mediated by BC6ENTG in series with BC6OTHER efflux across the apical membrane. CPR:falsenewlineThe purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes BC6OTHER and whether transepithelial BC6ENTC transport occurs, in part, through BC6OTHER uptake across the basolateral membrane mediated by BC6ENTG in series with BC6OTHER efflux across the apical membrane. CPR:falsenewlineThe purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes BC6OTHER and whether transepithelial BC6OTHER transport occurs, in part, through BC6ENTC uptake across the basolateral membrane mediated by BC6ENTG in series with BC6OTHER efflux across the apical membrane. CPR:9newlineThe purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes BC6OTHER and whether transepithelial BC6OTHER transport occurs, in part, through BC6OTHER uptake across the basolateral membrane mediated by BC6ENTG in series with BC6ENTC efflux across the apical membrane. CPR:falsenewlineLoss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the BC6ENTG receptor, conditions where high BC6OTHER levels are present; however, high affinity binding BC6ENTC was observed in broken cell preparations washed free of BC6OTHER . CPR:falsenewlineUnlike the majority of BC6ENTG , the BC6OTHER ( BC6ENTC ) BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6OTHER ). CPR:falsenewlineLoss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the BC6ENTG receptor, conditions where high BC6OTHER levels are present; however, high affinity binding BC6OTHER was observed in broken cell preparations washed free of BC6ENTC . CPR:falsenewlineThe BC6ENTC binding of BC6ENTG in broken cell membrane fractions was inhibited by addition of BC6OTHER (IC(50) 21 ± 1.8 nM). CPR:falsenewlineUnlike the majority of BC6ENTG , the BC6OTHER ( BC6OTHER ) BC6ENTC 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6OTHER ). CPR:falsenewlineUnlike the majority of BC6OTHER , the BC6ENTG BC6ENTC 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe BC6OTHER binding of BC6ENTG in broken cell membrane fractions was inhibited by addition of BC6ENTC (IC(50) 21 ± 1.8 nM). CPR:falsenewline BC6ENTG modulates BC6ENTC sensitivity of the BC6OTHER . CPR:falsenewline BC6OTHER modulates BC6ENTC sensitivity of the BC6ENTG . CPR:falsenewline BC6ENTG modulates BC6OTHER sensitivity of the BC6ENTC EP3 receptor. CPR:falsenewlineMoreover, mutation of BC6ENTG can alter this coupled equilibrium from BC6ENTC - insensitive agonist binding to more conventional BC6OTHER - sensitive binding. CPR:falsenewlineMoreover, mutation of BC6ENTG can alter this coupled equilibrium from BC6OTHER - insensitive agonist binding to more conventional BC6ENTC - sensitive binding. CPR:falsenewlineThis suggests that for the mutant receptors, BC6ENTG plays a critical role in linking the agonist bound receptor conformation to the BC6OTHER BC6ENTC bound state. CPR:falsenewlineThis suggests that for the mutant receptors, BC6OTHER plays a critical role in linking the agonist bound receptor conformation to the BC6ENTG BC6ENTC bound state. CPR:falsenewlineUnlike the majority of BC6ENTG , the BC6OTHER ( BC6OTHER ) BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6ENTC ( BC6OTHER ). CPR:falsenewlineUnlike the majority of BC6OTHER , the BC6ENTG BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6ENTC ( BC6OTHER ). CPR:falsenewlineUnlike the majority of BC6ENTG , the BC6OTHER ( BC6OTHER ) BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6ENTC ). CPR:falsenewlineUnlike the majority of BC6OTHER , the BC6ENTG BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6ENTC ). CPR:falsenewlineSeven point mutations were introduced into the conserved motif in the BC6ENTG ( BC6OTHER ) of BC6OTHER , resulting in acquisition of BC6ENTC - sensitive agonist binding. CPR:falsenewlineSeven point mutations were introduced into the conserved motif in the BC6OTHER ( BC6ENTG ) of BC6OTHER , resulting in acquisition of BC6ENTC - sensitive agonist binding. CPR:falsenewlineSeven point mutations were introduced into the conserved motif in the BC6OTHER ( BC6OTHER ) of BC6ENTG , resulting in acquisition of BC6ENTC - sensitive agonist binding. CPR:falsenewlineUnlike the majority of BC6ENTG , the BC6ENTC ( BC6OTHER ) BC6OTHER 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of BC6OTHER ( BC6OTHER ). CPR:falsenewlineLoss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the BC6ENTG receptor, conditions where high BC6ENTC levels are present; however, high affinity binding BC6OTHER was observed in broken cell preparations washed free of BC6OTHER . CPR:falsenewlineBinding and transactivation assays were used to compare affinities and transcriptional activities of BC6OTHER and BC6ENTC for the BC6ENTG , BC6OTHER ( BC6OTHER ). CPR:falsenewlineBinding and transactivation assays were used to compare affinities and transcriptional activities of BC6OTHER and BC6ENTC for the BC6OTHER , BC6ENTG ( BC6OTHER ). CPR:falsenewlineBinding and transactivation assays were used to compare affinities and transcriptional activities of BC6OTHER and BC6ENTC for the BC6OTHER , BC6OTHER ( BC6ENTG ). CPR:falsenewlineBinding and transactivation assays were used to compare affinities and transcriptional activities of BC6OTHER and BC6OTHER for the BC6ENTG , BC6ENTC receptors ( BC6OTHER ). CPR:falsenewlineBinding and transactivation assays were used to compare affinities and transcriptional activities of BC6OTHER and BC6OTHER for the BC6OTHER , BC6ENTC receptors ( BC6ENTG ). CPR:falsenewlineThe BC6ENTG BC6OTHER and BC6OTHER mediate the BC6ENTC activity of BC6OTHER . CPR:falsenewlineThe BC6OTHER BC6ENTG and BC6OTHER mediate the BC6ENTC activity of BC6OTHER . CPR:falsenewlineThe BC6OTHER BC6OTHER and BC6ENTG mediate the BC6ENTC activity of BC6OTHER . CPR:falsenewlineThe BC6ENTG BC6OTHER and BC6OTHER mediate the BC6OTHER activity of BC6ENTC . CPR:falsenewlineThe BC6OTHER BC6ENTG and BC6OTHER mediate the BC6OTHER activity of BC6ENTC . CPR:falsenewlineThe BC6OTHER BC6OTHER and BC6ENTG mediate the BC6OTHER activity of BC6ENTC . CPR:falsenewlineBinding and transactivation assays were used to compare affinities and transcriptional activities of BC6ENTC and BC6OTHER for the BC6ENTG , BC6OTHER ( BC6OTHER ). CPR:falsenewlineBinding and transactivation assays were used to compare affinities and transcriptional activities of BC6ENTC and BC6OTHER for the BC6OTHER , BC6ENTG ( BC6OTHER ). CPR:falsenewlineBinding and transactivation assays were used to compare affinities and transcriptional activities of BC6ENTC and BC6OTHER for the BC6OTHER , BC6OTHER ( BC6ENTG ). CPR:falsenewlineAll tested compounds proved to be potent BC6ENTG receptor and BC6ENTC transporter protein ( BC6OTHER ) ligands. CPR:falsenewlineAll tested compounds proved to be potent BC6OTHER receptor and BC6ENTC transporter protein ( BC6ENTG ) ligands. CPR:falsenewlineAccordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER were undertaken using the AMBER program. CPR:falsenewlineAccordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER were undertaken using the AMBER program. CPR:falsenewlineAccordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER were undertaken using the AMBER program. CPR:falsenewlineAccordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC were undertaken using the AMBER program. CPR:falsenewlineNon - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6ENTG ( BC6OTHER ), the enzyme that mediates biosynthesis of BC6ENTC and BC6OTHER from BC6OTHER . CPR:falsenewlineNon - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6OTHER ( BC6ENTG ), the enzyme that mediates biosynthesis of BC6ENTC and BC6OTHER from BC6OTHER . CPR:falsenewlineNon - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6ENTG ( BC6OTHER ), the enzyme that mediates biosynthesis of BC6OTHER and BC6ENTC from BC6OTHER . CPR:9newlineNon - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6OTHER ( BC6ENTG ), the enzyme that mediates biosynthesis of BC6OTHER and BC6ENTC from BC6OTHER . CPR:falsenewlineNon - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6ENTG ( BC6OTHER ), the enzyme that mediates biosynthesis of BC6OTHER and BC6OTHER from BC6ENTC . CPR:falsenewlineNon - BC6OTHER anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6OTHER ( BC6ENTG ), the enzyme that mediates biosynthesis of BC6OTHER and BC6OTHER from BC6ENTC . CPR:falsenewlineNon - BC6ENTC anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6ENTG ( BC6OTHER ), the enzyme that mediates biosynthesis of BC6OTHER and BC6OTHER from BC6OTHER . CPR:falsenewlineNon - BC6ENTC anti - inflammatory drugs (NSAIDs) are competitive inhibitors of BC6OTHER ( BC6ENTG ), the enzyme that mediates biosynthesis of BC6OTHER and BC6OTHER from BC6OTHER . CPR:falsenewlineAccordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER were undertaken using the AMBER program. CPR:falsenewlineAccordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER were undertaken using the AMBER program. CPR:falsenewlineAccordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER were undertaken using the AMBER program. CPR:falsenewlineAccordingly, docking of different BC6ENTG inhibitors, including selective and non - selective ligands: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER were undertaken using the AMBER program. CPR:falsenewlineUtilizing agonist - stimulated BC6OTHER autoradiography, we analyzed the ability of BC6ENTG to stimulate BC6ENTC binding in adult rat brain. CPR:falsenewlineTaken together, these findings support the view that (1) BC6ENTG is the only BC6OTHER peptide that binds to and activates the BC6OTHER receptor and (2) BC6OTHER does not bind or stimulate BC6ENTC binding in cells expressing the BC6OTHER . CPR:falsenewlineTaken together, these findings support the view that (1) BC6OTHER is the only BC6ENTG peptide that binds to and activates the BC6OTHER receptor and (2) BC6OTHER does not bind or stimulate BC6ENTC binding in cells expressing the BC6OTHER . CPR:falsenewlineTaken together, these findings support the view that (1) BC6OTHER is the only BC6OTHER peptide that binds to and activates the BC6ENTG receptor and (2) BC6OTHER does not bind or stimulate BC6ENTC binding in cells expressing the BC6OTHER . CPR:falsenewlineTaken together, these findings support the view that (1) BC6OTHER is the only BC6OTHER peptide that binds to and activates the BC6OTHER receptor and (2) BC6ENTG does not bind or stimulate BC6ENTC binding in cells expressing the BC6OTHER . CPR:falsenewlineTaken together, these findings support the view that (1) BC6OTHER is the only BC6OTHER peptide that binds to and activates the BC6OTHER receptor and (2) BC6OTHER does not bind or stimulate BC6ENTC binding in cells expressing the BC6ENTG . CPR:falsenewlineBC6ENTG ( BC6OTHER ) stimulated BC6ENTC binding in a pattern similar to that described for [ BC6OTHER ] - BC6OTHER at the endogenous BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTG ) stimulated BC6ENTC binding in a pattern similar to that described for [ BC6OTHER ] - BC6OTHER at the endogenous BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) stimulated BC6ENTC binding in a pattern similar to that described for [ BC6OTHER ] - BC6ENTG at the endogenous BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) stimulated BC6ENTC binding in a pattern similar to that described for [ BC6OTHER ] - BC6OTHER at the endogenous BC6ENTG . CPR:falsenewlineBC6ENTG ( BC6OTHER ) stimulated BC6OTHER binding in a pattern similar to that described for [ BC6ENTC ] - BC6OTHER at the endogenous BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTG ) stimulated BC6OTHER binding in a pattern similar to that described for [ BC6ENTC ] - BC6OTHER at the endogenous BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) stimulated BC6OTHER binding in a pattern similar to that described for [ BC6ENTC ] - BC6ENTG at the endogenous BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) stimulated BC6OTHER binding in a pattern similar to that described for [ BC6ENTC ] - BC6OTHER at the endogenous BC6ENTG . CPR:falsenewlineUtilizing agonist - stimulated BC6ENTC autoradiography, we analyzed the ability of BC6ENTG to stimulate BC6OTHER binding in adult rat brain. CPR:falsenewlineUnlike BC6ENTG , high concentrations of its BC6ENTC - terminal extension, BC6OTHER , stimulated BC6OTHER binding in a BC6OTHER - like distribution and the effect was blocked by BC6OTHER . CPR:falsenewlineUnlike BC6OTHER , high concentrations of its BC6ENTC - terminal extension, BC6ENTG , stimulated BC6OTHER binding in a BC6OTHER - like distribution and the effect was blocked by BC6OTHER . CPR:falsenewlineUnlike BC6OTHER , high concentrations of its BC6ENTC - terminal extension, BC6OTHER , stimulated BC6OTHER binding in a BC6ENTG - like distribution and the effect was blocked by BC6OTHER . CPR:falsenewlineUnlike BC6ENTG , high concentrations of its BC6OTHER - terminal extension, BC6OTHER , stimulated BC6ENTC binding in a BC6OTHER - like distribution and the effect was blocked by BC6OTHER . CPR:falsenewlineUnlike BC6OTHER , high concentrations of its BC6OTHER - terminal extension, BC6ENTG , stimulated BC6ENTC binding in a BC6OTHER - like distribution and the effect was blocked by BC6OTHER . CPR:falsenewlineUnlike BC6OTHER , high concentrations of its BC6OTHER - terminal extension, BC6OTHER , stimulated BC6ENTC binding in a BC6ENTG - like distribution and the effect was blocked by BC6OTHER . CPR:falsenewlineUnlike BC6ENTG , high concentrations of its BC6OTHER - terminal extension, BC6OTHER , stimulated BC6OTHER binding in a BC6OTHER - like distribution and the effect was blocked by BC6ENTC . CPR:falsenewlineUnlike BC6OTHER , high concentrations of its BC6OTHER - terminal extension, BC6ENTG , stimulated BC6OTHER binding in a BC6OTHER - like distribution and the effect was blocked by BC6ENTC . CPR:falsenewlineUnlike BC6OTHER , high concentrations of its BC6OTHER - terminal extension, BC6OTHER , stimulated BC6OTHER binding in a BC6ENTG - like distribution and the effect was blocked by BC6ENTC . CPR:falsenewlineBinding and BC6ENTC autoradiographic analysis of BC6OTHER products at the BC6ENTG and BC6OTHER . CPR:falsenewlineBinding and BC6ENTC autoradiographic analysis of BC6OTHER products at the BC6OTHER and BC6ENTG . CPR:falsenewlineBinding and BC6ENTC autoradiographic analysis of BC6ENTG products at the BC6OTHER and BC6OTHER . CPR:falsenewlineWe provide evidence that defective BC6ENTC catabolism promotes the development of fasting hypoglycemia in BC6ENTG - / - mice by limiting gluconeogenic substrate availability. CPR:falsenewlineBC6ENTG - / - liver and skeletal muscle show markedly reduced mRNA expression of BC6ENTC - degrading enzymes. CPR:falsenewlineFurthermore, the enzymatic activity of BC6ENTC aminotransferase ( BC6ENTG ), which converts the critical gluconeogenic BC6OTHER BC6OTHER into BC6OTHER , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes. CPR:falsenewlineFurthermore, the enzymatic activity of BC6ENTC aminotransferase ( BC6OTHER ), which converts the critical gluconeogenic BC6OTHER BC6OTHER into BC6OTHER , is decreased (approximately 50%) in BC6ENTG - / - hepatocytes. CPR:falsenewlineFurthermore, the enzymatic activity of BC6ENTG ( BC6OTHER ), which converts the critical gluconeogenic BC6ENTC BC6OTHER into BC6OTHER , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes. CPR:9newlineFurthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6ENTG ), which converts the critical gluconeogenic BC6ENTC BC6OTHER into BC6OTHER , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes. CPR:falsenewlineFurthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6OTHER ), which converts the critical gluconeogenic BC6ENTC BC6OTHER into BC6OTHER , is decreased (approximately 50%) in BC6ENTG - / - hepatocytes. CPR:falsenewlineFurthermore, the enzymatic activity of BC6ENTG ( BC6OTHER ), which converts the critical gluconeogenic BC6OTHER BC6ENTC into BC6OTHER , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes. CPR:9newlineFurthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6ENTG ), which converts the critical gluconeogenic BC6OTHER BC6ENTC into BC6OTHER , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes. CPR:falsenewlineFurthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6OTHER ), which converts the critical gluconeogenic BC6OTHER BC6ENTC into BC6OTHER , is decreased (approximately 50%) in BC6ENTG - / - hepatocytes. CPR:falsenewlineFurthermore, the enzymatic activity of BC6ENTG ( BC6OTHER ), which converts the critical gluconeogenic BC6OTHER BC6OTHER into BC6ENTC , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes. CPR:9newlineFurthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6ENTG ), which converts the critical gluconeogenic BC6OTHER BC6OTHER into BC6ENTC , is decreased (approximately 50%) in BC6OTHER - / - hepatocytes. CPR:falsenewlineFurthermore, the enzymatic activity of BC6OTHER aminotransferase ( BC6OTHER ), which converts the critical gluconeogenic BC6OTHER BC6OTHER into BC6ENTC , is decreased (approximately 50%) in BC6ENTG - / - hepatocytes. CPR:falsenewlineConsistent with this observation, intraperitoneal injection of BC6ENTC , but not BC6OTHER , rescues fasting hypoglycemia in BC6ENTG - / - mice. CPR:falsenewlineConsistent with this observation, intraperitoneal injection of BC6OTHER , but not BC6ENTC , rescues fasting hypoglycemia in BC6ENTG - / - mice. CPR:falsenewlineThis was the first study to investigate platelet BC6ENTC binding in BC6OTHER - dependent and age - matched control subjects in relation to the BC6ENTG genotype. CPR:falsenewlineThis was the first study to investigate platelet BC6OTHER binding in BC6ENTC - dependent and age - matched control subjects in relation to the BC6ENTG genotype. CPR:falsenewlineNo differences concerning BC6ENTG - alleles were found in these groups Furthermore, no significant interaction between these parameters and impulsivity was shown in BC6ENTC - dependent subjects. CPR:falsenewlineThese results do not support previous results of altered BC6ENTC binding sites in CHEM - dependent subjects or BC6ENTG S - allele carriers. CPR:falsenewlineBC6ENTG S - genotype carriers in both BC6ENTC - dependent and control subjects were expected to show significantly fewer binding sites and a lower dissociation constant. CPR:falsenewlineThe aim of this study was to investigate BC6ENTC binding and impulsivity in BC6OTHER - dependent and age - matched control subjects in relation to a 5' - promoter region BC6ENTG ( BC6OTHER ) polymorphism ( BC6OTHER ). CPR:falsenewlineThe aim of this study was to investigate BC6ENTC binding and impulsivity in BC6OTHER - dependent and age - matched control subjects in relation to a 5' - promoter region BC6OTHER transporter ( BC6ENTG ) polymorphism ( BC6OTHER ). CPR:falsenewlineThe aim of this study was to investigate BC6ENTC binding and impulsivity in BC6OTHER - dependent and age - matched control subjects in relation to a 5' - promoter region BC6OTHER transporter ( BC6OTHER ) polymorphism ( BC6ENTG ). CPR:falsenewlineBlood samples were taken from both BC6OTHER - dependent and control subjects to determine BC6ENTG genotypes using PCR of lymphocyte DNA, and to perform platelet BC6ENTC binding (binding capacity: B(max); and dissociation constant: K(D)). CPR:falsenewlineThe aim of this study was to investigate BC6OTHER binding and impulsivity in BC6ENTC - dependent and age - matched control subjects in relation to a 5' - promoter region BC6ENTG ( BC6OTHER ) polymorphism ( BC6OTHER ). CPR:falsenewlineThe aim of this study was to investigate BC6OTHER binding and impulsivity in BC6ENTC - dependent and age - matched control subjects in relation to a 5' - promoter region BC6OTHER transporter ( BC6ENTG ) polymorphism ( BC6OTHER ). CPR:falsenewlineThe aim of this study was to investigate BC6OTHER binding and impulsivity in BC6ENTC - dependent and age - matched control subjects in relation to a 5' - promoter region BC6OTHER transporter ( BC6OTHER ) polymorphism ( BC6ENTG ). CPR:falsenewlineBlood samples were taken from both BC6ENTC - dependent and control subjects to determine BC6ENTG genotypes using PCR of lymphocyte DNA, and to perform platelet BC6OTHER binding (binding capacity: B(max); and dissociation constant: K(D)). CPR:falsenewline BC6ENTC transporter gene regulatory region polymorphism ( BC6ENTG ), BC6OTHER binding in healthy control subjects and CHEM - dependent patients and their relationships to impulsivity. CPR:falsenewline BC6ENTG gene regulatory region polymorphism ( BC6OTHER ), BC6ENTC binding in healthy control subjects and CHEM - dependent patients and their relationships to impulsivity. CPR:falsenewline BC6OTHER gene regulatory region polymorphism ( BC6ENTG ), BC6ENTC binding in healthy control subjects and CHEM - dependent patients and their relationships to impulsivity. CPR:falsenewlineThe aim of this study was to investigate BC6OTHER binding and impulsivity in BC6OTHER - dependent and age - matched control subjects in relation to a 5' - promoter region BC6ENTC transporter ( BC6ENTG ) polymorphism ( BC6OTHER ). CPR:falsenewlineThe aim of this study was to investigate BC6OTHER binding and impulsivity in BC6OTHER - dependent and age - matched control subjects in relation to a 5' - promoter region BC6ENTC transporter ( BC6OTHER ) polymorphism ( BC6ENTG ). CPR:falsenewlineNovel CHEM analogues as potent BC6ENTG inhibitors. CPR:falsenewlineFinally, BC6ENTC treatment caused a significant increase in the level of BC6ENTG . CPR:falsenewlineOur results show that BC6ENTC directly inhibits stomach BC6OTHER production and secretion through BC6ENTG . CPR:9newlineOur results show that BC6ENTC directly inhibits stomach BC6ENTG production and secretion through BC6OTHER . CPR:4newlineBC6ENTC treatment is also associated with lower circulating levels of the BC6ENTG BC6OTHER . CPR:falsenewlineBC6ENTC treatment is also associated with lower circulating levels of the BC6OTHER BC6ENTG . CPR:falsenewline BC6ENTC directly inhibits BC6ENTG secretion through BC6OTHER in rat primary gastric cells. CPR:4newline BC6ENTC directly inhibits BC6OTHER secretion through BC6ENTG in rat primary gastric cells. CPR:4newline BC6OTHER directly inhibits BC6ENTG secretion through BC6ENTC - activated protein kinase in rat primary gastric cells. CPR:falsenewlineTo test whether BC6ENTC directly affects BC6ENTG cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined. CPR:falsenewlineTo test whether BC6ENTC directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6ENTG secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined. CPR:falsenewlineTo test whether BC6ENTC directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6ENTG gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined. CPR:falsenewlineTo test whether BC6ENTC directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6ENTG ( BC6OTHER ) were examined. CPR:falsenewlineTo test whether BC6ENTC directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6ENTG ) were examined. CPR:falsenewlineTo test whether BC6OTHER directly affects BC6ENTG cells, rat primary stomach cells were treated with BC6ENTC and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined. CPR:falsenewlineTo test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6ENTC and the levels of BC6ENTG secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined. CPR:falsenewlineTo test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6ENTC and the levels of BC6OTHER secretion, BC6ENTG gene expression and activation of BC6OTHER - activated protein kinase ( BC6OTHER ) were examined. CPR:falsenewlineTo test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6ENTC and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6ENTG ( BC6OTHER ) were examined. CPR:falsenewlineTo test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6ENTC and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6OTHER - activated protein kinase ( BC6ENTG ) were examined. CPR:falsenewlineTo test whether BC6OTHER directly affects BC6ENTG cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6ENTC - activated protein kinase ( BC6OTHER ) were examined. CPR:falsenewlineTo test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6ENTG secretion, BC6OTHER gene expression and activation of BC6ENTC - activated protein kinase ( BC6OTHER ) were examined. CPR:falsenewlineTo test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6ENTG gene expression and activation of BC6ENTC - activated protein kinase ( BC6OTHER ) were examined. CPR:falsenewlineTo test whether BC6OTHER directly affects BC6OTHER cells, rat primary stomach cells were treated with BC6OTHER and the levels of BC6OTHER secretion, BC6OTHER gene expression and activation of BC6ENTC - activated protein kinase ( BC6ENTG ) were examined. CPR:falsenewlineBC6ENTC significantly reduced BC6ENTG secretion and BC6OTHER mRNA production and both these effects were blocked by co - incubation with the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineBC6ENTC significantly reduced BC6OTHER secretion and BC6ENTG mRNA production and both these effects were blocked by co - incubation with the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineBC6ENTC significantly reduced BC6OTHER secretion and BC6OTHER mRNA production and both these effects were blocked by co - incubation with the BC6ENTG inhibitor BC6OTHER . CPR:falsenewlineBC6OTHER significantly reduced BC6ENTG secretion and BC6OTHER mRNA production and both these effects were blocked by co - incubation with the BC6OTHER inhibitor BC6ENTC . CPR:falsenewlineBC6OTHER significantly reduced BC6OTHER secretion and BC6ENTG mRNA production and both these effects were blocked by co - incubation with the BC6OTHER inhibitor BC6ENTC . CPR:falsenewlineBC6OTHER significantly reduced BC6OTHER secretion and BC6OTHER mRNA production and both these effects were blocked by co - incubation with the BC6ENTG inhibitor BC6ENTC . CPR:falsenewlineFurthermore, the BC6ENTG activator BC6ENTC ( BC6OTHER ) significantly inhibited BC6OTHER secretion. CPR:falsenewlineFurthermore, the BC6OTHER activator BC6ENTC ( BC6OTHER ) significantly inhibited BC6ENTG secretion. CPR:falsenewlineFurthermore, the BC6ENTG activator BC6OTHER ( BC6ENTC ) significantly inhibited BC6OTHER secretion. CPR:falsenewlineFurthermore, the BC6OTHER activator BC6OTHER ( BC6ENTC ) significantly inhibited BC6ENTG secretion. CPR:falsenewlineAmong the various enzymes, BC6OTHER inhibitable cytosolic BC6ENTG ( BC6OTHER ) was shown to catalyse bioreductive activation of BC6ENTC leading to cross - linking of the DNA and cytotoxicity. CPR:falsenewlineAmong the various enzymes, BC6OTHER inhibitable cytosolic BC6OTHER : BC6OTHER oxidoreductase1 ( BC6ENTG ) was shown to catalyse bioreductive activation of BC6ENTC leading to cross - linking of the DNA and cytotoxicity. CPR:falsenewlineHowever, the role of BC6ENTG in metabolic activation of BC6ENTC has been disputed. CPR:falsenewlineIn this report, we present cellular and animal models to demonstrate that BC6ENTG may play only a minor role in metabolic activation of BC6ENTC . CPR:falsenewlineWe further demonstrate that bioreductive activation of BC6ENTC is catalysed by a unique cytosolic activity which is related but distinct from BC6ENTG . CPR:falsenewlineA unique cytosolic activity related but distinct from BC6ENTG catalyses metabolic activation of BC6ENTC . CPR:9newlineThe cytosolic fractions from liver and colon tissues of BC6ENTG - / - mice showed similar amounts of DNA cross - linking upon exposure to BC6ENTC , as observed in BC6OTHER + / + mice. CPR:falsenewlineThe cytosolic fractions from liver and colon tissues of BC6OTHER - / - mice showed similar amounts of DNA cross - linking upon exposure to BC6ENTC , as observed in BC6ENTG + / + mice. CPR:falsenewlineThe unique cytosolic activity that activated BC6ENTC in cytosolic fractions of liver and colon tissues of BC6ENTG - / - mice was designated as cytosolic BC6OTHER reductase. CPR:falsenewlineThe unique cytosolic activity that activated BC6ENTC in cytosolic fractions of liver and colon tissues of BC6OTHER - / - mice was designated as cytosolic BC6ENTG . CPR:falsenewlineAmong the various enzymes, BC6ENTC inhibitable cytosolic BC6ENTG ( BC6OTHER ) was shown to catalyse bioreductive activation of BC6OTHER leading to cross - linking of the DNA and cytotoxicity. CPR:falsenewlineAmong the various enzymes, BC6ENTC inhibitable cytosolic BC6OTHER : BC6OTHER oxidoreductase1 ( BC6ENTG ) was shown to catalyse bioreductive activation of BC6OTHER leading to cross - linking of the DNA and cytotoxicity. CPR:falsenewlineThe unique cytosolic activity that activated BC6OTHER in cytosolic fractions of liver and colon tissues of BC6ENTG - / - mice was designated as cytosolic BC6ENTC reductase. CPR:falsenewlineThis activity, like BC6ENTG , was inhibited by BC6ENTC and immunologically related to BC6OTHER . CPR:falsenewlineThis activity, like BC6OTHER , was inhibited by BC6ENTC and immunologically related to BC6ENTG . CPR:falsenewlineAmong the various enzymes, BC6OTHER inhibitable cytosolic BC6ENTC : BC6OTHER oxidoreductase1 ( BC6ENTG ) was shown to catalyse bioreductive activation of BC6OTHER leading to cross - linking of the DNA and cytotoxicity. CPR:falsenewlineAmong the various enzymes, BC6OTHER inhibitable cytosolic BC6OTHER : BC6ENTC oxidoreductase1 ( BC6ENTG ) was shown to catalyse bioreductive activation of BC6OTHER leading to cross - linking of the DNA and cytotoxicity. CPR:falsenewlineBy using pharmacological and genetic manipulation of BC6ENTG ( BC6OTHER ), we demonstrate that compartmentalized BC6OTHER and BC6OTHER are responsible for selectively modulating the concentration of BC6ENTC in individual subcellular compartments. CPR:falsenewlineBy using pharmacological and genetic manipulation of BC6OTHER ( BC6ENTG ), we demonstrate that compartmentalized BC6OTHER and BC6OTHER are responsible for selectively modulating the concentration of BC6ENTC in individual subcellular compartments. CPR:falsenewlineBy using pharmacological and genetic manipulation of BC6OTHER ( BC6OTHER ), we demonstrate that compartmentalized BC6ENTG and BC6OTHER are responsible for selectively modulating the concentration of BC6ENTC in individual subcellular compartments. CPR:falsenewlineBy using pharmacological and genetic manipulation of BC6OTHER ( BC6OTHER ), we demonstrate that compartmentalized BC6OTHER and BC6ENTG are responsible for selectively modulating the concentration of BC6ENTC in individual subcellular compartments. CPR:falsenewlineWe propose a model whereby compartmentalized BC6ENTG , rather than representing an enzymatic barrier to BC6ENTC diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different BC6OTHER concentrations irrespective of their distance from the site of BC6OTHER synthesis. CPR:falsenewlineWe propose a model whereby compartmentalized BC6ENTG , rather than representing an enzymatic barrier to BC6OTHER diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different BC6ENTC concentrations irrespective of their distance from the site of BC6OTHER synthesis. CPR:falsenewlineWe propose a model whereby compartmentalized BC6ENTG , rather than representing an enzymatic barrier to BC6OTHER diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different BC6OTHER concentrations irrespective of their distance from the site of BC6ENTC synthesis. CPR:falsenewlineSuch organization results in the local activation of BC6ENTG subsets through the generation of confined intracellular gradients of BC6ENTC , but the mechanisms responsible for limiting the diffusion of BC6OTHER largely remain to be clarified. CPR:falsenewlineSuch organization results in the local activation of BC6ENTG subsets through the generation of confined intracellular gradients of BC6OTHER , but the mechanisms responsible for limiting the diffusion of BC6ENTC largely remain to be clarified. CPR:falsenewlineThere is a growing appreciation that the BC6ENTC ( BC6OTHER ) - BC6ENTG ( BC6OTHER ) signaling pathway is organized to form transduction units that function to deliver specific messages. CPR:falsenewlineThere is a growing appreciation that the BC6ENTC ( BC6OTHER ) - BC6OTHER ( BC6ENTG ) signaling pathway is organized to form transduction units that function to deliver specific messages. CPR:falsenewlineThere is a growing appreciation that the BC6OTHER ( BC6ENTC ) - BC6ENTG ( BC6OTHER ) signaling pathway is organized to form transduction units that function to deliver specific messages. CPR:falsenewlineThere is a growing appreciation that the BC6OTHER ( BC6ENTC ) - BC6OTHER ( BC6ENTG ) signaling pathway is organized to form transduction units that function to deliver specific messages. CPR:falsenewlineIn BC6ENTC hydratase deficiency (mutations in BC6ENTG ), it derives from BC6OTHER degradation. CPR:falsenewlineIn BC6ENTG deficiency (mutations in BC6OTHER ), it derives from BC6ENTC degradation. CPR:falsenewlineIn BC6OTHER hydratase deficiency (mutations in BC6ENTG ), it derives from BC6ENTC degradation. CPR:falsenewlineIt had higher levels of BC6ENTC ( BC6OTHER ), a nutraceutical compound exerting actions against BC6ENTG and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIt had higher levels of BC6ENTC ( BC6OTHER ), a nutraceutical compound exerting actions against BC6OTHER and BC6ENTG ( BC6OTHER ). CPR:falsenewlineIt had higher levels of BC6ENTC ( BC6OTHER ), a nutraceutical compound exerting actions against BC6OTHER and BC6OTHER ( BC6ENTG ). CPR:falsenewlineIt had higher levels of BC6OTHER ( BC6ENTC ), a nutraceutical compound exerting actions against BC6ENTG and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIt had higher levels of BC6OTHER ( BC6ENTC ), a nutraceutical compound exerting actions against BC6OTHER and BC6ENTG ( BC6OTHER ). CPR:falsenewlineIt had higher levels of BC6OTHER ( BC6ENTC ), a nutraceutical compound exerting actions against BC6OTHER and BC6OTHER ( BC6ENTG ). CPR:falsenewlineIts head - space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the BC6ENTG ( BC6OTHER ) - pathway (one having as precursors the BC6ENTC containing a BC6OTHER system). CPR:falsenewlineIts head - space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the BC6OTHER ( BC6ENTG ) - pathway (one having as precursors the BC6ENTC containing a BC6OTHER system). CPR:falsenewlineIts head - space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the BC6ENTG ( BC6OTHER ) - pathway (one having as precursors the BC6OTHER containing a BC6ENTC system). CPR:falsenewlineIts head - space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the BC6OTHER ( BC6ENTG ) - pathway (one having as precursors the BC6OTHER containing a BC6ENTC system). CPR:falsenewlineWe demonstrate that activation of BC6ENTG BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation. CPR:falsenewlineWe demonstrate that activation of BC6OTHER BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6ENTG ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation. CPR:falsenewlineWe demonstrate that activation of BC6OTHER BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6OTHER ( BC6ENTG ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation. CPR:falsenewlineWe demonstrate that activation of BC6OTHER BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6ENTG is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation. CPR:falsenewlineWe demonstrate that activation of BC6OTHER BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6ENTG consensus - site for BC6OTHER - mediated activation. CPR:falsenewlineWe demonstrate that activation of BC6OTHER BC6ENTC - 727 and BC6OTHER - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6ENTG - mediated activation. CPR:falsenewlineWe demonstrate that activation of BC6ENTG BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation. CPR:falsenewlineWe demonstrate that activation of BC6OTHER BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6ENTG ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation. CPR:falsenewlineWe demonstrate that activation of BC6OTHER BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6OTHER ( BC6ENTG ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation. CPR:falsenewlineWe demonstrate that activation of BC6OTHER BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6ENTG is dependent on a BC6OTHER consensus - site for BC6OTHER - mediated activation. CPR:falsenewlineWe demonstrate that activation of BC6OTHER BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6ENTG consensus - site for BC6OTHER - mediated activation. CPR:falsenewlineWe demonstrate that activation of BC6OTHER BC6OTHER - 727 and BC6ENTC - 705 phosphorylations is promoted by BC6OTHER ( BC6OTHER ) activity and that the BC6OTHER is dependent on a BC6OTHER consensus - site for BC6ENTG - mediated activation. CPR:falsenewlineAlleles of BC6ENTG ( BC6OTHER ) with elevated slippage rates were identified among BC6ENTC - sensitive mutants and were also isolated using a slippage - dependent reporter gene. CPR:falsenewlineAlleles of BC6OTHER ( BC6ENTG ) with elevated slippage rates were identified among BC6ENTC - sensitive mutants and were also isolated using a slippage - dependent reporter gene. CPR:falsenewlineBC6ENTC receptors in postmortem human spinal cord were analyzed using BC6OTHER ligand binding and immunoblotting with BC6ENTG subunit - specific antibodies. CPR:falsenewlineBC6ENTG in postmortem human spinal cord were analyzed using BC6OTHER ligand binding and immunoblotting with BC6ENTC receptor subunit - specific antibodies. CPR:falsenewlineNone of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native BC6ENTC receptors showed that BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER subunits could all be found in the human spinal cord of which BC6OTHER was preferentially located to the dorsal half. CPR:falsenewlineNone of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native BC6ENTC receptors showed that BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER subunits could all be found in the human spinal cord of which BC6OTHER was preferentially located to the dorsal half. CPR:falsenewlineNone of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native BC6ENTC receptors showed that BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER subunits could all be found in the human spinal cord of which BC6OTHER was preferentially located to the dorsal half. CPR:falsenewlineNone of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native BC6ENTC receptors showed that BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG subunits could all be found in the human spinal cord of which BC6OTHER was preferentially located to the dorsal half. CPR:falsenewlineNone of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native BC6ENTC receptors showed that BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER subunits could all be found in the human spinal cord of which BC6ENTG was preferentially located to the dorsal half. CPR:falsenewlineBC6ENTG in postmortem human spinal cord were analyzed using BC6ENTC ligand binding and immunoblotting with BC6OTHER receptor subunit - specific antibodies. CPR:falsenewlineBC6OTHER receptors in postmortem human spinal cord were analyzed using BC6ENTC ligand binding and immunoblotting with BC6ENTG subunit - specific antibodies. CPR:falsenewlineImmunoprecipitation of solubilized receptors revealed that BC6ENTG , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6ENTC receptors are BC6OTHER receptors assembled by at least three different receptor subunits. CPR:falsenewlineImmunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6ENTG , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6ENTC receptors are BC6OTHER receptors assembled by at least three different receptor subunits. CPR:falsenewlineImmunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6ENTG subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6ENTC receptors are BC6OTHER receptors assembled by at least three different receptor subunits. CPR:falsenewlineImmunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6ENTG subunit, indicating that native human spinal cord BC6ENTC receptors are BC6OTHER receptors assembled by at least three different receptor subunits. CPR:falsenewlineImmunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6ENTC receptors are BC6ENTG assembled by at least three different receptor subunits. CPR:falsenewlineImmunoprecipitation of solubilized receptors revealed that BC6ENTG , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6OTHER receptors are BC6ENTC receptors assembled by at least three different receptor subunits. CPR:falsenewlineImmunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6ENTG , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6OTHER receptors are BC6ENTC receptors assembled by at least three different receptor subunits. CPR:falsenewlineImmunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6ENTG subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6OTHER receptors are BC6ENTC receptors assembled by at least three different receptor subunits. CPR:falsenewlineImmunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6ENTG subunit, indicating that native human spinal cord BC6OTHER receptors are BC6ENTC receptors assembled by at least three different receptor subunits. CPR:falsenewlineImmunoprecipitation of solubilized receptors revealed that BC6OTHER , BC6OTHER , and BC6OTHER subunits coprecipitated with the BC6OTHER subunit, indicating that native human spinal cord BC6ENTG are BC6ENTC receptors assembled by at least three different receptor subunits. CPR:falsenewlineThus, the formation of BC6ENTC bonds in BC6ENTG is a potentially important reversible mechanism for alterations in the rates of sulfation of both endogenous and xenobiotic substrates. CPR:falsenewlineWe have examined the hypothesis that the formation of BC6ENTC bonds in BC6ENTG can reversibly regulate the catalytic function of the enzyme. CPR:falsenewlineThree BC6ENTC oxidants were used as model compounds to investigate their effects on homogeneous preparations of BC6ENTG : BC6OTHER , BC6OTHER , and BC6OTHER ) ( BC6OTHER ). CPR:falsenewlineThree BC6OTHER oxidants were used as model compounds to investigate their effects on homogeneous preparations of BC6ENTG : BC6ENTC , BC6OTHER , and BC6OTHER ) ( BC6OTHER ). CPR:falsenewlineThree BC6OTHER oxidants were used as model compounds to investigate their effects on homogeneous preparations of BC6ENTG : BC6OTHER , BC6ENTC , and BC6OTHER ) ( BC6OTHER ). CPR:falsenewlineThree BC6OTHER oxidants were used as model compounds to investigate their effects on homogeneous preparations of BC6ENTG : BC6OTHER , BC6OTHER , and BC6ENTC ) ( BC6OTHER ). CPR:falsenewlineThree BC6OTHER oxidants were used as model compounds to investigate their effects on homogeneous preparations of BC6ENTG : BC6OTHER , BC6OTHER , and BC6OTHER ) ( BC6ENTC ). CPR:falsenewlineStudies on the kinetics of the BC6ENTG - catalyzed sulfation of BC6ENTC ( BC6OTHER ) showed the effects of BC6OTHER bond formation on the substrate inhibition characteristics of the enzyme. CPR:9newlineModification of the Catalytic Function of BC6ENTG by Formation of BC6ENTC Bonds. CPR:falsenewlineStudies on the kinetics of the BC6ENTG - catalyzed sulfation of BC6OTHER ( BC6ENTC ) showed the effects of BC6OTHER bond formation on the substrate inhibition characteristics of the enzyme. CPR:9newlineStudies on the kinetics of the BC6ENTG - catalyzed sulfation of BC6OTHER ( BC6OTHER ) showed the effects of BC6ENTC bond formation on the substrate inhibition characteristics of the enzyme. CPR:falsenewlineThe BC6ENTG catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous BC6ENTC and BC6OTHER . CPR:9newlineThe BC6ENTG catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous BC6OTHER and BC6ENTC . CPR:9newlineBC6OTHER ( BC6OTHER , BC6OTHER ) is a small molecule BC6ENTG inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6ENTC kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6ENTC kinases from the BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6ENTC kinases from the BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6ENTC kinases from the BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6ENTC kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) families. CPR:falsenewlineWe investigated the efficacy of BC6ENTC at inhibiting mutants of the BC6ENTG BC6OTHER , BC6OTHER , and BC6OTHER , which are implicated in the pathogenesis of myeloid malignancies. CPR:falsenewlineWe investigated the efficacy of BC6ENTC at inhibiting mutants of the receptor BC6OTHER kinases BC6ENTG , BC6OTHER , and BC6OTHER , which are implicated in the pathogenesis of myeloid malignancies. CPR:falsenewlineWe investigated the efficacy of BC6ENTC at inhibiting mutants of the receptor BC6OTHER kinases BC6OTHER , BC6ENTG , and BC6OTHER , which are implicated in the pathogenesis of myeloid malignancies. CPR:falsenewlineWe investigated the efficacy of BC6ENTC at inhibiting mutants of the receptor BC6OTHER kinases BC6OTHER , BC6OTHER , and BC6ENTG , which are implicated in the pathogenesis of myeloid malignancies. CPR:falsenewlineWe investigated the efficacy of BC6OTHER at inhibiting mutants of the receptor BC6ENTC kinases BC6ENTG , BC6OTHER , and BC6OTHER , which are implicated in the pathogenesis of myeloid malignancies. CPR:falsenewlineWe investigated the efficacy of BC6OTHER at inhibiting mutants of the receptor BC6ENTC kinases BC6OTHER , BC6ENTG , and BC6OTHER , which are implicated in the pathogenesis of myeloid malignancies. CPR:falsenewlineWe investigated the efficacy of BC6OTHER at inhibiting mutants of the receptor BC6ENTC kinases BC6OTHER , BC6OTHER , and BC6ENTG , which are implicated in the pathogenesis of myeloid malignancies. CPR:falsenewlineDESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6ENTG - BC6OTHER , BC6OTHER with an internal tandem duplication or BC6OTHER point mutation, and the BC6OTHER ( BC6OTHER ) mutant. CPR:falsenewlineDESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6OTHER - BC6ENTG , BC6OTHER with an internal tandem duplication or BC6OTHER point mutation, and the BC6OTHER ( BC6OTHER ) mutant. CPR:falsenewlineDESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6OTHER - BC6OTHER , BC6ENTG with an internal tandem duplication or BC6OTHER point mutation, and the BC6OTHER ( BC6OTHER ) mutant. CPR:falsenewlineDESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6OTHER - BC6OTHER , BC6OTHER with an internal tandem duplication or BC6ENTG point mutation, and the BC6OTHER ( BC6OTHER ) mutant. CPR:falsenewlineDESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6OTHER - BC6OTHER , BC6OTHER with an internal tandem duplication or BC6OTHER point mutation, and the BC6ENTG ( BC6OTHER ) mutant. CPR:falsenewlineDESIGN AND METHODS: We tested the effect of BC6ENTC on the proliferation of hematopoietic cells transformed by BC6OTHER - BC6OTHER , BC6OTHER with an internal tandem duplication or BC6OTHER point mutation, and the BC6OTHER ( BC6ENTG ) mutant. CPR:falsenewlineThe direct effect of BC6ENTC on the activity of these BC6ENTG and their downstream signaling was tested using BC6OTHER - specific antibodies. CPR:falsenewlineThe ability of BC6ENTC to inhibit oncogenic BC6ENTG and BC6OTHER mutants and overcome resistance to other small molecule inhibitors. CPR:falsenewlineThe ability of BC6ENTC to inhibit oncogenic BC6OTHER and BC6ENTG mutants and overcome resistance to other small molecule inhibitors. CPR:falsenewlineThe direct effect of BC6OTHER on the activity of these BC6ENTG and their downstream signaling was tested using BC6ENTC - specific antibodies. CPR:falsenewlineRESULTS: We show that BC6ENTC is a potent inhibitor of BC6ENTG - BC6OTHER and BC6OTHER mutants, including some of the mutants that confer resistance to PKC412 and other BC6OTHER inhibitors. CPR:4newlineRESULTS: We show that BC6ENTC is a potent inhibitor of BC6OTHER - BC6ENTG and BC6OTHER mutants, including some of the mutants that confer resistance to PKC412 and other BC6OTHER inhibitors. CPR:4newlineRESULTS: We show that BC6ENTC is a potent inhibitor of BC6OTHER - BC6OTHER and BC6ENTG mutants, including some of the mutants that confer resistance to PKC412 and other BC6OTHER inhibitors. CPR:4newlineRESULTS: We show that BC6ENTC is a potent inhibitor of BC6OTHER - BC6OTHER and BC6OTHER mutants, including some of the mutants that confer resistance to PKC412 and other BC6ENTG inhibitors. CPR:falsenewlineBC6ENTC induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4 - 11 and MOLM - 13, both expressing BC6ENTG with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines. CPR:falsenewlineThe BC6ENTC - resistant BC6ENTG ( BC6OTHER ) mutant, associated with systemic mastocytosis, was found to be resistant to BC6OTHER . CPR:falsenewlineThe BC6ENTC - resistant BC6OTHER ( BC6ENTG ) mutant, associated with systemic mastocytosis, was found to be resistant to BC6OTHER . CPR:falsenewlineThe BC6OTHER - resistant BC6ENTG ( BC6OTHER ) mutant, associated with systemic mastocytosis, was found to be resistant to BC6ENTC . CPR:falsenewlineThe BC6OTHER - resistant BC6OTHER ( BC6ENTG ) mutant, associated with systemic mastocytosis, was found to be resistant to BC6ENTC . CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6ENTG inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families. CPR:4newlineBC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against BC6ENTG from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) families. CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) families. CPR:falsenewlineINTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of BC6ENTC for the treatment of myeloid malignancies expressing activated forms of BC6ENTG and BC6OTHER . CPR:falsenewlineINTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of BC6ENTC for the treatment of myeloid malignancies expressing activated forms of BC6OTHER and BC6ENTG . CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6ENTG inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against BC6ENTG from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) families. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6ENTG inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against BC6ENTG from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) families. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) is a small molecule BC6OTHER inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor BC6OTHER kinases from the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) families. CPR:falsenewlineIt is a state of relative water excess due to stimulated BC6ENTG ( BC6ENTC ) and fluid intake greater than obligatory losses. CPR:falsenewlineHowever, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER . CPR:falsenewlineHowever, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER . CPR:falsenewlineHowever, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER . CPR:falsenewlineHowever, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER . CPR:falsenewlineHowever, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and BC6OTHER . CPR:falsenewlineHowever, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER . CPR:falsenewlineHowever, several promising nonpeptide, BC6ENTG antagonists have been described; these agents are BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC . CPR:falsenewlineIt is a state of relative water excess due to stimulated BC6ENTC ( BC6ENTG ) and fluid intake greater than obligatory losses. CPR:falsenewlineA series of BC6ENTC , designed as mimics of a cationic high energy intermediate in the BC6OTHER cyclase(1) ( BC6ENTG ) - mediated cyclization of BC6OTHER to BC6OTHER was prepared from BC6OTHER . CPR:falsenewlineA series of BC6ENTC , designed as mimics of a cationic high energy intermediate in the BC6ENTG ( BC6OTHER ) - mediated cyclization of BC6OTHER to BC6OTHER was prepared from BC6OTHER . CPR:falsenewlineA series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6OTHER cyclase(1) ( BC6ENTG ) - mediated cyclization of BC6ENTC to BC6OTHER was prepared from BC6OTHER . CPR:falsenewlineA series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6ENTG ( BC6OTHER ) - mediated cyclization of BC6ENTC to BC6OTHER was prepared from BC6OTHER . CPR:falsenewlineA series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6OTHER cyclase(1) ( BC6ENTG ) - mediated cyclization of BC6OTHER to BC6ENTC was prepared from BC6OTHER . CPR:falsenewlineA series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6ENTG ( BC6OTHER ) - mediated cyclization of BC6OTHER to BC6ENTC was prepared from BC6OTHER . CPR:falsenewlineA series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6OTHER cyclase(1) ( BC6ENTG ) - mediated cyclization of BC6OTHER to BC6OTHER was prepared from BC6ENTC . CPR:falsenewlineA series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6ENTG ( BC6OTHER ) - mediated cyclization of BC6OTHER to BC6OTHER was prepared from BC6ENTC . CPR:falsenewlineA BC6ENTC derivative showed promising inhibition of BC6ENTG in combination with low cytotoxicity, and showed significant reduction of BC6OTHER biosynthesis in a human cell line. CPR:4newlineA BC6OTHER derivative showed promising inhibition of BC6ENTG in combination with low cytotoxicity, and showed significant reduction of BC6ENTC biosynthesis in a human cell line. CPR:falsenewlineA series of BC6OTHER , designed as mimics of a cationic high energy intermediate in the BC6ENTC cyclase(1) ( BC6ENTG ) - mediated cyclization of BC6OTHER to BC6OTHER was prepared from BC6OTHER . CPR:falsenewline BC6ENTC derived from BC6OTHER as a novel chemotype of BC6ENTG inhibitors. CPR:falsenewline BC6OTHER derived from BC6ENTC as a novel chemotype of BC6ENTG inhibitors. CPR:falsenewlineA series of substituted BC6ENTC has been synthesised and tested in vitro as potential pro - apoptotic BC6ENTG - inhibitory anticancer agents. CPR:4newlineActive compounds, such as the BC6ENTC analogue 6c, were found to exhibit sub - micromolar IC50 values in BC6ENTG expressing human cancer cell lines. CPR:falsenewlineSynthesis and evaluation of BC6ENTC as BC6ENTG inhibitory anticancer agents. CPR:4newlineThe development of specific BC6ENTG inhibitors and further experience with the dual enzyme inhibitor BC6ENTC will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options. CPR:falsenewlineBC6OTHER ( BC6ENTG ) predominates in the healthy brain, with BC6OTHER ( BC6OTHER ) considered to play a minor role in regulating brain BC6ENTC ( BC6OTHER ) levels. CPR:falsenewlineBC6OTHER ( BC6OTHER ) predominates in the healthy brain, with BC6ENTG ( BC6OTHER ) considered to play a minor role in regulating brain BC6ENTC ( BC6OTHER ) levels. CPR:falsenewlineBC6OTHER ( BC6OTHER ) predominates in the healthy brain, with BC6OTHER ( BC6ENTG ) considered to play a minor role in regulating brain BC6ENTC ( BC6OTHER ) levels. CPR:falsenewlineBC6ENTG ( BC6OTHER ) predominates in the healthy brain, with BC6OTHER ( BC6OTHER ) considered to play a minor role in regulating brain BC6ENTC ( BC6OTHER ) levels. CPR:falsenewlineBC6OTHER ( BC6ENTG ) predominates in the healthy brain, with BC6OTHER ( BC6OTHER ) considered to play a minor role in regulating brain BC6OTHER ( BC6ENTC ) levels. CPR:falsenewlineBC6OTHER ( BC6OTHER ) predominates in the healthy brain, with BC6ENTG ( BC6OTHER ) considered to play a minor role in regulating brain BC6OTHER ( BC6ENTC ) levels. CPR:falsenewlineBC6OTHER ( BC6OTHER ) predominates in the healthy brain, with BC6OTHER ( BC6ENTG ) considered to play a minor role in regulating brain BC6OTHER ( BC6ENTC ) levels. CPR:falsenewlineBC6ENTG ( BC6OTHER ) predominates in the healthy brain, with BC6OTHER ( BC6OTHER ) considered to play a minor role in regulating brain BC6OTHER ( BC6ENTC ) levels. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6ENTG ( BC6ENTC analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6ENTC analogues, BC6OTHER ) and the dual inhibitor of both BC6ENTG and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6ENTC analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6ENTG , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6ENTC analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6ENTG and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6ENTC analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6ENTG in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6ENTG ( BC6OTHER analogues, BC6ENTC ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6ENTC ) and the dual inhibitor of both BC6ENTG and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6ENTC ) and the dual inhibitor of both BC6OTHER and BC6ENTG , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6ENTC ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6ENTG and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6ENTC ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6OTHER , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6ENTG in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6ENTG ( BC6OTHER analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6ENTC , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6OTHER ) and the dual inhibitor of both BC6ENTG and BC6OTHER , BC6ENTC , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6ENTG , BC6ENTC , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6ENTC , indicates potential therapeutic benefits of inhibiting both BC6ENTG and BC6OTHER in AD and related dementias. CPR:falsenewlineExperimental evidence from the use of agents with enhanced selectivity for BC6OTHER ( BC6OTHER analogues, BC6OTHER ) and the dual inhibitor of both BC6OTHER and BC6OTHER , BC6ENTC , indicates potential therapeutic benefits of inhibiting both BC6OTHER and BC6ENTG in AD and related dementias. CPR:falsenewlineThe discovery of a BC6OTHER ( BC6OTHER ) led to the search for compounds that could selectively inhibit BC6ENTG in humans while sparing BC6ENTC formation from BC6OTHER . CPR:falsenewlineThe discovery of a BC6OTHER ( BC6OTHER ) led to the search for compounds that could selectively inhibit BC6OTHER in humans while sparing BC6ENTC formation from BC6ENTG . CPR:falsenewlineThe discovery of a BC6ENTG ( BC6OTHER ) led to the search for compounds that could selectively inhibit BC6OTHER in humans while sparing BC6ENTC formation from BC6OTHER . CPR:falsenewlineThe discovery of a BC6OTHER ( BC6ENTG ) led to the search for compounds that could selectively inhibit BC6OTHER in humans while sparing BC6ENTC formation from BC6OTHER . CPR:falsenewlineWe report here the pharmacological properties of a third selective BC6ENTG inhibitor, BC6ENTC , which is the most potent and in vitro selective of the marketed BC6OTHER inhibitors that we have studied. CPR:4newlineWe report here the pharmacological properties of a third selective BC6OTHER inhibitor, BC6ENTC , which is the most potent and in vitro selective of the marketed BC6ENTG inhibitors that we have studied. CPR:falsenewlineBC6ENTC potently inhibits recombinant BC6ENTG , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for BC6OTHER , 0.5 microM for BC6OTHER , and 5 microM for BC6OTHER . CPR:4newlineBC6OTHER potently inhibits recombinant BC6ENTG , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for BC6ENTC , 0.5 microM for BC6OTHER , and 5 microM for BC6OTHER . CPR:falsenewlineBC6OTHER potently inhibits recombinant BC6ENTG , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for BC6OTHER , 0.5 microM for BC6ENTC , and 5 microM for BC6OTHER . CPR:falsenewlineBC6OTHER potently inhibits recombinant BC6ENTG , with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for BC6OTHER , 0.5 microM for BC6OTHER , and 5 microM for BC6ENTC . CPR:falsenewlineUnique binding interactions of BC6OTHER with BC6ENTG translate into a fast rate of inactivation of BC6OTHER (110,000 M / s compared with 7000 M / s for BC6ENTC and 80 M / s for BC6OTHER ). CPR:falsenewlineUnique binding interactions of BC6OTHER with BC6OTHER translate into a fast rate of inactivation of BC6ENTG (110,000 M / s compared with 7000 M / s for BC6ENTC and 80 M / s for BC6OTHER ). CPR:falsenewlineUnique binding interactions of BC6ENTC with BC6ENTG translate into a fast rate of inactivation of BC6OTHER (110,000 M / s compared with 7000 M / s for BC6OTHER and 80 M / s for BC6OTHER ). CPR:falsenewlineUnique binding interactions of BC6ENTC with BC6OTHER translate into a fast rate of inactivation of BC6ENTG (110,000 M / s compared with 7000 M / s for BC6OTHER and 80 M / s for BC6OTHER ). CPR:falsenewline BC6ENTC : assessment of BC6ENTG potency and selectivity. CPR:falsenewlineUnique binding interactions of BC6OTHER with BC6ENTG translate into a fast rate of inactivation of BC6OTHER (110,000 M / s compared with 7000 M / s for BC6OTHER and 80 M / s for BC6ENTC ). CPR:falsenewlineUnique binding interactions of BC6OTHER with BC6OTHER translate into a fast rate of inactivation of BC6ENTG (110,000 M / s compared with 7000 M / s for BC6OTHER and 80 M / s for BC6ENTC ). CPR:falsenewlineThe overall saturation binding affinity for BC6ENTG of BC6ENTC is 2.6 nM (compared with 1.6 nM for BC6OTHER , 51 nM for BC6OTHER , and 260 nM for BC6OTHER ), with a slow off - rate (t(1 / 2) approximately 98 min). CPR:falsenewlineThe overall saturation binding affinity for BC6ENTG of BC6OTHER is 2.6 nM (compared with 1.6 nM for BC6ENTC , 51 nM for BC6OTHER , and 260 nM for BC6OTHER ), with a slow off - rate (t(1 / 2) approximately 98 min). CPR:falsenewlineThe overall saturation binding affinity for BC6ENTG of BC6OTHER is 2.6 nM (compared with 1.6 nM for BC6OTHER , 51 nM for BC6ENTC , and 260 nM for BC6OTHER ), with a slow off - rate (t(1 / 2) approximately 98 min). CPR:falsenewlineThe overall saturation binding affinity for BC6ENTG of BC6OTHER is 2.6 nM (compared with 1.6 nM for BC6OTHER , 51 nM for BC6OTHER , and 260 nM for BC6ENTC ), with a slow off - rate (t(1 / 2) approximately 98 min). CPR:falsenewlineBC6ENTC inhibits BC6ENTG in a competitive fashion only at very high concentrations (IC(50) = 150 microM). CPR:4newlineCollectively, these data provide a mechanistic basis for the potency and in vitro selectivity of BC6ENTC for BC6ENTG . CPR:falsenewlineBC6ENTC showed similar activity in the BC6ENTG assay ( BC6OTHER IC(50) = 0.24 microM; BC6OTHER IC(50) = 21.9 microM). CPR:falsenewlineBC6ENTC showed similar activity in the BC6OTHER assay ( BC6ENTG IC(50) = 0.24 microM; BC6OTHER IC(50) = 21.9 microM). CPR:falsenewlineBC6ENTC showed similar activity in the BC6OTHER assay ( BC6OTHER IC(50) = 0.24 microM; BC6ENTG IC(50) = 21.9 microM). CPR:falsenewlineThese characteristics of the bound BC6ENTC suggest that BC6ENTG catalysis is not facilitated by forming the resonance - stabilized structure of the BC6OTHER as seen in BC6OTHER . CPR:falsenewlineThese characteristics of the bound BC6ENTC suggest that BC6OTHER catalysis is not facilitated by forming the resonance - stabilized structure of the BC6OTHER as seen in BC6ENTG . CPR:falsenewlineThese characteristics of the bound BC6OTHER suggest that BC6ENTG catalysis is not facilitated by forming the resonance - stabilized structure of the BC6ENTC as seen in BC6OTHER . CPR:falsenewlineThese characteristics of the bound BC6OTHER suggest that BC6OTHER catalysis is not facilitated by forming the resonance - stabilized structure of the BC6ENTC as seen in BC6ENTG . CPR:falsenewlineBC6ENTG ( BC6OTHER dehydratase, BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6ENTC to yield BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER dehydratase, BC6ENTG ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6ENTC to yield BC6OTHER and BC6OTHER . CPR:9newlineBC6OTHER BC6ENTG , BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6ENTC to yield BC6OTHER and BC6OTHER . CPR:9newlineFormation of BC6ENTC by BC6ENTG is a two - step reaction in which the BC6OTHER group of BC6OTHER is cleaved to produce BC6OTHER , and then the BC6OTHER is deaminated by nonenzymatic hydrolysis to produce BC6OTHER . CPR:9newlineFormation of BC6OTHER by BC6ENTG is a two - step reaction in which the BC6ENTC group of BC6OTHER is cleaved to produce BC6OTHER , and then the BC6OTHER is deaminated by nonenzymatic hydrolysis to produce BC6OTHER . CPR:9newlineFormation of BC6OTHER by BC6ENTG is a two - step reaction in which the BC6OTHER group of BC6ENTC is cleaved to produce BC6OTHER , and then the BC6OTHER is deaminated by nonenzymatic hydrolysis to produce BC6OTHER . CPR:falsenewlineFormation of BC6OTHER by BC6ENTG is a two - step reaction in which the BC6OTHER group of BC6OTHER is cleaved to produce BC6ENTC , and then the BC6OTHER is deaminated by nonenzymatic hydrolysis to produce BC6OTHER . CPR:falsenewlineFormation of BC6OTHER by BC6ENTG is a two - step reaction in which the BC6OTHER group of BC6OTHER is cleaved to produce BC6OTHER , and then the BC6ENTC is deaminated by nonenzymatic hydrolysis to produce BC6OTHER . CPR:falsenewlineFormation of BC6OTHER by BC6ENTG is a two - step reaction in which the BC6OTHER group of BC6OTHER is cleaved to produce BC6OTHER , and then the BC6OTHER is deaminated by nonenzymatic hydrolysis to produce BC6ENTC . CPR:falsenewlineBC6ENTG ( BC6ENTC dehydratase, BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTC dehydratase, BC6ENTG ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER . CPR:falsenewlineBC6ENTG ( BC6OTHER dehydratase, BC6OTHER ) catalyzes the BC6ENTC ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER dehydratase, BC6ENTG ) catalyzes the BC6ENTC ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER BC6ENTG , BC6OTHER ) catalyzes the BC6ENTC ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER . CPR:9newlineThe BC6ENTG crystallized with BC6ENTC ( BC6OTHER ) was also determined at 2.6 A resolution by molecular replacement. CPR:falsenewlineBC6ENTG ( BC6OTHER dehydratase, BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6ENTC and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER dehydratase, BC6ENTG ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6ENTC and BC6OTHER . CPR:falsenewlineBC6OTHER BC6ENTG , BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6ENTC and BC6OTHER . CPR:9newlineThe BC6ENTG crystallized with BC6OTHER ( BC6ENTC ) was also determined at 2.6 A resolution by molecular replacement. CPR:falsenewlineBC6ENTG ( BC6OTHER dehydratase, BC6OTHER ) catalyzes the BC6OTHER ( BC6ENTC ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER dehydratase, BC6ENTG ) catalyzes the BC6OTHER ( BC6ENTC ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER BC6ENTG , BC6OTHER ) catalyzes the BC6OTHER ( BC6ENTC ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6OTHER . CPR:9newlineThe BC6ENTG contained CHEM - OMS BC6ENTC in the active site, indicating that BC6OTHER can form the BC6OTHER linkage with BC6OTHER , but the subsequent dehydration did not occur. CPR:falsenewlineThe BC6ENTG contained CHEM - OMS BC6OTHER in the active site, indicating that BC6ENTC can form the BC6OTHER linkage with BC6OTHER , but the subsequent dehydration did not occur. CPR:falsenewlineThe BC6ENTG contained CHEM - OMS BC6OTHER in the active site, indicating that BC6OTHER can form the BC6ENTC linkage with BC6OTHER , but the subsequent dehydration did not occur. CPR:falsenewlineThe BC6ENTG contained CHEM - OMS BC6OTHER in the active site, indicating that BC6OTHER can form the BC6OTHER linkage with BC6ENTC , but the subsequent dehydration did not occur. CPR:falsenewlineThe CHEM group of BC6ENTC is surrounded by a characteristic BC6ENTG ((168) BC6OTHER (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated. CPR:falsenewlineThe CHEM group of BC6ENTC is surrounded by a characteristic BC6OTHER ((168) BC6ENTG (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated. CPR:falsenewlineThe CHEM group of BC6OTHER is surrounded by a characteristic BC6ENTG ((168) BC6ENTC (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated. CPR:falsenewlineThe CHEM group of BC6OTHER is surrounded by a characteristic BC6ENTG ((168) BC6OTHER (172)) and forms BC6ENTC bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated. CPR:falsenewlineThe CHEM group of BC6OTHER is surrounded by a characteristic BC6OTHER ((168) BC6ENTG (172)) and forms BC6ENTC bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated. CPR:falsenewlineThe CHEM group of BC6OTHER is surrounded by a characteristic BC6ENTG ((168) BC6OTHER (172)) and forms BC6OTHER bonds with the BC6ENTC groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated. CPR:falsenewlineThe CHEM group of BC6OTHER is surrounded by a characteristic BC6OTHER ((168) BC6ENTG (172)) and forms BC6OTHER bonds with the BC6ENTC groups of those BC6OTHER residues, suggesting that the BC6OTHER group can be protonated. CPR:falsenewlineThe CHEM group of BC6OTHER is surrounded by a characteristic BC6ENTG ((168) BC6OTHER (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6ENTC residues, suggesting that the BC6OTHER group can be protonated. CPR:falsenewlineThe CHEM group of BC6OTHER is surrounded by a characteristic BC6OTHER ((168) BC6ENTG (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6ENTC residues, suggesting that the BC6OTHER group can be protonated. CPR:falsenewlineBC6ENTG ( BC6OTHER dehydratase, BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6ENTC . CPR:falsenewlineBC6OTHER ( BC6OTHER dehydratase, BC6ENTG ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6ENTC . CPR:9newlineBC6OTHER BC6ENTG , BC6OTHER ) catalyzes the BC6OTHER ( BC6OTHER ) - dependent dehydration of BC6OTHER to yield BC6OTHER and BC6ENTC . CPR:9newlineThe CHEM group of BC6OTHER is surrounded by a characteristic BC6ENTG ((168) BC6OTHER (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6ENTC group can be protonated. CPR:falsenewlineThe CHEM group of BC6OTHER is surrounded by a characteristic BC6OTHER ((168) BC6ENTG (172)) and forms BC6OTHER bonds with the BC6OTHER groups of those BC6OTHER residues, suggesting that the BC6ENTC group can be protonated. CPR:falsenewlineIn addition, BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineIn addition, BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineIn addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineIn addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineIn addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineIn addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineIn addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineA total of 68 chemicals including derivatives of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were examined for their abilities to interact with BC6ENTG . CPR:falsenewlineIn addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineIn addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineIn addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineIn addition, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineA total of 68 chemicals including derivatives of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER were examined for their abilities to interact with BC6ENTG . CPR:falsenewlineBC6ENTC 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:9newlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineA total of 68 chemicals including derivatives of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER were examined for their abilities to interact with BC6ENTG . CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineA total of 68 chemicals including derivatives of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER were examined for their abilities to interact with BC6ENTG . CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineBC6OTHER 7 - hydroxylation, catalyzed by BC6ENTG , was strongly inhibited by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ; these chemicals induced Type I spectral changes with low Ks values. CPR:falsenewlineA total of 68 chemicals including derivatives of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC were examined for their abilities to interact with BC6ENTG . CPR:falsenewlineFifty - one of these 68 chemicals induced stronger Type I binding spectra ( BC6ENTC low - to high - spin state shift) with BC6ENTG than those seen with BC6OTHER , i.e., the spectral binding intensities (ΔAmax / Ks ratio) determined with these chemicals were always higher for BC6OTHER . CPR:falsenewlineFifty - one of these 68 chemicals induced stronger Type I binding spectra ( BC6ENTC low - to high - spin state shift) with BC6OTHER than those seen with BC6ENTG , i.e., the spectral binding intensities (ΔAmax / Ks ratio) determined with these chemicals were always higher for BC6OTHER . CPR:falsenewlineFifty - one of these 68 chemicals induced stronger Type I binding spectra ( BC6ENTC low - to high - spin state shift) with BC6OTHER than those seen with BC6OTHER , i.e., the spectral binding intensities (ΔAmax / Ks ratio) determined with these chemicals were always higher for BC6ENTG . CPR:falsenewlineIn addition, BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were found to induce a Type I spectral change only with BC6ENTG . CPR:falsenewlineA total of 68 chemicals including derivatives of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were examined for their abilities to interact with BC6ENTG . CPR:falsenewlineInhibitors based on a BC6OTHER scaffold were discovered for BC6ENTC ( BC6OTHER ) desaturase 1 ( BC6ENTG ) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model. CPR:falsenewlineDiscovery of liver - targeted inhibitors of BC6ENTC desaturase ( BC6ENTG ). CPR:falsenewlineInhibitors based on a BC6OTHER scaffold were discovered for CHEM - CHEM ( BC6ENTC ) desaturase 1 ( BC6ENTG ) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model. CPR:falsenewlineInhibitors based on a BC6ENTC scaffold were discovered for CHEM - CHEM ( BC6OTHER ) desaturase 1 ( BC6ENTG ) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model. CPR:falsenewlineInhibitors based on a BC6ENTC scaffold were discovered for BC6ENTG ( BC6OTHER ) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model. CPR:falsenewlineWe have reported that BC6ENTG clones are sensitive to reactive BC6ENTC species (ROS) treatment by inducing autophagic cell death. CPR:falsenewlineBC6ENTG is one of four major classes of BC6ENTC / BC6OTHER phosphatases. CPR:falsenewlineBC6ENTG is one of four major classes of BC6OTHER / BC6ENTC phosphatases. CPR:falsenewlineThe BC6ENTG / BC6OTHER ratio increased and BC6OTHER expression decreased in MIN6 cells after BC6ENTC stimulation. CPR:falsenewlineThe BC6OTHER / BC6ENTG ratio increased and BC6OTHER expression decreased in MIN6 cells after BC6ENTC stimulation. CPR:falsenewlineThe BC6OTHER / BC6OTHER ratio increased and BC6ENTG expression decreased in MIN6 cells after BC6ENTC stimulation. CPR:falsenewlineAdditionally, treatment with BC6ENTC / BC6OTHER showed a higher BC6ENTG activity. CPR:falsenewlineAdditionally, treatment with BC6OTHER / BC6ENTC showed a higher BC6ENTG activity. CPR:falsenewlineEffects of High BC6ENTC and BC6OTHER Concentrations over the Relative Expression of BC6ENTG , BC6OTHER , and BC6OTHER in MIN6 Cells. CPR:falsenewlineEffects of High BC6ENTC and BC6OTHER Concentrations over the Relative Expression of BC6OTHER , BC6ENTG , and BC6OTHER in MIN6 Cells. CPR:falsenewlineEffects of High BC6ENTC and BC6OTHER Concentrations over the Relative Expression of BC6OTHER , BC6OTHER , and BC6ENTG in MIN6 Cells. CPR:falsenewlineEffects of High BC6OTHER and BC6ENTC Concentrations over the Relative Expression of BC6ENTG , BC6OTHER , and BC6OTHER in MIN6 Cells. CPR:falsenewlineEffects of High BC6OTHER and BC6ENTC Concentrations over the Relative Expression of BC6OTHER , BC6ENTG , and BC6OTHER in MIN6 Cells. CPR:falsenewlineEffects of High BC6OTHER and BC6ENTC Concentrations over the Relative Expression of BC6OTHER , BC6OTHER , and BC6ENTG in MIN6 Cells. CPR:falsenewlineOur study revealed that high BC6ENTC / BC6OTHER concentrations in MIN6 cells induced an increase of the BC6ENTG / BC6OTHER ratio, an indicator of increased cell apoptosis. CPR:falsenewlineOur study revealed that high BC6ENTC / BC6OTHER concentrations in MIN6 cells induced an increase of the BC6OTHER / BC6ENTG ratio, an indicator of increased cell apoptosis. CPR:falsenewlineOur study revealed that high BC6OTHER / BC6ENTC concentrations in MIN6 cells induced an increase of the BC6ENTG / BC6OTHER ratio, an indicator of increased cell apoptosis. CPR:falsenewlineOur study revealed that high BC6OTHER / BC6ENTC concentrations in MIN6 cells induced an increase of the BC6OTHER / BC6ENTG ratio, an indicator of increased cell apoptosis. CPR:falsenewlineThe purpose of this study was to describe the effect of different BC6ENTC and / or BC6OTHER concentrations over BC6ENTG , BC6OTHER , and BC6OTHER expressions in a β - pancreatic cell line (MIN6 cells). CPR:falsenewlineThe purpose of this study was to describe the effect of different BC6ENTC and / or BC6OTHER concentrations over BC6OTHER , BC6ENTG , and BC6OTHER expressions in a β - pancreatic cell line (MIN6 cells). CPR:falsenewlineThe purpose of this study was to describe the effect of different BC6ENTC and / or BC6OTHER concentrations over BC6OTHER , BC6OTHER , and BC6ENTG expressions in a β - pancreatic cell line (MIN6 cells). CPR:falsenewlineThe purpose of this study was to describe the effect of different BC6OTHER and / or BC6ENTC concentrations over BC6ENTG , BC6OTHER , and BC6OTHER expressions in a β - pancreatic cell line (MIN6 cells). CPR:falsenewlineThe purpose of this study was to describe the effect of different BC6OTHER and / or BC6ENTC concentrations over BC6OTHER , BC6ENTG , and BC6OTHER expressions in a β - pancreatic cell line (MIN6 cells). CPR:falsenewlineThe purpose of this study was to describe the effect of different BC6OTHER and / or BC6ENTC concentrations over BC6OTHER , BC6OTHER , and BC6ENTG expressions in a β - pancreatic cell line (MIN6 cells). CPR:falsenewlineMIN6 cells were pre - incubated with different BC6ENTC and / or BC6OTHER concentrations, and the relative mRNA abundance of the BC6ENTG / BC6OTHER ratio and of BC6OTHER genes was measured by qRT - PCR. CPR:falsenewlineMIN6 cells were pre - incubated with different BC6ENTC and / or BC6OTHER concentrations, and the relative mRNA abundance of the BC6OTHER / BC6ENTG ratio and of BC6OTHER genes was measured by qRT - PCR. CPR:falsenewlineMIN6 cells were pre - incubated with different BC6ENTC and / or BC6OTHER concentrations, and the relative mRNA abundance of the BC6OTHER / BC6OTHER ratio and of BC6ENTG genes was measured by qRT - PCR. CPR:falsenewlineMIN6 cells were pre - incubated with different BC6OTHER and / or BC6ENTC concentrations, and the relative mRNA abundance of the BC6ENTG / BC6OTHER ratio and of BC6OTHER genes was measured by qRT - PCR. CPR:falsenewlineMIN6 cells were pre - incubated with different BC6OTHER and / or BC6ENTC concentrations, and the relative mRNA abundance of the BC6OTHER / BC6ENTG ratio and of BC6OTHER genes was measured by qRT - PCR. CPR:falsenewlineMIN6 cells were pre - incubated with different BC6OTHER and / or BC6ENTC concentrations, and the relative mRNA abundance of the BC6OTHER / BC6OTHER ratio and of BC6ENTG genes was measured by qRT - PCR. CPR:falsenewlineBC6ENTG ( BC6OTHER ) activity, BC6ENTC uptake, BC6OTHER dismutase activity, and BC6OTHER content were also determined. CPR:falsenewlineBC6OTHER ( BC6ENTG ) activity, BC6ENTC uptake, BC6OTHER dismutase activity, and BC6OTHER content were also determined. CPR:falsenewlineBC6OTHER ( BC6OTHER ) activity, BC6ENTC uptake, BC6ENTG activity, and BC6OTHER content were also determined. CPR:falsenewlineBC6ENTG ( BC6OTHER ) activity, BC6OTHER uptake, BC6ENTC dismutase activity, and BC6OTHER content were also determined. CPR:falsenewlineBC6OTHER ( BC6ENTG ) activity, BC6OTHER uptake, BC6ENTC dismutase activity, and BC6OTHER content were also determined. CPR:falsenewlineBC6ENTG ( BC6OTHER ) activity, BC6OTHER uptake, BC6OTHER dismutase activity, and BC6ENTC content were also determined. CPR:falsenewlineBC6OTHER ( BC6ENTG ) activity, BC6OTHER uptake, BC6OTHER dismutase activity, and BC6ENTC content were also determined. CPR:falsenewlineBC6OTHER ( BC6OTHER ) activity, BC6OTHER uptake, BC6ENTG activity, and BC6ENTC content were also determined. CPR:falsenewlineThe L - type BC6OTHER channel ( BC6ENTG ) isoforms BC6OTHER and BC6OTHER display similar BC6OTHER ( BC6ENTC ) binding properties and are both expressed in mammalian brain. CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) isoforms BC6OTHER and BC6OTHER display similar BC6OTHER ( BC6ENTC ) binding properties and are both expressed in mammalian brain. CPR:falsenewlineThe L - type BC6OTHER channel ( BC6OTHER ) isoforms BC6ENTG and BC6OTHER display similar BC6OTHER ( BC6ENTC ) binding properties and are both expressed in mammalian brain. CPR:falsenewlineThe L - type BC6OTHER channel ( BC6OTHER ) isoforms BC6OTHER and BC6ENTG display similar BC6OTHER ( BC6ENTC ) binding properties and are both expressed in mammalian brain. CPR:falsenewlineThe L - type BC6ENTC channel ( BC6ENTG ) isoforms BC6OTHER and BC6OTHER display similar BC6OTHER ( BC6OTHER ) binding properties and are both expressed in mammalian brain. CPR:falsenewlineThe L - type BC6ENTC channel ( BC6OTHER ) isoforms BC6ENTG and BC6OTHER display similar BC6OTHER ( BC6OTHER ) binding properties and are both expressed in mammalian brain. CPR:falsenewlineThe L - type BC6ENTC channel ( BC6OTHER ) isoforms BC6OTHER and BC6ENTG display similar BC6OTHER ( BC6OTHER ) binding properties and are both expressed in mammalian brain. CPR:falsenewlineInhibition of BC6ENTC binding to BC6ENTG DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineInhibition of BC6ENTC binding to BC6OTHER DHP( - / - ) (predominantly BC6ENTG ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineInhibition of BC6ENTC binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6ENTG ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineInhibition of BC6ENTC binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6OTHER for the BC6ENTG binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineInhibition of BC6OTHER binding to BC6ENTG DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6ENTC and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineInhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6ENTG ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6ENTC and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineInhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6ENTG ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6ENTC and BC6OTHER for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineInhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6ENTC and BC6OTHER for the BC6ENTG binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineInhibition of BC6OTHER binding to BC6ENTG DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6ENTC for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineInhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6ENTG ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6ENTC for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineInhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6ENTG ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6ENTC for the BC6OTHER binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineInhibition of BC6OTHER binding to BC6OTHER DHP( - / - ) (predominantly BC6OTHER ) and wild - type (predominantly BC6OTHER ) brain membranes by unlabeled CHEM revealed a 3 - to 4 - fold selectivity of BC6OTHER and BC6ENTC for the BC6ENTG binding pocket, a finding further confirmed with heterologously expressed channels. CPR:falsenewlineIt is also unknown to what extent BC6ENTG and BC6OTHER contribute to L - type - specific BC6ENTC binding activity in brain. CPR:falsenewlineIt is also unknown to what extent BC6OTHER and BC6ENTG contribute to L - type - specific BC6ENTC binding activity in brain. CPR:falsenewlineBC6ENTC binding to BC6ENTG DHP( - / - ) and BC6OTHER - DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that BC6OTHER accounts for 10.7% of brain BC6OTHER . CPR:falsenewlineBC6ENTC binding to BC6OTHER DHP( - / - ) and BC6ENTG - DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that BC6OTHER accounts for 10.7% of brain BC6OTHER . CPR:falsenewlineBC6ENTC binding to BC6OTHER DHP( - / - ) and BC6OTHER - DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that BC6ENTG accounts for 10.7% of brain BC6OTHER . CPR:falsenewlineBC6ENTC binding to BC6OTHER DHP( - / - ) and BC6OTHER - DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that BC6OTHER accounts for 10.7% of brain BC6ENTG . CPR:falsenewlineThe L - type BC6OTHER channel ( BC6ENTG ) isoforms BC6OTHER and BC6OTHER display similar BC6ENTC ( BC6OTHER ) binding properties and are both expressed in mammalian brain. CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) isoforms BC6OTHER and BC6OTHER display similar BC6ENTC ( BC6OTHER ) binding properties and are both expressed in mammalian brain. CPR:falsenewlineThe L - type BC6OTHER channel ( BC6OTHER ) isoforms BC6ENTG and BC6OTHER display similar BC6ENTC ( BC6OTHER ) binding properties and are both expressed in mammalian brain. CPR:falsenewlineThe L - type BC6OTHER channel ( BC6OTHER ) isoforms BC6OTHER and BC6ENTG display similar BC6ENTC ( BC6OTHER ) binding properties and are both expressed in mammalian brain. CPR:falsenewlineExpression and BC6ENTC - binding properties of brain BC6ENTG isoforms. CPR:falsenewlineBC6ENTG - mediated signaling also modulates the BC6ENTC response. CPR:falsenewlineAnti - BC6ENTC (AEs) and BC6ENTG inhibitors (AIs) are used clinically to arrest the BC6OTHER - dependent growth of BC. CPR:falsenewlineAnti - BC6OTHER (AEs) and BC6ENTG inhibitors (AIs) are used clinically to arrest the BC6ENTC - dependent growth of BC. CPR:falsenewlineBC6ENTC effects are mediated not only through nuclear BC6ENTG but also through cytoplasmic / membrane BC6OTHER and BC6OTHER - coupled BC6OTHER . CPR:falsenewlineBC6ENTC effects are mediated not only through nuclear BC6OTHER but also through cytoplasmic / membrane BC6ENTG and BC6OTHER - coupled BC6OTHER . CPR:falsenewlineBC6ENTC effects are mediated not only through nuclear BC6OTHER but also through cytoplasmic / membrane BC6OTHER and BC6ENTG - coupled BC6OTHER . CPR:falsenewlineBC6ENTC effects are mediated not only through nuclear BC6OTHER but also through cytoplasmic / membrane BC6OTHER and BC6OTHER - coupled BC6ENTG . CPR:falsenewlineIn breast cancer (BC) epithelial cells, the mitogenic action of BC6ENTC is transduced through binding to two receptors, BC6ENTG and BC6OTHER , which act as transcription factors. CPR:falsenewlineIn breast cancer (BC) epithelial cells, the mitogenic action of BC6ENTC is transduced through binding to two receptors, BC6OTHER and BC6ENTG , which act as transcription factors. CPR:falsenewlineThe partners of extra - nuclear BC6ENTG include BC6OTHER and the BC6ENTC kinase BC6OTHER . CPR:falsenewlineThe partners of extra - nuclear BC6OTHER include BC6ENTG and the BC6ENTC kinase BC6OTHER . CPR:falsenewlineThe partners of extra - nuclear BC6OTHER include BC6OTHER and the BC6ENTC kinase BC6ENTG . CPR:falsenewlineFurther investigation demonstrated that 8k reduced BC6ENTC - induced activation of mitochondrial apoptosis by inhibiting the expression of BC6ENTG and elevating the expression of BC6OTHER . CPR:falsenewlineFurther investigation demonstrated that 8k reduced BC6ENTC - induced activation of mitochondrial apoptosis by inhibiting the expression of BC6OTHER and elevating the expression of BC6ENTG . CPR:falsenewlineTo evaluate the BC6ENTG balance and enzymatic alterations induced by environmental pesticide exposure during pregnancy, this transversal study explored placentas derived from non - exposed women (control group - CG), and from women living in a rural area (rural group - RG), collected during intensive BC6ENTC (OP) pesticide spraying season (RG - SS) and during non - spraying season (RG - NSS). CPR:falsenewlineBC6ENTG and BC6ENTC decarboxylase ( BC6OTHER ) enzymes were induced in syncytiotrophoblast and endothelial cells. CPR:falsenewlineBC6OTHER and BC6ENTC decarboxylase ( BC6ENTG ) enzymes were induced in syncytiotrophoblast and endothelial cells. CPR:falsenewlineEnvironmental pesticide exposure modulates BC6ENTG , BC6OTHER and BC6ENTC decarboxylase expression in human placenta. CPR:falsenewlineEnvironmental pesticide exposure modulates BC6OTHER , BC6ENTG and BC6ENTC decarboxylase expression in human placenta. CPR:falsenewlineIn the present studies, the BC6ENTG inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6ENTC were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6ENTG neutral antagonist BC6ENTC were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6ENTC were compared for their ability to modify BC6ENTG - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6ENTC were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6ENTG full agonist BC6OTHER . CPR:falsenewlineIn the present studies, the BC6ENTG inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6ENTC . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6ENTG neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6ENTC . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6ENTG - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6ENTC . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6ENTG full agonist BC6ENTC . CPR:falsenewlineResults indicate that BC6ENTC serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER . CPR:falsenewlineResults indicate that BC6ENTC serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER . CPR:falsenewlineResults indicate that BC6OTHER serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6ENTC , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER . CPR:falsenewlineResults indicate that BC6OTHER serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6ENTC , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER . CPR:falsenewlineResults indicate that BC6OTHER serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6OTHER , and that the inverse agonist BC6ENTC and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER . CPR:falsenewlineResults indicate that BC6OTHER serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6OTHER , and that the inverse agonist BC6ENTC and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER . CPR:falsenewline BC6ENTC discrimination and antagonism by BC6ENTG neutral and inverse agonist antagonists. CPR:6newlineBC6ENTC receptor 1 ( BC6ENTG ) inverse agonists (e.g., BC6OTHER ) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications. CPR:falsenewlineResults indicate that BC6OTHER serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6ENTC produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER . CPR:falsenewlineResults indicate that BC6OTHER serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6ENTC produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER . CPR:falsenewlineResults indicate that BC6OTHER serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6ENTC dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER . CPR:falsenewlineResults indicate that BC6OTHER serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6ENTC dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6OTHER . CPR:falsenewlineResults indicate that BC6OTHER serves as an effective BC6ENTG discriminative stimulus, with an onset and time course of action comparable with that of the BC6OTHER agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6ENTC . CPR:falsenewlineResults indicate that BC6OTHER serves as an effective BC6OTHER discriminative stimulus, with an onset and time course of action comparable with that of the BC6ENTG agonist BC6OTHER , and that the inverse agonist BC6OTHER and the neutral antagonist BC6OTHER produce dose - related rightward shifts in the BC6OTHER dose - effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of BC6ENTC . CPR:falsenewlineIn the present studies, the BC6ENTG inverse agonist BC6ENTC ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6ENTC ( BC6OTHER ) and the BC6ENTG neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6ENTC ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6ENTG - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6ENTC ( BC6OTHER ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6ENTG full agonist BC6OTHER . CPR:falsenewlineIn the present studies, the BC6ENTG inverse agonist BC6OTHER ( BC6ENTC ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6ENTC ) and the BC6ENTG neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6ENTC ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6ENTG - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6OTHER full agonist BC6OTHER . CPR:falsenewlineIn the present studies, the BC6OTHER inverse agonist BC6OTHER ( BC6ENTC ) and the BC6OTHER neutral antagonist BC6OTHER were compared for their ability to modify BC6OTHER - mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel BC6ENTG full agonist BC6OTHER . CPR:falsenewlineBC6ENTG ( BC6OTHER ) inverse agonists (e.g., BC6ENTC ) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications. CPR:5newlineBC6OTHER receptor 1 ( BC6ENTG ) inverse agonists (e.g., BC6ENTC ) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications. CPR:falsenewlineSeveral in vitro studies were conducted to evaluate the effect of BC6ENTC on 4 primary enzymes of the pathways of BC6OTHER metabolism, BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineSeveral in vitro studies were conducted to evaluate the effect of BC6ENTC on 4 primary enzymes of the pathways of BC6OTHER metabolism, BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineSeveral in vitro studies were conducted to evaluate the effect of BC6ENTC on 4 primary enzymes of the pathways of BC6OTHER metabolism, BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineSeveral in vitro studies were conducted to evaluate the effect of BC6ENTC on 4 primary enzymes of the pathways of BC6OTHER metabolism, BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineSeveral in vitro studies were conducted to evaluate the effect of BC6OTHER on 4 primary enzymes of the pathways of BC6ENTC metabolism, BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineSeveral in vitro studies were conducted to evaluate the effect of BC6OTHER on 4 primary enzymes of the pathways of BC6ENTC metabolism, BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineSeveral in vitro studies were conducted to evaluate the effect of BC6OTHER on 4 primary enzymes of the pathways of BC6ENTC metabolism, BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineSeveral in vitro studies were conducted to evaluate the effect of BC6OTHER on 4 primary enzymes of the pathways of BC6ENTC metabolism, BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineBC6ENTC inhibited both BC6ENTG and BC6OTHER with IC - 50 values of 43 microM and 227 microM, respectively. CPR:4newlineBC6ENTC inhibited both BC6OTHER and BC6ENTG with IC - 50 values of 43 microM and 227 microM, respectively. CPR:4newlineBC6ENTC also inhibited BC6ENTG with an IC - 50 of 43 microM. CPR:4newlineThe BC6ENTG was similarly inhibited by BC6ENTC with an IC - 50 of 61 microM. CPR:4newlineHence, BC6ENTC has the ability to inhibit both the BC6ENTG and BC6OTHER pathways of BC6OTHER metabolism with similar efficacy. CPR:falsenewlineHence, BC6ENTC has the ability to inhibit both the BC6OTHER and BC6ENTG pathways of BC6OTHER metabolism with similar efficacy. CPR:falsenewlineHence, BC6OTHER has the ability to inhibit both the BC6ENTG and BC6OTHER pathways of BC6ENTC metabolism with similar efficacy. CPR:9newlineHence, BC6OTHER has the ability to inhibit both the BC6OTHER and BC6ENTG pathways of BC6ENTC metabolism with similar efficacy. CPR:falsenewlineIn cell culture experiments, it was found that BC6ENTC inhibited BC6ENTG induced BC6OTHER production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations. CPR:4newlineIn cell culture experiments, it was found that BC6OTHER inhibited BC6ENTG induced BC6ENTC production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations. CPR:falsenewlineThe effect of a peripheral block on inflammation - induced BC6ENTC and BC6ENTG expression in rats. CPR:falsenewlineSystemic BC6ENTC did not modify either the hyperalgesia and local inflammation or BC6ENTG expression. CPR:falsenewlineBACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord BC6ENTG ( BC6OTHER ), with a subsequent increase in central BC6ENTC ( BC6OTHER ) levels associated with the development of hyperalgesia. CPR:falsenewlineBACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord BC6OTHER ( BC6ENTG ), with a subsequent increase in central BC6ENTC ( BC6OTHER ) levels associated with the development of hyperalgesia. CPR:falsenewlineBACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord BC6ENTG ( BC6OTHER ), with a subsequent increase in central BC6OTHER ( BC6ENTC ) levels associated with the development of hyperalgesia. CPR:falsenewlineBACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord BC6OTHER ( BC6ENTG ), with a subsequent increase in central BC6OTHER ( BC6ENTC ) levels associated with the development of hyperalgesia. CPR:falsenewlineIn this study, we evaluated the effect of BC6ENTC administered via a nerve block or via a systemic route on the spinal expression of BC6OTHER and BC6ENTG in a model of peripheral inflammation in rats. CPR:falsenewlineIn this study, we evaluated the effect of BC6OTHER administered via a nerve block or via a systemic route on the spinal expression of BC6ENTC and BC6ENTG in a model of peripheral inflammation in rats. CPR:falsenewlineLocal edema, thermal, and mechanical hyperalgesia as well as cerebrospinal fluid BC6ENTC concentration and BC6ENTG and BC6OTHER expression in the spinal cord in dorsal root ganglions were measured. CPR:falsenewlineLocal edema, thermal, and mechanical hyperalgesia as well as cerebrospinal fluid BC6ENTC concentration and BC6OTHER and BC6ENTG expression in the spinal cord in dorsal root ganglions were measured. CPR:falsenewlineExchange protein directly activated by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6ENTC . CPR:falsenewlineExchange protein directly activated by BC6OTHER ( BC6OTHER ) and BC6OTHER - dependent protein kinase ( BC6ENTG ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6ENTC . CPR:falsenewlineBC6ENTG ( BC6OTHER ) and BC6OTHER - dependent protein kinase ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6ENTC . CPR:falsenewlineExchange protein directly activated by BC6OTHER ( BC6ENTG ) and BC6OTHER - dependent protein kinase ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6ENTC . CPR:falsenewlineHerein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6ENTG antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6ENTG - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6ENTG activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6ENTG phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6ENTG - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6ENTC ( BC6OTHER ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6ENTG secretion in pancreatic β cells. CPR:falsenewlineExchange protein directly activated by BC6ENTC ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER . CPR:falsenewlineExchange protein directly activated by BC6ENTC ( BC6OTHER ) and BC6OTHER - dependent protein kinase ( BC6ENTG ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER . CPR:falsenewlineExchange protein directly activated by BC6ENTC ( BC6ENTG ) and BC6OTHER - dependent protein kinase ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER . CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6ENTG antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6ENTG - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6ENTG activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6ENTG phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6ENTG - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6ENTC ), a novel noncyclic BC6OTHER BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6ENTG secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6ENTG antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6OTHER antagonist that is capable of specifically blocking intracellular BC6ENTG - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6ENTG activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6ENTG phosphorylation, as well as BC6OTHER - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6ENTG - mediated BC6OTHER secretion in pancreatic β cells. CPR:falsenewlineHerein, we report the identification and characterization of BC6OTHER ( BC6OTHER ), a novel noncyclic BC6ENTC BC6OTHER antagonist that is capable of specifically blocking intracellular BC6OTHER - mediated BC6OTHER activation and BC6OTHER phosphorylation, as well as BC6OTHER - mediated BC6ENTG secretion in pancreatic β cells. CPR:falsenewlineExchange protein directly activated by BC6OTHER ( BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6ENTG ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER . CPR:falsenewlineBC6ENTG ( BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER . CPR:falsenewlineExchange protein directly activated by BC6OTHER ( BC6ENTG ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) are two intracellular receptors that mediate the effects of the prototypic second messenger BC6OTHER . CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6ENTC ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6ENTC ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6ENTC , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6ENTC , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6ENTC a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6ENTC a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6ENTC , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6ENTC , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe demonstrate that only treatment of HaCaT with BC6ENTC and BC6OTHER or a BC6ENTG ligand ( BC6OTHER ), induced BC6OTHER expression (protein and mRNA). CPR:falsenewlineWe demonstrate that only treatment of HaCaT with BC6ENTC and BC6OTHER or a BC6OTHER ligand ( BC6OTHER ), induced BC6ENTG expression (protein and mRNA). CPR:falsenewlineWe demonstrate that only treatment of HaCaT with BC6OTHER and BC6ENTC or a BC6ENTG ligand ( BC6OTHER ), induced BC6OTHER expression (protein and mRNA). CPR:falsenewlineWe demonstrate that only treatment of HaCaT with BC6OTHER and BC6ENTC or a BC6OTHER ligand ( BC6OTHER ), induced BC6ENTG expression (protein and mRNA). CPR:falsenewlineWe demonstrate that only treatment of HaCaT with BC6OTHER and BC6OTHER or a BC6ENTG ligand ( BC6ENTC ), induced BC6OTHER expression (protein and mRNA). CPR:falsenewlineWe demonstrate that only treatment of HaCaT with BC6OTHER and BC6OTHER or a BC6OTHER ligand ( BC6ENTC ), induced BC6ENTG expression (protein and mRNA). CPR:falsenewlineMoreover stimulation of BC6ENTG activity was increased by those BC6ENTC or BC6OTHER . CPR:falsenewlineMoreover stimulation of BC6ENTG activity was increased by those BC6OTHER or BC6ENTC . CPR:3newlineThe inhibitory effects of BC6ENTC and BC6OTHER ( BC6ENTG antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6ENTC and BC6OTHER ( BC6OTHER antagonists), on BC6ENTG expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6ENTC and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6ENTG activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6ENTC and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6ENTG is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6ENTC and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6ENTG induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6ENTC ( BC6ENTG antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6ENTC ( BC6OTHER antagonists), on BC6ENTG expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6ENTC ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6ENTG activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6ENTC ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6ENTG is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6ENTC ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6OTHER suggest that BC6OTHER is implicated in BC6ENTG induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6OTHER ( BC6ENTG antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6ENTC and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6ENTG expression and on stimulation of BC6OTHER activity by BC6ENTC and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6ENTG activity by BC6ENTC and BC6OTHER suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6ENTC and BC6OTHER suggest that BC6ENTG is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6ENTC and BC6OTHER suggest that BC6OTHER is implicated in BC6ENTG induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6OTHER ( BC6ENTG antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6ENTC suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6ENTG expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6ENTC suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6ENTG activity by BC6OTHER and BC6ENTC suggest that BC6OTHER is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6ENTC suggest that BC6ENTG is implicated in BC6OTHER induction. CPR:falsenewlineThe inhibitory effects of BC6OTHER and BC6OTHER ( BC6OTHER antagonists), on BC6OTHER expression and on stimulation of BC6OTHER activity by BC6OTHER and BC6ENTC suggest that BC6OTHER is implicated in BC6ENTG induction. CPR:falsenewlineFinally, BC6OTHER inhibitor CHEM BC6ENTC blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6ENTG activation. CPR:falsenewlineFinally, BC6ENTG inhibitor CHEM BC6ENTC blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation. CPR:falsenewlineFinally, BC6OTHER inhibitor CHEM BC6ENTC blocked the BC6OTHER effects on BC6ENTG induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation. CPR:falsenewlineFinally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6ENTC effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6ENTG activation. CPR:falsenewlineFinally, BC6ENTG inhibitor CHEM BC6OTHER blocked the BC6ENTC effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation. CPR:falsenewlineFinally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6ENTC effects on BC6ENTG induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation. CPR:falsenewlineFinally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6ENTC mobilization suggesting involvement of BC6OTHER metabolites in BC6ENTG activation. CPR:falsenewlineFinally, BC6ENTG inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6ENTC mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation. CPR:falsenewlineFinally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6ENTG induction, promoter activity and BC6ENTC mobilization suggesting involvement of BC6OTHER metabolites in BC6OTHER activation. CPR:falsenewline BC6ENTC induce the expression of BC6ENTG via BC6OTHER activation in human keratinocyte HaCaT cells. CPR:3newline BC6ENTC induce the expression of BC6OTHER via BC6ENTG activation in human keratinocyte HaCaT cells. CPR:3newlineFinally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6ENTC metabolites in BC6ENTG activation. CPR:falsenewlineFinally, BC6ENTG inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6OTHER induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6ENTC metabolites in BC6OTHER activation. CPR:falsenewlineFinally, BC6OTHER inhibitor CHEM BC6OTHER blocked the BC6OTHER effects on BC6ENTG induction, promoter activity and BC6OTHER mobilization suggesting involvement of BC6ENTC metabolites in BC6OTHER activation. CPR:falsenewlineThese findings demonstrate that BC6ENTC increased BC6ENTG activity is necessary for the BC6OTHER induction in HaCaT human keratinocyte cells. CPR:falsenewlineThese findings demonstrate that BC6ENTC increased BC6OTHER activity is necessary for the BC6ENTG induction in HaCaT human keratinocyte cells. CPR:falsenewlineGiven the anti - inflammatory properties of BC6ENTC , we suggest that induction of BC6ENTG in keratinocytes may be important in the anti - inflammatory and protective mechanism of action of BC6OTHER or n - 6. CPR:falsenewlineGiven the anti - inflammatory properties of BC6OTHER , we suggest that induction of BC6ENTG in keratinocytes may be important in the anti - inflammatory and protective mechanism of action of BC6ENTC or n - 6. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6ENTC ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6ENTC ( BC6OTHER ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6ENTC ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6ENTC ) a BC6OTHER , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6ENTC , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6ENTC , BC6OTHER ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6ENTC ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6ENTG ( BC6OTHER ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineWe examined in HaCaT keratinocyte cell line whether BC6OTHER ( BC6OTHER ) a BC6OTHER , BC6ENTC ( BC6OTHER ) a BC6OTHER , and BC6OTHER a BC6OTHER , modulate expression of BC6OTHER ( BC6ENTG ), an enzyme pivotal to skin inflammation and reparation. CPR:falsenewlineHere, we report that the transcription factor BC6ENTG ( BC6OTHER ) is essential for coupling BC6ENTC to BC6OTHER inhibition and subsequent neurite growth promotion in neurons. CPR:falsenewlineHere, we report that the transcription factor BC6OTHER ( BC6ENTG ) is essential for coupling BC6ENTC to BC6OTHER inhibition and subsequent neurite growth promotion in neurons. CPR:falsenewlineHere, we report that the transcription factor BC6OTHER ( BC6OTHER ) is essential for coupling BC6ENTC to BC6ENTG inhibition and subsequent neurite growth promotion in neurons. CPR:falsenewlineBC6ENTC activates BC6ENTG in neuron - like PC12 and B104 cells. CPR:3newlineA molecular mechanism for BC6ENTC - mediated BC6ENTG inhibition in neurons. CPR:4newlineBC6ENTC is a nonsteroidal anti - inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of BC6ENTG . CPR:4newlineActivation of BC6OTHER with traditional agonists mimics the BC6ENTG - inhibiting properties of BC6ENTC in PC12 cells and, like BC6OTHER , promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors. CPR:falsenewlineActivation of BC6ENTG with traditional agonists mimics the BC6OTHER - inhibiting properties of BC6ENTC in PC12 cells and, like BC6OTHER , promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors. CPR:falsenewlineActivation of BC6OTHER with traditional agonists mimics the BC6ENTG - inhibiting properties of BC6OTHER in PC12 cells and, like BC6ENTC , promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors. CPR:falsenewlineActivation of BC6ENTG with traditional agonists mimics the BC6OTHER - inhibiting properties of BC6OTHER in PC12 cells and, like BC6ENTC , promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors. CPR:falsenewlineMoreover, the effect of BC6ENTC on BC6ENTG activity and neurite growth in neuronal cultures is prevented by selective BC6OTHER inhibition. CPR:falsenewlineMoreover, the effect of BC6ENTC on BC6OTHER activity and neurite growth in neuronal cultures is prevented by selective BC6ENTG inhibition. CPR:falsenewlineThese findings support that BC6ENTG plays an essential role in mediating the BC6OTHER - inhibiting effect of BC6ENTC . CPR:falsenewlineThese findings support that BC6OTHER plays an essential role in mediating the BC6ENTG - inhibiting effect of BC6ENTC . CPR:falsenewlineElucidation of the novel molecular mechanisms linking BC6ENTC to BC6ENTG inhibition may provide additional therapeutic targets to the disorders characterized by BC6OTHER activation, including spinal cord injuries and Alzheimer's disease. CPR:falsenewlineElucidation of the novel molecular mechanisms linking BC6ENTC to BC6OTHER inhibition may provide additional therapeutic targets to the disorders characterized by BC6ENTG activation, including spinal cord injuries and Alzheimer's disease. CPR:falsenewlineRecently, we have demonstrated that BC6ENTC inhibits intracellular signaling of BC6ENTG and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents. CPR:4newlineIn addition, another study suggests that BC6ENTC reduces generation of BC6ENTG peptide via inactivation of BC6OTHER signaling, although it may also regulate BC6OTHER formation by direct inhibition of the BC6OTHER . CPR:falsenewlineIn addition, another study suggests that BC6ENTC reduces generation of BC6OTHER peptide via inactivation of BC6ENTG signaling, although it may also regulate BC6OTHER formation by direct inhibition of the BC6OTHER . CPR:falsenewlineIn addition, another study suggests that BC6ENTC reduces generation of BC6OTHER peptide via inactivation of BC6OTHER signaling, although it may also regulate BC6ENTG formation by direct inhibition of the BC6OTHER . CPR:falsenewlineIn addition, another study suggests that BC6ENTC reduces generation of BC6OTHER peptide via inactivation of BC6OTHER signaling, although it may also regulate BC6OTHER formation by direct inhibition of the BC6ENTG . CPR:falsenewlineThe molecular mechanisms by which BC6ENTC inhibits the BC6ENTG signal in neurons, however, remain unclear. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER ) is a novel antiallergic / BC6ENTG antagonistic drug that was synthesized and evaluated in our laboratories. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) is a novel antiallergic / BC6ENTG antagonistic drug that was synthesized and evaluated in our laboratories. CPR:falsenewlineBC6ENTC is a selective BC6ENTG antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as BC6OTHER and BC6OTHER from human polymorphonuclear leukocytes and eosinophils. CPR:6newlineBC6OTHER is a selective BC6ENTG antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as BC6ENTC and BC6OTHER from human polymorphonuclear leukocytes and eosinophils. CPR:falsenewlineBC6OTHER is a selective BC6ENTG antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as BC6OTHER and BC6ENTC from human polymorphonuclear leukocytes and eosinophils. CPR:falsenewlineBC6ENTC exerted no significant effects on action potential duration in isolated guinea pig ventricular myocytes, myocardium and BC6ENTG . CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER ) is a novel antiallergic / BC6ENTG antagonistic drug that was synthesized and evaluated in our laboratories. CPR:falsenewlineThis study compared the sedative profiles of the second - generation BC6ENTC , BC6OTHER and BC6OTHER , using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of BC6ENTG occupancy (H1RO) in the brain. CPR:falsenewlineThis study compared the sedative profiles of the second - generation BC6OTHER , BC6ENTC and BC6OTHER , using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of BC6ENTG occupancy (H1RO) in the brain. CPR:falsenewlineThis study compared the sedative profiles of the second - generation BC6OTHER , BC6OTHER and BC6ENTC , using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of BC6ENTG occupancy (H1RO) in the brain. CPR:falsenewlineBC6ENTG ( BC6OTHER ) antagonists, or BC6ENTC , often induce sedative side effects when used for the treatment of allergic disorders. CPR:falsenewlineBC6OTHER ( BC6ENTG ) antagonists, or BC6ENTC , often induce sedative side effects when used for the treatment of allergic disorders. CPR:falsenewlineBC6ENTC H1 - receptor ( BC6ENTG ) antagonists, or BC6OTHER , often induce sedative side effects when used for the treatment of allergic disorders. CPR:falsenewlineCentral effects of BC6OTHER and BC6OTHER : measurement of psychomotor performance, subjective sleepiness, and brain BC6ENTG occupancy using BC6ENTC positron emission tomography. CPR:falsenewlineCentral effects of BC6ENTC and BC6OTHER : measurement of psychomotor performance, subjective sleepiness, and brain BC6ENTG occupancy using BC6OTHER positron emission tomography. CPR:falsenewlineCentral effects of BC6OTHER and BC6ENTC : measurement of psychomotor performance, subjective sleepiness, and brain BC6ENTG occupancy using BC6OTHER positron emission tomography. CPR:falsenewline These data directly demonstrate that BC6ENTG is the major BC6ENTC uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo. CPR:9newlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTC / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary CHEM / BC6OTHER / BC6OTHER cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTC / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary BC6ENTG BC6OTHER cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6ENTC / BC6OTHER cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary CHEM / BC6OTHER / BC6OTHER cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6ENTC / BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary BC6ENTG BC6OTHER cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTG BC6ENTC cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary CHEM / BC6OTHER / BC6OTHER cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6ENTC cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary CHEM / BC6OTHER / BC6OTHER cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6ENTC cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary BC6ENTG BC6OTHER cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTG BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary BC6ENTC / BC6OTHER / BC6OTHER cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary BC6ENTC / BC6OTHER / BC6OTHER cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTG BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary CHEM / BC6ENTC / BC6OTHER cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary CHEM / BC6ENTC / BC6OTHER cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of BC6ENTG BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary CHEM / BC6OTHER / BC6ENTC cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6ENTG ), the gene encoding the salivary CHEM / BC6OTHER / BC6ENTC cotransporter. CPR:falsenewlineTo directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of CHEM / BC6OTHER / BC6OTHER cotransporter isoform 1 ( BC6OTHER ), the gene encoding the salivary BC6ENTG BC6ENTC cotransporter. CPR:falsenewlineThe salivary fluid secretory mechanism is thought to require BC6ENTG BC6ENTC cotransporter - mediated BC6OTHER uptake. CPR:falsenewlineThe salivary fluid secretory mechanism is thought to require BC6ENTG BC6OTHER cotransporter - mediated BC6ENTC uptake. CPR:9newlineConsistent with defective BC6ENTC uptake, a loss of BC6OTHER - sensitive BC6OTHER influx was observed in parotid acinar cells from mice lacking BC6ENTG . CPR:falsenewlineConsistent with defective BC6OTHER uptake, a loss of BC6ENTC - sensitive BC6OTHER influx was observed in parotid acinar cells from mice lacking BC6ENTG . CPR:falsenewlineConsistent with defective BC6OTHER uptake, a loss of BC6OTHER - sensitive BC6ENTC influx was observed in parotid acinar cells from mice lacking BC6ENTG . CPR:falsenewlineBC6ENTC / BC6OTHER exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking BC6ENTG is associated with anion exchanger - dependent BC6OTHER uptake. CPR:falsenewlineCl( - ) / BC6ENTC exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking BC6ENTG is associated with anion exchanger - dependent BC6OTHER uptake. CPR:falsenewlineSevere impairment of salivation in BC6ENTC / BC6OTHER / BC6OTHER cotransporter ( BC6ENTG ) - deficient mice. CPR:falsenewlineSevere impairment of salivation in CHEM / BC6ENTC / BC6OTHER cotransporter ( BC6ENTG ) - deficient mice. CPR:falsenewlineSevere impairment of salivation in BC6ENTG BC6ENTC cotransporter ( BC6OTHER ) - deficient mice. CPR:falsenewlineSevere impairment of salivation in CHEM / BC6OTHER / BC6ENTC cotransporter ( BC6ENTG ) - deficient mice. CPR:falsenewlineCl( - ) / BC6OTHER exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking BC6ENTG is associated with anion exchanger - dependent BC6ENTC uptake. CPR:9newlineBC6ENTG activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking BC6OTHER is associated with anion exchanger - dependent BC6ENTC uptake. CPR:9newlineIndeed, expression of the BC6ENTC / BC6OTHER exchanger BC6ENTG was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6OTHER / BC6OTHER cotransporter. CPR:falsenewlineIndeed, expression of the BC6ENTC / BC6OTHER exchanger BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6ENTG BC6OTHER cotransporter. CPR:falsenewlineIndeed, expression of the BC6OTHER / BC6ENTC exchanger BC6ENTG was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6OTHER / BC6OTHER cotransporter. CPR:falsenewlineIndeed, expression of the BC6OTHER / BC6ENTC exchanger BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6ENTG BC6OTHER cotransporter. CPR:falsenewlineIndeed, expression of the BC6ENTG BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6ENTC / BC6OTHER / BC6OTHER cotransporter. CPR:falsenewlineIndeed, expression of the BC6OTHER / BC6OTHER exchanger BC6ENTG was enhanced suggesting that this transporter compensates for the loss of functional BC6ENTC / BC6OTHER / BC6OTHER cotransporter. CPR:falsenewlineIndeed, expression of the BC6ENTG BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6ENTC / BC6OTHER cotransporter. CPR:falsenewlineIndeed, expression of the BC6OTHER / BC6OTHER exchanger BC6ENTG was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6ENTC / BC6OTHER cotransporter. CPR:falsenewlineIndeed, expression of the BC6ENTG BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6OTHER / BC6ENTC cotransporter. CPR:falsenewlineIndeed, expression of the BC6OTHER / BC6OTHER exchanger BC6ENTG was enhanced suggesting that this transporter compensates for the loss of functional BC6OTHER / BC6OTHER / BC6ENTC cotransporter. CPR:falsenewlineIndeed, expression of the BC6OTHER / BC6OTHER exchanger BC6OTHER was enhanced suggesting that this transporter compensates for the loss of functional BC6ENTG BC6ENTC cotransporter. CPR:falsenewlineFurthermore, the ability of the parotid gland to conserve BC6ENTC was abolished in BC6ENTG - deficient mice. CPR:falsenewlineWe examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6ENTG ( BC6OTHER ), and (2) blockade of BC6OTHER ( BC6ENTC ) synthesis in isolated human eosinophils in vitro. CPR:falsenewlineWe examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6OTHER ( BC6ENTG ), and (2) blockade of BC6OTHER ( BC6ENTC ) synthesis in isolated human eosinophils in vitro. CPR:falsenewlineEosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6ENTC in the presence of 10 pg / ml BC6ENTG ( BC6OTHER ) and activated with BC6OTHER ( BC6OTHER ) + BC6OTHER ( BC6OTHER ). CPR:falsenewlineEosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6ENTC in the presence of 10 pg / ml BC6OTHER ( BC6ENTG ) and activated with BC6OTHER ( BC6OTHER ) + BC6OTHER ( BC6OTHER ). CPR:falsenewlineEosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6ENTG ( BC6OTHER ) and activated with BC6ENTC ( BC6OTHER ) + BC6OTHER ( BC6OTHER ). CPR:falsenewlineEosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6OTHER ( BC6ENTG ) and activated with BC6ENTC ( BC6OTHER ) + BC6OTHER ( BC6OTHER ). CPR:falsenewlineEosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6ENTG ( BC6OTHER ) and activated with BC6OTHER ( BC6ENTC ) + BC6OTHER ( BC6OTHER ). CPR:falsenewlineEosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6OTHER ( BC6ENTG ) and activated with BC6OTHER ( BC6ENTC ) + BC6OTHER ( BC6OTHER ). CPR:falsenewlineEosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6ENTG ( BC6OTHER ) and activated with BC6OTHER ( BC6OTHER ) + BC6ENTC ( BC6OTHER ). CPR:falsenewlineEosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6OTHER ( BC6ENTG ) and activated with BC6OTHER ( BC6OTHER ) + BC6ENTC ( BC6OTHER ). CPR:falsenewlineEosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6ENTG ( BC6OTHER ) and activated with BC6OTHER ( BC6OTHER ) + BC6OTHER ( BC6ENTC ). CPR:falsenewlineEosinophils were isolated from peripheral blood, treated with either buffer or 10( - )10 M to 10( - )6 M BC6OTHER in the presence of 10 pg / ml BC6OTHER ( BC6ENTG ) and activated with BC6OTHER ( BC6OTHER ) + BC6OTHER ( BC6ENTC ). CPR:falsenewlineWe examined the effect of the highly lipophilic CHEM, BC6ENTC ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6ENTG ( BC6OTHER ), and (2) blockade of BC6OTHER ( BC6OTHER ) synthesis in isolated human eosinophils in vitro. CPR:falsenewlineWe examined the effect of the highly lipophilic CHEM, BC6ENTC ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6OTHER ( BC6ENTG ), and (2) blockade of BC6OTHER ( BC6OTHER ) synthesis in isolated human eosinophils in vitro. CPR:falsenewlineBy contrast, membrane expression of BC6ENTG , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10( - )10 M BC6ENTC , and inhibition of BC6OTHER synthesis was reversed by exogenous BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6ENTC / BC6OTHER - stimulated translocation of BC6ENTG to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by BC6OTHER . CPR:falsenewlineBC6OTHER / BC6ENTC - stimulated translocation of BC6ENTG to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by BC6OTHER . CPR:falsenewlineWe examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6ENTC ), in causing (1) inhibition of nuclear translocation of BC6ENTG ( BC6OTHER ), and (2) blockade of BC6OTHER ( BC6OTHER ) synthesis in isolated human eosinophils in vitro. CPR:falsenewlineWe examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6ENTC ), in causing (1) inhibition of nuclear translocation of BC6OTHER ( BC6ENTG ), and (2) blockade of BC6OTHER ( BC6OTHER ) synthesis in isolated human eosinophils in vitro. CPR:falsenewlineBC6OTHER / BC6OTHER - stimulated translocation of BC6ENTG to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by BC6ENTC . CPR:falsenewlineInhibition of BC6ENTG translocation and BC6ENTC secretion by BC6OTHER in exogenously activated human eosinophils. CPR:4newlineInhibition of BC6ENTG translocation and BC6OTHER secretion by BC6ENTC in exogenously activated human eosinophils. CPR:4newlineBy contrast, membrane expression of BC6ENTG , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10( - )10 M BC6OTHER , and inhibition of BC6ENTC synthesis was reversed by exogenous BC6OTHER ( BC6OTHER ). CPR:falsenewlineBy contrast, membrane expression of BC6ENTG , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10( - )10 M BC6OTHER , and inhibition of BC6OTHER synthesis was reversed by exogenous BC6ENTC ( BC6OTHER ). CPR:falsenewlineBy contrast, membrane expression of BC6ENTG , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10( - )10 M BC6OTHER , and inhibition of BC6OTHER synthesis was reversed by exogenous BC6OTHER ( BC6ENTC ). CPR:falsenewlineWe find that BC6ENTC causes a decrease in stimulated eosinophil secretion of BC6OTHER that is regulated by BC6ENTG ( BC6OTHER ). CPR:falsenewlineWe find that BC6ENTC causes a decrease in stimulated eosinophil secretion of BC6OTHER that is regulated by BC6OTHER ( BC6ENTG ). CPR:falsenewlineWe find that BC6OTHER causes a decrease in stimulated eosinophil secretion of BC6ENTC that is regulated by BC6ENTG ( BC6OTHER ). CPR:falsenewlineWe find that BC6OTHER causes a decrease in stimulated eosinophil secretion of BC6ENTC that is regulated by BC6OTHER ( BC6ENTG ). CPR:falsenewlineInhibition of BC6ENTC synthesis precedes the global cytotoxic effects of BC6OTHER as indicated by the simultaneous upregulation of BC6ENTG expression. CPR:falsenewlineInhibition of BC6OTHER synthesis precedes the global cytotoxic effects of BC6ENTC as indicated by the simultaneous upregulation of BC6ENTG expression. CPR:falsenewlineWe examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6ENTG ( BC6OTHER ), and (2) blockade of BC6ENTC ( BC6OTHER ) synthesis in isolated human eosinophils in vitro. CPR:falsenewlineWe examined the effect of the highly lipophilic CHEM, BC6OTHER ( BC6OTHER ), in causing (1) inhibition of nuclear translocation of BC6OTHER ( BC6ENTG ), and (2) blockade of BC6ENTC ( BC6OTHER ) synthesis in isolated human eosinophils in vitro. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTC agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewlineThere was no escape of i.c.v. - administered BC6OTHER from brain to the peripheral circulation ruling out a peripheral and supporting a central mechanism of BC6ENTC - BC6ENTG interaction. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6ENTC ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6ENTC ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6ENTC ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6ENTC ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6ENTC , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6ENTC , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6ENTC , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6ENTC , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6ENTC and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6ENTC and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6ENTC as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6ENTC as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6ENTC on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6ENTC on BC6OTHER - (i.p. CPR:falsenewlineBC6OTHER , a weak BC6ENTG antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6ENTC interactions. CPR:falsenewlineBC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6ENTG , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6ENTC interactions. CPR:falsenewlineBC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6ENTG mechanism(s) in BC6OTHER - BC6ENTC interactions. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6ENTC - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6ENTC - (i.p. CPR:falsenewlineBC6ENTC agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTG modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p. CPR:falsenewlineBC6ENTC agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6ENTG agonists and antagonists were given i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6ENTC and BC6OTHER reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6ENTC and BC6ENTG reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6OTHER agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewlineBC6ENTG agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6ENTC - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p. CPR:falsenewlineBC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6ENTC - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTG modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p. CPR:falsenewlineBC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6ENTC - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6ENTG agonists and antagonists were given i.p. CPR:falsenewline To clarify if the behavioral interaction between BC6OTHER and BC6ENTC reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. BC6ENTG agonists, BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , antagonists, BC6OTHER and BC6OTHER as well as BC6OTHER on BC6OTHER - (i.p. CPR:falsenewlineBC6ENTG agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTC modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p. CPR:falsenewlineBC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTC modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6ENTG agonists and antagonists were given i.p. CPR:falsenewlineBC6ENTG agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6ENTC and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p. CPR:falsenewlineBC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTG modulation of this effect of BC6ENTC and confirmed our previous reports in which BC6OTHER agonists and antagonists were given i.p. CPR:falsenewlineBC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6ENTC and confirmed our previous reports in which BC6ENTG agonists and antagonists were given i.p. CPR:falsenewlineBC6ENTG agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6OTHER modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6ENTC agonists and antagonists were given i.p. CPR:falsenewlineBC6OTHER agonists and antagonists dose dependently accentuated and attenuated, respectively, BC6OTHER - induced motor incoordination, thereby suggesting a central mechanism of BC6ENTG modulation of this effect of BC6OTHER and confirmed our previous reports in which BC6ENTC agonists and antagonists were given i.p. CPR:falsenewlineBC6ENTC , a weak BC6OTHER antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6ENTG interactions. CPR:falsenewlineBC6ENTC , a weak BC6ENTG antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6OTHER interactions. CPR:falsenewlineBC6ENTC , a weak BC6OTHER antagonist but potent inhibitor of BC6ENTG , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6OTHER interactions. CPR:falsenewlineBC6ENTC , a weak BC6OTHER antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6ENTG mechanism(s) in BC6OTHER - BC6OTHER interactions. CPR:falsenewlineBC6OTHER , a weak BC6ENTC antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6ENTG interactions. CPR:falsenewlineBC6OTHER , a weak BC6ENTC antagonist but potent inhibitor of BC6ENTG , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6OTHER interactions. CPR:falsenewlineBC6OTHER , a weak BC6ENTC antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6ENTG mechanism(s) in BC6OTHER - BC6OTHER interactions. CPR:falsenewlineResults from R - PIA and BC6ENTC experiments showed nearly a 40 - fold greater potency of R - vs. CHEM, suggesting predominance of BC6ENTG subtype. CPR:falsenewlineBC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6ENTC phosphodiesterase, did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6ENTG interactions. CPR:falsenewlineBC6OTHER , a weak BC6ENTG antagonist but potent inhibitor of BC6ENTC phosphodiesterase, did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6OTHER - BC6OTHER interactions. CPR:falsenewlineBC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6ENTC phosphodiesterase, did not alter CHEM's motor incoordination, further supporting involvement of brain BC6ENTG mechanism(s) in BC6OTHER - BC6OTHER interactions. CPR:falsenewlineBC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6ENTC - BC6ENTG interactions. CPR:falsenewlineBC6OTHER , a weak BC6ENTG antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6ENTC - BC6OTHER interactions. CPR:falsenewlineBC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6ENTG , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6OTHER mechanism(s) in BC6ENTC - BC6OTHER interactions. CPR:falsenewlineBC6OTHER , a weak BC6OTHER antagonist but potent inhibitor of BC6OTHER , did not alter CHEM's motor incoordination, further supporting involvement of brain BC6ENTG mechanism(s) in BC6ENTC - BC6OTHER interactions. CPR:falsenewlineHowever, BC6ENTC data indicate complexity of the mechanism(s) and point toward an additional involvement of a yet unknown subtype of BC6ENTG . CPR:falsenewlineNo effect of CHEM on blood or brain levels of BC6ENTC was noted and sufficient amount of the latter entered the brain to suggest BC6ENTG activation adequate to produce behavioral interaction with BC6OTHER . CPR:falsenewlineNo effect of CHEM on blood or brain levels of BC6OTHER was noted and sufficient amount of the latter entered the brain to suggest BC6ENTG activation adequate to produce behavioral interaction with BC6ENTC . CPR:falsenewlineThere was no escape of i.c.v. - administered BC6ENTC from brain to the peripheral circulation ruling out a peripheral and supporting a central mechanism of BC6OTHER - BC6ENTG interaction. CPR:falsenewlineUnlike bacterial BC6ENTG , the human isomerase reaction is stimulated by BC6ENTC ( BC6OTHER , BC6OTHER ). CPR:falsenewlineUnlike bacterial BC6ENTG , the human isomerase reaction is stimulated by BC6OTHER ( BC6ENTC , BC6OTHER ). CPR:falsenewlineUnlike bacterial BC6ENTG , the human isomerase reaction is stimulated by BC6OTHER ( BC6OTHER , BC6ENTC ). CPR:falsenewlineThe affinity labeling BC6ENTC analog, BC6OTHER ( BC6OTHER ), inactivates the BC6ENTG and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2 - 0.6 mM). CPR:falsenewlineThe affinity labeling BC6OTHER analog, BC6ENTC ( BC6OTHER ), inactivates the BC6ENTG and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2 - 0.6 mM). CPR:falsenewlineThe affinity labeling BC6OTHER analog, BC6OTHER ( BC6ENTC ), inactivates the BC6ENTG and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2 - 0.6 mM). CPR:falsenewlineAnalysis of coenzyme binding by BC6ENTG and BC6OTHER using BC6ENTC , an affinity labeling cofactor analog. CPR:falsenewlineAnalysis of coenzyme binding by human placental BC6OTHER dehydrogenase and BC6ENTG using BC6ENTC , an affinity labeling cofactor analog. CPR:falsenewlineAnalysis of coenzyme binding by human placental BC6ENTC dehydrogenase and BC6ENTG using BC6OTHER , an affinity labeling cofactor analog. CPR:falsenewlineBC6ENTC dehydrogenase and BC6ENTG copurify as a single, homogeneous protein from human placental microsomes. CPR:falsenewlineFSA is a cofactor site - directed reagent that binds with similar affinity as a competitive inhibitor of BC6ENTC reduction by BC6ENTG (Ki = 162 microM) or as a stimulator of isomerase (Km = 153 microM). CPR:9newlineThe BC6ENTC substrate, BC6OTHER , protects isomerase as well as BC6ENTG from inactivation by BC6OTHER . CPR:falsenewlineThe BC6OTHER substrate, BC6ENTC , protects isomerase as well as BC6ENTG from inactivation by BC6OTHER . CPR:falsenewlineThe BC6OTHER substrate, BC6OTHER , protects isomerase as well as BC6ENTG from inactivation by BC6ENTC . CPR:4newlineAffinity alkylation with 2 BC6ENTC suggests that the BC6ENTG and isomerase substrate BC6OTHER bind at different sites on the same protein. CPR:falsenewlineAffinity alkylation with 2 BC6OTHER suggests that the BC6ENTG and isomerase substrate BC6ENTC bind at different sites on the same protein. CPR:falsenewlineMoreover, treatment of high - fat - diet - fed BC6ENTG - knockout mice with a selective BC6OTHER inhibitor, BC6ENTC , improved vascular function, and also attenuated obesity. CPR:falsenewlineMoreover, treatment of high - fat - diet - fed BC6OTHER - knockout mice with a selective BC6ENTG inhibitor, BC6ENTC , improved vascular function, and also attenuated obesity. CPR:4newlineIncreased BC6ENTC / BC6OTHER - exchanger ( BC6ENTG ) and altered BC6OTHER ( BC6OTHER ) responses are observed in failing human heart. CPR:falsenewlineIncreased BC6ENTC / BC6OTHER - exchanger ( BC6OTHER ) and altered BC6ENTG ( BC6OTHER ) responses are observed in failing human heart. CPR:falsenewlineIncreased BC6ENTC / BC6OTHER - exchanger ( BC6OTHER ) and altered BC6OTHER ( BC6ENTG ) responses are observed in failing human heart. CPR:falsenewlineIncreased CHEM / BC6ENTC - exchanger ( BC6ENTG ) and altered BC6OTHER ( BC6OTHER ) responses are observed in failing human heart. CPR:falsenewlineIncreased CHEM / BC6ENTC - exchanger ( BC6OTHER ) and altered BC6ENTG ( BC6OTHER ) responses are observed in failing human heart. CPR:falsenewlineIncreased CHEM / BC6ENTC - exchanger ( BC6OTHER ) and altered BC6OTHER ( BC6ENTG ) responses are observed in failing human heart. CPR:falsenewlineResponses to BC6ENTC were largely mediated through the BC6ENTG in control myocytes. CPR:falsenewlineAdenovirally - mediated overexpression of BC6ENTG , at levels, which did not alter basal contraction of myocytes, markedly depressed the BC6ENTC concentration - response curve. CPR:falsenewlineResponses to BC6ENTC could be restored to normal by BC6ENTG blockade, suggesting a BC6OTHER - mediated inhibition of BC6OTHER signalling. CPR:falsenewlineResponses to BC6ENTC could be restored to normal by BC6OTHER blockade, suggesting a BC6ENTG - mediated inhibition of BC6OTHER signalling. CPR:falsenewlineResponses to BC6ENTC could be restored to normal by BC6OTHER blockade, suggesting a BC6OTHER - mediated inhibition of BC6ENTG signalling. CPR:falsenewlineBC6ENTG normalised BC6ENTC responses in BC6OTHER cells, indicating that BC6OTHER effects were mediated by BC6OTHER . CPR:falsenewlineBC6OTHER normalised BC6ENTC responses in BC6ENTG cells, indicating that BC6OTHER effects were mediated by BC6OTHER . CPR:falsenewlineBC6OTHER normalised BC6ENTC responses in BC6OTHER cells, indicating that BC6ENTG effects were mediated by BC6OTHER . CPR:falsenewlineBC6OTHER normalised BC6ENTC responses in BC6OTHER cells, indicating that BC6OTHER effects were mediated by BC6ENTG . CPR:falsenewlineLoss of BC6ENTG response in myocytes overexpressing the BC6ENTC / BC6OTHER - exchanger. CPR:falsenewlineLoss of BC6ENTG response in myocytes overexpressing the BC6OTHER / BC6ENTC - exchanger. CPR:falsenewlineSelective inhibition of BC6ENTG spares renal function and BC6ENTC synthesis in cirrhotic rats with ascites. CPR:falsenewlineRESULTS: Administration of BC6OTHER to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6ENTG / BC6OTHER inhibitor, BC6OTHER , resulted in a marked reduction in urine volume, urinary excretion of BC6ENTC , and glomerular filtration rate and in a significant impairment in renal water metabolism. CPR:falsenewlineRESULTS: Administration of BC6OTHER to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6OTHER / BC6ENTG inhibitor, BC6OTHER , resulted in a marked reduction in urine volume, urinary excretion of BC6ENTC , and glomerular filtration rate and in a significant impairment in renal water metabolism. CPR:falsenewlineThe current study evaluates the effects of a selective BC6ENTG inhibitor ( BC6ENTC ) on renal function in cirrhotic rats with ascites. CPR:4newlineRESULTS: Administration of BC6ENTC to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6ENTG / BC6OTHER inhibitor, BC6OTHER , resulted in a marked reduction in urine volume, urinary excretion of BC6OTHER , and glomerular filtration rate and in a significant impairment in renal water metabolism. CPR:falsenewlineRESULTS: Administration of BC6ENTC to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6OTHER / BC6ENTG inhibitor, BC6OTHER , resulted in a marked reduction in urine volume, urinary excretion of BC6OTHER , and glomerular filtration rate and in a significant impairment in renal water metabolism. CPR:falsenewlineRESULTS: Administration of BC6OTHER to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6ENTG / BC6OTHER inhibitor, BC6ENTC , resulted in a marked reduction in urine volume, urinary excretion of BC6OTHER , and glomerular filtration rate and in a significant impairment in renal water metabolism. CPR:falsenewlineRESULTS: Administration of BC6OTHER to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective BC6OTHER / BC6ENTG inhibitor, BC6ENTC , resulted in a marked reduction in urine volume, urinary excretion of BC6OTHER , and glomerular filtration rate and in a significant impairment in renal water metabolism. CPR:4newlineFurthermore, BC6ENTC , a specific BC6ENTG phosphorylation - inducing agent, increased BC6OTHER and BC6OTHER expression in the presence of VA. CPR:falsenewlineFurthermore, BC6ENTC , a specific BC6OTHER phosphorylation - inducing agent, increased BC6ENTG and BC6OTHER expression in the presence of VA. CPR:falsenewlineFurthermore, BC6ENTC , a specific BC6OTHER phosphorylation - inducing agent, increased BC6OTHER and BC6ENTG expression in the presence of VA. CPR:falsenewlineTherefore, we examined whether BC6ENTC (VA) sensitize BC6ENTG - induced apoptosis in cancer cells by induction of ER stress. CPR:falsenewline BC6ENTC sensitizes BC6ENTG - induced apoptosis via the upregulation of BC6OTHER in an BC6OTHER / BC6OTHER - dependent manner. CPR:falsenewline BC6ENTC sensitizes BC6OTHER - induced apoptosis via the upregulation of BC6ENTG in an BC6OTHER / BC6OTHER - dependent manner. CPR:3newline BC6ENTC sensitizes BC6OTHER - induced apoptosis via the upregulation of BC6OTHER in an BC6ENTG / BC6OTHER - dependent manner. CPR:falsenewline BC6ENTC sensitizes BC6OTHER - induced apoptosis via the upregulation of BC6OTHER in an BC6OTHER / BC6ENTG - dependent manner. CPR:falsenewlineBC6ENTC receptor - alpha ( BC6ENTG ) antagonists have been widely used for breast cancer therapy. CPR:falsenewlineWith the CHEM linked through the C7alpha position of BC6ENTC , the resulting PROTAC shows the most effective BC6ENTG degradation and highest affinity for the BC6OTHER receptor. CPR:falsenewlineWith the CHEM linked through the C7alpha position of BC6ENTC , the resulting PROTAC shows the most effective BC6OTHER degradation and highest affinity for the BC6ENTG . CPR:falsenewlineWith the CHEM linked through the C7alpha position of BC6OTHER , the resulting PROTAC shows the most effective BC6ENTG degradation and highest affinity for the BC6ENTC receptor. CPR:falsenewlineThis result provides an opportunity to develop a novel type of BC6ENTG antagonist that may overcome the resistance of breast tumors to conventional drugs such as BC6ENTC and BC6OTHER ( BC6OTHER ). CPR:falsenewlineThis result provides an opportunity to develop a novel type of BC6ENTG antagonist that may overcome the resistance of breast tumors to conventional drugs such as BC6OTHER and BC6ENTC ( BC6OTHER ). CPR:falsenewlineThis result provides an opportunity to develop a novel type of BC6ENTG antagonist that may overcome the resistance of breast tumors to conventional drugs such as BC6OTHER and BC6OTHER ( BC6ENTC ). CPR:falsenewlineRecent studies indicate that BC6ENTC initially acts as an antagonist, but later functions as an BC6ENTG agonist, promoting tumor growth. CPR:falsenewlineThe BC6ENTG - targeting PROTACs are composed of an BC6ENTC on one end and a BC6OTHER ( BC6OTHER ) - derived synthetic CHEM on the other. CPR:falsenewlineThe BC6OTHER - targeting PROTACs are composed of an BC6ENTC on one end and a BC6ENTG ( BC6OTHER ) - derived synthetic CHEM on the other. CPR:falsenewlineThe BC6OTHER - targeting PROTACs are composed of an BC6ENTC on one end and a BC6OTHER ( BC6ENTG ) - derived synthetic CHEM on the other. CPR:falsenewlineAltogether, our results prove the importance of BC6ENTC homeostasis in the BC6ENTG - effector system and suggest a possible mechanism by which this vitamin may regulate the neuronal cell survival in the adult hippocampus. CPR:falsenewlineWe previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by BC6ENTC in the rat dentate gyrus, increasing BC6ENTG phosphorylation. CPR:falsenewlineTo gain a better understanding of the molecular actions of BC6ENTC and examine the link among BC6OTHER , BC6ENTG and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6OTHER signaling pathway and neuronal survival in the rat hippocampus. CPR:falsenewlineTo gain a better understanding of the molecular actions of BC6ENTC and examine the link among BC6OTHER , BC6OTHER and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6ENTG signaling pathway and neuronal survival in the rat hippocampus. CPR:falsenewlineTo gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6ENTC , BC6ENTG and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6OTHER signaling pathway and neuronal survival in the rat hippocampus. CPR:falsenewlineTo gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6ENTC , BC6OTHER and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6ENTG signaling pathway and neuronal survival in the rat hippocampus. CPR:falsenewlineTo gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6OTHER , BC6ENTC and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6ENTG signaling pathway and neuronal survival in the rat hippocampus. CPR:falsenewlineTo gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6OTHER , BC6ENTG and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6ENTC on the BC6OTHER signaling pathway and neuronal survival in the rat hippocampus. CPR:falsenewlineTo gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6OTHER , BC6OTHER and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6ENTC on the BC6ENTG signaling pathway and neuronal survival in the rat hippocampus. CPR:falsenewlineTo gain a better understanding of the molecular actions of BC6OTHER and examine the link among BC6OTHER , BC6ENTG and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of BC6OTHER on the BC6ENTC signaling pathway and neuronal survival in the rat hippocampus. CPR:falsenewlineNo changes in BC6ENTG expression were detected in BC6ENTC - deficient rats. CPR:falsenewlineThese rats, however, showed a significant increase in the BC6ENTC receptor density and dissociation constant, which correlated with a significant increase in the protein levels of BC6ENTG . CPR:falsenewline BC6ENTC deficiency impairs the BC6ENTG - effector system and leads to BC6OTHER overactivation and cell death in the rat hippocampus. CPR:falsenewline BC6ENTC deficiency impairs the BC6OTHER - effector system and leads to BC6ENTG overactivation and cell death in the rat hippocampus. CPR:falsenewline BC6OTHER deficiency impairs the BC6ENTG - effector system and leads to BC6ENTC phosphatase overactivation and cell death in the rat hippocampus. CPR:falsenewlineThese rats, however, showed a significant increase in the BC6ENTG density and dissociation constant, which correlated with a significant increase in the protein levels of BC6ENTC receptors. CPR:falsenewlineNevertheless, BC6ENTC deficiency impaired the ability of the BC6ENTG to couple to the effectors BC6OTHER cyclase and BC6OTHER phosphatase by diminishing BC6OTHER functionality. CPR:falsenewlineNevertheless, BC6ENTC deficiency impaired the ability of the BC6OTHER receptors to couple to the effectors BC6OTHER cyclase and BC6ENTG by diminishing BC6OTHER functionality. CPR:falsenewlineNevertheless, BC6ENTC deficiency impaired the ability of the BC6OTHER receptors to couple to the effectors BC6OTHER cyclase and BC6OTHER phosphatase by diminishing BC6ENTG functionality. CPR:falsenewlineNevertheless, BC6OTHER deficiency impaired the ability of the BC6ENTC receptors to couple to the effectors BC6OTHER cyclase and BC6ENTG by diminishing BC6OTHER functionality. CPR:falsenewlineNevertheless, BC6OTHER deficiency impaired the ability of the BC6ENTC receptors to couple to the effectors BC6OTHER cyclase and BC6OTHER phosphatase by diminishing BC6ENTG functionality. CPR:falsenewlineNevertheless, BC6OTHER deficiency impaired the ability of the BC6ENTG to couple to the effectors BC6ENTC cyclase and BC6OTHER phosphatase by diminishing BC6OTHER functionality. CPR:falsenewlineNevertheless, BC6OTHER deficiency impaired the ability of the BC6OTHER receptors to couple to the effectors BC6ENTC cyclase and BC6ENTG by diminishing BC6OTHER functionality. CPR:falsenewlineNevertheless, BC6OTHER deficiency impaired the ability of the BC6OTHER receptors to couple to the effectors BC6ENTC cyclase and BC6OTHER phosphatase by diminishing BC6ENTG functionality. CPR:falsenewlineNevertheless, BC6OTHER deficiency impaired the ability of the BC6ENTG to couple to the effectors BC6OTHER cyclase and BC6ENTC phosphatase by diminishing BC6OTHER functionality. CPR:falsenewlineNevertheless, BC6OTHER deficiency impaired the ability of the BC6OTHER receptors to couple to the effectors BC6OTHER cyclase and BC6ENTC phosphatase by diminishing BC6ENTG functionality. CPR:falsenewlineFurthermore, BC6ENTC deficiency significantly increased BC6ENTG activity and BC6OTHER expression, as well as BC6OTHER activation, and decreased BC6OTHER phosphorylation. CPR:falsenewlineFurthermore, BC6ENTC deficiency significantly increased BC6OTHER phosphatase activity and BC6ENTG expression, as well as BC6OTHER activation, and decreased BC6OTHER phosphorylation. CPR:falsenewlineFurthermore, BC6ENTC deficiency significantly increased BC6OTHER phosphatase activity and BC6OTHER expression, as well as BC6ENTG activation, and decreased BC6OTHER phosphorylation. CPR:falsenewlineFurthermore, BC6ENTC deficiency significantly increased BC6OTHER phosphatase activity and BC6OTHER expression, as well as BC6OTHER activation, and decreased BC6ENTG phosphorylation. CPR:falsenewlineFurthermore, BC6OTHER deficiency significantly increased BC6ENTC phosphatase activity and BC6ENTG expression, as well as BC6OTHER activation, and decreased BC6OTHER phosphorylation. CPR:falsenewlineFurthermore, BC6OTHER deficiency significantly increased BC6ENTC phosphatase activity and BC6OTHER expression, as well as BC6ENTG activation, and decreased BC6OTHER phosphorylation. CPR:falsenewlineFurthermore, BC6OTHER deficiency significantly increased BC6ENTC phosphatase activity and BC6OTHER expression, as well as BC6OTHER activation, and decreased BC6ENTG phosphorylation. CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6ENTC ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6ENTG and BC6OTHER receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER . CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6ENTC ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6ENTG receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER . CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6ENTC ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6OTHER receptors and BC6ENTG antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER . CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6ENTC derivative agonist of BC6ENTG and BC6OTHER receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER . CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6ENTC derivative agonist of BC6OTHER and BC6ENTG receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER . CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6ENTC derivative agonist of BC6OTHER and BC6OTHER receptors and BC6ENTG antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER . CPR:falsenewlineOn the contrary, pretreatment with BC6ENTC worsened BC6OTHER - induced erosions, however, did not affect gastric mucus secretion, BC6ENTG content or BC6OTHER levels, although the non - protein BC6OTHER fraction was significantly decreased. CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6OTHER ( BC6ENTC ), a novel prokinetic BC6OTHER derivative agonist of BC6ENTG and BC6OTHER receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER . CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6OTHER ( BC6ENTC ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6ENTG receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER . CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6OTHER ( BC6ENTC ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6OTHER receptors and BC6ENTG antagonist, on mucosal injury produced by 50% (v / v) BC6OTHER . CPR:falsenewlineOn the contrary, pretreatment with BC6OTHER worsened BC6ENTC - induced erosions, however, did not affect gastric mucus secretion, BC6ENTG content or BC6OTHER levels, although the non - protein BC6OTHER fraction was significantly decreased. CPR:falsenewlineOn the contrary, pretreatment with BC6OTHER worsened BC6OTHER - induced erosions, however, did not affect gastric mucus secretion, BC6ENTG content or BC6ENTC levels, although the non - protein BC6OTHER fraction was significantly decreased. CPR:falsenewlineOn the contrary, pretreatment with BC6OTHER worsened BC6OTHER - induced erosions, however, did not affect gastric mucus secretion, BC6ENTG content or BC6OTHER levels, although the non - protein BC6ENTC fraction was significantly decreased. CPR:falsenewlineWe suggest that BC6ENTC dependent mechanisms through BC6ENTG receptor blockade and BC6OTHER receptor activation could be also involved. CPR:falsenewlineWe suggest that BC6ENTC dependent mechanisms through BC6OTHER receptor blockade and BC6ENTG receptor activation could be also involved. CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6ENTG and BC6OTHER receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6ENTC . CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6ENTG receptors and BC6OTHER antagonist, on mucosal injury produced by 50% (v / v) BC6ENTC . CPR:falsenewlineThis study was designed to determine the gastroprotective properties of BC6OTHER ( BC6OTHER ), a novel prokinetic BC6OTHER derivative agonist of BC6OTHER and BC6OTHER receptors and BC6ENTG antagonist, on mucosal injury produced by 50% (v / v) BC6ENTC . CPR:falsenewline Synthesis, biological evaluation, and molecular modeling of BC6OTHER derivatives as potent BC6ENTG inhibitors with anti - heart - failure activity in vivo. Novel BC6OTHER (GL) derivatives were designed and synthesized by introducing various BC6OTHER or BC6OTHER residues into the BC6ENTC chain and at C - 30. CPR:falsenewline Synthesis, biological evaluation, and molecular modeling of BC6OTHER derivatives as potent BC6ENTG inhibitors with anti - heart - failure activity in vivo. Novel BC6ENTC (GL) derivatives were designed and synthesized by introducing various BC6OTHER or BC6OTHER residues into the BC6OTHER chain and at C - 30. CPR:falsenewline Synthesis, biological evaluation, and molecular modeling of BC6OTHER derivatives as potent BC6ENTG inhibitors with anti - heart - failure activity in vivo. Novel BC6OTHER (GL) derivatives were designed and synthesized by introducing various BC6ENTC or BC6OTHER residues into the BC6OTHER chain and at C - 30. CPR:falsenewline Synthesis, biological evaluation, and molecular modeling of BC6OTHER derivatives as potent BC6ENTG inhibitors with anti - heart - failure activity in vivo. Novel BC6OTHER (GL) derivatives were designed and synthesized by introducing various BC6OTHER or BC6ENTC residues into the BC6OTHER chain and at C - 30. CPR:falsenewline Synthesis, biological evaluation, and molecular modeling of BC6ENTC derivatives as potent BC6ENTG inhibitors with anti - heart - failure activity in vivo. Novel BC6OTHER (GL) derivatives were designed and synthesized by introducing various BC6OTHER or BC6OTHER residues into the BC6OTHER chain and at C - 30. CPR:falsenewlineThe purpose of this investigation was to determine whether this pH - dependent uptake represents BC6OTHER / BC6ENTC cotransport via a BC6ENTG - like transport system. CPR:9newlineThe BC6ENTG cDNA was isolated (2296bp including both 5' and 3' untranslated regions and BC6OTHER and the BC6OTHER codes for a protein of 475 BC6ENTC (92% identity to BC6OTHER ). CPR:falsenewlineThe BC6OTHER cDNA was isolated (2296bp including both 5' and 3' untranslated regions and BC6ENTG and the BC6OTHER codes for a protein of 475 BC6ENTC (92% identity to BC6OTHER ). CPR:falsenewlineThe BC6OTHER cDNA was isolated (2296bp including both 5' and 3' untranslated regions and BC6OTHER and the BC6ENTG codes for a protein of 475 BC6ENTC (92% identity to BC6OTHER ). CPR:falsenewlineThe BC6OTHER cDNA was isolated (2296bp including both 5' and 3' untranslated regions and BC6OTHER and the BC6OTHER codes for a protein of 475 BC6ENTC (92% identity to BC6ENTG ). CPR:falsenewlineWhen expressed heterologously in a mammalian cell line, BC6ENTG mediates pH - dependent, BC6ENTC - independent uptake of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineWhen expressed heterologously in a mammalian cell line, BC6ENTG mediates pH - dependent, BC6OTHER - independent uptake of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER . CPR:9newlineWhen expressed heterologously in a mammalian cell line, BC6ENTG mediates pH - dependent, BC6OTHER - independent uptake of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER . CPR:9newlineWhen expressed heterologously in a mammalian cell line, BC6ENTG mediates pH - dependent, BC6OTHER - independent uptake of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER . CPR:9newlineWhen expressed heterologously in a mammalian cell line, BC6ENTG mediates pH - dependent, BC6OTHER - independent uptake of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC . CPR:9newlineIsolation and function of the BC6ENTC transporter PAT1 ( BC6OTHER ) from rabbit and discrimination between transport via BC6ENTG and BC6OTHER in renal brush - border membrane vesicles. CPR:falsenewlineIsolation and function of the BC6ENTC transporter PAT1 ( BC6OTHER ) from rabbit and discrimination between transport via BC6OTHER and BC6ENTG in renal brush - border membrane vesicles. CPR:falsenewlineIsolation and function of the BC6ENTC transporter PAT1 ( BC6ENTG ) from rabbit and discrimination between transport via BC6OTHER and BC6OTHER in renal brush - border membrane vesicles. CPR:9newlineIn the presence of BC6ENTC and under conditions in which BC6ENTG transport function was suppressed, a second BC6OTHER uptake system was detected that exhibited functional characteristics similar to those of the BC6OTHER . CPR:falsenewlineIn the presence of BC6ENTC and under conditions in which BC6OTHER transport function was suppressed, a second BC6OTHER uptake system was detected that exhibited functional characteristics similar to those of the BC6ENTG . CPR:falsenewlineIn the presence of BC6OTHER and under conditions in which BC6ENTG transport function was suppressed, a second BC6ENTC uptake system was detected that exhibited functional characteristics similar to those of the BC6OTHER . CPR:9newlineIn the presence of BC6OTHER and under conditions in which BC6OTHER transport function was suppressed, a second BC6ENTC uptake system was detected that exhibited functional characteristics similar to those of the BC6ENTG . CPR:9newlineThe functional characteristics of BC6ENTG in either mammalian cells or renal BBMV suggest that BC6OTHER is the low - affinity transporter of BC6ENTC , BC6OTHER and BC6OTHER believed to be defective in patients with iminoglycinuria. CPR:9newlineThe functional characteristics of BC6OTHER in either mammalian cells or renal BBMV suggest that BC6ENTG is the low - affinity transporter of BC6ENTC , BC6OTHER and BC6OTHER believed to be defective in patients with iminoglycinuria. CPR:9newlineThe functional characteristics of BC6ENTG in either mammalian cells or renal BBMV suggest that BC6OTHER is the low - affinity transporter of BC6OTHER , BC6ENTC and BC6OTHER believed to be defective in patients with iminoglycinuria. CPR:9newlineThe functional characteristics of BC6OTHER in either mammalian cells or renal BBMV suggest that BC6ENTG is the low - affinity transporter of BC6OTHER , BC6ENTC and BC6OTHER believed to be defective in patients with iminoglycinuria. CPR:9newlineThe functional characteristics of BC6ENTG in either mammalian cells or renal BBMV suggest that BC6OTHER is the low - affinity transporter of BC6OTHER , BC6OTHER and BC6ENTC believed to be defective in patients with iminoglycinuria. CPR:9newlineThe functional characteristics of BC6OTHER in either mammalian cells or renal BBMV suggest that BC6ENTG is the low - affinity transporter of BC6OTHER , BC6OTHER and BC6ENTC believed to be defective in patients with iminoglycinuria. CPR:9newlineThe purpose of this investigation was to determine whether this pH - dependent uptake represents BC6ENTC / BC6OTHER cotransport via a BC6ENTG - like transport system. CPR:9newlineCHEM - incubation with BC6ENTG or BC6OTHER but not BC6OTHER protected BC6OTHER from BC6ENTC . CPR:falsenewlineCHEM - incubation with BC6OTHER or BC6OTHER but not BC6OTHER protected BC6ENTG from BC6ENTC . CPR:falsenewlineInhibition of testicular BC6ENTG from laboratory animals and man by BC6ENTC and its isomers. CPR:4newlineCHEM inhibited BC6ENTG prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster. CPR:falsenewlineThe inhibitory effect of BC6ENTC and BC6OTHER upon testicular cytosolic BC6ENTG was measured in vitro. CPR:4newlineBC6ENTG activity measured in vitro in serum of men and hamsters was unaffected by BC6ENTC . CPR:falsenewlineBC6ENTC and its isomers were non - competitive inhibitors of BC6ENTG with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6OTHER . CPR:falsenewlineBC6ENTC and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6ENTG and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6OTHER . CPR:falsenewlineBC6ENTC and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6ENTG with respect to the substrate BC6OTHER . CPR:falsenewlineThe inhibitory effect of BC6OTHER and BC6ENTC upon testicular cytosolic BC6ENTG was measured in vitro. CPR:4newlineBC6OTHER and its isomers were non - competitive inhibitors of BC6ENTG with respect to the coenzyme BC6ENTC , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6OTHER . CPR:falsenewlineBC6OTHER and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6ENTC , competitive inhibitors of BC6ENTG and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6OTHER . CPR:falsenewlineBC6OTHER and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6ENTC , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6ENTG with respect to the substrate BC6OTHER . CPR:falsenewlineBC6OTHER and its isomers were non - competitive inhibitors of BC6ENTG with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6ENTC . CPR:falsenewlineBC6OTHER and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6ENTG and noncompetitive - competitive inhibitors of BC6OTHER with respect to the substrate BC6ENTC . CPR:falsenewlineBC6OTHER and its isomers were non - competitive inhibitors of BC6OTHER with respect to the coenzyme BC6OTHER , competitive inhibitors of BC6OTHER and noncompetitive - competitive inhibitors of BC6ENTG with respect to the substrate BC6ENTC . CPR:falsenewlineCHEM - incubation with BC6ENTG or BC6ENTC but not BC6OTHER protected BC6OTHER from BC6OTHER . CPR:falsenewlineCHEM - incubation with BC6OTHER or BC6ENTC but not BC6OTHER protected BC6ENTG from BC6OTHER . CPR:falsenewlineCHEM - incubation with BC6ENTG or BC6OTHER but not BC6ENTC protected BC6OTHER from BC6OTHER . CPR:falsenewlineCHEM - incubation with BC6OTHER or BC6OTHER but not BC6ENTC protected BC6ENTG from BC6OTHER . CPR:falsenewlineThese include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6ENTG ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, or blockers of biliary excretion of BC6ENTC . CPR:falsenewlineThese include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6OTHER ( BC6ENTG ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, or blockers of biliary excretion of BC6ENTC . CPR:falsenewlineThese include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6OTHER ( BC6OTHER ) inhibitors, BC6ENTG ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, or blockers of biliary excretion of BC6ENTC . CPR:falsenewlineThese include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6ENTG ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, or blockers of biliary excretion of BC6ENTC . CPR:falsenewlineThese include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, BC6ENTG ( BC6OTHER ) inhibitors, or blockers of biliary excretion of BC6ENTC . CPR:falsenewlineThese include intestinal alkalizing agents, oral antibiotics, enzyme inducers, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6OTHER ) inhibitors, BC6OTHER ( BC6ENTG ) inhibitors, or blockers of biliary excretion of BC6ENTC . CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6ENTG ( BC6OTHER ). CPR:4newlineBC6OTHER ( BC6OTHER , BC6ENTC ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6OTHER ( BC6ENTG ). CPR:4newlineEarly - onset diarrhea is observed immediately after BC6ENTC infusion and probably due to the inhibition of BC6ENTG activity, which can be eliminated by administration of BC6OTHER . CPR:falsenewlineEarly - onset diarrhea is observed immediately after BC6OTHER infusion and probably due to the inhibition of BC6ENTG activity, which can be eliminated by administration of BC6ENTC . CPR:falsenewlineLate - onset diarrhea appears to be associated with intestinal exposure to BC6ENTC ( BC6OTHER ), the major active metabolite of BC6OTHER , which may bind to BC6ENTG and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa. CPR:falsenewlineLate - onset diarrhea appears to be associated with intestinal exposure to BC6OTHER ( BC6ENTC ), the major active metabolite of BC6OTHER , which may bind to BC6ENTG and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa. CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6ENTG ( BC6OTHER ). CPR:4newlineBC6ENTC ( BC6OTHER , BC6OTHER ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6OTHER ( BC6ENTG ). CPR:4newlineLate - onset diarrhea appears to be associated with intestinal exposure to BC6OTHER ( BC6OTHER ), the major active metabolite of BC6ENTC , which may bind to BC6ENTG and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa. CPR:falsenewlineBC6ENTC and BC6OTHER may also stimulate the production of pro - inflammatory BC6ENTG and BC6OTHER ( BC6OTHER ), thus inducing the secretion of BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6ENTC may also stimulate the production of pro - inflammatory BC6ENTG and BC6OTHER ( BC6OTHER ), thus inducing the secretion of BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6ENTG ( BC6OTHER ). CPR:4newlineBC6OTHER ( BC6ENTC , BC6OTHER ) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting BC6OTHER ( BC6ENTG ). CPR:4newlineBC6OTHER and BC6OTHER may also stimulate the production of pro - inflammatory BC6ENTG and BC6ENTC ( BC6OTHER ), thus inducing the secretion of BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER may also stimulate the production of pro - inflammatory BC6ENTG and BC6OTHER ( BC6ENTC ), thus inducing the secretion of BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER may also stimulate the production of pro - inflammatory BC6ENTG and BC6OTHER ( BC6OTHER ), thus inducing the secretion of BC6ENTC and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER may also stimulate the production of pro - inflammatory BC6ENTG and BC6OTHER ( BC6OTHER ), thus inducing the secretion of BC6OTHER and BC6ENTC . CPR:falsenewlineProteins BC6ENTG and BC6OTHER were not found to be involved in BC6ENTC import. CPR:falsenewlineProteins BC6OTHER and BC6ENTG were not found to be involved in BC6ENTC import. CPR:falsenewlineThe presence of BC6ENTC hormones most probably causes the degradation of the BC6ENTG permease and impairment of BC6OTHER import. CPR:falsenewlineThe presence of BC6OTHER hormones most probably causes the degradation of the BC6ENTG permease and impairment of BC6ENTC import. CPR:falsenewlineThe expression of the osteoblast markers BC6OTHER ( BC6ENTG ) and BC6OTHER was decreased, while BC6OTHER ( BC6OTHER ) was augmented in BC6OTHER ( - / - ) and BC6ENTC - RANTES - treated mice. CPR:falsenewlineThe expression of the osteoblast markers BC6OTHER ( BC6OTHER ) and BC6ENTG was decreased, while BC6OTHER ( BC6OTHER ) was augmented in BC6OTHER ( - / - ) and BC6ENTC - RANTES - treated mice. CPR:falsenewlineThe expression of the osteoblast markers BC6OTHER ( BC6OTHER ) and BC6OTHER was decreased, while BC6ENTG ( BC6OTHER ) was augmented in BC6OTHER ( - / - ) and BC6ENTC - RANTES - treated mice. CPR:falsenewlineThe expression of the osteoblast markers BC6OTHER ( BC6OTHER ) and BC6OTHER was decreased, while BC6OTHER ( BC6ENTG ) was augmented in BC6OTHER ( - / - ) and BC6ENTC - RANTES - treated mice. CPR:falsenewlineThe expression of the osteoblast markers BC6OTHER ( BC6OTHER ) and BC6OTHER was decreased, while BC6OTHER ( BC6OTHER ) was augmented in BC6ENTG ( - / - ) and BC6ENTC - RANTES - treated mice. CPR:falsenewlineThe expression of the osteoblast markers BC6ENTG ( BC6OTHER ) and BC6OTHER was decreased, while BC6OTHER ( BC6OTHER ) was augmented in BC6OTHER ( - / - ) and BC6ENTC - RANTES - treated mice. CPR:falsenewlineOur results showed that bone remodeling was significantly decreased in BC6ENTG ( - / - ) and BC6OTHER ( - / - ) mice and in animals treated with BC6ENTC - RANTES (an antagonist of BC6OTHER and BC6OTHER ). CPR:falsenewlineOur results showed that bone remodeling was significantly decreased in BC6OTHER ( - / - ) and BC6ENTG ( - / - ) mice and in animals treated with BC6ENTC - RANTES (an antagonist of BC6OTHER and BC6OTHER ). CPR:falsenewlineOur results showed that bone remodeling was significantly decreased in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice and in animals treated with BC6ENTC - RANTES (an antagonist of BC6ENTG and BC6OTHER ). CPR:falsenewlineOur results showed that bone remodeling was significantly decreased in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice and in animals treated with BC6ENTC - RANTES (an antagonist of BC6OTHER and BC6ENTG ). CPR:falsenewlinemRNA levels of BC6ENTG ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES. CPR:falsenewlinemRNA levels of BC6OTHER ( BC6ENTG ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES. CPR:falsenewlinemRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES. CPR:falsenewlinemRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6ENTG ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES. CPR:falsenewlinemRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6ENTG ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES. CPR:falsenewlinemRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTG / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES. CPR:falsenewlinemRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6ENTG ( BC6OTHER ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES. CPR:falsenewlinemRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6ENTG ) ratio were diminished in the periodontium of BC6OTHER ( - / - ) mice and in the group treated with BC6ENTC - RANTES. CPR:falsenewlinemRNA levels of BC6OTHER ( BC6OTHER ), its ligand BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER / BC6OTHER ( BC6OTHER ) ratio were diminished in the periodontium of BC6ENTG ( - / - ) mice and in the group treated with BC6ENTC - RANTES. CPR:falsenewlineBC6ENTC - RANTES treatment also reduced the levels of BC6ENTG and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6ENTC - RANTES treatment also reduced the levels of BC6OTHER and BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6ENTC - RANTES treatment also reduced the levels of BC6OTHER and BC6OTHER ( BC6ENTG ). CPR:falsenewlineTo elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6ENTG - specific compound, BC6ENTC , a BC6OTHER - specific ligand, BC6OTHER , and a BC6OTHER coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction. CPR:falsenewlineTo elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6ENTC , a BC6ENTG - specific ligand, BC6OTHER , and a BC6OTHER coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction. CPR:falsenewlineTo elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6ENTC , a BC6OTHER - specific ligand, BC6OTHER , and a BC6ENTG coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction. CPR:falsenewlineTo elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6ENTG - specific compound, BC6OTHER , a BC6OTHER - specific ligand, BC6ENTC , and a BC6OTHER coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction. CPR:falsenewlineTo elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6OTHER , a BC6ENTG - specific ligand, BC6ENTC , and a BC6OTHER coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction. CPR:falsenewlineTo elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6OTHER , a BC6OTHER - specific ligand, BC6ENTC , and a BC6ENTG coagonist, BC6OTHER , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction. CPR:falsenewlineTo elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6ENTG - specific compound, BC6OTHER , a BC6OTHER - specific ligand, BC6OTHER , and a BC6OTHER coagonist, BC6ENTC , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction. CPR:falsenewlineTo elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6OTHER , a BC6ENTG - specific ligand, BC6OTHER , and a BC6OTHER coagonist, BC6ENTC , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction. CPR:falsenewlineTo elucidate the target genes regulated by these compounds, we treated Zucker diabetic CHEM (ZDF) for 15 days with a BC6OTHER - specific compound, BC6OTHER , a BC6OTHER - specific ligand, BC6OTHER , and a BC6ENTG coagonist, BC6ENTC , and measured the levels of several messenger RNAs (mRNAs) in liver by real - time polymerase chain reaction. CPR:falsenewlineBC6ENTC and BC6OTHER induced expression of BC6ENTG and BC6OTHER and reduced BC6OTHER and BC6OTHER mRNAs. CPR:falsenewlineBC6ENTC and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6ENTG and reduced BC6OTHER and BC6OTHER mRNAs. CPR:falsenewlineBC6ENTC and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6ENTG and BC6OTHER mRNAs. CPR:falsenewlineBC6ENTC and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6OTHER and BC6ENTG mRNAs. CPR:falsenewlineBC6OTHER and BC6ENTC induced expression of BC6ENTG and BC6OTHER and reduced BC6OTHER and BC6OTHER mRNAs. CPR:falsenewlineBC6OTHER and BC6ENTC induced expression of CHEM ( BC6OTHER ) oxidase and BC6ENTG and reduced BC6OTHER and BC6OTHER mRNAs. CPR:falsenewlineBC6OTHER and BC6ENTC induced expression of CHEM ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6ENTG and BC6OTHER mRNAs. CPR:falsenewlineBC6OTHER and BC6ENTC induced expression of CHEM ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6OTHER and BC6ENTG mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of BC6ENTC ( BC6OTHER ) oxidase and BC6ENTG and reduced BC6OTHER and BC6OTHER mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of BC6ENTC ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6ENTG and BC6OTHER mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of BC6ENTC ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6OTHER and BC6ENTG mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of CHEM ( BC6ENTC ) oxidase and BC6ENTG and reduced BC6OTHER and BC6OTHER mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of CHEM ( BC6ENTC ) oxidase and BC6OTHER and reduced BC6ENTG and BC6OTHER mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of CHEM ( BC6ENTC ) oxidase and BC6OTHER and reduced BC6OTHER and BC6ENTG mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of BC6ENTG and BC6ENTC hydratase and reduced BC6OTHER and BC6OTHER mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6ENTC hydratase and reduced BC6ENTG and BC6OTHER mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6ENTC hydratase and reduced BC6OTHER and BC6ENTG mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of BC6ENTG and BC6OTHER and reduced BC6OTHER and BC6ENTC carboxykinase mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6ENTG and reduced BC6OTHER and BC6ENTC carboxykinase mRNAs. CPR:falsenewlineBC6OTHER and BC6OTHER induced expression of CHEM ( BC6OTHER ) oxidase and BC6OTHER and reduced BC6ENTG and BC6ENTC carboxykinase mRNAs. CPR:falsenewlineBC6ENTC modestly increased BC6OTHER mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6ENTG and BC6OTHER carboxykinase in adipose tissue. CPR:falsenewlineBC6ENTC modestly increased BC6OTHER mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6OTHER transporter 4 and BC6ENTG in adipose tissue. CPR:falsenewlineBC6ENTC modestly increased BC6ENTG mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6OTHER transporter 4 and BC6OTHER carboxykinase in adipose tissue. CPR:falsenewlineBC6OTHER modestly increased BC6OTHER mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6ENTC transporter 4 and BC6ENTG in adipose tissue. CPR:falsenewlineBC6OTHER modestly increased BC6ENTG mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6ENTC transporter 4 and BC6OTHER carboxykinase in adipose tissue. CPR:falsenewlineBC6OTHER modestly increased BC6OTHER mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6ENTG and BC6ENTC carboxykinase in adipose tissue. CPR:falsenewlineBC6OTHER modestly increased BC6ENTG mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of BC6OTHER transporter 4 and BC6ENTC carboxykinase in adipose tissue. CPR:falsenewlineBC6ENTC bind to the BC6ENTG , and BC6OTHER are ligands of BC6OTHER . CPR:falsenewlineBC6ENTC bind to the BC6OTHER , and BC6OTHER are ligands of BC6ENTG . CPR:falsenewlineThe results of these studies suggest that activation of BC6ENTG as well as BC6OTHER in therapy for type 2 diabetes will enhance BC6ENTC and BC6OTHER control by combining actions in hepatic and peripheral tissues. CPR:falsenewlineThe results of these studies suggest that activation of BC6OTHER as well as BC6ENTG in therapy for type 2 diabetes will enhance BC6ENTC and BC6OTHER control by combining actions in hepatic and peripheral tissues. CPR:falsenewlineThe results of these studies suggest that activation of BC6ENTG as well as BC6OTHER in therapy for type 2 diabetes will enhance BC6OTHER and BC6ENTC control by combining actions in hepatic and peripheral tissues. CPR:falsenewlineThe results of these studies suggest that activation of BC6OTHER as well as BC6ENTG in therapy for type 2 diabetes will enhance BC6OTHER and BC6ENTC control by combining actions in hepatic and peripheral tissues. CPR:falsenewlineBC6OTHER bind to the BC6ENTG , and BC6ENTC are ligands of BC6OTHER . CPR:falsenewlineBC6OTHER bind to the BC6OTHER , and BC6ENTC are ligands of BC6ENTG . CPR:falsenewlineWe report the discovery of novel series of highly potent BC6ENTG agonists based on BC6OTHER , 1 and 2 by introducing and optimizing various BC6ENTC onto the BC6OTHER (9) - position of the BC6OTHER moiety. CPR:falsenewlineWe report the discovery of novel series of highly potent BC6ENTG agonists based on BC6OTHER , 1 and 2 by introducing and optimizing various BC6OTHER onto the BC6ENTC (9) - position of the BC6OTHER moiety. CPR:falsenewlineWe report the discovery of novel series of highly potent BC6ENTG agonists based on BC6OTHER , 1 and 2 by introducing and optimizing various BC6OTHER onto the BC6OTHER (9) - position of the BC6ENTC moiety. CPR:falsenewlineThe introduction of the BC6ENTC group resulted in not only improved water solubility but also enhanced BC6ENTG agonistic activity. CPR:5newlineWe report the discovery of novel series of highly potent BC6ENTG agonists based on BC6ENTC , 1 and 2 by introducing and optimizing various BC6OTHER onto the BC6OTHER (9) - position of the BC6OTHER moiety. CPR:falsenewlineSynthesis and evaluation of BC6ENTC derivatives as potent BC6ENTG agonists with high water solubility. CPR:5newlineFinally, the three drugs were compared with the BC6ENTG inhibitor BC6ENTC . CPR:falsenewlineThe goal of the present study was to compare the effects of three potent reference BC6ENTG inhibitors ( BC6ENTC , BC6OTHER , and BC6OTHER ) in BC6OTHER - depleted normotensive squirrel monkeys. CPR:4newlineThe goal of the present study was to compare the effects of three potent reference BC6ENTG inhibitors ( BC6OTHER , BC6ENTC , and BC6OTHER ) in BC6OTHER - depleted normotensive squirrel monkeys. CPR:4newlineThe goal of the present study was to compare the effects of three potent reference BC6ENTG inhibitors ( BC6OTHER , BC6OTHER , and BC6ENTC ) in BC6OTHER - depleted normotensive squirrel monkeys. CPR:4newlineOne possible explanation is that, in our model, BC6ENTC in contrast to BC6OTHER and BC6OTHER is able to inhibit BC6ENTG in a functionally important extraplasmatic compartment. CPR:4newlineOne possible explanation is that, in our model, BC6OTHER in contrast to BC6ENTC and BC6OTHER is able to inhibit BC6ENTG in a functionally important extraplasmatic compartment. CPR:4newlineOne possible explanation is that, in our model, BC6OTHER in contrast to BC6OTHER and BC6ENTC is able to inhibit BC6ENTG in a functionally important extraplasmatic compartment. CPR:4newlineThe goal of the present study was to compare the effects of three potent reference BC6ENTG inhibitors ( BC6OTHER , BC6OTHER , and BC6OTHER ) in BC6ENTC - depleted normotensive squirrel monkeys. CPR:4newlineBC6OTHER ( BC6OTHER ) accumulates in tissues and fluids of patients with Smith - Lemli - Opitz syndrome (SLOS), which is caused by mutations in the gene encoding BC6ENTC - Δ(7) - reductase ( BC6ENTG ). CPR:falsenewlineBC6OTHER ( BC6ENTC ) accumulates in tissues and fluids of patients with Smith - Lemli - Opitz syndrome (SLOS), which is caused by mutations in the gene encoding BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTC ) accumulates in tissues and fluids of patients with Smith - Lemli - Opitz syndrome (SLOS), which is caused by mutations in the gene encoding BC6OTHER ( BC6ENTG ). CPR:falsenewlineAs the high oxidizability of BC6ENTC may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineAs the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineAs the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineAs the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineAs the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineBC6ENTC ( BC6OTHER ) accumulates in tissues and fluids of patients with Smith - Lemli - Opitz syndrome (SLOS), which is caused by mutations in the gene encoding BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6ENTC ( BC6OTHER ) accumulates in tissues and fluids of patients with Smith - Lemli - Opitz syndrome (SLOS), which is caused by mutations in the gene encoding BC6OTHER ( BC6ENTG ). CPR:falsenewlineAs the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineAs the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6ENTC , BC6OTHER and BC6OTHER , respectively. CPR:falsenewlineAs the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6ENTC and BC6OTHER , respectively. CPR:falsenewlineAs the high oxidizability of BC6OTHER may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a BC6ENTG - KO mouse model of SLOS, including BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) that are formed from the oxidation of BC6OTHER , BC6OTHER and BC6ENTC , respectively. CPR:falsenewlineIn addition to a previously described BC6ENTC , BC6OTHER ( BC6OTHER ), we provide evidence for the chemical structures of three new BC6OTHER in the brain and / or liver tissue of BC6ENTG - KO mice, two of which were quantified. CPR:falsenewlineIn addition to a previously described BC6OTHER , BC6ENTC ( BC6OTHER ), we provide evidence for the chemical structures of three new BC6OTHER in the brain and / or liver tissue of BC6ENTG - KO mice, two of which were quantified. CPR:falsenewlineIn addition to a previously described BC6OTHER , BC6OTHER ( BC6ENTC ), we provide evidence for the chemical structures of three new BC6OTHER in the brain and / or liver tissue of BC6ENTG - KO mice, two of which were quantified. CPR:falsenewlineIn addition to a previously described BC6OTHER , BC6OTHER ( BC6OTHER ), we provide evidence for the chemical structures of three new BC6ENTC in the brain and / or liver tissue of BC6ENTG - KO mice, two of which were quantified. CPR:falsenewlineWe find that levels of BC6ENTC and BC6OTHER are also elevated in brain and / or liver tissues of BC6ENTG - KO mice relative to matching WT mice. CPR:falsenewlineWe find that levels of BC6OTHER and BC6ENTC are also elevated in brain and / or liver tissues of BC6ENTG - KO mice relative to matching WT mice. CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6ENTC . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6ENTC with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6ENTC ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6ENTC ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6ENTC ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6ENTC wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6ENTC ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6ENTC without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6ENTC (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6ENTC without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6ENTC ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6ENTG ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6ENTG ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6ENTG - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineThe expression of glycans was examined by BC6OTHER - histochemistry using BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6OTHER ) for BC6OTHER ( BC6OTHER ); BC6OTHER ( BC6ENTG ) for terminal BC6OTHER with / without BC6OTHER ( BC6OTHER wo BC6OTHER ); succynilated WGA (sWGA) for terminal BC6OTHER without BC6OTHER (terminal BC6OTHER without BC6OTHER ); BC6OTHER ( BC6OTHER ) for terminal BC6ENTC ( BC6OTHER terminal); and BC6OTHER ( BC6OTHER ) BC6OTHER . CPR:falsenewlineBC6ENTG showed a high similarity in the primary structure to other vertebrate counterparts, BC6OTHER contained additional sequences of 21 and 28 BC6ENTC , respectively, as in the case of other teleost fish species when compared with African clawed frog counterparts. CPR:falsenewlineBC6OTHER showed a high similarity in the primary structure to other vertebrate counterparts, BC6ENTG contained additional sequences of 21 and 28 BC6ENTC , respectively, as in the case of other teleost fish species when compared with African clawed frog counterparts. CPR:falsenewlineThe transcriptional activity of torafugu BC6ENTG was enhanced 4.5 - and 11.5 - fold by BC6ENTC and BC6OTHER ( BC6OTHER ) each at 10 microM, respectively, whereas that of BC6OTHER , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively. CPR:falsenewlineThe transcriptional activity of torafugu BC6OTHER was enhanced 4.5 - and 11.5 - fold by BC6ENTC and BC6OTHER ( BC6OTHER ) each at 10 microM, respectively, whereas that of BC6ENTG , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively. CPR:falsenewlineThe transcriptional activity of torafugu BC6ENTG was enhanced 4.5 - and 11.5 - fold by BC6OTHER and BC6ENTC ( BC6OTHER ) each at 10 microM, respectively, whereas that of BC6OTHER , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively. CPR:falsenewlineThe transcriptional activity of torafugu BC6OTHER was enhanced 4.5 - and 11.5 - fold by BC6OTHER and BC6ENTC ( BC6OTHER ) each at 10 microM, respectively, whereas that of BC6ENTG , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively. CPR:falsenewlineThe transcriptional activity of torafugu BC6ENTG was enhanced 4.5 - and 11.5 - fold by BC6OTHER and BC6OTHER ( BC6ENTC ) each at 10 microM, respectively, whereas that of BC6OTHER , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively. CPR:falsenewlineThe transcriptional activity of torafugu BC6OTHER was enhanced 4.5 - and 11.5 - fold by BC6OTHER and BC6OTHER ( BC6ENTC ) each at 10 microM, respectively, whereas that of BC6ENTG , 4.5 - and 7.3 - fold at the same concentration of the respective ligands, respectively. CPR:falsenewlineThe activities of torafugu BC6ENTG were also enhanced 5.6 - and 6.3 - fold by BC6ENTC at 1 microM, respectively, but not by BC6OTHER at this concentration. CPR:falsenewlineThe activities of torafugu BC6ENTG were also enhanced 5.6 - and 6.3 - fold by BC6OTHER at 1 microM, respectively, but not by BC6ENTC at this concentration. CPR:falsenewlineFurthermore, the activities of the two BC6ENTG were enhanced 4.3 - and 7.6 - fold by BC6ENTC , 4.4 - and 5.2 - fold by BC6OTHER , and 6.7 - and 8.0 - fold by BC6OTHER each at 50 microM, respectively. CPR:falsenewlineFurthermore, the activities of the two BC6ENTG were enhanced 4.3 - and 7.6 - fold by BC6OTHER , 4.4 - and 5.2 - fold by BC6ENTC , and 6.7 - and 8.0 - fold by BC6OTHER each at 50 microM, respectively. CPR:falsenewlineFurthermore, the activities of the two BC6ENTG were enhanced 4.3 - and 7.6 - fold by BC6OTHER , 4.4 - and 5.2 - fold by BC6OTHER , and 6.7 - and 8.0 - fold by BC6ENTC each at 50 microM, respectively. CPR:3newlineOn the other hand, the activities of BC6ENTG were not changed by BC6ENTC , BC6OTHER , BC6OTHER , nor CHEM. CPR:falsenewlineOn the other hand, the activities of BC6ENTG were not changed by BC6OTHER , BC6ENTC , BC6OTHER , nor CHEM. CPR:falsenewlineOn the other hand, the activities of BC6ENTG were not changed by BC6OTHER , BC6OTHER , BC6ENTC , nor CHEM. CPR:falsenewlineStructural and functional properties were investigated for four BC6OTHER ( BC6ENTG ), BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element. CPR:falsenewlineStructural and functional properties were investigated for four BC6OTHER ( BC6OTHER ), BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element. CPR:falsenewlineStructural and functional properties were investigated for four BC6OTHER ( BC6OTHER ), BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element. CPR:falsenewlineStructural and functional properties were investigated for four BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element. CPR:falsenewlineStructural and functional properties were investigated for four BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element. CPR:falsenewlineStructural and functional properties were investigated for four BC6ENTG ( BC6OTHER ), BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the BC6ENTC oxidase PPAR response element. CPR:falsenewlineWe found a strong interaction of baseline FEV(1) with the BC6ENTG ( BC6ENTC ) polymorphism in predicting bronchodilator response. CPR:falsenewlineGenetic variants at the BC6ENTG ( BC6OTHER ) may modify asthma severity and BC6ENTC responsiveness. CPR:falsenewlineGenetic variants at the BC6OTHER ( BC6ENTG ) may modify asthma severity and BC6ENTC responsiveness. CPR:falsenewlineWe tested the association of BC6ENTG genotypes with asthma severity and bronchodilator response to BC6ENTC in Puerto Ricans and Mexicans with asthma. CPR:falsenewlineMETHODS: We used both family - based and cross - sectional tests of association with 8 BC6ENTG single BC6ENTC polymorphisms in 684 Puerto Rican and Mexican families. CPR:falsenewlineWe developed a computational model of the hypothalamic - pituitary - gonadal (HPG) axis in female fathead minnows to predict dose - response and time - course (DRTC) behaviors for endocrine effects of the BC6ENTG inhibitor, BC6ENTC ( BC6OTHER ). CPR:falsenewlineWe developed a computational model of the hypothalamic - pituitary - gonadal (HPG) axis in female fathead minnows to predict dose - response and time - course (DRTC) behaviors for endocrine effects of the BC6ENTG inhibitor, BC6OTHER ( BC6ENTC ). CPR:falsenewlineFor model development, we used plasma BC6ENTC (E2) concentrations and ovarian BC6ENTG mRNA data from two time - course experiments, each of which included both an exposure and a depuration phase, and plasma E2 data from a third 4 - day study. CPR:falsenewlineThe model accurately predicted BC6ENTG mRNA fold changes for controls and three BC6ENTC doses (0, 0.5, and 3 µg / l) and plasma E2 dose response from the 4 - day study. CPR:falsenewlineBC6ENTG is a transmembrane glycoprotein that mediates BC6ENTC - dependent interactions between adjacent epithelial cells. CPR:falsenewlineBC6ENTC was the most potent BC6OTHER analog tested in BC6ENTG functional BC6OTHER turnover assays in the following cell types: human ciliary muscle (EC50 = 1.4 nM), human trabecular meshwork (EC50 = 3.6 nM), and mouse fibroblasts and rat aortic smooth muscle cells (EC50 = 2.6 nM). CPR:falsenewlineBC6OTHER was the most potent BC6ENTC analog tested in BC6ENTG functional BC6OTHER turnover assays in the following cell types: human ciliary muscle (EC50 = 1.4 nM), human trabecular meshwork (EC50 = 3.6 nM), and mouse fibroblasts and rat aortic smooth muscle cells (EC50 = 2.6 nM). CPR:falsenewlineBC6OTHER was the most potent BC6OTHER analog tested in BC6ENTG functional BC6ENTC turnover assays in the following cell types: human ciliary muscle (EC50 = 1.4 nM), human trabecular meshwork (EC50 = 3.6 nM), and mouse fibroblasts and rat aortic smooth muscle cells (EC50 = 2.6 nM). CPR:falsenewlineAlthough BC6ENTC exhibited a relatively high affinity for the BC6ENTG (Ki = 98 nM), it had significant functional activity at BC6OTHER (EC50 = 32 - 124 nM) and BC6OTHER (EC50 = 119 nM) receptors. CPR:falsenewlineAlthough BC6ENTC exhibited a relatively high affinity for the BC6OTHER (Ki = 98 nM), it had significant functional activity at BC6ENTG (EC50 = 32 - 124 nM) and BC6OTHER (EC50 = 119 nM) receptors. CPR:falsenewlineAlthough BC6ENTC exhibited a relatively high affinity for the BC6OTHER (Ki = 98 nM), it had significant functional activity at BC6OTHER (EC50 = 32 - 124 nM) and BC6ENTG (EC50 = 119 nM) receptors. CPR:falsenewlineBC6ENTC was less selective, exhibiting a relatively high affinity for the BC6ENTG (Ki = 83 nM), BC6OTHER (Ki = 95 nM), and BC6OTHER (Ki = 387 nM) receptors. CPR:falsenewlineBC6ENTC was less selective, exhibiting a relatively high affinity for the BC6OTHER (Ki = 83 nM), BC6ENTG (Ki = 95 nM), and BC6OTHER (Ki = 387 nM) receptors. CPR:falsenewlineBC6ENTC was less selective, exhibiting a relatively high affinity for the BC6OTHER (Ki = 83 nM), BC6OTHER (Ki = 95 nM), and BC6ENTG (Ki = 387 nM) receptors. CPR:falsenewlineOcular hypotensive FP BC6OTHER ( BC6OTHER ) analogs: BC6OTHER subtype binding affinities and selectivities, and agonist potencies at BC6ENTG and other BC6ENTC receptors in cultured cells. CPR:falsenewlineOcular hypotensive FP BC6OTHER ( BC6OTHER ) analogs: BC6ENTG subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6ENTC receptors in cultured cells. CPR:falsenewlineOcular hypotensive FP BC6ENTC ( BC6OTHER ) analogs: BC6OTHER subtype binding affinities and selectivities, and agonist potencies at BC6ENTG and other BC6OTHER in cultured cells. CPR:falsenewlineOcular hypotensive FP BC6ENTC ( BC6OTHER ) analogs: BC6OTHER subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6ENTG in cultured cells. CPR:falsenewlineOcular hypotensive FP BC6ENTC ( BC6OTHER ) analogs: BC6ENTG subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6OTHER in cultured cells. CPR:falsenewlineOcular hypotensive FP BC6OTHER ( BC6ENTC ) analogs: BC6OTHER subtype binding affinities and selectivities, and agonist potencies at BC6ENTG and other BC6OTHER in cultured cells. CPR:falsenewlineOcular hypotensive FP BC6OTHER ( BC6ENTC ) analogs: BC6OTHER subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6ENTG in cultured cells. CPR:falsenewlineOcular hypotensive FP BC6OTHER ( BC6ENTC ) analogs: BC6ENTG subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6OTHER in cultured cells. CPR:falsenewlineOcular hypotensive FP BC6OTHER ( BC6OTHER ) analogs: BC6ENTC receptor subtype binding affinities and selectivities, and agonist potencies at BC6ENTG and other BC6OTHER in cultured cells. CPR:falsenewlineOcular hypotensive FP BC6OTHER ( BC6OTHER ) analogs: BC6ENTC receptor subtype binding affinities and selectivities, and agonist potencies at BC6OTHER and other BC6ENTG in cultured cells. CPR:falsenewlineBC6ENTC exhibited functional activity at the BC6ENTG (EC50 = 2.7 nM) and BC6OTHER (EC50 = 2.8 - 3.8 nM in most cells) receptors. CPR:falsenewlineBC6ENTC exhibited functional activity at the BC6OTHER (EC50 = 2.7 nM) and BC6ENTG (EC50 = 2.8 - 3.8 nM in most cells) receptors. CPR:falsenewlineBC6ENTC (nonhydrolyzed CHEM) also behaved as an BC6ENTG agonist at the cloned BC6OTHER (EC50 = 681 nM), in h - TM (EC50 = 3245 nM) and other cell types. CPR:5newlineBC6ENTC (nonhydrolyzed CHEM) also behaved as an BC6OTHER agonist at the cloned BC6ENTG (EC50 = 681 nM), in h - TM (EC50 = 3245 nM) and other cell types. CPR:5newlineBC6ENTC and BC6OTHER bound with low affinity (Ki = 5.9 microM to > 22 microM) to the BC6ENTG , were not selective, but activated the BC6OTHER . CPR:falsenewlineBC6ENTC and BC6OTHER bound with low affinity (Ki = 5.9 microM to > 22 microM) to the BC6OTHER , were not selective, but activated the BC6ENTG . CPR:falsenewlineBC6OTHER and BC6ENTC bound with low affinity (Ki = 5.9 microM to > 22 microM) to the BC6ENTG , were not selective, but activated the BC6OTHER . CPR:falsenewlineBC6OTHER and BC6ENTC bound with low affinity (Ki = 5.9 microM to > 22 microM) to the BC6OTHER , were not selective, but activated the BC6ENTG . CPR:falsenewlineIn conclusion, BC6ENTC has the highest affinity, the highest BC6ENTG - selectivity, and the highest potency at the BC6OTHER as compared to the other ocular hypotensive PG analogs known so far, including BC6OTHER . CPR:falsenewlineIn conclusion, BC6ENTC has the highest affinity, the highest BC6OTHER - selectivity, and the highest potency at the BC6ENTG as compared to the other ocular hypotensive PG analogs known so far, including BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER has the highest affinity, the highest BC6ENTG - selectivity, and the highest potency at the BC6OTHER as compared to the other ocular hypotensive PG analogs known so far, including BC6ENTC . CPR:falsenewlineIn conclusion, BC6OTHER has the highest affinity, the highest BC6OTHER - selectivity, and the highest potency at the BC6ENTG as compared to the other ocular hypotensive PG analogs known so far, including BC6ENTC . CPR:falsenewlineBC6ENTC ( BC6OTHER ) was the most BC6ENTG - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6ENTG , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6ENTG (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6ENTG (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6ENTG (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6ENTG (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6ENTG (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6ENTC ( BC6OTHER ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6ENTG (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6OTHER ( BC6ENTC ) was the most BC6ENTG - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6ENTG , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6ENTG (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6ENTG (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6ENTG (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6ENTG (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6ENTG (Ki > 90,000 nM), and BC6OTHER (Ki = 121,000 nM) receptors. CPR:falsenewlineBC6OTHER ( BC6ENTC ) was the most BC6OTHER - selective compound, exhibiting a high affinity (Ki = 35 + / - 5 nM) for the BC6OTHER , and minimal affinity for BC6OTHER (Ki = 52,000 nM), BC6OTHER (Ki = 9540 nM), BC6OTHER (Ki = 3501 nM), BC6OTHER (Ki = 41,000 nM), BC6OTHER (Ki > 90,000 nM), and BC6ENTG (Ki = 121,000 nM) receptors. CPR:falsenewlineDNA damage is accepted as a consequence of BC6ENTC deprivation induced by chemotherapeutic inhibitors of BC6ENTG ( BC6OTHER ), but the types of damage and signaling responses remain incompletely understood. CPR:falsenewlineDNA damage is accepted as a consequence of BC6ENTC deprivation induced by chemotherapeutic inhibitors of BC6OTHER synthase ( BC6ENTG ), but the types of damage and signaling responses remain incompletely understood. CPR:falsenewlineWhen BC6ENTG , which is a central component of HR, was depleted by siRNA cells were sensitized to BC6ENTC ( BC6OTHER ), which specifically inhibits BC6OTHER . CPR:falsenewlineWhen BC6OTHER , which is a central component of HR, was depleted by siRNA cells were sensitized to BC6ENTC ( BC6OTHER ), which specifically inhibits BC6ENTG . CPR:falsenewlineWhen BC6ENTG , which is a central component of HR, was depleted by siRNA cells were sensitized to BC6OTHER ( BC6ENTC ), which specifically inhibits BC6OTHER . CPR:falsenewlineWhen BC6OTHER , which is a central component of HR, was depleted by siRNA cells were sensitized to BC6OTHER ( BC6ENTC ), which specifically inhibits BC6ENTG . CPR:falsenewlineTo our knowledge, this is the first demonstration in mammalian cells that depletion of BC6ENTG causes sensitivity to BC6ENTC deprivation. CPR:falsenewlineDNA damage is accepted as a consequence of BC6OTHER deprivation induced by chemotherapeutic inhibitors of BC6ENTC synthase ( BC6ENTG ), but the types of damage and signaling responses remain incompletely understood. CPR:falsenewlinePhosphorylation of BC6ENTG ( BC6OTHER subunit) and formation of damage - induced foci were strikingly evident following IC(50) doses of BC6ENTC . CPR:falsenewlinePhosphorylation of BC6OTHER ( BC6ENTG subunit) and formation of damage - induced foci were strikingly evident following IC(50) doses of BC6ENTC . CPR:falsenewlineBC6ENTC treatment also induced foci of BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER , although the extent of co - localization with BC6OTHER foci varied. CPR:falsenewlineBC6ENTC treatment also induced foci of BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER , although the extent of co - localization with BC6OTHER foci varied. CPR:falsenewlineBC6ENTC treatment also induced foci of BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER , although the extent of co - localization with BC6OTHER foci varied. CPR:falsenewlineBC6ENTC treatment also induced foci of BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , although the extent of co - localization with BC6OTHER foci varied. CPR:falsenewlineBC6ENTC treatment also induced foci of BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , although the extent of co - localization with BC6ENTG foci varied. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6ENTC tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6ENTC tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6OTHER ( BC6ENTC ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6OTHER ( BC6ENTC ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineFurthermore, there was no association between BC6ENTC and in vivo BC6ENTG sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6ENTC and in vivo BC6OTHER sensitivity or β - cell function relative to BC6ENTG sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6ENTC and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6ENTC and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6ENTG sensitivity in any of the groups. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6ENTC tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6ENTC tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6ENTG sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6ENTC concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6ENTG sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6ENTC concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6ENTC concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6ENTC concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6ENTG sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6ENTG sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6ENTC tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6ENTG sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6ENTC tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6ENTC tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6ENTC tolerance groups, and 2) no relationship between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function relative to BC6ENTG sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6ENTG sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6ENTC and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6ENTG sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6ENTC and in vivo BC6OTHER sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6ENTC and in vivo BC6ENTG sensitivity and β - cell function relative to BC6OTHER sensitivity in any of the groups. CPR:falsenewlineFurthermore, there was no association between BC6OTHER and in vivo BC6OTHER sensitivity or β - cell function relative to BC6OTHER sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma BC6OTHER concentrations across the BC6OTHER tolerance groups, and 2) no relationship between BC6ENTC and in vivo BC6OTHER sensitivity and β - cell function relative to BC6ENTG sensitivity in any of the groups. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6ENTC and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6ENTC and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6ENTC concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6OTHER ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6ENTC concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6ENTC ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6ENTG sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6OTHER sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineOBJECTIVETo 1) determine if plasma BC6ENTC ( BC6OTHER ) concentrations differ among obese youth with normal BC6OTHER tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between BC6OTHER and in vivo BC6OTHER sensitivity and β - cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma BC6OTHER concentrations were examined in banked specimens in 9 - to 20 - year - old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired BC6OTHER tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo BC6ENTG sensitivity and secretion measured by hyperinsulinemic - euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg / m(2), respectively. CPR:falsenewlineThe unusual { BC6ENTC }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6ENTG (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6OTHER active site. CPR:falsenewlineThe unusual { BC6ENTC }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6OTHER (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6ENTG active site. CPR:falsenewlineThe unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6ENTC BC6ENTG (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6OTHER active site. CPR:falsenewlineThe unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6ENTC BC6OTHER (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6ENTG active site. CPR:falsenewlineThe unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6ENTG (termed {ES - BC6ENTC }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6OTHER active site. CPR:falsenewlineThe unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6OTHER (termed {ES - BC6ENTC }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6OTHER - bound BC6ENTG active site. CPR:falsenewlineThe unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6ENTG (termed {ES - BC6OTHER }7) is a result of the BC6ENTC coordination of BC6OTHER in the BC6OTHER - bound BC6OTHER active site. CPR:falsenewlineThe unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6OTHER (termed {ES - BC6OTHER }7) is a result of the BC6ENTC coordination of BC6OTHER in the BC6OTHER - bound BC6ENTG active site. CPR:falsenewlineMammalian BC6ENTC dioxygenase ( BC6ENTG ) is a non - CHEM BC6OTHER metalloenzyme that catalyzes the first committed step in oxidative BC6OTHER catabolism. CPR:falsenewlineThe unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6ENTG (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6ENTC in the BC6OTHER - bound BC6OTHER active site. CPR:falsenewlineThe unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6OTHER (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6ENTC in the BC6OTHER - bound BC6ENTG active site. CPR:falsenewlineThe unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6ENTG (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6ENTC - bound BC6OTHER active site. CPR:falsenewlineThe unusual { BC6OTHER }7 (S = 1 / 2) electronic configuration adopted by the substrate - bound BC6OTHER BC6OTHER (termed {ES - BC6OTHER }7) is a result of the BC6OTHER coordination of BC6OTHER in the BC6ENTC - bound BC6ENTG active site. CPR:falsenewlineThe active site coordination of BC6ENTG comprises a mononuclear BC6ENTC ligated by the Nepsilon atoms of three protein - derived BC6OTHER , thus representing a new variant on the CHEM ( BC6OTHER ) facial triad motif. CPR:falsenewlineThe active site coordination of BC6OTHER comprises a mononuclear BC6ENTC ligated by the Nepsilon atoms of three protein - derived BC6OTHER , thus representing a new variant on the BC6ENTG . CPR:falsenewlineThe DFT - predicted geometric parameters for {ES - BC6ENTC }7 are in good agreement with the crystallographically determined substrate - bound active site configuration of BC6ENTG and are consistent with known BC6OTHER model complexes. CPR:falsenewlineThe DFT - predicted geometric parameters for {ES - BC6OTHER }7 are in good agreement with the crystallographically determined substrate - bound active site configuration of BC6ENTG and are consistent with known BC6ENTC model complexes. CPR:falsenewlineMoreover, the computed EPR parameters (g and A values) are in excellent agreement with experimental results for this BC6ENTG species and those obtained from comparable synthetic { BC6ENTC }7 (S = 1 / 2) BC6OTHER complexes. CPR:falsenewlineMoreover, the computed EPR parameters (g and A values) are in excellent agreement with experimental results for this BC6ENTG species and those obtained from comparable synthetic { BC6OTHER }7 (S = 1 / 2) BC6ENTC complexes. CPR:falsenewlineThe active site coordination of BC6ENTG comprises a mononuclear BC6OTHER ligated by the Nepsilon atoms of three protein - derived BC6ENTC , thus representing a new variant on the CHEM ( BC6OTHER ) facial triad motif. CPR:falsenewlineThe active site coordination of BC6OTHER comprises a mononuclear BC6OTHER ligated by the Nepsilon atoms of three protein - derived BC6ENTC , thus representing a new variant on the BC6ENTG . CPR:falsenewlineThe active site coordination of BC6ENTG comprises a mononuclear BC6OTHER ligated by the Nepsilon atoms of three protein - derived BC6OTHER , thus representing a new variant on the BC6ENTC ( BC6OTHER ) facial triad motif. CPR:falsenewlineThe active site coordination of BC6ENTG comprises a mononuclear BC6OTHER ligated by the Nepsilon atoms of three protein - derived BC6OTHER , thus representing a new variant on the CHEM ( BC6ENTC ) facial triad motif. CPR:falsenewlineHowever, upon addition of BC6ENTC to BC6ENTG in the presence of substrate BC6OTHER , a low - spin { BC6OTHER }7 (S = 1 / 2) signal that accounts for approximately 85% of the BC6OTHER within the enzyme develops. CPR:falsenewlineBC6ENTG ( BC6OTHER ) is a non - CHEM BC6ENTC metalloenzyme that catalyzes the first committed step in oxidative BC6OTHER catabolism. CPR:falsenewlineMammalian BC6OTHER dioxygenase ( BC6ENTG ) is a non - CHEM BC6ENTC metalloenzyme that catalyzes the first committed step in oxidative BC6OTHER catabolism. CPR:falsenewlineIn these experiments, BC6ENTG exhibits an ordered binding of BC6ENTC prior to BC6OTHER (and presumably BC6OTHER ) similar to that observed for the 2H1C class of non - CHEM BC6OTHER enzymes. CPR:falsenewlineIn these experiments, BC6OTHER exhibits an ordered binding of BC6ENTC prior to BC6OTHER (and presumably BC6OTHER ) similar to that observed for the BC6ENTG . CPR:falsenewlineIn these experiments, BC6ENTG exhibits an ordered binding of BC6OTHER prior to BC6ENTC (and presumably BC6OTHER ) similar to that observed for the 2H1C class of non - CHEM BC6OTHER enzymes. CPR:falsenewlineIn these experiments, BC6OTHER exhibits an ordered binding of BC6OTHER prior to BC6ENTC (and presumably BC6OTHER ) similar to that observed for the BC6ENTG . CPR:falsenewlineIn these experiments, BC6ENTG exhibits an ordered binding of BC6OTHER prior to BC6OTHER (and presumably BC6ENTC ) similar to that observed for the 2H1C class of non - CHEM BC6OTHER enzymes. CPR:falsenewlineIn these experiments, BC6OTHER exhibits an ordered binding of BC6OTHER prior to BC6OTHER (and presumably BC6ENTC ) similar to that observed for the BC6ENTG . CPR:falsenewlineIn these experiments, BC6ENTG exhibits an ordered binding of BC6OTHER prior to BC6OTHER (and presumably BC6OTHER ) similar to that observed for the BC6ENTC class of non - CHEM BC6OTHER enzymes. CPR:falsenewlineIn these experiments, BC6ENTG exhibits an ordered binding of BC6OTHER prior to BC6OTHER (and presumably BC6OTHER ) similar to that observed for the 2H1C class of non - CHEM BC6ENTC enzymes. CPR:falsenewlineMoreover, the BC6ENTG active site is essentially unreactive toward BC6ENTC in the absence of substrate, suggesting an obligate ordered binding of BC6OTHER prior to BC6OTHER . CPR:falsenewlineMoreover, the BC6ENTG active site is essentially unreactive toward BC6OTHER in the absence of substrate, suggesting an obligate ordered binding of BC6ENTC prior to BC6OTHER . CPR:falsenewlineHowever, upon addition of BC6OTHER to BC6ENTG in the presence of substrate BC6ENTC , a low - spin { BC6OTHER }7 (S = 1 / 2) signal that accounts for approximately 85% of the BC6OTHER within the enzyme develops. CPR:falsenewlineMoreover, the BC6ENTG active site is essentially unreactive toward BC6OTHER in the absence of substrate, suggesting an obligate ordered binding of BC6OTHER prior to BC6ENTC . CPR:falsenewlineCharacterization of the BC6ENTC adduct of substrate - bound BC6ENTG by electron paramagnetic resonance: electronic structure of the active site and mechanistic implications. CPR:falsenewlineHowever, upon addition of BC6OTHER to BC6ENTG in the presence of substrate BC6OTHER , a low - spin { BC6ENTC }7 (S = 1 / 2) signal that accounts for approximately 85% of the BC6OTHER within the enzyme develops. CPR:falsenewlineBC6ENTG ( BC6OTHER ) is a non - CHEM BC6OTHER metalloenzyme that catalyzes the first committed step in oxidative BC6ENTC catabolism. CPR:9newlineMammalian BC6OTHER dioxygenase ( BC6ENTG ) is a non - CHEM BC6OTHER metalloenzyme that catalyzes the first committed step in oxidative BC6ENTC catabolism. CPR:falsenewlineHowever, upon addition of BC6OTHER to BC6ENTG in the presence of substrate BC6OTHER , a low - spin { BC6OTHER }7 (S = 1 / 2) signal that accounts for approximately 85% of the BC6ENTC within the enzyme develops. CPR:falsenewlineThe binding of the antipsychotic drugs BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER was studied at the subtypes of the BC6ENTG . CPR:falsenewlineThe binding of the antipsychotic drugs BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER was studied at the subtypes of the BC6ENTG . CPR:falsenewlineThe binding of the antipsychotic drugs BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER was studied at the subtypes of the BC6ENTG . CPR:falsenewlineBinding of antipsychotic drugs at BC6OTHER : BC6ENTC is selective for the BC6ENTG . CPR:falsenewlineBinding of antipsychotic drugs at BC6ENTG : BC6ENTC is selective for the BC6OTHER . CPR:falsenewlineWith the exception of BC6ENTC , all the antipsychotic drugs tested failed to show selectivity for either of the BC6ENTG subtypes. CPR:falsenewlineThe binding of the antipsychotic drugs BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER was studied at the subtypes of the BC6ENTG . CPR:falsenewlineBC6ENTC was 120 - fold more selective for the BC6ENTG with respect to the BC6OTHER (Ki values: 2.3 + / - 1.2 nM and 283.6 + / - 174.1 nM respectively). CPR:falsenewlineBC6ENTC was 120 - fold more selective for the BC6OTHER with respect to the BC6ENTG (Ki values: 2.3 + / - 1.2 nM and 283.6 + / - 174.1 nM respectively). CPR:falsenewlineThe binding of the antipsychotic drugs BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC was studied at the subtypes of the BC6ENTG . CPR:falsenewlineSaturation experiments showed that BC6ENTC labelled a single population of binding sites in the spleen ( BC6ENTG ) and hippocampus ( BC6OTHER and BC6OTHER ) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively). CPR:falsenewlineSaturation experiments showed that BC6ENTC labelled a single population of binding sites in the spleen ( BC6OTHER ) and hippocampus ( BC6ENTG and BC6OTHER ) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively). CPR:falsenewlineSaturation experiments showed that BC6ENTC labelled a single population of binding sites in the spleen ( BC6OTHER ) and hippocampus ( BC6OTHER and BC6ENTG ) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively). CPR:falsenewlineThe binding of the antipsychotic drugs BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER was studied at the subtypes of the BC6ENTG . CPR:falsenewlineThe binding of the antipsychotic drugs BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER was studied at the subtypes of the BC6ENTG . CPR:falsenewlinePURPOSE: BC6ENTG deficiency is a recently described inborn error of BC6ENTC pathway. CPR:falsenewlineIt was concluded that the presence of the BC6ENTG in these isoforms is not relevant for the formation of the BC6OTHER / BC6OTHER complex in the absence of BC6ENTC , that is the interaction of BC6OTHER with inactive BC6OTHER . CPR:falsenewlineIt was concluded that the presence of the BC6OTHER in these isoforms is not relevant for the formation of the BC6ENTG / BC6OTHER complex in the absence of BC6ENTC , that is the interaction of BC6OTHER with inactive BC6OTHER . CPR:falsenewlineIt was concluded that the presence of the BC6OTHER in these isoforms is not relevant for the formation of the BC6OTHER / BC6ENTG complex in the absence of BC6ENTC , that is the interaction of BC6OTHER with inactive BC6OTHER . CPR:falsenewlineIt was concluded that the presence of the BC6OTHER in these isoforms is not relevant for the formation of the BC6OTHER / BC6OTHER complex in the absence of BC6ENTC , that is the interaction of BC6ENTG with inactive BC6OTHER . CPR:falsenewlineIt was concluded that the presence of the BC6OTHER in these isoforms is not relevant for the formation of the BC6OTHER / BC6OTHER complex in the absence of BC6ENTC , that is the interaction of BC6OTHER with inactive BC6ENTG . CPR:falsenewlineMultiple BC6ENTG forms are produced by distinct starting points and alternative splicing of the BC6ENTC - terminal exons. CPR:falsenewlineThe kinetics of onset of BC6OTHER ( BC6OTHER ) receptor desensitization by BC6OTHER , and the extent of attenuation of BC6ENTG desensitization by BC6ENTC , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons. CPR:falsenewlineThe kinetics of onset of BC6OTHER BC6ENTG desensitization by BC6OTHER , and the extent of attenuation of BC6OTHER receptor desensitization by BC6ENTC , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons. CPR:falsenewlineThe kinetics of onset of BC6ENTC ( BC6OTHER ) receptor desensitization by BC6OTHER , and the extent of attenuation of BC6ENTG desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons. CPR:falsenewlineThe kinetics of onset of BC6ENTC BC6ENTG desensitization by BC6OTHER , and the extent of attenuation of BC6OTHER receptor desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons. CPR:falsenewlineThe kinetics of onset of BC6OTHER ( BC6ENTC ) receptor desensitization by BC6OTHER , and the extent of attenuation of BC6ENTG desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons. CPR:falsenewlineThe complex patterns of sensitivity to BC6ENTC seen in hippocampal neurons could be reconstituted by assembly of recombinant BC6ENTG subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the BC6OTHER and BC6OTHER subunits. CPR:falsenewlineThe complex patterns of sensitivity to BC6ENTC seen in hippocampal neurons could be reconstituted by assembly of recombinant BC6OTHER subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the BC6ENTG and BC6OTHER subunits. CPR:falsenewlineThe complex patterns of sensitivity to BC6ENTC seen in hippocampal neurons could be reconstituted by assembly of recombinant BC6OTHER subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the BC6OTHER and BC6ENTG subunits. CPR:falsenewline BC6ENTG heterogeneity in rat hippocampal neurons revealed by differential sensitivity to BC6ENTC . CPR:falsenewlineThe complex patterns of sensitivity to BC6OTHER seen in hippocampal neurons could be reconstituted by assembly of recombinant BC6ENTC receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the BC6ENTG and BC6OTHER subunits. CPR:falsenewlineThe complex patterns of sensitivity to BC6OTHER seen in hippocampal neurons could be reconstituted by assembly of recombinant BC6ENTC receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the BC6OTHER and BC6ENTG subunits. CPR:falsenewlineRecovery from modulation by BC6ENTC was slower for BC6ENTG and BC6OTHER than for BC6OTHER and BC6OTHER . CPR:falsenewlineRecovery from modulation by BC6ENTC was slower for BC6OTHER and BC6ENTG than for BC6OTHER and BC6OTHER . CPR:falsenewlineRecovery from modulation by BC6ENTC was slower for BC6OTHER and BC6OTHER than for BC6ENTG and BC6OTHER . CPR:falsenewlineRecovery from modulation by BC6ENTC was slower for BC6OTHER and BC6OTHER than for BC6OTHER and BC6ENTG . CPR:falsenewlineThe kinetics of onset of BC6OTHER ( BC6OTHER ) receptor desensitization by BC6ENTC , and the extent of attenuation of BC6ENTG desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons. CPR:falsenewlineThe kinetics of onset of BC6OTHER BC6ENTG desensitization by BC6ENTC , and the extent of attenuation of BC6OTHER receptor desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons. CPR:falsenewlineCoexpression of the flip and flop splice variants of BC6ENTG , in the absence of BC6OTHER , revealed that heteromeric BC6ENTC receptors with intermediate sensitivity to BC6OTHER , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit. CPR:falsenewlineCoexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6ENTG , revealed that heteromeric BC6ENTC receptors with intermediate sensitivity to BC6OTHER , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit. CPR:falsenewlineCoexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6ENTC receptors with intermediate sensitivity to BC6OTHER , similar to responses observed for the combinations BC6ENTG or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit. CPR:falsenewlineCoexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6ENTC receptors with intermediate sensitivity to BC6OTHER , similar to responses observed for the combinations BC6OTHER or BC6ENTG , could be generated independently of the presence of the BC6OTHER subunit. CPR:falsenewlineCoexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6ENTC receptors with intermediate sensitivity to BC6OTHER , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6ENTG subunit. CPR:falsenewlineCoexpression of the flip and flop splice variants of BC6ENTG , in the absence of BC6OTHER , revealed that heteromeric BC6OTHER receptors with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit. CPR:falsenewlineCoexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6ENTG , revealed that heteromeric BC6OTHER receptors with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit. CPR:falsenewlineCoexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6ENTG with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit. CPR:falsenewlineCoexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6OTHER receptors with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6ENTG or BC6OTHER , could be generated independently of the presence of the BC6OTHER subunit. CPR:falsenewlineCoexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6OTHER receptors with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6OTHER or BC6ENTG , could be generated independently of the presence of the BC6OTHER subunit. CPR:falsenewlineCoexpression of the flip and flop splice variants of BC6OTHER , in the absence of BC6OTHER , revealed that heteromeric BC6OTHER receptors with intermediate sensitivity to BC6ENTC , similar to responses observed for the combinations BC6OTHER or BC6OTHER , could be generated independently of the presence of the BC6ENTG subunit. CPR:falsenewlineThe kinetics of onset of BC6OTHER BC6ENTG desensitization by BC6OTHER , and the extent of attenuation of BC6ENTC receptor desensitization by BC6OTHER , showed pronounced cell - to - cell variation in cultures of rat hippocampal neurons. CPR:falsenewlineHowever, recovery from modulation by BC6ENTC was twofold slower for BC6ENTG than for homomeric BC6OTHER , indicating that the BC6OTHER and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6OTHER . CPR:falsenewlineHowever, recovery from modulation by BC6ENTC was twofold slower for BC6OTHER than for homomeric BC6ENTG , indicating that the BC6OTHER and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6OTHER . CPR:falsenewlineHowever, recovery from modulation by BC6ENTC was twofold slower for BC6OTHER than for homomeric BC6OTHER , indicating that the BC6ENTG and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6OTHER . CPR:falsenewlineHowever, recovery from modulation by BC6ENTC was twofold slower for BC6OTHER than for homomeric BC6OTHER , indicating that the BC6OTHER and BC6ENTG subunits are not functionally equivalent in controlling sensitivity to BC6OTHER . CPR:falsenewlineHowever, recovery from modulation by BC6OTHER was twofold slower for BC6ENTG than for homomeric BC6OTHER , indicating that the BC6OTHER and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6ENTC . CPR:falsenewlineHowever, recovery from modulation by BC6OTHER was twofold slower for BC6OTHER than for homomeric BC6ENTG , indicating that the BC6OTHER and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6ENTC . CPR:falsenewlineHowever, recovery from modulation by BC6OTHER was twofold slower for BC6OTHER than for homomeric BC6OTHER , indicating that the BC6ENTG and BC6OTHER subunits are not functionally equivalent in controlling sensitivity to BC6ENTC . CPR:falsenewlineHowever, recovery from modulation by BC6OTHER was twofold slower for BC6OTHER than for homomeric BC6OTHER , indicating that the BC6OTHER and BC6ENTG subunits are not functionally equivalent in controlling sensitivity to BC6ENTC . CPR:falsenewlineThe juvenile visceral steatosis (jvs) mouse, having a mutation in the BC6ENTC transporter gene BC6ENTG , is a model of primary systemic BC6OTHER deficiency in humans (SCD, CHEM). CPR:falsenewlineThe juvenile visceral steatosis (jvs) mouse, having a mutation in the BC6OTHER transporter gene BC6ENTG , is a model of primary systemic BC6ENTC deficiency in humans (SCD, CHEM). CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6ENTC ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact. CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6ENTC ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact. CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6ENTC ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact. CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6ENTC ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact. CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6ENTC ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact. CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6ENTC ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact. CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6ENTC ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact. CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6ENTC ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact. CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6ENTC and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact. CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6ENTC and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact. CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6ENTC sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact. CPR:falsenewline BC6OTHER are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6ENTC sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact. CPR:falsenewlineBC6ENTC are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral BC6ENTG ( BC6OTHER ) by binding to one or more specific sites on the BC6OTHER . CPR:4newlineBC6ENTC are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic BC6OTHER receptor ( BC6ENTG ) by binding to one or more specific sites on the BC6OTHER . CPR:falsenewlineBC6ENTC are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic BC6OTHER receptor ( BC6OTHER ) by binding to one or more specific sites on the BC6ENTG . CPR:falsenewline BC6ENTC and BC6OTHER sites on the BC6ENTG and their allosteric interaction. CPR:falsenewline BC6OTHER and BC6ENTC sites on the BC6ENTG and their allosteric interaction. CPR:falsenewlineBC6OTHER are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic BC6ENTC receptor ( BC6ENTG ) by binding to one or more specific sites on the BC6OTHER . CPR:falsenewlineBC6OTHER are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic BC6ENTC receptor ( BC6OTHER ) by binding to one or more specific sites on the BC6ENTG . CPR:falsenewline BC6ENTC are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6ENTG , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6OTHER and to investigate if these sites interact. CPR:falsenewline BC6ENTC are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal BC6OTHER , which have no demonstrable general anesthetic activity in vivo. In this study, BC6OTHER ( BC6OTHER ), an analogue of the cationic noncompetitive inhibitor BC6OTHER ( BC6OTHER ), was used to characterize the BC6OTHER and BC6OTHER sites on the desensitized Torpedo californica BC6ENTG and to investigate if these sites interact. CPR:falsenewlineAIM: This study seeks to determine the role of the BC6ENTC transferases M1 and T1 null genotypes ( BC6ENTG *0 and BC6OTHER *0) in individual susceptibility to bladder cancer in a Tunisian population. CPR:falsenewlineAIM: This study seeks to determine the role of the BC6ENTC transferases M1 and T1 null genotypes ( BC6OTHER *0 and BC6ENTG *0) in individual susceptibility to bladder cancer in a Tunisian population. CPR:falsenewlineBC6ENTC was fortuitously found to be a novel, potent inhibitor of the BC6ENTG . CPR:4newlineIt showed high rat lymphoma growth - inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of BC6ENTG - - mediated BC6ENTC uptake, in contrast to its colonic metabolites, BC6OTHER and BC6OTHER . CPR:falsenewlineIt showed high rat lymphoma growth - inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of BC6ENTG - - mediated BC6OTHER uptake, in contrast to its colonic metabolites, BC6ENTC and BC6OTHER . CPR:9newlineIt showed high rat lymphoma growth - inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of BC6ENTG - - mediated BC6OTHER uptake, in contrast to its colonic metabolites, BC6OTHER and BC6ENTC . CPR:falsenewline BC6ENTC , a potent suppressor of lymphoma growth by inhibition of the BC6ENTG : a new action for an old drug. CPR:4newlineThe BC6ENTG represents a novel target for BC6ENTC - like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular BC6OTHER . CPR:falsenewlineThe BC6ENTG represents a novel target for BC6OTHER - like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular BC6ENTC . CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme BC6ENTC / BC6OTHER - N(1) - acetyltransferase ( BC6ENTG ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme BC6ENTC / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6ENTG ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme BC6ENTC / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6OTHER ( BC6ENTG ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / CHEM - acetyltransferase ( BC6ENTG ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / CHEM - acetyltransferase ( BC6OTHER ) and by BC6ENTG ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / CHEM - acetyltransferase ( BC6OTHER ) and by BC6OTHER ( BC6ENTG ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme BC6ENTG ( BC6OTHER ) and by BC6ENTC acetyltransferase ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6ENTG ) and by BC6ENTC acetyltransferase ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6ENTC acetyltransferase ( BC6ENTG ) to its monoacetylated derivative (MAT). CPR:falsenewlineThe acetylation of BC6ENTC is increased in BC6ENTG - overexpressing mice compared with wild - type mice. CPR:falsenewlineHowever, BC6ENTG - deficient mice metabolize BC6ENTC at the same rate as the wild - type mice, indicating the existence of another BC6OTHER respons 2ible for its metabolism in mice. CPR:falsenewlineHowever, BC6OTHER - deficient mice metabolize BC6ENTC at the same rate as the wild - type mice, indicating the existence of another BC6ENTG respons 2ible for its metabolism in mice. CPR:falsenewlineHere, we show that siRNA - mediated knockdown of BC6ENTG in HEPG2 cells and in primary hepatocytes from the BC6OTHER - deficient or wild - type mice reduced the metabolism of BC6ENTC to MAT. CPR:falsenewlineHere, we show that siRNA - mediated knockdown of BC6OTHER in HEPG2 cells and in primary hepatocytes from the BC6ENTG - deficient or wild - type mice reduced the metabolism of BC6ENTC to MAT. CPR:falsenewlineBy contrast, BC6ENTC ( BC6OTHER ), a charge - deficient BC6OTHER analog, was an extremely poor substrate of BC6OTHER and was metabolized by BC6ENTG in HEPG2 cells and in wild - type primary hepatocytes. CPR:9newlineBy contrast, BC6ENTC ( BC6OTHER ), a charge - deficient BC6OTHER analog, was an extremely poor substrate of BC6ENTG and was metabolized by BC6OTHER in HEPG2 cells and in wild - type primary hepatocytes. CPR:9newlineBy contrast, BC6OTHER ( BC6ENTC ), a charge - deficient BC6OTHER analog, was an extremely poor substrate of BC6OTHER and was metabolized by BC6ENTG in HEPG2 cells and in wild - type primary hepatocytes. CPR:9newlineBy contrast, BC6OTHER ( BC6ENTC ), a charge - deficient BC6OTHER analog, was an extremely poor substrate of BC6ENTG and was metabolized by BC6OTHER in HEPG2 cells and in wild - type primary hepatocytes. CPR:9newlineBy contrast, BC6OTHER ( BC6OTHER ), a charge - deficient BC6ENTC analog, was an extremely poor substrate of BC6OTHER and was metabolized by BC6ENTG in HEPG2 cells and in wild - type primary hepatocytes. CPR:9newlineBy contrast, BC6OTHER ( BC6OTHER ), a charge - deficient BC6ENTC analog, was an extremely poor substrate of BC6ENTG and was metabolized by BC6OTHER in HEPG2 cells and in wild - type primary hepatocytes. CPR:9newlineMetabolism of BC6OTHER and BC6OTHER by the BC6ENTG and BC6ENTC acetyltransferase. CPR:9newlineMetabolism of BC6ENTC and BC6OTHER by the CHEM / BC6OTHER - N(1) - acetyltransferase and BC6ENTG . CPR:9newlineMetabolism of BC6ENTC and BC6OTHER by the BC6ENTG and BC6OTHER . CPR:9newlineMetabolism of BC6OTHER and BC6ENTC by the CHEM / BC6OTHER - N(1) - acetyltransferase and BC6ENTG . CPR:9newlineMetabolism of BC6OTHER and BC6ENTC by the BC6ENTG and BC6OTHER . CPR:9newlineMetabolism of BC6OTHER and BC6OTHER by the BC6ENTC / BC6OTHER - N(1) - acetyltransferase and BC6ENTG . CPR:9newlineMetabolism of BC6OTHER and BC6OTHER by the CHEM / CHEM - acetyltransferase and BC6ENTG . CPR:9newlineThus, despite the similar structures of BC6ENTC and BC6OTHER , BC6ENTG is the main acetylator of BC6OTHER , whereas BC6OTHER is primarily acetylated by BC6OTHER . CPR:falsenewlineThus, despite the similar structures of BC6ENTC and BC6OTHER , BC6OTHER is the main acetylator of BC6OTHER , whereas BC6OTHER is primarily acetylated by BC6ENTG . CPR:falsenewlineThus, despite the similar structures of BC6OTHER and BC6ENTC , BC6ENTG is the main acetylator of BC6OTHER , whereas BC6OTHER is primarily acetylated by BC6OTHER . CPR:falsenewlineThus, despite the similar structures of BC6OTHER and BC6ENTC , BC6OTHER is the main acetylator of BC6OTHER , whereas BC6OTHER is primarily acetylated by BC6ENTG . CPR:falsenewlineThus, despite the similar structures of BC6OTHER and BC6OTHER , BC6ENTG is the main acetylator of BC6ENTC , whereas BC6OTHER is primarily acetylated by BC6OTHER . CPR:falsenewlineThus, despite the similar structures of BC6OTHER and BC6OTHER , BC6OTHER is the main acetylator of BC6ENTC , whereas BC6OTHER is primarily acetylated by BC6ENTG . CPR:falsenewlineThus, despite the similar structures of BC6OTHER and BC6OTHER , BC6ENTG is the main acetylator of BC6OTHER , whereas BC6ENTC is primarily acetylated by BC6OTHER . CPR:falsenewlineThus, despite the similar structures of BC6OTHER and BC6OTHER , BC6OTHER is the main acetylator of BC6OTHER , whereas BC6ENTC is primarily acetylated by BC6ENTG . CPR:falsenewlineWe recently showed that BC6ENTC is metabolized in vitro by BC6OTHER catabolic enzyme BC6ENTG ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:9newlineWe recently showed that BC6ENTC is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6ENTG ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6ENTC is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6ENTG ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6ENTC is metabolized in vitro by BC6OTHER catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6OTHER ( BC6ENTG ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6ENTC catabolic enzyme BC6ENTG ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6ENTC catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6ENTG ) and by BC6OTHER ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6ENTC catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6ENTG ( BC6OTHER ) to its monoacetylated derivative (MAT). CPR:falsenewlineWe recently showed that BC6OTHER is metabolized in vitro by BC6ENTC catabolic enzyme CHEM / BC6OTHER - N(1) - acetyltransferase ( BC6OTHER ) and by BC6OTHER ( BC6ENTG ) to its monoacetylated derivative (MAT). CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6ENTG of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6ENTC to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6ENTG suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6ENTC to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6ENTG , causes BC6ENTC to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6ENTC to be released from BC6ENTG . CPR:falsenewlineThe CHEM - sensitive BC6ENTC (CHEM) channels in pancreatic beta cells are critical in the regulation of BC6OTHER - induced BC6ENTG secretion. CPR:falsenewlineAlthough electrophysiological studies provide clues to the complex control of BC6ENTG by BC6ENTC , BC6OTHER , and pharmacological agents, the molecular mechanism of BC6OTHER regulation remains unclear. CPR:falsenewlineAlthough electrophysiological studies provide clues to the complex control of BC6OTHER by BC6ENTC , BC6OTHER , and pharmacological agents, the molecular mechanism of BC6ENTG regulation remains unclear. CPR:falsenewlineAlthough electrophysiological studies provide clues to the complex control of BC6ENTG by BC6OTHER , BC6ENTC , and pharmacological agents, the molecular mechanism of BC6OTHER regulation remains unclear. CPR:falsenewlineAlthough electrophysiological studies provide clues to the complex control of BC6OTHER by BC6OTHER , BC6ENTC , and pharmacological agents, the molecular mechanism of BC6ENTG regulation remains unclear. CPR:falsenewlineThe BC6ENTG is a heterooligomeric complex of BC6OTHER subunits of the BC6ENTC - binding - cassette superfamily with two BC6OTHER ( BC6OTHER and BC6OTHER ) and the pore - forming BC6OTHER subunits. CPR:falsenewlineThe BC6OTHER is a heterooligomeric complex of BC6ENTG subunits of the BC6ENTC - binding - cassette superfamily with two BC6OTHER ( BC6OTHER and BC6OTHER ) and the pore - forming BC6OTHER subunits. CPR:falsenewlineThe BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6ENTC - binding - cassette superfamily with two BC6ENTG ( BC6OTHER and BC6OTHER ) and the pore - forming BC6OTHER subunits. CPR:falsenewlineThe BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6ENTC - binding - cassette superfamily with two BC6OTHER ( BC6ENTG and BC6OTHER ) and the pore - forming BC6OTHER subunits. CPR:falsenewlineThe BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6ENTC - binding - cassette superfamily with two BC6OTHER ( BC6OTHER and BC6ENTG ) and the pore - forming BC6OTHER subunits. CPR:falsenewlineThe BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6ENTC - binding - cassette superfamily with two BC6OTHER ( BC6OTHER and BC6OTHER ) and the pore - forming BC6ENTG subunits. CPR:falsenewlineThe BC6ENTG is a heterooligomeric complex of BC6OTHER subunits of the BC6OTHER - binding - cassette superfamily with two BC6ENTC - binding folds ( BC6OTHER and BC6OTHER ) and the pore - forming BC6OTHER subunits. CPR:falsenewlineThe BC6OTHER is a heterooligomeric complex of BC6ENTG subunits of the BC6OTHER - binding - cassette superfamily with two BC6ENTC - binding folds ( BC6OTHER and BC6OTHER ) and the pore - forming BC6OTHER subunits. CPR:falsenewlineThe BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6OTHER - binding - cassette superfamily with two BC6ENTC - binding folds ( BC6ENTG and BC6OTHER ) and the pore - forming BC6OTHER subunits. CPR:falsenewlineThe BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6OTHER - binding - cassette superfamily with two BC6ENTC - binding folds ( BC6OTHER and BC6ENTG ) and the pore - forming BC6OTHER subunits. CPR:falsenewlineThe BC6OTHER is a heterooligomeric complex of BC6OTHER subunits of the BC6OTHER - binding - cassette superfamily with two BC6ENTC - binding folds ( BC6OTHER and BC6OTHER ) and the pore - forming BC6ENTG subunits. CPR:falsenewlineThe BC6ENTC - sensitive BC6OTHER (CHEM) channels in pancreatic beta cells are critical in the regulation of BC6OTHER - induced BC6ENTG secretion. CPR:falsenewlineHere, we report that BC6ENTC and BC6OTHER , but not the BC6OTHER salt of BC6OTHER , stabilize the binding of prebound BC6OTHER to BC6ENTG . CPR:falsenewlineHere, we report that BC6OTHER and BC6ENTC , but not the BC6OTHER salt of BC6OTHER , stabilize the binding of prebound BC6OTHER to BC6ENTG . CPR:falsenewlineHere, we report that BC6OTHER and BC6OTHER , but not the BC6ENTC salt of BC6OTHER , stabilize the binding of prebound BC6OTHER to BC6ENTG . CPR:falsenewlineThe CHEM - sensitive BC6OTHER (CHEM) channels in pancreatic beta cells are critical in the regulation of BC6ENTC - induced BC6ENTG secretion. CPR:falsenewlineThe BC6ENTG in pancreatic beta cells are critical in the regulation of BC6ENTC - induced BC6OTHER secretion. CPR:falsenewlineHere, we report that BC6OTHER and BC6OTHER , but not the BC6OTHER salt of BC6ENTC , stabilize the binding of prebound BC6OTHER to BC6ENTG . CPR:falsenewlineHere, we report that BC6OTHER and BC6OTHER , but not the BC6OTHER salt of BC6OTHER , stabilize the binding of prebound BC6ENTC to BC6ENTG . CPR:falsenewlineMutation in the BC6ENTG of BC6OTHER of BC6OTHER abolished this stabilizing effect of BC6ENTC . CPR:falsenewlineMutation in the BC6OTHER of BC6ENTG of BC6OTHER abolished this stabilizing effect of BC6ENTC . CPR:falsenewlineMutation in the BC6OTHER of BC6OTHER of BC6ENTG abolished this stabilizing effect of BC6ENTC . CPR:falsenewlineThese results suggest that BC6ENTG binds BC6ENTC strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6ENTC strongly at BC6ENTG and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6ENTC strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6ENTG or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6ENTC strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6ENTG , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6ENTC strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6ENTG . CPR:falsenewlineThese results suggest that BC6ENTG binds BC6OTHER strongly at BC6OTHER and that BC6ENTC , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6ENTG and that BC6ENTC , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6ENTC , either by direct binding to BC6ENTG or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6ENTC , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6ENTG , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6ENTC , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6ENTG . CPR:falsenewlineThese results suggest that BC6ENTG binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6ENTC at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6ENTG and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6ENTC at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6ENTG or by hydrolysis of bound BC6ENTC at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6ENTC at BC6ENTG , stabilizes prebound BC6OTHER binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6ENTC at BC6OTHER , stabilizes prebound BC6OTHER binding at BC6ENTG . CPR:falsenewlineThese results suggest that BC6ENTG binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6ENTC binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6ENTG and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6ENTC binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6ENTG or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6ENTC binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6ENTG , stabilizes prebound BC6ENTC binding at BC6OTHER . CPR:falsenewlineThese results suggest that BC6OTHER binds BC6OTHER strongly at BC6OTHER and that BC6OTHER , either by direct binding to BC6OTHER or by hydrolysis of bound BC6OTHER at BC6OTHER , stabilizes prebound BC6ENTC binding at BC6ENTG . CPR:falsenewlineThe BC6ENTC caused release of prebound BC6OTHER from BC6ENTG in the presence of BC6OTHER or BC6OTHER in a concentration - dependent manner. CPR:falsenewlineCooperative binding of BC6ENTC and BC6OTHER in the BC6ENTG is modulated by BC6OTHER . CPR:falsenewlineCooperative binding of BC6OTHER and BC6ENTC in the BC6ENTG is modulated by BC6OTHER . CPR:falsenewlineThe BC6OTHER caused release of prebound BC6ENTC from BC6ENTG in the presence of BC6OTHER or BC6OTHER in a concentration - dependent manner. CPR:falsenewlineCooperative binding of BC6OTHER and BC6OTHER in the BC6ENTG is modulated by BC6ENTC . CPR:falsenewlineThe BC6OTHER caused release of prebound BC6OTHER from BC6ENTG in the presence of BC6ENTC or BC6OTHER in a concentration - dependent manner. CPR:falsenewlineThe BC6OTHER caused release of prebound BC6OTHER from BC6ENTG in the presence of BC6OTHER or BC6ENTC in a concentration - dependent manner. CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6ENTC binding of the two BC6ENTG of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6ENTC binding of the two BC6OTHER of BC6ENTG suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6ENTC binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6ENTG , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6ENTC binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6ENTG . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6ENTG of BC6OTHER suggests that BC6ENTC both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6ENTG suggests that BC6ENTC both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6ENTC both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6ENTG , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6ENTC both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6ENTG . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6ENTG of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6ENTC and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6ENTG suggests that BC6OTHER both blocks this cooperative binding of BC6ENTC and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6ENTC and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6ENTG , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6ENTC and BC6OTHER and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6ENTG . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6ENTG of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6ENTC and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6ENTG suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6ENTC and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6ENTC and, in cooperation with the BC6OTHER bound at BC6ENTG , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6ENTC and, in cooperation with the BC6OTHER bound at BC6OTHER , causes BC6OTHER to be released from BC6ENTG . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6ENTG of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6ENTC bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6ENTG suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6ENTC bound at BC6OTHER , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6ENTC bound at BC6ENTG , causes BC6OTHER to be released from BC6OTHER . CPR:falsenewlineThis direct biochemical evidence of cooperative interaction in BC6OTHER binding of the two BC6OTHER of BC6OTHER suggests that BC6OTHER both blocks this cooperative binding of BC6OTHER and BC6OTHER and, in cooperation with the BC6ENTC bound at BC6OTHER , causes BC6OTHER to be released from BC6ENTG . CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels and increased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6ENTG ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6ENTG ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineCompared to the HC group, aqueous Mate tea extract significantly reduced BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels and increased BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased BC6OTHER ( BC6OTHER ) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6ENTG hyperphosphorylation (PHF - 1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of BC6ENTC - treated mice, an effect probably related to a decrease in BC6OTHER expression. CPR:falsenewlineBC6OTHER hyperphosphorylation (PHF - 1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of BC6ENTC - treated mice, an effect probably related to a decrease in BC6ENTG expression. CPR:falsenewlineInterestingly, BC6ENTC also phosphorylated BC6ENTG in SAMP8 mice, which was associated with an increase of BC6OTHER phosphorylation, contributing therefore to the reductions in BC6OTHER hyperphosphorylation. CPR:falsenewlineInterestingly, BC6ENTC also phosphorylated BC6OTHER in SAMP8 mice, which was associated with an increase of BC6ENTG phosphorylation, contributing therefore to the reductions in BC6OTHER hyperphosphorylation. CPR:falsenewlineInterestingly, BC6ENTC also phosphorylated BC6OTHER in SAMP8 mice, which was associated with an increase of BC6OTHER phosphorylation, contributing therefore to the reductions in BC6ENTG hyperphosphorylation. CPR:falsenewlineSynaptic pathology in SAMP8 mice, as shown by decreases in BC6ENTG and BC6OTHER , was also counteracted by BC6ENTC treatment. CPR:falsenewlineSynaptic pathology in SAMP8 mice, as shown by decreases in BC6OTHER and BC6ENTG , was also counteracted by BC6ENTC treatment. CPR:falsenewlineIn the present study we tested whether BC6ENTC , a BC6ENTG antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD - related markers shown by the senescence - accelerated mouse prone - 8 (SAMP8). CPR:falsenewline BC6ENTC restores cognitive deficits and improves BC6ENTG and BC6OTHER pathologies in a senescence - accelerated mouse model. CPR:falsenewline BC6ENTC restores cognitive deficits and improves BC6OTHER and BC6ENTG pathologies in a senescence - accelerated mouse model. CPR:falsenewlineCell proliferation and apoptosis rate were measured in HDMVEC by BC6ENTC ( BC6OTHER ) incorporation and BC6ENTG and BC6OTHER activity, respectively. CPR:falsenewlineCell proliferation and apoptosis rate were measured in HDMVEC by BC6ENTC ( BC6OTHER ) incorporation and BC6OTHER and BC6ENTG activity, respectively. CPR:falsenewlineCell proliferation and apoptosis rate were measured in HDMVEC by BC6OTHER ( BC6ENTC ) incorporation and BC6ENTG and BC6OTHER activity, respectively. CPR:falsenewlineCell proliferation and apoptosis rate were measured in HDMVEC by BC6OTHER ( BC6ENTC ) incorporation and BC6OTHER and BC6ENTG activity, respectively. CPR:falsenewlineFasting serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter). CPR:falsenewlineFasting serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter). CPR:falsenewlineFasting serum BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter). CPR:falsenewlineFasting serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC , as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter). CPR:falsenewlineFasting serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC , as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter). CPR:falsenewlineMore robust BC6ENTG secretion and microparticle generation with BC6OTHER - AP was attributable to stronger and more sustained phosphorylation of myosin light chain at BC6ENTC 19 and BC6OTHER 18. CPR:falsenewlineMore robust BC6OTHER secretion and microparticle generation with BC6ENTG - AP was attributable to stronger and more sustained phosphorylation of myosin light chain at BC6ENTC 19 and BC6OTHER 18. CPR:falsenewlineMore robust BC6ENTG secretion and microparticle generation with BC6OTHER - AP was attributable to stronger and more sustained phosphorylation of myosin light chain at BC6OTHER 19 and BC6ENTC 18. CPR:falsenewlineMore robust BC6OTHER secretion and microparticle generation with BC6ENTG - AP was attributable to stronger and more sustained phosphorylation of myosin light chain at BC6OTHER 19 and BC6ENTC 18. CPR:falsenewlineInhibited BC6ENTG undergoes aging to release BC6ENTC and BC6OTHER . CPR:falsenewlineInhibited BC6ENTG undergoes aging to release BC6OTHER and BC6ENTC . CPR:falsenewlineMass spectral analysis of BC6ENTC - inhibited BC6ENTG digested with BC6OTHER - C showed an BC6OTHER adduct (+106amu) on BC6OTHER 499, a residue far from the active site, but not on BC6OTHER - 438. CPR:falsenewlineMass spectral analysis of BC6OTHER - inhibited BC6ENTG digested with BC6ENTC - C showed an BC6OTHER adduct (+106amu) on BC6OTHER 499, a residue far from the active site, but not on BC6OTHER - 438. CPR:falsenewlineMass spectral analysis of BC6OTHER - inhibited BC6ENTG digested with BC6OTHER - C showed an BC6ENTC adduct (+106amu) on BC6OTHER 499, a residue far from the active site, but not on BC6OTHER - 438. CPR:falsenewlineMass spectral analysis of BC6OTHER - inhibited BC6ENTG digested with BC6OTHER - C showed an BC6OTHER adduct (+106amu) on BC6ENTC 499, a residue far from the active site, but not on BC6OTHER - 438. CPR:falsenewlineMass spectral analysis of BC6OTHER - inhibited BC6ENTG digested with BC6OTHER - C showed an BC6OTHER adduct (+106amu) on BC6OTHER 499, a residue far from the active site, but not on BC6ENTC - 438. CPR:falsenewline BC6ENTC makes multiple adducts on free BC6OTHER , but does not form an adduct on BC6OTHER 438 of BC6ENTG . CPR:falsenewline BC6OTHER makes multiple adducts on free BC6OTHER , but does not form an adduct on BC6ENTC 438 of BC6ENTG . CPR:falsenewline BC6OTHER makes multiple adducts on free BC6ENTC , but does not form an adduct on BC6OTHER 438 of BC6ENTG . CPR:falsenewlineBC6ENTC irreversibly inhibits BC6ENTG ( BC6OTHER ) in human plasma by forming adducts on the active site BC6OTHER ( BC6OTHER - 198). CPR:4newlineBC6ENTC irreversibly inhibits BC6OTHER ( BC6ENTG ) in human plasma by forming adducts on the active site BC6OTHER ( BC6OTHER - 198). CPR:falsenewlineBC6OTHER irreversibly inhibits BC6ENTG ( BC6OTHER ) in human plasma by forming adducts on the active site BC6ENTC ( BC6OTHER - 198). CPR:falsenewlineBC6OTHER irreversibly inhibits BC6OTHER ( BC6ENTG ) in human plasma by forming adducts on the active site BC6ENTC ( BC6OTHER - 198). CPR:falsenewlineBC6OTHER irreversibly inhibits BC6ENTG ( BC6OTHER ) in human plasma by forming adducts on the active site BC6OTHER ( BC6ENTC - 198). CPR:falsenewlineBC6OTHER irreversibly inhibits BC6OTHER ( BC6ENTG ) in human plasma by forming adducts on the active site BC6OTHER ( BC6ENTC - 198). CPR:falsenewlineBC6ENTC receptor ( BC6ENTG ) signaling is essential for prostate cancer (PCa) development in humans. CPR:falsenewlineFurthermore, we demonstrated that BC6ENTG binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6OTHER , and the BC6OTHER of BC6OTHER is required for the interaction of BC6OTHER and BC6OTHER proteins. CPR:falsenewlineFurthermore, we demonstrated that BC6OTHER binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6ENTG , and the BC6OTHER of BC6OTHER is required for the interaction of BC6OTHER and BC6OTHER proteins. CPR:falsenewlineFurthermore, we demonstrated that BC6OTHER binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6OTHER , and the BC6ENTG of BC6OTHER is required for the interaction of BC6OTHER and BC6OTHER proteins. CPR:falsenewlineFurthermore, we demonstrated that BC6OTHER binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6OTHER , and the BC6OTHER of BC6ENTG is required for the interaction of BC6OTHER and BC6OTHER proteins. CPR:falsenewlineFurthermore, we demonstrated that BC6OTHER binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6OTHER , and the BC6OTHER of BC6OTHER is required for the interaction of BC6ENTG and BC6OTHER proteins. CPR:falsenewlineFurthermore, we demonstrated that BC6OTHER binds to both the BC6ENTC - terminal domain and the ligand - binding domain of BC6OTHER , and the BC6OTHER of BC6OTHER is required for the interaction of BC6OTHER and BC6ENTG proteins. CPR:falsenewlineBC6ENTG perturbs the BC6ENTC - induced interaction between the BC6OTHER terminus and BC6OTHER terminus of BC6OTHER . CPR:falsenewlineBC6OTHER perturbs the BC6ENTC - induced interaction between the BC6OTHER terminus and BC6OTHER terminus of BC6ENTG . CPR:falsenewlineBC6ENTG perturbs the BC6OTHER - induced interaction between the BC6ENTC terminus and BC6OTHER terminus of BC6OTHER . CPR:falsenewlineBC6OTHER perturbs the BC6OTHER - induced interaction between the BC6ENTC terminus and BC6OTHER terminus of BC6ENTG . CPR:falsenewlineBC6ENTG perturbs the BC6OTHER - induced interaction between the BC6OTHER terminus and BC6ENTC terminus of BC6OTHER . CPR:falsenewlineBC6OTHER perturbs the BC6OTHER - induced interaction between the BC6OTHER terminus and BC6ENTC terminus of BC6ENTG . CPR:falsenewlineHere, we provide evidence that BC6ENTG physically interacts with BC6OTHER and functions as an BC6OTHER corespressor in both an BC6ENTC - dependent and BC6OTHER - independent manner. CPR:falsenewlineHere, we provide evidence that BC6OTHER physically interacts with BC6ENTG and functions as an BC6OTHER corespressor in both an BC6ENTC - dependent and BC6OTHER - independent manner. CPR:falsenewlineHere, we provide evidence that BC6OTHER physically interacts with BC6OTHER and functions as an BC6ENTG corespressor in both an BC6ENTC - dependent and BC6OTHER - independent manner. CPR:falsenewlineHere, we provide evidence that BC6ENTG physically interacts with BC6OTHER and functions as an BC6OTHER corespressor in both an BC6OTHER - dependent and BC6ENTC - independent manner. CPR:falsenewlineHere, we provide evidence that BC6OTHER physically interacts with BC6ENTG and functions as an BC6OTHER corespressor in both an BC6OTHER - dependent and BC6ENTC - independent manner. CPR:falsenewlineHere, we provide evidence that BC6OTHER physically interacts with BC6OTHER and functions as an BC6ENTG corespressor in both an BC6OTHER - dependent and BC6ENTC - independent manner. CPR:falsenewline Endogenous BC6ENTG ( BC6OTHER in human and BC6OTHER in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6OTHER . CPR:falsenewline Endogenous BC6OTHER ( BC6ENTG in human and BC6OTHER in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6OTHER . CPR:falsenewline Endogenous BC6OTHER ( BC6OTHER in human and BC6ENTG in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6OTHER . CPR:falsenewline Endogenous BC6OTHER ( BC6OTHER in human and BC6OTHER in mouse) and BC6ENTG colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6OTHER . CPR:falsenewline Endogenous BC6OTHER ( BC6OTHER in human and BC6OTHER in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6ENTG in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6OTHER . CPR:falsenewline Endogenous BC6OTHER ( BC6OTHER in human and BC6OTHER in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6ENTG ) - BC6OTHER . CPR:falsenewline Endogenous BC6OTHER ( BC6OTHER in human and BC6OTHER in mouse) and BC6OTHER colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of BC6OTHER in PCa cells significantly attenuates the activities of BC6ENTC response region ( BC6OTHER ) - BC6ENTG . CPR:falsenewlineBC6ENTC treatment (4 X 40 mg / day) increased the density of BC6ENTG by 25% after 2 days; concomitantly PRA and heart rate were reduced. CPR:falsenewlineBC6OTHER density, however, declined slowly being still significantly increased after 3 days, although BC6ENTC was not detectable in plasma after 24 h. The affinity of BC6OTHER to BC6ENTG was not changed during or after treatment. CPR:falsenewlineBC6ENTG density, however, declined slowly being still significantly increased after 3 days, although BC6ENTC was not detectable in plasma after 24 h. The affinity of BC6OTHER to BC6OTHER was not changed during or after treatment. CPR:falsenewlineBC6OTHER density, however, declined slowly being still significantly increased after 3 days, although BC6OTHER was not detectable in plasma after 24 h. The affinity of BC6ENTC to BC6ENTG was not changed during or after treatment. CPR:falsenewlineBC6ENTG density, however, declined slowly being still significantly increased after 3 days, although BC6OTHER was not detectable in plasma after 24 h. The affinity of BC6ENTC to BC6OTHER was not changed during or after treatment. CPR:falsenewlineBC6ENTC treatment (2 X 5 mg / day) caused a 30% decrease of BC6ENTG density and PRA after 2 days; both parameters remained reduced during treatment. CPR:falsenewlineBC6ENTC treatment (4 X 100 mg / day) led to a rapid fall in PRA, but did not significantly affect BC6ENTG density. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6ENTG antagonists BC6ENTC [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6ENTC [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6ENTG density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6ENTC [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6ENTG activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6ENTG antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6ENTC (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6ENTC (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6ENTG density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6ENTC (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6ENTG activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6ENTG antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6ENTC (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6ENTC (strong ISA) on lymphocyte BC6ENTG density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6ENTC (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6OTHER ) binding - - and plasma BC6ENTG activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6ENTG antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6ENTC ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6ENTG density - - assessed by BC6ENTC ( BC6OTHER ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6ENTC ( BC6OTHER ) binding - - and plasma BC6ENTG activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6ENTG antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6ENTC ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6ENTG density - - assessed by BC6OTHER ( BC6ENTC ) binding - - and plasma BC6OTHER activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineTo study the mechanism underlying this phenomenon, the effects of the nonselective BC6OTHER antagonists BC6OTHER [no intrinsic sympathomimetic activity (ISA)], BC6OTHER (weak ISA) and BC6OTHER (strong ISA) on lymphocyte BC6OTHER density - - assessed by BC6OTHER ( BC6ENTC ) binding - - and plasma BC6ENTG activity (PRA) were investigated in male healthy volunteers aged 23 - 35 years. CPR:falsenewlineAll three analogues bound to the myometrial BC6ENTC V1 receptor, albeit with much lower affinities than to the BC6ENTG . CPR:falsenewlineAll three analogues bound to the myometrial BC6ENTG , albeit with much lower affinities than to the BC6ENTC receptor. CPR:falsenewlineOnly BC6ENTC bound to the renal BC6ENTG though the binding affinity was very low (61.3 + / - 14.6 nM). CPR:falsenewlineBoth BC6ENTC , BC6OTHER CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6ENTG of a similar magnitude as BC6OTHER . CPR:falsenewlineBoth BC6ENTC , BC6OTHER CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6OTHER of a similar magnitude as BC6ENTG . CPR:falsenewlineBoth BC6OTHER , BC6ENTC CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6ENTG of a similar magnitude as BC6OTHER . CPR:falsenewlineBoth BC6OTHER , BC6ENTC CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6OTHER of a similar magnitude as BC6ENTG . CPR:falsenewlineBoth BC6OTHER , BC6OTHER CHEM and BC6ENTC metabolite II displayed binding affinities to the myometrial BC6ENTG of a similar magnitude as BC6OTHER . CPR:falsenewlineBoth BC6OTHER , BC6OTHER CHEM and BC6ENTC metabolite II displayed binding affinities to the myometrial BC6OTHER of a similar magnitude as BC6ENTG . CPR:falsenewlineBoth BC6OTHER , BC6OTHER CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6ENTC receptor of a similar magnitude as BC6ENTG . CPR:falsenewlineBoth BC6OTHER , BC6OTHER CHEM and BC6OTHER metabolite II displayed binding affinities to the myometrial BC6ENTG of a similar magnitude as BC6ENTC . CPR:falsenewlineBC6ENTC was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of BC6OTHER , as is the case for BC6ENTG . CPR:falsenewlineBC6OTHER was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of BC6ENTC , as is the case for BC6ENTG . CPR:falsenewlineHowever, maximal contractile effect of BC6ENTC was approximately 50% lower than that of BC6ENTG (2.70 + / - 0.12 g compared to 5.22 + / - 0.26 g) and EC50 was approximately ten times higher (48.0 + / - 8.20 nM compared to 5.62 + / - 1.22 nM). CPR:falsenewlineMetabolites of the analogue CHEM ( BC6ENTC ) following incubation with a rat kidney homogenate were isolated and their pharmacodynamic properties investigated. CPR:falsenewline BC6ENTG binding and uterotonic activity of BC6ENTC and its metabolites following enzymatic degradation. CPR:falsenewlineAll three compounds displayed antagonistic properties against BC6ENTG in vitro, with BC6ENTC being the strongest inhibitor (pA2 = 8.21) and BC6OTHER metabolite II (pA2 = 8.01) being stronger than BC6OTHER CHEM (pA2 = 7.81). CPR:falsenewlineAll three compounds displayed antagonistic properties against BC6ENTG in vitro, with BC6OTHER being the strongest inhibitor (pA2 = 8.21) and BC6ENTC metabolite II (pA2 = 8.01) being stronger than BC6OTHER CHEM (pA2 = 7.81). CPR:falsenewlineAll three compounds displayed antagonistic properties against BC6ENTG in vitro, with BC6OTHER being the strongest inhibitor (pA2 = 8.21) and BC6OTHER metabolite II (pA2 = 8.01) being stronger than BC6ENTC CHEM (pA2 = 7.81). CPR:falsenewlineThese results indicate that BC6ENTC is a partial agonist / antagonist to the BC6ENTG while the two metabolites BC6OTHER CHEM and BC6OTHER metabolite II are pure antagonists. CPR:5newlineThese results indicate that BC6OTHER is a partial agonist / antagonist to the BC6ENTG while the two metabolites BC6ENTC CHEM and BC6OTHER metabolite II are pure antagonists. CPR:falsenewlineThese results indicate that BC6OTHER is a partial agonist / antagonist to the BC6ENTG while the two metabolites BC6OTHER CHEM and BC6ENTC metabolite II are pure antagonists. CPR:falsenewlineIt was saturable, with between 1 and 2 mol of BC6ENTC bound to 1 mol of BC6ENTG . CPR:falsenewlineThe site at which BC6ENTC bound to BC6ENTG appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6OTHER , prevented the binding of BC6OTHER to BC6OTHER . CPR:falsenewlineThe site at which BC6ENTC bound to BC6OTHER appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6OTHER , prevented the binding of BC6OTHER to BC6ENTG . CPR:falsenewlineTo determine the factors that influence the interaction between BC6ENTC and BC6OTHER , the binding of BC6OTHER to BC6ENTG was determined by equilibrium dialysis under a variety of experimental conditions. CPR:falsenewlineTo determine the factors that influence the interaction between BC6ENTC and BC6ENTG , the binding of BC6OTHER to BC6OTHER was determined by equilibrium dialysis under a variety of experimental conditions. CPR:falsenewlineThe site at which BC6OTHER bound to BC6ENTG appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6ENTC , BC6OTHER and BC6OTHER , prevented the binding of BC6OTHER to BC6OTHER . CPR:falsenewlineThe site at which BC6OTHER bound to BC6OTHER appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6ENTC , BC6OTHER and BC6OTHER , prevented the binding of BC6OTHER to BC6ENTG . CPR:falsenewlineThe site at which BC6OTHER bound to BC6ENTG appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6ENTC and BC6OTHER , prevented the binding of BC6OTHER to BC6OTHER . CPR:falsenewlineThe site at which BC6OTHER bound to BC6OTHER appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6ENTC and BC6OTHER , prevented the binding of BC6OTHER to BC6ENTG . CPR:falsenewlineThe site at which BC6OTHER bound to BC6ENTG appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6ENTC , prevented the binding of BC6OTHER to BC6OTHER . CPR:falsenewlineThe site at which BC6OTHER bound to BC6OTHER appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6ENTC , prevented the binding of BC6OTHER to BC6ENTG . CPR:falsenewlineThe site at which BC6OTHER bound to BC6ENTG appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6OTHER , prevented the binding of BC6ENTC to BC6OTHER . CPR:falsenewlineThe site at which BC6OTHER bound to BC6OTHER appears to be similar to that at which certain antipsychotic agents bind, since several of them, including BC6OTHER , BC6OTHER and BC6OTHER , prevented the binding of BC6ENTC to BC6ENTG . CPR:falsenewlineHowever, in contrast to the reversible binding of most BC6ENTC to BC6ENTG , BC6OTHER bound to BC6OTHER irreversibly. CPR:falsenewlineHowever, in contrast to the reversible binding of most BC6ENTC to BC6OTHER , BC6OTHER bound to BC6ENTG irreversibly. CPR:falsenewlineHowever, in contrast to the reversible binding of most BC6OTHER to BC6ENTG , BC6ENTC bound to BC6OTHER irreversibly. CPR:falsenewlineHowever, in contrast to the reversible binding of most BC6OTHER to BC6OTHER , BC6ENTC bound to BC6ENTG irreversibly. CPR:falsenewlineThe binding of BC6ENTC to BC6ENTG was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6OTHER and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions. CPR:falsenewlineThe binding of BC6ENTC to BC6OTHER was fairly selective in that other BC6ENTG agents such as BC6OTHER , BC6OTHER and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions. CPR:falsenewlineThe binding of BC6ENTC to BC6OTHER was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6OTHER and BC6OTHER failed to bind to BC6ENTG when examined under the same experimental conditions. CPR:falsenewlineCharacteristics of the binding of BC6ENTC to BC6ENTG . CPR:falsenewlineTo determine the factors that influence the interaction between BC6OTHER and BC6OTHER , the binding of BC6ENTC to BC6ENTG was determined by equilibrium dialysis under a variety of experimental conditions. CPR:falsenewlineTo determine the factors that influence the interaction between BC6OTHER and BC6ENTG , the binding of BC6ENTC to BC6OTHER was determined by equilibrium dialysis under a variety of experimental conditions. CPR:falsenewlineThe binding of BC6OTHER to BC6ENTG was fairly selective in that other BC6OTHER agents such as BC6ENTC , BC6OTHER and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions. CPR:falsenewlineThe binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6ENTG agents such as BC6ENTC , BC6OTHER and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions. CPR:falsenewlineThe binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6OTHER agents such as BC6ENTC , BC6OTHER and BC6OTHER failed to bind to BC6ENTG when examined under the same experimental conditions. CPR:falsenewlineThe binding of BC6OTHER to BC6ENTG was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6ENTC and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions. CPR:falsenewlineThe binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6ENTG agents such as BC6OTHER , BC6ENTC and BC6OTHER failed to bind to BC6OTHER when examined under the same experimental conditions. CPR:falsenewlineThe binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6ENTC and BC6OTHER failed to bind to BC6ENTG when examined under the same experimental conditions. CPR:falsenewlineThe binding of BC6OTHER to BC6ENTG was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6OTHER and BC6ENTC failed to bind to BC6OTHER when examined under the same experimental conditions. CPR:falsenewlineThe binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6ENTG agents such as BC6OTHER , BC6OTHER and BC6ENTC failed to bind to BC6OTHER when examined under the same experimental conditions. CPR:falsenewlineThe binding of BC6OTHER to BC6OTHER was fairly selective in that other BC6OTHER agents such as BC6OTHER , BC6OTHER and BC6ENTC failed to bind to BC6ENTG when examined under the same experimental conditions. CPR:falsenewlineIn addition, BC6ENTC showed little or no BC6OTHER - dependent binding to the BC6ENTG , BC6OTHER or BC6OTHER . CPR:falsenewlineIn addition, BC6ENTC showed little or no BC6OTHER - dependent binding to the BC6OTHER , BC6ENTG or BC6OTHER . CPR:falsenewlineIn addition, BC6ENTC showed little or no BC6OTHER - dependent binding to the BC6OTHER , BC6OTHER or BC6ENTG . CPR:falsenewlineIn addition, BC6OTHER showed little or no BC6ENTC - dependent binding to the BC6ENTG , BC6OTHER or BC6OTHER . CPR:falsenewlineIn addition, BC6OTHER showed little or no BC6ENTC - dependent binding to the BC6OTHER , BC6ENTG or BC6OTHER . CPR:falsenewlineIn addition, BC6OTHER showed little or no BC6ENTC - dependent binding to the BC6OTHER , BC6OTHER or BC6ENTG . CPR:falsenewlineThe irreversible complex between BC6ENTC and BC6ENTG may be useful for inhibiting certain BC6OTHER - dependent reactions and for studying the various biological functions of BC6OTHER . CPR:falsenewlineThe irreversible complex between BC6ENTC and BC6OTHER may be useful for inhibiting certain BC6ENTG - dependent reactions and for studying the various biological functions of BC6OTHER . CPR:falsenewlineThe irreversible complex between BC6ENTC and BC6OTHER may be useful for inhibiting certain BC6OTHER - dependent reactions and for studying the various biological functions of BC6ENTG . CPR:falsenewlineThis interaction was found to be similar in some respects to the interaction between BC6ENTC and BC6ENTG . CPR:falsenewlineInhibition of BC6ENTG - primed eosinophil chemotaxis by BC6ENTC . CPR:falsenewlineCONCLUSIONS: The chemotactic responses toward BC6ENTG were inhibited by BC6ENTC at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol / L). CPR:4newlineThese BC6ENTG have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ). CPR:falsenewlineThese BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ). CPR:falsenewlineThese BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ). CPR:falsenewlineThese BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) / BC6ENTG , but not toward BC6OTHER ( BC6OTHER ). CPR:falsenewlineThese BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6ENTG ( BC6OTHER ). CPR:falsenewlineThese BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6ENTC , ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6ENTG ). CPR:falsenewlineThese BC6ENTG have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ). CPR:falsenewlineThese BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6ENTG ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ). CPR:falsenewlineThese BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6OTHER ( BC6ENTG ) / BC6OTHER , but not toward BC6OTHER ( BC6OTHER ). CPR:falsenewlineThese BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) / BC6ENTG , but not toward BC6OTHER ( BC6OTHER ). CPR:falsenewlineThese BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6ENTG ( BC6OTHER ). CPR:falsenewlineThese BC6OTHER have the capacity to modulate chemotactic responses of eosinophils toward platelet - activating factor, BC6OTHER , ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) / BC6OTHER , but not toward BC6OTHER ( BC6ENTG ). CPR:falsenewlineHere the effect of BC6ENTC on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with BC6ENTG or BC6OTHER toward CHEM, BC6OTHER / BC6OTHER was evaluated. CPR:falsenewlineHere the effect of BC6ENTC on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with BC6OTHER or BC6ENTG toward CHEM, BC6OTHER / BC6OTHER was evaluated. CPR:falsenewlineHere the effect of BC6ENTC on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with BC6OTHER or BC6OTHER toward CHEM, BC6ENTG / BC6OTHER was evaluated. CPR:falsenewlineHere the effect of BC6ENTC on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with BC6OTHER or BC6OTHER toward CHEM, BC6OTHER / BC6ENTG was evaluated. CPR:falsenewlineRESULTS: BC6ENTC inhibited the chemotactic response toward BC6OTHER and BC6OTHER / BC6OTHER of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6ENTG primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L). CPR:falsenewlineRESULTS: BC6ENTC inhibited the chemotactic response toward BC6OTHER and BC6ENTG / BC6OTHER of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L). CPR:falsenewlineRESULTS: BC6ENTC inhibited the chemotactic response toward BC6OTHER and BC6OTHER / BC6ENTG of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L). CPR:falsenewlineRESULTS: BC6ENTC inhibited the chemotactic response toward BC6OTHER and BC6OTHER / BC6OTHER of BC6ENTG primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L). CPR:falsenewlineRESULTS: BC6OTHER inhibited the chemotactic response toward BC6ENTC and BC6OTHER / BC6OTHER of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6ENTG primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L). CPR:falsenewlineRESULTS: BC6OTHER inhibited the chemotactic response toward BC6ENTC and BC6ENTG / BC6OTHER of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L). CPR:falsenewlineRESULTS: BC6OTHER inhibited the chemotactic response toward BC6ENTC and BC6OTHER / BC6ENTG of BC6OTHER primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L). CPR:falsenewlineRESULTS: BC6OTHER inhibited the chemotactic response toward BC6ENTC and BC6OTHER / BC6OTHER of BC6ENTG primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol / L), whereas these responses of BC6OTHER primed eosinophils was completely inhibited (IC50 approximately 1 nmol / L). CPR:falsenewlineThe following was demonstrated in the rat and confirmed in man: interaction of BC6ENTC with the BC6ENTG , antiandrogen activity against BC6OTHER (in particular against the early transient rise induced by BC6OTHER analogs) and adrenal BC6OTHER . CPR:falsenewlineThe following was demonstrated in the rat and confirmed in man: interaction of BC6ENTC with the prostatic BC6OTHER receptor, antiandrogen activity against BC6OTHER (in particular against the early transient rise induced by BC6ENTG analogs) and adrenal BC6OTHER . CPR:falsenewlineThe following was demonstrated in the rat and confirmed in man: interaction of BC6OTHER with the prostatic BC6ENTC receptor, antiandrogen activity against BC6OTHER (in particular against the early transient rise induced by BC6ENTG analogs) and adrenal BC6OTHER . CPR:falsenewlineThe following was demonstrated in the rat and confirmed in man: interaction of BC6OTHER with the BC6ENTG , antiandrogen activity against BC6ENTC (in particular against the early transient rise induced by BC6OTHER analogs) and adrenal BC6OTHER . CPR:falsenewlineThe following was demonstrated in the rat and confirmed in man: interaction of BC6OTHER with the prostatic BC6OTHER receptor, antiandrogen activity against BC6ENTC (in particular against the early transient rise induced by BC6ENTG analogs) and adrenal BC6OTHER . CPR:falsenewlineThe following was demonstrated in the rat and confirmed in man: interaction of BC6OTHER with the BC6ENTG , antiandrogen activity against BC6OTHER (in particular against the early transient rise induced by BC6OTHER analogs) and adrenal BC6ENTC . CPR:falsenewlineThe following was demonstrated in the rat and confirmed in man: interaction of BC6OTHER with the prostatic BC6OTHER receptor, antiandrogen activity against BC6OTHER (in particular against the early transient rise induced by BC6ENTG analogs) and adrenal BC6ENTC . CPR:falsenewlineThis mechanism occurs at therapeutic concentrations of BC6ENTC and is dissociated from BC6ENTG inhibition (the mechanism of bronchodilation) or the blockade of BC6OTHER , which are partially responsible for its side effects. CPR:falsenewlineThis mechanism occurs at therapeutic concentrations of BC6ENTC and is dissociated from BC6OTHER inhibition (the mechanism of bronchodilation) or the blockade of BC6ENTG , which are partially responsible for its side effects. CPR:falsenewlineThis mechanism occurs at therapeutic concentrations of BC6OTHER and is dissociated from BC6ENTG inhibition (the mechanism of bronchodilation) or the blockade of BC6ENTC receptors, which are partially responsible for its side effects. CPR:falsenewlineA molecular mechanism of action of BC6ENTC : Induction of BC6ENTG activity to decrease inflammatory gene expression. CPR:falsenewlineThus we have shown that low - dose BC6ENTC exerts an anti - asthma effect through increasing activation of BC6ENTG which is subsequently recruited by BC6OTHER to suppress inflammatory genes. CPR:falsenewlineThus we have shown that low - dose BC6OTHER exerts an anti - asthma effect through increasing activation of BC6ENTG which is subsequently recruited by BC6ENTC to suppress inflammatory genes. CPR:falsenewlineBC6ENTC act, at least in part, by recruitment of BC6ENTG ( BC6OTHER ) to the site of active inflammatory gene transcription. CPR:falsenewlineBC6ENTC act, at least in part, by recruitment of BC6OTHER ( BC6ENTG ) to the site of active inflammatory gene transcription. CPR:falsenewlineWe show both in vitro and in vivo that low - dose BC6ENTC enhances BC6ENTG activity in epithelial cells and macrophages. CPR:3newlineThis increased BC6ENTG activity is then available for BC6ENTC recruitment and predicts a cooperative interaction between BC6OTHER and BC6OTHER . CPR:falsenewlineThis increased BC6ENTG activity is then available for BC6OTHER recruitment and predicts a cooperative interaction between BC6ENTC and BC6OTHER . CPR:falsenewlineThis increased BC6ENTG activity is then available for BC6OTHER recruitment and predicts a cooperative interaction between BC6OTHER and BC6ENTC . CPR:falsenewlineBC6ENTC (0.1 to 10 microM) induced a BC6OTHER current and hyperpolarized CHO cells expressing BC6ENTG cells but not in wild - type cells. CPR:falsenewlineBC6OTHER (0.1 to 10 microM) induced a BC6ENTC current and hyperpolarized CHO cells expressing BC6ENTG cells but not in wild - type cells. CPR:falsenewlineBC6ENTC - induced currents in CHO - BC6ENTG cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6OTHER blocker, BC6OTHER (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6OTHER (10 mM). CPR:falsenewlineBC6ENTC - induced currents in CHO - BC6OTHER cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6ENTG blocker, BC6OTHER (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6OTHER (10 mM). CPR:falsenewlineBC6OTHER - induced currents in CHO - BC6ENTG cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6OTHER blocker, BC6ENTC (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6OTHER (10 mM). CPR:falsenewlineBC6OTHER - induced currents in CHO - BC6OTHER cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6ENTG blocker, BC6ENTC (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6OTHER (10 mM). CPR:falsenewlineBC6OTHER - induced currents in CHO - BC6ENTG cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6OTHER blocker, BC6OTHER (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6ENTC (10 mM). CPR:falsenewlineBC6OTHER - induced currents in CHO - BC6OTHER cells were inhibited by 60.6 + / - 11% (n = 4) by the BC6ENTG blocker, BC6OTHER (10 microM), and 82.7 + / - 5.4% (n = 4) by BC6ENTC (10 mM). CPR:falsenewlineThe mechanism by which BC6ENTC enhanced BC6ENTG currents involved large, drug - induced, leftward shifts in the voltage dependence of channel activation ( - 33.1 + / - 2.6 mV, n = 4, by 10 microM BC6OTHER ). CPR:falsenewline BC6ENTC , a novel anti - convulsant, enhances activation of BC6ENTG BC6OTHER . CPR:falsenewline BC6ENTC , a novel anti - convulsant, enhances activation of BC6OTHER BC6ENTG . CPR:falsenewline BC6OTHER , a novel anti - convulsant, enhances activation of BC6ENTG BC6ENTC channels. CPR:falsenewlineThe mechanism by which BC6OTHER enhanced BC6ENTG currents involved large, drug - induced, leftward shifts in the voltage dependence of channel activation ( - 33.1 + / - 2.6 mV, n = 4, by 10 microM BC6ENTC ). CPR:falsenewlineOur findings identify BC6ENTG channels as a molecular target for BC6ENTC and suggest that activation of BC6OTHER channels may be responsible for at least some of the anticonvulsant activity of this agent. CPR:falsenewlineOur findings identify BC6OTHER channels as a molecular target for BC6ENTC and suggest that activation of BC6ENTG channels may be responsible for at least some of the anticonvulsant activity of this agent. CPR:falsenewlineIn the present study, we sought to determine whether CHEM could enhance current through M - like currents in PC12 cells and BC6ENTG BC6ENTC channels expressed in Chinese hamster ovary cells (CHO - BC6OTHER ). CPR:falsenewlineIn the present study, we sought to determine whether CHEM could enhance current through M - like currents in PC12 cells and BC6OTHER BC6ENTC channels expressed in Chinese hamster ovary cells (CHO - BC6ENTG ). CPR:falsenewlineIt is physiologically generated by BC6ENTC - γ - lyase, BC6ENTG , and BC6OTHER sulfurtransferase. CPR:falsenewlineIt is physiologically generated by BC6ENTC - γ - lyase, BC6OTHER - β - synthase, and BC6ENTG . CPR:falsenewlineIt is physiologically generated by BC6ENTG , BC6ENTC - β - synthase, and BC6OTHER sulfurtransferase. CPR:falsenewlineIt is physiologically generated by BC6OTHER - γ - lyase, BC6ENTC - β - synthase, and BC6ENTG . CPR:falsenewlineIt is physiologically generated by BC6ENTG , BC6OTHER - β - synthase, and BC6ENTC sulfurtransferase. CPR:falsenewlineIt is physiologically generated by BC6OTHER - γ - lyase, BC6ENTG , and BC6ENTC sulfurtransferase. CPR:falsenewlineSubstantial evidence shows that BC6ENTC is involved in aging by inhibiting free - radical reactions, activating BC6ENTG , and probably interacting with the age - related gene BC6OTHER . CPR:falsenewlineSubstantial evidence shows that BC6ENTC is involved in aging by inhibiting free - radical reactions, activating BC6OTHER , and probably interacting with the age - related gene BC6ENTG . CPR:falsenewlineIn this study we explore the mechanisms by which a double mutation ( BC6ENTG / BC6OTHER ) in BC6OTHER ( BC6OTHER ) associated with dilated cardiomyopathy reduces the BC6ENTC - activated maximal tension of cardiac muscle. CPR:falsenewlineIn this study we explore the mechanisms by which a double mutation ( BC6OTHER / BC6ENTG ) in BC6OTHER ( BC6OTHER ) associated with dilated cardiomyopathy reduces the BC6ENTC - activated maximal tension of cardiac muscle. CPR:falsenewlineIn this study we explore the mechanisms by which a double mutation ( BC6OTHER / BC6OTHER ) in BC6ENTG ( BC6OTHER ) associated with dilated cardiomyopathy reduces the BC6ENTC - activated maximal tension of cardiac muscle. CPR:falsenewlineIn this study we explore the mechanisms by which a double mutation ( BC6OTHER / BC6OTHER ) in BC6OTHER ( BC6ENTG ) associated with dilated cardiomyopathy reduces the BC6ENTC - activated maximal tension of cardiac muscle. CPR:falsenewline Studying the single mutants (i.e. BC6ENTG or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations. CPR:falsenewline Studying the single mutants (i.e. BC6OTHER or BC6ENTG ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations. CPR:falsenewline Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6ENTG , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations. CPR:falsenewline Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6ENTG , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations. CPR:falsenewline Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6ENTG in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations. CPR:falsenewline Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6ENTG complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations. CPR:falsenewline Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6ENTG ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations. CPR:falsenewline Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6ENTG ), and the BC6ENTC sensitivity of contraction and BC6OTHER in cardiac muscle preparations. CPR:falsenewline Studying the single mutants (i.e. BC6OTHER or BC6OTHER ) indicates that BC6OTHER , but not BC6OTHER , causes a reduction in the CHEM affinity of BC6OTHER in BC6OTHER complex, BC6OTHER ( BC6OTHER ), and the BC6ENTC sensitivity of contraction and BC6ENTG in cardiac muscle preparations. CPR:falsenewlineLike conventional BC6ENTG inhibitors, BC6ENTC causes extracellular volume reduction and vasodilatation; moreover, it increases levels of BC6OTHER and BC6OTHER . CPR:falsenewlineLike conventional BC6OTHER inhibitors, BC6ENTC causes extracellular volume reduction and vasodilatation; moreover, it increases levels of BC6ENTG and BC6OTHER . CPR:falsenewlineLike conventional BC6OTHER inhibitors, BC6ENTC causes extracellular volume reduction and vasodilatation; moreover, it increases levels of BC6OTHER and BC6ENTG . CPR:falsenewlineLike conventional BC6ENTG inhibitors, BC6OTHER causes extracellular volume reduction and vasodilatation; moreover, it increases levels of BC6OTHER and BC6ENTC . CPR:falsenewlineLike conventional BC6OTHER inhibitors, BC6OTHER causes extracellular volume reduction and vasodilatation; moreover, it increases levels of BC6ENTG and BC6ENTC . CPR:falsenewlineThe preferred initial agents for the treatment of high blood pressure are low - dose BC6ENTC diuretics, beta blockers, BC6OTHER antagonists, and BC6ENTG ( BC6OTHER ) inhibitors. CPR:falsenewlineThe preferred initial agents for the treatment of high blood pressure are low - dose BC6ENTC diuretics, beta blockers, BC6OTHER antagonists, and BC6OTHER - converting enzyme ( BC6ENTG ) inhibitors. CPR:falsenewlineAdvances in antihypertensive combination therapy: benefits of low - dose BC6OTHER diuretics in conjunction with BC6ENTC , a BC6ENTG inhibitor. CPR:falsenewlineAdvances in antihypertensive combination therapy: benefits of low - dose BC6ENTC diuretics in conjunction with BC6OTHER , a BC6ENTG inhibitor. CPR:falsenewlineThe preferred initial agents for the treatment of high blood pressure are low - dose BC6OTHER diuretics, beta blockers, BC6ENTC antagonists, and BC6ENTG ( BC6OTHER ) inhibitors. CPR:falsenewlineThe preferred initial agents for the treatment of high blood pressure are low - dose BC6OTHER diuretics, beta blockers, BC6ENTC antagonists, and BC6OTHER - converting enzyme ( BC6ENTG ) inhibitors. CPR:falsenewlineThe preferred initial agents for the treatment of high blood pressure are low - dose BC6OTHER diuretics, beta blockers, BC6OTHER antagonists, and BC6ENTC - converting enzyme ( BC6ENTG ) inhibitors. CPR:falsenewlineBC6ENTC , the prototypical BC6ENTG inhibitor, inhibits not only BC6OTHER but also BC6OTHER . CPR:4newlineBC6ENTC , the prototypical BC6OTHER inhibitor, inhibits not only BC6ENTG but also BC6OTHER . CPR:4newlineBC6ENTC , the prototypical BC6OTHER inhibitor, inhibits not only BC6OTHER but also BC6ENTG . CPR:4newlineBC6ENTC forms a ring around the internal cavity in BC6ENTG through aromatic stacking interactions between the drug and BC6OTHER as well as between the drug molecules themselves. CPR:falsenewlineBC6ENTC forms a ring around the internal cavity in BC6OTHER through aromatic stacking interactions between the drug and BC6ENTG as well as between the drug molecules themselves. CPR:falsenewlineMammalian BC6ENTC dehydrogenase ( BC6ENTG ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6OTHER to BC6OTHER using BC6OTHER as coenzyme. CPR:falsenewlineBC6ENTG ( BC6OTHER ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6ENTC to BC6OTHER using BC6OTHER as coenzyme. CPR:9newlineMammalian BC6OTHER dehydrogenase ( BC6ENTG ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6ENTC to BC6OTHER using BC6OTHER as coenzyme. CPR:falsenewlineBC6ENTG ( BC6OTHER ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6OTHER to BC6ENTC using BC6OTHER as coenzyme. CPR:9newlineMammalian BC6OTHER dehydrogenase ( BC6ENTG ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6OTHER to BC6ENTC using BC6OTHER as coenzyme. CPR:falsenewlineBC6ENTG ( BC6OTHER ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6OTHER to BC6OTHER using BC6ENTC as coenzyme. CPR:9newlineMammalian BC6OTHER dehydrogenase ( BC6ENTG ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of BC6OTHER to BC6OTHER using BC6ENTC as coenzyme. CPR:falsenewlineThe recently discovered hyperinsulinism / hyperammonemia disorder showed that the loss of allosteric inhibition of BC6ENTG by BC6ENTC causes excessive secretion of BC6OTHER . CPR:falsenewlineThe recently discovered hyperinsulinism / hyperammonemia disorder showed that the loss of allosteric inhibition of BC6OTHER by BC6ENTC causes excessive secretion of BC6ENTG . CPR:falsenewlineSubsequent studies demonstrated that wild - type and hyperinsulinemia / hyperammonemia forms of BC6ENTG are inhibited by the green tea CHEM, BC6ENTC and BC6OTHER . CPR:falsenewlineSubsequent studies demonstrated that wild - type and hyperinsulinemia / hyperammonemia forms of BC6ENTG are inhibited by the green tea CHEM, BC6OTHER and BC6ENTC . CPR:falsenewlineThe observed inhibition on BC6ENTG , BC6OTHER , and BC6OTHER mRNA was blocked by the selective BC6OTHER antagonist BC6ENTC (10( - 6) M) and by BC6OTHER (10( - 6) M), a nonselective antagonist. CPR:falsenewlineThe observed inhibition on BC6OTHER , BC6ENTG , and BC6OTHER mRNA was blocked by the selective BC6OTHER antagonist BC6ENTC (10( - 6) M) and by BC6OTHER (10( - 6) M), a nonselective antagonist. CPR:falsenewlineThe observed inhibition on BC6OTHER , BC6OTHER , and BC6ENTG mRNA was blocked by the selective BC6OTHER antagonist BC6ENTC (10( - 6) M) and by BC6OTHER (10( - 6) M), a nonselective antagonist. CPR:falsenewlineThe observed inhibition on BC6OTHER , BC6OTHER , and BC6OTHER mRNA was blocked by the selective BC6ENTG antagonist BC6ENTC (10( - 6) M) and by BC6OTHER (10( - 6) M), a nonselective antagonist. CPR:falsenewlineThe observed inhibition on BC6ENTG , BC6OTHER , and BC6OTHER mRNA was blocked by the selective BC6OTHER antagonist BC6OTHER (10( - 6) M) and by BC6ENTC (10( - 6) M), a nonselective antagonist. CPR:falsenewlineThe observed inhibition on BC6OTHER , BC6ENTG , and BC6OTHER mRNA was blocked by the selective BC6OTHER antagonist BC6OTHER (10( - 6) M) and by BC6ENTC (10( - 6) M), a nonselective antagonist. CPR:falsenewlineThe observed inhibition on BC6OTHER , BC6OTHER , and BC6ENTG mRNA was blocked by the selective BC6OTHER antagonist BC6OTHER (10( - 6) M) and by BC6ENTC (10( - 6) M), a nonselective antagonist. CPR:falsenewlineThe observed inhibition on BC6OTHER , BC6OTHER , and BC6OTHER mRNA was blocked by the selective BC6ENTG antagonist BC6OTHER (10( - 6) M) and by BC6ENTC (10( - 6) M), a nonselective antagonist. CPR:falsenewlineThe selective BC6ENTG antagonist BC6ENTC (0.3 x 10( - 6) M) did not have any effect. CPR:falsenewlineSecretion of BC6ENTG protein in the presence of increasing concentrations of BC6ENTC followed a similar pattern as observed for BC6OTHER mRNA. CPR:falsenewlineSecretion of BC6OTHER protein in the presence of increasing concentrations of BC6ENTC followed a similar pattern as observed for BC6ENTG mRNA. CPR:falsenewlineIn addition, the BC6ENTG - mediated inhibition of BC6OTHER , BC6OTHER , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6ENTC ( BC6OTHER ) levels. CPR:falsenewlineIn addition, the BC6OTHER - mediated inhibition of BC6ENTG , BC6OTHER , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6ENTC ( BC6OTHER ) levels. CPR:falsenewlineIn addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6ENTG , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6ENTC ( BC6OTHER ) levels. CPR:falsenewlineIn addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6OTHER , and BC6ENTG mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6ENTC ( BC6OTHER ) levels. CPR:falsenewlineIn addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6OTHER , and BC6OTHER mRNA accumulation and BC6ENTG protein secretion were related to the accumulation of intracellular BC6ENTC ( BC6OTHER ) levels. CPR:falsenewlineIn addition, the BC6ENTG - mediated inhibition of BC6OTHER , BC6OTHER , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6OTHER ( BC6ENTC ) levels. CPR:falsenewlineIn addition, the BC6OTHER - mediated inhibition of BC6ENTG , BC6OTHER , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6OTHER ( BC6ENTC ) levels. CPR:falsenewlineIn addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6ENTG , and BC6OTHER mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6OTHER ( BC6ENTC ) levels. CPR:falsenewlineIn addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6OTHER , and BC6ENTG mRNA accumulation and BC6OTHER protein secretion were related to the accumulation of intracellular BC6OTHER ( BC6ENTC ) levels. CPR:falsenewlineIn addition, the BC6OTHER - mediated inhibition of BC6OTHER , BC6OTHER , and BC6OTHER mRNA accumulation and BC6ENTG protein secretion were related to the accumulation of intracellular BC6OTHER ( BC6ENTC ) levels. CPR:falsenewlineAlthough BC6ENTG mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6ENTC had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6OTHER levels. CPR:falsenewlineAlthough BC6OTHER mRNA was detectable in BC6ENTG - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6ENTC had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6OTHER levels. CPR:falsenewlineAlthough BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6ENTG expression: the BC6OTHER agonist BC6ENTC had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6OTHER levels. CPR:falsenewlineAlthough BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6ENTG agonist BC6ENTC had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6OTHER levels. CPR:falsenewlineAlthough BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6ENTC had no effect on the accumulation of the studied BC6ENTG mRNAs, and did not significantly affect cellular BC6OTHER levels. CPR:falsenewlineAlthough BC6ENTG mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6OTHER had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6ENTC levels. CPR:falsenewlineAlthough BC6OTHER mRNA was detectable in BC6ENTG - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6OTHER had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6ENTC levels. CPR:falsenewlineAlthough BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6ENTG expression: the BC6OTHER agonist BC6OTHER had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6ENTC levels. CPR:falsenewlineAlthough BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6ENTG agonist BC6OTHER had no effect on the accumulation of the studied BC6OTHER mRNAs, and did not significantly affect cellular BC6ENTC levels. CPR:falsenewlineAlthough BC6OTHER mRNA was detectable in BC6OTHER - activated T lymphocytes, we could not demonstrate a functional activity in the regulation of BC6OTHER expression: the BC6OTHER agonist BC6OTHER had no effect on the accumulation of the studied BC6ENTG mRNAs, and did not significantly affect cellular BC6ENTC levels. CPR:falsenewlineBC6ENTG ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTG ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced BC6ENTG , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6ENTG , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6ENTG mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6ENTG agonist BC6ENTC and by the selective BC6OTHER agonist BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6ENTC and by the selective BC6ENTG agonist BC6OTHER . CPR:falsenewlineBC6ENTG ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC . CPR:falsenewlineBC6OTHER ( BC6ENTG ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC . CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced BC6ENTG , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC . CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6ENTG , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC . CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6ENTG mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC . CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6ENTG agonist BC6OTHER and by the selective BC6OTHER agonist BC6ENTC . CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced BC6OTHER , BC6OTHER , and BC6OTHER mRNAs are dose - dependently inhibited by the nonselective BC6OTHER agonist BC6OTHER and by the selective BC6ENTG agonist BC6ENTC . CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6ENTC [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6ENTC [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6ENTC [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6ENTC [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6ENTC ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6ENTC ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6ENTC ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6ENTC ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6ENTC ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6ENTC ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6ENTC ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6ENTC ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6ENTC ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6ENTC ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6ENTC ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6ENTC ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6ENTC ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6ENTC ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6ENTC ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6ENTC ). CPR:falsenewlineThe number of BC6ENTC - diaphorase positive elements in the SON and the PVN was modulated by both BC6ENTG but, depending on the nucleus, BC6OTHER and BC6OTHER ligands induced different effects. CPR:falsenewlineThe number of BC6ENTC - diaphorase positive elements in the SON and the PVN was modulated by both BC6OTHER but, depending on the nucleus, BC6ENTG and BC6OTHER ligands induced different effects. CPR:falsenewlineThe number of BC6ENTC - diaphorase positive elements in the SON and the PVN was modulated by both BC6OTHER but, depending on the nucleus, BC6OTHER and BC6ENTG ligands induced different effects. CPR:falsenewlineRole of BC6ENTG on the modulation of BC6ENTC - diaphorase - positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats. CPR:falsenewlineModulation of the BC6OTHER producing system (demonstrated via the BC6ENTG histochemical reaction) by BC6ENTC has been established in several structures of the rat brain. CPR:falsenewlineRole of BC6ENTC receptors on the modulation of BC6ENTG - positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats. CPR:falsenewlineThese results suggest that the regulation of nitrergic system by BC6ENTG may play a role in the control of BC6ENTC - dependent physiological mechanisms regulated by the SON and the PVN. CPR:falsenewlineModulation of the BC6ENTC producing system (demonstrated via the BC6ENTG histochemical reaction) by BC6OTHER has been established in several structures of the rat brain. CPR:falsenewlineThe present study aimed to explore the possible regulation of BC6ENTC - diaphorase activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6ENTG ( BC6OTHER and BC6OTHER ) in this regulation. CPR:falsenewlineThe present study aimed to explore the possible regulation of BC6ENTC - diaphorase activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6OTHER receptors ( BC6ENTG and BC6OTHER ) in this regulation. CPR:falsenewlineThe present study aimed to explore the possible regulation of BC6ENTC - diaphorase activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6OTHER receptors ( BC6OTHER and BC6ENTG ) in this regulation. CPR:falsenewlineThe present study aimed to explore the possible regulation of BC6ENTG activity by BC6ENTC in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6OTHER receptors ( BC6OTHER and BC6OTHER ) in this regulation. CPR:falsenewlineThe present study aimed to explore the possible regulation of BC6OTHER - diaphorase activity by BC6ENTC in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6ENTG ( BC6OTHER and BC6OTHER ) in this regulation. CPR:falsenewlineThe present study aimed to explore the possible regulation of BC6OTHER - diaphorase activity by BC6ENTC in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6OTHER receptors ( BC6ENTG and BC6OTHER ) in this regulation. CPR:falsenewlineThe present study aimed to explore the possible regulation of BC6OTHER - diaphorase activity by BC6ENTC in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6OTHER receptors ( BC6OTHER and BC6ENTG ) in this regulation. CPR:falsenewlineThe present study aimed to explore the possible regulation of BC6ENTG activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6ENTC receptors ( BC6OTHER and BC6OTHER ) in this regulation. CPR:falsenewlineThe present study aimed to explore the possible regulation of BC6OTHER - diaphorase activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6ENTC receptors ( BC6ENTG and BC6OTHER ) in this regulation. CPR:falsenewlineThe present study aimed to explore the possible regulation of BC6OTHER - diaphorase activity by BC6OTHER in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of BC6ENTC receptors ( BC6OTHER and BC6ENTG ) in this regulation. CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6ENTC , a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6ENTC , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6ENTC , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6ENTC , a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6ENTC [ BC6OTHER ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6ENTG agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6ENTG agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6ENTG antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6OTHER antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineAdult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of BC6OTHER , a selective BC6OTHER agonist - BC6OTHER [ BC6ENTC ], a selective BC6OTHER agonist - BC6OTHER [ BC6OTHER ], a selective BC6OTHER antagonist - BC6OTHER [ BC6OTHER ] - BC6OTHER ] or a selective BC6ENTG antagonist - BC6OTHER ( BC6OTHER ). CPR:falsenewlineBoth microtubule and BC6OTHER are required for BC6ENTG - induced BC6ENTC uptake. CPR:falsenewlineBoth microtubule and BC6ENTG are required for BC6OTHER - induced BC6ENTC uptake. CPR:falsenewlineDisruption of microtubule prevented BC6ENTG - induced BC6OTHER remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6ENTC transporter isoform 4 ( BC6OTHER ) and BC6OTHER uptake. CPR:falsenewlineDisruption of microtubule prevented BC6OTHER - induced BC6ENTG remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6ENTC transporter isoform 4 ( BC6OTHER ) and BC6OTHER uptake. CPR:falsenewlineDisruption of microtubule prevented BC6OTHER - induced BC6OTHER remodeling and distal BC6ENTG signal transduction, with reduction in surface BC6ENTC transporter isoform 4 ( BC6OTHER ) and BC6OTHER uptake. CPR:falsenewlineDisruption of microtubule prevented BC6OTHER - induced BC6OTHER remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6ENTC transporter isoform 4 ( BC6ENTG ) and BC6OTHER uptake. CPR:falsenewlineDisruption of microtubule prevented BC6ENTG - induced BC6OTHER remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6OTHER transporter isoform 4 ( BC6OTHER ) and BC6ENTC uptake. CPR:falsenewlineDisruption of microtubule prevented BC6OTHER - induced BC6ENTG remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6OTHER transporter isoform 4 ( BC6OTHER ) and BC6ENTC uptake. CPR:falsenewlineDisruption of microtubule prevented BC6OTHER - induced BC6OTHER remodeling and distal BC6ENTG signal transduction, with reduction in surface BC6OTHER transporter isoform 4 ( BC6OTHER ) and BC6ENTC uptake. CPR:falsenewlineDisruption of microtubule prevented BC6OTHER - induced BC6OTHER remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6ENTG ( BC6OTHER ) and BC6ENTC uptake. CPR:falsenewlineDisruption of microtubule prevented BC6OTHER - induced BC6OTHER remodeling and distal BC6OTHER signal transduction, with reduction in surface BC6OTHER transporter isoform 4 ( BC6ENTG ) and BC6ENTC uptake. CPR:falsenewlineThough microtubule mediated BC6ENTG remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6OTHER - induced BC6OTHER remodeling, which relied on the activity of BC6OTHER and BC6OTHER . CPR:falsenewlineThough microtubule mediated BC6OTHER remodeling through BC6ENTG , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6OTHER - induced BC6OTHER remodeling, which relied on the activity of BC6OTHER and BC6OTHER . CPR:falsenewlineThough microtubule mediated BC6OTHER remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6ENTG , the mechanism is different from BC6OTHER - induced BC6OTHER remodeling, which relied on the activity of BC6OTHER and BC6OTHER . CPR:falsenewlineThough microtubule mediated BC6OTHER remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6ENTG - induced BC6OTHER remodeling, which relied on the activity of BC6OTHER and BC6OTHER . CPR:falsenewlineThough microtubule mediated BC6OTHER remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6OTHER - induced BC6ENTG remodeling, which relied on the activity of BC6OTHER and BC6OTHER . CPR:falsenewlineThough microtubule mediated BC6OTHER remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6OTHER - induced BC6OTHER remodeling, which relied on the activity of BC6ENTG and BC6OTHER . CPR:falsenewlineThough microtubule mediated BC6OTHER remodeling through BC6OTHER , reorganization of microtubule depended on BC6ENTC phosphorylation of BC6OTHER , the mechanism is different from BC6OTHER - induced BC6OTHER remodeling, which relied on the activity of BC6OTHER and BC6ENTG . CPR:falsenewlineInterestingly, BC6ENTG expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6ENTG BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6ENTC ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6OTHER clearance ratio (Ccr) and BC6ENTG protein. CPR:falsenewlineInterestingly, BC6ENTG expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6ENTG BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6OTHER protein. CPR:falsenewlineInterestingly, BC6OTHER expression positively correlated with urine BC6OTHER BC6OTHER ratio (ACR), BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ); while negatively correlated with BC6ENTC clearance ratio (Ccr) and BC6ENTG protein. CPR:falsenewlineBC6ENTC did not affect BC6ENTG responses. CPR:falsenewlineThese experiments show that in striatonigral projections, BC6ENTG inhibits the action of BC6OTHER in a BC6ENTC dependent manner blocking their modulatory effects on BC6OTHER release. CPR:falsenewlineThese experiments show that in striatonigral projections, BC6OTHER inhibits the action of BC6ENTG in a BC6ENTC dependent manner blocking their modulatory effects on BC6OTHER release. CPR:falsenewlineThese experiments show that in striatonigral projections, BC6ENTG inhibits the action of BC6OTHER in a BC6OTHER dependent manner blocking their modulatory effects on BC6ENTC release. CPR:falsenewlineThese experiments show that in striatonigral projections, BC6OTHER inhibits the action of BC6ENTG in a BC6OTHER dependent manner blocking their modulatory effects on BC6ENTC release. CPR:falsenewlineIn this study we examined whether the presynaptic effects of BC6ENTG stimulation in the substantia nigra reticulata (SNr) are modulated by BC6ENTC activation of BC6OTHER . CPR:falsenewlineIn this study we examined whether the presynaptic effects of BC6OTHER stimulation in the substantia nigra reticulata (SNr) are modulated by BC6ENTC activation of BC6ENTG . CPR:falsenewlineIn SNr synaptosomes two procedures that increase cytoplasmic BC6ENTC , BC6OTHER and BC6OTHER - depolarization, blocked the additional stimulation of BC6OTHER accumulation produced by coactivating BC6ENTG . CPR:falsenewlineIn SNr synaptosomes two procedures that increase cytoplasmic BC6OTHER , BC6ENTC and BC6OTHER - depolarization, blocked the additional stimulation of BC6OTHER accumulation produced by coactivating BC6ENTG . CPR:falsenewlineIn SNr synaptosomes two procedures that increase cytoplasmic BC6OTHER , BC6OTHER and BC6ENTC - depolarization, blocked the additional stimulation of BC6OTHER accumulation produced by coactivating BC6ENTG . CPR:falsenewlineImmunoblot studies showed that BC6OTHER - depolarization increased BC6OTHER phosphorylation in a BC6ENTC sensitive manner and promoted BC6ENTG binding to BC6OTHER . CPR:falsenewlineImmunoblot studies showed that BC6OTHER - depolarization increased BC6OTHER phosphorylation in a BC6ENTC sensitive manner and promoted BC6OTHER binding to BC6ENTG . CPR:falsenewlineImmunoblot studies showed that BC6OTHER - depolarization increased BC6ENTG phosphorylation in a BC6ENTC sensitive manner and promoted BC6OTHER binding to BC6OTHER . CPR:falsenewlineIn SNr synaptosomes two procedures that increase cytoplasmic BC6OTHER , BC6OTHER and BC6OTHER - depolarization, blocked the additional stimulation of BC6ENTC accumulation produced by coactivating BC6ENTG . CPR:falsenewlineThe selective BC6ENTG inhibitor BC6ENTC reversed the blockade produced by BC6OTHER and BC6OTHER - depolarization. CPR:falsenewlineThe selective BC6ENTG inhibitor BC6OTHER reversed the blockade produced by BC6ENTC and BC6OTHER - depolarization. CPR:falsenewlineThe selective BC6ENTG inhibitor BC6OTHER reversed the blockade produced by BC6OTHER and BC6ENTC - depolarization. CPR:falsenewlineImmunoblot studies showed that BC6ENTC - depolarization increased BC6OTHER phosphorylation in a BC6OTHER sensitive manner and promoted BC6ENTG binding to BC6OTHER . CPR:falsenewlineImmunoblot studies showed that BC6ENTC - depolarization increased BC6OTHER phosphorylation in a BC6OTHER sensitive manner and promoted BC6OTHER binding to BC6ENTG . CPR:falsenewlineImmunoblot studies showed that BC6ENTC - depolarization increased BC6ENTG phosphorylation in a BC6OTHER sensitive manner and promoted BC6OTHER binding to BC6OTHER . CPR:falsenewlineIn BC6ENTC - depolarized tissues, BC6ENTG potentiated BC6OTHER - induced stimulation of BC6OTHER release only when BC6OTHER was blocked with BC6OTHER . CPR:falsenewlineIn BC6ENTC - depolarized tissues, BC6OTHER potentiated BC6ENTG - induced stimulation of BC6OTHER release only when BC6OTHER was blocked with BC6OTHER . CPR:falsenewlineIn BC6ENTC - depolarized tissues, BC6OTHER potentiated BC6OTHER - induced stimulation of BC6OTHER release only when BC6ENTG was blocked with BC6OTHER . CPR:falsenewlinePresynaptic BC6ENTG modulates BC6OTHER activation in striatonigral terminals of the rat brain in a BC6ENTC dependent manner. CPR:falsenewlinePresynaptic BC6OTHER modulates BC6ENTG activation in striatonigral terminals of the rat brain in a BC6ENTC dependent manner. CPR:falsenewlinePresynaptic BC6ENTG modulates BC6ENTC D3 receptor activation in striatonigral terminals of the rat brain in a BC6OTHER dependent manner. CPR:falsenewlineIn BC6OTHER - depolarized tissues, BC6ENTG potentiated BC6OTHER - induced stimulation of BC6ENTC release only when BC6OTHER was blocked with BC6OTHER . CPR:falsenewlineIn BC6OTHER - depolarized tissues, BC6OTHER potentiated BC6ENTG - induced stimulation of BC6ENTC release only when BC6OTHER was blocked with BC6OTHER . CPR:falsenewlineIn BC6OTHER - depolarized tissues, BC6OTHER potentiated BC6OTHER - induced stimulation of BC6ENTC release only when BC6ENTG was blocked with BC6OTHER . CPR:falsenewlineIn BC6OTHER - depolarized tissues, BC6ENTG potentiated BC6OTHER - induced stimulation of BC6OTHER release only when BC6OTHER was blocked with BC6ENTC . CPR:falsenewlineIn BC6OTHER - depolarized tissues, BC6OTHER potentiated BC6ENTG - induced stimulation of BC6OTHER release only when BC6OTHER was blocked with BC6ENTC . CPR:falsenewlineIn BC6OTHER - depolarized tissues, BC6OTHER potentiated BC6OTHER - induced stimulation of BC6OTHER release only when BC6ENTG was blocked with BC6ENTC . CPR:falsenewlineIn the presence of this inhibitor, the selective BC6ENTG agonist BC6ENTC reduced the ED50 for the BC6OTHER agonist BC6OTHER from 56 to 4 nM. CPR:5newlineIn the presence of this inhibitor, the selective BC6OTHER agonist BC6ENTC reduced the ED50 for the BC6ENTG agonist BC6OTHER from 56 to 4 nM. CPR:falsenewlineIn the presence of this inhibitor, the selective BC6ENTG agonist BC6OTHER reduced the ED50 for the BC6OTHER agonist BC6ENTC from 56 to 4 nM. CPR:falsenewlineIn the presence of this inhibitor, the selective BC6OTHER agonist BC6OTHER reduced the ED50 for the BC6ENTG agonist BC6ENTC from 56 to 4 nM. CPR:falsenewlineAll the compounds were evaluated for their anti - tumor activity against MCF - 7, A549 and B16 - F10 tumor cell lines as well as BC6ENTG ( BC6OTHER ) - derived BC6ENTC ( BC6OTHER ) inhibitory activity of murine macrophage RAW 264.7 cell line. CPR:falsenewlineAll the compounds were evaluated for their anti - tumor activity against MCF - 7, A549 and B16 - F10 tumor cell lines as well as BC6OTHER ( BC6ENTG ) - derived BC6ENTC ( BC6OTHER ) inhibitory activity of murine macrophage RAW 264.7 cell line. CPR:falsenewlineAll the compounds were evaluated for their anti - tumor activity against MCF - 7, A549 and B16 - F10 tumor cell lines as well as BC6ENTG ( BC6OTHER ) - derived BC6OTHER ( BC6ENTC ) inhibitory activity of murine macrophage RAW 264.7 cell line. CPR:falsenewlineAll the compounds were evaluated for their anti - tumor activity against MCF - 7, A549 and B16 - F10 tumor cell lines as well as BC6OTHER ( BC6ENTG ) - derived BC6OTHER ( BC6ENTC ) inhibitory activity of murine macrophage RAW 264.7 cell line. CPR:falsenewlineRecent evidence suggests that processes other than BC6ENTC binding, such as phosphorylation of BC6ENTG ( BC6OTHER ) also controls contraction of vertebrate striated muscle (Cooke, R. (2011) Biophys. CPR:falsenewlineRecent evidence suggests that processes other than BC6ENTC binding, such as phosphorylation of BC6OTHER ( BC6ENTG ) also controls contraction of vertebrate striated muscle (Cooke, R. (2011) Biophys. CPR:falsenewlineWe find that: (i) relaxed cross - bridges, but not active ones, are statistically better ordered in muscle where the BC6ENTG is dephosporylated compared with BC6OTHER ; (ii) relaxed phosphorylated and dephosphorylated cross - bridges rotate equally slowly; and (iii) active phosphorylated cross - bridges rotate considerably faster than dephosphorylated ones during isometric contraction but the duty cycle remained the same, suggesting that both phosphorylated and dephosphorylated muscles develop the same isometric tension at full BC6ENTC saturation. CPR:falsenewlineWe find that: (i) relaxed cross - bridges, but not active ones, are statistically better ordered in muscle where the BC6OTHER is dephosporylated compared with BC6ENTG ; (ii) relaxed phosphorylated and dephosphorylated cross - bridges rotate equally slowly; and (iii) active phosphorylated cross - bridges rotate considerably faster than dephosphorylated ones during isometric contraction but the duty cycle remained the same, suggesting that both phosphorylated and dephosphorylated muscles develop the same isometric tension at full BC6ENTC saturation. CPR:falsenewlineElectron paramagnetic resonance (EPR) studies using BC6ENTC analog spin label probes showed that BC6OTHER heads are highly ordered in the relaxed fibers and have very low BC6ENTG activity. CPR:falsenewlineElectron paramagnetic resonance (EPR) studies using BC6ENTC analog spin label probes showed that BC6ENTG heads are highly ordered in the relaxed fibers and have very low BC6OTHER activity. CPR:falsenewlineAccumulated evidence in humans and animals shows that both BC6ENTC and H. pylori upregulate the expression of BC6ENTG both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of BC6OTHER . CPR:falsenewlineAccumulated evidence in humans and animals shows that both BC6ENTC and H. pylori upregulate the expression of BC6OTHER both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of BC6ENTG . CPR:falsenewlineIt was, therefore, proposed that H. pylori may in fact, antagonize, BC6ENTC - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6OTHER possibly derived from BC6OTHER expression and activity and to the overexpression of growth factors such as BC6ENTG and BC6OTHER . CPR:falsenewlineIt was, therefore, proposed that H. pylori may in fact, antagonize, BC6ENTC - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6OTHER possibly derived from BC6OTHER expression and activity and to the overexpression of growth factors such as BC6OTHER and BC6ENTG . CPR:falsenewlineIt was, therefore, proposed that H. pylori may in fact, antagonize, BC6ENTC - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6OTHER possibly derived from BC6ENTG expression and activity and to the overexpression of growth factors such as BC6OTHER and BC6OTHER . CPR:falsenewlineIt was, therefore, proposed that H. pylori may in fact, antagonize, BC6OTHER - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6ENTC possibly derived from BC6OTHER expression and activity and to the overexpression of growth factors such as BC6ENTG and BC6OTHER . CPR:falsenewlineIt was, therefore, proposed that H. pylori may in fact, antagonize, BC6OTHER - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6ENTC possibly derived from BC6OTHER expression and activity and to the overexpression of growth factors such as BC6OTHER and BC6ENTG . CPR:falsenewlineIt was, therefore, proposed that H. pylori may in fact, antagonize, BC6OTHER - induced delay of ulcer healing due to suppression of acid secretion by the enhancement in BC6ENTC possibly derived from BC6ENTG expression and activity and to the overexpression of growth factors such as BC6OTHER and BC6OTHER . CPR:falsenewlineMolecular docking studies were performed with BC6ENTG ( BC6OTHER : PDB 1E78), showing binding pattern with BC6ENTC residues BC6OTHER 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineMolecular docking studies were performed with BC6OTHER ( BC6ENTG : PDB 1E78), showing binding pattern with BC6ENTC residues BC6OTHER 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineMolecular docking studies were performed with BC6OTHER ( BC6OTHER : PDB 1E78), showing binding pattern with BC6ENTC residues BC6OTHER 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6ENTG interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineMolecular docking studies were performed with BC6ENTG ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6ENTC 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineMolecular docking studies were performed with BC6OTHER ( BC6ENTG : PDB 1E78), showing binding pattern with BC6OTHER residues BC6ENTC 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineMolecular docking studies were performed with BC6OTHER ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6ENTC 218, BC6OTHER 222 and BC6OTHER 444, identifies the ligand - BC6ENTG interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineMolecular docking studies were performed with BC6ENTG ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6ENTC 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineMolecular docking studies were performed with BC6OTHER ( BC6ENTG : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6ENTC 222 and BC6OTHER 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineMolecular docking studies were performed with BC6OTHER ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6ENTC 222 and BC6OTHER 444, identifies the ligand - BC6ENTG interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineMolecular docking studies were performed with BC6ENTG ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6OTHER 222 and BC6ENTC 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineMolecular docking studies were performed with BC6OTHER ( BC6ENTG : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6OTHER 222 and BC6ENTC 444, identifies the ligand - BC6OTHER interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineMolecular docking studies were performed with BC6OTHER ( BC6OTHER : PDB 1E78), showing binding pattern with BC6OTHER residues BC6OTHER 218, BC6OTHER 222 and BC6ENTC 444, identifies the ligand - BC6ENTG interaction for the transportation affinity of the ligand at the specific site of the target. CPR:falsenewlineAgents which have recently been shown to block BC6ENTG translation by regulating CHEM levels are the BC6ENTC , BC6OTHER ( BC6OTHER ), the antidiabetic BC6OTHER , and the antifungal agent, BC6OTHER . CPR:falsenewlineAgents which have recently been shown to block BC6ENTG translation by regulating CHEM levels are the BC6OTHER , BC6ENTC ( BC6OTHER ), the antidiabetic BC6OTHER , and the antifungal agent, BC6OTHER . CPR:falsenewlineA low toxicity maintenance regime, using BC6ENTC and readily available drugs, for mantle cell lymphoma and other malignancies with excess BC6ENTG levels. CPR:falsenewlineAgents which have recently been shown to block BC6ENTG translation by regulating CHEM levels are the BC6OTHER , BC6OTHER ( BC6ENTC ), the antidiabetic BC6OTHER , and the antifungal agent, BC6OTHER . CPR:falsenewlineAgents which have recently been shown to block BC6ENTG translation by regulating CHEM levels are the BC6OTHER , BC6OTHER ( BC6OTHER ), the antidiabetic BC6ENTC , and the antifungal agent, BC6OTHER . CPR:falsenewlineAgents which have recently been shown to block BC6ENTG translation by regulating CHEM levels are the BC6OTHER , BC6OTHER ( BC6OTHER ), the antidiabetic BC6OTHER , and the antifungal agent, BC6ENTC . CPR:falsenewlineTwo types of agent which have been shown to inhibit angiogenesis are the teratogen, BC6ENTC , and the selective inhibitors of BC6ENTG ( BC6OTHER ). CPR:falsenewlineTwo types of agent which have been shown to inhibit angiogenesis are the teratogen, BC6ENTC , and the selective inhibitors of BC6OTHER ( BC6ENTG ). CPR:falsenewlineBACKGROUND AND AIMS: BC6ENTG ( BC6OTHER ) is an important enzyme for DNA synthesis and the target for BC6ENTC ( BC6OTHER ). CPR:falsenewlineBACKGROUND AND AIMS: BC6OTHER synthase ( BC6ENTG ) is an important enzyme for DNA synthesis and the target for BC6ENTC ( BC6OTHER ). CPR:falsenewlineBACKGROUND AND AIMS: BC6ENTG ( BC6OTHER ) is an important enzyme for DNA synthesis and the target for BC6OTHER ( BC6ENTC ). CPR:falsenewlineBACKGROUND AND AIMS: BC6OTHER synthase ( BC6ENTG ) is an important enzyme for DNA synthesis and the target for BC6OTHER ( BC6ENTC ). CPR:falsenewlineBACKGROUND AND AIMS: BC6ENTC synthase ( BC6ENTG ) is an important enzyme for DNA synthesis and the target for BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6ENTC , a BC6OTHER ( BC6OTHER )ylated peptide - based erythropoiesis - stimulating agent, stimulates the BC6ENTG dimer that governs erythropoiesis. CPR:falsenewlineBC6OTHER , a BC6ENTC ( BC6OTHER )ylated peptide - based erythropoiesis - stimulating agent, stimulates the BC6ENTG dimer that governs erythropoiesis. CPR:falsenewlineBC6OTHER , a BC6OTHER ( BC6ENTC )ylated peptide - based erythropoiesis - stimulating agent, stimulates the BC6ENTG dimer that governs erythropoiesis. CPR:falsenewlineGenetic polymorphism and activities of BC6ENTG BC6OTHER dehydrogenases: implications for BC6ENTC metabolism and cytotoxicity. CPR:falsenewlineGenetic polymorphism and activities of BC6ENTG BC6ENTC dehydrogenases: implications for BC6OTHER metabolism and cytotoxicity. CPR:falsenewlineBC6ENTC dehydrogenase ( BC6ENTG ) and BC6OTHER dehydrogenase ( BC6OTHER ) exhibit genetic polymorphism and tissue specificity. CPR:falsenewlineBC6ENTC dehydrogenase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) exhibit genetic polymorphism and tissue specificity. CPR:falsenewlineBC6ENTC dehydrogenase ( BC6OTHER ) and BC6OTHER dehydrogenase ( BC6ENTG ) exhibit genetic polymorphism and tissue specificity. CPR:falsenewlineThese findings indicate that human pulmonary BC6ENTC - metabolizing activities differ significantly with respect to genetic polymorphism at both the BC6ENTG and the BC6OTHER loci. CPR:falsenewlineThese findings indicate that human pulmonary BC6ENTC - metabolizing activities differ significantly with respect to genetic polymorphism at both the BC6OTHER and the BC6ENTG loci. CPR:falsenewlineThe results suggest that individuals with high Vmax BC6ENTG and deficient in low - Km mitochondrial BC6OTHER , accounting for approximately 45% of the Chinese population, may end up with BC6ENTC accumulation during BC6OTHER consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite. CPR:falsenewlineThe results suggest that individuals with high Vmax BC6OTHER and deficient in low - Km mitochondrial BC6ENTG , accounting for approximately 45% of the Chinese population, may end up with BC6ENTC accumulation during BC6OTHER consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite. CPR:falsenewlineThe results suggest that individuals with high Vmax BC6ENTG and deficient in low - Km mitochondrial BC6OTHER , accounting for approximately 45% of the Chinese population, may end up with BC6OTHER accumulation during BC6ENTC consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite. CPR:falsenewlineThe results suggest that individuals with high Vmax BC6OTHER and deficient in low - Km mitochondrial BC6ENTG , accounting for approximately 45% of the Chinese population, may end up with BC6OTHER accumulation during BC6ENTC consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite. CPR:falsenewlineBC6ENTG ( BC6OTHER ) and BC6ENTC dehydrogenase ( BC6OTHER ) exhibit genetic polymorphism and tissue specificity. CPR:falsenewlineBC6OTHER dehydrogenase ( BC6ENTG ) and BC6ENTC dehydrogenase ( BC6OTHER ) exhibit genetic polymorphism and tissue specificity. CPR:falsenewlineBC6OTHER dehydrogenase ( BC6OTHER ) and BC6ENTC dehydrogenase ( BC6ENTG ) exhibit genetic polymorphism and tissue specificity. CPR:falsenewlineThe identity of the lung BC6ENTG was further demonstrated by their characteristic pH - activity profiles for BC6ENTC oxidation, Km values for CHEM and BC6OTHER , and inhibition by BC6OTHER or BC6OTHER . CPR:9newlineThe identity of the lung BC6ENTG was further demonstrated by their characteristic pH - activity profiles for BC6OTHER oxidation, Km values for CHEM and BC6ENTC , and inhibition by BC6OTHER or BC6OTHER . CPR:falsenewlineThe identity of the lung BC6ENTG was further demonstrated by their characteristic pH - activity profiles for BC6OTHER oxidation, Km values for CHEM and BC6OTHER , and inhibition by BC6ENTC or BC6OTHER . CPR:falsenewlineThe identity of the lung BC6ENTG was further demonstrated by their characteristic pH - activity profiles for BC6OTHER oxidation, Km values for CHEM and BC6OTHER , and inhibition by BC6OTHER or BC6ENTC . CPR:falsenewlineLoss of any of the enzymes needed to make either BC6OTHER or BC6OTHER (which also - prevent the production of BC6OTHER ) is lethal, but male mice lacking BC6ENTC synthase ( BC6ENTG ) due to a deletion of part of the X chromosome are viable on the B6C3H background. CPR:falsenewlineUse of (Gyro) Gy and BC6ENTG transgenic mice to study functions of BC6ENTC . CPR:falsenewlineAn essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement BC6ENTC and this can be accomplished by breeding with CAG - BC6ENTG mice that express BC6OTHER from a ubiquitous promoter. CPR:falsenewlineAn essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement BC6ENTC and this can be accomplished by breeding with CAG - BC6OTHER mice that express BC6ENTG from a ubiquitous promoter. CPR:falsenewlineLoss of any of the enzymes needed to make either BC6ENTC or BC6OTHER (which also - prevent the production of BC6OTHER ) is lethal, but male mice lacking BC6ENTG ( BC6OTHER ) due to a deletion of part of the X chromosome are viable on the B6C3H background. CPR:falsenewlineLoss of any of the enzymes needed to make either BC6ENTC or BC6OTHER (which also - prevent the production of BC6OTHER ) is lethal, but male mice lacking BC6OTHER ( BC6ENTG ) due to a deletion of part of the X chromosome are viable on the B6C3H background. CPR:falsenewlineLoss of any of the enzymes needed to make either BC6OTHER or BC6ENTC (which also - prevent the production of BC6OTHER ) is lethal, but male mice lacking BC6ENTG ( BC6OTHER ) due to a deletion of part of the X chromosome are viable on the B6C3H background. CPR:falsenewlineLoss of any of the enzymes needed to make either BC6OTHER or BC6ENTC (which also - prevent the production of BC6OTHER ) is lethal, but male mice lacking BC6OTHER ( BC6ENTG ) due to a deletion of part of the X chromosome are viable on the B6C3H background. CPR:falsenewlineLoss of any of the enzymes needed to make either BC6OTHER or BC6OTHER (which also - prevent the production of BC6ENTC ) is lethal, but male mice lacking BC6ENTG ( BC6OTHER ) due to a deletion of part of the X chromosome are viable on the B6C3H background. CPR:falsenewlineLoss of any of the enzymes needed to make either BC6OTHER or BC6OTHER (which also - prevent the production of BC6ENTC ) is lethal, but male mice lacking BC6OTHER ( BC6ENTG ) due to a deletion of part of the X chromosome are viable on the B6C3H background. CPR:falsenewlineHere, we report that BC6ENTG is necessary for expression of the vesicular BC6ENTC / BC6OTHER - antiport. CPR:falsenewlineHere, we report that BC6ENTG is necessary for expression of the vesicular BC6OTHER / BC6ENTC - antiport. CPR:falsenewlineThe results were congruent and highly significant: BC6ENTC / BC6OTHER - antiport activity is detectable only in acidic organelles expressing functional BC6ENTG . CPR:falsenewlineIn contrast, BC6ENTG - deficient cells - and cells where transgenically encoded BC6OTHER was acutely photo - inactivated - were devoid of any BC6ENTC / BC6OTHER - antiport activity. CPR:falsenewlineIn contrast, BC6OTHER - deficient cells - and cells where transgenically encoded BC6ENTG was acutely photo - inactivated - were devoid of any BC6ENTC / BC6OTHER - antiport activity. CPR:falsenewlineThe results were congruent and highly significant: BC6OTHER / BC6ENTC - antiport activity is detectable only in acidic organelles expressing functional BC6ENTG . CPR:falsenewline BC6ENTG is required for vesicular BC6ENTC / BC6OTHER - antiport activity. CPR:falsenewline BC6ENTG is required for vesicular BC6OTHER / BC6ENTC - antiport activity. CPR:falsenewlineIn contrast, BC6ENTG - deficient cells - and cells where transgenically encoded BC6OTHER was acutely photo - inactivated - were devoid of any BC6OTHER / BC6ENTC - antiport activity. CPR:falsenewlineIn contrast, BC6OTHER - deficient cells - and cells where transgenically encoded BC6ENTG was acutely photo - inactivated - were devoid of any BC6OTHER / BC6ENTC - antiport activity. CPR:falsenewlineTherefore, in addition to its previously described functions, BC6ENTG is involved in a rapid vesicular BC6ENTC sequestration through a BC6OTHER / BC6OTHER antiport. CPR:falsenewlineTherefore, in addition to its previously described functions, BC6ENTG is involved in a rapid vesicular BC6OTHER sequestration through a BC6ENTC / BC6OTHER antiport. CPR:falsenewlineTherefore, in addition to its previously described functions, BC6ENTG is involved in a rapid vesicular BC6OTHER sequestration through a BC6OTHER / BC6ENTC antiport. CPR:falsenewlineBC6ENTG , a vesicular protein interacting with membranes upon low - affinity BC6ENTC - binding, plays a major role in excitation - release coupling, by synchronizing BC6OTHER entry with fast neurotransmitter release. CPR:falsenewlineBC6ENTG , a vesicular protein interacting with membranes upon low - affinity BC6OTHER - binding, plays a major role in excitation - release coupling, by synchronizing BC6ENTC entry with fast neurotransmitter release. CPR:falsenewlineBC6ENTC uptake in PC12 cells, which express the BC6ENTG endogenously, was 20 - to 28 - fold lower than in transduced cells. CPR:9newlineIn vivo, A431 BC6ENTG tumors demonstrated a 33 - fold higher BC6ENTC uptake than parental tumors. CPR:9newlineBACKGROUND: The BC6ENTC transporter ( BC6ENTG ) is a high - affinity transporter for BC6OTHER . CPR:falsenewline CONCLUSIONS: Transduction of tumor cells with BC6ENTG cDNA causes highly specific uptake and significant retention of BC6ENTC analogs in vitro and in vivo. These characteristics make the BC6OTHER suitable as a reporter gene for non - invasive monitoring of gene transfer. CPR:falsenewline CONCLUSIONS: Transduction of tumor cells with BC6OTHER cDNA causes highly specific uptake and significant retention of BC6ENTC analogs in vitro and in vivo. These characteristics make the BC6ENTG suitable as a reporter gene for non - invasive monitoring of gene transfer. CPR:falsenewlineThe specificity of tracer uptake was determined by adding the BC6ENTG inhibitor BC6ENTC . CPR:falsenewlineParental and A431 BC6ENTG cells were xenotransplanted into nude mice and tumor uptake of BC6ENTC in vivo was determined after tracer administration. CPR:falsenewlineBACKGROUND: The BC6ENTG ( BC6OTHER ) is a high - affinity transporter for BC6ENTC . CPR:9newlineBACKGROUND: The BC6OTHER transporter ( BC6ENTG ) is a high - affinity transporter for BC6ENTC . CPR:falsenewlineFurthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6ENTG / BC6OTHER activation occur downstream of BC6OTHER activation. CPR:falsenewlineFurthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6OTHER / BC6ENTG activation occur downstream of BC6OTHER activation. CPR:falsenewlineFurthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6ENTG activation. CPR:falsenewlineFurthermore, the BC6ENTG inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6OTHER activation. CPR:falsenewlineFurthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6ENTG - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6OTHER activation. CPR:falsenewlineFurthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6ENTG expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6OTHER , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6OTHER activation. CPR:falsenewlineFurthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6ENTG / BC6OTHER , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6OTHER activation. CPR:falsenewlineFurthermore, the BC6OTHER inhibitor BC6ENTC inhibited BC6OTHER - induced BC6OTHER expression, cell migration and invasion, as well as the activation of BC6OTHER / BC6ENTG , suggesting that BC6OTHER / BC6OTHER activation occur downstream of BC6OTHER activation. CPR:falsenewlineInhibition of BC6ENTG / BC6OTHER activation with BC6ENTC blocks migration and invasion of CHEM - MB - 231 cells. CPR:falsenewlineInhibition of BC6OTHER / BC6ENTG activation with BC6ENTC blocks migration and invasion of CHEM - MB - 231 cells. CPR:falsenewlineThese findings suggest that BC6ENTC inhibited the BC6ENTG - induced invasion and migration of CHEM - MB - 231 cells via BC6OTHER - dependent BC6OTHER / BC6OTHER signaling, leading to the down - regulation of BC6OTHER expression. CPR:falsenewlineThese findings suggest that BC6ENTC inhibited the BC6OTHER - induced invasion and migration of CHEM - MB - 231 cells via BC6ENTG - dependent BC6OTHER / BC6OTHER signaling, leading to the down - regulation of BC6OTHER expression. CPR:falsenewlineThese findings suggest that BC6ENTC inhibited the BC6OTHER - induced invasion and migration of CHEM - MB - 231 cells via BC6OTHER - dependent BC6ENTG / BC6OTHER signaling, leading to the down - regulation of BC6OTHER expression. CPR:falsenewlineThese findings suggest that BC6ENTC inhibited the BC6OTHER - induced invasion and migration of CHEM - MB - 231 cells via BC6OTHER - dependent BC6OTHER / BC6ENTG signaling, leading to the down - regulation of BC6OTHER expression. CPR:falsenewlineThese findings suggest that BC6ENTC inhibited the BC6OTHER - induced invasion and migration of CHEM - MB - 231 cells via BC6OTHER - dependent BC6OTHER / BC6OTHER signaling, leading to the down - regulation of BC6ENTG expression. CPR:4newlineWe use BC6ENTG as a metastatic inducer of CHEM - MB - 231 cells to investigate the effect of BC6ENTC on cell migration and invasion. CPR:falsenewlineBC6ENTC suppressed BC6ENTG - mediated protein levels of BC6OTHER and BC6OTHER , and reduced BC6OTHER expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity. CPR:falsenewlineBC6ENTC suppressed BC6OTHER - mediated protein levels of BC6ENTG and BC6OTHER , and reduced BC6OTHER expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity. CPR:falsenewlineBC6ENTC suppressed BC6OTHER - mediated protein levels of BC6OTHER and BC6ENTG , and reduced BC6OTHER expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity. CPR:falsenewlineBC6ENTC suppressed BC6OTHER - mediated protein levels of BC6OTHER and BC6OTHER , and reduced BC6ENTG expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity. CPR:falsenewlineBC6ENTC abrogated BC6ENTG - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6OTHER 3 - kinase ( BC6OTHER ) / BC6OTHER . CPR:falsenewlineBC6ENTC abrogated BC6OTHER - induced phosphorylation of BC6ENTG ( BC6OTHER ) and BC6OTHER 3 - kinase ( BC6OTHER ) / BC6OTHER . CPR:falsenewlineBC6ENTC abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6ENTG ) and BC6OTHER 3 - kinase ( BC6OTHER ) / BC6OTHER . CPR:falsenewlineBC6ENTC abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) / BC6OTHER . CPR:falsenewlineBC6ENTC abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6OTHER 3 - kinase ( BC6ENTG ) / BC6OTHER . CPR:falsenewlineBC6ENTC abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6OTHER 3 - kinase ( BC6OTHER ) / BC6ENTG . CPR:falsenewlineBC6OTHER abrogated BC6ENTG - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER . CPR:falsenewlineBC6OTHER abrogated BC6OTHER - induced phosphorylation of BC6ENTG ( BC6OTHER ) and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER . CPR:falsenewlineBC6OTHER abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6ENTG ) and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER . CPR:falsenewlineBC6OTHER abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC 3 - kinase ( BC6ENTG ) / BC6OTHER . CPR:falsenewlineBC6OTHER abrogated BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6ENTG . CPR:falsenewlineThe specific BC6ENTG inhibitor, BC6ENTC , blocked significantly BC6OTHER - induced cell migration and invasion. CPR:falsenewlineThe specific BC6OTHER inhibitor, BC6ENTC , blocked significantly BC6ENTG - induced cell migration and invasion. CPR:falsenewlineIn conclusion, BC6OTHER is a potent BC6ENTC D2, D3 and BC6ENTG antagonist, and a novel anti - emetic agent with a broad - spectrum of anti - emetic activity. CPR:falsenewlineThe anti - emetic and pharmacological profile of BC6OTHER ( BC6OTHER ), a novel and potent BC6ENTC D2, D3 and BC6ENTG ligand, was investigated in the present study. CPR:falsenewlineThe anti - emetic and pharmacological profile of BC6OTHER ( BC6OTHER ), a novel and potent BC6ENTG and CHEM receptors ligand, was investigated in the present study. CPR:falsenewlineIn guinea - pig isolated colon, BC6ENTC produced a rightward shift of the concentration - response curves of BC6OTHER , a BC6ENTG agonist (pA2 value of 7.04). CPR:falsenewlineIn guinea - pig isolated colon, BC6OTHER produced a rightward shift of the concentration - response curves of BC6ENTC , a BC6ENTG agonist (pA2 value of 7.04). CPR:falsenewlineThe anti - emetic and pharmacological profile of BC6ENTC ( BC6OTHER ), a novel and potent BC6ENTG and BC6OTHER ligand, was investigated in the present study. CPR:falsenewlineThe anti - emetic and pharmacological profile of BC6ENTC ( BC6OTHER ), a novel and potent BC6OTHER and BC6ENTG ligand, was investigated in the present study. CPR:falsenewlineThe anti - emetic and pharmacological profile of BC6OTHER ( BC6ENTC ), a novel and potent BC6ENTG and BC6OTHER ligand, was investigated in the present study. CPR:falsenewlineThe anti - emetic and pharmacological profile of BC6OTHER ( BC6ENTC ), a novel and potent BC6OTHER and BC6ENTG ligand, was investigated in the present study. CPR:falsenewlineOther BC6ENTG antagonists also produced such a shift in the following antagonistic - potency order: BC6ENTC > BC6OTHER = BC6OTHER >> BC6OTHER . CPR:falsenewlineOther BC6ENTG antagonists also produced such a shift in the following antagonistic - potency order: BC6OTHER > BC6ENTC = BC6OTHER >> BC6OTHER . CPR:falsenewlineOther BC6ENTG antagonists also produced such a shift in the following antagonistic - potency order: BC6OTHER > BC6OTHER = BC6ENTC >> BC6OTHER . CPR:falsenewlineOther BC6ENTG antagonists also produced such a shift in the following antagonistic - potency order: BC6OTHER > BC6OTHER = BC6OTHER >> BC6ENTC . CPR:falsenewlineIn mice, BC6ENTC (1.0 - 3.0 mg kg( - 1) s.c.) potently inhibited hypothermia induced by the BC6ENTG agonist; BC6OTHER ( BC6OTHER ) (0.3 mg kg( - 1) s.c.). CPR:falsenewlineIn mice, BC6OTHER (1.0 - 3.0 mg kg( - 1) s.c.) potently inhibited hypothermia induced by the BC6ENTG agonist; BC6ENTC ( BC6OTHER ) (0.3 mg kg( - 1) s.c.). CPR:falsenewlineIn mice, BC6OTHER (1.0 - 3.0 mg kg( - 1) s.c.) potently inhibited hypothermia induced by the BC6ENTG agonist; BC6OTHER ( BC6ENTC ) (0.3 mg kg( - 1) s.c.). CPR:falsenewlineBC6ENTC and BC6OTHER , which have affinity for BC6ENTG , also inhibited BC6OTHER - induced hypothermia. CPR:falsenewlineBC6OTHER and BC6ENTC , which have affinity for BC6ENTG , also inhibited BC6OTHER - induced hypothermia. CPR:falsenewlineBC6OTHER and BC6OTHER , which have affinity for BC6ENTG , also inhibited BC6ENTC - induced hypothermia. CPR:falsenewlineThe broad - spectrum anti - emetic activity of BC6ENTC , a novel BC6ENTG and BC6OTHER antagonist. CPR:6newlineThe broad - spectrum anti - emetic activity of BC6ENTC , a novel BC6OTHER and BC6ENTG antagonist. CPR:falsenewlineThe broad - spectrum anti - emetic activity of BC6OTHER , a novel BC6ENTC D2, D3 and BC6ENTG antagonist. CPR:falsenewlineIn conclusion, BC6ENTC is a potent BC6ENTG and BC6OTHER antagonist, and a novel anti - emetic agent with a broad - spectrum of anti - emetic activity. CPR:6newlineIn conclusion, BC6ENTC is a potent BC6OTHER and BC6ENTG antagonist, and a novel anti - emetic agent with a broad - spectrum of anti - emetic activity. CPR:6newlineEvaluation of BC6ENTG ligands at the human BC6OTHER H4 receptor: identification of BC6ENTC as the first potent and selective BC6OTHER agonist. CPR:falsenewlineEvaluation of BC6OTHER ligands at the human BC6OTHER H4 receptor: identification of BC6ENTC as the first potent and selective BC6ENTG agonist. CPR:5newlineEvaluation of BC6OTHER ligands at the BC6ENTG : identification of BC6ENTC as the first potent and selective BC6OTHER agonist. CPR:falsenewlineEvaluation of BC6ENTC H1 - , CHEM- , and H3 - receptor ligands at the human BC6OTHER H4 receptor: identification of BC6OTHER as the first potent and selective BC6ENTG agonist. CPR:falsenewlineEvaluation of BC6ENTC H1 - , CHEM- , and H3 - receptor ligands at the BC6ENTG : identification of BC6OTHER as the first potent and selective BC6OTHER agonist. CPR:falsenewlineEvaluation of BC6ENTG ligands at the human BC6ENTC H4 receptor: identification of BC6OTHER as the first potent and selective BC6OTHER agonist. CPR:falsenewlineEvaluation of BC6OTHER ligands at the human BC6ENTC H4 receptor: identification of BC6OTHER as the first potent and selective BC6ENTG agonist. CPR:falsenewlineMoreover, BC6ENTC potently activated the BC6ENTG (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6OTHER antagonist BC6OTHER [ BC6OTHER ] (pA(2) = 7.8). CPR:falsenewlineMoreover, BC6ENTC potently activated the BC6OTHER (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6ENTG antagonist BC6OTHER [ BC6OTHER ] (pA(2) = 7.8). CPR:falsenewlineMoreover, BC6OTHER potently activated the BC6ENTG (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6OTHER antagonist BC6ENTC [ BC6OTHER ] (pA(2) = 7.8). CPR:falsenewlineMoreover, BC6OTHER potently activated the BC6OTHER (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6ENTG antagonist BC6ENTC [ BC6OTHER ] (pA(2) = 7.8). CPR:falsenewlineMoreover, BC6OTHER potently activated the BC6ENTG (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6OTHER antagonist BC6OTHER [ BC6ENTC ] (pA(2) = 7.8). CPR:falsenewlineMoreover, BC6OTHER potently activated the BC6OTHER (CHEM = 7.4 + / - 0.1; alpha = 1), and this response was competitively antagonized by the selective BC6ENTG antagonist BC6OTHER [ BC6ENTC ] (pA(2) = 7.8). CPR:falsenewlineThe identification of BC6ENTC as a potent BC6ENTG agonist is of major importance for future studies to unravel the physiological roles of the BC6OTHER . CPR:5newlineThe identification of BC6ENTC as a potent BC6OTHER agonist is of major importance for future studies to unravel the physiological roles of the BC6ENTG . CPR:5newlineThe BC6ENTC CHEM receptor ( BC6ENTG ) is involved in the chemotaxis of leukocytes and mast cells to sites of inflammation and is suggested to be a potential drug target for asthma and allergy. CPR:falsenewlineAlmost all of the tested BC6ENTG and BC6OTHER antagonists, including several important therapeutics, displaced less than 30% of specific BC6ENTC binding to the BC6OTHER at concentrations up to 10 microM. CPR:falsenewlineAlmost all of the tested BC6OTHER and BC6ENTG antagonists, including several important therapeutics, displaced less than 30% of specific BC6ENTC binding to the BC6OTHER at concentrations up to 10 microM. CPR:falsenewlineAlmost all of the tested BC6OTHER and BC6OTHER antagonists, including several important therapeutics, displaced less than 30% of specific BC6ENTC binding to the BC6ENTG at concentrations up to 10 microM. CPR:falsenewlineMost of the tested BC6ENTG agonists and BC6ENTC - based BC6OTHER ligands show micromolar - to - nanomolar range BC6OTHER affinity, and these ligands exert different intrinsic BC6OTHER activities, ranging from full agonists to inverse agonists. CPR:falsenewlineMost of the tested BC6OTHER agonists and BC6ENTC - based BC6ENTG ligands show micromolar - to - nanomolar range BC6OTHER affinity, and these ligands exert different intrinsic BC6OTHER activities, ranging from full agonists to inverse agonists. CPR:falsenewlineMost of the tested BC6OTHER agonists and BC6ENTC - based BC6OTHER ligands show micromolar - to - nanomolar range BC6ENTG affinity, and these ligands exert different intrinsic BC6OTHER activities, ranging from full agonists to inverse agonists. CPR:falsenewlineMost of the tested BC6OTHER agonists and BC6ENTC - based BC6OTHER ligands show micromolar - to - nanomolar range BC6OTHER affinity, and these ligands exert different intrinsic BC6ENTG activities, ranging from full agonists to inverse agonists. CPR:falsenewlineInterestingly, we identified BC6ENTC as a high - affinity BC6ENTG ligand (K(i) = 50 nM) that has a >100 - fold selectivity for the BC6OTHER over the other BC6OTHER receptor subtypes. CPR:falsenewlineInterestingly, we identified BC6ENTC as a high - affinity BC6OTHER ligand (K(i) = 50 nM) that has a >100 - fold selectivity for the BC6ENTG over the other BC6OTHER receptor subtypes. CPR:falsenewlineInterestingly, we identified BC6ENTC as a high - affinity BC6OTHER ligand (K(i) = 50 nM) that has a >100 - fold selectivity for the BC6OTHER over the other BC6ENTG subtypes. CPR:falsenewlineInterestingly, we identified BC6OTHER as a high - affinity BC6ENTG ligand (K(i) = 50 nM) that has a >100 - fold selectivity for the BC6OTHER over the other BC6ENTC receptor subtypes. CPR:falsenewlineInterestingly, we identified BC6OTHER as a high - affinity BC6OTHER ligand (K(i) = 50 nM) that has a >100 - fold selectivity for the BC6ENTG over the other BC6ENTC receptor subtypes. CPR:falsenewlineBC6ENTC reductase deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6OTHER synthesis. CPR:falsenewlineBC6ENTG deficiency impairs BC6ENTC synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6OTHER synthase (CblE / G) are associated with defective BC6OTHER synthesis. CPR:falsenewlineBC6OTHER reductase deficiency impairs BC6ENTC synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6OTHER synthesis. CPR:falsenewlineBC6ENTG deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6ENTC (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6OTHER synthase (CblE / G) are associated with defective BC6OTHER synthesis. CPR:falsenewlineBC6OTHER reductase deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6ENTC (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6OTHER synthesis. CPR:falsenewlineBC6ENTG deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6ENTC - and BC6OTHER and deficiencies of BC6OTHER synthase (CblE / G) are associated with defective BC6OTHER synthesis. CPR:falsenewlineBC6OTHER reductase deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6ENTC - and BC6OTHER and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6OTHER synthesis. CPR:falsenewlineBC6ENTG deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6ENTC and deficiencies of BC6OTHER synthase (CblE / G) are associated with defective BC6OTHER synthesis. CPR:falsenewlineBC6OTHER reductase deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6ENTC and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6OTHER synthesis. CPR:falsenewlineBC6ENTG deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6ENTC synthase (CblE / G) are associated with defective BC6OTHER synthesis. CPR:falsenewlineBC6ENTG deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6OTHER synthase (CblE / G) are associated with defective BC6ENTC synthesis. CPR:falsenewlineBC6OTHER reductase deficiency impairs BC6OTHER synthesis, defects in cytosolic reduction of BC6OTHER (CblC / D) impair the synthesis of both BC6OTHER - and BC6OTHER and deficiencies of BC6ENTG (CblE / G) are associated with defective BC6ENTC synthesis. CPR:falsenewlineEffect of BC6OTHER and BC6ENTC on BC6ENTG expression in Jurkat T cells. CPR:falsenewlineThe compounds BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) belong to inhibitors of BC6ENTG , whose low activity correlates with increase in transcription of various genes. CPR:4newlineThe compounds BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) belong to inhibitors of BC6ENTG , whose low activity correlates with increase in transcription of various genes. CPR:falsenewlineThe compounds BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) belong to inhibitors of BC6ENTG , whose low activity correlates with increase in transcription of various genes. CPR:4newlineThe compounds BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) belong to inhibitors of BC6ENTG , whose low activity correlates with increase in transcription of various genes. CPR:falsenewlineUsing the reverse - transcription and real - time quantitative PCR (RQ - PCR) analysis, we indicated that BC6ENTC and BC6OTHER did not profoundly affect on BC6ENTG transcription in Jurkat T leukemia cells clone E6 - 1. CPR:falsenewlineUsing the reverse - transcription and real - time quantitative PCR (RQ - PCR) analysis, we indicated that BC6OTHER and BC6ENTC did not profoundly affect on BC6ENTG transcription in Jurkat T leukemia cells clone E6 - 1. CPR:falsenewlineHowever, the flowcytometric analysis revealed that BC6ENTC and BC6OTHER decreased intracellular contents of BC6ENTG in these cells in dose dependent manner. CPR:4newlineHowever, the flowcytometric analysis revealed that BC6OTHER and BC6ENTC decreased intracellular contents of BC6ENTG in these cells in dose dependent manner. CPR:4newlineEffect of BC6ENTC and BC6OTHER on BC6ENTG expression in Jurkat T cells. CPR:falsenewlineFurthermore, h[ BC6ENTC ] - BC6OTHER reduced chemotherapy - induced apoptosis, decreased activation of BC6OTHER , and inhibited poly( BC6OTHER ) polymerase cleavage in heterologous cells transfected with the BC6ENTG . CPR:falsenewlineFurthermore, h[ BC6ENTC ] - BC6ENTG reduced chemotherapy - induced apoptosis, decreased activation of BC6OTHER , and inhibited poly( BC6OTHER ) polymerase cleavage in heterologous cells transfected with the BC6OTHER . CPR:falsenewlineFurthermore, h[ BC6ENTC ] - BC6OTHER reduced chemotherapy - induced apoptosis, decreased activation of BC6ENTG , and inhibited poly( BC6OTHER ) polymerase cleavage in heterologous cells transfected with the BC6OTHER . CPR:falsenewlineFurthermore, h[ BC6ENTC ] - BC6OTHER reduced chemotherapy - induced apoptosis, decreased activation of BC6OTHER , and inhibited BC6ENTG cleavage in heterologous cells transfected with the BC6OTHER . CPR:falsenewlineFurthermore, h[ BC6OTHER ] - BC6OTHER reduced chemotherapy - induced apoptosis, decreased activation of BC6OTHER , and inhibited poly( BC6ENTC ) polymerase cleavage in heterologous cells transfected with the BC6ENTG . CPR:falsenewlineFurthermore, h[ BC6OTHER ] - BC6ENTG reduced chemotherapy - induced apoptosis, decreased activation of BC6OTHER , and inhibited poly( BC6ENTC ) polymerase cleavage in heterologous cells transfected with the BC6OTHER . CPR:falsenewlineFurthermore, h[ BC6OTHER ] - BC6OTHER reduced chemotherapy - induced apoptosis, decreased activation of BC6ENTG , and inhibited poly( BC6ENTC ) polymerase cleavage in heterologous cells transfected with the BC6OTHER . CPR:falsenewlineWe report here that a human degradation - resistant BC6ENTG analogue, h[ BC6ENTC ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6OTHER or the antimetabolite BC6OTHER . CPR:falsenewlineWe report here that a human degradation - resistant BC6OTHER analogue, h[ BC6ENTC ] - BC6ENTG significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6OTHER or the antimetabolite BC6OTHER . CPR:falsenewlineWe report here that a human degradation - resistant BC6OTHER analogue, h[ BC6ENTC ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6ENTG inhibitor BC6OTHER or the antimetabolite BC6OTHER . CPR:falsenewlineWe report here that a human degradation - resistant BC6ENTG analogue, h[ BC6OTHER ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6ENTC or the antimetabolite BC6OTHER . CPR:falsenewlineWe report here that a human degradation - resistant BC6OTHER analogue, h[ BC6OTHER ] - BC6ENTG significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6ENTC or the antimetabolite BC6OTHER . CPR:falsenewlineWe report here that a human degradation - resistant BC6OTHER analogue, h[ BC6OTHER ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6ENTG inhibitor BC6ENTC or the antimetabolite BC6OTHER . CPR:falsenewlineWe report here that a human degradation - resistant BC6ENTG analogue, h[ BC6OTHER ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6OTHER or the antimetabolite BC6ENTC . CPR:falsenewlineWe report here that a human degradation - resistant BC6OTHER analogue, h[ BC6OTHER ] - BC6ENTG significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6OTHER inhibitor BC6OTHER or the antimetabolite BC6ENTC . CPR:falsenewlineWe report here that a human degradation - resistant BC6OTHER analogue, h[ BC6OTHER ] - BC6OTHER significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of BC6ENTG inhibitor BC6OTHER or the antimetabolite BC6ENTC . CPR:falsenewlineh[ BC6ENTC ] - BC6ENTG significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor - bearing mice treated with cyclical CHEM. CPR:falsenewlineOur optimized BC6ENTC production assay to measure BC6ENTG activity correlated closely with the direct measure of the rate of asymmetric BC6OTHER consumption. CPR:9newlineOur optimized BC6OTHER production assay to measure BC6ENTG activity correlated closely with the direct measure of the rate of asymmetric BC6ENTC consumption. CPR:falsenewlineUsing this assay, we found that both BC6ENTC and BC6OTHER inhibit renal cortical BC6ENTG activity in vitro. CPR:4newlineUsing this assay, we found that both BC6OTHER and BC6ENTC inhibit renal cortical BC6ENTG activity in vitro. CPR:4newlineBC6ENTG ( BC6OTHER ) metabolizes asymmetric BC6OTHER to generate BC6ENTC and is present in large quantities in the kidney. CPR:9newlineBC6OTHER dimethylaminohydrolase ( BC6ENTG ) metabolizes asymmetric BC6OTHER to generate BC6ENTC and is present in large quantities in the kidney. CPR:falsenewlineBC6ENTC dimethylaminohydrolase ( BC6ENTG ) metabolizes asymmetric BC6OTHER to generate BC6OTHER and is present in large quantities in the kidney. CPR:falsenewlineWe present a new study that optimizes the Prescott - Jones colorimetric assay to measure BC6ENTG - dependent BC6ENTC generation in kidney homogenates. CPR:falsenewlineWe found that the removal of BC6ENTC with BC6ENTG is necessary since BC6OTHER also produces a positive reaction. CPR:falsenewlineWe found that the removal of BC6OTHER with BC6ENTG is necessary since BC6ENTC also produces a positive reaction. CPR:falsenewlineDeproteinization with BC6ENTC was found to be optimal and that BC6ENTG inhibitors were not necessary. CPR:falsenewlineBC6ENTG or BC6ENTC synthase isoenzymes were not found to influence BC6OTHER production. CPR:falsenewlineBC6ENTG ( BC6OTHER ) metabolizes asymmetric BC6ENTC to generate BC6OTHER and is present in large quantities in the kidney. CPR:9newlineBC6OTHER dimethylaminohydrolase ( BC6ENTG ) metabolizes asymmetric BC6ENTC to generate BC6OTHER and is present in large quantities in the kidney. CPR:9newlineBC6ENTG or BC6OTHER synthase isoenzymes were not found to influence BC6ENTC production. CPR:falsenewlineBC6OTHER or BC6ENTG isoenzymes were not found to influence BC6ENTC production. CPR:falsenewline BC6ENTC enhances the depolarizing afterpotential of immunohistochemically identified BC6OTHER neurons in the rat supraoptic nucleus via BC6ENTG activation. CPR:falsenewline BC6OTHER enhances the depolarizing afterpotential of immunohistochemically identified BC6ENTC neurons in the rat supraoptic nucleus via BC6ENTG activation. CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6ENTC was mimicked by the BC6ENTG agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6ENTC was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6ENTG antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6ENTC was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTG antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTC H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6ENTG antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTC H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTG antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTG agonist BC6ENTC and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6ENTC and was reduced or blocked by the BC6ENTG antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6ENTC and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTG antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTG agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6ENTC , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6ENTG antagonist BC6ENTC , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6ENTC , but was not blocked or reduced in the presence of the BC6ENTG antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTG agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTC H2 - receptor antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6ENTG antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTC H2 - receptor antagonist, BC6OTHER . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6ENTG agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6ENTC . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6ENTG antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6OTHER H2 - receptor antagonist, BC6ENTC . CPR:falsenewlineThe enhancement of the depolarizing afterpotential by BC6OTHER was mimicked by the BC6OTHER H1 - receptor agonist BC6OTHER and was reduced or blocked by the BC6OTHER antagonist BC6OTHER , but was not blocked or reduced in the presence of the BC6ENTG antagonist, BC6ENTC . CPR:falsenewlineIn summary, these results show that the excitatory effect of BC6ENTC on immunohistochemically identified BC6OTHER neurons in the supraoptic nucleus is due in part to the BC6ENTG - mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential. CPR:falsenewlineIn summary, these results show that the excitatory effect of BC6OTHER on immunohistochemically identified BC6ENTC neurons in the supraoptic nucleus is due in part to the BC6ENTG - mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential. CPR:falsenewlineTranscripts of BC6ENTG genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the BC6OTHER genes were more responsive to BC6ENTC exposure in vitro, especially to the organic form. CPR:falsenewlineTranscripts of BC6OTHER genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the BC6ENTG genes were more responsive to BC6ENTC exposure in vitro, especially to the organic form. CPR:falsenewlineInterestingly, BC6ENTG was the most sensitive to BC6ENTC availability in non stressful conditions, whereas BC6OTHER and BC6OTHER were highly induced by exposure to BC6OTHER levels that had some toxic effects on the cells. CPR:falsenewlineInterestingly, BC6OTHER was the most sensitive to BC6ENTC availability in non stressful conditions, whereas BC6ENTG and BC6OTHER were highly induced by exposure to BC6OTHER levels that had some toxic effects on the cells. CPR:falsenewlineInterestingly, BC6OTHER was the most sensitive to BC6ENTC availability in non stressful conditions, whereas BC6OTHER and BC6ENTG were highly induced by exposure to BC6OTHER levels that had some toxic effects on the cells. CPR:falsenewlineInterestingly, BC6ENTG was the most sensitive to BC6OTHER availability in non stressful conditions, whereas BC6OTHER and BC6OTHER were highly induced by exposure to BC6ENTC levels that had some toxic effects on the cells. CPR:falsenewlineInterestingly, BC6OTHER was the most sensitive to BC6OTHER availability in non stressful conditions, whereas BC6ENTG and BC6OTHER were highly induced by exposure to BC6ENTC levels that had some toxic effects on the cells. CPR:falsenewlineInterestingly, BC6OTHER was the most sensitive to BC6OTHER availability in non stressful conditions, whereas BC6OTHER and BC6ENTG were highly induced by exposure to BC6ENTC levels that had some toxic effects on the cells. CPR:falsenewlineOur results lead us to conclude that trout BC6ENTG transcripts expression level may represent a sensitive biomarker for BC6ENTC intake, helping to evaluate if BC6OTHER concentration and chemical speciation impact on cell homeostasis. CPR:falsenewlineOur results lead us to conclude that trout BC6ENTG transcripts expression level may represent a sensitive biomarker for BC6OTHER intake, helping to evaluate if BC6ENTC concentration and chemical speciation impact on cell homeostasis. CPR:falsenewlineBC6ENTC peroxidase ( BC6ENTG ) is the largest and the most studied BC6OTHER family. CPR:falsenewlineBC6ENTC peroxidase ( BC6OTHER ) is the largest and the most studied BC6ENTG family. CPR:falsenewlineCytosolic BC6ENTC peroxidase ( BC6ENTG , BC6OTHER ) and phospholipid BC6OTHER BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6ENTC peroxidase ( BC6OTHER , BC6ENTG ) and phospholipid BC6OTHER BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) and BC6ENTG BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6OTHER BC6OTHER peroxidase ( BC6ENTG , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6OTHER BC6OTHER peroxidase ( BC6OTHER , BC6ENTG ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineBC6ENTG ( BC6OTHER , BC6OTHER ) and phospholipid BC6ENTC BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6OTHER peroxidase ( BC6ENTG , BC6OTHER ) and phospholipid BC6ENTC BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6OTHER peroxidase ( BC6OTHER , BC6ENTG ) and phospholipid BC6ENTC BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6ENTC BC6OTHER peroxidase ( BC6ENTG , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6ENTC BC6OTHER peroxidase ( BC6OTHER , BC6ENTG ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineBC6ENTG ( BC6OTHER , BC6OTHER ) and phospholipid BC6OTHER BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6OTHER peroxidase ( BC6ENTG , BC6OTHER ) and phospholipid BC6OTHER BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6OTHER peroxidase ( BC6OTHER , BC6ENTG ) and phospholipid BC6OTHER BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) and BC6ENTG BC6ENTC peroxidase ( BC6OTHER , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6OTHER BC6ENTC peroxidase ( BC6ENTG , BC6OTHER ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCytosolic BC6OTHER peroxidase ( BC6OTHER , BC6OTHER ) and phospholipid BC6OTHER BC6ENTC peroxidase ( BC6OTHER , BC6ENTG ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell. CPR:falsenewlineCharacterization of BC6ENTG and CHEM - BC6OTHER BC6OTHER peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6ENTC exposure. CPR:falsenewlineCharacterization of cytosolic BC6OTHER peroxidase and BC6ENTG BC6OTHER peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6ENTC exposure. CPR:falsenewlineCharacterization of cytosolic BC6ENTC peroxidase and BC6ENTG BC6OTHER peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6OTHER exposure. CPR:falsenewlineCharacterization of BC6ENTG and CHEM - BC6ENTC BC6OTHER peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6OTHER exposure. CPR:falsenewlineCharacterization of BC6ENTG and CHEM - BC6OTHER BC6ENTC peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6OTHER exposure. CPR:falsenewlineCharacterization of cytosolic BC6OTHER peroxidase and BC6ENTG BC6ENTC peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro BC6OTHER exposure. CPR:falsenewlineBC6ENTG , a phase II enzyme, was inhibited by both BC6OTHER and BC6OTHER but no such inhibition was noted in BC6OTHER - treated animals pre - exposed to BC6ENTC . CPR:falsenewlineBC6ENTG , a phase II enzyme, was inhibited by both BC6ENTC and BC6OTHER but no such inhibition was noted in BC6OTHER - treated animals pre - exposed to BC6OTHER . CPR:falsenewlineBC6ENTG , a phase II enzyme, was inhibited by both BC6OTHER and BC6ENTC but no such inhibition was noted in BC6OTHER - treated animals pre - exposed to BC6OTHER . CPR:falsenewlineBC6ENTG , a phase II enzyme, was inhibited by both BC6OTHER and BC6OTHER but no such inhibition was noted in BC6ENTC - treated animals pre - exposed to BC6OTHER . CPR:falsenewlineUpon BC6ENTC pre - exposure, brain BC6ENTG increased, while BC6OTHER ( BC6OTHER ) decreased. CPR:falsenewlineUpon BC6ENTC pre - exposure, brain BC6OTHER increased, while BC6ENTG ( BC6OTHER ) decreased. CPR:falsenewlineUpon BC6ENTC pre - exposure, brain BC6OTHER increased, while BC6OTHER ( BC6ENTG ) decreased. CPR:falsenewlineThe toxic effects of BC6ENTG significantly attenuated with BC6ENTC pre - exposure. CPR:falsenewlineNext, BC6OTHER significantly decreased the levels of BC6ENTC - ERK2 and BC6ENTG in BC6OTHER or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration. CPR:falsenewlineNext, BC6OTHER significantly decreased the levels of BC6ENTC - ERK2 and BC6OTHER in BC6ENTG or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration. CPR:falsenewlineNext, BC6OTHER significantly decreased the levels of BC6ENTC - ERK2 and BC6OTHER in BC6OTHER or BC6ENTG siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration. CPR:falsenewlineNext, BC6OTHER significantly decreased the levels of BC6ENTG and BC6ENTC - Akt in BC6OTHER or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration. CPR:falsenewlineNext, BC6OTHER significantly decreased the levels of BC6OTHER and BC6ENTC - Akt in BC6ENTG or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration. CPR:falsenewlineNext, BC6OTHER significantly decreased the levels of BC6OTHER and BC6ENTC - Akt in BC6OTHER or BC6ENTG siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration. CPR:falsenewline BC6ENTC attenuates metastasis via both BC6ENTG and BC6OTHER / BC6OTHER pathways in BC6OTHER - treated liver cancer HepG2 cells. CPR:falsenewline BC6ENTC attenuates metastasis via both BC6OTHER and BC6ENTG / BC6OTHER pathways in BC6OTHER - treated liver cancer HepG2 cells. CPR:falsenewline BC6ENTC attenuates metastasis via both BC6OTHER and BC6OTHER / BC6ENTG pathways in BC6OTHER - treated liver cancer HepG2 cells. CPR:falsenewline BC6ENTC attenuates metastasis via both BC6OTHER and BC6OTHER / BC6OTHER pathways in BC6ENTG - treated liver cancer HepG2 cells. CPR:falsenewlineIn conclusion, BC6ENTC attenuates BC6ENTG - induced HepG2 cells metastasis involving both BC6OTHER and BC6OTHER / BC6OTHER pathways and are potentially useful as anti - metastatic agents for the treatment of hepatoma. CPR:falsenewlineIn conclusion, BC6ENTC attenuates BC6OTHER - induced HepG2 cells metastasis involving both BC6ENTG and BC6OTHER / BC6OTHER pathways and are potentially useful as anti - metastatic agents for the treatment of hepatoma. CPR:falsenewlineIn conclusion, BC6ENTC attenuates BC6OTHER - induced HepG2 cells metastasis involving both BC6OTHER and BC6ENTG / BC6OTHER pathways and are potentially useful as anti - metastatic agents for the treatment of hepatoma. CPR:falsenewlineIn conclusion, BC6ENTC attenuates BC6OTHER - induced HepG2 cells metastasis involving both BC6OTHER and BC6OTHER / BC6ENTG pathways and are potentially useful as anti - metastatic agents for the treatment of hepatoma. CPR:falsenewlineWe use BC6ENTG as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER on BC6OTHER / BC6OTHER - mediated tumor invasion and metastasis. CPR:falsenewlineWe use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER on BC6ENTG / BC6OTHER - mediated tumor invasion and metastasis. CPR:falsenewlineWe use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER on BC6OTHER / BC6ENTG - mediated tumor invasion and metastasis. CPR:falsenewlineWe use BC6ENTG as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER on BC6OTHER / BC6OTHER - mediated tumor invasion and metastasis. CPR:falsenewlineWe use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER on BC6ENTG / BC6OTHER - mediated tumor invasion and metastasis. CPR:falsenewlineWe use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER on BC6OTHER / BC6ENTG - mediated tumor invasion and metastasis. CPR:falsenewlineWe use BC6ENTG as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER on BC6OTHER / BC6OTHER - mediated tumor invasion and metastasis. CPR:falsenewlineWe use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER on BC6ENTG / BC6OTHER - mediated tumor invasion and metastasis. CPR:falsenewlineWe use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER on BC6OTHER / BC6ENTG - mediated tumor invasion and metastasis. CPR:falsenewlineWe use BC6ENTG as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC on BC6OTHER / BC6OTHER - mediated tumor invasion and metastasis. CPR:falsenewlineWe use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC on BC6ENTG / BC6OTHER - mediated tumor invasion and metastasis. CPR:falsenewlineWe use BC6OTHER as an invasive inducer of human HepG2 cells to investigate the effect of four CHEM including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC on BC6OTHER / BC6ENTG - mediated tumor invasion and metastasis. CPR:falsenewlineAmong them, BC6ENTC markedly inhibited BC6ENTG - induced the abilities of the adhesion, invasion, and migration by cell - matrix adhesion assay and transwell - chamber invasion / migration assay under non - cytotoxic concentrations. CPR:4newlineData also showed BC6ENTC inhibited BC6ENTG - induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia. CPR:falsenewlineFurthermore, BC6ENTC could inhibit BC6ENTG - induced the membrane localization of phosphorylated BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER and BC6OTHER . CPR:falsenewlineFurthermore, BC6ENTC could inhibit BC6OTHER - induced the membrane localization of phosphorylated BC6ENTG , BC6OTHER , and BC6OTHER , but not BC6OTHER and BC6OTHER . CPR:falsenewlineFurthermore, BC6ENTC could inhibit BC6OTHER - induced the membrane localization of phosphorylated BC6OTHER , BC6ENTG , and BC6OTHER , but not BC6OTHER and BC6OTHER . CPR:falsenewlineFurthermore, BC6ENTC could inhibit BC6OTHER - induced the membrane localization of phosphorylated BC6OTHER , BC6OTHER , and BC6ENTG , but not BC6OTHER and BC6OTHER . CPR:falsenewlineFurthermore, BC6ENTC could inhibit BC6OTHER - induced the membrane localization of phosphorylated BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6ENTG and BC6OTHER . CPR:falsenewlineFurthermore, BC6ENTC could inhibit BC6OTHER - induced the membrane localization of phosphorylated BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER and BC6ENTG . CPR:falsenewlineNext, BC6ENTC significantly decreased the levels of BC6ENTG and BC6OTHER in BC6OTHER or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration. CPR:falsenewlineNext, BC6ENTC significantly decreased the levels of BC6OTHER and BC6ENTG in BC6OTHER or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration. CPR:falsenewlineNext, BC6ENTC significantly decreased the levels of BC6OTHER and BC6OTHER in BC6ENTG or BC6OTHER siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration. CPR:falsenewlineNext, BC6ENTC significantly decreased the levels of BC6OTHER and BC6OTHER in BC6OTHER or BC6ENTG siRNA - transfected cells concomitantly with a marked reduction on cell invasion and migration. CPR:falsenewlineBC6OTHER and BC6OTHER metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6ENTC , and therefore their coadministration is contraindicated. CPR:falsenewlineBC6OTHER and BC6OTHER metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6ENTC , and therefore their coadministration is contraindicated. CPR:falsenewlineBC6ENTC is also a BC6ENTG substrate, but less potent drug - drug interactions have been reported with BC6OTHER inhibitors. CPR:falsenewlineBC6ENTC is also a BC6OTHER substrate, but less potent drug - drug interactions have been reported with BC6ENTG inhibitors. CPR:falsenewlineAll HIV PIs except BC6ENTC are coadministered with a low dose of BC6OTHER , a potent BC6ENTG inhibitor to improve their pharmacokinetic properties. CPR:falsenewlineDrug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6ENTC , BC6OTHER and BC6OTHER are metabolized through BC6ENTG , while the metabolism of the other CHEM is independent of this BC6OTHER . CPR:falsenewlineDrug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6ENTC , BC6OTHER and BC6OTHER are metabolized through BC6OTHER , while the metabolism of the other CHEM is independent of this BC6ENTG . CPR:falsenewlineDrug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6OTHER , BC6ENTC and BC6OTHER are metabolized through BC6ENTG , while the metabolism of the other CHEM is independent of this BC6OTHER . CPR:falsenewlineDrug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6OTHER , BC6ENTC and BC6OTHER are metabolized through BC6OTHER , while the metabolism of the other CHEM is independent of this BC6ENTG . CPR:falsenewlineDrug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6OTHER , BC6OTHER and BC6ENTC are metabolized through BC6ENTG , while the metabolism of the other CHEM is independent of this BC6OTHER . CPR:falsenewlineDrug - drug interactions are dependent on CHEM' pharmacokinetic profile: BC6OTHER , BC6OTHER and BC6ENTC are metabolized through BC6OTHER , while the metabolism of the other CHEM is independent of this BC6ENTG . CPR:falsenewlineDrug - drug interactions between BC6ENTC reductase inhibitors (CHEM) and antiviral BC6ENTG inhibitors. CPR:falsenewlineAll HIV PIs except BC6OTHER are coadministered with a low dose of BC6ENTC , a potent BC6ENTG inhibitor to improve their pharmacokinetic properties. CPR:falsenewlineThe HCV - PIs BC6ENTC and BC6OTHER are both, to different extents, inhibitors of BC6ENTG . CPR:falsenewlineThe HCV - PIs BC6OTHER and BC6ENTC are both, to different extents, inhibitors of BC6ENTG . CPR:4newlineBC6ENTC and BC6OTHER metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated. CPR:falsenewlineBC6ENTC and BC6OTHER metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated. CPR:falsenewlineBC6OTHER and BC6ENTC metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated. CPR:falsenewlineBC6OTHER and BC6ENTC metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated. CPR:falsenewlineBC6OTHER and BC6OTHER metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6ENTC - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated. CPR:falsenewlineBC6OTHER and BC6OTHER metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6ENTC - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated. CPR:falsenewlineBC6OTHER and BC6OTHER metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6OTHER - or BC6ENTC - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated. CPR:falsenewlineBC6OTHER and BC6OTHER metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6OTHER - or BC6ENTC - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6OTHER or BC6OTHER , and therefore their coadministration is contraindicated. CPR:falsenewlineBC6OTHER and BC6OTHER metabolized through BC6ENTG have the highest potency for drug - drug interaction with potent BC6OTHER inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6ENTC or BC6OTHER , and therefore their coadministration is contraindicated. CPR:falsenewlineBC6OTHER and BC6OTHER metabolized through BC6OTHER have the highest potency for drug - drug interaction with potent BC6ENTG inhibitors such as BC6OTHER - or BC6OTHER - boosted HIV - PI or the hepatitis C virus (HCV) PI, BC6ENTC or BC6OTHER , and therefore their coadministration is contraindicated. CPR:falsenewlineFrom these results, it is proposed that BC6ENTG activity determines BC6ENTC concentrations by regulating BC6OTHER availability. CPR:falsenewlineFrom these results, it is proposed that BC6ENTG activity determines BC6OTHER concentrations by regulating BC6ENTC availability. CPR:falsenewlineAn BC6ENTG antagonist, BC6ENTC augments BC6OTHER uptake and BC6OTHER protein expression in 3T3 - L1 adipocytes. CPR:falsenewlineAn BC6OTHER AT1 receptor antagonist, BC6ENTC augments BC6OTHER uptake and BC6ENTG protein expression in 3T3 - L1 adipocytes. CPR:falsenewlineAn BC6ENTG antagonist, BC6OTHER augments BC6ENTC uptake and BC6OTHER protein expression in 3T3 - L1 adipocytes. CPR:falsenewlineAn BC6OTHER AT1 receptor antagonist, BC6OTHER augments BC6ENTC uptake and BC6ENTG protein expression in 3T3 - L1 adipocytes. CPR:falsenewlineWe thus examined the effect of BC6ENTC on BC6ENTG action using 3T3 - L1 adipocytes. CPR:falsenewlineTreatment of both differentiating adipocytes and fully differentiated adipocytes with BC6ENTC caused a dose - dependent increase in mRNA levels for BC6ENTG target genes such as BC6OTHER and BC6OTHER . CPR:falsenewlineTreatment of both differentiating adipocytes and fully differentiated adipocytes with BC6ENTC caused a dose - dependent increase in mRNA levels for BC6OTHER target genes such as BC6ENTG and BC6OTHER . CPR:falsenewlineTreatment of both differentiating adipocytes and fully differentiated adipocytes with BC6ENTC caused a dose - dependent increase in mRNA levels for BC6OTHER target genes such as BC6OTHER and BC6ENTG . CPR:falsenewlineEvidence has accumulated that some of the BC6ENTC AT1 receptor antagonists have BC6ENTG - sensitizing property. CPR:falsenewlineBy contrast, BC6ENTC attenuated BC6ENTG mRNA level in differentiated adipocytes. CPR:falsenewlineOf note, we demonstrated for the first time that BC6ENTC augmented BC6ENTG protein expression and BC6OTHER uptake both in basal and BC6OTHER - stimulated state of adipocytes, which may contribute, at least partly, to its BC6OTHER - sensitizing ability. CPR:falsenewlineOf note, we demonstrated for the first time that BC6ENTC augmented BC6OTHER protein expression and BC6OTHER uptake both in basal and BC6ENTG - stimulated state of adipocytes, which may contribute, at least partly, to its BC6OTHER - sensitizing ability. CPR:falsenewlineOf note, we demonstrated for the first time that BC6ENTC augmented BC6OTHER protein expression and BC6OTHER uptake both in basal and BC6OTHER - stimulated state of adipocytes, which may contribute, at least partly, to its BC6ENTG - sensitizing ability. CPR:falsenewlineOf note, we demonstrated for the first time that BC6OTHER augmented BC6ENTG protein expression and BC6ENTC uptake both in basal and BC6OTHER - stimulated state of adipocytes, which may contribute, at least partly, to its BC6OTHER - sensitizing ability. CPR:falsenewlineOf note, we demonstrated for the first time that BC6OTHER augmented BC6OTHER protein expression and BC6ENTC uptake both in basal and BC6ENTG - stimulated state of adipocytes, which may contribute, at least partly, to its BC6OTHER - sensitizing ability. CPR:falsenewlineOf note, we demonstrated for the first time that BC6OTHER augmented BC6OTHER protein expression and BC6ENTC uptake both in basal and BC6OTHER - stimulated state of adipocytes, which may contribute, at least partly, to its BC6ENTG - sensitizing ability. CPR:falsenewlineAn BC6ENTC AT1 receptor antagonist, BC6OTHER augments BC6OTHER uptake and BC6ENTG protein expression in 3T3 - L1 adipocytes. CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a small - molecule inhibitor that has been shown to target members of multiple classes of BC6ENTG that are known to be involved in tumor cell proliferation and tumor angiogenesis. CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a small - molecule inhibitor that has been shown to target members of multiple classes of BC6ENTG that are known to be involved in tumor cell proliferation and tumor angiogenesis. CPR:falsenewline BC6ENTC : recent update on activity as a single agent and in combination with BC6ENTG in patients with advanced - stage renal cell carcinoma. CPR:falsenewlineThe involvement of BC6ENTG in the absorption of BC6ENTC was clearly shown by coperfusion of BC6OTHER with the BC6OTHER inhibitor BC6OTHER . CPR:9newlineThe involvement of BC6OTHER in the absorption of BC6ENTC was clearly shown by coperfusion of BC6OTHER with the BC6ENTG inhibitor BC6OTHER . CPR:falsenewlineThe involvement of BC6ENTG in the absorption of BC6OTHER was clearly shown by coperfusion of BC6ENTC with the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineThe involvement of BC6OTHER in the absorption of BC6OTHER was clearly shown by coperfusion of BC6ENTC with the BC6ENTG inhibitor BC6OTHER . CPR:falsenewlineThe involvement of BC6ENTG in the absorption of BC6OTHER was clearly shown by coperfusion of BC6OTHER with the BC6OTHER inhibitor BC6ENTC . CPR:falsenewlineThe involvement of BC6OTHER in the absorption of BC6OTHER was clearly shown by coperfusion of BC6OTHER with the BC6ENTG inhibitor BC6ENTC . CPR:falsenewlineInvolvement of BC6ENTG mediated metabolism in the absorption of BC6ENTC could not be demonstrated in this rat model. CPR:falsenewlineUpon studying the drug - drug interaction of BC6ENTC with BC6OTHER , data were indicative for an inhibitory effect of BC6OTHER on BC6ENTG as the main mechanism for the increased transport of BC6OTHER across the small intestine. CPR:falsenewlineUpon studying the drug - drug interaction of BC6OTHER with BC6ENTC , data were indicative for an inhibitory effect of BC6OTHER on BC6ENTG as the main mechanism for the increased transport of BC6OTHER across the small intestine. CPR:falsenewlineUpon studying the drug - drug interaction of BC6OTHER with BC6OTHER , data were indicative for an inhibitory effect of BC6ENTC on BC6ENTG as the main mechanism for the increased transport of BC6OTHER across the small intestine. CPR:falsenewlineUpon studying the drug - drug interaction of BC6OTHER with BC6OTHER , data were indicative for an inhibitory effect of BC6OTHER on BC6ENTG as the main mechanism for the increased transport of BC6ENTC across the small intestine. CPR:falsenewlineTo evaluate to what extent the regional differences in expression of BC6ENTG and BC6OTHER affect the absorption of a dual substrate, we investigated the transport of BC6ENTC across different small intestinal segments (duodenum, proximal jejunum and ileum). CPR:falsenewlineTo evaluate to what extent the regional differences in expression of BC6OTHER and BC6ENTG affect the absorption of a dual substrate, we investigated the transport of BC6ENTC across different small intestinal segments (duodenum, proximal jejunum and ileum). CPR:falsenewlineIndirect systemic and direct oral factor Xa and direct oral BC6ENTG inhibitors with improved pharmacologic profiles compared with heparins and BC6ENTC antagonists are currently in clinical development. CPR:falsenewlineThis overview focuses on the indirect CHEM dependent BC6ENTC derivatives of BC6OTHER and on the most advanced oral direct inhibitors to BC6ENTG ( BC6OTHER and BC6OTHER ) and IIa ( BC6OTHER ). CPR:falsenewlineThis overview focuses on the indirect CHEM dependent BC6OTHER derivatives of BC6ENTC and on the most advanced oral direct inhibitors to BC6ENTG ( BC6OTHER and BC6OTHER ) and IIa ( BC6OTHER ). CPR:falsenewlineThis overview focuses on the indirect CHEM dependent BC6OTHER derivatives of BC6OTHER and on the most advanced oral direct inhibitors to BC6ENTG ( BC6ENTC and BC6OTHER ) and IIa ( BC6OTHER ). CPR:falsenewlineThis overview focuses on the indirect CHEM dependent BC6OTHER derivatives of BC6OTHER and on the most advanced oral direct inhibitors to BC6ENTG ( BC6OTHER and BC6ENTC ) and IIa ( BC6OTHER ). CPR:falsenewlineThis overview focuses on the indirect CHEM dependent BC6OTHER derivatives of BC6OTHER and on the most advanced oral direct inhibitors to BC6ENTG ( BC6OTHER and BC6OTHER ) and IIa ( BC6ENTC ). CPR:falsenewlineThis agent acts synergistically with many BC6ENTC , such as BC6OTHER , BC6OTHER , and the like, and with BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall. CPR:falsenewlineThis agent acts synergistically with many BC6OTHER , such as BC6ENTC , BC6OTHER , and the like, and with BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall. CPR:falsenewlineThis agent acts synergistically with many BC6OTHER , such as BC6OTHER , BC6ENTC , and the like, and with BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall. CPR:falsenewlineThis agent acts synergistically with many BC6OTHER , such as BC6OTHER , BC6OTHER , and the like, and with BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall. CPR:falsenewlineThis agent acts synergistically with many BC6OTHER , such as BC6OTHER , BC6OTHER , and the like, and with BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall. CPR:falsenewlineThis agent acts synergistically with many BC6OTHER , such as BC6OTHER , BC6OTHER , and the like, and with BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall. CPR:falsenewlineThis agent acts synergistically with many BC6OTHER , such as BC6OTHER , BC6OTHER , and the like, and with BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the BC6ENTG of the bacterial cell wall. CPR:falsenewlineBinding of BC6OTHER to BC6OTHER produces lysis, binding to BC6ENTC - binding protein 2 produces round cells, and binding to BC6ENTG produces long filaments. CPR:falsenewlineBinding of BC6OTHER to BC6ENTG produces lysis, binding to BC6ENTC - binding protein 2 produces round cells, and binding to BC6OTHER produces long filaments. CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6ENTC - binding protein 1, which is divided into BC6ENTG , a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6OTHER . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6ENTC - binding protein 1, which is divided into BC6OTHER , a BC6ENTG , and BC6OTHER , which acts as a replacement for BC6OTHER . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6ENTC - binding protein 1, which is divided into BC6OTHER , a BC6OTHER , and BC6ENTG , which acts as a replacement for BC6OTHER . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6ENTC - binding protein 1, which is divided into BC6OTHER , a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6ENTG . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6ENTG , which is divided into BC6ENTC - binding protein 1Bs, a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6OTHER . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6ENTC - binding protein 1Bs, a BC6ENTG , and BC6OTHER , which acts as a replacement for BC6OTHER . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6ENTC - binding protein 1Bs, a BC6OTHER , and BC6ENTG , which acts as a replacement for BC6OTHER . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6ENTC - binding protein 1Bs, a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6ENTG . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6ENTG , which is divided into BC6OTHER , a BC6OTHER , and BC6ENTC - binding protein 1A, which acts as a replacement for BC6OTHER . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6ENTG , a BC6OTHER , and BC6ENTC - binding protein 1A, which acts as a replacement for BC6OTHER . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6OTHER , a BC6ENTG , and BC6ENTC - binding protein 1A, which acts as a replacement for BC6OTHER . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6OTHER , a BC6OTHER , and BC6ENTC - binding protein 1A, which acts as a replacement for BC6ENTG . CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6ENTG , which is divided into BC6OTHER , a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6ENTC - binding protein 1Bs. CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6ENTG , a BC6OTHER , and BC6OTHER , which acts as a replacement for BC6ENTC - binding protein 1Bs. CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6OTHER , a BC6ENTG , and BC6OTHER , which acts as a replacement for BC6ENTC - binding protein 1Bs. CPR:falsenewlineSelection of mutants has shown that there are three essential proteins: BC6OTHER , which is divided into BC6OTHER , a BC6OTHER , and BC6ENTG , which acts as a replacement for BC6ENTC - binding protein 1Bs. CPR:falsenewlineBC6ENTC - binding protein 2 is a BC6ENTG - elongation initiating enzyme and BC6OTHER is a septal BC6OTHER - synthesizing enzyme. CPR:falsenewlineBC6ENTC - binding protein 2 is a BC6OTHER - elongation initiating enzyme and BC6ENTG is a septal BC6OTHER - synthesizing enzyme. CPR:falsenewlineBC6ENTC - binding protein 2 is a BC6OTHER - elongation initiating enzyme and BC6OTHER is a septal BC6ENTG - synthesizing enzyme. CPR:falsenewlineBinding of BC6OTHER to BC6OTHER produces lysis, binding to BC6ENTG produces round cells, and binding to BC6ENTC - binding protein 3 produces long filaments. CPR:falsenewlineBinding of BC6OTHER to BC6ENTG produces lysis, binding to BC6OTHER produces round cells, and binding to BC6ENTC - binding protein 3 produces long filaments. CPR:falsenewlineBC6ENTG is a BC6OTHER - elongation initiating enzyme and BC6ENTC - binding protein 3 is a septal BC6OTHER - synthesizing enzyme. CPR:falsenewlineBC6OTHER is a BC6ENTG - elongation initiating enzyme and BC6ENTC - binding protein 3 is a septal BC6OTHER - synthesizing enzyme. CPR:falsenewlineBC6OTHER is a BC6OTHER - elongation initiating enzyme and BC6ENTC - binding protein 3 is a septal BC6ENTG - synthesizing enzyme. CPR:falsenewlineBinding of BC6ENTC to BC6OTHER produces lysis, binding to BC6ENTG produces round cells, and binding to BC6OTHER produces long filaments. CPR:falsenewlineBinding of BC6ENTC to BC6OTHER produces lysis, binding to BC6OTHER produces round cells, and binding to BC6ENTG produces long filaments. CPR:falsenewlineBinding of BC6ENTC to BC6ENTG produces lysis, binding to BC6OTHER produces round cells, and binding to BC6OTHER produces long filaments. CPR:falsenewlineBinding of BC6OTHER to BC6ENTC - binding protein 1Bs produces lysis, binding to BC6ENTG produces round cells, and binding to BC6OTHER produces long filaments. CPR:falsenewlineBinding of BC6OTHER to BC6ENTC - binding protein 1Bs produces lysis, binding to BC6OTHER produces round cells, and binding to BC6ENTG produces long filaments. CPR:falsenewline BC6ENTG and role of BC6ENTC in causing bacterial cell death. CPR:falsenewlineBC6ENTC is a BC6OTHER derivative that binds specifically to BC6ENTG . CPR:falsenewlineBC6OTHER is a BC6ENTC derivative that binds specifically to BC6ENTG . CPR:falsenewlineThe compound is more BC6ENTG stable than BC6ENTC and has no major delay in entry into the periplasmic space as do some BC6OTHER . CPR:falsenewlineThe compound is more BC6ENTG stable than BC6OTHER and has no major delay in entry into the periplasmic space as do some BC6ENTC . CPR:falsenewlineAfter 18 h incubation with 0.5 μM BC6ENTC and subsequent red light irradiation (3.6 J / cm(2)), a high number of cells die by apoptosis, as evaluated by morphological alterations, immunofluorescent relocalization of BC6ENTG from cytosol to mitochondria, and TUNEL assay. CPR:falsenewlineNew modes of therapy have recently been introduced, and data on the BC6ENTG ( BC6OTHER ) - specific inhibitors BC6ENTC and BC6OTHER suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs. CPR:falsenewlineNew modes of therapy have recently been introduced, and data on the BC6OTHER ( BC6ENTG ) - specific inhibitors BC6ENTC and BC6OTHER suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs. CPR:falsenewlineNew modes of therapy have recently been introduced, and data on the BC6ENTG ( BC6OTHER ) - specific inhibitors BC6OTHER and BC6ENTC suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs. CPR:4newlineNew modes of therapy have recently been introduced, and data on the BC6OTHER ( BC6ENTG ) - specific inhibitors BC6OTHER and BC6ENTC suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs. CPR:falsenewlineEvidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6ENTC and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence. CPR:falsenewlineEvidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6ENTC and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence. CPR:falsenewlineEvidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6ENTC by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence. CPR:falsenewlineEvidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6ENTC by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence. CPR:falsenewlineEvidence for a role of BC6ENTC and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence. CPR:falsenewlineEvidence for a role of BC6ENTC and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence. CPR:falsenewlineEvidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6ENTC dependence. CPR:falsenewlineEvidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6ENTC dependence. CPR:falsenewlineEvidence for a role of BC6OTHER and BC6ENTC in the control of BC6OTHER intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence. CPR:falsenewlineEvidence for a role of BC6OTHER and BC6ENTC in the control of BC6OTHER intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence. CPR:falsenewlineThe aim of the present study was, therefore, to evaluate several BC6ENTG inhibitors for their capacity to affect BC6ENTC self - administration in rats trained to self - administer BC6OTHER (10% v / v) orally in a free - choice two - lever operant task. CPR:falsenewlineThe aim of the present study was, therefore, to evaluate several BC6ENTG inhibitors for their capacity to affect BC6OTHER self - administration in rats trained to self - administer BC6ENTC (10% v / v) orally in a free - choice two - lever operant task. CPR:falsenewlineThe nonselective and irreversible BC6ENTG inhibitors, BC6ENTC (3 - 10 mg / kg), BC6OTHER (1 - 3 mg / kg), and BC6OTHER (30 mg / kg), decreased rates of responding maintained by BC6OTHER reinforcement. CPR:4newlineThe nonselective and irreversible BC6ENTG inhibitors, BC6OTHER (3 - 10 mg / kg), BC6ENTC (1 - 3 mg / kg), and BC6OTHER (30 mg / kg), decreased rates of responding maintained by BC6OTHER reinforcement. CPR:falsenewlineThe nonselective and irreversible BC6ENTG inhibitors, BC6OTHER (3 - 10 mg / kg), BC6OTHER (1 - 3 mg / kg), and BC6ENTC (30 mg / kg), decreased rates of responding maintained by BC6OTHER reinforcement. CPR:falsenewlineThe irreversible BC6ENTG inhibitors, BC6ENTC (30 mg / kg) and BC6OTHER (3 - 10 mg / kg) also decreased responding maintained by BC6OTHER reinforcement; these results are consistent with previous findings that both drugs decreased BC6OTHER intake in mice. CPR:falsenewlineEvidence for a role of BC6OTHER and BC6OTHER in the control of BC6ENTC intake in animals suggests that BC6ENTG ( BC6OTHER ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence. CPR:falsenewlineEvidence for a role of BC6OTHER and BC6OTHER in the control of BC6ENTC intake in animals suggests that BC6OTHER oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence. CPR:falsenewlineThe nonselective and irreversible BC6ENTG inhibitors, BC6OTHER (3 - 10 mg / kg), BC6OTHER (1 - 3 mg / kg), and BC6OTHER (30 mg / kg), decreased rates of responding maintained by BC6ENTC reinforcement. CPR:falsenewlineThe reversible BC6ENTG inhibitor, BC6ENTC (0.3 - 3 mg / kg), and the irreversible BC6OTHER inhibitor, BC6OTHER (10 - 30 mg / kg), also reduced BC6OTHER self - administration. CPR:falsenewlineThe reversible BC6OTHER inhibitor, BC6ENTC (0.3 - 3 mg / kg), and the irreversible BC6ENTG inhibitor, BC6OTHER (10 - 30 mg / kg), also reduced BC6OTHER self - administration. CPR:falsenewlineThe reversible BC6ENTG inhibitor, BC6OTHER (0.3 - 3 mg / kg), and the irreversible BC6OTHER inhibitor, BC6ENTC (10 - 30 mg / kg), also reduced BC6OTHER self - administration. CPR:falsenewlineThe reversible BC6OTHER inhibitor, BC6OTHER (0.3 - 3 mg / kg), and the irreversible BC6ENTG inhibitor, BC6ENTC (10 - 30 mg / kg), also reduced BC6OTHER self - administration. CPR:falsenewlineThe reversible BC6ENTG inhibitor, BC6OTHER (0.3 - 3 mg / kg), and the irreversible BC6OTHER inhibitor, BC6OTHER (10 - 30 mg / kg), also reduced BC6ENTC self - administration. CPR:falsenewlineThe reversible BC6OTHER inhibitor, BC6OTHER (0.3 - 3 mg / kg), and the irreversible BC6ENTG inhibitor, BC6OTHER (10 - 30 mg / kg), also reduced BC6ENTC self - administration. CPR:falsenewlineReduction of oral BC6ENTC self - administration in rats by BC6ENTG inhibitors. CPR:falsenewlineThe irreversible BC6ENTG inhibitors, BC6OTHER (30 mg / kg) and BC6ENTC (3 - 10 mg / kg) also decreased responding maintained by BC6OTHER reinforcement; these results are consistent with previous findings that both drugs decreased BC6OTHER intake in mice. CPR:falsenewlineEvidence for a role of BC6OTHER and BC6OTHER in the control of BC6OTHER intake in animals suggests that BC6ENTC oxidase ( BC6ENTG ) inhibitors, which increase the synaptic availability of BC6OTHER and BC6OTHER by blocking their metabolism, might have efficacy in the treatment of BC6OTHER dependence. CPR:falsenewlineThe irreversible BC6ENTG inhibitors, BC6OTHER (30 mg / kg) and BC6OTHER (3 - 10 mg / kg) also decreased responding maintained by BC6ENTC reinforcement; these results are consistent with previous findings that both drugs decreased BC6OTHER intake in mice. CPR:falsenewlineThe irreversible BC6ENTG inhibitors, BC6OTHER (30 mg / kg) and BC6OTHER (3 - 10 mg / kg) also decreased responding maintained by BC6OTHER reinforcement; these results are consistent with previous findings that both drugs decreased BC6ENTC intake in mice. CPR:falsenewlineIn conclusion, the present results showing that several BC6ENTG inhibitors decreased BC6ENTC self - administration in rats are consistent with previous findings that synaptic levels of BC6OTHER and BC6OTHER play a critical role in the control of BC6OTHER self - administration. CPR:falsenewlineIn conclusion, the present results showing that several BC6ENTG inhibitors decreased BC6OTHER self - administration in rats are consistent with previous findings that synaptic levels of BC6ENTC and BC6OTHER play a critical role in the control of BC6OTHER self - administration. CPR:falsenewlineIn conclusion, the present results showing that several BC6ENTG inhibitors decreased BC6OTHER self - administration in rats are consistent with previous findings that synaptic levels of BC6OTHER and BC6ENTC play a critical role in the control of BC6OTHER self - administration. CPR:falsenewlineIn conclusion, the present results showing that several BC6ENTG inhibitors decreased BC6OTHER self - administration in rats are consistent with previous findings that synaptic levels of BC6OTHER and BC6OTHER play a critical role in the control of BC6ENTC self - administration. CPR:falsenewlineDelivery of CHEM transdermally (EMSAM((R))) bypasses hepatic first pass metabolism, thereby avoiding significant inhibition of gastrointestinal and hepatic BC6ENTG activity (ie, reduced risk of BC6ENTC - provoked events) while still providing sufficient levels of BC6OTHER in the brain to produce an antidepressant effect. CPR:falsenewlineDelivery of CHEM transdermally (EMSAM((R))) bypasses hepatic first pass metabolism, thereby avoiding significant inhibition of gastrointestinal and hepatic BC6ENTG activity (ie, reduced risk of BC6OTHER - provoked events) while still providing sufficient levels of BC6ENTC in the brain to produce an antidepressant effect. CPR:falsenewlineNon - selective inhibition of BC6ENTC oxidase ( BC6ENTG ) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects. CPR:falsenewlineCurrently, the use of orally administered BC6ENTG inhibitor antidepressants (eg, BC6ENTC , BC6OTHER ) is limited by the risk of BC6OTHER - provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary BC6OTHER . CPR:falsenewlineCurrently, the use of orally administered BC6ENTG inhibitor antidepressants (eg, BC6OTHER , BC6ENTC ) is limited by the risk of BC6OTHER - provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary BC6OTHER . CPR:falsenewlineCurrently, the use of orally administered BC6ENTG inhibitor antidepressants (eg, BC6OTHER , BC6OTHER ) is limited by the risk of BC6ENTC - provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary BC6OTHER . CPR:falsenewlineCurrently, the use of orally administered BC6ENTG inhibitor antidepressants (eg, BC6OTHER , BC6OTHER ) is limited by the risk of BC6OTHER - provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary BC6ENTC . CPR:falsenewlineBC6ENTC [(+) - 1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of BC6OTHER by the BC6ENTG , and as such, is an important biomarker for pharmaceutical companies conducting research in this field. CPR:falsenewlineBC6OTHER [(+) - 1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of BC6ENTC by the BC6ENTG , and as such, is an important biomarker for pharmaceutical companies conducting research in this field. CPR:falsenewlineAn investigation of the absolute configuration of the potent BC6ENTG antagonist BC6ENTC using vibrational circular dichroism. CPR:6newlineA review of the structural and functional features of BC6ENTC , an BC6ENTG blocker. CPR:4newlineThe marked antihypertensive efficacy of BC6ENTC may result from a unique pharmacological interaction of the drug with the BC6ENTG receptor, resulting in a potent, long - lasting, dose - dependent blockade of BC6OTHER . CPR:falsenewlineThe marked antihypertensive efficacy of BC6ENTC may result from a unique pharmacological interaction of the drug with the BC6OTHER receptor, resulting in a potent, long - lasting, dose - dependent blockade of BC6ENTG . CPR:falsenewlineThe marked antihypertensive efficacy of BC6OTHER may result from a unique pharmacological interaction of the drug with the BC6ENTG receptor, resulting in a potent, long - lasting, dose - dependent blockade of BC6ENTC . CPR:falsenewlineEffective inhibition of BC6ENTC is provided by the latest class of antihypertensive medications, the BC6ENTG receptor blockers (ARBs). CPR:falsenewlineThe BC6OTHER ( BC6ENTC ) type 1 (AT1) receptor - mediated effects of BC6ENTG play a key role in the pathophysiology of hypertension. CPR:falsenewlineThe BC6ENTC ( BC6OTHER ) type 1 (AT1) receptor - mediated effects of BC6ENTG play a key role in the pathophysiology of hypertension. CPR:falsenewlineThe BC6ENTG - mediated effects of BC6ENTC play a key role in the pathophysiology of hypertension. CPR:falsenewlineIn these tissues, BC6ENTC , BC6OTHER (a non - selective BC6ENTG antagonist), and BC6OTHER (an BC6OTHER antagonist) competitively antagonized contraction in a concentration - dependent manner. CPR:falsenewlineIn these tissues, BC6ENTC , BC6OTHER (a non - selective BC6OTHER antagonist), and BC6OTHER (an BC6ENTG antagonist) competitively antagonized contraction in a concentration - dependent manner. CPR:falsenewlineIn these tissues, BC6OTHER , BC6ENTC (a non - selective BC6ENTG antagonist), and BC6OTHER (an BC6OTHER antagonist) competitively antagonized contraction in a concentration - dependent manner. CPR:falsenewlineIn these tissues, BC6OTHER , BC6ENTC (a non - selective BC6OTHER antagonist), and BC6OTHER (an BC6ENTG antagonist) competitively antagonized contraction in a concentration - dependent manner. CPR:falsenewlineIn these tissues, BC6OTHER , BC6OTHER (a non - selective BC6ENTG antagonist), and BC6ENTC (an BC6OTHER antagonist) competitively antagonized contraction in a concentration - dependent manner. CPR:falsenewlineIn these tissues, BC6OTHER , BC6OTHER (a non - selective BC6OTHER antagonist), and BC6ENTC (an BC6ENTG antagonist) competitively antagonized contraction in a concentration - dependent manner. CPR:falsenewlineWe examined the effect of BC6OTHER (3 - inverted question mark BC6ENTC BC6OTHER inverted question mark - BC6OTHER ), a new BC6ENTG antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs. CPR:falsenewlineWe examined the effect of BC6OTHER (3 - inverted question mark BC6OTHER BC6ENTC inverted question mark - BC6OTHER ), a new BC6ENTG antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs. CPR:falsenewline BC6ENTC showed higher selectivity for canine prostate both in vitro and in vivo. In prostate, an important role of the BC6ENTG is suggested in the smooth muscle contraction mediated by BC6OTHER . CPR:falsenewline BC6ENTC showed higher selectivity for canine prostate both in vitro and in vivo. In prostate, an important role of the BC6OTHER is suggested in the smooth muscle contraction mediated by BC6ENTG . CPR:falsenewlineBC6ENTC is expected to be an effective BC6ENTG antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system. CPR:6newlineWe examined the effect of BC6OTHER (3 - inverted question mark BC6OTHER BC6OTHER inverted question mark - BC6ENTC ), a new BC6ENTG antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs. CPR:falsenewlineWe examined the effect of BC6ENTC (3 - inverted question mark BC6OTHER BC6OTHER inverted question mark - BC6OTHER ), a new BC6ENTG antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs. CPR:falsenewlineBC6ENTG ( BC6OTHER ) is an BC6OTHER belonging to the BC6ENTC - binding cassette transporter superfamily expressed in several organs. CPR:falsenewlineBC6OTHER ( BC6ENTG ) is an BC6OTHER belonging to the BC6ENTC - binding cassette transporter superfamily expressed in several organs. CPR:falsenewlineBC6OTHER ( BC6OTHER ) is an BC6ENTG belonging to the BC6ENTC - binding cassette transporter superfamily expressed in several organs. CPR:falsenewlineIn conclusion, in this cellular model, BC6ENTC effectively protects against PQ toxicity by inducing BC6ENTG and through the interaction with the BC6OTHER transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications. CPR:falsenewlineIn conclusion, in this cellular model, BC6ENTC effectively protects against PQ toxicity by inducing BC6OTHER and through the interaction with the BC6ENTG , suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications. CPR:falsenewlineIn conclusion, in this cellular model, BC6OTHER effectively protects against PQ toxicity by inducing BC6ENTG and through the interaction with the BC6ENTC transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications. CPR:falsenewlineThe herbicide BC6ENTC (PQ) is a BC6ENTG substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote. CPR:9newlineThe aim of the present work was to evaluate the effectiveness of such an antidote by testing whether BC6ENTC ( BC6OTHER ), a known BC6ENTG inducer, could efficiently protect Caco - 2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real - life intoxication scenario. CPR:falsenewlineThe aim of the present work was to evaluate the effectiveness of such an antidote by testing whether BC6OTHER ( BC6ENTC ), a known BC6ENTG inducer, could efficiently protect Caco - 2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real - life intoxication scenario. CPR:falsenewlineActivity - dependent cleavage of brain BC6ENTC decarboxylase 65 by BC6ENTG . CPR:falsenewlinePreviously, we reported that BC6OTHER decarboxylase isoform 65 ( BC6OTHER ) could be cleaved in vitro to release a stable truncated form which lacks BC6ENTC 1 - 69 from the BC6OTHER - terminus, BC6ENTG . CPR:falsenewlinePreviously, we reported that BC6ENTG ( BC6OTHER ) could be cleaved in vitro to release a stable truncated form which lacks BC6ENTC 1 - 69 from the BC6OTHER - terminus, BC6OTHER . CPR:falsenewlinePreviously, we reported that BC6OTHER decarboxylase isoform 65 ( BC6ENTG ) could be cleaved in vitro to release a stable truncated form which lacks BC6ENTC 1 - 69 from the BC6OTHER - terminus, BC6OTHER . CPR:falsenewlinePreviously, we reported that BC6OTHER decarboxylase isoform 65 ( BC6OTHER ) could be cleaved in vitro to release a stable truncated form which lacks BC6OTHER 1 - 69 from the BC6ENTC - terminus, BC6ENTG . CPR:falsenewlinePreviously, we reported that BC6ENTG ( BC6OTHER ) could be cleaved in vitro to release a stable truncated form which lacks BC6OTHER 1 - 69 from the BC6ENTC - terminus, BC6OTHER . CPR:falsenewlinePreviously, we reported that BC6OTHER decarboxylase isoform 65 ( BC6ENTG ) could be cleaved in vitro to release a stable truncated form which lacks BC6OTHER 1 - 69 from the BC6ENTC - terminus, BC6OTHER . CPR:falsenewlinePreviously, we reported that BC6ENTC decarboxylase isoform 65 ( BC6OTHER ) could be cleaved in vitro to release a stable truncated form which lacks BC6OTHER 1 - 69 from the BC6OTHER - terminus, BC6ENTG . CPR:falsenewlinePreviously, we reported that BC6ENTC decarboxylase isoform 65 ( BC6ENTG ) could be cleaved in vitro to release a stable truncated form which lacks BC6OTHER 1 - 69 from the BC6OTHER - terminus, BC6OTHER . CPR:falsenewlineBC6ENTC - chelating reagents such as BC6OTHER and BC6OTHER prevented the cleavage of BC6ENTG . CPR:falsenewlineBC6OTHER - chelating reagents such as BC6ENTC and BC6OTHER prevented the cleavage of BC6ENTG . CPR:falsenewlineBC6OTHER - chelating reagents such as BC6OTHER and BC6ENTC prevented the cleavage of BC6ENTG . CPR:falsenewlineIn addition, our data suggested that BC6OTHER , a BC6ENTC - dependent BC6OTHER protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6OTHER to truncated BC6ENTG in the brain. CPR:falsenewlineIn addition, our data suggested that BC6ENTG , a BC6ENTC - dependent BC6OTHER protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6OTHER to truncated BC6OTHER in the brain. CPR:falsenewlineIn addition, our data suggested that BC6OTHER , a BC6ENTC - dependent BC6OTHER protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6ENTG to truncated BC6OTHER in the brain. CPR:falsenewlineIn addition, our data suggested that BC6OTHER , a BC6OTHER - dependent BC6ENTC protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6OTHER to truncated BC6ENTG in the brain. CPR:falsenewlineIn addition, our data suggested that BC6ENTG , a BC6OTHER - dependent BC6ENTC protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6OTHER to truncated BC6OTHER in the brain. CPR:falsenewlineIn addition, our data suggested that BC6OTHER , a BC6OTHER - dependent BC6ENTC protease, is activated upon neuronal stimulation and could be responsible for the conversion of full - length BC6ENTG to truncated BC6OTHER in the brain. CPR:falsenewlineBC6OTHER has greater selectivity for BC6ENTG than BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER has greater selectivity for BC6ENTG than BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER . CPR:falsenewlineBC6ENTC is a selective BC6ENTG inhibitor which has little or no effect on the BC6OTHER isoenzyme at doses up to 1000 mg / day. CPR:falsenewlineBC6ENTC is a selective BC6OTHER inhibitor which has little or no effect on the BC6ENTG isoenzyme at doses up to 1000 mg / day. CPR:falsenewlineBC6OTHER has greater selectivity for BC6ENTG than BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER . CPR:falsenewlineBC6OTHER has greater selectivity for BC6ENTG than BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC . CPR:falsenewlineBC6ENTC has greater selectivity for BC6ENTG than BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewline The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6ENTC , BC6OTHER and BC6OTHER , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82. CPR:falsenewline The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6ENTC and BC6OTHER , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82. CPR:falsenewline The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6OTHER and BC6ENTC , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82. CPR:falsenewline The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6OTHER and BC6OTHER , respectively, suggesting that the three BC6ENTC could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82. CPR:falsenewline The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6OTHER and BC6OTHER , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6ENTC and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82. CPR:falsenewline The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6OTHER and BC6OTHER , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6ENTC with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6OTHER with 0.82. CPR:falsenewline The pharmacokinetics parameters were determined by using noncompartmental analyses, including the AUC(0 - t) in plasma (1695.22, 1326.45 and 636.98mg*h / L), the AUC(0 - t) in brain (1812.35, 2125.17 and 1145.83ng*h / g) as well as the T1 / 2 in plasma (0.66, 0.82, 0.97h) and brain (0.96, 1.1, 0.99h) for BC6OTHER , BC6OTHER and BC6OTHER , respectively, suggesting that the three BC6OTHER could easily pass through the BBB in vivo. In the in vitro model we observed high permeability of BC6OTHER and BC6OTHER with the BC6ENTG - mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of BC6ENTC with 0.82. CPR:falsenewlineBC6ENTC decreased expression of pro - inflammatory BC6ENTG , such as BC6OTHER , BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6ENTC decreased expression of pro - inflammatory BC6OTHER , such as BC6ENTG , BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6ENTC decreased expression of pro - inflammatory BC6OTHER , such as BC6OTHER , BC6ENTG BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6ENTC decreased expression of pro - inflammatory BC6OTHER , such as BC6OTHER , BC6OTHER BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6ENTC decreased expression of pro - inflammatory BC6OTHER , such as BC6OTHER , BC6OTHER BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineBC6ENTC decreased expression of pro - inflammatory BC6OTHER , such as BC6OTHER , BC6OTHER BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineThe inhibitory effect of BC6ENTC on theses pro - inflammatory BC6ENTG was related with BC6OTHER BC6OTHER , and BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER . CPR:4newlineThe inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6ENTG BC6OTHER , and BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6ENTG , and BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6OTHER , and BC6ENTG BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6OTHER , and BC6OTHER BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6OTHER , and BC6OTHER BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineThe inhibitory effect of BC6ENTC on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6OTHER , and BC6OTHER BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineThe inhibitory effect of BC6OTHER on theses pro - inflammatory BC6ENTG was related with BC6OTHER BC6ENTC - terminal kinases, and BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe inhibitory effect of BC6OTHER on theses pro - inflammatory BC6OTHER was related with BC6ENTG BC6ENTC - terminal kinases, and BC6OTHER BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe inhibitory effect of BC6OTHER on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6ENTC - terminal kinases, and BC6ENTG BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe inhibitory effect of BC6OTHER on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6ENTC - terminal kinases, and BC6OTHER BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe inhibitory effect of BC6OTHER on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6ENTC - terminal kinases, and BC6OTHER BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineThe inhibitory effect of BC6OTHER on theses pro - inflammatory BC6OTHER was related with BC6OTHER BC6ENTC - terminal kinases, and BC6OTHER BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineFurthermore, BC6ENTC attenuated BC6ENTG - mediated passive cutaneous anaphylaxis and the expression of BC6OTHER at the inflamed tissue. CPR:falsenewlineFurthermore, BC6ENTC attenuated BC6OTHER - mediated passive cutaneous anaphylaxis and the expression of BC6ENTG at the inflamed tissue. CPR:falsenewlineFurthermore, BC6OTHER attenuated BC6ENTG - mediated passive cutaneous anaphylaxis and the expression of BC6ENTC receptor 1 at the inflamed tissue. CPR:falsenewlineOur results showed that BC6ENTC down - regulates mast cell - derived allergic inflammatory reactions by blocking BC6OTHER release and expression of pro - inflammatory BC6ENTG . CPR:4newlineOur results showed that BC6OTHER down - regulates mast cell - derived allergic inflammatory reactions by blocking BC6ENTC release and expression of pro - inflammatory BC6ENTG . CPR:falsenewlineThe short lifetime of BC6ENTC makes this detection very challenging in measuring BC6ENTG responses. CPR:falsenewlineIt has been known for decades that BC6ENTC ( BC6OTHER ) leads to BC6OTHER accumulation on BC6ENTG activation by inhibiting BC6OTHER , the final enzyme of the BC6OTHER metabolic cascade. CPR:falsenewlineIt has been known for decades that BC6ENTC ( BC6OTHER ) leads to BC6OTHER accumulation on BC6OTHER activation by inhibiting BC6ENTG , the final enzyme of the BC6OTHER metabolic cascade. CPR:4newlineIt has been known for decades that BC6OTHER ( BC6ENTC ) leads to BC6OTHER accumulation on BC6ENTG activation by inhibiting BC6OTHER , the final enzyme of the BC6OTHER metabolic cascade. CPR:4newlineIt has been known for decades that BC6OTHER ( BC6ENTC ) leads to BC6OTHER accumulation on BC6OTHER activation by inhibiting BC6ENTG , the final enzyme of the BC6OTHER metabolic cascade. CPR:4newlineIt has been known for decades that BC6OTHER ( BC6OTHER ) leads to BC6ENTC accumulation on BC6ENTG activation by inhibiting BC6OTHER , the final enzyme of the BC6OTHER metabolic cascade. CPR:falsenewlineIt has been known for decades that BC6OTHER ( BC6OTHER ) leads to BC6ENTC accumulation on BC6OTHER activation by inhibiting BC6ENTG , the final enzyme of the BC6OTHER metabolic cascade. CPR:falsenewlineIt has been known for decades that BC6OTHER ( BC6OTHER ) leads to BC6OTHER accumulation on BC6ENTG activation by inhibiting BC6OTHER , the final enzyme of the BC6ENTC metabolic cascade. CPR:falsenewlineIt has been known for decades that BC6OTHER ( BC6OTHER ) leads to BC6OTHER accumulation on BC6OTHER activation by inhibiting BC6ENTG , the final enzyme of the BC6ENTC metabolic cascade. CPR:falsenewlineWe show here that BC6ENTC can be used as a surrogate of BC6OTHER to monitor BC6ENTG activation. CPR:falsenewlineWe show here that BC6OTHER can be used as a surrogate of BC6ENTC to monitor BC6ENTG activation. CPR:falsenewlineIt has the advantage over the traditional BC6ENTC assay of allowing the measurement of inverse agonist activity as well as the analysis of BC6ENTG activity in any nontransfected primary cultures. CPR:falsenewline BC6ENTC as a surrogate of BC6OTHER to monitor BC6ENTG activation. CPR:falsenewline BC6OTHER as a surrogate of BC6ENTC to monitor BC6ENTG activation. CPR:falsenewlineBC6ENTG ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6ENTC triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6ENTC triggered by BC6OTHER ( BC6OTHER ), a BC6ENTG hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6ENTG ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6ENTC triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6ENTG ( BC6OTHER ) activities traditionally are assessed by measuring BC6ENTC triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6ENTG ) activities traditionally are assessed by measuring BC6ENTC triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6ENTG ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6ENTC ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6ENTC ( BC6OTHER ), a BC6ENTG hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6ENTG ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6ENTC ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6ENTG ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6ENTC ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6ENTG ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6ENTC ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6ENTG ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6ENTC ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6ENTC ), a BC6ENTG hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6ENTG ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6ENTC ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6ENTG ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6ENTC ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6ENTG ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6ENTC ), a BC6OTHER hydrolysis product, or by measuring the production of BC6OTHER using cumbersome radioactive assays. CPR:falsenewlineBC6ENTG ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6ENTC using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6OTHER ), a BC6ENTG hydrolysis product, or by measuring the production of BC6ENTC using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6ENTG ) - coupled BC6OTHER ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6ENTC using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6ENTG ( BC6OTHER ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6ENTC using cumbersome radioactive assays. CPR:falsenewlineBC6OTHER ( BC6OTHER ) - coupled BC6OTHER ( BC6ENTG ) activities traditionally are assessed by measuring BC6OTHER triggered by BC6OTHER ( BC6OTHER ), a BC6OTHER hydrolysis product, or by measuring the production of BC6ENTC using cumbersome radioactive assays. CPR:falsenewlineBC6ENTG , BC6ENTC - BC6OTHER - transferase and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity. CPR:falsenewlineBC6OTHER , BC6ENTC - BC6OTHER - transferase and BC6ENTG activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity. CPR:falsenewlineBC6ENTG , CHEM - BC6ENTC - transferase and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity. CPR:falsenewlineBC6OTHER , CHEM - BC6ENTC - transferase and BC6ENTG activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity. CPR:falsenewlineBC6ENTG , CHEM - BC6OTHER - transferase and BC6ENTC oxidase activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity. CPR:falsenewlineBC6OTHER , BC6ENTG and BC6ENTC oxidase activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity. CPR:falsenewlineBC6ENTG , CHEM - BC6OTHER - transferase and BC6OTHER activities were not altered by BC6ENTC treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity. CPR:falsenewlineBC6OTHER , BC6ENTG and BC6OTHER activities were not altered by BC6ENTC treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity. CPR:falsenewlineBC6OTHER , CHEM - BC6OTHER - transferase and BC6ENTG activities were not altered by BC6ENTC treatment or withdrawal, as well as protein BC6OTHER and BC6OTHER immunoreactivity. CPR:falsenewlineBC6ENTG , CHEM - BC6OTHER - transferase and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6ENTC and BC6OTHER immunoreactivity. CPR:falsenewlineBC6OTHER , BC6ENTG and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6ENTC and BC6OTHER immunoreactivity. CPR:falsenewlineBC6OTHER , CHEM - BC6OTHER - transferase and BC6ENTG activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6ENTC and BC6OTHER immunoreactivity. CPR:falsenewlineBC6ENTG , CHEM - BC6OTHER - transferase and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6ENTC immunoreactivity. CPR:falsenewlineBC6OTHER , BC6ENTG and BC6OTHER activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6ENTC immunoreactivity. CPR:falsenewlineBC6OTHER , CHEM - BC6OTHER - transferase and BC6ENTG activities were not altered by BC6OTHER treatment or withdrawal, as well as protein BC6OTHER and BC6ENTC immunoreactivity. CPR:falsenewlineImmunoprecipitation of BC6ENTG followed by analysis of BC6ENTC revealed increased levels of nitrated BC6OTHER , suggesting the mechanism underlying the BC6OTHER withdrawal - induced decrease in enzyme activity. CPR:falsenewlineImmunoprecipitation of BC6OTHER followed by analysis of BC6ENTC revealed increased levels of nitrated BC6ENTG , suggesting the mechanism underlying the BC6OTHER withdrawal - induced decrease in enzyme activity. CPR:falsenewlineImmunoprecipitation of BC6ENTG followed by analysis of BC6OTHER revealed increased levels of nitrated BC6OTHER , suggesting the mechanism underlying the BC6ENTC withdrawal - induced decrease in enzyme activity. CPR:falsenewlineImmunoprecipitation of BC6OTHER followed by analysis of BC6OTHER revealed increased levels of nitrated BC6ENTG , suggesting the mechanism underlying the BC6ENTC withdrawal - induced decrease in enzyme activity. CPR:falsenewlineAltogether, our results indicate the BC6ENTC withdrawal elicits oxidative / nitrosative damage in the rat cerebral cortex, and that changes in BC6ENTG activity and mitochondrial BC6OTHER dismutase activities may underlie such harmful effects. CPR:falsenewlineAltogether, our results indicate the BC6ENTC withdrawal elicits oxidative / nitrosative damage in the rat cerebral cortex, and that changes in BC6OTHER activity and BC6ENTG activities may underlie such harmful effects. CPR:falsenewlineAltogether, our results indicate the BC6OTHER withdrawal elicits oxidative / nitrosative damage in the rat cerebral cortex, and that changes in BC6ENTC oxidase activity and BC6ENTG activities may underlie such harmful effects. CPR:falsenewlineAltogether, our results indicate the BC6OTHER withdrawal elicits oxidative / nitrosative damage in the rat cerebral cortex, and that changes in BC6ENTG activity and mitochondrial BC6ENTC dismutase activities may underlie such harmful effects. CPR:falsenewlineCHEM are inhibitors of the enzyme BC6ENTG , the rate - limiting step in BC6ENTC biosynthesis. CPR:falsenewlineWe found that BC6ENTC withdrawal decreased levels of BC6OTHER and BC6ENTG activity, whereas increased BC6OTHER oxidase activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex. CPR:falsenewlineWe found that BC6ENTC withdrawal decreased levels of BC6OTHER and mitochondrial BC6OTHER dismutase activity, whereas increased BC6ENTG activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex. CPR:falsenewlineWe found that BC6OTHER withdrawal decreased levels of BC6ENTC and BC6ENTG activity, whereas increased BC6OTHER oxidase activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex. CPR:falsenewlineWe found that BC6OTHER withdrawal decreased levels of BC6ENTC and mitochondrial BC6OTHER dismutase activity, whereas increased BC6ENTG activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex. CPR:falsenewlineWe found that BC6OTHER withdrawal decreased levels of BC6OTHER and mitochondrial BC6ENTC dismutase activity, whereas increased BC6ENTG activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex. CPR:falsenewlineWe found that BC6OTHER withdrawal decreased levels of BC6OTHER and BC6ENTG activity, whereas increased BC6ENTC oxidase activity and immunoreactivity for the protein nitration marker BC6OTHER in the cerebral cortex. CPR:falsenewlineWe found that BC6OTHER withdrawal decreased levels of BC6OTHER and BC6ENTG activity, whereas increased BC6OTHER oxidase activity and immunoreactivity for the protein nitration marker BC6ENTC in the cerebral cortex. CPR:falsenewlineWe found that BC6OTHER withdrawal decreased levels of BC6OTHER and mitochondrial BC6OTHER dismutase activity, whereas increased BC6ENTG activity and immunoreactivity for the protein nitration marker BC6ENTC in the cerebral cortex. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6ENTC on BC6ENTG ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on neuronal BC6OTHER channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6ENTC on voltage - operated human skeletal muscle BC6OTHER channels ( BC6ENTG ) and the effect of one compound ( BC6OTHER ) on neuronal BC6OTHER channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6ENTC on voltage - operated human skeletal muscle BC6OTHER channels ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on BC6ENTG ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6ENTC on voltage - operated human skeletal muscle BC6OTHER channels ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on neuronal BC6OTHER channels ( BC6ENTG ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6ENTC channels ( BC6ENTG ) and the effect of one compound ( BC6OTHER ) on neuronal BC6OTHER channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6ENTC channels ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on BC6ENTG ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6ENTC channels ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on neuronal BC6OTHER channels ( BC6ENTG ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on BC6ENTG ( BC6OTHER ) and the effect of one compound ( BC6ENTC ) on neuronal BC6OTHER channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6OTHER channels ( BC6ENTG ) and the effect of one compound ( BC6ENTC ) on neuronal BC6OTHER channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6OTHER channels ( BC6OTHER ) and the effect of one compound ( BC6ENTC ) on BC6ENTG ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6OTHER channels ( BC6OTHER ) and the effect of one compound ( BC6ENTC ) on neuronal BC6OTHER channels ( BC6ENTG ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on BC6ENTG ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on neuronal BC6ENTC channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6OTHER channels ( BC6ENTG ) and the effect of one compound ( BC6OTHER ) on neuronal BC6ENTC channels ( BC6OTHER ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineEXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of BC6OTHER on voltage - operated human skeletal muscle BC6OTHER channels ( BC6OTHER ) and the effect of one compound ( BC6OTHER ) on neuronal BC6ENTC channels ( BC6ENTG ) heterologously expressed in human embryonic kidney cell line 293. CPR:falsenewlineThe IC(50) for block of resting channels at - 150 mV was 2.3, 3.9 and 11.3 microM in BC6ENTG , respectively, and 29.2 microM for BC6ENTC in BC6OTHER . CPR:falsenewlineThe IC(50) for block of resting channels at - 150 mV was 2.3, 3.9 and 11.3 microM in BC6OTHER , respectively, and 29.2 microM for BC6ENTC in BC6ENTG . CPR:falsenewlineEstimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6ENTC , BC6OTHER and BC6OTHER in BC6ENTG , and 450 nM for BC6OTHER in BC6OTHER . CPR:falsenewlineEstimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6ENTC , BC6OTHER and BC6OTHER in BC6OTHER , and 450 nM for BC6OTHER in BC6ENTG . CPR:falsenewlineHigh - affinity blockade of BC6ENTG by BC6ENTC analogues. CPR:4newlineEstimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6ENTC and BC6OTHER in BC6ENTG , and 450 nM for BC6OTHER in BC6OTHER . CPR:falsenewlineEstimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6ENTC and BC6OTHER in BC6OTHER , and 450 nM for BC6OTHER in BC6ENTG . CPR:falsenewlineEstimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6OTHER and BC6ENTC in BC6ENTG , and 450 nM for BC6OTHER in BC6OTHER . CPR:falsenewlineEstimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6OTHER and BC6ENTC in BC6OTHER , and 450 nM for BC6OTHER in BC6ENTG . CPR:falsenewlineEstimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6OTHER and BC6OTHER in BC6ENTG , and 450 nM for BC6ENTC in BC6OTHER . CPR:falsenewlineEstimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for BC6OTHER , BC6OTHER and BC6OTHER in BC6OTHER , and 450 nM for BC6ENTC in BC6ENTG . CPR:falsenewlineCONCLUSIONS AND IMPLICATIONS: BC6ENTC analogues constitute a novel class of BC6ENTG - blocking drugs possessing almost 100 - fold higher potency compared with the local anaesthetic and anti - arrhythmic drug BC6OTHER . CPR:falsenewlineCONCLUSIONS AND IMPLICATIONS: BC6OTHER analogues constitute a novel class of BC6ENTG - blocking drugs possessing almost 100 - fold higher potency compared with the local anaesthetic and anti - arrhythmic drug BC6ENTC . CPR:falsenewlineBoth BC6ENTC treatments, induced a significant decrease (p<0.01) in uterine BC6ENTG ( BC6OTHER ) content, had no effect on uterine BC6OTHER ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6ENTC treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6ENTG ) content, had no effect on uterine BC6OTHER ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6ENTC treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6OTHER ) content, had no effect on uterine BC6ENTG ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6ENTC treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6OTHER ) content, had no effect on uterine BC6OTHER ( BC6ENTG ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6ENTC treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6OTHER ) content, had no effect on uterine BC6OTHER ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6ENTG , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6ENTC receptor alpha ( BC6ENTG ) content, had no effect on uterine BC6OTHER ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6ENTC receptor alpha ( BC6OTHER ) content, had no effect on uterine BC6ENTG ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6ENTC receptor alpha ( BC6OTHER ) content, had no effect on uterine BC6OTHER ( BC6ENTG ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6ENTC receptor alpha ( BC6OTHER ) content, had no effect on uterine BC6OTHER ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6ENTG , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6ENTG ( BC6OTHER ) content, had no effect on uterine BC6ENTC receptor ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6ENTG ) content, had no effect on uterine BC6ENTC receptor ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6OTHER ) content, had no effect on uterine BC6ENTC receptor ( BC6ENTG ) protein expression and caused marked nuclear localization of BC6OTHER , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineBoth BC6OTHER treatments, induced a significant decrease (p<0.01) in uterine BC6OTHER ( BC6OTHER ) content, had no effect on uterine BC6ENTC receptor ( BC6OTHER ) protein expression and caused marked nuclear localization of BC6ENTG , in both luminal and glandular uterine epithelium, as compared to vehicle - treated animals. CPR:falsenewlineFurthermore, we detected that BC6ENTC treatment induced BC6ENTG ( BC6OTHER ) CHEM 9 phosphorylation, which correlates with BC6OTHER nuclear localization. CPR:falsenewlineFurthermore, we detected that BC6ENTC treatment induced BC6OTHER ( BC6ENTG ) CHEM 9 phosphorylation, which correlates with BC6OTHER nuclear localization. CPR:falsenewlineFurthermore, we detected that BC6ENTC treatment induced BC6OTHER ( BC6OTHER ) CHEM 9 phosphorylation, which correlates with BC6ENTG nuclear localization. CPR:falsenewlineAgonistic activity of BC6ENTC on activation of BC6ENTG / BC6OTHER pathway in the rat uterus during the estrous cycle. CPR:falsenewlineAgonistic activity of BC6ENTC on activation of BC6OTHER / BC6ENTG pathway in the rat uterus during the estrous cycle. CPR:falsenewlineWe observed that the administration of BC6ENTC at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of BC6ENTG phosphorylation at BC6OTHER 473 as compared to vehicle - treated animals, whereas BC6OTHER treatment at 00:00h on estrus day had no effect on these parameters. CPR:falsenewlineWe observed that the administration of BC6OTHER at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of BC6ENTG phosphorylation at BC6ENTC 473 as compared to vehicle - treated animals, whereas BC6OTHER treatment at 00:00h on estrus day had no effect on these parameters. CPR:falsenewlineWe observed that the administration of BC6OTHER at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of BC6ENTG phosphorylation at BC6OTHER 473 as compared to vehicle - treated animals, whereas BC6ENTC treatment at 00:00h on estrus day had no effect on these parameters. CPR:falsenewlineThe overall results indicate that BC6ENTC may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the BC6ENTG pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model. CPR:falsenewlineWe examined the ability of BC6ENTC ( BC6OTHER ) to block uterine cell proliferation via BC6OTHER / BC6ENTG pathway in the uterus of the rat during the estrous cycle. CPR:falsenewlineWe examined the ability of BC6ENTC ( BC6OTHER ) to block uterine cell proliferation via BC6ENTG / BC6OTHER pathway in the uterus of the rat during the estrous cycle. CPR:falsenewlineWe examined the ability of BC6OTHER ( BC6ENTC ) to block uterine cell proliferation via BC6OTHER / BC6ENTG pathway in the uterus of the rat during the estrous cycle. CPR:falsenewlineWe examined the ability of BC6OTHER ( BC6ENTC ) to block uterine cell proliferation via BC6ENTG / BC6OTHER pathway in the uterus of the rat during the estrous cycle. CPR:falsenewlinePretreatment with a combination of BC6ENTC ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6ENTG . CPR:falsenewlinePretreatment with a combination of BC6ENTC ( BC6OTHER , a selective BC6ENTG antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER . CPR:falsenewlinePretreatment with a combination of BC6ENTC ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6ENTC , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6ENTG . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6ENTC , a selective BC6ENTG antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6ENTC , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6ENTC ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6ENTG . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) and BC6ENTC ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6ENTC ( BC6OTHER , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6ENTC , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6ENTG . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) and BC6OTHER ( BC6ENTC , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6ENTC , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6ENTC ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6ENTG . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6ENTC ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6ENTC ; however, the relaxation in response to BC6OTHER was unaffected by the blockade of BC6OTHER . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6ENTC was unaffected by the blockade of BC6ENTG . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) and BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6ENTC was unaffected by the blockade of BC6OTHER . CPR:falsenewlinePretreatment with a combination of BC6OTHER ( BC6OTHER , a selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER , a selective BC6ENTG antagonist) (0.1 microM for each) produced a 14 - fold rightward shift of the concentration - response curve for BC6OTHER ; however, the relaxation in response to BC6ENTC was unaffected by the blockade of BC6OTHER . CPR:falsenewlineIn the presence of BC6ENTC and BC6OTHER (0.1 microM for each), the concentration - response curves for BC6OTHER and BC6OTHER were shifted to the right by a nonselective BC6ENTG antagonist, BC6OTHER (3 and 10 microM). CPR:falsenewlineIn the presence of BC6OTHER and BC6ENTC (0.1 microM for each), the concentration - response curves for BC6OTHER and BC6OTHER were shifted to the right by a nonselective BC6ENTG antagonist, BC6OTHER (3 and 10 microM). CPR:falsenewlineIn the presence of BC6OTHER and BC6OTHER (0.1 microM for each), the concentration - response curves for BC6ENTC and BC6OTHER were shifted to the right by a nonselective BC6ENTG antagonist, BC6OTHER (3 and 10 microM). CPR:falsenewlineIn the presence of BC6OTHER and BC6OTHER (0.1 microM for each), the concentration - response curves for BC6OTHER and BC6ENTC were shifted to the right by a nonselective BC6ENTG antagonist, BC6OTHER (3 and 10 microM). CPR:falsenewlineIn the presence of BC6OTHER and BC6OTHER (0.1 microM for each), the concentration - response curves for BC6OTHER and BC6OTHER were shifted to the right by a nonselective BC6ENTG antagonist, BC6ENTC (3 and 10 microM). CPR:falsenewlineBC6ENTC and a nonconventional BC6ENTG agonist, BC6OTHER ( BC6OTHER ), induced concentration - dependent relaxation of BC6OTHER (0.3 microM) preconstricted spiral preparations. CPR:5newlineBC6OTHER and a nonconventional BC6ENTG agonist, BC6ENTC ( BC6OTHER ), induced concentration - dependent relaxation of BC6OTHER (0.3 microM) preconstricted spiral preparations. CPR:5newlineBC6OTHER and a nonconventional BC6ENTG agonist, BC6OTHER ( BC6ENTC ), induced concentration - dependent relaxation of BC6OTHER (0.3 microM) preconstricted spiral preparations. CPR:5newlineBC6OTHER and a nonconventional BC6ENTG agonist, BC6OTHER ( BC6OTHER ), induced concentration - dependent relaxation of BC6ENTC (0.3 microM) preconstricted spiral preparations. CPR:5newlineAgents that specifically target BC6OTHER , such as BC6ENTC , as well as new molecules that function both upstream and downstream of BC6ENTG , are being actively investigated. CPR:falsenewlineAgents that specifically target BC6ENTG , such as BC6ENTC , as well as new molecules that function both upstream and downstream of BC6OTHER , are being actively investigated. CPR:falsenewlineThese observations show substrate - and enzyme - specific BC6ENTG inhibition by BC6OTHER and support the possibility that a certain BC6OTHER (s) may be the molecular target for BC6ENTC action. CPR:4newlineThese observations show substrate - and enzyme - specific BC6OTHER inhibition by BC6OTHER and support the possibility that a certain BC6ENTG (s) may be the molecular target for BC6ENTC action. CPR:falsenewlineHere we report that BC6ENTC is a potent inhibitor of the BC6ENTG ( BC6OTHER ). CPR:4newlineHere we report that BC6ENTC is a potent inhibitor of the protein - BC6OTHER - phosphatase - meg1 ( BC6ENTG ). CPR:4newlineHere we report that BC6OTHER is a potent inhibitor of the protein - BC6ENTC - phosphatase - meg1 ( BC6ENTG ). CPR:falsenewlineTwo substrates were employed in this study: CHEM BC6ENTC and the CHEM peptide BC6ENTG - pY527. CPR:falsenewlineWith either substrate, BC6ENTC was a slow binding inhibitor of BC6ENTG . CPR:4newlineAmong the other BC6ENTC studied, BC6OTHER was more potent and selective for BC6ENTG . CPR:falsenewlineAmong the other BC6OTHER studied, BC6ENTC was more potent and selective for BC6ENTG . CPR:falsenewlineThe hydrolysis of CHEM BC6ENTC by BC6ENTG and BC6OTHER was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER . CPR:9newlineThe hydrolysis of CHEM BC6ENTC by BC6OTHER and BC6ENTG was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER . CPR:9newlineThe hydrolysis of CHEM BC6ENTC by BC6OTHER and BC6OTHER was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6ENTG , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER . CPR:9newlineThe hydrolysis of CHEM BC6OTHER by BC6ENTG and BC6OTHER was sensitive to BC6ENTC , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER . CPR:falsenewlineThe hydrolysis of CHEM BC6OTHER by BC6OTHER and BC6ENTG was sensitive to BC6ENTC , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER . CPR:falsenewlineThe hydrolysis of CHEM BC6OTHER by BC6OTHER and BC6OTHER was sensitive to BC6ENTC , with IC50 values of less than 1 microM; BC6ENTG , however, under the same conditions, was inhibited by only 50% with 141 microM BC6OTHER . CPR:falsenewlineThe hydrolysis of CHEM BC6OTHER by BC6ENTG and BC6OTHER was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6ENTC . CPR:falsenewlineThe hydrolysis of CHEM BC6OTHER by BC6OTHER and BC6ENTG was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6OTHER , however, under the same conditions, was inhibited by only 50% with 141 microM BC6ENTC . CPR:falsenewlineThe hydrolysis of CHEM BC6OTHER by BC6OTHER and BC6OTHER was sensitive to BC6OTHER , with IC50 values of less than 1 microM; BC6ENTG , however, under the same conditions, was inhibited by only 50% with 141 microM BC6ENTC . CPR:falsenewlineSimilarly, with the BC6ENTG - pY527 substrate, BC6ENTC inhibition was also BC6OTHER dependent. CPR:falsenewlineSimilarly, with the BC6OTHER - pY527 substrate, BC6ENTC inhibition was also BC6ENTG dependent. CPR:falsenewlineBC6ENTC inhibited BC6ENTG with an IC50 value of 23 microM, BC6OTHER with an IC50 value of 2 microM, and did not inhibit BC6OTHER at concentrations up to 1 mM. CPR:falsenewlineBC6ENTC inhibited BC6OTHER with an IC50 value of 23 microM, BC6ENTG with an IC50 value of 2 microM, and did not inhibit BC6OTHER at concentrations up to 1 mM. CPR:falsenewlineBC6ENTC inhibited BC6OTHER with an IC50 value of 23 microM, BC6OTHER with an IC50 value of 2 microM, and did not inhibit BC6ENTG at concentrations up to 1 mM. CPR:falsenewline BC6ENTC inhibition of BC6ENTG . CPR:4newlineThe BC6ENTC inhibition of these three BC6ENTG and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor. CPR:4newlineBC6ENTG inhibition by BC6ENTC or BC6OTHER was diminished by the CHEM BC6OTHER , or by the reducing agent BC6OTHER , suggesting that a metal ion and the oxidation of a BC6OTHER residue are required for full inhibition. CPR:falsenewlineBC6ENTG inhibition by BC6OTHER or BC6ENTC was diminished by the CHEM BC6OTHER , or by the reducing agent BC6OTHER , suggesting that a metal ion and the oxidation of a BC6OTHER residue are required for full inhibition. CPR:4newlineBC6ENTG inhibition by BC6OTHER or BC6OTHER was diminished by the CHEM BC6ENTC , or by the reducing agent BC6OTHER , suggesting that a metal ion and the oxidation of a BC6OTHER residue are required for full inhibition. CPR:falsenewlineBC6ENTG inhibition by BC6OTHER or BC6OTHER was diminished by the CHEM BC6OTHER , or by the reducing agent BC6ENTC , suggesting that a metal ion and the oxidation of a BC6OTHER residue are required for full inhibition. CPR:falsenewlineBC6ENTG inhibition by BC6OTHER or BC6OTHER was diminished by the CHEM BC6OTHER , or by the reducing agent BC6OTHER , suggesting that a metal ion and the oxidation of a BC6ENTC residue are required for full inhibition. CPR:falsenewlineThese observations show substrate - and enzyme - specific BC6ENTG inhibition by BC6ENTC and support the possibility that a certain BC6OTHER (s) may be the molecular target for BC6OTHER action. CPR:4newlineThese observations show substrate - and enzyme - specific BC6OTHER inhibition by BC6ENTC and support the possibility that a certain BC6ENTG (s) may be the molecular target for BC6OTHER action. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to BC6ENTG and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6ENTC channels from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6ENTG , and that BC6OTHER limit SRF by slowing recovery of BC6ENTC channels from inactivation. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6ENTC which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6ENTC which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTC receptors ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6ENTC ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6ENTC ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTC receptor weak partial agonist ( BC6OTHER ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6ENTG ( BC6OTHER ) at high nanomolar concentrations and by a BC6OTHER weak partial agonist ( BC6ENTC ) at micromolar concentrations. CPR:falsenewlineLimitation of SRF was produced by the anticonvulsant BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) at low to mid nanomolar concentrations, by a convulsant BC6OTHER which does not bind to high affinity BC6OTHER ( BC6OTHER ) at high nanomolar concentrations and by a BC6ENTG weak partial agonist ( BC6ENTC ) at micromolar concentrations. CPR:falsenewlineThe limitation of SRF by BC6ENTC was not prevented by inverse or partial agonists at the BC6ENTG , including BC6OTHER and the BC6OTHER . CPR:falsenewlineThe limitation of SRF by BC6OTHER was not prevented by inverse or partial agonists at the BC6ENTG , including BC6ENTC and the BC6OTHER . CPR:falsenewlineThe limitation of SRF by BC6OTHER was not prevented by inverse or partial agonists at the BC6ENTG , including BC6OTHER and the BC6ENTC . CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6ENTC , but not BC6OTHER , to BC6ENTG and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6ENTC , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6ENTG , and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6ENTC , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6ENTG from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6ENTC , to BC6ENTG and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6ENTC , to voltage - dependent BC6OTHER channels and not to high affinity central BC6ENTG , and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6ENTC , to voltage - dependent BC6OTHER channels and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6ENTG from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6ENTC channels and not to high affinity central BC6ENTG , and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6ENTC channels and not to high affinity central BC6OTHER receptors, and that BC6OTHER limit SRF by slowing recovery of BC6ENTG from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to BC6ENTG and not to high affinity central BC6ENTC receptors, and that BC6OTHER limit SRF by slowing recovery of BC6OTHER from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6ENTC receptors, and that BC6OTHER limit SRF by slowing recovery of BC6ENTG from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to BC6ENTG and not to high affinity central BC6OTHER receptors, and that BC6ENTC limit SRF by slowing recovery of BC6OTHER from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6ENTG , and that BC6ENTC limit SRF by slowing recovery of BC6OTHER from inactivation. CPR:falsenewlineThese findings suggest that limitation of SRF was produced by binding of BC6OTHER , but not BC6OTHER , to voltage - dependent BC6OTHER channels and not to high affinity central BC6OTHER receptors, and that BC6ENTC limit SRF by slowing recovery of BC6ENTG from inactivation. CPR:falsenewlineChanges in gene expression associated with loss of function of the BC6ENTG BC6ENTC dehydrogenase in mouse embryonic fibroblasts. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6ENTC biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6ENTG , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6ENTC biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6ENTG , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6ENTC biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6ENTG ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6ENTC biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6ENTG and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6ENTC biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6ENTG ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6ENTC synthesis, 3 ( BC6ENTG , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6ENTC synthesis, 3 ( BC6OTHER , BC6ENTG , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6ENTC synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6ENTG ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6ENTC synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6ENTG and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6ENTC synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6OTHER - regulatory proteins, and 2 ( BC6OTHER and BC6ENTG ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6ENTG , BC6OTHER , and BC6OTHER ) encode BC6ENTC - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6ENTG , and BC6OTHER ) encode BC6ENTC - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6ENTG ) encode BC6ENTC - regulatory proteins, and 2 ( BC6OTHER and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6ENTC - regulatory proteins, and 2 ( BC6ENTG and BC6OTHER ) are lipid transporters. CPR:falsenewlineAmong 44 genes that showed higher expression in the CHEM versus wt cells grown in LDS, 11 function in BC6OTHER biosynthesis, 7 are involved in BC6OTHER synthesis, 3 ( BC6OTHER , BC6OTHER , and BC6OTHER ) encode BC6ENTC - regulatory proteins, and 2 ( BC6OTHER and BC6ENTG ) are lipid transporters. CPR:falsenewlineOne of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6ENTC BC6OTHER dehydrogenase - like ( BC6ENTG ) encoding a BC6OTHER dehydrogenase. CPR:falsenewlineOne of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6ENTC BC6OTHER dehydrogenase - like ( BC6OTHER ) encoding a BC6ENTG . CPR:falsenewlineOne of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6OTHER BC6ENTC dehydrogenase - like ( BC6ENTG ) encoding a BC6OTHER dehydrogenase. CPR:falsenewlineOne of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6OTHER BC6ENTC dehydrogenase - like ( BC6OTHER ) encoding a BC6ENTG . CPR:falsenewlineOne of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6ENTG ( BC6OTHER ) encoding a BC6ENTC dehydrogenase. CPR:falsenewlineOne of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X - linked gene BC6OTHER BC6OTHER dehydrogenase - like ( BC6ENTG ) encoding a BC6ENTC dehydrogenase. CPR:falsenewlineInhibition of the BC6ENTG - depalmitoylating enzyme BC6ENTC protein thioesterases APT1 and - 2 is a new approach to modulating the BC6OTHER cycle. CPR:falsenewlineInhibition of the BC6OTHER - depalmitoylating enzyme BC6ENTC protein thioesterases APT1 and - 2 is a new approach to modulating the BC6ENTG cycle. CPR:falsenewlineHere we present BC6ENTC and BC6OTHER derivatives as a new class of potent and nontoxic BC6ENTG inhibitors. CPR:4newlineHere we present BC6OTHER and BC6ENTC derivatives as a new class of potent and nontoxic BC6ENTG inhibitors. CPR:falsenewline BC6ENTC - based inhibitors of BC6ENTG . CPR:falsenewlineOral BC6ENTC (as a representative of the BC6OTHER family) inhibited diabetes - induced increase in BC6ENTG DNA - binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina. CPR:falsenewlineOral BC6OTHER (as a representative of the BC6ENTC family) inhibited diabetes - induced increase in BC6ENTG DNA - binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina. CPR:falsenewlineAll three BC6ENTC inhibited the diabetes - induced translocation of BC6ENTG (a subunit of BC6OTHER ) into nuclei of CHEM vascular endothelial cells of the isolated CHEM vasculature, as well as of BC6OTHER and BC6OTHER into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole - CHEM sections. CPR:falsenewlineAll three BC6ENTC inhibited the diabetes - induced translocation of BC6OTHER (a subunit of BC6ENTG ) into nuclei of CHEM vascular endothelial cells of the isolated CHEM vasculature, as well as of BC6OTHER and BC6OTHER into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole - CHEM sections. CPR:falsenewlineAll three BC6ENTC inhibited the diabetes - induced translocation of BC6OTHER (a subunit of BC6OTHER ) into nuclei of CHEM vascular endothelial cells of the isolated CHEM vasculature, as well as of BC6ENTG and BC6OTHER into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole - CHEM sections. CPR:falsenewlineAll three BC6ENTC inhibited the diabetes - induced translocation of BC6OTHER (a subunit of BC6OTHER ) into nuclei of CHEM vascular endothelial cells of the isolated CHEM vasculature, as well as of BC6OTHER and BC6ENTG into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole - CHEM sections. CPR:falsenewlineBC6ENTC (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6ENTG , including vascular cell adhesion molecule, BC6OTHER , inducible BC6OTHER synthase, and BC6OTHER in whole - CHEM lysate. CPR:falsenewlineBC6ENTC (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6ENTG , inducible BC6OTHER synthase, and BC6OTHER in whole - CHEM lysate. CPR:falsenewlineBC6ENTC (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6OTHER , BC6ENTG , and BC6OTHER in whole - CHEM lysate. CPR:falsenewlineBC6ENTC (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6OTHER , inducible BC6OTHER synthase, and BC6ENTG in whole - CHEM lysate. CPR:falsenewlineBC6OTHER (also as a representative of the BC6ENTC ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6ENTG , including vascular cell adhesion molecule, BC6OTHER , inducible BC6OTHER synthase, and BC6OTHER in whole - CHEM lysate. CPR:falsenewlineBC6OTHER (also as a representative of the BC6ENTC ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6ENTG , inducible BC6OTHER synthase, and BC6OTHER in whole - CHEM lysate. CPR:falsenewlineBC6OTHER (also as a representative of the BC6ENTC ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6OTHER , BC6ENTG , and BC6OTHER in whole - CHEM lysate. CPR:falsenewlineBC6OTHER (also as a representative of the BC6ENTC ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6OTHER , inducible BC6OTHER synthase, and BC6ENTG in whole - CHEM lysate. CPR:falsenewlineBC6OTHER (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6ENTG , including vascular cell adhesion molecule, BC6OTHER , inducible BC6ENTC synthase, and BC6OTHER in whole - CHEM lysate. CPR:falsenewlineBC6OTHER (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6ENTG , inducible BC6ENTC synthase, and BC6OTHER in whole - CHEM lysate. CPR:falsenewlineBC6OTHER (also as a representative of the BC6OTHER ) inhibited the diabetes - induced upregulation of several inflammatory gene products, which are regulated by BC6OTHER , including vascular cell adhesion molecule, BC6OTHER , inducible BC6ENTC synthase, and BC6ENTG in whole - CHEM lysate. CPR:falsenewlineBC6ENTC , in doses administrated in our experiments, inhibited BC6ENTG B and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy. CPR:4newlineAdditionally, more specific mechanisms exist where xenobiotics act as ligands, including the BC6ENTC receptor, BC6ENTG and the BC6OTHER family of transcription factors. CPR:falsenewlineAdditionally, more specific mechanisms exist where xenobiotics act as ligands, including the BC6ENTC receptor, BC6OTHER and the BC6ENTG family of transcription factors. CPR:falsenewlineWe expressed cardiac or BC6ENTG subunits in combination with beta2a and alpha2 / delta subunits in human embryonic kidney cells, and used 2 mM BC6ENTC as the permeant ion. CPR:falsenewlineIsoform - specific inhibition of BC6ENTG by BC6ENTC is independent of isoform - specific gating properties. CPR:4newlineBC6ENTC ( BC6OTHER ) block BC6ENTG more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state. CPR:4newlineWe thus conclude that the more potent BC6ENTC inhibition of smooth muscle versus BC6ENTG is not attributable to differences in channel inactivation or activation. CPR:falsenewlineBC6ENTC (a BC6OTHER antagonist) blocks the BC6ENTG more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels. CPR:falsenewlineIntrinsic, gating - independent BC6ENTG binding affinity differences must be invoked to explain the isoform - specific sensitivity of the BC6ENTC block. CPR:falsenewlineBC6OTHER (a BC6ENTC antagonist) blocks the BC6ENTG more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels. CPR:falsenewlineBC6OTHER ( BC6ENTC ) block BC6ENTG more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state. CPR:4newlineDesign, Synthesis and Biological Evaluation of BC6OTHER Derivatives as BC6ENTG Ligands with Potential for Treatment of BC6ENTC Abuse. CPR:falsenewlineDesign, Synthesis and Biological Evaluation of BC6ENTC Derivatives as BC6ENTG Ligands with Potential for Treatment of BC6OTHER Abuse. CPR:falsenewlineCollectively, these initial findings suggest that design and systematic modification of BC6OTHER such as 3 may lead to development of novel CHEM ligands with dual BC6OTHER antagonist / BC6ENTG agonist activity with potential for use as treatments of BC6ENTC abuse. CPR:falsenewlineCollectively, these initial findings suggest that design and systematic modification of BC6OTHER such as 3 may lead to development of novel CHEM ligands with dual BC6ENTG antagonist / BC6OTHER agonist activity with potential for use as treatments of BC6ENTC abuse. CPR:falsenewlineAttenuation of increased endocannabinoid signaling with a BC6ENTG neutral antagonist might offer a new therapeutic direction for treatment of BC6ENTC abuse. CPR:falsenewlineWe have recently reported that a CHEM - hydroxylated metabolite of the synthetic BC6ENTC CHEM BC6OTHER (3) exhibits neutral antagonist activity at BC6ENTG and thus may serve as a promising lead for the development of novel BC6OTHER abuse therapies. CPR:falsenewlineWe have recently reported that a CHEM - hydroxylated metabolite of the synthetic BC6OTHER CHEM BC6ENTC (3) exhibits neutral antagonist activity at BC6ENTG and thus may serve as a promising lead for the development of novel BC6OTHER abuse therapies. CPR:6newlineWe have recently reported that a CHEM - hydroxylated metabolite of the synthetic BC6OTHER CHEM BC6OTHER (3) exhibits neutral antagonist activity at BC6ENTG and thus may serve as a promising lead for the development of novel BC6ENTC abuse therapies. CPR:falsenewlineIn the current study, we show that systematic modification of an BC6ENTC scaffold identifies two new compounds with dual BC6ENTG antagonist / BC6OTHER agonist activity. CPR:falsenewlineIn the current study, we show that systematic modification of an BC6ENTC scaffold identifies two new compounds with dual BC6OTHER antagonist / BC6ENTG agonist activity. CPR:falsenewlineSimilar to the BC6ENTG antagonist / inverse agonist CHEM, analogues 27 and 30 decrease oral BC6ENTC self - administration, without affecting total fluid intake and block the development of BC6OTHER - conditioned place preference. CPR:falsenewlineSimilar to the BC6ENTG antagonist / inverse agonist CHEM, analogues 27 and 30 decrease oral BC6OTHER self - administration, without affecting total fluid intake and block the development of BC6ENTC - conditioned place preference. CPR:falsenewlineCollectively, these initial findings suggest that design and systematic modification of BC6ENTC such as 3 may lead to development of novel CHEM ligands with dual BC6OTHER antagonist / BC6ENTG agonist activity with potential for use as treatments of BC6OTHER abuse. CPR:falsenewlineCollectively, these initial findings suggest that design and systematic modification of BC6ENTC such as 3 may lead to development of novel CHEM ligands with dual BC6ENTG antagonist / BC6OTHER agonist activity with potential for use as treatments of BC6OTHER abuse. CPR:falsenewlineIn rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6ENTC , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6ENTC and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6ENTC and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6ENTC plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6ENTC plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6ENTC , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTC , BC6ENTG and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTC , BC6OTHER and BC6ENTG metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6ENTC and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6ENTC and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTC and BC6ENTG metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6ENTC metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6ENTC metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6ENTC metabolites not found in human plasma. CPR:falsenewlineBC6ENTC and BC6OTHER reduced the production of BC6ENTG and BC6OTHER with more effect being observed with BC6OTHER . CPR:falsenewlineBC6ENTC and BC6OTHER reduced the production of BC6OTHER and BC6ENTG with more effect being observed with BC6OTHER . CPR:falsenewlineBC6OTHER and BC6ENTC reduced the production of BC6ENTG and BC6OTHER with more effect being observed with BC6OTHER . CPR:falsenewlineBC6OTHER and BC6ENTC reduced the production of BC6OTHER and BC6ENTG with more effect being observed with BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER reduced the production of BC6ENTC and BC6ENTG with more effect being observed with BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER reduced the production of BC6ENTG and BC6ENTC with more effect being observed with BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER reduced the production of BC6ENTG and BC6OTHER with more effect being observed with BC6ENTC . CPR:falsenewlineBC6OTHER and BC6OTHER reduced the production of BC6OTHER and BC6ENTG with more effect being observed with BC6ENTC . CPR:4newlineBC6ENTC and BC6OTHER increased the production of both BC6ENTG and BC6OTHER but not that of BC6OTHER and BC6OTHER . CPR:falsenewlineBC6ENTC and BC6OTHER increased the production of both BC6OTHER and BC6ENTG but not that of BC6OTHER and BC6OTHER . CPR:falsenewlineBC6ENTC and BC6OTHER increased the production of both BC6OTHER and BC6OTHER but not that of BC6ENTG and BC6OTHER . CPR:falsenewlineBC6ENTC and BC6OTHER increased the production of both BC6OTHER and BC6OTHER but not that of BC6OTHER and BC6ENTG . CPR:falsenewlineBC6OTHER and BC6ENTC increased the production of both BC6ENTG and BC6OTHER but not that of BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6ENTC increased the production of both BC6OTHER and BC6ENTG but not that of BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6ENTC increased the production of both BC6OTHER and BC6OTHER but not that of BC6ENTG and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6ENTC increased the production of both BC6OTHER and BC6OTHER but not that of BC6OTHER and BC6ENTG . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6ENTC and BC6ENTG but not that of BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6ENTC and BC6OTHER but not that of BC6ENTG and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6ENTC and BC6OTHER but not that of BC6OTHER and BC6ENTG . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6ENTG and BC6ENTC but not that of BC6OTHER and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6ENTC but not that of BC6ENTG and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6ENTC but not that of BC6OTHER and BC6ENTG . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6ENTG and BC6OTHER but not that of BC6ENTC and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6ENTG but not that of BC6ENTC and BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6OTHER but not that of BC6ENTC and BC6ENTG . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6ENTG and BC6OTHER but not that of BC6OTHER and BC6ENTC . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6ENTG but not that of BC6OTHER and BC6ENTC . CPR:falsenewlineBC6OTHER and BC6OTHER increased the production of both BC6OTHER and BC6OTHER but not that of BC6ENTG and BC6ENTC . CPR:falsenewlineThis study shows that the potency of BC6ENTC in comparison with BC6OTHER is more than 100 - fold lower in human, but less than 10 - fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of BC6ENTG / BC6OTHER inhibition in relation to effects in humans. CPR:falsenewlineThis study shows that the potency of BC6ENTC in comparison with BC6OTHER is more than 100 - fold lower in human, but less than 10 - fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of BC6OTHER / BC6ENTG inhibition in relation to effects in humans. CPR:falsenewlineThis study shows that the potency of BC6OTHER in comparison with BC6ENTC is more than 100 - fold lower in human, but less than 10 - fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of BC6ENTG / BC6OTHER inhibition in relation to effects in humans. CPR:falsenewlineThis study shows that the potency of BC6OTHER in comparison with BC6ENTC is more than 100 - fold lower in human, but less than 10 - fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of BC6OTHER / BC6ENTG inhibition in relation to effects in humans. CPR:falsenewlineIn addition the production of BC6ENTG was enhanced in the presence of these inhibitors with a greater accumulation being observed with BC6ENTC . CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTC ( BC6ENTG ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTC (79 / 81 BC6OTHER ) BC6ENTG in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTC (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6ENTG / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTC (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6OTHER / BC6ENTG inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTG (79 / 81 BC6ENTC ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6ENTC ) BC6ENTG in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6ENTC ) BC6OTHER in the presence of two new dual BC6ENTG / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6ENTC ) BC6OTHER in the presence of two new dual BC6OTHER / BC6ENTG inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTG (79 / 81 BC6OTHER ) BC6ENTC in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER ( BC6ENTG ) BC6ENTC in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6ENTC in the presence of two new dual BC6ENTG / BC6OTHER inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6ENTC in the presence of two new dual BC6OTHER / BC6ENTG inhibitors ( BC6OTHER and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTG (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6ENTC and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER ( BC6ENTG ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6ENTC and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6ENTG in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6ENTC and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6ENTG / BC6OTHER inhibitors ( BC6ENTC and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6OTHER / BC6ENTG inhibitors ( BC6ENTC and BC6OTHER ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6ENTG (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6ENTC ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER ( BC6ENTG ) BC6OTHER in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6ENTC ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6ENTG in the presence of two new dual BC6OTHER / BC6OTHER inhibitors ( BC6OTHER and BC6ENTC ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6ENTG / BC6OTHER inhibitors ( BC6OTHER and BC6ENTC ) currently under clinical trial. CPR:falsenewlineIn this work a novel approach combining HPLC - UV on - line with oaTOF - MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BC6OTHER (79 / 81 BC6OTHER ) BC6OTHER in the presence of two new dual BC6OTHER / BC6ENTG inhibitors ( BC6OTHER and BC6ENTC ) currently under clinical trial. CPR:falsenewlineIn human plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineIn human plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineSeveral studies have suggested that the accumulation of BC6ENTC , or that of one its metabolites BK1 - 8, is involved in the occurrence of side effects such as AE associated with the use of various BC6ENTG i. CPR:falsenewlineIn human plasma the BC6ENTG half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineIn human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6ENTC (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineIn human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTC was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineIn human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTC , BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineIn human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6ENTC , BC6OTHER and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6ENTG and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTC , BC6OTHER and BC6ENTG . CPR:falsenewlineIn human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6ENTC and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6ENTC and BC6OTHER . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTC and BC6ENTG . CPR:falsenewlineIn human plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6ENTC . CPR:falsenewlineIn human plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (3.8 microM) or BC6OTHER (32 nM) were 38.7 + / - 2.4, 51.2 + / - 4.7 and 114.7 + / - 9.3 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6ENTC . CPR:falsenewlineUnlike BC6ENTC , BC6OTHER abolished the production of BC6ENTG and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6ENTC , BC6OTHER abolished the production of BC6OTHER and BC6ENTG , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6ENTC , BC6OTHER abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6ENTG inhibition effect over BC6OTHER as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6ENTC , BC6OTHER abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6ENTG activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6ENTC abolished the production of BC6ENTG and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6ENTC abolished the production of BC6OTHER and BC6ENTG , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6ENTC abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6ENTG inhibition effect over BC6OTHER as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6ENTC abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6ENTG activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER abolished the production of BC6ENTC and BC6ENTG , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER abolished the production of BC6ENTC and BC6OTHER , suggesting a better BC6ENTG inhibition effect over BC6OTHER as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER abolished the production of BC6ENTC and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6ENTG activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER abolished the production of BC6ENTG and BC6ENTC , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER abolished the production of BC6OTHER and BC6ENTC , suggesting a better BC6ENTG inhibition effect over BC6OTHER as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER abolished the production of BC6OTHER and BC6ENTC , suggesting a better BC6OTHER inhibition effect over BC6OTHER as no BC6ENTG activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER abolished the production of BC6ENTG and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6ENTC as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER abolished the production of BC6OTHER and BC6ENTG , suggesting a better BC6OTHER inhibition effect over BC6ENTC as no BC6OTHER activity was found. CPR:falsenewlineUnlike BC6OTHER , BC6OTHER abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6ENTG inhibition effect over BC6ENTC as no BC6OTHER activity was found. CPR:4newlineUnlike BC6OTHER , BC6OTHER abolished the production of BC6OTHER and BC6OTHER , suggesting a better BC6OTHER inhibition effect over BC6ENTC as no BC6ENTG activity was found. CPR:falsenewlineInvestigation of BC6ENTG metabolism in human and rat plasma in the presence of the dual BC6OTHER / BC6OTHER inhibitors BC6ENTC and BC6OTHER . CPR:falsenewlineInvestigation of BC6OTHER metabolism in human and rat plasma in the presence of the dual BC6ENTG / BC6OTHER inhibitors BC6ENTC and BC6OTHER . CPR:falsenewlineInvestigation of BC6OTHER metabolism in human and rat plasma in the presence of the dual BC6OTHER / BC6ENTG inhibitors BC6ENTC and BC6OTHER . CPR:falsenewlineThe production of BC6ENTG was reduced with BC6ENTC while no significant change was observed with BC6OTHER after 4 h of incubation. CPR:falsenewlineInvestigation of BC6ENTG metabolism in human and rat plasma in the presence of the dual BC6OTHER / BC6OTHER inhibitors BC6OTHER and BC6ENTC . CPR:falsenewlineInvestigation of BC6OTHER metabolism in human and rat plasma in the presence of the dual BC6ENTG / BC6OTHER inhibitors BC6OTHER and BC6ENTC . CPR:falsenewlineInvestigation of BC6OTHER metabolism in human and rat plasma in the presence of the dual BC6OTHER / BC6ENTG inhibitors BC6OTHER and BC6ENTC . CPR:falsenewlineInvestigation of BC6ENTC metabolism in human and rat plasma in the presence of the dual BC6ENTG / BC6OTHER inhibitors BC6OTHER and BC6OTHER . CPR:falsenewlineInvestigation of BC6ENTC metabolism in human and rat plasma in the presence of the dual BC6OTHER / BC6ENTG inhibitors BC6OTHER and BC6OTHER . CPR:falsenewlineThe production of BC6ENTG was reduced with BC6OTHER while no significant change was observed with BC6ENTC after 4 h of incubation. CPR:falsenewlineIn rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTC half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6ENTC (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTG was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6ENTC (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6OTHER was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6ENTG half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG plus BC6OTHER , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6ENTG , BC6OTHER and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6ENTG and BC6OTHER metabolites not found in human plasma. CPR:falsenewlineIn rat plasma the BC6OTHER half - life values in the absence or in the presence of BC6OTHER (530 nM) or BC6OTHER (50 nM) were 9.31 + / - 1.7, 22.06 + / - 3.1 and 25.3 + / - 1.7 min, respectively and BC6ENTC was degraded into BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER plus BC6OTHER , BC6OTHER and BC6ENTG metabolites not found in human plasma. CPR:falsenewlineClonal T cells defined as a predominance of a single BC6ENTG gene usage, in one case verified by BC6OTHER CDR3 fragment analysis and BC6ENTC sequencing, emerged within the CD52 - / CD8+ cell population during CHEM therapy in 2 CLL patients, both achieving a long - lasting remission. CPR:falsenewlineClonal T cells defined as a predominance of a single BC6OTHER gene usage, in one case verified by BC6ENTG CDR3 fragment analysis and BC6ENTC sequencing, emerged within the CD52 - / CD8+ cell population during CHEM therapy in 2 CLL patients, both achieving a long - lasting remission. CPR:falsenewlineIn addition, our exploration further revealed that the suppressive action of BC6ENTC on inflammation was mediated via inhibiting BC6OTHER ( BC6ENTG ) activation. CPR:4newlineIn addition, our exploration further revealed that the suppressive action of BC6ENTC on inflammation was mediated via inhibiting BC6ENTG ( BC6OTHER ) activation. CPR:4newline BC6ENTC inhibits LPS plus BC6ENTG - induced inflammatory response in astrocytes primary cultures. CPR:falsenewlineCollectively, these results suggest that BC6ENTC can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of BC6ENTG could be the major determinant for its anti - inflammatory mechanism. CPR:falsenewlineTo further investigate the protective effect and underlying mechanism of BC6ENTC , astrocytes were pretreated with low (0.1mM) and high dose (0.5mM) BC6OTHER for 1h prior to LPS plus BC6ENTG stimulation. CPR:falsenewlineTo further investigate the protective effect and underlying mechanism of BC6OTHER , astrocytes were pretreated with low (0.1mM) and high dose (0.5mM) BC6ENTC for 1h prior to LPS plus BC6ENTG stimulation. CPR:falsenewlineBiochemical analyses showed that BC6ENTC and ROS production and BC6ENTG activity were significantly reduced by BC6OTHER . CPR:falsenewlineBiochemical analyses showed that BC6OTHER and ROS production and BC6ENTG activity were significantly reduced by BC6ENTC . CPR:4newlineData at transcriptional level also demonstrated that BC6ENTC potently attenuated gene expressions involved in inflammation, such as BC6ENTG , BC6OTHER and BC6OTHER . CPR:4newlineData at transcriptional level also demonstrated that BC6ENTC potently attenuated gene expressions involved in inflammation, such as BC6OTHER , BC6ENTG and BC6OTHER . CPR:4newlineData at transcriptional level also demonstrated that BC6ENTC potently attenuated gene expressions involved in inflammation, such as BC6OTHER , BC6OTHER and BC6ENTG . CPR:4newlineConsistent with the results of a computer analysis, the binding of BC6ENTG to BC6OTHER ( BC6ENTC ) was significantly decreased to 38% that of the wild type. CPR:falsenewlineHowever, a BC6ENTC - BC6OTHER - transferase pull - down assay showed reduced binding of BC6ENTG with BC6OTHER in the absence of BC6OTHER and impaired release in the presence of BC6OTHER . CPR:falsenewlineHowever, a BC6ENTC - BC6OTHER - transferase pull - down assay showed reduced binding of BC6OTHER with BC6ENTG in the absence of BC6OTHER and impaired release in the presence of BC6OTHER . CPR:falsenewlineHowever, a BC6OTHER - BC6ENTC - transferase pull - down assay showed reduced binding of BC6ENTG with BC6OTHER in the absence of BC6OTHER and impaired release in the presence of BC6OTHER . CPR:falsenewlineHowever, a BC6OTHER - BC6ENTC - transferase pull - down assay showed reduced binding of BC6OTHER with BC6ENTG in the absence of BC6OTHER and impaired release in the presence of BC6OTHER . CPR:falsenewlineHowever, a BC6OTHER - BC6OTHER - transferase pull - down assay showed reduced binding of BC6ENTG with BC6OTHER in the absence of BC6ENTC and impaired release in the presence of BC6OTHER . CPR:falsenewlineHowever, a BC6OTHER - BC6OTHER - transferase pull - down assay showed reduced binding of BC6OTHER with BC6ENTG in the absence of BC6ENTC and impaired release in the presence of BC6OTHER . CPR:falsenewlineHowever, a BC6OTHER - BC6OTHER - transferase pull - down assay showed reduced binding of BC6ENTG with BC6OTHER in the absence of BC6OTHER and impaired release in the presence of BC6ENTC . CPR:falsenewlineHowever, a BC6OTHER - BC6OTHER - transferase pull - down assay showed reduced binding of BC6OTHER with BC6ENTG in the absence of BC6OTHER and impaired release in the presence of BC6ENTC . CPR:falsenewlineOur findings suggest that BC6ENTG causes reduced association with and impaired release of BC6OTHER , resulting in RTH predominantly at the pituitary level, and that slightly elevated serum BC6OTHER level with high dose of BC6ENTC might be optimum for normal growth. CPR:falsenewlineOur findings suggest that BC6OTHER causes reduced association with and impaired release of BC6ENTG , resulting in RTH predominantly at the pituitary level, and that slightly elevated serum BC6OTHER level with high dose of BC6ENTC might be optimum for normal growth. CPR:falsenewlineOur findings suggest that BC6OTHER causes reduced association with and impaired release of BC6OTHER , resulting in RTH predominantly at the pituitary level, and that slightly elevated serum BC6ENTG level with high dose of BC6ENTC might be optimum for normal growth. CPR:falsenewlineAs the RTH mutant, BC6ENTG , was new, the optimum dose of BC6ENTC was unclear. CPR:falsenewlineSUMMARY: The patient was a newborn female having severe hypothyroidism with a free BC6ENTC level of 0.36 ng / dL and a serum BC6ENTG level of 177 microU / mL. CPR:falsenewlineSupplementation with BC6ENTC at a dose of >350 microg / day did not normalize the serum BC6ENTG level; however, the patient showed normal growth and intelligence at 14 years of age. CPR:falsenewlineConsistent with the results of a computer analysis, the binding of BC6ENTG to BC6ENTC ( BC6OTHER ) was significantly decreased to 38% that of the wild type. CPR:falsenewlineBC6ENTC dehydrogenase 5 ( BC6ENTG ) is a member of the mammalian BC6OTHER dehydrogenase family of yet undefined functions. CPR:falsenewlineBC6ENTC dehydrogenase 5 ( BC6OTHER ) is a member of the BC6ENTG family of yet undefined functions. CPR:falsenewlineA rat BC6ENTC dehydrogenase structure of similar type has been isolated at the cDNA level using BC6ENTG as a screening probe, where the rat cDNA structure displayed several atypical properties. CPR:falsenewlineBC6OTHER ( BC6ENTG ) is a member of the mammalian BC6ENTC dehydrogenase family of yet undefined functions. CPR:falsenewlineBC6ENTG ( BC6OTHER ) is a member of the mammalian BC6ENTC dehydrogenase family of yet undefined functions. CPR:falsenewlineHowever, no soluble BC6ENTG protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other BC6OTHER , including fused to BC6ENTC - BC6OTHER - transferase. CPR:falsenewlineHowever, no soluble BC6OTHER protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other BC6ENTG , including fused to BC6ENTC - BC6OTHER - transferase. CPR:falsenewlineHowever, no soluble BC6ENTG protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other BC6OTHER , including fused to BC6OTHER - BC6ENTC - transferase. CPR:falsenewlineHowever, no soluble BC6OTHER protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other BC6ENTG , including fused to BC6OTHER - BC6ENTC - transferase. CPR:falsenewlineAnalysis of mammalian BC6ENTC dehydrogenase 5 ( BC6ENTG ): characterisation of BC6OTHER with comparisons to the corresponding human variant. CPR:falsenewlineAnalysis of mammalian BC6ENTC dehydrogenase 5 ( BC6OTHER ): characterisation of BC6ENTG with comparisons to the corresponding human variant. CPR:falsenewlineA streamlined and high - yielding synthesis of BC6ENTC (1), a potent BC6ENTG antagonist, is described. CPR:6newlinePractical asymmetric synthesis of BC6ENTC , a potent human BC6ENTG antagonist, via a stereoselective CHEM - catalyzed trans acetalization reaction. CPR:6newlineFurthermore, BC6ENTG inhibition in astrocytes is associated with the rapid onset of intracellular BC6ENTC oscillations. CPR:falsenewlineSurprisingly, this rapid BC6ENTC influx is blocked by the BC6ENTG antagonist, BC6OTHER . CPR:falsenewlineSurprisingly, this rapid BC6ENTC influx is blocked by the CHEM - type BC6OTHER channel antagonist, BC6ENTG . CPR:falsenewlineSurprisingly, this rapid BC6OTHER influx is blocked by the BC6ENTC - type BC6OTHER channel antagonist, BC6ENTG . CPR:falsenewlineSurprisingly, this rapid BC6OTHER influx is blocked by the CHEM - type BC6ENTC channel antagonist, BC6ENTG . CPR:falsenewlineWhile the function of BC6ENTC - type BC6OTHER channels within astrocytes is controversial, these BC6ENTG have been linked to BC6OTHER - dependent vesicular gliotransmitter release. CPR:falsenewlineWhile the function of CHEM - type BC6ENTC channels within astrocytes is controversial, these BC6ENTG have been linked to BC6OTHER - dependent vesicular gliotransmitter release. CPR:falsenewlineWhile the function of BC6ENTG within astrocytes is controversial, these voltage - gated BC6ENTC channels have been linked to BC6OTHER - dependent vesicular gliotransmitter release. CPR:falsenewlineWhile the function of BC6ENTG within astrocytes is controversial, these voltage - gated BC6OTHER channels have been linked to BC6ENTC - dependent vesicular gliotransmitter release. CPR:falsenewlineWhile the function of CHEM - type BC6OTHER channels within astrocytes is controversial, these BC6ENTG have been linked to BC6ENTC - dependent vesicular gliotransmitter release. CPR:falsenewlineWhen extracellular BC6ENTC and BC6OTHER levels are measured following BC6ENTG inhibition within our enriched astrocyte cultures, no alterations in BC6OTHER levels are observed, whereas BC6OTHER levels in the extracellular environment significantly increase. CPR:falsenewlineWhen extracellular BC6OTHER and BC6ENTC levels are measured following BC6ENTG inhibition within our enriched astrocyte cultures, no alterations in BC6OTHER levels are observed, whereas BC6OTHER levels in the extracellular environment significantly increase. CPR:falsenewlineWhen extracellular BC6OTHER and BC6OTHER levels are measured following BC6ENTG inhibition within our enriched astrocyte cultures, no alterations in BC6ENTC levels are observed, whereas BC6OTHER levels in the extracellular environment significantly increase. CPR:falsenewlineLoss of BC6ENTG Activity in Cortical Astrocytes Decreases BC6OTHER Uptake and Induces Neurotoxic Release of BC6ENTC . CPR:falsenewlineLoss of BC6ENTG Activity in Cortical Astrocytes Decreases BC6ENTC Uptake and Induces Neurotoxic Release of BC6OTHER . CPR:falsenewlineWhen extracellular BC6OTHER and BC6OTHER levels are measured following BC6ENTG inhibition within our enriched astrocyte cultures, no alterations in BC6OTHER levels are observed, whereas BC6ENTC levels in the extracellular environment significantly increase. CPR:falsenewlineExtracellular BC6ENTC accumulation associated with BC6ENTG inhibition contributes both to BC6OTHER oscillations within astrocytes and ultimately cortical neuron toxicity. CPR:falsenewlineExtracellular BC6OTHER accumulation associated with BC6ENTG inhibition contributes both to BC6ENTC oscillations within astrocytes and ultimately cortical neuron toxicity. CPR:falsenewlineThus, a loss of BC6ENTG signaling within astrocytes dysregulates BC6ENTC uptake and supports BC6OTHER release, two processes that would compromise neuronal survival following ischemic / excitotoxic insults. CPR:falsenewlineThus, a loss of BC6ENTG signaling within astrocytes dysregulates BC6OTHER uptake and supports BC6ENTC release, two processes that would compromise neuronal survival following ischemic / excitotoxic insults. CPR:falsenewlineThe extent of BC6ENTC / calmodulin - dependent protein kinase II ( BC6ENTG ) inactivation in the brain following ischemia correlates with the extent of damage. CPR:falsenewlineWe have previously shown that a loss of BC6ENTG activity in neurons is detrimental to neuronal viability by inducing excitotoxic BC6ENTC release. CPR:falsenewlineIn the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular BC6ENTC is reduced when BC6ENTG is inhibited. CPR:falsenewlineIn conclusion, the BC6ENTG antagonist properties of BC6ENTC increase BC6OTHER and BC6OTHER levels both alone and in association with CHEM. CPR:falsenewlineIn conclusion, the BC6ENTG antagonist properties of BC6OTHER increase BC6ENTC and BC6OTHER levels both alone and in association with CHEM. CPR:falsenewlineIn conclusion, the BC6ENTG antagonist properties of BC6OTHER increase BC6OTHER and BC6ENTC levels both alone and in association with CHEM. CPR:falsenewlineHowever, in contrast to the selective BC6ENTG antagonist, BC6ENTC , the BC6OTHER agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels. CPR:falsenewlineHowever, in contrast to the selective BC6OTHER antagonist, BC6ENTC , the BC6ENTG agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels. CPR:falsenewlineHowever, in contrast to the selective BC6ENTG antagonist, BC6OTHER , the BC6ENTC (1A) agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels. CPR:falsenewlineHowever, in contrast to the selective BC6ENTG antagonist, BC6OTHER , the BC6OTHER agonist actions of BC6ENTC suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels. CPR:falsenewlineHowever, in contrast to the selective BC6OTHER antagonist, BC6OTHER , the BC6ENTG agonist actions of BC6ENTC suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels. CPR:falsenewlineHowever, in contrast to the selective BC6ENTG antagonist, BC6OTHER , the BC6OTHER agonist actions of BC6OTHER suppress BC6ENTC levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels. CPR:falsenewlineHowever, in contrast to the selective BC6OTHER antagonist, BC6OTHER , the BC6ENTG agonist actions of BC6OTHER suppress BC6ENTC levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6OTHER levels. CPR:falsenewlineHowever, in contrast to the selective BC6ENTG antagonist, BC6OTHER , the BC6OTHER agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6ENTC upon BC6OTHER levels. CPR:falsenewlineHowever, in contrast to the selective BC6OTHER antagonist, BC6OTHER , the BC6ENTG agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6ENTC upon BC6OTHER levels. CPR:falsenewlineHowever, in contrast to the selective BC6ENTG antagonist, BC6OTHER , the BC6OTHER agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6ENTC levels. CPR:falsenewlineHowever, in contrast to the selective BC6OTHER antagonist, BC6OTHER , the BC6ENTG agonist actions of BC6OTHER suppress BC6OTHER levels alone and underlie its inability to augment the influence of BC6OTHER upon BC6ENTC levels. CPR:falsenewlineBC6ENTC displays marked affinity at BC6ENTG , significant affinity for BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER and weak affinity for BC6OTHER . CPR:falsenewlineBC6ENTC displays marked affinity at BC6OTHER , significant affinity for BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER and weak affinity for BC6OTHER . CPR:falsenewlineBC6ENTC displays marked affinity at BC6OTHER , significant affinity for BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER and weak affinity for BC6OTHER . CPR:falsenewlineBC6ENTC displays marked affinity at BC6OTHER , significant affinity for BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER and weak affinity for BC6OTHER . CPR:falsenewlineBC6ENTC displays marked affinity at BC6OTHER , significant affinity for BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG and weak affinity for BC6OTHER . CPR:falsenewlineBC6ENTC displays marked affinity at BC6OTHER , significant affinity for BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER and weak affinity for BC6ENTG . CPR:falsenewlineIn [ BC6ENTC ]GTPgammaS binding protocols, BC6OTHER exerts antagonist actions at BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites. CPR:falsenewlineIn [ BC6ENTC ]GTPgammaS binding protocols, BC6OTHER exerts antagonist actions at BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites. CPR:falsenewlineIn [ BC6ENTC ]GTPgammaS binding protocols, BC6OTHER exerts antagonist actions at BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites. CPR:falsenewlineIn [ BC6ENTC ]GTPgammaS binding protocols, BC6OTHER exerts antagonist actions at BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG sites, yet partial agonist actions at BC6OTHER sites. CPR:falsenewlineIn [ BC6ENTC ]GTPgammaS binding protocols, BC6OTHER exerts antagonist actions at BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6ENTG sites. CPR:falsenewlineIn [ BC6OTHER ]GTPgammaS binding protocols, BC6ENTC exerts antagonist actions at BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites. CPR:6newlineIn [ BC6OTHER ]GTPgammaS binding protocols, BC6ENTC exerts antagonist actions at BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites. CPR:falsenewlineIn [ BC6OTHER ]GTPgammaS binding protocols, BC6ENTC exerts antagonist actions at BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER sites, yet partial agonist actions at BC6OTHER sites. CPR:falsenewlineIn [ BC6OTHER ]GTPgammaS binding protocols, BC6ENTC exerts antagonist actions at BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG sites, yet partial agonist actions at BC6OTHER sites. CPR:falsenewlineIn [ BC6OTHER ]GTPgammaS binding protocols, BC6ENTC exerts antagonist actions at BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER sites, yet partial agonist actions at BC6ENTG sites. CPR:falsenewlineHerein, we evaluate the interaction of the BC6OTHER , BC6ENTC , as compared to BC6OTHER , at multiple BC6ENTG and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely - moving rats. CPR:falsenewlineHerein, we evaluate the interaction of the BC6ENTG , BC6ENTC , as compared to BC6OTHER , at multiple BC6OTHER and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely - moving rats. CPR:falsenewlineIn vivo, agonist actions of BC6ENTC at BC6ENTG sites are revealed by BC6OTHER - reversible induction of hypothermia in the rat. CPR:falsenewlineIn vivo, agonist actions of BC6OTHER at BC6ENTG sites are revealed by BC6ENTC - reversible induction of hypothermia in the rat. CPR:falsenewlineIn guinea pigs, antagonist actions of BC6ENTC at BC6ENTG receptors are revealed by blockade of hypothermia evoked by the BC6OTHER agonist, BC6OTHER . CPR:falsenewlineIn guinea pigs, antagonist actions of BC6ENTC at BC6OTHER receptors are revealed by blockade of hypothermia evoked by the BC6ENTG agonist, BC6OTHER . CPR:falsenewlineIn guinea pigs, antagonist actions of BC6OTHER at BC6ENTC (1B) receptors are revealed by blockade of hypothermia evoked by the BC6ENTG agonist, BC6OTHER . CPR:falsenewlineIn guinea pigs, antagonist actions of BC6OTHER at BC6ENTG receptors are revealed by blockade of hypothermia evoked by the BC6ENTC (1B) agonist, BC6OTHER . CPR:falsenewlineIn guinea pigs, antagonist actions of BC6OTHER at BC6ENTG receptors are revealed by blockade of hypothermia evoked by the BC6OTHER agonist, BC6ENTC . CPR:falsenewlineIn guinea pigs, antagonist actions of BC6OTHER at BC6OTHER receptors are revealed by blockade of hypothermia evoked by the BC6ENTG agonist, BC6ENTC . CPR:falsenewlineHerein, we evaluate the interaction of the BC6OTHER , BC6OTHER , as compared to BC6ENTC , at multiple BC6ENTG and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely - moving rats. CPR:falsenewlineHerein, we evaluate the interaction of the BC6ENTG , BC6OTHER , as compared to BC6ENTC , at multiple BC6OTHER and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely - moving rats. CPR:falsenewlineIn distinction to BC6ENTC , BC6OTHER shows only modest partial agonist actions at BC6ENTG sites versus marked antagonist actions at BC6OTHER . CPR:falsenewlineIn distinction to BC6ENTC , BC6OTHER shows only modest partial agonist actions at BC6OTHER sites versus marked antagonist actions at BC6ENTG . CPR:falsenewlineIn distinction to BC6OTHER , BC6ENTC shows only modest partial agonist actions at BC6ENTG sites versus marked antagonist actions at BC6OTHER . CPR:falsenewlineIn distinction to BC6OTHER , BC6ENTC shows only modest partial agonist actions at BC6OTHER sites versus marked antagonist actions at BC6ENTG . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6ENTC ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6ENTC BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER )(1A), BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER )(1A), BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6ENTC ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6OTHER (CHEM), BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER (CHEM), BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER (CHEM), BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER (CHEM), BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6OTHER (CHEM), BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER )(1A), BC6ENTC (1B), BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER BC6ENTG , BC6ENTC (1B), BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTC (1B), BC6ENTG and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTC (1B), BC6OTHER and BC6ENTG . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTC (1B), BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTC (1D) and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER BC6ENTG , BC6OTHER , BC6ENTC (1D) and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTG , BC6ENTC (1D) and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTC (1D) and BC6ENTG . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTC (1D) and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6ENTC D(2) and D(3) receptors. CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC D(2) and D(3) receptors. CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTG , BC6OTHER and BC6ENTC D(2) and D(3) receptors. CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTG and BC6ENTC D(2) and D(3) receptors. CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6ENTC D(2) and D(3) receptors. CPR:falsenewlineAgonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineAgonist and antagonist actions of BC6ENTC as compared to BC6OTHER at BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6OTHER BC6OTHER , BC6OTHER BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineAgonist and antagonist actions of BC6OTHER as compared to BC6ENTC at BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER )(1A), BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn conclusion, these findings indicate that BC6ENTC is a new potent antagonist radioligand which recognizes with high affinity both BC6ENTG and BC6OTHER and represents thus an excellent tool to study BC6OTHER in the rat brain. CPR:falsenewlineIn conclusion, these findings indicate that BC6ENTC is a new potent antagonist radioligand which recognizes with high affinity both BC6OTHER and BC6ENTG and represents thus an excellent tool to study BC6OTHER in the rat brain. CPR:falsenewlineIn conclusion, these findings indicate that BC6ENTC is a new potent antagonist radioligand which recognizes with high affinity both BC6OTHER and BC6OTHER and represents thus an excellent tool to study BC6ENTG in the rat brain. CPR:falsenewlineIn conclusion, these findings indicate that BC6OTHER is a new potent antagonist radioligand which recognizes with high affinity both BC6ENTC NT1 and BC6ENTG and represents thus an excellent tool to study BC6OTHER in the rat brain. CPR:falsenewlineIn conclusion, these findings indicate that BC6OTHER is a new potent antagonist radioligand which recognizes with high affinity both BC6ENTC NT1 and BC6OTHER and represents thus an excellent tool to study BC6ENTG in the rat brain. CPR:falsenewlineThe present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of BC6ENTG , BC6ENTC ( BC6OTHER ), in the rat brain. CPR:6newlineIn conclusion, these findings indicate that BC6OTHER is a new potent antagonist radioligand which recognizes with high affinity both BC6ENTG and BC6OTHER and represents thus an excellent tool to study BC6ENTC receptors in the rat brain. CPR:falsenewlineIn conclusion, these findings indicate that BC6OTHER is a new potent antagonist radioligand which recognizes with high affinity both BC6OTHER and BC6ENTG and represents thus an excellent tool to study BC6ENTC receptors in the rat brain. CPR:falsenewlineThe present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of BC6ENTG , BC6OTHER ( BC6ENTC ), in the rat brain. CPR:6newlineBC6ENTC binding was inhibited by BC6OTHER , the related nonpeptide receptor antagonist, BC6OTHER ( BC6OTHER ) and BC6ENTG . CPR:falsenewlineBC6OTHER binding was inhibited by BC6ENTC , the related nonpeptide receptor antagonist, BC6OTHER ( BC6OTHER ) and BC6ENTG . CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6ENTC H1 receptor antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6ENTG (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6ENTC H1 receptor antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineBC6OTHER binding was inhibited by BC6OTHER , the related nonpeptide receptor antagonist, BC6ENTC ( BC6OTHER ) and BC6ENTG . CPR:falsenewlineBC6OTHER binding was inhibited by BC6OTHER , the related nonpeptide receptor antagonist, BC6OTHER ( BC6ENTC ) and BC6ENTG . CPR:falsenewlineCharacterization of binding sites of a new BC6ENTG antagonist, BC6ENTC , in the rat brain. CPR:6newlineSaturation and competition studies in the presence or absence of the BC6ENTG antagonist, BC6ENTC , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6ENTC , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6ENTG (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6ENTC , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6ENTG antagonist, BC6OTHER , revealed that BC6ENTC bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6ENTC bound with similar affinities to both the BC6OTHER - insensitive BC6ENTG (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6ENTC bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6ENTG antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6ENTC - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6ENTC - insensitive BC6ENTG (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6ENTC - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6ENTG antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6ENTC NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6ENTC NT1 receptors (20% of the total binding population) and the recently cloned BC6OTHER - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6ENTG antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6ENTC - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6ENTG (20% of the total binding population) and the recently cloned BC6ENTC - sensitive BC6OTHER (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineSaturation and competition studies in the presence or absence of the BC6OTHER antagonist, BC6OTHER , revealed that BC6OTHER bound with similar affinities to both the BC6OTHER - insensitive BC6OTHER NT1 receptors (20% of the total binding population) and the recently cloned BC6ENTC - sensitive BC6ENTG (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively). CPR:falsenewlineBC6ENTC caused a significant concentration - dependent increase in limb abnormalities, which was correlated with its BC6ENTG inhibitory effect. CPR:4newlineThe signaling of both BC6ENTG and BC6OTHER , key regulators of chondrogenesis, was downregulated by BC6ENTC . CPR:4newlineThe signaling of both BC6OTHER and BC6ENTG , key regulators of chondrogenesis, was downregulated by BC6ENTC . CPR:4newlineIn contrast, BC6ENTC had little effect on limb morphology and no significant effect on BC6ENTG activity or the expression of marker genes. CPR:falsenewlineDisturbances in these signaling pathways are likely to be a consequence of BC6ENTG inhibition because BC6ENTC did not affect their expressions. CPR:falsenewline BC6ENTC ( BC6OTHER ), the BC6OTHER derivative of BC6OTHER , does not inhibit BC6ENTG activity and is a weak teratogen in vivo. The detailed mechanism of action of BC6OTHER as a teratogen is not known. CPR:falsenewline BC6OTHER ( BC6ENTC ), the BC6OTHER derivative of BC6OTHER , does not inhibit BC6ENTG activity and is a weak teratogen in vivo. The detailed mechanism of action of BC6OTHER as a teratogen is not known. CPR:falsenewline BC6OTHER ( BC6OTHER ), the BC6ENTC derivative of BC6OTHER , does not inhibit BC6ENTG activity and is a weak teratogen in vivo. The detailed mechanism of action of BC6OTHER as a teratogen is not known. CPR:falsenewline BC6OTHER ( BC6OTHER ), the BC6OTHER derivative of BC6ENTC , does not inhibit BC6ENTG activity and is a weak teratogen in vivo. The detailed mechanism of action of BC6OTHER as a teratogen is not known. CPR:falsenewlineIn utero exposure to BC6ENTC ( BC6OTHER ), a BC6ENTG ( BC6OTHER ) inhibitor, causes neural tube, heart, and limb defects. CPR:4newlineIn utero exposure to BC6ENTC ( BC6OTHER ), a BC6OTHER ( BC6ENTG ) inhibitor, causes neural tube, heart, and limb defects. CPR:4newline BC6OTHER ( BC6OTHER ), the BC6OTHER derivative of BC6OTHER , does not inhibit BC6ENTG activity and is a weak teratogen in vivo. The detailed mechanism of action of BC6ENTC as a teratogen is not known. CPR:falsenewlineIn utero exposure to BC6OTHER ( BC6ENTC ), a BC6ENTG ( BC6OTHER ) inhibitor, causes neural tube, heart, and limb defects. CPR:falsenewlineIn utero exposure to BC6OTHER ( BC6ENTC ), a BC6OTHER ( BC6ENTG ) inhibitor, causes neural tube, heart, and limb defects. CPR:falsenewlineMechanistically, BC6ENTG is recruited to DSBs via the BC6ENTC - terminal BC6OTHER - SQ / TQ domain of BC6OTHER , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6OTHER . CPR:falsenewlineMechanistically, BC6OTHER is recruited to DSBs via the BC6ENTC - terminal BC6OTHER - SQ / TQ domain of BC6ENTG , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6OTHER . CPR:falsenewlineMechanistically, BC6OTHER is recruited to DSBs via the BC6ENTC - terminal BC6OTHER - SQ / TQ domain of BC6OTHER , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6ENTG . CPR:falsenewlineMechanistically, BC6ENTG is recruited to DSBs via the BC6OTHER - terminal BC6ENTC - SQ / TQ domain of BC6OTHER , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6OTHER . CPR:falsenewlineMechanistically, BC6OTHER is recruited to DSBs via the BC6OTHER - terminal BC6ENTC - SQ / TQ domain of BC6ENTG , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6OTHER . CPR:falsenewlineMechanistically, BC6OTHER is recruited to DSBs via the BC6OTHER - terminal BC6ENTC - SQ / TQ domain of BC6OTHER , and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of BC6ENTG . CPR:falsenewlineBC6ENTG ( BC6OTHER ) in the liver catalyzes most of the BC6ENTC transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. CPR:9newlineBC6OTHER : BC6OTHER aminotransferase ( BC6ENTG ) in the liver catalyzes most of the BC6ENTC transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. CPR:falsenewlineThe effects of BC6ENTC deficiency on hepatic BC6ENTG isoenzymes, designated BC6OTHER and BC6OTHER , respectively, were examined with male rats; BC6OTHER is located both in the peroxisomes and in the mitochondria, and BC6OTHER only in the mitochondria. CPR:falsenewlineThe effects of BC6ENTC deficiency on hepatic BC6OTHER isoenzymes, designated BC6ENTG and BC6OTHER , respectively, were examined with male rats; BC6OTHER is located both in the peroxisomes and in the mitochondria, and BC6OTHER only in the mitochondria. CPR:falsenewlineThe effects of BC6ENTC deficiency on hepatic BC6OTHER isoenzymes, designated BC6OTHER and BC6ENTG , respectively, were examined with male rats; BC6OTHER is located both in the peroxisomes and in the mitochondria, and BC6OTHER only in the mitochondria. CPR:falsenewlineThe effects of BC6ENTC deficiency on hepatic BC6OTHER isoenzymes, designated BC6OTHER and BC6OTHER , respectively, were examined with male rats; BC6ENTG is located both in the peroxisomes and in the mitochondria, and BC6OTHER only in the mitochondria. CPR:falsenewlineThe effects of BC6ENTC deficiency on hepatic BC6OTHER isoenzymes, designated BC6OTHER and BC6OTHER , respectively, were examined with male rats; BC6OTHER is located both in the peroxisomes and in the mitochondria, and BC6ENTG only in the mitochondria. CPR:falsenewlineThe holo activity of combined peroxisomal and mitochondrial BC6ENTG with a low Km for BC6ENTC rapidly decreased after a lag time of about 2 days during feeding of the BC6OTHER - deficient diet (by 50% in 5 days, by 86% in 14 days). CPR:falsenewlineThe holo activity of combined peroxisomal and mitochondrial BC6ENTG with a low Km for BC6OTHER rapidly decreased after a lag time of about 2 days during feeding of the BC6ENTC - deficient diet (by 50% in 5 days, by 86% in 14 days). CPR:falsenewlineThe holo activity of BC6OTHER with a high Km for BC6ENTC decreased more slowly than BC6ENTG (by 33% in 14 days, by 60% in 28 days). CPR:falsenewlineThe holo activity of BC6ENTG with a high Km for BC6ENTC decreased more slowly than BC6OTHER (by 33% in 14 days, by 60% in 28 days). CPR:9newlineThe effect of BC6ENTC deficiency on BC6ENTG isoenzymes in rat liver. CPR:falsenewlineUrinary excretion of BC6ENTC began to increase in 8 - 9 days, when BC6ENTG remained intact but most of BC6OTHER is depleted. CPR:falsenewlineUrinary excretion of BC6ENTC began to increase in 8 - 9 days, when BC6OTHER remained intact but most of BC6ENTG is depleted. CPR:falsenewlineWhen the defect in the BC6ENTC transamination in vivo in BC6OTHER deficiency is considered, these findings suggest that it is due to the deficiency of BC6ENTG . CPR:falsenewlineWhen the defect in the BC6OTHER transamination in vivo in BC6ENTC deficiency is considered, these findings suggest that it is due to the deficiency of BC6ENTG . CPR:falsenewlineThe importance of peroxisomal BC6ENTG is discussed, since peroxisomes have been described to be probably the major site of BC6ENTC formation. CPR:falsenewlineBC6ENTC : BC6OTHER aminotransferase ( BC6ENTG ) in the liver catalyzes most of the BC6OTHER transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. CPR:falsenewlineBC6OTHER : BC6ENTC aminotransferase ( BC6ENTG ) in the liver catalyzes most of the BC6OTHER transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. CPR:falsenewlineBC6ENTC eliminated all Leydig cells in the control testis on day 4 post - BC6OTHER , as judged by undetectable serum BC6OTHER level and no BC6ENTG positive ( BC6OTHER (pos)) cells in the interstitium. CPR:falsenewlineBC6ENTC eliminated all Leydig cells in the control testis on day 4 post - BC6OTHER , as judged by undetectable serum BC6OTHER level and no BC6OTHER positive ( BC6ENTG (pos)) cells in the interstitium. CPR:falsenewlineBC6OTHER eliminated all Leydig cells in the control testis on day 4 post - BC6ENTC , as judged by undetectable serum BC6OTHER level and no BC6ENTG positive ( BC6OTHER (pos)) cells in the interstitium. CPR:falsenewlineBC6OTHER eliminated all Leydig cells in the control testis on day 4 post - BC6ENTC , as judged by undetectable serum BC6OTHER level and no BC6OTHER positive ( BC6ENTG (pos)) cells in the interstitium. CPR:falsenewlineBC6OTHER eliminated all Leydig cells in the control testis on day 4 post - BC6OTHER , as judged by undetectable serum BC6ENTC level and no BC6ENTG positive ( BC6OTHER (pos)) cells in the interstitium. CPR:falsenewlineBC6OTHER eliminated all Leydig cells in the control testis on day 4 post - BC6OTHER , as judged by undetectable serum BC6ENTC level and no BC6OTHER positive ( BC6ENTG (pos)) cells in the interstitium. CPR:falsenewlineBC6OTHER eliminated all Leydig cells in the control testis on day 4 post - BC6OTHER , as judged by undetectable serum BC6OTHER level and no BC6ENTC dehydrogenase positive ( BC6ENTG (pos)) cells in the interstitium. CPR:falsenewlineHowever, in BC6ENTC - treated groups, there were detectable serum BC6OTHER concentrations and some oval - shaped BC6ENTG (pos) cells in the interstitium. CPR:falsenewlineHowever, in BC6OTHER - treated groups, there were detectable serum BC6ENTC concentrations and some oval - shaped BC6ENTG (pos) cells in the interstitium. CPR:falsenewlineThese BC6OTHER (pos) cells were not stained by the antibody against BC6ENTC dehydrogenase 1 ( BC6ENTG 1), a marker for Leydig cells at a more advanced stage. CPR:falsenewlineThese BC6ENTG (pos) cells were not stained by the antibody against BC6ENTC dehydrogenase 1 ( BC6OTHER 1), a marker for Leydig cells at a more advanced stage. CPR:falsenewlineHowever, there were detectable concentrations of BC6ENTG , BC6OTHER and BC6OTHER mRNAs but undetectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells. CPR:falsenewlineHowever, there were detectable concentrations of BC6OTHER , BC6ENTG and BC6OTHER mRNAs but undetectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells. CPR:falsenewlineHowever, there were detectable concentrations of BC6OTHER , BC6OTHER and BC6ENTG mRNAs but undetectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells. CPR:falsenewlineHowever, there were detectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER mRNAs but undetectable concentrations of BC6ENTG , BC6OTHER and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells. CPR:falsenewlineHowever, there were detectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER mRNAs but undetectable concentrations of BC6OTHER , BC6ENTG and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells. CPR:falsenewlineHowever, there were detectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER mRNAs but undetectable concentrations of BC6OTHER , BC6OTHER and BC6ENTG in the BC6ENTC - treated testes, indicating that these BC6OTHER (pos) cells were newly formed progenitor Leydig cells. CPR:falsenewlineHowever, there were detectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER mRNAs but undetectable concentrations of BC6OTHER , BC6OTHER and BC6OTHER in the BC6ENTC - treated testes, indicating that these BC6ENTG (pos) cells were newly formed progenitor Leydig cells. CPR:falsenewlineThe mRNA level for BC6ENTG ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6ENTC , but not in the BC6OTHER treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes. CPR:falsenewlineThe mRNA level for BC6OTHER ( BC6ENTG , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6ENTC , but not in the BC6OTHER treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes. CPR:falsenewlineThe mRNA level for BC6OTHER ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6ENTC , but not in the BC6OTHER treated testes, suggesting that these BC6ENTG positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes. CPR:falsenewlineThe mRNA level for BC6ENTG ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6ENTC treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes. CPR:falsenewlineThe mRNA level for BC6OTHER ( BC6ENTG , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6ENTC treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes. CPR:falsenewlineThe mRNA level for BC6OTHER ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6ENTC treated testes, suggesting that these BC6ENTG positive stem cells were differentiated into progenitor Leydig cells in the BC6OTHER - treated testes. CPR:falsenewlineThe mRNA level for BC6ENTG ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6OTHER treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6ENTC - treated testes. CPR:falsenewlineThe mRNA level for BC6OTHER ( BC6ENTG , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6OTHER treated testes, suggesting that these BC6OTHER positive stem cells were differentiated into progenitor Leydig cells in the BC6ENTC - treated testes. CPR:falsenewlineThe mRNA level for BC6OTHER ( BC6OTHER , biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post - BC6OTHER , but not in the BC6OTHER treated testes, suggesting that these BC6ENTG positive stem cells were differentiated into progenitor Leydig cells in the BC6ENTC - treated testes. CPR:falsenewlineIn this small library of novel bioactive macrocyclic BC6ENTC derivatives, designed to evaluate structure - activity relationships essential in overcoming multidrug resistance (MDR), some correlations between MDR reversal and molecular weight, accessible solvent areas, and BC6OTHER / water partition coefficient were identified that can contribute to the development of new selective BC6ENTG reversal agents. CPR:falsenewlineIn this small library of novel bioactive macrocyclic BC6OTHER derivatives, designed to evaluate structure - activity relationships essential in overcoming multidrug resistance (MDR), some correlations between MDR reversal and molecular weight, accessible solvent areas, and BC6ENTC / water partition coefficient were identified that can contribute to the development of new selective BC6ENTG reversal agents. CPR:falsenewlineBC6ENTC - independent BC6OTHER [ BC6ENTG ; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6ENTC - independent BC6OTHER [ BC6OTHER D - isomerase; BC6ENTG , BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6ENTC - independent BC6OTHER [ BC6OTHER D - isomerase; BC6OTHER D - isomerase, BC6ENTG ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6ENTC - independent BC6ENTG [ BC6OTHER D - isomerase; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6OTHER [ BC6ENTG ; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6ENTC in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6OTHER [ BC6OTHER D - isomerase; BC6ENTG , BC6OTHER ] is an enzyme responsible for biosynthesis of BC6ENTC in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6OTHER [ BC6OTHER D - isomerase; BC6OTHER D - isomerase, BC6ENTG ] is an enzyme responsible for biosynthesis of BC6ENTC in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6ENTG [ BC6OTHER D - isomerase; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6ENTC in the central nervous system. CPR:9newlineBC6OTHER - independent BC6ENTC synthase [ BC6ENTG ; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6ENTC synthase [ BC6OTHER D - isomerase; BC6ENTG , BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6ENTC synthase [ BC6OTHER D - isomerase; BC6OTHER D - isomerase, BC6ENTG ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6OTHER [ BC6ENTC D - isomerase; BC6ENTG , BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6OTHER [ BC6ENTC D - isomerase; BC6OTHER D - isomerase, BC6ENTG ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6ENTG [ BC6ENTC D - isomerase; BC6OTHER D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6OTHER [ BC6ENTG ; BC6ENTC D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6OTHER [ BC6OTHER D - isomerase; BC6ENTC D - isomerase, BC6ENTG ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineBC6OTHER - independent BC6ENTG [ BC6OTHER D - isomerase; BC6ENTC D - isomerase, BC6OTHER ] is an enzyme responsible for biosynthesis of BC6OTHER in the central nervous system. CPR:falsenewlineFollowing BC6OTHER treatment, BC6ENTG was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring. CPR:falsenewlineFollowing BC6OTHER treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6ENTG by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring. CPR:falsenewlineFollowing BC6OTHER treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6ENTG to BC6OTHER during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring. CPR:falsenewlineFollowing BC6OTHER treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6ENTG during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring. CPR:falsenewlineFollowing BC6OTHER treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6ENTG - BC6OTHER interactions might have facilitated junction restructuring. CPR:falsenewlineFollowing BC6OTHER treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6ENTC - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6ENTG interactions might have facilitated junction restructuring. CPR:falsenewlineInterestingly, BC6ENTG was found to associate with BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6OTHER . CPR:falsenewlineInterestingly, BC6OTHER was found to associate with BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6OTHER . CPR:falsenewlineInterestingly, BC6OTHER was found to associate with BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6OTHER . CPR:falsenewlineInterestingly, BC6OTHER was found to associate with BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6OTHER . CPR:falsenewlineInterestingly, BC6OTHER was found to associate with BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6OTHER . CPR:falsenewlineInterestingly, BC6OTHER was found to associate with BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6ENTG , and BC6OTHER . CPR:falsenewlineInterestingly, BC6OTHER was found to associate with BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM - rich BC6ENTC kinase 2, BC6OTHER , and BC6ENTG . CPR:falsenewlineFollowing BC6ENTC treatment, BC6ENTG was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring. CPR:falsenewlineFollowing BC6ENTC treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6ENTG by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring. CPR:falsenewlineFollowing BC6ENTC treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6ENTG to BC6OTHER during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring. CPR:falsenewlineFollowing BC6ENTC treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6ENTG during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6OTHER interactions might have facilitated junction restructuring. CPR:falsenewlineFollowing BC6ENTC treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6ENTG - BC6OTHER interactions might have facilitated junction restructuring. CPR:falsenewlineFollowing BC6ENTC treatment, BC6OTHER was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for BC6OTHER by 6 - 16 h. Interestingly, there was a loss in the binding of BC6OTHER to BC6OTHER during BC6OTHER - induced germ cell loss, suggesting that a loss of BC6OTHER - BC6ENTG interactions might have facilitated junction restructuring. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6ENTC and its metabolite BC6OTHER ( BC6OTHER ), erythrocyte BC6ENTG activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6ENTC and its metabolite BC6OTHER ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6ENTG activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6ENTC and its metabolite BC6OTHER ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6ENTG ( BC6OTHER ) activity. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6ENTC and its metabolite BC6OTHER ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6ENTG ) activity. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6ENTC ( BC6OTHER ), erythrocyte BC6ENTG activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6ENTC ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6ENTG activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6ENTC ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6ENTG ( BC6OTHER ) activity. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6ENTC ( BC6OTHER ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6ENTG ) activity. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6OTHER ( BC6ENTC ), erythrocyte BC6ENTG activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6OTHER ( BC6ENTC ), erythrocyte BC6OTHER activity, CSF BC6ENTG activity, and plasma and CSF BC6OTHER ( BC6OTHER ) activity. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6OTHER ( BC6ENTC ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6ENTG ( BC6OTHER ) activity. CPR:falsenewlineCSF specimens and samples of blood cells and blood plasma were analyzed at intervals for BC6OTHER and its metabolite BC6OTHER ( BC6ENTC ), erythrocyte BC6OTHER activity, CSF BC6OTHER activity, and plasma and CSF BC6OTHER ( BC6ENTG ) activity. CPR:falsenewlinePreferential cerebrospinal fluid BC6ENTG inhibition by BC6ENTC in humans. CPR:4newlineInhibition of BC6ENTG in the CSF after BC6ENTC administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours. CPR:4newlinePlasma BC6ENTG activity was significantly lower after BC6ENTC than after placebo, but this was not clinically relevant. CPR:falsenewlineThis study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6ENTC ( BC6OTHER ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6ENTG in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme. CPR:4newlineThis study sought to examine the feasibility of prolonged assessment of BC6ENTG ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6ENTC ( BC6OTHER ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme. CPR:falsenewlineThis study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6ENTG ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6ENTC ( BC6OTHER ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme. CPR:4newlineBC6ENTG activity in CSF was significantly lower after BC6ENTC than after placebo for up to 3.6 hours after dosing, but this difference was not sustained. CPR:falsenewlineThis study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6ENTC ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6ENTG in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme. CPR:4newlineThis study sought to examine the feasibility of prolonged assessment of BC6ENTG ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6ENTC ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme. CPR:falsenewlineThis study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6ENTG ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6ENTC ; BC6OTHER , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme. CPR:falsenewlineThis study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6OTHER ; BC6ENTC , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6ENTG in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme. CPR:4newlineThis study sought to examine the feasibility of prolonged assessment of BC6ENTG ( BC6OTHER ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6OTHER ; BC6ENTC , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme. CPR:falsenewlineThis study sought to examine the feasibility of prolonged assessment of BC6OTHER ( BC6ENTG ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that BC6OTHER ( BC6OTHER ; BC6ENTC , Novartis Pharma AG, Basel, Switzerland) selectively inhibits BC6OTHER in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme. CPR:falsenewlineThis study confirms the feasibility of using continuous measurement of BC6ENTG activity in CSF over prolonged periods, that BC6ENTC markedly inhibits CSF BC6OTHER after a single oral dose of 3 mg, and that the inhibition of central BC6OTHER is substantially greater than that of peripheral BC6OTHER or BC6OTHER . CPR:falsenewlineThis study confirms the feasibility of using continuous measurement of BC6OTHER activity in CSF over prolonged periods, that BC6ENTC markedly inhibits CSF BC6ENTG after a single oral dose of 3 mg, and that the inhibition of central BC6OTHER is substantially greater than that of peripheral BC6OTHER or BC6OTHER . CPR:4newlineThis study confirms the feasibility of using continuous measurement of BC6OTHER activity in CSF over prolonged periods, that BC6ENTC markedly inhibits CSF BC6OTHER after a single oral dose of 3 mg, and that the inhibition of central BC6ENTG is substantially greater than that of peripheral BC6OTHER or BC6OTHER . CPR:falsenewlineThis study confirms the feasibility of using continuous measurement of BC6OTHER activity in CSF over prolonged periods, that BC6ENTC markedly inhibits CSF BC6OTHER after a single oral dose of 3 mg, and that the inhibition of central BC6OTHER is substantially greater than that of peripheral BC6ENTG or BC6OTHER . CPR:falsenewlineThis study confirms the feasibility of using continuous measurement of BC6OTHER activity in CSF over prolonged periods, that BC6ENTC markedly inhibits CSF BC6OTHER after a single oral dose of 3 mg, and that the inhibition of central BC6OTHER is substantially greater than that of peripheral BC6OTHER or BC6ENTG . CPR:falsenewlineBC6ENTC decreased the peak amplitude of hippocampal area CA1 BC6ENTG - mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 + / - 0.8 microM) with no apparent effect on response kinetics. CPR:falsenewlineBC6ENTC prolonged the decay time constant of BC6ENTG - mediated e.p.s.cs (EC50 35.7 + / - 6.5 microM) with less pronounced effects in slowing e.p.s.c. CPR:falsenewlineBC6ENTC (330 microM) shifted the concentration - response curve for the effects of BC6OTHER on BC6ENTG - mediated e.p.s.c. CPR:falsenewlineBC6OTHER (330 microM) shifted the concentration - response curve for the effects of BC6ENTC on BC6ENTG - mediated e.p.s.c. CPR:falsenewlineLikewise, BC6ENTC (30 - 100 microM)) shifted the concentration - response curve for the effects of BC6OTHER on BC6ENTG - mediated e.p.s.c. CPR:falsenewlineLikewise, BC6OTHER (30 - 100 microM)) shifted the concentration - response curve for the effects of BC6ENTC on BC6ENTG - mediated e.p.s.c. CPR:falsenewlineIn conclusion, BC6ENTC and the BC6OTHER seem to bind to different sites on BC6ENTG but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site. CPR:falsenewlineIn conclusion, BC6OTHER and the BC6ENTC seem to bind to different sites on BC6ENTG but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site. CPR:falsenewlineThe interactions of BC6ENTC and BC6OTHER on BC6ENTG - mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization. CPR:falsenewlineThe interactions of BC6OTHER and BC6ENTC on BC6ENTG - mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization. CPR:falsenewlineInteractions of BC6ENTC and BC6OTHER at BC6ENTG : patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. CPR:falsenewlineInteractions of BC6OTHER and BC6ENTC at BC6ENTG : patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. CPR:falsenewline BC6ENTC : a novel anti - Parkinsonian BC6ENTG inhibitor with neuroprotective activity. CPR:4newlineBC6ENTC ( BC6OTHER ) is a novel, highly potent irreversible BC6ENTG inhibitor, anti - Parkinsonian drug. CPR:4newlineBC6OTHER ( BC6ENTC ) is a novel, highly potent irreversible BC6ENTG inhibitor, anti - Parkinsonian drug. CPR:4newlineIts S - isomer, BC6ENTC is thousand times less potent as an BC6ENTG inhibitor. CPR:4newlineHowever, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of BC6ENTC does not depend on inhibition of BC6ENTG , but rather is associated with the BC6OTHER moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating BC6OTHER family proteins. CPR:falsenewlineHowever, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of BC6ENTC does not depend on inhibition of BC6OTHER , but rather is associated with the BC6OTHER moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating BC6ENTG family proteins. CPR:falsenewlineHowever, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of BC6OTHER does not depend on inhibition of BC6ENTG , but rather is associated with the BC6ENTC moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating BC6OTHER family proteins. CPR:falsenewlineHowever, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of BC6OTHER does not depend on inhibition of BC6OTHER , but rather is associated with the BC6ENTC moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating BC6ENTG family proteins. CPR:falsenewlineThe most potent compound 5 ( BC6ENTC ) has demonstrated to inhibit BC6ENTG activity, downregulate phosphorylation of BC6OTHER , increase the expression of cleaved BC6OTHER , inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values. CPR:4newlineThe most potent compound 5 ( BC6ENTC ) has demonstrated to inhibit BC6OTHER activity, downregulate phosphorylation of BC6ENTG , increase the expression of cleaved BC6OTHER , inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values. CPR:4newlineThe most potent compound 5 ( BC6ENTC ) has demonstrated to inhibit BC6OTHER activity, downregulate phosphorylation of BC6OTHER , increase the expression of cleaved BC6ENTG , inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values. CPR:falsenewlineFurthermore, compound 5 significantly suppressed BC6ENTC receptor ( BC6ENTG ) - negative breast cancer CHEM - MB - 231 xenograft tumor growth in vivo (p.o. CPR:falsenewlineFragment - based drug design and identification of BC6ENTC , a novel orally bioavailable BC6ENTG inhibitor for cancer therapy. CPR:4newlineUrinary BC6OTHER , fasting plasma BC6ENTC (FPG), fasting serum BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER , and other chemistry laboratory parameters of T2DM participants and controls were measured. CPR:falsenewlineUrinary BC6OTHER , fasting plasma BC6ENTC (FPG), fasting serum BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG , and other chemistry laboratory parameters of T2DM participants and controls were measured. CPR:falsenewlineUrinary BC6ENTG , fasting plasma BC6ENTC (FPG), fasting serum BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER , and other chemistry laboratory parameters of T2DM participants and controls were measured. CPR:falsenewlineUrinary BC6OTHER , fasting plasma BC6ENTC (FPG), fasting serum BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER , and other chemistry laboratory parameters of T2DM participants and controls were measured. CPR:falsenewlineUrinary BC6OTHER , fasting plasma BC6ENTC (FPG), fasting serum BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER , and other chemistry laboratory parameters of T2DM participants and controls were measured. CPR:falsenewlineUrinary BC6OTHER , fasting plasma BC6ENTC (FPG), fasting serum BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER , and other chemistry laboratory parameters of T2DM participants and controls were measured. CPR:falsenewlineAlthough genetic polymorphisms in the endothelial BC6ENTC synthase ( BC6ENTG ) gene may impair endogenous BC6OTHER formation, there is little information about how BC6OTHER polymorphisms and haplotypes affect the responses to BC6OTHER . CPR:falsenewlineAlthough genetic polymorphisms in the endothelial BC6ENTC synthase ( BC6OTHER ) gene may impair endogenous BC6OTHER formation, there is little information about how BC6ENTG polymorphisms and haplotypes affect the responses to BC6OTHER . CPR:falsenewlineOur findings show evidence that BC6ENTG polymorphisms affect the responses of PED and clinical ED patients to BC6ENTC . CPR:falsenewlineAlthough genetic polymorphisms in the endothelial BC6OTHER synthase ( BC6ENTG ) gene may impair endogenous BC6ENTC formation, there is little information about how BC6OTHER polymorphisms and haplotypes affect the responses to BC6OTHER . CPR:falsenewlineAlthough genetic polymorphisms in the endothelial BC6OTHER synthase ( BC6OTHER ) gene may impair endogenous BC6ENTC formation, there is little information about how BC6ENTG polymorphisms and haplotypes affect the responses to BC6OTHER . CPR:falsenewlineAlthough genetic polymorphisms in the BC6ENTG ( BC6OTHER ) gene may impair endogenous BC6ENTC formation, there is little information about how BC6OTHER polymorphisms and haplotypes affect the responses to BC6OTHER . CPR:falsenewlineAlthough genetic polymorphisms in the endothelial BC6OTHER synthase ( BC6ENTG ) gene may impair endogenous BC6OTHER formation, there is little information about how BC6OTHER polymorphisms and haplotypes affect the responses to BC6ENTC . CPR:falsenewlineAlthough genetic polymorphisms in the endothelial BC6OTHER synthase ( BC6OTHER ) gene may impair endogenous BC6OTHER formation, there is little information about how BC6ENTG polymorphisms and haplotypes affect the responses to BC6ENTC . CPR:falsenewlineAlthough genetic polymorphisms in the BC6ENTG ( BC6OTHER ) gene may impair endogenous BC6OTHER formation, there is little information about how BC6OTHER polymorphisms and haplotypes affect the responses to BC6ENTC . CPR:falsenewline BC6ENTG genotypes and haplotypes modify the responses to BC6ENTC in patients with erectile dysfunction. CPR:falsenewline Variation in their effectiveness as positive reinforcers was not a function of differences in effectiveness as BC6ENTC uptake blockers, but may be related to relative potency over the concentrations that are achieved in vivo. Effects at BC6ENTG may limit the reinforcing effects of local anesthetics. CPR:falsenewlineOBJECTIVES: The hypothesis of the present study was that differences among BC6ENTC transporter ( BC6ENTG ) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as BC6OTHER uptake inhibitors. CPR:falsenewlineOBJECTIVES: The hypothesis of the present study was that differences among BC6ENTG ( BC6OTHER ) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as BC6ENTC uptake inhibitors. CPR:falsenewlineOBJECTIVES: The hypothesis of the present study was that differences among BC6OTHER ( BC6ENTG ) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as BC6ENTC uptake inhibitors. CPR:falsenewlineAccordingly, self - administration of a group of local anesthetics that are BC6ENTG ligands was compared to their effects as BC6ENTC uptake blockers in vitro in brain tissue. CPR:falsenewlineAs possible long - term effects of honey after its withdrawal, statistically significant reductions in midarm circumference (P=.000), triceps skin fold thickness (P=.006), SSFT (P=.003), FSG (P=.005), 2 - h postprandial serum BC6ENTC (P=.000), TG (P=.003), and BC6OTHER (P=.043), and significant increases in BC6ENTG (P=.002) and BC6OTHER (P=.003) were observed. CPR:falsenewlineAs possible long - term effects of honey after its withdrawal, statistically significant reductions in midarm circumference (P=.000), triceps skin fold thickness (P=.006), SSFT (P=.003), FSG (P=.005), 2 - h postprandial serum BC6ENTC (P=.000), TG (P=.003), and BC6OTHER (P=.043), and significant increases in BC6OTHER (P=.002) and BC6ENTG (P=.003) were observed. CPR:falsenewlineAs possible long - term effects of honey after its withdrawal, statistically significant reductions in midarm circumference (P=.000), triceps skin fold thickness (P=.006), SSFT (P=.003), FSG (P=.005), 2 - h postprandial serum BC6ENTC (P=.000), TG (P=.003), and BC6ENTG (P=.043), and significant increases in BC6OTHER (P=.002) and BC6OTHER (P=.003) were observed. CPR:falsenewlineThe main outcome measures were serum BC6ENTC , lipids, and BC6ENTG , and anthropometric measurements. CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6ENTC (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6ENTG (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6ENTC (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6ENTG ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6ENTC (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6ENTG ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6ENTC (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6ENTG ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6ENTC (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6ENTG ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6ENTC (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6ENTG (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6ENTC (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6ENTG ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6ENTC (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6ENTG ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6ENTC (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6ENTG ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6ENTC (P=.0001), serum BC6OTHER (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6ENTG ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6ENTC (TG; P=.0001), and BC6ENTG (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6ENTC (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6ENTG ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6ENTC (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6ENTG ; P=.0004) and 2 - h BC6OTHER ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6ENTC (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6ENTG ( BC6OTHER ; P=.002). CPR:falsenewlineThe intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum BC6OTHER (FSG; P=.001), total BC6OTHER (P=.0001), serum BC6ENTC (TG; P=.0001), and BC6OTHER (P=.0009), and significant increases in BC6OTHER ( BC6OTHER ; P=.0004) and 2 - h BC6OTHER ( BC6ENTG ; P=.002). CPR:falsenewlineIn cultures from severely obese subjects, BC6ENTC induced a decrease of BC6ENTG antigen secretion from newly differentiated omental adipocytes by 49 + / - 8% (p < 0.01) and from subcutaneous adipocytes by 30 + / - 7% (p < 0.05). CPR:4newlineExposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to BC6ENTC induced a similar reduction of BC6ENTG concentration in the culture medium (by 35 + / - 11%, p < 0.05, and 33 + / - 8%, p < 0.05 compared with control, respectively). CPR:falsenewlineCONCLUSION / INTERPRETATION: This study provides evidence that BC6ENTC reduces BC6ENTG production in human adipocytes, probably at the transcriptional level. CPR:4newlineIn this study, we investigated the effect of BC6ENTC , a ligand of the BC6ENTG BC6OTHER , on BC6OTHER expression and secretion in human adipocytes. CPR:falsenewlineIn this study, we investigated the effect of BC6ENTC , a ligand of the BC6OTHER BC6ENTG , on BC6OTHER expression and secretion in human adipocytes. CPR:falsenewlineIn this study, we investigated the effect of BC6ENTC , a ligand of the BC6OTHER BC6OTHER , on BC6ENTG expression and secretion in human adipocytes. CPR:falsenewlineRESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal - weight females to 1 microgram / ml BC6ENTC for 72 h caused a reduction of both BC6ENTG secretion (by 29 + / - 5%; p < 0.01) and BC6OTHER mRNA expression (by 26 + / - 3%; p < 0.05). CPR:4newlineRESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal - weight females to 1 microgram / ml BC6ENTC for 72 h caused a reduction of both BC6OTHER secretion (by 29 + / - 5%; p < 0.01) and BC6ENTG mRNA expression (by 26 + / - 3%; p < 0.05). CPR:4newline BC6ENTC reduces BC6ENTG expression and secretion in cultured human adipocytes. CPR:falsenewlineBC6ENTC were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively. CPR:falsenewlineBC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6ENTC production, with EC50 values for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the D2 BC6ENTC receptor and BC6OTHER inhibition of BC6ENTG ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the D2 BC6ENTC receptor and BC6OTHER inhibition of BC6OTHER ( BC6ENTG ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the D2 BC6ENTC receptor and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a BC6ENTG , were evaluated. CPR:falsenewlineBC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively. CPR:falsenewlineBC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively. CPR:falsenewlineBC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively. CPR:falsenewlineBC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively. CPR:falsenewlineBC6OTHER were also effective in inhibiting BC6ENTG - stimulated BC6OTHER production, with EC50 values for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC of 8 + / - 2, 47 + / - 2, 28 + / - 2, 2 + / - 1, and 8 + / - 1 nM, respectively. CPR:falsenewlineInhibition of BC6ENTC production by BC6OTHER was blocked by the BC6ENTG antagonist, BC6OTHER (IC50, 300 + / - 150 nM). CPR:falsenewlineInhibition of BC6OTHER production by BC6ENTC was blocked by the BC6ENTG antagonist, BC6OTHER (IC50, 300 + / - 150 nM). CPR:falsenewlineBC6ENTC inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6ENTG ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated. CPR:falsenewlineBC6ENTC inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6OTHER ( BC6ENTG ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated. CPR:falsenewlineBC6ENTC inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a BC6ENTG , were evaluated. CPR:falsenewlineBC6ENTC inhibition of radioligand binding to the BC6ENTG and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6ENTC inhibition of BC6ENTG ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6ENTC inhibition of BC6OTHER ( BC6ENTG ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6ENTC inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a BC6ENTG , were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the BC6ENTG and BC6ENTC inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated. CPR:falsenewlineInhibition of BC6OTHER production by BC6OTHER was blocked by the BC6ENTG antagonist, BC6ENTC (IC50, 300 + / - 150 nM). CPR:falsenewlineOur results indicate that ergot compounds, especially BC6ENTC , bind to BC6ENTG and elicit second messenger responses similar to that of BC6OTHER . CPR:falsenewlineOur results indicate that ergot compounds, especially BC6OTHER , bind to BC6ENTG and elicit second messenger responses similar to that of BC6ENTC . CPR:falsenewline BC6ENTC binding and activation of BC6ENTG in GH4ZR7 cells. CPR:falsenewlineThese findings suggest that some of the deleterious effects of consumption of endophyte - infected tall fescue, which contains several BC6ENTC including BC6OTHER , may be due to BC6ENTG activation. CPR:falsenewlineThese findings suggest that some of the deleterious effects of consumption of endophyte - infected tall fescue, which contains several BC6OTHER including BC6ENTC , may be due to BC6ENTG activation. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6ENTG ( BC6OTHER ) - stimulated BC6ENTC production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6OTHER ( BC6ENTG ) - stimulated BC6ENTC production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6ENTC production in GH4ZR7 cells, stably transfected with a BC6ENTG , were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the BC6ENTG and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6ENTC production in GH4ZR7 cells, stably transfected with a rat D2 BC6OTHER receptor, were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6ENTG ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6ENTC receptor, were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the D2 BC6OTHER receptor and BC6OTHER inhibition of BC6OTHER ( BC6ENTG ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6ENTC receptor, were evaluated. CPR:falsenewlineBC6OTHER inhibition of radioligand binding to the BC6ENTG and BC6OTHER inhibition of BC6OTHER ( BC6OTHER ) - stimulated BC6OTHER production in GH4ZR7 cells, stably transfected with a rat D2 BC6ENTC receptor, were evaluated. CPR:falsenewlineBC6ENTC inhibition of the binding of the BC6ENTG - specific radioligand, BC6OTHER , exhibited a KI (inhibition constant) of 6.9 + / - 2.6 nM, whereas BC6OTHER was much less potent (370 + / - 160 nM). CPR:falsenewlineBC6OTHER inhibition of the binding of the BC6ENTG - specific radioligand, BC6ENTC , exhibited a KI (inhibition constant) of 6.9 + / - 2.6 nM, whereas BC6OTHER was much less potent (370 + / - 160 nM). CPR:falsenewlineBC6OTHER inhibition of the binding of the BC6ENTG - specific radioligand, BC6OTHER , exhibited a KI (inhibition constant) of 6.9 + / - 2.6 nM, whereas BC6ENTC was much less potent (370 + / - 160 nM). CPR:falsenewlineIn our previous study, we identified the BC6ENTC receptor alpha ( BC6ENTG ) as a relevant enhancer of BC6OTHER - induced signal transduction leading to transactivation of BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn our previous study, we identified the BC6ENTC receptor alpha ( BC6OTHER ) as a relevant enhancer of BC6ENTG - induced signal transduction leading to transactivation of BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn our previous study, we identified the BC6ENTC receptor alpha ( BC6OTHER ) as a relevant enhancer of BC6OTHER - induced signal transduction leading to transactivation of BC6ENTG ( BC6OTHER ). CPR:falsenewlineIn our previous study, we identified the BC6ENTC receptor alpha ( BC6OTHER ) as a relevant enhancer of BC6OTHER - induced signal transduction leading to transactivation of BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. CPR:falsenewlineBC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. CPR:falsenewlineBC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER , BC6OTHER inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. CPR:falsenewlineBC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. CPR:falsenewlineBC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. CPR:falsenewlineBC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. CPR:falsenewlineBC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC inhibitors and BC6OTHER are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. CPR:falsenewlineBC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER inhibitors and BC6ENTC are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. CPR:falsenewlineBC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG inhibitors and BC6ENTC are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. CPR:falsenewlineEffects of BC6OTHER were compared to those of the BC6OTHER reuptake inhibitor, BC6OTHER (10 mg / kg / day), and the partial BC6ENTG agonist, BC6ENTC (10 mg / kg / day), two compounds which have demonstrated clinical efficacy against PTSD. CPR:falsenewlineRATIONALE: The selective BC6ENTG antagonist BC6ENTC has been previously shown to attenuate the long - term cognitive deficit produced by traumatic stress exposure. CPR:6newlineThe BC6ENTG antagonist BC6OTHER prevents stress - induced cognitive deficit associated with hippocampal dysfunction: Comparison with BC6ENTC and BC6OTHER . CPR:falsenewlineThe BC6ENTG antagonist BC6OTHER prevents stress - induced cognitive deficit associated with hippocampal dysfunction: Comparison with BC6OTHER and BC6ENTC . CPR:falsenewlineThe BC6ENTG antagonist BC6ENTC prevents stress - induced cognitive deficit associated with hippocampal dysfunction: Comparison with BC6OTHER and BC6OTHER . CPR:falsenewlineCONCLUSIONS: These findings confirm that the BC6ENTG antagonist BC6ENTC is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress. CPR:6newlineEffects of BC6ENTC were compared to those of the BC6OTHER reuptake inhibitor, BC6OTHER (10 mg / kg / day), and the partial BC6ENTG agonist, BC6OTHER (10 mg / kg / day), two compounds which have demonstrated clinical efficacy against PTSD. CPR:falsenewlineEffects of BC6OTHER were compared to those of the BC6ENTC reuptake inhibitor, BC6OTHER (10 mg / kg / day), and the partial BC6ENTG agonist, BC6OTHER (10 mg / kg / day), two compounds which have demonstrated clinical efficacy against PTSD. CPR:falsenewlineEffects of BC6OTHER were compared to those of the BC6OTHER reuptake inhibitor, BC6ENTC (10 mg / kg / day), and the partial BC6ENTG agonist, BC6OTHER (10 mg / kg / day), two compounds which have demonstrated clinical efficacy against PTSD. CPR:falsenewlineThe BC6ENTG - blocking action of BC6OTHER per se does not appear to be involved in the rapid pressor response to BC6ENTC . CPR:falsenewlineBC6OTHER (0.03 - 3 mg / kg) produced dose - dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the BC6ENTG antagonist, BC6ENTC . CPR:falsenewlineBC6ENTC (0.03 - 3 mg / kg) produced dose - dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the BC6ENTG antagonist, BC6OTHER . CPR:falsenewlineBC6ENTC uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineBC6OTHER uptake inhibitors structurally analogous to BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse BC6ENTG selectivities ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) either did not produce a rapid pressor response or produced only a small pressor response. CPR:falsenewlineAt nonconvulsant doses, the BC6ENTG blockers BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER produced a small pressor response or no increase in BP. CPR:4newlineAt nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER produced a small pressor response or no increase in BP. CPR:4newlineAt nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER produced a small pressor response or no increase in BP. CPR:falsenewlineAt nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER produced a small pressor response or no increase in BP. CPR:4newlineAt nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER produced a small pressor response or no increase in BP. CPR:falsenewlineAt nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER produced a small pressor response or no increase in BP. CPR:falsenewlineAt nonconvulsant doses, the BC6ENTG blockers BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC produced a small pressor response or no increase in BP. CPR:4newline BC6ENTC transporter and BC6ENTG mechanisms in the rapid pressor response to BC6OTHER . CPR:falsenewline BC6ENTG and BC6ENTC channel mechanisms in the rapid pressor response to BC6OTHER . CPR:falsenewline BC6ENTG and BC6OTHER mechanisms in the rapid pressor response to BC6ENTC . CPR:falsenewline BC6OTHER and BC6ENTG mechanisms in the rapid pressor response to BC6ENTC . CPR:falsenewlineThe present data suggest that the inhibition of BC6ENTG BC6ENTC transporter functions, either alone or in combination, does not mediate the rapid pressor response to BC6OTHER . CPR:falsenewlineThe present data suggest that the inhibition of BC6ENTG BC6OTHER transporter functions, either alone or in combination, does not mediate the rapid pressor response to BC6ENTC . CPR:falsenewlineThe BC6ENTG - blocking action of BC6ENTC per se does not appear to be involved in the rapid pressor response to BC6OTHER . CPR:falsenewlineFull - length cDNAs of BC6OTHER ( BC6OTHER ) were cloned by screening a human placental cDNA library, which encode a 243 CHEM protein, identical to human BC6ENTC pyrophosphokinase ( BC6ENTG ) as confirmed by protein sequence analysis. CPR:falsenewlineFull - length cDNAs of BC6ENTG ( BC6OTHER ) were cloned by screening a human placental cDNA library, which encode a 243 CHEM protein, identical to human BC6ENTC pyrophosphokinase ( BC6OTHER ) as confirmed by protein sequence analysis. CPR:falsenewlineFull - length cDNAs of BC6OTHER ( BC6ENTG ) were cloned by screening a human placental cDNA library, which encode a 243 CHEM protein, identical to human BC6ENTC pyrophosphokinase ( BC6OTHER ) as confirmed by protein sequence analysis. CPR:falsenewlineAs BC6ENTC metabolism deficiencies have been seen in placental infarcts previously, these indicate that BC6ENTG / BC6OTHER may have a role in placental diseases. CPR:falsenewlineAs BC6ENTC metabolism deficiencies have been seen in placental infarcts previously, these indicate that BC6OTHER / BC6ENTG may have a role in placental diseases. CPR:falsenewlineCloning, sequencing, structural and molecular biological characterization of BC6OTHER ( BC6OTHER ) / human BC6ENTC pyrophosphokinase ( BC6ENTG ). CPR:falsenewlineCloning, sequencing, structural and molecular biological characterization of BC6ENTG ( BC6OTHER ) / human BC6ENTC pyrophosphokinase ( BC6OTHER ). CPR:falsenewlineCloning, sequencing, structural and molecular biological characterization of BC6OTHER ( BC6ENTG ) / human BC6ENTC pyrophosphokinase ( BC6OTHER ). CPR:falsenewlineThe BC6ENTC secretory response is mediated via a non - BC6ENTG pathway, and the driving force for BC6OTHER secretion is enhanced by the effect of BC6OTHER activation to also inhibit epithelial BC6OTHER transport. CPR:falsenewlineThe BC6ENTC secretory response is mediated via a non - BC6OTHER pathway, and the driving force for BC6OTHER secretion is enhanced by the effect of BC6ENTG activation to also inhibit epithelial BC6OTHER transport. CPR:falsenewlineThe BC6OTHER secretory response is mediated via a non - BC6ENTG pathway, and the driving force for BC6ENTC secretion is enhanced by the effect of BC6OTHER activation to also inhibit epithelial BC6OTHER transport. CPR:falsenewlineThe BC6OTHER secretory response is mediated via a non - BC6OTHER pathway, and the driving force for BC6ENTC secretion is enhanced by the effect of BC6ENTG activation to also inhibit epithelial BC6OTHER transport. CPR:falsenewlineThe BC6OTHER secretory response is mediated via a non - BC6ENTG pathway, and the driving force for BC6OTHER secretion is enhanced by the effect of BC6OTHER activation to also inhibit epithelial BC6ENTC transport. CPR:falsenewlineThe BC6OTHER secretory response is mediated via a non - BC6OTHER pathway, and the driving force for BC6OTHER secretion is enhanced by the effect of BC6ENTG activation to also inhibit epithelial BC6ENTC transport. CPR:falsenewlineBC6ENTC is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated BC6ENTG agonists. CPR:falsenewlineSafety and tolerability of BC6ENTC inhalation solution, a novel BC6ENTG agonist: results of a phase 1 / phase 2 multicenter study in mild to moderate cystic fibrosis. CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a selective BC6ENTG agonist that stimulates ciliary beat frequency and BC6OTHER secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF. CPR:5newlineBC6OTHER ( BC6OTHER ) is a selective BC6ENTG agonist that stimulates ciliary beat frequency and BC6ENTC secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF. CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a selective BC6ENTG agonist that stimulates ciliary beat frequency and BC6OTHER secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF. CPR:falsenewlineThree lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6ENTC ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG . CPR:falsenewlineThree lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6ENTC - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG . CPR:falsenewlineThree lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6ENTC induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG . CPR:falsenewlineThree lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6ENTC - labeled BC6ENTG . CPR:falsenewlineWe have found that certain BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts. CPR:falsenewlineThe extent of BC6ENTG loss is less than for BC6OTHER , and the BC6OTHER do not reappear at the surface when BC6ENTC is removed. CPR:falsenewlineThe extent of BC6OTHER loss is less than for BC6ENTG , and the BC6OTHER do not reappear at the surface when BC6ENTC is removed. CPR:falsenewlineThe extent of BC6OTHER loss is less than for BC6OTHER , and the BC6ENTG do not reappear at the surface when BC6ENTC is removed. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts. CPR:falsenewlineBC6ENTC did not induce a loss of cell surface BC6ENTG , a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of BC6OTHER was specific for membrane receptors and not a result of bulk depletion of plasma membrane. CPR:falsenewlineBC6OTHER did not induce a loss of cell surface BC6ENTG , a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of BC6ENTC was specific for membrane receptors and not a result of bulk depletion of plasma membrane. CPR:falsenewlineLoss of BC6OTHER and BC6ENTG surface binding induced by BC6OTHER and BC6ENTC . CPR:falsenewlineLoss of BC6ENTG and BC6OTHER surface binding induced by BC6OTHER and BC6ENTC . CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] and BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts. CPR:falsenewlineLoss of BC6OTHER and BC6ENTG surface binding induced by BC6ENTC and BC6OTHER . CPR:falsenewlineLoss of BC6ENTG and BC6OTHER surface binding induced by BC6ENTC and BC6OTHER . CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6ENTC [e.g., BC6OTHER ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts. CPR:falsenewlineSince both BC6ENTC and BC6OTHER are potent inhibitors of BC6ENTG , we investigated the possibility that inhibition of BC6OTHER was responsible for the loss of receptors. CPR:falsenewlineSince both BC6ENTC and BC6OTHER are potent inhibitors of BC6OTHER , we investigated the possibility that inhibition of BC6ENTG was responsible for the loss of receptors. CPR:falsenewlineSince both BC6OTHER and BC6ENTC are potent inhibitors of BC6ENTG , we investigated the possibility that inhibition of BC6OTHER was responsible for the loss of receptors. CPR:falsenewlineSince both BC6OTHER and BC6ENTC are potent inhibitors of BC6OTHER , we investigated the possibility that inhibition of BC6ENTG was responsible for the loss of receptors. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6ENTC ( BC6OTHER )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] induce a loss of cell - surface receptors for BC6ENTG , and BC6OTHER ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] induce a loss of cell - surface receptors for BC6OTHER , and BC6ENTG ( BC6OTHER ) in fibroblasts. CPR:falsenewlineWe have found that certain BC6OTHER [e.g., BC6OTHER ( BC6OTHER )] and BC6OTHER [e.g., BC6OTHER ( BC6ENTC )] induce a loss of cell - surface receptors for BC6OTHER , and BC6OTHER ( BC6ENTG ) in fibroblasts. CPR:falsenewlineThree lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6ENTC , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG . CPR:falsenewlineThree lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6ENTC that is a poor inhibitor of calmodulin, is nearly as effective as BC6OTHER at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG . CPR:falsenewlineThree lines of evidence suggest that BC6ENTG inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6ENTG functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6ENTG into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6ENTG over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6ENTG , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6ENTG , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6ENTG , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6OTHER . CPR:falsenewlineThree lines of evidence suggest that BC6OTHER inhibition is not responsible for the inhibition of binding and endocytosis: 1) BC6OTHER , a BC6OTHER that is a poor inhibitor of calmodulin, is nearly as effective as BC6ENTC at inhibiting endocytosis; CHEM, a potent inhibitor of several BC6OTHER functions, did not cause a loss of binding; 2) the microinjection of BC6OTHER into cells did not reverse the effects of BC6OTHER ; using pressure microinjection, we introduced up to a 100 - fold excess of BC6OTHER over native levels into individual gerbil fibroma cells; using BC6OTHER - labeled BC6OTHER , we saw that the BC6OTHER induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells; 3) we injected BC6OTHER , a BC6OTHER , into cells (1 - 3 pg / cell) and observed no effect on the receptor - mediated endocytosis of BC6OTHER - labeled BC6ENTG . CPR:falsenewlineWild - type enzymes and variants of BC6ENTG ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6ENTG and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTG ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6ENTC ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6ENTG ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6ENTG and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTG ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6ENTC , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6ENTG ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6ENTG and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates. CPR:9newlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates. CPR:9newlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates. CPR:9newlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTG ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6ENTC ( BC6OTHER ) as substrates. CPR:9newlineWild - type enzymes and variants of BC6ENTG ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6ENTG and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTG ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6OTHER ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6ENTC ) as substrates. CPR:falsenewlineAll three BC6ENTG proteins showed similar K(m) and V(max) for BC6ENTC and BC6OTHER deamination, except for BC6OTHER 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6OTHER deamination. CPR:falsenewlineAll three BC6OTHER proteins showed similar K(m) and V(max) for BC6ENTC and BC6OTHER deamination, except for BC6ENTG 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6OTHER deamination. CPR:falsenewlineAll three BC6ENTG proteins showed similar K(m) and V(max) for BC6OTHER and BC6ENTC deamination, except for BC6OTHER 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6OTHER deamination. CPR:falsenewlineAll three BC6OTHER proteins showed similar K(m) and V(max) for BC6OTHER and BC6ENTC deamination, except for BC6ENTG 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6OTHER deamination. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6ENTC deaminase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6ENTC deaminase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6ENTC deaminase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineAll three BC6ENTG proteins showed similar K(m) and V(max) for BC6OTHER and BC6OTHER deamination, except for BC6OTHER 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6ENTC deamination. CPR:falsenewlineAll three BC6OTHER proteins showed similar K(m) and V(max) for BC6OTHER and BC6OTHER deamination, except for BC6ENTG 70Thr, which had a 2.5 - fold lower K(m) and 6 - fold lower V(max) for BC6ENTC deamination. CPR:falsenewlineAll four BC6ENTG proteins yielded comparable metabolic activity for BC6ENTC and BC6OTHER monophosphorylation, except for BC6OTHER 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6OTHER monophosphorylation due to a 40% decrease in K(m) (P < 0.05). CPR:falsenewlineAll four BC6OTHER proteins yielded comparable metabolic activity for BC6ENTC and BC6OTHER monophosphorylation, except for BC6ENTG 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6OTHER monophosphorylation due to a 40% decrease in K(m) (P < 0.05). CPR:falsenewlineAll four BC6ENTG proteins yielded comparable metabolic activity for BC6OTHER and BC6ENTC monophosphorylation, except for BC6OTHER 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6OTHER monophosphorylation due to a 40% decrease in K(m) (P < 0.05). CPR:falsenewlineAll four BC6OTHER proteins yielded comparable metabolic activity for BC6OTHER and BC6ENTC monophosphorylation, except for BC6ENTG 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6OTHER monophosphorylation due to a 40% decrease in K(m) (P < 0.05). CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:9newlineBC6ENTC ( BC6OTHER , BC6OTHER ) is metabolized by BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:9newlineBC6ENTC ( BC6OTHER , BC6OTHER ) is metabolized by BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:9newlineBC6ENTC ( BC6OTHER , BC6OTHER ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:9newlineBC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6ENTC kinase ( BC6ENTG ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6ENTG ( BC6OTHER ) and BC6ENTC kinase ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER ) is metabolized by BC6OTHER ( BC6ENTG ) and BC6ENTC kinase ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineAll four BC6ENTG proteins yielded comparable metabolic activity for BC6OTHER and BC6OTHER monophosphorylation, except for BC6OTHER 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6ENTC monophosphorylation due to a 40% decrease in K(m) (P < 0.05). CPR:falsenewlineAll four BC6OTHER proteins yielded comparable metabolic activity for BC6OTHER and BC6OTHER monophosphorylation, except for BC6ENTG 24Val, which demonstrated an approximately 2 - fold increase (P < 0.05) in the intrinsic clearance of BC6ENTC monophosphorylation due to a 40% decrease in K(m) (P < 0.05). CPR:falsenewlinePharmacogenomics of BC6OTHER metabolism: functional analysis of genetic variants in BC6ENTG and BC6ENTC kinase. CPR:falsenewlinePharmacogenomics of BC6ENTC metabolism: functional analysis of genetic variants in BC6OTHER and BC6ENTG . CPR:falsenewlinePharmacogenomics of BC6ENTC metabolism: functional analysis of genetic variants in BC6ENTG and BC6OTHER . CPR:falsenewlinePharmacogenomics of BC6OTHER metabolism: functional analysis of genetic variants in BC6ENTC deaminase and BC6ENTG . CPR:falsenewlineBC6ENTG did not significantly contribute to BC6ENTC monophosphorylation. CPR:falsenewlineIn conclusion, the BC6ENTG substitution does not significantly modulate BC6OTHER activity toward BC6ENTC , and therefore would not contribute to interindividual variability in response to BC6OTHER . CPR:falsenewlineIn conclusion, the BC6OTHER substitution does not significantly modulate BC6ENTG activity toward BC6ENTC , and therefore would not contribute to interindividual variability in response to BC6OTHER . CPR:falsenewlineIn conclusion, the BC6ENTG substitution does not significantly modulate BC6OTHER activity toward BC6OTHER , and therefore would not contribute to interindividual variability in response to BC6ENTC . CPR:falsenewlineIn conclusion, the BC6OTHER substitution does not significantly modulate BC6ENTG activity toward BC6OTHER , and therefore would not contribute to interindividual variability in response to BC6ENTC . CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:9newlineBC6OTHER ( BC6ENTC , BC6OTHER ) is metabolized by BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER ) is metabolized by BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:9newlineThe higher in vitro catalytic efficiency of BC6ENTG 24Val toward BC6ENTC monophosphorylation may be relevant to BC6OTHER clinical response. CPR:9newlineThe higher in vitro catalytic efficiency of BC6ENTG 24Val toward BC6OTHER monophosphorylation may be relevant to BC6ENTC clinical response. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) is metabolized by BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) is metabolized by BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC ) is metabolized by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear. CPR:falsenewlineWild - type enzymes and variants of BC6ENTG ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6ENTG and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:falsenewlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG , and BC6OTHER ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:9newlineWild - type enzymes and variants of BC6OTHER ( BC6OTHER and BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTG ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for BC6ENTC ( BC6OTHER ), BC6OTHER , and its metabolite BC6OTHER ( BC6OTHER ) as substrates. CPR:9newlineWe propose that volatile anesthetics inhibit BC6ENTC - ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6ENTG , BC6OTHER , and BC6OTHER kinase (Schoenborn, B. P., and CHEM, R. M. (1967) Adv. CPR:falsenewlineWe propose that volatile anesthetics inhibit BC6ENTC - ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6OTHER , BC6ENTG , and BC6OTHER kinase (Schoenborn, B. P., and CHEM, R. M. (1967) Adv. CPR:falsenewlineWe propose that volatile anesthetics inhibit BC6ENTC - ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6OTHER , BC6OTHER , and BC6ENTG (Schoenborn, B. P., and CHEM, R. M. (1967) Adv. CPR:falsenewlineWe propose that volatile anesthetics inhibit BC6ENTG by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6OTHER , BC6OTHER , and BC6ENTC kinase (Schoenborn, B. P., and CHEM, R. M. (1967) Adv. CPR:falsenewlineWe propose that volatile anesthetics inhibit BC6OTHER - ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6ENTG , BC6OTHER , and BC6ENTC kinase (Schoenborn, B. P., and CHEM, R. M. (1967) Adv. CPR:falsenewlineWe propose that volatile anesthetics inhibit BC6OTHER - ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for BC6OTHER , BC6ENTG , and BC6ENTC kinase (Schoenborn, B. P., and CHEM, R. M. (1967) Adv. CPR:falsenewlineWe have investigated the mechanism of the inhibitory action of several anesthetics on the purified erythrocyte BC6ENTG by employing fluorescence spectroscopy measurements that report changes in the environment of intrinsic BC6ENTC and of an extrinsic probe attached in the active site of the enzyme. CPR:falsenewlineBC6ENTG - facilitated BC6OTHER efflux and lipid parameters did not differ between BC6OTHER - producing and non - BC6ENTC - producing women. CPR:falsenewlineCONCLUSION: In postmenopausal women, isolated BC6ENTC treatment does not affect BC6ENTG - dependent BC6OTHER efflux potential from macrophages but increases circulating BC6OTHER level, which could provide beneficial vascular effects. CPR:falsenewlineCONCLUSION: In postmenopausal women, isolated BC6ENTC treatment does not affect BC6OTHER - dependent BC6OTHER efflux potential from macrophages but increases circulating BC6ENTG level, which could provide beneficial vascular effects. CPR:falsenewlineCONCLUSION: In postmenopausal women, isolated BC6OTHER treatment does not affect BC6ENTG - dependent BC6ENTC efflux potential from macrophages but increases circulating BC6OTHER level, which could provide beneficial vascular effects. CPR:falsenewlineCONCLUSION: In postmenopausal women, isolated BC6OTHER treatment does not affect BC6OTHER - dependent BC6ENTC efflux potential from macrophages but increases circulating BC6ENTG level, which could provide beneficial vascular effects. CPR:falsenewlineWe studied in a clinical trial whether isolated BC6OTHER treatment in postmenopausal women could affect reverse BC6ENTC transport as evaluated by BC6ENTG - ( BC6OTHER ), dependent BC6OTHER efflux from macrophages. CPR:falsenewlineWe studied in a clinical trial whether isolated BC6OTHER treatment in postmenopausal women could affect reverse BC6ENTC transport as evaluated by BC6OTHER - ( BC6ENTG ), dependent BC6OTHER efflux from macrophages. CPR:falsenewlineWe studied in a clinical trial whether isolated BC6OTHER treatment in postmenopausal women could affect reverse BC6OTHER transport as evaluated by BC6ENTC - binding cassette A1 - ( BC6ENTG ), dependent BC6OTHER efflux from macrophages. CPR:falsenewlineWe studied in a clinical trial whether isolated BC6OTHER treatment in postmenopausal women could affect reverse BC6OTHER transport as evaluated by BC6ENTG - ( BC6OTHER ), dependent BC6ENTC efflux from macrophages. CPR:falsenewlineWe studied in a clinical trial whether isolated BC6OTHER treatment in postmenopausal women could affect reverse BC6OTHER transport as evaluated by BC6OTHER - ( BC6ENTG ), dependent BC6ENTC efflux from macrophages. CPR:falsenewlineBC6ENTC - labeled J774 macrophage cells, with and without BC6OTHER up - regulation, were incubated with the samples, and BC6OTHER - dependent BC6OTHER efflux and serum lipid and BC6ENTG levels were assessed. CPR:falsenewlineBC6ENTC - labeled J774 macrophage cells, with and without BC6ENTG up - regulation, were incubated with the samples, and BC6OTHER - dependent BC6OTHER efflux and serum lipid and BC6OTHER levels were assessed. CPR:falsenewlineBC6ENTC - labeled J774 macrophage cells, with and without BC6OTHER up - regulation, were incubated with the samples, and BC6ENTG - dependent BC6OTHER efflux and serum lipid and BC6OTHER levels were assessed. CPR:falsenewlineBC6OTHER - labeled J774 macrophage cells, with and without BC6OTHER up - regulation, were incubated with the samples, and BC6OTHER - dependent BC6ENTC efflux and serum lipid and BC6ENTG levels were assessed. CPR:falsenewlineBC6OTHER - labeled J774 macrophage cells, with and without BC6ENTG up - regulation, were incubated with the samples, and BC6OTHER - dependent BC6ENTC efflux and serum lipid and BC6OTHER levels were assessed. CPR:falsenewlineBC6OTHER - labeled J774 macrophage cells, with and without BC6OTHER up - regulation, were incubated with the samples, and BC6ENTG - dependent BC6ENTC efflux and serum lipid and BC6OTHER levels were assessed. CPR:falsenewlineEffect of isolated BC6ENTC supplementation on BC6ENTG - dependent BC6OTHER efflux potential in postmenopausal women. CPR:falsenewlineEffect of isolated BC6OTHER supplementation on BC6ENTG - dependent BC6ENTC efflux potential in postmenopausal women. CPR:falsenewlineThus, BC6ENTC supplementation did not affect BC6ENTG - dependent BC6OTHER efflux to serum. CPR:falsenewlineThus, BC6OTHER supplementation did not affect BC6ENTG - dependent BC6ENTC efflux to serum. CPR:falsenewlineHowever, as a novel finding, BC6ENTC treatment increased a subclass of BC6ENTG , the BC6OTHER levels by 18% without affecting any other serum lipid concentrations. CPR:falsenewlineHowever, as a novel finding, BC6ENTC treatment increased a subclass of BC6OTHER , the BC6ENTG levels by 18% without affecting any other serum lipid concentrations. CPR:falsenewlineWe studied in a clinical trial whether isolated BC6ENTC treatment in postmenopausal women could affect reverse BC6OTHER transport as evaluated by BC6ENTG - ( BC6OTHER ), dependent BC6OTHER efflux from macrophages. CPR:falsenewlineWe studied in a clinical trial whether isolated BC6ENTC treatment in postmenopausal women could affect reverse BC6OTHER transport as evaluated by BC6OTHER - ( BC6ENTG ), dependent BC6OTHER efflux from macrophages. CPR:falsenewlineBC6ENTG - facilitated BC6ENTC efflux and lipid parameters did not differ between BC6OTHER - producing and non - BC6OTHER - producing women. CPR:falsenewlineBC6ENTG - facilitated BC6OTHER efflux and lipid parameters did not differ between BC6ENTC - producing and non - BC6OTHER - producing women. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6ENTC absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG ) produced by BC6OTHER ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) produced by BC6ENTC ( BC6OTHER / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) produced by BC6OTHER ( BC6ENTC / BC6OTHER ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells. CPR:falsenewlineThis study evaluates the production of inflammatory biomarkers ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and the influence of gene expression transporters and enzymes related to BC6OTHER absorption and metabolism ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) produced by BC6OTHER ( BC6OTHER / BC6ENTC ) in Caco - 2 cells. CPR:falsenewlineIn non - pre - treated cells, only BC6ENTG were down - regulated by BC6ENTC , showing a greater influence upon BC6OTHER expression. CPR:4newlineIn non - pre - treated cells, only BC6OTHER were down - regulated by BC6ENTC , showing a greater influence upon BC6ENTG expression. CPR:4newlineCell - pre - incubation with BC6ENTC induced changes in BC6ENTG expression levels after BC6OTHER - incubation; however, the energetic metabolism inhibition reduced BC6OTHER expression only in BC6OTHER - incubated cells. CPR:falsenewlineCell - pre - incubation with BC6ENTC induced changes in BC6OTHER expression levels after BC6OTHER - incubation; however, the energetic metabolism inhibition reduced BC6ENTG expression only in BC6OTHER - incubated cells. CPR:falsenewlineCell - pre - incubation with BC6ENTG induced changes in BC6OTHER expression levels after BC6OTHER - incubation; however, the energetic metabolism inhibition reduced BC6OTHER expression only in BC6ENTC - incubated cells. CPR:falsenewlineCell - pre - incubation with BC6OTHER induced changes in BC6ENTG expression levels after BC6OTHER - incubation; however, the energetic metabolism inhibition reduced BC6OTHER expression only in BC6ENTC - incubated cells. CPR:falsenewlineCell - pre - incubation with BC6OTHER induced changes in BC6OTHER expression levels after BC6OTHER - incubation; however, the energetic metabolism inhibition reduced BC6ENTG expression only in BC6ENTC - incubated cells. CPR:falsenewlineCell - pre - incubation with BC6ENTG induced changes in BC6OTHER expression levels after BC6ENTC - incubation; however, the energetic metabolism inhibition reduced BC6OTHER expression only in BC6OTHER - incubated cells. CPR:falsenewlineCell - pre - incubation with BC6OTHER induced changes in BC6ENTG expression levels after BC6ENTC - incubation; however, the energetic metabolism inhibition reduced BC6OTHER expression only in BC6OTHER - incubated cells. CPR:falsenewlineCell - pre - incubation with BC6OTHER induced changes in BC6OTHER expression levels after BC6ENTC - incubation; however, the energetic metabolism inhibition reduced BC6ENTG expression only in BC6OTHER - incubated cells. CPR:falsenewlineRelative expression of c BC6ENTG and inflammation markers through the induction of BC6ENTC - mediated stress in Caco - 2 cells. CPR:falsenewlineIn non - pre - treated cells, BC6ENTG was up - regulated by both BC6ENTC . CPR:3newlineThese results suggest that internalization and excretion of BC6ENTC is probably influenced by [ BC6OTHER ]i, which also could mediate BC6ENTG activity in POPs metabolism. CPR:9newlineThese results suggest that internalization and excretion of BC6OTHER is probably influenced by [ BC6ENTC ]i, which also could mediate BC6ENTG activity in POPs metabolism. CPR:9newlineThe predicted structure of BC6ENTG showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6ENTG , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6ENTG and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6ENTG has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6ENTG , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6ENTG , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6ENTG , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6ENTG , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6ENTG , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTC protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTG , from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6ENTG showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6ENTG , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6ENTG and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTG , from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6ENTG has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6ENTG , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6ENTG , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6ENTG , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6ENTG , a BC6OTHER , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6ENTG , and a BC6OTHER protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6ENTC - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTG , from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6ENTG showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6ENTG , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6ENTG and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTG , from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6ENTG has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6ENTG , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6ENTG , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6ENTG , an BC6OTHER , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6ENTG , a BC6OTHER , and a BC6ENTC protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6ENTG , and a BC6ENTC protease domain, from its BC6OTHER - terminus. CPR:falsenewlineThe predicted structure of BC6ENTG showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6ENTG , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6ENTG and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6ENTG , from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6ENTG has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6ENTG , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6ENTG , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6ENTG , an BC6OTHER , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6ENTG , a BC6OTHER , and a BC6OTHER protease domain, from its BC6ENTC - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6ENTG , and a BC6OTHER protease domain, from its BC6ENTC - terminus. CPR:falsenewlineThe predicted structure of BC6OTHER showed three BC6OTHER , a BC6OTHER and a BC6OTHER protease domain, from its BC6OTHER - terminus, although BC6OTHER has a BC6OTHER , an BC6OTHER , a BC6OTHER , an BC6OTHER , a BC6OTHER , and a BC6ENTG , from its BC6ENTC - terminus. CPR:falsenewlineThus, BC6ENTG was a heterodimer composed of 50 - kDa and 17 - kDa subunits, bridged by a BC6ENTC linkage. CPR:falsenewlineBoth subunits had novel BC6ENTC sequences, indicating that BC6ENTG was a novel hyaluronan - binding protein in human plasma. CPR:falsenewlineThe BC6ENTC sequence deduced from the BC6OTHER sequence of the cloned BC6ENTG cDNA exhibited significant homology to that of BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe BC6ENTC sequence deduced from the BC6OTHER sequence of the cloned BC6OTHER cDNA exhibited significant homology to that of BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe BC6ENTC sequence deduced from the BC6OTHER sequence of the cloned BC6OTHER cDNA exhibited significant homology to that of BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe BC6OTHER sequence deduced from the BC6ENTC sequence of the cloned BC6ENTG cDNA exhibited significant homology to that of BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe BC6OTHER sequence deduced from the BC6ENTC sequence of the cloned BC6OTHER cDNA exhibited significant homology to that of BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe BC6OTHER sequence deduced from the BC6ENTC sequence of the cloned BC6OTHER cDNA exhibited significant homology to that of BC6OTHER ( BC6ENTG ). CPR:falsenewlinePurification and characterization of a novel BC6ENTG ( BC6OTHER ) from human plasma: it has three EGF, a kringle and a BC6ENTC protease domain, similar to hepatocyte growth factor activator. CPR:falsenewlinePurification and characterization of a novel BC6OTHER ( BC6ENTG ) from human plasma: it has three EGF, a kringle and a BC6ENTC protease domain, similar to hepatocyte growth factor activator. CPR:falsenewlineHowever, plasma pro - BC6ENTG and BC6ENTC concentrations were closely correlated (P < .0001; r = 0.73). CPR:falsenewlineMoreover, the active permethylated BC6ENTC aglycon derivatives examined exhibit BC6ENTG VRE antimicrobial activity at levels that approach (typically within 2 - fold) their activity against sensitive bacteria. CPR:falsenewlineConsistent with an adult - onset isolated GHD model, mutant animals are hypoglycemic and display increased BC6ENTG sensitivity and BC6ENTC clearance. CPR:falsenewlineOxidation with BC6OTHER was similarly assessed, and adhesion of BC6ENTG and BC6OTHER from BC6ENTC buffered saline was then assayed by QCM and imaged by AFM. CPR:falsenewlineOxidation with BC6OTHER was similarly assessed, and adhesion of BC6OTHER and BC6ENTG from BC6ENTC buffered saline was then assayed by QCM and imaged by AFM. CPR:falsenewlineBC6ENTC - functionalized sensors adsorbed multilayers of aggregated BC6ENTG , whereas BC6OTHER and BC6OTHER - terminated monolayers are consistent with small protein aggregates. CPR:falsenewlineSelective oxidation of BC6OTHER self - assembled BC6OTHER monolayers to BC6ENTC is shown to transform the adhesion of model proteins BC6ENTG and BC6OTHER upon them. CPR:falsenewlineSelective oxidation of BC6OTHER self - assembled BC6OTHER monolayers to BC6ENTC is shown to transform the adhesion of model proteins BC6OTHER and BC6ENTG upon them. CPR:falsenewlineBC6OTHER - functionalized sensors adsorbed multilayers of aggregated BC6ENTG , whereas BC6ENTC and BC6OTHER - terminated monolayers are consistent with small protein aggregates. CPR:falsenewlineBC6OTHER - functionalized sensors adsorbed multilayers of aggregated BC6ENTG , whereas BC6OTHER and BC6ENTC - terminated monolayers are consistent with small protein aggregates. CPR:falsenewlineSelective oxidation of BC6ENTC self - assembled BC6OTHER monolayers to BC6OTHER is shown to transform the adhesion of model proteins BC6ENTG and BC6OTHER upon them. CPR:falsenewlineSelective oxidation of BC6ENTC self - assembled BC6OTHER monolayers to BC6OTHER is shown to transform the adhesion of model proteins BC6OTHER and BC6ENTG upon them. CPR:falsenewlineSelective oxidation of BC6OTHER self - assembled BC6ENTC monolayers to BC6OTHER is shown to transform the adhesion of model proteins BC6ENTG and BC6OTHER upon them. CPR:falsenewlineSelective oxidation of BC6OTHER self - assembled BC6ENTC monolayers to BC6OTHER is shown to transform the adhesion of model proteins BC6OTHER and BC6ENTG upon them. CPR:falsenewlineOxidation with BC6ENTC was similarly assessed, and adhesion of BC6ENTG and BC6OTHER from BC6OTHER buffered saline was then assayed by QCM and imaged by AFM. CPR:falsenewlineOxidation with BC6ENTC was similarly assessed, and adhesion of BC6OTHER and BC6ENTG from BC6OTHER buffered saline was then assayed by QCM and imaged by AFM. CPR:falsenewlineThe key difference in structure of BC6ENTG and BC6OTHER is replacement of BC6ENTC with BC6OTHER at position 560. CPR:falsenewlineThe key difference in structure of BC6OTHER and BC6ENTG is replacement of BC6ENTC with BC6OTHER at position 560. CPR:falsenewlineThe key difference in structure of BC6ENTG and BC6OTHER is replacement of BC6OTHER with BC6ENTC at position 560. CPR:falsenewlineThe key difference in structure of BC6OTHER and BC6ENTG is replacement of BC6OTHER with BC6ENTC at position 560. CPR:falsenewlineA series of compounds based on a BC6ENTC scaffold that are potent and selective inhibitors of BC6ENTG ( BC6OTHER ) activity are described. CPR:4newlineA series of compounds based on a BC6ENTC scaffold that are potent and selective inhibitors of BC6OTHER ( BC6ENTG ) activity are described. CPR:4newlineDiscovery of BC6ENTC based BC6ENTG inhibitors. CPR:falsenewlineAfter pretreatment with single BC6ENTC , cells were stimulated with pro - inflammatory BC6OTHER ( BC6ENTG , BC6OTHER , BC6OTHER ). CPR:falsenewlineAfter pretreatment with single BC6ENTC , cells were stimulated with pro - inflammatory BC6OTHER ( BC6OTHER , BC6ENTG , BC6OTHER ). CPR:falsenewlineAfter pretreatment with single BC6ENTC , cells were stimulated with pro - inflammatory BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTG ). CPR:falsenewlineAfter pretreatment with single BC6ENTC , cells were stimulated with pro - inflammatory BC6ENTG ( BC6OTHER , BC6OTHER , BC6OTHER ). CPR:falsenewlineWe show that BC6ENTG and BC6OTHER do not reveal activity towards the checked CHEM, but that BC6OTHER reduces CHEM to BC6ENTC , and is thus also involved in CHEM metabolism. CPR:falsenewlineWe show that BC6OTHER and BC6ENTG do not reveal activity towards the checked CHEM, but that BC6OTHER reduces CHEM to BC6ENTC , and is thus also involved in CHEM metabolism. CPR:falsenewlineWe show that BC6OTHER and BC6OTHER do not reveal activity towards the checked CHEM, but that BC6ENTG reduces CHEM to BC6ENTC , and is thus also involved in CHEM metabolism. CPR:9newlineThree BC6ENTC dehydrogenases ( BC6OTHER ) were tested for CHEM converting abilities: BC6ENTG and BC6OTHER . CPR:falsenewlineThree BC6ENTC dehydrogenases ( BC6OTHER ) were tested for CHEM converting abilities: BC6OTHER and BC6ENTG . CPR:falsenewlineThree BC6ENTC dehydrogenases ( BC6ENTG ) were tested for CHEM converting abilities: BC6OTHER and BC6OTHER . CPR:falsenewline BC6ENTG , a BC6ENTC dehydrogenase causing Leber's congenital amaurosis, is also involved in CHEM metabolism. CPR:9newlineBC6OTHER administration enhanced BC6ENTC ( BC6OTHER ) activity, BC6ENTG ( BC6OTHER ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6ENTC ( BC6OTHER ) activity, BC6OTHER ( BC6ENTG ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6ENTC ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6ENTG / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6ENTC ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6OTHER / BC6ENTG pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6ENTC ) activity, BC6ENTG ( BC6OTHER ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6ENTC ) activity, BC6OTHER ( BC6ENTG ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6ENTC ) activity, BC6OTHER ( BC6OTHER ) expression and BC6ENTG / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6ENTC ) activity, BC6OTHER ( BC6OTHER ) expression and BC6OTHER / BC6ENTG pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6ENTG ( BC6OTHER ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6ENTC injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6ENTG ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6ENTC injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6ENTG / BC6OTHER pathway activation, which might ameliorate BC6ENTC injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6OTHER / BC6ENTG pathway activation, which might ameliorate BC6ENTC injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6ENTG ( BC6OTHER ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6ENTC species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6ENTG ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6ENTC species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6ENTG / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6ENTC species (ROS) formation in mice. CPR:falsenewlineBC6OTHER administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6OTHER / BC6ENTG pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6ENTC species (ROS) formation in mice. CPR:falsenewlineIn addition to the effect on ROS, BC6ENTC ameliorated BC6OTHER - reduced BC6ENTG ( BC6OTHER ) expression. CPR:falsenewlineIn addition to the effect on ROS, BC6ENTC ameliorated BC6OTHER - reduced BC6OTHER ( BC6ENTG ) expression. CPR:falsenewlineIn addition to the effect on ROS, BC6OTHER ameliorated BC6ENTC - reduced BC6ENTG ( BC6OTHER ) expression. CPR:falsenewlineIn addition to the effect on ROS, BC6OTHER ameliorated BC6ENTC - reduced BC6OTHER ( BC6ENTG ) expression. CPR:falsenewlineTaken together, our data demonstrate that BC6ENTC attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6ENTG expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6ENTC attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6ENTG / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6ENTC attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6ENTG pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6ENTC attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6ENTG expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6ENTC - induced dopaminergic neuronal degeneration via modulating BC6ENTG expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6ENTC - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6ENTG / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6ENTC - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6ENTG pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6ENTC - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6ENTG expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6ENTG expression, BC6OTHER / BC6OTHER pathway and BC6ENTC activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6ENTG / BC6OTHER pathway and BC6ENTC activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6ENTG pathway and BC6ENTC activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6OTHER pathway and BC6ENTC activation, which subsequently ameliorate BC6OTHER - induced ROS formation and decrease of BC6ENTG expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6ENTG expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6ENTC - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6ENTG / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6ENTC - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6ENTG pathway and BC6OTHER activation, which subsequently ameliorate BC6ENTC - induced ROS formation and decrease of BC6OTHER expression. CPR:falsenewlineTaken together, our data demonstrate that BC6OTHER attenuates BC6OTHER - induced dopaminergic neuronal degeneration via modulating BC6OTHER expression, BC6OTHER / BC6OTHER pathway and BC6OTHER activation, which subsequently ameliorate BC6ENTC - induced ROS formation and decrease of BC6ENTG expression. CPR:falsenewlineBC6ENTC administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6ENTG ( BC6OTHER ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6ENTC administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6ENTG ) expression and BC6OTHER / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6ENTC administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6ENTG / BC6OTHER pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineBC6ENTC administration enhanced BC6OTHER ( BC6OTHER ) activity, BC6OTHER ( BC6OTHER ) expression and BC6OTHER / BC6ENTG pathway activation, which might ameliorate BC6OTHER injection - induced progressive elevation of reactive BC6OTHER species (ROS) formation in mice. CPR:falsenewlineWe have identified BC6ENTC deaminase, an enzyme involved in BC6OTHER metabolism whose deficiency is associated with severe combined immunodeficiency, as a BC6ENTG binding protein that is not able to bind to BC6OTHER . CPR:falsenewlineWe have identified BC6ENTC deaminase, an enzyme involved in BC6OTHER metabolism whose deficiency is associated with severe combined immunodeficiency, as a BC6OTHER binding protein that is not able to bind to BC6ENTG . CPR:falsenewlineWe have identified BC6ENTG , an enzyme involved in BC6ENTC metabolism whose deficiency is associated with severe combined immunodeficiency, as a BC6OTHER binding protein that is not able to bind to BC6OTHER . CPR:falsenewlineWe have identified BC6OTHER deaminase, an enzyme involved in BC6ENTC metabolism whose deficiency is associated with severe combined immunodeficiency, as a BC6ENTG binding protein that is not able to bind to BC6OTHER . CPR:falsenewlineWe have identified BC6OTHER deaminase, an enzyme involved in BC6ENTC metabolism whose deficiency is associated with severe combined immunodeficiency, as a BC6OTHER binding protein that is not able to bind to BC6ENTG . CPR:falsenewline BC6ENTC deaminase is a specific partner for the BC6ENTG isoform BC6OTHER . CPR:falsenewline BC6ENTC deaminase is a specific partner for the BC6OTHER isoform BC6ENTG . CPR:falsenewlineinjection of a subthreshold dose of BC6ENTC , a use - dependent BC6ENTG antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice. CPR:falsenewlineAmong all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6ENTC attached to the BC6OTHER atom, BC6OTHER - BC6ENTG , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6OTHER . CPR:falsenewlineAmong all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6ENTC attached to the BC6OTHER atom, BC6OTHER - BC6OTHER , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6ENTG . CPR:falsenewlineAmong all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6ENTC atom, BC6OTHER - BC6ENTG , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6OTHER . CPR:falsenewlineAmong all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6ENTC atom, BC6OTHER - BC6OTHER , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6ENTG . CPR:falsenewlineAmong all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6ENTC - BC6ENTG , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6OTHER . CPR:falsenewlineAmong all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6ENTC - BC6OTHER , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6ENTG . CPR:falsenewlineAmong all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6OTHER - BC6ENTG , conferred the greatest protection to the active site of aged or nonaged BC6ENTC conjugates of BC6OTHER . CPR:falsenewlineAmong all the BC6OTHER tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6OTHER - BC6OTHER , conferred the greatest protection to the active site of aged or nonaged BC6ENTC conjugates of BC6ENTG . CPR:falsenewlineMonoclonal antibody 25B1 generated against BC6ENTC inhibited fetal BC6OTHER has been extensively characterized with respect to its BC6ENTG properties. CPR:falsenewlineMonoclonal antibody 25B1 generated against BC6ENTC inhibited fetal BC6ENTG has been extensively characterized with respect to its BC6OTHER properties. CPR:falsenewlineMonoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of BC6ENTG against denaturation by heat or BC6ENTC following phosphorylation by CHEM BC6OTHER compounds. CPR:falsenewlineMonoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of BC6OTHER against denaturation by heat or BC6ENTC following phosphorylation by CHEM BC6ENTG compounds. CPR:falsenewlineAmong all the BC6ENTC tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6OTHER - BC6ENTG , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6OTHER . CPR:falsenewlineAmong all the BC6ENTC tested, the combination of a CHEM group and a negatively charged BC6OTHER attached to the BC6OTHER atom, BC6OTHER - BC6OTHER , conferred the greatest protection to the active site of aged or nonaged BC6OTHER conjugates of BC6ENTG . CPR:falsenewlineHere, we demonstrate that BC6ENTG ( BC6OTHER ) modulates the action of BC6OTHER - mediated signalling by interacting with BC6ENTC kinase Jak2 ( BC6OTHER ) in a BC6OTHER - dependent manner. CPR:falsenewlineHere, we demonstrate that BC6OTHER ( BC6ENTG ) modulates the action of BC6OTHER - mediated signalling by interacting with BC6ENTC kinase Jak2 ( BC6OTHER ) in a BC6OTHER - dependent manner. CPR:falsenewlineHere, we demonstrate that BC6OTHER ( BC6OTHER ) modulates the action of BC6ENTG - mediated signalling by interacting with BC6ENTC kinase Jak2 ( BC6OTHER ) in a BC6OTHER - dependent manner. CPR:falsenewlineHere, we demonstrate that BC6OTHER ( BC6OTHER ) modulates the action of BC6OTHER - mediated signalling by interacting with BC6ENTC kinase Jak2 ( BC6ENTG ) in a BC6OTHER - dependent manner. CPR:falsenewlineHere, we demonstrate that BC6OTHER ( BC6OTHER ) modulates the action of BC6OTHER - mediated signalling by interacting with BC6ENTC kinase Jak2 ( BC6OTHER ) in a BC6ENTG - dependent manner. CPR:falsenewlineInterestingly, BC6ENTG physically linked BC6OTHER and protein BC6ENTC phosphatase - 1B ( BC6OTHER ) by binding to both using different domains, and this process was implicated in the modulation of BC6OTHER signalling through BC6OTHER . CPR:falsenewlineInterestingly, BC6OTHER physically linked BC6ENTG and protein BC6ENTC phosphatase - 1B ( BC6OTHER ) by binding to both using different domains, and this process was implicated in the modulation of BC6OTHER signalling through BC6OTHER . CPR:falsenewlineInterestingly, BC6OTHER physically linked BC6OTHER and protein BC6ENTC phosphatase - 1B ( BC6ENTG ) by binding to both using different domains, and this process was implicated in the modulation of BC6OTHER signalling through BC6OTHER . CPR:falsenewlineInterestingly, BC6OTHER physically linked BC6OTHER and protein BC6ENTC phosphatase - 1B ( BC6OTHER ) by binding to both using different domains, and this process was implicated in the modulation of BC6ENTG signalling through BC6OTHER . CPR:falsenewlineInterestingly, BC6OTHER physically linked BC6OTHER and protein BC6ENTC phosphatase - 1B ( BC6OTHER ) by binding to both using different domains, and this process was implicated in the modulation of BC6OTHER signalling through BC6ENTG . CPR:falsenewline BC6ENTG negatively regulates BC6OTHER signalling by forming a ternary complex with BC6OTHER and protein BC6ENTC phosphatase - 1B. CPR:falsenewline BC6OTHER negatively regulates BC6OTHER signalling by forming a ternary complex with BC6ENTG and protein BC6ENTC phosphatase - 1B. CPR:falsenewline BC6OTHER negatively regulates BC6ENTG signalling by forming a ternary complex with BC6OTHER and protein BC6ENTC phosphatase - 1B. CPR:falsenewlineIn contrast, BC6OTHER - like nonselective NSAIDs such as BC6OTHER and BC6ENTC inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6ENTG but the constitutively expressed, cytoprotective BC6OTHER as well. CPR:falsenewlineIn contrast, BC6OTHER - like nonselective NSAIDs such as BC6OTHER and BC6ENTC inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6OTHER but the constitutively expressed, cytoprotective BC6ENTG as well. CPR:falsenewlineSelective BC6OTHER inhibitors, such as BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6ENTG but not BC6OTHER . CPR:falsenewlineSelective BC6OTHER inhibitors, such as BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6ENTG . CPR:falsenewlineSelective BC6ENTG inhibitors, such as BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6OTHER . CPR:4newlineSelective BC6OTHER inhibitors, such as BC6OTHER , BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6ENTG but not BC6OTHER . CPR:falsenewlineSelective BC6OTHER inhibitors, such as BC6OTHER , BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6ENTG . CPR:falsenewlineSelective BC6ENTG inhibitors, such as BC6OTHER , BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6OTHER . CPR:falsenewlineSelective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6ENTG but not BC6OTHER . CPR:falsenewlineSelective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6ENTG . CPR:falsenewlineSelective BC6ENTG inhibitors, such as BC6OTHER , BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6OTHER . CPR:falsenewlineSelective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6ENTG but not BC6OTHER . CPR:falsenewlineSelective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6ENTG . CPR:falsenewlineSelective BC6ENTG inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6OTHER . CPR:falsenewlineSelective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ), are NSAIDs that have been modified chemically to preferentially inhibit BC6ENTG but not BC6OTHER . CPR:falsenewlineSelective BC6OTHER inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6ENTG . CPR:falsenewlineSelective BC6ENTG inhibitors, such as BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ), are NSAIDs that have been modified chemically to preferentially inhibit BC6OTHER but not BC6OTHER . CPR:falsenewlineFor instance, BC6ENTC inhibits the growth of cultured colon cancer cells (HCA - 7 and Moser - S) that express BC6ENTG but has no effect on HCT - 116 tumor cells that do not express BC6OTHER . CPR:falsenewlineFor instance, BC6ENTC inhibits the growth of cultured colon cancer cells (HCA - 7 and Moser - S) that express BC6OTHER but has no effect on HCT - 116 tumor cells that do not express BC6ENTG . CPR:falsenewlineBC6ENTC induces apoptosis in BC6ENTG expressing LNCaP prostate cancer cells and, surprisingly, in colon cancer S / KS cells that does not express BC6OTHER . CPR:falsenewlineBC6ENTC induces apoptosis in BC6OTHER expressing LNCaP prostate cancer cells and, surprisingly, in colon cancer S / KS cells that does not express BC6ENTG . CPR:falsenewlineThis effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down - regulation of BC6ENTG , as has been demonstrated for some nonselective NSAIDs, for instance, BC6ENTC . CPR:falsenewlineBC6ENTG produces BC6ENTC that inhibit apoptosis and stimulate angiogenesis and invasiveness. CPR:falsenewlineSelective BC6ENTG inhibitors reduce BC6ENTC synthesis, restore apoptosis, and inhibit cancer cell proliferation. CPR:falsenewlineIn contrast, BC6ENTC - like nonselective NSAIDs such as BC6OTHER and BC6OTHER inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6ENTG but the constitutively expressed, cytoprotective BC6OTHER as well. CPR:falsenewlineIn contrast, BC6ENTC - like nonselective NSAIDs such as BC6OTHER and BC6OTHER inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6OTHER but the constitutively expressed, cytoprotective BC6ENTG as well. CPR:falsenewlineIn contrast, BC6OTHER - like nonselective NSAIDs such as BC6ENTC and BC6OTHER inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6ENTG but the constitutively expressed, cytoprotective BC6OTHER as well. CPR:falsenewlineIn contrast, BC6OTHER - like nonselective NSAIDs such as BC6ENTC and BC6OTHER inhibit not only the enzymatic action of the highly inducible, proinflammatory BC6OTHER but the constitutively expressed, cytoprotective BC6ENTG as well. CPR:falsenewlineThe large - conductance, BC6ENTG blocker, iberiotoxin, attenuated BC6ENTC actions. CPR:falsenewlineEffects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic BC6ENTC receptors and BC6ENTG , but also inhibition via actions at BC6OTHER and BC6OTHER on these neurons. CPR:falsenewlineEffects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic BC6ENTC receptors and BC6OTHER , but also inhibition via actions at BC6ENTG and BC6OTHER on these neurons. CPR:falsenewlineEffects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic BC6ENTC receptors and BC6OTHER , but also inhibition via actions at BC6OTHER and BC6ENTG on these neurons. CPR:falsenewlineBoth outward currents were significantly reduced by the BC6ENTG antagonist BC6ENTC and the BC6OTHER - induced current was blocked by the specific BC6OTHER antagonist BC6OTHER . CPR:falsenewlineBoth outward currents were significantly reduced by the BC6OTHER antagonist BC6ENTC and the BC6OTHER - induced current was blocked by the specific BC6ENTG antagonist BC6OTHER . CPR:falsenewlineTherefore, electrophysiological responses and changes in levels of intracellular BC6ENTC in mouse cholinergic LDT neurons following application of specific BC6ENTG agonists and antagonists were examined. CPR:falsenewlineUnexpectedly, both the BC6ENTG specific agonist, BC6ENTC , and the BC6OTHER ( BC6OTHER ) agonist, BC6OTHER (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization. CPR:falsenewlineUnexpectedly, both the BC6OTHER specific agonist, BC6ENTC , and the BC6ENTG ( BC6OTHER ) agonist, BC6OTHER (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization. CPR:falsenewlineUnexpectedly, both the BC6OTHER specific agonist, BC6ENTC , and the BC6OTHER ( BC6ENTG ) agonist, BC6OTHER (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization. CPR:falsenewlineUnexpectedly, both the BC6ENTG specific agonist, BC6OTHER , and the BC6OTHER ( BC6OTHER ) agonist, BC6ENTC (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization. CPR:falsenewlineUnexpectedly, both the BC6OTHER specific agonist, BC6OTHER , and the BC6ENTG ( BC6OTHER ) agonist, BC6ENTC (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization. CPR:falsenewlineUnexpectedly, both the BC6OTHER specific agonist, BC6OTHER , and the BC6OTHER ( BC6ENTG ) agonist, BC6ENTC (LY), induced a BC6OTHER - insensitive outward current / hyperpolarization. CPR:falsenewlineUnexpectedly, both the BC6ENTG specific agonist, BC6OTHER , and the BC6OTHER ( BC6OTHER ) agonist, BC6OTHER (LY), induced a BC6ENTC - insensitive outward current / hyperpolarization. CPR:falsenewlineUnexpectedly, both the BC6OTHER specific agonist, BC6OTHER , and the BC6ENTG ( BC6OTHER ) agonist, BC6OTHER (LY), induced a BC6ENTC - insensitive outward current / hyperpolarization. CPR:falsenewlineUnexpectedly, both the BC6OTHER specific agonist, BC6OTHER , and the BC6OTHER ( BC6ENTG ) agonist, BC6OTHER (LY), induced a BC6ENTC - insensitive outward current / hyperpolarization. CPR:falsenewlineBoth outward currents were significantly reduced by the BC6ENTG antagonist BC6OTHER and the BC6ENTC - induced current was blocked by the specific BC6OTHER antagonist BC6OTHER . CPR:falsenewlineBoth outward currents were significantly reduced by the BC6OTHER antagonist BC6OTHER and the BC6ENTC - induced current was blocked by the specific BC6ENTG antagonist BC6OTHER . CPR:falsenewlineBoth outward currents were significantly reduced by the BC6ENTG antagonist BC6OTHER and the BC6OTHER - induced current was blocked by the specific BC6OTHER antagonist BC6ENTC . CPR:falsenewlineBoth outward currents were significantly reduced by the BC6OTHER antagonist BC6OTHER and the BC6OTHER - induced current was blocked by the specific BC6ENTG antagonist BC6ENTC . CPR:falsenewlineIn Experiment 2, BC6ENTC induced a significant decrease (p<0.05) in BC6ENTG number and binding affinity at both 0.5 and 4 hours compared with controls. CPR:falsenewlineBC6ENTC and BC6OTHER did not alter BC6ENTG number or binding affinity significantly at each time point studied compared with controls. CPR:falsenewlineBC6OTHER and BC6ENTC did not alter BC6ENTG number or binding affinity significantly at each time point studied compared with controls. CPR:falsenewlineIn conclusion, BC6ENTC may inhibit the uterine response to BC6ENTG by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6ENTC may inhibit the uterine response to BC6OTHER by decreasing BC6ENTG numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6ENTC may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6ENTG binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6ENTC may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTG antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6ENTC by decreasing BC6ENTG numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6ENTC by decreasing BC6OTHER numbers and BC6ENTG binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6ENTC by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTG antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6ENTG by decreasing BC6ENTC receptor numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6ENTC receptor numbers and BC6ENTG binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6ENTC receptor numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTG antagonist activity of BC6OTHER . CPR:falsenewlineBC6ENTC antagonist (OTA), BC6OTHER , was developed by our group and shown to inhibit either spontaneous or BC6ENTG - induced uterine contractions in primates. CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6ENTG by decreasing BC6OTHER numbers and BC6ENTC binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6ENTG numbers and BC6ENTC binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6ENTC binding affinity, which might explain the prolonged BC6ENTG antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6ENTG by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTC antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6ENTG numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTC antagonist activity of BC6OTHER . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6ENTG binding affinity, which might explain the prolonged BC6ENTC antagonist activity of BC6OTHER . CPR:falsenewlineThe purpose of the present study was to confirm the duration of BC6ENTC to block BC6ENTG - induced uterine contractions in estrous rats. CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6ENTG by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6ENTC . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6ENTG numbers and BC6OTHER binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6ENTC . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6ENTG binding affinity, which might explain the prolonged BC6OTHER antagonist activity of BC6ENTC . CPR:falsenewlineIn conclusion, BC6OTHER may inhibit the uterine response to BC6OTHER by decreasing BC6OTHER numbers and BC6OTHER binding affinity, which might explain the prolonged BC6ENTG antagonist activity of BC6ENTC . CPR:falsenewlineBC6ENTG antagonist (OTA), BC6ENTC , was developed by our group and shown to inhibit either spontaneous or BC6OTHER - induced uterine contractions in primates. CPR:falsenewlineBC6OTHER antagonist (OTA), BC6ENTC , was developed by our group and shown to inhibit either spontaneous or BC6ENTG - induced uterine contractions in primates. CPR:falsenewlineBC6ENTG antagonist (OTA), BC6OTHER , was developed by our group and shown to inhibit either spontaneous or BC6ENTC - induced uterine contractions in primates. CPR:falsenewlineIn Experiment 1, BC6ENTC , BC6OTHER and BC6OTHER inhibited the integrated uterine response to BC6ENTG at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05). CPR:falsenewlineIn Experiment 1, BC6OTHER , BC6ENTC and BC6OTHER inhibited the integrated uterine response to BC6ENTG at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05). CPR:falsenewlineIn Experiment 1, BC6OTHER , BC6OTHER and BC6ENTC inhibited the integrated uterine response to BC6ENTG at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05). CPR:falsenewlineAt a mechanistic level both extracts down - regulated BC6ENTG activation, which is associated with BC6ENTC - induced BC6OTHER resistance. CPR:falsenewlineAt a mechanistic level both extracts down - regulated BC6OTHER activation, which is associated with BC6ENTC - induced BC6ENTG resistance. CPR:falsenewlineProtein levels of the BC6ENTC transporter ( BC6ENTG ) involved in BC6OTHER transport via these two pathways were also increased. CPR:falsenewlineProtein levels of the BC6ENTG ( BC6OTHER ) involved in BC6ENTC transport via these two pathways were also increased. CPR:9newlineProtein levels of the BC6OTHER ( BC6ENTG ) involved in BC6ENTC transport via these two pathways were also increased. CPR:9newlineThis in vitro study therefore confirms that rooibos can ameliorate BC6ENTC - induced BC6ENTG resistance in C2C12 skeletal muscle cells. CPR:falsenewlineIncreased levels of BC6ENTC ( BC6OTHER ), specifically BC6OTHER such as BC6OTHER are associated with BC6ENTG resistance of muscle, fat and liver. CPR:falsenewlineRooibos (Aspalathus linearis) and its unique BC6ENTC , BC6OTHER , shown to reduce hyperglycemia in diabetic rats, could play a role in preventing or ameliorating the development of BC6ENTG resistance. CPR:falsenewlineIncreased levels of BC6OTHER ( BC6ENTC ), specifically BC6OTHER such as BC6OTHER are associated with BC6ENTG resistance of muscle, fat and liver. CPR:falsenewlineRooibos (Aspalathus linearis) and its unique BC6OTHER , BC6ENTC , shown to reduce hyperglycemia in diabetic rats, could play a role in preventing or ameliorating the development of BC6ENTG resistance. CPR:falsenewlineIncreased levels of BC6OTHER ( BC6OTHER ), specifically BC6ENTC such as BC6OTHER are associated with BC6ENTG resistance of muscle, fat and liver. CPR:falsenewlineIncreased levels of BC6OTHER ( BC6OTHER ), specifically BC6OTHER such as BC6ENTC are associated with BC6ENTG resistance of muscle, fat and liver. CPR:falsenewlineAmelioration of BC6ENTC - induced BC6ENTG resistance in C2C12 muscle cells by rooibos (Aspalathus linearis). CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6ENTC , was abolished by the BC6ENTG antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6ENTC , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6ENTG antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6ENTC , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6ENTG antagonist, BC6OTHER . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6ENTG agonist, BC6ENTC , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER . CPR:5newlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6ENTG antagonist, BC6ENTC , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6ENTC , the potent BC6ENTG antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6ENTC , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6ENTG antagonist, BC6OTHER . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6ENTG agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6ENTC , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6OTHER . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6ENTG antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6ENTC and the preferential BC6OTHER antagonist, BC6OTHER . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6ENTG antagonist, BC6ENTC and the preferential BC6OTHER antagonist, BC6OTHER . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6ENTC and the preferential BC6ENTG antagonist, BC6OTHER . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6ENTG agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6ENTC and the preferential BC6OTHER antagonist, BC6OTHER . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6ENTG antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6ENTC . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6ENTG antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6ENTC . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6OTHER agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6ENTG antagonist, BC6ENTC . CPR:falsenewlineIn the hot - plate test in mice, the antinociceptive action of the BC6ENTG agonist, BC6OTHER , was abolished by the BC6OTHER antagonist, BC6OTHER , the potent BC6OTHER antagonist, BC6OTHER and the preferential BC6OTHER antagonist, BC6ENTC . CPR:falsenewlineIn contrast, the preferential BC6ENTG ligands ('antagonists'), BC6ENTC , BC6OTHER and BC6OTHER were inactive. CPR:falsenewlineIn contrast, the preferential BC6ENTG ligands ('antagonists'), BC6OTHER , BC6ENTC and BC6OTHER were inactive. CPR:falsenewlineIn contrast, the preferential BC6ENTG ligands ('antagonists'), BC6OTHER , BC6OTHER and BC6ENTC were inactive. CPR:falsenewlineThe preferential BC6ENTG partial agonist, BC6ENTC , partially inhibited BC6OTHER - induced antinociception. CPR:5newlineThe preferential BC6ENTG partial agonist, BC6OTHER , partially inhibited BC6ENTC - induced antinociception. CPR:falsenewlineEA (15mg / kgb.w., p.o.×14days) treatment modulated enhanced BC6ENTC level, lipid peroxidation, BC6ENTG activity, BC6OTHER production and protein BC6OTHER formation in lungs of rats exposed to toxic anticancer drugs. CPR:falsenewlineEA (15mg / kgb.w., p.o.×14days) treatment modulated enhanced BC6OTHER level, lipid peroxidation, BC6ENTG activity, BC6ENTC production and protein BC6OTHER formation in lungs of rats exposed to toxic anticancer drugs. CPR:falsenewlineEA (15mg / kgb.w., p.o.×14days) treatment modulated enhanced BC6OTHER level, lipid peroxidation, BC6ENTG activity, BC6OTHER production and protein BC6ENTC formation in lungs of rats exposed to toxic anticancer drugs. CPR:falsenewlineAs discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities. CPR:falsenewlineAs discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities. CPR:falsenewlineAs discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities. CPR:falsenewlineAs discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities. CPR:falsenewlineAs discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities. CPR:4newlineAs discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities. CPR:4newlineAs discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6ENTC in breast cancer by blocking BC6ENTG and BC6OTHER activities. CPR:falsenewlineAs discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6ENTC in breast cancer by blocking BC6OTHER and BC6ENTG activities. CPR:falsenewlineAs discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6ENTC - dehydrogenase type 1 activities. CPR:falsenewlineIn conclusion, treatment with anti - aromatases combined with anti - BC6ENTG or BC6ENTC - dehydrogenase type 1 could provide new therapeutic possibilities in the treatment of patients with hormone - dependent breast cancer. CPR:falsenewlineThese include BC6ENTG , BC6OTHER , BC6ENTC - dehydrogenases, BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineThese include BC6OTHER , BC6ENTG , BC6ENTC - dehydrogenases, BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineThese include BC6OTHER , BC6OTHER , BC6ENTC - dehydrogenases, BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineThese include BC6OTHER , BC6OTHER , BC6ENTC - dehydrogenases, BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineThese include BC6OTHER , BC6OTHER , BC6ENTC - dehydrogenases, BC6OTHER , BC6OTHER and BC6ENTG . CPR:falsenewlineAs discussed in this review, various BC6ENTC including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities. CPR:falsenewlineAs discussed in this review, various BC6ENTC including BC6OTHER and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities. CPR:4newlineAs discussed in this review, various BC6OTHER including BC6ENTC and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities. CPR:falsenewlineAs discussed in this review, various BC6OTHER including BC6ENTC and its CHEM- derivative, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities. CPR:falsenewlineAs discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6ENTG and BC6OTHER activities. CPR:falsenewlineAs discussed in this review, various BC6OTHER including BC6OTHER and its CHEM- derivative, BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER can reduce intratissular levels of BC6OTHER in breast cancer by blocking BC6OTHER and BC6ENTG activities. CPR:falsenewlineHowever, BC6OTHER at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of BC6ENTC , indicating the BC6ENTG and not an BC6OTHER as their primary site of action. CPR:falsenewlineHowever, BC6OTHER at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of BC6ENTC , indicating the BC6OTHER and not an BC6ENTG as their primary site of action. CPR:falsenewlineNo trans - stimulation of BC6ENTC outflow was observed by the BC6ENTG and BC6OTHER substrate CHEM at 100 microM. CPR:falsenewlineNo trans - stimulation of BC6ENTC outflow was observed by the BC6OTHER and BC6ENTG substrate CHEM at 100 microM. CPR:falsenewlineOur observations indicate an BC6ENTG - mediated transmembrane transport of BC6ENTC . CPR:9newlineAmongst the three BC6ENTG expressed in the SCG, BC6OTHER best fits the profile of substrates and antagonists that cause trans - stimulation and trans - inhibition, respectively, of BC6ENTC release. CPR:falsenewlineAmongst the three BC6OTHER expressed in the SCG, BC6ENTG best fits the profile of substrates and antagonists that cause trans - stimulation and trans - inhibition, respectively, of BC6ENTC release. CPR:falsenewlineReuptake of extracellular BC6ENTC ( BC6OTHER ) into superior cervical ganglion (SCG) neurones is mediated by means of the BC6ENTG ( BC6OTHER , uptake 1). CPR:9newlineReuptake of extracellular BC6ENTC ( BC6OTHER ) into superior cervical ganglion (SCG) neurones is mediated by means of the BC6OTHER transporter ( BC6ENTG , uptake 1). CPR:9newlineReuptake of extracellular BC6OTHER ( BC6ENTC ) into superior cervical ganglion (SCG) neurones is mediated by means of the BC6ENTG ( BC6OTHER , uptake 1). CPR:9newlineReuptake of extracellular BC6OTHER ( BC6ENTC ) into superior cervical ganglion (SCG) neurones is mediated by means of the BC6OTHER transporter ( BC6ENTG , uptake 1). CPR:9newlineMaking use of the BC6ENTG as a powerful, neurone - specific transporter system, we loaded BC6ENTC ( BC6OTHER ) into cultured rat SCG neurones. CPR:falsenewlineTwo observations suggest that a depletion of storage vesicles by CHEM accounts for the latter phenomenon: first, the primary radioactive product isolated from supernatants of cultures loaded with BC6ENTC was the metabolite BC6OTHER ; and second, inhibition of BC6ENTG significantly reduced the radioactive outflow in response to CHEM. CPR:falsenewlineMaking use of the BC6ENTG as a powerful, neurone - specific transporter system, we loaded BC6OTHER ( BC6ENTC ) into cultured rat SCG neurones. CPR:falsenewlineThe ensuing radioactive outflow from these cultures was enhanced by BC6ENTC and BC6OTHER , but reduced (in the presence of BC6OTHER ) by the BC6ENTG inhibitors CHEM, BC6OTHER and BC6OTHER . CPR:falsenewlineThe ensuing radioactive outflow from these cultures was enhanced by BC6OTHER and BC6ENTC , but reduced (in the presence of BC6OTHER ) by the BC6ENTG inhibitors CHEM, BC6OTHER and BC6OTHER . CPR:falsenewlineThe ensuing radioactive outflow from these cultures was enhanced by BC6OTHER and BC6OTHER , but reduced (in the presence of BC6ENTC ) by the BC6ENTG inhibitors CHEM, BC6OTHER and BC6OTHER . CPR:falsenewlineThe ensuing radioactive outflow from these cultures was enhanced by BC6OTHER and BC6OTHER , but reduced (in the presence of BC6OTHER ) by the BC6ENTG inhibitors CHEM, BC6ENTC and BC6OTHER . CPR:falsenewlineThe ensuing radioactive outflow from these cultures was enhanced by BC6OTHER and BC6OTHER , but reduced (in the presence of BC6OTHER ) by the BC6ENTG inhibitors CHEM, BC6OTHER and BC6ENTC . CPR:falsenewlineTwo observations suggest that a depletion of storage vesicles by CHEM accounts for the latter phenomenon: first, the primary radioactive product isolated from supernatants of cultures loaded with BC6OTHER was the metabolite BC6ENTC ; and second, inhibition of BC6ENTG significantly reduced the radioactive outflow in response to CHEM. CPR:falsenewlineReuptake of extracellular BC6OTHER ( BC6OTHER ) into superior cervical ganglion (SCG) neurones is mediated by means of the BC6ENTC transporter ( BC6ENTG , uptake 1). CPR:9newlineThe outflow of BC6ENTC was significantly enhanced by BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER as potential substrates for BC6ENTG - related BC6OTHER . CPR:9newlineThe outflow of BC6ENTC was significantly enhanced by BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER as potential substrates for BC6OTHER - related BC6ENTG . CPR:9newlineThe outflow of BC6OTHER was significantly enhanced by BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER as potential substrates for BC6ENTG - related BC6OTHER . CPR:9newlineThe outflow of BC6OTHER was significantly enhanced by BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER as potential substrates for BC6OTHER - related BC6ENTG . CPR:9newlineThe outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER as potential substrates for BC6ENTG - related BC6OTHER . CPR:9newlineThe outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER as potential substrates for BC6OTHER - related BC6ENTG . CPR:9newlineThe outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER as potential substrates for BC6ENTG - related BC6OTHER . CPR:9newlineThe outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER as potential substrates for BC6OTHER - related BC6ENTG . CPR:9newlineThe outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC as potential substrates for BC6ENTG - related BC6OTHER . CPR:9newlineThe outflow of BC6OTHER was significantly enhanced by BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC as potential substrates for BC6OTHER - related BC6ENTG . CPR:9newlineHowever, BC6ENTC at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of BC6OTHER , indicating the BC6ENTG and not an BC6OTHER as their primary site of action. CPR:falsenewlineHowever, BC6ENTC at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of BC6OTHER , indicating the BC6OTHER and not an BC6ENTG as their primary site of action. CPR:falsenewlineCounterregulatory responses and BC6OTHER / BC6OTHER concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6ENTC clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6ENTG - Fc, chronic VMH knockdown, or overexpression of BC6OTHER using an adenoassociated viral construct. CPR:falsenewlineCounterregulatory responses and BC6OTHER / BC6OTHER concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6ENTC clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6OTHER - Fc, chronic VMH knockdown, or overexpression of BC6ENTG using an adenoassociated viral construct. CPR:falsenewline BC6ENTG - BC6OTHER interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local BC6ENTC / BC6OTHER balance during hypoglycemia. CPR:falsenewline BC6OTHER - BC6ENTG interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local BC6ENTC / BC6OTHER balance during hypoglycemia. CPR:falsenewline BC6ENTG - BC6OTHER interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local BC6OTHER / BC6ENTC balance during hypoglycemia. CPR:falsenewline BC6OTHER - BC6ENTG interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local BC6OTHER / BC6ENTC balance during hypoglycemia. CPR:falsenewlineOverexpression of VMH BC6OTHER transiently increased local BC6ENTC concentrations, whereas BC6ENTG knockdown produced profound suppression of VMH interstitial fluid BC6OTHER concentrations in the basal state and during hypoglycemia. CPR:falsenewlineOverexpression of VMH BC6ENTG transiently increased local BC6ENTC concentrations, whereas BC6OTHER knockdown produced profound suppression of VMH interstitial fluid BC6OTHER concentrations in the basal state and during hypoglycemia. CPR:falsenewlineOverexpression of VMH BC6OTHER transiently increased local BC6OTHER concentrations, whereas BC6ENTG knockdown produced profound suppression of VMH interstitial fluid BC6ENTC concentrations in the basal state and during hypoglycemia. CPR:falsenewlineOverexpression of VMH BC6ENTG transiently increased local BC6OTHER concentrations, whereas BC6OTHER knockdown produced profound suppression of VMH interstitial fluid BC6ENTC concentrations in the basal state and during hypoglycemia. CPR:falsenewlineChanges in BC6ENTG / BC6OTHER interactions within the VMH, a key brain BC6ENTC - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6OTHER cycling. CPR:falsenewlineChanges in BC6OTHER / BC6ENTG interactions within the VMH, a key brain BC6ENTC - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6OTHER cycling. CPR:falsenewlineChanges in BC6ENTG / BC6OTHER interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6ENTC homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6OTHER cycling. CPR:falsenewlineChanges in BC6OTHER / BC6ENTG interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6ENTC homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6OTHER cycling. CPR:falsenewlineChanges in BC6ENTG / BC6OTHER interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6ENTC / BC6OTHER cycling. CPR:falsenewlineChanges in BC6OTHER / BC6ENTG interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6ENTC / BC6OTHER cycling. CPR:falsenewlineChanges in BC6ENTG / BC6OTHER interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6ENTC cycling. CPR:falsenewlineChanges in BC6OTHER / BC6ENTG interactions within the VMH, a key brain BC6OTHER - sensing region, act in concert with islets to restore BC6OTHER homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in BC6OTHER / BC6ENTC cycling. CPR:falsenewlineGiven the similarities between islet and ventromedial hypothalamus (VMH) BC6ENTC sensing, we tested the hypothesis that the BC6ENTG / BC6OTHER system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well. CPR:falsenewlineGiven the similarities between islet and ventromedial hypothalamus (VMH) BC6ENTC sensing, we tested the hypothesis that the BC6OTHER / BC6ENTG system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well. CPR:falsenewlineCounterregulatory responses and BC6ENTC / BC6OTHER concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6OTHER clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6ENTG - Fc, chronic VMH knockdown, or overexpression of BC6OTHER using an adenoassociated viral construct. CPR:falsenewlineCounterregulatory responses and BC6ENTC / BC6OTHER concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6OTHER clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6OTHER - Fc, chronic VMH knockdown, or overexpression of BC6ENTG using an adenoassociated viral construct. CPR:falsenewlineCounterregulatory responses and BC6OTHER / BC6ENTC concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6OTHER clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6ENTG - Fc, chronic VMH knockdown, or overexpression of BC6OTHER using an adenoassociated viral construct. CPR:falsenewlineCounterregulatory responses and BC6OTHER / BC6ENTC concentrations in the VMH were assessed during a hyperinsulinemic - hypoglycemic BC6OTHER clamp study in chronically catheterized awake male Sprague - Dawley rats that received an acute VMH microinjection of BC6OTHER - Fc, chronic VMH knockdown, or overexpression of BC6ENTG using an adenoassociated viral construct. CPR:falsenewlineInhibition of cardiac voltage - gated BC6ENTC channels ( BC6ENTG ) is antiarrhythmic and cardioprotective. CPR:falsenewlineLate INa induced by the BC6ENTG long QT mutant BC6OTHER was reduced by BC6ENTC and BC6OTHER . CPR:falsenewlineLate INa induced by the BC6OTHER long QT mutant BC6ENTG was reduced by BC6ENTC and BC6OTHER . CPR:falsenewlineLate INa induced by the BC6ENTG long QT mutant BC6OTHER was reduced by BC6OTHER and BC6ENTC . CPR:falsenewlineLate INa induced by the BC6OTHER long QT mutant BC6ENTG was reduced by BC6OTHER and BC6ENTC . CPR:falsenewlineIn contrast, the BC6ENTC catabolising enzymes BC6ENTG and BC6OTHER which are known to be BC6OTHER - responsive were not expressed at all in the developing eye. CPR:falsenewlineIn contrast, the BC6ENTC catabolising enzymes BC6OTHER and BC6ENTG which are known to be BC6OTHER - responsive were not expressed at all in the developing eye. CPR:falsenewlineIn contrast, the BC6OTHER catabolising enzymes BC6ENTG and BC6OTHER which are known to be BC6ENTC - responsive were not expressed at all in the developing eye. CPR:falsenewlineIn contrast, the BC6OTHER catabolising enzymes BC6OTHER and BC6ENTG which are known to be BC6ENTC - responsive were not expressed at all in the developing eye. CPR:falsenewlineUsing a photo incorporable analogue of the general anesthetic, BC6OTHER , we identified two transmembrane BC6ENTC that were affinity labelled in purified BC6ENTG . CPR:falsenewlineHomology protein structural modelling positions these two residues, alphaM1 - 11' and betaM3 - 4', close to each other in a single type of intersubunit BC6ENTC binding pocket at the BC6ENTG . CPR:falsenewlinePURPOSE: The purpose of this review is to summarize current knowledge of detailed biochemical evidence for the role of BC6ENTC type A receptors ( BC6ENTG ) in the mechanisms of general anesthesia. CPR:falsenewlinePRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate BC6ENTG - mediated inhibitory transmission, site - directed mutagenesis comparing sequences of BC6OTHER subunits of varying sensitivity led to identification of BC6ENTC residues in the transmembrane domain that are critical for the drug actions in vitro. CPR:falsenewlinePRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate BC6OTHER - mediated inhibitory transmission, site - directed mutagenesis comparing sequences of BC6ENTG subunits of varying sensitivity led to identification of BC6ENTC residues in the transmembrane domain that are critical for the drug actions in vitro. CPR:falsenewlineUsing a photo incorporable analogue of the general anesthetic, BC6ENTC , we identified two transmembrane BC6OTHER that were affinity labelled in purified BC6ENTG . CPR:falsenewlineThe BC6OTHER / BC6OTHER pathway and the energy sensor BC6ENTC - activated protein kinase ( BC6ENTG ) are attractive therapeutic targets as a part of preventive management of disease. CPR:falsenewlineThe BC6ENTG / BC6OTHER pathway and the energy sensor BC6ENTC - activated protein kinase ( BC6OTHER ) are attractive therapeutic targets as a part of preventive management of disease. CPR:falsenewlineThe BC6OTHER / BC6ENTG pathway and the energy sensor BC6ENTC - activated protein kinase ( BC6OTHER ) are attractive therapeutic targets as a part of preventive management of disease. CPR:falsenewlineSeveral effects of BC6ENTC are useful in this scenario, including a reduction in the activities of BC6ENTG and modulation of cellular metabolism through BC6OTHER inhibitors, BC6OTHER activators, calorie - restriction mimetics or epigenetic regulators. CPR:falsenewlineSeveral effects of BC6ENTC are useful in this scenario, including a reduction in the activities of BC6OTHER and modulation of cellular metabolism through BC6ENTG inhibitors, BC6OTHER activators, calorie - restriction mimetics or epigenetic regulators. CPR:falsenewlineSeveral effects of BC6ENTC are useful in this scenario, including a reduction in the activities of BC6OTHER and modulation of cellular metabolism through BC6OTHER inhibitors, BC6ENTG activators, calorie - restriction mimetics or epigenetic regulators. CPR:falsenewlineMultifunctional targets of dietary BC6ENTC in disease: a case for the BC6ENTG network and energy metabolism. CPR:falsenewlineIn conclusion, our results demonstrate that Jurkat T cells express BC6ENTC receptors functionally active in controlling cell growth and adhesion to BC6ENTG . CPR:falsenewlineStimulation of BC6ENTC receptors modulates Jurkat T cell growth and adhesion to BC6ENTG . CPR:falsenewlineRT - PCR and immunofluorescence / confocal microscopy analysis showed that Jurkat T cells express the BC6ENTG and BC6OTHER subunits of the BC6ENTC receptors. CPR:falsenewlineRT - PCR and immunofluorescence / confocal microscopy analysis showed that Jurkat T cells express the BC6OTHER and BC6ENTG subunits of the BC6ENTC receptors. CPR:falsenewlineExposure of Jurkat cells to either BC6ENTC [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER . CPR:falsenewlineExposure of Jurkat cells to either BC6ENTC [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG . CPR:falsenewlineExposure of Jurkat cells to either BC6OTHER [ BC6ENTC ] or BC6OTHER ( BC6OTHER ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER . CPR:falsenewlineExposure of Jurkat cells to either BC6OTHER [ BC6ENTC ] or BC6OTHER ( BC6OTHER ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG . CPR:falsenewlineExposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6ENTC ( BC6OTHER ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER . CPR:falsenewlineExposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6ENTC ( BC6OTHER ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG . CPR:falsenewlineExposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6ENTC ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER . CPR:falsenewlineExposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6ENTC ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG . CPR:falsenewlineExposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6ENTC receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG . CPR:falsenewlineExposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6ENTC (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER . CPR:falsenewlineExposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6ENTC (1 microM) and BC6OTHER (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG . CPR:falsenewlineExposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6ENTG antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6ENTC (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6OTHER . CPR:falsenewlineExposure of Jurkat cells to either BC6OTHER [ BC6OTHER ] or BC6OTHER ( BC6OTHER ), two selective BC6OTHER receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas BC6OTHER (1 microM) and BC6ENTC (10 microM) significantly increased (137.2+ / - 22.0%; P<0.01) Jurkat T cell adhesion to BC6ENTG . CPR:falsenewlineThese results reveal, for the first time, the differential distribution of BC6ENTG in fast - and slow - twitch muscles, which might support the crucial role of BC6ENTC - dependent signaling in controlling the synapse - specific expression of BC6OTHER in fast - twitch muscles. CPR:falsenewlineThese results reveal, for the first time, the differential distribution of BC6OTHER in fast - and slow - twitch muscles, which might support the crucial role of BC6ENTC - dependent signaling in controlling the synapse - specific expression of BC6ENTG in fast - twitch muscles. CPR:falsenewlineBC6ENTG is expressed at the neuromuscular junction (NMJ) in fast - twitch muscle, and this expression depends on trophic factors supplied by motor neurons signaling via a BC6ENTC - dependent pathway in muscle. CPR:falsenewlineTo further elucidate the molecular basis of BC6ENTG synaptic expression, here we investigated the expression and localization of BC6ENTC - responsive element binding protein ( BC6OTHER ) at the synaptic and extra - synaptic regions of fast - and slow - twitch muscles from adult rats. CPR:falsenewlineTo further elucidate the molecular basis of BC6OTHER synaptic expression, here we investigated the expression and localization of BC6ENTC - responsive element binding protein ( BC6ENTG ) at the synaptic and extra - synaptic regions of fast - and slow - twitch muscles from adult rats. CPR:falsenewlineExpression of BC6ENTC - responsive element binding proteins ( BC6OTHER ) in fast - and slow - twitch muscles: A signaling pathway to account for the synaptic expression of BC6ENTG ( BC6OTHER ) of BC6OTHER at the rat neuromuscular junction. CPR:falsenewlineExpression of BC6ENTC - responsive element binding proteins ( BC6OTHER ) in fast - and slow - twitch muscles: A signaling pathway to account for the synaptic expression of BC6OTHER ( BC6ENTG ) of BC6OTHER at the rat neuromuscular junction. CPR:falsenewlineExpression of BC6ENTC - responsive element binding proteins ( BC6OTHER ) in fast - and slow - twitch muscles: A signaling pathway to account for the synaptic expression of BC6OTHER ( BC6OTHER ) of BC6ENTG at the rat neuromuscular junction. CPR:falsenewlineExpression of BC6ENTC - responsive element binding proteins ( BC6ENTG ) in fast - and slow - twitch muscles: A signaling pathway to account for the synaptic expression of BC6OTHER ( BC6OTHER ) of BC6OTHER at the rat neuromuscular junction. CPR:falsenewlineIn contrast, BC6ENTG exerts glucoregulatory actions via slowing of gastric emptying and BC6ENTC - dependent inhibition of BC6OTHER secretion. CPR:falsenewlineIn contrast, BC6OTHER exerts glucoregulatory actions via slowing of gastric emptying and BC6ENTC - dependent inhibition of BC6ENTG secretion. CPR:falsenewlineThis review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the BC6ENTG peptides BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineThis review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the BC6OTHER peptides BC6ENTC - dependent insulinotropic polypeptide ( BC6ENTG ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineThis review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the BC6OTHER peptides BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineThis review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the BC6OTHER peptides BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6ENTG activation leads to BC6ENTC - dependent BC6OTHER secretion, induction of beta - cell proliferation, and enhanced resistance to apoptosis. CPR:falsenewlineBC6OTHER activation leads to BC6ENTC - dependent BC6ENTG secretion, induction of beta - cell proliferation, and enhanced resistance to apoptosis. CPR:falsenewlineBC6ENTC , an BC6OTHER that reversibly inhibits BC6ENTG and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option. CPR:4newlineBC6OTHER , an BC6ENTC that reversibly inhibits BC6ENTG and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option. CPR:4newlineTherefore, we examined whether the BC6ENTG - I BC6ENTC improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults. CPR:falsenewlineThe effects of the BC6ENTG inhibitor BC6ENTC on cognitive performance in healthy adults: a behavioral - electroencephalography study. CPR:4newlineIn early pregnancy, there were no significant differences in BC6ENTG sensitivity ( BC6OTHER sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for BC6OTHER resistance [HOMA - IR]) and BC6OTHER secretion (a ratio of the total area - under - the - BC6OTHER - curve to the total area - under - the - BC6ENTC - curve [AUCins / glu] and insulinogenic index [IGI]) between the NGT and late - onset GDM groups. CPR:falsenewlineIn early pregnancy, there were no significant differences in BC6OTHER sensitivity ( BC6ENTG sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for BC6OTHER resistance [HOMA - IR]) and BC6OTHER secretion (a ratio of the total area - under - the - BC6OTHER - curve to the total area - under - the - BC6ENTC - curve [AUCins / glu] and insulinogenic index [IGI]) between the NGT and late - onset GDM groups. CPR:falsenewlineIn early pregnancy, there were no significant differences in BC6OTHER sensitivity ( BC6OTHER sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for BC6ENTG resistance [HOMA - IR]) and BC6OTHER secretion (a ratio of the total area - under - the - BC6OTHER - curve to the total area - under - the - BC6ENTC - curve [AUCins / glu] and insulinogenic index [IGI]) between the NGT and late - onset GDM groups. CPR:falsenewlineIn early pregnancy, there were no significant differences in BC6OTHER sensitivity ( BC6OTHER sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for BC6OTHER resistance [HOMA - IR]) and BC6ENTG secretion (a ratio of the total area - under - the - BC6OTHER - curve to the total area - under - the - BC6ENTC - curve [AUCins / glu] and insulinogenic index [IGI]) between the NGT and late - onset GDM groups. CPR:falsenewlineIn early pregnancy, there were no significant differences in BC6OTHER sensitivity ( BC6OTHER sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for BC6OTHER resistance [HOMA - IR]) and BC6OTHER secretion (a ratio of the total area - under - the - BC6ENTG - curve to the total area - under - the - BC6ENTC - curve [AUCins / glu] and insulinogenic index [IGI]) between the NGT and late - onset GDM groups. CPR:falsenewlineOther groups received either an infusion of the selective BC6ENTG antagonist ( BC6ENTC ; 10 nmol; intra - mPFC) or vehicle, 10 min prior to BC6OTHER preceding LFS600, or prior to a supra - threshold LTD protocol (900 pulses, 1 Hz; LFS900). CPR:falsenewlineOther groups received either an infusion of the selective BC6ENTG antagonist ( BC6OTHER ; 10 nmol; intra - mPFC) or vehicle, 10 min prior to BC6ENTC preceding LFS600, or prior to a supra - threshold LTD protocol (900 pulses, 1 Hz; LFS900). CPR:falsenewlineOur results show that BC6ENTC converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, BC6OTHER does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that BC6ENTG pre - activation is essential to the muscarinic enhancement of mPFC synaptic depression, since BC6OTHER microinjection into the mPFC blocked the conversion of transient depression into long - lasting LTD produced by BC6OTHER . CPR:falsenewlineOur results show that BC6OTHER converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, BC6ENTC does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that BC6ENTG pre - activation is essential to the muscarinic enhancement of mPFC synaptic depression, since BC6OTHER microinjection into the mPFC blocked the conversion of transient depression into long - lasting LTD produced by BC6OTHER . CPR:falsenewlineOur results show that BC6OTHER converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, BC6OTHER does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that BC6ENTG pre - activation is essential to the muscarinic enhancement of mPFC synaptic depression, since BC6ENTC microinjection into the mPFC blocked the conversion of transient depression into long - lasting LTD produced by BC6OTHER . CPR:falsenewlineOur results show that BC6OTHER converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, BC6OTHER does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that BC6ENTG pre - activation is essential to the muscarinic enhancement of mPFC synaptic depression, since BC6OTHER microinjection into the mPFC blocked the conversion of transient depression into long - lasting LTD produced by BC6ENTC . CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6ENTC ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6ENTC ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6ENTC ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6OTHER ( BC6ENTC ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6ENTC ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6ENTC ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6ENTC - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6ENTC - dependent BC6OTHER uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6ENTC - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6ENTC uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6ENTC uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6ENTC uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTC phosphatase and by BC6OTHER blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTC phosphatase and by BC6ENTG blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6ENTG each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6ENTC ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6ENTC ). CPR:falsenewlineElectrical stimulation, BC6OTHER , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6ENTC ). CPR:falsenewlineElectrical stimulation transiently elevated extracellular BC6ENTC and caused BC6ENTG phosphorylation that was additive to BC6OTHER and inhibited by BC6OTHER . CPR:falsenewlineElectrical stimulation transiently elevated extracellular BC6ENTC and caused BC6OTHER phosphorylation that was additive to BC6ENTG and inhibited by BC6OTHER . CPR:falsenewlineElectrical stimulation transiently elevated extracellular BC6OTHER and caused BC6ENTG phosphorylation that was additive to BC6OTHER and inhibited by BC6ENTC . CPR:falsenewlineElectrical stimulation transiently elevated extracellular BC6OTHER and caused BC6OTHER phosphorylation that was additive to BC6ENTG and inhibited by BC6ENTC . CPR:falsenewlineExogenous BC6ENTC transiently activated BC6ENTG and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6ENTC transiently activated BC6OTHER and, inhibiting BC6ENTG ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6ENTC transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6ENTG ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6ENTC transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6ENTG as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6ENTC transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6ENTG mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6ENTC transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6OTHER uptake and BC6ENTG phosphorylation. CPR:falsenewlineExogenous BC6OTHER transiently activated BC6ENTG and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6ENTG ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6ENTG ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6ENTG as well as dominant - negative BC6OTHER mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6ENTG mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6ENTC - dependent BC6OTHER uptake and BC6ENTG phosphorylation. CPR:falsenewlineBC6OTHER - dependent BC6OTHER uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC . CPR:falsenewlineBC6OTHER - dependent BC6OTHER uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC . CPR:falsenewlineBC6OTHER - dependent BC6OTHER uptake was also inhibited by the BC6ENTG subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC . CPR:falsenewlineExogenous BC6OTHER transiently activated BC6ENTG and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6ENTG ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6ENTG ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6ENTG as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6ENTG mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6OTHER phosphorylation. CPR:falsenewlineExogenous BC6OTHER transiently activated BC6OTHER and, inhibiting BC6OTHER ( BC6OTHER ) or BC6OTHER as well as dominant - negative BC6OTHER mutant, reduced BC6OTHER - dependent BC6ENTC uptake and BC6ENTG phosphorylation. CPR:falsenewlineBC6ENTC - dependent BC6OTHER uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER . CPR:falsenewlineBC6ENTC - dependent BC6OTHER uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER . CPR:falsenewlineBC6ENTC - dependent BC6OTHER uptake was also inhibited by the BC6ENTG subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER . CPR:falsenewlineBC6OTHER - dependent BC6ENTC uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER . CPR:9newlineBC6OTHER - dependent BC6ENTC uptake was also inhibited by the BC6OTHER subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER . CPR:9newlineBC6OTHER - dependent BC6ENTC uptake was also inhibited by the BC6ENTG subunit - interacting peptide βark - ct and by the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER . CPR:falsenewlineElectrical Stimuli Release BC6ENTC to Increase BC6ENTG Translocation and BC6OTHER Uptake via BC6OTHER - BC6OTHER - BC6OTHER in Skeletal Muscle Cells. CPR:falsenewlineElectrical Stimuli Release BC6ENTC to Increase BC6OTHER Translocation and BC6OTHER Uptake via BC6ENTG - BC6OTHER - BC6OTHER in Skeletal Muscle Cells. CPR:falsenewlineElectrical Stimuli Release BC6ENTC to Increase BC6OTHER Translocation and BC6OTHER Uptake via BC6OTHER - BC6ENTG - BC6OTHER in Skeletal Muscle Cells. CPR:falsenewlineElectrical Stimuli Release BC6ENTC to Increase BC6OTHER Translocation and BC6OTHER Uptake via BC6OTHER - BC6OTHER - BC6ENTG in Skeletal Muscle Cells. CPR:falsenewlineElectrical Stimuli Release BC6OTHER to Increase BC6ENTG Translocation and BC6ENTC Uptake via BC6OTHER - BC6OTHER - BC6OTHER in Skeletal Muscle Cells. CPR:falsenewlineElectrical Stimuli Release BC6OTHER to Increase BC6OTHER Translocation and BC6ENTC Uptake via BC6ENTG - BC6OTHER - BC6OTHER in Skeletal Muscle Cells. CPR:falsenewlineElectrical Stimuli Release BC6OTHER to Increase BC6OTHER Translocation and BC6ENTC Uptake via BC6OTHER - BC6ENTG - BC6OTHER in Skeletal Muscle Cells. CPR:falsenewlineElectrical Stimuli Release BC6OTHER to Increase BC6OTHER Translocation and BC6ENTC Uptake via BC6OTHER - BC6OTHER - BC6ENTG in Skeletal Muscle Cells. CPR:falsenewlineBC6ENTC caused translocation of BC6ENTG myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6OTHER reduced by dominant - negative BC6OTHER or BC6OTHER BC6OTHER - dead mutants, and potentiated by BC6OTHER . CPR:falsenewlineBC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6ENTG / BC6OTHER reduced by dominant - negative BC6OTHER or BC6OTHER BC6OTHER - dead mutants, and potentiated by BC6OTHER . CPR:falsenewlineBC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6ENTG reduced by dominant - negative BC6OTHER or BC6OTHER BC6OTHER - dead mutants, and potentiated by BC6OTHER . CPR:falsenewlineBC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6OTHER reduced by dominant - negative BC6ENTG or BC6OTHER BC6OTHER - dead mutants, and potentiated by BC6OTHER . CPR:falsenewlineBC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6OTHER reduced by dominant - negative BC6OTHER or BC6ENTG BC6OTHER - dead mutants, and potentiated by BC6OTHER . CPR:falsenewlineBC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6OTHER reduced by dominant - negative BC6OTHER or BC6OTHER BC6ENTG - dead mutants, and potentiated by BC6OTHER . CPR:falsenewlineBC6ENTC caused translocation of BC6OTHER myc - eGFP to the cell surface, mechanistically mediated by increased exocytosis involving BC6OTHER / BC6OTHER reduced by dominant - negative BC6OTHER or BC6OTHER BC6OTHER - dead mutants, and potentiated by BC6ENTG . CPR:falsenewlineBC6ENTC stimulated BC6OTHER uptake in normal and BC6ENTG - resistant adult muscle fibers, resembling the reported effect of exercise. CPR:falsenewlineBC6OTHER stimulated BC6ENTC uptake in normal and BC6ENTG - resistant adult muscle fibers, resembling the reported effect of exercise. CPR:falsenewlineBC6ENTC is released from skeletal muscle by contractile activity and can autocrinely signal through BC6ENTG , and we hypothesized it may influence BC6OTHER uptake. CPR:falsenewlineHence, the BC6ENTC - induced pathway may be tapped to bypass BC6ENTG resistance. CPR:falsenewlineSkeletal muscle BC6ENTC uptake in response to exercise is preserved in BC6ENTG - resistant conditions, but the signals involved are debated. CPR:falsenewlineBC6OTHER is released from skeletal muscle by contractile activity and can autocrinely signal through BC6ENTG , and we hypothesized it may influence BC6ENTC uptake. CPR:falsenewlineElectrical stimulation, BC6ENTC , and BC6ENTG each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6OTHER blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6ENTC , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6ENTG and by BC6OTHER blockade ( BC6OTHER ). CPR:falsenewlineElectrical stimulation, BC6ENTC , and BC6OTHER each increased fluorescent BC6OTHER ( BC6OTHER ) uptake in primary myotubes, but only electrical stimulation and BC6OTHER - dependent BC6OTHER uptake were inhibited by BC6OTHER and by BC6ENTG blockade ( BC6OTHER ). CPR:falsenewlineIn conclusion, this study provides the first evidence implicating that BC6ENTC inhibits BC6ENTG - induced ROS accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6OTHER signaling. CPR:falsenewlineIn conclusion, this study provides the first evidence implicating that BC6ENTC inhibits BC6OTHER - induced ROS accumulation and myofibroblast differentiation via enhanced BC6ENTG - BC6OTHER signaling. CPR:falsenewlineIn conclusion, this study provides the first evidence implicating that BC6ENTC inhibits BC6OTHER - induced ROS accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6ENTG signaling. CPR:falsenewline BC6OTHER ( BC6ENTC ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6OTHER on BC6ENTG ( BC6OTHER - induced myofibroblast differentiation of corneal fibroblasts in vitro. CPR:falsenewline BC6OTHER ( BC6ENTC ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6OTHER on BC6OTHER ( BC6ENTG - induced myofibroblast differentiation of corneal fibroblasts in vitro. CPR:falsenewline BC6OTHER ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6ENTC on BC6ENTG ( BC6OTHER - induced myofibroblast differentiation of corneal fibroblasts in vitro. CPR:falsenewline BC6OTHER ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6ENTC on BC6OTHER ( BC6ENTG - induced myofibroblast differentiation of corneal fibroblasts in vitro. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6ENTC , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6ENTC , the BC6ENTG inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6ENTC , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6ENTC , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6ENTC , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6ENTC , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6ENTC oxidase inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTC oxidase inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTC oxidase inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTC oxidase inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTC oxidase inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTG inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTG inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTG inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6ENTC ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTG inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6ENTC ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6OTHER , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6ENTG in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6ENTC , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6ENTG inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6ENTC , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) activator BC6ENTC , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) activator BC6ENTC , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) activator BC6ENTC , or small interfering RNA. CPR:falsenewlineHuman immortalized corneal fibroblasts were treated with BC6OTHER in the presence of BC6OTHER , the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ), the antioxidant BC6OTHER ( BC6OTHER ), the BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) activator BC6ENTC , or small interfering RNA. CPR:falsenewline BC6ENTC ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6OTHER on BC6ENTG ( BC6OTHER - induced myofibroblast differentiation of corneal fibroblasts in vitro. CPR:falsenewline BC6ENTC ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6OTHER species (ROS) scavenging by BC6OTHER on BC6OTHER ( BC6ENTG - induced myofibroblast differentiation of corneal fibroblasts in vitro. CPR:falsenewlineROS, BC6ENTC , intracellular BC6OTHER ( BC6OTHER ) level, cellular total antioxidant capacity, and the activation of BC6ENTG - BC6OTHER signaling were determined with various assays. CPR:falsenewlineROS, BC6ENTC , intracellular BC6OTHER ( BC6OTHER ) level, cellular total antioxidant capacity, and the activation of BC6OTHER - BC6ENTG signaling were determined with various assays. CPR:falsenewlineROS, BC6OTHER , intracellular BC6ENTC ( BC6OTHER ) level, cellular total antioxidant capacity, and the activation of BC6ENTG - BC6OTHER signaling were determined with various assays. CPR:falsenewlineROS, BC6OTHER , intracellular BC6ENTC ( BC6OTHER ) level, cellular total antioxidant capacity, and the activation of BC6OTHER - BC6ENTG signaling were determined with various assays. CPR:falsenewlineROS, BC6OTHER , intracellular BC6OTHER ( BC6ENTC ) level, cellular total antioxidant capacity, and the activation of BC6ENTG - BC6OTHER signaling were determined with various assays. CPR:falsenewlineROS, BC6OTHER , intracellular BC6OTHER ( BC6ENTC ) level, cellular total antioxidant capacity, and the activation of BC6OTHER - BC6ENTG signaling were determined with various assays. CPR:falsenewlineTreatment with BC6ENTC and the BC6ENTG - BC6OTHER activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6OTHER . CPR:falsenewlineTreatment with BC6ENTC and the BC6OTHER - BC6ENTG activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6OTHER . CPR:falsenewlineTreatment with BC6ENTC and the BC6OTHER - BC6OTHER activator resulted in increased inhibition of the BC6ENTG - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6OTHER . CPR:falsenewline BC6ENTC inhibits BC6OTHER - induced reactive BC6OTHER species accumulation and myofibroblast differentiation via enhanced BC6ENTG - BC6OTHER signaling. CPR:falsenewline BC6ENTC inhibits BC6OTHER - induced reactive BC6OTHER species accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6ENTG signaling. CPR:falsenewline BC6ENTC inhibits BC6ENTG - induced reactive BC6OTHER species accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6OTHER signaling. CPR:falsenewline BC6OTHER inhibits BC6OTHER - induced reactive BC6ENTC species accumulation and myofibroblast differentiation via enhanced BC6ENTG - BC6OTHER signaling. CPR:falsenewline BC6OTHER inhibits BC6OTHER - induced reactive BC6ENTC species accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6ENTG signaling. CPR:falsenewline BC6OTHER inhibits BC6ENTG - induced reactive BC6ENTC species accumulation and myofibroblast differentiation via enhanced BC6OTHER - BC6OTHER signaling. CPR:falsenewlineTreatment with BC6OTHER and the BC6ENTG - BC6OTHER activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6ENTC or BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER and the BC6OTHER - BC6ENTG activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6ENTC or BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER and the BC6OTHER - BC6OTHER activator resulted in increased inhibition of the BC6ENTG - induced myofibroblast differentiation as compared with treatment with BC6ENTC or BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER and the BC6ENTG - BC6OTHER activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6ENTC . CPR:falsenewlineTreatment with BC6OTHER and the BC6OTHER - BC6ENTG activator resulted in increased inhibition of the BC6OTHER - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6ENTC . CPR:falsenewlineTreatment with BC6OTHER and the BC6OTHER - BC6OTHER activator resulted in increased inhibition of the BC6ENTG - induced myofibroblast differentiation as compared with treatment with BC6OTHER or BC6ENTC . CPR:falsenewlineFurthermore, BC6ENTC also decreased cellular ROS and BC6OTHER accumulation induced by BC6ENTG , whereas it elevated intracellular BC6OTHER level and cellular total antioxidant capacity. CPR:falsenewlineFurthermore, BC6OTHER also decreased cellular ROS and BC6ENTC accumulation induced by BC6ENTG , whereas it elevated intracellular BC6OTHER level and cellular total antioxidant capacity. CPR:falsenewlineFurthermore, BC6OTHER also decreased cellular ROS and BC6OTHER accumulation induced by BC6ENTG , whereas it elevated intracellular BC6ENTC level and cellular total antioxidant capacity. CPR:falsenewlineIn addition, BC6ENTC induced BC6ENTG nuclear translocation and up - regulated the expression of BC6OTHER - BC6OTHER downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6OTHER on myofibroblast differentiation. CPR:falsenewlineIn addition, BC6ENTC induced BC6OTHER nuclear translocation and up - regulated the expression of BC6ENTG - BC6OTHER downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6OTHER on myofibroblast differentiation. CPR:falsenewlineIn addition, BC6ENTC induced BC6OTHER nuclear translocation and up - regulated the expression of BC6OTHER - BC6ENTG downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6OTHER on myofibroblast differentiation. CPR:falsenewlineIn addition, BC6ENTC induced BC6OTHER nuclear translocation and up - regulated the expression of BC6OTHER - BC6OTHER downstream antioxidant genes, whereas BC6ENTG knockdown by RNA interference blocked the inhibition of BC6OTHER on myofibroblast differentiation. CPR:falsenewline BC6OTHER ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6ENTC species (ROS) scavenging by BC6OTHER on BC6ENTG ( BC6OTHER - induced myofibroblast differentiation of corneal fibroblasts in vitro. CPR:falsenewline BC6OTHER ( BC6OTHER ) has been shown to prevent fibrosis in vitro and in vivo. The present study aimed at investigating the role of reactive BC6ENTC species (ROS) scavenging by BC6OTHER on BC6OTHER ( BC6ENTG - induced myofibroblast differentiation of corneal fibroblasts in vitro. CPR:falsenewlineIn addition, BC6OTHER induced BC6ENTG nuclear translocation and up - regulated the expression of BC6OTHER - BC6OTHER downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6ENTC on myofibroblast differentiation. CPR:falsenewlineIn addition, BC6OTHER induced BC6OTHER nuclear translocation and up - regulated the expression of BC6ENTG - BC6OTHER downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6ENTC on myofibroblast differentiation. CPR:falsenewlineIn addition, BC6OTHER induced BC6OTHER nuclear translocation and up - regulated the expression of BC6OTHER - BC6ENTG downstream antioxidant genes, whereas BC6OTHER knockdown by RNA interference blocked the inhibition of BC6ENTC on myofibroblast differentiation. CPR:falsenewlineIn addition, BC6OTHER induced BC6OTHER nuclear translocation and up - regulated the expression of BC6OTHER - BC6OTHER downstream antioxidant genes, whereas BC6ENTG knockdown by RNA interference blocked the inhibition of BC6ENTC on myofibroblast differentiation. CPR:falsenewlineThis approach is validated by the clinical efficacy and safety of BC6ENTC , the pioneering drug for selective BC6ENTG inhibitor therapy for ED. CPR:4newlineBC6ENTC exhibits inhibitory potency against BC6OTHER and a 10 - fold lower dose - related inhibitory potency against rod outer segment BC6OTHER , the predominant BC6ENTG in the phototransduction cascade in rods. CPR:4newlineBC6ENTC exhibits inhibitory potency against BC6ENTG and a 10 - fold lower dose - related inhibitory potency against rod outer segment BC6OTHER , the predominant BC6OTHER in the phototransduction cascade in rods. CPR:4newlineBC6ENTC exhibits inhibitory potency against BC6OTHER and a 10 - fold lower dose - related inhibitory potency against rod outer segment BC6ENTG , the predominant BC6OTHER in the phototransduction cascade in rods. CPR:4newlineAs free BC6ENTC plasma concentrations approach concentrations sufficient to inhibit CHEM BC6ENTG , usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently. CPR:4newlinePublished literature on the BC6ENTC - BC6OTHER ( BC6OTHER ) pathway for penile erection and on BC6ENTG inhibition using CHEM as the model for pharmacologic BC6OTHER inhibition are assessed. CPR:falsenewlinePublished literature on the BC6ENTC - BC6OTHER ( BC6OTHER ) pathway for penile erection and on BC6OTHER inhibition using CHEM as the model for pharmacologic BC6ENTG inhibition are assessed. CPR:falsenewlineSelective inhibition of BC6ENTG is a rational therapeutic approach in ED, as proved by the clinical success of BC6ENTC . CPR:falsenewlinePublished literature on the BC6OTHER - BC6ENTC ( BC6OTHER ) pathway for penile erection and on BC6ENTG inhibition using CHEM as the model for pharmacologic BC6OTHER inhibition are assessed. CPR:falsenewlinePublished literature on the BC6OTHER - BC6ENTC ( BC6OTHER ) pathway for penile erection and on BC6OTHER inhibition using CHEM as the model for pharmacologic BC6ENTG inhibition are assessed. CPR:falsenewlinePublished literature on the BC6OTHER - BC6OTHER ( BC6ENTC ) pathway for penile erection and on BC6ENTG inhibition using CHEM as the model for pharmacologic BC6OTHER inhibition are assessed. CPR:falsenewlinePublished literature on the BC6OTHER - BC6OTHER ( BC6ENTC ) pathway for penile erection and on BC6OTHER inhibition using CHEM as the model for pharmacologic BC6ENTG inhibition are assessed. CPR:falsenewlineBC6ENTG is the predominant BC6OTHER in the corpus cavernosum, and BC6ENTC is its primary substrate. CPR:9newlineBC6OTHER is the predominant BC6ENTG in the corpus cavernosum, and BC6ENTC is its primary substrate. CPR:9newlineTherefore, in men with ED, elevation of BC6ENTC in corpus cavernosal tissue via selective inhibition of BC6OTHER - specific BC6ENTG is a means of improving erectile function at minimal risk of adverse events. CPR:falsenewlineTherefore, in men with ED, elevation of BC6OTHER in corpus cavernosal tissue via selective inhibition of BC6ENTC - specific BC6ENTG is a means of improving erectile function at minimal risk of adverse events. CPR:falsenewlineHere we show that BC6OTHER increases proliferation and differentiation and opposes BC6ENTC - induced apoptosis in human osteoblastic MG - 63 cells containing two BC6ENTG ( BC6OTHER ) isoforms. CPR:falsenewlineHere we show that BC6OTHER increases proliferation and differentiation and opposes BC6ENTC - induced apoptosis in human osteoblastic MG - 63 cells containing two BC6OTHER ( BC6ENTG ) isoforms. CPR:falsenewlineHere we show that BC6OTHER increases proliferation and differentiation and opposes BC6OTHER - induced apoptosis in human osteoblastic MG - 63 cells containing two BC6ENTC receptor ( BC6ENTG ) isoforms. CPR:falsenewlineBC6ENTC promotes proliferation by altering cell cycle distribution whereas BC6OTHER - mediated survival may be associated with up - regulation of BC6ENTG expression. CPR:falsenewlineBC6OTHER promotes proliferation by altering cell cycle distribution whereas BC6ENTC - mediated survival may be associated with up - regulation of BC6ENTG expression. CPR:falsenewlineTreatment with the BC6ENTG antagonist BC6ENTC abolishes the above actions of BC6OTHER on osteoblast - derived cells. CPR:falsenewlineTreatment with the BC6ENTG antagonist BC6OTHER abolishes the above actions of BC6ENTC on osteoblast - derived cells. CPR:falsenewline BC6ENTC stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG - 63 cells via BC6ENTG - dependent BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER activation. CPR:falsenewline BC6ENTC stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG - 63 cells via BC6OTHER - dependent BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER activation. CPR:3newline BC6ENTC stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG - 63 cells via BC6OTHER - dependent BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER activation. CPR:3newline BC6ENTC stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG - 63 cells via BC6OTHER - dependent BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER activation. CPR:3newline BC6ENTC stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG - 63 cells via BC6OTHER - dependent BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG activation. CPR:3newlineUsing small interfering double - stranded RNA technology, we further demonstrate that the effects of BC6ENTC on proliferation, differentiation and survival are mediated by both BC6ENTG and BC6OTHER . CPR:falsenewlineUsing small interfering double - stranded RNA technology, we further demonstrate that the effects of BC6ENTC on proliferation, differentiation and survival are mediated by both BC6OTHER and BC6ENTG . CPR:falsenewlineMoreover, we also demonstrate that BC6ENTC functions at least partially through activation of BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER signaling. CPR:3newlineMoreover, we also demonstrate that BC6ENTC functions at least partially through activation of BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER signaling. CPR:3newlineMoreover, we also demonstrate that BC6ENTC functions at least partially through activation of BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER signaling. CPR:3newlineMoreover, we also demonstrate that BC6ENTC functions at least partially through activation of BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG signaling. CPR:3newlineHere we show that BC6ENTC increases proliferation and differentiation and opposes BC6OTHER - induced apoptosis in human osteoblastic MG - 63 cells containing two BC6ENTG ( BC6OTHER ) isoforms. CPR:falsenewlineHere we show that BC6ENTC increases proliferation and differentiation and opposes BC6OTHER - induced apoptosis in human osteoblastic MG - 63 cells containing two BC6OTHER ( BC6ENTG ) isoforms. CPR:falsenewlineFurthermore, BC6ENTG - stimulated T - I cell proliferation and the expression of BC6OTHER BC6OTHER , BC6OTHER and BC6OTHER were also blocked by BC6ENTC . CPR:falsenewlineFurthermore, BC6OTHER - stimulated T - I cell proliferation and the expression of BC6ENTG BC6OTHER , BC6OTHER and BC6OTHER were also blocked by BC6ENTC . CPR:falsenewlineFurthermore, BC6OTHER - stimulated T - I cell proliferation and the expression of BC6OTHER BC6ENTG , BC6OTHER and BC6OTHER were also blocked by BC6ENTC . CPR:falsenewlineFurthermore, BC6OTHER - stimulated T - I cell proliferation and the expression of BC6OTHER BC6OTHER , BC6ENTG and BC6OTHER were also blocked by BC6ENTC . CPR:falsenewlineFurthermore, BC6OTHER - stimulated T - I cell proliferation and the expression of BC6OTHER BC6OTHER , BC6OTHER and BC6ENTG were also blocked by BC6ENTC . CPR:falsenewlinePharmacological inhibition of BC6ENTG with BC6ENTC abrogated the BC6OTHER - induced phosphorylation of BC6OTHER , BC6OTHER and its downstream effector, BC6OTHER . CPR:falsenewlinePharmacological inhibition of BC6OTHER with BC6ENTC abrogated the BC6ENTG - induced phosphorylation of BC6OTHER , BC6OTHER and its downstream effector, BC6OTHER . CPR:falsenewlinePharmacological inhibition of BC6OTHER with BC6ENTC abrogated the BC6OTHER - induced phosphorylation of BC6ENTG , BC6OTHER and its downstream effector, BC6OTHER . CPR:falsenewlinePharmacological inhibition of BC6OTHER with BC6ENTC abrogated the BC6OTHER - induced phosphorylation of BC6OTHER , BC6ENTG and its downstream effector, BC6OTHER . CPR:falsenewlinePharmacological inhibition of BC6OTHER with BC6ENTC abrogated the BC6OTHER - induced phosphorylation of BC6OTHER , BC6OTHER and its downstream effector, BC6ENTG . CPR:falsenewlineThe present study examined the effect of BC6OTHER - mediated activation of the mammalian target of BC6ENTC complex 1 ( BC6ENTG ) signaling network on the proliferation of primary culture of theca - interstitial (T - I) cells. CPR:falsenewlineThe present study examined the effect of BC6ENTG - mediated activation of the mammalian target of BC6ENTC complex 1 ( BC6OTHER ) signaling network on the proliferation of primary culture of theca - interstitial (T - I) cells. CPR:falsenewlineThe drug had a potent cytotoxic effect on RIN cells expressing BC6ENTG , but had no effect on cells lacking BC6OTHER expression, as indicated by histological analysis and measurement of the blood BC6ENTC levels of treated animals. CPR:falsenewlineThe drug had a potent cytotoxic effect on RIN cells expressing BC6OTHER , but had no effect on cells lacking BC6ENTG expression, as indicated by histological analysis and measurement of the blood BC6ENTC levels of treated animals. CPR:falsenewlineThe preferential cytotoxic effect of BC6ENTC on BC6OTHER - expressing cell lines was confirmed by in vitro analysis of BC6OTHER - expressing and untransfected RIN cells, as well as BC6ENTG - and BC6OTHER - overexpressing AtT - 20ins cells. CPR:falsenewlineThe preferential cytotoxic effect of BC6ENTC on BC6OTHER - expressing cell lines was confirmed by in vitro analysis of BC6OTHER - expressing and untransfected RIN cells, as well as BC6OTHER - and BC6ENTG - overexpressing AtT - 20ins cells. CPR:falsenewlineThe preferential cytotoxic effect of BC6ENTC on BC6ENTG - expressing cell lines was confirmed by in vitro analysis of BC6OTHER - expressing and untransfected RIN cells, as well as BC6OTHER - and BC6OTHER - overexpressing AtT - 20ins cells. CPR:falsenewlineThe preferential cytotoxic effect of BC6ENTC on BC6OTHER - expressing cell lines was confirmed by in vitro analysis of BC6ENTG - expressing and untransfected RIN cells, as well as BC6OTHER - and BC6OTHER - overexpressing AtT - 20ins cells. CPR:falsenewlineConsistent with these data, only BC6ENTG - expressing RIN or AtT - 20ins cells transported BC6ENTC efficiently. CPR:falsenewlineWe conclude that expression of BC6ENTG is required for efficient killing of neuroendocrine cells by BC6ENTC , and this effect is related to specific recognition of the drug as a transported substrate by BC6OTHER but not BC6OTHER . CPR:falsenewlineWe conclude that expression of BC6OTHER is required for efficient killing of neuroendocrine cells by BC6ENTC , and this effect is related to specific recognition of the drug as a transported substrate by BC6ENTG but not BC6OTHER . CPR:falsenewlineWe conclude that expression of BC6OTHER is required for efficient killing of neuroendocrine cells by BC6ENTC , and this effect is related to specific recognition of the drug as a transported substrate by BC6OTHER but not BC6ENTG . CPR:falsenewlineIn the current study, we have used insulinoma (RIN) and AtT - 20ins cell lines engineered for overexpression of BC6ENTG or BC6OTHER to investigate the role of BC6ENTC transporter isoforms in mediating BC6OTHER cytotoxicity. CPR:falsenewlineIn the current study, we have used insulinoma (RIN) and AtT - 20ins cell lines engineered for overexpression of BC6OTHER or BC6ENTG to investigate the role of BC6ENTC transporter isoforms in mediating BC6OTHER cytotoxicity. CPR:falsenewlineIn the current study, we have used insulinoma (RIN) and AtT - 20ins cell lines engineered for overexpression of BC6ENTG or BC6OTHER to investigate the role of BC6OTHER transporter isoforms in mediating BC6ENTC cytotoxicity. CPR:falsenewlineIn the current study, we have used insulinoma (RIN) and AtT - 20ins cell lines engineered for overexpression of BC6OTHER or BC6ENTG to investigate the role of BC6OTHER transporter isoforms in mediating BC6ENTC cytotoxicity. CPR:falsenewlineIn the current study, we have used insulinoma (RIN) and AtT - 20ins cell lines engineered for overexpression of BC6OTHER or BC6OTHER to investigate the role of BC6ENTG isoforms in mediating BC6ENTC cytotoxicity. CPR:falsenewlineThe in vivo effects of BC6ENTC were evaluated by implantation of RIN cells expressing or lacking BC6ENTG into athymic nude rats. CPR:falsenewlineBoth BC6ENTC , but BC6OTHER to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6ENTG - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells. CPR:falsenewlineBoth BC6ENTC , but BC6OTHER to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6ENTG - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells. CPR:falsenewlineBoth BC6ENTC , but BC6OTHER to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6ENTG was unaltered on activated T cells. CPR:falsenewlineBoth BC6OTHER , but BC6ENTC to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6ENTG - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells. CPR:falsenewlineBoth BC6OTHER , but BC6ENTC to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6ENTG - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells. CPR:falsenewlineBoth BC6OTHER , but BC6ENTC to a lesser extent compared with BC6OTHER , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6ENTG was unaltered on activated T cells. CPR:falsenewlineBoth BC6OTHER , but BC6OTHER to a lesser extent compared with BC6ENTC , selectively and dose - dependently reduced the percentage of BC6ENTG - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells. CPR:falsenewlineBoth BC6OTHER , but BC6OTHER to a lesser extent compared with BC6ENTC , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6ENTG - dependent fashion, whereas the expression of the cell surface marker BC6OTHER was unaltered on activated T cells. CPR:falsenewlineBoth BC6OTHER , but BC6OTHER to a lesser extent compared with BC6ENTC , selectively and dose - dependently reduced the percentage of BC6OTHER - expressing Th cells in a BC6OTHER - dependent fashion, whereas the expression of the cell surface marker BC6ENTG was unaltered on activated T cells. CPR:falsenewlineIn monocytes, both BC6ENTC and BC6OTHER increased BC6ENTG without affecting BC6OTHER and BC6OTHER . CPR:3newlineIn monocytes, both BC6ENTC and BC6OTHER increased BC6OTHER without affecting BC6ENTG and BC6OTHER . CPR:falsenewlineIn monocytes, both BC6ENTC and BC6OTHER increased BC6OTHER without affecting BC6OTHER and BC6ENTG . CPR:falsenewlineIn monocytes, both BC6OTHER and BC6ENTC increased BC6ENTG without affecting BC6OTHER and BC6OTHER . CPR:falsenewlineIn monocytes, both BC6OTHER and BC6ENTC increased BC6OTHER without affecting BC6ENTG and BC6OTHER . CPR:falsenewlineIn monocytes, both BC6OTHER and BC6ENTC increased BC6OTHER without affecting BC6OTHER and BC6ENTG . CPR:falsenewlineSingle nucleotide polymorphisms (SNPs) in the BC6ENTC - BC6OTHER - methyltransferase ( BC6ENTG ) gene have been related to cognitive function. CPR:falsenewlineSingle nucleotide polymorphisms (SNPs) in the CHEM - BC6ENTC - methyltransferase ( BC6ENTG ) gene have been related to cognitive function. CPR:falsenewlineAdenovirus - delivered BC6ENTG treatment for BC6ENTC - induced acute lung injury. CPR:falsenewlineThe lung injury induced by BC6ENTC was markedly reduced after the injection of Ad / BC6ENTG . CPR:falsenewlineThe increase of BC6ENTG and BC6OTHER and decrease of BC6OTHER in the serum and bronchoalveolar lavage fluid of BC6ENTC - exposed animals were abolished by the administration of Ad / BC6OTHER . CPR:falsenewlineThe increase of BC6OTHER and BC6ENTG and decrease of BC6OTHER in the serum and bronchoalveolar lavage fluid of BC6ENTC - exposed animals were abolished by the administration of Ad / BC6OTHER . CPR:falsenewlineThe increase of BC6OTHER and BC6OTHER and decrease of BC6ENTG in the serum and bronchoalveolar lavage fluid of BC6ENTC - exposed animals were abolished by the administration of Ad / BC6OTHER . CPR:falsenewlineThe increase of BC6OTHER and BC6OTHER and decrease of BC6OTHER in the serum and bronchoalveolar lavage fluid of BC6ENTC - exposed animals were abolished by the administration of Ad / BC6ENTG . CPR:falsenewlineDiscussion and conclusions: BC6ENTG has the beneficial effects on BC6ENTC - induced lung injury. CPR:falsenewlineThe adenovirus - delivered BC6ENTG may have the potential as a novel approach for the treatment of the acute lung injury caused by BC6ENTC gas inhalation in humans. CPR:falsenewlineObjective: In this study, the histopathological changes of the lungs after exposure to BC6ENTC and the effect of BC6ENTG treatment were examined. CPR:falsenewlineIsolation and characterization of labeled peptides from BC6ENTC - modified BC6ENTG indicated that peptides encompassing residues 38 - 75, 107 - 126, and 127 - 148 contained BC6OTHER label. CPR:falsenewlineIsolation and characterization of labeled peptides from BC6OTHER - modified BC6ENTG indicated that peptides encompassing residues 38 - 75, 107 - 126, and 127 - 148 contained BC6ENTC label. CPR:falsenewlineDrug - protein interactions: isolation and characterization of covalent adducts of BC6ENTC and BC6ENTG . CPR:falsenewlineBC6ENTC , an alpha - adrenergic antagonist containing a BC6OTHER group, labels BC6ENTG in the presence of BC6OTHER . CPR:falsenewlineBC6OTHER , an alpha - adrenergic antagonist containing a BC6OTHER group, labels BC6ENTG in the presence of BC6ENTC . CPR:falsenewlineAdducts of BC6ENTG and BC6ENTC were separated by high - performance liquid chromatography into four major fractions: two containing 0.6 and 1.2 mol of drug per mol of protein and two different fractions each containing 2.0 mol / mol. CPR:falsenewlineEach adduct had a reduced ability to activate BC6ENTC phosphodiesterase and BC6ENTG , and the BC6OTHER binding capacities of the BC6OTHER - BC6OTHER adducts were diminished to the extent of BC6OTHER incorporation into each adduct. CPR:falsenewlineEach adduct had a reduced ability to activate BC6ENTC phosphodiesterase and BC6OTHER , and the BC6OTHER binding capacities of the BC6OTHER - BC6ENTG adducts were diminished to the extent of BC6OTHER incorporation into each adduct. CPR:falsenewlineEach adduct had a reduced ability to activate BC6ENTG and BC6OTHER , and the BC6ENTC binding capacities of the BC6OTHER - BC6OTHER adducts were diminished to the extent of BC6OTHER incorporation into each adduct. CPR:falsenewlineEach adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6ENTG , and the BC6ENTC binding capacities of the BC6OTHER - BC6OTHER adducts were diminished to the extent of BC6OTHER incorporation into each adduct. CPR:falsenewlineEach adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6OTHER , and the BC6ENTC binding capacities of the BC6OTHER - BC6ENTG adducts were diminished to the extent of BC6OTHER incorporation into each adduct. CPR:falsenewlineBC6OTHER , an alpha - adrenergic antagonist containing a BC6ENTC group, labels BC6ENTG in the presence of BC6OTHER . CPR:falsenewlineEach adduct had a reduced ability to activate BC6ENTG and BC6OTHER , and the BC6OTHER binding capacities of the BC6ENTC - BC6OTHER adducts were diminished to the extent of BC6OTHER incorporation into each adduct. CPR:falsenewlineEach adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6ENTG , and the BC6OTHER binding capacities of the BC6ENTC - BC6OTHER adducts were diminished to the extent of BC6OTHER incorporation into each adduct. CPR:falsenewlineEach adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6OTHER , and the BC6OTHER binding capacities of the BC6ENTC - BC6ENTG adducts were diminished to the extent of BC6OTHER incorporation into each adduct. CPR:falsenewlineEach adduct had a reduced ability to activate BC6ENTG and BC6OTHER , and the BC6OTHER binding capacities of the BC6OTHER - BC6OTHER adducts were diminished to the extent of BC6ENTC incorporation into each adduct. CPR:falsenewlineEach adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6ENTG , and the BC6OTHER binding capacities of the BC6OTHER - BC6OTHER adducts were diminished to the extent of BC6ENTC incorporation into each adduct. CPR:falsenewlineEach adduct had a reduced ability to activate BC6OTHER phosphodiesterase and BC6OTHER , and the BC6OTHER binding capacities of the BC6OTHER - BC6ENTG adducts were diminished to the extent of BC6ENTC incorporation into each adduct. CPR:falsenewlineNovel highly affine BC6ENTG ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6ENTC - methyltransferase, chemically show structural elements of the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineNovel highly affine BC6OTHER H3 receptor ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6ENTC - methyltransferase, chemically show structural elements of the BC6ENTG inhibitor BC6OTHER . CPR:falsenewlineNovel highly affine BC6ENTC H3 receptor ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6ENTG , chemically show structural elements of the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineNovel highly affine BC6ENTC H3 receptor ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6OTHER - methyltransferase, chemically show structural elements of the BC6ENTG inhibitor BC6OTHER . CPR:falsenewlineNovel highly affine BC6OTHER H3 receptor ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6ENTG , chemically show structural elements of the BC6OTHER inhibitor BC6ENTC . CPR:falsenewlineNovel highly affine BC6ENTG ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6OTHER - methyltransferase, chemically show structural elements of the BC6OTHER inhibitor BC6ENTC . CPR:falsenewlineNovel highly affine BC6OTHER H3 receptor ligands with additional inhibitory effects on the main BC6OTHER metabolizing enzyme in the brain, BC6OTHER - methyltransferase, chemically show structural elements of the BC6ENTG inhibitor BC6ENTC . CPR:falsenewlineBC6ENTG antagonism, inhibition of metabolisation of neuronal BC6ENTC as well as inhibition of hydrolysis of BC6OTHER are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease. CPR:falsenewlineBC6ENTG antagonism, inhibition of metabolisation of neuronal BC6OTHER as well as inhibition of hydrolysis of BC6ENTC are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease. CPR:falsenewlineSome of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of BC6ENTG and of BC6OTHER which is another catalytic enzyme hydrolysing BC6ENTC . CPR:falsenewlineSome of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of BC6OTHER and of BC6ENTG which is another catalytic enzyme hydrolysing BC6ENTC . CPR:9newlineSome compounds with (sub)nanomolar activities on the BC6ENTC - related targets are also active in the nanomolar concentration range on both BC6ENTG targets being 5 - to 40 - times more potent than BC6OTHER . CPR:falsenewlineSome compounds with (sub)nanomolar activities on the BC6OTHER - related targets are also active in the nanomolar concentration range on both BC6ENTG targets being 5 - to 40 - times more potent than BC6ENTC . CPR:falsenewlineNovel highly affine BC6OTHER H3 receptor ligands with additional inhibitory effects on the main BC6ENTC metabolizing enzyme in the brain, BC6ENTG , chemically show structural elements of the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineNovel highly affine BC6ENTG ligands with additional inhibitory effects on the main BC6ENTC metabolizing enzyme in the brain, BC6OTHER - methyltransferase, chemically show structural elements of the BC6OTHER inhibitor BC6OTHER . CPR:falsenewlineNovel highly affine BC6OTHER H3 receptor ligands with additional inhibitory effects on the main BC6ENTC metabolizing enzyme in the brain, BC6OTHER - methyltransferase, chemically show structural elements of the BC6ENTG inhibitor BC6OTHER . CPR:falsenewlineConsistent with this, we found that knockdown of BC6OTHER inhibits, whereas ectopic expression of BC6OTHER enhances, BC6ENTC - induced degradation of BC6ENTG protein. CPR:falsenewlineConsistent with this, we found that knockdown of BC6ENTG inhibits, whereas ectopic expression of BC6OTHER enhances, BC6ENTC - induced degradation of BC6OTHER protein. CPR:falsenewlineConsistent with this, we found that knockdown of BC6OTHER inhibits, whereas ectopic expression of BC6ENTG enhances, BC6ENTC - induced degradation of BC6OTHER protein. CPR:falsenewlineImportantly, we found that knockdown of BC6ENTG sensitizes, whereas ectopic expression of BC6OTHER inhibits, growth suppression induced by BC6ENTC . CPR:falsenewlineImportantly, we found that knockdown of BC6OTHER sensitizes, whereas ectopic expression of BC6ENTG inhibits, growth suppression induced by BC6ENTC . CPR:falsenewlineTogether, these data suggest that BC6ENTC degrades BC6ENTG protein at least in part via BC6OTHER - dependent proteolysis and that inhibition of BC6OTHER expression facilitates tumor cells to BC6OTHER - induced death. CPR:falsenewlineTogether, these data suggest that BC6ENTC degrades BC6OTHER protein at least in part via BC6ENTG - dependent proteolysis and that inhibition of BC6OTHER expression facilitates tumor cells to BC6OTHER - induced death. CPR:falsenewlineTogether, these data suggest that BC6ENTC degrades BC6OTHER protein at least in part via BC6OTHER - dependent proteolysis and that inhibition of BC6ENTG expression facilitates tumor cells to BC6OTHER - induced death. CPR:falsenewlineTogether, these data suggest that BC6OTHER degrades BC6ENTG protein at least in part via BC6OTHER - dependent proteolysis and that inhibition of BC6OTHER expression facilitates tumor cells to BC6ENTC - induced death. CPR:falsenewlineTogether, these data suggest that BC6OTHER degrades BC6OTHER protein at least in part via BC6ENTG - dependent proteolysis and that inhibition of BC6OTHER expression facilitates tumor cells to BC6ENTC - induced death. CPR:falsenewlineTogether, these data suggest that BC6OTHER degrades BC6OTHER protein at least in part via BC6OTHER - dependent proteolysis and that inhibition of BC6ENTG expression facilitates tumor cells to BC6ENTC - induced death. CPR:falsenewlineHere we found that BC6ENTC , a frontline agent for acute promyelocytic leukemia, inhibits BC6ENTG but not BC6OTHER expression in time - and dose - dependent manners. CPR:falsenewlineHere we found that BC6ENTC , a frontline agent for acute promyelocytic leukemia, inhibits BC6OTHER but not BC6ENTG expression in time - and dose - dependent manners. CPR:falsenewlineIn addition, we found that BC6ENTC decreases the stability of BC6ENTG protein via a BC6OTHER - dependent pathway but has little effect on the level of BC6OTHER transcript. CPR:falsenewlineIn addition, we found that BC6ENTC decreases the stability of BC6OTHER protein via a BC6ENTG - dependent pathway but has little effect on the level of BC6OTHER transcript. CPR:falsenewlineIn addition, we found that BC6ENTC decreases the stability of BC6OTHER protein via a BC6OTHER - dependent pathway but has little effect on the level of BC6ENTG transcript. CPR:falsenewlineFurthermore, we found that BC6ENTC activates the BC6ENTG and consequently induces BC6OTHER expression. CPR:3newlineFurthermore, we found that BC6ENTC activates the BC6OTHER and consequently induces BC6ENTG expression. CPR:3newline BC6ENTC suppresses cell survival via BC6ENTG - mediated proteasomal degradation of BC6OTHER protein. CPR:falsenewline BC6ENTC suppresses cell survival via BC6OTHER - mediated proteasomal degradation of BC6ENTG protein. CPR:falsenewlineIn the current study dietary relevant mixtures of BC6ENTC and their metabolites, BC6OTHER and their metabolites, BC6OTHER , and a mixture containing all of them, were examined for effects on adipogenesis in 3T3 - L1 adipocytes, as well as tested for their BC6ENTG activating abilities. CPR:falsenewlineIn the current study dietary relevant mixtures of BC6OTHER and their metabolites, BC6ENTC and their metabolites, BC6OTHER , and a mixture containing all of them, were examined for effects on adipogenesis in 3T3 - L1 adipocytes, as well as tested for their BC6ENTG activating abilities. CPR:falsenewlineIn the current study dietary relevant mixtures of BC6OTHER and their metabolites, BC6OTHER and their metabolites, BC6ENTC , and a mixture containing all of them, were examined for effects on adipogenesis in 3T3 - L1 adipocytes, as well as tested for their BC6ENTG activating abilities. CPR:falsenewlineFurthermore, a mixture of BC6ENTC parent compounds, and a mixture of BC6OTHER metabolites were found to have BC6ENTG activating abilities. CPR:falsenewlineFurthermore, a mixture of BC6OTHER parent compounds, and a mixture of BC6ENTC metabolites were found to have BC6ENTG activating abilities. CPR:falsenewlineThe repeated exposures of CHEM, compared to single administration of CHEM, increased oral bioavailability and affected the pharmacokinetics of BC6ENTC and BC6OTHER , by inhibiting BC6ENTG . CPR:4newlineThe repeated exposures of CHEM, compared to single administration of CHEM, increased oral bioavailability and affected the pharmacokinetics of BC6OTHER and BC6ENTC , by inhibiting BC6ENTG . CPR:4newlineThe objective of this article is to examine the effects of single and repeated administrations of CHEM on pharmacokinetics of a BC6ENTG substrate, BC6ENTC , and its major metabolite, BC6OTHER , in rats. CPR:9newlineThe objective of this article is to examine the effects of single and repeated administrations of CHEM on pharmacokinetics of a BC6ENTG substrate, BC6OTHER , and its major metabolite, BC6ENTC , in rats. CPR:falsenewlineThe specific activity of only BC6ENTC aminotransferase ( BC6ENTG ), the rate - limiting enzyme in the conversion of BC6OTHER to BC6OTHER , increased in 2 weeks of hypertrophy. CPR:falsenewlineThe specific activity of only BC6ENTG ( BC6OTHER ), the rate - limiting enzyme in the conversion of BC6ENTC to BC6OTHER , increased in 2 weeks of hypertrophy. CPR:9newlineThe specific activity of only BC6OTHER ( BC6ENTG ), the rate - limiting enzyme in the conversion of BC6ENTC to BC6OTHER , increased in 2 weeks of hypertrophy. CPR:9newlineThe specific activity of only BC6ENTG ( BC6OTHER ), the rate - limiting enzyme in the conversion of BC6OTHER to BC6ENTC , increased in 2 weeks of hypertrophy. CPR:9newlineThe specific activity of only BC6OTHER ( BC6ENTG ), the rate - limiting enzyme in the conversion of BC6OTHER to BC6ENTC , increased in 2 weeks of hypertrophy. CPR:9newlineThe present study investigates enzyme activities of the CHEM cycle, BC6ENTG and BC6ENTC - BC6OTHER inter - conversion in the hypertrophied kidney after unilateral nephrectomy in mice. CPR:falsenewlineThe present study investigates enzyme activities of the CHEM cycle, BC6ENTG and BC6OTHER - BC6ENTC inter - conversion in the hypertrophied kidney after unilateral nephrectomy in mice. CPR:falsenewlineAnabolic effects of BC6ENTC on skeletal muscle are mediated by BC6ENTG activation. CPR:falsenewlineThese results indicate that the anabolic effects of BC6ENTC are dependent on interaction with the BC6ENTG . CPR:falsenewlineThese effects were not mimicked by oral administration of the BC6ENTG agonist BC6ENTC even at high dose (52 mg / kg diet), and the effects of BC6OTHER were not inhibited by addition of BC6OTHER (200 mg / kg diet). CPR:falsenewlineThese effects were not mimicked by oral administration of the BC6ENTG agonist BC6OTHER even at high dose (52 mg / kg diet), and the effects of BC6ENTC were not inhibited by addition of BC6OTHER (200 mg / kg diet). CPR:falsenewlineThese effects were not mimicked by oral administration of the BC6ENTG agonist BC6OTHER even at high dose (52 mg / kg diet), and the effects of BC6OTHER were not inhibited by addition of BC6ENTC (200 mg / kg diet). CPR:falsenewlineThe potent anabolic effects of the BC6OTHER agonist BC6ENTC on skeletal muscle have been reported to be independent of actions on BC6ENTG . CPR:falsenewlineThe potent anabolic effects of the BC6ENTG agonist BC6ENTC on skeletal muscle have been reported to be independent of actions on BC6OTHER . CPR:5newlinePosttranslational modification of the BC6ENTG ( BC6OTHER ) by BC6OTHER ( BC6ENTC ) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity. CPR:9newlinePosttranslational modification of the BC6OTHER ( BC6ENTG ) by BC6OTHER ( BC6ENTC ) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity. CPR:falsenewlineAs shown in a cell culture model, BC6OTHER - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6ENTG or lipopolysaccharide induced BC6OTHER - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6ENTC - NCAM. CPR:falsenewlineAs shown in a cell culture model, BC6OTHER - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6ENTG - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6ENTC - NCAM. CPR:falsenewlineAs shown in a cell culture model, BC6OTHER - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6OTHER - mediated BC6ENTG shedding, resulting in the secretion of soluble BC6ENTC - NCAM. CPR:falsenewlineAs shown in a cell culture model, BC6OTHER - BC6ENTG was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6OTHER - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6ENTC - NCAM. CPR:falsenewlineInterestingly, BC6ENTC chains of secreted BC6ENTG neutralized the cytotoxic activity of extracellular BC6OTHER as well as DNA / BC6OTHER - network - containing "neutrophil extracellular traps", which are formed during invasion of microorganisms. CPR:falsenewlineInterestingly, BC6ENTC chains of secreted BC6OTHER neutralized the cytotoxic activity of extracellular BC6ENTG as well as DNA / BC6OTHER - network - containing "neutrophil extracellular traps", which are formed during invasion of microorganisms. CPR:falsenewlineInterestingly, BC6ENTC chains of secreted BC6OTHER neutralized the cytotoxic activity of extracellular BC6OTHER as well as DNA / BC6ENTG - network - containing "neutrophil extracellular traps", which are formed during invasion of microorganisms. CPR:falsenewlineHere, we describe a novel function of BC6ENTG ( BC6ENTC - NCAM) in innate immunity of the lung. CPR:falsenewlineIn mature lung tissue of healthy donors, BC6ENTC was exclusively attached to the transmembrane isoform BC6ENTG and located to intracellular compartments of epithelial cells. CPR:falsenewlineIn patients with chronic obstructive pulmonary disease, however, increased BC6ENTC levels and processing of the BC6ENTG carrier were observed. CPR:falsenewlineProcessing of BC6ENTG was reproduced in a mouse model by BC6ENTC administration leading to an activation of the inflammasome and secretion of BC6OTHER . CPR:falsenewlineProcessing of BC6OTHER was reproduced in a mouse model by BC6ENTC administration leading to an activation of the inflammasome and secretion of BC6ENTG . CPR:falsenewlinePosttranslational modification of the BC6ENTG ( BC6OTHER ) by BC6ENTC ( BC6OTHER ) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity. CPR:9newlinePosttranslational modification of the BC6OTHER ( BC6ENTG ) by BC6ENTC ( BC6OTHER ) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity. CPR:9newlineAs shown in a cell culture model, BC6ENTC - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6ENTG or lipopolysaccharide induced BC6OTHER - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6OTHER - NCAM. CPR:falsenewlineAs shown in a cell culture model, BC6ENTC - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6ENTG - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6OTHER - NCAM. CPR:falsenewlineAs shown in a cell culture model, BC6ENTC - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6OTHER - mediated BC6ENTG shedding, resulting in the secretion of soluble BC6OTHER - NCAM. CPR:falsenewlineAs shown in a cell culture model, BC6ENTC - BC6OTHER was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6OTHER - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6ENTG . CPR:falsenewlineAs shown in a cell culture model, BC6ENTC - BC6ENTG was kept in the late trans - Golgi apparatus of lung epithelial cells and stimulation by BC6OTHER or lipopolysaccharide induced BC6OTHER - mediated BC6OTHER shedding, resulting in the secretion of soluble BC6OTHER - NCAM. CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6ENTC (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6ENTC (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6ENTC (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6ENTC (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6ENTC (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6ENTC (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6ENTC (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6ENTC (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6ENTC (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6ENTC (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6ENTC (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6ENTC (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6ENTC (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6ENTC (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6ENTC (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6ENTC (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6ENTC (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6ENTC (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6ENTC (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6ENTC (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTC - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6ENTC - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTC - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6ENTC . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6ENTC . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6ENTC . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6ENTC . CPR:falsenewlineBinding of a full - length heparin chain to this site of BC6ENTG in the presence of BC6ENTC makes a significant contribution to acceleration of the BC6OTHER inhibition by BC6OTHER through a ternary complex bridging or template mechanism. CPR:falsenewlineBinding of a full - length heparin chain to this site of BC6OTHER in the presence of BC6ENTC makes a significant contribution to acceleration of the BC6ENTG inhibition by BC6OTHER through a ternary complex bridging or template mechanism. CPR:falsenewlineBinding of a full - length heparin chain to this site of BC6OTHER in the presence of BC6ENTC makes a significant contribution to acceleration of the BC6OTHER inhibition by BC6ENTG through a ternary complex bridging or template mechanism. CPR:falsenewlineRecent studies have indicated that the basic residues BC6ENTC (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6ENTC (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6ENTC (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6ENTC (93), BC6OTHER (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6ENTC (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6ENTG numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6ENTC (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6ENTG that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6ENTC (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6ENTG of the BC6OTHER was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineRecent studies have indicated that the basic residues BC6OTHER (93), BC6ENTC (96), BC6OTHER (125), BC6OTHER (165), BC6OTHER (169), BC6OTHER (236), and BC6OTHER (240) ( BC6OTHER numbering) constitute an exosite in the catalytic domain of BC6OTHER that can effectively bind heparin only if the acidic BC6OTHER - terminal CHEM domain of the BC6ENTG was neutralized by physiological levels of BC6OTHER . CPR:falsenewlineMoreover, certain basic residues of this site, particularly BC6ENTC (165) and BC6OTHER (169), play a key role in BC6ENTG and / or BC6OTHER recognition by BC6OTHER in the prothrombinase complex. CPR:falsenewlineMoreover, certain basic residues of this site, particularly BC6ENTC (165) and BC6OTHER (169), play a key role in BC6OTHER and / or BC6ENTG recognition by BC6OTHER in the prothrombinase complex. CPR:falsenewlineMoreover, certain basic residues of this site, particularly BC6ENTC (165) and BC6OTHER (169), play a key role in BC6OTHER and / or BC6OTHER recognition by BC6ENTG in the prothrombinase complex. CPR:falsenewlineMoreover, certain basic residues of this site, particularly BC6OTHER (165) and BC6ENTC (169), play a key role in BC6ENTG and / or BC6OTHER recognition by BC6OTHER in the prothrombinase complex. CPR:falsenewlineMoreover, certain basic residues of this site, particularly BC6OTHER (165) and BC6ENTC (169), play a key role in BC6OTHER and / or BC6ENTG recognition by BC6OTHER in the prothrombinase complex. CPR:falsenewlineMoreover, certain basic residues of this site, particularly BC6OTHER (165) and BC6ENTC (169), play a key role in BC6OTHER and / or BC6OTHER recognition by BC6ENTG in the prothrombinase complex. CPR:falsenewlineOut of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6OTHER 82 - BC6OTHER 96, and BC6ENTC 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis. CPR:falsenewlineOut of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6OTHER 82 - BC6OTHER 96, and BC6OTHER 113 - BC6ENTC 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis. CPR:falsenewlineOut of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6OTHER 82 - BC6OTHER 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6ENTC 113 - BC6OTHER 122 was used as a template for peptide synthesis. CPR:falsenewlineOut of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6OTHER 82 - BC6OTHER 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6ENTC 122 was used as a template for peptide synthesis. CPR:falsenewlineThe peptide BC6ENTC (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6ENTG - BC6OTHER binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineThe peptide BC6ENTC (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6ENTG binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineThe peptide BC6ENTC (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6ENTG induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineThe peptide BC6ENTC (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6OTHER induced BC6ENTG activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineThe peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6ENTC with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6ENTG - BC6OTHER binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineThe peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6ENTC with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6ENTG binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineThe peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6ENTC with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6ENTG induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineThe peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6ENTC with a BC6OTHER residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6OTHER induced BC6ENTG activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineThe peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6ENTC residue in the template sequence, significantly (p<0.05) inhibited BC6ENTG - BC6OTHER binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineThe peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6ENTC residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6ENTG binding, and BC6OTHER induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineThe peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6ENTC residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6ENTG induced BC6OTHER activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineThe peptide BC6OTHER (YLEIEFSLKHR), obtained by direct substitution of BC6OTHER with a BC6ENTC residue in the template sequence, significantly (p<0.05) inhibited BC6OTHER - BC6OTHER binding, and BC6OTHER induced BC6ENTG activity and formation of multinucleated osteoclasts without any cytotoxicity. CPR:falsenewlineResults confirmed that BC6ENTC peptide inhibited pro - inflammatory BC6ENTG in the sera and hind paw tissues of AIA rats through its suppressive effect on BC6OTHER induced nuclear translocation of BC6OTHER . CPR:4newlineResults confirmed that BC6ENTC peptide inhibited pro - inflammatory BC6OTHER in the sera and hind paw tissues of AIA rats through its suppressive effect on BC6ENTG induced nuclear translocation of BC6OTHER . CPR:falsenewlineResults confirmed that BC6ENTC peptide inhibited pro - inflammatory BC6OTHER in the sera and hind paw tissues of AIA rats through its suppressive effect on BC6OTHER induced nuclear translocation of BC6ENTG . CPR:falsenewlineOut of the three putative sites (i.e., BC6ENTC 70 - BC6OTHER 78, BC6OTHER 82 - BC6OTHER 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis. CPR:falsenewlineOut of the three putative sites (i.e., BC6OTHER 70 - BC6ENTC 78, BC6OTHER 82 - BC6OTHER 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis. CPR:falsenewlineOut of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6ENTC 82 - BC6OTHER 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis. CPR:falsenewlineOut of the three putative sites (i.e., BC6OTHER 70 - BC6OTHER 78, BC6OTHER 82 - BC6ENTC 96, and BC6OTHER 113 - BC6OTHER 122) available on OPG for BC6ENTG binding, BC6OTHER 113 - BC6OTHER 122 was used as a template for peptide synthesis. CPR:falsenewlineWe conclude that BC6ENTC binds at two sites in the recombinant BC6ENTG . CPR:falsenewlineTo verify the hypothesis that the non - conventional partial agonist BC6OTHER binds at two BC6OTHER sites, BC6ENTG , expressed in CHO cells, were labelled with BC6ENTC . CPR:falsenewlineTo verify the hypothesis that the non - conventional partial agonist BC6OTHER binds at two BC6ENTG sites, BC6OTHER , expressed in CHO cells, were labelled with BC6ENTC . CPR:falsenewlineBC6ENTC dissociated from the BC6ENTG with a fast component (k(off)=0.45 min( - 1)), consistent with the L - site, and a slow component (k(off)=0.017 - 0.033 min( - 1)), consistent with the CHEM - site. CPR:falsenewlineTo verify the hypothesis that the non - conventional partial agonist BC6ENTC binds at two BC6OTHER sites, BC6ENTG , expressed in CHO cells, were labelled with BC6OTHER . CPR:falsenewlineTo verify the hypothesis that the non - conventional partial agonist BC6ENTC binds at two BC6ENTG sites, BC6OTHER , expressed in CHO cells, were labelled with BC6OTHER . CPR:falsenewlineBinding of BC6ENTC at two sites in recombinant BC6ENTG and interaction with beta - blockers. CPR:falsenewlineMETHODS: Activation and repolarization characteristics of the explanted heart of a patient with a loss - of - function mutation in BC6ENTG ( BC6OTHER ) and dilated cardiomyopathy were determined after induction of right - sided ST - segment elevation by BC6ENTC . CPR:falsenewlineMETHODS: Activation and repolarization characteristics of the explanted heart of a patient with a loss - of - function mutation in BC6OTHER ( BC6ENTG ) and dilated cardiomyopathy were determined after induction of right - sided ST - segment elevation by BC6ENTC . CPR:falsenewlineA series of BC6OTHER analogs were designed and the interaction between BC6ENTC and BC6ENTG studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of BC6OTHER . CPR:falsenewlineA series of BC6ENTC analogs were designed and the interaction between BC6OTHER and BC6ENTG studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of BC6OTHER . CPR:falsenewlineA series of BC6OTHER analogs were designed and the interaction between BC6OTHER and BC6ENTG studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of BC6ENTC . CPR:falsenewlineThe nonsteroidal anti - inflammatory drugs BC6ENTC and BC6OTHER were modified in an attempt to alter the kinetics of inhibitor binding by BC6ENTG . CPR:falsenewlineThe nonsteroidal anti - inflammatory drugs BC6OTHER and BC6ENTC were modified in an attempt to alter the kinetics of inhibitor binding by BC6ENTG . CPR:falsenewlineManipulation of kinetic profiles in BC6ENTC BC6ENTG inhibitors. CPR:falsenewlineOur results suggest that only negatively charged BC6ENTC derivatives have a BC6ENTG - dependent microtubule inhibitory effect. CPR:falsenewlineThe negatively charged BC6ENTC has been found previously to be a BC6ENTG ( BC6OTHER ) - dependent microtubule inhibitor [Wallin M, Deinum J and CHEM, FEBS Lett 179: 289 - 293, 1985]. CPR:falsenewlineThe negatively charged BC6ENTC has been found previously to be a BC6OTHER ( BC6ENTG ) - dependent microtubule inhibitor [Wallin M, Deinum J and CHEM, FEBS Lett 179: 289 - 293, 1985]. CPR:falsenewlineIn the present study the binding of BC6ENTC to BC6ENTG and BC6OTHER was investigated. CPR:falsenewlineIn the present study the binding of BC6ENTC to BC6OTHER and BC6ENTG was investigated. CPR:falsenewlineBoth these BC6ENTG were found to have two to three binding sites for BC6ENTC which is compatible with the reported number of basic BC6OTHER repeats of these BC6OTHER , considered to be the ultimate BC6OTHER binding domains. CPR:falsenewlineBoth these BC6OTHER were found to have two to three binding sites for BC6ENTC which is compatible with the reported number of basic BC6OTHER repeats of these BC6ENTG , considered to be the ultimate BC6OTHER binding domains. CPR:falsenewlineBoth these BC6OTHER were found to have two to three binding sites for BC6ENTC which is compatible with the reported number of basic BC6OTHER repeats of these BC6OTHER , considered to be the ultimate BC6ENTG binding domains. CPR:falsenewlineBoth these BC6ENTG were found to have two to three binding sites for BC6OTHER which is compatible with the reported number of basic BC6ENTC repeats of these BC6OTHER , considered to be the ultimate BC6OTHER binding domains. CPR:falsenewlineBoth these BC6OTHER were found to have two to three binding sites for BC6OTHER which is compatible with the reported number of basic BC6ENTC repeats of these BC6ENTG , considered to be the ultimate BC6OTHER binding domains. CPR:falsenewlineBoth these BC6OTHER were found to have two to three binding sites for BC6OTHER which is compatible with the reported number of basic BC6ENTC repeats of these BC6OTHER , considered to be the ultimate BC6ENTG binding domains. CPR:falsenewlineThe Kd for the binding of BC6ENTC to BC6ENTG was estimated to be 20 microM at 4 degrees, and for the binding of tau, 200 microM. CPR:falsenewlineTwo new negatively charged BC6ENTC derivatives, BC6OTHER and BC6OTHER , were found to be similar BC6ENTG - dependent microtubule inhibitors. CPR:falsenewlineTwo new negatively charged BC6OTHER derivatives, BC6ENTC and BC6OTHER , were found to be similar BC6ENTG - dependent microtubule inhibitors. CPR:falsenewlineTwo new negatively charged BC6OTHER derivatives, BC6OTHER and BC6ENTC , were found to be similar BC6ENTG - dependent microtubule inhibitors. CPR:falsenewlineA positively charged derivative, BC6ENTC , did not inhibit microtubule assembly or alter the composition of the coassembled BC6ENTG . CPR:falsenewlineThe uncharged BC6ENTC bound to both BC6ENTG and BC6OTHER , but no effects were seen on microtubule assembly, the composition of coassembled BC6OTHER or the microtubule morphology. CPR:falsenewlineThe uncharged BC6ENTC bound to both BC6OTHER and BC6ENTG , but no effects were seen on microtubule assembly, the composition of coassembled BC6OTHER or the microtubule morphology. CPR:falsenewlineThe uncharged BC6ENTC bound to both BC6OTHER and BC6OTHER , but no effects were seen on microtubule assembly, the composition of coassembled BC6ENTG or the microtubule morphology. CPR:falsenewlineImportantly, treatment with BC6ENTC did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of BC6ENTG signaling that do not target BC6OTHER . CPR:falsenewlineImportantly, treatment with BC6ENTC did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of BC6OTHER signaling that do not target BC6ENTG . CPR:falsenewlineCollectively, these data suggest that BC6ENTC is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated BC6ENTG and BC6OTHER signaling. CPR:falsenewlineCollectively, these data suggest that BC6ENTC is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated BC6OTHER and BC6ENTG signaling. CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a small - molecule BC6ENTG inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:4newlineBC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6ENTG and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6ENTG ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6ENTG ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other BC6ENTG that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a small - molecule BC6ENTG inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:4newlineBC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6ENTG and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6ENTG ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6ENTG ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other BC6ENTG that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6OTHER kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a small - molecule BC6ENTG inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6ENTG and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6ENTG ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6ENTG ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a small - molecule BC6OTHER inhibitor with potent activity toward BC6OTHER and BC6OTHER ( BC6OTHER ), as well as a number of other receptor BC6ENTC kinases that have also been implicated in tumor pathobiology, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineTreatment with BC6ENTC inhibited BC6ENTG and BC6OTHER phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro. CPR:falsenewlineTreatment with BC6ENTC inhibited BC6OTHER and BC6ENTG phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro. CPR:falsenewline BC6ENTC ( BC6OTHER ), a novel BC6ENTG and BC6OTHER inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. CPR:4newline BC6ENTC ( BC6OTHER ), a novel BC6OTHER and BC6ENTG inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. CPR:4newline BC6OTHER ( BC6ENTC ), a novel BC6ENTG and BC6OTHER inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. CPR:4newline BC6OTHER ( BC6ENTC ), a novel BC6OTHER and BC6ENTG inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. CPR:4newlineThese agents include newer BC6ENTG - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6ENTC receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6ENTG agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6ENTC receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTG inhibitors, free BC6ENTC receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6ENTC receptor agonists, BC6ENTG inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6ENTC receptor agonists, BC6OTHER inhibitors, BC6ENTG activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6ENTG - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6ENTC dehydrogenase type 1 inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6ENTG agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6ENTC dehydrogenase type 1 inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTG inhibitors, free BC6OTHER receptor agonists, BC6ENTC dehydrogenase type 1 inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, BC6ENTG agonists, BC6ENTC dehydrogenase type 1 inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6ENTC dehydrogenase type 1 inhibitors, BC6ENTG activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6ENTG - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTC - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6ENTG agonists, as well as new therapeutic classes such as BC6ENTC - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTC - coupled BC6OTHER cotransporter 2 inhibitors, BC6ENTG agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTC - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6ENTG inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6ENTC - coupled BC6OTHER cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6ENTG activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6ENTG - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6ENTC cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6ENTG agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6ENTC cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6ENTC cotransporter 2 inhibitors, BC6ENTG agonists, BC6OTHER inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6ENTC cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6ENTG inhibitors, BC6OTHER activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThese agents include newer BC6OTHER - based therapies and BC6OTHER agonists, as well as new therapeutic classes such as BC6OTHER - coupled BC6ENTC cotransporter 2 inhibitors, free BC6OTHER receptor agonists, BC6OTHER inhibitors, BC6ENTG activators, and several others that may enter clinical use over the next decade. CPR:falsenewlineThis trial investigated the possibility of pharmacokinetic interactions between the BC6ENTG antagonist BC6ENTC and the BC6OTHER diuretic BC6OTHER in healthy subjects. CPR:6newlineThis trial investigated the possibility of pharmacokinetic interactions between the BC6ENTG antagonist BC6OTHER and the BC6ENTC diuretic BC6OTHER in healthy subjects. CPR:falsenewlineThis trial investigated the possibility of pharmacokinetic interactions between the BC6ENTG antagonist BC6OTHER and the BC6OTHER diuretic BC6ENTC in healthy subjects. CPR:falsenewlineWhen using double staining with BC6ENTC for mineralized matrix and BC6OTHER for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6ENTG ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6OTHER - Cre; BC6OTHER (flox / flox) mice. CPR:falsenewlineWhen using double staining with BC6ENTC for mineralized matrix and BC6OTHER for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6OTHER ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6ENTG - Cre; BC6OTHER (flox / flox) mice. CPR:falsenewlineWhen using double staining with BC6ENTC for mineralized matrix and BC6OTHER for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6OTHER ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6OTHER - Cre; BC6ENTG (flox / flox) mice. CPR:falsenewlineWhen using double staining with BC6OTHER for mineralized matrix and BC6ENTC for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6ENTG ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6OTHER - Cre; BC6OTHER (flox / flox) mice. CPR:falsenewlineWhen using double staining with BC6OTHER for mineralized matrix and BC6ENTC for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6OTHER ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6ENTG - Cre; BC6OTHER (flox / flox) mice. CPR:falsenewlineWhen using double staining with BC6OTHER for mineralized matrix and BC6ENTC for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in BC6OTHER ( - / - ) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in BC6OTHER - Cre; BC6ENTG (flox / flox) mice. CPR:falsenewlineOur findings indicate that serum BC6ENTC levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6ENTG level <10 pg / ml (or poor plasma BC6OTHER response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineOur findings indicate that serum BC6ENTC levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6ENTG response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineOur findings indicate that serum BC6ENTC levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6OTHER response to BC6ENTG ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineOur findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6ENTG level <10 pg / ml (or poor plasma BC6OTHER response to BC6OTHER ) and (2) serum BC6ENTC ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineOur findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6ENTG response to BC6OTHER ) and (2) serum BC6ENTC ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineOur findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6OTHER response to BC6ENTG ) and (2) serum BC6ENTC ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineOur findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6ENTG level <10 pg / ml (or poor plasma BC6OTHER response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6ENTC levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineOur findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6ENTG response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6ENTC levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineOur findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6OTHER response to BC6ENTG ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6ENTC levels, urine free BC6OTHER levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineOur findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6ENTG level <10 pg / ml (or poor plasma BC6OTHER response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6ENTC levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineOur findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6ENTG response to BC6OTHER ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6ENTC levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineOur findings indicate that serum BC6OTHER levels ≥1.8 μg / dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal BC6OTHER level <10 pg / ml (or poor plasma BC6OTHER response to BC6ENTG ) and (2) serum BC6OTHER ≥5 μg / dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum BC6OTHER levels, urine free BC6ENTC levels, adrenal scintigraphy, and clinical manifestation. CPR:falsenewlineBC6ENTC were designed and synthesized as potent BC6OTHER - BC6ENTG inhibitors. CPR:4newlineBC6ENTC were designed and synthesized as potent BC6ENTG - BC6OTHER inhibitors. CPR:4newlineAn X - ray crystal structure of optimized compound 9b bound in the active site of BC6ENTG showed that the CHEM scaffold provides 5 BC6ENTC bonding interactions in addition to projecting groups for interactions within the S1, S2 and S3 pockets. CPR:falsenewlineDesign and synthesis of BC6ENTC as potent BC6ENTG - BC6OTHER inhibitors. CPR:4newlineDesign and synthesis of BC6ENTC as potent BC6OTHER - BC6ENTG inhibitors. CPR:4newlineWhen the cloned BC6ENTG was transfected into COS 1 cells, BC6OTHER stimulated intracellular BC6ENTC accumulation with an EC50 of 0.1 nM, whereas BC6OTHER was >250 - fold less potent (EC50 27.6 nM). CPR:falsenewlineWhen the cloned BC6OTHER was transfected into COS 1 cells, BC6ENTG stimulated intracellular BC6ENTC accumulation with an EC50 of 0.1 nM, whereas BC6OTHER was >250 - fold less potent (EC50 27.6 nM). CPR:falsenewlineWhen the cloned BC6OTHER was transfected into COS 1 cells, BC6OTHER stimulated intracellular BC6ENTC accumulation with an EC50 of 0.1 nM, whereas BC6ENTG was >250 - fold less potent (EC50 27.6 nM). CPR:falsenewlineStimulation of the transfected BC6ENTG by salmon calcitonin also resulted in BC6ENTC hydrolysis with an EC50 of 2.5 nM. CPR:9newlineNative BC6ENTG stimulates BC6OTHER secretion in a BC6ENTC - dependent manner, as well as suppressing BC6OTHER production and slowing gastric emptying. CPR:falsenewlineNative BC6OTHER stimulates BC6ENTG secretion in a BC6ENTC - dependent manner, as well as suppressing BC6OTHER production and slowing gastric emptying. CPR:falsenewlineNative BC6OTHER stimulates BC6OTHER secretion in a BC6ENTC - dependent manner, as well as suppressing BC6ENTG production and slowing gastric emptying. CPR:falsenewlineBC6ENTC , an antirheumatic gold compound, is an inhibitor of BC6OTHER enzymes, such as BC6OTHER and BC6ENTG . CPR:falsenewlineBC6ENTC , an antirheumatic gold compound, is an inhibitor of BC6ENTG , such as BC6OTHER and BC6OTHER peroxidase. CPR:4newlineBC6ENTC , an antirheumatic gold compound, is an inhibitor of BC6OTHER enzymes, such as BC6ENTG and BC6OTHER peroxidase. CPR:falsenewlineBC6OTHER , an antirheumatic gold compound, is an inhibitor of BC6ENTG , such as BC6OTHER and BC6ENTC peroxidase. CPR:falsenewlineBC6OTHER , an antirheumatic gold compound, is an inhibitor of BC6OTHER enzymes, such as BC6ENTG and BC6ENTC peroxidase. CPR:falsenewlineThe activity of BC6ENTG and BC6ENTC peroxidase was determined in liver and heart tissues in an attempt to correlate enzymatic activity with heart recovery after ischaemia - reperfusion. CPR:falsenewlineBC6OTHER , an antirheumatic gold compound, is an inhibitor of BC6ENTC enzymes, such as BC6OTHER and BC6ENTG . CPR:falsenewlineBC6OTHER , an antirheumatic gold compound, is an inhibitor of BC6ENTC enzymes, such as BC6ENTG and BC6OTHER peroxidase. CPR:falsenewlineThere was significantly less BC6ENTG activity in rat liver extracts, whereas the level of BC6ENTC activity remained unchanged, demonstrating that the dose of BC6OTHER used was able to selectively inhibit one of these enzyme systems. CPR:falsenewlineThere was significantly less BC6ENTG activity in rat liver extracts, whereas the level of BC6OTHER activity remained unchanged, demonstrating that the dose of BC6ENTC used was able to selectively inhibit one of these enzyme systems. CPR:falsenewlineTo map supercoiling, we used BC6ENTC as a DNA structure probe to show that the human genome is organized into BC6ENTG . CPR:falsenewlineMoreover, BC6ENTC could also down - regulate the expression and activity of BC6ENTG ( BC6OTHER ). CPR:4newlineMoreover, BC6ENTC could also down - regulate the expression and activity of BC6OTHER ( BC6ENTG ). CPR:4newlineIt undergoes extensive biotransformation, which is affected by poor metabolism by BC6ENTG in a small percentage of the population; these patients have greater exposure to and slower elimination of BC6ENTC than extensive metabolizers. CPR:falsenewlineBC6ENTG inhibitors, such as BC6ENTC , are associated with changes in BC6OTHER pharmacokinetics similar to those observed among poor BC6OTHER metabolizers. CPR:falsenewlineBC6OTHER inhibitors, such as BC6ENTC , are associated with changes in BC6OTHER pharmacokinetics similar to those observed among poor BC6ENTG metabolizers. CPR:falsenewlineBC6ENTG inhibitors, such as BC6OTHER , are associated with changes in BC6ENTC pharmacokinetics similar to those observed among poor BC6OTHER metabolizers. CPR:falsenewlineBC6OTHER inhibitors, such as BC6OTHER , are associated with changes in BC6ENTC pharmacokinetics similar to those observed among poor BC6ENTG metabolizers. CPR:falsenewlineBC6ENTC appeared better tolerated among extensive BC6ENTG metabolizers than among poor metabolizers. CPR:falsenewlineBC6ENTC has a high affinity and selectivity for BC6ENTG , but little or no affinity for various BC6OTHER . CPR:falsenewlineBC6ENTC has a high affinity and selectivity for BC6OTHER transporters, but little or no affinity for various BC6ENTG . CPR:falsenewlineBC6OTHER has a high affinity and selectivity for BC6ENTC transporters, but little or no affinity for various BC6ENTG . CPR:falsenewlineBC6ENTC is a moderate inhibitor of BC6ENTG ( BC6OTHER ) with KI values of 19, 16 and 4.5 µM, respectively. CPR:4newlineBC6OTHER is a moderate inhibitor of BC6ENTG ( BC6ENTC ) with KI values of 19, 16 and 4.5 µM, respectively. CPR:falsenewlineBC6ENTC is both a substrate and inhibitor (IC50 = 1.9 µM) of BC6ENTG . CPR:9newlineBC6ENTC is highly bound to plasma proteins and has minimal interaction with BC6ENTG . CPR:falsenewlineBC6ENTC is not a potent reversible inhibitor of BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER is not a potent reversible inhibitor of BC6ENTG ( BC6ENTC ). CPR:falsenewlineIt has a particular selectivity profile for the known nuclear BC6ENTC receptors with low affinity for BC6ENTG and no transactivating potential for BC6OTHER . CPR:falsenewlineIt has a particular selectivity profile for the known nuclear BC6ENTC receptors with low affinity for BC6OTHER and no transactivating potential for BC6ENTG . CPR:falsenewlineFurthermore, BC6ENTC does not bind to members of the cellular BC6ENTG family. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6ENTC metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6ENTG ( BC6OTHER ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6ENTC metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6ENTG ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6ENTC metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6ENTG and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6ENTC metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6OTHER and BC6ENTG or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6ENTC ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6ENTG ( BC6OTHER ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6ENTC ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6ENTG ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6ENTC ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6ENTG and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6ENTC ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6OTHER and BC6ENTG or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6ENTC to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6ENTG ( BC6OTHER ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6ENTC to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6ENTG ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6ENTC to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6ENTG and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6ENTC to plasma protein in calves; (c) species differences in the sensitivity to BC6OTHER of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6OTHER and BC6ENTG or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6ENTC of the BC6ENTG ( BC6OTHER ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6ENTC of the BC6OTHER ( BC6ENTG ) isoenzymes, BC6OTHER and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6ENTC of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6ENTG and BC6OTHER or; (d) a combination of these factors. CPR:falsenewlineThese differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active BC6OTHER metabolite, BC6OTHER ; (b) a greater degree of binding of BC6OTHER to plasma protein in calves; (c) species differences in the sensitivity to BC6ENTC of the BC6OTHER ( BC6OTHER ) isoenzymes, BC6OTHER and BC6ENTG or; (d) a combination of these factors. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6OTHER - induced skin swelling. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6ENTG - induced skin swelling. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6OTHER - induced skin swelling. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6ENTG - induced skin swelling. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6OTHER - induced skin swelling. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6ENTG - induced skin swelling. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6OTHER - induced skin swelling. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6OTHER ), and BC6ENTG - induced skin swelling. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6ENTC ( BC6OTHER ), and BC6OTHER - induced skin swelling. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6ENTC ( BC6OTHER ), and BC6ENTG - induced skin swelling. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6ENTC ), and BC6OTHER - induced skin swelling. CPR:falsenewlineThe higher concentrations in calves were insufficient to inhibit significantly exudate BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER concentrations and exudate leucocyte numbers, serum BC6OTHER ( BC6ENTC ), and BC6ENTG - induced skin swelling. CPR:falsenewlineThese results suggest that both BC6ENTG ) increase the BC6OTHER sensitivity of contractile elements, and that the BC6ENTC sensitization produced by BC6OTHER is mediated through BC6OTHER and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta. CPR:falsenewlineThese results suggest that both BC6OTHER ) increase the BC6OTHER sensitivity of contractile elements, and that the BC6ENTC sensitization produced by BC6ENTG is mediated through BC6OTHER and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta. CPR:falsenewlineThese results suggest that both BC6OTHER ) increase the BC6OTHER sensitivity of contractile elements, and that the BC6ENTC sensitization produced by BC6OTHER is mediated through BC6ENTG and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta. CPR:falsenewlineThese results suggest that both BC6OTHER ) increase the BC6OTHER sensitivity of contractile elements, and that the BC6ENTC sensitization produced by BC6OTHER is mediated through BC6OTHER and BC6ENTG , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta. CPR:falsenewlineIn beta - CHEM - skinned strips of BC6ENTC - pretreated smooth muscle, the enhancement of BC6OTHER contraction produced by BC6OTHER was significantly decreased, whereas the amplitude was the same as that produced by BC6OTHER or BC6OTHER ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6OTHER (100 nM). CPR:falsenewlineIn beta - CHEM - skinned strips of BC6OTHER - pretreated smooth muscle, the enhancement of BC6ENTC contraction produced by BC6OTHER was significantly decreased, whereas the amplitude was the same as that produced by BC6OTHER or BC6OTHER ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6OTHER (100 nM). CPR:falsenewlineIn beta - CHEM - skinned strips of BC6OTHER - pretreated smooth muscle, the enhancement of BC6OTHER contraction produced by BC6ENTC was significantly decreased, whereas the amplitude was the same as that produced by BC6OTHER or BC6OTHER ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6OTHER (100 nM). CPR:falsenewlineIn beta - CHEM - skinned strips of BC6OTHER - pretreated smooth muscle, the enhancement of BC6OTHER contraction produced by BC6OTHER was significantly decreased, whereas the amplitude was the same as that produced by BC6ENTC or BC6OTHER ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6OTHER (100 nM). CPR:falsenewlineIn beta - CHEM - skinned strips of BC6OTHER - pretreated smooth muscle, the enhancement of BC6OTHER contraction produced by BC6OTHER was significantly decreased, whereas the amplitude was the same as that produced by BC6OTHER or BC6ENTC ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6OTHER (100 nM). CPR:falsenewlineIn beta - CHEM - skinned strips of BC6OTHER - pretreated smooth muscle, the enhancement of BC6OTHER contraction produced by BC6OTHER was significantly decreased, whereas the amplitude was the same as that produced by BC6OTHER or BC6OTHER ; this enhancement was inhibited by the selective BC6ENTG antagonist BC6ENTC (100 nM). CPR:falsenewline BC6ENTG subtypes mediating the regulation and modulation of BC6ENTC sensitization in rabbit thoracic aorta. CPR:falsenewlineFurthermore, the phosphorylation of BC6ENTG produced by BC6ENTC was greater than that produced by BC6OTHER . CPR:3newlineFurthermore, the phosphorylation of BC6ENTG produced by BC6OTHER was greater than that produced by BC6ENTC . CPR:falsenewlineThese results suggest that both BC6ENTG ) increase the BC6ENTC sensitivity of contractile elements, and that the BC6OTHER sensitization produced by BC6OTHER is mediated through BC6OTHER and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta. CPR:falsenewlineThese results suggest that both BC6OTHER ) increase the BC6ENTC sensitivity of contractile elements, and that the BC6OTHER sensitization produced by BC6ENTG is mediated through BC6OTHER and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta. CPR:falsenewlineThese results suggest that both BC6OTHER ) increase the BC6ENTC sensitivity of contractile elements, and that the BC6OTHER sensitization produced by BC6OTHER is mediated through BC6ENTG and BC6OTHER , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta. CPR:falsenewlineThese results suggest that both BC6OTHER ) increase the BC6ENTC sensitivity of contractile elements, and that the BC6OTHER sensitization produced by BC6OTHER is mediated through BC6OTHER and BC6ENTG , and plays an important role in contraction of smooth muscle of rabbit thoracic aorta. CPR:falsenewlineImmunoreactivity for a second putative BC6ENTC transporter, BC6ENTG , was present in the apical region of cells with almost the same distribution as BC6OTHER . CPR:falsenewlineImmunoreactivity for a second putative BC6ENTC transporter, BC6OTHER , was present in the apical region of cells with almost the same distribution as BC6ENTG . CPR:falsenewlineRecent studies have identified a family of putative BC6ENTC transporters; mRNA for two members of this family, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), is expressed in the kidney. CPR:falsenewlineRecent studies have identified a family of putative BC6ENTC transporters; mRNA for two members of this family, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), is expressed in the kidney. CPR:falsenewlineRecent studies have identified a family of putative BC6ENTC transporters; mRNA for two members of this family, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), is expressed in the kidney. CPR:falsenewlineRecent studies have identified a family of putative BC6ENTC transporters; mRNA for two members of this family, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), is expressed in the kidney. CPR:falsenewlineThese findings suggest that BC6ENTG and BC6OTHER may play important and cell - specific roles in BC6ENTC transport and signaling in these regions of the kidney. CPR:9newlineThese findings suggest that BC6OTHER and BC6ENTG may play important and cell - specific roles in BC6ENTC transport and signaling in these regions of the kidney. CPR:9newlineColocalization of BC6OTHER with BC6OTHER , the BC6ENTC - sensitive transporter, and the BC6OTHER BC6OTHER and BC6OTHER demonstrated BC6ENTG immunoreactivity in all CNT cells and all CCD and ICT principal cells. CPR:falsenewlineColocalization of BC6ENTG with BC6OTHER , the BC6ENTC - sensitive transporter, and the BC6OTHER BC6OTHER and BC6OTHER demonstrated BC6OTHER immunoreactivity in all CNT cells and all CCD and ICT principal cells. CPR:falsenewlineColocalization of BC6OTHER with BC6ENTG , the BC6ENTC - sensitive transporter, and the BC6OTHER BC6OTHER and BC6OTHER demonstrated BC6OTHER immunoreactivity in all CNT cells and all CCD and ICT principal cells. CPR:falsenewlineColocalization of BC6OTHER with BC6OTHER , the BC6ENTC - sensitive transporter, and the BC6ENTG BC6OTHER and BC6OTHER demonstrated BC6OTHER immunoreactivity in all CNT cells and all CCD and ICT principal cells. CPR:falsenewlineColocalization of BC6OTHER with BC6OTHER , the BC6ENTC - sensitive transporter, and the BC6OTHER BC6ENTG and BC6OTHER demonstrated BC6OTHER immunoreactivity in all CNT cells and all CCD and ICT principal cells. CPR:falsenewlineColocalization of BC6OTHER with BC6OTHER , the BC6ENTC - sensitive transporter, and the BC6OTHER BC6OTHER and BC6ENTG demonstrated BC6OTHER immunoreactivity in all CNT cells and all CCD and ICT principal cells. CPR:falsenewlineLocalization of the BC6ENTC transporter proteins BC6ENTG and BC6OTHER in mouse kidney. CPR:falsenewlineLocalization of the BC6ENTC transporter proteins BC6OTHER and BC6ENTG in mouse kidney. CPR:falsenewlineThese cells express high levels of BC6ENTC A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6ENTG BC6OTHER . CPR:falsenewlineThese cells express high levels of BC6ENTC A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6OTHER - and BC6OTHER - regulated 32 - kDa phosphoprotein BC6ENTG . CPR:falsenewlineThese cells express high levels of BC6ENTG , which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6ENTC - and BC6OTHER - regulated 32 - kDa phosphoprotein BC6OTHER . CPR:falsenewlineThese cells express high levels of BC6OTHER A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6ENTC - and BC6OTHER - regulated 32 - kDa phosphoprotein BC6ENTG . CPR:falsenewlineThese cells express high levels of BC6ENTG , which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6OTHER - and BC6ENTC - regulated 32 - kDa phosphoprotein BC6OTHER . CPR:falsenewlineThese cells express high levels of BC6OTHER A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the BC6OTHER - and BC6ENTC - regulated 32 - kDa phosphoprotein BC6ENTG . CPR:falsenewlineEffect of BC6ENTC on serum BC6ENTG levels. CPR:falsenewlineThe mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean BC6ENTG level after 1 week of treatment with BC6ENTC (3.14 ng / mL) was 14.2% higher than that at baseline (2.75 ng / mL; P < .05). CPR:falsenewlineThis increase may suggest that both BC6ENTG and BC6ENTC may affect appetite via similar receptors and that BC6OTHER does not impair leptin activity through these receptors. CPR:falsenewlineThis increase may suggest that both BC6ENTG and BC6OTHER may affect appetite via similar receptors and that BC6ENTC does not impair leptin activity through these receptors. CPR:falsenewlineBC6ENTG is a 167 BC6ENTC protein encoded by the obesity gene that is synthesized in adipose tissue and interacts with receptors in the hypothalamus linked to the regulation of appetite and metabolism. CPR:falsenewlineBC6ENTC is a BC6OTHER BC6OTHER that increases appetite through its antiserotonergic effect on BC6ENTG receptors in the brain. CPR:falsenewlineBC6OTHER is a BC6ENTC BC6OTHER that increases appetite through its antiserotonergic effect on BC6ENTG receptors in the brain. CPR:falsenewlineBC6OTHER is a BC6OTHER BC6ENTC that increases appetite through its antiserotonergic effect on BC6ENTG receptors in the brain. CPR:falsenewlineAlthough both BC6ENTG and BC6ENTC are effective in controlling appetite, their interaction has not been addressed in clinical studies. CPR:falsenewlineThe aim of present study was to identify BC6ENTG ( BC6OTHER ) isoforms which can catalyze the BC6OTHER - demethylation of BC6OTHER to BC6ENTC , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain. CPR:falsenewlineThe aim of present study was to identify BC6OTHER ( BC6ENTG ) isoforms which can catalyze the BC6OTHER - demethylation of BC6OTHER to BC6ENTC , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain. CPR:falsenewlineThe aim of present study was to identify BC6ENTG ( BC6OTHER ) isoforms which can catalyze the BC6OTHER - demethylation of BC6OTHER to BC6OTHER , and to find out whether that alternative pathway of BC6ENTC synthesis may take place in the brain. CPR:falsenewlineThe aim of present study was to identify BC6OTHER ( BC6ENTG ) isoforms which can catalyze the BC6OTHER - demethylation of BC6OTHER to BC6OTHER , and to find out whether that alternative pathway of BC6ENTC synthesis may take place in the brain. CPR:falsenewlineOf the BC6ENTG isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6ENTC - demethylation of BC6OTHER to BC6OTHER , but they were less effective than the BC6OTHER . CPR:falsenewlineOf the BC6OTHER isoforms studied, BC6ENTG isoforms were the most efficient in catalyzing the BC6ENTC - demethylation of BC6OTHER to BC6OTHER , but they were less effective than the BC6OTHER . CPR:falsenewlineOf the BC6OTHER isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6ENTC - demethylation of BC6OTHER to BC6OTHER , but they were less effective than the BC6ENTG . CPR:falsenewlineOf the BC6ENTG isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6ENTC to BC6OTHER , but they were less effective than the BC6OTHER . CPR:falsenewlineOf the BC6OTHER isoforms studied, BC6ENTG isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6ENTC to BC6OTHER , but they were less effective than the BC6OTHER . CPR:falsenewlineOf the BC6OTHER isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6ENTC to BC6OTHER , but they were less effective than the BC6ENTG . CPR:falsenewlineOf the BC6ENTG isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6OTHER to BC6ENTC , but they were less effective than the BC6OTHER . CPR:falsenewlineOf the BC6OTHER isoforms studied, BC6ENTG isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6OTHER to BC6ENTC , but they were less effective than the BC6OTHER . CPR:falsenewlineOf the BC6OTHER isoforms studied, BC6OTHER isoforms were the most efficient in catalyzing the BC6OTHER - demethylation of BC6OTHER to BC6ENTC , but they were less effective than the BC6ENTG . CPR:falsenewlineThe catalytic competence of BC6ENTG in the synthesis of BC6ENTC from BC6OTHER in the brain: an in vitro study. CPR:9newlineThe catalytic competence of BC6ENTG in the synthesis of BC6OTHER from BC6ENTC in the brain: an in vitro study. CPR:9newlineThe reaction was inhibited by the specific BC6ENTG inhibitors BC6ENTC and BC6OTHER . CPR:4newlineThe reaction was inhibited by the specific BC6ENTG inhibitors BC6OTHER and BC6ENTC . CPR:4newlineHuman liver microsomes of the wild - type BC6ENTG metabolized BC6ENTC to BC6OTHER more effectively than did the defective BC6OTHER *4*4 ones. CPR:9newlineHuman liver microsomes of the wild - type BC6OTHER metabolized BC6ENTC to BC6OTHER more effectively than did the defective BC6ENTG *4*4 ones. CPR:9newlineHuman liver microsomes of the wild - type BC6ENTG metabolized BC6OTHER to BC6ENTC more effectively than did the defective BC6OTHER *4*4 ones. CPR:9newlineHuman liver microsomes of the wild - type BC6OTHER metabolized BC6OTHER to BC6ENTC more effectively than did the defective BC6ENTG *4*4 ones. CPR:9newlineThe obtained results indicate that BC6ENTG isoforms catalyze the formation of BC6ENTC from BC6OTHER , and that the deficit or genetic defect of BC6OTHER may affect BC6OTHER metabolism in the brain. CPR:9newlineThe obtained results indicate that BC6OTHER isoforms catalyze the formation of BC6ENTC from BC6OTHER , and that the deficit or genetic defect of BC6ENTG may affect BC6OTHER metabolism in the brain. CPR:falsenewlineThe obtained results indicate that BC6ENTG isoforms catalyze the formation of BC6OTHER from BC6ENTC , and that the deficit or genetic defect of BC6OTHER may affect BC6OTHER metabolism in the brain. CPR:falsenewlineThe obtained results indicate that BC6OTHER isoforms catalyze the formation of BC6OTHER from BC6ENTC , and that the deficit or genetic defect of BC6ENTG may affect BC6OTHER metabolism in the brain. CPR:falsenewlineThe obtained results indicate that BC6ENTG isoforms catalyze the formation of BC6OTHER from BC6OTHER , and that the deficit or genetic defect of BC6OTHER may affect BC6ENTC metabolism in the brain. CPR:falsenewlineThe obtained results indicate that BC6OTHER isoforms catalyze the formation of BC6OTHER from BC6OTHER , and that the deficit or genetic defect of BC6ENTG may affect BC6ENTC metabolism in the brain. CPR:falsenewlineThe aim of present study was to identify BC6ENTG ( BC6OTHER ) isoforms which can catalyze the BC6ENTC - demethylation of BC6OTHER to BC6OTHER , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain. CPR:falsenewlineThe aim of present study was to identify BC6OTHER ( BC6ENTG ) isoforms which can catalyze the BC6ENTC - demethylation of BC6OTHER to BC6OTHER , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain. CPR:falsenewlineThe aim of present study was to identify BC6ENTG ( BC6OTHER ) isoforms which can catalyze the BC6OTHER - demethylation of BC6ENTC to BC6OTHER , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain. CPR:falsenewlineThe aim of present study was to identify BC6OTHER ( BC6ENTG ) isoforms which can catalyze the BC6OTHER - demethylation of BC6ENTC to BC6OTHER , and to find out whether that alternative pathway of BC6OTHER synthesis may take place in the brain. CPR:falsenewlineTriple pharmacological blockade of the BC6ENTG - BC6OTHER - BC6ENTC system in nondiabetic CKD: an open - label crossover randomized controlled trial. CPR:falsenewlineTriple pharmacological blockade of the BC6OTHER - BC6ENTG - BC6ENTC system in nondiabetic CKD: an open - label crossover randomized controlled trial. CPR:falsenewlineWe evaluated the hypothesis that the addition of an BC6ENTC receptor antagonist to an BC6ENTG ( BC6OTHER ) inhibitor and BC6OTHER type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade). CPR:falsenewlineWe evaluated the hypothesis that the addition of an BC6ENTC receptor antagonist to an BC6OTHER ( BC6ENTG ) inhibitor and BC6OTHER type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade). CPR:falsenewlineWe evaluated the hypothesis that the addition of an BC6ENTC receptor antagonist to an BC6OTHER ( BC6OTHER ) inhibitor and BC6ENTG blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade). CPR:falsenewlineWe evaluated the hypothesis that the addition of an BC6ENTC receptor antagonist to an BC6OTHER ( BC6OTHER ) inhibitor and BC6OTHER type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6ENTG inhibitor and ARB (double RAAS blockade). CPR:falsenewlineCONCLUSIONS: Administration of an BC6ENTC receptor antagonist in addition to double RAAS blockade with an BC6ENTG inhibitor and ARB may slow the progression of chronic kidney disease. CPR:falsenewlineWe evaluated the hypothesis that the addition of an BC6ENTG antagonist to an BC6OTHER ( BC6OTHER ) inhibitor and BC6ENTC type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade). CPR:falsenewlineWe evaluated the hypothesis that the addition of an BC6OTHER receptor antagonist to an BC6ENTG ( BC6OTHER ) inhibitor and BC6ENTC type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade). CPR:falsenewlineWe evaluated the hypothesis that the addition of an BC6OTHER receptor antagonist to an BC6OTHER ( BC6ENTG ) inhibitor and BC6ENTC type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6OTHER inhibitor and ARB (double RAAS blockade). CPR:falsenewlineWe evaluated the hypothesis that the addition of an BC6OTHER receptor antagonist to an BC6OTHER ( BC6OTHER ) inhibitor and BC6ENTC type 1 (AT - 1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an BC6ENTG inhibitor and ARB (double RAAS blockade). CPR:falsenewlineBACKGROUND: Agents inhibiting the BC6ENTG - BC6OTHER - BC6ENTC (RAAS) system have an important role in slowing the progression of chronic kidney disease. CPR:falsenewlineBACKGROUND: Agents inhibiting the BC6OTHER - BC6ENTG - BC6ENTC (RAAS) system have an important role in slowing the progression of chronic kidney disease. CPR:falsenewlineINTERVENTIONS: In the 8 - week run - in period, all participants received the BC6ENTG inhibitor BC6ENTC (5 mg), the ARB BC6OTHER n (80 mg), and the diuretic BC6OTHER (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130 / 80 mm CHEM. CPR:falsenewlineINTERVENTIONS: In the 8 - week run - in period, all participants received the BC6ENTG inhibitor BC6OTHER (5 mg), the ARB BC6ENTC n (80 mg), and the diuretic BC6OTHER (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130 / 80 mm CHEM. CPR:falsenewlineINTERVENTIONS: In the 8 - week run - in period, all participants received the BC6ENTG inhibitor BC6OTHER (5 mg), the ARB BC6OTHER n (80 mg), and the diuretic BC6ENTC (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130 / 80 mm CHEM. CPR:falsenewlineDisruption of the BC6ENTG also affected growth in a BC6OTHER - defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent BC6ENTC ( BC6OTHER ). CPR:falsenewlineDisruption of the BC6OTHER also affected growth in a BC6ENTG - defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent BC6ENTC ( BC6OTHER ). CPR:falsenewlineDisruption of the BC6ENTG also affected growth in a BC6OTHER - defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent BC6OTHER ( BC6ENTC ). CPR:falsenewlineDisruption of the BC6OTHER also affected growth in a BC6ENTG - defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent BC6OTHER ( BC6ENTC ). CPR:falsenewlinePromoter replacements conferring constitutive expression of BC6ENTG revealed that the transcriptional induction in response to BC6ENTC is required to maintain induced levels of BC6OTHER . CPR:falsenewlinePromoter replacements conferring constitutive expression of BC6OTHER revealed that the transcriptional induction in response to BC6ENTC is required to maintain induced levels of BC6ENTG . CPR:falsenewlineIts pathogenesis is complex, and involves a state of 'lipotoxicity' in which BC6ENTG resistance, with increased BC6ENTC release from adipose tissue to the liver, play a key role in the onset of a 'lipotoxic liver disease' and its progression to NASH. CPR:falsenewlineBC6ENTC synthase ( BC6ENTG ), the key metabolic multi - enzyme that is responsible for the terminal catalytic step in the de novo CHEM biosynthesis, plays an active role in the development, maintenance, and enhancement of the malignant phenotype in a subset of breast carcinomas. CPR:falsenewlineSK - Br3 cells cultured in the presence of BC6ENTG ( BC6OTHER ) inhibitors BC6ENTC and BC6OTHER ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions. CPR:falsenewlineSK - Br3 cells cultured in the presence of BC6OTHER ( BC6ENTG ) inhibitors BC6ENTC and BC6OTHER ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions. CPR:falsenewlineSK - Br3 cells cultured in the presence of BC6OTHER ( BC6OTHER ) inhibitors BC6ENTC and BC6OTHER ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6ENTG activity when compared with control cells growing in drug - free culture conditions. CPR:falsenewlineSK - Br3 cells cultured in the presence of BC6ENTG ( BC6OTHER ) inhibitors BC6OTHER and BC6ENTC ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions. CPR:falsenewlineSK - Br3 cells cultured in the presence of BC6OTHER ( BC6ENTG ) inhibitors BC6OTHER and BC6ENTC ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions. CPR:falsenewlineSK - Br3 cells cultured in the presence of BC6OTHER ( BC6OTHER ) inhibitors BC6OTHER and BC6ENTC ( BC6OTHER ) demonstrated a 2 - to 3 - fold increase in BC6ENTG activity when compared with control cells growing in drug - free culture conditions. CPR:4newlineSK - Br3 cells cultured in the presence of BC6ENTG ( BC6OTHER ) inhibitors BC6OTHER and BC6OTHER ( BC6ENTC ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions. CPR:falsenewlineSK - Br3 cells cultured in the presence of BC6OTHER ( BC6ENTG ) inhibitors BC6OTHER and BC6OTHER ( BC6ENTC ) demonstrated a 2 - to 3 - fold increase in BC6OTHER activity when compared with control cells growing in drug - free culture conditions. CPR:falsenewlineSK - Br3 cells cultured in the presence of BC6OTHER ( BC6OTHER ) inhibitors BC6OTHER and BC6OTHER ( BC6ENTC ) demonstrated a 2 - to 3 - fold increase in BC6ENTG activity when compared with control cells growing in drug - free culture conditions. CPR:falsenewlineWe failed to observe any significant activation of BC6ENTG following exposure to the anti - metabolite BC6ENTC , the alkylating drug BC6OTHER , or the microtubule interfering - agents BC6OTHER and BC6OTHER . CPR:falsenewlineWe failed to observe any significant activation of BC6ENTG following exposure to the anti - metabolite BC6OTHER , the alkylating drug BC6ENTC , or the microtubule interfering - agents BC6OTHER and BC6OTHER . CPR:falsenewlineWe failed to observe any significant activation of BC6ENTG following exposure to the anti - metabolite BC6OTHER , the alkylating drug BC6OTHER , or the microtubule interfering - agents BC6ENTC and BC6OTHER . CPR:falsenewlineWe failed to observe any significant activation of BC6ENTG following exposure to the anti - metabolite BC6OTHER , the alkylating drug BC6OTHER , or the microtubule interfering - agents BC6OTHER and BC6ENTC . CPR:falsenewline BC6ENTG ( BC6OTHER ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER genes. CPR:falsenewline BC6OTHER ( BC6OTHER ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6ENTG , BC6OTHER / BC6OTHER and BC6OTHER genes. CPR:falsenewline BC6OTHER ( BC6OTHER ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6OTHER , BC6ENTG / BC6OTHER and BC6OTHER genes. CPR:falsenewline BC6OTHER ( BC6OTHER ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6OTHER , BC6OTHER / BC6ENTG and BC6OTHER genes. CPR:falsenewline BC6OTHER ( BC6OTHER ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6OTHER , BC6OTHER / BC6OTHER and BC6ENTG genes. CPR:falsenewline BC6OTHER ( BC6ENTG ) inhibitors up - regulate BC6ENTC synthase gene expression in SK - Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER genes. CPR:falsenewlineIn vitro experiments assessed the inhibition of BC6ENTG and BC6OTHER enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6ENTC (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6OTHER (10 mg single dose). CPR:falsenewlineIn vitro experiments assessed the inhibition of BC6OTHER and BC6ENTG enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6ENTC (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6OTHER (10 mg single dose). CPR:falsenewlineIn vitro experiments assessed the inhibition of BC6ENTG and BC6OTHER enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6ENTC (40 mg single dose) and BC6OTHER (10 mg single dose). CPR:falsenewlineIn vitro experiments assessed the inhibition of BC6OTHER and BC6ENTG enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6ENTC (40 mg single dose) and BC6OTHER (10 mg single dose). CPR:falsenewlineIn vitro experiments assessed the inhibition of BC6ENTG and BC6OTHER enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6ENTC (10 mg single dose). CPR:falsenewlineIn vitro experiments assessed the inhibition of BC6OTHER and BC6ENTG enzymes by BC6OTHER , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6ENTC (10 mg single dose). CPR:falsenewlineIn vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6ENTG ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6OTHER . CPR:4newlineIn vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6OTHER . CPR:4newlineIn vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6OTHER . CPR:4newlineIn vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6OTHER . CPR:4newlineIn vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6OTHER . CPR:4newlineIn vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ), BC6OTHER , BC6OTHER , or BC6OTHER . CPR:4newlineIn vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), BC6ENTG , BC6OTHER , or BC6OTHER . CPR:4newlineIn vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER , BC6ENTG , or BC6OTHER . CPR:4newlineIn vitro, BC6ENTC demonstrated little / weak inhibition (IC50 values >30 μM) towards BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER , BC6OTHER , or BC6ENTG . CPR:4newlineThis work investigated the drug interaction potential of BC6ENTC , a novel BC6OTHER agonist, with the BC6ENTG inhibitors BC6OTHER and BC6OTHER . CPR:falsenewlineThis work investigated the drug interaction potential of BC6ENTC , a novel BC6ENTG agonist, with the BC6OTHER inhibitors BC6OTHER and BC6OTHER . CPR:falsenewlineHowever, BC6ENTC inhibited BC6ENTG and BC6OTHER , which are transporters involved in CHEM disposition. CPR:4newlineHowever, BC6ENTC inhibited BC6OTHER and BC6ENTG , which are transporters involved in CHEM disposition. CPR:4newlineIn the clinical study, small increases in the AUC(0 - inf) of BC6ENTC [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6OTHER [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6OTHER , which is consistent with an inhibitory effect on intestinal BC6OTHER and BC6ENTG . CPR:4newlineIn the clinical study, small increases in the AUC(0 - inf) of BC6ENTC [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6OTHER [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6OTHER , which is consistent with an inhibitory effect on intestinal BC6ENTG and BC6OTHER . CPR:4newlineIn the clinical study, small increases in the AUC(0 - inf) of BC6OTHER [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6ENTC [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6OTHER , which is consistent with an inhibitory effect on intestinal BC6OTHER and BC6ENTG . CPR:4newlineIn the clinical study, small increases in the AUC(0 - inf) of BC6OTHER [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6ENTC [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6OTHER , which is consistent with an inhibitory effect on intestinal BC6ENTG and BC6OTHER . CPR:falsenewlineIn the clinical study, small increases in the AUC(0 - inf) of BC6OTHER [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6OTHER [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6ENTC , which is consistent with an inhibitory effect on intestinal BC6OTHER and BC6ENTG . CPR:4newlineIn the clinical study, small increases in the AUC(0 - inf) of BC6OTHER [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and BC6OTHER [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co - administered with BC6ENTC , which is consistent with an inhibitory effect on intestinal BC6ENTG and BC6OTHER . CPR:4newlineEvaluation of drug interactions of BC6ENTC (a BC6ENTG agonist) with CHEM: from in vitro data to clinical study design. CPR:falsenewlineIn contrast, BC6ENTC did not inhibit BC6ENTG based on the lack of changes in BC6OTHER acid exposure [mean AUC(0 - inf) ratio (90% CI) of 1.05 (0.91, 1.21)]. CPR:falsenewlineIn contrast, BC6OTHER did not inhibit BC6ENTG based on the lack of changes in BC6ENTC acid exposure [mean AUC(0 - inf) ratio (90% CI) of 1.05 (0.91, 1.21)]. CPR:falsenewlineThis work investigated the drug interaction potential of BC6OTHER , a novel BC6OTHER agonist, with the BC6ENTG inhibitors BC6ENTC and BC6OTHER . CPR:falsenewlineThis work investigated the drug interaction potential of BC6OTHER , a novel BC6ENTG agonist, with the BC6OTHER inhibitors BC6ENTC and BC6OTHER . CPR:falsenewlineThis study provides a mechanistic understanding of the in vivo inhibition of BC6ENTG and enzymes by BC6ENTC . CPR:4newlineThis work investigated the drug interaction potential of BC6OTHER , a novel BC6OTHER agonist, with the BC6ENTG inhibitors BC6OTHER and BC6ENTC . CPR:falsenewlineThis work investigated the drug interaction potential of BC6OTHER , a novel BC6ENTG agonist, with the BC6OTHER inhibitors BC6OTHER and BC6ENTC . CPR:falsenewlineIn vitro experiments assessed the inhibition of BC6ENTG and BC6OTHER enzymes by BC6ENTC , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6OTHER (10 mg single dose). CPR:falsenewlineIn vitro experiments assessed the inhibition of BC6OTHER and BC6ENTG enzymes by BC6ENTC , and a clinical drug interaction study investigated the effect of BC6OTHER (300 mg CHEM) on the pharmacokinetic profile of BC6OTHER (40 mg single dose) and BC6OTHER (10 mg single dose). CPR:falsenewlineIn particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTC / BC6ENTG ( BC6OTHER / BC6OTHER ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis. CPR:falsenewlineIn particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTC / BC6OTHER ( BC6ENTG / BC6OTHER ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis. CPR:falsenewlineIn particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTC / BC6OTHER ( BC6OTHER / BC6ENTG ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis. CPR:falsenewlineIn particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTC / BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6ENTG ( BC6OTHER ), have been associated with poor prognosis and metastasis. CPR:falsenewlineIn particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTC / BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6OTHER ( BC6ENTG ), have been associated with poor prognosis and metastasis. CPR:falsenewlineIn particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6ENTG / BC6ENTC receptors ( BC6OTHER / BC6OTHER ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis. CPR:falsenewlineIn particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6OTHER / BC6ENTC receptors ( BC6ENTG / BC6OTHER ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis. CPR:falsenewlineIn particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6OTHER / BC6ENTC receptors ( BC6OTHER / BC6ENTG ) and BC6OTHER ( BC6OTHER ), have been associated with poor prognosis and metastasis. CPR:falsenewlineIn particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6OTHER / BC6ENTC receptors ( BC6OTHER / BC6OTHER ) and BC6ENTG ( BC6OTHER ), have been associated with poor prognosis and metastasis. CPR:falsenewlineIn particular, triple negative breast cancers (TNBCs), which do not express the genes for BC6OTHER / BC6ENTC receptors ( BC6OTHER / BC6OTHER ) and BC6OTHER ( BC6ENTG ), have been associated with poor prognosis and metastasis. CPR:falsenewlineBC6ENTC and BC6OTHER induced apoptosis by BC6ENTG downregulation. CPR:falsenewlineBC6OTHER and BC6ENTC induced apoptosis by BC6ENTG downregulation. CPR:falsenewlineImportantly, BC6ENTC and BC6OTHER exerted more potent inhibitory effects on the proliferation, BC6ENTG expression and invasive phenotype of CHEM - MB - 231 than BC6OTHER . CPR:4newlineImportantly, BC6OTHER and BC6ENTC exerted more potent inhibitory effects on the proliferation, BC6ENTG expression and invasive phenotype of CHEM - MB - 231 than BC6OTHER . CPR:falsenewlineImportantly, BC6OTHER and BC6OTHER exerted more potent inhibitory effects on the proliferation, BC6ENTG expression and invasive phenotype of CHEM - MB - 231 than BC6ENTC . CPR:falsenewlineBoth inhibitors, moreover, blunted the BC6ENTG secretory responses to beta - adrenergic agonist - generated second messenger, BC6OTHER as well as BC6OTHER cyclase activator, BC6ENTC . CPR:falsenewlineBoth inhibitors, moreover, blunted the BC6OTHER secretory responses to beta - adrenergic agonist - generated second messenger, BC6OTHER as well as BC6ENTG activator, BC6ENTC . CPR:falsenewlineThe BC6OTHER secretory responses to BC6ENTC , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6ENTG autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER . CPR:falsenewlineThe BC6OTHER secretory responses to BC6ENTC , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6ENTG inhibitor, BC6OTHER . CPR:falsenewlineThe BC6ENTG secretory responses to BC6ENTC , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER . CPR:falsenewlineThe BC6OTHER secretory responses to BC6ENTC , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTG BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER . CPR:falsenewlineThe BC6OTHER secretory responses to BC6ENTC , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6ENTG responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER . CPR:falsenewlineThe BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6ENTC , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6ENTG autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER . CPR:falsenewlineThe BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6ENTC , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6ENTG inhibitor, BC6OTHER . CPR:falsenewlineThe BC6ENTG secretory responses to BC6OTHER , furthermore, were inhibited by BC6ENTC , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER . CPR:falsenewlineThe BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6ENTC , a selective inhibitor of BC6ENTG BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER . CPR:falsenewlineThe BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6ENTC , a selective inhibitor of BC6OTHER BC6ENTG responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER . CPR:falsenewlineThe BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTC kinase BC6OTHER responsible for ligand - independent BC6ENTG autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER . CPR:falsenewlineThe BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTC kinase BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6ENTG inhibitor, BC6OTHER . CPR:falsenewlineThe BC6ENTG secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTC kinase BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER . CPR:falsenewlineThe BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTC kinase BC6ENTG responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6OTHER . CPR:falsenewlineThe BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6ENTG autophosphorylation, but not by BC6OTHER inhibitor, BC6ENTC . CPR:falsenewlineThe BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6ENTG inhibitor, BC6ENTC . CPR:falsenewlineThe BC6ENTG secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6ENTC . CPR:falsenewlineThe BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6ENTG BC6OTHER responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6ENTC . CPR:falsenewlineThe BC6OTHER secretory responses to BC6OTHER , furthermore, were inhibited by BC6OTHER , a selective inhibitor of BC6OTHER BC6ENTG responsible for ligand - independent BC6OTHER autophosphorylation, but not by BC6OTHER inhibitor, BC6ENTC . CPR:falsenewlineThe inhibition of BC6ENTG , moreover, did not cause attenuation in BC6OTHER secretion in response to BC6ENTC and BC6OTHER . CPR:falsenewlineThe inhibition of BC6OTHER , moreover, did not cause attenuation in BC6ENTG secretion in response to BC6ENTC and BC6OTHER . CPR:falsenewlineThe inhibition of BC6ENTG , moreover, did not cause attenuation in BC6OTHER secretion in response to BC6OTHER and BC6ENTC . CPR:falsenewlineThe inhibition of BC6OTHER , moreover, did not cause attenuation in BC6ENTG secretion in response to BC6OTHER and BC6ENTC . CPR:falsenewlineIn many systems, the integration of converging regulatory signals that relay on BC6OTHER ( BC6ENTG ) activation into functional cellular pathways requires the involvement of receptor BC6ENTC kinase. CPR:falsenewlineIn many systems, the integration of converging regulatory signals that relay on BC6ENTG ( BC6OTHER ) activation into functional cellular pathways requires the involvement of receptor BC6ENTC kinase. CPR:falsenewlineUsing BC6ENTC - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6ENTG secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6OTHER , as well as BC6OTHER , a specific inhibitor of BC6OTHER . CPR:falsenewlineUsing BC6ENTC - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6ENTG BC6OTHER inhibitor, BC6OTHER , as well as BC6OTHER , a specific inhibitor of BC6OTHER . CPR:falsenewlineUsing BC6ENTC - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6ENTG inhibitor, BC6OTHER , as well as BC6OTHER , a specific inhibitor of BC6OTHER . CPR:falsenewlineUsing BC6ENTC - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6OTHER , as well as BC6OTHER , a specific inhibitor of BC6ENTG . CPR:falsenewlineUsing BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6ENTG secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6ENTC , as well as BC6OTHER , a specific inhibitor of BC6OTHER . CPR:falsenewlineUsing BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6ENTG BC6OTHER inhibitor, BC6ENTC , as well as BC6OTHER , a specific inhibitor of BC6OTHER . CPR:falsenewlineUsing BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6ENTG inhibitor, BC6ENTC , as well as BC6OTHER , a specific inhibitor of BC6OTHER . CPR:falsenewlineUsing BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6ENTC , as well as BC6OTHER , a specific inhibitor of BC6ENTG . CPR:falsenewlineUsing BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6ENTG secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6OTHER , as well as BC6ENTC , a specific inhibitor of BC6OTHER . CPR:falsenewlineUsing BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6ENTG BC6OTHER inhibitor, BC6OTHER , as well as BC6ENTC , a specific inhibitor of BC6OTHER . CPR:falsenewlineUsing BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6ENTG inhibitor, BC6OTHER , as well as BC6ENTC , a specific inhibitor of BC6OTHER . CPR:falsenewlineUsing BC6OTHER - labeled gastric mucosal cells, we show that stimulatory effect of beta - adrenergic agonist, CHEM, on BC6OTHER secretion was inhibited by BC6OTHER BC6OTHER inhibitor, BC6OTHER , as well as BC6ENTC , a specific inhibitor of BC6ENTG . CPR:falsenewlineBoth inhibitors, moreover, blunted the BC6ENTG secretory responses to beta - adrenergic agonist - generated second messenger, BC6ENTC as well as BC6OTHER cyclase activator, BC6OTHER . CPR:falsenewlineBoth inhibitors, moreover, blunted the BC6OTHER secretory responses to beta - adrenergic agonist - generated second messenger, BC6ENTC as well as BC6ENTG activator, BC6OTHER . CPR:falsenewlineBoth inhibitors, moreover, blunted the BC6ENTG secretory responses to beta - adrenergic agonist - generated second messenger, BC6OTHER as well as BC6ENTC cyclase activator, BC6OTHER . CPR:falsenewlineBC6ENTG catalyse the last step in BC6ENTC biosynthesis, the formation of BC6OTHER from BC6OTHER , a reaction dependent on BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER . CPR:9newlineBC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6ENTC from BC6OTHER , a reaction dependent on BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER . CPR:9newlineBC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6OTHER from BC6ENTC , a reaction dependent on BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineBC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6OTHER from BC6OTHER , a reaction dependent on BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineBC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6OTHER from BC6OTHER , a reaction dependent on BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER . CPR:falsenewlineBC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6OTHER from BC6OTHER , a reaction dependent on BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER . CPR:falsenewlineBC6ENTG catalyse the last step in BC6OTHER biosynthesis, the formation of BC6OTHER from BC6OTHER , a reaction dependent on BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC . CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ), an BC6ENTG antagonist, is approved in many countries worldwide for the treatment of hypertension. CPR:6newlineBC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER ), an BC6ENTG antagonist, is approved in many countries worldwide for the treatment of hypertension. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER ), an BC6ENTG antagonist, is approved in many countries worldwide for the treatment of hypertension. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ), an BC6ENTG antagonist, is approved in many countries worldwide for the treatment of hypertension. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC ), an BC6ENTG antagonist, is approved in many countries worldwide for the treatment of hypertension. CPR:falsenewlineBC6ENTC (30 mg / kg) or BC6OTHER treatment (30 mg / kg) did not reduce the levels of BC6ENTG or BC6OTHER immunostaining. CPR:falsenewlineBC6ENTC (30 mg / kg) or BC6OTHER treatment (30 mg / kg) did not reduce the levels of BC6OTHER or BC6ENTG immunostaining. CPR:falsenewlineBC6ENTC , a selective BC6ENTG , and its active metabolite BC6OTHER may inhibit apoptosis and inflammation after cerebral ischemia. CPR:falsenewlineBC6OTHER (30 mg / kg) or BC6ENTC treatment (30 mg / kg) did not reduce the levels of BC6ENTG or BC6OTHER immunostaining. CPR:falsenewlineBC6OTHER (30 mg / kg) or BC6ENTC treatment (30 mg / kg) did not reduce the levels of BC6OTHER or BC6ENTG immunostaining. CPR:falsenewlineBC6ENTC (30 mg / kg) also significantly decreased the protein levels of BC6ENTG but not BC6OTHER or BC6OTHER in the cortex ipsilateral to the middle cerebral artery occlusion. CPR:falsenewlineBC6ENTC (30 mg / kg) also significantly decreased the protein levels of BC6OTHER but not BC6ENTG or BC6OTHER in the cortex ipsilateral to the middle cerebral artery occlusion. CPR:falsenewlineBC6ENTC (30 mg / kg) also significantly decreased the protein levels of BC6OTHER but not BC6OTHER or BC6ENTG in the cortex ipsilateral to the middle cerebral artery occlusion. CPR:falsenewlineBC6OTHER , a selective BC6ENTG , and its active metabolite BC6ENTC may inhibit apoptosis and inflammation after cerebral ischemia. CPR:falsenewlineThe improved survival rates for obese mice chronically treated with BC6ENTC suggest that chronic BC6ENTG inhibition potentially results in additional quality - adjusted life - years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy. CPR:falsenewlineMETHODS: After 1 month of HFD alone, the mice were given the BC6ENTG inhibitor BC6ENTC for a further 11 months. CPR:4newlineEnhanced beta cell function and anti - inflammatory effect after chronic treatment with the BC6ENTG inhibitor BC6ENTC in an advanced - aged diet - induced obesity mouse model. CPR:4newlineReplacement of the BC6OTHER groups of BC6OTHER with BC6ENTC or larger BC6OTHER groups yields BC6OTHER with selectivity for BC6ENTG , particularly when combined with an BC6OTHER moiety. CPR:falsenewlineReplacement of the BC6OTHER groups of BC6OTHER with BC6OTHER or larger BC6ENTC groups yields BC6OTHER with selectivity for BC6ENTG , particularly when combined with an BC6OTHER moiety. CPR:falsenewlineReplacement of the BC6OTHER groups of BC6OTHER with BC6OTHER or larger BC6OTHER groups yields BC6ENTC with selectivity for BC6ENTG , particularly when combined with an BC6OTHER moiety. CPR:falsenewlineReplacement of the BC6OTHER groups of BC6OTHER with BC6OTHER or larger BC6OTHER groups yields BC6OTHER with selectivity for BC6ENTG , particularly when combined with an BC6ENTC moiety. CPR:falsenewlineBC6OTHER modulates a variety of physiological functions through interaction with BC6ENTG , where agonists mediate inhibition and stimulation, respectively, of BC6ENTC cyclase. CPR:falsenewlineBC6ENTC modulates a variety of physiological functions through interaction with A1 and A2 BC6OTHER receptors, where agonists mediate inhibition and stimulation, respectively, of BC6ENTG . CPR:falsenewlineBC6ENTC modulates a variety of physiological functions through interaction with BC6ENTG , where agonists mediate inhibition and stimulation, respectively, of BC6OTHER . CPR:falsenewlineCertain analogs of BC6ENTC in which the BC6OTHER group at the 1 - or 7 - position is replaced with a CHEM or BC6OTHER group display selectivity for BC6ENTG . CPR:falsenewlineCertain analogs of BC6OTHER in which the BC6ENTC group at the 1 - or 7 - position is replaced with a CHEM or BC6OTHER group display selectivity for BC6ENTG . CPR:falsenewlineCertain analogs of BC6OTHER in which the BC6OTHER group at the 1 - or 7 - position is replaced with a CHEM or BC6ENTC group display selectivity for BC6ENTG . CPR:falsenewlineThe profile of a series of BC6ENTC analogs or of BC6OTHER antagonists can be used to define the nature of BC6ENTG . CPR:falsenewlineThe profile of a series of BC6OTHER analogs or of BC6ENTC antagonists can be used to define the nature of BC6ENTG . CPR:falsenewlineBC6ENTC analogs in particular the BC6OTHER - substituted compounds are more potent at BC6ENTG than at BC6OTHER . CPR:falsenewlineBC6ENTC analogs in particular the BC6OTHER - substituted compounds are more potent at BC6OTHER than at BC6ENTG . CPR:falsenewlineBC6OTHER analogs in particular the BC6ENTC - substituted compounds are more potent at BC6ENTG than at BC6OTHER . CPR:falsenewlineBC6OTHER analogs in particular the BC6ENTC - substituted compounds are more potent at BC6OTHER than at BC6ENTG . CPR:falsenewlineCertain of the BC6ENTC conjugates are highly selective for BC6ENTG . CPR:falsenewlineThe subregion of the BC6ENTC receptor that interacts with the BC6OTHER - substituent is different for BC6ENTG , particularly with respect to BC6OTHER interactions, bulk tolerance and stereoselectivity. CPR:falsenewlineThe subregion of the BC6ENTG that interacts with the BC6ENTC - substituent is different for BC6OTHER , particularly with respect to BC6OTHER interactions, bulk tolerance and stereoselectivity. CPR:falsenewlineThe subregion of the BC6OTHER that interacts with the BC6ENTC - substituent is different for BC6ENTG , particularly with respect to BC6OTHER interactions, bulk tolerance and stereoselectivity. CPR:falsenewlineThe subregion of the BC6ENTG that interacts with the BC6OTHER - substituent is different for BC6OTHER , particularly with respect to BC6ENTC interactions, bulk tolerance and stereoselectivity. CPR:falsenewlineThe subregion of the BC6OTHER that interacts with the BC6OTHER - substituent is different for BC6ENTG , particularly with respect to BC6ENTC interactions, bulk tolerance and stereoselectivity. CPR:falsenewlineBC6OTHER modulates a variety of physiological functions through interaction with A1 and A2 BC6ENTC receptors, where agonists mediate inhibition and stimulation, respectively, of BC6ENTG . CPR:falsenewlineBC6ENTC are classical antagonists for BC6ENTG for many of their pharmacological actions may be due to blockade of BC6OTHER receptors. CPR:falsenewlineBC6ENTC are classical antagonists for BC6OTHER receptors for many of their pharmacological actions may be due to blockade of BC6ENTG . CPR:falsenewlineBC6OTHER are classical antagonists for BC6ENTC receptors for many of their pharmacological actions may be due to blockade of BC6ENTG . CPR:falsenewlineBC6OTHER are classical antagonists for BC6ENTG for many of their pharmacological actions may be due to blockade of BC6ENTC receptors. CPR:falsenewlineBC6ENTC and BC6OTHER are virtually non - selective for BC6ENTG . CPR:falsenewlineBC6OTHER and BC6ENTC are virtually non - selective for BC6ENTG . CPR:falsenewlineReplacement of the BC6ENTC groups of BC6OTHER with BC6OTHER or larger BC6OTHER groups yields BC6OTHER with selectivity for BC6ENTG , particularly when combined with an BC6OTHER moiety. CPR:falsenewlineReplacement of the BC6OTHER groups of BC6ENTC with BC6OTHER or larger BC6OTHER groups yields BC6OTHER with selectivity for BC6ENTG , particularly when combined with an BC6OTHER moiety. CPR:falsenewlineBC6ENTG antagonism with BC6ENTC reduced responses to BC6OTHER in controls but not during inflammation. CPR:falsenewlineBC6ENTG antagonism with BC6OTHER reduced responses to BC6ENTC in controls but not during inflammation. CPR:falsenewlineResponses to the mast cell degranulator 48 / 80 mimicked those to BC6ENTC in inflamed tissue but not in controls, and more BC6OTHER - containing mast cells were seen close to BC6ENTG - containing fibres in inflamed serosa. CPR:falsenewlineResponses to the mast cell degranulator 48 / 80 mimicked those to BC6OTHER in inflamed tissue but not in controls, and more BC6ENTC - containing mast cells were seen close to BC6ENTG - containing fibres in inflamed serosa. CPR:falsenewlineBC6ENTC affected mainly the BC6OTHER transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total BC6ENTG protein content or the BC6OTHER mRNA level. CPR:falsenewlineBC6ENTC affected mainly the BC6OTHER transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total BC6OTHER protein content or the BC6ENTG mRNA level. CPR:falsenewlineBC6ENTC affected mainly the BC6ENTG transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total BC6OTHER protein content or the BC6OTHER mRNA level. CPR:falsenewlineEffect of long - term BC6ENTC treatment on the BC6ENTG in Caco - 2 cells. CPR:falsenewlineThese results suggest that the effect of BC6ENTC on the expression of BC6ENTG is post - translational and has shown itself to be independent of BC6OTHER and BC6OTHER activity. CPR:falsenewlineThese results suggest that the effect of BC6ENTC on the expression of BC6OTHER is post - translational and has shown itself to be independent of BC6ENTG and BC6OTHER activity. CPR:falsenewlineThese results suggest that the effect of BC6ENTC on the expression of BC6OTHER is post - translational and has shown itself to be independent of BC6OTHER and BC6ENTG activity. CPR:falsenewlineThe chronic effect of SSRIs on the activity of the BC6ENTC transporter ( BC6ENTG ) has been less studied and the results have been contradictory. CPR:falsenewlineThe aim of this study was to determine the specific effect of long - term BC6ENTC treatment on BC6ENTG ( BC6OTHER ) in vitro, by using the human enterocyte - like cell line Caco - 2. CPR:falsenewlineThe aim of this study was to determine the specific effect of long - term BC6ENTC treatment on human BC6OTHER transporter ( BC6ENTG ) in vitro, by using the human enterocyte - like cell line Caco - 2. CPR:falsenewlineThe aim of this study was to determine the specific effect of long - term BC6OTHER treatment on human BC6ENTC transporter ( BC6ENTG ) in vitro, by using the human enterocyte - like cell line Caco - 2. CPR:falsenewlineThe cytosolic BC6ENTG is expressed primarily in liver and adipose tissue, and uses BC6ENTC as a key building block in BC6OTHER biosynthesis. CPR:falsenewlineThe cytosolic BC6ENTG is expressed primarily in liver and adipose tissue, and uses BC6OTHER as a key building block in BC6ENTC biosynthesis. CPR:9newlineThe mitochondrial BC6ENTG is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of BC6ENTC oxidation. CPR:falsenewlineDiscovery of BC6ENTG inhibitors: comparison of a fluorescence intensity - based BC6ENTC assay and a fluorescence polarization - based BC6OTHER Assay for high - throughput screening. CPR:falsenewlineDiscovery of BC6ENTG inhibitors: comparison of a fluorescence intensity - based BC6OTHER assay and a fluorescence polarization - based BC6ENTC Assay for high - throughput screening. CPR:falsenewlineBC6ENTC carboxylase ( BC6ENTG ) enzymes exist as two isoforms, BC6OTHER and BC6OTHER , which play critical roles in BC6OTHER biosynthesis and oxidation. CPR:falsenewlineBC6ENTC carboxylase ( BC6OTHER ) enzymes exist as two isoforms, BC6ENTG and BC6OTHER , which play critical roles in BC6OTHER biosynthesis and oxidation. CPR:falsenewlineBC6ENTC carboxylase ( BC6OTHER ) enzymes exist as two isoforms, BC6OTHER and BC6ENTG , which play critical roles in BC6OTHER biosynthesis and oxidation. CPR:falsenewlineBC6ENTG ( BC6OTHER ) enzymes exist as two isoforms, BC6OTHER and BC6OTHER , which play critical roles in BC6ENTC biosynthesis and oxidation. CPR:9newlineBC6OTHER carboxylase ( BC6ENTG ) enzymes exist as two isoforms, BC6OTHER and BC6OTHER , which play critical roles in BC6ENTC biosynthesis and oxidation. CPR:falsenewlineBC6OTHER carboxylase ( BC6OTHER ) enzymes exist as two isoforms, BC6ENTG and BC6OTHER , which play critical roles in BC6ENTC biosynthesis and oxidation. CPR:falsenewlineBC6OTHER carboxylase ( BC6OTHER ) enzymes exist as two isoforms, BC6OTHER and BC6ENTG , which play critical roles in BC6ENTC biosynthesis and oxidation. CPR:falsenewlineBC6ENTG inhibitors were identified by these high - throughput screening methods and were confirmed in a radiometric high performance liquid chromatography assay of BC6ENTC production. CPR:falsenewlineFrom these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6ENTG , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6ENTG , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6ENTG , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6ENTG ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6ENTG ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6ENTG ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6ENTG family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6ENTC levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6ENTG . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6ENTG , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6ENTG , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6ENTG , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6ENTG ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6ENTG ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6ENTG ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6ENTG family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6ENTC BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6ENTG . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6ENTG , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6ENTG , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6ENTG , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6ENTG ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6ENTG ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6ENTG ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6ENTG family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6OTHER . CPR:falsenewlineFrom these results we conclude that 1) BC6OTHER levels in circulating platelets reflect ongoing signaling through BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER ; 2) platelet BC6OTHER BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors display strong preferences among BC6OTHER family members with little evidence of redundancy; and 3) these receptor preferences do not extend to BC6ENTG . CPR:falsenewlinePlatelet agonists such as BC6ENTC and CHEM suppress BC6OTHER - stimulated BC6OTHER formation by activating receptors coupled to BC6ENTG family members, four of which are present in platelets. CPR:falsenewlineFinally, the failure of BC6ENTC and BC6OTHER to inhibit basal, as opposed to BC6OTHER - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6ENTG signaling pathways that involve effectors other than BC6OTHER . CPR:falsenewlineFinally, the failure of BC6ENTC and BC6OTHER to inhibit basal, as opposed to BC6OTHER - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6OTHER signaling pathways that involve effectors other than BC6ENTG . CPR:falsenewlineFinally, the failure of BC6OTHER and BC6ENTC to inhibit basal, as opposed to BC6OTHER - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6ENTG signaling pathways that involve effectors other than BC6OTHER . CPR:falsenewlineFinally, the failure of BC6OTHER and BC6ENTC to inhibit basal, as opposed to BC6OTHER - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6OTHER signaling pathways that involve effectors other than BC6ENTG . CPR:falsenewlineFinally, the failure of BC6OTHER and BC6OTHER to inhibit basal, as opposed to BC6ENTC - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6ENTG signaling pathways that involve effectors other than BC6OTHER . CPR:falsenewlineFinally, the failure of BC6OTHER and BC6OTHER to inhibit basal, as opposed to BC6ENTC - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6OTHER signaling pathways that involve effectors other than BC6ENTG . CPR:falsenewlineFinally, the failure of BC6OTHER and BC6OTHER to inhibit basal, as opposed to BC6OTHER - stimulated, BC6ENTC formation highlights the need during platelet activation for BC6ENTG signaling pathways that involve effectors other than BC6OTHER . CPR:falsenewlineFinally, the failure of BC6OTHER and BC6OTHER to inhibit basal, as opposed to BC6OTHER - stimulated, BC6ENTC formation highlights the need during platelet activation for BC6OTHER signaling pathways that involve effectors other than BC6ENTG . CPR:falsenewlineFinally, the failure of BC6OTHER and BC6OTHER to inhibit basal, as opposed to BC6OTHER - stimulated, BC6OTHER formation highlights the need during platelet activation for BC6ENTG signaling pathways that involve effectors other than BC6ENTC cyclase. CPR:falsenewlinePlatelet agonists such as BC6OTHER and CHEM suppress BC6ENTC - stimulated BC6OTHER formation by activating receptors coupled to BC6ENTG family members, four of which are present in platelets. CPR:falsenewlinePlatelet agonists such as BC6OTHER and CHEM suppress BC6OTHER - stimulated BC6ENTC formation by activating receptors coupled to BC6ENTG family members, four of which are present in platelets. CPR:falsenewlineTo address questions about the specificity of receptor: BC6ENTG coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6ENTG - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTG , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6ENTG family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTG , BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6ENTC formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6ENTG . CPR:falsenewlineTo address questions about the specificity of receptor: BC6ENTG coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTC cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6ENTG - mediated pathways that do not involve BC6ENTC cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTC cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6ENTG family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTC cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTG , BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTC cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6OTHER , BC6ENTG . CPR:falsenewlineTo address questions about the specificity of receptor: BC6ENTG coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTC receptor, BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6ENTG - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTC receptor, BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6ENTG , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTC receptor, BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6ENTG family members and compared the results with platelets from mice that lacked the BC6ENTC receptor, BC6OTHER . CPR:falsenewlineTo address questions about the specificity of receptor: BC6OTHER coupling, the regulation of BC6OTHER formation in vivo and the contribution of BC6OTHER - mediated pathways that do not involve BC6OTHER , we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed BC6OTHER family members and compared the results with platelets from mice that lacked the BC6ENTC receptor, BC6ENTG . CPR:falsenewlineAs reported previously, loss of BC6ENTG or BC6OTHER inhibited aggregation in response to BC6ENTC and BC6OTHER , respectively, producing defects that could not be reversed by adding an BC6OTHER inhibitor. CPR:falsenewlineAs reported previously, loss of BC6OTHER or BC6ENTG inhibited aggregation in response to BC6ENTC and BC6OTHER , respectively, producing defects that could not be reversed by adding an BC6OTHER inhibitor. CPR:falsenewlineAs reported previously, loss of BC6OTHER or BC6OTHER inhibited aggregation in response to BC6ENTC and BC6OTHER , respectively, producing defects that could not be reversed by adding an BC6ENTG inhibitor. CPR:falsenewlineAs reported previously, loss of BC6ENTG or BC6OTHER inhibited aggregation in response to BC6OTHER and BC6ENTC , respectively, producing defects that could not be reversed by adding an BC6OTHER inhibitor. CPR:falsenewlineAs reported previously, loss of BC6OTHER or BC6ENTG inhibited aggregation in response to BC6OTHER and BC6ENTC , respectively, producing defects that could not be reversed by adding an BC6OTHER inhibitor. CPR:falsenewlineAs reported previously, loss of BC6OTHER or BC6OTHER inhibited aggregation in response to BC6OTHER and BC6ENTC , respectively, producing defects that could not be reversed by adding an BC6ENTG inhibitor. CPR:falsenewlineAs reported previously, loss of BC6ENTG or BC6OTHER inhibited aggregation in response to BC6OTHER and BC6OTHER , respectively, producing defects that could not be reversed by adding an BC6ENTC cyclase inhibitor. CPR:falsenewlineAs reported previously, loss of BC6OTHER or BC6ENTG inhibited aggregation in response to BC6OTHER and BC6OTHER , respectively, producing defects that could not be reversed by adding an BC6ENTC cyclase inhibitor. CPR:falsenewlineLoss of either BC6ENTG or BC6OTHER impaired the ability of BC6ENTC and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6ENTG impaired the ability of BC6ENTC and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6OTHER impaired the ability of BC6ENTC and BC6OTHER to inhibit BC6OTHER - stimulated BC6ENTG activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6OTHER impaired the ability of BC6ENTC and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6ENTG did not. CPR:falsenewlineLoss of either BC6ENTG or BC6OTHER impaired the ability of BC6OTHER and BC6ENTC to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6ENTG impaired the ability of BC6OTHER and BC6ENTC to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6ENTC to inhibit BC6OTHER - stimulated BC6ENTG activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6ENTC to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6ENTG did not. CPR:falsenewlineLoss of either BC6ENTG or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6ENTC - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6ENTG impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6ENTC - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6ENTC - stimulated BC6ENTG activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6ENTC - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6ENTG did not. CPR:falsenewlineLoss of either BC6ENTG or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6ENTC cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6ENTG impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6ENTC cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6ENTC cyclase activity and caused a 40% - 50% rise in basal BC6OTHER levels, whereas loss of BC6ENTG did not. CPR:falsenewlineLoss of either BC6ENTG or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6ENTC levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6ENTG impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6ENTC levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6ENTG activity and caused a 40% - 50% rise in basal BC6ENTC levels, whereas loss of BC6OTHER did not. CPR:falsenewlineLoss of either BC6OTHER or BC6OTHER impaired the ability of BC6OTHER and BC6OTHER to inhibit BC6OTHER - stimulated BC6OTHER cyclase activity and caused a 40% - 50% rise in basal BC6ENTC levels, whereas loss of BC6ENTG did not. CPR:falsenewlineConversely, deletion of BC6ENTG abolished responses to BC6ENTC and caused BC6OTHER levels to fall by 30%, effects that did not translate into enhanced responsiveness to agonists ex vivo. CPR:falsenewlineConversely, deletion of BC6ENTG abolished responses to BC6OTHER and caused BC6ENTC levels to fall by 30%, effects that did not translate into enhanced responsiveness to agonists ex vivo. CPR:falsenewlineBC6OTHER trapped in membranes was displaceable by the structurally unrelated BC6ENTG inhibitor, BC6OTHER , in a concentration - dependent manner, implying interaction of retained BC6ENTC with the BC6OTHER . CPR:falsenewlineBC6OTHER trapped in membranes was displaceable by the structurally unrelated BC6OTHER inhibitor, BC6OTHER , in a concentration - dependent manner, implying interaction of retained BC6ENTC with the BC6ENTG . CPR:falsenewlineThe present study examined the potential membrane retention of BC6OTHER ( BC6ENTC ) following exposures of 293 - BC6ENTG cells to BC6OTHER , and its effect on BC6OTHER uptake. CPR:falsenewlineThe results demonstrate that BC6ENTC and BC6OTHER are persistently retained in cell membranes, at least partly in association with the BC6ENTG . CPR:falsenewlineThe results demonstrate that BC6OTHER and BC6ENTC are persistently retained in cell membranes, at least partly in association with the BC6ENTG . CPR:falsenewlineThe retention and slow diffusion of BC6ENTC and BC6OTHER from membranes may contribute to their pharmacological and modulatory action on BC6ENTG . CPR:falsenewlineThe retention and slow diffusion of BC6OTHER and BC6ENTC from membranes may contribute to their pharmacological and modulatory action on BC6ENTG . CPR:falsenewlineThe persistent membrane retention of BC6ENTC causes lasting inhibition of BC6ENTG function. CPR:falsenewlineThe present study examined the potential membrane retention of BC6OTHER ( BC6OTHER ) following exposures of 293 - BC6ENTG cells to BC6ENTC , and its effect on BC6OTHER uptake. CPR:falsenewlineThe present study examined the potential membrane retention of BC6OTHER ( BC6OTHER ) following exposures of 293 - BC6ENTG cells to BC6OTHER , and its effect on BC6ENTC uptake. CPR:falsenewlineBC6ENTC trapped in membranes was displaceable by the structurally unrelated BC6ENTG inhibitor, BC6OTHER , in a concentration - dependent manner, implying interaction of retained BC6OTHER with the BC6OTHER . CPR:falsenewlineBC6ENTC trapped in membranes was displaceable by the structurally unrelated BC6OTHER inhibitor, BC6OTHER , in a concentration - dependent manner, implying interaction of retained BC6OTHER with the BC6ENTG . CPR:falsenewlineBC6OTHER trapped in membranes was displaceable by the structurally unrelated BC6ENTG inhibitor, BC6ENTC , in a concentration - dependent manner, implying interaction of retained BC6OTHER with the BC6OTHER . CPR:falsenewlineBC6OTHER trapped in membranes was displaceable by the structurally unrelated BC6OTHER inhibitor, BC6ENTC , in a concentration - dependent manner, implying interaction of retained BC6OTHER with the BC6ENTG . CPR:falsenewlineThe present study examined the potential membrane retention of BC6ENTC ( BC6OTHER ) following exposures of 293 - BC6ENTG cells to BC6OTHER , and its effect on BC6OTHER uptake. CPR:falsenewlineIn order to address one aspect of the feasibility of performing time - resolved studies on BC6ENTG , a data set has been collected using the Laue technique on a trigonal crystal of BC6OTHER soaked with the reversible inhibitor BC6ENTC , using a total X - ray exposure time of 24 ms. Electron - density maps obtained from the Laue data, which are of surprisingly good quality compared with similar maps from monochromatic data, show essentially the same features. CPR:falsenewlineIn order to address one aspect of the feasibility of performing time - resolved studies on BC6OTHER , a data set has been collected using the Laue technique on a trigonal crystal of BC6ENTG soaked with the reversible inhibitor BC6ENTC , using a total X - ray exposure time of 24 ms. Electron - density maps obtained from the Laue data, which are of surprisingly good quality compared with similar maps from monochromatic data, show essentially the same features. CPR:falsenewlineThe enzyme ( BC6OTHER ) has a very high catalytic activity for the BC6ENTC hydration reaction, being similar kinetically to the human (h) isoform BC6ENTG , although it is devoid of the BC6OTHER 64 proton shuttle. CPR:falsenewlineThe enzyme ( BC6ENTG ) has a very high catalytic activity for the BC6ENTC hydration reaction, being similar kinetically to the human (h) isoform BC6OTHER , although it is devoid of the BC6OTHER 64 proton shuttle. CPR:falsenewlineThe enzyme ( BC6OTHER ) has a very high catalytic activity for the BC6OTHER hydration reaction, being similar kinetically to the human (h) isoform BC6ENTG , although it is devoid of the BC6ENTC 64 proton shuttle. CPR:falsenewlineThe enzyme ( BC6ENTG ) has a very high catalytic activity for the BC6OTHER hydration reaction, being similar kinetically to the human (h) isoform BC6OTHER , although it is devoid of the BC6ENTC 64 proton shuttle. CPR:falsenewlineA large number of BC6ENTC and some BC6OTHER were investigated as BC6ENTG inhibitors. CPR:4newlineA large number of BC6OTHER and some BC6ENTC were investigated as BC6ENTG inhibitors. CPR:falsenewlineCloning, Characterization, and BC6ENTC and BC6OTHER Inhibition Studies of an BC6ENTG from Trypanosoma cruzi, the Causative Agent of Chagas Disease. CPR:4newlineCloning, Characterization, and BC6OTHER and BC6ENTC Inhibition Studies of an BC6ENTG from Trypanosoma cruzi, the Causative Agent of Chagas Disease. CPR:falsenewlineEffect of BC6ENTC on BC6ENTG production in endotoxic shock. CPR:falsenewlineAbrupt removal of BC6ENTC or BC6OTHER from the culture medium prior to LPS stimulation, however, caused significantly augmented BC6ENTG production. CPR:falsenewlineAbrupt removal of BC6OTHER or BC6ENTC from the culture medium prior to LPS stimulation, however, caused significantly augmented BC6ENTG production. CPR:falsenewlineTherefore, BC6ENTC and other BC6ENTG inhibitors may also enhance sensitivity to LPS during a period of time following discontinuation of therapy. CPR:falsenewline We now demonstrate that BC6ENTC , a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS) - induced BC6ENTG production at concentrations readily achieved in vivo. This inhibition is apparent in murine macrophages, in macrophage cell lines, in vivo, and in cell lines containing a reporter gene construct that substitutes the CHEM transferase (CAT) coding sequence for the BC6OTHER coding sequence and introns. CPR:falsenewline We now demonstrate that BC6ENTC , a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS) - induced BC6OTHER production at concentrations readily achieved in vivo. This inhibition is apparent in murine macrophages, in macrophage cell lines, in vivo, and in cell lines containing a reporter gene construct that substitutes the CHEM transferase (CAT) coding sequence for the BC6ENTG coding sequence and introns. CPR:falsenewlineCombined application of BC6ENTC and BC6OTHER caused additive inhibition of BC6ENTG biosynthesis in vitro. CPR:falsenewlineCombined application of BC6OTHER and BC6ENTC caused additive inhibition of BC6ENTG biosynthesis in vitro. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at BC6ENTG (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6ENTG ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6ENTG , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6ENTG and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6ENTG stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6ENTC receptors ( BC6ENTG ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineBC6ENTC , an endogenous neurotransmitter candidate for the BC6ENTG , was identified as the most selective agent for a subcomponent of platelet BC6OTHER . CPR:falsenewlineBC6ENTC , an endogenous neurotransmitter candidate for the I1 - BC6OTHER receptor, was identified as the most selective agent for a subcomponent of platelet BC6ENTG . CPR:falsenewlineBC6OTHER , an endogenous neurotransmitter candidate for the I1 - BC6ENTC receptor, was identified as the most selective agent for a subcomponent of platelet BC6ENTG . CPR:falsenewlineThe affinity of BC6ENTC at the high affinity component of platelet BC6ENTG was 1400 - fold selective over BC6OTHER , 5000 - fold selective over BC6OTHER and 800 - fold selective over BC6OTHER . CPR:falsenewlineThe affinity of BC6ENTC at the high affinity component of platelet BC6OTHER was 1400 - fold selective over BC6ENTG , 5000 - fold selective over BC6OTHER and 800 - fold selective over BC6OTHER . CPR:falsenewlineThe affinity of BC6ENTC at the high affinity component of platelet BC6OTHER was 1400 - fold selective over BC6OTHER , 5000 - fold selective over BC6ENTG and 800 - fold selective over BC6OTHER . CPR:falsenewlineThe affinity of BC6ENTC at the high affinity component of platelet BC6OTHER was 1400 - fold selective over BC6OTHER , 5000 - fold selective over BC6OTHER and 800 - fold selective over BC6ENTG . CPR:falsenewlineBC6ENTC and BC6OTHER also displayed selectivities for a high affinity component of the platelet BC6ENTG over BC6OTHER . CPR:falsenewlineBC6ENTC and BC6OTHER also displayed selectivities for a high affinity component of the platelet BC6OTHER over BC6ENTG . CPR:falsenewlineBC6OTHER and BC6ENTC also displayed selectivities for a high affinity component of the platelet BC6ENTG over BC6OTHER . CPR:falsenewlineBC6OTHER and BC6ENTC also displayed selectivities for a high affinity component of the platelet BC6OTHER over BC6ENTG . CPR:falsenewlineComparison of ligand binding affinities at human I1 - BC6ENTC binding sites and the high affinity state of BC6ENTG subtypes. CPR:falsenewlineBC6ENTC was the most selective compound for the high affinity state of the BC6ENTG , displaying 7 - , 23 - and 9 - fold higher affinity than BC6OTHER , BC6OTHER and platelet I1 - BC6OTHER binding sites, respectively. CPR:falsenewlineBC6ENTC was the most selective compound for the high affinity state of the BC6OTHER , displaying 7 - , 23 - and 9 - fold higher affinity than BC6ENTG , BC6OTHER and platelet I1 - BC6OTHER binding sites, respectively. CPR:falsenewlineBC6ENTC was the most selective compound for the high affinity state of the BC6OTHER , displaying 7 - , 23 - and 9 - fold higher affinity than BC6OTHER , BC6ENTG and platelet I1 - BC6OTHER binding sites, respectively. CPR:falsenewlineBC6ENTC was the most selective compound for the high affinity state of the BC6OTHER , displaying 7 - , 23 - and 9 - fold higher affinity than BC6OTHER , BC6OTHER and platelet BC6ENTG , respectively. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at BC6ENTG (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6ENTG ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6ENTG , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6ENTG and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6ENTG stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic BC6ENTG ( BC6OTHER ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6ENTG ), the affinities of 22 ligands for BC6ENTC binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineBC6OTHER was the most selective compound for the high affinity state of the BC6ENTG , displaying 7 - , 23 - and 9 - fold higher affinity than BC6OTHER , BC6OTHER and platelet I1 - BC6ENTC binding sites, respectively. CPR:falsenewlineBC6OTHER was the most selective compound for the high affinity state of the BC6OTHER , displaying 7 - , 23 - and 9 - fold higher affinity than BC6ENTG , BC6OTHER and platelet I1 - BC6ENTC binding sites, respectively. CPR:falsenewlineBC6OTHER was the most selective compound for the high affinity state of the BC6OTHER , displaying 7 - , 23 - and 9 - fold higher affinity than BC6OTHER , BC6ENTG and platelet I1 - BC6ENTC binding sites, respectively. CPR:falsenewlineBC6ENTC displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6ENTG as compared to BC6OTHER - or BC6OTHER , and was > 100,000 - fold selective over platelet I1 - BC6OTHER sites. CPR:falsenewlineBC6ENTC displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6OTHER as compared to BC6ENTG - or BC6OTHER , and was > 100,000 - fold selective over platelet I1 - BC6OTHER sites. CPR:falsenewlineBC6ENTC displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6OTHER as compared to BC6OTHER - or BC6ENTG , and was > 100,000 - fold selective over platelet I1 - BC6OTHER sites. CPR:falsenewlineBC6ENTC displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6OTHER as compared to BC6OTHER - or BC6OTHER , and was > 100,000 - fold selective over platelet BC6ENTG . CPR:falsenewlineBC6OTHER displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6ENTG as compared to BC6OTHER - or BC6OTHER , and was > 100,000 - fold selective over platelet I1 - BC6ENTC sites. CPR:falsenewlineBC6OTHER displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6OTHER as compared to BC6ENTG - or BC6OTHER , and was > 100,000 - fold selective over platelet I1 - BC6ENTC sites. CPR:falsenewlineBC6OTHER displayed, respectively, 18 - and 31 - fold selectivity for the high affinity state of the BC6OTHER as compared to BC6OTHER - or BC6ENTG , and was > 100,000 - fold selective over platelet I1 - BC6ENTC sites. CPR:falsenewlineThus, BC6ENTG and the platelet I1 - BC6ENTC binding site can be clearly discriminated based on their affinities for certain compounds. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6ENTG ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6ENTG , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6ENTG and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6ENTG stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic BC6ENTG ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6ENTG ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6ENTC binding sites (analyzed under BC6OTHER mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at BC6ENTG (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6ENTG ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6ENTG , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6OTHER , BC6ENTG and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6ENTG stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic BC6ENTG ( BC6OTHER ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineTo identify selective compounds for nonadrenergic I1 - BC6OTHER receptors ( BC6ENTG ), the affinities of 22 ligands for BC6OTHER binding have been compared at human platelet I1 - BC6OTHER binding sites (analyzed under BC6ENTC mask of BC6OTHER ) and at BC6OTHER , BC6OTHER and BC6OTHER stably expressed on transfected Chinese hamster ovary cells. CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6ENTG , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:4newlineBC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6ENTG , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:4newlineBC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6ENTG - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:4newlineBC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6ENTG , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:4newlineBC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6ENTG , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:4newlineBC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6ENTG represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:4newlineBC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6ENTG , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6ENTG , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6ENTG - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6ENTG , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6ENTG , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6ENTG represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6ENTG , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6ENTG , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6ENTG - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6ENTG , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6ENTG , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6ENTG represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6ENTG , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6ENTG , BC6OTHER - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6ENTG - BC6OTHER , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6ENTG , BC6OTHER , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6ENTG , and BC6OTHER represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of BC6OTHER , BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER , and BC6ENTG represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. CPR:falsenewlineThe reported mechanism of BC6ENTC resistance in GISTs involves missense mutation in the BC6ENTG of BC6OTHER including BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe reported mechanism of BC6ENTC resistance in GISTs involves missense mutation in the BC6OTHER of BC6ENTG including BC6OTHER , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe reported mechanism of BC6ENTC resistance in GISTs involves missense mutation in the BC6OTHER of BC6OTHER including BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe reported mechanism of BC6ENTC resistance in GISTs involves missense mutation in the BC6OTHER of BC6OTHER including BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineThe reported mechanism of BC6ENTC resistance in GISTs involves missense mutation in the BC6OTHER of BC6OTHER including BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineFibroblast cultures from the patient exhibited severe reduction of the CHEM - sensitive BC6ENTC - - >UQ oxidoreductase activity of BC6ENTG , which was insensitive to BC6OTHER stimulation. CPR:falsenewlineFibroblast cultures from the patient exhibited severe reduction of the CHEM - sensitive BC6ENTG activity of BC6OTHER , which was insensitive to BC6ENTC stimulation. CPR:falsenewlineFibroblast cultures from the patient exhibited severe reduction of the CHEM - sensitive BC6OTHER - - >UQ oxidoreductase activity of BC6ENTG , which was insensitive to BC6ENTC stimulation. CPR:falsenewlineBlocking BC6OTHER signaling with the BC6OTHER / BC6OTHER kinase inhibitor (KI) BC6ENTC decreased the postradiation survival of irradiated BC6ENTG - transformed cells and normal cells but had no effect on the survival of unirradiated cells. CPR:falsenewlineBlocking BC6ENTG signaling with the BC6OTHER / BC6OTHER kinase inhibitor (KI) BC6ENTC decreased the postradiation survival of irradiated BC6OTHER - transformed cells and normal cells but had no effect on the survival of unirradiated cells. CPR:falsenewlineBlocking BC6OTHER signaling with the BC6ENTG / BC6OTHER kinase inhibitor (KI) BC6ENTC decreased the postradiation survival of irradiated BC6OTHER - transformed cells and normal cells but had no effect on the survival of unirradiated cells. CPR:falsenewlineBlocking BC6OTHER signaling with the BC6OTHER / BC6ENTG kinase inhibitor (KI) BC6ENTC decreased the postradiation survival of irradiated BC6OTHER - transformed cells and normal cells but had no effect on the survival of unirradiated cells. CPR:falsenewlineBC6ENTG - CM and BC6OTHER also increase BC6OTHER activity downstream of the BC6OTHER and increase postradiation survival, both of which are abrogated by BC6ENTC . CPR:falsenewlineBC6OTHER - CM and BC6ENTG also increase BC6OTHER activity downstream of the BC6OTHER and increase postradiation survival, both of which are abrogated by BC6ENTC . CPR:falsenewlineBC6OTHER - CM and BC6OTHER also increase BC6ENTG activity downstream of the BC6OTHER and increase postradiation survival, both of which are abrogated by BC6ENTC . CPR:falsenewlineBC6OTHER - CM and BC6OTHER also increase BC6OTHER activity downstream of the BC6ENTG and increase postradiation survival, both of which are abrogated by BC6ENTC . CPR:falsenewlineThus, BC6ENTG utilizes autocrine signaling through BC6OTHER to increase radioresistance, and the BC6OTHER KI BC6ENTC acts as a radiosensitizer. CPR:falsenewlineThus, BC6OTHER utilizes autocrine signaling through BC6ENTG to increase radioresistance, and the BC6OTHER KI BC6ENTC acts as a radiosensitizer. CPR:falsenewlineThus, BC6OTHER utilizes autocrine signaling through BC6OTHER to increase radioresistance, and the BC6ENTG KI BC6ENTC acts as a radiosensitizer. CPR:falsenewlineThe observation that BC6ENTG - transformed cells can be sensitized to killing by ionizing radiation with BC6ENTC demonstrates that BC6OTHER KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on BC6OTHER - driven autocrine signaling through BC6OTHER . CPR:falsenewlineThe observation that BC6OTHER - transformed cells can be sensitized to killing by ionizing radiation with BC6ENTC demonstrates that BC6ENTG KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on BC6OTHER - driven autocrine signaling through BC6OTHER . CPR:falsenewlineThe observation that BC6OTHER - transformed cells can be sensitized to killing by ionizing radiation with BC6ENTC demonstrates that BC6OTHER KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on BC6ENTG - driven autocrine signaling through BC6OTHER . CPR:falsenewlineThe observation that BC6OTHER - transformed cells can be sensitized to killing by ionizing radiation with BC6ENTC demonstrates that BC6OTHER KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on BC6OTHER - driven autocrine signaling through BC6ENTG . CPR:falsenewlineAlthough not all of the signaling pathways for radioresistance are well defined, it is now clear that BC6ENTG - dependent signaling pathways involved in radioresistance include those mediated by BC6ENTC 3' - kinase ( BC6OTHER ) and BC6OTHER . CPR:falsenewlineAlthough not all of the signaling pathways for radioresistance are well defined, it is now clear that BC6OTHER - dependent signaling pathways involved in radioresistance include those mediated by BC6ENTC 3' - kinase ( BC6ENTG ) and BC6OTHER . CPR:falsenewlineAlthough not all of the signaling pathways for radioresistance are well defined, it is now clear that BC6OTHER - dependent signaling pathways involved in radioresistance include those mediated by BC6ENTC 3' - kinase ( BC6OTHER ) and BC6ENTG . CPR:falsenewlineHowever at IC80, BC6OTHER (+134.4%) and BC6OTHER (+29.7%) had greater BC6ENTG selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6ENTC ( - 12.9%) had lower BC6OTHER selectivity than at IC50. CPR:falsenewlineHowever at IC80, BC6OTHER (+134.4%) and BC6OTHER (+29.7%) had greater BC6OTHER selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6ENTC ( - 12.9%) had lower BC6ENTG selectivity than at IC50. CPR:falsenewlineWe report on the inhibitory activity of the NSAIDs BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , on blood BC6ENTG in the horse using in vitro enzyme - linked assays. CPR:falsenewlineWe report on the inhibitory activity of the NSAIDs BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , on blood BC6ENTG in the horse using in vitro enzyme - linked assays. CPR:falsenewlineWe report on the inhibitory activity of the NSAIDs BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , on blood BC6ENTG in the horse using in vitro enzyme - linked assays. CPR:falsenewline BC6ENTG and BC6OTHER inhibition in horse blood by BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER : an in vitro analysis. CPR:4newline BC6OTHER and BC6ENTG inhibition in horse blood by BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER : an in vitro analysis. CPR:4newline BC6ENTG and BC6OTHER inhibition in horse blood by BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER : an in vitro analysis. CPR:4newline BC6OTHER and BC6ENTG inhibition in horse blood by BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER : an in vitro analysis. CPR:4newline BC6ENTG and BC6OTHER inhibition in horse blood by BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER : an in vitro analysis. CPR:4newline BC6OTHER and BC6ENTG inhibition in horse blood by BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER : an in vitro analysis. CPR:4newline BC6ENTG and BC6OTHER inhibition in horse blood by BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC : an in vitro analysis. CPR:4newline BC6OTHER and BC6ENTG inhibition in horse blood by BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC : an in vitro analysis. CPR:4newlineAs expected, comparison of IC50 indicated that BC6ENTC and BC6OTHER are more selective inhibitors of BC6ENTG than BC6OTHER and BC6OTHER ; BC6OTHER was the most advantageous for horses of four NSAIDs examined. CPR:falsenewlineAs expected, comparison of IC50 indicated that BC6OTHER and BC6ENTC are more selective inhibitors of BC6ENTG than BC6OTHER and BC6OTHER ; BC6OTHER was the most advantageous for horses of four NSAIDs examined. CPR:falsenewlineAs expected, comparison of IC50 indicated that BC6OTHER and BC6OTHER are more selective inhibitors of BC6ENTG than BC6ENTC and BC6OTHER ; BC6OTHER was the most advantageous for horses of four NSAIDs examined. CPR:4newlineAs expected, comparison of IC50 indicated that BC6OTHER and BC6OTHER are more selective inhibitors of BC6ENTG than BC6OTHER and BC6ENTC ; BC6OTHER was the most advantageous for horses of four NSAIDs examined. CPR:4newlineAs expected, comparison of IC50 indicated that BC6OTHER and BC6OTHER are more selective inhibitors of BC6ENTG than BC6OTHER and BC6OTHER ; BC6ENTC was the most advantageous for horses of four NSAIDs examined. CPR:falsenewlineHowever at IC80, BC6ENTC (+134.4%) and BC6OTHER (+29.7%) had greater BC6ENTG selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6OTHER selectivity than at IC50. CPR:falsenewlineHowever at IC80, BC6ENTC (+134.4%) and BC6OTHER (+29.7%) had greater BC6OTHER selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6ENTG selectivity than at IC50. CPR:falsenewlineHowever at IC80, BC6OTHER (+134.4%) and BC6ENTC (+29.7%) had greater BC6ENTG selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6OTHER selectivity than at IC50. CPR:falsenewlineHowever at IC80, BC6OTHER (+134.4%) and BC6ENTC (+29.7%) had greater BC6OTHER selectivity than at IC50, and BC6OTHER ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6ENTG selectivity than at IC50. CPR:falsenewlineHowever at IC80, BC6OTHER (+134.4%) and BC6OTHER (+29.7%) had greater BC6ENTG selectivity than at IC50, and BC6ENTC ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6OTHER selectivity than at IC50. CPR:falsenewlineHowever at IC80, BC6OTHER (+134.4%) and BC6OTHER (+29.7%) had greater BC6OTHER selectivity than at IC50, and BC6ENTC ( - 41.2%) and BC6OTHER ( - 12.9%) had lower BC6ENTG selectivity than at IC50. CPR:falsenewlineWe report on the inhibitory activity of the NSAIDs BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , on blood BC6ENTG in the horse using in vitro enzyme - linked assays. CPR:falsenewlineIn addition, SCPP11 (at 50mg / kg) could also increased in thymus indexes as well as BC6ENTG and BC6OTHER levels in serum in vivo and significantly enhance the phagocytosis activity and the productions of BC6ENTC of RAW264.7 in vitro. CPR:falsenewlineIn addition, SCPP11 (at 50mg / kg) could also increased in thymus indexes as well as BC6OTHER and BC6ENTG levels in serum in vivo and significantly enhance the phagocytosis activity and the productions of BC6ENTC of RAW264.7 in vitro. CPR:falsenewlineBC6ENTC (intravenous, 1 mg / kg), whose serotonergic actions include BC6ENTG and BC6OTHER antagonism, typically raised BC6OTHER levels (four of five cells) and always blocked inhibition by BC6OTHER (n = 3). CPR:falsenewlineBC6ENTC (intravenous, 1 mg / kg), whose serotonergic actions include BC6OTHER and BC6ENTG antagonism, typically raised BC6OTHER levels (four of five cells) and always blocked inhibition by BC6OTHER (n = 3). CPR:falsenewlineBC6OTHER (intravenous, 1 mg / kg), whose serotonergic actions include BC6ENTG and BC6OTHER antagonism, typically raised BC6ENTC levels (four of five cells) and always blocked inhibition by BC6OTHER (n = 3). CPR:falsenewlineBC6OTHER (intravenous, 1 mg / kg), whose serotonergic actions include BC6OTHER and BC6ENTG antagonism, typically raised BC6ENTC levels (four of five cells) and always blocked inhibition by BC6OTHER (n = 3). CPR:falsenewlineBC6OTHER (intravenous, 1 mg / kg), whose serotonergic actions include BC6ENTG and BC6OTHER antagonism, typically raised BC6OTHER levels (four of five cells) and always blocked inhibition by BC6ENTC (n = 3). CPR:falsenewlineBC6OTHER (intravenous, 1 mg / kg), whose serotonergic actions include BC6OTHER and BC6ENTG antagonism, typically raised BC6OTHER levels (four of five cells) and always blocked inhibition by BC6ENTC (n = 3). CPR:falsenewlineThe released BC6ENTC could contribute to the inhibition of off(M) cells and excitation of on(M) cells by noxious stimulation, since inhibitory BC6ENTG receptors and excitatory BC6OTHER receptors, respectively, have previously been shown to dominate their serotonergic responses. CPR:falsenewlineThe released BC6ENTC could contribute to the inhibition of off(M) cells and excitation of on(M) cells by noxious stimulation, since inhibitory BC6OTHER receptors and excitatory BC6ENTG receptors, respectively, have previously been shown to dominate their serotonergic responses. CPR:falsenewlineIontophoresis of BC6ENTC , whose serotonergic actions include antagonism and partial agonism at BC6ENTG receptors, also increased BC6OTHER and decreased firing (n=4). CPR:falsenewlineIontophoresis of BC6OTHER , whose serotonergic actions include antagonism and partial agonism at BC6ENTG receptors, also increased BC6ENTC and decreased firing (n=4). CPR:falsenewlineOBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized BC6OTHER (a selective, long - acting BC6ENTG agonist that is the BC6ENTC ) and BC6OTHER versus placebo in patients with chronic obstructive pulmonary disease (COPD). CPR:falsenewlineOBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized BC6OTHER (a selective, long - acting BC6ENTG agonist that is the BC6OTHER ) and BC6ENTC versus placebo in patients with chronic obstructive pulmonary disease (COPD). CPR:falsenewlineOBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized BC6ENTC (a selective, long - acting BC6ENTG agonist that is the BC6OTHER ) and BC6OTHER versus placebo in patients with chronic obstructive pulmonary disease (COPD). CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6ENTG ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6ENTG ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6ENTG , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6ENTG , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6ENTG ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6ENTG ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6ENTG ) as well as BC6OTHER sensitivity and endogenous BC6OTHER production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6ENTG sensitivity and endogenous BC6OTHER production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6ENTG ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6ENTG ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6ENTG , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6ENTG , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6ENTG ), BC6OTHER ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6ENTG ( BC6OTHER ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6ENTG ) as well as BC6OTHER sensitivity and endogenous BC6ENTC production. CPR:falsenewlineWe characterised 62 non - diabetic, middle - aged, Caucasians with and without the T risk allele of rs7903146 in BC6OTHER ( BC6OTHER ) with regard to secretion of BC6OTHER , BC6OTHER , BC6OTHER - dependent insulinotropic polypeptide ( BC6OTHER ), BC6OTHER ( BC6OTHER ) as well as BC6ENTG sensitivity and endogenous BC6ENTC production. CPR:falsenewlineWe found no significant differences in endogenous BC6ENTC production, hepatic BC6ENTG sensitivity or fasting concentrations of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER between the groups. CPR:falsenewlineWe found no significant differences in endogenous BC6ENTC production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER between the groups. CPR:falsenewlineWe found no significant differences in endogenous BC6ENTC production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER between the groups. CPR:falsenewlineWe found no significant differences in endogenous BC6ENTC production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG between the groups. CPR:falsenewlineWe found no significant differences in endogenous BC6OTHER production, hepatic BC6ENTG sensitivity or fasting concentrations of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER between the groups. CPR:falsenewlineWe found no significant differences in endogenous BC6OTHER production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6ENTC , BC6ENTG , BC6OTHER and BC6OTHER between the groups. CPR:falsenewlineWe found no significant differences in endogenous BC6OTHER production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6ENTC , BC6OTHER , BC6ENTG and BC6OTHER between the groups. CPR:falsenewlineWe found no significant differences in endogenous BC6OTHER production, hepatic BC6OTHER sensitivity or fasting concentrations of BC6ENTC , BC6OTHER , BC6OTHER and BC6ENTG between the groups. CPR:falsenewlineFurthermore, co - injection of encapsulated BC6ENTG - ligands with BC6ENTC particles carrying BC6OTHER HIV - 1 antigen allowed a 100 fold increase in antibody responses in comparison to Alum. CPR:falsenewlineFurthermore, co - injection of encapsulated BC6OTHER - ligands with BC6ENTC particles carrying BC6ENTG HIV - 1 antigen allowed a 100 fold increase in antibody responses in comparison to Alum. CPR:falsenewlineThese results suggest that encapsulation of BC6ENTG ligands into BC6ENTC - NPs could be an effective way to improve vaccine efficiency. CPR:falsenewlineAs activation of intracytoplasmic BC6ENTG is able to induce proinflammatory molecules, the added value of encapsulation of BC6OTHER and BC6OTHER receptor ligands into BC6ENTC ( BC6OTHER ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated. CPR:falsenewlineAs activation of intracytoplasmic BC6OTHER is able to induce proinflammatory molecules, the added value of encapsulation of BC6ENTG and BC6OTHER receptor ligands into BC6ENTC ( BC6OTHER ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated. CPR:falsenewlineAs activation of intracytoplasmic BC6OTHER is able to induce proinflammatory molecules, the added value of encapsulation of BC6OTHER and BC6ENTG receptor ligands into BC6ENTC ( BC6OTHER ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated. CPR:falsenewlineAs activation of intracytoplasmic BC6ENTG is able to induce proinflammatory molecules, the added value of encapsulation of BC6OTHER and BC6OTHER receptor ligands into BC6OTHER ( BC6ENTC ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated. CPR:falsenewlineAs activation of intracytoplasmic BC6OTHER is able to induce proinflammatory molecules, the added value of encapsulation of BC6ENTG and BC6OTHER receptor ligands into BC6OTHER ( BC6ENTC ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated. CPR:falsenewlineAs activation of intracytoplasmic BC6OTHER is able to induce proinflammatory molecules, the added value of encapsulation of BC6OTHER and BC6ENTG receptor ligands into BC6OTHER ( BC6ENTC ) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated. CPR:falsenewlineBC6ENTG ligands encapsulated into BC6ENTC NPs were efficiently taken up by DCs and subsequently induced a strong up - regulation of maturation markers and the enhancement of proinflammatory BC6OTHER secretion by DCs. CPR:falsenewlineBC6OTHER ligands encapsulated into BC6ENTC NPs were efficiently taken up by DCs and subsequently induced a strong up - regulation of maturation markers and the enhancement of proinflammatory BC6ENTG secretion by DCs. CPR:falsenewlineEncapsulation of BC6ENTG and BC6OTHER receptor ligands into BC6ENTC nanoparticles potentiates their immune properties. CPR:falsenewlineEncapsulation of BC6OTHER and BC6ENTG receptor ligands into BC6ENTC nanoparticles potentiates their immune properties. CPR:falsenewlineThe current study examined the bioactivation potential of BC6ENTG inverse agonists, BC6OTHER (1) and BC6ENTC (2), containing a fused BC6OTHER motif in the core structure. CPR:5newlineThe current study examined the bioactivation potential of BC6ENTG inverse agonists, BC6OTHER (1) and BC6OTHER (2), containing a fused BC6ENTC motif in the core structure. CPR:falsenewlineThe current study examined the bioactivation potential of BC6ENTG inverse agonists, BC6ENTC (1) and BC6OTHER (2), containing a fused BC6OTHER motif in the core structure. CPR:5newlineReactive Metabolite Trapping Studies on BC6ENTC - based Inverse Agonists of the BC6ENTG . CPR:falsenewlineMeasurement of Transport Activities of BC6ENTC in BC6ENTG and BC6OTHER Using LC - MS / MS. CPR:9newlineMeasurement of Transport Activities of BC6ENTC in BC6OTHER and BC6ENTG Using LC - MS / MS. CPR:falsenewlineMeasurement of Transport Activities of BC6OTHER in BC6ENTC Export Pump and BC6ENTG Using LC - MS / MS. CPR:falsenewlineThe analytical method was applied to measurements of transport activities in membrane vesicles obtained from BC6ENTG - , and human BC6ENTC export pump - expressing Sf9 cells for conjugated BC6OTHER . CPR:falsenewlineThe analytical method was applied to measurements of transport activities in membrane vesicles obtained from BC6ENTG - , and human BC6OTHER export pump - expressing Sf9 cells for conjugated BC6ENTC . CPR:falsenewlineThe analytical method was applied to measurements of transport activities in membrane vesicles obtained from BC6OTHER - , and BC6ENTG - expressing Sf9 cells for conjugated BC6ENTC . CPR:falsenewlineThe present study demonstrated that BC6ENTG vesicles accepted conjugated BC6ENTC along with common BC6OTHER such as BC6OTHER and BC6OTHER . CPR:9newlineThe present study demonstrated that BC6ENTG vesicles accepted conjugated BC6OTHER along with common BC6ENTC such as BC6OTHER and BC6OTHER . CPR:falsenewlineThe present study demonstrated that BC6ENTG vesicles accepted conjugated BC6OTHER along with common BC6OTHER such as BC6ENTC and BC6OTHER . CPR:falsenewlineThe present study demonstrated that BC6ENTG vesicles accepted conjugated BC6OTHER along with common BC6OTHER such as BC6OTHER and BC6ENTC . CPR:falsenewlineHere, we show that the BC6ENTG is the brain binding site of BC6ENTC ( BC6OTHER ), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy. CPR:falsenewlineFurthermore, there is a high degree of correlation between binding affinities of a series of BC6OTHER derivatives to BC6ENTG in fibroblasts and to the BC6ENTC - binding site in brain. CPR:falsenewlineHere, we show that the BC6ENTG is the brain binding site of BC6OTHER ( BC6ENTC ), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy. CPR:falsenewlineThe BC6ENTG is the binding site for the antiepileptic drug BC6ENTC . CPR:falsenewlineThese experimental results suggest that BC6ENTG is the binding site of BC6ENTC in the brain and that BC6OTHER acts by modulating the function of BC6OTHER , supporting previous indications that BC6OTHER possesses a mechanism of action distinct from that of other antiepileptic drugs. CPR:falsenewlineThese experimental results suggest that BC6OTHER is the binding site of BC6ENTC in the brain and that BC6OTHER acts by modulating the function of BC6ENTG , supporting previous indications that BC6OTHER possesses a mechanism of action distinct from that of other antiepileptic drugs. CPR:falsenewlineThese experimental results suggest that BC6ENTG is the binding site of BC6OTHER in the brain and that BC6ENTC acts by modulating the function of BC6OTHER , supporting previous indications that BC6OTHER possesses a mechanism of action distinct from that of other antiepileptic drugs. CPR:falsenewlineThese experimental results suggest that BC6OTHER is the binding site of BC6OTHER in the brain and that BC6ENTC acts by modulating the function of BC6ENTG , supporting previous indications that BC6OTHER possesses a mechanism of action distinct from that of other antiepileptic drugs. CPR:falsenewlineThese experimental results suggest that BC6ENTG is the binding site of BC6OTHER in the brain and that BC6OTHER acts by modulating the function of BC6OTHER , supporting previous indications that BC6ENTC possesses a mechanism of action distinct from that of other antiepileptic drugs. CPR:falsenewlineThese experimental results suggest that BC6OTHER is the binding site of BC6OTHER in the brain and that BC6OTHER acts by modulating the function of BC6ENTG , supporting previous indications that BC6ENTC possesses a mechanism of action distinct from that of other antiepileptic drugs. CPR:falsenewlineBrain membranes and purified synaptic vesicles from mice lacking BC6ENTG do not bind a tritiated BC6ENTC derivative, indicating that BC6OTHER is necessary for BC6OTHER binding. CPR:falsenewlineBrain membranes and purified synaptic vesicles from mice lacking BC6OTHER do not bind a tritiated BC6ENTC derivative, indicating that BC6ENTG is necessary for BC6OTHER binding. CPR:falsenewlineBrain membranes and purified synaptic vesicles from mice lacking BC6ENTG do not bind a tritiated BC6OTHER derivative, indicating that BC6OTHER is necessary for BC6ENTC binding. CPR:falsenewlineBrain membranes and purified synaptic vesicles from mice lacking BC6OTHER do not bind a tritiated BC6OTHER derivative, indicating that BC6ENTG is necessary for BC6ENTC binding. CPR:falsenewlineBC6ENTC and related compounds bind to BC6ENTG expressed in fibroblasts, indicating that BC6OTHER is sufficient for BC6OTHER binding. CPR:falsenewlineBC6ENTC and related compounds bind to BC6OTHER expressed in fibroblasts, indicating that BC6ENTG is sufficient for BC6OTHER binding. CPR:falsenewlineBC6OTHER and related compounds bind to BC6ENTG expressed in fibroblasts, indicating that BC6OTHER is sufficient for BC6ENTC binding. CPR:falsenewlineBC6OTHER and related compounds bind to BC6OTHER expressed in fibroblasts, indicating that BC6ENTG is sufficient for BC6ENTC binding. CPR:falsenewlineFurthermore, there is a high degree of correlation between binding affinities of a series of BC6ENTC derivatives to BC6ENTG in fibroblasts and to the BC6OTHER - binding site in brain. CPR:falsenewlineBC6ENTG has mostly been studied in the context of the leukemic BC6OTHER - BC6OTHER fusion protein, which lacks the BC6ENTC - terminal PHD fingers of BC6OTHER . CPR:falsenewlineBC6OTHER has mostly been studied in the context of the leukemic BC6ENTG - BC6OTHER fusion protein, which lacks the BC6ENTC - terminal PHD fingers of BC6OTHER . CPR:falsenewlineBC6OTHER has mostly been studied in the context of the leukemic BC6OTHER - BC6ENTG fusion protein, which lacks the BC6ENTC - terminal PHD fingers of BC6OTHER . CPR:falsenewlineBC6OTHER has mostly been studied in the context of the leukemic BC6OTHER - BC6OTHER fusion protein, which lacks the BC6ENTC - terminal PHD fingers of BC6ENTG . CPR:falsenewlineIn this study, we used genetic and biochemical approaches to examine the BC6ENTG region of the Caenorhabditis elegans ortholog of BC6OTHER , BC6ENTC finger protein 1 ( BC6OTHER ). CPR:falsenewlineIn this study, we used genetic and biochemical approaches to examine the BC6OTHER region of the Caenorhabditis elegans ortholog of BC6ENTG , BC6ENTC finger protein 1 ( BC6OTHER ). CPR:falsenewlineIn this study, we used genetic and biochemical approaches to examine the BC6OTHER region of the Caenorhabditis elegans ortholog of BC6OTHER , BC6ENTC finger protein 1 ( BC6ENTG ). CPR:falsenewlineWe demonstrate that the BC6ENTG region is essential for viability and that the first BC6OTHER contributes to the preferred binding of BC6OTHER to BC6ENTC 4 - methylated histone H3 tails. CPR:falsenewlineWe demonstrate that the BC6OTHER region is essential for viability and that the first BC6ENTG contributes to the preferred binding of BC6OTHER to BC6ENTC 4 - methylated histone H3 tails. CPR:falsenewlineWe demonstrate that the BC6OTHER region is essential for viability and that the first BC6OTHER contributes to the preferred binding of BC6ENTG to BC6ENTC 4 - methylated histone H3 tails. CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6ENTG ( BC6OTHER ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6ENTG ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6ENTC through BC6ENTG ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6ENTG ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6ENTG phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6ENTG / BC6OTHER plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6ENTC through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6ENTG plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6ENTG ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6ENTG ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6ENTG ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6ENTG phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6ENTG / BC6OTHER plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6ENTC - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6ENTG plays an important role in cell growth suppression by BC6OTHER . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6ENTG ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6ENTC . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6ENTG ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6ENTC . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through BC6ENTG ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6ENTC . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6ENTG ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6ENTC . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6ENTG phosphorylation downstream of BC6OTHER / BC6OTHER plays an important role in cell growth suppression by BC6ENTC . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6ENTG / BC6OTHER plays an important role in cell growth suppression by BC6ENTC . CPR:falsenewlineWe have previously demonstrated that phosphorylation of BC6OTHER ( BC6OTHER ) at 194 BC6OTHER through c - jun BC6OTHER - terminal kinase ( BC6OTHER ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that BC6OTHER phosphorylation downstream of BC6OTHER / BC6ENTG plays an important role in cell growth suppression by BC6ENTC . CPR:falsenewlineIn this study, the clinicopathological association of BC6ENTG ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6ENTG ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6ENTG expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6ENTG / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6ENTG ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6ENTG / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6ENTC , BC6OTHER , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6ENTG ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6ENTG ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6ENTG ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6ENTG expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6ENTG / BC6OTHER ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6ENTG ( BC6OTHER / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6ENTG / BC6OTHER ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineIn this study, the clinicopathological association of BC6OTHER ( BC6OTHER ) with BC6OTHER , BC6ENTC , c - erbB - 2 receptors, BC6OTHER expressions and BC6OTHER / BC6OTHER ( BC6OTHER / BC6ENTG ) was analyzed immunohistochemically using 107 human breast cancer specimens. CPR:falsenewlineAlso, reactive astrogliosis takes part of the early responses to the insult with BC6ENTC , evidenced by upregulated BC6ENTG in Western blot, PCR and immunofluorescence analysis. CPR:falsenewlineSix days after BC6ENTC injection we found persistent astrogliosis, increased BC6OTHER (PI) positive cells in BC6OTHER positive population evidenced by flow cytometry and reduced immunofluorescence for BC6ENTG , suggesting that the in vivo exposure to BC6OTHER progressed to neuronal death. CPR:falsenewlineSix days after BC6ENTC injection we found persistent astrogliosis, increased BC6OTHER (PI) positive cells in BC6ENTG positive population evidenced by flow cytometry and reduced immunofluorescence for BC6OTHER , suggesting that the in vivo exposure to BC6OTHER progressed to neuronal death. CPR:falsenewlineSix days after BC6OTHER injection we found persistent astrogliosis, increased BC6ENTC (PI) positive cells in BC6OTHER positive population evidenced by flow cytometry and reduced immunofluorescence for BC6ENTG , suggesting that the in vivo exposure to BC6OTHER progressed to neuronal death. CPR:falsenewlineSix days after BC6OTHER injection we found persistent astrogliosis, increased BC6ENTC (PI) positive cells in BC6ENTG positive population evidenced by flow cytometry and reduced immunofluorescence for BC6OTHER , suggesting that the in vivo exposure to BC6OTHER progressed to neuronal death. CPR:falsenewlineSix days after BC6OTHER injection we found persistent astrogliosis, increased BC6OTHER (PI) positive cells in BC6OTHER positive population evidenced by flow cytometry and reduced immunofluorescence for BC6ENTG , suggesting that the in vivo exposure to BC6ENTC progressed to neuronal death. CPR:falsenewlineSix days after BC6OTHER injection we found persistent astrogliosis, increased BC6OTHER (PI) positive cells in BC6ENTG positive population evidenced by flow cytometry and reduced immunofluorescence for BC6OTHER , suggesting that the in vivo exposure to BC6ENTC progressed to neuronal death. CPR:falsenewlineNeurodegeneration was related with decreased BC6ENTC uptake and decreased BC6ENTG immunoreactivity, however BC6OTHER ( BC6OTHER 9) was not altered in BC6OTHER injected rat. CPR:falsenewlineNeurodegeneration was related with decreased BC6ENTC uptake and decreased BC6OTHER immunoreactivity, however BC6ENTG ( BC6OTHER 9) was not altered in BC6OTHER injected rat. CPR:falsenewlineNeurodegeneration was related with decreased BC6OTHER uptake and decreased BC6ENTG immunoreactivity, however BC6OTHER ( BC6ENTC 9) was not altered in BC6OTHER injected rat. CPR:falsenewlineNeurodegeneration was related with decreased BC6OTHER uptake and decreased BC6OTHER immunoreactivity, however BC6ENTG ( BC6ENTC 9) was not altered in BC6OTHER injected rat. CPR:falsenewlineNeurodegeneration was related with decreased BC6OTHER uptake and decreased BC6ENTG immunoreactivity, however BC6OTHER ( BC6OTHER 9) was not altered in BC6ENTC injected rat. CPR:falsenewlineNeurodegeneration was related with decreased BC6OTHER uptake and decreased BC6OTHER immunoreactivity, however BC6ENTG ( BC6OTHER 9) was not altered in BC6ENTC injected rat. CPR:falsenewlineTherefore, the present results show that the earlier cerebellar responses to BC6ENTC include disruption of cytoskeletal homeostasis that could be related with BC6ENTG and BC6OTHER activation and reactive astrogliosis. CPR:falsenewlineTherefore, the present results show that the earlier cerebellar responses to BC6ENTC include disruption of cytoskeletal homeostasis that could be related with BC6OTHER and BC6ENTG activation and reactive astrogliosis. CPR:3newlineThe later events of the neurodegenerative process are characterized by persistent astrogliosis and activation of apoptotic neuronal death through BC6ENTG mediated mechanisms, which could be related with BC6ENTC excitotoxicity. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6ENTG - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6ENTG - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6ENTG ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6ENTG : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6ENTG , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6ENTG and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6ENTG ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6ENTG ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6ENTG ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6ENTG and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6ENTG ) and BC6ENTC - dependent protein kinase ( BC6OTHER ) activities. CPR:falsenewlineThe earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte ( BC6OTHER - BC6OTHER - and BC6OTHER ) and neuron ( BC6OTHER : BC6OTHER , BC6OTHER and BC6OTHER ); increased BC6OTHER ( BC6OTHER ) ( BC6OTHER and BC6OTHER ) and BC6ENTC - dependent protein kinase ( BC6ENTG ) activities. CPR:falsenewlineIn conclusion, these results show that BC6ENTC and BC6OTHER interact with BC6ENTG - mediated substrate transport to different extents. CPR:falsenewlineIn conclusion, these results show that BC6OTHER and BC6ENTC interact with BC6ENTG - mediated substrate transport to different extents. CPR:falsenewlineInhibition of BC6ENTG can explain the previously observed effects of BC6ENTC and BC6OTHER on hepatic organic anion elimination. CPR:falsenewlineInhibition of BC6ENTG can explain the previously observed effects of BC6OTHER and BC6ENTC on hepatic organic anion elimination. CPR:falsenewlineTherefore, we investigated the effects of BC6ENTC and BC6OTHER on the BC6ENTG of human liver and determined whether BC6OTHER is a substrate of 1 or several of these carriers. CPR:falsenewlineTherefore, we investigated the effects of BC6OTHER and BC6ENTC on the BC6ENTG of human liver and determined whether BC6OTHER is a substrate of 1 or several of these carriers. CPR:falsenewlineTherefore, we investigated the effects of BC6OTHER and BC6OTHER on the BC6ENTG of human liver and determined whether BC6ENTC is a substrate of 1 or several of these carriers. CPR:falsenewlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6ENTG ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6ENTG ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6ENTG ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6ENTG ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTG ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6ENTG ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6ENTG ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6ENTG ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6ENTG ), and BC6OTHER ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6ENTG ) ( BC6OTHER ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineIn complementary RNA (cRNA) - injected Xenopus laevis oocytes, BC6ENTC (10 micromol / L) cis - inhibited BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), BC6OTHER ( BC6OTHER ) ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) ( BC6ENTG ) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. CPR:4newlineBC6ENTC (10 micromol / L) inhibited BC6ENTG - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6OTHER - mediated BC6OTHER transport was below 15%. CPR:falsenewlineBC6ENTC (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6ENTG - , BC6OTHER - , and BC6OTHER - mediated BC6OTHER transport was below 15%. CPR:falsenewlineBC6ENTC (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6ENTG - , and BC6OTHER - mediated BC6OTHER transport was below 15%. CPR:falsenewlineBC6ENTC (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6ENTG - mediated BC6OTHER transport was below 15%. CPR:falsenewlineBC6OTHER (10 micromol / L) inhibited BC6ENTG - mediated BC6ENTC uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6OTHER - mediated BC6OTHER transport was below 15%. CPR:9newlineBC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6ENTC uptake by 50%, whereas inhibition of BC6ENTG - , BC6OTHER - , and BC6OTHER - mediated BC6OTHER transport was below 15%. CPR:9newlineBC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6ENTC uptake by 50%, whereas inhibition of BC6OTHER - , BC6ENTG - , and BC6OTHER - mediated BC6OTHER transport was below 15%. CPR:9newlineBC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6ENTC uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6ENTG - mediated BC6OTHER transport was below 15%. CPR:9newlineIn rats, BC6ENTC and BC6OTHER were shown to interfere with hepatic organic anion uptake by inhibition of the BC6ENTG BC6OTHER and BC6OTHER . CPR:4newlineIn rats, BC6ENTC and BC6OTHER were shown to interfere with hepatic organic anion uptake by inhibition of the BC6OTHER BC6ENTG and BC6OTHER . CPR:4newlineIn rats, BC6ENTC and BC6OTHER were shown to interfere with hepatic organic anion uptake by inhibition of the BC6OTHER BC6OTHER and BC6ENTG . CPR:4newlineBC6OTHER (10 micromol / L) inhibited BC6ENTG - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6OTHER - mediated BC6ENTC transport was below 15%. CPR:9newlineBC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6ENTG - , BC6OTHER - , and BC6OTHER - mediated BC6ENTC transport was below 15%. CPR:9newlineBC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6ENTG - , and BC6OTHER - mediated BC6ENTC transport was below 15%. CPR:9newlineBC6OTHER (10 micromol / L) inhibited BC6OTHER - mediated BC6OTHER uptake by 50%, whereas inhibition of BC6OTHER - , BC6OTHER - , and BC6ENTG - mediated BC6ENTC transport was below 15%. CPR:9newline100 micromol / L BC6ENTC inhibited BC6ENTG - and BC6OTHER - , BC6OTHER - and BC6OTHER - mediated BC6OTHER uptake by 66%, 96%, 25%, and 49%, respectively. CPR:4newline100 micromol / L BC6ENTC inhibited BC6OTHER - and BC6ENTG - , BC6OTHER - and BC6OTHER - mediated BC6OTHER uptake by 66%, 96%, 25%, and 49%, respectively. CPR:4newline100 micromol / L BC6ENTC inhibited BC6OTHER - and BC6OTHER - , BC6ENTG - and BC6OTHER - mediated BC6OTHER uptake by 66%, 96%, 25%, and 49%, respectively. CPR:4newline100 micromol / L BC6ENTC inhibited BC6OTHER - and BC6OTHER - , BC6OTHER - and BC6ENTG - mediated BC6OTHER uptake by 66%, 96%, 25%, and 49%, respectively. CPR:4newlineIn rats, BC6OTHER and BC6ENTC were shown to interfere with hepatic organic anion uptake by inhibition of the BC6ENTG BC6OTHER and BC6OTHER . CPR:4newlineIn rats, BC6OTHER and BC6ENTC were shown to interfere with hepatic organic anion uptake by inhibition of the BC6OTHER BC6ENTG and BC6OTHER . CPR:4newlineIn rats, BC6OTHER and BC6ENTC were shown to interfere with hepatic organic anion uptake by inhibition of the BC6OTHER BC6OTHER and BC6ENTG . CPR:4newline100 micromol / L BC6OTHER inhibited BC6ENTG - and BC6OTHER - , BC6OTHER - and BC6OTHER - mediated BC6ENTC uptake by 66%, 96%, 25%, and 49%, respectively. CPR:9newline100 micromol / L BC6OTHER inhibited BC6OTHER - and BC6ENTG - , BC6OTHER - and BC6OTHER - mediated BC6ENTC uptake by 66%, 96%, 25%, and 49%, respectively. CPR:9newline100 micromol / L BC6OTHER inhibited BC6OTHER - and BC6OTHER - , BC6ENTG - and BC6OTHER - mediated BC6ENTC uptake by 66%, 96%, 25%, and 49%, respectively. CPR:9newline100 micromol / L BC6OTHER inhibited BC6OTHER - and BC6OTHER - , BC6OTHER - and BC6ENTG - mediated BC6ENTC uptake by 66%, 96%, 25%, and 49%, respectively. CPR:9newlineDirect transport of BC6ENTC could be shown for BC6ENTG (apparent K(m) value 13 micromol / L) and BC6OTHER (2.3 micromol / L). CPR:9newlineDirect transport of BC6ENTC could be shown for BC6OTHER (apparent K(m) value 13 micromol / L) and BC6ENTG (2.3 micromol / L). CPR:9newlineThe data also showed significant decrease in the levels of serum BC6ENTC , BC6ENTG and BC6OTHER and significant increase in the level of serum BC6OTHER in BC6OTHER - intoxicated rats. CPR:falsenewlineThe data also showed significant decrease in the levels of serum BC6ENTC , BC6OTHER and BC6ENTG and significant increase in the level of serum BC6OTHER in BC6OTHER - intoxicated rats. CPR:falsenewlineThe data also showed significant decrease in the levels of serum BC6ENTC , BC6OTHER and BC6OTHER and significant increase in the level of serum BC6ENTG in BC6OTHER - intoxicated rats. CPR:falsenewlineThe data also showed significant decrease in the levels of serum BC6OTHER , BC6ENTG and BC6OTHER and significant increase in the level of serum BC6OTHER in BC6ENTC - intoxicated rats. CPR:falsenewlineThe data also showed significant decrease in the levels of serum BC6OTHER , BC6OTHER and BC6ENTG and significant increase in the level of serum BC6OTHER in BC6ENTC - intoxicated rats. CPR:falsenewlineThe data also showed significant decrease in the levels of serum BC6OTHER , BC6OTHER and BC6OTHER and significant increase in the level of serum BC6ENTG in BC6ENTC - intoxicated rats. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6ENTC ( BC6OTHER , 2) were synthesized and evaluated for binding to the BC6ENTG BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6ENTC ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6ENTC ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6ENTC ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells. CPR:falsenewlineChase studies with BC6ENTC and BC6OTHER demonstrated that this uptake is the result of preferential binding to the BC6ENTG . CPR:falsenewlineChase studies with BC6OTHER and BC6ENTC demonstrated that this uptake is the result of preferential binding to the BC6ENTG . CPR:falsenewlineSynthesis, radiosynthesis, and biological evaluation of BC6ENTC : candidate radioligands for in vivo imaging of the BC6ENTG with positron emission tomography. CPR:falsenewlineBC6ENTC ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the BC6ENTG BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6ENTC ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6ENTC ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6ENTC ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6ENTC , 2) were synthesized and evaluated for binding to the BC6ENTG BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6ENTC , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6ENTC , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6ENTC , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6ENTC , BC6OTHER , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6ENTC , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6ENTC , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the BC6ENTG BC6ENTC , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6ENTC , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6ENTC , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6ENTC , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the BC6ENTG BC6OTHER , and BC6ENTC transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6ENTC transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6ENTC transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6OTHER , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6ENTC transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells. CPR:falsenewlineCompound 2 has a significantly higher affinity for the BC6ENTG than 1, and this may be a result of the different size and electronegativity of the BC6ENTC atoms. CPR:falsenewlineMicroPET imaging in nonhuman primates with [ BC6ENTC ]1 and [ BC6OTHER ]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the BC6ENTG - rich brain regions and peak uptake being achieved in about 55 min postinjection. CPR:falsenewlineBC6OTHER ( BC6ENTC , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the BC6ENTG BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6ENTC , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6ENTG , BC6OTHER , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6ENTC , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6ENTG , and BC6OTHER , respectively) using transfected cells. CPR:falsenewlineBC6OTHER ( BC6ENTC , 1) and BC6OTHER ( BC6OTHER , 2) were synthesized and evaluated for binding to the human BC6OTHER , BC6OTHER , and BC6OTHER transporters ( BC6OTHER , BC6OTHER , and BC6ENTG , respectively) using transfected cells. CPR:falsenewlineMicroPET imaging in nonhuman primates with [ BC6OTHER ]1 and [ BC6ENTC ]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the BC6ENTG - rich brain regions and peak uptake being achieved in about 55 min postinjection. CPR:falsenewlineIn nonsmokers, BC6ENTG and BC6ENTC were negatively correlated with BC6OTHER and correlated with BC6OTHER ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6OTHER . CPR:falsenewlineIn nonsmokers, BC6OTHER and BC6ENTC were negatively correlated with BC6ENTG and correlated with BC6OTHER ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6OTHER . CPR:falsenewlineIn nonsmokers, BC6ENTG and BC6OTHER were negatively correlated with BC6OTHER and correlated with BC6ENTC ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6OTHER . CPR:falsenewlineIn nonsmokers, BC6OTHER and BC6OTHER were negatively correlated with BC6ENTG and correlated with BC6ENTC ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6OTHER . CPR:falsenewlineIn nonsmokers, BC6ENTG and BC6OTHER were negatively correlated with BC6OTHER and correlated with BC6OTHER ( BC6ENTC ), and BC6OTHER was negatively correlated with BC6OTHER . CPR:falsenewlineIn nonsmokers, BC6OTHER and BC6OTHER were negatively correlated with BC6ENTG and correlated with BC6OTHER ( BC6ENTC ), and BC6OTHER was negatively correlated with BC6OTHER . CPR:falsenewlineIn nonsmokers, BC6ENTG and BC6OTHER were negatively correlated with BC6OTHER and correlated with BC6OTHER ( BC6OTHER ), and BC6ENTC was negatively correlated with BC6OTHER . CPR:falsenewlineIn nonsmokers, BC6OTHER and BC6OTHER were negatively correlated with BC6ENTG and correlated with BC6OTHER ( BC6OTHER ), and BC6ENTC was negatively correlated with BC6OTHER . CPR:falsenewlineIn nonsmokers, BC6ENTG and BC6OTHER were negatively correlated with BC6OTHER and correlated with BC6OTHER ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6ENTC . CPR:falsenewlineIn nonsmokers, BC6OTHER and BC6OTHER were negatively correlated with BC6ENTG and correlated with BC6OTHER ( BC6OTHER ), and BC6OTHER was negatively correlated with BC6ENTC . CPR:falsenewlineBC6ENTG was negatively correlated with BC6ENTC in all the sprayers, but was correlated with BC6OTHER in smokers and with BC6OTHER in nonsmokers. CPR:falsenewlineBC6OTHER was negatively correlated with BC6ENTC in all the sprayers, but was correlated with BC6ENTG in smokers and with BC6OTHER in nonsmokers. CPR:falsenewlineBC6ENTG was negatively correlated with BC6OTHER in all the sprayers, but was correlated with BC6OTHER in smokers and with BC6ENTC in nonsmokers. CPR:falsenewlineBC6OTHER was negatively correlated with BC6OTHER in all the sprayers, but was correlated with BC6ENTG in smokers and with BC6ENTC in nonsmokers. CPR:falsenewlineIn smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6ENTC and BC6OTHER and BC6ENTG were negatively correlated with BC6OTHER . CPR:falsenewlineIn smokers, BC6ENTG was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6ENTC and BC6OTHER and BC6OTHER were negatively correlated with BC6OTHER . CPR:falsenewlineIn smokers, BC6OTHER was negatively correlated with BC6ENTG , BC6OTHER was negatively correlated with BC6ENTC and BC6OTHER and BC6OTHER were negatively correlated with BC6OTHER . CPR:falsenewlineIn smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6ENTG was negatively correlated with BC6ENTC and BC6OTHER and BC6OTHER were negatively correlated with BC6OTHER . CPR:falsenewlineIn smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6OTHER and BC6ENTC and BC6ENTG were negatively correlated with BC6OTHER . CPR:falsenewlineIn smokers, BC6ENTG was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6OTHER and BC6ENTC and BC6OTHER were negatively correlated with BC6OTHER . CPR:falsenewlineIn smokers, BC6OTHER was negatively correlated with BC6ENTG , BC6OTHER was negatively correlated with BC6OTHER and BC6ENTC and BC6OTHER were negatively correlated with BC6OTHER . CPR:falsenewlineIn smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6ENTG was negatively correlated with BC6OTHER and BC6ENTC and BC6OTHER were negatively correlated with BC6OTHER . CPR:falsenewlineIn smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6OTHER and BC6OTHER and BC6ENTG were negatively correlated with BC6ENTC . CPR:falsenewlineIn smokers, BC6ENTG was negatively correlated with BC6OTHER , BC6OTHER was negatively correlated with BC6OTHER and BC6OTHER and BC6OTHER were negatively correlated with BC6ENTC . CPR:falsenewlineIn smokers, BC6OTHER was negatively correlated with BC6ENTG , BC6OTHER was negatively correlated with BC6OTHER and BC6OTHER and BC6OTHER were negatively correlated with BC6ENTC . CPR:falsenewlineIn smokers, BC6OTHER was negatively correlated with BC6OTHER , BC6ENTG was negatively correlated with BC6OTHER and BC6OTHER and BC6OTHER were negatively correlated with BC6ENTC . CPR:falsenewlineBC6ENTC was negatively correlated with BC6ENTG , BC6OTHER and BC6OTHER . CPR:falsenewlineBC6ENTC was negatively correlated with BC6OTHER , BC6ENTG and BC6OTHER . CPR:falsenewlineBC6OTHER was negatively correlated with BC6ENTG , BC6OTHER and BC6ENTC . CPR:falsenewlineBC6OTHER was negatively correlated with BC6OTHER , BC6ENTG and BC6ENTC . CPR:falsenewlineResults revealed that BC6ENTC , BC6ENTG ( BC6OTHER ) and BC6OTHER peroxidase ( BC6OTHER ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers. CPR:falsenewlineResults revealed that BC6ENTC , BC6OTHER ( BC6ENTG ) and BC6OTHER peroxidase ( BC6OTHER ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers. CPR:falsenewlineResults revealed that BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers. CPR:falsenewlineResults revealed that BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6OTHER peroxidase ( BC6ENTG ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers. CPR:falsenewlineResults revealed that BC6OTHER , BC6ENTG ( BC6OTHER ) and BC6ENTC peroxidase ( BC6OTHER ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers. CPR:falsenewlineResults revealed that BC6OTHER , BC6OTHER ( BC6ENTG ) and BC6ENTC peroxidase ( BC6OTHER ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers. CPR:falsenewlineResults revealed that BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC peroxidase ( BC6ENTG ) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers. CPR:falsenewlineBC6ENTC and BC6ENTG were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6ENTC and BC6OTHER were correlated with smoking index and BC6ENTG ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6ENTC and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6ENTG ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6ENTC and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6ENTC and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6ENTG were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6OTHER were correlated with smoking index and BC6ENTG ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6ENTG ), BC6ENTC dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6ENTG ) enzyme and BC6OTHER ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6ENTG were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6ENTC ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6OTHER were correlated with smoking index and BC6ENTG ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6ENTC ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6ENTG ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6ENTC ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) enzyme and BC6ENTC ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) enzyme and BC6ENTC ( BC6OTHER ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6ENTG were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6ENTC ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6OTHER were correlated with smoking index and BC6ENTG ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6ENTC ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6ENTG ), BC6OTHER dismutase ( BC6OTHER ) enzyme and BC6OTHER ( BC6ENTC ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) enzyme and BC6OTHER ( BC6ENTC ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineBC6OTHER and BC6OTHER were correlated with smoking index and BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) enzyme and BC6OTHER ( BC6ENTC ) were inversely correlated with duration of pesticides' exposure. CPR:falsenewlineGiven the treatment with three doses of BC6ENTC (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6ENTG and BC6OTHER in serum by single intragastric gavaged BC6OTHER . CPR:falsenewlineGiven the treatment with three doses of BC6ENTC (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6OTHER and BC6ENTG in serum by single intragastric gavaged BC6OTHER . CPR:falsenewlineTo examine the role of BC6OTHER ( - BC6OTHER ) group in improvement of endothelial dysfunction with BC6OTHER ( BC6ENTG ) inhibitors in experimental high dose of BC6ENTC dieted rats. CPR:falsenewlineTo examine the role of BC6OTHER ( - BC6OTHER ) group in improvement of endothelial dysfunction with BC6ENTG ( BC6OTHER ) inhibitors in experimental high dose of BC6ENTC dieted rats. CPR:falsenewlineGiven the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6ENTC , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6ENTG and BC6OTHER in serum by single intragastric gavaged BC6OTHER . CPR:falsenewlineGiven the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6ENTC , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6OTHER and BC6ENTG in serum by single intragastric gavaged BC6OTHER . CPR:falsenewlineGiven the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6ENTC , the decreased level of BC6OTHER , activity of BC6ENTG and BC6OTHER in serum by single intragastric gavaged BC6OTHER . CPR:falsenewlineGiven the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6ENTC , the decreased level of BC6OTHER , activity of BC6OTHER and BC6ENTG in serum by single intragastric gavaged BC6OTHER . CPR:falsenewlineGiven the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6ENTC , activity of BC6ENTG and BC6OTHER in serum by single intragastric gavaged BC6OTHER . CPR:falsenewlineGiven the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6ENTC , activity of BC6OTHER and BC6ENTG in serum by single intragastric gavaged BC6OTHER . CPR:falsenewlineGiven the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6ENTG and BC6OTHER in serum by single intragastric gavaged BC6ENTC . CPR:falsenewlineGiven the treatment with three doses of BC6OTHER (15 approximately 45 mg / kg) markedly attenuated inhibition of vasodilator responses to BC6OTHER , and eliminated the increased level of BC6OTHER , the decreased level of BC6OTHER , activity of BC6OTHER and BC6ENTG in serum by single intragastric gavaged BC6ENTC . CPR:falsenewlineHowever, there were some significant differences among BC6ENTC (30 mg / kg or 45 mg / kg), BC6OTHER (20 mg / kg), and BC6OTHER particular in the activity of BC6ENTG and BC6OTHER . CPR:falsenewlineHowever, there were some significant differences among BC6ENTC (30 mg / kg or 45 mg / kg), BC6OTHER (20 mg / kg), and BC6OTHER particular in the activity of BC6OTHER and BC6ENTG . CPR:falsenewlineHowever, there were some significant differences among BC6OTHER (30 mg / kg or 45 mg / kg), BC6ENTC (20 mg / kg), and BC6OTHER particular in the activity of BC6ENTG and BC6OTHER . CPR:falsenewlineHowever, there were some significant differences among BC6OTHER (30 mg / kg or 45 mg / kg), BC6ENTC (20 mg / kg), and BC6OTHER particular in the activity of BC6OTHER and BC6ENTG . CPR:falsenewlineHowever, there were some significant differences among BC6OTHER (30 mg / kg or 45 mg / kg), BC6OTHER (20 mg / kg), and BC6ENTC particular in the activity of BC6ENTG and BC6OTHER . CPR:falsenewlineHowever, there were some significant differences among BC6OTHER (30 mg / kg or 45 mg / kg), BC6OTHER (20 mg / kg), and BC6ENTC particular in the activity of BC6OTHER and BC6ENTG . CPR:falsenewlineThese results suggested that BC6ENTC can protect the vascular endothelium against the damages induced by BC6OTHER in rats, and the beneficial effects of BC6OTHER may be related to attenuating the decrease in BC6ENTG activity and BC6OTHER levels. CPR:falsenewlineBC6ENTG ( BC6OTHER ) and BC6OTHER activity, BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6ENTG ) and BC6OTHER activity, BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6ENTG activity, BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) in serum were analyzed. CPR:falsenewlineThese results suggested that BC6OTHER can protect the vascular endothelium against the damages induced by BC6ENTC in rats, and the beneficial effects of BC6OTHER may be related to attenuating the decrease in BC6ENTG activity and BC6OTHER levels. CPR:falsenewlineThese results suggested that BC6OTHER can protect the vascular endothelium against the damages induced by BC6OTHER in rats, and the beneficial effects of BC6ENTC may be related to attenuating the decrease in BC6ENTG activity and BC6OTHER levels. CPR:falsenewlineWe compared the effects of BC6ENTC (an BC6ENTG inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6ENTC (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6ENTG - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6ENTC (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineThese results suggested that BC6OTHER can protect the vascular endothelium against the damages induced by BC6OTHER in rats, and the beneficial effects of BC6OTHER may be related to attenuating the decrease in BC6ENTG activity and BC6ENTC levels. CPR:falsenewlineTo examine the role of BC6ENTC ( - BC6OTHER ) group in improvement of endothelial dysfunction with BC6OTHER ( BC6ENTG ) inhibitors in experimental high dose of BC6OTHER dieted rats. CPR:falsenewlineTo examine the role of BC6ENTC ( - BC6OTHER ) group in improvement of endothelial dysfunction with BC6ENTG ( BC6OTHER ) inhibitors in experimental high dose of BC6OTHER dieted rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6ENTC group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6ENTC group), BC6OTHER (an BC6ENTG - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6ENTC group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6OTHER group), BC6ENTC (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6ENTC (an BC6ENTG - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6ENTC (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6ENTC group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6ENTG - inhibitor without - BC6ENTC group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6ENTC group), BC6OTHER (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6ENTC (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6ENTG - inhibitor without - BC6OTHER group), BC6ENTC (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6ENTC (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineBC6ENTG ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6ENTG ) and BC6OTHER activity, BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6ENTG activity, BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) in serum were analyzed. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6ENTC group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6ENTG - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6ENTC group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6ENTC group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6OTHER - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineTo examine the role of BC6OTHER ( - BC6ENTC ) group in improvement of endothelial dysfunction with BC6OTHER ( BC6ENTG ) inhibitors in experimental high dose of BC6OTHER dieted rats. CPR:falsenewlineTo examine the role of BC6OTHER ( - BC6ENTC ) group in improvement of endothelial dysfunction with BC6ENTG ( BC6OTHER ) inhibitors in experimental high dose of BC6OTHER dieted rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6ENTG inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6ENTC - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6ENTG - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6OTHER inhibitor) on endothelial dysfunction injured by BC6ENTC - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineWe compared the effects of BC6OTHER (an BC6OTHER inhibitor with - BC6OTHER group), BC6OTHER (an BC6OTHER - inhibitor without - BC6OTHER group), BC6OTHER (only - BC6OTHER group not BC6ENTG inhibitor) on endothelial dysfunction injured by BC6ENTC - induced hyperhomocysteinemia (HHcy) in rats. CPR:falsenewlineBC6ENTG ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6ENTG ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6ENTG activity, BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6ENTG ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) in serum were analyzed. CPR:falsenewlineTo examine the role of BC6OTHER ( - BC6OTHER ) group in improvement of endothelial dysfunction with BC6ENTC - converting enzyme ( BC6ENTG ) inhibitors in experimental high dose of BC6OTHER dieted rats. CPR:falsenewlineComparison of BC6ENTC and BC6OTHER to study the role of the BC6OTHER - group in improvement of endothelial dysfunction with BC6ENTG inhibitors in high dieted BC6OTHER mice. CPR:falsenewlineComparison of BC6OTHER and BC6OTHER to study the role of the BC6OTHER - group in improvement of endothelial dysfunction with BC6ENTG inhibitors in high dieted BC6ENTC mice. CPR:falsenewlineComparison of BC6OTHER and BC6ENTC to study the role of the BC6OTHER - group in improvement of endothelial dysfunction with BC6ENTG inhibitors in high dieted BC6OTHER mice. CPR:falsenewlineComparison of BC6OTHER and BC6OTHER to study the role of the BC6ENTC - group in improvement of endothelial dysfunction with BC6ENTG inhibitors in high dieted BC6OTHER mice. CPR:falsenewlineBC6ENTG ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6ENTG ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6ENTG activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6ENTG ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER dismutase ( BC6ENTG ) in serum were analyzed. CPR:falsenewlineBC6ENTG ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6ENTG ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6ENTG activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) in serum were analyzed. CPR:falsenewlineBC6OTHER ( BC6OTHER ) and BC6OTHER activity, BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6ENTG ) in serum were analyzed. CPR:falsenewlineIt was found that a single intragastric gavage by BC6ENTC resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6ENTG and BC6OTHER , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group. CPR:falsenewlineIt was found that a single intragastric gavage by BC6ENTC resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6OTHER and BC6ENTG , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group. CPR:falsenewlineIt was found that a single intragastric gavage by BC6ENTC resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6OTHER and BC6OTHER , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6ENTG activity compared with the control group. CPR:falsenewlineIt was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6ENTC and decreased the activity of BC6ENTG and BC6OTHER , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group. CPR:falsenewlineIt was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6ENTC and decreased the activity of BC6OTHER and BC6ENTG , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group. CPR:falsenewlineIt was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6ENTC and decreased the activity of BC6OTHER and BC6OTHER , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6ENTG activity compared with the control group. CPR:falsenewlineIt was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6ENTG and BC6OTHER , similarly decreased the level of BC6ENTC in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group. CPR:falsenewlineIt was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6OTHER and BC6ENTG , similarly decreased the level of BC6ENTC in the serum; but had no effects on endothelium - independent relaxation and BC6OTHER - converting enzyme activity compared with the control group. CPR:falsenewlineIt was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6OTHER and BC6OTHER , similarly decreased the level of BC6ENTC in the serum; but had no effects on endothelium - independent relaxation and BC6ENTG activity compared with the control group. CPR:falsenewlineIt was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6ENTG and BC6OTHER , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6ENTC - converting enzyme activity compared with the control group. CPR:falsenewlineIt was found that a single intragastric gavage by BC6OTHER resulted in inhibition of endothelium - dependent relaxation, markedly increased the serum level of BC6OTHER and decreased the activity of BC6OTHER and BC6ENTG , similarly decreased the level of BC6OTHER in the serum; but had no effects on endothelium - independent relaxation and BC6ENTC - converting enzyme activity compared with the control group. CPR:falsenewlineHere, we explored the role of inducible BC6ENTC synthase ( BC6ENTG ) in the BC6OTHER - nitrosation of proteins involved in the early steps of the BC6OTHER - signaling pathway and BC6OTHER resistance in the skeletal muscle of aged mice. CPR:falsenewlineHere, we explored the role of inducible BC6ENTC synthase ( BC6OTHER ) in the BC6OTHER - nitrosation of proteins involved in the early steps of the BC6ENTG - signaling pathway and BC6OTHER resistance in the skeletal muscle of aged mice. CPR:falsenewlineHere, we explored the role of inducible BC6ENTC synthase ( BC6OTHER ) in the BC6OTHER - nitrosation of proteins involved in the early steps of the BC6OTHER - signaling pathway and BC6ENTG resistance in the skeletal muscle of aged mice. CPR:falsenewlineHere, we explored the role of BC6ENTG ( BC6OTHER ) in the BC6ENTC - nitrosation of proteins involved in the early steps of the BC6OTHER - signaling pathway and BC6OTHER resistance in the skeletal muscle of aged mice. CPR:falsenewlineHere, we explored the role of inducible BC6OTHER synthase ( BC6ENTG ) in the BC6ENTC - nitrosation of proteins involved in the early steps of the BC6OTHER - signaling pathway and BC6OTHER resistance in the skeletal muscle of aged mice. CPR:falsenewlineHere, we explored the role of inducible BC6OTHER synthase ( BC6OTHER ) in the BC6ENTC - nitrosation of proteins involved in the early steps of the BC6ENTG - signaling pathway and BC6OTHER resistance in the skeletal muscle of aged mice. CPR:falsenewlineHere, we explored the role of inducible BC6OTHER synthase ( BC6OTHER ) in the BC6ENTC - nitrosation of proteins involved in the early steps of the BC6OTHER - signaling pathway and BC6ENTG resistance in the skeletal muscle of aged mice. CPR:falsenewlineAging increased BC6ENTG expression and BC6ENTC - nitrosation of major proteins involved in BC6OTHER signaling, thereby reducing BC6OTHER sensitivity in skeletal muscle. CPR:falsenewlineAging increased BC6OTHER expression and BC6ENTC - nitrosation of major proteins involved in BC6ENTG signaling, thereby reducing BC6OTHER sensitivity in skeletal muscle. CPR:falsenewlineAging increased BC6OTHER expression and BC6ENTC - nitrosation of major proteins involved in BC6OTHER signaling, thereby reducing BC6ENTG sensitivity in skeletal muscle. CPR:falsenewlineConversely, aged BC6ENTG - null mice were protected from BC6ENTC - nitrosation - induced BC6OTHER resistance. CPR:falsenewlineConversely, aged BC6OTHER - null mice were protected from BC6ENTC - nitrosation - induced BC6ENTG resistance. CPR:falsenewlineMoreover, pharmacological treatment with an BC6ENTG inhibitor and acute exercise reduced BC6OTHER - induced BC6ENTC - nitrosation and increased BC6OTHER sensitivity in the muscle of aged animals. CPR:falsenewlineMoreover, pharmacological treatment with an BC6OTHER inhibitor and acute exercise reduced BC6ENTG - induced BC6ENTC - nitrosation and increased BC6OTHER sensitivity in the muscle of aged animals. CPR:falsenewlineMoreover, pharmacological treatment with an BC6OTHER inhibitor and acute exercise reduced BC6OTHER - induced BC6ENTC - nitrosation and increased BC6ENTG sensitivity in the muscle of aged animals. CPR:falsenewlineThese findings indicate that the BC6ENTG resistance observed in aged mice is mainly mediated through the BC6ENTC - nitrosation of the BC6OTHER - signaling pathway. CPR:falsenewlineThese findings indicate that the BC6OTHER resistance observed in aged mice is mainly mediated through the BC6ENTC - nitrosation of the BC6ENTG - signaling pathway. CPR:falsenewlineTargeted disruption of inducible BC6ENTC synthase protects against aging, BC6OTHER - nitrosation, and BC6ENTG resistance in muscle of male mice. CPR:falsenewlineTargeted disruption of BC6ENTG protects against aging, BC6ENTC - nitrosation, and BC6OTHER resistance in muscle of male mice. CPR:falsenewlineTargeted disruption of inducible BC6OTHER synthase protects against aging, BC6ENTC - nitrosation, and BC6ENTG resistance in muscle of male mice. CPR:falsenewlineThe purpose of this review is to summarize current knowledge about BC6ENTC - dependent activation by BC6OTHER of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6ENTG - dependent genes. CPR:falsenewlineThe purpose of this review is to summarize current knowledge about BC6ENTC - dependent activation by BC6ENTG of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6OTHER - dependent genes. CPR:falsenewlineThe purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6OTHER of genes involved in reverse BC6ENTC transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6ENTG - dependent genes. CPR:falsenewlineThe purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6ENTG of genes involved in reverse BC6ENTC transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6OTHER - dependent genes. CPR:falsenewlineThe purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6OTHER of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6ENTC homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6ENTG - dependent genes. CPR:falsenewlineThe purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6ENTG of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6ENTC homeostasis can teach us about the critical pathways of BC6OTHER generation for expression of BC6OTHER - dependent genes. CPR:falsenewlineThe purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6OTHER of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6ENTC generation for expression of BC6ENTG - dependent genes. CPR:falsenewlineThe purpose of this review is to summarize current knowledge about BC6OTHER - dependent activation by BC6ENTG of genes involved in reverse BC6OTHER transport, and what these defects of cell BC6OTHER homeostasis can teach us about the critical pathways of BC6ENTC generation for expression of BC6OTHER - dependent genes. CPR:falsenewline BC6ENTC generation and BC6ENTG - dependent reverse BC6OTHER transport: not all roads lead to Rome. CPR:falsenewline BC6OTHER generation and BC6ENTG - dependent reverse BC6ENTC transport: not all roads lead to Rome. CPR:falsenewlineCell BC6OTHER metabolism is a tightly regulated process, dependent in part on activation of BC6OTHER ( BC6ENTG ) to increase expression of genes mediating removal of excess BC6ENTC from cells in the reverse BC6OTHER transport pathway. CPR:falsenewlineCell BC6OTHER metabolism is a tightly regulated process, dependent in part on activation of BC6ENTG ( BC6OTHER ) to increase expression of genes mediating removal of excess BC6ENTC from cells in the reverse BC6OTHER transport pathway. CPR:falsenewlineCell BC6OTHER metabolism is a tightly regulated process, dependent in part on activation of BC6OTHER ( BC6ENTG ) to increase expression of genes mediating removal of excess BC6OTHER from cells in the reverse BC6ENTC transport pathway. CPR:falsenewlineCell BC6OTHER metabolism is a tightly regulated process, dependent in part on activation of BC6ENTG ( BC6OTHER ) to increase expression of genes mediating removal of excess BC6OTHER from cells in the reverse BC6ENTC transport pathway. CPR:falsenewlineBC6ENTG are thought to be activated predominantly by BC6ENTC generated enzymatically from BC6OTHER in different cell organelles. CPR:9newlineBC6ENTG are thought to be activated predominantly by BC6OTHER generated enzymatically from BC6ENTC in different cell organelles. CPR:9newlineDefects resulting in slowed release of BC6ENTC from late endosomes and lysosomes or reduction in BC6ENTG activity lead to specific blocks in BC6OTHER production and impaired BC6OTHER - dependent gene activation. CPR:falsenewlineDefects resulting in slowed release of BC6ENTC from late endosomes and lysosomes or reduction in BC6OTHER - 27 - hydroxylase activity lead to specific blocks in BC6OTHER production and impaired BC6ENTG - dependent gene activation. CPR:falsenewlineDefects resulting in slowed release of BC6OTHER from late endosomes and lysosomes or reduction in BC6ENTC - 27 - hydroxylase activity lead to specific blocks in BC6OTHER production and impaired BC6ENTG - dependent gene activation. CPR:falsenewlineCell BC6ENTC metabolism is a tightly regulated process, dependent in part on activation of BC6OTHER ( BC6ENTG ) to increase expression of genes mediating removal of excess BC6OTHER from cells in the reverse BC6OTHER transport pathway. CPR:falsenewlineCell BC6ENTC metabolism is a tightly regulated process, dependent in part on activation of BC6ENTG ( BC6OTHER ) to increase expression of genes mediating removal of excess BC6OTHER from cells in the reverse BC6OTHER transport pathway. CPR:falsenewlineDefects resulting in slowed release of BC6OTHER from late endosomes and lysosomes or reduction in BC6ENTG activity lead to specific blocks in BC6ENTC production and impaired BC6OTHER - dependent gene activation. CPR:falsenewlineDefects resulting in slowed release of BC6OTHER from late endosomes and lysosomes or reduction in BC6OTHER - 27 - hydroxylase activity lead to specific blocks in BC6ENTC production and impaired BC6ENTG - dependent gene activation. CPR:falsenewlineA series of substituted BC6ENTC were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6ENTG transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6OTHER - dependent firefly luciferase reporter construct ( BC6OTHER - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6OTHER assay. CPR:falsenewlineA series of substituted BC6ENTC were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6OTHER transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6ENTG - dependent firefly luciferase reporter construct ( BC6OTHER - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6OTHER assay. CPR:falsenewlineA series of substituted BC6ENTC were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6OTHER transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6OTHER - dependent firefly luciferase reporter construct ( BC6ENTG - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6OTHER assay. CPR:falsenewlineA series of substituted BC6OTHER were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6ENTG transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6OTHER - dependent firefly luciferase reporter construct ( BC6OTHER - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6ENTC assay. CPR:falsenewlineA series of substituted BC6OTHER were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6OTHER transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6ENTG - dependent firefly luciferase reporter construct ( BC6OTHER - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6ENTC assay. CPR:falsenewlineA series of substituted BC6OTHER were synthesized and evaluated for their ability to inhibit hypoxia - induced BC6OTHER transcriptional activity using a cell - based reporter assay in HeLa cells expressing the BC6OTHER - dependent firefly luciferase reporter construct ( BC6ENTG - Luc) and constitutively expressing CMV - driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the BC6ENTC assay. CPR:falsenewlineThe porcine heart BC6ENTC dehydrogenase ( BC6ENTG ) refolding assay revealed that compound 1l inhibited BC6OTHER chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of BC6OTHER (IC(50): 10.9 ± 0.63 μM). CPR:falsenewlineThe porcine heart BC6ENTC dehydrogenase ( BC6OTHER ) refolding assay revealed that compound 1l inhibited BC6ENTG chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of BC6OTHER (IC(50): 10.9 ± 0.63 μM). CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) refolding assay revealed that compound 1l inhibited BC6OTHER chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of BC6ENTC (IC(50): 10.9 ± 0.63 μM). CPR:4newlineThe porcine heart BC6OTHER dehydrogenase ( BC6ENTG ) refolding assay revealed that compound 1l inhibited BC6OTHER chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of BC6ENTC (IC(50): 10.9 ± 0.63 μM). CPR:falsenewlineThe porcine heart BC6OTHER dehydrogenase ( BC6OTHER ) refolding assay revealed that compound 1l inhibited BC6ENTG chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of BC6ENTC (IC(50): 10.9 ± 0.63 μM). CPR:falsenewlineDevelopment of BC6OTHER inhibitors: effect of BC6ENTC substituents on BC6ENTG transcriptional activity under hypoxia. CPR:falsenewlineDevelopment of BC6ENTG inhibitors: effect of BC6ENTC substituents on BC6OTHER transcriptional activity under hypoxia. CPR:falsenewlineThese BC6ENTC , but not CHEM, showed a certain level of inhibition of human - cDNA - expressed BC6ENTG . CPR:4newlineIn a comparison of GLT and grapefruit juice, GLT showed weaker inhibition of BC6ENTG activities and of BC6ENTC 1' - hydroxylation than grapefruit juice. CPR:falsenewlineTherefore, we studied whether GLT had potential for inhibition or induction of BC6ENTG ( BC6OTHER ) and an influence on the action of BC6ENTC . CPR:falsenewlineTherefore, we studied whether GLT had potential for inhibition or induction of BC6OTHER ( BC6ENTG ) and an influence on the action of BC6ENTC . CPR:falsenewlineThe recent identification of BC6ENTC permeability of the lysosomal BC6ENTG BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport. CPR:falsenewlineThe recent identification of BC6ENTC permeability of the lysosomal BC6OTHER BC6ENTG ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport. CPR:falsenewlineThe recent identification of BC6ENTC permeability of the lysosomal BC6OTHER BC6OTHER ( BC6ENTG ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport. CPR:falsenewlineThe recent identification of BC6ENTC permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6ENTG , suggested a role for BC6OTHER in BC6OTHER transport. CPR:falsenewlineThe recent identification of BC6ENTC permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6ENTG in BC6OTHER transport. CPR:falsenewlineThe recent identification of BC6OTHER permeability of the lysosomal BC6ENTG BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6ENTC levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport. CPR:falsenewlineThe recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6ENTG ( BC6OTHER ), and the evidence of abnormal BC6ENTC levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport. CPR:falsenewlineThe recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6ENTG ), and the evidence of abnormal BC6ENTC levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6OTHER transport. CPR:falsenewlineThe recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6ENTC levels in cells deficient in BC6ENTG , suggested a role for BC6OTHER in BC6OTHER transport. CPR:falsenewlineThe recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6ENTC levels in cells deficient in BC6OTHER , suggested a role for BC6ENTG in BC6OTHER transport. CPR:falsenewlineThe recent identification of BC6OTHER permeability of the lysosomal BC6ENTG BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6ENTC transport. CPR:falsenewlineThe recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6ENTG ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6ENTC transport. CPR:falsenewlineThe recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6ENTG ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6OTHER in BC6ENTC transport. CPR:falsenewlineThe recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6ENTG , suggested a role for BC6OTHER in BC6ENTC transport. CPR:falsenewlineThe recent identification of BC6OTHER permeability of the lysosomal BC6OTHER BC6OTHER ( BC6OTHER ), and the evidence of abnormal BC6OTHER levels in cells deficient in BC6OTHER , suggested a role for BC6ENTG in BC6ENTC transport. CPR:falsenewlineIn agreement with the previously published data, an acute siRNA (small interfering RNA) - driven BC6ENTG KD (knockdown) leads to the build - up of large cytoplasmic vesicles positive for LysoTracker™ and BC6ENTC staining, when cells are exposed to high concentrations of BC6OTHER . CPR:falsenewlineIn agreement with the previously published data, an acute siRNA (small interfering RNA) - driven BC6ENTG KD (knockdown) leads to the build - up of large cytoplasmic vesicles positive for LysoTracker™ and BC6OTHER staining, when cells are exposed to high concentrations of BC6ENTC . CPR:falsenewlineWe now show that lysosomal enlargement and BC6ENTC build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6ENTG ) or the BC6OTHER transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6ENTC build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6OTHER ) or the BC6ENTG . CPR:falsenewlineWe now show that lysosomal enlargement and BC6ENTC build - up in BC6ENTG - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6OTHER ) or the BC6OTHER transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6ENTC build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTG BC6OTHER ( BC6OTHER ) or the BC6OTHER transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6ENTC build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6ENTG ( BC6OTHER ) or the BC6OTHER transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6ENTC are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6ENTG ) or the BC6OTHER transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6ENTC are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6OTHER ) or the BC6ENTG . CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6ENTG - KD cells exposed to BC6ENTC are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6OTHER ) or the BC6OTHER transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6ENTC are ameliorated by KD of the BC6ENTG BC6OTHER ( BC6OTHER ) or the BC6OTHER transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6ENTC are ameliorated by KD of the BC6OTHER BC6ENTG ( BC6OTHER ) or the BC6OTHER transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTC - sensitive transcription factor BC6OTHER ( BC6ENTG ) or the BC6OTHER transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTC - sensitive transcription factor BC6OTHER ( BC6OTHER ) or the BC6ENTG . CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6ENTG - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTC - sensitive transcription factor BC6OTHER ( BC6OTHER ) or the BC6OTHER transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTC - sensitive transcription factor BC6ENTG ( BC6OTHER ) or the BC6OTHER transporter CHEM. CPR:falsenewline BC6ENTC - dependent lysosomal enlargement in BC6OTHER - deficient cells involves BC6OTHER transcription factor and BC6ENTG ( BC6OTHER ) transporter. CPR:falsenewline BC6ENTC - dependent lysosomal enlargement in BC6OTHER - deficient cells involves BC6OTHER transcription factor and BC6OTHER ( BC6ENTG ) transporter. CPR:falsenewline BC6ENTC - dependent lysosomal enlargement in BC6ENTG - deficient cells involves BC6OTHER transcription factor and BC6OTHER ( BC6OTHER ) transporter. CPR:falsenewline BC6ENTC - dependent lysosomal enlargement in BC6OTHER - deficient cells involves BC6ENTG transcription factor and BC6OTHER ( BC6OTHER ) transporter. CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6ENTG ) or the BC6ENTC transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6ENTG - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6OTHER ( BC6OTHER ) or the BC6ENTC transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6ENTG BC6OTHER ( BC6OTHER ) or the BC6ENTC transporter CHEM. CPR:falsenewlineWe now show that lysosomal enlargement and BC6OTHER build - up in BC6OTHER - KD cells exposed to BC6OTHER are ameliorated by KD of the BC6OTHER BC6ENTG ( BC6OTHER ) or the BC6ENTC transporter CHEM. CPR:falsenewlineBC6ENTG KD is associated with a build - up of cytoplasmic BC6ENTC and with enhanced transcriptional response of mRNA for BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER KD is associated with a build - up of cytoplasmic BC6ENTC and with enhanced transcriptional response of mRNA for BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER KD is associated with a build - up of cytoplasmic BC6ENTC and with enhanced transcriptional response of mRNA for BC6OTHER ( BC6ENTG ). CPR:falsenewlineCellular BC6ENTC is controlled by BC6ENTG and by BC6OTHER transporters. CPR:falsenewlineCellular BC6ENTC is controlled by BC6OTHER - chelating proteins and by BC6ENTG . CPR:falsenewlineBC6ENTG KD did not suppress lysosomal secretion, but it did delay BC6ENTC leak from the lysosomes into the cytoplasm. CPR:falsenewlineThese results underscore a role for BC6ENTG in BC6ENTC metabolism. CPR:9newlineFurthermore, they suggest that BC6ENTG works in concert with BC6OTHER to regulate BC6ENTC translocation between the cytoplasm and lysosomes. CPR:falsenewlineFurthermore, they suggest that BC6OTHER works in concert with BC6ENTG to regulate BC6ENTC translocation between the cytoplasm and lysosomes. CPR:falsenewlineCellular BC6OTHER is controlled by BC6ENTC - chelating proteins and by BC6ENTG . CPR:falsenewlineCellular BC6OTHER is controlled by BC6ENTG and by BC6ENTC transporters. CPR:falsenewlineAirway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6ENTC and BC6OTHER (HE) staining, Th1 / Th2 and Th17 BC6ENTG were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6OTHER ( BC6OTHER ) was evaluated by western blotting. CPR:falsenewlineAirway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6ENTC and BC6OTHER (HE) staining, Th1 / Th2 and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6ENTG ( BC6OTHER ) was evaluated by western blotting. CPR:falsenewlineAirway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6ENTC and BC6OTHER (HE) staining, Th1 / Th2 and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6OTHER ( BC6ENTG ) was evaluated by western blotting. CPR:falsenewlineAirway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6OTHER and BC6ENTC (HE) staining, Th1 / Th2 and Th17 BC6ENTG were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6OTHER ( BC6OTHER ) was evaluated by western blotting. CPR:falsenewlineAirway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6OTHER and BC6ENTC (HE) staining, Th1 / Th2 and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6ENTG ( BC6OTHER ) was evaluated by western blotting. CPR:falsenewlineAirway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The BC6OTHER and BC6ENTC (HE) staining, Th1 / Th2 and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the BC6OTHER ( BC6ENTG ) was evaluated by western blotting. CPR:falsenewlineImmunoregulatory effects of BC6ENTC exerts anti - asthmatic effects via modulation of Th1 / Th2 BC6ENTG and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in BC6OTHER - sensitized mice. CPR:falsenewlineImmunoregulatory effects of BC6ENTC exerts anti - asthmatic effects via modulation of Th1 / Th2 BC6OTHER and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in BC6ENTG - sensitized mice. CPR:falsenewlineOf these, the BC6ENTG inhibitor BC6ENTC and BC6OTHER inhibitor BC6OTHER have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe. CPR:falsenewlineOf these, the BC6OTHER inhibitor BC6ENTC and BC6ENTG inhibitor BC6OTHER have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe. CPR:falsenewlineOf these, the BC6ENTG inhibitor BC6OTHER and BC6OTHER inhibitor BC6ENTC have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe. CPR:falsenewlineOf these, the BC6OTHER inhibitor BC6OTHER and BC6ENTG inhibitor BC6ENTC have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe. CPR:falsenewlineIn addition, the BC6ENTG inhibitor BC6ENTC is in late - stage clinical development. CPR:4newlineHowever, alterations of BC6ENTC and BC6OTHER pharmacokinetics upon interactions with inhibitors and inducers of BC6ENTG or BC6OTHER may complicate the use of these compounds in daily practice, whereas BC6OTHER elimination largely depends on renal function. CPR:falsenewlineHowever, alterations of BC6ENTC and BC6OTHER pharmacokinetics upon interactions with inhibitors and inducers of BC6OTHER or BC6ENTG may complicate the use of these compounds in daily practice, whereas BC6OTHER elimination largely depends on renal function. CPR:falsenewlineHowever, alterations of BC6OTHER and BC6ENTC pharmacokinetics upon interactions with inhibitors and inducers of BC6ENTG or BC6OTHER may complicate the use of these compounds in daily practice, whereas BC6OTHER elimination largely depends on renal function. CPR:falsenewlineHowever, alterations of BC6OTHER and BC6ENTC pharmacokinetics upon interactions with inhibitors and inducers of BC6OTHER or BC6ENTG may complicate the use of these compounds in daily practice, whereas BC6OTHER elimination largely depends on renal function. CPR:falsenewlineHowever, alterations of BC6OTHER and BC6OTHER pharmacokinetics upon interactions with inhibitors and inducers of BC6ENTG or BC6OTHER may complicate the use of these compounds in daily practice, whereas BC6ENTC elimination largely depends on renal function. CPR:falsenewlineHowever, alterations of BC6OTHER and BC6OTHER pharmacokinetics upon interactions with inhibitors and inducers of BC6OTHER or BC6ENTG may complicate the use of these compounds in daily practice, whereas BC6ENTC elimination largely depends on renal function. CPR:falsenewlineCompared to control BC6ENTG , ABLP BC6OTHER showed a 40% decrease of BC6ENTC and an 11 - fold increased BC6OTHER concentration. CPR:falsenewlineCompared to control BC6OTHER , ABLP BC6ENTG showed a 40% decrease of BC6ENTC and an 11 - fold increased BC6OTHER concentration. CPR:falsenewlineCompared to control BC6ENTG , ABLP BC6OTHER showed a 40% decrease of BC6OTHER and an 11 - fold increased BC6ENTC concentration. CPR:falsenewlineCompared to control BC6OTHER , ABLP BC6ENTG showed a 40% decrease of BC6OTHER and an 11 - fold increased BC6ENTC concentration. CPR:falsenewlineThe test procedure was verified with respect to intestinal BC6ENTC hydrolysis by demonstrating a linear relationship between BC6OTHER / BC6OTHER excretion and log jejunal mucosal BC6ENTG activity by in vitro assay (R2 = 0.95) in a further group of subjects. CPR:9newlineThe test procedure was verified with respect to intestinal BC6OTHER hydrolysis by demonstrating a linear relationship between BC6ENTC / BC6OTHER excretion and log jejunal mucosal BC6ENTG activity by in vitro assay (R2 = 0.95) in a further group of subjects. CPR:9newlineThe test procedure was verified with respect to intestinal BC6OTHER hydrolysis by demonstrating a linear relationship between BC6OTHER / BC6ENTC excretion and log jejunal mucosal BC6ENTG activity by in vitro assay (R2 = 0.95) in a further group of subjects. CPR:9newlineDifferential BC6ENTC / BC6OTHER / BC6OTHER absorption provides a non - invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal BC6ENTG deficiency. CPR:falsenewlineDifferential BC6OTHER / BC6ENTC / BC6OTHER absorption provides a non - invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal BC6ENTG deficiency. CPR:falsenewlineDifferential BC6OTHER / BC6OTHER / BC6ENTC absorption provides a non - invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal BC6ENTG deficiency. CPR:falsenewlineIn addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL( - 1) BC6ENTC showed a higher BC6ENTG activity than controls. CPR:falsenewlineChronic exposure to BC6ENTC provoked then structural changes but also functional changes in the capacity of biofilm BC6ENTG activity to respond to a sudden increase in concentration, suggesting a selection of species with higher antioxidant capacity. CPR:falsenewlineUnder control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTC peroxidase ( BC6ENTG ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6OTHER reductase ( BC6OTHER ) activities during the slow growth phase. CPR:falsenewlineUnder control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTC peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6ENTG ( BC6OTHER ) and BC6OTHER reductase ( BC6OTHER ) activities during the slow growth phase. CPR:falsenewlineUnder control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTC peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6ENTG ) and BC6OTHER reductase ( BC6OTHER ) activities during the slow growth phase. CPR:falsenewlineUnder control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTC peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities during the slow growth phase. CPR:falsenewlineUnder control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTC peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6OTHER reductase ( BC6ENTG ) activities during the slow growth phase. CPR:falsenewlineUnder control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6ENTG ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6ENTC reductase ( BC6OTHER ) activities during the slow growth phase. CPR:falsenewlineUnder control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6OTHER peroxidase ( BC6ENTG ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6ENTC reductase ( BC6OTHER ) activities during the slow growth phase. CPR:falsenewlineUnder control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6OTHER peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6ENTG ( BC6OTHER ) and BC6ENTC reductase ( BC6OTHER ) activities during the slow growth phase. CPR:falsenewlineUnder control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6OTHER peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6ENTG ) and BC6ENTC reductase ( BC6OTHER ) activities during the slow growth phase. CPR:falsenewlineUnder control conditions, the AEA of biofilms were found to change throughout time with a significant increase in BC6OTHER peroxidase ( BC6OTHER ) activity during the exponential growth and a more important role of BC6OTHER ( BC6OTHER ) and BC6ENTC reductase ( BC6ENTG ) activities during the slow growth phase. CPR:falsenewlineThe main molecular target of BC6ENTC antifungals is the BC6ENTG protein BC6OTHER / BC6OTHER . CPR:falsenewlineThe main molecular target of BC6ENTC antifungals is the BC6OTHER protein BC6ENTG / BC6OTHER . CPR:falsenewlineThe main molecular target of BC6ENTC antifungals is the BC6OTHER protein BC6OTHER / BC6ENTG . CPR:falsenewlineThe BC6ENTC , of which BC6OTHER is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe BC6ENTC , of which BC6OTHER is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe BC6ENTC , of which BC6OTHER is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe BC6ENTC , of which BC6OTHER is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe BC6OTHER , of which BC6ENTC is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe BC6OTHER , of which BC6ENTC is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ). CPR:falsenewlineThe BC6OTHER , of which BC6ENTC is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe BC6OTHER , of which BC6ENTC is the sole representative in human therapy, affect two targets in the CHEM pathway: BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe BC6ENTC group are protein synthesis inhibitors that work by blocking the function of BC6ENTG . CPR:falsenewlineOur results suggest that modification of multiple BC6ENTC residues by electrophilic compounds can generate both activation and desensitization of the BC6ENTG channel. CPR:falsenewlineElectrophilic chemicals activate both insect and vertebrate BC6ENTG via covalent modification of BC6ENTC residues in the BC6OTHER - terminal region. CPR:falsenewlineElectrophilic chemicals activate both insect and vertebrate BC6ENTG via covalent modification of BC6OTHER residues in the BC6ENTC - terminal region. CPR:falsenewlineAlthough naturally occurring electrophilic plant compounds, such as mustard oil and BC6ENTC , are BC6ENTG agonists, it is unknown whether arthropod - produced electrophiles activate BC6OTHER . CPR:falsenewlineAlthough naturally occurring electrophilic plant compounds, such as mustard oil and BC6ENTC , are BC6OTHER agonists, it is unknown whether arthropod - produced electrophiles activate BC6ENTG . CPR:falsenewlineWe characterized the effects of the electrophilic arthropod defensive compound BC6ENTC ( BC6OTHER ) on the BC6ENTG channel. CPR:falsenewlineWe characterized the effects of the electrophilic arthropod defensive compound BC6OTHER ( BC6ENTC ) on the BC6ENTG channel. CPR:falsenewlineWe used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6ENTG or BC6OTHER with three BC6ENTC - substituted BC6OTHER crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6OTHER ). CPR:falsenewlineWe used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6ENTG with three BC6ENTC - substituted BC6OTHER crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6OTHER ). CPR:falsenewlineWe used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6ENTC - substituted BC6OTHER crucial for electrophile activation ( BC6ENTG , BC6OTHER , BC6OTHER ). CPR:falsenewlineWe used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6ENTC - substituted BC6OTHER crucial for electrophile activation ( BC6OTHER , BC6ENTG , BC6OTHER ). CPR:falsenewlineWe used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6ENTC - substituted BC6OTHER crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6ENTG ). CPR:falsenewlineWe used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6ENTG or BC6OTHER with three BC6OTHER - substituted BC6ENTC crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6OTHER ). CPR:falsenewlineWe used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6ENTG with three BC6OTHER - substituted BC6ENTC crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6OTHER ). CPR:falsenewlineWe used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6OTHER - substituted BC6ENTC crucial for electrophile activation ( BC6ENTG , BC6OTHER , BC6OTHER ). CPR:falsenewlineWe used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6OTHER - substituted BC6ENTC crucial for electrophile activation ( BC6OTHER , BC6ENTG , BC6OTHER ). CPR:falsenewlineWe used whole - cell recordings of human embryonic kidney cells heterologously expressing either wild - type BC6OTHER or BC6OTHER with three BC6OTHER - substituted BC6ENTC crucial for electrophile activation ( BC6OTHER , BC6OTHER , BC6ENTG ). CPR:falsenewlineWe found that BC6ENTC activates BC6ENTG starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline. CPR:falsenewline BC6ENTC Reveals a BC6OTHER - Dependent Desensitization Mechanism of BC6ENTG . CPR:falsenewline BC6OTHER Reveals a BC6ENTC - Dependent Desensitization Mechanism of BC6ENTG . CPR:falsenewlineThe current reduction we found at higher BC6ENTC concentrations was a CHEM - dependent desensitization of BC6ENTG , and did not require prior activation. CPR:falsenewlineInterestingly, following BC6ENTC desensitization, wild - type BC6ENTG had dramatically reduced response to the nonelectrophile agonist BC6OTHER , whereas the triple BC6OTHER mutant BC6OTHER retained its full response. CPR:falsenewlineInterestingly, following BC6ENTC desensitization, wild - type BC6OTHER had dramatically reduced response to the nonelectrophile agonist BC6OTHER , whereas the triple BC6OTHER mutant BC6ENTG retained its full response. CPR:falsenewlineInterestingly, following BC6OTHER desensitization, wild - type BC6ENTG had dramatically reduced response to the nonelectrophile agonist BC6ENTC , whereas the triple BC6OTHER mutant BC6OTHER retained its full response. CPR:falsenewlineInterestingly, following BC6OTHER desensitization, wild - type BC6OTHER had dramatically reduced response to the nonelectrophile agonist BC6ENTC , whereas the triple BC6OTHER mutant BC6ENTG retained its full response. CPR:falsenewlineInterestingly, following BC6OTHER desensitization, wild - type BC6ENTG had dramatically reduced response to the nonelectrophile agonist BC6OTHER , whereas the triple BC6ENTC mutant BC6OTHER retained its full response. CPR:falsenewlineInterestingly, following BC6OTHER desensitization, wild - type BC6OTHER had dramatically reduced response to the nonelectrophile agonist BC6OTHER , whereas the triple BC6ENTC mutant BC6ENTG retained its full response. CPR:falsenewlinefor 15 days or along with a BC6ENTG agonist BC6ENTC ( BC6OTHER ; 30 μg / 100 g BW, oral) and were found to improve in the BC6OTHER co - treated condition. CPR:falsenewlinefor 15 days or along with a BC6ENTG agonist BC6OTHER ( BC6ENTC ; 30 μg / 100 g BW, oral) and were found to improve in the BC6OTHER co - treated condition. CPR:falsenewlinefor 15 days or along with a BC6ENTG agonist BC6OTHER ( BC6OTHER ; 30 μg / 100 g BW, oral) and were found to improve in the BC6ENTC co - treated condition. CPR:falsenewlineHyperthyroidism - induced oxidative stress, reduction in BC6ENTG activity, and myocardial BC6ENTC concentration were also significantly checked by BC6OTHER . CPR:falsenewlineHyperthyroidism - induced oxidative stress, reduction in BC6ENTG activity, and myocardial BC6OTHER concentration were also significantly checked by BC6ENTC . CPR:falsenewlineOverexpression of BC6ENTG ( BC6OTHER ) is also caused by the mammalian target of BC6ENTC ( BC6OTHER ), a key component of signaling pathways inside the cell, involved in cell proliferation. CPR:falsenewlineOverexpression of BC6OTHER ( BC6ENTG ) is also caused by the mammalian target of BC6ENTC ( BC6OTHER ), a key component of signaling pathways inside the cell, involved in cell proliferation. CPR:falsenewlineOverexpression of BC6OTHER ( BC6OTHER ) is also caused by the mammalian target of BC6ENTC ( BC6ENTG ), a key component of signaling pathways inside the cell, involved in cell proliferation. CPR:falsenewline BC6ENTC , BC6OTHER and BC6ENTG inhibitors in renal cancer. CPR:falsenewline BC6OTHER , BC6ENTC and BC6ENTG inhibitors in renal cancer. CPR:falsenewlineBC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor. CPR:4newlineBC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor. CPR:falsenewlineBC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor. CPR:falsenewlineBC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor. CPR:4newlineBC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG ), while BC6OTHER is an BC6OTHER inhibitor. CPR:falsenewlineBC6ENTC and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6ENTG inhibitor. CPR:falsenewlineBC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor. CPR:4newlineBC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor. CPR:falsenewlineBC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor. CPR:falsenewlineBC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ), while BC6OTHER is an BC6OTHER inhibitor. CPR:4newlineBC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG ), while BC6OTHER is an BC6OTHER inhibitor. CPR:falsenewlineBC6OTHER and BC6ENTC are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6OTHER is an BC6ENTG inhibitor. CPR:falsenewlineBC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6ENTC is an BC6OTHER inhibitor. CPR:falsenewlineBC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6ENTC is an BC6OTHER inhibitor. CPR:falsenewlineBC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER ), while BC6ENTC is an BC6OTHER inhibitor. CPR:falsenewlineBC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ), while BC6ENTC is an BC6OTHER inhibitor. CPR:falsenewlineBC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG ), while BC6ENTC is an BC6OTHER inhibitor. CPR:falsenewlineBC6OTHER and BC6OTHER are synthetic, orally active agents shown to directly inhibit BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ), while BC6ENTC is an BC6ENTG inhibitor. CPR:falsenewlineBC6ENTG is unusual due to its 11 - BC6ENTC bulge. CPR:falsenewlineThe simulations indicate that the long bulge is a stalk - specific eight - BC6ENTC insertion into consensual BC6ENTG only subtly modifying its structural dynamics. CPR:falsenewlineStill, even bsc0χOL3 is unable to fully stabilize an essential BC6ENTC - edge BC6OTHER - bond between the bulge and non - canonical stem of the BC6ENTG . CPR:falsenewlineStill, even bsc0χOL3 is unable to fully stabilize an essential BC6OTHER - edge BC6ENTC - bond between the bulge and non - canonical stem of the BC6ENTG . CPR:falsenewlineThe available X - ray structures contain only BC6ENTG BC6OTHER which in addition differ in orientation (anti vs syn) of the BC6ENTC . CPR:falsenewlineThe available X - ray structures contain only BC6OTHER BC6ENTG which in addition differ in orientation (anti vs syn) of the BC6ENTC . CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6ENTG [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6ENTG [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6ENTG [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6ENTG [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6ENTG [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6ENTG [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6ENTG [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6ENTG [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6ENTG [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6ENTG [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTG [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6ENTG [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6ENTG [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6ENTG [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTG [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6ENTG [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6ENTG [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTC receptors ( BC6OTHER [8.6], BC6ENTG [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6ENTG [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6ENTG [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6ENTG [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6ENTG [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6ENTG [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6ENTG [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6ENTG [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6ENTG [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6ENTG [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6ENTG [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6ENTG [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6ENTG [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6ENTG [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTG [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6ENTG [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTG ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6ENTG [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6ENTG [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTC receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6OTHER receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6ENTG [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6ENTG [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6ENTG [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6ENTG [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6ENTG [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6ENTG [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6ENTG [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6ENTG [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6ENTG [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6ENTG [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6ENTG [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6ENTG [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6ENTG [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6ENTG [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6ENTG [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6ENTG ( BC6OTHER [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6ENTG [8.6], BC6OTHER [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineIn comparison with the antipsychotics, CHEM showed high affinity and a different rank order of binding affinities (pKi) for BC6OTHER ( BC6OTHER [8.6], BC6ENTG [8.4], BC6OTHER [10.2], BC6OTHER [9.8], BC6OTHER [10.5], BC6OTHER [8.8], BC6OTHER [9.6] and BC6OTHER [9.9]), BC6OTHER [8.9], BC6OTHER [8.9], BC6OTHER [9.5] and BC6OTHER [8.9]), BC6OTHER receptors (D1 [8.9], BC6OTHER [8.9], BC6OTHER [9.4] and BC6OTHER [9.0]) and BC6ENTC receptors (H1 [9.0] and BC6OTHER [8.2]). CPR:falsenewlineThese results are consistent with the interpretation that both BC6OTHER and BC6OTHER inhibit BC6OTHER formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of BC6ENTC in the BC6ENTG reaction. CPR:9newlineSimilar concentrations also inhibited the formation of BC6ENTC ( BC6OTHER ) by BC6ENTG , a detergent - solubilized cell free particulate enzyme from RBL cells which is capable of coupling BC6OTHER to BC6OTHER . CPR:9newlineSimilar concentrations also inhibited the formation of BC6OTHER ( BC6ENTC ) by BC6ENTG , a detergent - solubilized cell free particulate enzyme from RBL cells which is capable of coupling BC6OTHER to BC6OTHER . CPR:9newlineSimilar concentrations also inhibited the formation of BC6OTHER ( BC6OTHER ) by BC6ENTG , a detergent - solubilized cell free particulate enzyme from RBL cells which is capable of coupling BC6ENTC to BC6OTHER . CPR:9newlineSimilar concentrations also inhibited the formation of BC6OTHER ( BC6OTHER ) by BC6ENTG , a detergent - solubilized cell free particulate enzyme from RBL cells which is capable of coupling BC6OTHER to BC6ENTC . CPR:falsenewlineThe EC50 for inhibition of the BC6ENTG of RBL cells was directly proportional to the BC6ENTC concentration in the incubations, ranging from 1.5 mM at 10 microM BC6OTHER to over 40 mM at 500 microM BC6OTHER . CPR:falsenewlineThe EC50 for inhibition of the BC6ENTG of RBL cells was directly proportional to the BC6OTHER concentration in the incubations, ranging from 1.5 mM at 10 microM BC6ENTC to over 40 mM at 500 microM BC6OTHER . CPR:falsenewlineThe EC50 for inhibition of the BC6ENTG of RBL cells was directly proportional to the BC6OTHER concentration in the incubations, ranging from 1.5 mM at 10 microM BC6OTHER to over 40 mM at 500 microM BC6ENTC . CPR:falsenewlineKinetic analysis revealed that the inhibition of the BC6ENTG reaction by BC6ENTC was competitive with respect to BC6OTHER . CPR:4newlineKinetic analysis revealed that the inhibition of the BC6ENTG reaction by BC6OTHER was competitive with respect to BC6ENTC . CPR:4newlineIn contrast to BC6ENTC , BC6OTHER ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6OTHER synthetase of these cells. CPR:falsenewlineIn contrast to BC6ENTC , BC6OTHER ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6OTHER step (EC50 5 microM), did not inhibit the BC6ENTG of these cells. CPR:falsenewlineIn contrast to BC6OTHER , BC6ENTC ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6OTHER synthetase of these cells. CPR:4newlineIn contrast to BC6OTHER , BC6ENTC ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6OTHER step (EC50 5 microM), did not inhibit the BC6ENTG of these cells. CPR:falsenewlineIn contrast to BC6OTHER , BC6OTHER ( BC6ENTC ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6OTHER synthetase of these cells. CPR:4newlineIn contrast to BC6OTHER , BC6OTHER ( BC6ENTC ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6OTHER step (EC50 5 microM), did not inhibit the BC6ENTG of these cells. CPR:falsenewlineIn contrast to BC6OTHER , BC6OTHER ( BC6OTHER ; BC6ENTC ), which inhibits the formation of BC6OTHER in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6OTHER synthetase of these cells. CPR:4newlineIn contrast to BC6OTHER , BC6OTHER ( BC6OTHER ; BC6ENTC ), which inhibits the formation of BC6OTHER in RBL cells at the BC6OTHER step (EC50 5 microM), did not inhibit the BC6ENTG of these cells. CPR:falsenewlineIn contrast to BC6OTHER , BC6OTHER ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6ENTC in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6OTHER synthetase of these cells. CPR:falsenewlineIn contrast to BC6OTHER , BC6OTHER ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6ENTC in RBL cells at the BC6OTHER step (EC50 5 microM), did not inhibit the BC6ENTG of these cells. CPR:falsenewlineInhibition of the BC6OTHER of rat basophil leukemia cells by BC6OTHER , and synergism between BC6ENTC and BC6OTHER , a BC6ENTG inhibitor. CPR:falsenewlineInhibition of the BC6ENTG of rat basophil leukemia cells by BC6OTHER , and synergism between BC6ENTC and BC6OTHER , a BC6OTHER inhibitor. CPR:falsenewlineInhibition of the BC6OTHER of rat basophil leukemia cells by BC6OTHER , and synergism between BC6OTHER and BC6ENTC , a BC6ENTG inhibitor. CPR:falsenewlineInhibition of the BC6ENTG of rat basophil leukemia cells by BC6OTHER , and synergism between BC6OTHER and BC6ENTC , a BC6OTHER inhibitor. CPR:4newlineInhibition of the BC6ENTC synthetase of rat basophil leukemia cells by BC6OTHER , and synergism between BC6OTHER and BC6OTHER , a BC6ENTG inhibitor. CPR:falsenewlineInhibition of the BC6OTHER of rat basophil leukemia cells by BC6ENTC , and synergism between BC6OTHER and BC6OTHER , a BC6ENTG inhibitor. CPR:falsenewlineInhibition of the BC6ENTG of rat basophil leukemia cells by BC6ENTC , and synergism between BC6OTHER and BC6OTHER , a BC6OTHER inhibitor. CPR:4newlineIn contrast to BC6OTHER , BC6OTHER ( BC6OTHER ; BC6OTHER ), which inhibits the formation of BC6OTHER in RBL cells at the BC6ENTG step (EC50 5 microM), did not inhibit the BC6ENTC synthetase of these cells. CPR:falsenewlineThese results are consistent with the interpretation that both BC6ENTC and BC6OTHER inhibit BC6OTHER formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of BC6OTHER in the BC6ENTG reaction. CPR:falsenewlineThese results are consistent with the interpretation that both BC6OTHER and BC6ENTC inhibit BC6OTHER formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of BC6OTHER in the BC6ENTG reaction. CPR:falsenewlineThese results are consistent with the interpretation that both BC6OTHER and BC6OTHER inhibit BC6ENTC formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of BC6OTHER in the BC6ENTG reaction. CPR:falsenewlineHere we show that BC6ENTG and BC6OTHER cooperatively repress BC6ENTC receptor - dependent activity of BC6OTHER - class endogenous retroviruses (ERVs) in liver. CPR:falsenewlineHere we show that BC6OTHER and BC6ENTG cooperatively repress BC6ENTC receptor - dependent activity of BC6OTHER - class endogenous retroviruses (ERVs) in liver. CPR:falsenewlineHere we show that BC6OTHER and BC6OTHER cooperatively repress BC6ENTC receptor - dependent activity of BC6ENTG - class endogenous retroviruses (ERVs) in liver. CPR:falsenewlineSimilar to the BC6ENTG , BC6OTHER is activated only by the naturally occurring BC6ENTC isomer of PS and not the BC6OTHER stereoisomer. CPR:falsenewlineSimilar to the plasma membrane BC6OTHER transporter, BC6ENTG is activated only by the naturally occurring BC6ENTC isomer of PS and not the BC6OTHER stereoisomer. CPR:falsenewlineSimilar to the BC6ENTG , BC6OTHER is activated only by the naturally occurring BC6OTHER isomer of PS and not the BC6ENTC stereoisomer. CPR:falsenewlineSimilar to the plasma membrane BC6OTHER transporter, BC6ENTG is activated only by the naturally occurring BC6OTHER isomer of PS and not the BC6ENTC stereoisomer. CPR:falsenewlineMost modifications of the BC6ENTC headgroup structure decrease recognition by the plasma membrane BC6ENTG . CPR:falsenewlineActivation of BC6ENTG is also reduced by these modifications; BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6OTHER . CPR:falsenewlineActivation of BC6OTHER is also reduced by these modifications; BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6ENTG . CPR:falsenewlineActivation of BC6ENTG is also reduced by these modifications; BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6OTHER . CPR:falsenewlineActivation of BC6OTHER is also reduced by these modifications; BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6ENTG . CPR:falsenewlineActivation of BC6ENTG is also reduced by these modifications; BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6OTHER . CPR:falsenewlineActivation of BC6OTHER is also reduced by these modifications; BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , which are not transported by the plasma membrane flippase, do not activate BC6ENTG . CPR:falsenewlineActivation of BC6ENTG is also reduced by these modifications; BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , which are not transported by the plasma membrane flippase, do not activate BC6OTHER . CPR:falsenewlineActivation of BC6OTHER is also reduced by these modifications; BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , which are not transported by the plasma membrane flippase, do not activate BC6ENTG . CPR:falsenewlineWeakly translocated lipids ( BC6ENTC , BC6OTHER , and BC6OTHER ) are also weak BC6ENTG activators. CPR:falsenewlineThe purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6ENTC , BC6OTHER , or BC6OTHER , is minimally activated by BC6OTHER or BC6OTHER ( BC6OTHER ), and is maximally activated by BC6OTHER . CPR:falsenewlineWeakly translocated lipids ( BC6OTHER , BC6ENTC , and BC6OTHER ) are also weak BC6ENTG activators. CPR:falsenewlineWeakly translocated lipids ( BC6OTHER , BC6OTHER , and BC6ENTC ) are also weak BC6ENTG activators. CPR:falsenewlineHowever, BC6ENTC , which is transported by the plasma membrane BC6ENTG at a rate equivalent to BC6OTHER , is incapable of activating BC6OTHER activity. CPR:falsenewlineHowever, BC6ENTC , which is transported by the plasma membrane BC6OTHER at a rate equivalent to BC6OTHER , is incapable of activating BC6ENTG activity. CPR:falsenewlineHowever, BC6OTHER , which is transported by the plasma membrane BC6ENTG at a rate equivalent to BC6ENTC , is incapable of activating BC6OTHER activity. CPR:falsenewlineHowever, BC6OTHER , which is transported by the plasma membrane BC6OTHER at a rate equivalent to BC6ENTC , is incapable of activating BC6ENTG activity. CPR:falsenewlineThis aminophospholipid " BC6ENTG " selectively transports BC6ENTC to the cytosolic leaflet of the bilayer and is sensitive to BC6OTHER , BC6OTHER , and modification by BC6OTHER reagents. CPR:9newlineThese results indicate that the BC6ENTG activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6ENTC selectivity, dependence upon BC6OTHER but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER . CPR:falsenewlineThese results indicate that the BC6OTHER activity of the secretory granule BC6ENTG is activated by phospholipids binding to a specific site whose properties ( BC6ENTC selectivity, dependence upon BC6OTHER but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER . CPR:falsenewlineThese results indicate that the BC6OTHER activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6ENTC selectivity, dependence upon BC6OTHER but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6ENTG . CPR:falsenewlineThese results indicate that the BC6ENTG activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6ENTC but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER . CPR:falsenewlineThese results indicate that the BC6OTHER activity of the secretory granule BC6ENTG is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6ENTC but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER . CPR:falsenewlineThese results indicate that the BC6OTHER activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6ENTC but not BC6OTHER , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6ENTG . CPR:falsenewlineThese results indicate that the BC6ENTG activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6OTHER but not BC6ENTC , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER . CPR:falsenewlineThese results indicate that the BC6OTHER activity of the secretory granule BC6ENTG is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6OTHER but not BC6ENTC , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6OTHER . CPR:falsenewlineThese results indicate that the BC6OTHER activity of the secretory granule BC6OTHER is activated by phospholipids binding to a specific site whose properties ( BC6OTHER selectivity, dependence upon BC6OTHER but not BC6ENTC , stereochemistry, and CHEM sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane BC6ENTG . CPR:falsenewlineThis aminophospholipid " BC6ENTG " selectively transports BC6OTHER to the cytosolic leaflet of the bilayer and is sensitive to BC6ENTC , BC6OTHER , and modification by BC6OTHER reagents. CPR:falsenewlineThis aminophospholipid " BC6ENTG " selectively transports BC6OTHER to the cytosolic leaflet of the bilayer and is sensitive to BC6OTHER , BC6ENTC , and modification by BC6OTHER reagents. CPR:falsenewlineThe purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6ENTC , or BC6OTHER , is minimally activated by BC6OTHER or BC6OTHER ( BC6OTHER ), and is maximally activated by BC6OTHER . CPR:falsenewlineThis aminophospholipid " BC6ENTG " selectively transports BC6OTHER to the cytosolic leaflet of the bilayer and is sensitive to BC6OTHER , BC6OTHER , and modification by BC6ENTC reagents. CPR:falsenewlineA candidate BC6ENTC flippase ATP8A1 ( BC6ENTG ), originally isolated from bovine secretory vesicles, is a member of this subfamily based on sequence homology to the founding member of the subfamily, the BC6OTHER , which has been linked to ribosomal assembly, the formation of Golgi - coated vesicles, and the maintenance of PS asymmetry. CPR:falsenewlineA candidate BC6ENTC flippase ATP8A1 ( BC6OTHER ), originally isolated from bovine secretory vesicles, is a member of this subfamily based on sequence homology to the founding member of the subfamily, the BC6ENTG , which has been linked to ribosomal assembly, the formation of Golgi - coated vesicles, and the maintenance of PS asymmetry. CPR:falsenewlineTo determine if BC6ENTG has biochemical characteristics consistent with a BC6ENTC flippase, a murine homologue of this enzyme was expressed in insect cells and purified. CPR:falsenewlineThe purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6OTHER , or BC6ENTC , is minimally activated by BC6OTHER or BC6OTHER ( BC6OTHER ), and is maximally activated by BC6OTHER . CPR:falsenewlineThe purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6OTHER , or BC6OTHER , is minimally activated by BC6ENTC or BC6OTHER ( BC6OTHER ), and is maximally activated by BC6OTHER . CPR:falsenewlineThe purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6OTHER , or BC6OTHER , is minimally activated by BC6OTHER or BC6ENTC ( BC6OTHER ), and is maximally activated by BC6OTHER . CPR:falsenewlineThe purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6OTHER , or BC6OTHER , is minimally activated by BC6OTHER or BC6OTHER ( BC6ENTC ), and is maximally activated by BC6OTHER . CPR:falsenewlineThe purified BC6ENTG is inactive in detergent micelles or in micelles containing BC6OTHER , BC6OTHER , or BC6OTHER , is minimally activated by BC6OTHER or BC6OTHER ( BC6OTHER ), and is maximally activated by BC6ENTC . CPR:falsenewlineSimilar to the plasma membrane BC6ENTC transporter, BC6ENTG is activated only by the naturally occurring BC6OTHER isomer of PS and not the BC6OTHER stereoisomer. CPR:falsenewlineIn another experiment, topical application of CFB, CFE or BC6ENTC prior to UVB irradiation (200mJ / cm(2)) on BALB / c mice, inhibited the UVB - elevated protein levels of BC6ENTG , BC6OTHER , and BC6OTHER . CPR:falsenewlineIn another experiment, topical application of CFB, CFE or BC6ENTC prior to UVB irradiation (200mJ / cm(2)) on BALB / c mice, inhibited the UVB - elevated protein levels of BC6OTHER , BC6ENTG , and BC6OTHER . CPR:falsenewlineIn another experiment, topical application of CFB, CFE or BC6ENTC prior to UVB irradiation (200mJ / cm(2)) on BALB / c mice, inhibited the UVB - elevated protein levels of BC6OTHER , BC6OTHER , and BC6ENTG . CPR:falsenewlineIn HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6ENTC and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6ENTC fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6ENTC C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6ENTC ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6ENTC ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6OTHER synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6ENTG ( BC6OTHER ), inducible BC6ENTC synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6ENTG ), inducible BC6ENTC synthase ( BC6OTHER ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6ENTC synthase ( BC6ENTG ), and BC6OTHER ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6ENTC synthase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ). CPR:falsenewlineIn HaCaT cells, BC6OTHER and BC6OTHER fractions of 80% BC6OTHER C. fragile extract (CFB or CFE) and a single compound, BC6OTHER ( BC6OTHER ) isolated from CFE attenuated UVB (60mJ / cm(2)) - induced cytotoxicity and reduced expression of pro - inflammatory proteins including BC6OTHER ( BC6OTHER ), inducible BC6ENTC synthase ( BC6OTHER ), and BC6OTHER ( BC6ENTG ). CPR:falsenewlineBeta 2 - but not BC6ENTG are involved in BC6ENTC enhancement of aggressive behavior in long - term isolated mice. CPR:falsenewlineTaken together with our previous finding that the BC6ENTC - induced enhancement of aggressive behavior can be blocked by BC6OTHER , an BC6ENTG antagonist, the present results indicate that not only alpha 2 - but also BC6OTHER stimulation plays important roles in modulation of aggressive behavior in long - term isolated mice. CPR:falsenewlineTaken together with our previous finding that the BC6ENTC - induced enhancement of aggressive behavior can be blocked by BC6OTHER , an BC6OTHER antagonist, the present results indicate that not only alpha 2 - but also BC6ENTG stimulation plays important roles in modulation of aggressive behavior in long - term isolated mice. CPR:falsenewlineTaken together with our previous finding that the BC6OTHER - induced enhancement of aggressive behavior can be blocked by BC6ENTC , an BC6ENTG antagonist, the present results indicate that not only alpha 2 - but also BC6OTHER stimulation plays important roles in modulation of aggressive behavior in long - term isolated mice. CPR:falsenewlineTaken together with our previous finding that the BC6OTHER - induced enhancement of aggressive behavior can be blocked by BC6ENTC , an BC6OTHER antagonist, the present results indicate that not only alpha 2 - but also BC6ENTG stimulation plays important roles in modulation of aggressive behavior in long - term isolated mice. CPR:falsenewlineIntraperitoneal administration of BC6ENTC (2.5 - 10 mg / kg), a nonselective BC6ENTG antagonist, dose dependently attenuated the BC6OTHER - induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses. CPR:falsenewlineIntraperitoneal administration of BC6OTHER (2.5 - 10 mg / kg), a nonselective BC6ENTG antagonist, dose dependently attenuated the BC6ENTC - induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses. CPR:falsenewlineThe effects of several BC6ENTG antagonists on the BC6ENTC - induced increase in aggressive behavior in long - term isolated mice were examined. CPR:falsenewlineBC6ENTC (1.25 - 5 mg / kg, IP), a selective BC6ENTG antagonist, also blocked the CHEM - induced enhancement of aggressive behavior in a dose - dependent manner, whereas BC6OTHER (5 - 20 mg / kg, IP), a selective BC6OTHER antagonist, did not affect it. CPR:falsenewlineBC6ENTC (1.25 - 5 mg / kg, IP), a selective BC6OTHER antagonist, also blocked the CHEM - induced enhancement of aggressive behavior in a dose - dependent manner, whereas BC6OTHER (5 - 20 mg / kg, IP), a selective BC6ENTG antagonist, did not affect it. CPR:falsenewlineBC6OTHER (1.25 - 5 mg / kg, IP), a selective BC6ENTG antagonist, also blocked the CHEM - induced enhancement of aggressive behavior in a dose - dependent manner, whereas BC6ENTC (5 - 20 mg / kg, IP), a selective BC6OTHER antagonist, did not affect it. CPR:falsenewlineBC6OTHER (1.25 - 5 mg / kg, IP), a selective BC6OTHER antagonist, also blocked the CHEM - induced enhancement of aggressive behavior in a dose - dependent manner, whereas BC6ENTC (5 - 20 mg / kg, IP), a selective BC6ENTG antagonist, did not affect it. CPR:falsenewlineMoreover, BC6ENTC (0.1 - 0.5 mg / kg, IP), a lipophilic BC6ENTG agonist, significantly increased the duration of basal aggressive behavior. CPR:falsenewlineBC6OTHER and BC6ENTC possessed similar affinity for BC6ENTG . CPR:falsenewlineCooperative effects for BC6ENTG differ between BC6ENTC and its metabolites. CPR:falsenewlineWe hypothesized that BC6ENTC metabolites have lower affinity than BC6OTHER toward BC6ENTG and limited ability to induce cooperative effects during metabolism. CPR:falsenewlineWe hypothesized that BC6OTHER metabolites have lower affinity than BC6ENTC toward BC6ENTG and limited ability to induce cooperative effects during metabolism. CPR:falsenewlineTo test the hypothesis, we determined the potency and mechanism of inhibition for BC6ENTC and its metabolites toward oxidation of BC6OTHER using BC6ENTG Supersomes® and human liver microsomes. CPR:9newlineTo test the hypothesis, we determined the potency and mechanism of inhibition for BC6OTHER and its metabolites toward oxidation of BC6ENTC using BC6ENTG Supersomes® and human liver microsomes. CPR:9newlineBC6ENTC and BC6OTHER possessed similar affinity for BC6ENTG . CPR:falsenewlineWhile BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6ENTG - BC6OTHER - BC6OTHER ( BC6OTHER ) complex. CPR:falsenewlineWhile BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6ENTG - BC6OTHER ( BC6OTHER ) complex. CPR:falsenewlineWhile BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6ENTG ( BC6OTHER ) complex. CPR:falsenewlineWhile BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6OTHER ( BC6ENTG ) complex. CPR:falsenewlineWhile BC6ENTG in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6OTHER ( BC6OTHER ) complex. CPR:falsenewlineWhile BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6ENTG ( BC6OTHER ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6OTHER ( BC6OTHER ) complex. CPR:falsenewlineWhile BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6ENTG ) mRNA, BC6OTHER is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6OTHER ( BC6OTHER ) complex. CPR:falsenewlineWhile BC6OTHER in hypoxia translocates to the nucleus where it transcribes the target genes including BC6OTHER ( BC6OTHER ) mRNA, BC6ENTG is degraded under normoxia, which involves its BC6ENTC hydroxylation and subsequent binding to the BC6OTHER - BC6OTHER - BC6OTHER ( BC6OTHER ) complex. CPR:falsenewlineThe BC6ENTG agonist CHEM's ability to reduce aggressive behavior in humans and its interaction with the well - known aggression - enhancing drug BC6ENTC were examined. CPR:falsenewlineRATIONALE: The BC6ENTC 1(B / D) ( BC6ENTG ) receptor has shown potential as a target for decreasing aggression. CPR:falsenewlineA series of studies is reviewed that assesses the relationship between BC6ENTG released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6ENTC ) in comparison to a dual BC6OTHER / BC6OTHER inhibitor ( BC6OTHER ). CPR:falsenewlineA series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6ENTG inhibitor ( BC6ENTC ) in comparison to a dual BC6OTHER / BC6OTHER inhibitor ( BC6OTHER ). CPR:falsenewlineA series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6ENTC ) in comparison to a dual BC6ENTG / BC6OTHER inhibitor ( BC6OTHER ). CPR:falsenewlineA series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6ENTC ) in comparison to a dual BC6OTHER / BC6ENTG inhibitor ( BC6OTHER ). CPR:falsenewlineA series of studies is reviewed that assesses the relationship between BC6ENTG released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6OTHER ) in comparison to a dual BC6OTHER / BC6OTHER inhibitor ( BC6ENTC ). CPR:falsenewlineA series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6ENTG inhibitor ( BC6OTHER ) in comparison to a dual BC6OTHER / BC6OTHER inhibitor ( BC6ENTC ). CPR:falsenewlineA series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6OTHER ) in comparison to a dual BC6ENTG / BC6OTHER inhibitor ( BC6ENTC ). CPR:falsenewlineA series of studies is reviewed that assesses the relationship between BC6OTHER released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective BC6OTHER inhibitor ( BC6OTHER ) in comparison to a dual BC6OTHER / BC6ENTG inhibitor ( BC6ENTC ). CPR:falsenewlineThree replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6ENTC ( BC6OTHER ; a product of both BC6ENTG and BC6OTHER ) and BC6OTHER (as a biomarker for BC6OTHER activity) with parallel assessments of pain. CPR:falsenewlineThree replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6ENTC ( BC6OTHER ; a product of both BC6OTHER and BC6ENTG ) and BC6OTHER (as a biomarker for BC6OTHER activity) with parallel assessments of pain. CPR:falsenewlineThree replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6ENTC ( BC6OTHER ; a product of both BC6OTHER and BC6OTHER ) and BC6OTHER (as a biomarker for BC6ENTG activity) with parallel assessments of pain. CPR:falsenewlineThree replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6ENTC ; a product of both BC6ENTG and BC6OTHER ) and BC6OTHER (as a biomarker for BC6OTHER activity) with parallel assessments of pain. CPR:falsenewlineThree replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6ENTC ; a product of both BC6OTHER and BC6ENTG ) and BC6OTHER (as a biomarker for BC6OTHER activity) with parallel assessments of pain. CPR:falsenewlineThree replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6ENTC ; a product of both BC6OTHER and BC6OTHER ) and BC6OTHER (as a biomarker for BC6ENTG activity) with parallel assessments of pain. CPR:falsenewlineThree replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6OTHER ; a product of both BC6ENTG and BC6OTHER ) and BC6ENTC (as a biomarker for BC6OTHER activity) with parallel assessments of pain. CPR:falsenewlineThree replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6OTHER ; a product of both BC6OTHER and BC6ENTG ) and BC6ENTC (as a biomarker for BC6OTHER activity) with parallel assessments of pain. CPR:falsenewlineThree replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of BC6OTHER ( BC6OTHER ; a product of both BC6OTHER and BC6OTHER ) and BC6ENTC (as a biomarker for BC6ENTG activity) with parallel assessments of pain. CPR:falsenewlineThe time course of BC6ENTC production was consistent with early release due to BC6ENTG activity followed by increased production 2 - 3 hours after surgery, consistent with BC6OTHER expression. CPR:falsenewlineThe time course of BC6ENTC production was consistent with early release due to BC6OTHER activity followed by increased production 2 - 3 hours after surgery, consistent with BC6ENTG expression. CPR:falsenewlineBC6ENTC selectively suppressed BC6OTHER but not BC6OTHER at time points consistent with BC6ENTG activity, while producing analgesia. CPR:falsenewlineBC6OTHER selectively suppressed BC6ENTC but not BC6OTHER at time points consistent with BC6ENTG activity, while producing analgesia. CPR:falsenewlineBC6OTHER selectively suppressed BC6OTHER but not BC6ENTC at time points consistent with BC6ENTG activity, while producing analgesia. CPR:falsenewlineThese studies demonstrate the ability to assess the time course and selective effects of BC6ENTG inhibitors in vivo and suggest that suppression of BC6OTHER mediated BC6ENTC is temporally related to NSAID analgesia. CPR:falsenewlineThese studies demonstrate the ability to assess the time course and selective effects of BC6OTHER inhibitors in vivo and suggest that suppression of BC6ENTG mediated BC6ENTC is temporally related to NSAID analgesia. CPR:falsenewlineIt appears likely that the BC6ENTG blocked by BC6ENTC obviated the pulmonary vasodilator effect of BC6OTHER therapy. CPR:falsenewlineIt appears likely that the BC6ENTG blocked by BC6OTHER obviated the pulmonary vasodilator effect of BC6ENTC therapy. CPR:falsenewlineHere, we identified BC6ENTG ( BC6OTHER ) as a BC6ENTC - binding protein. CPR:falsenewlineHere, we identified BC6OTHER ( BC6ENTG ) as a BC6ENTC - binding protein. CPR:falsenewlineBC6ENTC initiates its teratogenic effects by binding to BC6ENTG and inhibiting the associated BC6OTHER activity. CPR:falsenewlineBC6ENTC initiates its teratogenic effects by binding to BC6OTHER and inhibiting the associated BC6ENTG activity. CPR:4newlineAt each menstruation a bolus injection of 10 pmol / kg of BC6ENTG was administered before and during infusion of either 300 microg / min of BC6ENTC or placebo. CPR:falsenewlineIschemia markers in plasma and pain recorded by a visual analog scale were measured before and after each BC6ENTG injection as well as before and after the start of either BC6ENTC or placebo infusion. CPR:falsenewlineIntrauterine pressure, ischemia markers, and experienced pain during administration of a BC6ENTG antagonist in spontaneous and BC6ENTC - induced dysmenorrhea. CPR:falsenewlineIntrauterine pressure, ischemia markers, and experienced pain during administration of a BC6ENTC V1a receptor antagonist in spontaneous and BC6ENTG - induced dysmenorrhea. CPR:falsenewlineIn subjects with dysmenorrhea the increase in pain following the administration of BC6ENTG was significantly lower during BC6ENTC than during placebo infusion. CPR:falsenewlineCONCLUSIONS: BC6ENTC reduces BC6ENTG - induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea. CPR:falsenewlineThe dysmenorrhea pain evoked by BC6ENTC correlated poorly with area under the curve, which may suggest that the effect is mediated by more than one BC6ENTG . CPR:falsenewlineExposure to BC6ENTC (a BC6ENTG antagonist), but not BC6OTHER (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6OTHER mRNA. CPR:falsenewlineExposure to BC6ENTC (a BC6OTHER antagonist), but not BC6OTHER (a BC6ENTG antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6OTHER mRNA. CPR:falsenewlineExposure to BC6ENTC (a BC6OTHER antagonist), but not BC6OTHER (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6ENTG mRNA. CPR:falsenewlineExposure to BC6OTHER (a BC6ENTG antagonist), but not BC6ENTC (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6OTHER mRNA. CPR:falsenewlineExposure to BC6OTHER (a BC6OTHER antagonist), but not BC6ENTC (a BC6ENTG antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6OTHER mRNA. CPR:falsenewlineExposure to BC6OTHER (a BC6OTHER antagonist), but not BC6ENTC (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6OTHER - sensitive I(sc) and the induced changes in BC6ENTG mRNA. CPR:falsenewlineExposure to BC6OTHER (a BC6ENTG antagonist), but not BC6OTHER (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6ENTC - sensitive I(sc) and the induced changes in BC6OTHER mRNA. CPR:falsenewlineExposure to BC6OTHER (a BC6OTHER antagonist), but not BC6OTHER (a BC6ENTG antagonist), precluded both the CHEM - induced elevation in BC6ENTC - sensitive I(sc) and the induced changes in BC6OTHER mRNA. CPR:falsenewlineExposure to BC6OTHER (a BC6OTHER antagonist), but not BC6OTHER (a BC6OTHER antagonist), precluded both the CHEM - induced elevation in BC6ENTC - sensitive I(sc) and the induced changes in BC6ENTG mRNA. CPR:falsenewlineWe conclude that BC6ENTC movement across mammary epithelia is modulated by CHEM via a BC6ENTG - mediated mechanism that regulates the expression of the BC6OTHER . CPR:falsenewlineWe conclude that BC6ENTC movement across mammary epithelia is modulated by CHEM via a BC6OTHER - mediated mechanism that regulates the expression of the BC6ENTG . CPR:falsenewlineBC6ENTG expression and activity could account for the low BC6ENTC concentration that is typical of milk. CPR:falsenewlineWe hypothesized that CHEM exposure modulates epithelial BC6ENTC channel ( BC6ENTG ) expression and / or activity in bovine mammary epithelial cells. CPR:falsenewlineMETHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two BC6ENTG region polymorphisms ( BC6OTHER and - 141C Ins / Del) and were randomly assigned to receive 16 weeks of treatment with either BC6ENTC or BC6OTHER . CPR:falsenewlineMETHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two BC6OTHER region polymorphisms ( BC6ENTG and - 141C Ins / Del) and were randomly assigned to receive 16 weeks of treatment with either BC6ENTC or BC6OTHER . CPR:falsenewlineMETHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two BC6ENTG region polymorphisms ( BC6OTHER and - 141C Ins / Del) and were randomly assigned to receive 16 weeks of treatment with either BC6OTHER or BC6ENTC . CPR:falsenewlineMETHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two BC6OTHER region polymorphisms ( BC6ENTG and - 141C Ins / Del) and were randomly assigned to receive 16 weeks of treatment with either BC6OTHER or BC6ENTC . CPR:falsenewlineBC6ENTC , a potent inhibitor of BC6ENTG , at high concentration (500 microm ) caused only a 72% decrease in the utilization of BC6OTHER . CPR:4newlineBC6OTHER , a potent inhibitor of BC6ENTG , at high concentration (500 microm ) caused only a 72% decrease in the utilization of BC6ENTC . CPR:falsenewlineThe BC6ENTG / BC6OTHER interaction occurred on the BC6ENTC and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability. CPR:falsenewlineThe BC6OTHER / BC6ENTG interaction occurred on the BC6ENTC and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability. CPR:falsenewlineThe BC6OTHER / BC6OTHER interaction occurred on the BC6ENTC and BC6OTHER termini of BC6ENTG ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability. CPR:falsenewlineThe BC6OTHER / BC6OTHER interaction occurred on the BC6ENTC and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6ENTG protein stability. CPR:falsenewlineThe BC6ENTG / BC6OTHER interaction occurred on the BC6OTHER and BC6ENTC termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability. CPR:falsenewlineThe BC6OTHER / BC6ENTG interaction occurred on the BC6OTHER and BC6ENTC termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability. CPR:falsenewlineThe BC6OTHER / BC6OTHER interaction occurred on the BC6OTHER and BC6ENTC termini of BC6ENTG ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability. CPR:falsenewlineThe BC6OTHER / BC6OTHER interaction occurred on the BC6OTHER and BC6ENTC termini of BC6OTHER ; a single internal deletion from BC6OTHER 455 to 466 (Δ455 - 466) was found to significantly reduce BC6ENTG protein stability. CPR:falsenewlineThe BC6ENTG / BC6OTHER interaction occurred on the BC6OTHER and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6ENTC 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability. CPR:falsenewlineThe BC6OTHER / BC6ENTG interaction occurred on the BC6OTHER and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6ENTC 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability. CPR:falsenewlineThe BC6OTHER / BC6OTHER interaction occurred on the BC6OTHER and BC6OTHER termini of BC6ENTG ; a single internal deletion from BC6ENTC 455 to 466 (Δ455 - 466) was found to significantly reduce BC6OTHER protein stability. CPR:falsenewlineThe BC6OTHER / BC6OTHER interaction occurred on the BC6OTHER and BC6OTHER termini of BC6OTHER ; a single internal deletion from BC6ENTC 455 to 466 (Δ455 - 466) was found to significantly reduce BC6ENTG protein stability. CPR:falsenewlineCerebral BC6ENTC H1 receptor ( BC6ENTG ) binding was measured in 10 patients with major depression and in 10 normal age - matched subjects using PET and BC6OTHER . CPR:falsenewlineCerebral BC6ENTG ( BC6OTHER ) binding was measured in 10 patients with major depression and in 10 normal age - matched subjects using PET and BC6ENTC . CPR:falsenewlineCerebral BC6OTHER H1 receptor ( BC6ENTG ) binding was measured in 10 patients with major depression and in 10 normal age - matched subjects using PET and BC6ENTC . CPR:falsenewlineBC6ENTC also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6OTHER and BC6OTHER precursor BC6OTHER , whereas BC6OTHER (and BC6OTHER ) worsened it. CPR:falsenewlineBC6OTHER also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6ENTC and BC6OTHER precursor BC6OTHER , whereas BC6OTHER (and BC6OTHER ) worsened it. CPR:falsenewlineBC6OTHER also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6OTHER and BC6ENTC precursor BC6OTHER , whereas BC6OTHER (and BC6OTHER ) worsened it. CPR:falsenewlineBC6OTHER also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6OTHER and BC6OTHER precursor BC6ENTC , whereas BC6OTHER (and BC6OTHER ) worsened it. CPR:falsenewlineBC6OTHER also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6OTHER and BC6OTHER precursor BC6OTHER , whereas BC6ENTC (and BC6OTHER ) worsened it. CPR:falsenewlineBC6OTHER also attenuated the hypolocomotion induced by the BC6ENTG agonist BC6OTHER and BC6OTHER precursor BC6OTHER , whereas BC6OTHER (and BC6ENTC ) worsened it. CPR:falsenewlineA combined pharmacological and genetic approach was undertaken to investigate the contribution of endogenous BC6ENTC to the motor actions of BC6ENTG ( BC6OTHER ) ligands. CPR:falsenewlineA combined pharmacological and genetic approach was undertaken to investigate the contribution of endogenous BC6ENTC to the motor actions of BC6OTHER ( BC6ENTG ) ligands. CPR:falsenewlineMotor facilitation induced by BC6ENTG and BC6OTHER antagonists was lost in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6OTHER ( - / - ) mice. CPR:falsenewlineMotor facilitation induced by BC6OTHER and BC6ENTG antagonists was lost in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6OTHER ( - / - ) mice. CPR:falsenewlineMotor facilitation induced by BC6OTHER and BC6OTHER antagonists was lost in BC6ENTG ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6OTHER ( - / - ) mice. CPR:falsenewlineMotor facilitation induced by BC6OTHER and BC6OTHER antagonists was lost in BC6OTHER ( - / - ) and BC6ENTG ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6OTHER ( - / - ) mice. CPR:falsenewlineMotor facilitation induced by BC6OTHER and BC6OTHER antagonists was lost in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6ENTG antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6OTHER ( - / - ) mice. CPR:falsenewlineMotor facilitation induced by BC6OTHER and BC6OTHER antagonists was lost in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6ENTG ( - / - ) but preserved in BC6OTHER ( - / - ) mice. CPR:falsenewlineMotor facilitation induced by BC6OTHER and BC6OTHER antagonists was lost in BC6OTHER ( - / - ) and BC6OTHER ( - / - ) mice whereas motor inhibition induced by BC6OTHER antagonists (and BC6ENTC ) was lost in BC6OTHER ( - / - ) but preserved in BC6ENTG ( - / - ) mice. CPR:falsenewlineWe demonstrate that motor actions of BC6ENTG ligands rely on the modulation of endogenous BC6ENTC . CPR:falsenewlineThe involvement of the various BC6ENTG subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6ENTG and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6ENTG antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6ENTG / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6ENTG ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6ENTG / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6ENTC ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6ENTG knockout mice. CPR:falsenewlineThe involvement of the various BC6ENTG subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6ENTG and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6ENTG antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6ENTG / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6ENTG ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6ENTG / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTG ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6ENTG ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6ENTG knockout mice. CPR:falsenewlineThe involvement of the various BC6ENTG subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6ENTG and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6ENTG antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6ENTG / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6ENTG ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6ENTG / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTG ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6ENTG ( BC6OTHER ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptor antagonists, and by using BC6ENTG knockout mice. CPR:falsenewlineThe involvement of the various BC6ENTG subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6ENTG and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6ENTG antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6ENTG / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6ENTG ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6ENTG / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6ENTC ) receptor antagonists, and by using BC6OTHER knockout mice. CPR:falsenewlineThe involvement of the various BC6OTHER subtypes in the motor effects of BC6OTHER and BC6OTHER antagonists was evaluated pharmacologically, using BC6OTHER / BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptor antagonists, and by using BC6ENTG knockout mice. CPR:falsenewlineBased on our previously published work on BC6ENTG antagonists, we have synthesized a series of BC6ENTC that inhibit the BC6OTHER / BC6OTHER interaction. CPR:falsenewlineBased on our previously published work on BC6OTHER antagonists, we have synthesized a series of BC6ENTC that inhibit the BC6ENTG / BC6OTHER interaction. CPR:falsenewlineBased on our previously published work on BC6OTHER antagonists, we have synthesized a series of BC6ENTC that inhibit the BC6OTHER / BC6ENTG interaction. CPR:falsenewlineThese data demonstrate that BC6ENTC are a unique class of BC6ENTG inhibitors with high potency. CPR:4newline BC6ENTC : a unique class of BC6ENTG inhibitors. CPR:falsenewlineBiological evaluation revealed that most tested compounds were potent BC6ENTG ( BC6OTHER ) inhibitors, among them, the BC6ENTC derivative 11h displayed the most potent BC6OTHER inhibitory activity with an IC50 value of 0.247 μM. CPR:falsenewlineBiological evaluation revealed that most tested compounds were potent BC6OTHER ( BC6ENTG ) inhibitors, among them, the BC6ENTC derivative 11h displayed the most potent BC6OTHER inhibitory activity with an IC50 value of 0.247 μM. CPR:falsenewlineBiological evaluation revealed that most tested compounds were potent BC6OTHER ( BC6OTHER ) inhibitors, among them, the BC6ENTC derivative 11h displayed the most potent BC6ENTG inhibitory activity with an IC50 value of 0.247 μM. CPR:4newlineDesign, Synthesis, Biological Evaluation, and Docking Studies of BC6OTHER Derivatives with a BC6ENTC Moiety as Potent BC6ENTG Inhibitors. CPR:falsenewlineDesign, Synthesis, Biological Evaluation, and Docking Studies of BC6ENTC Derivatives with a BC6OTHER Moiety as Potent BC6ENTG Inhibitors. CPR:4newlineAdministration of low, but not high, doses of oral BC6ENTC in DSS - treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of BC6ENTG . CPR:4newlineTreatment with BC6ENTC or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6ENTG at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6ENTC or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6ENTG at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6ENTC or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6ENTG , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6ENTC or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6ENTG . CPR:falsenewlineTreatment with BC6OTHER or BC6ENTC resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6ENTG at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER or BC6ENTC resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6ENTG at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER or BC6ENTC resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6ENTG , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER or BC6ENTC resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6ENTG . CPR:falsenewlineTreatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6ENTG at BC6ENTC 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6ENTC 10, phosphorylation of BC6ENTG at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6ENTC 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6ENTG , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6ENTC 10, phosphorylation of BC6OTHER at BC6OTHER 15, expression of BC6OTHER , and decreased expression of BC6ENTG . CPR:falsenewlineTreatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6ENTG at BC6OTHER 10, phosphorylation of BC6OTHER at BC6ENTC 15, expression of BC6OTHER , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6ENTG at BC6ENTC 15, expression of BC6OTHER , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6ENTC 15, expression of BC6ENTG , and decreased expression of BC6OTHER . CPR:falsenewlineTreatment with BC6OTHER or BC6OTHER resulted in arresting the CHEM - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of BC6OTHER at BC6OTHER 10, phosphorylation of BC6OTHER at BC6ENTC 15, expression of BC6OTHER , and decreased expression of BC6ENTG . CPR:falsenewlineInhibition of Th1 / Th17 responses via suppression of BC6ENTG and BC6OTHER activation contributes to the amelioration of murine experimental colitis by a natural BC6OTHER CHEM BC6ENTC . CPR:falsenewlineInhibition of Th1 / Th17 responses via suppression of BC6OTHER and BC6ENTG activation contributes to the amelioration of murine experimental colitis by a natural BC6OTHER CHEM BC6ENTC . CPR:falsenewlineMoreover, BC6ENTC treatment inhibited the phosphorylations of BC6ENTG and BC6OTHER in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively. CPR:4newlineMoreover, BC6ENTC treatment inhibited the phosphorylations of BC6OTHER and BC6ENTG in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively. CPR:4newlineFurther study showed that BC6ENTC dose - dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro - inflammatory BC6ENTG levels of activated T cells. CPR:4newlineInhibition of Th1 / Th17 responses via suppression of BC6ENTG and BC6OTHER activation contributes to the amelioration of murine experimental colitis by a natural BC6ENTC CHEM BC6OTHER . CPR:falsenewlineInhibition of Th1 / Th17 responses via suppression of BC6OTHER and BC6ENTG activation contributes to the amelioration of murine experimental colitis by a natural BC6ENTC CHEM BC6OTHER . CPR:falsenewlineBC6ENTG overexpression in mice significantly increases plasma BC6OTHER levels while silencing BC6OTHER decreases BC6ENTC levels. CPR:falsenewlineBC6OTHER overexpression in mice significantly increases plasma BC6OTHER levels while silencing BC6ENTG decreases BC6ENTC levels. CPR:falsenewlineIn mice, this reduction in BC6ENTG expression is due primarily to downregulation by BC6ENTC . CPR:4newlineBC6ENTG expression is induced by dietary BC6ENTC by a mechanism that involves the BC6OTHER ( BC6OTHER ), a BC6OTHER - activated nuclear receptor. CPR:falsenewlineBC6OTHER expression is induced by dietary BC6ENTC by a mechanism that involves the BC6ENTG ( BC6OTHER ), a BC6OTHER - activated nuclear receptor. CPR:falsenewlineBC6OTHER expression is induced by dietary BC6ENTC by a mechanism that involves the BC6OTHER ( BC6ENTG ), a BC6OTHER - activated nuclear receptor. CPR:falsenewlineBC6ENTG expression is induced by dietary BC6OTHER by a mechanism that involves the BC6OTHER ( BC6OTHER ), a BC6ENTC - activated nuclear receptor. CPR:falsenewlineBC6OTHER expression is induced by dietary BC6OTHER by a mechanism that involves the BC6ENTG ( BC6OTHER ), a BC6ENTC - activated nuclear receptor. CPR:falsenewlineBC6OTHER expression is induced by dietary BC6OTHER by a mechanism that involves the BC6OTHER ( BC6ENTG ), a BC6ENTC - activated nuclear receptor. CPR:falsenewlineAnalysis of natural genetic variation among inbred strains of mice indicates that BC6ENTG and BC6ENTC are significantly correlated, and BC6OTHER levels explain 11% of the variation in atherosclerosis. CPR:falsenewlineAnalysis of natural genetic variation among inbred strains of mice indicates that BC6ENTG and BC6OTHER are significantly correlated, and BC6ENTC levels explain 11% of the variation in atherosclerosis. CPR:falsenewlineWe demonstrate that two BC6ENTC mono - oxygenase family members, BC6ENTG and BC6OTHER , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER . CPR:9newlineWe demonstrate that two BC6ENTC mono - oxygenase family members, BC6OTHER and BC6ENTG , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER . CPR:9newlineWe demonstrate that two BC6ENTG family members, BC6OTHER and BC6OTHER , oxidize BC6ENTC ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER . CPR:9newlineWe demonstrate that two BC6OTHER mono - oxygenase family members, BC6ENTG and BC6OTHER , oxidize BC6ENTC ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER . CPR:9newlineWe demonstrate that two BC6OTHER mono - oxygenase family members, BC6OTHER and BC6ENTG , oxidize BC6ENTC ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER . CPR:9newlineWe demonstrate that two BC6ENTG family members, BC6OTHER and BC6OTHER , oxidize BC6OTHER ( BC6ENTC ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER . CPR:9newlineWe demonstrate that two BC6OTHER mono - oxygenase family members, BC6ENTG and BC6OTHER , oxidize BC6OTHER ( BC6ENTC ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER . CPR:9newlineWe demonstrate that two BC6OTHER mono - oxygenase family members, BC6OTHER and BC6ENTG , oxidize BC6OTHER ( BC6ENTC ), derived from gut flora metabolism of BC6OTHER , to BC6OTHER . CPR:9newlineWe demonstrate that two BC6ENTG family members, BC6OTHER and BC6OTHER , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6ENTC , to BC6OTHER . CPR:9newlineWe demonstrate that two BC6OTHER mono - oxygenase family members, BC6ENTG and BC6OTHER , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6ENTC , to BC6OTHER . CPR:9newlineWe demonstrate that two BC6OTHER mono - oxygenase family members, BC6OTHER and BC6ENTG , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6ENTC , to BC6OTHER . CPR:9newlineWe demonstrate that two BC6ENTG family members, BC6OTHER and BC6OTHER , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6ENTC . CPR:9newlineWe demonstrate that two BC6OTHER mono - oxygenase family members, BC6ENTG and BC6OTHER , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6ENTC . CPR:9newlineWe demonstrate that two BC6OTHER mono - oxygenase family members, BC6OTHER and BC6ENTG , oxidize BC6OTHER ( BC6OTHER ), derived from gut flora metabolism of BC6OTHER , to BC6ENTC . CPR:9newlineBC6ENTG overexpression in mice significantly increases plasma BC6ENTC levels while silencing BC6OTHER decreases BC6OTHER levels. CPR:falsenewlineBC6OTHER overexpression in mice significantly increases plasma BC6ENTC levels while silencing BC6ENTG decreases BC6OTHER levels. CPR:falsenewlineBG also showed a protective effect in the presence of a BC6ENTG inhibitor ( BC6ENTC , BC6OTHER ), demonstrating that BG does not act through an anti - mutagenic mechanism of action involving BC6OTHER . CPR:falsenewlineBG also showed a protective effect in the presence of a BC6OTHER inhibitor ( BC6ENTC , BC6OTHER ), demonstrating that BG does not act through an anti - mutagenic mechanism of action involving BC6ENTG . CPR:falsenewlineBG also showed a protective effect in the presence of a BC6ENTG inhibitor ( BC6OTHER , BC6ENTC ), demonstrating that BG does not act through an anti - mutagenic mechanism of action involving BC6OTHER . CPR:falsenewlineBG also showed a protective effect in the presence of a BC6OTHER inhibitor ( BC6OTHER , BC6ENTC ), demonstrating that BG does not act through an anti - mutagenic mechanism of action involving BC6ENTG . CPR:falsenewlineBC6ENTC + BC6OTHER were more effective than placebo+ BC6OTHER in reducing body weight and BMI, glycemic control, HOMA - IR, BC6ENTG and BC6OTHER resistance measurements. CPR:falsenewlineBC6ENTC + BC6OTHER were more effective than placebo+ BC6OTHER in reducing body weight and BMI, glycemic control, HOMA - IR, BC6OTHER and BC6ENTG resistance measurements. CPR:falsenewlineBC6OTHER + BC6ENTC were more effective than placebo+ BC6OTHER in reducing body weight and BMI, glycemic control, HOMA - IR, BC6ENTG and BC6OTHER resistance measurements. CPR:falsenewlineBC6OTHER + BC6ENTC were more effective than placebo+ BC6OTHER in reducing body weight and BMI, glycemic control, HOMA - IR, BC6OTHER and BC6ENTG resistance measurements. CPR:falsenewlineBC6OTHER + BC6OTHER were more effective than placebo+ BC6ENTC in reducing body weight and BMI, glycemic control, HOMA - IR, BC6ENTG and BC6OTHER resistance measurements. CPR:falsenewlineBC6OTHER + BC6OTHER were more effective than placebo+ BC6ENTC in reducing body weight and BMI, glycemic control, HOMA - IR, BC6OTHER and BC6ENTG resistance measurements. CPR:falsenewlineEvaluation of the positive effects on BC6ENTG - resistance and β - cell measurements of BC6OTHER in addition to BC6ENTC in type 2 diabetic patients. CPR:falsenewlineEvaluation of the positive effects on BC6ENTG - resistance and β - cell measurements of BC6ENTC in addition to BC6OTHER in type 2 diabetic patients. CPR:falsenewlineWe also recorded a significant correlation between M value increase and the decrease of BC6ENTG , BC6OTHER , and BC6OTHER obtained with BC6ENTC + BC6OTHER . CPR:falsenewlineWe also recorded a significant correlation between M value increase and the decrease of BC6OTHER , BC6ENTG , and BC6OTHER obtained with BC6ENTC + BC6OTHER . CPR:falsenewlineWe also recorded a significant correlation between M value increase and the decrease of BC6OTHER , BC6OTHER , and BC6ENTG obtained with BC6ENTC + BC6OTHER . CPR:4newlineWe also recorded a significant correlation between M value increase and the decrease of BC6ENTG , BC6OTHER , and BC6OTHER obtained with BC6OTHER + BC6ENTC . CPR:falsenewlineWe also recorded a significant correlation between M value increase and the decrease of BC6OTHER , BC6ENTG , and BC6OTHER obtained with BC6OTHER + BC6ENTC . CPR:falsenewlineWe also recorded a significant correlation between M value increase and the decrease of BC6OTHER , BC6OTHER , and BC6ENTG obtained with BC6OTHER + BC6ENTC . CPR:4newlineBC6ENTC , in addition to BC6OTHER , proved to be effective in improving β - cell function and in reducing BC6ENTG resistance measurements. CPR:falsenewlineBC6OTHER , in addition to BC6ENTC , proved to be effective in improving β - cell function and in reducing BC6ENTG resistance measurements. CPR:falsenewlineWe examined BC6ENTC , BC6OTHER and BC6OTHER serum concentrations and polymorphism of the BC6ENTG BC6OTHER gene in Turkish children with neural tube defects. CPR:falsenewlineWe examined BC6ENTC , BC6OTHER and BC6OTHER serum concentrations and polymorphism of the BC6OTHER BC6ENTG gene in Turkish children with neural tube defects. CPR:falsenewlineWe examined BC6OTHER , BC6ENTC and BC6OTHER serum concentrations and polymorphism of the BC6ENTG BC6OTHER gene in Turkish children with neural tube defects. CPR:falsenewlineWe examined BC6OTHER , BC6ENTC and BC6OTHER serum concentrations and polymorphism of the BC6OTHER BC6ENTG gene in Turkish children with neural tube defects. CPR:falsenewlineWe examined BC6OTHER , BC6OTHER and BC6ENTC serum concentrations and polymorphism of the BC6ENTG BC6OTHER gene in Turkish children with neural tube defects. CPR:falsenewlineWe examined BC6OTHER , BC6OTHER and BC6ENTC serum concentrations and polymorphism of the BC6OTHER BC6ENTG gene in Turkish children with neural tube defects. CPR:falsenewlineThe levels of BC6ENTC , BC6OTHER and BC6OTHER serum concentrations in NTDs were evaluated and compared, along with information concerning alleles of the BC6ENTG gene. CPR:falsenewlineThe levels of BC6OTHER , BC6ENTC and BC6OTHER serum concentrations in NTDs were evaluated and compared, along with information concerning alleles of the BC6ENTG gene. CPR:falsenewlineThe levels of BC6OTHER , BC6OTHER and BC6ENTC serum concentrations in NTDs were evaluated and compared, along with information concerning alleles of the BC6ENTG gene. CPR:falsenewlineAssociation between neural tube defects (NTDs) and BC6OTHER polymorphism of the BC6ENTC reductase ( BC6ENTG ) gene was suspected, because the BC6OTHER gene codes for a key enzyme in BC6OTHER metabolism. CPR:falsenewlineAssociation between neural tube defects (NTDs) and BC6OTHER polymorphism of the BC6ENTC reductase ( BC6OTHER ) gene was suspected, because the BC6ENTG gene codes for a key enzyme in BC6OTHER metabolism. CPR:falsenewlineAssociation between neural tube defects (NTDs) and BC6ENTG polymorphism of the BC6ENTC reductase ( BC6OTHER ) gene was suspected, because the BC6OTHER gene codes for a key enzyme in BC6OTHER metabolism. CPR:falsenewline BC6ENTG polymorphism of the BC6OTHER gene does not affect BC6OTHER , BC6OTHER , and BC6ENTC serum levels in Turkish children with neural tube defects. CPR:falsenewline BC6OTHER polymorphism of the BC6ENTG gene does not affect BC6OTHER , BC6OTHER , and BC6ENTC serum levels in Turkish children with neural tube defects. CPR:falsenewline BC6ENTG polymorphism of the BC6ENTC reductase gene does not affect BC6OTHER , BC6OTHER , and BC6OTHER serum levels in Turkish children with neural tube defects. CPR:falsenewline BC6ENTG polymorphism of the BC6OTHER gene does not affect BC6ENTC , BC6OTHER , and BC6OTHER serum levels in Turkish children with neural tube defects. CPR:falsenewline BC6OTHER polymorphism of the BC6ENTG gene does not affect BC6ENTC , BC6OTHER , and BC6OTHER serum levels in Turkish children with neural tube defects. CPR:falsenewline BC6ENTG polymorphism of the BC6OTHER gene does not affect BC6OTHER , BC6ENTC , and BC6OTHER serum levels in Turkish children with neural tube defects. CPR:falsenewline BC6OTHER polymorphism of the BC6ENTG gene does not affect BC6OTHER , BC6ENTC , and BC6OTHER serum levels in Turkish children with neural tube defects. CPR:falsenewlineWe concluded that BC6ENTG BC6OTHER gene polymorphism does not affect BC6ENTC , BC6OTHER and BC6OTHER metabolism in Turkish children with NTDs. CPR:falsenewlineWe concluded that BC6OTHER BC6ENTG gene polymorphism does not affect BC6ENTC , BC6OTHER and BC6OTHER metabolism in Turkish children with NTDs. CPR:falsenewlineWe concluded that BC6ENTG BC6OTHER gene polymorphism does not affect BC6OTHER , BC6ENTC and BC6OTHER metabolism in Turkish children with NTDs. CPR:falsenewlineWe concluded that BC6OTHER BC6ENTG gene polymorphism does not affect BC6OTHER , BC6ENTC and BC6OTHER metabolism in Turkish children with NTDs. CPR:falsenewlineWe concluded that BC6ENTG BC6OTHER gene polymorphism does not affect BC6OTHER , BC6OTHER and BC6ENTC metabolism in Turkish children with NTDs. CPR:falsenewlineWe concluded that BC6OTHER BC6ENTG gene polymorphism does not affect BC6OTHER , BC6OTHER and BC6ENTC metabolism in Turkish children with NTDs. CPR:falsenewlineAssociation between neural tube defects (NTDs) and BC6OTHER polymorphism of the BC6OTHER ( BC6ENTG ) gene was suspected, because the BC6OTHER gene codes for a key enzyme in BC6ENTC metabolism. CPR:falsenewlineAssociation between neural tube defects (NTDs) and BC6OTHER polymorphism of the BC6OTHER ( BC6OTHER ) gene was suspected, because the BC6ENTG gene codes for a key enzyme in BC6ENTC metabolism. CPR:falsenewlineAssociation between neural tube defects (NTDs) and BC6ENTG polymorphism of the BC6OTHER ( BC6OTHER ) gene was suspected, because the BC6OTHER gene codes for a key enzyme in BC6ENTC metabolism. CPR:falsenewlineAssociation between neural tube defects (NTDs) and BC6OTHER polymorphism of the BC6ENTG ( BC6OTHER ) gene was suspected, because the BC6OTHER gene codes for a key enzyme in BC6ENTC metabolism. CPR:falsenewlineBC6ENTC induced G2 / M phase cell cycle arrest and modulated the levels of BC6ENTG and BC6OTHER in Hec1A cells. CPR:falsenewlineBC6ENTC induced G2 / M phase cell cycle arrest and modulated the levels of BC6OTHER and BC6ENTG in Hec1A cells. CPR:falsenewlineKnockdown of BC6ENTG using specific siRNAs partially abrogated BC6ENTC - induced cell growth inhibition. CPR:falsenewlineAdditional mechanistic studies revealed that BC6ENTC treatment resulted in an increase in phosphorylation of BC6ENTG and BC6OTHER - BC6OTHER . CPR:3newlineAdditional mechanistic studies revealed that BC6ENTC treatment resulted in an increase in phosphorylation of BC6OTHER and BC6ENTG - BC6OTHER . CPR:3newlineAdditional mechanistic studies revealed that BC6ENTC treatment resulted in an increase in phosphorylation of BC6OTHER and BC6OTHER - BC6ENTG . CPR:3newline BC6ENTC , isolated from dietary mugwort (Artemisia princeps), induces G2 / M cell cycle arrest by inactivating BC6ENTG - BC6OTHER via BC6OTHER - BC6OTHER activation. CPR:4newline BC6ENTC , isolated from dietary mugwort (Artemisia princeps), induces G2 / M cell cycle arrest by inactivating BC6OTHER - BC6ENTG via BC6OTHER - BC6OTHER activation. CPR:4newline BC6ENTC , isolated from dietary mugwort (Artemisia princeps), induces G2 / M cell cycle arrest by inactivating BC6OTHER - BC6OTHER via BC6ENTG - BC6OTHER activation. CPR:3newline BC6ENTC , isolated from dietary mugwort (Artemisia princeps), induces G2 / M cell cycle arrest by inactivating BC6OTHER - BC6OTHER via BC6OTHER - BC6ENTG activation. CPR:3newlineCHEM, an BC6ENTG inhibitor, reversed BC6ENTC - induced cell growth inhibition, in part. CPR:falsenewlineMoreover, BC6ENTC treatment resulted in phosphorylation of BC6ENTG , and pretreatment with the BC6OTHER inhibitor, BC6OTHER , attenuated cell growth inhibition by BC6OTHER . CPR:falsenewlineMoreover, BC6ENTC treatment resulted in phosphorylation of BC6OTHER , and pretreatment with the BC6ENTG inhibitor, BC6OTHER , attenuated cell growth inhibition by BC6OTHER . CPR:falsenewlineMoreover, BC6OTHER treatment resulted in phosphorylation of BC6ENTG , and pretreatment with the BC6OTHER inhibitor, BC6ENTC , attenuated cell growth inhibition by BC6OTHER . CPR:falsenewlineMoreover, BC6OTHER treatment resulted in phosphorylation of BC6OTHER , and pretreatment with the BC6ENTG inhibitor, BC6ENTC , attenuated cell growth inhibition by BC6OTHER . CPR:falsenewlineMoreover, BC6OTHER treatment resulted in phosphorylation of BC6ENTG , and pretreatment with the BC6OTHER inhibitor, BC6OTHER , attenuated cell growth inhibition by BC6ENTC . CPR:falsenewlineMoreover, BC6OTHER treatment resulted in phosphorylation of BC6OTHER , and pretreatment with the BC6ENTG inhibitor, BC6OTHER , attenuated cell growth inhibition by BC6ENTC . CPR:falsenewlineThese data suggest that BC6ENTC , isolated from Japanese mugwort, modulates the BC6ENTG / BC6OTHER / BC6OTHER pathway, leading to inactivation of the BC6OTHER - BC6OTHER complex, followed by G2 / M cell cycle arrest in endometrial cancer cells. CPR:falsenewlineThese data suggest that BC6ENTC , isolated from Japanese mugwort, modulates the BC6OTHER / BC6ENTG / BC6OTHER pathway, leading to inactivation of the BC6OTHER - BC6OTHER complex, followed by G2 / M cell cycle arrest in endometrial cancer cells. CPR:falsenewlineThese data suggest that BC6ENTC , isolated from Japanese mugwort, modulates the BC6OTHER / BC6OTHER / BC6ENTG pathway, leading to inactivation of the BC6OTHER - BC6OTHER complex, followed by G2 / M cell cycle arrest in endometrial cancer cells. CPR:falsenewlineThese data suggest that BC6ENTC , isolated from Japanese mugwort, modulates the BC6OTHER / BC6OTHER / BC6OTHER pathway, leading to inactivation of the BC6ENTG - BC6OTHER complex, followed by G2 / M cell cycle arrest in endometrial cancer cells. CPR:4newlineThese data suggest that BC6ENTC , isolated from Japanese mugwort, modulates the BC6OTHER / BC6OTHER / BC6OTHER pathway, leading to inactivation of the BC6OTHER - BC6ENTG complex, followed by G2 / M cell cycle arrest in endometrial cancer cells. CPR:4newlineTo explore the functional properties of the two alleles, a full - length cDNA encoding the beta subunit, a key functional component of the BC6ENTC receptor, was isolated from Caenorhabditis elegans ( BC6ENTG , corresponding to the BC6OTHER ) and coexpressed in Xenopus oocytes with the BC6OTHER alleles. CPR:falsenewlineTo explore the functional properties of the two alleles, a full - length cDNA encoding the beta subunit, a key functional component of the BC6ENTC receptor, was isolated from Caenorhabditis elegans ( BC6OTHER , corresponding to the BC6ENTG ) and coexpressed in Xenopus oocytes with the BC6OTHER alleles. CPR:falsenewlineTo explore the functional properties of the two alleles, a full - length cDNA encoding the beta subunit, a key functional component of the BC6ENTC receptor, was isolated from Caenorhabditis elegans ( BC6OTHER , corresponding to the BC6OTHER ) and coexpressed in Xenopus oocytes with the BC6ENTG alleles. CPR:falsenewlineTwo alleles of the BC6ENTG gene, which encodes a putative BC6ENTC receptor alpha / gamma subunit, were isolated from Haemonchus contortus. CPR:falsenewlineWhen BC6ENTG was coexpressed with either the BC6OTHER allele or the BC6OTHER allele in Xenopus oocytes, BC6ENTC ( BC6OTHER ) - responsive channels with different sensitivity to the agonist were formed. CPR:falsenewlineWhen BC6OTHER was coexpressed with either the BC6ENTG allele or the BC6OTHER allele in Xenopus oocytes, BC6ENTC ( BC6OTHER ) - responsive channels with different sensitivity to the agonist were formed. CPR:falsenewlineWhen BC6OTHER was coexpressed with either the BC6OTHER allele or the BC6ENTG allele in Xenopus oocytes, BC6ENTC ( BC6OTHER ) - responsive channels with different sensitivity to the agonist were formed. CPR:falsenewlineWhen BC6ENTG was coexpressed with either the BC6OTHER allele or the BC6OTHER allele in Xenopus oocytes, CHEM ( BC6ENTC ) - responsive channels with different sensitivity to the agonist were formed. CPR:falsenewlineWhen BC6OTHER was coexpressed with either the BC6ENTG allele or the BC6OTHER allele in Xenopus oocytes, CHEM ( BC6ENTC ) - responsive channels with different sensitivity to the agonist were formed. CPR:falsenewlineWhen BC6OTHER was coexpressed with either the BC6OTHER allele or the BC6ENTG allele in Xenopus oocytes, CHEM ( BC6ENTC ) - responsive channels with different sensitivity to the agonist were formed. CPR:falsenewlineStudy of the nematode putative BC6ENTG subunits: evidence for modulation by BC6ENTC . CPR:falsenewlineHowever, when coapplied with 10 micro m BC6ENTC , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6ENTG / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6ENTC , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6ENTG receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6ENTC , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6ENTG / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6ENTC , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6ENTG receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6ENTC potentiated the BC6OTHER - evoked current of the BC6ENTG / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6ENTC potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6ENTG receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6ENTC potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6ENTG / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6ENTC potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6ENTG receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6ENTC - evoked current of the BC6ENTG / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6ENTC - evoked current of the BC6OTHER / BC6ENTG receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6ENTC - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6ENTG / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6ENTC - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6OTHER response of the BC6OTHER / BC6ENTG receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6ENTG / BC6OTHER receptor, but attenuated the BC6ENTC response of the BC6OTHER / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6ENTG receptor, but attenuated the BC6ENTC response of the BC6OTHER / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6ENTC response of the BC6ENTG / BC6OTHER receptor. CPR:falsenewlineHowever, when coapplied with 10 micro m BC6OTHER , BC6OTHER potentiated the BC6OTHER - evoked current of the BC6OTHER / BC6OTHER receptor, but attenuated the BC6ENTC response of the BC6OTHER / BC6ENTG receptor. CPR:falsenewlineWe demonstrated that the coexpressed BC6ENTG and BC6OTHER receptors are BC6ENTC - responsive, and provide evidence for the possible involvement of BC6OTHER receptors in the mechanism of BC6OTHER resistance. CPR:falsenewlineWe demonstrated that the coexpressed BC6OTHER and BC6ENTG receptors are BC6ENTC - responsive, and provide evidence for the possible involvement of BC6OTHER receptors in the mechanism of BC6OTHER resistance. CPR:falsenewlineWe demonstrated that the coexpressed BC6OTHER and BC6OTHER receptors are BC6ENTC - responsive, and provide evidence for the possible involvement of BC6ENTG in the mechanism of BC6OTHER resistance. CPR:falsenewlineWe demonstrated that the coexpressed BC6ENTG and BC6OTHER receptors are BC6OTHER - responsive, and provide evidence for the possible involvement of BC6ENTC receptors in the mechanism of BC6OTHER resistance. CPR:falsenewlineWe demonstrated that the coexpressed BC6OTHER and BC6ENTG receptors are BC6OTHER - responsive, and provide evidence for the possible involvement of BC6ENTC receptors in the mechanism of BC6OTHER resistance. CPR:falsenewlineWe demonstrated that the coexpressed BC6ENTG and BC6OTHER receptors are BC6OTHER - responsive, and provide evidence for the possible involvement of BC6OTHER receptors in the mechanism of BC6ENTC resistance. CPR:falsenewlineWe demonstrated that the coexpressed BC6OTHER and BC6ENTG receptors are BC6OTHER - responsive, and provide evidence for the possible involvement of BC6OTHER receptors in the mechanism of BC6ENTC resistance. CPR:falsenewlineWe demonstrated that the coexpressed BC6OTHER and BC6OTHER receptors are BC6OTHER - responsive, and provide evidence for the possible involvement of BC6ENTG in the mechanism of BC6ENTC resistance. CPR:falsenewlineThese two alleles were shown previously to be associated with BC6ENTC susceptibility ( BC6ENTG ) and resistance ( BC6OTHER ), respectively. CPR:falsenewlineThese two alleles were shown previously to be associated with BC6ENTC susceptibility ( BC6OTHER ) and resistance ( BC6ENTG ), respectively. CPR:falsenewlineBC6ENTC exhibited the predicted binding mode and demonstrated high inhibitory activity for BC6ENTG in enzyme - and cell - based assays. CPR:4newlineBC6ENTG ( BC6OTHER ) catalyzes the oxidation of BC6OTHER including BC6ENTC , a coagonist of the BC6OTHER receptor. CPR:9newlineBC6OTHER oxidase ( BC6OTHER ) catalyzes the oxidation of BC6OTHER including BC6ENTC , a coagonist of the BC6ENTG . CPR:9newlineBC6OTHER oxidase ( BC6ENTG ) catalyzes the oxidation of BC6OTHER including BC6ENTC , a coagonist of the BC6OTHER receptor. CPR:9newline BC6ENTC Derivatives as Novel BC6ENTG Inhibitors. CPR:4newlineBC6ENTC oxidase ( BC6OTHER ) catalyzes the oxidation of BC6OTHER including BC6OTHER , a coagonist of the BC6ENTG . CPR:falsenewlineBC6ENTC oxidase ( BC6ENTG ) catalyzes the oxidation of BC6OTHER including BC6OTHER , a coagonist of the BC6OTHER receptor. CPR:falsenewlineBC6ENTG ( BC6OTHER ) catalyzes the oxidation of BC6OTHER including BC6OTHER , a coagonist of the BC6ENTC receptor. CPR:9newlineBC6OTHER oxidase ( BC6ENTG ) catalyzes the oxidation of BC6OTHER including BC6OTHER , a coagonist of the BC6ENTC receptor. CPR:9newlineWe identified a series of BC6ENTC derivatives as novel BC6ENTG inhibitors with high potency and substantial cell permeability using fragment - based drug design. CPR:4newlineBC6ENTG ( BC6OTHER ) catalyzes the oxidation of BC6ENTC including BC6OTHER , a coagonist of the BC6OTHER receptor. CPR:9newlineBC6OTHER oxidase ( BC6OTHER ) catalyzes the oxidation of BC6ENTC including BC6OTHER , a coagonist of the BC6ENTG . CPR:9newlineBC6OTHER oxidase ( BC6ENTG ) catalyzes the oxidation of BC6ENTC including BC6OTHER , a coagonist of the BC6OTHER receptor. CPR:9newline Oral BC6ENTC ( BC6OTHER (®)), a selective BC6OTHER BC6ENTG receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight - related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes). CPR:falsenewline Oral BC6OTHER ( BC6ENTC (®)), a selective BC6OTHER BC6ENTG receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight - related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes). CPR:falsenewline Oral BC6OTHER ( BC6OTHER (®)), a selective BC6ENTC BC6ENTG receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight - related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes). CPR:falsenewlineThe present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6ENTC synthase ( BC6ENTG ; BC6OTHER - BC6OTHER : BC6OTHER glucosyltransferase). CPR:falsenewlineThe present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6ENTC synthase ( BC6OTHER ; BC6ENTG BC6OTHER glucosyltransferase). CPR:falsenewlineThe present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6OTHER ( BC6ENTG ; BC6ENTC - BC6OTHER : BC6OTHER glucosyltransferase). CPR:falsenewlineThe present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6ENTG ( BC6OTHER ; BC6ENTC - BC6OTHER : BC6OTHER glucosyltransferase). CPR:falsenewlineThe present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6OTHER ( BC6ENTG ; BC6OTHER - BC6ENTC : BC6OTHER glucosyltransferase). CPR:falsenewlineThe present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6ENTG ( BC6OTHER ; BC6OTHER - BC6ENTC : BC6OTHER glucosyltransferase). CPR:falsenewlineThe present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6OTHER ( BC6ENTG ; BC6OTHER - BC6OTHER : BC6ENTC glucosyltransferase). CPR:falsenewlineThe present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6OTHER ( BC6OTHER ; BC6ENTG BC6ENTC glucosyltransferase). CPR:falsenewlineThe present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of BC6ENTG ( BC6OTHER ; BC6OTHER - BC6OTHER : BC6ENTC glucosyltransferase). CPR:falsenewlineConsequently, mice with inducible forebrain neuron - specific deletion of the BC6ENTC - BC6OTHER : BC6OTHER glucosyltransferase gene ( BC6ENTG ) display obesity, hypothermia, and lower sympathetic activity. CPR:falsenewlineConsequently, mice with inducible forebrain neuron - specific deletion of the BC6OTHER - BC6ENTC : BC6OTHER glucosyltransferase gene ( BC6ENTG ) display obesity, hypothermia, and lower sympathetic activity. CPR:falsenewlineConsequently, mice with inducible forebrain neuron - specific deletion of the BC6ENTG BC6ENTC glucosyltransferase gene ( BC6OTHER ) display obesity, hypothermia, and lower sympathetic activity. CPR:falsenewlineConsequently, mice with inducible forebrain neuron - specific deletion of the BC6OTHER - BC6OTHER : BC6ENTC glucosyltransferase gene ( BC6ENTG ) display obesity, hypothermia, and lower sympathetic activity. CPR:falsenewlineBC6ENTC , an effective compound derived from foxtail - like sophora herb and seed, has been reported that it can alleviate non - alcoholic steatohepatitis (NASH) in rats and affect BC6ENTG synthesis. CPR:falsenewlineMoreover, compared with the model group, BC6ENTC could significantly increase BC6OTHER (>5.82 - fold), BC6OTHER (>1.29 - fold) and BC6ENTG (>3.27 - fold) protein expressions, and reduce BC6OTHER (<0.30 - fold) and BC6OTHER (<0.20 - fold) protein expression. CPR:falsenewlineMoreover, compared with the model group, BC6ENTC could significantly increase BC6OTHER (>5.82 - fold), BC6OTHER (>1.29 - fold) and BC6OTHER (>3.27 - fold) protein expressions, and reduce BC6ENTG (<0.30 - fold) and BC6OTHER (<0.20 - fold) protein expression. CPR:falsenewlineMoreover, compared with the model group, BC6ENTC could significantly increase BC6OTHER (>5.82 - fold), BC6OTHER (>1.29 - fold) and BC6OTHER (>3.27 - fold) protein expressions, and reduce BC6OTHER (<0.30 - fold) and BC6ENTG (<0.20 - fold) protein expression. CPR:falsenewlineMoreover, compared with the model group, BC6ENTC could significantly increase BC6ENTG (>5.82 - fold), BC6OTHER (>1.29 - fold) and BC6OTHER (>3.27 - fold) protein expressions, and reduce BC6OTHER (<0.30 - fold) and BC6OTHER (<0.20 - fold) protein expression. CPR:falsenewlineMoreover, compared with the model group, BC6ENTC could significantly increase BC6OTHER (>5.82 - fold), BC6ENTG (>1.29 - fold) and BC6OTHER (>3.27 - fold) protein expressions, and reduce BC6OTHER (<0.30 - fold) and BC6OTHER (<0.20 - fold) protein expression. CPR:falsenewlineWe concluded that BC6ENTC could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of BC6ENTG . CPR:falsenewlineWhile BC6ENTC treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of BC6ENTG expression (<0.57 - fold) and increase of BC6OTHER expression (>1.48 - fold). CPR:falsenewlineWhile BC6ENTC treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of BC6OTHER expression (<0.57 - fold) and increase of BC6ENTG expression (>1.48 - fold). CPR:falsenewline BC6ENTC alleviates hepatocyte steatosis through activating BC6ENTG signaling pathway. CPR:falsenewlineTaken together, the levels of plasma four FAs with shorter BC6OTHER chains were higher in pregnant BC6ENTG mice than in other genotypes, and BC6OTHER exposure decreased these specific FA concentrations only in BC6OTHER mice, similarly to BC6ENTC levels. CPR:falsenewlineTaken together, the levels of plasma four FAs with shorter BC6OTHER chains were higher in pregnant BC6OTHER mice than in other genotypes, and BC6OTHER exposure decreased these specific FA concentrations only in BC6ENTG mice, similarly to BC6ENTC levels. CPR:falsenewlineTo identify the BC6OTHER (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6ENTG ), BC6OTHER - null ( BC6OTHER - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6ENTC . CPR:falsenewlineTo identify the BC6OTHER (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6ENTG - null ( BC6OTHER - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6ENTC . CPR:falsenewlineTo identify the BC6OTHER (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6ENTG - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6ENTC . CPR:falsenewlineTo identify the BC6OTHER (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6OTHER - null) and BC6ENTG ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6ENTC . CPR:falsenewlineTo identify the BC6OTHER (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6OTHER - null) and BC6OTHER ( BC6ENTG ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6ENTC . CPR:falsenewlineThe plasma levels of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER were higher in the pregnant control BC6ENTG mice than in BC6OTHER - null and BC6OTHER mice. CPR:falsenewlineThe plasma levels of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6ENTG - null and BC6OTHER mice. CPR:falsenewlineThe plasma levels of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6OTHER - null and BC6ENTG mice. CPR:falsenewlineThe plasma levels of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER were higher in the pregnant control BC6ENTG mice than in BC6OTHER - null and BC6OTHER mice. CPR:falsenewlineThe plasma levels of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6ENTG - null and BC6OTHER mice. CPR:falsenewlineThe plasma levels of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6OTHER - null and BC6ENTG mice. CPR:falsenewlineThe plasma levels of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER were higher in the pregnant control BC6ENTG mice than in BC6OTHER - null and BC6OTHER mice. CPR:falsenewlineThe plasma levels of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6ENTG - null and BC6OTHER mice. CPR:falsenewlineThe plasma levels of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER were higher in the pregnant control BC6OTHER mice than in BC6OTHER - null and BC6ENTG mice. CPR:falsenewlineThe plasma levels of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC were higher in the pregnant control BC6ENTG mice than in BC6OTHER - null and BC6OTHER mice. CPR:falsenewlineThe plasma levels of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC were higher in the pregnant control BC6OTHER mice than in BC6ENTG - null and BC6OTHER mice. CPR:falsenewlineThe plasma levels of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC were higher in the pregnant control BC6OTHER mice than in BC6OTHER - null and BC6ENTG mice. CPR:falsenewlineBC6ENTC exposure significantly decreased the levels of these four FAs only in pregnant BC6ENTG mice. CPR:falsenewlineTo identify the BC6ENTC (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6ENTG ), BC6OTHER - null ( BC6OTHER - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6OTHER . CPR:falsenewlineTo identify the BC6ENTC (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6ENTG - null ( BC6OTHER - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6OTHER . CPR:falsenewlineTo identify the BC6ENTC (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6ENTG - null) and BC6OTHER ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6OTHER . CPR:falsenewlineTo identify the BC6ENTC (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6OTHER - null) and BC6ENTG ( BC6OTHER ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6OTHER . CPR:falsenewlineTo identify the BC6ENTC (FA) species involved and to understand the underlying mechanisms, pregnant Sv / 129 wild - type ( BC6OTHER ), BC6OTHER - null ( BC6OTHER - null) and BC6OTHER ( BC6ENTG ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% BC6OTHER . CPR:falsenewlineHowever, BC6ENTC exposure did not clearly influence BC6ENTG nor BC6OTHER expressions in the liver of all maternal mice. CPR:falsenewlineHowever, BC6ENTC exposure did not clearly influence BC6OTHER nor BC6ENTG expressions in the liver of all maternal mice. CPR:falsenewlineTaken together, the levels of plasma four FAs with shorter BC6ENTC chains were higher in pregnant BC6ENTG mice than in other genotypes, and BC6OTHER exposure decreased these specific FA concentrations only in BC6OTHER mice, similarly to BC6OTHER levels. CPR:falsenewlineTaken together, the levels of plasma four FAs with shorter BC6ENTC chains were higher in pregnant BC6OTHER mice than in other genotypes, and BC6OTHER exposure decreased these specific FA concentrations only in BC6ENTG mice, similarly to BC6OTHER levels. CPR:falsenewlineTaken together, the levels of plasma four FAs with shorter BC6OTHER chains were higher in pregnant BC6ENTG mice than in other genotypes, and BC6ENTC exposure decreased these specific FA concentrations only in BC6OTHER mice, similarly to BC6OTHER levels. CPR:falsenewlineTaken together, the levels of plasma four FAs with shorter BC6OTHER chains were higher in pregnant BC6OTHER mice than in other genotypes, and BC6ENTC exposure decreased these specific FA concentrations only in BC6ENTG mice, similarly to BC6OTHER levels. CPR:falsenewlineWith exposure to BC6ENTC , a selective BC6ENTG inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective BC6OTHER inhibitors in breast cancer prophylaxis. CPR:falsenewlineWith exposure to BC6ENTC , a selective BC6OTHER inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective BC6ENTG inhibitors in breast cancer prophylaxis. CPR:falsenewlineMETHODS: We conducted a case - control study to measure the association between selective BC6ENTG inhibitors, particularly BC6ENTC , BC6OTHER , BC6OTHER and non - specific NSAID subgroups, and breast cancer risk. CPR:falsenewlineMETHODS: We conducted a case - control study to measure the association between selective BC6ENTG inhibitors, particularly BC6OTHER , BC6ENTC , BC6OTHER and non - specific NSAID subgroups, and breast cancer risk. CPR:falsenewlineMETHODS: We conducted a case - control study to measure the association between selective BC6ENTG inhibitors, particularly BC6OTHER , BC6OTHER , BC6ENTC and non - specific NSAID subgroups, and breast cancer risk. CPR:falsenewlineBACKGROUND: Recent epidemiologic and laboratory studies have suggested that non - BC6ENTC anti - inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of BC6ENTG ( BC6OTHER ). CPR:falsenewlineBACKGROUND: Recent epidemiologic and laboratory studies have suggested that non - BC6ENTC anti - inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of BC6OTHER ( BC6ENTG ). CPR:falsenewlineSystemic administration of BC6ENTC recapitulates many of its effects when administered centrally, raising the questions of whether and to what extent circulating BC6ENTG contributes to energy regulation. CPR:falsenewlineThe neuropeptide BC6ENTG has emerged as an important BC6ENTC in the regulation of energy balance. CPR:falsenewlineSystemic administration of BC6ENTG recapitulates many of its effects when administered centrally, raising the questions of whether and to what extent circulating BC6ENTC contributes to energy regulation. CPR:falsenewlineA comparison of BC6OTHER with BC6ENTC across the whole BC6ENTG panel revealed overlapping, but distinct, inhibition profiles. CPR:4newlineBC6ENTC did not inhibit BC6ENTG or BC6OTHER , but prominently targeted the apoptosis - linked BC6OTHER . CPR:falsenewlineBC6ENTC did not inhibit BC6OTHER or BC6ENTG , but prominently targeted the apoptosis - linked BC6OTHER . CPR:falsenewlineBC6ENTC did not inhibit BC6OTHER or BC6OTHER , but prominently targeted the apoptosis - linked BC6ENTG . CPR:falsenewlineGlobal target profile of the BC6ENTG inhibitor BC6ENTC in primary chronic myeloid leukemia cells. CPR:falsenewlineAlthough in vivo BC6ENTC is inactive against BC6ENTG BC6OTHER , we found this clinically important mutant to be enzymatically inhibited in the mid - nanomolar range. CPR:falsenewlineAlthough in vivo BC6ENTC is inactive against BC6OTHER BC6ENTG , we found this clinically important mutant to be enzymatically inhibited in the mid - nanomolar range. CPR:falsenewlineFinally, BC6ENTC is the first BC6ENTG inhibitor shown to target BC6OTHER , recently implicated in myeloid leukemia cell proliferation. CPR:falsenewlineFinally, BC6ENTC is the first BC6OTHER inhibitor shown to target BC6ENTG , recently implicated in myeloid leukemia cell proliferation. CPR:falsenewlineHere, we characterized the target profile of the dual BC6ENTG / BC6OTHER inhibitor BC6ENTC employing a two - tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro BC6OTHER assays against a large recombinant BC6OTHER panel. CPR:falsenewlineHere, we characterized the target profile of the dual BC6OTHER / BC6ENTG inhibitor BC6ENTC employing a two - tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro BC6OTHER assays against a large recombinant BC6OTHER panel. CPR:falsenewlineHere, we characterized the target profile of the dual BC6OTHER / BC6OTHER inhibitor BC6ENTC employing a two - tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro BC6ENTG assays against a large recombinant BC6OTHER panel. CPR:falsenewlineHere, we characterized the target profile of the dual BC6OTHER / BC6OTHER inhibitor BC6ENTC employing a two - tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro BC6OTHER assays against a large recombinant BC6ENTG panel. CPR:falsenewlineThe combined strategy resulted in a global survey of BC6ENTC targets comprised of over 45 novel BC6ENTG BC6OTHER kinases. CPR:falsenewlineThe combined strategy resulted in a global survey of BC6OTHER targets comprised of over 45 novel BC6ENTG BC6ENTC kinases. CPR:falsenewlineA comparison of BC6ENTC with BC6OTHER across the whole BC6ENTG panel revealed overlapping, but distinct, inhibition profiles. CPR:4newlineThese findings indicate that MBE and its BC6ENTC suppress the light - induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of BC6ENTG may be involved in the underlying mechanism. CPR:falsenewlineMaqui berry (Aristotelia chilensis) and the constituent BC6ENTC inhibit BC6ENTG cell death induced by visible light. CPR:falsenewlineBC6ENTC - evoked currents were completely and reversibly blocked by the competitive BC6ENTG antagonist BC6OTHER (IC50 = 1.7 microM), indicating expression of BC6OTHER but not BC6OTHER . CPR:falsenewlineBC6ENTC - evoked currents were completely and reversibly blocked by the competitive BC6OTHER antagonist BC6OTHER (IC50 = 1.7 microM), indicating expression of BC6ENTG but not BC6OTHER . CPR:falsenewlineBC6ENTC - evoked currents were completely and reversibly blocked by the competitive BC6OTHER antagonist BC6OTHER (IC50 = 1.7 microM), indicating expression of BC6OTHER but not BC6ENTG . CPR:falsenewlineBC6OTHER - evoked currents were completely and reversibly blocked by the competitive BC6ENTG antagonist BC6ENTC (IC50 = 1.7 microM), indicating expression of BC6OTHER but not BC6OTHER . CPR:falsenewlineBC6OTHER - evoked currents were completely and reversibly blocked by the competitive BC6OTHER antagonist BC6ENTC (IC50 = 1.7 microM), indicating expression of BC6ENTG but not BC6OTHER . CPR:falsenewlineBC6OTHER - evoked currents were completely and reversibly blocked by the competitive BC6OTHER antagonist BC6ENTC (IC50 = 1.7 microM), indicating expression of BC6OTHER but not BC6ENTG . CPR:falsenewlineTheir affinity for BC6ENTC was moderate (EC50 = 30 microM), and the Hill coefficient was 1.3, corresponding to two BC6ENTG . CPR:falsenewlineFurthermore, BC6ENTC receptors of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6ENTG . CPR:falsenewlineFurthermore, BC6ENTG of horizontal cells were modulated by extracellular application of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6OTHER . CPR:falsenewlineFurthermore, BC6OTHER receptors of horizontal cells were modulated by extracellular application of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6ENTG . CPR:falsenewlineFurthermore, BC6ENTG of horizontal cells were modulated by extracellular application of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6OTHER . CPR:falsenewlineFurthermore, BC6OTHER receptors of horizontal cells were modulated by extracellular application of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6ENTG . CPR:falsenewlineFurthermore, BC6ENTG of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6OTHER . CPR:falsenewlineFurthermore, BC6OTHER receptors of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6ENTG . CPR:falsenewlineFurthermore, BC6ENTG of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6OTHER . CPR:falsenewlineFurthermore, BC6OTHER receptors of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , thus showing typical pharmacological properties of CNS BC6ENTG . CPR:falsenewlineFurthermore, BC6ENTG of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , thus showing typical pharmacological properties of CNS BC6OTHER . CPR:falsenewlineFurthermore, BC6OTHER receptors of horizontal cells were modulated by extracellular application of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , thus showing typical pharmacological properties of CNS BC6ENTG . CPR:falsenewlineIn terms of the mechanisms, we found that BC6ENTC BC6OTHER hydrolase ( BC6ENTG ) which degrades BC6OTHER , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age - dependent differences. CPR:falsenewlineIn terms of the mechanisms, we found that CHEM BC6ENTC hydrolase ( BC6ENTG ) which degrades BC6OTHER , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age - dependent differences. CPR:falsenewlineIn terms of the mechanisms, we found that CHEM BC6OTHER hydrolase ( BC6ENTG ) which degrades BC6ENTC , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age - dependent differences. CPR:falsenewlineIn terms of the mechanisms, we found that BC6ENTG ( BC6OTHER ) which degrades BC6ENTC , was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age - dependent differences. CPR:9newlineHowever, enzymes contributing to oxidative metabolism of BC6ENTC , namely BC6ENTG and BC6OTHER , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of BC6OTHER . CPR:9newlineHowever, enzymes contributing to oxidative metabolism of BC6ENTC , namely BC6OTHER and BC6ENTG , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of BC6OTHER . CPR:9newlineHowever, enzymes contributing to oxidative metabolism of BC6OTHER , namely BC6ENTG and BC6OTHER , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of BC6ENTC . CPR:9newlineHowever, enzymes contributing to oxidative metabolism of BC6OTHER , namely BC6OTHER and BC6ENTG , were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of BC6ENTC . CPR:9newlineBC6OTHER activation induces numerous proinflammatory gene products including BC6ENTG , BC6OTHER ( BC6OTHER ), and inducible BC6ENTC synthase ( BC6OTHER ). CPR:falsenewlineBC6OTHER activation induces numerous proinflammatory gene products including BC6OTHER , BC6ENTG ( BC6OTHER ), and inducible BC6ENTC synthase ( BC6OTHER ). CPR:falsenewlineBC6OTHER activation induces numerous proinflammatory gene products including BC6OTHER , BC6OTHER ( BC6ENTG ), and inducible BC6ENTC synthase ( BC6OTHER ). CPR:falsenewlineBC6OTHER activation induces numerous proinflammatory gene products including BC6OTHER , BC6OTHER ( BC6OTHER ), and inducible BC6ENTC synthase ( BC6ENTG ). CPR:falsenewlineBC6ENTG activation induces numerous proinflammatory gene products including BC6OTHER , BC6OTHER ( BC6OTHER ), and inducible BC6ENTC synthase ( BC6OTHER ). CPR:falsenewlineHere, we report biochemical evidence that BC6ENTC alone induces BC6ENTG activation, resulting in the induced expression of BC6OTHER and BC6OTHER . CPR:falsenewlineHere, we report biochemical evidence that BC6ENTC alone induces BC6OTHER activation, resulting in the induced expression of BC6ENTG and BC6OTHER . CPR:falsenewlineHere, we report biochemical evidence that BC6ENTC alone induces BC6OTHER activation, resulting in the induced expression of BC6OTHER and BC6ENTG . CPR:falsenewline BC6ENTC induces the expression of BC6ENTG and inducible BC6OTHER synthase. CPR:falsenewline BC6ENTC induces the expression of BC6OTHER and BC6ENTG . CPR:falsenewline BC6OTHER induces the expression of BC6ENTG and inducible BC6ENTC synthase. CPR:falsenewlineSedation and BC6ENTG antagonism: studies in man with the enantiomers of BC6OTHER and BC6ENTC . CPR:falsenewlineSedation and BC6ENTG antagonism: studies in man with the enantiomers of BC6ENTC and BC6OTHER . CPR:falsenewlineHerein, the derangement of the BC6ENTC / BC6ENTG pathway and its impact on transformation - linked changes of mitochondrial functions is investigated. CPR:falsenewlineExogenous stimulation of BC6ENTG activity, achieved by BC6ENTC treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6OTHER activity, achieved by BC6ENTC treatment, protected BC6ENTG - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6OTHER activity, achieved by BC6ENTC treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6ENTG activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6ENTG activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6ENTC deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6ENTG - transformed cells from apoptosis induced by BC6ENTC deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6ENTC deprivation, enhanced BC6ENTG activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineOncogenic BC6ENTG expression is associated with derangement of the BC6ENTC / BC6OTHER pathway and BC6OTHER - reversible alterations of mitochondrial dynamics and respiration. CPR:falsenewlineOncogenic BC6OTHER expression is associated with derangement of the BC6ENTC / BC6ENTG pathway and BC6OTHER - reversible alterations of mitochondrial dynamics and respiration. CPR:falsenewlineOncogenic BC6ENTG expression is associated with derangement of the BC6OTHER / BC6OTHER pathway and BC6ENTC - reversible alterations of mitochondrial dynamics and respiration. CPR:falsenewlineOncogenic BC6OTHER expression is associated with derangement of the BC6OTHER / BC6ENTG pathway and BC6ENTC - reversible alterations of mitochondrial dynamics and respiration. CPR:falsenewlineExogenous stimulation of BC6ENTG activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6ENTC ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6ENTG - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6ENTC ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6ENTG activity, intracellular BC6ENTC ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6ENTG activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6ENTC ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6ENTG - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6ENTC ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6ENTG activity, intracellular BC6OTHER ( BC6ENTC ) levels, mitochondrial fusion and decreased intracellular reactive BC6OTHER species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6ENTG activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6ENTC species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6ENTG - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6OTHER activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6ENTC species (ROS) levels. CPR:falsenewlineExogenous stimulation of BC6OTHER activity, achieved by BC6OTHER treatment, protected BC6OTHER - transformed cells from apoptosis induced by BC6OTHER deprivation, enhanced BC6ENTG activity, intracellular BC6OTHER ( BC6OTHER ) levels, mitochondrial fusion and decreased intracellular reactive BC6ENTC species (ROS) levels. CPR:falsenewlineThese findings support the notion that BC6ENTC shortage - induced apoptosis, specific of BC6ENTG - transformed cells, is associated to a derangement of BC6OTHER signaling that leads to BC6OTHER decrease, reduction of BC6OTHER formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs. CPR:falsenewlineThese findings support the notion that BC6ENTC shortage - induced apoptosis, specific of BC6OTHER - transformed cells, is associated to a derangement of BC6ENTG signaling that leads to BC6OTHER decrease, reduction of BC6OTHER formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs. CPR:falsenewlineThese findings support the notion that BC6ENTC shortage - induced apoptosis, specific of BC6OTHER - transformed cells, is associated to a derangement of BC6OTHER signaling that leads to BC6ENTG decrease, reduction of BC6OTHER formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs. CPR:falsenewlineThese findings support the notion that BC6OTHER shortage - induced apoptosis, specific of BC6ENTG - transformed cells, is associated to a derangement of BC6OTHER signaling that leads to BC6OTHER decrease, reduction of BC6ENTC formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs. CPR:falsenewlineThese findings support the notion that BC6OTHER shortage - induced apoptosis, specific of BC6OTHER - transformed cells, is associated to a derangement of BC6ENTG signaling that leads to BC6OTHER decrease, reduction of BC6ENTC formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs. CPR:falsenewlineThese findings support the notion that BC6OTHER shortage - induced apoptosis, specific of BC6OTHER - transformed cells, is associated to a derangement of BC6OTHER signaling that leads to BC6ENTG decrease, reduction of BC6ENTC formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs. CPR:falsenewlineIn previous papers, it has been shown that BC6ENTG transformed mouse cells are much more sensitive as compared with normal cells to BC6ENTC withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of BC6OTHER . CPR:falsenewlineIn previous papers, it has been shown that BC6OTHER transformed mouse cells are much more sensitive as compared with normal cells to BC6ENTC withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of BC6ENTG . CPR:falsenewlineRecent observations suggest that transformed cells have a derangement in the BC6ENTC / BC6ENTG ( BC6OTHER / BC6OTHER ) pathway, which is known to regulate several mitochondrial functions. CPR:falsenewlineRecent observations suggest that transformed cells have a derangement in the BC6ENTC / BC6OTHER - dependent protein kinase ( BC6OTHER / BC6ENTG ) pathway, which is known to regulate several mitochondrial functions. CPR:falsenewlineRecent observations suggest that transformed cells have a derangement in the BC6OTHER / BC6ENTC - dependent protein kinase ( BC6OTHER / BC6ENTG ) pathway, which is known to regulate several mitochondrial functions. CPR:falsenewlineRecent observations suggest that transformed cells have a derangement in the BC6OTHER / BC6ENTG ( BC6ENTC / BC6OTHER ) pathway, which is known to regulate several mitochondrial functions. CPR:falsenewlineRecent observations suggest that transformed cells have a derangement in the BC6OTHER / BC6OTHER - dependent protein kinase ( BC6ENTC / BC6ENTG ) pathway, which is known to regulate several mitochondrial functions. CPR:falsenewlineIncubation with BC6ENTC (0.2 - 1 mM) activated BC6OTHER in both human islets and MIN6 beta - cells in parallel with an inhibition of BC6ENTG secretion, whereas leptin (10 - 100 nM) was without effect in MIN6 cells. CPR:falsenewlineIncubation with BC6ENTC (0.2 - 1 mM) activated BC6ENTG in both human islets and MIN6 beta - cells in parallel with an inhibition of BC6OTHER secretion, whereas leptin (10 - 100 nM) was without effect in MIN6 cells. CPR:falsenewline BC6ENTC , but not leptin, regulates BC6OTHER in pancreatic islets: impact on BC6OTHER - stimulated BC6ENTG secretion. CPR:falsenewline BC6ENTC , but not leptin, regulates BC6ENTG in pancreatic islets: impact on BC6OTHER - stimulated BC6OTHER secretion. CPR:falsenewline BC6OTHER , but not leptin, regulates BC6ENTC - activated protein kinase in pancreatic islets: impact on BC6OTHER - stimulated BC6ENTG secretion. CPR:falsenewline BC6OTHER , but not leptin, regulates BC6OTHER in pancreatic islets: impact on BC6ENTC - stimulated BC6ENTG secretion. CPR:falsenewline BC6OTHER , but not leptin, regulates BC6ENTG in pancreatic islets: impact on BC6ENTC - stimulated BC6OTHER secretion. CPR:falsenewlineBC6ENTC , a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6ENTC , a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of BC6OTHER - activated protein kinase ( BC6ENTG ). CPR:falsenewlineThese studies demonstrate that BC6ENTG activity is subject to regulation by both BC6ENTC and BC6OTHER in pancreatic islets and clonal beta - cells. CPR:falsenewlineThese studies demonstrate that BC6ENTG activity is subject to regulation by both BC6OTHER and BC6ENTC in pancreatic islets and clonal beta - cells. CPR:falsenewlineThe inhibitory effects of BC6ENTC on BC6ENTG secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes. CPR:falsenewlineBC6OTHER , a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of BC6ENTC - activated protein kinase ( BC6ENTG ). CPR:falsenewlineWhether BC6ENTC or the satiety factor leptin, which also stimulates BC6ENTG in muscle, regulates this enzyme in pancreatic islets is unknown. CPR:falsenewlineHere, we explore whether 1) BC6ENTC , BC6OTHER , or leptin regulates BC6ENTG activity in isolated islets from rodent and human and 2) whether changes in BC6OTHER activity modulate BC6OTHER secretion from human islets. CPR:falsenewlineHere, we explore whether 1) BC6ENTC , BC6OTHER , or leptin regulates BC6OTHER activity in isolated islets from rodent and human and 2) whether changes in BC6ENTG activity modulate BC6OTHER secretion from human islets. CPR:falsenewlineHere, we explore whether 1) BC6ENTC , BC6OTHER , or leptin regulates BC6OTHER activity in isolated islets from rodent and human and 2) whether changes in BC6OTHER activity modulate BC6ENTG secretion from human islets. CPR:falsenewlineHere, we explore whether 1) BC6OTHER , BC6ENTC , or leptin regulates BC6ENTG activity in isolated islets from rodent and human and 2) whether changes in BC6OTHER activity modulate BC6OTHER secretion from human islets. CPR:falsenewlineHere, we explore whether 1) BC6OTHER , BC6ENTC , or leptin regulates BC6OTHER activity in isolated islets from rodent and human and 2) whether changes in BC6ENTG activity modulate BC6OTHER secretion from human islets. CPR:falsenewlineHere, we explore whether 1) BC6OTHER , BC6ENTC , or leptin regulates BC6OTHER activity in isolated islets from rodent and human and 2) whether changes in BC6OTHER activity modulate BC6ENTG secretion from human islets. CPR:falsenewlineIncreases in BC6ENTC concentration from 0 to 3 and from 3 to 17 mM inhibited BC6ENTG activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells. CPR:4newlineThese data support the hypothesis that mutations of BC6ENTG may provide the "activated BC6ENTC kinase signal" that is thought to be important for leukemogenesis. CPR:falsenewlineAs expected, mutations of BC6ENTC kinase genes ( BC6OTHER , BC6OTHER , and BC6ENTG ) were common in de novo AML, with a cumulative frequency of 30%. CPR:falsenewlineAs expected, mutations of BC6ENTC kinase genes ( BC6ENTG , BC6OTHER , and BC6OTHER ) were common in de novo AML, with a cumulative frequency of 30%. CPR:falsenewlineAs expected, mutations of BC6ENTC kinase genes ( BC6OTHER , BC6ENTG , and BC6OTHER ) were common in de novo AML, with a cumulative frequency of 30%. CPR:falsenewlineThis anti - proliferative effect was abolished by elevating [ BC6ENTC ]i. BC6OTHER overexpression induced VSMC proliferation, and potentiated BC6OTHER - induced proliferation, by inducing BC6OTHER phosphorylation, BC6OTHER and BC6ENTG . CPR:falsenewlineThis anti - proliferative effect was abolished by elevating [ BC6ENTC ]i. BC6ENTG overexpression induced VSMC proliferation, and potentiated BC6OTHER - induced proliferation, by inducing BC6OTHER phosphorylation, BC6OTHER and BC6OTHER . CPR:falsenewlineThis anti - proliferative effect was abolished by elevating [ BC6ENTC ]i. BC6OTHER overexpression induced VSMC proliferation, and potentiated BC6ENTG - induced proliferation, by inducing BC6OTHER phosphorylation, BC6OTHER and BC6OTHER . CPR:falsenewlineThis anti - proliferative effect was abolished by elevating [ BC6ENTC ]i. BC6OTHER overexpression induced VSMC proliferation, and potentiated BC6OTHER - induced proliferation, by inducing BC6ENTG phosphorylation, BC6OTHER and BC6OTHER . CPR:falsenewlineThis anti - proliferative effect was abolished by elevating [ BC6ENTC ]i. BC6OTHER overexpression induced VSMC proliferation, and potentiated BC6OTHER - induced proliferation, by inducing BC6OTHER phosphorylation, BC6ENTG and BC6OTHER . CPR:falsenewlineThe BC6ENTG BC6OTHER Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling BC6ENTC - dependent Signaling. CPR:falsenewlineThe BC6ENTG BC6ENTC Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling BC6OTHER - dependent Signaling. CPR:falsenewlinePharmacological stimulation of BC6ENTG unexpectedly suppressed proliferation by inhibiting the rise in [ BC6ENTC ]i and abolishing the expression and activity of BC6OTHER and BC6OTHER . CPR:falsenewlinePharmacological stimulation of BC6OTHER unexpectedly suppressed proliferation by inhibiting the rise in [ BC6ENTC ]i and abolishing the expression and activity of BC6ENTG and BC6OTHER . CPR:falsenewlinePharmacological stimulation of BC6OTHER unexpectedly suppressed proliferation by inhibiting the rise in [ BC6ENTC ]i and abolishing the expression and activity of BC6OTHER and BC6ENTG . CPR:falsenewlineIn conclusion, BC6ENTG plays an important role in VSMC proliferation via controlling BC6ENTC - dependent signaling pathways and its modulation may therefore constitute a new therapeutic target for cell proliferative diseases such as atherosclerosis. CPR:falsenewlineThe BC6ENTG BC6ENTC channel KCa3.1 contributes to a variety of cell activation processes in pathologies such as inflammation, carcinogenesis and vascular remodeling. CPR:falsenewlineBC6ENTG ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTG ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6ENTG blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6ENTG ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6ENTG and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6ENTC concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6ENTG ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTG ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6ENTG blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6ENTG ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6ENTG and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6ENTC ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6ENTG ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTG ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6ENTG blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6ENTG ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6ENTG and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6ENTC ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6ENTG ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTG ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6ENTG blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6ENTG ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6ENTG and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6ENTC ]i and attenuating the expression of phosphorylated BC6OTHER response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6ENTG ). CPR:falsenewlineBC6ENTG ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTG ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6ENTG blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6ENTG ), BC6OTHER and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6ENTG and BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6OTHER and BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6OTHER ) - induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular BC6OTHER concentration ([ BC6OTHER ]i) and was enhanced by elevating [ BC6OTHER ]i. BC6OTHER blockade or knockdown inhibited proliferation by suppressing the rise in [ BC6OTHER ]i and attenuating the expression of phosphorylated BC6ENTC response element binding protein ( BC6OTHER ), BC6OTHER and BC6OTHER ( BC6ENTG ). CPR:falsenewline BC6ENTG binding of BC6OTHER in vivo: increased receptor number with low - dose BC6ENTC . CPR:falsenewline BC6ENTG binding of BC6ENTC in vivo: increased receptor number with low - dose BC6OTHER . CPR:falsenewlineThe apparent affinity of BC6ENTG for BC6ENTC in mice receiving BC6OTHER (0.05 mg / kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of BC6OTHER increased receptor number. CPR:falsenewlineThe apparent affinity of BC6ENTG for BC6OTHER in mice receiving BC6ENTC (0.05 mg / kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of BC6OTHER increased receptor number. CPR:falsenewlineThe apparent affinity of BC6ENTG for BC6OTHER in mice receiving BC6OTHER (0.05 mg / kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of BC6ENTC increased receptor number. CPR:falsenewlineThese results suggest that BC6ENTG compensates for the loss of functional BC6OTHER in cells derived from BC6OTHER knockout mice and mediates the majority of high affinity BC6ENTC transport. CPR:9newlineThese results suggest that BC6OTHER compensates for the loss of functional BC6ENTG in cells derived from BC6OTHER knockout mice and mediates the majority of high affinity BC6ENTC transport. CPR:9newlineThese results suggest that BC6OTHER compensates for the loss of functional BC6OTHER in cells derived from BC6ENTG knockout mice and mediates the majority of high affinity BC6ENTC transport. CPR:9newlineThe majority of BC6ENTC transport is mediated by BC6ENTG , although several other carriers have been kinetically defined. CPR:9newlineBC6ENTG cationic BC6ENTC transport is mediated by proteins encoded by a family of genes, BC6OTHER , BC6OTHER , and BC6OTHER . CPR:9newlineBC6OTHER cationic BC6ENTC transport is mediated by proteins encoded by a family of genes, BC6ENTG , BC6OTHER , and BC6OTHER . CPR:9newlineBC6OTHER cationic BC6ENTC transport is mediated by proteins encoded by a family of genes, BC6OTHER , BC6ENTG , and BC6OTHER . CPR:9newlineBC6OTHER cationic BC6ENTC transport is mediated by proteins encoded by a family of genes, BC6OTHER , BC6OTHER , and BC6ENTG . CPR:9newlineHigh affinity BC6ENTC transport was investigated in embryonic fibroblast cells derived from BC6ENTG knockout mice that lack functional BC6OTHER . CPR:9newlineHigh affinity BC6ENTC transport was investigated in embryonic fibroblast cells derived from BC6OTHER knockout mice that lack functional BC6ENTG . CPR:9newlineHowever, the apparent affinity for BC6ENTC transport was 2.4 times lower in BC6ENTG ( - / - ) cells when compared with wild type cells, a property characteristic of BC6OTHER - mediated transport. CPR:falsenewlineHowever, the apparent affinity for BC6ENTC transport was 2.4 times lower in BC6OTHER ( - / - ) cells when compared with wild type cells, a property characteristic of BC6ENTG - mediated transport. CPR:falsenewlineIncreased BC6ENTG - mediated cationic BC6ENTC transport functionally compensates in BC6OTHER knockout cell lines. CPR:9newlineIncreased BC6OTHER - mediated cationic BC6ENTC transport functionally compensates in BC6ENTG knockout cell lines. CPR:falsenewlineThe BC6ENTG subunit contains several functional domains: the BC6ENTC - terminal heptad repeat (NHR) domains fold a triple stranded coiled - coil forming a meta - stable prefusion intermediate. CPR:falsenewlineWith a BC6ENTC modification at BC6OTHER - terminal, the inhibitor containing BC6ENTG mutation represented higher anti - viral activity than C34 - BC6OTHER combination without mutation. CPR:falsenewlineWith a BC6OTHER modification at BC6ENTC - terminal, the inhibitor containing BC6ENTG mutation represented higher anti - viral activity than C34 - BC6OTHER combination without mutation. CPR:falsenewlineWith a BC6OTHER modification at BC6OTHER - terminal, the inhibitor containing BC6ENTG mutation represented higher anti - viral activity than C34 - BC6ENTC combination without mutation. CPR:falsenewlineIn Drosophila, BC6ENTG is a multifunctional synthetase encoded by a unique gene and composed of three domains: the BC6ENTC - and BC6OTHER - terminal domains catalyze the aminoacylation of BC6OTHER and CHEM tRNA species, respectively, and the central domain is made of 75 BC6OTHER repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J. CPR:falsenewlineIn Drosophila, BC6ENTG is a multifunctional synthetase encoded by a unique gene and composed of three domains: the BC6OTHER - and BC6ENTC - terminal domains catalyze the aminoacylation of BC6OTHER and CHEM tRNA species, respectively, and the central domain is made of 75 BC6OTHER repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J. CPR:falsenewlineIn Drosophila, BC6ENTG is a multifunctional synthetase encoded by a unique gene and composed of three domains: the BC6OTHER - and BC6OTHER - terminal domains catalyze the aminoacylation of BC6ENTC and CHEM tRNA species, respectively, and the central domain is made of 75 BC6OTHER repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J. CPR:falsenewlineIn Drosophila, BC6ENTG is a multifunctional synthetase encoded by a unique gene and composed of three domains: the BC6OTHER - and BC6OTHER - terminal domains catalyze the aminoacylation of BC6OTHER and CHEM tRNA species, respectively, and the central domain is made of 75 BC6ENTC repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J. CPR:falsenewlineEvolution of the BC6ENTC - tRNA synthetase family and the organization of the Drosophila BC6ENTG gene. CPR:falsenewlineEvolution of the BC6ENTG family and the organization of the Drosophila BC6ENTC - CHEM - tRNA synthetase gene. CPR:falsenewlineAmong the measured compounds, BC6ENTC and BC6OTHER (two BC6OTHER ), as well as BC6OTHER (a BC6OTHER ), exhibit BC6ENTG agonistic activity at concentrations comparable with those reached under pharmacological treatment. CPR:5newlineAmong the measured compounds, BC6OTHER and BC6ENTC (two BC6OTHER ), as well as BC6OTHER (a BC6OTHER ), exhibit BC6ENTG agonistic activity at concentrations comparable with those reached under pharmacological treatment. CPR:5newlineAmong the measured compounds, BC6OTHER and BC6OTHER (two BC6ENTC ), as well as BC6OTHER (a BC6OTHER ), exhibit BC6ENTG agonistic activity at concentrations comparable with those reached under pharmacological treatment. CPR:5newlineAmong the measured compounds, BC6OTHER and BC6OTHER (two BC6OTHER ), as well as BC6ENTC (a BC6OTHER ), exhibit BC6ENTG agonistic activity at concentrations comparable with those reached under pharmacological treatment. CPR:5newlineAmong the measured compounds, BC6OTHER and BC6OTHER (two BC6OTHER ), as well as BC6OTHER (a BC6ENTC ), exhibit BC6ENTG agonistic activity at concentrations comparable with those reached under pharmacological treatment. CPR:5newlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTC receptor stimulating BC6ENTG release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTC receptor stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6ENTG ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTC receptor stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6ENTG ) improving BC6OTHER resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTC receptor stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6ENTG resistance ( BC6OTHER ). CPR:falsenewlineThe most active of these compounds, BC6ENTC , is shown to be as potent as BC6OTHER at inducing BC6ENTG target gene expression. CPR:falsenewlineThe most active of these compounds, BC6OTHER , is shown to be as potent as BC6ENTC at inducing BC6ENTG target gene expression. CPR:falsenewlineThis dual mode of action of BC6ENTC and BC6OTHER may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the BC6ENTG and BC6OTHER . CPR:falsenewlineThis dual mode of action of BC6ENTC and BC6OTHER may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the BC6OTHER and BC6ENTG . CPR:falsenewlineThis dual mode of action of BC6OTHER and BC6ENTC may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the BC6ENTG and BC6OTHER . CPR:falsenewlineThis dual mode of action of BC6OTHER and BC6ENTC may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the BC6OTHER and BC6ENTG . CPR:falsenewlineThis dual mode of action of BC6OTHER and BC6OTHER may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the BC6ENTC receptor and BC6ENTG . CPR:falsenewline BC6ENTC and BC6OTHER exhibit BC6ENTG activity: a combined virtual screening and biological assay approach. CPR:falsenewline BC6OTHER and BC6ENTC exhibit BC6ENTG activity: a combined virtual screening and biological assay approach. CPR:falsenewlineBC6ENTC , BC6OTHER , and other BC6OTHER may be promising leads in the development of new BC6ENTG agonists. CPR:falsenewlineBC6OTHER , BC6ENTC , and other BC6OTHER may be promising leads in the development of new BC6ENTG agonists. CPR:falsenewlineBC6OTHER , BC6OTHER , and other BC6ENTC may be promising leads in the development of new BC6ENTG agonists. CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6ENTG release ( BC6ENTC , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6ENTC , BC6OTHER ), or target the BC6ENTG ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6ENTC , BC6OTHER ), or target the BC6OTHER ( BC6ENTG ) improving BC6OTHER resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6ENTC , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6ENTG resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTG stimulating BC6OTHER release ( BC6ENTC , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6ENTG release ( BC6OTHER , BC6ENTC ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6ENTC ), or target the BC6ENTG ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6ENTC ), or target the BC6OTHER ( BC6ENTG ) improving BC6OTHER resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6ENTC ), or target the BC6OTHER ( BC6OTHER ) improving BC6ENTG resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTG stimulating BC6OTHER release ( BC6OTHER , BC6ENTC ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6OTHER ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6ENTG release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6ENTC ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6ENTG ( BC6OTHER ) improving BC6OTHER resistance ( BC6ENTC ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6ENTG ) improving BC6OTHER resistance ( BC6ENTC ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6OTHER stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6ENTG resistance ( BC6ENTC ). CPR:falsenewlineMost drugs currently employed in the treatment of type 2 diabetes either target the BC6ENTG stimulating BC6OTHER release ( BC6OTHER , BC6OTHER ), or target the BC6OTHER ( BC6OTHER ) improving BC6OTHER resistance ( BC6ENTC ). CPR:falsenewlineOur work shows that BC6ENTC and BC6OTHER additionally bind to BC6ENTG and exhibit BC6OTHER agonistic activity. CPR:falsenewlineOur work shows that BC6ENTC and BC6OTHER additionally bind to BC6OTHER and exhibit BC6ENTG agonistic activity. CPR:falsenewlineOur work shows that BC6OTHER and BC6ENTC additionally bind to BC6ENTG and exhibit BC6OTHER agonistic activity. CPR:falsenewlineOur work shows that BC6OTHER and BC6ENTC additionally bind to BC6OTHER and exhibit BC6ENTG agonistic activity. CPR:falsenewlineIn the presence of BC6ENTG , BC6ENTC suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6OTHER . CPR:falsenewlineIn the presence of BC6OTHER , BC6ENTC suppressed the expression of BC6ENTG and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6OTHER . CPR:falsenewlineIn the presence of BC6OTHER , BC6ENTC suppressed the expression of BC6OTHER and BC6ENTG as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6OTHER . CPR:falsenewlineIn the presence of BC6OTHER , BC6ENTC suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6ENTG , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6OTHER . CPR:falsenewlineIn the presence of BC6OTHER , BC6ENTC suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6ENTG and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6OTHER . CPR:falsenewlineIn the presence of BC6OTHER , BC6ENTC suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6ENTG in PBMC, contributing to the anti - inflammatory effect of BC6OTHER . CPR:falsenewlineIn the presence of BC6ENTG , BC6OTHER suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6ENTC . CPR:falsenewlineIn the presence of BC6OTHER , BC6OTHER suppressed the expression of BC6ENTG and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6ENTC . CPR:falsenewlineIn the presence of BC6OTHER , BC6OTHER suppressed the expression of BC6OTHER and BC6ENTG as well as the production of BC6OTHER , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6ENTC . CPR:falsenewlineIn the presence of BC6OTHER , BC6OTHER suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6ENTG , BC6OTHER and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6ENTC . CPR:falsenewlineIn the presence of BC6OTHER , BC6OTHER suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6ENTG and BC6OTHER in PBMC, contributing to the anti - inflammatory effect of BC6ENTC . CPR:falsenewlineIn the presence of BC6OTHER , BC6OTHER suppressed the expression of BC6OTHER and BC6OTHER as well as the production of BC6OTHER , BC6OTHER and BC6ENTG in PBMC, contributing to the anti - inflammatory effect of BC6ENTC . CPR:falsenewlineThe effects of BC6ENTC were abolished by the addition of the product of the BC6OTHER , BC6OTHER , indicating the involvement of BC6ENTG in the action of BC6OTHER . CPR:falsenewlineThe effects of BC6ENTC were abolished by the addition of the product of the BC6ENTG , BC6OTHER , indicating the involvement of BC6OTHER reductase in the action of BC6OTHER . CPR:falsenewlineThe effects of BC6OTHER were abolished by the addition of the product of the BC6ENTC reductase, BC6OTHER , indicating the involvement of BC6ENTG in the action of BC6OTHER . CPR:falsenewline BC6ENTC induces BC6ENTG production in human peripheral blood mononuclear cells. CPR:9newlineThe effects of BC6OTHER were abolished by the addition of the product of the BC6OTHER , BC6ENTC , indicating the involvement of BC6ENTG in the action of BC6OTHER . CPR:falsenewlineThe effects of BC6OTHER were abolished by the addition of the product of the BC6ENTG , BC6ENTC , indicating the involvement of BC6OTHER reductase in the action of BC6OTHER . CPR:falsenewlineThe effects of BC6OTHER were abolished by the addition of the product of the BC6ENTG , BC6OTHER , indicating the involvement of BC6ENTC reductase in the action of BC6OTHER . CPR:falsenewlineThe effects of BC6OTHER were abolished by the addition of the product of the BC6OTHER , BC6OTHER , indicating the involvement of BC6ENTG in the action of BC6ENTC . CPR:falsenewlineThe effects of BC6OTHER were abolished by the addition of the product of the BC6ENTG , BC6OTHER , indicating the involvement of BC6OTHER reductase in the action of BC6ENTC . CPR:falsenewlineThe effects of CHEM on immune response depend on the inhibition of BC6OTHER ( BC6ENTC ) reductase and BC6ENTG , which is a ligand of BC6OTHER . CPR:falsenewlineThe effects of CHEM on immune response depend on the inhibition of BC6OTHER ( BC6ENTC ) reductase and BC6OTHER , which is a ligand of BC6ENTG . CPR:falsenewlineBC6ENTC , an BC6ENTG inhibitor with mild inhibition of BC6OTHER , induced the production of BC6OTHER , BC6OTHER and BC6OTHER in human peripheral blood mononuclear cells (PBMC). CPR:4newlineBC6ENTC , an BC6OTHER reductase inhibitor with mild inhibition of BC6ENTG , induced the production of BC6OTHER , BC6OTHER and BC6OTHER in human peripheral blood mononuclear cells (PBMC). CPR:falsenewlineBC6ENTC , an BC6OTHER reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6ENTG , BC6OTHER and BC6OTHER in human peripheral blood mononuclear cells (PBMC). CPR:falsenewlineBC6ENTC , an BC6OTHER reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6OTHER , BC6ENTG and BC6OTHER in human peripheral blood mononuclear cells (PBMC). CPR:falsenewlineBC6ENTC , an BC6OTHER reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6OTHER , BC6OTHER and BC6ENTG in human peripheral blood mononuclear cells (PBMC). CPR:falsenewlineBC6OTHER , an BC6ENTC reductase inhibitor with mild inhibition of BC6ENTG , induced the production of BC6OTHER , BC6OTHER and BC6OTHER in human peripheral blood mononuclear cells (PBMC). CPR:falsenewlineBC6OTHER , an BC6ENTC reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6ENTG , BC6OTHER and BC6OTHER in human peripheral blood mononuclear cells (PBMC). CPR:falsenewlineBC6OTHER , an BC6ENTC reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6OTHER , BC6ENTG and BC6OTHER in human peripheral blood mononuclear cells (PBMC). CPR:falsenewlineBC6OTHER , an BC6ENTC reductase inhibitor with mild inhibition of BC6OTHER , induced the production of BC6OTHER , BC6OTHER and BC6ENTG in human peripheral blood mononuclear cells (PBMC). CPR:falsenewlineThe BC6ENTG production is located upstream of the BC6OTHER cascade activated by BC6ENTC . CPR:falsenewlineThe BC6OTHER production is located upstream of the BC6ENTG cascade activated by BC6ENTC . CPR:falsenewlineMoreover, BC6ENTC concentration - dependently inhibited the expression of BC6ENTG and induced the expression of BC6OTHER on monocytes. CPR:falsenewlineMoreover, BC6ENTC concentration - dependently inhibited the expression of BC6OTHER and induced the expression of BC6ENTG on monocytes. CPR:falsenewlineThe effects of CHEM on immune response depend on the inhibition of BC6ENTC ( BC6OTHER ) reductase and BC6ENTG , which is a ligand of BC6OTHER . CPR:falsenewlineThe effects of CHEM on immune response depend on the inhibition of BC6ENTC ( BC6OTHER ) reductase and BC6OTHER , which is a ligand of BC6ENTG . CPR:falsenewlineBC6ENTC - activated protein kinase ( BC6ENTG ) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of BC6OTHER uptake into skeletal muscle and the inhibition of liver gluconeogenesis. CPR:falsenewlineBC6ENTG ( BC6OTHER ) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of BC6ENTC uptake into skeletal muscle and the inhibition of liver gluconeogenesis. CPR:9newlineBC6OTHER ( BC6ENTG ) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of BC6ENTC uptake into skeletal muscle and the inhibition of liver gluconeogenesis. CPR:falsenewlineWe recently reported that BC6ENTG is activated by BC6ENTC in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic BC6OTHER production. CPR:3newlineWe recently reported that BC6ENTG is activated by BC6OTHER in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic BC6ENTC production. CPR:falsenewlineIn the present study, we evaluated whether therapeutic doses of BC6ENTC increase BC6ENTG activity in vivo in subjects with type 2 diabetes. CPR:3newlineBC6ENTC treatment for 10 weeks significantly increased BC6ENTG activity in the skeletal muscle, and this was associated with increased phosphorylation of BC6OTHER on CHEM172 and decreased BC6OTHER activity. CPR:falsenewlineBC6ENTC treatment for 10 weeks significantly increased BC6OTHER activity in the skeletal muscle, and this was associated with increased phosphorylation of BC6ENTG on CHEM172 and decreased BC6OTHER activity. CPR:falsenewlineBC6ENTC treatment for 10 weeks significantly increased BC6OTHER activity in the skeletal muscle, and this was associated with increased phosphorylation of BC6OTHER on CHEM172 and decreased BC6ENTG activity. CPR:falsenewlineBC6OTHER treatment for 10 weeks significantly increased BC6ENTG activity in the skeletal muscle, and this was associated with increased phosphorylation of BC6OTHER on CHEM172 and decreased BC6ENTC carboxylase - 2 activity. CPR:falsenewlineBC6OTHER treatment for 10 weeks significantly increased BC6OTHER activity in the skeletal muscle, and this was associated with increased phosphorylation of BC6ENTG on CHEM172 and decreased BC6ENTC carboxylase - 2 activity. CPR:falsenewline BC6ENTC increases BC6ENTG activity in skeletal muscle of subjects with type 2 diabetes. CPR:falsenewlineThe increase in BC6ENTG activity was likely due to a change in muscle energy status because BC6ENTC and BC6OTHER concentrations were lower after BC6OTHER treatment. CPR:falsenewlineThe increase in BC6ENTG activity was likely due to a change in muscle energy status because BC6OTHER and BC6ENTC concentrations were lower after BC6OTHER treatment. CPR:falsenewlineThe increase in BC6ENTG activity was likely due to a change in muscle energy status because BC6OTHER and BC6OTHER concentrations were lower after BC6ENTC treatment. CPR:falsenewlineBC6ENTC - induced increases in BC6ENTG activity were associated with higher rates of BC6OTHER disposal and muscle glycogen concentrations. CPR:falsenewlineBC6OTHER - induced increases in BC6ENTG activity were associated with higher rates of BC6ENTC disposal and muscle glycogen concentrations. CPR:falsenewlineAnalysis of the patient family showed that heterozygotes for this BC6ENTG gene mutation, in spite of a 69% lower BC6OTHER enzymatic activity than that of healthy subjects, had no detectable BC6ENTC concentrations in both serum and urine. CPR:falsenewlineAnalysis of the patient family showed that heterozygotes for this BC6OTHER gene mutation, in spite of a 69% lower BC6ENTG enzymatic activity than that of healthy subjects, had no detectable BC6ENTC concentrations in both serum and urine. CPR:falsenewlineResults of renal biopsy prompted us to undertake a biochemical and molecular biological evaluation of the patient for suspected BC6ENTC phosphoribosyltransferase ( BC6ENTG ) deficiency. CPR:falsenewlineIn vivo, CHEM inhibited tumor growth in mice bearing tumor with endogenous BC6ENTG (BxPC - 3: control, mean = 1.6 x 10(9) photons / s, versus CHEM, mean = 4.4 x 10(8) photons / s, difference = 1.2 x 10(9) photons / s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons / s; P<.001, n = 5; MPanc - 96: control, mean = 1.1 x 10(10) photons / s, versus CHEM, mean = 4.8 x 10(9) photons / s, difference = 6.2 x 10(9) photons / s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons / s; P = .009, n = 5) and increased the effectiveness of BC6ENTC (BxPC - 3: BC6OTHER , mean = 9.2 x 10(8) photons / s, versus combination, mean = 1.8 x 10(8) photons / s, difference = 7.4 x 10(8) photons / s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons / s; P<.001; MPanc - 96: BC6OTHER , mean = 4.1 x 10(9) photons / s, versus combination, mean = 2.0 x 10(9) photons / s, difference = 2.1 x 10(9) photons / s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons / s; P<.001). CPR:falsenewlineIn vivo, CHEM inhibited tumor growth in mice bearing tumor with endogenous BC6ENTG (BxPC - 3: control, mean = 1.6 x 10(9) photons / s, versus CHEM, mean = 4.4 x 10(8) photons / s, difference = 1.2 x 10(9) photons / s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons / s; P<.001, n = 5; MPanc - 96: control, mean = 1.1 x 10(10) photons / s, versus CHEM, mean = 4.8 x 10(9) photons / s, difference = 6.2 x 10(9) photons / s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons / s; P = .009, n = 5) and increased the effectiveness of BC6OTHER (BxPC - 3: BC6ENTC , mean = 9.2 x 10(8) photons / s, versus combination, mean = 1.8 x 10(8) photons / s, difference = 7.4 x 10(8) photons / s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons / s; P<.001; MPanc - 96: BC6OTHER , mean = 4.1 x 10(9) photons / s, versus combination, mean = 2.0 x 10(9) photons / s, difference = 2.1 x 10(9) photons / s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons / s; P<.001). CPR:falsenewlineIn vivo, CHEM inhibited tumor growth in mice bearing tumor with endogenous BC6ENTG (BxPC - 3: control, mean = 1.6 x 10(9) photons / s, versus CHEM, mean = 4.4 x 10(8) photons / s, difference = 1.2 x 10(9) photons / s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons / s; P<.001, n = 5; MPanc - 96: control, mean = 1.1 x 10(10) photons / s, versus CHEM, mean = 4.8 x 10(9) photons / s, difference = 6.2 x 10(9) photons / s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons / s; P = .009, n = 5) and increased the effectiveness of BC6OTHER (BxPC - 3: BC6OTHER , mean = 9.2 x 10(8) photons / s, versus combination, mean = 1.8 x 10(8) photons / s, difference = 7.4 x 10(8) photons / s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons / s; P<.001; MPanc - 96: BC6ENTC , mean = 4.1 x 10(9) photons / s, versus combination, mean = 2.0 x 10(9) photons / s, difference = 2.1 x 10(9) photons / s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons / s; P<.001). CPR:falsenewlineCONCLUSION: CHEM binds BC6ENTG , prevents activation of RAGE, inhibits tumor growth, and increases the effectiveness of BC6ENTC in experimental models. CPR:falsenewlinePURPOSE: Cellular BC6OTHER - binding protein ( BC6ENTG ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6ENTC found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells. CPR:falsenewlinePURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6ENTG gene, is a BC6OTHER with 316 BC6ENTC found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells. CPR:falsenewlinePURPOSE: BC6ENTG ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6ENTC found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells. CPR:falsenewlinePURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6ENTG with 316 BC6ENTC found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells. CPR:falsenewlinePURPOSE: Cellular BC6OTHER - binding protein ( BC6ENTG ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6OTHER found in the BC6ENTC pigment epithelium (RPE) and in BC6OTHER Muller cells. CPR:falsenewlinePURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6ENTG gene, is a BC6OTHER with 316 BC6OTHER found in the BC6ENTC pigment epithelium (RPE) and in BC6OTHER Muller cells. CPR:falsenewlinePURPOSE: BC6ENTG ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6OTHER found in the BC6ENTC pigment epithelium (RPE) and in BC6OTHER Muller cells. CPR:falsenewlinePURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6ENTG with 316 BC6OTHER found in the BC6ENTC pigment epithelium (RPE) and in BC6OTHER Muller cells. CPR:falsenewlinePURPOSE: Cellular BC6ENTC - binding protein ( BC6ENTG ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells. CPR:falsenewlinePURPOSE: Cellular BC6ENTC - binding protein ( BC6OTHER ), transcribed from the BC6ENTG gene, is a BC6OTHER with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells. CPR:falsenewlinePURPOSE: Cellular BC6ENTC - binding protein ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6ENTG with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6OTHER Muller cells. CPR:falsenewlinePURPOSE: Cellular BC6OTHER - binding protein ( BC6ENTG ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6ENTC Muller cells. CPR:falsenewlinePURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6ENTG gene, is a BC6OTHER with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6ENTC Muller cells. CPR:falsenewlinePURPOSE: BC6ENTG ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6OTHER with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6ENTC Muller cells. CPR:falsenewlinePURPOSE: Cellular BC6OTHER - binding protein ( BC6OTHER ), transcribed from the BC6OTHER gene, is a BC6ENTG with 316 BC6OTHER found in the BC6OTHER pigment epithelium (RPE) and in BC6ENTC Muller cells. CPR:falsenewlineIt is thought to play a critical role in the visual cycle by functioning as an acceptor of BC6ENTC from the BC6ENTG reaction. CPR:9newlineHere, we report that a specific 29 - BC6ENTC peptide derived from the intracellular domain fragment of BC6OTHER interacts with and potentiates binding of BC6ENTG to BC6OTHER - expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced BC6OTHER and BC6OTHER signaling. CPR:falsenewlineHere, we report that a specific 29 - BC6ENTC peptide derived from the intracellular domain fragment of BC6OTHER interacts with and potentiates binding of BC6OTHER to BC6ENTG - expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced BC6OTHER and BC6OTHER signaling. CPR:falsenewlineHere, we report that a specific 29 - BC6ENTC peptide derived from the intracellular domain fragment of BC6OTHER interacts with and potentiates binding of BC6OTHER to BC6OTHER - expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced BC6ENTG and BC6OTHER signaling. CPR:falsenewlineHere, we report that a specific 29 - BC6ENTC peptide derived from the intracellular domain fragment of BC6OTHER interacts with and potentiates binding of BC6OTHER to BC6OTHER - expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced BC6OTHER and BC6ENTG signaling. CPR:falsenewlineHere, we report that a specific 29 - BC6ENTC peptide derived from the intracellular domain fragment of BC6ENTG interacts with and potentiates binding of BC6OTHER to BC6OTHER - expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced BC6OTHER and BC6OTHER signaling. CPR:falsenewlineAn endogenous intracellular domain fragment of BC6ENTG ( BC6OTHER ) containing these 29 BC6ENTC is produced by regulated proteolysis of the full - length receptor. CPR:falsenewlineAn endogenous intracellular domain fragment of BC6OTHER ( BC6ENTG ) containing these 29 BC6ENTC is produced by regulated proteolysis of the full - length receptor. CPR:falsenewlineThe mitogenic effect of BC6ENTC on bone cells was inhibited by antiandrogens ( BC6OTHER and BC6OTHER ) which compete for binding to the BC6ENTG . CPR:falsenewlineThe mitogenic effect of BC6OTHER on bone cells was inhibited by antiandrogens ( BC6ENTC and BC6OTHER ) which compete for binding to the BC6ENTG . CPR:falsenewlineThe mitogenic effect of BC6OTHER on bone cells was inhibited by antiandrogens ( BC6OTHER and BC6ENTC ) which compete for binding to the BC6ENTG . CPR:falsenewlineIn addition to effects on cell proliferation, BC6ENTC increased the percentage of BC6ENTG ( BC6OTHER ) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens. CPR:falsenewlineIn addition to effects on cell proliferation, BC6ENTC increased the percentage of BC6OTHER ( BC6ENTG ) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens. CPR:falsenewlineWe conclude that BC6ENTC can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the BC6ENTG BC6OTHER , presumably by an BC6OTHER receptor mediated mechanism. CPR:falsenewlineWe conclude that BC6ENTC can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the BC6OTHER BC6ENTG , presumably by an BC6OTHER receptor mediated mechanism. CPR:falsenewlineWe conclude that BC6ENTC can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the BC6OTHER BC6OTHER , presumably by an BC6ENTG mediated mechanism. CPR:falsenewlineWe conclude that BC6OTHER can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the BC6ENTG BC6OTHER , presumably by an BC6ENTC receptor mediated mechanism. CPR:falsenewlineWe conclude that BC6OTHER can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the BC6OTHER BC6ENTG , presumably by an BC6ENTC receptor mediated mechanism. CPR:falsenewline BC6ENTG Deficiency Impairs Secretory Vesicle Biogenesis and Leads to Growth Retardation and Decreased BC6ENTC Tolerance. CPR:falsenewlineFrom these results, it was suggested that the contraction induced by BC6OTHER in the rat coronary artery in the presence of BC6OTHER and BC6OTHER is endothelium dependent, and involves reactive BC6OTHER species and endothelial BC6ENTG metabolites of BC6ENTC . CPR:falsenewlineBC6ENTC radical scavengers, BC6ENTG and BC6OTHER , significantly attenuated the contraction. CPR:falsenewlineBC6ENTC radical scavengers, BC6OTHER and BC6ENTG , significantly attenuated the contraction. CPR:falsenewlineBC6ENTG ( BC6OTHER ) inhibitors ( BC6ENTC , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6ENTG ) inhibitors ( BC6ENTC , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6ENTC , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6ENTC , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER , BC6ENTC and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER , BC6ENTC and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6ENTC and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6ENTC and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6ENTC ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER , BC6OTHER and BC6ENTC ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6ENTC ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6ENTC ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6ENTC - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6ENTC - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6ENTC - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6ENTC - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6OTHER and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6ENTC and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6ENTC and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6ENTC and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6ENTC and BC6OTHER ) slightly attenuated the contraction. CPR:falsenewlineBC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6ENTC ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6ENTC ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6ENTG ( BC6OTHER ) inhibitors at high concentrations ( BC6OTHER and BC6ENTC ) slightly attenuated the contraction. CPR:falsenewlineBC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER , BC6OTHER and BC6OTHER ) attenuated the BC6OTHER - induced contraction in a concentration - dependent manner, and BC6OTHER ( BC6ENTG ) inhibitors at high concentrations ( BC6OTHER and BC6ENTC ) slightly attenuated the contraction. CPR:falsenewlineA BC6ENTG inhibitor ( BC6ENTC ) attenuated the contraction to a small extent only at high concentrations. CPR:4newlineA BC6ENTG antagonist ( BC6ENTC ) attenuated the contraction in a concentration - dependent manner. CPR:falsenewline BC6ENTC - induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive BC6OTHER species and BC6ENTG metabolites. CPR:falsenewline BC6OTHER - induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive BC6ENTC species and BC6ENTG metabolites. CPR:falsenewlineA BC6ENTG antagonist ( BC6ENTC ) attenuated the contraction in part and an BC6OTHER antagonist ( BC6OTHER ) nearly abolished the contraction. CPR:falsenewlineA BC6OTHER antagonist ( BC6ENTC ) attenuated the contraction in part and an BC6ENTG antagonist ( BC6OTHER ) nearly abolished the contraction. CPR:falsenewlineA BC6ENTG antagonist ( BC6OTHER ) attenuated the contraction in part and an BC6OTHER antagonist ( BC6ENTC ) nearly abolished the contraction. CPR:falsenewlineA BC6OTHER antagonist ( BC6OTHER ) attenuated the contraction in part and an BC6ENTG antagonist ( BC6ENTC ) nearly abolished the contraction. CPR:falsenewlineFrom these results, it was suggested that the contraction induced by BC6ENTC in the rat coronary artery in the presence of BC6OTHER and BC6OTHER is endothelium dependent, and involves reactive BC6OTHER species and endothelial BC6ENTG metabolites of BC6OTHER . CPR:falsenewlineFrom these results, it was suggested that the contraction induced by BC6OTHER in the rat coronary artery in the presence of BC6ENTC and BC6OTHER is endothelium dependent, and involves reactive BC6OTHER species and endothelial BC6ENTG metabolites of BC6OTHER . CPR:falsenewlineFrom these results, it was suggested that the contraction induced by BC6OTHER in the rat coronary artery in the presence of BC6OTHER and BC6ENTC is endothelium dependent, and involves reactive BC6OTHER species and endothelial BC6ENTG metabolites of BC6OTHER . CPR:falsenewlineFrom these results, it was suggested that the contraction induced by BC6OTHER in the rat coronary artery in the presence of BC6OTHER and BC6OTHER is endothelium dependent, and involves reactive BC6ENTC species and endothelial BC6ENTG metabolites of BC6OTHER . CPR:falsenewlineThe effects of repeated administration of the BC6OTHER antidepressant drug, BC6OTHER ( BC6ENTC ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6ENTG and BC6OTHER receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats. CPR:falsenewlineThe effects of repeated administration of the BC6OTHER antidepressant drug, BC6OTHER ( BC6ENTC ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6OTHER and BC6ENTG receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats. CPR:falsenewlineAfter 7 days of BC6ENTC administration the number of BC6ENTG was lower in frontal and occipital cortex and hippocampus. CPR:falsenewline BC6ENTC administration in the olfactory bulbectomized rat: changes in brain BC6OTHER and BC6ENTG binding sites and their relationship to behaviour. CPR:falsenewline BC6ENTC administration in the olfactory bulbectomized rat: changes in brain BC6ENTG and BC6OTHER binding sites and their relationship to behaviour. CPR:falsenewlineAdministration of BC6ENTC for 14 or 21 days did not further reduce the number of BC6ENTG . CPR:falsenewlineThe BC6ENTC induced reduction in BC6ENTG did not differ in OB and sham - operated control rats. CPR:falsenewlineBC6ENTC administration for up to 21 days produced a progressive reduction in the number of BC6ENTG receptors in frontal cortex, without significant alterations in occipital cortex. CPR:falsenewlineThe time course of the reduction in the number of BC6ENTG receptors was similar to that of the BC6ENTC - induced behavioural changes whereas that for the reduction in BC6OTHER was clearly different. CPR:falsenewlineThe time course of the reduction in the number of BC6OTHER receptors was similar to that of the BC6ENTC - induced behavioural changes whereas that for the reduction in BC6ENTG was clearly different. CPR:falsenewlineThe present results suggest that the action of BC6ENTC in this animal model is unlikely to be directly related to a reduction in BC6ENTG but may be related to a reduction in frontal cortical BC6OTHER receptors. CPR:falsenewlineThe present results suggest that the action of BC6ENTC in this animal model is unlikely to be directly related to a reduction in BC6OTHER but may be related to a reduction in frontal cortical BC6ENTG receptors. CPR:falsenewlineThe effects of repeated administration of the BC6ENTC antidepressant drug, BC6OTHER ( BC6OTHER ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6ENTG and BC6OTHER receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats. CPR:falsenewlineThe effects of repeated administration of the BC6ENTC antidepressant drug, BC6OTHER ( BC6OTHER ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6OTHER and BC6ENTG receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats. CPR:falsenewlineThe effects of repeated administration of the BC6OTHER antidepressant drug, BC6ENTC ( BC6OTHER ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6ENTG and BC6OTHER receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats. CPR:falsenewlineThe effects of repeated administration of the BC6OTHER antidepressant drug, BC6ENTC ( BC6OTHER ), on behaviour (locomotor activity and rearing) and the number and affinity of brain BC6OTHER and BC6ENTG receptor binding sites were examined in olfactory bulbectomized (OB) and sham - operated control rats. CPR:falsenewlineBC6ENTG release was higher ( approximately 1.6 - fold) in 25 mM (high) compared with 5 mM (normal) BC6ENTC . CPR:falsenewlineBC6ENTG increases BC6ENTC transport (half maximal effect approximately 1.6 ng / ml) in normal BC6OTHER , but did not alter high BC6OTHER - increased BC6OTHER transport. CPR:falsenewlineBC6ENTG increases BC6OTHER transport (half maximal effect approximately 1.6 ng / ml) in normal BC6ENTC , but did not alter high BC6OTHER - increased BC6OTHER transport. CPR:falsenewlineBC6ENTG increases BC6OTHER transport (half maximal effect approximately 1.6 ng / ml) in normal BC6OTHER , but did not alter high BC6ENTC - increased BC6OTHER transport. CPR:falsenewlineBC6ENTG increases BC6OTHER transport (half maximal effect approximately 1.6 ng / ml) in normal BC6OTHER , but did not alter high BC6OTHER - increased BC6ENTC transport. CPR:falsenewlineBC6ENTG and high BC6ENTC increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6ENTC increased BC6ENTG mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6ENTC increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and BC6ENTG ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6ENTC increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6ENTG ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6ENTC increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6ENTG phosphorylation. CPR:falsenewlineBC6ENTG and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6ENTC formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6ENTG mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6ENTC formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6ENTC formation from BC6OTHER (index of BC6OTHER synthesis) and BC6ENTG ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6ENTC formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6ENTG ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6ENTC formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6ENTG phosphorylation. CPR:falsenewlineBC6ENTG and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6ENTC (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6ENTG mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6ENTC (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6ENTC (index of BC6OTHER synthesis) and BC6ENTG ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6ENTC (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6ENTG ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6ENTC (index of BC6OTHER synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6ENTG phosphorylation. CPR:falsenewlineBC6ENTG and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6ENTC synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6ENTG mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6ENTC synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6ENTC synthesis) and BC6ENTG ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6ENTC synthesis) and endothelial BC6OTHER synthase ( BC6ENTG ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6ENTC synthesis) and endothelial BC6OTHER synthase ( BC6OTHER ) protein abundance, but did not alter BC6ENTG phosphorylation. CPR:falsenewlineBC6ENTG and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6ENTC synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6ENTG mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6ENTC synthase ( BC6OTHER ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6ENTC synthase ( BC6ENTG ) protein abundance, but did not alter BC6OTHER phosphorylation. CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER mRNA expression ( approximately 8 - fold) and maximal transport velocity (V(max)), BC6OTHER formation from BC6OTHER (index of BC6OTHER synthesis) and endothelial BC6ENTC synthase ( BC6OTHER ) protein abundance, but did not alter BC6ENTG phosphorylation. CPR:falsenewlineBC6ENTG and high BC6ENTC increased BC6OTHER ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6OTHER ( BC6OTHER inhibitor). CPR:falsenewlineBC6OTHER and high BC6ENTC increased BC6ENTG ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6OTHER ( BC6OTHER inhibitor). CPR:falsenewlineBC6OTHER and high BC6ENTC increased BC6OTHER ( BC6ENTG ) and BC6OTHER phosphorylation, an effect blocked by BC6OTHER ( BC6OTHER inhibitor). CPR:falsenewlineBC6OTHER and high BC6ENTC increased BC6OTHER ( BC6OTHER ) and BC6ENTG phosphorylation, an effect blocked by BC6OTHER ( BC6OTHER inhibitor). CPR:falsenewlineBC6OTHER and high BC6ENTC increased BC6OTHER ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6OTHER ( BC6ENTG inhibitor). CPR:falsenewline BC6ENTC stimulation of BC6OTHER transport and BC6OTHER synthesis results from activation of BC6ENTG and BC6OTHER requiring functional BC6OTHER in human umbilical vein endothelium. CPR:falsenewline BC6ENTC stimulation of BC6OTHER transport and BC6OTHER synthesis results from activation of BC6OTHER and BC6ENTG requiring functional BC6OTHER in human umbilical vein endothelium. CPR:falsenewline BC6ENTC stimulation of BC6OTHER transport and BC6OTHER synthesis results from activation of BC6OTHER and BC6OTHER requiring functional BC6ENTG in human umbilical vein endothelium. CPR:falsenewline BC6OTHER stimulation of BC6ENTC transport and BC6OTHER synthesis results from activation of BC6ENTG and BC6OTHER requiring functional BC6OTHER in human umbilical vein endothelium. CPR:falsenewline BC6OTHER stimulation of BC6ENTC transport and BC6OTHER synthesis results from activation of BC6OTHER and BC6ENTG requiring functional BC6OTHER in human umbilical vein endothelium. CPR:9newline BC6OTHER stimulation of BC6ENTC transport and BC6OTHER synthesis results from activation of BC6OTHER and BC6OTHER requiring functional BC6ENTG in human umbilical vein endothelium. CPR:falsenewline BC6OTHER stimulation of BC6OTHER transport and BC6ENTC synthesis results from activation of BC6ENTG and BC6OTHER requiring functional BC6OTHER in human umbilical vein endothelium. CPR:9newline BC6OTHER stimulation of BC6OTHER transport and BC6ENTC synthesis results from activation of BC6OTHER and BC6ENTG requiring functional BC6OTHER in human umbilical vein endothelium. CPR:9newline BC6OTHER stimulation of BC6OTHER transport and BC6ENTC synthesis results from activation of BC6OTHER and BC6OTHER requiring functional BC6ENTG in human umbilical vein endothelium. CPR:falsenewlineBC6ENTG and high BC6OTHER increased BC6OTHER ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6ENTC ( BC6OTHER inhibitor). CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6ENTG ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6ENTC ( BC6OTHER inhibitor). CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER ( BC6ENTG ) and BC6OTHER phosphorylation, an effect blocked by BC6ENTC ( BC6OTHER inhibitor). CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER ( BC6OTHER ) and BC6ENTG phosphorylation, an effect blocked by BC6ENTC ( BC6OTHER inhibitor). CPR:falsenewlineBC6OTHER and high BC6OTHER increased BC6OTHER ( BC6OTHER ) and BC6OTHER phosphorylation, an effect blocked by BC6ENTC ( BC6ENTG inhibitor). CPR:falsenewlineHowever, BC6ENTG and high BC6ENTC were ineffective in cells expressing a truncated, negative dominant BC6OTHER . CPR:falsenewlineHowever, BC6OTHER and high BC6ENTC were ineffective in cells expressing a truncated, negative dominant BC6ENTG . CPR:falsenewlineHigh BC6ENTC increases BC6OTHER transport and BC6ENTG expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC. CPR:falsenewlineHigh BC6ENTC increases BC6OTHER transport and BC6OTHER expression following BC6ENTG activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC. CPR:falsenewlineHigh BC6ENTC increases BC6OTHER transport and BC6OTHER expression following BC6OTHER activation by BC6ENTG involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC. CPR:falsenewlineHigh BC6ENTC increases BC6OTHER transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6ENTG ( BC6OTHER ) and BC6OTHER in HUVEC. CPR:falsenewlineHigh BC6ENTC increases BC6OTHER transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6ENTG ) and BC6OTHER in HUVEC. CPR:falsenewlineHigh BC6ENTC increases BC6OTHER transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6ENTG in HUVEC. CPR:falsenewlineHigh BC6OTHER increases BC6ENTC transport and BC6ENTG expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC. CPR:falsenewlineHigh BC6OTHER increases BC6ENTC transport and BC6OTHER expression following BC6ENTG activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC. CPR:falsenewlineHigh BC6OTHER increases BC6ENTC transport and BC6OTHER expression following BC6OTHER activation by BC6ENTG involving BC6OTHER ( BC6OTHER ) and BC6OTHER in HUVEC. CPR:falsenewlineHigh BC6OTHER increases BC6ENTC transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6ENTG ( BC6OTHER ) and BC6OTHER in HUVEC. CPR:falsenewlineHigh BC6OTHER increases BC6ENTC transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6ENTG ) and BC6OTHER in HUVEC. CPR:falsenewlineHigh BC6OTHER increases BC6ENTC transport and BC6OTHER expression following BC6OTHER activation by BC6OTHER involving BC6OTHER ( BC6OTHER ) and BC6ENTG in HUVEC. CPR:falsenewlineElevated extracellular BC6ENTC increases BC6ENTG ( BC6OTHER ) release from human umbilical vein endothelium (HUVEC). CPR:falsenewlineElevated extracellular BC6ENTC increases BC6OTHER ( BC6ENTG ) release from human umbilical vein endothelium (HUVEC). CPR:falsenewlineWe studied whether BC6ENTC - stimulation of BC6OTHER transport and BC6OTHER synthesis involves BC6ENTG in primary cultures of HUVEC. CPR:falsenewlineWe studied whether BC6OTHER - stimulation of BC6ENTC transport and BC6OTHER synthesis involves BC6ENTG in primary cultures of HUVEC. CPR:falsenewlineWe studied whether BC6OTHER - stimulation of BC6OTHER transport and BC6ENTC synthesis involves BC6ENTG in primary cultures of HUVEC. CPR:falsenewlineRESULTS: BC6OTHER inhibited constitutive and / or ligand - induced BC6ENTG or BC6OTHER BC6ENTC phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line. CPR:falsenewlineRESULTS: BC6OTHER inhibited constitutive and / or ligand - induced BC6OTHER or BC6ENTG BC6ENTC phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line. CPR:falsenewlineEffects of the BC6ENTG / BC6OTHER BC6OTHER inhibitor BC6ENTC on BC6OTHER - and BC6OTHER - overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. CPR:falsenewlineEffects of the BC6OTHER / BC6ENTG BC6OTHER inhibitor BC6ENTC on BC6OTHER - and BC6OTHER - overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. CPR:4newlineEffects of the BC6OTHER / BC6OTHER BC6ENTG inhibitor BC6ENTC on BC6OTHER - and BC6OTHER - overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. CPR:4newlineEffects of the BC6OTHER / BC6OTHER BC6OTHER inhibitor BC6ENTC on BC6ENTG - and BC6OTHER - overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. CPR:falsenewlineEffects of the BC6OTHER / BC6OTHER BC6OTHER inhibitor BC6ENTC on BC6OTHER - and BC6ENTG - overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. CPR:falsenewlineBC6ENTC radiosensitized BC6ENTG - overexpressing cell lines, but BC6OTHER - overexpressing cells were unable to form colonies after brief exposure to BC6OTHER even in the absence of radiation, and thus could not be evaluated for radiosensitization. CPR:falsenewlineBC6ENTC radiosensitized BC6OTHER - overexpressing cell lines, but BC6ENTG - overexpressing cells were unable to form colonies after brief exposure to BC6OTHER even in the absence of radiation, and thus could not be evaluated for radiosensitization. CPR:falsenewlineBC6OTHER radiosensitized BC6ENTG - overexpressing cell lines, but BC6OTHER - overexpressing cells were unable to form colonies after brief exposure to BC6ENTC even in the absence of radiation, and thus could not be evaluated for radiosensitization. CPR:falsenewlineBC6OTHER radiosensitized BC6OTHER - overexpressing cell lines, but BC6ENTG - overexpressing cells were unable to form colonies after brief exposure to BC6ENTC even in the absence of radiation, and thus could not be evaluated for radiosensitization. CPR:falsenewlineExploration of potential mechanisms of resistance in SUM185 cells revealed failure of BC6ENTC to inhibit downstream BC6ENTG and BC6OTHER activation, despite inhibition of BC6OTHER phosphorylation. CPR:falsenewlineExploration of potential mechanisms of resistance in SUM185 cells revealed failure of BC6ENTC to inhibit downstream BC6OTHER and BC6ENTG activation, despite inhibition of BC6OTHER phosphorylation. CPR:falsenewlineExploration of potential mechanisms of resistance in SUM185 cells revealed failure of BC6ENTC to inhibit downstream BC6OTHER and BC6OTHER activation, despite inhibition of BC6ENTG phosphorylation. CPR:falsenewlineCONCLUSION: BC6ENTC potently inhibits receptor phosphorylation in either BC6ENTG - or BC6OTHER - overexpressing cell lines and has both antiproliferative and radiosensitizing effects. CPR:falsenewlineCONCLUSION: BC6ENTC potently inhibits receptor phosphorylation in either BC6OTHER - or BC6ENTG - overexpressing cell lines and has both antiproliferative and radiosensitizing effects. CPR:falsenewlineResistance to BC6ENTC was not due to a lack of receptor inhibition, but rather with a lack of inhibition of BC6ENTG and BC6OTHER , suggesting that measurement of inhibition of crucial signaling pathways may better predict response than inhibition of receptor phosphorylation. CPR:falsenewlineResistance to BC6ENTC was not due to a lack of receptor inhibition, but rather with a lack of inhibition of BC6OTHER and BC6ENTG , suggesting that measurement of inhibition of crucial signaling pathways may better predict response than inhibition of receptor phosphorylation. CPR:falsenewlineTo gauge the potential clinical utility of targeting both BC6ENTG and BC6OTHER to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6OTHER / BC6OTHER inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6OTHER - or BC6OTHER - overexpressing human breast cancer cell lines. CPR:falsenewlineTo gauge the potential clinical utility of targeting both BC6OTHER and BC6ENTG to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6OTHER / BC6OTHER inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6OTHER - or BC6OTHER - overexpressing human breast cancer cell lines. CPR:falsenewlineTo gauge the potential clinical utility of targeting both BC6OTHER and BC6OTHER to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6ENTG / BC6OTHER inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6OTHER - or BC6OTHER - overexpressing human breast cancer cell lines. CPR:falsenewlineTo gauge the potential clinical utility of targeting both BC6OTHER and BC6OTHER to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6OTHER / BC6ENTG inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6OTHER - or BC6OTHER - overexpressing human breast cancer cell lines. CPR:falsenewlineTo gauge the potential clinical utility of targeting both BC6OTHER and BC6OTHER to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6OTHER / BC6OTHER inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6ENTG - or BC6OTHER - overexpressing human breast cancer cell lines. CPR:falsenewlineTo gauge the potential clinical utility of targeting both BC6OTHER and BC6OTHER to control growth and radiosensitize human breast cancers, we examined the effect of a dual BC6OTHER / BC6OTHER inhibitor, BC6ENTC , on the proliferation and radiation response of either BC6OTHER - or BC6ENTG - overexpressing human breast cancer cell lines. CPR:falsenewlineMETHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress BC6ENTG or BC6OTHER and luminal mammary epithelial H16N2 cells stably transfected with BC6OTHER were evaluated for the effect of BC6ENTC on inhibition of ligand - induced or BC6OTHER phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling. CPR:falsenewlineMETHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress BC6OTHER or BC6ENTG and luminal mammary epithelial H16N2 cells stably transfected with BC6OTHER were evaluated for the effect of BC6ENTC on inhibition of ligand - induced or BC6OTHER phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling. CPR:falsenewlineMETHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress BC6OTHER or BC6OTHER and luminal mammary epithelial H16N2 cells stably transfected with BC6ENTG were evaluated for the effect of BC6ENTC on inhibition of ligand - induced or BC6OTHER phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling. CPR:falsenewlineMETHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress BC6OTHER or BC6OTHER and luminal mammary epithelial H16N2 cells stably transfected with BC6OTHER were evaluated for the effect of BC6ENTC on inhibition of ligand - induced or BC6ENTG phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling. CPR:falsenewlineRESULTS: BC6ENTC inhibited constitutive and / or ligand - induced BC6ENTG or BC6OTHER BC6OTHER phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line. CPR:falsenewlineRESULTS: BC6ENTC inhibited constitutive and / or ligand - induced BC6OTHER or BC6ENTG BC6OTHER phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line. CPR:falsenewlineBC6ENTG levels were negatively correlated with variables of vagal control, reaching significance for rMSSD and log(10)HF, but not for pvRSA, during the last four phases of the hyperglycaemic clamp (hyperglycaemic second phase, BC6OTHER first and second phases, and BC6ENTC ). CPR:falsenewlineBC6OTHER levels were negatively correlated with variables of vagal control, reaching significance for rMSSD and log(10)HF, but not for pvRSA, during the last four phases of the hyperglycaemic clamp (hyperglycaemic second phase, BC6ENTG first and second phases, and BC6ENTC ). CPR:falsenewlineAdministration of the beta cell secretagogues BC6ENTG and BC6ENTC led to a significant increase in HR, but this was not paired with a significant reduction in HRV measures. CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6ENTG (achieved by administering BC6OTHER plus BC6ENTC , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6ENTG plus BC6ENTC , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6ENTC , BC6OTHER only, BC6OTHER and BC6ENTG , and BC6OTHER and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6ENTC , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6ENTG combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6ENTG (achieved by administering BC6OTHER plus BC6OTHER , BC6ENTC only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6ENTG plus BC6OTHER , BC6ENTC only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6ENTC only, BC6OTHER and BC6ENTG , and BC6OTHER and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6ENTC only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6ENTG combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6ENTG (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6ENTC and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6ENTG plus BC6OTHER , BC6OTHER only, BC6ENTC and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6ENTC and BC6ENTG , and BC6OTHER and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6ENTC and BC6OTHER , and BC6OTHER and BC6ENTG combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6ENTG (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6ENTC and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6ENTG plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6ENTC and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6ENTG , and BC6ENTC and BC6OTHER combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6ENTC and BC6ENTG combined with BC6OTHER ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6ENTG (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6ENTC ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6ENTG plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER combined with BC6ENTC ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6ENTG , and BC6OTHER and BC6OTHER combined with BC6ENTC ). CPR:falsenewlineThree variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart - rate variability [HRV] caused by peak - valley respiratory sinus arrhythmia [pvRSA], and high - frequency power [CHEM]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of BC6OTHER (achieved by administering BC6OTHER plus BC6OTHER , BC6OTHER only, BC6OTHER and BC6OTHER , and BC6OTHER and BC6ENTG combined with BC6ENTC ). CPR:falsenewlineConjugates bearing the anticancer agents BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6OTHER and the BC6ENTG targeting peptide WDLAWMFRLPVG were synthesized and characterized. CPR:falsenewlineConjugates bearing the anticancer agents BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), or BC6OTHER and the BC6ENTG targeting peptide WDLAWMFRLPVG were synthesized and characterized. CPR:falsenewlineConjugates bearing the anticancer agents BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), or BC6OTHER and the BC6ENTG targeting peptide WDLAWMFRLPVG were synthesized and characterized. CPR:falsenewlineConjugates bearing the anticancer agents BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), or BC6OTHER and the BC6ENTG targeting peptide WDLAWMFRLPVG were synthesized and characterized. CPR:falsenewlineConjugates bearing the anticancer agents BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6ENTC and the BC6ENTG targeting peptide WDLAWMFRLPVG were synthesized and characterized. CPR:falsenewlineBC6ENTG targeted BC6ENTC and BC6OTHER conjugates demonstrated active binding comparable to native targeting peptide. CPR:falsenewlineBC6ENTG targeted BC6OTHER and BC6ENTC conjugates demonstrated active binding comparable to native targeting peptide. CPR:falsenewlineSynergistic enhancement of cancer therapy using a combination of BC6ENTG targeted BC6ENTC copolymer - drug conjugates and gold nanorod induced hyperthermia. CPR:falsenewlineBC6ENTG targeted BC6ENTC conjugates exhibited high potency against DU145 cells with an IC50 of 2.4nM. CPR:falsenewlineBC6ENTG targeted BC6ENTC and BC6OTHER conjugates demonstrated synergistic effects in combination with hyperthermia with combination index values of 0.65 and 0.45 respectively. CPR:falsenewlineBC6ENTG targeted BC6OTHER and BC6ENTC conjugates demonstrated synergistic effects in combination with hyperthermia with combination index values of 0.65 and 0.45 respectively. CPR:falsenewlineBased on these results, BC6ENTG targeted BC6ENTC conjugates were selected for in vivo evaluation. CPR:falsenewlineIn DU145 tumor bearing mice, a single treatment of tumor hyperthermia, induced via gold nanorod mediated plasmonic photothermal therapy, and intravenous administration of BC6ENTG targeted BC6ENTC copolymer - BC6OTHER at 10mg / kg resulted in maintained tumor regression for a period of 30days. CPR:falsenewlineIn DU145 tumor bearing mice, a single treatment of tumor hyperthermia, induced via gold nanorod mediated plasmonic photothermal therapy, and intravenous administration of BC6ENTG targeted BC6OTHER copolymer - BC6ENTC at 10mg / kg resulted in maintained tumor regression for a period of 30days. CPR:falsenewlineIn this study, tumor hyperthermia was utilized as a means to increase the active delivery of BC6ENTG ( BC6OTHER ) targeted BC6ENTC ( BC6OTHER ) copolymer - drug conjugates. CPR:falsenewlineIn this study, tumor hyperthermia was utilized as a means to increase the active delivery of BC6OTHER ( BC6ENTG ) targeted BC6ENTC ( BC6OTHER ) copolymer - drug conjugates. CPR:falsenewlineIn this study, tumor hyperthermia was utilized as a means to increase the active delivery of BC6ENTG ( BC6OTHER ) targeted BC6OTHER ( BC6ENTC ) copolymer - drug conjugates. CPR:falsenewlineIn this study, tumor hyperthermia was utilized as a means to increase the active delivery of BC6OTHER ( BC6ENTG ) targeted BC6OTHER ( BC6ENTC ) copolymer - drug conjugates. CPR:falsenewlineFollowing hyperthermia, induced expression of cell surface BC6ENTG ( BC6OTHER ) BC6ENTC regulated protein 78kDa ( BC6OTHER ) was utilized for targeted drug therapy. CPR:falsenewlineFollowing hyperthermia, induced expression of cell surface BC6OTHER ( BC6ENTG ) BC6ENTC regulated protein 78kDa ( BC6OTHER ) was utilized for targeted drug therapy. CPR:falsenewlineFollowing hyperthermia, induced expression of cell surface BC6OTHER ( BC6OTHER ) BC6ENTC regulated protein 78kDa ( BC6ENTG ) was utilized for targeted drug therapy. CPR:falsenewlineThe carcinogenic relevance of BC6ENTG - BC6OTHER locus ncRNA induction was further supported by in vivo genetic dependence on constitutive BC6ENTC receptor and BC6OTHER pathways. CPR:falsenewlineThe carcinogenic relevance of BC6OTHER - BC6ENTG locus ncRNA induction was further supported by in vivo genetic dependence on constitutive BC6ENTC receptor and BC6OTHER pathways. CPR:falsenewlineThe carcinogenic relevance of BC6OTHER - BC6OTHER locus ncRNA induction was further supported by in vivo genetic dependence on constitutive BC6ENTC receptor and BC6ENTG pathways. CPR:falsenewline Here, we have investigated the temporal sequence of molecular and pathological perturbations at early stages of BC6ENTC (PB) mediated liver tumor promotion in vivo. Molecular profiling (mRNA, microRNA [miRNA], DNA methylation, and proteins) of mouse liver during 13 weeks of PB treatment revealed progressive increases in hepatic expression of long noncoding RNAs and miRNAs originating from the BC6ENTG - BC6OTHER imprinted gene cluster, a locus that has recently been associated with stem cell pluripotency in mice and various neoplasms in humans. CPR:falsenewline Here, we have investigated the temporal sequence of molecular and pathological perturbations at early stages of BC6ENTC (PB) mediated liver tumor promotion in vivo. Molecular profiling (mRNA, microRNA [miRNA], DNA methylation, and proteins) of mouse liver during 13 weeks of PB treatment revealed progressive increases in hepatic expression of long noncoding RNAs and miRNAs originating from the BC6OTHER - BC6ENTG imprinted gene cluster, a locus that has recently been associated with stem cell pluripotency in mice and various neoplasms in humans. CPR:falsenewlinePB induction of the BC6ENTG - BC6OTHER cluster noncoding RNA (ncRNA) Meg3 was localized to BC6ENTC synthetase - positive hypertrophic perivenous hepatocytes, suggesting a role for BC6OTHER signaling in the dysregulation of BC6OTHER - BC6OTHER ncRNAs. CPR:falsenewlinePB induction of the BC6OTHER - BC6ENTG cluster noncoding RNA (ncRNA) Meg3 was localized to BC6ENTC synthetase - positive hypertrophic perivenous hepatocytes, suggesting a role for BC6OTHER signaling in the dysregulation of BC6OTHER - BC6OTHER ncRNAs. CPR:falsenewlinePB induction of the BC6OTHER - BC6OTHER cluster noncoding RNA (ncRNA) Meg3 was localized to BC6ENTC synthetase - positive hypertrophic perivenous hepatocytes, suggesting a role for BC6ENTG signaling in the dysregulation of BC6OTHER - BC6OTHER ncRNAs. CPR:falsenewlinePB induction of the BC6OTHER - BC6OTHER cluster noncoding RNA (ncRNA) Meg3 was localized to BC6ENTC synthetase - positive hypertrophic perivenous hepatocytes, suggesting a role for BC6OTHER signaling in the dysregulation of BC6ENTG - BC6OTHER ncRNAs. CPR:falsenewlinePB induction of the BC6OTHER - BC6OTHER cluster noncoding RNA (ncRNA) Meg3 was localized to BC6ENTC synthetase - positive hypertrophic perivenous hepatocytes, suggesting a role for BC6OTHER signaling in the dysregulation of BC6OTHER - BC6ENTG ncRNAs. CPR:falsenewlineThe noted conformational changes where the BC6OTHER position is closer to the BC6OTHER position of BC6OTHER provided the first experimental data for understanding the molecular mechanism of the catalytic function of BC6ENTG in the isomerization of BC6OTHER to BC6ENTC . CPR:falsenewlineThe binding of BC6ENTC to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6OTHER in a concentration - dependent manner. CPR:falsenewlineThe binding of BC6ENTC to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6ENTG in a concentration - dependent manner. CPR:falsenewlineThe binding of BC6OTHER to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6ENTC , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6OTHER in a concentration - dependent manner. CPR:falsenewlineThe binding of BC6OTHER to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6ENTC , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6ENTG in a concentration - dependent manner. CPR:falsenewlineThe binding of BC6OTHER to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6ENTC , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6OTHER in a concentration - dependent manner. CPR:falsenewlineThe binding of BC6OTHER to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6ENTC , and BC6OTHER of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6ENTG in a concentration - dependent manner. CPR:falsenewlineThe binding of BC6OTHER to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6ENTC of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6OTHER in a concentration - dependent manner. CPR:falsenewlineThe binding of BC6OTHER to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6ENTC of BC6OTHER were observed upon BC6OTHER binding to the engineered BC6ENTG in a concentration - dependent manner. CPR:falsenewlineThe binding of BC6OTHER to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6ENTC were observed upon BC6OTHER binding to the engineered BC6OTHER in a concentration - dependent manner. CPR:falsenewlineThe binding of BC6OTHER to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6ENTC were observed upon BC6OTHER binding to the engineered BC6ENTG in a concentration - dependent manner. CPR:falsenewlineThe binding of BC6OTHER to the BC6ENTG protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6ENTC binding to the engineered BC6OTHER in a concentration - dependent manner. CPR:falsenewlineThe binding of BC6OTHER to the BC6OTHER protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at BC6OTHER , BC6OTHER , and BC6OTHER of BC6OTHER were observed upon BC6ENTC binding to the engineered BC6ENTG in a concentration - dependent manner. CPR:falsenewlineThe detailed conformational change and 3D structure of the BC6ENTG - bound BC6ENTC were further demonstrated by 2D BC6OTHER NMR experiments using the transferred NOE technique. CPR:falsenewlineThe detailed conformational change and 3D structure of the BC6ENTG - bound BC6OTHER were further demonstrated by 2D BC6ENTC NMR experiments using the transferred NOE technique. CPR:falsenewlineThe distances between the protons BC6ENTC and BC6OTHER , BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER are shorter following their binding to the BC6ENTG in solution - down to within 5 A. CPR:falsenewlineHigh - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6OTHER ) mimic ( BC6ENTC ) to the engineered BC6ENTG ( BC6OTHER ) in solution. CPR:falsenewlineHigh - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6OTHER ) mimic ( BC6ENTC ) to the engineered BC6OTHER ( BC6OTHER ) synthase ( BC6ENTG ) in solution. CPR:falsenewlineThe distances between the protons BC6OTHER and BC6ENTC , BC6OTHER and BC6OTHER , and BC6OTHER and BC6OTHER are shorter following their binding to the BC6ENTG in solution - down to within 5 A. CPR:falsenewlineThe distances between the protons BC6OTHER and BC6OTHER , BC6ENTC and BC6OTHER , and BC6OTHER and BC6OTHER are shorter following their binding to the BC6ENTG in solution - down to within 5 A. CPR:falsenewlineThe distances between the protons BC6OTHER and BC6OTHER , BC6OTHER and BC6ENTC , and BC6OTHER and BC6OTHER are shorter following their binding to the BC6ENTG in solution - down to within 5 A. CPR:falsenewlineThe distances between the protons BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER , and BC6ENTC and BC6OTHER are shorter following their binding to the BC6ENTG in solution - down to within 5 A. CPR:falsenewlineThe distances between the protons BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER , and BC6OTHER and BC6ENTC are shorter following their binding to the BC6ENTG in solution - down to within 5 A. CPR:falsenewlineHigh - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6ENTC ) mimic ( BC6OTHER ) to the engineered BC6ENTG ( BC6OTHER ) in solution. CPR:falsenewlineHigh - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6ENTC ) mimic ( BC6OTHER ) to the engineered BC6OTHER ( BC6OTHER ) synthase ( BC6ENTG ) in solution. CPR:falsenewlineThe bound conformation of BC6ENTC fits the crystal structure of the BC6ENTG substrate binding pocket considerably better than that of the unbound BC6OTHER . CPR:falsenewlineCharacterization of the substrate mimic bound to engineered BC6ENTG in solution using high - resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of BC6ENTC . CPR:falsenewlineThe bound conformation of BC6OTHER fits the crystal structure of the BC6ENTG substrate binding pocket considerably better than that of the unbound BC6ENTC . CPR:falsenewlineHigh - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6OTHER ) mimic ( BC6OTHER ) to the engineered BC6ENTC ( BC6OTHER ) synthase ( BC6ENTG ) in solution. CPR:falsenewlineFor example, CHEM282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the BC6ENTG - bound form of BC6ENTC and the BC6OTHER crystal structure. CPR:falsenewlineFor example, CHEM282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the BC6OTHER - bound form of BC6ENTC and the BC6ENTG crystal structure. CPR:falsenewlineHigh - resolution NMR spectroscopy was used to determine the docking of a substrate ( BC6OTHER ) mimic ( BC6OTHER ) to the engineered BC6OTHER ( BC6ENTC ) synthase ( BC6ENTG ) in solution. CPR:falsenewlineThe noted conformational changes where the BC6ENTC position is closer to the BC6OTHER position of BC6OTHER provided the first experimental data for understanding the molecular mechanism of the catalytic function of BC6ENTG in the isomerization of BC6OTHER to BC6OTHER . CPR:falsenewlineThe noted conformational changes where the BC6OTHER position is closer to the BC6ENTC position of BC6OTHER provided the first experimental data for understanding the molecular mechanism of the catalytic function of BC6ENTG in the isomerization of BC6OTHER to BC6OTHER . CPR:falsenewlineThe noted conformational changes where the BC6OTHER position is closer to the BC6OTHER position of BC6ENTC provided the first experimental data for understanding the molecular mechanism of the catalytic function of BC6ENTG in the isomerization of BC6OTHER to BC6OTHER . CPR:falsenewlineThe noted conformational changes where the BC6OTHER position is closer to the BC6OTHER position of BC6OTHER provided the first experimental data for understanding the molecular mechanism of the catalytic function of BC6ENTG in the isomerization of BC6ENTC to BC6OTHER . CPR:falsenewlineX - linked hypophosphatemia (XLH / HYP) - with renal BC6OTHER wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6ENTC - metallopeptidase BC6ENTG gene ( BC6OTHER - regulating gene with homologies to BC6OTHER on the X chromosome). CPR:falsenewlineX - linked hypophosphatemia (XLH / HYP) - with renal BC6OTHER wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6ENTC - metallopeptidase BC6OTHER gene ( BC6OTHER - regulating gene with homologies to BC6ENTG on the X chromosome). CPR:falsenewlineX - linked hypophosphatemia (XLH / HYP) - with renal BC6OTHER wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6ENTG BC6OTHER gene ( BC6ENTC - regulating gene with homologies to BC6OTHER on the X chromosome). CPR:falsenewlineX - linked hypophosphatemia (XLH / HYP) - with renal BC6OTHER wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6OTHER - metallopeptidase BC6ENTG gene ( BC6ENTC - regulating gene with homologies to BC6OTHER on the X chromosome). CPR:falsenewlineX - linked hypophosphatemia (XLH / HYP) - with renal BC6OTHER wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6OTHER - metallopeptidase BC6OTHER gene ( BC6ENTC - regulating gene with homologies to BC6ENTG on the X chromosome). CPR:falsenewlineX - linked hypophosphatemia (XLH / HYP) - with renal BC6ENTC wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6ENTG BC6OTHER gene ( BC6OTHER - regulating gene with homologies to BC6OTHER on the X chromosome). CPR:falsenewlineX - linked hypophosphatemia (XLH / HYP) - with renal BC6ENTC wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6OTHER - metallopeptidase BC6ENTG gene ( BC6OTHER - regulating gene with homologies to BC6OTHER on the X chromosome). CPR:falsenewlineX - linked hypophosphatemia (XLH / HYP) - with renal BC6ENTC wasting, hypophosphatemia, osteomalacia, and tooth abscesses - is caused by mutations in the BC6OTHER - metallopeptidase BC6OTHER gene ( BC6OTHER - regulating gene with homologies to BC6ENTG on the X chromosome). CPR:falsenewlineInactivating mutations in BC6ENTG lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6ENTC - and BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6OTHER - linked glycoproteins). CPR:falsenewlineInactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6ENTC - and BC6OTHER - rich motif ( BC6ENTG ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6OTHER - linked glycoproteins). CPR:falsenewlineInactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6ENTC - and BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6ENTG family (small, integrin - binding ligand BC6OTHER - linked glycoproteins). CPR:falsenewlineInactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6ENTC - and BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family ( BC6ENTG ). CPR:falsenewlineInactivating mutations in BC6ENTG lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6ENTC - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6OTHER - linked glycoproteins). CPR:falsenewlineInactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, BC6ENTG BC6ENTC - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6OTHER - linked glycoproteins). CPR:falsenewlineInactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6ENTC - rich motif ( BC6ENTG ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6OTHER - linked glycoproteins). CPR:falsenewlineInactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6ENTC - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6ENTG family (small, integrin - binding ligand BC6OTHER - linked glycoproteins). CPR:falsenewlineInactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6ENTC - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family ( BC6ENTG ). CPR:falsenewlineInactivating mutations in BC6ENTG lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6ENTC - linked glycoproteins). CPR:falsenewlineInactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, BC6ENTG BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6ENTC - linked glycoproteins). CPR:falsenewlineInactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6OTHER - rich motif ( BC6ENTG ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6OTHER family (small, integrin - binding ligand BC6ENTC - linked glycoproteins). CPR:falsenewlineInactivating mutations in BC6OTHER lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization - inhibiting, acidic BC6OTHER - and BC6OTHER - rich motif ( BC6OTHER ) - containing peptides, which are proteolytically derived from the mineral - binding matrix proteins of the BC6ENTG family (small, integrin - binding ligand BC6ENTC - linked glycoproteins). CPR:falsenewlineThe net accumulation of BC6OTHER ( BC6ENTC ) and the BC6OTHER - DNA adduct levels were reduced in BC6ENTG KD and BC6OTHER KD cells. CPR:falsenewlineThe net accumulation of BC6OTHER ( BC6ENTC ) and the BC6OTHER - DNA adduct levels were reduced in BC6OTHER KD and BC6ENTG KD cells. CPR:falsenewlineThe net accumulation of BC6OTHER ( BC6OTHER ) and the BC6ENTC - DNA adduct levels were reduced in BC6ENTG KD and BC6OTHER KD cells. CPR:falsenewlineThe net accumulation of BC6OTHER ( BC6OTHER ) and the BC6ENTC - DNA adduct levels were reduced in BC6OTHER KD and BC6ENTG KD cells. CPR:falsenewlineThe endogenous mRNA levels of BC6ENTC influx transporter BC6OTHER were found to be significantly reduced in the knockdown cells, and exogenous expression of BC6ENTG restored their sensitivity to CHEM. CPR:falsenewlineThe endogenous mRNA levels of BC6ENTC influx transporter BC6ENTG were found to be significantly reduced in the knockdown cells, and exogenous expression of BC6OTHER restored their sensitivity to CHEM. CPR:falsenewline BC6ENTG and BC6OTHER regulate sensitivity to BC6OTHER by controlling expression of the CHEM and BC6ENTC influx transporter BC6OTHER . CPR:falsenewline BC6OTHER and BC6OTHER regulate sensitivity to BC6OTHER by controlling expression of the CHEM and BC6ENTC influx transporter BC6ENTG . CPR:falsenewline BC6OTHER and BC6ENTG regulate sensitivity to BC6OTHER by controlling expression of the CHEM and BC6ENTC influx transporter BC6OTHER . CPR:falsenewline BC6ENTG and BC6OTHER regulate sensitivity to BC6ENTC by controlling expression of the CHEM and BC6OTHER influx transporter BC6OTHER . CPR:falsenewline BC6OTHER and BC6OTHER regulate sensitivity to BC6ENTC by controlling expression of the CHEM and BC6OTHER influx transporter BC6ENTG . CPR:falsenewline BC6OTHER and BC6ENTG regulate sensitivity to BC6ENTC by controlling expression of the CHEM and BC6OTHER influx transporter BC6OTHER . CPR:falsenewline BC6OTHER and BC6OTHER regulate sensitivity to BC6ENTC by controlling expression of the BC6ENTG BC6OTHER . CPR:falsenewline BC6ENTG and BC6OTHER regulate sensitivity to BC6OTHER by controlling expression of the BC6ENTC and BC6OTHER influx transporter BC6OTHER . CPR:falsenewline BC6OTHER and BC6OTHER regulate sensitivity to BC6OTHER by controlling expression of the BC6ENTC and BC6OTHER influx transporter BC6ENTG . CPR:falsenewline BC6OTHER and BC6ENTG regulate sensitivity to BC6OTHER by controlling expression of the BC6ENTC and BC6OTHER influx transporter BC6OTHER . CPR:falsenewlineBaseline BC6ENTC ( BC6OTHER ) level, BC6OTHER uptake, and BC6OTHER cytotoxicity were also reduced in BC6ENTG KD and BC6OTHER KD cells. CPR:falsenewlineBaseline BC6ENTC ( BC6OTHER ) level, BC6OTHER uptake, and BC6OTHER cytotoxicity were also reduced in BC6OTHER KD and BC6ENTG KD cells. CPR:falsenewlineBaseline BC6OTHER ( BC6ENTC ) level, BC6OTHER uptake, and BC6OTHER cytotoxicity were also reduced in BC6ENTG KD and BC6OTHER KD cells. CPR:falsenewlineBaseline BC6OTHER ( BC6ENTC ) level, BC6OTHER uptake, and BC6OTHER cytotoxicity were also reduced in BC6OTHER KD and BC6ENTG KD cells. CPR:falsenewlineBaseline BC6OTHER ( BC6OTHER ) level, BC6ENTC uptake, and BC6OTHER cytotoxicity were also reduced in BC6ENTG KD and BC6OTHER KD cells. CPR:falsenewlineBaseline BC6OTHER ( BC6OTHER ) level, BC6ENTC uptake, and BC6OTHER cytotoxicity were also reduced in BC6OTHER KD and BC6ENTG KD cells. CPR:falsenewlineBaseline BC6OTHER ( BC6OTHER ) level, BC6OTHER uptake, and BC6ENTC cytotoxicity were also reduced in BC6ENTG KD and BC6OTHER KD cells. CPR:falsenewlineBaseline BC6OTHER ( BC6OTHER ) level, BC6OTHER uptake, and BC6ENTC cytotoxicity were also reduced in BC6OTHER KD and BC6ENTG KD cells. CPR:falsenewlineBC6ENTC - dependent BC6ENTG activity was also markedly reduced in both types of BC6OTHER knockdown cells when incubated with the substrate BC6OTHER . CPR:9newlineBC6ENTC - dependent BC6OTHER activity was also markedly reduced in both types of BC6ENTG knockdown cells when incubated with the substrate BC6OTHER . CPR:falsenewlineBC6OTHER - dependent BC6ENTG activity was also markedly reduced in both types of BC6OTHER knockdown cells when incubated with the substrate BC6ENTC . CPR:9newlineBC6OTHER - dependent BC6OTHER activity was also markedly reduced in both types of BC6ENTG knockdown cells when incubated with the substrate BC6ENTC . CPR:falsenewlineThese results indicate that BC6ENTG and BC6OTHER affect sensitivity of the ovarian cancer cells to the cytotoxic effect of CHEM by regulating expression of the BC6ENTC transporter BC6OTHER . CPR:falsenewlineThese results indicate that BC6OTHER and BC6ENTG affect sensitivity of the ovarian cancer cells to the cytotoxic effect of CHEM by regulating expression of the BC6ENTC transporter BC6OTHER . CPR:falsenewlineThese results indicate that BC6OTHER and BC6OTHER affect sensitivity of the ovarian cancer cells to the cytotoxic effect of CHEM by regulating expression of the BC6ENTC transporter BC6ENTG . CPR:falsenewlineWe found that knockdown of the expression of either BC6ENTG or BC6OTHER produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to BC6ENTC (CHEM). CPR:falsenewlineWe found that knockdown of the expression of either BC6OTHER or BC6ENTG produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to BC6ENTC (CHEM). CPR:falsenewlineThe net accumulation of BC6ENTC ( BC6OTHER ) and the BC6OTHER - DNA adduct levels were reduced in BC6ENTG KD and BC6OTHER KD cells. CPR:falsenewlineThe net accumulation of BC6ENTC ( BC6OTHER ) and the BC6OTHER - DNA adduct levels were reduced in BC6OTHER KD and BC6ENTG KD cells. CPR:falsenewlineGitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the BC6ENTC - sensitive BC6OTHER co - transporter ( BC6ENTG ). CPR:falsenewlineGitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the CHEM - sensitive BC6ENTC co - transporter ( BC6ENTG ). CPR:falsenewlineDifferent forms of therapy, BC6ENTC and BC6OTHER substitution, BC6OTHER and BC6OTHER failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized BC6ENTG levels in the three patients with short stature. CPR:falsenewlineDifferent forms of therapy, BC6OTHER and BC6ENTC substitution, BC6OTHER and BC6OTHER failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized BC6ENTG levels in the three patients with short stature. CPR:falsenewlineDifferent forms of therapy, BC6OTHER and BC6OTHER substitution, BC6ENTC and BC6OTHER failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized BC6ENTG levels in the three patients with short stature. CPR:falsenewlineDifferent forms of therapy, BC6OTHER and BC6OTHER substitution, BC6OTHER and BC6ENTC failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized BC6ENTG levels in the three patients with short stature. CPR:falsenewlineWe show that the binding of BC6OTHER photoaffinity label to authentic BC6ENTG is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6ENTC . CPR:falsenewlineWe show that the binding of BC6OTHER photoaffinity label to authentic BC6OTHER is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6ENTG from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6ENTC . CPR:falsenewlineWe show that the binding of BC6OTHER photoaffinity label to authentic BC6OTHER is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6ENTG may be involved in the immunomodulatory activity of BC6ENTC . CPR:falsenewlineThe immunomodulatory activity of BC6ENTC has been ascribed to the selective inhibition of BC6ENTG from monocytes. CPR:4newlineWe show that the binding of BC6ENTC photoaffinity label to authentic BC6ENTG is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6OTHER . CPR:falsenewlineWe show that the binding of BC6ENTC photoaffinity label to authentic BC6OTHER is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6ENTG from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6OTHER . CPR:falsenewlineWe show that the binding of BC6ENTC photoaffinity label to authentic BC6OTHER is competed with both BC6OTHER and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6ENTG may be involved in the immunomodulatory activity of BC6OTHER . CPR:falsenewlineWe show that the binding of BC6OTHER photoaffinity label to authentic BC6ENTG is competed with both BC6ENTC and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6OTHER . CPR:falsenewlineWe show that the binding of BC6OTHER photoaffinity label to authentic BC6OTHER is competed with both BC6ENTC and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6ENTG from human monocytes, suggesting that BC6OTHER may be involved in the immunomodulatory activity of BC6OTHER . CPR:falsenewlineWe show that the binding of BC6OTHER photoaffinity label to authentic BC6OTHER is competed with both BC6ENTC and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of BC6OTHER from human monocytes, suggesting that BC6ENTG may be involved in the immunomodulatory activity of BC6OTHER . CPR:falsenewlineBinding of BC6ENTC to BC6ENTG may be involved in its inhibition of BC6OTHER production. CPR:falsenewlineBinding of BC6ENTC to BC6OTHER may be involved in its inhibition of BC6ENTG production. CPR:falsenewlineThe role of extranuclear signaling actions of BC6ENTG in mediating BC6ENTC regulation of gene expression and the cell cycle. CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6ENTG activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6ENTG . CPR:falsenewlineBC6OTHER induction of the BC6ENTG gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTG , was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6ENTG activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6ENTG / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6ENTG pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6ENTG ( BC6OTHER ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6ENTG ) gene that contains a functional BC6ENTC response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6ENTC induction of cell cycle progression was also abrogated in cells expressing BC6ENTG , and no effect of BC6OTHER on BC6OTHER expression and cell cycle was observed in the presence of BC6OTHER . CPR:falsenewlineBC6ENTC induction of cell cycle progression was also abrogated in cells expressing BC6OTHER , and no effect of BC6OTHER on BC6ENTG expression and cell cycle was observed in the presence of BC6OTHER . CPR:falsenewlineBC6ENTC induction of cell cycle progression was also abrogated in cells expressing BC6OTHER , and no effect of BC6OTHER on BC6OTHER expression and cell cycle was observed in the presence of BC6ENTG . CPR:falsenewlineBC6OTHER induction of cell cycle progression was also abrogated in cells expressing BC6ENTG , and no effect of BC6ENTC on BC6OTHER expression and cell cycle was observed in the presence of BC6OTHER . CPR:falsenewlineBC6OTHER induction of cell cycle progression was also abrogated in cells expressing BC6OTHER , and no effect of BC6ENTC on BC6ENTG expression and cell cycle was observed in the presence of BC6OTHER . CPR:falsenewlineBC6OTHER induction of cell cycle progression was also abrogated in cells expressing BC6OTHER , and no effect of BC6ENTC on BC6OTHER expression and cell cycle was observed in the presence of BC6ENTG . CPR:falsenewlineThese results highlight the importance of BC6ENTG activation of the BC6OTHER / BC6OTHER signaling pathway for BC6ENTC - induced transcription of select target genes and cell cycle progression. CPR:falsenewlineThese results highlight the importance of BC6OTHER activation of the BC6ENTG / BC6OTHER signaling pathway for BC6ENTC - induced transcription of select target genes and cell cycle progression. CPR:falsenewlineThese results highlight the importance of BC6OTHER activation of the BC6OTHER / BC6ENTG signaling pathway for BC6ENTC - induced transcription of select target genes and cell cycle progression. CPR:falsenewlineBC6ENTC activation of BC6ENTG / BC6OTHER occurred outside the nucleus with the BC6OTHER that was distributed between the cytoplasm and nucleus, but not with BC6OTHER that was predominantly nuclear. CPR:falsenewlineBC6ENTC activation of BC6OTHER / BC6ENTG occurred outside the nucleus with the BC6OTHER that was distributed between the cytoplasm and nucleus, but not with BC6OTHER that was predominantly nuclear. CPR:falsenewlineBC6ENTC activation of BC6OTHER / BC6OTHER occurred outside the nucleus with the BC6ENTG that was distributed between the cytoplasm and nucleus, but not with BC6OTHER that was predominantly nuclear. CPR:falsenewlineBC6ENTC activation of BC6OTHER / BC6OTHER occurred outside the nucleus with the BC6OTHER that was distributed between the cytoplasm and nucleus, but not with BC6ENTG that was predominantly nuclear. CPR:falsenewlineHuman BC6ENTC receptor ( BC6OTHER ) contains a motif that interacts with the BC6OTHER of BC6OTHER and mediates rapid activation of BC6ENTG and downstream BC6OTHER ( BC6OTHER ) without relying on the transcriptional activity of the receptor. CPR:falsenewlineHuman BC6ENTC receptor ( BC6OTHER ) contains a motif that interacts with the BC6OTHER of BC6OTHER and mediates rapid activation of BC6OTHER and downstream BC6ENTG ( BC6OTHER ) without relying on the transcriptional activity of the receptor. CPR:falsenewlineHuman BC6ENTC receptor ( BC6OTHER ) contains a motif that interacts with the BC6OTHER of BC6OTHER and mediates rapid activation of BC6OTHER and downstream BC6OTHER ( BC6ENTG ) without relying on the transcriptional activity of the receptor. CPR:falsenewlineHuman BC6ENTC receptor ( BC6ENTG ) contains a motif that interacts with the BC6OTHER of BC6OTHER and mediates rapid activation of BC6OTHER and downstream BC6OTHER ( BC6OTHER ) without relying on the transcriptional activity of the receptor. CPR:falsenewlineHuman BC6ENTC receptor ( BC6OTHER ) contains a motif that interacts with the BC6ENTG of BC6OTHER and mediates rapid activation of BC6OTHER and downstream BC6OTHER ( BC6OTHER ) without relying on the transcriptional activity of the receptor. CPR:falsenewlineHuman BC6ENTC receptor ( BC6OTHER ) contains a motif that interacts with the BC6OTHER of BC6ENTG and mediates rapid activation of BC6OTHER and downstream BC6OTHER ( BC6OTHER ) without relying on the transcriptional activity of the receptor. CPR:falsenewlineBreast cancer cells stably expressing wild - type BC6ENTG or BC6OTHER with disrupting point mutations in the BC6OTHER ( BC6OTHER ) that do not affect the transcriptional activity of BC6OTHER , were compared for effects of BC6ENTC on endogenous target gene expression and cell proliferation. CPR:falsenewlineBreast cancer cells stably expressing wild - type BC6OTHER or BC6ENTG with disrupting point mutations in the BC6OTHER ( BC6OTHER ) that do not affect the transcriptional activity of BC6OTHER , were compared for effects of BC6ENTC on endogenous target gene expression and cell proliferation. CPR:falsenewlineBreast cancer cells stably expressing wild - type BC6OTHER or BC6OTHER with disrupting point mutations in the BC6ENTG ( BC6OTHER ) that do not affect the transcriptional activity of BC6OTHER , were compared for effects of BC6ENTC on endogenous target gene expression and cell proliferation. CPR:falsenewlineBreast cancer cells stably expressing wild - type BC6OTHER or BC6OTHER with disrupting point mutations in the BC6OTHER ( BC6ENTG ) that do not affect the transcriptional activity of BC6OTHER , were compared for effects of BC6ENTC on endogenous target gene expression and cell proliferation. CPR:falsenewlineBreast cancer cells stably expressing wild - type BC6OTHER or BC6OTHER with disrupting point mutations in the BC6OTHER ( BC6OTHER ) that do not affect the transcriptional activity of BC6ENTG , were compared for effects of BC6ENTC on endogenous target gene expression and cell proliferation. CPR:falsenewlineBC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTG was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6ENTG activation of BC6OTHER . CPR:falsenewlineBC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6ENTG . CPR:falsenewlineBC6ENTC induction of the BC6ENTG gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6ENTC induction of the BC6OTHER gene, which lacks a BC6ENTG , was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6ENTG activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6ENTG / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6ENTG pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6ENTG ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6ENTC induction of the BC6OTHER gene, which lacks a BC6OTHER response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6ENTG ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6ENTG was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6ENTG activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6ENTG . CPR:falsenewlineBC6OTHER induction of the BC6ENTG gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6ENTG activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6ENTG / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6ENTG pathway, whereas induction of the BC6OTHER ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6ENTG ( BC6OTHER ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineBC6OTHER induction of the BC6OTHER gene, which lacks a BC6ENTC response element, was dependent on BC6OTHER activation of the BC6OTHER / BC6OTHER pathway, whereas induction of the BC6OTHER ( BC6ENTG ) gene that contains a functional BC6OTHER response element was unaffected by mutations that interfere with BC6OTHER activation of BC6OTHER . CPR:falsenewlineThe subtypes of BC6ENTG mediating contractions to exogenous BC6ENTC ( BC6OTHER ) in rat aorta have been examined in both biochemical and functional studies. CPR:falsenewlineThe affinity of the same antagonists for the BC6ENTG was evaluated by utilizing membranes from rat hippocampus pretreated with BC6ENTC , and rat liver, respectively. CPR:falsenewlineThe subtypes of BC6ENTG mediating contractions to exogenous BC6OTHER ( BC6ENTC ) in rat aorta have been examined in both biochemical and functional studies. CPR:falsenewlineMediation of BC6ENTC - induced contractions of rat aorta by the BC6ENTG subtype. CPR:falsenewlineBC6ENTC and BC6OTHER were confirmed as selective for the BC6ENTG , whereas BC6OTHER was alpha 1B - selective. CPR:falsenewlineBC6OTHER and BC6ENTC were confirmed as selective for the BC6ENTG , whereas BC6OTHER was alpha 1B - selective. CPR:falsenewlineBC6OTHER and BC6OTHER were confirmed as selective for the BC6ENTG , whereas BC6ENTC was alpha 1B - selective. CPR:falsenewlineIncubation of rat aortic membranes with the irreversible BC6ENTG antagonist, BC6ENTC ( BC6OTHER : 10 microM) did not change the KD of BC6OTHER binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax). CPR:falsenewlineIncubation of rat aortic membranes with the irreversible BC6ENTG antagonist, BC6OTHER ( BC6ENTC : 10 microM) did not change the KD of BC6OTHER binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax). CPR:falsenewlineIncubation of rat aortic membranes with the irreversible BC6ENTG antagonist, BC6OTHER ( BC6OTHER : 10 microM) did not change the KD of BC6ENTC binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax). CPR:falsenewlineThe BC6ENTC action of BC6OTHER are mediated by the BC6OTHER BC6OTHER BC6ENTG and BC6OTHER . CPR:falsenewlineThe BC6ENTC action of BC6OTHER are mediated by the BC6OTHER BC6OTHER BC6OTHER and BC6ENTG . CPR:falsenewlineThe BC6ENTC action of BC6OTHER are mediated by the BC6ENTG BC6OTHER BC6OTHER and BC6OTHER . CPR:falsenewlineThe BC6ENTC action of BC6OTHER are mediated by the BC6OTHER BC6ENTG BC6OTHER and BC6OTHER . CPR:falsenewlineThe BC6OTHER action of BC6ENTC are mediated by the BC6OTHER BC6OTHER BC6ENTG and BC6OTHER . CPR:falsenewlineThe BC6OTHER action of BC6ENTC are mediated by the BC6OTHER BC6OTHER BC6OTHER and BC6ENTG . CPR:falsenewlineThe BC6OTHER action of BC6ENTC are mediated by the BC6ENTG BC6OTHER BC6OTHER and BC6OTHER . CPR:falsenewlineThe BC6OTHER action of BC6ENTC are mediated by the BC6OTHER BC6ENTG BC6OTHER and BC6OTHER . CPR:falsenewlineThe BC6OTHER action of BC6OTHER are mediated by the BC6OTHER BC6ENTC receptors BC6ENTG and BC6OTHER . CPR:falsenewlineThe BC6OTHER action of BC6OTHER are mediated by the BC6OTHER BC6ENTC receptors BC6OTHER and BC6ENTG . CPR:falsenewlineThe BC6OTHER action of BC6OTHER are mediated by the BC6ENTG BC6ENTC receptors BC6OTHER and BC6OTHER . CPR:falsenewlineDown - regulation of BC6ENTG ( BC6OTHER ) expression, an BC6OTHER - target gene, by BC6ENTC and BC6OTHER was accompanied by the blockade of the mutated BC6OTHER . CPR:4newlineDown - regulation of BC6OTHER ( BC6ENTG ) expression, an BC6OTHER - target gene, by BC6ENTC and BC6OTHER was accompanied by the blockade of the mutated BC6OTHER . CPR:4newlineDown - regulation of BC6OTHER ( BC6OTHER ) expression, an BC6ENTG - target gene, by BC6ENTC and BC6OTHER was accompanied by the blockade of the mutated BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER ( BC6OTHER ) expression, an BC6OTHER - target gene, by BC6ENTC and BC6OTHER was accompanied by the blockade of the mutated BC6ENTG . CPR:4newlineDown - regulation of BC6ENTG ( BC6OTHER ) expression, an BC6OTHER - target gene, by BC6OTHER and BC6ENTC was accompanied by the blockade of the mutated BC6OTHER . CPR:4newlineDown - regulation of BC6OTHER ( BC6ENTG ) expression, an BC6OTHER - target gene, by BC6OTHER and BC6ENTC was accompanied by the blockade of the mutated BC6OTHER . CPR:4newlineDown - regulation of BC6OTHER ( BC6OTHER ) expression, an BC6ENTG - target gene, by BC6OTHER and BC6ENTC was accompanied by the blockade of the mutated BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER ( BC6OTHER ) expression, an BC6OTHER - target gene, by BC6OTHER and BC6ENTC was accompanied by the blockade of the mutated BC6ENTG . CPR:4newlineDown - regulation of BC6ENTG ( BC6OTHER ) expression, an BC6OTHER - target gene, by BC6OTHER and BC6OTHER was accompanied by the blockade of the mutated BC6ENTC receptor. CPR:4newlineDown - regulation of BC6OTHER ( BC6ENTG ) expression, an BC6OTHER - target gene, by BC6OTHER and BC6OTHER was accompanied by the blockade of the mutated BC6ENTC receptor. CPR:4newlineDown - regulation of BC6OTHER ( BC6OTHER ) expression, an BC6ENTG - target gene, by BC6OTHER and BC6OTHER was accompanied by the blockade of the mutated BC6ENTC receptor. CPR:falsenewlineExposure of LNCaP cells to BC6ENTC for 24 hr caused transcriptional inhibition of BC6ENTG in a concentration - dependent manner. CPR:4newlineThe levels of BC6ENTG mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of BC6ENTC , respectively (IC50 = 10.97 + / - 1.68 microM). CPR:falsenewlineBinding of BC6ENTC to m - BC6ENTG in LNCaP cells resulted in a concentration - dependent stimulation of BC6OTHER expression, suggesting that BC6OTHER acted as an agonist of the m - BC6OTHER . CPR:falsenewlineBinding of BC6ENTC to m - BC6OTHER in LNCaP cells resulted in a concentration - dependent stimulation of BC6ENTG expression, suggesting that BC6OTHER acted as an agonist of the m - BC6OTHER . CPR:falsenewlineBinding of BC6ENTC to m - BC6OTHER in LNCaP cells resulted in a concentration - dependent stimulation of BC6OTHER expression, suggesting that BC6OTHER acted as an agonist of the m - BC6ENTG . CPR:falsenewlineBinding of BC6OTHER to m - BC6ENTG in LNCaP cells resulted in a concentration - dependent stimulation of BC6OTHER expression, suggesting that BC6ENTC acted as an agonist of the m - BC6OTHER . CPR:falsenewlineBinding of BC6OTHER to m - BC6OTHER in LNCaP cells resulted in a concentration - dependent stimulation of BC6ENTG expression, suggesting that BC6ENTC acted as an agonist of the m - BC6OTHER . CPR:falsenewlineBinding of BC6OTHER to m - BC6OTHER in LNCaP cells resulted in a concentration - dependent stimulation of BC6OTHER expression, suggesting that BC6ENTC acted as an agonist of the m - BC6ENTG . CPR:falsenewlineOur data indicate that BC6ENTC metabolites perform as BC6OTHER antagonists of BC6ENTG , an additional mechanism involved in the therapeutic effect of BC6OTHER in patients with prostate cancer. CPR:falsenewlineOur data indicate that BC6OTHER metabolites perform as BC6ENTC antagonists of BC6ENTG , an additional mechanism involved in the therapeutic effect of BC6OTHER in patients with prostate cancer. CPR:falsenewlineOur data indicate that BC6OTHER metabolites perform as BC6OTHER antagonists of BC6ENTG , an additional mechanism involved in the therapeutic effect of BC6ENTC in patients with prostate cancer. CPR:falsenewlineAnalogous to the antiandrogens, BC6ENTC and BC6OTHER , binding of BC6OTHER metabolites to the BC6ENTG was observed. CPR:falsenewlineWe investigated, by displacement of BC6ENTC in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6ENTC in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6ENTC in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6ENTC in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6ENTC , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6ENTC , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6ENTC , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6ENTC , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6ENTC and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6ENTC and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6ENTC and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6ENTC and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6ENTC , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6ENTC , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6ENTC , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6ENTC , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineAnalogous to the antiandrogens, BC6OTHER and BC6ENTC , binding of BC6OTHER metabolites to the BC6ENTG was observed. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6ENTC , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6ENTC , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6ENTC , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6ENTC , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6ENTC , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6ENTC , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6ENTC , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6ENTC , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTC receptor (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTC receptor (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTG in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTC receptor (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6OTHER in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6ENTG (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTC receptor in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6ENTG ) in LNCaP cells and to the wild - type BC6ENTC receptor in wild - type BC6OTHER cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewlineWe investigated, by displacement of BC6OTHER in the presence of 2.5 mM of BC6OTHER , the binding of BC6OTHER and its metabolites, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as other antiandrogen agents including BC6OTHER , BC6OTHER , and BC6OTHER , to the mutated BC6OTHER (m - BC6OTHER ) in LNCaP cells and to the wild - type BC6ENTC receptor in wild - type BC6ENTG cDNA expression plasmid (w - pAR0) cDNA - transfected HeLa cells. CPR:falsenewline BC6ENTC antagonistic effect of BC6OTHER ( BC6OTHER ) metabolites on wild - type and mutated BC6ENTG . CPR:falsenewline BC6OTHER antagonistic effect of BC6ENTC ( BC6OTHER ) metabolites on wild - type and mutated BC6ENTG . CPR:falsenewline BC6OTHER antagonistic effect of BC6OTHER ( BC6ENTC ) metabolites on wild - type and mutated BC6ENTG . CPR:falsenewlineAnalogous to the antiandrogens, BC6OTHER and BC6OTHER , binding of BC6ENTC metabolites to the BC6ENTG was observed. CPR:falsenewlineEven though its inability to shift between the trivalent and a divalent oxidation state precludes that BC6ENTC behaves as an BC6OTHER analogue in every respect, it strongly interferes with cellular acquisition of CHEM from blood by competitive interaction with BC6ENTG and BC6OTHER - mediated endocytosis. CPR:falsenewlineEven though its inability to shift between the trivalent and a divalent oxidation state precludes that BC6ENTC behaves as an BC6OTHER analogue in every respect, it strongly interferes with cellular acquisition of CHEM from blood by competitive interaction with BC6OTHER and BC6ENTG - mediated endocytosis. CPR:falsenewlineEven though its inability to shift between the trivalent and a divalent oxidation state precludes that BC6OTHER behaves as an BC6ENTC analogue in every respect, it strongly interferes with cellular acquisition of CHEM from blood by competitive interaction with BC6ENTG and BC6OTHER - mediated endocytosis. CPR:falsenewlineEven though its inability to shift between the trivalent and a divalent oxidation state precludes that BC6OTHER behaves as an BC6ENTC analogue in every respect, it strongly interferes with cellular acquisition of CHEM from blood by competitive interaction with BC6OTHER and BC6ENTG - mediated endocytosis. CPR:falsenewlineFurthermore, BC6ENTC also seems to affect intracellular availability of BC6OTHER already taken up via this pathway, probably due to its inhibitory activity on BC6ENTG . CPR:falsenewlineFurthermore, BC6OTHER also seems to affect intracellular availability of BC6ENTC already taken up via this pathway, probably due to its inhibitory activity on BC6ENTG . CPR:falsenewlineApart from the consequences of BC6ENTC deprivation, BC6OTHER exerts cytotoxic effects by direct interaction with the BC6OTHER - dependent enzyme BC6ENTG , resulting in reduced CHEM pools and inhibition of DNA synthesis. CPR:falsenewlineBoth the abundance of BC6ENTG and upregulation of BC6ENTC reductase render tumors susceptible to BC6OTHER - induced cytotoxicity. CPR:falsenewlineApart from the consequences of BC6OTHER deprivation, BC6ENTC exerts cytotoxic effects by direct interaction with the BC6OTHER - dependent enzyme BC6ENTG , resulting in reduced CHEM pools and inhibition of DNA synthesis. CPR:falsenewlineApart from the consequences of BC6OTHER deprivation, BC6OTHER exerts cytotoxic effects by direct interaction with the BC6ENTC - dependent enzyme BC6ENTG , resulting in reduced CHEM pools and inhibition of DNA synthesis. CPR:falsenewlineBoth the abundance of BC6ENTG and upregulation of BC6OTHER render tumors susceptible to BC6ENTC - induced cytotoxicity. CPR:falsenewlineBoth the abundance of BC6OTHER and upregulation of BC6ENTG render tumors susceptible to BC6ENTC - induced cytotoxicity. CPR:falsenewlineHowever, some experimental findings raise the question whether these effects resulting from the BC6ENTC - mimicking properties of BC6OTHER are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting BC6ENTG polymerization. CPR:falsenewlineHowever, some experimental findings raise the question whether these effects resulting from the BC6OTHER - mimicking properties of BC6ENTC are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting BC6ENTG polymerization. CPR:falsenewlineIn the current study, we crossed BC6ENTG .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6ENTC and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6ENTG knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6ENTC and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6ENTG ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6ENTC and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6ENTG ligand, and two therapeutically relevant BC6OTHER , BC6ENTC and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6ENTG .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6ENTC . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6ENTG knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6ENTC . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6ENTG ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6ENTC . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6ENTG ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6ENTC . CPR:falsenewlineAll three agents induced BC6OTHER .fLUC expression (bioluminescence), but only BC6ENTC and BC6OTHER appeared to act primarily via BC6ENTG . CPR:falsenewlineAll three agents induced BC6ENTG .fLUC expression (bioluminescence), but only BC6ENTC and BC6OTHER appeared to act primarily via BC6OTHER . CPR:falsenewlineAll three agents induced BC6OTHER .fLUC expression (bioluminescence), but only BC6OTHER and BC6ENTC appeared to act primarily via BC6ENTG . CPR:falsenewlineAll three agents induced BC6ENTG .fLUC expression (bioluminescence), but only BC6OTHER and BC6ENTC appeared to act primarily via BC6OTHER . CPR:falsenewlineBC6ENTC , a BC6ENTG ligand, modestly induced BC6OTHER .fLUC in BC6OTHER (+ / +) and BC6OTHER ( - / - ) strains, consistent with BC6OTHER 's minor role in BC6OTHER regulation. CPR:falsenewlineBC6ENTC , a BC6OTHER ligand, modestly induced BC6ENTG .fLUC in BC6OTHER (+ / +) and BC6OTHER ( - / - ) strains, consistent with BC6OTHER 's minor role in BC6OTHER regulation. CPR:falsenewlineBC6ENTC , a BC6OTHER ligand, modestly induced BC6OTHER .fLUC in BC6ENTG (+ / +) and BC6OTHER ( - / - ) strains, consistent with BC6OTHER 's minor role in BC6OTHER regulation. CPR:falsenewlineBC6ENTC , a BC6OTHER ligand, modestly induced BC6OTHER .fLUC in BC6OTHER (+ / +) and BC6ENTG ( - / - ) strains, consistent with BC6OTHER 's minor role in BC6OTHER regulation. CPR:falsenewlineBC6ENTC , a BC6OTHER ligand, modestly induced BC6OTHER .fLUC in BC6OTHER (+ / +) and BC6OTHER ( - / - ) strains, consistent with BC6ENTG 's minor role in BC6OTHER regulation. CPR:falsenewlineBC6ENTC , a BC6OTHER ligand, modestly induced BC6OTHER .fLUC in BC6OTHER (+ / +) and BC6OTHER ( - / - ) strains, consistent with BC6OTHER 's minor role in BC6ENTG regulation. CPR:falsenewlineIn the current study, we crossed BC6ENTG .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6ENTC ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6ENTG knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6ENTC ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6ENTG ( - / - )) genetic background and injected mice with BC6ENTC ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6ENTC ( BC6OTHER ), a strong BC6ENTG ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6ENTG .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6ENTC ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6ENTG knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6ENTC ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6ENTG ( - / - )) genetic background and injected mice with BC6OTHER ( BC6ENTC ), a strong BC6OTHER ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6ENTC ), a strong BC6ENTG ligand, and two therapeutically relevant BC6OTHER , BC6OTHER and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6ENTG .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6ENTC , BC6OTHER and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6ENTG knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6ENTC , BC6OTHER and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6ENTG ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6OTHER ligand, and two therapeutically relevant BC6ENTC , BC6OTHER and BC6OTHER . CPR:falsenewlineIn the current study, we crossed BC6OTHER .fLUC mice into the BC6OTHER knockout ( BC6OTHER ( - / - )) genetic background and injected mice with BC6OTHER ( BC6OTHER ), a strong BC6ENTG ligand, and two therapeutically relevant BC6ENTC , BC6OTHER and BC6OTHER . CPR:falsenewlineWe determined whether an BC6ENTC - converting enzyme ( BC6ENTG ) inhibitor, BC6OTHER , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6OTHER complex. CPR:falsenewlineWe determined whether an BC6ENTC - converting enzyme ( BC6OTHER ) inhibitor, BC6OTHER , inhibits BC6ENTG activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6OTHER complex. CPR:falsenewlineWe determined whether an BC6ENTC - converting enzyme ( BC6OTHER ) inhibitor, BC6OTHER , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6ENTG - BC6OTHER complex. CPR:falsenewlineWe determined whether an BC6ENTG ( BC6OTHER ) inhibitor, BC6ENTC , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6OTHER complex. CPR:4newlineWe determined whether an BC6OTHER - converting enzyme ( BC6ENTG ) inhibitor, BC6ENTC , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6OTHER complex. CPR:4newlineWe determined whether an BC6OTHER - converting enzyme ( BC6OTHER ) inhibitor, BC6ENTC , inhibits BC6ENTG activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6OTHER complex. CPR:4newlineWe determined whether an BC6OTHER - converting enzyme ( BC6OTHER ) inhibitor, BC6ENTC , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6ENTG - BC6OTHER complex. CPR:falsenewlineWe determined whether an BC6ENTG ( BC6OTHER ) inhibitor, BC6OTHER , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6ENTC complex. CPR:falsenewlineWe determined whether an BC6OTHER - converting enzyme ( BC6ENTG ) inhibitor, BC6OTHER , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6ENTC complex. CPR:falsenewlineWe determined whether an BC6OTHER - converting enzyme ( BC6OTHER ) inhibitor, BC6OTHER , inhibits BC6ENTG activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6OTHER - BC6ENTC complex. CPR:falsenewlineWe determined whether an BC6OTHER - converting enzyme ( BC6OTHER ) inhibitor, BC6OTHER , inhibits BC6OTHER activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the BC6ENTG - BC6ENTC complex. CPR:falsenewlineMETHODS: The inhibitory effect of BC6ENTC on BC6ENTG activity was measured in peritoneal effluents from 17 patients on CAPD. CPR:4newlineMolecular models of the BC6ENTG - BC6ENTC complex were simulated by 1000 iterations of random docking and energy minimization. CPR:falsenewlineRESULTS: BC6ENTC directly inhibited BC6ENTG activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol / l), and that BC6OTHER binding to the BC6OTHER active site could be formed in each complex model without molecular distortion. CPR:falsenewlineRESULTS: BC6ENTC directly inhibited BC6OTHER activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol / l), and that BC6OTHER binding to the BC6ENTG active site could be formed in each complex model without molecular distortion. CPR:falsenewlineRESULTS: BC6OTHER directly inhibited BC6ENTG activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol / l), and that BC6ENTC binding to the BC6OTHER active site could be formed in each complex model without molecular distortion. CPR:falsenewlineRESULTS: BC6OTHER directly inhibited BC6OTHER activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol / l), and that BC6ENTC binding to the BC6ENTG active site could be formed in each complex model without molecular distortion. CPR:falsenewlineCONCLUSION: BC6OTHER inhibitors, such as BC6ENTC , may be applied as important compounds for BC6ENTG inhibition in inflammation caused by CAPD. CPR:4newlineCONCLUSION: BC6ENTG inhibitors, such as BC6ENTC , may be applied as important compounds for BC6OTHER inhibition in inflammation caused by CAPD. CPR:4newline BC6ENTC directly inhibits BC6ENTG activity in continuous ambulatory peritoneal dialysis therapy. CPR:4newlineBoth, BC6ENTG overexpression and BC6OTHER knockdown led to a strong reduction of endogenous reactive - BC6ENTC species (ROS), DNA damage and senescence. CPR:falsenewlineBoth, BC6OTHER overexpression and BC6ENTG knockdown led to a strong reduction of endogenous reactive - BC6ENTC species (ROS), DNA damage and senescence. CPR:falsenewlineImportantly, pharmacological inhibition of BC6ENTG in human melanoma cells also reconstituted senescence in the majority of cell lines, and BC6OTHER knockdown reduced tumorigenic effects such as proliferation, BC6ENTC resistance and soft agar growth. CPR:falsenewlineImportantly, pharmacological inhibition of BC6OTHER in human melanoma cells also reconstituted senescence in the majority of cell lines, and BC6ENTG knockdown reduced tumorigenic effects such as proliferation, BC6ENTC resistance and soft agar growth. CPR:falsenewlineWe observed that BC6ENTG drives the evasion of reactive - BC6ENTC stress - induced melanocyte senescence, caused by activated receptor BC6OTHER kinase signaling. CPR:falsenewlineWe observed that BC6OTHER drives the evasion of reactive - BC6ENTC stress - induced melanocyte senescence, caused by activated BC6ENTG signaling. CPR:falsenewlineWe observed that BC6ENTG drives the evasion of reactive - BC6OTHER stress - induced melanocyte senescence, caused by activated receptor BC6ENTC kinase signaling. CPR:falsenewlineThe next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6ENTC kinase inhibitor targeting BC6ENTG / BC6OTHER as well as the BC6OTHER ( BC6OTHER ), BC6OTHER . CPR:falsenewlineThe next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6ENTC kinase inhibitor targeting BC6OTHER / BC6ENTG as well as the BC6OTHER ( BC6OTHER ), BC6OTHER . CPR:falsenewlineThe next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6ENTC kinase inhibitor targeting BC6OTHER / BC6OTHER as well as the BC6ENTG ( BC6OTHER ), BC6OTHER . CPR:falsenewlineThe next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6ENTC kinase inhibitor targeting BC6OTHER / BC6OTHER as well as the BC6OTHER ( BC6ENTG ), BC6OTHER . CPR:falsenewlineThe next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6OTHER kinase inhibitor targeting BC6ENTG / BC6OTHER as well as the BC6OTHER ( BC6OTHER ), BC6ENTC . CPR:falsenewlineThe next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6OTHER kinase inhibitor targeting BC6OTHER / BC6ENTG as well as the BC6OTHER ( BC6OTHER ), BC6ENTC . CPR:falsenewlineThe next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6OTHER kinase inhibitor targeting BC6OTHER / BC6OTHER as well as the BC6ENTG ( BC6OTHER ), BC6ENTC . CPR:falsenewlineThe next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral BC6OTHER kinase inhibitor targeting BC6OTHER / BC6OTHER as well as the BC6OTHER ( BC6ENTG ), BC6ENTC . CPR:falsenewlineA humanized antibody to BC6ENTG / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6ENTC , BC6OTHER , and BC6OTHER . CPR:falsenewlineA humanized antibody to BC6OTHER / BC6ENTG , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6ENTC , BC6OTHER , and BC6OTHER . CPR:falsenewlineA humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6ENTG / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6ENTC , BC6OTHER , and BC6OTHER . CPR:falsenewlineA humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6ENTG overexpressing breast cancer sequenced with chemotherapy including BC6ENTC , BC6OTHER , and BC6OTHER . CPR:falsenewlineA humanized antibody to BC6ENTG / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6ENTC , and BC6OTHER . CPR:falsenewlineA humanized antibody to BC6OTHER / BC6ENTG , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6ENTC , and BC6OTHER . CPR:falsenewlineA humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6ENTG / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6ENTC , and BC6OTHER . CPR:falsenewlineA humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6ENTG overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6ENTC , and BC6OTHER . CPR:falsenewlineA humanized antibody to BC6ENTG / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6OTHER , and BC6ENTC . CPR:falsenewlineA humanized antibody to BC6OTHER / BC6ENTG , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6OTHER , and BC6ENTC . CPR:falsenewlineA humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6ENTG / BC6OTHER overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6OTHER , and BC6ENTC . CPR:falsenewlineA humanized antibody to BC6OTHER / BC6OTHER , trastuzumab, is now FDA approved for the treatment of early stage, BC6OTHER / BC6ENTG overexpressing breast cancer sequenced with chemotherapy including BC6OTHER , BC6OTHER , and BC6ENTC . CPR:falsenewlineThese compounds resulted from our efforts to merge the pharmacophores of selective BC6OTHER inhibitor BC6ENTC with a mimic of the BC6OTHER ( BC6OTHER ) sequence of BC6ENTG to obtain designed multiple ligands with potential antithrombotic activity. CPR:falsenewlineThese compounds resulted from our efforts to merge the pharmacophores of selective BC6ENTG inhibitor BC6ENTC with a mimic of the BC6OTHER ( BC6OTHER ) sequence of BC6OTHER to obtain designed multiple ligands with potential antithrombotic activity. CPR:falsenewlineThese compounds resulted from our efforts to merge the pharmacophores of selective BC6OTHER inhibitor BC6ENTC with a mimic of the BC6ENTG ( BC6OTHER ) sequence of BC6OTHER to obtain designed multiple ligands with potential antithrombotic activity. CPR:falsenewlineThese compounds resulted from our efforts to merge the pharmacophores of selective BC6OTHER inhibitor BC6ENTC with a mimic of the BC6OTHER ( BC6ENTG ) sequence of BC6OTHER to obtain designed multiple ligands with potential antithrombotic activity. CPR:falsenewlineThese compounds resulted from our efforts to merge the pharmacophores of selective BC6OTHER inhibitor BC6OTHER with a mimic of the BC6ENTC ( BC6OTHER ) sequence of BC6ENTG to obtain designed multiple ligands with potential antithrombotic activity. CPR:falsenewlineThese compounds resulted from our efforts to merge the pharmacophores of selective BC6ENTG inhibitor BC6OTHER with a mimic of the BC6ENTC ( BC6OTHER ) sequence of BC6OTHER to obtain designed multiple ligands with potential antithrombotic activity. CPR:falsenewlineThese compounds resulted from our efforts to merge the pharmacophores of selective BC6OTHER inhibitor BC6OTHER with a mimic of the BC6ENTC ( BC6ENTG ) sequence of BC6OTHER to obtain designed multiple ligands with potential antithrombotic activity. CPR:falsenewlineResulting from this study, a structurally novel class of submicromolar fibrinogen BC6ENTG binding inhibitor bearing BC6ENTC moiety is also described. CPR:falsenewlineMoreover, BC6ENTC resulted in activation of astrocytes, up - regulation of BC6ENTG in cortex and down - regulation of BC6OTHER in hippocampus and cortex. CPR:falsenewlineMoreover, BC6ENTC resulted in activation of astrocytes, up - regulation of BC6OTHER in cortex and down - regulation of BC6ENTG in hippocampus and cortex. CPR:falsenewlineInterestingly, BC6ENTC increased proteins' levels of BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and the BC6OTHER BC6OTHER , and decreased BC6OTHER levels. CPR:falsenewlineInterestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and the BC6OTHER BC6OTHER , and decreased BC6OTHER levels. CPR:falsenewlineInterestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and the BC6OTHER BC6OTHER , and decreased BC6OTHER levels. CPR:falsenewlineInterestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and the BC6OTHER BC6OTHER , and decreased BC6OTHER levels. CPR:falsenewlineInterestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and the BC6ENTG BC6OTHER , and decreased BC6OTHER levels. CPR:falsenewlineInterestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and the BC6OTHER BC6ENTG , and decreased BC6OTHER levels. CPR:falsenewlineInterestingly, BC6ENTC increased proteins' levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and the BC6OTHER BC6OTHER , and decreased BC6ENTG levels. CPR:falsenewlineThe activity of BC6ENTG was down - regulated while the level of BC6ENTC was up - regulated in rat brain. CPR:falsenewlineVarious high - BC6ENTC - type glycan modifications of BC6OTHER reductase ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6ENTG . CPR:falsenewlineVarious high - BC6ENTC - type glycan modifications of BC6ENTG ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6OTHER . CPR:falsenewlineVarious high - BC6ENTC - type glycan modifications of BC6OTHER reductase ( BC6ENTG ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6OTHER . CPR:falsenewlineVarious high - BC6OTHER - type glycan modifications of BC6OTHER reductase ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6ENTC ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6ENTG . CPR:falsenewlineVarious high - BC6OTHER - type glycan modifications of BC6ENTG ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6ENTC ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6OTHER . CPR:falsenewlineVarious high - BC6OTHER - type glycan modifications of BC6OTHER reductase ( BC6ENTG ) were achieved by ligand - based approach using glycan - BC6ENTC ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6OTHER . CPR:falsenewlineVarious high - BC6OTHER - type glycan modifications of BC6OTHER reductase ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6ENTC ) conjugates as tight binding glycan bearing ligands for BC6ENTG . CPR:falsenewlineVarious high - BC6OTHER - type glycan modifications of BC6ENTG ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6ENTC ) conjugates as tight binding glycan bearing ligands for BC6OTHER . CPR:falsenewlineVarious high - BC6OTHER - type glycan modifications of BC6OTHER reductase ( BC6ENTG ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6ENTC ) conjugates as tight binding glycan bearing ligands for BC6OTHER . CPR:falsenewlineThe resulting glycan - BC6ENTC conjugates and the corresponding artificial glycoproteins could be useful as CHEM - and glycoprotein - probes to perform quantitative analysis of BC6ENTG such as BC6OTHER , BC6OTHER or BC6OTHER . CPR:falsenewlineThe resulting glycan - BC6ENTC conjugates and the corresponding artificial glycoproteins could be useful as CHEM - and glycoprotein - probes to perform quantitative analysis of BC6OTHER such as BC6ENTG , BC6OTHER or BC6OTHER . CPR:falsenewlineThe resulting glycan - BC6ENTC conjugates and the corresponding artificial glycoproteins could be useful as CHEM - and glycoprotein - probes to perform quantitative analysis of BC6OTHER such as BC6OTHER , BC6ENTG or BC6OTHER . CPR:falsenewlineThe resulting glycan - BC6ENTC conjugates and the corresponding artificial glycoproteins could be useful as CHEM - and glycoprotein - probes to perform quantitative analysis of BC6OTHER such as BC6OTHER , BC6OTHER or BC6ENTG . CPR:falsenewlineVarious high - BC6OTHER - type glycan modifications of BC6ENTC reductase ( BC6OTHER ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6ENTG . CPR:falsenewlineVarious high - BC6OTHER - type glycan modifications of BC6ENTC reductase ( BC6ENTG ) were achieved by ligand - based approach using glycan - BC6OTHER ( BC6OTHER ) conjugates as tight binding glycan bearing ligands for BC6OTHER . CPR:falsenewlineHigh - BC6ENTC - type glycan modifications of BC6ENTG using glycan - BC6OTHER conjugates. CPR:falsenewlineHigh - BC6OTHER - type glycan modifications of BC6ENTG using glycan - BC6ENTC conjugates. CPR:falsenewlineBecause these speeds are significantly faster than the responses to antagonists, these data indicate that BC6ENTC and BC6OTHER are allosteric ligands and actively induce a conformation of the BC6ENTG with a reduced affinity for its agonists. CPR:falsenewlineBecause these speeds are significantly faster than the responses to antagonists, these data indicate that BC6OTHER and BC6ENTC are allosteric ligands and actively induce a conformation of the BC6ENTG with a reduced affinity for its agonists. CPR:falsenewlineCyan fluorescent protein was fused to the BC6ENTC terminus of the BC6ENTG , and a specific binding sequence for the small fluorescent compound BC6OTHER arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH. CPR:falsenewlineCyan fluorescent protein was fused to the BC6OTHER terminus of the BC6ENTG , and a specific binding sequence for the small fluorescent compound BC6ENTC arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH. CPR:falsenewlineOur studies demonstrate that BC6OTHER , BC6OTHER and another immunomodulatory drug, BC6ENTC , bound endogenous BC6ENTG and recombinant BC6OTHER - BC6OTHER ( BC6OTHER ) complexes. CPR:falsenewlineOur studies demonstrate that BC6OTHER , BC6OTHER and another immunomodulatory drug, BC6ENTC , bound endogenous BC6OTHER and recombinant BC6ENTG - BC6OTHER ( BC6OTHER ) complexes. CPR:falsenewlineOur studies demonstrate that BC6OTHER , BC6OTHER and another immunomodulatory drug, BC6ENTC , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6ENTG ( BC6OTHER ) complexes. CPR:falsenewlineOur studies demonstrate that BC6OTHER , BC6OTHER and another immunomodulatory drug, BC6ENTC , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6OTHER ( BC6ENTG ) complexes. CPR:falsenewlineBC6ENTG mediated antiproliferative activities of BC6ENTC and BC6OTHER in myeloma cells, as well as BC6OTHER - and BC6OTHER - induced BC6OTHER production in T cells. CPR:falsenewlineBC6OTHER mediated antiproliferative activities of BC6ENTC and BC6OTHER in myeloma cells, as well as BC6OTHER - and BC6OTHER - induced BC6ENTG production in T cells. CPR:falsenewlineBC6ENTG mediated antiproliferative activities of BC6OTHER and BC6ENTC in myeloma cells, as well as BC6OTHER - and BC6OTHER - induced BC6OTHER production in T cells. CPR:falsenewlineBC6OTHER mediated antiproliferative activities of BC6OTHER and BC6ENTC in myeloma cells, as well as BC6OTHER - and BC6OTHER - induced BC6ENTG production in T cells. CPR:falsenewlineBC6ENTG mediated antiproliferative activities of BC6OTHER and BC6OTHER in myeloma cells, as well as BC6ENTC - and BC6OTHER - induced BC6OTHER production in T cells. CPR:falsenewlineBC6OTHER mediated antiproliferative activities of BC6OTHER and BC6OTHER in myeloma cells, as well as BC6ENTC - and BC6OTHER - induced BC6ENTG production in T cells. CPR:falsenewlineBC6ENTG mediated antiproliferative activities of BC6OTHER and BC6OTHER in myeloma cells, as well as BC6OTHER - and BC6ENTC - induced BC6OTHER production in T cells. CPR:falsenewlineBC6OTHER mediated antiproliferative activities of BC6OTHER and BC6OTHER in myeloma cells, as well as BC6OTHER - and BC6ENTC - induced BC6ENTG production in T cells. CPR:falsenewlineBC6ENTC and BC6OTHER inhibited autoubiquitination of BC6ENTG in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6OTHER (YW / AA). CPR:falsenewlineBC6ENTC and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6ENTG , but not BC6OTHER - binding defective BC6OTHER (YW / AA). CPR:falsenewlineBC6ENTC and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6ENTG (YW / AA). CPR:falsenewlineBC6OTHER and BC6ENTC inhibited autoubiquitination of BC6ENTG in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6OTHER (YW / AA). CPR:falsenewlineBC6OTHER and BC6ENTC inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6ENTG , but not BC6OTHER - binding defective BC6OTHER (YW / AA). CPR:falsenewlineBC6OTHER and BC6ENTC inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6ENTG (YW / AA). CPR:falsenewlineBC6OTHER and BC6OTHER inhibited autoubiquitination of BC6ENTG in HEK293T cells expressing BC6ENTC - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6OTHER (YW / AA). CPR:falsenewlineBC6OTHER and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6ENTC - binding competent wild - type BC6ENTG , but not BC6OTHER - binding defective BC6OTHER (YW / AA). CPR:falsenewlineBC6OTHER and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6ENTC - binding competent wild - type BC6OTHER , but not BC6OTHER - binding defective BC6ENTG (YW / AA). CPR:falsenewlineBC6OTHER and BC6OTHER inhibited autoubiquitination of BC6ENTG in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6ENTC - binding defective BC6OTHER (YW / AA). CPR:falsenewlineBC6OTHER and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6ENTG , but not BC6ENTC - binding defective BC6OTHER (YW / AA). CPR:falsenewlineBC6OTHER and BC6OTHER inhibited autoubiquitination of BC6OTHER in HEK293T cells expressing BC6OTHER - binding competent wild - type BC6OTHER , but not BC6ENTC - binding defective BC6ENTG (YW / AA). CPR:falsenewlineOverexpression of BC6OTHER wild - type protein, but not BC6OTHER (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6OTHER and BC6OTHER expression and increases in BC6OTHER ( BC6ENTG ) expression. CPR:falsenewlineOverexpression of BC6ENTG wild - type protein, but not BC6OTHER (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6OTHER and BC6OTHER expression and increases in BC6OTHER ( BC6OTHER ) expression. CPR:falsenewlineOverexpression of BC6OTHER wild - type protein, but not BC6ENTG (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6OTHER and BC6OTHER expression and increases in BC6OTHER ( BC6OTHER ) expression. CPR:falsenewlineOverexpression of BC6OTHER wild - type protein, but not BC6OTHER (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6ENTG and BC6OTHER expression and increases in BC6OTHER ( BC6OTHER ) expression. CPR:falsenewlineOverexpression of BC6OTHER wild - type protein, but not BC6OTHER (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6OTHER and BC6ENTG expression and increases in BC6OTHER ( BC6OTHER ) expression. CPR:falsenewlineOverexpression of BC6OTHER wild - type protein, but not BC6OTHER (YW / AA) mutant protein, in KMS12 myeloma cells, amplified BC6ENTC - mediated reductions in BC6OTHER and BC6OTHER expression and increases in BC6ENTG ( BC6OTHER ) expression. CPR:falsenewline BC6ENTG is a direct protein target for immunomodulatory and antiproliferative activities of BC6OTHER and BC6ENTC . CPR:falsenewline BC6ENTG is a direct protein target for immunomodulatory and antiproliferative activities of BC6ENTC and BC6OTHER . CPR:falsenewlineLong - term selection for BC6ENTC resistance in H929 myeloma cell lines was accompanied by a reduction in BC6ENTG , while in DF15R myeloma cells resistant to both BC6OTHER and BC6OTHER , BC6OTHER protein was undetectable. CPR:falsenewlineLong - term selection for BC6ENTC resistance in H929 myeloma cell lines was accompanied by a reduction in BC6OTHER , while in DF15R myeloma cells resistant to both BC6OTHER and BC6OTHER , BC6ENTG protein was undetectable. CPR:falsenewlineLong - term selection for BC6OTHER resistance in H929 myeloma cell lines was accompanied by a reduction in BC6ENTG , while in DF15R myeloma cells resistant to both BC6ENTC and BC6OTHER , BC6OTHER protein was undetectable. CPR:falsenewlineLong - term selection for BC6OTHER resistance in H929 myeloma cell lines was accompanied by a reduction in BC6OTHER , while in DF15R myeloma cells resistant to both BC6ENTC and BC6OTHER , BC6ENTG protein was undetectable. CPR:falsenewlineLong - term selection for BC6OTHER resistance in H929 myeloma cell lines was accompanied by a reduction in BC6ENTG , while in DF15R myeloma cells resistant to both BC6OTHER and BC6ENTC , BC6OTHER protein was undetectable. CPR:falsenewlineLong - term selection for BC6OTHER resistance in H929 myeloma cell lines was accompanied by a reduction in BC6OTHER , while in DF15R myeloma cells resistant to both BC6OTHER and BC6ENTC , BC6ENTG protein was undetectable. CPR:falsenewlineOur biophysical, biochemical and gene silencing studies show that BC6ENTG is a proximate, therapeutically important molecular target of BC6ENTC and BC6OTHER . CPR:falsenewlineOur biophysical, biochemical and gene silencing studies show that BC6ENTG is a proximate, therapeutically important molecular target of BC6OTHER and BC6ENTC . CPR:falsenewlineThe ubiquitously expressed E3 ligase protein BC6ENTG ( BC6OTHER ) has been identified as the primary teratogenic target of BC6ENTC . CPR:falsenewlineThe ubiquitously expressed E3 ligase protein BC6OTHER ( BC6ENTG ) has been identified as the primary teratogenic target of BC6ENTC . CPR:falsenewlineOur studies demonstrate that BC6ENTC , BC6OTHER and another immunomodulatory drug, BC6OTHER , bound endogenous BC6ENTG and recombinant BC6OTHER - BC6OTHER ( BC6OTHER ) complexes. CPR:falsenewlineOur studies demonstrate that BC6ENTC , BC6OTHER and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6ENTG - BC6OTHER ( BC6OTHER ) complexes. CPR:falsenewlineOur studies demonstrate that BC6ENTC , BC6OTHER and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6ENTG ( BC6OTHER ) complexes. CPR:falsenewlineOur studies demonstrate that BC6ENTC , BC6OTHER and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6OTHER ( BC6ENTG ) complexes. CPR:falsenewlineOur studies demonstrate that BC6OTHER , BC6ENTC and another immunomodulatory drug, BC6OTHER , bound endogenous BC6ENTG and recombinant BC6OTHER - BC6OTHER ( BC6OTHER ) complexes. CPR:falsenewlineOur studies demonstrate that BC6OTHER , BC6ENTC and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6ENTG - BC6OTHER ( BC6OTHER ) complexes. CPR:falsenewlineOur studies demonstrate that BC6OTHER , BC6ENTC and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6ENTG ( BC6OTHER ) complexes. CPR:falsenewlineOur studies demonstrate that BC6OTHER , BC6ENTC and another immunomodulatory drug, BC6OTHER , bound endogenous BC6OTHER and recombinant BC6OTHER - BC6OTHER ( BC6ENTG ) complexes. CPR:falsenewlineThis mutation is the first described in exon 9 and impairs the last 27 BC6ENTC of the BC6ENTG . CPR:falsenewlineRESULTS: BC6ENTC unmasked the inhibitory effect of BC6ENTG stimulation with BC6OTHER and significantly attenuated the stimulated release of BC6OTHER and subsequent BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER unmasked the inhibitory effect of BC6ENTG stimulation with BC6ENTC and significantly attenuated the stimulated release of BC6OTHER and subsequent BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER unmasked the inhibitory effect of BC6ENTG stimulation with BC6OTHER and significantly attenuated the stimulated release of BC6ENTC and subsequent BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER unmasked the inhibitory effect of BC6ENTG stimulation with BC6OTHER and significantly attenuated the stimulated release of BC6OTHER and subsequent BC6ENTC . CPR:falsenewlineInhibition corresponded to increased BC6ENTC production caused by BC6OTHER alone or BC6OTHER plus BC6OTHER and blocked proportionately the phosphorylation and activation of BC6ENTG in CHEM / B - activated eosinophils. CPR:falsenewlineInhibition corresponded to increased BC6OTHER production caused by BC6ENTC alone or BC6OTHER plus BC6OTHER and blocked proportionately the phosphorylation and activation of BC6ENTG in CHEM / B - activated eosinophils. CPR:falsenewlineInhibition corresponded to increased BC6OTHER production caused by BC6OTHER alone or BC6ENTC plus BC6OTHER and blocked proportionately the phosphorylation and activation of BC6ENTG in CHEM / B - activated eosinophils. CPR:falsenewlineInhibition corresponded to increased BC6OTHER production caused by BC6OTHER alone or BC6OTHER plus BC6ENTC and blocked proportionately the phosphorylation and activation of BC6ENTG in CHEM / B - activated eosinophils. CPR:falsenewlineCONCLUSIONS: Inhibition of BC6ENTC by BC6OTHER unmasks BC6ENTG blockade of BC6OTHER synthesis caused by CHEM / B. CPR:falsenewlineCONCLUSIONS: Inhibition of BC6ENTG by BC6ENTC unmasks BC6OTHER blockade of BC6OTHER synthesis caused by CHEM / B. CPR:4newlineCONCLUSIONS: Inhibition of BC6OTHER by BC6ENTC unmasks BC6ENTG blockade of BC6OTHER synthesis caused by CHEM / B. CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6ENTC concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6ENTC concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6ENTC concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineCONCLUSIONS: Inhibition of BC6ENTG by BC6OTHER unmasks BC6OTHER blockade of BC6ENTC synthesis caused by CHEM / B. CPR:falsenewlineCONCLUSIONS: Inhibition of BC6OTHER by BC6OTHER unmasks BC6ENTG blockade of BC6ENTC synthesis caused by CHEM / B. CPR:falsenewlineWe postulated that selective blockade of BC6ENTC in eosinophils would unmask the inhibitory effect of BC6ENTG stimulation and that this inhibition would result from decreased phosphor - ylation of BC6OTHER ( BC6OTHER ). CPR:falsenewlineWe postulated that selective blockade of BC6ENTC in eosinophils would unmask the inhibitory effect of BC6OTHER stimulation and that this inhibition would result from decreased phosphor - ylation of BC6ENTG ( BC6OTHER ). CPR:falsenewlineWe postulated that selective blockade of BC6ENTC in eosinophils would unmask the inhibitory effect of BC6OTHER stimulation and that this inhibition would result from decreased phosphor - ylation of BC6OTHER ( BC6ENTG ). CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTC inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTC inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6ENTC blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6ENTC blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6ENTC blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6ENTC and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6ENTC and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6ENTC and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6ENTC plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6ENTC plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6ENTC plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6ENTC (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6ENTC (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6ENTC (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTC inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTC inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6OTHER . CPR:falsenewlineBlockade of BC6OTHER synthesis caused by additive inhibition of BC6ENTG phosphorylation: Effect of BC6OTHER and BC6ENTC inhibition in human eosinophils. CPR:falsenewlineBlockade of BC6ENTC synthesis caused by additive inhibition of BC6OTHER phosphorylation: Effect of BC6OTHER and BC6ENTG inhibition in human eosinophils. CPR:falsenewlineBlockade of BC6ENTC synthesis caused by additive inhibition of BC6ENTG phosphorylation: Effect of BC6OTHER and BC6OTHER inhibition in human eosinophils. CPR:falsenewlineBlockade of BC6OTHER synthesis caused by additive inhibition of BC6OTHER phosphorylation: Effect of BC6ENTC and BC6ENTG inhibition in human eosinophils. CPR:falsenewlineBlockade of BC6OTHER synthesis caused by additive inhibition of BC6ENTG phosphorylation: Effect of BC6ENTC and BC6OTHER inhibition in human eosinophils. CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6ENTC synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6ENTC synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6ENTC synthesis is regulated by BC6OTHER . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6ENTG inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6ENTC . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6ENTG inhibition plus BC6OTHER agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6ENTC . CPR:falsenewlineOBJECTIVE: To determine (a) whether BC6OTHER inhibition alone with BC6OTHER blocked secretions of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) caused by activation of eosinophils with BC6OTHER plus BC6OTHER (CHEM / B), (b) to determine if BC6OTHER inhibition plus BC6ENTG agonist act additively to augment endogenous BC6OTHER concentration, and (c) to determine the mechanism by which additive inhibition of BC6OTHER and BC6OTHER synthesis is regulated by BC6ENTC . CPR:falsenewlineRelease of BC6ENTC and BC6OTHER , intracellular BC6OTHER concentration, and phosphorylation and activation of BC6ENTG were determined. CPR:falsenewlineRelease of BC6OTHER and BC6ENTC , intracellular BC6OTHER concentration, and phosphorylation and activation of BC6ENTG were determined. CPR:falsenewlineRelease of BC6OTHER and BC6OTHER , intracellular BC6ENTC concentration, and phosphorylation and activation of BC6ENTG were determined. CPR:falsenewlineBC6ENTC is an BC6ENTG antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH). CPR:falsenewlineBC6ENTG mediates the vasoconstrictor effect of BC6OTHER on vascular smooth muscle, whereas BC6OTHER is expressed primarily on vascular endothelial cells where it induces BC6ENTC synthesis and acts to clear BC6OTHER from the circulation. CPR:falsenewlineBC6OTHER mediates the vasoconstrictor effect of BC6ENTG on vascular smooth muscle, whereas BC6OTHER is expressed primarily on vascular endothelial cells where it induces BC6ENTC synthesis and acts to clear BC6OTHER from the circulation. CPR:falsenewlineBC6OTHER mediates the vasoconstrictor effect of BC6OTHER on vascular smooth muscle, whereas BC6ENTG is expressed primarily on vascular endothelial cells where it induces BC6ENTC synthesis and acts to clear BC6OTHER from the circulation. CPR:falsenewlineBC6OTHER mediates the vasoconstrictor effect of BC6OTHER on vascular smooth muscle, whereas BC6OTHER is expressed primarily on vascular endothelial cells where it induces BC6ENTC synthesis and acts to clear BC6ENTG from the circulation. CPR:falsenewlineBC6ENTC is the first BC6ENTG selective ERA approved for use in the US. CPR:falsenewlineEnhancement of radiosensitivity by BC6ENTG inhibitor, BC6ENTC and BC6OTHER , in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction. CPR:falsenewlineEnhancement of radiosensitivity by BC6ENTG inhibitor, BC6OTHER and BC6ENTC , in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction. CPR:4newlineSimilar to BC6ENTC and BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) are BC6ENTG inhibitors. CPR:falsenewlineSimilar to BC6OTHER and BC6ENTC , BC6OTHER and BC6OTHER ( BC6OTHER ) are BC6ENTG inhibitors. CPR:falsenewlineSimilar to BC6OTHER and BC6OTHER , BC6ENTC and BC6OTHER ( BC6OTHER ) are BC6ENTG inhibitors. CPR:falsenewlineSimilar to BC6OTHER and BC6OTHER , BC6OTHER and BC6ENTC ( BC6OTHER ) are BC6ENTG inhibitors. CPR:falsenewlineSimilar to BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC ) are BC6ENTG inhibitors. CPR:falsenewlineTo test this hypothesis, constructs were evaluated consisting of an BC6ENTG : human BC6ENTC binding protein 12 ( BC6OTHER ) attached to an BC6OTHER . CPR:falsenewlineTo test this hypothesis, constructs were evaluated consisting of an BC6OTHER : human BC6ENTC binding protein 12 ( BC6ENTG ) attached to an BC6OTHER . CPR:falsenewlineTo test this hypothesis, constructs were evaluated consisting of an BC6OTHER : human BC6ENTC binding protein 12 ( BC6OTHER ) attached to an BC6ENTG . CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTG and the effect of BC6ENTC on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6ENTC on growth, expression of marker of stem cells and thyroid differentiation ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6ENTC on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6ENTC on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6ENTC on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTG and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC symporter expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC symporter expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC symporter expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC symporter expression) were analysed. CPR:falsenewlineThyroid stem and progenitor cells expressed BC6ENTC receptor alpha and beta with an 8 time higher expression level of BC6ENTG mRNA compared to differentiated thyrocytes. CPR:falsenewlineThyroid stem and progenitor cells expressed BC6ENTG with an 8 time higher expression level of BC6ENTC receptor alpha mRNA compared to differentiated thyrocytes. CPR:falsenewlineIn contrast, TSH - induced differentiation of progenitor cells, in particular the expression of the BC6ENTG , was significantly inhibited by BC6ENTC CHEM conclusion, BC6OTHER stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem / progenitor cells. CPR:falsenewlineIn contrast, TSH - induced differentiation of progenitor cells, in particular the expression of the BC6ENTG , was significantly inhibited by BC6OTHER CHEM conclusion, BC6ENTC stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem / progenitor cells. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6ENTC to induce thyrosphere formation, the expression of BC6ENTG and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6ENTC to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6ENTC to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6ENTC to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6ENTC to induce thyrosphere formation, the expression of BC6OTHER receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTC receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTC receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTC receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER expression) were analysed. CPR:falsenewlineIn thyroid stem / progenitor cells derived from nodular goitres the ability of BC6OTHER to induce thyrosphere formation, the expression of BC6ENTC receptors and the effect of BC6OTHER on growth, expression of marker of stem cells and thyroid differentiation ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG expression) were analysed. CPR:falsenewlineTo assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineTo assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineTo assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineTo assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineTo assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineTo assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineTo assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineTo assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineTo assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineTo assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineTo assess the feasibility of targeting these high BC6ENTG levels for chemotherapy, BC6OTHER inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineTo assess the feasibility of targeting these high BC6OTHER levels for chemotherapy, BC6ENTG inhibitors BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ) were incubated (72 h) with NCI - H727 human lung carcinoid cells. CPR:falsenewlineIn studying kinetics of BC6ENTC hydroxylase and BC6ENTG ( BC6OTHER ) in human carcinoid hepatic metastases and adjacent normal liver (J. CPR:falsenewlineIn studying kinetics of BC6ENTC hydroxylase and BC6OTHER decarboxylase ( BC6ENTG ) in human carcinoid hepatic metastases and adjacent normal liver (J. CPR:falsenewlineIn studying kinetics of BC6ENTG and BC6ENTC decarboxylase ( BC6OTHER ) in human carcinoid hepatic metastases and adjacent normal liver (J. CPR:falsenewlineIn studying kinetics of BC6OTHER hydroxylase and BC6ENTC decarboxylase ( BC6ENTG ) in human carcinoid hepatic metastases and adjacent normal liver (J. CPR:falsenewlineFor lung tumor lines (carcinoid, two SCLC, and one large cell lung carcinoma), BC6ENTG activity was correlated with the potency of BC6ENTC - induced cytotoxicity. CPR:falsenewlineHowever, carcinoid cell death was not solely attributable to complete inhibition of either BC6ENTG activity or the BC6ENTC synthetic pathway. CPR:falsenewlineWattakaka volubilis BC6ENTC mixture (WVSM) and BC6OTHER (1 - 50μM) significantly inhibited the BC6ENTG and BC6OTHER enzymes resulting in low levels of CHEM and CHEM in LPS - induced RAW 264.7 macrophage cells. CPR:falsenewlineWattakaka volubilis BC6ENTC mixture (WVSM) and BC6OTHER (1 - 50μM) significantly inhibited the BC6OTHER and BC6ENTG enzymes resulting in low levels of CHEM and CHEM in LPS - induced RAW 264.7 macrophage cells. CPR:falsenewlineWattakaka volubilis BC6OTHER mixture (WVSM) and BC6ENTC (1 - 50μM) significantly inhibited the BC6ENTG and BC6OTHER enzymes resulting in low levels of CHEM and CHEM in LPS - induced RAW 264.7 macrophage cells. CPR:4newlineWattakaka volubilis BC6OTHER mixture (WVSM) and BC6ENTC (1 - 50μM) significantly inhibited the BC6OTHER and BC6ENTG enzymes resulting in low levels of CHEM and CHEM in LPS - induced RAW 264.7 macrophage cells. CPR:4newlineBC6OTHER and BC6ENTC (an activator of BC6ENTG ) increased inhibition of BC6OTHER and BC6OTHER , as well as autophagy in CRC cells. CPR:falsenewlineBC6OTHER and BC6ENTC (an activator of BC6OTHER ) increased inhibition of BC6ENTG and BC6OTHER , as well as autophagy in CRC cells. CPR:falsenewlineBC6OTHER and BC6ENTC (an activator of BC6OTHER ) increased inhibition of BC6OTHER and BC6ENTG , as well as autophagy in CRC cells. CPR:falsenewlineBC6OTHER and BC6OTHER (an activator of BC6ENTG ) increased inhibition of BC6ENTC and BC6OTHER , as well as autophagy in CRC cells. CPR:falsenewlineBC6OTHER and BC6OTHER (an activator of BC6OTHER ) increased inhibition of BC6ENTC and BC6ENTG , as well as autophagy in CRC cells. CPR:falsenewlineRectal mucosal samples from patients given BC6ENTC had reduced phosphorylation of BC6ENTG and BC6OTHER . CPR:falsenewlineRectal mucosal samples from patients given BC6ENTC had reduced phosphorylation of BC6OTHER and BC6ENTG . CPR:falsenewlineCONCLUSIONS: BC6ENTC is an inhibitor of BC6ENTG and an activator of BC6OTHER , targeting regulators of intracellular energy homeostasis and metabolism. CPR:4newlineCONCLUSIONS: BC6ENTC is an inhibitor of BC6OTHER and an activator of BC6ENTG , targeting regulators of intracellular energy homeostasis and metabolism. CPR:4newlineCONCLUSIONS: BC6OTHER is an inhibitor of BC6ENTC and an activator of BC6ENTG , targeting regulators of intracellular energy homeostasis and metabolism. CPR:falsenewlineCancer cells have defects in signaling via the mechanistic target of BC6ENTC ( BC6ENTG ), which regulates proliferation. CPR:falsenewlineCancer cells have defects in signaling via the BC6ENTG ( BC6ENTC ), which regulates proliferation. CPR:falsenewlineWe investigated whether BC6ENTC affects BC6ENTG ( BC6OTHER ) and BC6OTHER signaling in CRC cells. CPR:falsenewlineWe investigated whether BC6ENTC affects BC6OTHER ( BC6ENTG ) and BC6OTHER signaling in CRC cells. CPR:falsenewlineWe investigated whether BC6ENTC affects BC6OTHER ( BC6OTHER ) and BC6ENTG signaling in CRC cells. CPR:falsenewlineWe investigated whether BC6OTHER affects BC6ENTC - activated protein kinase ( BC6ENTG ) and BC6OTHER signaling in CRC cells. CPR:falsenewlineWe investigated whether BC6OTHER affects BC6ENTC - activated protein kinase ( BC6OTHER ) and BC6ENTG signaling in CRC cells. CPR:falsenewlineRESULTS: BC6OTHER reduced BC6OTHER signaling in CRC cells by inhibiting the BC6ENTC effectors BC6ENTG and BC6OTHER . CPR:4newlineRESULTS: BC6OTHER reduced BC6OTHER signaling in CRC cells by inhibiting the BC6ENTC effectors BC6OTHER and BC6ENTG . CPR:4newlineRESULTS: BC6OTHER reduced BC6ENTG signaling in CRC cells by inhibiting the BC6ENTC effectors BC6OTHER and BC6OTHER . CPR:falsenewlineWe investigated whether BC6OTHER affects BC6ENTG ( BC6OTHER ) and BC6ENTC signaling in CRC cells. CPR:falsenewlineWe investigated whether BC6OTHER affects BC6OTHER ( BC6ENTG ) and BC6ENTC signaling in CRC cells. CPR:falsenewlineMETHODS: The effects of BC6ENTC on BC6ENTG signaling, the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting. CPR:falsenewlineMETHODS: The effects of BC6ENTC on BC6OTHER signaling, the BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting. CPR:falsenewlineMETHODS: The effects of BC6ENTC on BC6OTHER signaling, the BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting. CPR:falsenewlineMETHODS: The effects of BC6ENTC on BC6OTHER signaling, the BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting. CPR:falsenewlineMETHODS: The effects of BC6ENTC on BC6OTHER signaling, the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) were examined in CRC cells by immunoblotting. CPR:falsenewlineMETHODS: The effects of BC6ENTC on BC6OTHER signaling, the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ) were examined in CRC cells by immunoblotting. CPR:falsenewlineMETHODS: The effects of BC6OTHER on BC6ENTC signaling, the BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting. CPR:falsenewlineMETHODS: The effects of BC6OTHER on BC6ENTC signaling, the BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting. CPR:falsenewlineMETHODS: The effects of BC6OTHER on BC6ENTC signaling, the BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ) were examined in CRC cells by immunoblotting. CPR:falsenewlineMETHODS: The effects of BC6OTHER on BC6ENTC signaling, the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) were examined in CRC cells by immunoblotting. CPR:falsenewlineMETHODS: The effects of BC6OTHER on BC6ENTC signaling, the BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ) were examined in CRC cells by immunoblotting. CPR:falsenewlinePhosphorylation of BC6ENTG was measured; the effects of loss of BC6OTHER on the BC6ENTC - induced effects of BC6OTHER were determined using small interfering RNA (siRNA) in CRC cells and in BC6OTHER - / - ) mouse embryonic fibroblasts. CPR:falsenewlinePhosphorylation of BC6OTHER was measured; the effects of loss of BC6ENTG on the BC6ENTC - induced effects of BC6OTHER were determined using small interfering RNA (siRNA) in CRC cells and in BC6OTHER - / - ) mouse embryonic fibroblasts. CPR:falsenewlinePhosphorylation of BC6OTHER was measured; the effects of loss of BC6OTHER on the BC6ENTC - induced effects of BC6ENTG were determined using small interfering RNA (siRNA) in CRC cells and in BC6OTHER - / - ) mouse embryonic fibroblasts. CPR:falsenewlinePhosphorylation of BC6OTHER was measured; the effects of loss of BC6OTHER on the BC6ENTC - induced effects of BC6OTHER were determined using small interfering RNA (siRNA) in CRC cells and in BC6ENTG - / - ) mouse embryonic fibroblasts. CPR:falsenewlinePhosphorylation of BC6ENTG was measured; the effects of loss of BC6OTHER on the BC6OTHER - induced effects of BC6ENTC were determined using small interfering RNA (siRNA) in CRC cells and in BC6OTHER - / - ) mouse embryonic fibroblasts. CPR:falsenewlinePhosphorylation of BC6OTHER was measured; the effects of loss of BC6ENTG on the BC6OTHER - induced effects of BC6ENTC were determined using small interfering RNA (siRNA) in CRC cells and in BC6OTHER - / - ) mouse embryonic fibroblasts. CPR:falsenewlinePhosphorylation of BC6OTHER was measured; the effects of loss of BC6OTHER on the BC6OTHER - induced effects of BC6ENTC were determined using small interfering RNA (siRNA) in CRC cells and in BC6ENTG - / - ) mouse embryonic fibroblasts. CPR:falsenewlineRESULTS: BC6ENTC reduced BC6OTHER signaling in CRC cells by inhibiting the BC6ENTG effectors BC6OTHER and BC6OTHER . CPR:4newlineRESULTS: BC6ENTC reduced BC6OTHER signaling in CRC cells by inhibiting the BC6OTHER effectors BC6ENTG and BC6OTHER . CPR:4newlineRESULTS: BC6ENTC reduced BC6OTHER signaling in CRC cells by inhibiting the BC6OTHER effectors BC6OTHER and BC6ENTG . CPR:4newlineRESULTS: BC6ENTC reduced BC6ENTG signaling in CRC cells by inhibiting the BC6OTHER effectors BC6OTHER and BC6OTHER . CPR:4newlineRESULTS: BC6OTHER reduced BC6ENTC signaling in CRC cells by inhibiting the BC6ENTG effectors BC6OTHER and BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER reduced BC6ENTC signaling in CRC cells by inhibiting the BC6OTHER effectors BC6ENTG and BC6OTHER . CPR:falsenewlineRESULTS: BC6OTHER reduced BC6ENTC signaling in CRC cells by inhibiting the BC6OTHER effectors BC6OTHER and BC6ENTG . CPR:falsenewline BC6ENTC inhibits BC6ENTG signaling, activates BC6OTHER , and induces autophagy in colorectal cancer cells. CPR:4newline BC6ENTC inhibits BC6OTHER signaling, activates BC6ENTG , and induces autophagy in colorectal cancer cells. CPR:falsenewline BC6OTHER inhibits BC6ENTC signaling, activates BC6ENTG , and induces autophagy in colorectal cancer cells. CPR:falsenewlineBC6ENTC changed nucleotide ratios and activated BC6ENTG in CRC cells. CPR:falsenewline BC6OTHER inhibits BC6ENTG signaling, activates BC6ENTC - activated protein kinase, and induces autophagy in colorectal cancer cells. CPR:falsenewlineBC6ENTC was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6ENTG , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER . CPR:falsenewlineBC6ENTC was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6ENTG - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER . CPR:falsenewlineBC6ENTC was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6ENTG - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER . CPR:falsenewlineBC6ENTC was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTG . CPR:falsenewlineBC6ENTG was still inhibited by BC6ENTC in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER . CPR:4newlineBC6OTHER was still inhibited by BC6ENTC in CRC cells after siRNA knockdown of BC6ENTG , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER . CPR:falsenewlineBC6OTHER was still inhibited by BC6ENTC in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6ENTG - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER . CPR:falsenewlineBC6OTHER was still inhibited by BC6ENTC in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6ENTG - independent mechanisms of BC6OTHER - induced inhibition of BC6OTHER . CPR:falsenewlineBC6OTHER was still inhibited by BC6ENTC in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTG . CPR:falsenewlineBC6ENTG was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6ENTC - induced inhibition of BC6OTHER . CPR:4newlineBC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6ENTG , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6ENTC - induced inhibition of BC6OTHER . CPR:falsenewlineBC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6ENTG - dependent and BC6OTHER - independent mechanisms of BC6ENTC - induced inhibition of BC6OTHER . CPR:falsenewlineBC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6ENTG - independent mechanisms of BC6ENTC - induced inhibition of BC6OTHER . CPR:falsenewlineBC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6ENTC - induced inhibition of BC6ENTG . CPR:4newlineBC6ENTG was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTC . CPR:falsenewlineBC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6ENTG , indicating BC6OTHER - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTC . CPR:falsenewlineBC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6ENTG - dependent and BC6OTHER - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTC . CPR:falsenewlineBC6OTHER was still inhibited by BC6OTHER in CRC cells after siRNA knockdown of BC6OTHER , indicating BC6OTHER - dependent and BC6ENTG - independent mechanisms of BC6OTHER - induced inhibition of BC6ENTC . CPR:falsenewlineBC6ENTC induced autophagy, a feature of BC6ENTG inhibition. CPR:falsenewlineBC6ENTC and BC6OTHER (an activator of BC6ENTG ) increased inhibition of BC6OTHER and BC6OTHER , as well as autophagy in CRC cells. CPR:falsenewlineBC6ENTC and BC6OTHER (an activator of BC6OTHER ) increased inhibition of BC6ENTG and BC6OTHER , as well as autophagy in CRC cells. CPR:falsenewlineBC6ENTC and BC6OTHER (an activator of BC6OTHER ) increased inhibition of BC6OTHER and BC6ENTG , as well as autophagy in CRC cells. CPR:falsenewlineThe editing of BC6ENTG is also completely lost in albino mutants and BC6ENTC - treated seedlings. CPR:falsenewlineIn addition, the expression of nucleus - encoded BC6ENTG dependent transcripts is specifically induced by BC6ENTC , and the splicing of BC6OTHER transcripts is significantly reduced in the albino mutants and inhibitor - treated seedlings. CPR:falsenewlineIn addition, the expression of nucleus - encoded BC6OTHER dependent transcripts is specifically induced by BC6ENTC , and the splicing of BC6ENTG transcripts is significantly reduced in the albino mutants and inhibitor - treated seedlings. CPR:falsenewlineBy contrast, the editing of some sites is completely lost or significantly reduced in other non - green tissues; for instance, the editing of BC6ENTG , BC6OTHER , and BC6OTHER is completely lost in roots and in BC6ENTC - treated seedlings. CPR:falsenewlineBy contrast, the editing of some sites is completely lost or significantly reduced in other non - green tissues; for instance, the editing of BC6OTHER , BC6ENTG , and BC6OTHER is completely lost in roots and in BC6ENTC - treated seedlings. CPR:falsenewlineBy contrast, the editing of some sites is completely lost or significantly reduced in other non - green tissues; for instance, the editing of BC6OTHER , BC6OTHER , and BC6ENTG is completely lost in roots and in BC6ENTC - treated seedlings. CPR:falsenewlineRats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6ENTC dismutase, BC6ENTG and BC6OTHER in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6ENTC dismutase, BC6OTHER peroxidase and BC6ENTG in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6ENTC for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6ENTG , BC6OTHER peroxidase and BC6OTHER in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6ENTC for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6ENTG and BC6OTHER in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6ENTC for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6OTHER peroxidase and BC6ENTG in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6ENTC ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6ENTG , BC6OTHER peroxidase and BC6OTHER in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6ENTC ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6ENTG and BC6OTHER in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6ENTC ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6OTHER peroxidase and BC6ENTG in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6ENTC ) levels and significantly decreased enzymatic antioxidants BC6ENTG , BC6OTHER peroxidase and BC6OTHER in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6ENTC ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6ENTG and BC6OTHER in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6ENTC ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6OTHER peroxidase and BC6ENTG in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6ENTG , BC6ENTC peroxidase and BC6OTHER in the frontal cortex tissue. CPR:falsenewlineRats intoxicated with BC6OTHER for 30 days, significantly increased tissue BC6OTHER ( BC6OTHER ) levels and significantly decreased enzymatic antioxidants BC6OTHER , BC6ENTC peroxidase and BC6ENTG in the frontal cortex tissue. CPR:falsenewlineThe BC6ENTG immunopositivity was increased in degenerating neurons of the BC6ENTC group. CPR:falsenewlineHowever, the precise mechanism by which BC6OTHER counteracts BC6ENTG - mediated BC6ENTC hepatotoxicity through BC6OTHER system is still remained unclear. CPR:falsenewlineHowever, the precise mechanism by which BC6OTHER counteracts BC6OTHER - mediated BC6ENTC hepatotoxicity through BC6ENTG system is still remained unclear. CPR:falsenewlineOur data showed that chronic BC6ENTC over - activated BC6ENTG but suppressed BC6OTHER with concurrent hepatic oxidative damage, which was partially normalized by BC6OTHER (100mg / kg.bw.). CPR:falsenewlineOur data showed that chronic BC6ENTC over - activated BC6OTHER but suppressed BC6ENTG with concurrent hepatic oxidative damage, which was partially normalized by BC6OTHER (100mg / kg.bw.). CPR:falsenewlineNaturally occuring BC6OTHER protects hepatocytes from BC6ENTC - induced oxidative stress, and BC6OTHER ( BC6ENTG ) induction and BC6OTHER ( BC6OTHER ) metabolite may be implicated in the beneficial effect. CPR:falsenewlineNaturally occuring BC6OTHER protects hepatocytes from BC6ENTC - induced oxidative stress, and BC6ENTG ( BC6OTHER ) induction and BC6OTHER ( BC6OTHER ) metabolite may be implicated in the beneficial effect. CPR:falsenewlineOur data showed that chronic BC6OTHER over - activated BC6ENTG but suppressed BC6OTHER with concurrent hepatic oxidative damage, which was partially normalized by BC6ENTC (100mg / kg.bw.). CPR:falsenewlineOur data showed that chronic BC6OTHER over - activated BC6OTHER but suppressed BC6ENTG with concurrent hepatic oxidative damage, which was partially normalized by BC6ENTC (100mg / kg.bw.). CPR:falsenewlineBC6ENTC (100μM) induced BC6ENTG and depleted CHEM pool when incubated to human hepatocytes. CPR:falsenewlineBC6ENTC - stimulated (100mM) BC6ENTG upregulation was suppressed by BC6OTHER but further enhanced by BC6OTHER inhibition with resultant BC6OTHER accumulation. CPR:falsenewlineBC6ENTC - stimulated (100mM) BC6OTHER upregulation was suppressed by BC6OTHER but further enhanced by BC6ENTG inhibition with resultant BC6OTHER accumulation. CPR:falsenewlineBC6OTHER - stimulated (100mM) BC6ENTG upregulation was suppressed by BC6ENTC but further enhanced by BC6OTHER inhibition with resultant BC6OTHER accumulation. CPR:falsenewlineBC6OTHER - stimulated (100mM) BC6OTHER upregulation was suppressed by BC6ENTC but further enhanced by BC6ENTG inhibition with resultant BC6OTHER accumulation. CPR:falsenewlineBC6OTHER - stimulated (100mM) BC6ENTG upregulation was suppressed by BC6OTHER but further enhanced by BC6OTHER inhibition with resultant BC6ENTC accumulation. CPR:falsenewlineBC6OTHER - stimulated (100mM) BC6OTHER upregulation was suppressed by BC6OTHER but further enhanced by BC6ENTG inhibition with resultant BC6ENTC accumulation. CPR:falsenewlineBC6ENTC scavenging blocked the suppression of BC6OTHER only on BC6ENTG activity. CPR:falsenewlineBC6OTHER donor dose - dependently inactivated BC6OTHER of BC6ENTC - incubated microsome, which was mimicked by BC6ENTG substrate but abolished by BC6OTHER scavenger. CPR:falsenewlineBC6OTHER donor dose - dependently inactivated BC6ENTG of BC6ENTC - incubated microsome, which was mimicked by BC6OTHER substrate but abolished by BC6OTHER scavenger. CPR:falsenewlineBC6OTHER scavenging blocked the suppression of BC6ENTC only on BC6ENTG activity. CPR:falsenewlineNaturally occuring BC6OTHER protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6ENTC oxygenase - 1 ( BC6ENTG ) induction and BC6OTHER ( BC6OTHER ) metabolite may be implicated in the beneficial effect. CPR:falsenewlineBC6ENTC donor dose - dependently inactivated BC6OTHER of BC6OTHER - incubated microsome, which was mimicked by BC6ENTG substrate but abolished by BC6OTHER scavenger. CPR:falsenewlineBC6ENTC donor dose - dependently inactivated BC6ENTG of BC6OTHER - incubated microsome, which was mimicked by BC6OTHER substrate but abolished by BC6OTHER scavenger. CPR:falsenewline BC6ENTC suppressed BC6ENTG - dependent BC6OTHER hepatotoxicity via depleting CHEM pool and releasing BC6OTHER . CPR:falsenewline BC6OTHER suppressed BC6ENTG - dependent BC6ENTC hepatotoxicity via depleting CHEM pool and releasing BC6OTHER . CPR:falsenewline BC6OTHER suppressed BC6ENTG - dependent BC6OTHER hepatotoxicity via depleting CHEM pool and releasing BC6ENTC . CPR:falsenewlineBC6OTHER donor dose - dependently inactivated BC6OTHER of BC6OTHER - incubated microsome, which was mimicked by BC6ENTG substrate but abolished by BC6ENTC scavenger. CPR:falsenewlineBC6OTHER donor dose - dependently inactivated BC6ENTG of BC6OTHER - incubated microsome, which was mimicked by BC6OTHER substrate but abolished by BC6ENTC scavenger. CPR:falsenewlineThus, BC6ENTG - mediated BC6ENTC hepatotoxicity was alleviated by BC6OTHER through BC6OTHER induction. CPR:falsenewlineThus, BC6OTHER - mediated BC6ENTC hepatotoxicity was alleviated by BC6OTHER through BC6ENTG induction. CPR:falsenewlineThus, BC6ENTG - mediated BC6OTHER hepatotoxicity was alleviated by BC6ENTC through BC6OTHER induction. CPR:falsenewlineThus, BC6OTHER - mediated BC6OTHER hepatotoxicity was alleviated by BC6ENTC through BC6ENTG induction. CPR:falsenewlineDepleted CHEM pool and BC6ENTC releasing limited protein synthesis and inhibited enzymatic activity of BC6ENTG , respectively. CPR:falsenewlineNaturally occuring BC6OTHER protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6OTHER ( BC6ENTG ) induction and BC6ENTC ( BC6OTHER ) metabolite may be implicated in the beneficial effect. CPR:falsenewlineNaturally occuring BC6OTHER protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6ENTG ( BC6OTHER ) induction and BC6ENTC ( BC6OTHER ) metabolite may be implicated in the beneficial effect. CPR:falsenewlineNaturally occuring BC6OTHER protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6OTHER ( BC6ENTG ) induction and BC6OTHER ( BC6ENTC ) metabolite may be implicated in the beneficial effect. CPR:falsenewlineNaturally occuring BC6OTHER protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6ENTG ( BC6OTHER ) induction and BC6OTHER ( BC6ENTC ) metabolite may be implicated in the beneficial effect. CPR:falsenewlineNaturally occuring BC6ENTC protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6OTHER ( BC6ENTG ) induction and BC6OTHER ( BC6OTHER ) metabolite may be implicated in the beneficial effect. CPR:falsenewlineNaturally occuring BC6ENTC protects hepatocytes from BC6OTHER - induced oxidative stress, and BC6ENTG ( BC6OTHER ) induction and BC6OTHER ( BC6OTHER ) metabolite may be implicated in the beneficial effect. CPR:falsenewlineHowever, the precise mechanism by which BC6ENTC counteracts BC6ENTG - mediated BC6OTHER hepatotoxicity through BC6OTHER system is still remained unclear. CPR:falsenewlineHowever, the precise mechanism by which BC6ENTC counteracts BC6OTHER - mediated BC6OTHER hepatotoxicity through BC6ENTG system is still remained unclear. CPR:falsenewline BC6ENTG - receptor antagonism in hypertension: what has been learned with BC6ENTC ? CPR:falsenewlineBC6ENTC is a long - acting BC6OTHER antagonist acting specifically at the level of the Type 1 - receptor subtype ( BC6ENTG - receptor). CPR:falsenewlineBC6ENTC is a long - acting BC6ENTG antagonist acting specifically at the level of the Type 1 - receptor subtype ( BC6OTHER - receptor). CPR:falsenewlineBC6OTHER is a long - acting BC6ENTC antagonist acting specifically at the level of the Type 1 - receptor subtype ( BC6ENTG - receptor). CPR:falsenewlineBC6ENTC may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this BC6ENTG - blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro - inflammatory effects of BC6OTHER . CPR:falsenewlineBC6ENTC may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this BC6OTHER - blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro - inflammatory effects of BC6ENTG . CPR:falsenewlineBC6OTHER may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this BC6ENTG - blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro - inflammatory effects of BC6ENTC . CPR:falsenewlineThe antidepressant BC6ENTC has been shown to decrease synaptic membrane concentrations of the BC6OTHER re - uptake transporter ( BC6ENTG ) in vivo and in vitro, on both an acute and a chronic basis. CPR:falsenewlineThe antidepressant BC6ENTC has been shown to decrease synaptic membrane concentrations of the BC6ENTG ( BC6OTHER ) in vivo and in vitro, on both an acute and a chronic basis. CPR:falsenewlineIn this study, we treated SK - N - SHSY5Y cells with 100 nM BC6ENTC for 24 or 72 h, and measured BC6OTHER binding (as an estimate of BC6ENTG ) and BC6OTHER mRNA by quantitative reverse transcription polymerase chain reaction. CPR:falsenewlineIn this study, we treated SK - N - SHSY5Y cells with 100 nM BC6ENTC for 24 or 72 h, and measured BC6OTHER binding (as an estimate of BC6OTHER ) and BC6ENTG mRNA by quantitative reverse transcription polymerase chain reaction. CPR:falsenewlineIn this study, we treated SK - N - SHSY5Y cells with 100 nM BC6OTHER for 24 or 72 h, and measured BC6ENTC binding (as an estimate of BC6ENTG ) and BC6OTHER mRNA by quantitative reverse transcription polymerase chain reaction. CPR:falsenewlineIn this study, we treated SK - N - SHSY5Y cells with 100 nM BC6OTHER for 24 or 72 h, and measured BC6ENTC binding (as an estimate of BC6OTHER ) and BC6ENTG mRNA by quantitative reverse transcription polymerase chain reaction. CPR:falsenewlineWe conclude that decreased BC6ENTG synthesis may contribute to the chronic, but not acute, effect of BC6ENTC to downregulate the BC6OTHER . CPR:falsenewlineWe conclude that decreased BC6OTHER synthesis may contribute to the chronic, but not acute, effect of BC6ENTC to downregulate the BC6ENTG . CPR:4newlineThe antidepressant BC6OTHER has been shown to decrease synaptic membrane concentrations of the BC6ENTC re - uptake transporter ( BC6ENTG ) in vivo and in vitro, on both an acute and a chronic basis. CPR:falsenewline BC6ENTC treatment decreases BC6OTHER binding and BC6ENTG mRNA in SK - N - SHSY5Y cells. CPR:falsenewline BC6OTHER treatment decreases BC6ENTC binding and BC6ENTG mRNA in SK - N - SHSY5Y cells. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTC diphosphohydrolase), BC6ENTG , BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTC diphosphohydrolase), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6ENTG and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTC diphosphohydrolase), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTG ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTC diphosphohydrolase), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6ENTG ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6ENTG ( BC6ENTC diphosphohydrolase), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineIn lymphocytes, the BC6OTHER and BC6ENTG activities were increased in all groups treated with BC6ENTC when compared to control (P<0.05). CPR:3newlineIn lymphocytes, the BC6ENTG and BC6OTHER activities were increased in all groups treated with BC6ENTC when compared to control (P<0.05). CPR:3newlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6ENTC pyrophosphatase / phosphodiesterase), BC6ENTG and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6ENTC pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTG ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6ENTC pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6ENTG ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6ENTG ( BC6OTHER ), Ecto - NPP ( BC6ENTC pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTG ), Ecto - NPP ( BC6ENTC pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), BC6ENTG , BC6OTHER and BC6ENTC deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6ENTG and BC6ENTC deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTC deaminase ( BC6ENTG ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6ENTG ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTC deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6OTHER on ectonucleotidase activities such as BC6OTHER ( BC6ENTG ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTC deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), BC6ENTG , BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6ENTG and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6ENTG ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6OTHER ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6ENTG ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6ENTG ( BC6OTHER ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineThis study evaluated the effects of BC6ENTC on ectonucleotidase activities such as BC6OTHER ( BC6ENTG ), Ecto - NPP ( BC6OTHER pyrophosphatase / phosphodiesterase), BC6OTHER and BC6OTHER deaminase ( BC6OTHER ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. CPR:falsenewlineEfficacies and potencies of these ligands were determined relative to the endogenous ligand BC6ENTG and the common mu agonist, BC6ENTC . CPR:falsenewlineAdditionally, the role of BC6ENTG ( BC6OTHER ; BC6OTHER ) and BC6OTHER ( BC6OTHER ; BC6OTHER ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats. CPR:9newlineAdditionally, the role of BC6OTHER ( BC6ENTG ; BC6OTHER ) and BC6OTHER ( BC6OTHER ; BC6OTHER ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats. CPR:falsenewlineAdditionally, the role of BC6OTHER ( BC6OTHER ; BC6ENTG ) and BC6OTHER ( BC6OTHER ; BC6OTHER ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats. CPR:falsenewlineAdditionally, the role of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6ENTG ( BC6OTHER ; BC6OTHER ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats. CPR:9newlineAdditionally, the role of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER ( BC6ENTG ; BC6OTHER ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats. CPR:falsenewlineAdditionally, the role of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER ( BC6OTHER ; BC6ENTG ) in BC6ENTC disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats. CPR:falsenewlineThe fecal elimination, IC, and systemic clearance of BC6ENTC were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with BC6OTHER , a dual BC6ENTG and BC6OTHER inhibitor). CPR:falsenewlineThe fecal elimination, IC, and systemic clearance of BC6ENTC were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with BC6OTHER , a dual BC6OTHER and BC6ENTG inhibitor). CPR:falsenewlineInvestigating the enteroenteric recirculation of BC6ENTC , a BC6ENTG inhibitor: administration of activated CHEM to bile duct - cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. CPR:4newlineThe fecal elimination, IC, and systemic clearance of BC6OTHER were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with BC6ENTC , a dual BC6ENTG and BC6OTHER inhibitor). CPR:4newlineThe fecal elimination, IC, and systemic clearance of BC6OTHER were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with BC6ENTC , a dual BC6OTHER and BC6ENTG inhibitor). CPR:falsenewline BC6ENTG appeared to play a more important role for absorption and intestinal and renal elimination of BC6ENTC than BC6OTHER in transporter - KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species. CPR:9newline BC6OTHER appeared to play a more important role for absorption and intestinal and renal elimination of BC6ENTC than BC6ENTG in transporter - KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species. CPR:falsenewlineThe BC6ENTC - lowering drug CHEM inhibits BC6ENTG signaling by binding to an allosteric site on BC6OTHER ( BC6OTHER chain), which leads to immunomodulation. CPR:falsenewlineThe BC6ENTC - lowering drug CHEM inhibits BC6OTHER signaling by binding to an allosteric site on BC6ENTG ( BC6OTHER chain), which leads to immunomodulation. CPR:falsenewlineThe BC6ENTC - lowering drug CHEM inhibits BC6OTHER signaling by binding to an allosteric site on BC6OTHER ( BC6ENTG chain), which leads to immunomodulation. CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6ENTC ); BC6ENTG ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6ENTC ); BC6OTHER acetyltransferase ( BC6ENTG ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6ENTC ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both BC6ENTG ( BC6OTHER and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6ENTC ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6ENTG and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6ENTC ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6ENTG , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6ENTC acetyltransferase ( BC6ENTG ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6ENTC acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both BC6ENTG ( BC6OTHER and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6ENTC acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6ENTG and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6ENTC acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6ENTG , respectively). CPR:falsenewlineWe found that BC6ENTC abolishes anti - BC6ENTG mAb - induced increases in lymphocytic cholinergic activity in a manner independent of its BC6OTHER - lowering activity. CPR:falsenewlineWe found that BC6OTHER abolishes anti - BC6ENTG mAb - induced increases in lymphocytic cholinergic activity in a manner independent of its BC6ENTC - lowering activity. CPR:falsenewlineCollectively then, these results indicate that BC6ENTG contributes to the regulation of lymphocytic cholinergic activity via BC6OTHER - mediated pathways and suggest that BC6ENTC exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity. CPR:falsenewlineCollectively then, these results indicate that BC6OTHER contributes to the regulation of lymphocytic cholinergic activity via BC6ENTG - mediated pathways and suggest that BC6ENTC exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity. CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6ENTG ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6ENTC receptors ( BC6OTHER and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6ENTG ), its synthesizing enzyme; and both muscarinic and nicotinic BC6ENTC receptors ( BC6OTHER and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6ENTC receptors ( BC6ENTG and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6OTHER ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6ENTC receptors ( BC6OTHER and BC6ENTG , respectively). CPR:falsenewlineStimulation of lymphocytes with BC6ENTG , which activates T cells via the BC6OTHER / BC6OTHER complex, enhances the synthesis and release of BC6ENTC and up - regulates expression of BC6OTHER and BC6OTHER mRNAs. CPR:falsenewlineStimulation of lymphocytes with BC6OTHER , which activates T cells via the BC6ENTG / BC6OTHER complex, enhances the synthesis and release of BC6ENTC and up - regulates expression of BC6OTHER and BC6OTHER mRNAs. CPR:falsenewlineStimulation of lymphocytes with BC6OTHER , which activates T cells via the BC6OTHER / BC6ENTG complex, enhances the synthesis and release of BC6ENTC and up - regulates expression of BC6OTHER and BC6OTHER mRNAs. CPR:falsenewlineStimulation of lymphocytes with BC6OTHER , which activates T cells via the BC6OTHER / BC6OTHER complex, enhances the synthesis and release of BC6ENTC and up - regulates expression of BC6ENTG and BC6OTHER mRNAs. CPR:falsenewlineStimulation of lymphocytes with BC6OTHER , which activates T cells via the BC6OTHER / BC6OTHER complex, enhances the synthesis and release of BC6ENTC and up - regulates expression of BC6OTHER and BC6ENTG mRNAs. CPR:falsenewlineIn addition, activation of BC6ENTG and increases in intracellular BC6ENTC also enhance cholinergic activity in T cells, and BC6OTHER ( BC6OTHER ; BC6OTHER / BC6OTHER ) is an important mediator of leukocyte migration and T cell activation. CPR:falsenewlineIn addition, activation of BC6OTHER and increases in intracellular BC6ENTC also enhance cholinergic activity in T cells, and BC6ENTG ( BC6OTHER ; BC6OTHER / BC6OTHER ) is an important mediator of leukocyte migration and T cell activation. CPR:falsenewlineIn addition, activation of BC6OTHER and increases in intracellular BC6ENTC also enhance cholinergic activity in T cells, and BC6OTHER ( BC6ENTG ; BC6OTHER / BC6OTHER ) is an important mediator of leukocyte migration and T cell activation. CPR:falsenewlineIn addition, activation of BC6OTHER and increases in intracellular BC6ENTC also enhance cholinergic activity in T cells, and BC6OTHER ( BC6OTHER ; BC6ENTG / BC6OTHER ) is an important mediator of leukocyte migration and T cell activation. CPR:falsenewlineIn addition, activation of BC6OTHER and increases in intracellular BC6ENTC also enhance cholinergic activity in T cells, and BC6OTHER ( BC6OTHER ; BC6OTHER / BC6ENTG ) is an important mediator of leukocyte migration and T cell activation. CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6ENTC ( BC6OTHER ); BC6ENTG ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6ENTC ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6ENTG ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6ENTC ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both BC6ENTG ( BC6OTHER and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6ENTC ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6ENTG and BC6OTHER , respectively). CPR:falsenewlineLymphocytes possess the essential components of a cholinergic system, including BC6ENTC ( BC6OTHER ); BC6OTHER acetyltransferase ( BC6OTHER ), its synthesizing enzyme; and both muscarinic and nicotinic BC6OTHER receptors ( BC6OTHER and BC6ENTG , respectively). CPR:falsenewlineAnti - BC6ENTG monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6OTHER and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells. CPR:falsenewlineAnti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6ENTG containing antibodies against BC6OTHER , BC6OTHER and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells. CPR:falsenewlineAnti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6ENTG , BC6OTHER and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells. CPR:falsenewlineAnti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6ENTG and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells. CPR:falsenewlineAnti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6OTHER and BC6ENTG all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells. CPR:falsenewlineAnti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6OTHER and BC6OTHER all increase BC6ENTG activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6OTHER mRNAs in T cells. CPR:falsenewlineAnti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6OTHER and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6ENTG and BC6OTHER mRNAs in T cells. CPR:falsenewlineAnti - BC6OTHER monoclonal antibody (mAb) as well as antithymocyte BC6OTHER containing antibodies against BC6OTHER , BC6OTHER and BC6OTHER all increase BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6ENTG mRNAs in T cells. CPR:falsenewlineQuantitative analysis of the interaction of BC6ENTG with chemicals and BC6ENTC receptor coactivator 1 using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse. CPR:falsenewlineBC6OTHER and BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER showed compound - specific but similar affinities for both BC6ENTG . CPR:falsenewlineBC6OTHER and BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER showed compound - specific but similar affinities for both BC6ENTG . CPR:falsenewlineBC6OTHER and BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER showed compound - specific but similar affinities for both BC6ENTG . CPR:falsenewlineBC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER showed compound - specific but similar affinities for both BC6ENTG . CPR:falsenewlineBC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC showed compound - specific but similar affinities for both BC6ENTG . CPR:falsenewlineThe constitutive BC6ENTC receptor ( BC6ENTG ) not only displays a high basal transcriptional activity but also acts as a ligand - dependent transcriptional factor. CPR:falsenewlineThe objectives of this study are to establish a high - throughput tool to screen BC6ENTG ligands and to clarify how BC6OTHER proteins from the Baikal seal ( BC6OTHER ) and the mouse ( BC6OTHER ) interact with chemicals and BC6ENTC receptor coactivator 1 ( BC6OTHER ). CPR:falsenewlineThe objectives of this study are to establish a high - throughput tool to screen BC6OTHER ligands and to clarify how BC6ENTG proteins from the Baikal seal ( BC6OTHER ) and the mouse ( BC6OTHER ) interact with chemicals and BC6ENTC receptor coactivator 1 ( BC6OTHER ). CPR:falsenewlineThe objectives of this study are to establish a high - throughput tool to screen BC6OTHER ligands and to clarify how BC6OTHER proteins from the Baikal seal ( BC6ENTG ) and the mouse ( BC6OTHER ) interact with chemicals and BC6ENTC receptor coactivator 1 ( BC6OTHER ). CPR:falsenewlineThe objectives of this study are to establish a high - throughput tool to screen BC6OTHER ligands and to clarify how BC6OTHER proteins from the Baikal seal ( BC6OTHER ) and the mouse ( BC6ENTG ) interact with chemicals and BC6ENTC receptor coactivator 1 ( BC6OTHER ). CPR:falsenewlineThe objectives of this study are to establish a high - throughput tool to screen BC6OTHER ligands and to clarify how BC6OTHER proteins from the Baikal seal ( BC6OTHER ) and the mouse ( BC6OTHER ) interact with chemicals and BC6ENTC receptor coactivator 1 ( BC6ENTG ). CPR:falsenewlineBC6ENTC and BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER showed compound - specific but similar affinities for both BC6ENTG . CPR:falsenewlineQuantitative analysis of the interaction of constitutive BC6ENTC receptor with chemicals and BC6ENTG using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse. CPR:falsenewlineThus, BC6ENTG antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as BC6ENTC . CPR:falsenewlineIt is currently not known how much this BC6ENTG antagonism of BC6ENTC contributes to the therapeutic or adverse side effects of BC6OTHER . CPR:falsenewlineIt is currently not known how much this BC6ENTG antagonism of BC6OTHER contributes to the therapeutic or adverse side effects of BC6ENTC . CPR:falsenewlineThe current studies with Sprague - Dawley rats were conducted to determine the participation of BC6ENTG subtype in sensorimotor plasticity and memory function affected by BC6ENTC using tests of prepulse inhibition (PPI) and radial - arm maze choice accuracy. CPR:falsenewlineIn the current project, we found that the selective BC6ENTG antagonist BC6ENTC also reversed the BC6OTHER - induced impairment in PPI of tactile startle with an auditory prepulse. CPR:6newlineIn the current project, we found that the selective BC6ENTG antagonist BC6OTHER also reversed the BC6ENTC - induced impairment in PPI of tactile startle with an auditory prepulse. CPR:falsenewline BC6ENTG involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of BC6ENTC . CPR:falsenewlineBC6ENTG blockade is one of the more prominent actions of the multi - receptor acting antipsychotic BC6ENTC . CPR:falsenewlineIn summary, the therapeutic effect of BC6ENTC in reversing PPI impairment was mimicked by the BC6ENTG antagonist BC6OTHER , while BC6OTHER had a mixed effect on cognition. CPR:falsenewlineIn summary, the therapeutic effect of BC6OTHER in reversing PPI impairment was mimicked by the BC6ENTG antagonist BC6ENTC , while BC6OTHER had a mixed effect on cognition. CPR:falsenewlineIn summary, the therapeutic effect of BC6OTHER in reversing PPI impairment was mimicked by the BC6ENTG antagonist BC6OTHER , while BC6ENTC had a mixed effect on cognition. CPR:falsenewlineUNLABELLED: BC6ENTC is a BC6ENTG antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. CPR:falsenewlineEvidence has been obtained in man for interaction with BC6ENTG in the brain; and in the peripheral circulation BC6ENTC does not, as do other beta blockers, increase peripheral vascular resistance, but reduces it. CPR:falsenewlineIt is suggested that all the additional actions of BC6ENTC can be attributed to a partial agonist action on BC6ENTG . CPR:5newline BC6ENTC : a BC6ENTG antagonist with unique additional actions. CPR:falsenewlineInhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6ENTG activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER . CPR:falsenewlineInhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6ENTG ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER . CPR:falsenewlineInhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6OTHER ( BC6ENTG ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER . CPR:falsenewlineInhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6ENTG ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER . CPR:falsenewlineInhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6ENTG ) phosphorylation and degradation, an inhibitor of BC6OTHER . CPR:falsenewlineInhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6ENTG . CPR:falsenewlineInhibition of the BC6ENTG pathway was responsible for this effect since the BC6ENTC inhibited BC6OTHER - induced BC6OTHER activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER . CPR:falsenewlineInhibition of the BC6OTHER pathway was responsible for this effect since the BC6ENTC inhibited BC6ENTG - induced BC6OTHER activation, activation of BC6OTHER ( BC6OTHER ) and suppressed inhibitor of BC6OTHER ( BC6OTHER ) phosphorylation and degradation, an inhibitor of BC6OTHER . CPR:falsenewlineCONCLUSIONS AND IMPLICATIONS: Together, these data suggest that BC6ENTC significantly suppressed osteoclastogenesis induced by BC6ENTG and tumour cells via the BC6OTHER signalling pathway. CPR:falsenewlineCONCLUSIONS AND IMPLICATIONS: Together, these data suggest that BC6ENTC significantly suppressed osteoclastogenesis induced by BC6OTHER and tumour cells via the BC6ENTG signalling pathway. CPR:falsenewlineTo search for an inhibitor of cancer - induced bone loss, we investigated the effect of BC6ENTC , a semi - synthetic BC6OTHER derived from the plant Gloriosa CHEM and clinically used as a muscle relaxant, on osteoclastogenesis induced by BC6ENTG ( BC6OTHER ) and tumour cells. CPR:falsenewlineTo search for an inhibitor of cancer - induced bone loss, we investigated the effect of BC6ENTC , a semi - synthetic BC6OTHER derived from the plant Gloriosa CHEM and clinically used as a muscle relaxant, on osteoclastogenesis induced by BC6OTHER ( BC6ENTG ) and tumour cells. CPR:falsenewlineTo search for an inhibitor of cancer - induced bone loss, we investigated the effect of BC6OTHER , a semi - synthetic BC6ENTC derived from the plant Gloriosa CHEM and clinically used as a muscle relaxant, on osteoclastogenesis induced by BC6ENTG ( BC6OTHER ) and tumour cells. CPR:falsenewlineTo search for an inhibitor of cancer - induced bone loss, we investigated the effect of BC6OTHER , a semi - synthetic BC6ENTC derived from the plant Gloriosa CHEM and clinically used as a muscle relaxant, on osteoclastogenesis induced by BC6OTHER ( BC6ENTG ) and tumour cells. CPR:falsenewlineEXPERIMENTAL APPROACH: We used RAW 264.7 (murine macrophage) cells, a well - established system for osteoclastogenesis, and evaluated the effect of BC6ENTC on BC6ENTG - induced BC6OTHER signalling and osteoclastogenesis as well as on osteoclastogenesis induced by tumour cells. CPR:falsenewlineEXPERIMENTAL APPROACH: We used RAW 264.7 (murine macrophage) cells, a well - established system for osteoclastogenesis, and evaluated the effect of BC6ENTC on BC6OTHER - induced BC6ENTG signalling and osteoclastogenesis as well as on osteoclastogenesis induced by tumour cells. CPR:falsenewlineKEY RESULTS: BC6ENTC suppressed osteoclastogenesis induced by BC6ENTG , and by breast cancer and multiple myeloma cells. CPR:falsenewline BC6ENTC suppresses osteoclastogenesis induced by BC6ENTG and cancer cells through inhibition of inflammatory pathways: a new use for an old drug. CPR:falsenewlineOur findings that BC6OTHER / BC6ENTC target both BC6ENTG and BC6OTHER may have implications for understanding the impact of nitrosylation on cellular redox homeostasis. CPR:falsenewlineOur findings that BC6OTHER / BC6ENTC target both BC6OTHER and BC6ENTG may have implications for understanding the impact of nitrosylation on cellular redox homeostasis. CPR:falsenewlineIn this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6ENTG ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6ENTG ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the BC6ENTG , a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6ENTG ( BC6OTHER ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6ENTG ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6ENTC / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6ENTG . CPR:falsenewlineIn this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6ENTG ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6OTHER ( BC6ENTG ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the BC6ENTG , a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6ENTG ( BC6OTHER ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6ENTG ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6OTHER / BC6ENTC may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6OTHER Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6ENTG . CPR:falsenewlineIn this study we investigated how BC6OTHER / BC6OTHER may affect the redox cycle of BC6ENTG ( BC6OTHER ), a representative of the 2 - BC6ENTC Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6OTHER / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6ENTG ), a representative of the 2 - BC6ENTC Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6OTHER / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6ENTC Prxs, a group of BC6ENTG ( BC6OTHER ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6OTHER / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6ENTC Prxs, a group of BC6OTHER ( BC6ENTG ) - dependent BC6OTHER . CPR:falsenewlineIn this study we investigated how BC6OTHER / BC6OTHER may affect the redox cycle of BC6OTHER ( BC6OTHER ), a representative of the 2 - BC6ENTC Prxs, a group of BC6OTHER ( BC6OTHER ) - dependent BC6ENTG . CPR:falsenewlineWe found that, both in a cell - free system and in cells, BC6ENTC / BC6OTHER donors such as BC6OTHER and BC6OTHER readily induced the BC6OTHER - nitrosylation of BC6ENTG , causing structural and functional alterations. CPR:falsenewlineWe found that, both in a cell - free system and in cells, BC6OTHER / BC6ENTC donors such as BC6OTHER and BC6OTHER readily induced the BC6OTHER - nitrosylation of BC6ENTG , causing structural and functional alterations. CPR:falsenewlineWe found that, both in a cell - free system and in cells, BC6OTHER / BC6OTHER donors such as BC6ENTC and BC6OTHER readily induced the BC6OTHER - nitrosylation of BC6ENTG , causing structural and functional alterations. CPR:falsenewlineWe found that, both in a cell - free system and in cells, BC6OTHER / BC6OTHER donors such as BC6OTHER and BC6ENTC readily induced the BC6OTHER - nitrosylation of BC6ENTG , causing structural and functional alterations. CPR:falsenewlineWe found that, both in a cell - free system and in cells, BC6OTHER / BC6OTHER donors such as BC6OTHER and BC6OTHER readily induced the BC6ENTC - nitrosylation of BC6ENTG , causing structural and functional alterations. CPR:falsenewlineIn particular, nitrosylation promoted BC6ENTC formation involving the pair of catalytic BC6OTHER ( BC6OTHER - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6ENTG , leading to loss of BC6OTHER activity. CPR:falsenewlineIn particular, nitrosylation promoted BC6ENTC formation involving the pair of catalytic BC6OTHER ( BC6OTHER - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6OTHER , leading to loss of BC6ENTG activity. CPR:falsenewlineIn particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6ENTC ( BC6OTHER - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6ENTG , leading to loss of BC6OTHER activity. CPR:falsenewlineIn particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6ENTC ( BC6OTHER - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6OTHER , leading to loss of BC6ENTG activity. CPR:falsenewlineIn particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6OTHER ( BC6ENTC - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6ENTG , leading to loss of BC6OTHER activity. CPR:falsenewlineIn particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6OTHER ( BC6ENTC - 52 and BC6OTHER - 173) and disrupted the oligomeric structure of BC6OTHER , leading to loss of BC6ENTG activity. CPR:falsenewlineIn particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6OTHER ( BC6OTHER - 52 and BC6ENTC - 173) and disrupted the oligomeric structure of BC6ENTG , leading to loss of BC6OTHER activity. CPR:falsenewlineIn particular, nitrosylation promoted BC6OTHER formation involving the pair of catalytic BC6OTHER ( BC6OTHER - 52 and BC6ENTC - 173) and disrupted the oligomeric structure of BC6OTHER , leading to loss of BC6ENTG activity. CPR:falsenewlineA highly potent inhibition of the BC6ENTG catalytic reaction by BC6ENTC / BC6OTHER was seen in assays employing the coupled BC6OTHER - BC6OTHER system. CPR:4newlineA highly potent inhibition of the BC6OTHER catalytic reaction by BC6ENTC / BC6OTHER was seen in assays employing the coupled BC6ENTG - BC6OTHER system. CPR:4newlineA highly potent inhibition of the BC6OTHER catalytic reaction by BC6ENTC / BC6OTHER was seen in assays employing the coupled BC6OTHER - BC6ENTG system. CPR:4newlineA highly potent inhibition of the BC6ENTG catalytic reaction by BC6OTHER / BC6ENTC was seen in assays employing the coupled BC6OTHER - BC6OTHER system. CPR:4newlineA highly potent inhibition of the BC6OTHER catalytic reaction by BC6OTHER / BC6ENTC was seen in assays employing the coupled BC6ENTG - BC6OTHER system. CPR:falsenewlineA highly potent inhibition of the BC6OTHER catalytic reaction by BC6OTHER / BC6ENTC was seen in assays employing the coupled BC6OTHER - BC6ENTG system. CPR:4newlineIn this setting, BC6ENTC (10 μm) effectively blocked the BC6ENTG - mediated regeneration of BC6OTHER . CPR:falsenewlineIn this setting, BC6ENTC (10 μm) effectively blocked the BC6OTHER - mediated regeneration of BC6ENTG . CPR:falsenewlineThis effect appeared to be due to both competition between BC6ENTC and BC6ENTG for the BC6OTHER system and direct modulation by BC6OTHER of BC6OTHER activity. CPR:falsenewlineThis effect appeared to be due to both competition between BC6ENTC and BC6OTHER for the BC6ENTG system and direct modulation by BC6OTHER of BC6OTHER activity. CPR:falsenewlineThis effect appeared to be due to both competition between BC6ENTC and BC6OTHER for the BC6OTHER system and direct modulation by BC6OTHER of BC6ENTG activity. CPR:falsenewlineThis effect appeared to be due to both competition between BC6OTHER and BC6ENTG for the BC6OTHER system and direct modulation by BC6ENTC of BC6OTHER activity. CPR:falsenewlineThis effect appeared to be due to both competition between BC6OTHER and BC6OTHER for the BC6ENTG system and direct modulation by BC6ENTC of BC6OTHER activity. CPR:falsenewlineThis effect appeared to be due to both competition between BC6OTHER and BC6OTHER for the BC6OTHER system and direct modulation by BC6ENTC of BC6ENTG activity. CPR:falsenewlineOur findings that BC6ENTC / BC6OTHER target both BC6ENTG and BC6OTHER may have implications for understanding the impact of nitrosylation on cellular redox homeostasis. CPR:falsenewlineOur findings that BC6ENTC / BC6OTHER target both BC6OTHER and BC6ENTG may have implications for understanding the impact of nitrosylation on cellular redox homeostasis. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) specific for BC6ENTG kinase. CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineBC6ENTC kinases ( BC6ENTG ) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ), and BC6OTHER ( BC6OTHER , BC6OTHER ). CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6ENTC ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6ENTC ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6ENTC ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6ENTC ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6ENTC ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6ENTC ( BC6OTHER , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6ENTC , BC6OTHER ). CPR:falsenewlineThe following BC6ENTG blockers for treatment of various human tumors are in clinical development: BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ), and BC6OTHER ( BC6OTHER , BC6ENTC ). CPR:falsenewlineDuring the last few years, thorough analysis of the mechanism underlying BC6ENTC kinase's activity led to novel cancer therapy using BC6ENTG blockers. CPR:falsenewlineThe most successful example of BC6ENTG blockers is BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ), the inhibitor of BC6OTHER / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:4newlineThe most successful example of BC6OTHER blockers is BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ), the inhibitor of BC6ENTG / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:falsenewlineThe most successful example of BC6OTHER blockers is BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ), the inhibitor of BC6OTHER / BC6ENTG oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:falsenewlineThe most successful example of BC6ENTG blockers is BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ), the inhibitor of BC6OTHER / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:falsenewlineThe most successful example of BC6OTHER blockers is BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ), the inhibitor of BC6ENTG / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:falsenewlineThe most successful example of BC6OTHER blockers is BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ), the inhibitor of BC6OTHER / BC6ENTG oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:falsenewlineThe most successful example of BC6ENTG blockers is BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ), the inhibitor of BC6OTHER / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:falsenewlineThe most successful example of BC6OTHER blockers is BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ), the inhibitor of BC6ENTG / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:falsenewlineThe most successful example of BC6OTHER blockers is BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ), the inhibitor of BC6OTHER / BC6ENTG oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:falsenewlineThe most successful example of BC6ENTG blockers is BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ), the inhibitor of BC6OTHER / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:falsenewlineThe most successful example of BC6OTHER blockers is BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ), the inhibitor of BC6ENTG / BC6OTHER oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:falsenewlineThe most successful example of BC6OTHER blockers is BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ), the inhibitor of BC6OTHER / BC6ENTG oncoprotein, which has become a first - line therapy for chronic myelogenous leukemia. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6ENTC ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6ENTC ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6ENTC ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER , BC6OTHER ) specific for BC6ENTG BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6OTHER kinase. CPR:falsenewlineOthers kinase inhibitors used recently in cancer therapy include BC6OTHER ( BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER , BC6OTHER ) specific for BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) specific for BC6ENTG kinase. CPR:falsenewlineExtracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6ENTC ) bound to BC6ENTG ( BC6OTHER , BC6OTHER ). CPR:falsenewlineExtracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6ENTC ) bound to BC6OTHER ( BC6ENTG , BC6OTHER ). CPR:falsenewlineExtracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6ENTC ) bound to BC6OTHER ( BC6OTHER , BC6ENTG ). CPR:falsenewlineIntracellular protein - bound BC6ENTC fractionated with BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activity. CPR:falsenewlineIntracellular protein - bound BC6ENTC fractionated with BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activity. CPR:falsenewlineIntracellular protein - bound BC6ENTC fractionated with BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activity. CPR:falsenewlineIntracellular protein - bound BC6ENTC fractionated with BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activity. CPR:falsenewlineIntracellular protein - bound BC6OTHER fractionated with BC6ENTC synthase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activity. CPR:falsenewlineIntracellular protein - bound BC6OTHER fractionated with BC6ENTC synthase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activity. CPR:falsenewlineIntracellular protein - bound BC6OTHER fractionated with BC6ENTC synthase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activity. CPR:falsenewlineIntracellular protein - bound BC6OTHER fractionated with BC6ENTG ( BC6OTHER ) and BC6ENTC mutase ( BC6OTHER ) activity. CPR:falsenewlineIntracellular protein - bound BC6OTHER fractionated with BC6OTHER ( BC6ENTG ) and BC6ENTC mutase ( BC6OTHER ) activity. CPR:falsenewlineIntracellular protein - bound BC6OTHER fractionated with BC6OTHER ( BC6OTHER ) and BC6ENTC mutase ( BC6ENTG ) activity. CPR:falsenewlineCells propagated in medium containing BC6ENTC and BC6OTHER showed a substantial increase in BC6ENTG activity which paralleled the increase in the intracellular concentration of BC6OTHER and the BC6OTHER bound to the enzyme. CPR:falsenewlineCells propagated in medium containing BC6OTHER and BC6ENTC showed a substantial increase in BC6ENTG activity which paralleled the increase in the intracellular concentration of BC6OTHER and the BC6OTHER bound to the enzyme. CPR:falsenewlineCells propagated in medium containing BC6OTHER and BC6OTHER showed a substantial increase in BC6ENTG activity which paralleled the increase in the intracellular concentration of BC6ENTC and the BC6OTHER bound to the enzyme. CPR:falsenewlineCells propagated in medium containing BC6OTHER and BC6OTHER showed a substantial increase in BC6ENTG activity which paralleled the increase in the intracellular concentration of BC6OTHER and the BC6ENTC bound to the enzyme. CPR:falsenewlineExtracellular BC6ENTC (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6ENTG ( BC6OTHER , BC6OTHER ). CPR:falsenewlineExtracellular BC6ENTC (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6OTHER ( BC6ENTG , BC6OTHER ). CPR:falsenewlineExtracellular BC6ENTC (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6OTHER ( BC6OTHER , BC6ENTG ). CPR:falsenewlineExtracellular BC6OTHER (protein bound and free) and intracellular BC6ENTC (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6ENTG ( BC6OTHER , BC6OTHER ). CPR:falsenewlineExtracellular BC6OTHER (protein bound and free) and intracellular BC6ENTC (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6OTHER ( BC6ENTG , BC6OTHER ). CPR:falsenewlineExtracellular BC6OTHER (protein bound and free) and intracellular BC6ENTC (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6OTHER ( BC6OTHER ) bound to BC6OTHER ( BC6OTHER , BC6ENTG ). CPR:falsenewlineExtracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6ENTC ( BC6OTHER ) bound to BC6ENTG ( BC6OTHER , BC6OTHER ). CPR:falsenewlineExtracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6ENTC ( BC6OTHER ) bound to BC6OTHER ( BC6ENTG , BC6OTHER ). CPR:falsenewlineExtracellular BC6OTHER (protein bound and free) and intracellular BC6OTHER (protein bound and free) were determined after culturing L - 1210 cells in the presence of BC6ENTC ( BC6OTHER ) bound to BC6OTHER ( BC6OTHER , BC6ENTG ). CPR:falsenewlineBC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6ENTC (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6ENTC (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6ENTC (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6ENTC (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6ENTC ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6ENTC ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6ENTC ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6ENTC ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTC reductase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTC reductase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTC reductase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6ENTC peroxidase ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6ENTC peroxidase ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTC peroxidase ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6ENTC - Px) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6ENTC - Px) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6ENTC - Px) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6ENTC ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6ENTC ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6ENTC ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6ENTC ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6ENTC ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6ENTC ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6ENTC ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6ENTC ) level, as well as BC6OTHER ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6ENTC ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6ENTC ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6ENTC ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6ENTC ( BC6OTHER ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6ENTC ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6ENTC ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6ENTC ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6ENTC ) and BC6OTHER modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6ENTC and total - BC6OTHER content, BC6OTHER / BC6OTHER ratio, BC6ENTG activity significantly decreased in cerebral cortex of rats, coupling with the increase of BC6OTHER level. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6ENTC modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6ENTC modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6ENTC modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and total BC6OTHER (total - BC6OTHER ) content, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities, BC6OTHER ( BC6OTHER ) level, as well as BC6OTHER ( BC6OTHER ) and BC6ENTC modified proteins in homogenates of cerebral cortex were measured. CPR:falsenewlineBC6OTHER and total - BC6ENTC content, BC6OTHER / BC6OTHER ratio, BC6ENTG activity significantly decreased in cerebral cortex of rats, coupling with the increase of BC6OTHER level. CPR:falsenewlineBC6OTHER and total - BC6OTHER content, BC6ENTC / BC6OTHER ratio, BC6ENTG activity significantly decreased in cerebral cortex of rats, coupling with the increase of BC6OTHER level. CPR:falsenewlineBC6OTHER and total - BC6OTHER content, BC6OTHER / BC6ENTC ratio, BC6ENTG activity significantly decreased in cerebral cortex of rats, coupling with the increase of BC6OTHER level. CPR:falsenewlineBC6OTHER and total - BC6OTHER content, BC6OTHER / BC6OTHER ratio, BC6ENTG activity significantly decreased in cerebral cortex of rats, coupling with the increase of BC6ENTC level. CPR:falsenewlineNevertheless, BC6ENTG is involved in the expression of genes that control BC6ENTC and lipid metabolism and is an important target for drugs against type 2 diabetes, dyslipidemia, atherosclerosis, and cardiovascular disease. CPR:falsenewlineFull agonists to the BC6ENTG , such as BC6ENTC , have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity. CPR:5newlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6ENTG - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6ENTG ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6ENTG - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6ENTG ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6ENTG - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6ENTG ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of BC6ENTG ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6ENTG , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6ENTG ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6ENTG - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6ENTG ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTC (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6ENTG agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTG modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6ENTG - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6ENTG ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6ENTG - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6ENTG ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6ENTG - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6ENTG ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of BC6ENTG ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6ENTG , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6ENTG ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6ENTG - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6ENTG ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6ENTC ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6ENTG agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTG modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6ENTG - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6ENTG ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6ENTG - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6ENTG ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6ENTG - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6ENTG ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of BC6ENTG ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6ENTG , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6ENTG ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6ENTG - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6ENTG ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6ENTC antagonist, or modulators of metabotropic BC6OTHER receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6ENTG agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6ENTG modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6ENTG - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6ENTG ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6ENTG - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6ENTG ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6ENTG - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6ENTG ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6ENTG , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6ENTG ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6ENTG - BC6OTHER ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6ENTG ) or BC6OTHER agonist in PPC. CPR:falsenewlineResults from microinfusion studies show that anticonvulsant efficacy is obtained by BC6OTHER (A) modulators or cholinergic antagonists ( BC6OTHER - BC6OTHER ) in AT, cholinergic antagonists ( BC6OTHER - BC6OTHER ) in MS, combined glutamatergic ( BC6OTHER ) and cholinergic antagonist ( BC6OTHER - BC6OTHER ), BC6OTHER antagonist, or modulators of metabotropic BC6ENTC receptors ( BC6OTHER , BC6OTHER ) in PRC, and cholinergic antagonist ( BC6OTHER - BC6OTHER ) or BC6ENTG agonist in PPC. CPR:falsenewlineThe recently discovered BC6ENTC enzyme " BC6ENTG " ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6ENTC enzyme "mitochondrial BC6OTHER Reducing Component" ( BC6ENTG ) catalyses together with its BC6OTHER BC6OTHER and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6ENTC enzyme "mitochondrial BC6OTHER Reducing Component" ( BC6OTHER ) catalyses together with its BC6ENTG BC6OTHER and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6ENTC enzyme "mitochondrial BC6OTHER Reducing Component" ( BC6OTHER ) catalyses together with its BC6OTHER BC6ENTG and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6ENTC enzyme "mitochondrial BC6OTHER Reducing Component" ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6ENTG the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme "mitochondrial BC6ENTC Reducing Component" ( BC6ENTG ) catalyses together with its BC6OTHER BC6OTHER and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme "mitochondrial BC6ENTC Reducing Component" ( BC6OTHER ) catalyses together with its BC6ENTG BC6OTHER and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme "mitochondrial BC6ENTC Reducing Component" ( BC6OTHER ) catalyses together with its BC6OTHER BC6ENTG and BC6OTHER the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme "mitochondrial BC6ENTC Reducing Component" ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6ENTG the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme " BC6ENTG " ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6ENTC cytochrome b(5) reductase the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme "mitochondrial BC6OTHER Reducing Component" ( BC6ENTG ) catalyses together with its BC6OTHER BC6OTHER and BC6ENTC cytochrome b(5) reductase the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme "mitochondrial BC6OTHER Reducing Component" ( BC6OTHER ) catalyses together with its BC6ENTG BC6OTHER and BC6ENTC cytochrome b(5) reductase the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme "mitochondrial BC6OTHER Reducing Component" ( BC6OTHER ) catalyses together with its BC6OTHER BC6ENTG and BC6ENTC cytochrome b(5) reductase the reduction of BC6OTHER - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme " BC6ENTG " ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6OTHER the reduction of BC6ENTC - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme "mitochondrial BC6OTHER Reducing Component" ( BC6ENTG ) catalyses together with its BC6OTHER BC6OTHER and BC6OTHER the reduction of BC6ENTC - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme "mitochondrial BC6OTHER Reducing Component" ( BC6OTHER ) catalyses together with its BC6ENTG BC6OTHER and BC6OTHER the reduction of BC6ENTC - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme "mitochondrial BC6OTHER Reducing Component" ( BC6OTHER ) catalyses together with its BC6OTHER BC6ENTG and BC6OTHER the reduction of BC6ENTC - hydroxylated prodrugs. CPR:falsenewlineThe recently discovered BC6OTHER enzyme "mitochondrial BC6OTHER Reducing Component" ( BC6OTHER ) catalyses together with its BC6OTHER BC6OTHER and BC6ENTG the reduction of BC6ENTC - hydroxylated prodrugs. CPR:falsenewlineIn vitro biotransformation assays with porcine subcellular fractions and the reconstituted human enzymes demonstrate an BC6ENTG - dependent BC6ENTC - reduction of BC6OTHER . CPR:9newlineActivation of the anti - cancer agent BC6ENTC by the BC6ENTG enzyme system. CPR:falsenewlineIn vitro biotransformation assays with porcine subcellular fractions and the reconstituted human enzymes demonstrate an BC6ENTG - dependent BC6OTHER - reduction of BC6ENTC . CPR:9newlineBC6ENTC ( BC6OTHER ®) is a new small molecule BC6ENTG inhibitor. CPR:4newlineBC6OTHER ( BC6ENTC ®) is a new small molecule BC6ENTG inhibitor. CPR:falsenewlineThe effect of BC6ENTC level on this end - point was modulated by the BC6ENTG genotype (P for interaction = 0.02), with TT cells grown at low BC6OTHER concentration apparently resistant to the induction of radiation - induced bridges. CPR:falsenewlineThe effect of BC6OTHER level on this end - point was modulated by the BC6ENTG genotype (P for interaction = 0.02), with TT cells grown at low BC6ENTC concentration apparently resistant to the induction of radiation - induced bridges. CPR:falsenewlineThe BC6ENTG polymorphism of the BC6ENTC reductase ( BC6OTHER ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on BC6OTHER status. CPR:falsenewlineThe BC6OTHER polymorphism of the BC6ENTC reductase ( BC6ENTG ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on BC6OTHER status. CPR:falsenewlineThe BC6ENTG polymorphism of the BC6OTHER ( BC6OTHER ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on BC6ENTC status. CPR:falsenewlineThe BC6OTHER polymorphism of the BC6ENTG ( BC6OTHER ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on BC6ENTC status. CPR:falsenewlineThe BC6OTHER polymorphism of the BC6OTHER ( BC6ENTG ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on BC6ENTC status. CPR:falsenewlineIn this work the effect of BC6ENTC deficiency on genome stability and radiosensitivity has been investigated in cultured lymphocytes of 12 subjects with different BC6ENTG genotype (four for each genotype). CPR:falsenewlineEffects of BC6ENTC deficiency and BC6ENTG BC6OTHER polymorphism on spontaneous and radiation - induced micronuclei in human lymphocytes. CPR:falsenewlineEffects of BC6ENTC deficiency and BC6OTHER BC6ENTG polymorphism on spontaneous and radiation - induced micronuclei in human lymphocytes. CPR:falsenewlineThe results obtained indicate that BC6ENTC deficiency induces to a comparable extent chromosome loss and breakage, irrespective of the BC6ENTG genotype. CPR:falsenewlineAlso nucleoplasmic bridges and buds were significantly increased under low BC6ENTC supply; the increase in bridges was mainly observed in TT cells, highlighting a significant effect of the BC6ENTG genotype (P = 0.006) on this biomarker. CPR:falsenewlineBC6ENTC concentration significantly affected radiation - induced micronuclei (P < 0.001): the increased incidence of radiation - induced micronuclei with low BC6OTHER was mainly accounted for by carriers of the variant BC6ENTG allele (both homozygotes and heterozygotes), but the overall effect of genotype did not attain statistical significance. CPR:falsenewlineBC6OTHER concentration significantly affected radiation - induced micronuclei (P < 0.001): the increased incidence of radiation - induced micronuclei with low BC6ENTC was mainly accounted for by carriers of the variant BC6ENTG allele (both homozygotes and heterozygotes), but the overall effect of genotype did not attain statistical significance. CPR:falsenewlineA cDNA clone similar to human BC6ENTC dehydratase ( BC6ENTG ) is deposited in the GenBank / EMBL databases, but its structural and functional bases remain unknown. CPR:falsenewlineThe purified protein showed BC6ENTC and BC6OTHER dehydratase activity, demonstrating to be an isoform of BC6ENTG . CPR:falsenewlineThe purified protein showed BC6OTHER and BC6ENTC dehydratase activity, demonstrating to be an isoform of BC6ENTG . CPR:falsenewlineRemoval of CHEM128 from the hepatic BC6ENTG consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for BC6ENTC , whereas addition of a BC6OTHER residue to the isoform was without effect. CPR:falsenewlineRemoval of CHEM128 from the hepatic BC6ENTG consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for BC6OTHER , whereas addition of a BC6ENTC residue to the isoform was without effect. CPR:falsenewline BC6OTHER and nonsteroidal anti - inflammatory drugs induce conformational changes in the human BC6ENTC synthase - 2 ( BC6ENTG ). CPR:falsenewlineBy using the technique of site - directed spin labeling combined with EPR spectroscopy, we have observed that binding of BC6ENTC and nonsteroidal anti - inflammatory drugs induces conformational changes in the BC6ENTG ( BC6OTHER ). CPR:falsenewlineBy using the technique of site - directed spin labeling combined with EPR spectroscopy, we have observed that binding of BC6ENTC and nonsteroidal anti - inflammatory drugs induces conformational changes in the human BC6OTHER synthase enzyme ( BC6ENTG ). CPR:falsenewlineProteolysis protection assays had previously provided circumstantial evidence that binding of CHEM and non - BC6ENTC anti - inflammatory drugs alters the conformation of BC6ENTG , but the present experiments are the first to directly measure such changes. CPR:falsenewlineThe finding that BC6ENTC can also induce a conformational change in BC6ENTG was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the BC6OTHER catalytic mechanism. CPR:falsenewlineThe finding that BC6ENTC can also induce a conformational change in BC6OTHER was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the BC6ENTG catalytic mechanism. CPR:falsenewlineBy using the technique of site - directed spin labeling combined with EPR spectroscopy, we have observed that binding of BC6OTHER and nonsteroidal anti - inflammatory drugs induces conformational changes in the human BC6ENTC synthase enzyme ( BC6ENTG ). CPR:falsenewlineLine shape broadening resulting from spin - spin coupling of BC6ENTC pairs introduced into the membrane - binding helices of BC6ENTG was used to calculate the inter - helical distances and changes in these distances that occur in response to binding various ligands. CPR:falsenewlineHowever, inter - helical distances calculated and determined by EPR for BC6ENTG complexed with BC6ENTC , BC6OTHER , and BC6OTHER were in close agreement with those obtained from the cognate crystal structures. CPR:falsenewlineHowever, inter - helical distances calculated and determined by EPR for BC6ENTG complexed with BC6OTHER , BC6ENTC , and BC6OTHER were in close agreement with those obtained from the cognate crystal structures. CPR:falsenewlineHowever, inter - helical distances calculated and determined by EPR for BC6ENTG complexed with BC6OTHER , BC6OTHER , and BC6ENTC were in close agreement with those obtained from the cognate crystal structures. CPR:falsenewline BC6ENTC and nonsteroidal anti - inflammatory drugs induce conformational changes in the human BC6OTHER synthase - 2 ( BC6ENTG ). CPR:falsenewline BC6ENTC and nonsteroidal anti - inflammatory drugs induce conformational changes in the BC6ENTG ( BC6OTHER ). CPR:falsenewlineWe found that BC6ENTC NPs were highly cytotoxic to hepatocytes (LC(50) BC6ENTG : 2.5 μg / cm(2)) and affected hepatocyte homeostasis by reducing BC6OTHER release. CPR:falsenewlineWe found that BC6ENTC NPs were highly cytotoxic to hepatocytes (LC(50) BC6OTHER dehydrogenase: 2.5 μg / cm(2)) and affected hepatocyte homeostasis by reducing BC6ENTG release. CPR:falsenewlineWe found that BC6OTHER NPs were highly cytotoxic to hepatocytes (LC(50) BC6ENTC dehydrogenase: 2.5 μg / cm(2)) and affected hepatocyte homeostasis by reducing BC6ENTG release. CPR:falsenewlineWe observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6ENTG ( BC6OTHER ) / BC6OTHER , BC6OTHER , and BC6OTHER expression in both models and increased BC6OTHER protein release in vitro. CPR:falsenewlineWe observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6OTHER ( BC6ENTG ) / BC6OTHER , BC6OTHER , and BC6OTHER expression in both models and increased BC6OTHER protein release in vitro. CPR:falsenewlineWe observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6OTHER ( BC6OTHER ) / BC6ENTG , BC6OTHER , and BC6OTHER expression in both models and increased BC6OTHER protein release in vitro. CPR:falsenewlineWe observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6OTHER ( BC6OTHER ) / BC6OTHER , BC6ENTG , and BC6OTHER expression in both models and increased BC6OTHER protein release in vitro. CPR:falsenewlineWe observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6OTHER ( BC6OTHER ) / BC6OTHER , BC6OTHER , and BC6ENTG expression in both models and increased BC6OTHER protein release in vitro. CPR:falsenewlineWe observed similar effects of BC6ENTC NPs on inflammatory mediator expression in vitro and in vivo with increase of BC6OTHER ( BC6OTHER ) / BC6OTHER , BC6OTHER , and BC6OTHER expression in both models and increased BC6ENTG protein release in vitro. CPR:falsenewlineTreatment with BC6OTHER ( BC6OTHER ), an inhibitor of transmethylation - suppressive BC6ENTC ( BC6OTHER ) hydrolase ( BC6ENTG ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner. CPR:falsenewlineTreatment with BC6OTHER ( BC6OTHER ), an inhibitor of transmethylation - suppressive CHEM ( BC6ENTC ) hydrolase ( BC6ENTG ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner. CPR:falsenewlineTreatment with BC6OTHER ( BC6OTHER ), an inhibitor of transmethylation - suppressive BC6ENTG ( BC6OTHER ), enhanced the level of BC6ENTC and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner. CPR:falsenewlineTreatment with BC6OTHER ( BC6OTHER ), an inhibitor of transmethylation - suppressive CHEM ( BC6OTHER ) hydrolase ( BC6ENTG ), enhanced the level of BC6ENTC and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner. CPR:falsenewlineThrough immunoblotting analysis, it was found that BC6ENTC was capable of indirectly diminishing the phosphorylation of oncogenic BC6ENTG and its BC6OTHER activity. CPR:4newlineThrough immunoblotting analysis, it was found that BC6ENTC was capable of indirectly diminishing the phosphorylation of oncogenic BC6OTHER and its BC6ENTG activity. CPR:4newlineInvolvement of BC6ENTG and the BC6OTHER cytoskeleton in the antitumorigenic action of BC6ENTC . CPR:falsenewlineInvolvement of BC6OTHER and the BC6ENTG cytoskeleton in the antitumorigenic action of BC6ENTC . CPR:falsenewlineInterestingly, BC6ENTC disrupted BC6ENTG cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of BC6OTHER and BC6OTHER / BC6OTHER , which is linked to various tumorigenic responses. CPR:falsenewlineInterestingly, BC6ENTC disrupted BC6OTHER cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of BC6ENTG and BC6OTHER / BC6OTHER , which is linked to various tumorigenic responses. CPR:4newlineInterestingly, BC6ENTC disrupted BC6OTHER cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of BC6OTHER and BC6ENTG / BC6OTHER , which is linked to various tumorigenic responses. CPR:4newlineInterestingly, BC6ENTC disrupted BC6OTHER cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of BC6OTHER and BC6OTHER / BC6ENTG , which is linked to various tumorigenic responses. CPR:4newlineIn agreement with these data, the exogenous treatment of BC6ENTC or inhibition of BC6ENTG by specific siRNA or another type of inhibitor, BC6OTHER ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6ENTC or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6ENTG , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6ENTC or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6ENTG cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6ENTC or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6ENTG and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6ENTC or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6ENTG . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6ENTG by specific siRNA or another type of inhibitor, BC6ENTC ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6ENTC ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6ENTG , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6ENTC ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6ENTG cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6ENTC ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6ENTG and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6ENTC ( BC6OTHER ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6ENTG . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6ENTG by specific siRNA or another type of inhibitor, BC6OTHER ( BC6ENTC ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6ENTC ), similarly resulted in antitumorigenic responses, suppressive activity on BC6ENTG , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6ENTC ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6ENTG cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6ENTC ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6ENTG and BC6OTHER . CPR:falsenewlineIn agreement with these data, the exogenous treatment of BC6OTHER or inhibition of BC6OTHER by specific siRNA or another type of inhibitor, BC6OTHER ( BC6ENTC ), similarly resulted in antitumorigenic responses, suppressive activity on BC6OTHER , the alteration of BC6OTHER cytoskeleton, and a change of the colocalization pattern between BC6OTHER and BC6ENTG . CPR:falsenewlineTaken together, these results suggest that BC6ENTC / BC6ENTG - mediated transmethylation could be linked to the tumorigenic processes through cross - regulation between the BC6OTHER cytoskeleton and BC6OTHER BC6OTHER activity. CPR:falsenewlineTaken together, these results suggest that BC6ENTC / BC6OTHER - mediated transmethylation could be linked to the tumorigenic processes through cross - regulation between the BC6ENTG cytoskeleton and BC6OTHER BC6OTHER activity. CPR:falsenewlineTaken together, these results suggest that BC6ENTC / BC6OTHER - mediated transmethylation could be linked to the tumorigenic processes through cross - regulation between the BC6OTHER cytoskeleton and BC6ENTG BC6OTHER activity. CPR:falsenewlineTaken together, these results suggest that BC6ENTC / BC6OTHER - mediated transmethylation could be linked to the tumorigenic processes through cross - regulation between the BC6OTHER cytoskeleton and BC6OTHER BC6ENTG activity. CPR:falsenewlineTreatment with BC6ENTC ( BC6OTHER ), an inhibitor of transmethylation - suppressive BC6ENTG ( BC6OTHER ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner. CPR:falsenewlineTreatment with BC6ENTC ( BC6OTHER ), an inhibitor of transmethylation - suppressive CHEM ( BC6OTHER ) hydrolase ( BC6ENTG ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner. CPR:falsenewlineTreatment with BC6OTHER ( BC6ENTC ), an inhibitor of transmethylation - suppressive BC6ENTG ( BC6OTHER ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner. CPR:falsenewlineTreatment with BC6OTHER ( BC6ENTC ), an inhibitor of transmethylation - suppressive CHEM ( BC6OTHER ) hydrolase ( BC6ENTG ), enhanced the level of BC6OTHER and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose - dependent manner. CPR:falsenewlineBC6ENTG - regulated expression of these enzymes leads to an increase in the intracellular generation of BC6OTHER ( BC6OTHER ) from BC6ENTC . CPR:falsenewlineBC6ENTC regulates gene expression via the activation of the BC6ENTG in human DCs, and BC6OTHER acutely regulates BC6OTHER expression. CPR:falsenewlineBC6ENTC regulates gene expression via the activation of the BC6OTHER in human DCs, and BC6ENTG acutely regulates BC6OTHER expression. CPR:falsenewlineBC6ENTC regulates gene expression via the activation of the BC6OTHER in human DCs, and BC6OTHER acutely regulates BC6ENTG expression. CPR:falsenewlineBC6OTHER regulates gene expression via the activation of the BC6ENTC receptor (RAR)alpha in human DCs, and BC6ENTG acutely regulates BC6OTHER expression. CPR:falsenewlineBC6OTHER regulates gene expression via the activation of the BC6ENTC receptor (RAR)alpha in human DCs, and BC6OTHER acutely regulates BC6ENTG expression. CPR:falsenewlineThe BC6ENTC - induced elevated expression of BC6ENTG is coupled to enhanced iNKT cell activation. CPR:falsenewline BC6ENTG controls BC6OTHER expression by turning on BC6ENTC synthesis in developing human dendritic cells. CPR:falsenewline BC6OTHER controls BC6ENTG expression by turning on BC6ENTC synthesis in developing human dendritic cells. CPR:falsenewlineFurthermore, in vivo relevant lipids such as oxidized low - density lipoprotein can also elicit BC6ENTC signaling leading to BC6ENTG up - regulation. CPR:falsenewlineThese data show that regulation of BC6ENTC metabolism and signaling is part of the BC6ENTG - controlled transcriptional events in DCs. CPR:falsenewlineHere we demonstrate that BC6ENTG , turns on BC6ENTC synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6OTHER ). CPR:3newlineHere we demonstrate that BC6OTHER , turns on BC6ENTC synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6ENTG and BC6OTHER dehydrogenase type 2 ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6ENTC synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6ENTG ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6ENTC synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6ENTG ). CPR:falsenewlineHere we demonstrate that BC6ENTG , turns on BC6OTHER synthesis by inducing the expression of BC6ENTC and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6ENTC and BC6OTHER metabolizing enzymes such as BC6ENTG and BC6OTHER dehydrogenase type 2 ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6ENTC and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6ENTG ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6ENTC and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6ENTG ). CPR:falsenewlineHere we demonstrate that BC6ENTG , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6ENTC metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6ENTC metabolizing enzymes such as BC6ENTG and BC6OTHER dehydrogenase type 2 ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6ENTC metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6ENTG ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6ENTC metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6ENTG ). CPR:9newlineHere we demonstrate that BC6ENTG , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6ENTC dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6ENTC dehydrogenase 10 and BC6ENTG ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6ENTC dehydrogenase 10 and BC6OTHER dehydrogenase type 2 ( BC6ENTG ). CPR:falsenewlineHere we demonstrate that BC6ENTG , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6ENTC dehydrogenase type 2 ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6ENTG and BC6ENTC dehydrogenase type 2 ( BC6OTHER ). CPR:falsenewlineHere we demonstrate that BC6OTHER , turns on BC6OTHER synthesis by inducing the expression of BC6OTHER and BC6OTHER metabolizing enzymes such as BC6OTHER dehydrogenase 10 and BC6ENTC dehydrogenase type 2 ( BC6ENTG ). CPR:falsenewlineBC6ENTG - regulated expression of these enzymes leads to an increase in the intracellular generation of BC6ENTC ( BC6OTHER ) from BC6OTHER . CPR:falsenewlineBC6ENTG - regulated expression of these enzymes leads to an increase in the intracellular generation of BC6OTHER ( BC6ENTC ) from BC6OTHER . CPR:falsenewlinePreviously, we and others have shown that mutations in the BC6ENTG gene encoding an BC6ENTC - binding cassette (ABC) transporter underlie the skin disease HI. CPR:falsenewlineMoreover, GTC - treated groups showed lower levels of total BC6ENTC and BC6ENTG BC6OTHER , whereas the level of BC6OTHER BC6OTHER increased. CPR:falsenewlineMoreover, GTC - treated groups showed lower levels of total BC6ENTC and BC6OTHER BC6OTHER , whereas the level of BC6ENTG BC6OTHER increased. CPR:falsenewlineMoreover, GTC - treated groups showed lower levels of total BC6OTHER and BC6ENTG BC6ENTC , whereas the level of BC6OTHER BC6OTHER increased. CPR:falsenewlineMoreover, GTC - treated groups showed lower levels of total BC6OTHER and BC6OTHER BC6ENTC , whereas the level of BC6ENTG BC6OTHER increased. CPR:falsenewlineMoreover, GTC - treated groups showed lower levels of total BC6OTHER and BC6ENTG BC6OTHER , whereas the level of BC6OTHER BC6ENTC increased. CPR:falsenewlineMoreover, GTC - treated groups showed lower levels of total BC6OTHER and BC6OTHER BC6OTHER , whereas the level of BC6ENTG BC6ENTC increased. CPR:falsenewlineGreen tea BC6ENTC leads to global improvement among Alzheimer's disease - related phenotypes in BC6OTHER / BC6OTHER - BC6ENTG Tg mice. CPR:falsenewlineGreen tea BC6ENTC leads to global improvement among Alzheimer's disease - related phenotypes in BC6ENTG / BC6OTHER - BC6OTHER Tg mice. CPR:falsenewlineGreen tea BC6ENTC leads to global improvement among Alzheimer's disease - related phenotypes in BC6OTHER / BC6ENTG - BC6OTHER Tg mice. CPR:falsenewlineAll GCs including the antagonistic compound BC6ENTC efficiently reduced BC6ENTG - mediated transactivation to comparable extents, suggesting that ligand - induced nuclear localization of the BC6OTHER is sufficient for transrepression. CPR:falsenewlineAll GCs including the antagonistic compound BC6ENTC efficiently reduced BC6OTHER - mediated transactivation to comparable extents, suggesting that ligand - induced nuclear localization of the BC6ENTG is sufficient for transrepression. CPR:falsenewlineOur findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD. CPR:falsenewlineOur findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD. CPR:falsenewlineOur findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD. CPR:falsenewlineOur findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD. CPR:falsenewlineOur findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD. CPR:falsenewlineOur findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) on bronchodilatory response to anticholinergic agents in patients with COPD. CPR:falsenewlineOur findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) on bronchodilatory response to anticholinergic agents in patients with COPD. CPR:falsenewlineBC6ENTC ( BC6OTHER [ BC6OTHER ]) might be an effective therapy in this case, since BC6OTHER targets both BC6ENTG and BC6OTHER oncoproteins. CPR:falsenewlineBC6ENTC ( BC6OTHER [ BC6OTHER ]) might be an effective therapy in this case, since BC6OTHER targets both BC6OTHER and BC6ENTG oncoproteins. CPR:falsenewlineBC6OTHER ( BC6ENTC [ BC6OTHER ]) might be an effective therapy in this case, since BC6OTHER targets both BC6ENTG and BC6OTHER oncoproteins. CPR:falsenewlineBC6OTHER ( BC6ENTC [ BC6OTHER ]) might be an effective therapy in this case, since BC6OTHER targets both BC6OTHER and BC6ENTG oncoproteins. CPR:falsenewlineBC6OTHER ( BC6OTHER [ BC6ENTC ]) might be an effective therapy in this case, since BC6OTHER targets both BC6ENTG and BC6OTHER oncoproteins. CPR:falsenewlineBC6OTHER ( BC6OTHER [ BC6ENTC ]) might be an effective therapy in this case, since BC6OTHER targets both BC6OTHER and BC6ENTG oncoproteins. CPR:falsenewlineBC6OTHER ( BC6OTHER [ BC6OTHER ]) might be an effective therapy in this case, since BC6ENTC targets both BC6ENTG and BC6OTHER oncoproteins. CPR:falsenewlineBC6OTHER ( BC6OTHER [ BC6OTHER ]) might be an effective therapy in this case, since BC6ENTC targets both BC6OTHER and BC6ENTG oncoproteins. CPR:falsenewlineA series of BC6ENTG inhibitors have been identified based upon a BC6ENTC scaffold using structure - based drug design methods. CPR:falsenewlineSynthesis of derivatives of BC6ENTC and their inhibitory activities against BC6OTHER ( BC6ENTG ). CPR:4newlineSynthesis of derivatives of BC6ENTC and their inhibitory activities against BC6ENTG ( BC6OTHER ). CPR:4newlineAs BC6OTHER undergoes BC6ENTC - dependent co - oxygenation catalyzed by BC6ENTG , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6OTHER . CPR:falsenewlineAs BC6OTHER undergoes BC6ENTC - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6ENTG and BC6OTHER . CPR:falsenewlineAs BC6OTHER undergoes BC6ENTC - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6ENTG . CPR:falsenewlineAs BC6OTHER undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6ENTG , we propose that it is an oxygenated derivative of BC6ENTC , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6OTHER . CPR:falsenewlineAs BC6OTHER undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6ENTC , rather than the parent compound, which is responsible for the inactivation of BC6ENTG and BC6OTHER . CPR:falsenewlineAs BC6OTHER undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6ENTC , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6ENTG . CPR:falsenewlineAs BC6OTHER undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6ENTG , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6ENTC synthase. CPR:falsenewlineAs BC6OTHER undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6ENTG and BC6ENTC synthase. CPR:falsenewlineBC6OTHER ( BC6ENTC ), a nonsteroidal anti - inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6OTHER ( BC6ENTC ), a nonsteroidal anti - inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of BC6OTHER synthase ( BC6ENTG ). CPR:falsenewlineMost reducing cofactors for the peroxidase protect BC6ENTG and BC6ENTC synthase from inactivation by BC6OTHER . CPR:falsenewlineMost reducing cofactors for the peroxidase protect BC6ENTG and BC6OTHER from inactivation by BC6ENTC . CPR:4newlineMost reducing cofactors for the peroxidase protect BC6OTHER and BC6ENTG from inactivation by BC6ENTC . CPR:4newlineBC6ENTC ( BC6OTHER ), a nonsteroidal anti - inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6ENTC ( BC6OTHER ), a nonsteroidal anti - inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of BC6OTHER synthase ( BC6ENTG ). CPR:falsenewlineUsing ram seminal vesicle microsomes as a source of BC6ENTG and BC6ENTC synthase, we have examined the interaction of BC6OTHER and exogenous BC6OTHER . CPR:falsenewlineUsing ram seminal vesicle microsomes as a source of BC6ENTG and BC6OTHER , we have examined the interaction of BC6ENTC and exogenous BC6OTHER . CPR:falsenewlineUsing ram seminal vesicle microsomes as a source of BC6OTHER and BC6ENTG , we have examined the interaction of BC6ENTC and exogenous BC6OTHER . CPR:falsenewlineUsing ram seminal vesicle microsomes as a source of BC6ENTG and BC6OTHER , we have examined the interaction of BC6OTHER and exogenous BC6ENTC . CPR:falsenewlineUsing ram seminal vesicle microsomes as a source of BC6OTHER and BC6ENTG , we have examined the interaction of BC6OTHER and exogenous BC6ENTC . CPR:falsenewlineChromatographic analysis of the metabolism of BC6ENTC in this system revealed that BC6OTHER - dependent inactivation of BC6ENTG is markedly increased in the presence of 100 microM BC6OTHER . CPR:falsenewlineChromatographic analysis of the metabolism of BC6OTHER in this system revealed that BC6ENTC - dependent inactivation of BC6ENTG is markedly increased in the presence of 100 microM BC6OTHER . CPR:falsenewlineChromatographic analysis of the metabolism of BC6OTHER in this system revealed that BC6OTHER - dependent inactivation of BC6ENTG is markedly increased in the presence of 100 microM BC6ENTC . CPR:falsenewlineBC6ENTG is even more sensitive to inactivation by the combined BC6OTHER and BC6OTHER treatment, with a corresponding half - maximal effect at BC6ENTC concentrations near 25 microM. CPR:4newlineBC6ENTG is even more sensitive to inactivation by the combined BC6ENTC and BC6OTHER treatment, with a corresponding half - maximal effect at BC6OTHER concentrations near 25 microM. CPR:4newlineBC6ENTG is even more sensitive to inactivation by the combined BC6OTHER and BC6ENTC treatment, with a corresponding half - maximal effect at BC6OTHER concentrations near 25 microM. CPR:4newlineInactivation of BC6ENTC synthase and BC6ENTG by BC6OTHER . CPR:falsenewlineInactivation of BC6ENTG and BC6ENTC synthase by BC6OTHER . CPR:falsenewlineInactivation of BC6ENTG and BC6OTHER by BC6ENTC . CPR:4newlineInactivation of BC6OTHER and BC6ENTG by BC6ENTC . CPR:4newlineThis BC6ENTC - and BC6OTHER - dependent inactivation is demonstrable whether BC6OTHER is generated in situ from BC6OTHER or is added exogenously, supporting a direct effect of the treatment on BC6ENTG . CPR:falsenewlineThis BC6OTHER - and BC6ENTC - dependent inactivation is demonstrable whether BC6OTHER is generated in situ from BC6OTHER or is added exogenously, supporting a direct effect of the treatment on BC6ENTG . CPR:falsenewlineThis BC6OTHER - and BC6OTHER - dependent inactivation is demonstrable whether BC6ENTC is generated in situ from BC6OTHER or is added exogenously, supporting a direct effect of the treatment on BC6ENTG . CPR:falsenewlineThis BC6OTHER - and BC6OTHER - dependent inactivation is demonstrable whether BC6OTHER is generated in situ from BC6ENTC or is added exogenously, supporting a direct effect of the treatment on BC6ENTG . CPR:falsenewlineBC6OTHER ( BC6OTHER ), a nonsteroidal anti - inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of BC6ENTC synthase ( BC6ENTG ). CPR:falsenewlineAs BC6ENTC undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6ENTG , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6OTHER . CPR:9newlineAs BC6ENTC undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6ENTG and BC6OTHER . CPR:falsenewlineAs BC6ENTC undergoes BC6OTHER - dependent co - oxygenation catalyzed by BC6OTHER , we propose that it is an oxygenated derivative of BC6OTHER , rather than the parent compound, which is responsible for the inactivation of BC6OTHER and BC6ENTG . CPR:falsenewlineAdministration of BC6OTHER increased BC6ENTC 240 / 244 phosphorylation in a subpopulation of BC6OTHER - ergic medium spiny neurons (MSNs), which express BC6ENTG ( BC6OTHER ). CPR:falsenewlineAdministration of BC6OTHER increased BC6ENTC 240 / 244 phosphorylation in a subpopulation of BC6OTHER - ergic medium spiny neurons (MSNs), which express BC6OTHER ( BC6ENTG ). CPR:falsenewlineAdministration of BC6OTHER increased BC6OTHER 240 / 244 phosphorylation in a subpopulation of BC6ENTC - ergic medium spiny neurons (MSNs), which express BC6ENTG ( BC6OTHER ). CPR:falsenewlineAdministration of BC6OTHER increased BC6OTHER 240 / 244 phosphorylation in a subpopulation of BC6ENTC - ergic medium spiny neurons (MSNs), which express BC6OTHER ( BC6ENTG ). CPR:falsenewlineAdministration of BC6OTHER increased BC6OTHER 240 / 244 phosphorylation in a subpopulation of BC6OTHER - ergic medium spiny neurons (MSNs), which express BC6ENTC D2 receptors ( BC6ENTG ). CPR:falsenewlineThis effect was prevented by BC6ENTC , an inhibitor of the BC6ENTG ( BC6OTHER ), or by BC6OTHER , a selective inhibitor of the BC6OTHER ( BC6OTHER ). CPR:falsenewlineThis effect was prevented by BC6ENTC , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6ENTG ), or by BC6OTHER , a selective inhibitor of the BC6OTHER ( BC6OTHER ). CPR:falsenewlineThis effect was prevented by BC6ENTC , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6OTHER ), or by BC6OTHER , a selective inhibitor of the BC6ENTG ( BC6OTHER ). CPR:falsenewlineThis effect was prevented by BC6ENTC , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6OTHER ), or by BC6OTHER , a selective inhibitor of the BC6OTHER ( BC6ENTG ). CPR:falsenewlineThis effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6ENTC complex 1 ( BC6ENTG ), or by BC6OTHER , a selective inhibitor of the BC6OTHER ( BC6OTHER ). CPR:falsenewlineThis effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6ENTC complex 1 ( BC6OTHER ), or by BC6OTHER , a selective inhibitor of the BC6ENTG ( BC6OTHER ). CPR:falsenewlineThis effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6ENTC complex 1 ( BC6OTHER ), or by BC6OTHER , a selective inhibitor of the BC6OTHER ( BC6ENTG ). CPR:falsenewlineThis effect was prevented by BC6OTHER , an inhibitor of the BC6ENTG ( BC6OTHER ), or by BC6ENTC , a selective inhibitor of the BC6OTHER ( BC6OTHER ). CPR:falsenewlineThis effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6ENTG ), or by BC6ENTC , a selective inhibitor of the BC6OTHER ( BC6OTHER ). CPR:falsenewlineThis effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6OTHER ), or by BC6ENTC , a selective inhibitor of the BC6ENTG ( BC6OTHER ). CPR:falsenewlineThis effect was prevented by BC6OTHER , an inhibitor of the mammalian target of BC6OTHER complex 1 ( BC6OTHER ), or by BC6ENTC , a selective inhibitor of the BC6OTHER ( BC6ENTG ). CPR:falsenewlineWe also found that the effect of BC6ENTC on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of BC6ENTG ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ). CPR:falsenewlineWe also found that the effect of BC6ENTC on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6ENTG ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ). CPR:falsenewlineWe also found that the effect of BC6ENTC on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6ENTG ( BC6OTHER ). CPR:falsenewlineWe also found that the effect of BC6ENTC on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6ENTG ). CPR:falsenewlineWe also found that the effect of BC6OTHER on BC6ENTC 240 / 244 phosphorylation was prevented by functional inactivation of BC6ENTG ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ). CPR:falsenewlineWe also found that the effect of BC6OTHER on BC6ENTC 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6ENTG ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ). CPR:falsenewlineWe also found that the effect of BC6OTHER on BC6ENTC 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6ENTG ( BC6OTHER ). CPR:falsenewlineWe also found that the effect of BC6OTHER on BC6ENTC 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6ENTG ). CPR:falsenewlineWe also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6ENTG ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ). CPR:falsenewlineWe also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6ENTG ( BC6OTHER ). CPR:falsenewlineWe also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6ENTG ). CPR:falsenewlineWe also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa ( BC6ENTG ), an endogenous inhibitor of BC6OTHER ( BC6OTHER ). CPR:falsenewlineWe also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6ENTG ( BC6OTHER ). CPR:falsenewlineWe also found that the effect of BC6OTHER on BC6OTHER 240 / 244 phosphorylation was prevented by functional inactivation of CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa ( BC6OTHER ), an endogenous inhibitor of BC6OTHER ( BC6ENTG ). CPR:falsenewlineIn line with this observation, incubation of striatal slices with BC6ENTC and BC6OTHER , two inhibitors of BC6ENTG , increased BC6OTHER 240 / 244 phosphorylation. CPR:falsenewline BC6ENTC promotes BC6OTHER - dependent phosphorylation of BC6OTHER via CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6ENTG . CPR:falsenewline BC6ENTC promotes BC6ENTG - dependent phosphorylation of BC6OTHER via CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER . CPR:falsenewline BC6ENTC promotes BC6OTHER - dependent phosphorylation of BC6ENTG via CHEM - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER . CPR:falsenewline BC6ENTC promotes BC6OTHER - dependent phosphorylation of BC6OTHER via BC6ENTG and inhibition of BC6OTHER . CPR:falsenewline BC6OTHER promotes BC6OTHER - dependent phosphorylation of BC6OTHER via BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6ENTG . CPR:falsenewline BC6OTHER promotes BC6ENTG - dependent phosphorylation of BC6OTHER via BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER . CPR:falsenewline BC6OTHER promotes BC6OTHER - dependent phosphorylation of BC6ENTG via BC6ENTC - and BC6OTHER - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER . CPR:falsenewline BC6OTHER promotes BC6OTHER - dependent phosphorylation of BC6OTHER via CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa and inhibition of BC6ENTG . CPR:falsenewline BC6OTHER promotes BC6ENTG - dependent phosphorylation of BC6OTHER via CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER . CPR:falsenewline BC6OTHER promotes BC6OTHER - dependent phosphorylation of BC6ENTG via CHEM - and BC6ENTC - regulated phosphoprotein of 32 kDa and inhibition of BC6OTHER . CPR:falsenewlineIn line with this observation, incubation of striatal slices with BC6OTHER and BC6ENTC , two inhibitors of BC6ENTG , increased BC6OTHER 240 / 244 phosphorylation. CPR:falsenewlineIn line with this observation, incubation of striatal slices with BC6OTHER and BC6OTHER , two inhibitors of BC6ENTG , increased BC6ENTC 240 / 244 phosphorylation. CPR:falsenewlineThese results show that BC6ENTC promotes BC6ENTG - and BC6OTHER - dependent phosphorylation of BC6OTHER at BC6OTHER 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER . CPR:falsenewlineThese results show that BC6ENTC promotes BC6OTHER - and BC6ENTG - dependent phosphorylation of BC6OTHER at BC6OTHER 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER . CPR:falsenewlineThese results show that BC6ENTC promotes BC6OTHER - and BC6OTHER - dependent phosphorylation of BC6ENTG at BC6OTHER 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER . CPR:falsenewlineThese results show that BC6ENTC promotes BC6OTHER - and BC6OTHER - dependent phosphorylation of BC6OTHER at BC6OTHER 240 / 244, in a subpopulation of striatal MSNs expressing BC6ENTG . CPR:falsenewlineThese results show that BC6OTHER promotes BC6ENTG - and BC6OTHER - dependent phosphorylation of BC6OTHER at BC6ENTC 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER . CPR:falsenewlineThese results show that BC6OTHER promotes BC6OTHER - and BC6ENTG - dependent phosphorylation of BC6OTHER at BC6ENTC 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER . CPR:falsenewlineThese results show that BC6OTHER promotes BC6OTHER - and BC6OTHER - dependent phosphorylation of BC6ENTG at BC6ENTC 240 / 244, in a subpopulation of striatal MSNs expressing BC6OTHER . CPR:falsenewlineThese results show that BC6OTHER promotes BC6OTHER - and BC6OTHER - dependent phosphorylation of BC6OTHER at BC6ENTC 240 / 244, in a subpopulation of striatal MSNs expressing BC6ENTG . CPR:falsenewlineThey also indicate that this effect is exerted by suppressing dephosphorylation at BC6ENTC 240 / 244, through BC6ENTG - dependent activation of BC6OTHER and inhibition of BC6OTHER . CPR:falsenewlineThey also indicate that this effect is exerted by suppressing dephosphorylation at BC6ENTC 240 / 244, through BC6OTHER - dependent activation of BC6ENTG and inhibition of BC6OTHER . CPR:falsenewlineThey also indicate that this effect is exerted by suppressing dephosphorylation at BC6ENTC 240 / 244, through BC6OTHER - dependent activation of BC6OTHER and inhibition of BC6ENTG . CPR:falsenewlineHere, we examined the effects produced by BC6ENTC , a typical antipsychotic drug, on the phosphorylation of BC6ENTG at BC6OTHER 240 / 244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders. CPR:falsenewlineHere, we examined the effects produced by BC6OTHER , a typical antipsychotic drug, on the phosphorylation of BC6ENTG at BC6ENTC 240 / 244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders. CPR:falsenewlineAdministration of BC6ENTC increased BC6OTHER 240 / 244 phosphorylation in a subpopulation of BC6OTHER - ergic medium spiny neurons (MSNs), which express BC6ENTG ( BC6OTHER ). CPR:falsenewlineAdministration of BC6ENTC increased BC6OTHER 240 / 244 phosphorylation in a subpopulation of BC6OTHER - ergic medium spiny neurons (MSNs), which express BC6OTHER ( BC6ENTG ). CPR:falsenewlineSources of BC6OTHER include dietary proteins and endogenous synthesis by BC6ENTG and BC6ENTC lyase. CPR:falsenewlineBC6ENTC is converted to BC6OTHER by BC6ENTG in the liver and BC6OTHER in the kidney. CPR:9newlineBC6ENTC is converted to BC6OTHER by BC6OTHER in the liver and BC6ENTG in the kidney. CPR:9newlineBC6OTHER is converted to BC6ENTC by BC6ENTG in the liver and BC6OTHER in the kidney. CPR:9newlineBC6OTHER is converted to BC6ENTC by BC6OTHER in the liver and BC6ENTG in the kidney. CPR:9newlineWe hypothesized that preservation of plasma BC6ENTC in CRF may be, partly, due to downregulation / inhibition of BC6ENTG . CPR:falsenewlineIn addition, BC6ENTG activity was measured in the presence of different BC6ENTC concentrations to simulate azotemia in vitro. CPR:falsenewlineMETHODS: BC6ENTC synthetase, BC6ENTG protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5 / 6 nephrectomy or sham operation. CPR:falsenewlineEffect of chronic renal failure on BC6ENTG and BC6ENTC synthetase expression. CPR:falsenewlineSources of BC6ENTC include dietary proteins and endogenous synthesis by BC6ENTG and BC6OTHER . CPR:9newlineSources of BC6ENTC include dietary proteins and endogenous synthesis by BC6OTHER synthetase and BC6ENTG . CPR:9newlineHowever, in vitro experiments simulating a uremic milieu revealed a marked concentration - dependent inhibition of BC6ENTG activity by BC6ENTC in the tissue lysates. CPR:4newlineCONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of BC6ENTG , the inherent rise in BC6ENTC concentration inhibits its enzymatic activity. CPR:falsenewlineSources of BC6OTHER include dietary proteins and endogenous synthesis by BC6ENTC synthetase and BC6ENTG . CPR:falsenewlineBC6ENTC was used to test whether any potential effect was due to activation of BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6ENTC was used to test whether any potential effect was due to activation of endothelial BC6OTHER synthase ( BC6ENTG ). CPR:falsenewlineBC6OTHER was used to test whether any potential effect was due to activation of endothelial BC6ENTC synthase ( BC6ENTG ). CPR:falsenewlineOur purpose was to test the impact of single and / or combined treatment with the BC6OTHER - receptor blocker BC6ENTC and the BC6ENTG inhibitor BC6OTHER on infarct size and neuroscore in transient cerebral ischemia in rats. CPR:falsenewlineOur purpose was to test the impact of single and / or combined treatment with the BC6ENTG - receptor blocker BC6ENTC and the BC6OTHER reductase inhibitor BC6OTHER on infarct size and neuroscore in transient cerebral ischemia in rats. CPR:falsenewlineReduction of cerebral infarct size by the BC6ENTG - receptor blocker BC6OTHER , the BC6OTHER inhibitor BC6ENTC and their combination. CPR:falsenewlineReduction of cerebral infarct size by the BC6OTHER - receptor blocker BC6OTHER , the BC6ENTG inhibitor BC6ENTC and their combination. CPR:falsenewlineReduction of cerebral infarct size by the BC6ENTG - receptor blocker BC6ENTC , the BC6OTHER inhibitor BC6OTHER and their combination. CPR:falsenewlineReduction of cerebral infarct size by the BC6OTHER - receptor blocker BC6ENTC , the BC6ENTG inhibitor BC6OTHER and their combination. CPR:falsenewlineReduction of cerebral infarct size by the BC6ENTG - receptor blocker BC6OTHER , the BC6ENTC reductase inhibitor BC6OTHER and their combination. CPR:falsenewlineOur purpose was to test the impact of single and / or combined treatment with the BC6ENTG - receptor blocker BC6OTHER and the BC6ENTC reductase inhibitor BC6OTHER on infarct size and neuroscore in transient cerebral ischemia in rats. CPR:falsenewlineOur purpose was to test the impact of single and / or combined treatment with the BC6OTHER - receptor blocker BC6OTHER and the BC6ENTG inhibitor BC6ENTC on infarct size and neuroscore in transient cerebral ischemia in rats. CPR:falsenewlineOur purpose was to test the impact of single and / or combined treatment with the BC6ENTG - receptor blocker BC6OTHER and the BC6OTHER reductase inhibitor BC6ENTC on infarct size and neuroscore in transient cerebral ischemia in rats. CPR:falsenewlineVarious biochemical processes including oligomerization, BC6ENTC BC6OTHER / CHEM binding, and BC6ENTG interaction play a role in regulating the ternary death complex. CPR:falsenewlineVarious biochemical processes including oligomerization, BC6OTHER BC6ENTC / CHEM binding, and BC6ENTG interaction play a role in regulating the ternary death complex. CPR:falsenewlineThe BC6ENTG is predicted to transfer either BC6OTHER or a CHEM ( BC6ENTC ) to the aglycone. CPR:falsenewlineTargeted disruption of the gene encoding the BC6ENTC - glycosyltransferase, BC6ENTG , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6ENTC - glycosyltransferase, BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6ENTC - glycosyltransferase, BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTG involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6ENTG , BC6OTHER , abolished BC6ENTC production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6ENTG , abolished BC6ENTC production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6ENTC production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6ENTC production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTG involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6ENTG , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTC BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6ENTG , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTC BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a BC6ENTC BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6ENTG , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6ENTC cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6ENTG , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6ENTC cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a CHEM BC6ENTC cyclase involved in the formation of the BC6OTHER - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6ENTG , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6ENTC - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6ENTG , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6ENTC - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6ENTC - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTG involved in the formation of the BC6ENTC - BC6OTHER moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6ENTG , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6ENTC moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6ENTG , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6ENTC moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6ENTG confirms the activity of this enzyme as a CHEM BC6OTHER cyclase involved in the formation of the BC6OTHER - BC6ENTC moiety. CPR:falsenewlineTargeted disruption of the gene encoding the BC6OTHER , BC6OTHER , abolished BC6OTHER production, and recombinant expression of BC6OTHER confirms the activity of this enzyme as a BC6ENTG involved in the formation of the BC6OTHER - BC6ENTC moiety. CPR:falsenewlineThis includes BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6ENTG , an BC6OTHER - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTG , and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6ENTC core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6ENTG ) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTC - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTC - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTC - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTC - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6ENTG , an BC6ENTC - methyltransferase, and an BC6OTHER - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTC - methyltransferase, and an BC6ENTG ) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6OTHER - methyltransferase, and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6ENTG , an BC6OTHER - methyltransferase, and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThis includes BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) required for the formation of the BC6OTHER core unit, as well as a suite of tailoring enzymes (e.g., four BC6OTHER , an BC6ENTG , and an BC6ENTC - glycosyltransferase) necessary for further modifications of the core structure. CPR:falsenewlineThe BC6ENTG is predicted to transfer either BC6ENTC or a CHEM ( BC6OTHER ) to the aglycone. CPR:falsenewlineDown - regulation of BC6ENTG by BC6OTHER was blocked by BC6OTHER ( BC6ENTC ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER by BC6OTHER was blocked by BC6OTHER ( BC6ENTC ), a BC6ENTG inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER by BC6OTHER was blocked by BC6OTHER ( BC6ENTC ), a BC6OTHER inhibitor and by expression of BC6ENTG - BC6OTHER , a dominant negative form of BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER by BC6OTHER was blocked by BC6OTHER ( BC6ENTC ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6ENTG , a dominant negative form of BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER by BC6OTHER was blocked by BC6OTHER ( BC6ENTC ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6ENTG . CPR:falsenewlineThe BC6ENTG reduction was inhibited by BC6ENTC , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6OTHER antagonist. CPR:falsenewlineThe BC6OTHER reduction was inhibited by BC6ENTC , an BC6ENTG antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6OTHER antagonist. CPR:falsenewlineThe BC6OTHER reduction was inhibited by BC6ENTC , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6ENTG antagonist. CPR:falsenewlineThe BC6ENTG reduction was inhibited by BC6OTHER , an BC6ENTC ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6OTHER antagonist. CPR:falsenewlineThe BC6OTHER reduction was inhibited by BC6OTHER , an BC6ENTC ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6ENTG antagonist. CPR:falsenewlineThe BC6ENTG reduction was inhibited by BC6OTHER , an CHEM ( BC6ENTC ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6OTHER antagonist. CPR:falsenewlineThe BC6OTHER reduction was inhibited by BC6OTHER , an CHEM ( BC6ENTC ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6ENTG antagonist. CPR:falsenewlineThe BC6ENTG reduction was inhibited by BC6OTHER , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6ENTC ( BC6OTHER ), an BC6OTHER antagonist. CPR:falsenewlineThe BC6OTHER reduction was inhibited by BC6OTHER , an BC6ENTG antagonist, but not by BC6ENTC ( BC6OTHER ), an BC6OTHER antagonist. CPR:falsenewlineThe BC6OTHER reduction was inhibited by BC6OTHER , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6ENTC ( BC6OTHER ), an BC6ENTG antagonist. CPR:falsenewlineThe BC6ENTG reduction was inhibited by BC6OTHER , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6ENTC ), an BC6OTHER antagonist. CPR:falsenewlineThe BC6OTHER reduction was inhibited by BC6OTHER , an BC6ENTG antagonist, but not by BC6OTHER ( BC6ENTC ), an BC6OTHER antagonist. CPR:falsenewlineThe BC6OTHER reduction was inhibited by BC6OTHER , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6ENTC ), an BC6ENTG antagonist. CPR:falsenewlineThe BC6ENTG reduction was inhibited by BC6OTHER , an CHEM ( BC6OTHER ) receptor antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6ENTC receptor antagonist. CPR:falsenewlineThe BC6OTHER reduction was inhibited by BC6OTHER , an BC6ENTG antagonist, but not by BC6OTHER ( BC6OTHER ), an BC6ENTC receptor antagonist. CPR:falsenewlineBC6ENTC and BC6OTHER ( BC6OTHER ), two BC6OTHER chelators, but not BC6OTHER , an BC6ENTG blocker, prevented BC6OTHER degradation. CPR:falsenewlineBC6ENTC and BC6OTHER ( BC6OTHER ), two BC6OTHER chelators, but not BC6OTHER , an L - type BC6OTHER channel blocker, prevented BC6ENTG degradation. CPR:falsenewlineBC6OTHER and BC6ENTC ( BC6OTHER ), two BC6OTHER chelators, but not BC6OTHER , an BC6ENTG blocker, prevented BC6OTHER degradation. CPR:falsenewlineBC6OTHER and BC6ENTC ( BC6OTHER ), two BC6OTHER chelators, but not BC6OTHER , an L - type BC6OTHER channel blocker, prevented BC6ENTG degradation. CPR:falsenewlineBC6OTHER and BC6OTHER ( BC6ENTC ), two BC6OTHER chelators, but not BC6OTHER , an BC6ENTG blocker, prevented BC6OTHER degradation. CPR:falsenewlineBC6OTHER and BC6OTHER ( BC6ENTC ), two BC6OTHER chelators, but not BC6OTHER , an L - type BC6OTHER channel blocker, prevented BC6ENTG degradation. CPR:falsenewlineOur results suggest that BC6ENTC induces BC6ENTG degradation by BC6OTHER through an BC6OTHER receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression. CPR:falsenewlineOur results suggest that BC6ENTC induces BC6OTHER degradation by BC6ENTG through an BC6OTHER receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression. CPR:falsenewlineOur results suggest that BC6ENTC induces BC6OTHER degradation by BC6OTHER through an BC6ENTG - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression. CPR:falsenewlineOur results suggest that BC6ENTC induces BC6OTHER degradation by BC6OTHER through an BC6OTHER receptor - BC6OTHER pathway and that BC6ENTG degradation may play an important role in regulating BC6OTHER surface expression. CPR:falsenewlineOur results suggest that BC6ENTC induces BC6OTHER degradation by BC6OTHER through an BC6OTHER receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6ENTG surface expression. CPR:falsenewlineBC6OTHER and BC6OTHER ( BC6OTHER ), two BC6ENTC chelators, but not BC6OTHER , an BC6ENTG blocker, prevented BC6OTHER degradation. CPR:falsenewlineBC6OTHER and BC6OTHER ( BC6OTHER ), two BC6ENTC chelators, but not BC6OTHER , an L - type BC6OTHER channel blocker, prevented BC6ENTG degradation. CPR:falsenewlineBC6OTHER and BC6OTHER ( BC6OTHER ), two BC6OTHER chelators, but not BC6ENTC , an BC6ENTG blocker, prevented BC6OTHER degradation. CPR:falsenewlineBC6OTHER and BC6OTHER ( BC6OTHER ), two BC6OTHER chelators, but not BC6ENTC , an L - type BC6OTHER channel blocker, prevented BC6ENTG degradation. CPR:falsenewlineBC6OTHER and BC6OTHER ( BC6OTHER ), two BC6OTHER chelators, but not BC6OTHER , an L - type BC6ENTC channel blocker, prevented BC6ENTG degradation. CPR:falsenewlineFurthermore, BC6ENTC prevented BC6OTHER - stimulated reduction in surface amount of BC6ENTG , and knockdown of BC6OTHER by RNAi against BC6OTHER reduced surface BC6OTHER in neurons. CPR:falsenewlineFurthermore, BC6ENTC prevented BC6OTHER - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6ENTG by RNAi against BC6OTHER reduced surface BC6OTHER in neurons. CPR:falsenewlineFurthermore, BC6ENTC prevented BC6OTHER - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6OTHER by RNAi against BC6ENTG reduced surface BC6OTHER in neurons. CPR:falsenewlineFurthermore, BC6ENTC prevented BC6OTHER - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6OTHER by RNAi against BC6OTHER reduced surface BC6ENTG in neurons. CPR:falsenewlineFurthermore, BC6OTHER prevented BC6ENTC - stimulated reduction in surface amount of BC6ENTG , and knockdown of BC6OTHER by RNAi against BC6OTHER reduced surface BC6OTHER in neurons. CPR:falsenewlineFurthermore, BC6OTHER prevented BC6ENTC - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6ENTG by RNAi against BC6OTHER reduced surface BC6OTHER in neurons. CPR:falsenewlineFurthermore, BC6OTHER prevented BC6ENTC - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6OTHER by RNAi against BC6ENTG reduced surface BC6OTHER in neurons. CPR:falsenewlineFurthermore, BC6OTHER prevented BC6ENTC - stimulated reduction in surface amount of BC6OTHER , and knockdown of BC6OTHER by RNAi against BC6OTHER reduced surface BC6ENTG in neurons. CPR:falsenewline BC6ENTC stimulates BC6OTHER degradation by BC6OTHER - BC6OTHER system to regulate surface expression of BC6ENTG . CPR:falsenewline BC6ENTC stimulates BC6ENTG degradation by BC6OTHER - BC6OTHER system to regulate surface expression of BC6OTHER . CPR:falsenewline BC6ENTC stimulates BC6OTHER degradation by BC6ENTG - BC6OTHER system to regulate surface expression of BC6OTHER . CPR:falsenewline BC6ENTC stimulates BC6OTHER degradation by BC6OTHER - BC6ENTG system to regulate surface expression of BC6OTHER . CPR:falsenewline BC6OTHER stimulates BC6ENTC receptor interacting protein 1 degradation by BC6OTHER - BC6OTHER system to regulate surface expression of BC6ENTG . CPR:falsenewline BC6OTHER stimulates BC6ENTC receptor interacting protein 1 degradation by BC6ENTG - BC6OTHER system to regulate surface expression of BC6OTHER . CPR:falsenewline BC6OTHER stimulates BC6ENTC receptor interacting protein 1 degradation by BC6OTHER - BC6ENTG system to regulate surface expression of BC6OTHER . CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) is a scaffolding protein in postsynaptic density (PSD), tethering BC6ENTC receptors to other signaling proteins. CPR:falsenewlineThe BC6OTHER receptor interacting protein 1 ( BC6ENTG ) is a scaffolding protein in postsynaptic density (PSD), tethering BC6ENTC receptors to other signaling proteins. CPR:falsenewlineOur results suggest that BC6OTHER induces BC6ENTG degradation by BC6OTHER through an BC6ENTC receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression. CPR:falsenewlineOur results suggest that BC6OTHER induces BC6OTHER degradation by BC6ENTG through an BC6ENTC receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression. CPR:falsenewlineOur results suggest that BC6OTHER induces BC6OTHER degradation by BC6OTHER through an BC6ENTC receptor - BC6OTHER pathway and that BC6ENTG degradation may play an important role in regulating BC6OTHER surface expression. CPR:falsenewlineOur results suggest that BC6OTHER induces BC6OTHER degradation by BC6OTHER through an BC6ENTC receptor - BC6OTHER pathway and that BC6OTHER degradation may play an important role in regulating BC6ENTG surface expression. CPR:falsenewlineOur results suggest that BC6OTHER induces BC6ENTG degradation by BC6OTHER through an BC6OTHER receptor - BC6ENTC pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression. CPR:falsenewlineOur results suggest that BC6OTHER induces BC6OTHER degradation by BC6ENTG through an BC6OTHER receptor - BC6ENTC pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression. CPR:falsenewlineOur results suggest that BC6OTHER induces BC6OTHER degradation by BC6OTHER through an BC6ENTG - BC6ENTC pathway and that BC6OTHER degradation may play an important role in regulating BC6OTHER surface expression. CPR:falsenewlineOur results suggest that BC6OTHER induces BC6OTHER degradation by BC6OTHER through an BC6OTHER receptor - BC6ENTC pathway and that BC6ENTG degradation may play an important role in regulating BC6OTHER surface expression. CPR:falsenewlineOur results suggest that BC6OTHER induces BC6OTHER degradation by BC6OTHER through an BC6OTHER receptor - BC6ENTC pathway and that BC6OTHER degradation may play an important role in regulating BC6ENTG surface expression. CPR:falsenewlineHere we report that BC6ENTC stimulation caused a rapid reduction in protein levels of BC6ENTG , but not that of BC6OTHER receptor BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures. CPR:falsenewlineHere we report that BC6ENTC stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6OTHER receptor BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures. CPR:falsenewlineHere we report that BC6ENTC stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6OTHER receptor BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures. CPR:falsenewlineHere we report that BC6ENTC stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6OTHER receptor BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ) in rat primary cortical neuron cultures. CPR:falsenewlineHere we report that BC6ENTC stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6OTHER receptor BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ) in rat primary cortical neuron cultures. CPR:falsenewlineHere we report that BC6OTHER stimulation caused a rapid reduction in protein levels of BC6ENTG , but not that of BC6ENTC receptor BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures. CPR:falsenewlineHere we report that BC6OTHER stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6ENTC receptor BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures. CPR:falsenewlineHere we report that BC6OTHER stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6ENTC receptor BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ) in rat primary cortical neuron cultures. CPR:falsenewlineHere we report that BC6OTHER stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6ENTC receptor BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ) in rat primary cortical neuron cultures. CPR:falsenewlineHere we report that BC6OTHER stimulation caused a rapid reduction in protein levels of BC6OTHER , but not that of BC6ENTC receptor BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ) in rat primary cortical neuron cultures. CPR:falsenewlineThe BC6ENTC receptor interacting protein 1 ( BC6OTHER ) is a scaffolding protein in postsynaptic density (PSD), tethering BC6ENTG to other signaling proteins. CPR:falsenewlineThe BC6ENTC receptor interacting protein 1 ( BC6ENTG ) is a scaffolding protein in postsynaptic density (PSD), tethering BC6OTHER to other signaling proteins. CPR:falsenewlineDown - regulation of BC6ENTG by BC6ENTC was blocked by BC6OTHER ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER . CPR:4newlineDown - regulation of BC6OTHER by BC6ENTC was blocked by BC6OTHER ( BC6OTHER ), a BC6ENTG inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER by BC6ENTC was blocked by BC6OTHER ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6ENTG - BC6OTHER , a dominant negative form of BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER by BC6ENTC was blocked by BC6OTHER ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6ENTG , a dominant negative form of BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER by BC6ENTC was blocked by BC6OTHER ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6ENTG . CPR:falsenewlineDown - regulation of BC6ENTG by BC6OTHER was blocked by BC6ENTC ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER by BC6OTHER was blocked by BC6ENTC ( BC6OTHER ), a BC6ENTG inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER by BC6OTHER was blocked by BC6ENTC ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6ENTG - BC6OTHER , a dominant negative form of BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER by BC6OTHER was blocked by BC6ENTC ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6ENTG , a dominant negative form of BC6OTHER . CPR:falsenewlineDown - regulation of BC6OTHER by BC6OTHER was blocked by BC6ENTC ( BC6OTHER ), a BC6OTHER inhibitor and by expression of BC6OTHER - BC6OTHER , a dominant negative form of BC6ENTG . CPR:falsenewlineThere was a positive correlation between BC6ENTG levels and fasting plasma BC6ENTC in hyperprolactinemic women. CPR:falsenewlineForty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age - matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma BC6ENTC , BC6ENTG levels, BC6OTHER resistance measured by homeostasis model assessment (HOMA) - BC6OTHER resistance index, beta cell function measured by HOMA - β index, BC6OTHER and BC6OTHER levels. CPR:falsenewlineForty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age - matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma BC6ENTC , BC6OTHER levels, BC6ENTG resistance measured by homeostasis model assessment (HOMA) - BC6OTHER resistance index, beta cell function measured by HOMA - β index, BC6OTHER and BC6OTHER levels. CPR:falsenewlineForty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age - matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma BC6ENTC , BC6OTHER levels, BC6OTHER resistance measured by homeostasis model assessment (HOMA) - BC6ENTG resistance index, beta cell function measured by HOMA - β index, BC6OTHER and BC6OTHER levels. CPR:falsenewlineForty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age - matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma BC6ENTC , BC6OTHER levels, BC6OTHER resistance measured by homeostasis model assessment (HOMA) - BC6OTHER resistance index, beta cell function measured by HOMA - β index, BC6ENTG and BC6OTHER levels. CPR:falsenewlineForty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age - matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma BC6ENTC , BC6OTHER levels, BC6OTHER resistance measured by homeostasis model assessment (HOMA) - BC6OTHER resistance index, beta cell function measured by HOMA - β index, BC6OTHER and BC6ENTG levels. CPR:falsenewlineBC6ENTG and BC6OTHER may form metabolons with BC6OTHER and BC6OTHER , respectively, but no BC6ENTC enzyme is known to associate with BC6OTHER . CPR:falsenewlineBC6OTHER and BC6ENTG may form metabolons with BC6OTHER and BC6OTHER , respectively, but no BC6ENTC enzyme is known to associate with BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER may form metabolons with BC6ENTG and BC6OTHER , respectively, but no BC6ENTC enzyme is known to associate with BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER may form metabolons with BC6OTHER and BC6ENTG , respectively, but no BC6ENTC enzyme is known to associate with BC6OTHER . CPR:falsenewlineBC6OTHER and BC6OTHER may form metabolons with BC6OTHER and BC6OTHER , respectively, but no BC6ENTC enzyme is known to associate with BC6ENTG . CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6ENTC BC6ENTG reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ). CPR:9newlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6ENTC BC6OTHER reactions, including BC6ENTG ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6ENTC BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6ENTG ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6ENTC BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6ENTC BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6ENTG ). CPR:falsenewlineMost halogenated BC6ENTC are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins. CPR:9newlineMost halogenated BC6OTHER are metabolized by BC6ENTC BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins. CPR:falsenewlineMost halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6ENTC , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins. CPR:falsenewlineMost halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6ENTC , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins. CPR:falsenewlineMost halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6ENTC (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins. CPR:falsenewlineMost halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6ENTC ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins. CPR:falsenewlineMost halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6ENTC (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins. CPR:falsenewlineMost halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6ENTC ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins. CPR:falsenewlineMost halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6ENTC to give a BC6OTHER , which reacts with BC6OTHER groups of BC6OTHER residues in proteins. CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6ENTG reactions, including mitochondrial BC6ENTC aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6ENTC aminotransferase ( BC6ENTG ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6ENTC aminotransferase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6ENTC aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6ENTG ). CPR:falsenewlineMost halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6ENTC , which reacts with BC6OTHER groups of BC6OTHER residues in proteins. CPR:falsenewlineMost halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6ENTC groups of BC6OTHER residues in proteins. CPR:falsenewlineMost halogenated BC6OTHER are metabolized by BC6OTHER BC6ENTG to BC6OTHER , BC6OTHER , and an BC6OTHER (with BC6OTHER ) or an BC6OTHER (with BC6OTHER ) that may eliminate BC6OTHER to give a BC6OTHER , which reacts with BC6OTHER groups of BC6ENTC residues in proteins. CPR:falsenewlineNine mammalian BC6ENTC ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6ENTG reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6ENTC ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including BC6ENTG ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6ENTC ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6ENTG ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6ENTC ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6ENTC ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6ENTG ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6ENTC ) - containing enzymes catalyze BC6OTHER BC6ENTG reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6ENTC ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including BC6ENTG ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6ENTC ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6ENTG ), and mitochondrial BC6OTHER aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6ENTC ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6ENTC ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6OTHER aminotransferase ( BC6ENTG ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6ENTG reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6ENTC aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including BC6ENTG ( BC6OTHER ), and mitochondrial BC6ENTC aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6ENTG ), and mitochondrial BC6ENTC aminotransferase ( BC6OTHER ). CPR:falsenewlineNine mammalian BC6OTHER ( BC6OTHER ) - containing enzymes catalyze BC6OTHER BC6OTHER reactions, including mitochondrial BC6OTHER aminotransferase ( BC6OTHER ), and mitochondrial BC6ENTC aminotransferase ( BC6ENTG ). CPR:falsenewlineMost of the BC6ENTC BC6ENTG are syncatalytically inactivated. CPR:falsenewlineInterestingly, the BC6ENTC - and BC6OTHER dehydrogenase complexes ( BC6ENTG and BC6OTHER ), but not the BC6OTHER dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation. CPR:falsenewlineInterestingly, the BC6ENTC - and BC6OTHER dehydrogenase complexes ( BC6OTHER and BC6ENTG ), but not the BC6OTHER dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation. CPR:falsenewlineInterestingly, the BC6ENTC - and BC6OTHER dehydrogenase complexes ( BC6OTHER and BC6OTHER ), but not the BC6ENTG ( BC6OTHER ), are susceptible to inactivation. CPR:falsenewlineInterestingly, the BC6ENTC - and BC6OTHER dehydrogenase complexes ( BC6OTHER and BC6OTHER ), but not the BC6OTHER dehydrogenase complex ( BC6ENTG ), are susceptible to inactivation. CPR:falsenewlineInterestingly, the BC6OTHER - and BC6ENTC dehydrogenase complexes ( BC6ENTG and BC6OTHER ), but not the BC6OTHER dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation. CPR:falsenewlineInterestingly, the BC6OTHER - and BC6ENTC dehydrogenase complexes ( BC6OTHER and BC6ENTG ), but not the BC6OTHER dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation. CPR:falsenewlineInterestingly, the BC6OTHER - and BC6ENTC dehydrogenase complexes ( BC6OTHER and BC6OTHER ), but not the BC6ENTG ( BC6OTHER ), are susceptible to inactivation. CPR:falsenewlineInterestingly, the BC6OTHER - and BC6ENTC dehydrogenase complexes ( BC6OTHER and BC6OTHER ), but not the BC6OTHER dehydrogenase complex ( BC6ENTG ), are susceptible to inactivation. CPR:falsenewlineInterestingly, the BC6ENTG ( BC6OTHER and BC6OTHER ), but not the BC6ENTC dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation. CPR:falsenewlineInterestingly, the BC6OTHER - and BC6OTHER dehydrogenase complexes ( BC6ENTG and BC6OTHER ), but not the BC6ENTC dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation. CPR:falsenewlineInterestingly, the BC6OTHER - and BC6OTHER dehydrogenase complexes ( BC6OTHER and BC6ENTG ), but not the BC6ENTC dehydrogenase complex ( BC6OTHER ), are susceptible to inactivation. CPR:falsenewlineInterestingly, the BC6OTHER - and BC6OTHER dehydrogenase complexes ( BC6OTHER and BC6OTHER ), but not the BC6ENTC dehydrogenase complex ( BC6ENTG ), are susceptible to inactivation. CPR:falsenewlineThis study shows ability of BC6OTHER to raise plasma BC6OTHER concentrations, mainly through BC6ENTG upregulation, and to decrease bile production through reduction in BC6OTHER - mediated BC6ENTC - independent bile flow. CPR:falsenewlineThis study shows ability of BC6OTHER to raise plasma BC6OTHER concentrations, mainly through BC6OTHER upregulation, and to decrease bile production through reduction in BC6ENTG - mediated BC6ENTC - independent bile flow. CPR:falsenewlineAccordingly, the main BC6ENTC transporter on the hepatocyte canalicular membrane, BC6ENTG ( BC6OTHER ), was significantly decreased at the protein level. CPR:falsenewlineAccordingly, the main BC6ENTC transporter on the hepatocyte canalicular membrane, BC6OTHER ( BC6ENTG ), was significantly decreased at the protein level. CPR:falsenewlineWhile protein levels of the main hepatic BC6ENTC transporters were unchanged, the rate - limiting enzyme in the BC6OTHER synthesis, BC6ENTG , was significantly increased by BC6OTHER . CPR:falsenewlineWhile protein levels of the main BC6ENTG were unchanged, the rate - limiting enzyme in the BC6ENTC synthesis, BC6OTHER , was significantly increased by BC6OTHER . CPR:falsenewlineWhile protein levels of the main hepatic BC6OTHER transporters were unchanged, the rate - limiting enzyme in the BC6ENTC synthesis, BC6ENTG , was significantly increased by BC6OTHER . CPR:falsenewlineWhile protein levels of the main BC6ENTG were unchanged, the rate - limiting enzyme in the BC6OTHER synthesis, BC6OTHER , was significantly increased by BC6ENTC . CPR:falsenewlineWhile protein levels of the main hepatic BC6OTHER transporters were unchanged, the rate - limiting enzyme in the BC6OTHER synthesis, BC6ENTG , was significantly increased by BC6ENTC . CPR:falsenewlineCholestatic effect of BC6ENTC in rats is mediated via decreased expression of BC6ENTG . CPR:falsenewlineIn contrast, BC6ENTC markedly downregulated major BC6ENTG ( BC6OTHER and BC6OTHER ) and regulatory molecules ( BC6OTHER and BC6OTHER ) in the ileum. CPR:4newlineIn contrast, BC6ENTC markedly downregulated major BC6OTHER transporters ( BC6ENTG and BC6OTHER ) and regulatory molecules ( BC6OTHER and BC6OTHER ) in the ileum. CPR:4newlineIn contrast, BC6ENTC markedly downregulated major BC6OTHER transporters ( BC6OTHER and BC6ENTG ) and regulatory molecules ( BC6OTHER and BC6OTHER ) in the ileum. CPR:4newlineIn contrast, BC6ENTC markedly downregulated major BC6OTHER transporters ( BC6OTHER and BC6OTHER ) and regulatory molecules ( BC6ENTG and BC6OTHER ) in the ileum. CPR:4newlineIn contrast, BC6ENTC markedly downregulated major BC6OTHER transporters ( BC6OTHER and BC6OTHER ) and regulatory molecules ( BC6OTHER and BC6ENTG ) in the ileum. CPR:4newlineIn contrast, BC6OTHER markedly downregulated major BC6ENTC transporters ( BC6ENTG and BC6OTHER ) and regulatory molecules ( BC6OTHER and BC6OTHER ) in the ileum. CPR:4newlineIn contrast, BC6OTHER markedly downregulated major BC6ENTC transporters ( BC6OTHER and BC6ENTG ) and regulatory molecules ( BC6OTHER and BC6OTHER ) in the ileum. CPR:4newlineIn contrast, BC6OTHER markedly downregulated major BC6ENTC transporters ( BC6OTHER and BC6OTHER ) and regulatory molecules ( BC6ENTG and BC6OTHER ) in the ileum. CPR:4newlineIn contrast, BC6OTHER markedly downregulated major BC6ENTC transporters ( BC6OTHER and BC6OTHER ) and regulatory molecules ( BC6OTHER and BC6ENTG ) in the ileum. CPR:4newlineThis study shows ability of BC6ENTC to raise plasma BC6OTHER concentrations, mainly through BC6ENTG upregulation, and to decrease bile production through reduction in BC6OTHER - mediated BC6OTHER - independent bile flow. CPR:falsenewlineThis study shows ability of BC6ENTC to raise plasma BC6OTHER concentrations, mainly through BC6OTHER upregulation, and to decrease bile production through reduction in BC6ENTG - mediated BC6OTHER - independent bile flow. CPR:falsenewlineThis study shows ability of BC6OTHER to raise plasma BC6ENTC concentrations, mainly through BC6ENTG upregulation, and to decrease bile production through reduction in BC6OTHER - mediated BC6OTHER - independent bile flow. CPR:falsenewlineThis study shows ability of BC6OTHER to raise plasma BC6ENTC concentrations, mainly through BC6OTHER upregulation, and to decrease bile production through reduction in BC6ENTG - mediated BC6OTHER - independent bile flow. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6ENTC (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6ENTC (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6ENTC (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6ENTC (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC dismutase, BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC dismutase, BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC dismutase, BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6ENTC , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6ENTC , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6ENTC , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6ENTC , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6ENTC , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6ENTC , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6ENTC , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6ENTC , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6ENTC , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6ENTC , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6ENTC , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6ENTC , liver lipid BC6OTHER contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6ENTC contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6ENTC contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6ENTC contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6ENTC contents, and antioxidant capacity in BC6OTHER mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6ENTC mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6ENTC mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6ENTC mediated oxidative stress induced mice. CPR:falsenewlineSimilarly, intraperitoneal administration of BC6OTHER (100mg / kg BW) and sandalwood oil (1g / kg BW) for two weeks modulated parameters such as serum BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , free BC6OTHER , protein BC6OTHER , BC6OTHER , liver lipid BC6OTHER contents, and antioxidant capacity in BC6ENTC mediated oxidative stress induced mice. CPR:falsenewlineIn sum the results of the present study indicate that BC6OTHER - induced expression of BC6ENTG expression depends on a novel BC6ENTC response element. CPR:falsenewlineBC6OTHER is known to induce expression of the BC6ENTG ( BC6OTHER ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6ENTC . CPR:falsenewlineBC6OTHER is known to induce expression of the BC6OTHER ( BC6ENTG ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6ENTC . CPR:falsenewlineBC6OTHER is known to induce expression of the BC6OTHER ( BC6OTHER ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6ENTG expression by BC6ENTC . CPR:falsenewlineThe BC6ENTC - treated HL - 60 cells used here expressed all BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER . CPR:falsenewlineThe BC6ENTC - treated HL - 60 cells used here expressed all BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER . CPR:falsenewlineThe BC6ENTC - treated HL - 60 cells used here expressed all BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER . CPR:falsenewlineThe BC6ENTC - treated HL - 60 cells used here expressed all BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) subtypes (as detected by Northern analysis) except BC6OTHER . CPR:falsenewlineThe BC6ENTC - treated HL - 60 cells used here expressed all BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6ENTG . CPR:falsenewlineThe BC6OTHER - treated HL - 60 cells used here expressed all BC6ENTC receptor ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER . CPR:falsenewlineThe BC6OTHER - treated HL - 60 cells used here expressed all BC6ENTC receptor ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER . CPR:falsenewlineThe BC6OTHER - treated HL - 60 cells used here expressed all BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) subtypes (as detected by Northern analysis) except BC6OTHER . CPR:falsenewlineThe BC6OTHER - treated HL - 60 cells used here expressed all BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6ENTG . CPR:falsenewlineThe BC6OTHER - treated HL - 60 cells used here expressed all BC6ENTG ( BC6OTHER ) and BC6ENTC X receptor ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER . CPR:falsenewlineThe BC6OTHER - treated HL - 60 cells used here expressed all BC6OTHER ( BC6ENTG ) and BC6ENTC X receptor ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6OTHER . CPR:falsenewlineThe BC6OTHER - treated HL - 60 cells used here expressed all BC6OTHER ( BC6OTHER ) and BC6ENTC X receptor ( BC6ENTG ) subtypes (as detected by Northern analysis) except BC6OTHER . CPR:falsenewlineThe BC6OTHER - treated HL - 60 cells used here expressed all BC6OTHER ( BC6OTHER ) and BC6ENTC X receptor ( BC6OTHER ) subtypes (as detected by Northern analysis) except BC6ENTG . CPR:falsenewlineA 5' - flanking region capable of supporting BC6ENTC - induced BC6ENTG activation in HL - 60 cells was found to contain a 205 - bp sequence in the distal portion that was necessary for transcriptional activation by BC6OTHER . CPR:falsenewlineA 5' - flanking region capable of supporting BC6OTHER - induced BC6ENTG activation in HL - 60 cells was found to contain a 205 - bp sequence in the distal portion that was necessary for transcriptional activation by BC6ENTC . CPR:falsenewlineWithin this sequence BC6OTHER footprinting revealed that BC6ENTC induced binding of a BC6OTHER to an element containing two BC6ENTG . CPR:falsenewlineWithin this sequence BC6ENTG footprinting revealed that BC6ENTC induced binding of a BC6OTHER to an element containing two BC6OTHER . CPR:falsenewlineWithin this sequence BC6OTHER footprinting revealed that BC6ENTC induced binding of a BC6ENTG to an element containing two BC6OTHER . CPR:falsenewlineA novel BC6OTHER regulates BC6ENTC - induced BC6ENTG expression. CPR:falsenewlineA novel BC6ENTG regulates BC6ENTC - induced BC6OTHER expression. CPR:falsenewlineA novel BC6ENTC - responsive element regulates BC6OTHER - induced BC6ENTG expression. CPR:falsenewlineBC6ENTC is known to induce expression of the BC6ENTG ( BC6OTHER ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6OTHER . CPR:falsenewlineBC6ENTC is known to induce expression of the BC6OTHER ( BC6ENTG ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6OTHER . CPR:falsenewlineBC6ENTC is known to induce expression of the BC6OTHER ( BC6OTHER ) gene which propels BC6OTHER - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6ENTG expression by BC6OTHER . CPR:falsenewlineBoth BC6ENTG were needed for binding the complex, and mutation of either BC6OTHER caused the loss of transcriptional activation by BC6ENTC . CPR:falsenewlineBoth BC6OTHER were needed for binding the complex, and mutation of either BC6ENTG caused the loss of transcriptional activation by BC6ENTC . CPR:falsenewlineThe ability of this cis - acting BC6ENTG to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6ENTG ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6ENTG ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6ENTG ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6ENTG ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTG ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6ENTG ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6ENTC also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6OTHER response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6ENTG gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6ENTG to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6ENTG ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6ENTG ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6ENTG ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6ENTG ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6ENTG ) site between the transcriptional start and first exon of the BC6OTHER gene, were necessary. CPR:falsenewlineThe ability of this cis - acting BC6OTHER to activate transcription in response to BC6OTHER also depended on downstream sequences where an BC6OTHER ( BC6OTHER ) site and a BC6OTHER ( BC6OTHER ) site between this element and the transcriptional start, as well as a BC6ENTC response element binding factor ( BC6OTHER ) site between the transcriptional start and first exon of the BC6ENTG gene, were necessary. CPR:falsenewlineA transcription factor - transcription factor binding array analysis of nuclear lysate from BC6ENTC - treated cells indicated several prominent BC6ENTG binding partners; among these, BC6OTHER , BC6OTHER , and BC6OTHER were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex. CPR:falsenewlineA transcription factor - transcription factor binding array analysis of nuclear lysate from BC6ENTC - treated cells indicated several prominent BC6OTHER binding partners; among these, BC6ENTG , BC6OTHER , and BC6OTHER were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex. CPR:falsenewlineA transcription factor - transcription factor binding array analysis of nuclear lysate from BC6ENTC - treated cells indicated several prominent BC6OTHER binding partners; among these, BC6OTHER , BC6ENTG , and BC6OTHER were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex. CPR:falsenewlineA transcription factor - transcription factor binding array analysis of nuclear lysate from BC6ENTC - treated cells indicated several prominent BC6OTHER binding partners; among these, BC6OTHER , BC6OTHER , and BC6ENTG were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex. CPR:falsenewlineIn sum the results of the present study indicate that BC6ENTC - induced expression of BC6ENTG expression depends on a novel BC6OTHER . CPR:falsenewlineIn sum the results of the present study indicate that BC6ENTC - induced expression of BC6OTHER expression depends on a novel BC6ENTG . CPR:falsenewlineBC6OTHER is known to induce expression of the BC6ENTG ( BC6OTHER ) gene which propels BC6ENTC - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6OTHER . CPR:falsenewlineBC6OTHER is known to induce expression of the BC6OTHER ( BC6ENTG ) gene which propels BC6ENTC - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6OTHER expression by BC6OTHER . CPR:falsenewlineBC6OTHER is known to induce expression of the BC6OTHER ( BC6OTHER ) gene which propels BC6ENTC - induced cell cycle arrest and differentiation of HL - 60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of BC6ENTG expression by BC6OTHER . CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER 's active form) failed to prevent E2 - induced proteolysis of BC6ENTG and migration, but rather triggered BC6OTHER cleavage coincident with augmented migration. CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER 's active form) failed to prevent E2 - induced proteolysis of BC6OTHER and migration, but rather triggered BC6ENTG cleavage coincident with augmented migration. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER 's active form) failed to prevent E2 - induced proteolysis of BC6ENTG and migration, but rather triggered BC6OTHER cleavage coincident with augmented migration. CPR:falsenewlineBC6OTHER ( BC6ENTC , BC6OTHER 's active form) failed to prevent E2 - induced proteolysis of BC6OTHER and migration, but rather triggered BC6ENTG cleavage coincident with augmented migration. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC 's active form) failed to prevent E2 - induced proteolysis of BC6ENTG and migration, but rather triggered BC6OTHER cleavage coincident with augmented migration. CPR:falsenewlineBC6OTHER ( BC6OTHER , BC6ENTC 's active form) failed to prevent E2 - induced proteolysis of BC6OTHER and migration, but rather triggered BC6ENTG cleavage coincident with augmented migration. CPR:falsenewlineBC6ENTC - induced BC6OTHER truncation also occurred in SK - BR - 3 cells that express BC6OTHER and lack BC6OTHER , but not in CHEM - MB - 231 cells that express neither BC6ENTG nor BC6OTHER . CPR:falsenewlineBC6ENTC - induced BC6OTHER truncation also occurred in SK - BR - 3 cells that express BC6OTHER and lack BC6OTHER , but not in CHEM - MB - 231 cells that express neither BC6OTHER nor BC6ENTG . CPR:falsenewlineBC6ENTC - induced BC6ENTG truncation also occurred in SK - BR - 3 cells that express BC6OTHER and lack BC6OTHER , but not in CHEM - MB - 231 cells that express neither BC6OTHER nor BC6OTHER . CPR:falsenewlineBC6ENTC - induced BC6OTHER truncation also occurred in SK - BR - 3 cells that express BC6ENTG and lack BC6OTHER , but not in CHEM - MB - 231 cells that express neither BC6OTHER nor BC6OTHER . CPR:falsenewlineBC6ENTC - induced BC6OTHER truncation also occurred in SK - BR - 3 cells that express BC6OTHER and lack BC6ENTG , but not in CHEM - MB - 231 cells that express neither BC6OTHER nor BC6OTHER . CPR:falsenewline BC6ENTC - stimulated processing of BC6OTHER is mediated via BC6OTHER ( BC6ENTG and accompanied by enhanced migration in MCF - 7 breast cancer cells. CPR:falsenewline BC6ENTC - stimulated processing of BC6ENTG is mediated via BC6OTHER ( BC6OTHER and accompanied by enhanced migration in MCF - 7 breast cancer cells. CPR:falsenewline BC6ENTC - stimulated processing of BC6OTHER is mediated via BC6ENTG ( BC6OTHER and accompanied by enhanced migration in MCF - 7 breast cancer cells. CPR:falsenewlineFurthermore, BC6ENTC - stimulated cleavage of BC6ENTG and migration were tremendously attenuated by G15, a BC6OTHER antagonist, or siRNA against BC6OTHER . CPR:falsenewlineFurthermore, BC6ENTC - stimulated cleavage of BC6OTHER and migration were tremendously attenuated by G15, a BC6ENTG antagonist, or siRNA against BC6OTHER . CPR:falsenewlineFurthermore, BC6ENTC - stimulated cleavage of BC6OTHER and migration were tremendously attenuated by G15, a BC6OTHER antagonist, or siRNA against BC6ENTG . CPR:falsenewlineBC6ENTC (E2) has been recently shown to induce BC6ENTG processing in breast cancer cells. CPR:falsenewlineIn addition, inhibitors for BC6ENTG or BC6OTHER remarkably suppressed BC6ENTC - induced truncation of BC6OTHER , suggesting involvement of BC6OTHER signaling. CPR:falsenewlineIn addition, inhibitors for BC6OTHER or BC6ENTG remarkably suppressed BC6ENTC - induced truncation of BC6OTHER , suggesting involvement of BC6OTHER signaling. CPR:falsenewlineIn addition, inhibitors for BC6OTHER or BC6OTHER remarkably suppressed BC6ENTC - induced truncation of BC6ENTG , suggesting involvement of BC6OTHER signaling. CPR:falsenewlineIn addition, inhibitors for BC6OTHER or BC6OTHER remarkably suppressed BC6ENTC - induced truncation of BC6OTHER , suggesting involvement of BC6ENTG signaling. CPR:falsenewlineCollectively, our data indicate that BC6ENTC contributes to the production of proteolyzed BC6ENTG via BC6OTHER with augmented migration in MCF - 7 cells. CPR:9newlineCollectively, our data indicate that BC6ENTC contributes to the production of proteolyzed BC6OTHER via BC6ENTG with augmented migration in MCF - 7 cells. CPR:9newlineWe therefore addressed possible effects of BC6ENTC on the generation of cleaved BC6ENTG and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6OTHER receptor α ( BC6OTHER ). CPR:falsenewlineWe therefore addressed possible effects of BC6ENTC on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6ENTG and BC6OTHER receptor α ( BC6OTHER ). CPR:falsenewlineWe therefore addressed possible effects of BC6ENTC on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6ENTG ( BC6OTHER ). CPR:falsenewlineWe therefore addressed possible effects of BC6ENTC on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6OTHER receptor α ( BC6ENTG ). CPR:falsenewlineWe therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6ENTG and its signal mechanism(s) in BC6ENTC - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6OTHER receptor α ( BC6OTHER ). CPR:falsenewlineWe therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6ENTC - responsive MCF - 7 breast cancer cells that express both BC6ENTG and BC6OTHER receptor α ( BC6OTHER ). CPR:falsenewlineWe therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6ENTC - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6ENTG ( BC6OTHER ). CPR:falsenewlineWe therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6ENTC - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6OTHER receptor α ( BC6ENTG ). CPR:falsenewlineWe therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6ENTG and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6ENTC receptor α ( BC6OTHER ). CPR:falsenewlineWe therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6ENTG and BC6ENTC receptor α ( BC6OTHER ). CPR:falsenewlineWe therefore addressed possible effects of BC6OTHER on the generation of cleaved BC6OTHER and its signal mechanism(s) in BC6OTHER - responsive MCF - 7 breast cancer cells that express both BC6OTHER and BC6ENTC receptor α ( BC6ENTG ). CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) activity and BC6OTHER ( BC6ENTC ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit. CPR:falsenewlineThe BC6OTHER dismutase ( BC6ENTG ) activity and BC6OTHER ( BC6ENTC ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit. CPR:falsenewlineProtection of BC6ENTC against AGEs - induced endothelial dysfunction through inhibiting BC6OTHER / BC6ENTG pathway activation in human umbilical vein endothelial cells. CPR:falsenewlineProtection of BC6ENTC against AGEs - induced endothelial dysfunction through inhibiting BC6ENTG / BC6OTHER pathway activation in human umbilical vein endothelial cells. CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6ENTC species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit. CPR:falsenewlineThe BC6OTHER dismutase ( BC6ENTG ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6ENTC species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit. CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6ENTC ( BC6OTHER ) kit. CPR:falsenewlineThe BC6OTHER dismutase ( BC6ENTG ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6ENTC ( BC6OTHER ) kit. CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6ENTC ) kit. CPR:falsenewlineThe BC6OTHER dismutase ( BC6ENTG ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6ENTC ) kit. CPR:falsenewlineGA significantly increased antioxidant enzyme BC6ENTG activity and decreased CHEM degradation product BC6ENTC level in a dose - dependent manner. CPR:falsenewlineThe BC6ENTC dismutase ( BC6ENTG ) activity and BC6OTHER ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit. CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) activity and BC6ENTC ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit. CPR:falsenewlineThe BC6OTHER dismutase ( BC6ENTG ) activity and BC6ENTC ( BC6OTHER ) level in cell supernatant were detected by kits while the intracellular reactive BC6OTHER species (ROS) generation was determined by BC6OTHER ( BC6OTHER ) kit. CPR:falsenewlineBC6ENTC ( BC6OTHER , BC6OTHER ) is a relatively selective inhibitor of BC6ENTG ( BC6OTHER ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections. CPR:4newlineBC6ENTC ( BC6OTHER , BC6OTHER ) is a relatively selective inhibitor of BC6OTHER ( BC6ENTG ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections. CPR:4newlineBC6OTHER ( BC6ENTC , BC6OTHER ) is a relatively selective inhibitor of BC6ENTG ( BC6OTHER ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections. CPR:4newlineBC6OTHER ( BC6ENTC , BC6OTHER ) is a relatively selective inhibitor of BC6OTHER ( BC6ENTG ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections. CPR:4newlineBC6OTHER ( BC6OTHER , BC6ENTC ) is a relatively selective inhibitor of BC6ENTG ( BC6OTHER ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections. CPR:4newlineBC6OTHER ( BC6OTHER , BC6ENTC ) is a relatively selective inhibitor of BC6OTHER ( BC6ENTG ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections. CPR:4newlineAffinity chromatography investigations have shown that BC6ENTC also interacts with BC6ENTG . CPR:falsenewlineBC6ENTG ( BC6OTHER ) catalyzes the phosphorylation of BC6ENTC , BC6OTHER , and BC6OTHER in the presence of BC6OTHER and BC6OTHER . CPR:9newlineBC6OTHER ( BC6ENTG ) catalyzes the phosphorylation of BC6ENTC , BC6OTHER , and BC6OTHER in the presence of BC6OTHER and BC6OTHER . CPR:9newlineBC6ENTG ( BC6OTHER ) catalyzes the phosphorylation of BC6OTHER , BC6ENTC , and BC6OTHER in the presence of BC6OTHER and BC6OTHER . CPR:9newlineBC6OTHER ( BC6ENTG ) catalyzes the phosphorylation of BC6OTHER , BC6ENTC , and BC6OTHER in the presence of BC6OTHER and BC6OTHER . CPR:9newlineTo understand this interaction, we determined the crystal structure of BC6ENTG in complex with BC6ENTC , BC6OTHER , and BC6OTHER , the two latter derivatives being designed to bind to BC6OTHER but not to BC6OTHER . CPR:falsenewlineTo understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6ENTC , BC6OTHER , and BC6OTHER , the two latter derivatives being designed to bind to BC6ENTG but not to BC6OTHER . CPR:falsenewlineTo understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6ENTC , BC6OTHER , and BC6OTHER , the two latter derivatives being designed to bind to BC6OTHER but not to BC6ENTG . CPR:falsenewlineTo understand this interaction, we determined the crystal structure of BC6ENTG in complex with BC6OTHER , BC6ENTC , and BC6OTHER , the two latter derivatives being designed to bind to BC6OTHER but not to BC6OTHER . CPR:falsenewlineTo understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6OTHER , BC6ENTC , and BC6OTHER , the two latter derivatives being designed to bind to BC6ENTG but not to BC6OTHER . CPR:falsenewlineTo understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6OTHER , BC6ENTC , and BC6OTHER , the two latter derivatives being designed to bind to BC6OTHER but not to BC6ENTG . CPR:falsenewlineTo understand this interaction, we determined the crystal structure of BC6ENTG in complex with BC6OTHER , BC6OTHER , and BC6ENTC , the two latter derivatives being designed to bind to BC6OTHER but not to BC6OTHER . CPR:falsenewlineTo understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6OTHER , BC6OTHER , and BC6ENTC , the two latter derivatives being designed to bind to BC6ENTG but not to BC6OTHER . CPR:falsenewlineTo understand this interaction, we determined the crystal structure of BC6OTHER in complex with BC6OTHER , BC6OTHER , and BC6ENTC , the two latter derivatives being designed to bind to BC6OTHER but not to BC6ENTG . CPR:falsenewlineBC6ENTC kinase ( BC6ENTG ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6OTHER in the presence of BC6OTHER and BC6OTHER . CPR:falsenewlineBC6ENTG ( BC6OTHER ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6ENTC in the presence of BC6OTHER and BC6OTHER . CPR:9newlineBC6OTHER ( BC6ENTG ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6ENTC in the presence of BC6OTHER and BC6OTHER . CPR:9newlineStructural analysis revealed that these three BC6ENTC bind similarly in the BC6OTHER - binding site of BC6ENTG rather than in the anticipated BC6OTHER - binding site. CPR:falsenewlineStructural analysis revealed that these three BC6OTHER bind similarly in the BC6ENTC - binding site of BC6ENTG rather than in the anticipated BC6OTHER - binding site. CPR:falsenewlineStructural analysis revealed that these three BC6OTHER bind similarly in the BC6OTHER - binding site of BC6ENTG rather than in the anticipated BC6ENTC - binding site. CPR:falsenewlineCrystal structure of BC6ENTG in complex with BC6ENTC and derivatives. CPR:falsenewlineBC6ENTG ( BC6OTHER ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6OTHER in the presence of BC6ENTC and BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTG ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6OTHER in the presence of BC6ENTC and BC6OTHER . CPR:9newlineThis work provides detailed structural information on the interactions between BC6ENTG and BC6ENTC and analogs. CPR:falsenewlineBC6ENTG ( BC6OTHER ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6OTHER in the presence of BC6OTHER and BC6ENTC . CPR:falsenewlineBC6OTHER ( BC6ENTG ) catalyzes the phosphorylation of BC6OTHER , BC6OTHER , and BC6OTHER in the presence of BC6OTHER and BC6ENTC . CPR:9newlineIt could also aid in the design of BC6ENTC derivatives displaying strict selectivity for either BC6ENTG or BC6OTHER . CPR:falsenewlineIt could also aid in the design of BC6ENTC derivatives displaying strict selectivity for either BC6OTHER or BC6ENTG . CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6ENTC ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6ENTG ( BC6OTHER ) activation. CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6ENTC ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6OTHER ( BC6ENTG ) activation. CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6ENTC ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6ENTG ( BC6OTHER ) activation. CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6ENTC ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6OTHER ( BC6ENTG ) activation. CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6ENTC to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6ENTG ( BC6OTHER ) activation. CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6ENTC to BC6OTHER ( BC6OTHER / BC6OTHER ) and an increased BC6OTHER ( BC6ENTG ) activation. CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6ENTC ( BC6OTHER / BC6OTHER ) and an increased BC6ENTG ( BC6OTHER ) activation. CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6ENTC ( BC6OTHER / BC6OTHER ) and an increased BC6OTHER ( BC6ENTG ) activation. CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6ENTC / BC6OTHER ) and an increased BC6ENTG ( BC6OTHER ) activation. CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6ENTC / BC6OTHER ) and an increased BC6OTHER ( BC6ENTG ) activation. CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6ENTC ) and an increased BC6ENTG ( BC6OTHER ) activation. CPR:falsenewlineAltered antioxidant levels were demonstrated by depletion of BC6OTHER ( BC6OTHER ), a decreased ratio of reduced BC6OTHER to BC6OTHER ( BC6OTHER / BC6ENTC ) and an increased BC6OTHER ( BC6ENTG ) activation. CPR:falsenewlineEnzyme assays showed that BC6ENTC dismutase ( BC6ENTG ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and CHEM - BC6OTHER - transferase ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6ENTC dismutase ( BC6OTHER ) activity was elevated whereas BC6ENTG ( BC6OTHER ) and CHEM - BC6OTHER - transferase ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6ENTC dismutase ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6ENTG ) and CHEM - BC6OTHER - transferase ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6ENTC dismutase ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6ENTC dismutase ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and CHEM - BC6OTHER - transferase ( BC6ENTG ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6ENTG ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6OTHER ( BC6ENTG ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6ENTG ( BC6OTHER ) and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6ENTG ) and BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and BC6ENTC - BC6OTHER - transferase ( BC6ENTG ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6ENTG ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and CHEM - BC6ENTC - transferase ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6OTHER ( BC6ENTG ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and CHEM - BC6ENTC - transferase ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6ENTG ( BC6OTHER ) and CHEM - BC6ENTC - transferase ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6ENTG ) and CHEM - BC6ENTC - transferase ( BC6OTHER ) activities were depressed. CPR:falsenewlineEnzyme assays showed that BC6OTHER ( BC6OTHER ) activity was elevated whereas BC6OTHER ( BC6OTHER ) and CHEM - BC6ENTC - transferase ( BC6ENTG ) activities were depressed. CPR:falsenewlineFurther analyses revealed that BC6ENTC - QD exposure resulted in apoptosis, indicated by changes in levels of BC6ENTG activity, BC6OTHER ( BC6OTHER ) cleavage and BC6OTHER externalization. CPR:falsenewlineFurther analyses revealed that BC6ENTC - QD exposure resulted in apoptosis, indicated by changes in levels of BC6OTHER activity, BC6ENTG ( BC6OTHER ) cleavage and BC6OTHER externalization. CPR:falsenewlineFurther analyses revealed that BC6ENTC - QD exposure resulted in apoptosis, indicated by changes in levels of BC6OTHER activity, BC6OTHER ( BC6ENTG ) cleavage and BC6OTHER externalization. CPR:falsenewlineFurther analyses revealed that BC6OTHER - QD exposure resulted in apoptosis, indicated by changes in levels of BC6ENTG activity, BC6ENTC polymerase ( BC6OTHER ) cleavage and BC6OTHER externalization. CPR:falsenewlineFurther analyses revealed that BC6OTHER - QD exposure resulted in apoptosis, indicated by changes in levels of BC6OTHER activity, BC6ENTC polymerase ( BC6ENTG ) cleavage and BC6OTHER externalization. CPR:falsenewlineFurther analyses revealed that BC6OTHER - QD exposure resulted in apoptosis, indicated by changes in levels of BC6ENTG activity, BC6OTHER ( BC6OTHER ) cleavage and BC6ENTC externalization. CPR:falsenewlineFurther analyses revealed that BC6OTHER - QD exposure resulted in apoptosis, indicated by changes in levels of BC6OTHER activity, BC6ENTG ( BC6OTHER ) cleavage and BC6ENTC externalization. CPR:falsenewlineFurther analyses revealed that BC6OTHER - QD exposure resulted in apoptosis, indicated by changes in levels of BC6OTHER activity, BC6OTHER ( BC6ENTG ) cleavage and BC6ENTC externalization. CPR:falsenewlineExtrinsic apoptotic pathway markers such as BC6ENTG levels and BC6OTHER activity increased as a result of BC6ENTC - QD exposure. CPR:falsenewlineExtrinsic apoptotic pathway markers such as BC6OTHER levels and BC6ENTG activity increased as a result of BC6ENTC - QD exposure. CPR:falsenewlineFurther, BC6ENTG ( BC6OTHER ) such as c - Jun BC6ENTC - terminal kinases ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER were all activated. CPR:falsenewlineFurther, BC6OTHER ( BC6ENTG ) such as c - Jun BC6ENTC - terminal kinases ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER were all activated. CPR:falsenewlineFurther, BC6OTHER ( BC6OTHER ) such as c - Jun BC6ENTC - terminal kinases ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER were all activated. CPR:falsenewlineFurther, BC6OTHER ( BC6OTHER ) such as c - Jun BC6ENTC - terminal kinases ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER were all activated. CPR:falsenewlineFurther, BC6OTHER ( BC6OTHER ) such as c - Jun BC6ENTC - terminal kinases ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER were all activated. CPR:falsenewlineFurther, BC6OTHER ( BC6OTHER ) such as c - Jun BC6ENTC - terminal kinases ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG were all activated. CPR:falsenewlineOur findings reveal that BC6ENTC - QDs cause oxidative stress, interfere with antioxidant defenses and activate protein BC6ENTG , leading to apoptosis via both extrinsic and intrinsic pathways. CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6ENTC ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6ENTC ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6ENTC complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6ENTC complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6ENTC ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6ENTC ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6ENTC complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6ENTC complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6ENTC . CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6ENTC . CPR:falsenewlineThis shift in conformational population at higher BC6ENTC ion concentrations and to lower enzyme activity may be due to longer residence time of the BC6OTHER in the BC6ENTG pocket. CPR:falsenewlinePhysiologic levels of BC6OTHER ions decrease BC6ENTG activity in part by increasing BC6ENTC binding affinity to the enzyme. CPR:falsenewlineThis shift in conformational population at higher BC6OTHER ion concentrations and to lower enzyme activity may be due to longer residence time of the BC6ENTC in the BC6ENTG pocket. CPR:falsenewlineThe results from monitoring enzyme catalysis in the absence of BC6ENTC suggests that the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime is the form initially produced, and the complex with the longer fluorescence lifetime is produced through isomerization. CPR:falsenewlineThe results from monitoring enzyme catalysis in the absence of BC6OTHER suggests that the BC6ENTG - BC6ENTC complex with the shorter fluorescence lifetime is the form initially produced, and the complex with the longer fluorescence lifetime is produced through isomerization. CPR:falsenewlineBC6ENTC dehydrogenase 1 ( BC6ENTG ) catalyzes the oxidation of toxic BC6OTHER to BC6OTHER . CPR:falsenewlineWe used this technique to investigate the effects of BC6ENTC ions on the BC6ENTG - BC6OTHER binding characteristics and enzyme catalysis. CPR:falsenewlineWe used this technique to investigate the effects of BC6OTHER ions on the BC6ENTG - BC6ENTC binding characteristics and enzyme catalysis. CPR:falsenewlineFrom the resolved free and bound BC6ENTC fluorescence signatures, the KD values for both BC6OTHER conformations in BC6ENTG ranged from about 24 μM to 1 μM for BC6OTHER ion concentrations of 0 - 6000 μM, respectively. CPR:falsenewlineFrom the resolved free and bound BC6OTHER fluorescence signatures, the KD values for both BC6ENTC conformations in BC6ENTG ranged from about 24 μM to 1 μM for BC6OTHER ion concentrations of 0 - 6000 μM, respectively. CPR:falsenewlineBC6ENTG ( BC6OTHER ) catalyzes the oxidation of toxic BC6ENTC to BC6OTHER . CPR:9newlineBC6OTHER ( BC6ENTG ) catalyzes the oxidation of toxic BC6ENTC to BC6OTHER . CPR:9newlineFrom the resolved free and bound BC6OTHER fluorescence signatures, the KD values for both BC6OTHER conformations in BC6ENTG ranged from about 24 μM to 1 μM for BC6ENTC ion concentrations of 0 - 6000 μM, respectively. CPR:falsenewlineBC6ENTG ( BC6OTHER ) catalyzes the oxidation of toxic BC6OTHER to BC6ENTC . CPR:9newlineBC6OTHER ( BC6ENTG ) catalyzes the oxidation of toxic BC6OTHER to BC6ENTC . CPR:9newlineFluorescence lifetime analysis and effect of BC6ENTC ions on binding of BC6OTHER to BC6ENTG . CPR:falsenewlineFluorescence lifetime analysis and effect of BC6OTHER ions on binding of BC6ENTC to BC6ENTG . CPR:falsenewlinePhysiologic levels of BC6ENTC ions decrease BC6ENTG activity in part by increasing BC6OTHER binding affinity to the enzyme. CPR:falsenewlineAs the BC6ENTC ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineAs the BC6ENTC ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6OTHER ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6ENTC ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6ENTG - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6OTHER - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineAs the BC6OTHER ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s( - 1) (0 μM BC6ENTC ) to 0.050 s( - 1) (6000 μM BC6OTHER ) and a distinct shift in steady - state conformational population from one that favors the BC6OTHER - BC6OTHER complex with the shorter fluorescence lifetime (33% excess) in the absence of BC6OTHER ion to one that favors the BC6ENTG - BC6OTHER complex with the longer fluorescence lifetime (13% excess) at 6000 μM BC6OTHER . CPR:falsenewlineCrystallographic analysis of the BC6ENTG with bound BC6ENTC inhibitors at 2.0 A resolution. CPR:falsenewlineCrystallographic comparison with the structurally related BC6ENTG binary complex with the oxidized cofactor BC6ENTC revealed overlapping binding sites for the BC6OTHER and the cofactor, compatible with a competitive type of inhibition of the BC6OTHER versus CHEM. CPR:falsenewlineCrystallographic comparison with the structurally related BC6ENTG binary complex with the oxidized cofactor BC6OTHER revealed overlapping binding sites for the BC6ENTC and the cofactor, compatible with a competitive type of inhibition of the BC6OTHER versus CHEM. CPR:falsenewlineThe BC6ENTG represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by BC6ENTC derivatives. CPR:falsenewlineCrystallographic comparison with the structurally related BC6ENTG binary complex with the oxidized cofactor BC6OTHER revealed overlapping binding sites for the BC6OTHER and the cofactor, compatible with a competitive type of inhibition of the BC6ENTC versus CHEM. CPR:falsenewlineHere we present the crystal structure of the dimeric catalytic domain (residues 117 - 424) of human BC6ENTC hydroxylase ( BC6ENTG ), cocrystallized with various potent and well - known BC6OTHER inhibitors and refined at a resolution of 2.0 A. CPR:falsenewlineHere we present the crystal structure of the dimeric catalytic domain (residues 117 - 424) of BC6ENTG ( BC6OTHER ), cocrystallized with various potent and well - known BC6ENTC inhibitors and refined at a resolution of 2.0 A. CPR:falsenewlineHere we present the crystal structure of the dimeric catalytic domain (residues 117 - 424) of human BC6OTHER hydroxylase ( BC6ENTG ), cocrystallized with various potent and well - known BC6ENTC inhibitors and refined at a resolution of 2.0 A. CPR:falsenewlineWith a fluorogenic peptide substrate for BC6ENTC proteases, a deficiency in BC6ENTG activity was found in the tumors. CPR:falsenewlineTo gain further insight into the functionality of the BC6ENTG pathway, cDNA microarrays were performed and the expression levels of a panel of 21 BC6OTHER - specific target genes were determined in BC6ENTC - induced tumors that overexpress the ligand. CPR:falsenewlineTo gain further insight into the functionality of the BC6OTHER pathway, cDNA microarrays were performed and the expression levels of a panel of 21 BC6ENTG - specific target genes were determined in BC6ENTC - induced tumors that overexpress the ligand. CPR:falsenewlineTo determine the expression and activation status of BC6ENTG in chemically induced tumors, 6 - wk - old A / J mice were injected intraperitoneally with either BC6ENTC ( BC6OTHER ) (10 mg / kg body weight, once a week for 6 wk) or CHEM solution, and colon tumors were isolated 24 wk following the last injection. CPR:falsenewlineTo determine the expression and activation status of BC6ENTG in chemically induced tumors, 6 - wk - old A / J mice were injected intraperitoneally with either BC6OTHER ( BC6ENTC ) (10 mg / kg body weight, once a week for 6 wk) or CHEM solution, and colon tumors were isolated 24 wk following the last injection. CPR:falsenewlineDefective processing of the BC6ENTG in BC6ENTC - induced mouse colon tumors. CPR:falsenewlineIn a mouse tumor model, removal of only the BC6ENTC - terminal propeptide from full - length BC6ENTG was sufficient to enhance angiogenesis and tumor growth. CPR:falsenewlineBC6ENTG is an angiogenic and lymphangiogenic glycoprotein that can be proteolytically processed generating various forms differing in subunit composition due to the presence or absence of BC6ENTC - and BC6OTHER - terminal propeptides. CPR:falsenewlineBC6ENTG is an angiogenic and lymphangiogenic glycoprotein that can be proteolytically processed generating various forms differing in subunit composition due to the presence or absence of BC6OTHER - and BC6ENTC - terminal propeptides. CPR:falsenewlineWe report for the first time that BC6ENTG binds heparin, and that the BC6ENTC - terminal propeptide significantly enhances this interaction (removal of this propeptide from full - length BC6OTHER completely prevents heparin binding). CPR:falsenewlineWe report for the first time that BC6OTHER binds heparin, and that the BC6ENTC - terminal propeptide significantly enhances this interaction (removal of this propeptide from full - length BC6ENTG completely prevents heparin binding). CPR:falsenewlineWe also show that removal of either the BC6ENTC - or BC6OTHER - terminal propeptide is required for BC6ENTG to drive formation of BC6OTHER / BC6OTHER heterodimers which have recently been shown to positively regulate angiogenic sprouting. CPR:falsenewlineWe also show that removal of either the BC6ENTC - or BC6OTHER - terminal propeptide is required for BC6OTHER to drive formation of BC6ENTG / BC6OTHER heterodimers which have recently been shown to positively regulate angiogenic sprouting. CPR:falsenewlineWe also show that removal of either the BC6ENTC - or BC6OTHER - terminal propeptide is required for BC6OTHER to drive formation of BC6OTHER / BC6ENTG heterodimers which have recently been shown to positively regulate angiogenic sprouting. CPR:falsenewlineWe also show that removal of either the BC6OTHER - or BC6ENTC - terminal propeptide is required for BC6ENTG to drive formation of BC6OTHER / BC6OTHER heterodimers which have recently been shown to positively regulate angiogenic sprouting. CPR:falsenewlineWe also show that removal of either the BC6OTHER - or BC6ENTC - terminal propeptide is required for BC6OTHER to drive formation of BC6ENTG / BC6OTHER heterodimers which have recently been shown to positively regulate angiogenic sprouting. CPR:falsenewlineWe also show that removal of either the BC6OTHER - or BC6ENTC - terminal propeptide is required for BC6OTHER to drive formation of BC6OTHER / BC6ENTG heterodimers which have recently been shown to positively regulate angiogenic sprouting. CPR:falsenewline BC6ENTC and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6OTHER and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6ENTG in rat testes. CPR:falsenewline BC6ENTC and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6ENTG and BC6OTHER and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes. CPR:falsenewline BC6ENTC and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6ENTG and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes. CPR:falsenewline BC6OTHER and BC6ENTC alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6OTHER and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6ENTG in rat testes. CPR:falsenewline BC6OTHER and BC6ENTC alleviate intermittent hypoxia induced abnormal BC6ENTG and BC6OTHER and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes. CPR:falsenewline BC6OTHER and BC6ENTC alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6ENTG and low BC6OTHER by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes. CPR:falsenewline BC6OTHER and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6OTHER and low BC6ENTC by suppressing endoplasmic reticulum stress and activated BC6ENTG in rat testes. CPR:falsenewline BC6OTHER and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6ENTG and BC6OTHER and low BC6ENTC by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes. CPR:falsenewline BC6OTHER and BC6OTHER alleviate intermittent hypoxia induced abnormal BC6OTHER and BC6ENTG and low BC6ENTC by suppressing endoplasmic reticulum stress and activated BC6OTHER in rat testes. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6OTHER ), therefore, BC6ENTC ( BC6OTHER ) an inhibitor of BC6ENTG and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTG ( BC6OTHER ), therefore, BC6ENTC ( BC6OTHER ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6ENTG ), therefore, BC6ENTC ( BC6OTHER ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6OTHER ), therefore, BC6OTHER ( BC6ENTC ) an inhibitor of BC6ENTG and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTG ( BC6OTHER ), therefore, BC6OTHER ( BC6ENTC ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6ENTG ), therefore, BC6OTHER ( BC6ENTC ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6OTHER ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6ENTG and BC6ENTC (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTG ( BC6OTHER ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6OTHER and BC6ENTC (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6ENTG ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6OTHER and BC6ENTC (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6OTHER ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6ENTG and BC6OTHER (RS), a BC6ENTC influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTG ( BC6OTHER ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6ENTC influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6OTHER oxidase ( BC6ENTG ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6ENTC influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineHypoxic rats displayed lower serum BC6ENTC and higher BC6ENTG and BC6OTHER . CPR:falsenewlineHypoxic rats displayed lower serum BC6ENTC and higher BC6OTHER and BC6ENTG . CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTC oxidase ( BC6OTHER ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6ENTG and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineWe hypothesized that hypoxia induced testicular damage is mediated by an activated BC6ENTC oxidase ( BC6ENTG ), therefore, BC6OTHER ( BC6OTHER ) an inhibitor of BC6OTHER and BC6OTHER (RS), a BC6OTHER influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis. CPR:falsenewlineBC6ENTC and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and BC6ENTG in testes. CPR:falsenewlinePharmacodynamic data suggest that BC6ENTC - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6OTHER - BC6OTHER is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates. CPR:falsenewlinePharmacodynamic data suggest that BC6OTHER - BC6ENTC is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6OTHER - BC6OTHER is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates. CPR:falsenewlineBC6OTHER (formerly BC6ENTC , BC6OTHER ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6ENTG and some BC6OTHER enzymes. CPR:falsenewlineBC6OTHER (formerly BC6ENTC , BC6OTHER ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6OTHER and some BC6ENTG enzymes. CPR:falsenewlineBC6OTHER (formerly BC6ENTC , BC6OTHER ) is a synthetic non - BC6OTHER , BC6ENTG inhibitor that inhibits the activities of BC6OTHER and some BC6OTHER enzymes. CPR:falsenewlinePharmacodynamic data suggest that BC6OTHER - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6ENTC alone.Clinical trials to date have reported that BC6OTHER - BC6OTHER is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates. CPR:falsenewlinePharmacodynamic data suggest that BC6OTHER - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6ENTC - BC6OTHER is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates. CPR:falsenewlinePharmacodynamic data suggest that BC6OTHER - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6OTHER - BC6ENTC is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates. CPR:falsenewlinePharmacodynamic data suggest that BC6OTHER - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6OTHER - BC6OTHER is as effective as standard BC6ENTC therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6OTHER - resistant Gram - negative isolates. CPR:falsenewlinePharmacodynamic data suggest that BC6OTHER - BC6OTHER is rapidly bactericidal versus BC6ENTG - producing Gram - negative bacilli that are not inhibited by BC6OTHER alone.Clinical trials to date have reported that BC6OTHER - BC6OTHER is as effective as standard BC6OTHER therapy in complicated intra - abdominal infection and complicated urinary tract infection, including infection caused by BC6ENTC - resistant Gram - negative isolates. CPR:falsenewlineBC6ENTC (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6ENTG and some BC6OTHER enzymes. CPR:4newlineBC6ENTC (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6OTHER and some BC6ENTG enzymes. CPR:4newlineBC6ENTC (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6OTHER , BC6ENTG inhibitor that inhibits the activities of BC6OTHER and some BC6OTHER enzymes. CPR:4newlineBC6ENTC - BC6OTHER appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug - related treatment - emergent adverse events reported to date.In conclusion, BC6OTHER serves to broaden the spectrum of BC6OTHER versus BC6ENTG - producing Gram - negative bacilli. CPR:falsenewlineBC6OTHER - BC6ENTC appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug - related treatment - emergent adverse events reported to date.In conclusion, BC6OTHER serves to broaden the spectrum of BC6OTHER versus BC6ENTG - producing Gram - negative bacilli. CPR:falsenewlineBC6OTHER - BC6OTHER appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug - related treatment - emergent adverse events reported to date.In conclusion, BC6ENTC serves to broaden the spectrum of BC6OTHER versus BC6ENTG - producing Gram - negative bacilli. CPR:falsenewlineBC6OTHER - BC6OTHER appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug - related treatment - emergent adverse events reported to date.In conclusion, BC6OTHER serves to broaden the spectrum of BC6ENTC versus BC6ENTG - producing Gram - negative bacilli. CPR:falsenewlineBC6OTHER (formerly BC6OTHER , BC6ENTC ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6ENTG and some BC6OTHER enzymes. CPR:falsenewlineBC6OTHER (formerly BC6OTHER , BC6ENTC ) is a synthetic non - BC6OTHER , BC6OTHER inhibitor that inhibits the activities of BC6OTHER and some BC6ENTG enzymes. CPR:falsenewlineBC6OTHER (formerly BC6OTHER , BC6ENTC ) is a synthetic non - BC6OTHER , BC6ENTG inhibitor that inhibits the activities of BC6OTHER and some BC6OTHER enzymes. CPR:falsenewlinePotential future roles for BC6ENTC - BC6OTHER include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and / or BC6OTHER . CPR:falsenewlinePotential future roles for BC6ENTC - BC6OTHER include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and / or BC6OTHER . CPR:falsenewlinePotential future roles for BC6ENTC - BC6OTHER include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and / or BC6OTHER . CPR:falsenewlinePotential future roles for BC6ENTC - BC6OTHER include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and / or BC6OTHER . CPR:falsenewlinePotential future roles for BC6ENTC - BC6OTHER include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and / or BC6ENTG . CPR:falsenewlinePotential future roles for BC6OTHER - BC6ENTC include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and / or BC6OTHER . CPR:falsenewlinePotential future roles for BC6OTHER - BC6ENTC include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and / or BC6OTHER . CPR:falsenewlinePotential future roles for BC6OTHER - BC6ENTC include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and / or BC6OTHER . CPR:falsenewlinePotential future roles for BC6OTHER - BC6ENTC include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and / or BC6OTHER . CPR:falsenewlinePotential future roles for BC6OTHER - BC6ENTC include the treatment of suspected or documented infections caused by resistant Gram - negative - bacilli producing BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and / or BC6ENTG . CPR:falsenewlineAlthough not a BC6ENTC , the chemical structure of BC6OTHER closely resembles portions of the BC6OTHER bicyclic ring system, and BC6OTHER has been shown to bond covalently to BC6ENTG . CPR:falsenewlineAlthough not a BC6OTHER , the chemical structure of BC6ENTC closely resembles portions of the BC6OTHER bicyclic ring system, and BC6OTHER has been shown to bond covalently to BC6ENTG . CPR:falsenewlineAlthough not a BC6OTHER , the chemical structure of BC6OTHER closely resembles portions of the BC6ENTC bicyclic ring system, and BC6OTHER has been shown to bond covalently to BC6ENTG . CPR:falsenewlineAlthough not a BC6OTHER , the chemical structure of BC6OTHER closely resembles portions of the BC6OTHER bicyclic ring system, and BC6ENTC has been shown to bond covalently to BC6ENTG . CPR:falsenewlineBC6OTHER (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6ENTC , BC6OTHER inhibitor that inhibits the activities of BC6ENTG and some BC6OTHER enzymes. CPR:falsenewlineBC6OTHER (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6ENTC , BC6OTHER inhibitor that inhibits the activities of BC6OTHER and some BC6ENTG enzymes. CPR:falsenewlineBC6OTHER (formerly BC6OTHER , BC6OTHER ) is a synthetic non - BC6ENTC , BC6ENTG inhibitor that inhibits the activities of BC6OTHER and some BC6OTHER enzymes. CPR:falsenewlineThe addition of BC6ENTC greatly (4 - 1024 - fold minimum inhibitory concentration [MIC] reduction) improves the activity of BC6OTHER versus most species of Enterobacteriaceae depending on the presence or absence of BC6ENTG enzyme(s). CPR:falsenewlineThe addition of BC6OTHER greatly (4 - 1024 - fold minimum inhibitory concentration [MIC] reduction) improves the activity of BC6ENTC versus most species of Enterobacteriaceae depending on the presence or absence of BC6ENTG enzyme(s). CPR:falsenewline BC6ENTC - BC6OTHER : a novel BC6OTHER / BC6ENTG inhibitor combination. CPR:falsenewline BC6OTHER - BC6ENTC : a novel BC6OTHER / BC6ENTG inhibitor combination. CPR:falsenewline BC6OTHER - BC6OTHER : a novel BC6ENTC / BC6ENTG inhibitor combination. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6ENTC / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6ENTC , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6ENTC species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6ENTC - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6ENTG ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6ENTG , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6ENTG , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6ENTG , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTC regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTG , BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6ENTG ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6ENTG , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6ENTG , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6ENTG , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6ENTC synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6ENTG , BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6ENTG ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6ENTG , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6ENTG , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6ENTG , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6ENTG BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER expressions. CPR:falsenewlineThe administration of GS significantly decreased BC6OTHER regulatory element binding protein - 1, BC6OTHER ?>Bp65, BC6OTHER , inducible BC6OTHER synthase, BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC - terminal BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG expressions. CPR:falsenewlineThe results showed that levels of BC6ENTC , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6ENTC , non - esterified BC6OTHER , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6ENTG BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6ENTC , BC6OTHER BC6OTHER , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6ENTG BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6ENTG BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6ENTG BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6OTHER was augmented by GS treatment. CPR:falsenewlineThe results showed that levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , total BC6OTHER , non - esterified BC6OTHER , BC6OTHER BC6ENTC , very BC6OTHER BC6OTHER / BC6OTHER BC6OTHER , reactive BC6OTHER species (ROS), and BC6OTHER - reactive substance (TBARS) in serum were down - regulated, while BC6ENTG was augmented by GS treatment. CPR:falsenewlineBC6OTHER ( BC6ENTG ) is currently the most suitable bioscavenger for the prophylaxis of highly toxic BC6ENTC (OP) nerve agents. CPR:falsenewlineBC6ENTG ( BC6OTHER ) is currently the most suitable bioscavenger for the prophylaxis of highly toxic BC6ENTC (OP) nerve agents. CPR:falsenewlineStudies have indicated that the three - dimensional structure and the domains of BC6ENTG ( BC6ENTC pocket, lip of the active center gorge, and the anionic substrate - binding domain) that are critical for the binding of substrate are also essential for the selectivity and binding of inhibitors including OPs. CPR:falsenewline BC6ENTC residues at the CHEM - and C - termini are essential for the folding of active BC6ENTG polypeptide. CPR:falsenewlineBC6OTHER [ BC6ENTC ] is a second - generation BC6OTHER pharmacophore that selectively and irreversibly inhibits brain BC6ENTG and is specifically designed for the treatment of Parkinson's disease (PD). CPR:4newlineBC6OTHER [ BC6OTHER ] is a second - generation BC6ENTC pharmacophore that selectively and irreversibly inhibits brain BC6ENTG and is specifically designed for the treatment of Parkinson's disease (PD). CPR:4newlineBACKGROUND: Inhibitors of BC6ENTC oxidase ( BC6ENTG ) with selectivity and specificity for BC6OTHER ( BC6OTHER ) prolong the duration of action of both endogenously and exogenously derived BC6OTHER . CPR:falsenewlineBACKGROUND: Inhibitors of BC6ENTC oxidase ( BC6OTHER ) with selectivity and specificity for BC6ENTG ( BC6OTHER ) prolong the duration of action of both endogenously and exogenously derived BC6OTHER . CPR:falsenewlineBACKGROUND: Inhibitors of BC6ENTC oxidase ( BC6OTHER ) with selectivity and specificity for BC6OTHER ( BC6ENTG ) prolong the duration of action of both endogenously and exogenously derived BC6OTHER . CPR:falsenewlineIn experimental models, BC6ENTC has been found to have neuroprotective properties that may be independent of BC6ENTG inhibition. CPR:falsenewlineThe search terms were BC6ENTG , neuroprotection, Parkinson disease, BC6ENTC , BC6OTHER , and BC6OTHER . CPR:falsenewlineThe search terms were BC6ENTG , neuroprotection, Parkinson disease, BC6OTHER , BC6ENTC , and BC6OTHER . CPR:falsenewlineThe search terms were BC6ENTG , neuroprotection, Parkinson disease, BC6OTHER , BC6OTHER , and BC6ENTC . CPR:falsenewlineComprehensive review of BC6ENTC , a second - generation BC6ENTG inhibitor, for the treatment of Parkinson's disease. CPR:4newlineBased on the results from those studies, we concluded that BC6ENTC PO QD, at the therapeutic dosage range of 0.5 to 1 rag / d, is effective and well tolerated and completely, selectively, and specifically inhibited BC6ENTG . CPR:4newlineBACKGROUND: Inhibitors of BC6ENTG ( BC6OTHER ) with selectivity and specificity for BC6OTHER ( BC6OTHER ) prolong the duration of action of both endogenously and exogenously derived BC6ENTC . CPR:falsenewlineBACKGROUND: Inhibitors of BC6OTHER ( BC6ENTG ) with selectivity and specificity for BC6OTHER ( BC6OTHER ) prolong the duration of action of both endogenously and exogenously derived BC6ENTC . CPR:falsenewlineBACKGROUND: Inhibitors of BC6OTHER ( BC6OTHER ) with selectivity and specificity for BC6ENTG ( BC6OTHER ) prolong the duration of action of both endogenously and exogenously derived BC6ENTC . CPR:falsenewlineBACKGROUND: Inhibitors of BC6OTHER ( BC6OTHER ) with selectivity and specificity for BC6OTHER ( BC6ENTG ) prolong the duration of action of both endogenously and exogenously derived BC6ENTC . CPR:falsenewlineBC6ENTC [ BC6OTHER ] is a second - generation BC6OTHER pharmacophore that selectively and irreversibly inhibits brain BC6ENTG and is specifically designed for the treatment of Parkinson's disease (PD). CPR:4newlineT - Cells from BC6ENTG + Human Subjects Are Activated with BC6ENTC through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms. CPR:falsenewlineThese data suggest that T - cells can be activated by BC6ENTC through a direct interaction with surface and intracellular BC6ENTG ( BC6OTHER ) molecules. CPR:falsenewlineThese data suggest that T - cells can be activated by BC6ENTC through a direct interaction with surface and intracellular BC6OTHER ( BC6ENTG ) molecules. CPR:falsenewlineWith the former, BC6ENTC seemingly participates in the BC6ENTG BC6OTHER binding interaction. CPR:falsenewlineWith the former, BC6ENTC seemingly participates in the BC6OTHER BC6ENTG binding interaction. CPR:falsenewlineIn contrast, the latter pathway likely involves BC6ENTG binding peptides displayed as a consequence of BC6ENTC exposure, but not BC6OTHER itself. CPR:falsenewlineIn contrast, the latter pathway likely involves BC6ENTG binding peptides displayed as a consequence of BC6OTHER exposure, but not BC6ENTC itself. CPR:falsenewlineThe objectives of this study were to characterize the functionality of drug - responsive CD8+ T - cell clones generated from BC6ENTG + drug - naive subjects and to explore the relationship between BC6ENTC accumulation in antigen presenting cells and the T - cell response. CPR:falsenewlineSeventy - four CD8+ clones expressing different BC6ENTG were shown to proliferate and kill target cells via different mechanisms when exposed to BC6ENTC . CPR:falsenewlineThe mutant BC6OTHER ( BC6ENTG ) contained a total of 5 BC6ENTC substitutions that conferred an activating to inhibitory ratio of 25 (A / I ratio; BC6OTHER - R131: BC6OTHER ). CPR:falsenewlineThe mutant BC6OTHER ( BC6OTHER ) contained a total of 5 BC6ENTC substitutions that conferred an activating to inhibitory ratio of 25 (A / I ratio; BC6ENTG - R131: BC6OTHER ). CPR:falsenewlineThe mutant BC6OTHER ( BC6OTHER ) contained a total of 5 BC6ENTC substitutions that conferred an activating to inhibitory ratio of 25 (A / I ratio; BC6OTHER - R131: BC6ENTG ). CPR:falsenewlineThe mutant BC6ENTG ( BC6OTHER ) contained a total of 5 BC6ENTC substitutions that conferred an activating to inhibitory ratio of 25 (A / I ratio; BC6OTHER - R131: BC6OTHER ). CPR:falsenewlineSingle - strand conformational analysis and BC6ENTC sequencing of the entire coding region of the BC6ENTG gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 ( BC6OTHER ) and 14 ( BC6OTHER ), neither of which was associated with NIDDM in this population. CPR:falsenewlineSingle - strand conformational analysis and BC6ENTC sequencing of the entire coding region of the BC6OTHER gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 ( BC6ENTG ) and 14 ( BC6OTHER ), neither of which was associated with NIDDM in this population. CPR:falsenewlineSingle - strand conformational analysis and BC6ENTC sequencing of the entire coding region of the BC6OTHER gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 ( BC6OTHER ) and 14 ( BC6ENTG ), neither of which was associated with NIDDM in this population. CPR:falsenewlineBC6ENTG is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6OTHER molecule on the BC6ENTC - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6OTHER - peptide. CPR:falsenewlineBC6OTHER is a BC6ENTG that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6OTHER molecule on the BC6ENTC - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6OTHER - peptide. CPR:falsenewlineBC6OTHER is a BC6OTHER that initiates the sequential processing of BC6ENTG to BC6OTHER by cleaving the BC6OTHER molecule on the BC6ENTC - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6OTHER - peptide. CPR:falsenewlineBC6OTHER is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6ENTG by cleaving the BC6OTHER molecule on the BC6ENTC - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6OTHER - peptide. CPR:falsenewlineBC6OTHER is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6ENTG molecule on the BC6ENTC - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6OTHER - peptide. CPR:falsenewlineBC6ENTG is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6OTHER molecule on the BC6OTHER - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6ENTC - peptide. CPR:falsenewlineBC6OTHER is a BC6ENTG that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6OTHER molecule on the BC6OTHER - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6ENTC - peptide. CPR:falsenewlineBC6OTHER is a BC6OTHER that initiates the sequential processing of BC6ENTG to BC6OTHER by cleaving the BC6OTHER molecule on the BC6OTHER - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6ENTC - peptide. CPR:falsenewlineBC6OTHER is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6ENTG by cleaving the BC6OTHER molecule on the BC6OTHER - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6ENTC - peptide. CPR:falsenewlineBC6OTHER is a BC6OTHER that initiates the sequential processing of BC6OTHER to BC6OTHER by cleaving the BC6ENTG molecule on the BC6OTHER - terminal side of the dibasic peptide, CHEM, joining the B - chain and BC6ENTC - peptide. CPR:falsenewlineExpressions of BC6ENTG and BC6OTHER , but not BC6OTHER , are coordinately regulated by BC6ENTC , consistent with the important role of BC6OTHER in regulating BC6OTHER processing. CPR:falsenewlineExpressions of BC6OTHER and BC6ENTG , but not BC6OTHER , are coordinately regulated by BC6ENTC , consistent with the important role of BC6OTHER in regulating BC6OTHER processing. CPR:falsenewlineExpressions of BC6OTHER and BC6OTHER , but not BC6ENTG , are coordinately regulated by BC6ENTC , consistent with the important role of BC6OTHER in regulating BC6OTHER processing. CPR:falsenewlineExpressions of BC6OTHER and BC6OTHER , but not BC6OTHER , are coordinately regulated by BC6ENTC , consistent with the important role of BC6ENTG in regulating BC6OTHER processing. CPR:falsenewlineExpressions of BC6OTHER and BC6OTHER , but not BC6OTHER , are coordinately regulated by BC6ENTC , consistent with the important role of BC6OTHER in regulating BC6ENTG processing. CPR:falsenewlineThe residence time of a stoichiometric bioscavenger, BC6OTHER ( BC6ENTG ), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs ( BC6ENTC , anti - muscarinic, anticonvulsant). CPR:falsenewlineThe residence time of a stoichiometric bioscavenger, BC6ENTG ( BC6OTHER ), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs ( BC6ENTC , anti - muscarinic, anticonvulsant). CPR:falsenewlineA combination of nerve agent therapy drugs ( BC6ENTC , anti - muscarinic, anticonvulsant) with BC6ENTG (i.m.) CPR:falsenewlineBC6ENTG responded only to BC6ENTC . CPR:falsenewlineThese findings suggest that BC6OTHER specifically suppresses the barrel rotation evoked by BC6ENTC in a long - lasting manner possibly acting through BC6ENTG . CPR:falsenewlinewt., IP) 3 days or 7 days prior to the injection of BC6ENTC significantly inhibited the response rate of barrel rotation induced by BC6OTHER , but not that induced by BC6ENTG (1 microgram / rat, ICV). CPR:falsenewlinewt., IP) 3 days or 7 days prior to the injection of BC6OTHER significantly inhibited the response rate of barrel rotation induced by BC6ENTC , but not that induced by BC6ENTG (1 microgram / rat, ICV). CPR:falsenewlineIntracerebroventricular administration of BC6ENTC (5 micrograms / rat), a BC6ENTG analogue, induced barrel rotation in rats. CPR:falsenewlineThe suppressive effect of BC6ENTC on barrel rotation could be partially countered by BC6OTHER , a selective peripheral BC6ENTG BC6OTHER antagonist. CPR:falsenewlineThe suppressive effect of BC6ENTC on barrel rotation could be partially countered by BC6OTHER , a selective peripheral BC6OTHER BC6ENTG antagonist. CPR:falsenewlineThe suppressive effect of BC6OTHER on barrel rotation could be partially countered by BC6ENTC , a selective peripheral BC6ENTG BC6OTHER antagonist. CPR:falsenewlineThe suppressive effect of BC6OTHER on barrel rotation could be partially countered by BC6ENTC , a selective peripheral BC6OTHER BC6ENTG antagonist. CPR:falsenewlineThese findings suggest that BC6ENTC specifically suppresses the barrel rotation evoked by BC6OTHER in a long - lasting manner possibly acting through BC6ENTG . CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6ENTG , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTG (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6ENTG and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6ENTC transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6ENTG in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6ENTG , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTG (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters ( BC6ENTG ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6ENTG and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6ENTG ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6ENTG ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6ENTG itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTC decarboxylase - 67 ( BC6OTHER ) and BC6OTHER itself, have shown that BC6ENTG in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6ENTG , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTG (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters ( BC6ENTG ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6ENTG and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6ENTC itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6OTHER transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC itself, have shown that BC6ENTG in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewline[ BC6OTHER ] ( BC6ENTC ), a selective BC6ENTG antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection. CPR:falsenewlineAs GABAergic synapses in the PVN impinge directly on oxytocinergic neurons or on excitatory glutamatergic synapses, which also impinge on oxytocinergic neurons, these results suggest that the blockade of BC6ENTG decreases BC6ENTC release in the PVN, increasing in turn glutamatergic neurotransmission to activate oxytocinergic neurons mediating penile erection. CPR:falsenewlineThe present findings confirm that PVN BC6ENTG , localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of BC6OTHER by BC6ENTC increases the density of these receptors in the PVN. CPR:falsenewlineThe present findings confirm that PVN BC6OTHER , localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of BC6ENTG by BC6ENTC increases the density of these receptors in the PVN. CPR:falsenewline[ BC6ENTC ] ( BC6OTHER ), a selective BC6ENTG antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6ENTG , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters ( BC6ENTG ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6ENTG and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6OTHER itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG itself, have shown that BC6OTHER in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineDouble immunofluorescence studies with selective antibodies against BC6OTHER , BC6ENTC transporters (vesicular BC6OTHER transporters 1 and 2 ( BC6OTHER and BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER itself, have shown that BC6ENTG in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies. CPR:falsenewlineThese profiles suggest a mechanism of action for each agent, BC6ENTG agonism for BC6ENTC and alpha 1 antagonism for BC6OTHER and BC6OTHER . CPR:falsenewlineThese profiles suggest a mechanism of action for each agent, BC6ENTG agonism for BC6OTHER and alpha 1 antagonism for BC6ENTC and BC6OTHER . CPR:falsenewlineThese profiles suggest a mechanism of action for each agent, BC6ENTG agonism for BC6OTHER and alpha 1 antagonism for BC6OTHER and BC6ENTC . CPR:falsenewlineThe BC6ENTG agonist activity reported here clearly distinguishes BC6ENTC from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions. CPR:5newlineWhile it is an antagonist at these latter receptors, BC6ENTC behaves as a BC6ENTG agonist in vitro in BC6OTHER measurements. CPR:5newlineWhile it is an antagonist at these latter receptors, BC6ENTC behaves as a BC6OTHER agonist in vitro in BC6ENTG measurements. CPR:5newlineWhile it is an antagonist at these latter receptors, BC6OTHER behaves as a BC6ENTG agonist in vitro in BC6ENTC cyclase measurements. CPR:falsenewlineThe goal of the present study was to examine the BC6ENTG properties of BC6ENTC in vivo using as a marker of central BC6OTHER activity the inhibition of firing of BC6OTHER - containing neurons in the dorsal raphe nucleus. CPR:falsenewlineThe goal of the present study was to examine the BC6OTHER properties of BC6ENTC in vivo using as a marker of central BC6ENTG activity the inhibition of firing of BC6OTHER - containing neurons in the dorsal raphe nucleus. CPR:falsenewlineThe goal of the present study was to examine the BC6ENTG properties of BC6OTHER in vivo using as a marker of central BC6OTHER activity the inhibition of firing of BC6ENTC - containing neurons in the dorsal raphe nucleus. CPR:falsenewlineThe goal of the present study was to examine the BC6OTHER properties of BC6OTHER in vivo using as a marker of central BC6ENTG activity the inhibition of firing of BC6ENTC - containing neurons in the dorsal raphe nucleus. CPR:falsenewlineBC6ENTC is a novel antipsychotic agent which binds with high affinity to BC6OTHER (Ki = 3.4 nM), in addition to BC6ENTG , BC6OTHER , and BC6OTHER sites. CPR:falsenewlineBC6ENTC is a novel antipsychotic agent which binds with high affinity to BC6OTHER (Ki = 3.4 nM), in addition to BC6OTHER , BC6ENTG , and BC6OTHER sites. CPR:falsenewlineBC6ENTC is a novel antipsychotic agent which binds with high affinity to BC6OTHER (Ki = 3.4 nM), in addition to BC6OTHER , BC6OTHER , and BC6ENTG sites. CPR:falsenewlineBC6ENTC is a novel antipsychotic agent which binds with high affinity to BC6ENTG (Ki = 3.4 nM), in addition to BC6OTHER , BC6OTHER , and BC6OTHER sites. CPR:falsenewlinePretreatment with the BC6ENTG antagonist BC6ENTC (10 micrograms / kg i.v.) CPR:6newlineComparison of the novel antipsychotic BC6ENTC with BC6OTHER and BC6OTHER : inhibition of dorsal raphe cell firing and the role of BC6ENTG activation. CPR:falsenewlineComparison of the novel antipsychotic BC6OTHER with BC6ENTC and BC6OTHER : inhibition of dorsal raphe cell firing and the role of BC6ENTG activation. CPR:falsenewlineComparison of the novel antipsychotic BC6OTHER with BC6OTHER and BC6ENTC : inhibition of dorsal raphe cell firing and the role of BC6ENTG activation. CPR:falsenewlineBecause all three agents also bind to BC6ENTG , antagonists of which inhibit BC6ENTC neuronal firing, this aspect of their pharmacology was assessed with BC6OTHER ( BC6OTHER ), a BC6OTHER re - uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity. CPR:falsenewlineBecause all three agents also bind to BC6ENTG , antagonists of which inhibit BC6OTHER neuronal firing, this aspect of their pharmacology was assessed with BC6ENTC ( BC6OTHER ), a BC6OTHER re - uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity. CPR:falsenewlineBecause all three agents also bind to BC6ENTG , antagonists of which inhibit BC6OTHER neuronal firing, this aspect of their pharmacology was assessed with BC6OTHER ( BC6ENTC ), a BC6OTHER re - uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity. CPR:falsenewlineBecause all three agents also bind to BC6ENTG , antagonists of which inhibit BC6OTHER neuronal firing, this aspect of their pharmacology was assessed with BC6OTHER ( BC6OTHER ), a BC6ENTC re - uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity. CPR:falsenewlineThrough demonstrating the selective inhibition of BC6ENTG - related T - lymphocyte responses by BC6ENTC , our results emphasize the substantial role of BC6OTHER - BC6OTHER complexes in T - cell activation. CPR:4newlineThrough demonstrating the selective inhibition of BC6OTHER - related T - lymphocyte responses by BC6ENTC , our results emphasize the substantial role of BC6ENTG - BC6OTHER complexes in T - cell activation. CPR:falsenewlineThrough demonstrating the selective inhibition of BC6OTHER - related T - lymphocyte responses by BC6ENTC , our results emphasize the substantial role of BC6OTHER - BC6ENTG complexes in T - cell activation. CPR:falsenewlineImproper function of these proteins can be induced by selective disruption of their complexes with BC6ENTG using the BC6ENTC BC6OTHER . CPR:falsenewlineImproper function of these proteins can be induced by selective disruption of their complexes with BC6ENTG using the BC6OTHER BC6ENTC . CPR:falsenewlineIn this study, we demonstrate that BC6ENTC treatment blocks BC6ENTG secretion, BC6OTHER expression, and proliferation of stimulated T - lymphocytes. CPR:4newlineIn this study, we demonstrate that BC6ENTC treatment blocks BC6OTHER secretion, BC6ENTG expression, and proliferation of stimulated T - lymphocytes. CPR:4newlineMoreover, BC6ENTC decreases the amount and phosphorylation of BC6ENTG and BC6OTHER BC6OTHER and prevents activation of the BC6OTHER BC6OTHER . CPR:falsenewlineMoreover, BC6ENTC decreases the amount and phosphorylation of BC6OTHER and BC6ENTG BC6OTHER and prevents activation of the BC6OTHER BC6OTHER . CPR:falsenewlineMoreover, BC6ENTC decreases the amount and phosphorylation of BC6OTHER and BC6OTHER BC6ENTG and prevents activation of the BC6OTHER BC6OTHER . CPR:falsenewlineMoreover, BC6ENTC decreases the amount and phosphorylation of BC6OTHER and BC6OTHER BC6OTHER and prevents activation of the BC6ENTG BC6OTHER . CPR:falsenewlineMoreover, BC6ENTC decreases the amount and phosphorylation of BC6OTHER and BC6OTHER BC6OTHER and prevents activation of the BC6OTHER BC6ENTG . CPR:falsenewlineBC6ENTC also disrupts the BC6ENTG - mediated activation of BC6OTHER ( BC6OTHER ). CPR:falsenewlineBC6ENTC also disrupts the BC6OTHER - mediated activation of BC6ENTG ( BC6OTHER ). CPR:falsenewlineBC6ENTC also disrupts the BC6OTHER - mediated activation of BC6OTHER ( BC6ENTG ). CPR:falsenewlineTreatment with BC6ENTC , however, does not affect the activation of BC6OTHER , which is a plasma membrane enzyme coupled to the BC6ENTG after T - cell stimulation. CPR:falsenewlineTreatment with BC6ENTC , however, does not affect the activation of BC6ENTG , which is a plasma membrane enzyme coupled to the BC6OTHER after T - cell stimulation. CPR:falsenewlineThe BC6ENTG - specific inhibitor BC6ENTC selectively disrupts BC6OTHER - mediated signaling events of T - lymphocyte activation. CPR:4newlineThe BC6OTHER - specific inhibitor BC6ENTC selectively disrupts BC6ENTG - mediated signaling events of T - lymphocyte activation. CPR:falsenewlineThe efficacy of the combination of BC6ENTC and BC6ENTG inhibitors for diabetic patients on hemodialysis (HD) has not been prospectively evaluated; therefore, we evaluated the efficacy and safety of BC6OTHER in these patients. CPR:falsenewlineThe efficacy of the combination of BC6OTHER and BC6ENTG inhibitors for diabetic patients on hemodialysis (HD) has not been prospectively evaluated; therefore, we evaluated the efficacy and safety of BC6ENTC in these patients. CPR:falsenewlineThe efficacy of the treatment was determined by monitoring plasma BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) levels and using homeostasis model assessment of BC6ENTG resistance (HOMA - IR). CPR:falsenewlineThe efficacy of the treatment was determined by monitoring plasma BC6ENTC , BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) levels and using homeostasis model assessment of BC6OTHER resistance (HOMA - IR). CPR:falsenewlineThe efficacy of the treatment was determined by monitoring plasma BC6ENTC , BC6OTHER ( BC6ENTG ), and BC6OTHER ( BC6OTHER ) levels and using homeostasis model assessment of BC6OTHER resistance (HOMA - IR). CPR:falsenewlineThe efficacy of the treatment was determined by monitoring plasma BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) levels and using homeostasis model assessment of BC6OTHER resistance (HOMA - IR). CPR:falsenewlineThe efficacy of the treatment was determined by monitoring plasma BC6ENTC , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTG ) levels and using homeostasis model assessment of BC6OTHER resistance (HOMA - IR). CPR:falsenewlineOBJECTIVE: BC6ENTC , a rapid - and short - acting insulinotropic BC6ENTG ligand, exhibits hypoglycemic action unlike other BC6OTHER . CPR:falsenewlineBC6ENTC reduced fasting plasma BC6OTHER and BC6ENTG levels after 4 weeks and BC6OTHER levels after 8 weeks. CPR:falsenewlineBC6ENTC reduced fasting plasma BC6OTHER and BC6OTHER levels after 4 weeks and BC6ENTG levels after 8 weeks. CPR:falsenewlineBC6OTHER reduced fasting plasma BC6ENTC and BC6ENTG levels after 4 weeks and BC6OTHER levels after 8 weeks. CPR:falsenewlineBC6OTHER reduced fasting plasma BC6ENTC and BC6OTHER levels after 4 weeks and BC6ENTG levels after 8 weeks. CPR:falsenewlineOBJECTIVE: BC6OTHER , a rapid - and short - acting insulinotropic BC6ENTG ligand, exhibits hypoglycemic action unlike other BC6ENTC . CPR:falsenewlineBC6ENTC (a specific inhibitor of BC6OTHER BC6OTHER ) markedly suppressed the increased expression of BC6ENTG and BC6OTHER in BC6OTHER - induced NPDFs. CPR:falsenewlineBC6ENTC (a specific inhibitor of BC6OTHER BC6OTHER ) markedly suppressed the increased expression of BC6OTHER and BC6ENTG in BC6OTHER - induced NPDFs. CPR:falsenewlineBC6ENTC (a specific inhibitor of BC6OTHER BC6OTHER ) markedly suppressed the increased expression of BC6OTHER and BC6OTHER in BC6ENTG - induced NPDFs. CPR:falsenewlineBC6ENTC (a specific inhibitor of BC6ENTG BC6OTHER ) markedly suppressed the increased expression of BC6OTHER and BC6OTHER in BC6OTHER - induced NPDFs. CPR:falsenewlineBC6ENTC (a specific inhibitor of BC6OTHER BC6ENTG ) markedly suppressed the increased expression of BC6OTHER and BC6OTHER in BC6OTHER - induced NPDFs. CPR:falsenewlineBC6ENTC exerts suppressive effects on phenotype changes and ECM production in NPDFs via BC6ENTG signaling pathway interference. CPR:falsenewlineNPDFs were pre - treated with BC6ENTC prior to induction by BC6ENTG . CPR:falsenewlineIn BC6ENTG - induced NPDFs, BC6ENTC significantly inhibited the expression of BC6OTHER and BC6OTHER mRNA and reduced BC6OTHER and BC6OTHER protein levels. CPR:falsenewlineIn BC6OTHER - induced NPDFs, BC6ENTC significantly inhibited the expression of BC6ENTG and BC6OTHER mRNA and reduced BC6OTHER and BC6OTHER protein levels. CPR:4newlineIn BC6OTHER - induced NPDFs, BC6ENTC significantly inhibited the expression of BC6OTHER and BC6ENTG mRNA and reduced BC6OTHER and BC6OTHER protein levels. CPR:4newlineIn BC6OTHER - induced NPDFs, BC6ENTC significantly inhibited the expression of BC6OTHER and BC6OTHER mRNA and reduced BC6ENTG and BC6OTHER protein levels. CPR:4newlineIn BC6OTHER - induced NPDFs, BC6ENTC significantly inhibited the expression of BC6OTHER and BC6OTHER mRNA and reduced BC6OTHER and BC6ENTG protein levels. CPR:4newlineBC6ENTC only suppressed the expression of BC6ENTG among the evaluated signaling molecules. CPR:falsenewline BC6ENTC inhibits myofibroblast differentiation in nasal polyp - derived fibroblasts via the BC6ENTG pathway. CPR:falsenewlineBC6ENTC has demonstrated efficacy against BC6ENTG - rearranged NSCLC, and has potential for broader application in select subsets of lung cancer. CPR:falsenewlineBC6ENTC is an oral BC6ENTG inhibitor (TKI), which silences the protein product of the BC6OTHER fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing BC6OTHER . CPR:falsenewlineBC6ENTC is an oral BC6OTHER kinase inhibitor (TKI), which silences the protein product of the BC6ENTG fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing BC6OTHER . CPR:falsenewlineBC6ENTC is an oral BC6OTHER kinase inhibitor (TKI), which silences the protein product of the BC6OTHER fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing BC6ENTG . CPR:falsenewlineBC6OTHER is an oral BC6ENTC kinase inhibitor (TKI), which silences the protein product of the BC6ENTG fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing BC6OTHER . CPR:falsenewlineBC6OTHER is an oral BC6ENTC kinase inhibitor (TKI), which silences the protein product of the BC6OTHER fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing BC6ENTG . CPR:falsenewlineEmerging data suggest that BC6ENTC may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the BC6ENTG oncogene, or translocation of the BC6OTHER oncogene. CPR:falsenewlineEmerging data suggest that BC6ENTC may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the BC6OTHER oncogene, or translocation of the BC6ENTG oncogene. CPR:falsenewlineBC6ENTC is an inhibitor of BC6ENTG which is able to block the absorption of 30% of ingested fat. CPR:falsenewlineBC6ENTC receptor coactivator 1 ( BC6ENTG ), silencing mediator for CHEM and BC6OTHER receptors, and cell proliferation were evaluated by immunohistochemistry. CPR:falsenewlineBC6ENTC receptor coactivator 1 ( BC6OTHER ), silencing mediator for BC6ENTG , and cell proliferation were evaluated by immunohistochemistry. CPR:falsenewlineBC6ENTG ( BC6OTHER ), silencing mediator for BC6ENTC and BC6OTHER receptors, and cell proliferation were evaluated by immunohistochemistry. CPR:falsenewlineBC6OTHER ( BC6ENTG ), silencing mediator for BC6ENTC and BC6OTHER receptors, and cell proliferation were evaluated by immunohistochemistry. CPR:falsenewlineBC6ENTG ( BC6OTHER ), silencing mediator for CHEM and BC6ENTC receptors, and cell proliferation were evaluated by immunohistochemistry. CPR:falsenewlineBC6OTHER ( BC6ENTG ), silencing mediator for CHEM and BC6ENTC receptors, and cell proliferation were evaluated by immunohistochemistry. CPR:falsenewline BC6ENTC alters expression of endometrial BC6ENTG and their cofactors in new users of BC6OTHER . CPR:falsenewline BC6OTHER alters expression of endometrial BC6ENTG and their cofactors in new users of BC6ENTC . CPR:falsenewlineRESULT(S): The expression of endometrial BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER was increased significantly after 1 week of BC6ENTC , but the increase was no longer seen after 10 weeks. CPR:falsenewlineRESULT(S): The expression of endometrial BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER was increased significantly after 1 week of BC6ENTC , but the increase was no longer seen after 10 weeks. CPR:falsenewlineRESULT(S): The expression of endometrial BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER was increased significantly after 1 week of BC6ENTC , but the increase was no longer seen after 10 weeks. CPR:falsenewlineRESULT(S): The expression of endometrial BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG was increased significantly after 1 week of BC6ENTC , but the increase was no longer seen after 10 weeks. CPR:falsenewlineOBJECTIVE: To evaluate the effect of CHEM on the expression of endometrial BC6ENTG and their co - factors in depot BC6ENTC (CHEM) users. CPR:falsenewlineCONCLUSION(S): Short - term exposure of BC6ENTC in new starters of CHEM increases the expression of endometrial BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER and promotes cell proliferation. CPR:falsenewlineCONCLUSION(S): Short - term exposure of BC6ENTC in new starters of CHEM increases the expression of endometrial BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER and promotes cell proliferation. CPR:falsenewlineCONCLUSION(S): Short - term exposure of BC6ENTC in new starters of CHEM increases the expression of endometrial BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER and promotes cell proliferation. CPR:falsenewlineCONCLUSION(S): Short - term exposure of BC6ENTC in new starters of CHEM increases the expression of endometrial BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG and promotes cell proliferation. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6ENTG and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6OTHER and BC6ENTG ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6ENTG ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6ENTG and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6ENTG ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6ENTC receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6ENTG messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6ENTG ( BC6OTHER and BC6OTHER ), BC6ENTC receptors A and B ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6ENTG and BC6OTHER ), BC6ENTC receptors A and B ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6ENTG ), BC6ENTC receptors A and B ( BC6OTHER and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6ENTC receptors A and B ( BC6ENTG and BC6OTHER ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6ENTC receptors A and B ( BC6OTHER and BC6ENTG ), and BC6OTHER receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6ENTC receptors A and B ( BC6OTHER and BC6OTHER ), and BC6ENTG messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6ENTG ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6ENTG and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6ENTG ), BC6OTHER receptors A and B ( BC6OTHER and BC6OTHER ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6ENTG ( BC6OTHER and BC6OTHER ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6ENTG and BC6OTHER ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineMAIN OUTCOME MEASURE(S): The expression of BC6OTHER receptor subtypes alpha and beta ( BC6OTHER and BC6OTHER ), BC6OTHER receptors A and B ( BC6OTHER and BC6ENTG ), and BC6ENTC receptor messenger RNA and protein was detected by real - time polymerase chain reaction and immunohistochemistry, respectively. CPR:falsenewlineThese results are consistent with the premise that BC6ENTC synthetase inhibition is responsible for the antibacterial actions and support further studies on BC6ENTG as a new target for antibacterial agents. CPR:falsenewlineThese results are consistent with the premise that BC6ENTG inhibition is responsible for the antibacterial actions and support further studies on BC6ENTC synthetase as a new target for antibacterial agents. CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6ENTG ) that inhibits BC6OTHER signalling downstream of BC6OTHER . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6OTHER ) that inhibits BC6ENTG signalling downstream of BC6OTHER . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6OTHER ) that inhibits BC6OTHER signalling downstream of BC6ENTG . CPR:falsenewlineBC6ENTC ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of BC6ENTG ( BC6OTHER ) that inhibits BC6OTHER signalling downstream of BC6OTHER . CPR:4newlineBC6OTHER ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6ENTC kinase ( BC6ENTG ) that inhibits BC6OTHER signalling downstream of BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6ENTC kinase ( BC6OTHER ) that inhibits BC6ENTG signalling downstream of BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6OTHER ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6ENTC kinase ( BC6OTHER ) that inhibits BC6OTHER signalling downstream of BC6ENTG . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6ENTG ) that inhibits BC6OTHER signalling downstream of BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6OTHER ) that inhibits BC6ENTG signalling downstream of BC6OTHER . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a first - in - class, potent, orally administered, covalent inhibitor of Bruton's BC6OTHER kinase ( BC6OTHER ) that inhibits BC6OTHER signalling downstream of BC6ENTG . CPR:falsenewlineBC6OTHER ( BC6ENTC ) is a first - in - class, potent, orally administered, covalent inhibitor of BC6ENTG ( BC6OTHER ) that inhibits BC6OTHER signalling downstream of BC6OTHER . CPR:4newlineGiven its efficacy and tolerability, once - daily, oral BC6ENTC is an emerging treatment option for patients with relapsed / refractory MCL or CLL and CLL patients with del 17p or BC6ENTG mutation. CPR:falsenewlineOral BC6ENTC is indicated for the treatment of patients with relapsed / refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or BC6ENTG mutation. CPR:falsenewlineBC6ENTC are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, BC6ENTG , and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6ENTC are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6ENTG , and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6ENTC are signaling molecules that activate BC6ENTG , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6ENTC are signaling molecules that activate BC6OTHER , such as BC6ENTG , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6ENTC are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTG , constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6ENTC receptor, and BC6ENTG , and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6ENTG , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6ENTC receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6ENTG , BC6OTHER X receptor, constitutive BC6ENTC receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTG , constitutive BC6ENTC receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, BC6ENTG , and BC6ENTC receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6ENTG , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6ENTC receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6ENTG , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6ENTC receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTG , constitutive BC6OTHER receptor, and BC6ENTC receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, BC6ENTG , and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6ENTC , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6ENTG , and play a critical role in the regulation of lipid, BC6ENTC , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6ENTG , such as BC6OTHER , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6ENTC , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6ENTG , BC6OTHER X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6ENTC , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTG , constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6ENTC , energy, and drug metabolism. CPR:falsenewlineThese BC6ENTG regulate phase I oxidation, phase II conjugation, and phase III transport in BC6ENTC and drug metabolism in the digestive system. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTC X receptor, BC6ENTG , and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6OTHER , BC6ENTC X receptor, constitutive BC6OTHER receptor, and BC6ENTG , and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6ENTG , such as BC6OTHER , BC6ENTC X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewlineBC6OTHER are signaling molecules that activate BC6OTHER , such as BC6ENTG , BC6ENTC X receptor, constitutive BC6OTHER receptor, and BC6OTHER receptor, and play a critical role in the regulation of lipid, BC6OTHER , energy, and drug metabolism. CPR:falsenewline BC6ENTG in BC6ENTC metabolism. CPR:9newlineThe BC6OTHER (natural products) such as BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC carry the common molecular structure of BC6OTHER that possessed positive ionotropic effect and BC6ENTG blocking activity. CPR:falsenewlineThe BC6OTHER (natural products) such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER carry the common molecular structure of BC6ENTC that possessed positive ionotropic effect and BC6ENTG blocking activity. CPR:falsenewlineThe human BC6ENTC - a - go - go - related gene ( BC6ENTG ) is a BC6OTHER channel protein mainly expressed in the heart and the nervous systems and its blockade by non - cardiovascular acting drugs resulted in tachycardia and sudden death. CPR:falsenewlineThe human BC6ENTC - a - go - go - related gene ( BC6OTHER ) is a BC6ENTG protein mainly expressed in the heart and the nervous systems and its blockade by non - cardiovascular acting drugs resulted in tachycardia and sudden death. CPR:falsenewlineThe human BC6OTHER - a - go - go - related gene ( BC6ENTG ) is a BC6ENTC channel protein mainly expressed in the heart and the nervous systems and its blockade by non - cardiovascular acting drugs resulted in tachycardia and sudden death. CPR:falsenewlineThe BC6ENTG ( BC6OTHER ) is a BC6ENTC channel protein mainly expressed in the heart and the nervous systems and its blockade by non - cardiovascular acting drugs resulted in tachycardia and sudden death. CPR:falsenewlineThe BC6ENTC (natural products) such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER carry the common molecular structure of BC6OTHER that possessed positive ionotropic effect and BC6ENTG blocking activity. CPR:falsenewlineThe BC6OTHER (natural products) such as BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER carry the common molecular structure of BC6OTHER that possessed positive ionotropic effect and BC6ENTG blocking activity. CPR:falsenewlineThe BC6OTHER (natural products) such as BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER carry the common molecular structure of BC6OTHER that possessed positive ionotropic effect and BC6ENTG blocking activity. CPR:falsenewlineThe BC6OTHER (natural products) such as BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER carry the common molecular structure of BC6OTHER that possessed positive ionotropic effect and BC6ENTG blocking activity. CPR:falsenewlineThe CHEM ( BC6ENTC ) receptors of type 6 ( BC6OTHER ) are quite different from all other BC6ENTG , as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop. CPR:falsenewlineThe CHEM ( BC6ENTC ) receptors of type 6 ( BC6ENTG ) are quite different from all other BC6OTHER receptors, as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop. CPR:falsenewlineThe CHEM ( BC6OTHER ) receptors of type 6 ( BC6OTHER ) are quite different from all other BC6ENTG , as they include a short third cytoplasmatic loop and a long BC6ENTC - terminal tail, and one intron located in the middle of the third cytoplasmatic loop. CPR:falsenewlineThe CHEM ( BC6OTHER ) receptors of type 6 ( BC6ENTG ) are quite different from all other BC6OTHER receptors, as they include a short third cytoplasmatic loop and a long BC6ENTC - terminal tail, and one intron located in the middle of the third cytoplasmatic loop. CPR:falsenewlineThe BC6ENTG of type 6 ( BC6OTHER ) are quite different from all other BC6OTHER receptors, as they include a short third cytoplasmatic loop and a long BC6ENTC - terminal tail, and one intron located in the middle of the third cytoplasmatic loop. CPR:falsenewlineA lot of controversies still exist regarding their binding affinity, effects of BC6ENTG ligands on brain BC6ENTC , behavioral syndromes regulated by them, and brain distribution. CPR:falsenewlineThe BC6ENTC ( BC6OTHER ) receptors of type 6 ( BC6OTHER ) are quite different from all other BC6ENTG , as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop. CPR:falsenewlineThe BC6ENTC ( BC6OTHER ) receptors of type 6 ( BC6ENTG ) are quite different from all other BC6OTHER receptors, as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop. CPR:falsenewlineThe CHEM ( BC6OTHER ) receptors of type 6 ( BC6ENTG ) are quite different from all other BC6ENTC receptors, as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop. CPR:falsenewlineThe BC6ENTG of type 6 ( BC6OTHER ) are quite different from all other BC6ENTC receptors, as they include a short third cytoplasmatic loop and a long BC6OTHER - terminal tail, and one intron located in the middle of the third cytoplasmatic loop. CPR:falsenewline BC6ENTC receptors of type 6 ( BC6ENTG ): from neuroscience to clinical pharmacology. CPR:falsenewlineThese findings are the first to show that long - term exposure to BC6ENTC during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, BC6ENTG ( BC6OTHER ) phosphorylation and BC6OTHER activity in the striatum. CPR:falsenewlineThese findings are the first to show that long - term exposure to BC6ENTC during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, BC6OTHER ( BC6ENTG ) phosphorylation and BC6OTHER activity in the striatum. CPR:falsenewlineThese findings are the first to show that long - term exposure to BC6ENTC during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, BC6OTHER ( BC6OTHER ) phosphorylation and BC6ENTG activity in the striatum. CPR:falsenewlineBC6ENTC exposure (20 mg / kg) increased BC6ENTG ( BC6OTHER ) and BC6OTHER phosphorylation, but decreased BC6OTHER - CHEM - 34 phosphorylation. CPR:falsenewlineBC6ENTC exposure (20 mg / kg) increased BC6OTHER ( BC6ENTG ) and BC6OTHER phosphorylation, but decreased BC6OTHER - CHEM - 34 phosphorylation. CPR:falsenewlineBC6ENTC exposure (20 mg / kg) increased BC6OTHER ( BC6OTHER ) and BC6ENTG phosphorylation, but decreased BC6OTHER - CHEM - 34 phosphorylation. CPR:falsenewlineBC6ENTC exposure (20 mg / kg) increased BC6OTHER ( BC6OTHER ) and BC6OTHER phosphorylation, but decreased BC6ENTG - CHEM - 34 phosphorylation. CPR:falsenewlineBC6ENTC (10 and 20 mg / kg) increased BC6ENTG activity and BC6OTHER production (a biological marker of lipid peroxidation). CPR:falsenewlineBC6OTHER (10 and 20 mg / kg) increased BC6ENTG activity and BC6ENTC production (a biological marker of lipid peroxidation). CPR:falsenewlineNotably, the antioxidant BC6ENTC ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6ENTG ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production. CPR:falsenewlineNotably, the antioxidant BC6ENTC ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6ENTG ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production. CPR:falsenewlineNotably, the antioxidant BC6ENTC ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6ENTG activity and BC6OTHER production. CPR:falsenewlineNotably, the antioxidant BC6OTHER ™ reversed the BC6ENTC (20 mg / kg) - dependent augmentation in BC6ENTG ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production. CPR:falsenewlineNotably, the antioxidant BC6OTHER ™ reversed the BC6ENTC (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6ENTG ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production. CPR:falsenewlineNotably, the antioxidant BC6OTHER ™ reversed the BC6ENTC (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6ENTG activity and BC6OTHER production. CPR:falsenewlineNotably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6ENTG ( BC6OTHER ) phosphorylation and reduced the BC6ENTC (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production. CPR:falsenewlineNotably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6ENTG ) phosphorylation and reduced the BC6ENTC (20 mg / kg) - induced BC6OTHER activity and BC6OTHER production. CPR:falsenewlineNotably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6OTHER ) phosphorylation and reduced the BC6ENTC (20 mg / kg) - induced BC6ENTG activity and BC6OTHER production. CPR:falsenewlineNotably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6ENTG ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6ENTC production. CPR:falsenewlineNotably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6ENTG ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6OTHER activity and BC6ENTC production. CPR:falsenewlineNotably, the antioxidant BC6OTHER ™ reversed the BC6OTHER (20 mg / kg) - dependent augmentation in BC6OTHER ( BC6OTHER ) phosphorylation and reduced the BC6OTHER (20 mg / kg) - induced BC6ENTG activity and BC6ENTC production. CPR:falsenewlineThis report reviews published and unpublished data that suggest that BC6OTHER acts as a selective partial agonist at the BC6ENTG and does not affect BC6ENTC receptors at therapeutic doses. CPR:falsenewlineIt has been claimed that partial agonism of the BC6ENTC D(2) and 5 - HT(1A) receptors and antagonism of the BC6ENTG receptor contribute to the clinical profile of BC6OTHER , a so - called BC6OTHER - and BC6OTHER stabiliser. CPR:falsenewlineIt has been claimed that partial agonism of the BC6ENTG and antagonism of the BC6OTHER receptor contribute to the clinical profile of BC6ENTC , a so - called BC6OTHER - and BC6OTHER stabiliser. CPR:falsenewlineIt has been claimed that partial agonism of the BC6OTHER D(2) and 5 - HT(1A) receptors and antagonism of the BC6ENTG receptor contribute to the clinical profile of BC6ENTC , a so - called BC6OTHER - and BC6OTHER stabiliser. CPR:falsenewlineIt has been claimed that partial agonism of the BC6ENTG and antagonism of the BC6OTHER receptor contribute to the clinical profile of BC6OTHER , a so - called BC6ENTC - and BC6OTHER stabiliser. CPR:falsenewlineIt has been claimed that partial agonism of the BC6OTHER D(2) and 5 - HT(1A) receptors and antagonism of the BC6ENTG receptor contribute to the clinical profile of BC6OTHER , a so - called BC6ENTC - and BC6OTHER stabiliser. CPR:falsenewlineIt has been claimed that partial agonism of the BC6ENTG and antagonism of the BC6OTHER receptor contribute to the clinical profile of BC6OTHER , a so - called BC6OTHER - and BC6ENTC stabiliser. CPR:falsenewlineIt has been claimed that partial agonism of the BC6OTHER D(2) and 5 - HT(1A) receptors and antagonism of the BC6ENTG receptor contribute to the clinical profile of BC6OTHER , a so - called BC6OTHER - and BC6ENTC stabiliser. CPR:falsenewlineThis report reviews published and unpublished data that suggest that BC6ENTC acts as a selective partial agonist at the BC6ENTG and does not affect BC6OTHER at therapeutic doses. CPR:falsenewlineThis report reviews published and unpublished data that suggest that BC6ENTC acts as a selective partial agonist at the BC6OTHER D(2) receptor and does not affect BC6ENTG at therapeutic doses. CPR:falsenewlineThis report reviews published and unpublished data that suggest that BC6OTHER acts as a selective partial agonist at the BC6ENTC D(2) receptor and does not affect BC6ENTG at therapeutic doses. CPR:falsenewlineBC6OTHER was compared throughout the study to the pDC survival factors, BC6ENTG and BC6OTHER ; BC6ENTC more effectively matures pDC than either BC6OTHER or BC6OTHER alone. CPR:falsenewlineBC6OTHER was compared throughout the study to the pDC survival factors, BC6OTHER and BC6ENTG ; BC6ENTC more effectively matures pDC than either BC6OTHER or BC6OTHER alone. CPR:falsenewlineBC6OTHER was compared throughout the study to the pDC survival factors, BC6OTHER and BC6OTHER ; BC6ENTC more effectively matures pDC than either BC6ENTG or BC6OTHER alone. CPR:falsenewlineBC6OTHER was compared throughout the study to the pDC survival factors, BC6OTHER and BC6OTHER ; BC6ENTC more effectively matures pDC than either BC6OTHER or BC6ENTG alone. CPR:falsenewlineThese results demonstrate that BC6ENTC molecules directly induce pDC maturation as determined by BC6ENTG induction, BC6OTHER and co - stimulatory marker expression and prolonging viability. CPR:falsenewlineThese results demonstrate that BC6ENTC molecules directly induce pDC maturation as determined by BC6OTHER induction, BC6ENTG and co - stimulatory marker expression and prolonging viability. CPR:falsenewlinePlasmacytoid dendritic cells produce BC6ENTG and mature in response to the BC6OTHER agonists, BC6OTHER and BC6ENTC . CPR:falsenewlinePlasmacytoid dendritic cells produce BC6OTHER and mature in response to the BC6ENTG agonists, BC6OTHER and BC6ENTC . CPR:falsenewlinePlasmacytoid dendritic cells produce BC6ENTG and mature in response to the BC6OTHER agonists, BC6ENTC and BC6OTHER . CPR:falsenewlinePlasmacytoid dendritic cells produce BC6OTHER and mature in response to the BC6ENTG agonists, BC6ENTC and BC6OTHER . CPR:falsenewlineThe immune response modifiers, BC6ENTC and BC6OTHER , are BC6ENTG agonists that induce BC6OTHER in numerous species, including humans. CPR:falsenewlineThe immune response modifiers, BC6ENTC and BC6OTHER , are BC6OTHER agonists that induce BC6ENTG in numerous species, including humans. CPR:falsenewlineHere, we characterize the activation of human pDC with the BC6ENTG agonists BC6ENTC and BC6OTHER . CPR:5newlineHere, we characterize the activation of human pDC with the BC6ENTG agonists BC6OTHER and BC6ENTC . CPR:5newlineResults indicate that BC6ENTC and BC6OTHER induce BC6ENTG and BC6OTHER from purified pDC, and pDC are the principle BC6OTHER - producing cells in the blood. CPR:falsenewlineResults indicate that BC6ENTC and BC6OTHER induce BC6OTHER and BC6ENTG from purified pDC, and pDC are the principle BC6OTHER - producing cells in the blood. CPR:falsenewlineResults indicate that BC6ENTC and BC6OTHER induce BC6OTHER and BC6OTHER from purified pDC, and pDC are the principle BC6ENTG - producing cells in the blood. CPR:falsenewlineResults indicate that BC6OTHER and BC6ENTC induce BC6ENTG and BC6OTHER from purified pDC, and pDC are the principle BC6OTHER - producing cells in the blood. CPR:falsenewlineResults indicate that BC6OTHER and BC6ENTC induce BC6OTHER and BC6ENTG from purified pDC, and pDC are the principle BC6OTHER - producing cells in the blood. CPR:falsenewlineResults indicate that BC6OTHER and BC6ENTC induce BC6OTHER and BC6OTHER from purified pDC, and pDC are the principle BC6ENTG - producing cells in the blood. CPR:falsenewlineThe immune response modifiers, BC6OTHER and BC6ENTC , are BC6ENTG agonists that induce BC6OTHER in numerous species, including humans. CPR:falsenewlineThe immune response modifiers, BC6OTHER and BC6ENTC , are BC6OTHER agonists that induce BC6ENTG in numerous species, including humans. CPR:falsenewlineBC6ENTC - stimulated pDC also produce a number of other BC6ENTG including BC6OTHER and BC6OTHER . CPR:falsenewlineBC6ENTC - stimulated pDC also produce a number of other BC6OTHER including BC6ENTG and BC6OTHER . CPR:falsenewlineBC6ENTC - stimulated pDC also produce a number of other BC6OTHER including BC6OTHER and BC6ENTG . CPR:falsenewlineBC6ENTC enhances co - stimulatory marker expression, BC6ENTG expression, and pDC viability. CPR:falsenewlineBC6ENTC was compared throughout the study to the pDC survival factors, BC6ENTG and BC6OTHER ; BC6OTHER more effectively matures pDC than either BC6OTHER or BC6OTHER alone. CPR:falsenewlineBC6ENTC was compared throughout the study to the pDC survival factors, BC6OTHER and BC6ENTG ; BC6OTHER more effectively matures pDC than either BC6OTHER or BC6OTHER alone. CPR:falsenewlineBC6ENTC was compared throughout the study to the pDC survival factors, BC6OTHER and BC6OTHER ; BC6OTHER more effectively matures pDC than either BC6ENTG or BC6OTHER alone. CPR:falsenewlineBC6ENTC was compared throughout the study to the pDC survival factors, BC6OTHER and BC6OTHER ; BC6OTHER more effectively matures pDC than either BC6OTHER or BC6ENTG alone. CPR:falsenewlineIn addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTG ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6ENTG ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTG ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6ENTG ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6ENTC dismutase ( BC6ENTG ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6ENTG ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6ENTC dismutase ( BC6OTHER ) mimetics and BC6OTHER ( BC6ENTG ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6ENTG ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6ENTG ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6ENTG ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6ENTG ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6ENTG ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6ENTG ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6ENTG ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTC peroxidase ( BC6OTHER ) mimetics and BC6OTHER synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6ENTG ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6ENTG ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6ENTG ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6ENTG ( BC6OTHER ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6ENTG ) mimetics and BC6OTHER ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6ENTG ( BC6OTHER ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewlineIn addition, other antioxidants like BC6OTHER ( BC6OTHER ) mimetics and BC6OTHER ( BC6ENTG ) are shown to decrease markers of oxidative stress in patients with emphysema, while others like BC6OTHER peroxidase ( BC6OTHER ) mimetics and BC6ENTC synthase ( BC6OTHER ) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models). CPR:falsenewline Recommended management may include use of BC6ENTG inhibitors (e.g. BC6ENTC ) and wound care on a case - by - case basis. CPR:falsenewlineIdentification of cDNAs encoding two human alpha class BC6ENTC transferases ( BC6OTHER and BC6OTHER ) and the heterologous expression of BC6ENTG . CPR:falsenewlineIdentification of cDNAs encoding two human alpha class BC6ENTC transferases ( BC6ENTG and BC6OTHER ) and the heterologous expression of BC6OTHER . CPR:falsenewlineIdentification of cDNAs encoding two human alpha class BC6ENTC transferases ( BC6OTHER and BC6ENTG ) and the heterologous expression of BC6OTHER . CPR:falsenewlineIn no other subject any activation of platelets by BC6OTHER inhibitors was observed and there were no statistically significant differences between BC6OTHER genotypes with respect to the effects of BC6ENTG inhibitors on basal or BC6ENTC - stimulated BC6OTHER expression. CPR:falsenewlineIn no other subject any activation of platelets by BC6OTHER inhibitors was observed and there were no statistically significant differences between BC6OTHER genotypes with respect to the effects of BC6OTHER inhibitors on basal or BC6ENTC - stimulated BC6ENTG expression. CPR:falsenewlineIn no other subject any activation of platelets by BC6ENTG inhibitors was observed and there were no statistically significant differences between BC6OTHER genotypes with respect to the effects of BC6OTHER inhibitors on basal or BC6ENTC - stimulated BC6OTHER expression. CPR:falsenewlineIn no other subject any activation of platelets by BC6OTHER inhibitors was observed and there were no statistically significant differences between BC6ENTG genotypes with respect to the effects of BC6OTHER inhibitors on basal or BC6ENTC - stimulated BC6OTHER expression. CPR:falsenewlineThe effects of CHEM (1 - 10 microg / ml), BC6ENTC (3 - 30 nM), or BC6OTHER (0.3 - 3 microg / ml) on basal and BC6OTHER (3 microM) - induced BC6ENTG externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease. CPR:falsenewlineThe effects of CHEM (1 - 10 microg / ml), BC6OTHER (3 - 30 nM), or BC6ENTC (0.3 - 3 microg / ml) on basal and BC6OTHER (3 microM) - induced BC6ENTG externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease. CPR:falsenewlineThe effects of CHEM (1 - 10 microg / ml), BC6OTHER (3 - 30 nM), or BC6OTHER (0.3 - 3 microg / ml) on basal and BC6ENTC (3 microM) - induced BC6ENTG externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease. CPR:falsenewlineAlthough a significant platelet hyperreactivity was observed in the patients, the BC6ENTG genotype did not influence basal or BC6ENTC - induced BC6OTHER expression. CPR:falsenewlineAlthough a significant platelet hyperreactivity was observed in the patients, the BC6OTHER genotype did not influence basal or BC6ENTC - induced BC6ENTG expression. CPR:falsenewlineA moderate (twofold) stimulation of BC6ENTG expression by CHEM but not by BC6ENTC or BC6OTHER was observed in one patient. CPR:falsenewlineA moderate (twofold) stimulation of BC6ENTG expression by CHEM but not by BC6OTHER or BC6ENTC was observed in one patient. CPR:falsenewlineHerein, we report ischemic - reperfused myocardial infarction (MI) repair with siRNA against Src homology region 2 domain - containing BC6ENTC phosphatase - 1 ( BC6ENTG ), which is known as a key factor involved in regulating the progress of apoptosis in many cell types. CPR:falsenewlineA low molecular weight BC6ENTC modified with BC6OTHER (CHEM) - based delivery strategy was suggested for the cardiac application of BC6ENTG siRNA to overcome the poor gene delivery efficiency to myocardium due to the highly charged structures of the compact cardiac muscles. CPR:falsenewlineA low molecular weight BC6OTHER modified with BC6ENTC (CHEM) - based delivery strategy was suggested for the cardiac application of BC6ENTG siRNA to overcome the poor gene delivery efficiency to myocardium due to the highly charged structures of the compact cardiac muscles. CPR:falsenewlineAnti - apoptotic cardioprotective effects of BC6ENTG gene silencing against ischemia - reperfusion injury: Use of BC6ENTC - modified low molecular weight BC6OTHER as a cardiac siRNA - carrier. CPR:falsenewlineAnti - apoptotic cardioprotective effects of BC6ENTG gene silencing against ischemia - reperfusion injury: Use of BC6OTHER - modified low molecular weight BC6ENTC as a cardiac siRNA - carrier. CPR:falsenewlineAdditionally, these effects of BC6ENTC on γ - BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER / BC6OTHER ) were reduced by an BC6OTHER inhibitor. CPR:falsenewlineAdditionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER ( BC6OTHER / BC6OTHER ) were reduced by an BC6OTHER inhibitor. CPR:falsenewlineAdditionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER ( BC6OTHER / BC6OTHER ) were reduced by an BC6OTHER inhibitor. CPR:falsenewlineAdditionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG ( BC6OTHER / BC6OTHER ) were reduced by an BC6OTHER inhibitor. CPR:falsenewlineAdditionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTG / BC6OTHER ) were reduced by an BC6OTHER inhibitor. CPR:falsenewlineAdditionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER / BC6ENTG ) were reduced by an BC6OTHER inhibitor. CPR:falsenewlineAdditionally, these effects of BC6ENTC on γ - BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER / BC6OTHER ) were reduced by an BC6ENTG inhibitor. CPR:falsenewlineAdditionally, these effects of BC6ENTC on γ - BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER / BC6OTHER ) were reduced by an BC6OTHER inhibitor. CPR:falsenewlineOsteoblasts survive the BC6ENTC treatment by activation of BC6ENTG - mediated pathway. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineFurthermore, we analyzed the BC6ENTG - mediated BC6ENTC cyclase activity in isolated membranes from these cell lines. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineThe aim of this study was, therefore, to provide comparative binding characteristics of agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER ) and antagonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) at all three subtypes of BC6ENTG in an identical cellular background. CPR:falsenewlineIn summary, activation of BC6ENTG and oxidative stress were observed after BC6OTHER / BC6OTHER cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6ENTC / BC6OTHER - induced cytotoxicity. CPR:falsenewlineIn summary, activation of BC6OTHER and oxidative stress were observed after BC6OTHER / BC6ENTG cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6ENTC / BC6OTHER - induced cytotoxicity. CPR:falsenewlineIn summary, activation of BC6OTHER and oxidative stress were observed after BC6OTHER / BC6OTHER cotreatment, and BC6ENTG inhibitors and a lipid - soluble free - radical scavenger attenuated BC6ENTC / BC6OTHER - induced cytotoxicity. CPR:falsenewlineIn summary, activation of BC6OTHER and oxidative stress were observed after BC6OTHER / BC6OTHER cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6ENTC / BC6ENTG - induced cytotoxicity. CPR:falsenewlineWe demonstrated previously that BC6ENTG ( BC6OTHER ) plays an important role in a rat model of BC6ENTC - induced hepatotoxicity under inflammatory stress. CPR:falsenewlineWe demonstrated previously that BC6OTHER ( BC6ENTG ) plays an important role in a rat model of BC6ENTC - induced hepatotoxicity under inflammatory stress. CPR:falsenewlineIn this study, we developed a model in vitro to study the roles of BC6ENTG activation and oxidative stress in BC6OTHER potentiation of BC6ENTC cytotoxicity. CPR:falsenewlineIn this study, we developed a model in vitro to study the roles of BC6OTHER activation and oxidative stress in BC6ENTG potentiation of BC6ENTC cytotoxicity. CPR:falsenewlineBC6ENTC caused cell death in Hepa1c1c7 cells, and BC6ENTG cotreatment potentiated its toxicity. CPR:falsenewlineActivation of BC6ENTG was observed in BC6ENTC / BC6OTHER - cotreated cells, and caspase inhibitors provided minor protection from cytotoxicity. CPR:falsenewlineActivation of BC6OTHER was observed in BC6ENTC / BC6ENTG - cotreated cells, and caspase inhibitors provided minor protection from cytotoxicity. CPR:falsenewlineIntracellular reactive BC6ENTC species (ROS) generation and lipid peroxidation were observed after treatment with BC6OTHER and were further elevated by BC6ENTG cotreatment. CPR:falsenewlineIntracellular reactive BC6OTHER species (ROS) generation and lipid peroxidation were observed after treatment with BC6ENTC and were further elevated by BC6ENTG cotreatment. CPR:falsenewlineAdding water - soluble antioxidants ( BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER ) produced only minor attenuation of BC6OTHER / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6OTHER alone. CPR:falsenewlineAdding water - soluble antioxidants ( BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER ) produced only minor attenuation of BC6OTHER / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6OTHER alone. CPR:falsenewlineAdding water - soluble antioxidants ( BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER ) produced only minor attenuation of BC6OTHER / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6OTHER alone. CPR:falsenewlineAdding water - soluble antioxidants ( BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC ) produced only minor attenuation of BC6OTHER / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6OTHER alone. CPR:falsenewlineAdding water - soluble antioxidants ( BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER ) produced only minor attenuation of BC6ENTC / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6OTHER alone. CPR:falsenewlineAdding water - soluble antioxidants ( BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER ) produced only minor attenuation of BC6OTHER / BC6ENTG - induced cytotoxicity and did not influence the effect of BC6ENTC alone. CPR:falsenewline BC6ENTG potentiates the cytotoxicity of BC6ENTC in Hepa1c1c7 cells: roles of BC6OTHER activation and oxidative stress. CPR:falsenewline BC6OTHER potentiates the cytotoxicity of BC6ENTC in Hepa1c1c7 cells: roles of BC6ENTG activation and oxidative stress. CPR:falsenewlineOn the other hand, BC6ENTC ( BC6OTHER ), which reduced lipid peroxidation and ROS generation, prevented BC6OTHER toxicity and caused pronounced reduction in cytotoxicity from BC6OTHER / BC6ENTG cotreatment. CPR:falsenewlineOn the other hand, BC6OTHER ( BC6ENTC ), which reduced lipid peroxidation and ROS generation, prevented BC6OTHER toxicity and caused pronounced reduction in cytotoxicity from BC6OTHER / BC6ENTG cotreatment. CPR:falsenewlineOn the other hand, BC6OTHER ( BC6OTHER ), which reduced lipid peroxidation and ROS generation, prevented BC6ENTC toxicity and caused pronounced reduction in cytotoxicity from BC6OTHER / BC6ENTG cotreatment. CPR:falsenewlineOn the other hand, BC6OTHER ( BC6OTHER ), which reduced lipid peroxidation and ROS generation, prevented BC6OTHER toxicity and caused pronounced reduction in cytotoxicity from BC6ENTC / BC6ENTG cotreatment. CPR:falsenewlineBC6ENTC plus a BC6ENTG inhibitor completely abolished BC6OTHER / BC6OTHER - induced cytotoxicity. CPR:falsenewlineBC6ENTC plus a BC6OTHER inhibitor completely abolished BC6OTHER / BC6ENTG - induced cytotoxicity. CPR:falsenewlineBC6OTHER plus a BC6ENTG inhibitor completely abolished BC6ENTC / BC6OTHER - induced cytotoxicity. CPR:falsenewlineBC6OTHER plus a BC6OTHER inhibitor completely abolished BC6ENTC / BC6ENTG - induced cytotoxicity. CPR:falsenewlineIn summary, activation of BC6ENTG and oxidative stress were observed after BC6ENTC / BC6OTHER cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6OTHER / BC6OTHER - induced cytotoxicity. CPR:falsenewlineIn summary, activation of BC6OTHER and oxidative stress were observed after BC6ENTC / BC6ENTG cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6OTHER / BC6OTHER - induced cytotoxicity. CPR:falsenewlineIn summary, activation of BC6OTHER and oxidative stress were observed after BC6ENTC / BC6OTHER cotreatment, and BC6ENTG inhibitors and a lipid - soluble free - radical scavenger attenuated BC6OTHER / BC6OTHER - induced cytotoxicity. CPR:falsenewlineIn summary, activation of BC6OTHER and oxidative stress were observed after BC6ENTC / BC6OTHER cotreatment, and BC6OTHER inhibitors and a lipid - soluble free - radical scavenger attenuated BC6OTHER / BC6ENTG - induced cytotoxicity. CPR:falsenewlineIn plasma membranes prepared from these isolated brown fat cells by BC6ENTC extraction there was a similar enrichment of activity of BC6ENTG and of the plasma membrane marker enzyme, BC6OTHER . CPR:falsenewlineIn plasma membranes prepared from these isolated brown fat cells by BC6ENTC extraction there was a similar enrichment of activity of BC6OTHER and of the plasma membrane marker enzyme, BC6ENTG . CPR:falsenewline BC6ENTG activities in brown adipose tissue of the rat: identification of BC6OTHER - sensitive ( BC6ENTC - resistant) activity at the fat cell membrane. CPR:falsenewline BC6ENTG activities in brown adipose tissue of the rat: identification of BC6ENTC - sensitive ( BC6OTHER - resistant) activity at the fat cell membrane. CPR:falsenewlinePositive staining of mitochondria was achieved in the presence of the BC6ENTG substrate, BC6ENTC . CPR:falsenewlineStaining around the edges of the brown fat cells was observed with the BC6ENTG substrates, BC6ENTC and BC6OTHER . CPR:falsenewlineStaining around the edges of the brown fat cells was observed with the BC6ENTG substrates, BC6OTHER and BC6ENTC . CPR:falsenewlineStaining was largely absent when substrate was omitted or after pretreatment with the irreversible BC6ENTG inhibitor, BC6ENTC and the slowly reversible inhibitor, BC6OTHER . CPR:falsenewlineStaining was largely absent when substrate was omitted or after pretreatment with the irreversible BC6ENTG inhibitor, BC6OTHER and the slowly reversible inhibitor, BC6ENTC . CPR:falsenewlineIt was found that the specific activities of both BC6ENTC oxidase A ( BC6ENTG ) and of the BC6OTHER - sensitive BC6OTHER - resistant CHEM oxidase ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue. CPR:falsenewlineIt was found that the specific activities of both BC6ENTC oxidase A ( BC6OTHER ) and of the BC6ENTG ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue. CPR:falsenewlineIt was found that the specific activities of both BC6ENTC oxidase A ( BC6OTHER ) and of the BC6OTHER - sensitive BC6OTHER - resistant CHEM oxidase ( BC6ENTG ) were higher in isolated fat cells than in the original whole tissue. CPR:falsenewlineIt was found that the specific activities of both BC6ENTG ( BC6OTHER ) and of the BC6ENTC - sensitive BC6OTHER - resistant CHEM oxidase ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue. CPR:falsenewlineIt was found that the specific activities of both BC6OTHER oxidase A ( BC6ENTG ) and of the BC6ENTC - sensitive BC6OTHER - resistant CHEM oxidase ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue. CPR:falsenewlineIt was found that the specific activities of both BC6OTHER oxidase A ( BC6OTHER ) and of the BC6ENTC - sensitive BC6OTHER - resistant CHEM oxidase ( BC6ENTG ) were higher in isolated fat cells than in the original whole tissue. CPR:falsenewlineIt was found that the specific activities of both BC6ENTG ( BC6OTHER ) and of the BC6OTHER - sensitive BC6ENTC - resistant CHEM oxidase ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue. CPR:falsenewlineIt was found that the specific activities of both BC6OTHER oxidase A ( BC6ENTG ) and of the BC6OTHER - sensitive BC6ENTC - resistant CHEM oxidase ( BC6OTHER ) were higher in isolated fat cells than in the original whole tissue. CPR:falsenewlineIt was found that the specific activities of both BC6OTHER oxidase A ( BC6OTHER ) and of the BC6OTHER - sensitive BC6ENTC - resistant CHEM oxidase ( BC6ENTG ) were higher in isolated fat cells than in the original whole tissue. CPR:falsenewlineMoreover, it was suggested that promotion of BC6ENTG mRNA expression in Th2 cells was partially involved due to an increase in level of BC6ENTC in splenic tissue and the breakdown of Th cell responses locally in the splenic tissue, which then affected the maintenance of Th2 cell functions in the microenvironment of tumor - bearing mice. CPR:falsenewlineIn addition, BC6ENTC levels in splenic tissue or serum and BC6OTHER mRNA expression (mRNA encoding BC6ENTG ) in CD4+ T cells were increased in these mice. CPR:falsenewlineIn addition, BC6ENTC levels in splenic tissue or serum and BC6ENTG mRNA expression (mRNA encoding BC6OTHER side - chain cleavage p450 enzyme) in CD4+ T cells were increased in these mice. CPR:falsenewlineIn addition, BC6OTHER levels in splenic tissue or serum and BC6ENTG mRNA expression (mRNA encoding BC6ENTC side - chain cleavage p450 enzyme) in CD4+ T cells were increased in these mice. CPR:falsenewlineWhen the anti - CHEM drug BC6ENTC ( BC6ENTG inhibitor) was administered to B16F10 mice, BC6OTHER levels in splenic tissue or serum and BC6OTHER mRNA expression were decreased at 14 days after tumor inoculation. CPR:falsenewlineWhen the anti - CHEM drug BC6ENTC ( BC6OTHER inhibitor) was administered to B16F10 mice, BC6OTHER levels in splenic tissue or serum and BC6ENTG mRNA expression were decreased at 14 days after tumor inoculation. CPR:falsenewlineWhen the anti - CHEM drug BC6OTHER ( BC6ENTG inhibitor) was administered to B16F10 mice, BC6ENTC levels in splenic tissue or serum and BC6OTHER mRNA expression were decreased at 14 days after tumor inoculation. CPR:falsenewlineWhen the anti - CHEM drug BC6OTHER ( BC6OTHER inhibitor) was administered to B16F10 mice, BC6ENTC levels in splenic tissue or serum and BC6ENTG mRNA expression were decreased at 14 days after tumor inoculation. CPR:falsenewlineThe structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively. CPR:9newlineThe structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6ENTC ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively. CPR:falsenewlineThe structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6OTHER ( BC6ENTC ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively. CPR:falsenewlineBC6ENTG catalyzes the phosphorylation of BC6ENTC resulting in an BC6OTHER , and the phosphorylation of BC6OTHER giving rise to an BC6OTHER . CPR:falsenewlineBC6ENTG catalyzes the phosphorylation of BC6OTHER resulting in an BC6ENTC , and the phosphorylation of BC6OTHER giving rise to an BC6OTHER . CPR:falsenewlineBC6ENTG catalyzes the phosphorylation of BC6OTHER resulting in an BC6OTHER , and the phosphorylation of BC6ENTC giving rise to an BC6OTHER . CPR:falsenewlineBC6ENTG catalyzes the phosphorylation of BC6OTHER resulting in an BC6OTHER , and the phosphorylation of BC6OTHER giving rise to an BC6ENTC . CPR:falsenewlineBC6ENTC kinase from Herpes simplex virus type 1 ( BC6ENTG ) was crystallized in an BC6OTHER - terminally truncated but fully active form. CPR:falsenewlineBC6ENTG from Herpes simplex virus type 1 ( BC6OTHER ) was crystallized in an BC6ENTC - terminally truncated but fully active form. CPR:falsenewlineBC6OTHER from Herpes simplex virus type 1 ( BC6ENTG ) was crystallized in an BC6ENTC - terminally truncated but fully active form. CPR:falsenewlineCavity and water molecules reduce the substrate specificity to such an extent that BC6ENTG can BC6ENTC various substrate analogues useful in pharmaceutical applications. CPR:falsenewlineBC6ENTC is structurally homologous to the well - known BC6ENTG but contains large additional peptide segments. CPR:falsenewlineBC6ENTG is structurally homologous to the well - known BC6ENTC kinases but contains large additional peptide segments. CPR:falsenewlineThe structures of BC6ENTG complexed with BC6ENTC at the BC6OTHER - site and BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively. CPR:falsenewlineThe structures of BC6ENTG complexed with BC6OTHER at the BC6ENTC - site and BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively. CPR:falsenewlineThe structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively. CPR:falsenewlineThe structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively. CPR:falsenewlineThe structures of BC6ENTG complexed with BC6OTHER at the BC6OTHER - site and BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), or BC6OTHER ( BC6OTHER ) at the substrate - site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively. CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTC synthase) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6ENTG ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6ENTG knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTC synthase) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6ENTG , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTC synthase) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTG , BC6OTHER sulphurtransferase and BC6ENTC synthase) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTG and BC6ENTC synthase) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTC synthase) and detoxifying enzymes ( BC6ENTG and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6ENTG ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6ENTG knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6ENTG , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTG , BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTG and BC6OTHER ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTG ) and detoxifying enzymes ( BC6ENTC BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6ENTG ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6ENTG knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6ENTG , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTG , BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTG and BC6OTHER ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTG ) and detoxifying enzymes (CHEM BC6ENTC - transferase μ 2 and BC6OTHER ). CPR:falsenewlineAt the metabolomic level, BC6ENTG silencing caused no overt changes, though there was some evidence for a subtle increase in intracellular BC6ENTC quantities. CPR:falsenewlineBC6ENTG expression was suppressed by means of RNA interference technology, and the overall outcome of this treatment on the hepatocellular proteome and metabolome was investigated using tandem mass tag - based differential protein profiling and BC6ENTC NMR spectroscopy, respectively. CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTC - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6ENTG ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6ENTG knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTC - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6ENTG , BC6ENTC - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTC - regulated protein 75, BC6ENTG and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTC - regulated protein 75, BC6OTHER sulphurtransferase and BC6ENTG ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTC - regulated protein 75, BC6OTHER sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTG and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTC sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6ENTG ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6ENTG knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTC sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6ENTG , BC6OTHER - regulated protein 75, BC6ENTC sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6ENTG , BC6ENTC sulphurtransferase and BC6OTHER ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTC sulphurtransferase and BC6ENTG ) and detoxifying enzymes (CHEM BC6OTHER - transferase μ 2 and BC6OTHER ). CPR:falsenewlineGlobal protein profiling revealed a number of targets of the BC6OTHER knock - down procedure, including mitochondrial proteins ( BC6OTHER , BC6OTHER - regulated protein 75, BC6ENTC sulphurtransferase and BC6OTHER ) and detoxifying enzymes ( BC6ENTG and BC6OTHER ). CPR:falsenewlineBC6ENTC (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6ENTG or if (2) whole blood clots were formed in the presence of exogenous BC6OTHER and a BC6OTHER analogue. CPR:falsenewlineBC6ENTC (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6OTHER or if (2) whole blood clots were formed in the presence of exogenous BC6ENTG and a BC6OTHER analogue. CPR:falsenewlineBC6OTHER (0.06 mM) and BC6ENTC (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6ENTG or if (2) whole blood clots were formed in the presence of exogenous BC6OTHER and a BC6OTHER analogue. CPR:falsenewlineBC6OTHER (0.06 mM) and BC6ENTC (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6OTHER or if (2) whole blood clots were formed in the presence of exogenous BC6ENTG and a BC6OTHER analogue. CPR:falsenewlineBC6OTHER (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6ENTC analogue and exogenous BC6ENTG or if (2) whole blood clots were formed in the presence of exogenous BC6OTHER and a BC6OTHER analogue. CPR:falsenewlineBC6OTHER (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6ENTC analogue and exogenous BC6OTHER or if (2) whole blood clots were formed in the presence of exogenous BC6ENTG and a BC6OTHER analogue. CPR:falsenewlineBC6OTHER (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6ENTG or if (2) whole blood clots were formed in the presence of exogenous BC6OTHER and a BC6ENTC analogue. CPR:falsenewlineBC6OTHER (0.06 mM) and BC6OTHER (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a BC6OTHER analogue and exogenous BC6OTHER or if (2) whole blood clots were formed in the presence of exogenous BC6ENTG and a BC6ENTC analogue. CPR:falsenewlineInhibitory effects of BC6ENTC analogues on BC6ENTG induced whole blood clot lysis. CPR:falsenewlineThe BC6OTHER analogues BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe BC6OTHER analogues BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6OTHER ( BC6ENTG ). CPR:falsenewlineHowever, their inhibitory effect was markedly reduced if clots were formed in the presence of BC6ENTG and then exposed to either of the BC6ENTC analogues. CPR:falsenewlineThe data suggest that BC6ENTC analogues, even at low concentrations, reduce the rate of BC6ENTG induced whole blood clot lysis by several mechanisms. CPR:falsenewlineThe BC6OTHER analogues BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe BC6OTHER analogues BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe BC6ENTC analogues BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe BC6ENTC analogues BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe BC6OTHER analogues BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe BC6OTHER analogues BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe present study utilized blood from normal volunteers and BC6ENTC - BC6ENTG in a dilute whole blood clot assay to determine the relative concentrations of BC6OTHER analogues required for inhibition of clot lysis induced by exogenous BC6OTHER . CPR:falsenewlineThe present study utilized blood from normal volunteers and BC6ENTC - BC6OTHER in a dilute whole blood clot assay to determine the relative concentrations of BC6OTHER analogues required for inhibition of clot lysis induced by exogenous BC6ENTG . CPR:falsenewlineThe BC6OTHER analogues BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6ENTG ( BC6OTHER ). CPR:falsenewlineThe BC6OTHER analogues BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received BC6OTHER ( BC6ENTG ). CPR:falsenewlineThe present study utilized blood from normal volunteers and BC6OTHER - BC6ENTG in a dilute whole blood clot assay to determine the relative concentrations of BC6ENTC analogues required for inhibition of clot lysis induced by exogenous BC6OTHER . CPR:falsenewlineThe present study utilized blood from normal volunteers and BC6OTHER - BC6OTHER in a dilute whole blood clot assay to determine the relative concentrations of BC6ENTC analogues required for inhibition of clot lysis induced by exogenous BC6ENTG . CPR:falsenewlineMolecular study did not reveal the same mutations in the cardiac BC6ENTC channel gene ( BC6ENTG ) as previously reported in Brugada syndrome. CPR:falsenewlineBC6ENTC antagonists bind to BC6ENTG at an intracellular allosteric site denoted site II. CPR:falsenewlineSynthesis and structure - activity relationships of BC6ENTC as allosteric BC6OTHER ( BC6ENTG ) antagonists. CPR:6newlineSynthesis and structure - activity relationships of BC6ENTC as allosteric BC6ENTG ( BC6OTHER ) antagonists. CPR:6newlineA series of BC6ENTC were synthesized and examined as BC6ENTG antagonists. CPR:6newlineThe vasopressor response to the BC6ENTG activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6ENTC , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6ENTC , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6ENTC , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTG antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6ENTG activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6ENTC (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6ENTC (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6ENTC (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTG antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6ENTG activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6ENTC is also a BC6OTHER antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6ENTC is also a BC6OTHER antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6ENTC is also a BC6ENTG antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6ENTG activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTC channel antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTC channel antagonist, consistent with our previous in vitro studies. CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6ENTC was nearly abolished by combined pretreatment of the rats with high doses of the BC6ENTG antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER . CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6ENTC was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6ENTG antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER . CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6ENTC was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6ENTG . CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6ENTG antagonist, BC6ENTC (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER . CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6ENTC (1 mg / kg, iv), and the nonselective BC6ENTG antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER . CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6ENTC (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6ENTG . CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6ENTG antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6ENTC (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER . CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6ENTG antagonist, BC6ENTC (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6OTHER . CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6ENTC (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6OTHER may be accounted for by blockade of BC6ENTG . CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6ENTG antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6ENTC may be accounted for by blockade of BC6OTHER . CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6ENTG antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6ENTC may be accounted for by blockade of BC6OTHER . CPR:falsenewlineIn anesthetized spontaneously hypertensive rats, the antihypertensive activity of BC6OTHER was nearly abolished by combined pretreatment of the rats with high doses of the BC6OTHER antagonist, BC6OTHER (1 mg / kg, iv), and the nonselective BC6OTHER antagonist, BC6OTHER (3 mg / kg, iv), suggesting that the majority of the antihypertensive response produced by BC6ENTC may be accounted for by blockade of BC6ENTG . CPR:falsenewlineWe therefore conclude that BC6ENTC , at antihypertensive doses, is an antagonist of BC6ENTG , and also of BC6OTHER in vascular smooth muscle. CPR:falsenewlineWe therefore conclude that BC6ENTC , at antihypertensive doses, is an antagonist of BC6OTHER , and also of BC6ENTG in vascular smooth muscle. CPR:falsenewlineThus, BC6ENTC blocks both BC6ENTG at antihypertensive doses, with modest selectivity being observed for the BC6OTHER subtype. CPR:4newlineThus, BC6ENTC blocks both BC6OTHER at antihypertensive doses, with modest selectivity being observed for the BC6ENTG subtype. CPR:4newlineWe therefore conclude that BC6OTHER , at antihypertensive doses, is an antagonist of BC6ENTG , and also of BC6ENTC channels in vascular smooth muscle. CPR:falsenewlineBC6ENTC (0.3 mg / kg, iv) produced a significant inhibition of the BC6ENTG mediated positive chronotropic response to BC6OTHER . CPR:falsenewlineBC6OTHER (0.3 mg / kg, iv) produced a significant inhibition of the BC6ENTG mediated positive chronotropic response to BC6ENTC . CPR:falsenewlineThis same dose of BC6ENTC also inhibited, but to a lesser degree, the BC6OTHER mediated vasodepressor response to BC6OTHER in pithed rats whose blood pressure was elevated by a constant intravenous infusion of BC6ENTG . CPR:falsenewlineThis same dose of BC6ENTC also inhibited, but to a lesser degree, the BC6ENTG mediated vasodepressor response to BC6OTHER in pithed rats whose blood pressure was elevated by a constant intravenous infusion of BC6OTHER . CPR:falsenewlineThis same dose of BC6OTHER also inhibited, but to a lesser degree, the BC6OTHER mediated vasodepressor response to BC6ENTC in pithed rats whose blood pressure was elevated by a constant intravenous infusion of BC6ENTG . CPR:falsenewlineThis same dose of BC6OTHER also inhibited, but to a lesser degree, the BC6ENTG mediated vasodepressor response to BC6ENTC in pithed rats whose blood pressure was elevated by a constant intravenous infusion of BC6OTHER . CPR:falsenewlineThe mechanism(s) responsible for arterial vasodilation observed following acute administration of BC6ENTC , a novel vasodilator / BC6ENTG antagonist, has been investigated in rats. CPR:falsenewlineBC6ENTC produced significant inhibition of the BC6ENTG mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses. CPR:falsenewlineBC6ENTC produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6ENTG mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses. CPR:falsenewlineBC6ENTC produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6ENTG antagonist at antihypertensive doses. CPR:falsenewlineBC6OTHER produced significant inhibition of the BC6ENTG mediated pressor response to BC6ENTC in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses. CPR:falsenewlineBC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6ENTC in the pithed rat, but had no effect on the BC6ENTG mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses. CPR:falsenewlineBC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6ENTC in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6OTHER is also an BC6ENTG antagonist at antihypertensive doses. CPR:falsenewlineBC6OTHER produced significant inhibition of the BC6ENTG mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6ENTC , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses. CPR:falsenewlineBC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6ENTG mediated pressor response to BC6ENTC , suggesting that BC6OTHER is also an BC6OTHER antagonist at antihypertensive doses. CPR:falsenewlineBC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6ENTC , suggesting that BC6OTHER is also an BC6ENTG antagonist at antihypertensive doses. CPR:falsenewlineBC6OTHER produced significant inhibition of the BC6ENTG mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6ENTC is also an BC6OTHER antagonist at antihypertensive doses. CPR:falsenewlineBC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6ENTG mediated pressor response to BC6OTHER , suggesting that BC6ENTC is also an BC6OTHER antagonist at antihypertensive doses. CPR:falsenewlineBC6OTHER produced significant inhibition of the BC6OTHER mediated pressor response to BC6OTHER in the pithed rat, but had no effect on the BC6OTHER mediated pressor response to BC6OTHER , suggesting that BC6ENTC is also an BC6ENTG antagonist at antihypertensive doses. CPR:falsenewlineBC6ENTC had no effect on the pressor response elicited by BC6ENTG , indicating a lack of nonspecific vasodilator activity. CPR:falsenewlineThe vasopressor response to the BC6ENTC channel activator, BC6OTHER , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6ENTC channel activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTG antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6ENTG activator, BC6ENTC , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6OTHER channel activator, BC6ENTC , which is mediated through the opening of BC6ENTG and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6OTHER channel activator, BC6ENTC , which is mediated through the opening of voltage dependent BC6OTHER channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTG antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6ENTG activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6ENTC channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6OTHER antagonist, consistent with our previous in vitro studies. CPR:falsenewlineThe vasopressor response to the BC6OTHER channel activator, BC6OTHER , which is mediated through the opening of voltage dependent BC6ENTC channels and the subsequent translocation of extracellular BC6OTHER , was significantly inhibited by BC6OTHER (1 mg / kg, iv), suggesting that BC6OTHER is also a BC6ENTG antagonist, consistent with our previous in vitro studies. CPR:falsenewlineIntrahypothalamic administration of BC6ENTG (1 or 5 pmol / mouse) significantly and dose - dependently suppressed the development of postischemic BC6ENTC intolerance on day 1 and development of neuronal damage on day 3. CPR:falsenewlineBC6ENTG (a BC6ENTC - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6OTHER ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6OTHER metabolism. CPR:falsenewlineBC6OTHER (a BC6ENTC - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6ENTG ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6OTHER metabolism. CPR:falsenewlineBC6OTHER (a BC6ENTC - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6OTHER ; a member of the BC6ENTG family) play roles in many physiologic functions, including regulation of BC6OTHER metabolism. CPR:falsenewlineBC6OTHER (a BC6ENTC - sensing neuropeptide in the hypothalamus) and BC6ENTG ( BC6OTHER ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6OTHER metabolism. CPR:falsenewlineThe MCAO - induced decrease in BC6ENTG levels in the liver and skeletal muscle on day 1 was recovered to control levels by BC6OTHER , and this effect of BC6OTHER was reversed by the administration of BC6ENTC as well as by hypothalamic BC6OTHER knockdown. CPR:falsenewlineThe MCAO - induced decrease in BC6OTHER levels in the liver and skeletal muscle on day 1 was recovered to control levels by BC6ENTG , and this effect of BC6OTHER was reversed by the administration of BC6ENTC as well as by hypothalamic BC6OTHER knockdown. CPR:falsenewlineThe MCAO - induced decrease in BC6OTHER levels in the liver and skeletal muscle on day 1 was recovered to control levels by BC6OTHER , and this effect of BC6ENTG was reversed by the administration of BC6ENTC as well as by hypothalamic BC6OTHER knockdown. CPR:falsenewlineThe MCAO - induced decrease in BC6OTHER levels in the liver and skeletal muscle on day 1 was recovered to control levels by BC6OTHER , and this effect of BC6OTHER was reversed by the administration of BC6ENTC as well as by hypothalamic BC6ENTG knockdown. CPR:falsenewlineThese results suggest that suppression of postischemic BC6ENTC intolerance by BC6ENTG assists in the prevention of cerebral ischemic neuronal damage. CPR:4newlineBC6ENTG (a BC6OTHER - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6OTHER ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6ENTC metabolism. CPR:falsenewlineBC6OTHER (a BC6OTHER - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6ENTG ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6ENTC metabolism. CPR:falsenewlineBC6OTHER (a BC6OTHER - sensing neuropeptide in the hypothalamus) and BC6OTHER ( BC6OTHER ; a member of the BC6ENTG family) play roles in many physiologic functions, including regulation of BC6ENTC metabolism. CPR:falsenewlineBC6OTHER (a BC6OTHER - sensing neuropeptide in the hypothalamus) and BC6ENTG ( BC6OTHER ; a member of the BC6OTHER family) play roles in many physiologic functions, including regulation of BC6ENTC metabolism. CPR:falsenewlineSmall interfering RNA directed BC6ENTG , BC6OTHER , and BC6ENTC [ BC6OTHER ; a specific BC6OTHER antagonist] were administered directly into the hypothalamus. CPR:falsenewlineSmall interfering RNA directed BC6OTHER , BC6ENTG , and BC6ENTC [ BC6OTHER ; a specific BC6OTHER antagonist] were administered directly into the hypothalamus. CPR:falsenewlineSmall interfering RNA directed BC6OTHER , BC6OTHER , and BC6ENTC [ BC6OTHER ; a specific BC6ENTG antagonist] were administered directly into the hypothalamus. CPR:falsenewlineSmall interfering RNA directed BC6ENTG , BC6OTHER , and BC6OTHER [ BC6ENTC ; a specific BC6OTHER antagonist] were administered directly into the hypothalamus. CPR:falsenewlineSmall interfering RNA directed BC6OTHER , BC6ENTG , and BC6OTHER [ BC6ENTC ; a specific BC6OTHER antagonist] were administered directly into the hypothalamus. CPR:falsenewlineSmall interfering RNA directed BC6OTHER , BC6OTHER , and BC6OTHER [ BC6ENTC ; a specific BC6ENTG antagonist] were administered directly into the hypothalamus. CPR:falsenewline BC6ENTG suppresses postischemic BC6ENTC intolerance and neuronal damage through hypothalamic BC6OTHER . CPR:falsenewline BC6OTHER suppresses postischemic BC6ENTC intolerance and neuronal damage through hypothalamic BC6ENTG . CPR:falsenewlineThe phosphorylation by BC6ENTG resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6OTHER - 779 were substituted with BC6ENTC to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6ENTG because a BC6OTHER mutant in which BC6OTHER - 776 and BC6OTHER - 779 were substituted with BC6ENTC to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6ENTG mutant in which BC6OTHER - 776 and BC6OTHER - 779 were substituted with BC6ENTC to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6OTHER - 779 were substituted with BC6ENTC to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6ENTG and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6OTHER - 779 were substituted with BC6ENTC to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6ENTG mutant. CPR:falsenewlineBC6OTHER ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6ENTC by BC6ENTG ( BC6OTHER ). CPR:9newlineBC6OTHER ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6ENTC by BC6OTHER ( BC6ENTG ). CPR:9newlineBC6OTHER ( BC6OTHER ) acts as an allosteric activator of BC6ENTG ( BC6OTHER ) and is converted to BC6ENTC by BC6OTHER ( BC6OTHER ). CPR:9newlineBC6OTHER ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6ENTG ) and is converted to BC6ENTC by BC6OTHER ( BC6OTHER ). CPR:9newlinePhosphorylation and up - regulation of BC6ENTC kinase gamma via its interaction with BC6ENTG . CPR:falsenewlineBC6ENTC ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6OTHER by BC6ENTG ( BC6OTHER ). CPR:9newlineBC6ENTC ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6OTHER by BC6OTHER ( BC6ENTG ). CPR:9newlineBC6ENTC ( BC6OTHER ) acts as an allosteric activator of BC6ENTG ( BC6OTHER ) and is converted to BC6OTHER by BC6OTHER ( BC6OTHER ). CPR:9newlineBC6ENTC ( BC6OTHER ) acts as an allosteric activator of BC6OTHER ( BC6ENTG ) and is converted to BC6OTHER by BC6OTHER ( BC6OTHER ). CPR:9newlineBC6OTHER ( BC6ENTC ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6OTHER by BC6ENTG ( BC6OTHER ). CPR:9newlineBC6OTHER ( BC6ENTC ) acts as an allosteric activator of BC6OTHER ( BC6OTHER ) and is converted to BC6OTHER by BC6OTHER ( BC6ENTG ). CPR:9newlineBC6OTHER ( BC6ENTC ) acts as an allosteric activator of BC6ENTG ( BC6OTHER ) and is converted to BC6OTHER by BC6OTHER ( BC6OTHER ). CPR:9newlineBC6OTHER ( BC6ENTC ) acts as an allosteric activator of BC6OTHER ( BC6ENTG ) and is converted to BC6OTHER by BC6OTHER ( BC6OTHER ). CPR:9newlineBC6ENTG directly associated with BC6OTHER through its accessory domain (AD), depending on BC6ENTC as well as BC6OTHER / BC6OTHER in vitro. CPR:falsenewlineBC6OTHER directly associated with BC6ENTG through its accessory domain (AD), depending on BC6ENTC as well as BC6OTHER / BC6OTHER in vitro. CPR:falsenewlineBC6ENTG directly associated with BC6OTHER through its accessory domain (AD), depending on BC6OTHER as well as BC6ENTC / BC6OTHER in vitro. CPR:falsenewlineBC6OTHER directly associated with BC6ENTG through its accessory domain (AD), depending on BC6OTHER as well as BC6ENTC / BC6OTHER in vitro. CPR:falsenewlineBC6ENTG directly associated with BC6OTHER through its accessory domain (AD), depending on BC6OTHER as well as BC6OTHER / BC6ENTC in vitro. CPR:falsenewlineBC6OTHER directly associated with BC6ENTG through its accessory domain (AD), depending on BC6OTHER as well as BC6OTHER / BC6ENTC in vitro. CPR:falsenewlineMass spectrometric analysis and mutation studies revealed that BC6ENTG BC6ENTC - 776 and BC6OTHER - 779 in the AD of BC6OTHER . CPR:falsenewlineMass spectrometric analysis and mutation studies revealed that BC6OTHER BC6ENTC - 776 and BC6OTHER - 779 in the AD of BC6ENTG . CPR:falsenewlineMass spectrometric analysis and mutation studies revealed that BC6ENTG BC6OTHER - 776 and BC6ENTC - 779 in the AD of BC6OTHER . CPR:falsenewlineMass spectrometric analysis and mutation studies revealed that BC6OTHER BC6OTHER - 776 and BC6ENTC - 779 in the AD of BC6ENTG . CPR:falsenewlineThe phosphorylation by BC6ENTG resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6ENTC - 776 and BC6OTHER - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6ENTG because a BC6OTHER mutant in which BC6ENTC - 776 and BC6OTHER - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6ENTG mutant in which BC6ENTC - 776 and BC6OTHER - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6ENTC - 776 and BC6OTHER - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6ENTG and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6ENTC - 776 and BC6OTHER - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6ENTG mutant. CPR:falsenewlineThe phosphorylation by BC6ENTG resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6ENTC - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6ENTG because a BC6OTHER mutant in which BC6OTHER - 776 and BC6ENTC - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6ENTG mutant in which BC6OTHER - 776 and BC6ENTC - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6ENTC - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6ENTG and an unphosphorylatable BC6OTHER mutant. CPR:falsenewlineThe phosphorylation by BC6OTHER resulted in activation of BC6OTHER because a BC6OTHER mutant in which BC6OTHER - 776 and BC6ENTC - 779 were substituted with BC6OTHER to mimic phosphorylation exhibited significantly higher activity compared with wild type BC6OTHER and an unphosphorylatable BC6ENTG mutant. CPR:falsenewlineThe neurospecific BC6ENTC 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6OTHER ) which, via the BC6ENTG ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6OTHER . CPR:falsenewlineThe neurospecific BC6ENTC 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6OTHER ) which, via the BC6OTHER ( BC6ENTG ), can increase the expression and synthesis of astrocyte BC6OTHER . CPR:falsenewlineThe neurospecific BC6ENTC 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6OTHER ) which, via the BC6OTHER ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6ENTG . CPR:falsenewlineThe neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6ENTC into BC6OTHER ( BC6OTHER ) which, via the BC6ENTG ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6OTHER . CPR:falsenewlineThe neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6ENTC into BC6OTHER ( BC6OTHER ) which, via the BC6OTHER ( BC6ENTG ), can increase the expression and synthesis of astrocyte BC6OTHER . CPR:falsenewlineThe neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6ENTC into BC6OTHER ( BC6OTHER ) which, via the BC6OTHER ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6ENTG . CPR:falsenewlineThe neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6ENTC ( BC6OTHER ) which, via the BC6ENTG ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6OTHER . CPR:falsenewlineThe neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6ENTC ( BC6OTHER ) which, via the BC6OTHER ( BC6ENTG ), can increase the expression and synthesis of astrocyte BC6OTHER . CPR:falsenewlineThe neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6ENTC ( BC6OTHER ) which, via the BC6OTHER ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6ENTG . CPR:falsenewlineBC6ENTC also increases BC6ENTG ( BC6OTHER ) deposition and BC6OTHER pathology. CPR:3newlineBC6ENTC also increases BC6OTHER ( BC6ENTG ) deposition and BC6OTHER pathology. CPR:falsenewlineBC6ENTC also increases BC6OTHER ( BC6OTHER ) deposition and BC6ENTG pathology. CPR:falsenewlineThe neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6ENTC ) which, via the BC6ENTG ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6OTHER . CPR:falsenewlineThe neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6ENTC ) which, via the BC6OTHER ( BC6ENTG ), can increase the expression and synthesis of astrocyte BC6OTHER . CPR:falsenewlineThe neurospecific BC6OTHER 24 - hydroxylase converts excess brain BC6OTHER into BC6OTHER ( BC6ENTC ) which, via the BC6OTHER ( BC6OTHER ), can increase the expression and synthesis of astrocyte BC6ENTG . CPR:falsenewlineBC6ENTG , BC6ENTC , BC6OTHER and BC6OTHER were correlated in Alzheimer disease (AD) samples. CPR:falsenewlineBC6OTHER , BC6ENTC , BC6ENTG and BC6OTHER were correlated in Alzheimer disease (AD) samples. CPR:falsenewlineBC6OTHER , BC6ENTC , BC6OTHER and BC6ENTG were correlated in Alzheimer disease (AD) samples. CPR:falsenewlineExcess of BC6ENTC converted into BC6OTHER may up - regulate BC6ENTG synthesis which is a scavenger for BC6OTHER and BC6OTHER . CPR:9newlineExcess of BC6ENTC converted into BC6OTHER may up - regulate BC6OTHER synthesis which is a scavenger for BC6ENTG and BC6OTHER . CPR:9newlineExcess of BC6ENTC converted into BC6OTHER may up - regulate BC6OTHER synthesis which is a scavenger for BC6OTHER and BC6ENTG . CPR:9newlineExcess of BC6OTHER converted into BC6ENTC may up - regulate BC6ENTG synthesis which is a scavenger for BC6OTHER and BC6OTHER . CPR:9newlineExcess of BC6OTHER converted into BC6ENTC may up - regulate BC6OTHER synthesis which is a scavenger for BC6ENTG and BC6OTHER . CPR:9newlineExcess of BC6OTHER converted into BC6ENTC may up - regulate BC6OTHER synthesis which is a scavenger for BC6OTHER and BC6ENTG . CPR:9newlineIn AD this protective mechanism seems to be inefficient, probably due to the presence of high concentrations of BC6ENTC , microvascular dysfunction and the decreased efficiency of BC6ENTG as lipid transporter and BC6OTHER scavenger. CPR:falsenewlineIn AD this protective mechanism seems to be inefficient, probably due to the presence of high concentrations of BC6ENTC , microvascular dysfunction and the decreased efficiency of BC6OTHER as lipid transporter and BC6ENTG scavenger. CPR:falsenewlineAnalysis of side chain BC6ENTC in the CSF is likely to provided useful information about BC6OTHER metabolism and BC6ENTG function in the pathogenesis of AD. CPR:falsenewlineAnalysis of side chain BC6OTHER in the CSF is likely to provided useful information about BC6ENTC metabolism and BC6ENTG function in the pathogenesis of AD. CPR:falsenewlineThe BC6ENTC complexes retain potency in BC6ENTG mutant colon cells. CPR:falsenewlineIn general, antiproliferative activity is greatly enhanced by low levels of the BC6ENTG inhibitor BC6ENTC . CPR:4newlineThe contrasting activity of BC6ENTC versus BC6OTHER and BC6OTHER anticancer complexes: control of cell selectivity, cross - resistance, BC6ENTG dependence, and apoptosis pathway. CPR:falsenewlineThe contrasting activity of BC6OTHER versus BC6ENTC and BC6OTHER anticancer complexes: control of cell selectivity, cross - resistance, BC6ENTG dependence, and apoptosis pathway. CPR:falsenewlineThe contrasting activity of BC6OTHER versus BC6OTHER and BC6ENTC anticancer complexes: control of cell selectivity, cross - resistance, BC6ENTG dependence, and apoptosis pathway. CPR:falsenewlineConversely, BC6ENTG mRNAs increased 100 to 500% at various time points in pregnant and lactating mice and corresponded with enhanced in vitro sulfation of BC6ENTC in liver S9 fractions. CPR:9newlineProtein expression of BC6ENTG also decreased and corresponded with reduced in vitro glucuronidation of BC6ENTC in S9 fractions from livers of pregnant mice. CPR:falsenewlineFurther characterization showed that BC6ENTC suppresses both wild - type and BC6ENTG mutant BC6OTHER activity in vitro. CPR:falsenewlineFurther characterization showed that BC6ENTC suppresses both wild - type and BC6OTHER mutant BC6ENTG activity in vitro. CPR:4newlineIn addition, BC6ENTC demonstrated significant activity against several receptor BC6OTHER kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6ENTG , BC6OTHER BC6OTHER , and BC6OTHER . CPR:falsenewlineIn addition, BC6ENTC demonstrated significant activity against several receptor BC6OTHER kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER , and BC6OTHER . CPR:falsenewlineIn addition, BC6ENTC demonstrated significant activity against several receptor BC6OTHER kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6OTHER BC6ENTG , and BC6OTHER . CPR:falsenewlineIn addition, BC6ENTC demonstrated significant activity against several receptor BC6OTHER kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER , and BC6ENTG . CPR:falsenewlineIn addition, BC6ENTC demonstrated significant activity against several BC6ENTG involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER , and BC6OTHER . CPR:falsenewlineIn addition, BC6ENTC demonstrated significant activity against several receptor BC6OTHER kinases involved in neovascularization and tumor progression, including BC6ENTG , BC6OTHER , BC6OTHER BC6OTHER , and BC6OTHER . CPR:falsenewlineIn addition, BC6OTHER demonstrated significant activity against several receptor BC6ENTC kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6ENTG , BC6OTHER BC6OTHER , and BC6OTHER . CPR:falsenewlineIn addition, BC6OTHER demonstrated significant activity against several receptor BC6ENTC kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER , and BC6OTHER . CPR:falsenewlineIn addition, BC6OTHER demonstrated significant activity against several receptor BC6ENTC kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6OTHER BC6ENTG , and BC6OTHER . CPR:falsenewlineIn addition, BC6OTHER demonstrated significant activity against several receptor BC6ENTC kinases involved in neovascularization and tumor progression, including BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER , and BC6ENTG . CPR:falsenewlineIn addition, BC6OTHER demonstrated significant activity against several receptor BC6ENTC kinases involved in neovascularization and tumor progression, including BC6ENTG , BC6OTHER , BC6OTHER BC6OTHER , and BC6OTHER . CPR:falsenewlineBC6ENTC , which belongs chemically to a class that can be described as BC6OTHER , was selected for further pharmacologic characterization based on potent inhibition of BC6ENTG and its favorable BC6OTHER selectivity profile. CPR:4newlineBC6ENTC , which belongs chemically to a class that can be described as BC6OTHER , was selected for further pharmacologic characterization based on potent inhibition of BC6OTHER and its favorable BC6ENTG selectivity profile. CPR:falsenewlineBC6OTHER , which belongs chemically to a class that can be described as BC6ENTC , was selected for further pharmacologic characterization based on potent inhibition of BC6ENTG and its favorable BC6OTHER selectivity profile. CPR:falsenewlineBC6OTHER , which belongs chemically to a class that can be described as BC6ENTC , was selected for further pharmacologic characterization based on potent inhibition of BC6OTHER and its favorable BC6ENTG selectivity profile. CPR:falsenewlineTo further analyze the mechanism governing the BC6ENTG - BC6ENTC interaction, we examined the effect of BC6OTHER on various recombinant BC6OTHER expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration. CPR:falsenewlineTo further analyze the mechanism governing the BC6OTHER channel - BC6ENTC interaction, we examined the effect of BC6OTHER on various recombinant BC6ENTG expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration. CPR:falsenewlineTo further analyze the mechanism governing the BC6ENTG - BC6OTHER interaction, we examined the effect of BC6ENTC on various recombinant BC6OTHER expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration. CPR:falsenewlineTo further analyze the mechanism governing the BC6OTHER channel - BC6OTHER interaction, we examined the effect of BC6ENTC on various recombinant BC6ENTG expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration. CPR:falsenewlineTo further analyze the mechanism governing the BC6ENTG - BC6OTHER interaction, we examined the effect of BC6OTHER on various recombinant BC6ENTC channels expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration. CPR:falsenewlineTo further analyze the mechanism governing the BC6ENTG - BC6OTHER interaction, we examined the effect of BC6OTHER on various recombinant BC6OTHER expressed in mammalian cells from their cloned cDNAs, using BC6ENTC as the permeant ion at physiological concentration. CPR:falsenewlineTo further analyze the mechanism governing the BC6OTHER channel - BC6OTHER interaction, we examined the effect of BC6OTHER on various recombinant BC6ENTG expressed in mammalian cells from their cloned cDNAs, using BC6ENTC as the permeant ion at physiological concentration. CPR:falsenewlineBC6ENTC blocked alpha1A and alpha1E with a Kd comparable to that reported for BC6ENTG , but had a lower affinity (approximately 30 - fold) for alpha1C. CPR:falsenewlineBC6ENTC ( BC6OTHER ) belongs to a new chemical class of these molecules which differs from other BC6OTHER antagonists by its ability to potently block BC6ENTG . CPR:4newlineDeterminants of voltage - dependent inactivation affect BC6ENTC block of BC6ENTG . CPR:falsenewlineBC6OTHER ( BC6ENTC ) belongs to a new chemical class of these molecules which differs from other BC6OTHER antagonists by its ability to potently block BC6ENTG . CPR:falsenewlineTherefore, we conclude that the tissue and sub - cellular localization of BC6ENTG subunits as well as their specific associations are essential parameters to understand the in vivo effects of BC6ENTC . CPR:falsenewlineBC6OTHER ( BC6OTHER ) belongs to a new chemical class of these molecules which differs from other BC6ENTC antagonists by its ability to potently block BC6ENTG . CPR:falsenewlineTo further analyze the mechanism governing the BC6ENTC channel - BC6OTHER interaction, we examined the effect of BC6OTHER on various recombinant BC6ENTG expressed in mammalian cells from their cloned cDNAs, using BC6OTHER as the permeant ion at physiological concentration. CPR:falsenewlineBC6ENTC ( BC6OTHER ), an BC6ENTG inhibitor, is currently under evaluation for its anticancer activity in clinical trials. CPR:4newlineBC6OTHER ( BC6ENTC ), an BC6ENTG inhibitor, is currently under evaluation for its anticancer activity in clinical trials. CPR:4newlineWe have demonstrated that BC6ENTC receptor ( BC6ENTG ) is overexpressed in lung adenocarcinoma (AD). CPR:falsenewlineHere we investigated whether BC6ENTG plays a role in BC6ENTC - mediated anticancer activity by functioning as a downstream target or by modulating its anticancer efficacy. CPR:falsenewline BC6ENTG is a target of BC6ENTC and enhances its anticancer activity in lung adenocarcinoma cells. CPR:falsenewlineAlthough treatment with BC6ENTC reduced BC6ENTG levels and BC6OTHER - regulated gene expression in lung AD cells, BC6OTHER expression increased anticancer activity of BC6OTHER . CPR:falsenewlineAlthough treatment with BC6ENTC reduced BC6OTHER levels and BC6ENTG - regulated gene expression in lung AD cells, BC6OTHER expression increased anticancer activity of BC6OTHER . CPR:falsenewlineAlthough treatment with BC6ENTC reduced BC6OTHER levels and BC6OTHER - regulated gene expression in lung AD cells, BC6ENTG expression increased anticancer activity of BC6OTHER . CPR:falsenewlineAlthough treatment with BC6OTHER reduced BC6ENTG levels and BC6OTHER - regulated gene expression in lung AD cells, BC6OTHER expression increased anticancer activity of BC6ENTC . CPR:falsenewlineAlthough treatment with BC6OTHER reduced BC6OTHER levels and BC6ENTG - regulated gene expression in lung AD cells, BC6OTHER expression increased anticancer activity of BC6ENTC . CPR:falsenewlineAlthough treatment with BC6OTHER reduced BC6OTHER levels and BC6OTHER - regulated gene expression in lung AD cells, BC6ENTG expression increased anticancer activity of BC6ENTC . CPR:falsenewlineIn addition, BC6ENTC treatment reduced cell viability, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER levels in BC6OTHER - expressing lung AD cells. CPR:4newlineIn addition, BC6ENTC treatment reduced cell viability, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER levels in BC6OTHER - expressing lung AD cells. CPR:falsenewlineIn addition, BC6ENTC treatment reduced cell viability, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER levels in BC6OTHER - expressing lung AD cells. CPR:4newlineIn addition, BC6ENTC treatment reduced cell viability, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER levels in BC6OTHER - expressing lung AD cells. CPR:falsenewlineIn addition, BC6ENTC treatment reduced cell viability, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG levels in BC6OTHER - expressing lung AD cells. CPR:4newlineIn addition, BC6ENTC treatment reduced cell viability, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER levels in BC6ENTG - expressing lung AD cells. CPR:falsenewlineBC6ENTC : BC6OTHER oxidoreductase ( BC6ENTG ), which is regulated by BC6OTHER , was shown to increase anticancer activity of BC6OTHER in cells. CPR:falsenewlineBC6ENTC : BC6OTHER oxidoreductase ( BC6OTHER ), which is regulated by BC6ENTG , was shown to increase anticancer activity of BC6OTHER in cells. CPR:falsenewlineBC6OTHER : BC6ENTC oxidoreductase ( BC6ENTG ), which is regulated by BC6OTHER , was shown to increase anticancer activity of BC6OTHER in cells. CPR:falsenewlineBC6OTHER : BC6ENTC oxidoreductase ( BC6OTHER ), which is regulated by BC6ENTG , was shown to increase anticancer activity of BC6OTHER in cells. CPR:falsenewlineBC6ENTG ( BC6OTHER ), which is regulated by BC6OTHER , was shown to increase anticancer activity of BC6ENTC in cells. CPR:falsenewlineBC6OTHER : BC6OTHER oxidoreductase ( BC6ENTG ), which is regulated by BC6OTHER , was shown to increase anticancer activity of BC6ENTC in cells. CPR:falsenewlineBC6OTHER : BC6OTHER oxidoreductase ( BC6OTHER ), which is regulated by BC6ENTG , was shown to increase anticancer activity of BC6ENTC in cells. CPR:falsenewlineKnockdown of BC6ENTG expression attenuated the reduction of cell cycle regulators by BC6ENTC treatment in BC6OTHER overexpressed cells. CPR:falsenewlineKnockdown of BC6OTHER expression attenuated the reduction of cell cycle regulators by BC6ENTC treatment in BC6ENTG overexpressed cells. CPR:falsenewlineWe demonstrated that BC6ENTG protein not only functions as a downstream target of BC6ENTC , but also enhances anticancer activity of BC6OTHER in lung AD cells. CPR:falsenewlineWe demonstrated that BC6ENTG protein not only functions as a downstream target of BC6OTHER , but also enhances anticancer activity of BC6ENTC in lung AD cells. CPR:falsenewlineCombination chemotherapy with a BC6ENTG antagonist ( BC6ENTC ) and BC6OTHER in a mouse model of human African trypanosomiasis. CPR:falsenewlineCombination chemotherapy with a BC6ENTG antagonist ( BC6OTHER ) and BC6ENTC in a mouse model of human African trypanosomiasis. CPR:falsenewlineIn this study we investigated the effects of combination chemotherapy with BC6ENTC and a BC6ENTG antagonist BC6OTHER ( BC6OTHER ) in this mouse model. CPR:falsenewlineIn this study we investigated the effects of combination chemotherapy with BC6OTHER and a BC6ENTG antagonist BC6ENTC ( BC6OTHER ) in this mouse model. CPR:falsenewlineIn this study we investigated the effects of combination chemotherapy with BC6OTHER and a BC6ENTG antagonist BC6OTHER ( BC6ENTC ) in this mouse model. CPR:falsenewlineThe rate limiting enzyme of beta - oxidation ( BC6ENTG ) was significantly over - expressed in the liver with BC6ENTC treatment. CPR:falsenewlineThese results indicate that BC6ENTC suppresses body weight gain in mice, possibly at least related to the up - regulation of BC6ENTG gene expression. CPR:3newline BC6ENTG polymorphisms and measures of impulsivity, aggression, and sensation seeking among African - American BC6ENTC - dependent individuals. CPR:falsenewlineThe findings do not seem to support an association between these polymorphisms in the BC6ENTG gene and impulsive - aggressive traits among BC6ENTC - dependent African - American individuals. CPR:falsenewlineConsiderable evidence indicates that serotonergic mechanisms, particularly the BC6OTHER transporter ( BC6ENTG ), may mediate central effects of BC6ENTC and may also be involved in impulsive and aggressive behavior. CPR:falsenewlineConsiderable evidence indicates that serotonergic mechanisms, particularly the BC6ENTG ( BC6OTHER ), may mediate central effects of BC6ENTC and may also be involved in impulsive and aggressive behavior. CPR:falsenewlineWe investigated whether polymorphisms in the BC6ENTG gene were related to traits of impulsivity, sensation seeking, and aggression among BC6ENTC abusers. CPR:falsenewlineTwo polymorphisms of the BC6ENTG gene were examined involving the 5' promoter ( BC6OTHER ) region and a 17 base pair BC6OTHER ( BC6OTHER ) marker among BC6ENTC patients. CPR:falsenewlineTwo polymorphisms of the BC6OTHER gene were examined involving the 5' promoter ( BC6ENTG ) region and a 17 base pair BC6OTHER ( BC6OTHER ) marker among BC6ENTC patients. CPR:falsenewlineTwo polymorphisms of the BC6OTHER gene were examined involving the 5' promoter ( BC6OTHER ) region and a 17 base pair BC6ENTG ( BC6OTHER ) marker among BC6ENTC patients. CPR:falsenewlineTwo polymorphisms of the BC6OTHER gene were examined involving the 5' promoter ( BC6OTHER ) region and a 17 base pair BC6OTHER ( BC6ENTG ) marker among BC6ENTC patients. CPR:falsenewlineConsiderable evidence indicates that serotonergic mechanisms, particularly the BC6ENTC transporter ( BC6ENTG ), may mediate central effects of BC6OTHER and may also be involved in impulsive and aggressive behavior. CPR:falsenewlineHowever, other BC6ENTC , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER . CPR:falsenewlineHowever, other BC6ENTC , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER . CPR:falsenewlineHowever, other BC6ENTC , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG . CPR:falsenewlineHowever, other BC6OTHER , including BC6ENTC , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER . CPR:falsenewlineHowever, other BC6OTHER , including BC6ENTC , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER . CPR:falsenewlineHowever, other BC6OTHER , including BC6ENTC , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6ENTC and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6ENTC and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6ENTC and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6ENTC , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6ENTC , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6ENTC , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6ENTC and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6ENTC and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6ENTC and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6ENTC group, also mediate physiological responses through binding to BC6ENTG ( BC6OTHER ) and BC6OTHER . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6ENTC group, also mediate physiological responses through binding to BC6OTHER ( BC6ENTG ) and BC6OTHER . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6ENTC group, also mediate physiological responses through binding to BC6OTHER ( BC6OTHER ) and BC6ENTG . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTC receptor - α ( BC6ENTG ) and BC6OTHER . CPR:falsenewlineHowever, other BC6OTHER , including BC6OTHER , BC6OTHER and BC6OTHER , which have a CHEM ring containing a BC6OTHER and a C19 BC6OTHER group, also mediate physiological responses through binding to BC6ENTC receptor - α ( BC6OTHER ) and BC6ENTG . CPR:falsenewlineMoreover, selective BC6ENTC response modulators (SERMs) with diverse structures also regulate transcription of BC6ENTG and BC6OTHER . CPR:falsenewlineMoreover, selective BC6ENTC response modulators (SERMs) with diverse structures also regulate transcription of BC6OTHER and BC6ENTG . CPR:falsenewlineFurther studies of the role of these BC6ENTC and SERMs in regulating responses mediated by BC6ENTG and BC6OTHER a variety of tissues, during different stages of development, are likely to uncover additional estrogenic activities. CPR:falsenewlineFurther studies of the role of these BC6ENTC and SERMs in regulating responses mediated by BC6OTHER and BC6ENTG a variety of tissues, during different stages of development, are likely to uncover additional estrogenic activities. CPR:falsenewlineCrystal structures of E2 in the BC6ENTC receptor ( BC6ENTG ) confirm the importance of the A ring in stabilizing E2 in the BC6OTHER . CPR:falsenewlineCrystal structures of E2 in the BC6ENTC receptor ( BC6OTHER ) confirm the importance of the A ring in stabilizing E2 in the BC6ENTG . CPR:falsenewlineIngestion of competitive inhibitors of BC6ENTG such as CHEM and BC6ENTC result in a similar but milder clinical phenotype. CPR:falsenewlineAt a pre - receptor level, glucocorticoid action is modulated by BC6ENTC dehydrogenases ( BC6ENTG ). CPR:falsenewlineBC6ENTG activates BC6ENTC to BC6OTHER to facilitate BC6OTHER ( BC6OTHER ) - mediated action. CPR:falsenewlineBC6OTHER activates BC6ENTC to BC6OTHER to facilitate BC6ENTG ( BC6OTHER ) - mediated action. CPR:falsenewlineBC6OTHER activates BC6ENTC to BC6OTHER to facilitate BC6OTHER ( BC6ENTG ) - mediated action. CPR:falsenewlineBC6ENTG activates BC6OTHER to BC6ENTC to facilitate BC6OTHER ( BC6OTHER ) - mediated action. CPR:falsenewlineBC6OTHER activates BC6OTHER to BC6ENTC to facilitate BC6ENTG ( BC6OTHER ) - mediated action. CPR:falsenewlineBC6OTHER activates BC6OTHER to BC6ENTC to facilitate BC6OTHER ( BC6ENTG ) - mediated action. CPR:falsenewline By contrast, BC6ENTG plays a pivotal role in BC6ENTC target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6OTHER ) by BC6OTHER . CPR:falsenewline By contrast, BC6OTHER plays a pivotal role in BC6ENTC target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6ENTG ( BC6OTHER ) by BC6OTHER . CPR:falsenewline By contrast, BC6OTHER plays a pivotal role in BC6ENTC target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6ENTG ) by BC6OTHER . CPR:falsenewline By contrast, BC6ENTG plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6ENTC to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6OTHER ) by BC6OTHER . CPR:falsenewline By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6ENTC to BC6OTHER ) to prevent activation of the BC6ENTG ( BC6OTHER ) by BC6OTHER . CPR:falsenewline By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6ENTC to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6ENTG ) by BC6OTHER . CPR:falsenewline By contrast, BC6ENTG plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6ENTC ) to prevent activation of the BC6OTHER ( BC6OTHER ) by BC6OTHER . CPR:falsenewline By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6ENTC ) to prevent activation of the BC6ENTG ( BC6OTHER ) by BC6OTHER . CPR:falsenewline By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6ENTC ) to prevent activation of the BC6OTHER ( BC6ENTG ) by BC6OTHER . CPR:falsenewline By contrast, BC6ENTG plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6OTHER ) by BC6ENTC . CPR:falsenewline By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6ENTG ( BC6OTHER ) by BC6ENTC . CPR:falsenewline By contrast, BC6OTHER plays a pivotal role in BC6OTHER target tissues where it catalyses the opposite reaction (i.e. inactivation of BC6OTHER to BC6OTHER ) to prevent activation of the BC6OTHER ( BC6ENTG ) by BC6ENTC . CPR:falsenewlineMutations in the BC6ENTG gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which BC6ENTC activates the BC6OTHER resulting in severe hypertension and hypokalemia. CPR:falsenewlineMutations in the BC6OTHER gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which BC6ENTC activates the BC6ENTG resulting in severe hypertension and hypokalemia. CPR:falsenewlineThis manuscript presents the preclinical profile of BC6ENTC , a novel BC6ENTG ( BC6OTHER ) selective inhibitor. CPR:4newlineThis manuscript presents the preclinical profile of BC6ENTC , a novel BC6OTHER ( BC6ENTG ) selective inhibitor. CPR:4newlineEx vivo, BC6ENTC inhibited BC6ENTG - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6OTHER - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1). CPR:falsenewlineEx vivo, BC6ENTC inhibited BC6OTHER - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6ENTG - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1). CPR:falsenewlineEx vivo, BC6OTHER inhibited BC6ENTG - derived BC6ENTC ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6OTHER - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1). CPR:falsenewlineEx vivo, BC6OTHER inhibited BC6OTHER - derived BC6ENTC ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6ENTG - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1). CPR:falsenewlineEx vivo, BC6OTHER inhibited BC6ENTG - derived BC6OTHER ( BC6ENTC ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6OTHER - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1). CPR:falsenewlineEx vivo, BC6OTHER inhibited BC6OTHER - derived BC6OTHER ( BC6ENTC ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6ENTG - derived production of BC6OTHER ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1). CPR:falsenewlineEx vivo, BC6OTHER inhibited BC6ENTG - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6OTHER - derived production of BC6ENTC ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1). CPR:falsenewlineEx vivo, BC6OTHER inhibited BC6OTHER - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6ENTG - derived production of BC6ENTC ( BC6OTHER ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1). CPR:falsenewlineEx vivo, BC6OTHER inhibited BC6ENTG - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6OTHER - derived production of BC6OTHER ( BC6ENTC ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1). CPR:falsenewlineEx vivo, BC6OTHER inhibited BC6OTHER - derived BC6OTHER ( BC6OTHER ) generation with an ID(50) of 33 mg kg( - 1), whereas BC6ENTG - derived production of BC6OTHER ( BC6ENTC ) in the lipopolysaccharide - stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg( - 1). CPR:falsenewlinePreclinical pharmacology of BC6ENTC : a novel selective inhibitor of BC6ENTG . CPR:4newlineHowever, consistent with its low BC6ENTG inhibitory activity, BC6ENTC at a dose of 100 mg kg( - 1) orally caused no ulcers and was significantly less ulcerogenic than BC6OTHER (P<0.05). CPR:falsenewlineBC6ENTC inhibited purified BC6ENTG and BC6OTHER with K(i) values of 3 and 0.06 microM, respectively. CPR:4newlineBC6ENTC inhibited purified BC6OTHER and BC6ENTG with K(i) values of 3 and 0.06 microM, respectively. CPR:4newlineHowever, consistent with its low BC6ENTG inhibitory activity, BC6OTHER at a dose of 100 mg kg( - 1) orally caused no ulcers and was significantly less ulcerogenic than BC6ENTC (P<0.05). CPR:falsenewlineBC6ENTC is a highly selective BC6ENTG inhibitor with anti - inflammatory, analgesic and antipyretic activities comparable with BC6OTHER , the reference NSAID, but with much improved gastrointestinal safety. CPR:4newlineBC6OTHER is a highly selective BC6ENTG inhibitor with anti - inflammatory, analgesic and antipyretic activities comparable with BC6ENTC , the reference NSAID, but with much improved gastrointestinal safety. CPR:falsenewlineIn cellular assays, BC6ENTC had an IC(50) of 0.14 microM in BC6ENTG - expressing dermal fibroblasts, but caused no inhibition of BC6OTHER at concentrations up to 30 microM (HEK 293 cells transfected with BC6OTHER ). CPR:falsenewlineIn cellular assays, BC6ENTC had an IC(50) of 0.14 microM in BC6OTHER - expressing dermal fibroblasts, but caused no inhibition of BC6ENTG at concentrations up to 30 microM (HEK 293 cells transfected with BC6OTHER ). CPR:falsenewlineIn cellular assays, BC6ENTC had an IC(50) of 0.14 microM in BC6OTHER - expressing dermal fibroblasts, but caused no inhibition of BC6OTHER at concentrations up to 30 microM (HEK 293 cells transfected with BC6ENTG ). CPR:falsenewlineIn a human whole blood assay, IC(50) values for BC6ENTC were 0.13 microM for BC6ENTG and 67 microM for BC6OTHER ( BC6OTHER / BC6OTHER selectivity ratio 515). CPR:4newlineIn a human whole blood assay, IC(50) values for BC6ENTC were 0.13 microM for BC6OTHER and 67 microM for BC6ENTG ( BC6OTHER / BC6OTHER selectivity ratio 515). CPR:4newlineIn a human whole blood assay, IC(50) values for BC6ENTC were 0.13 microM for BC6OTHER and 67 microM for BC6OTHER ( BC6ENTG / BC6OTHER selectivity ratio 515). CPR:falsenewlineIn a human whole blood assay, IC(50) values for BC6ENTC were 0.13 microM for BC6OTHER and 67 microM for BC6OTHER ( BC6OTHER / BC6ENTG selectivity ratio 515). CPR:falsenewlineA series of BC6ENTC derivatives were synthesized and evaluated for BC6OTHER inhibition, BC6ENTG expression and suppression of cancer cell growth in vitro. CPR:falsenewlineA series of BC6ENTC derivatives were synthesized and evaluated for BC6ENTG inhibition, BC6OTHER expression and suppression of cancer cell growth in vitro. CPR:falsenewlineStructure - based design, synthesis and evaluation of novel BC6ENTC derivatives as BC6ENTG inhibitors and potential for cancer polypharmacology. CPR:4newlineImmunocytochemical analyses and function were consistent with BC6ENTG localization to T - tubules intercalated with BC6ENTC and BC6OTHER in slow (soleus) and fast (extensor digitorum longus, EDL) muscles. CPR:falsenewlineImmunocytochemical analyses and function were consistent with BC6OTHER localization to T - tubules intercalated with BC6ENTC and BC6ENTG in slow (soleus) and fast (extensor digitorum longus, EDL) muscles. CPR:falsenewlineImmunocytochemical analyses and function were consistent with BC6ENTG localization to T - tubules intercalated with BC6OTHER and BC6ENTC receptors in slow (soleus) and fast (extensor digitorum longus, EDL) muscles. CPR:falsenewlineDuring repetitive stimulation of skeletal muscle, extracellular BC6ENTC levels raise, activating BC6ENTG , increasing BC6OTHER influx, and enhancing contractile force, a response called potentiation. CPR:falsenewlineConsistent with two BC6ENTC uptake pathways, induced uptake of BC6OTHER , a fluorescent BC6OTHER derivative, was decreased by inhibition of HCs or BC6ENTG ( BC6OTHER ), and blocked by dual blockade. CPR:9newlineConsistent with two BC6ENTC uptake pathways, induced uptake of BC6OTHER , a fluorescent BC6OTHER derivative, was decreased by inhibition of HCs or BC6OTHER ( BC6ENTG ), and blocked by dual blockade. CPR:9newlineConsistent with two BC6OTHER uptake pathways, induced uptake of BC6ENTC , a fluorescent BC6OTHER derivative, was decreased by inhibition of HCs or BC6ENTG ( BC6OTHER ), and blocked by dual blockade. CPR:9newlineConsistent with two BC6OTHER uptake pathways, induced uptake of BC6ENTC , a fluorescent BC6OTHER derivative, was decreased by inhibition of HCs or BC6OTHER ( BC6ENTG ), and blocked by dual blockade. CPR:9newlineConsistent with two BC6OTHER uptake pathways, induced uptake of BC6OTHER , a fluorescent BC6ENTC derivative, was decreased by inhibition of HCs or BC6ENTG ( BC6OTHER ), and blocked by dual blockade. CPR:9newlineConsistent with two BC6OTHER uptake pathways, induced uptake of BC6OTHER , a fluorescent BC6ENTC derivative, was decreased by inhibition of HCs or BC6OTHER ( BC6ENTG ), and blocked by dual blockade. CPR:9newlineConsistent with two BC6OTHER uptake pathways, induced uptake of BC6OTHER , a fluorescent BC6OTHER derivative, was decreased by inhibition of HCs or BC6ENTC transporter ( BC6ENTG ), and blocked by dual blockade. CPR:9newlineBC6OTHER release, BC6ENTC uptake, and potentiation induced by repetitive electrical stimulation were blocked by HC blockers and did not occur in muscles of BC6ENTG knockout mice. CPR:falsenewlineBC6ENTC release, BC6OTHER uptake, and potentiation induced by repetitive electrical stimulation were blocked by HC blockers and did not occur in muscles of BC6ENTG knockout mice. CPR:falsenewlineThe BC6ENTC required for potentiation of skeletal muscle contraction is released via BC6ENTG hemichannels. CPR:falsenewlineDuring repetitive stimulation of skeletal muscle, extracellular BC6OTHER levels raise, activating BC6ENTG , increasing BC6ENTC influx, and enhancing contractile force, a response called potentiation. CPR:falsenewlineMRS2179, a BC6ENTG blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles BC6ENTC activates BC6OTHER but not BC6OTHER . CPR:falsenewlineMRS2179, a BC6OTHER blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles BC6ENTC activates BC6ENTG but not BC6OTHER . CPR:falsenewlineMRS2179, a BC6OTHER blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles BC6ENTC activates BC6OTHER but not BC6ENTG . CPR:falsenewlinePhosphorylation on BC6ENTC and BC6OTHER residues of BC6ENTG was increased during potentiation, possibly mediating HC opening. CPR:falsenewlinePhosphorylation on BC6OTHER and BC6ENTC residues of BC6ENTG was increased during potentiation, possibly mediating HC opening. CPR:falsenewlineOpening of BC6ENTG HCs during repetitive activation allows efflux of BC6ENTC , influx of BC6OTHER and possibly BC6OTHER too, which are required for potentiation of contraction. CPR:falsenewlineOpening of BC6ENTG HCs during repetitive activation allows efflux of BC6OTHER , influx of BC6ENTC and possibly BC6OTHER too, which are required for potentiation of contraction. CPR:falsenewlineOpening of BC6ENTG HCs during repetitive activation allows efflux of BC6OTHER , influx of BC6OTHER and possibly BC6ENTC too, which are required for potentiation of contraction. CPR:falsenewlineWe found that BC6ENTC appears to be released through BC6ENTG hemichannels ( BC6OTHER HCs). CPR:falsenewlineWe found that BC6ENTC appears to be released through BC6OTHER hemichannels ( BC6ENTG HCs). CPR:falsenewlineWestern blot analysis indicated that BC6ENTC inhibits the BC6ENTG / BC6OTHER / BC6OTHER pathway. CPR:4newlineWestern blot analysis indicated that BC6ENTC inhibits the BC6OTHER / BC6ENTG / BC6OTHER pathway. CPR:4newlineWestern blot analysis indicated that BC6ENTC inhibits the BC6OTHER / BC6OTHER / BC6ENTG pathway. CPR:4newline BC6ENTC induces apoptosis through suppression of BC6ENTG signaling pathway in HL - 60 cells. CPR:4newlineTaken together, our study suggested, for the first time, that the pro - apoptotic effects of BC6ENTC on HL - 60 cells were mediated through BC6ENTG signaling pathway. CPR:falsenewlineBC6ENTG was administered to BC6ENTC - treated rats intraperitoneally at a dose of 300μg / kg / injection from day 8 to day 30 every other day. CPR:falsenewlineAfter the animals were sacrificed on day 15 and 30, BC6ENTC levels, the protein expressions of BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER signaling, and histopathology in lung tissues were analyzed. CPR:falsenewlineAfter the animals were sacrificed on day 15 and 30, BC6ENTC levels, the protein expressions of BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER signaling, and histopathology in lung tissues were analyzed. CPR:falsenewlineAfter the animals were sacrificed on day 15 and 30, BC6ENTC levels, the protein expressions of BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER signaling, and histopathology in lung tissues were analyzed. CPR:falsenewlineAfter the animals were sacrificed on day 15 and 30, BC6ENTC levels, the protein expressions of BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG signaling, and histopathology in lung tissues were analyzed. CPR:falsenewlineThe BC6ENTC contents in BC6ENTG treated groups were significantly lower than the BC6OTHER groups (P<0.05). CPR:falsenewlineThe BC6OTHER contents in BC6ENTG treated groups were significantly lower than the BC6ENTC groups (P<0.05). CPR:falsenewline BC6ENTG inhibits BC6ENTC - induced pulmonary fibrosis in rats. CPR:falsenewlineHistopathological results showed BC6ENTG could reduce the progression of BC6ENTC induced fibrosis. CPR:falsenewlineFurthermore, the expression of BC6ENTG , a marker of BC6OTHER / BC6OTHER signaling, was significantly up - regulated in BC6OTHER treated groups (P<0.05) compared with the BC6ENTC groups. CPR:falsenewlineFurthermore, the expression of BC6OTHER , a marker of BC6ENTG / BC6OTHER signaling, was significantly up - regulated in BC6OTHER treated groups (P<0.05) compared with the BC6ENTC groups. CPR:falsenewlineFurthermore, the expression of BC6OTHER , a marker of BC6OTHER / BC6ENTG signaling, was significantly up - regulated in BC6OTHER treated groups (P<0.05) compared with the BC6ENTC groups. CPR:falsenewlineFurthermore, the expression of BC6OTHER , a marker of BC6OTHER / BC6OTHER signaling, was significantly up - regulated in BC6ENTG treated groups (P<0.05) compared with the BC6ENTC groups. CPR:falsenewlineOn the contrary, the expression of BC6ENTG , a marker for BC6OTHER / BC6OTHER signaling, reduced significantly in BC6OTHER - treated groups compared with BC6ENTC groups (P<0.05). CPR:falsenewlineOn the contrary, the expression of BC6OTHER , a marker for BC6ENTG / BC6OTHER signaling, reduced significantly in BC6OTHER - treated groups compared with BC6ENTC groups (P<0.05). CPR:falsenewlineOn the contrary, the expression of BC6OTHER , a marker for BC6OTHER / BC6ENTG signaling, reduced significantly in BC6OTHER - treated groups compared with BC6ENTC groups (P<0.05). CPR:falsenewlineOn the contrary, the expression of BC6OTHER , a marker for BC6OTHER / BC6OTHER signaling, reduced significantly in BC6ENTG - treated groups compared with BC6ENTC groups (P<0.05). CPR:falsenewlineIn conclusion, the pulmonary fibrosis induced by BC6ENTC in rats was significantly reduced with the therapeutic treatment of BC6ENTG . CPR:falsenewlineThere is no study to investigate BC6ENTG 's role in the development of pulmonary fibrosis induced by BC6ENTC . CPR:falsenewlineIn the current study, we used the rat model to explore the potential antifibrotic role of BC6ENTG and its underlying mechanism in BC6ENTC - induced pulmonary fibrosis. CPR:falsenewlineControl group received saline, BC6ENTC group received BC6OTHER and BC6ENTG treated group received BC6OTHER and BC6OTHER . CPR:falsenewlineControl group received saline, BC6ENTC group received BC6OTHER and BC6OTHER treated group received BC6OTHER and BC6ENTG . CPR:falsenewlineControl group received saline, BC6OTHER group received BC6ENTC and BC6ENTG treated group received BC6OTHER and BC6OTHER . CPR:falsenewlineControl group received saline, BC6OTHER group received BC6ENTC and BC6OTHER treated group received BC6OTHER and BC6ENTG . CPR:falsenewlineControl group received saline, BC6OTHER group received BC6OTHER and BC6ENTG treated group received BC6ENTC and BC6OTHER . CPR:falsenewlineControl group received saline, BC6OTHER group received BC6OTHER and BC6OTHER treated group received BC6ENTC and BC6ENTG . CPR:falsenewlineWe have identified BC6ENTC ( BC6OTHER ) as a novel ZBG that is compatible with BC6ENTG inhibition. CPR:4newlineWe have identified BC6OTHER ( BC6ENTC ) as a novel ZBG that is compatible with BC6ENTG inhibition. CPR:4newlineBC6ENTC inhibits BC6ENTG and BC6OTHER with an IC50 of 681 and 3675 nM, respectively. CPR:4newlineBC6ENTC inhibits BC6OTHER and BC6ENTG with an IC50 of 681 and 3675 nM, respectively. CPR:4newlineSmall molecules bearing CHEM as the BC6ENTC binding group (ZBG) have been the most effective BC6ENTG inhibitors ( BC6OTHER i) to date. CPR:falsenewlineSmall molecules bearing CHEM as the BC6ENTC binding group (ZBG) have been the most effective BC6OTHER inhibitors ( BC6ENTG i) to date. CPR:falsenewlineRemarkably, BC6ENTC gives no inhibition of BC6ENTG . CPR:falsenewlineSubsequent optimization led to several novel BC6ENTC - based BC6ENTG i that are selective for BC6OTHER and BC6OTHER . CPR:falsenewlineSubsequent optimization led to several novel BC6ENTC - based BC6OTHER i that are selective for BC6ENTG and BC6OTHER . CPR:falsenewlineSubsequent optimization led to several novel BC6ENTC - based BC6OTHER i that are selective for BC6OTHER and BC6ENTG . CPR:falsenewline BC6ENTC as Novel BC6OTHER Binding Group for Selective BC6ENTG Inhibition. CPR:4newline BC6OTHER as Novel BC6ENTC Binding Group for Selective BC6ENTG Inhibition. CPR:falsenewlineThis 16.2 - fold (range, 5.5 - 47.9) displacement to the right of the BC6OTHER concentration - response curve by a selective BC6ENTG antagonist emphasizes the central role of BC6ENTC in the airways response to this nucleotide. CPR:falsenewlineThe effect of BC6ENTG antagonism with BC6ENTC on concentration - related BC6OTHER - induced bronchoconstriction in asthma. CPR:falsenewlineThe effect of BC6ENTG antagonism with BC6OTHER on concentration - related BC6ENTC - induced bronchoconstriction in asthma. CPR:falsenewlineSelective BC6ENTG antagonists inhibit BC6OTHER ( BC6OTHER ) - induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time - response curve following inhalation of the provocation concentration of BC6ENTC required to produce a 20% decrease in FEV1 from baseline (PC20). CPR:falsenewlineSelective BC6ENTG antagonists inhibit BC6ENTC ( BC6OTHER ) - induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time - response curve following inhalation of the provocation concentration of BC6OTHER required to produce a 20% decrease in FEV1 from baseline (PC20). CPR:falsenewlineSelective BC6ENTG antagonists inhibit BC6OTHER ( BC6ENTC ) - induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time - response curve following inhalation of the provocation concentration of BC6OTHER required to produce a 20% decrease in FEV1 from baseline (PC20). CPR:falsenewlineThis 16.2 - fold (range, 5.5 - 47.9) displacement to the right of the BC6ENTC concentration - response curve by a selective BC6ENTG antagonist emphasizes the central role of BC6OTHER in the airways response to this nucleotide. CPR:falsenewlineWe also rescued BC6ENTC - resistant clones using exogenous BC6ENTG without inhibitory phosphorylation sites, indicating that the mitotic surge of BC6OTHER activity is dispensable for cell proliferation. CPR:falsenewlineWe also rescued BC6ENTC - resistant clones using exogenous BC6OTHER without inhibitory phosphorylation sites, indicating that the mitotic surge of BC6ENTG activity is dispensable for cell proliferation. CPR:falsenewlineThe complexity of BC6ENTG regulation has made it difficult to determine whether these different roles require different thresholds of BC6OTHER activity and whether the surge of activity as inhibitory BC6ENTC are removed at mitotic onset is essential for cell proliferation. CPR:falsenewlineThe complexity of BC6OTHER regulation has made it difficult to determine whether these different roles require different thresholds of BC6ENTG activity and whether the surge of activity as inhibitory BC6ENTC are removed at mitotic onset is essential for cell proliferation. CPR:falsenewlineWe rescued cells lethally depleted of endogenous BC6ENTG with an exogenous BC6OTHER conferring sensitivity to one BC6ENTC analogue inhibitor ( BC6OTHER ) and resistance to another ( BC6OTHER ). CPR:falsenewlineWe rescued cells lethally depleted of endogenous BC6OTHER with an exogenous BC6ENTG conferring sensitivity to one BC6ENTC analogue inhibitor ( BC6OTHER ) and resistance to another ( BC6OTHER ). CPR:falsenewlineWe rescued cells lethally depleted of endogenous BC6ENTG with an exogenous BC6OTHER conferring sensitivity to one BC6OTHER analogue inhibitor ( BC6ENTC ) and resistance to another ( BC6OTHER ). CPR:falsenewlineWe rescued cells lethally depleted of endogenous BC6OTHER with an exogenous BC6ENTG conferring sensitivity to one BC6OTHER analogue inhibitor ( BC6ENTC ) and resistance to another ( BC6OTHER ). CPR:falsenewlineWe rescued cells lethally depleted of endogenous BC6ENTG with an exogenous BC6OTHER conferring sensitivity to one BC6OTHER analogue inhibitor ( BC6OTHER ) and resistance to another ( BC6ENTC ). CPR:falsenewlineWe rescued cells lethally depleted of endogenous BC6OTHER with an exogenous BC6ENTG conferring sensitivity to one BC6OTHER analogue inhibitor ( BC6OTHER ) and resistance to another ( BC6ENTC ). CPR:falsenewlineAt no BC6ENTC concentration was mitosis in rescued clones prevented without also inducing endoreduplication, suggesting that these two key roles for BC6ENTG are not simply controlled by different BC6OTHER activity thresholds. CPR:falsenewlineAt no BC6ENTC concentration was mitosis in rescued clones prevented without also inducing endoreduplication, suggesting that these two key roles for BC6OTHER are not simply controlled by different BC6ENTG activity thresholds. CPR:falsenewlineOn the other hand, peptides modified with BC6ENTC , apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to BC6ENTG . CPR:falsenewlineDesign, synthesis and structure - activity relationship of new BC6ENTG analogues containing BC6ENTC derivatives in position 2. CPR:falsenewlineIn this study, we present the synthesis and pharmacological properties of new analogues of BC6ENTG modified in the BC6ENTC - terminal part of the molecule with BC6OTHER derivatives: BC6OTHER ( BC6OTHER ) and BC6OTHER . CPR:falsenewlineIn this study, we present the synthesis and pharmacological properties of new analogues of BC6ENTG modified in the BC6OTHER - terminal part of the molecule with BC6ENTC derivatives: BC6OTHER ( BC6OTHER ) and BC6OTHER . CPR:falsenewlineIn this study, we present the synthesis and pharmacological properties of new analogues of BC6ENTG modified in the BC6OTHER - terminal part of the molecule with BC6OTHER derivatives: BC6ENTC ( BC6OTHER ) and BC6OTHER . CPR:falsenewlineIn this study, we present the synthesis and pharmacological properties of new analogues of BC6ENTG modified in the BC6OTHER - terminal part of the molecule with BC6OTHER derivatives: BC6OTHER ( BC6ENTC ) and BC6OTHER . CPR:falsenewlineIn this study, we present the synthesis and pharmacological properties of new analogues of BC6ENTG modified in the BC6OTHER - terminal part of the molecule with BC6OTHER derivatives: BC6OTHER ( BC6OTHER ) and BC6ENTC . CPR:falsenewlineMoreover, the effects of the BC6ENTG agonist BC6ENTC ( BC6OTHER ) - induced locomotor hypoactivity were significantly increased when BC6OTHER proteins were abundant. CPR:falsenewlineMoreover, the effects of the BC6OTHER agonist BC6ENTC ( BC6OTHER ) - induced locomotor hypoactivity were significantly increased when BC6ENTG proteins were abundant. CPR:falsenewlineMoreover, the effects of the BC6ENTG agonist BC6OTHER ( BC6ENTC ) - induced locomotor hypoactivity were significantly increased when BC6OTHER proteins were abundant. CPR:falsenewlineMoreover, the effects of the BC6OTHER agonist BC6OTHER ( BC6ENTC ) - induced locomotor hypoactivity were significantly increased when BC6ENTG proteins were abundant. CPR:falsenewlineThe BC6ENTC D3 receptor ( BC6ENTG ) in the ventral striatum is thought to influence motivation and motor functions. CPR:falsenewlineThe transcription of BC6ENTG was enhanced by the BC6ENTC - related orphan receptor α ( BC6OTHER ), and its activation was inhibited by the BC6OTHER BC6OTHER , an endogenous antagonist of BC6OTHER . CPR:falsenewlineThe transcription of BC6OTHER was enhanced by the BC6ENTC - related orphan receptor α ( BC6ENTG ), and its activation was inhibited by the BC6OTHER BC6OTHER , an endogenous antagonist of BC6OTHER . CPR:falsenewlineThe transcription of BC6OTHER was enhanced by the BC6ENTC - related orphan receptor α ( BC6OTHER ), and its activation was inhibited by the BC6ENTG BC6OTHER , an endogenous antagonist of BC6OTHER . CPR:falsenewlineThe transcription of BC6OTHER was enhanced by the BC6ENTC - related orphan receptor α ( BC6OTHER ), and its activation was inhibited by the BC6OTHER BC6ENTG , an endogenous antagonist of BC6OTHER . CPR:falsenewlineThe transcription of BC6OTHER was enhanced by the BC6ENTC - related orphan receptor α ( BC6OTHER ), and its activation was inhibited by the BC6OTHER BC6OTHER , an endogenous antagonist of BC6ENTG . CPR:falsenewlineThe serum or BC6ENTC - induced oscillation in the expression of BC6ENTG in cells was abrogated by the downregulation or overexpression of BC6OTHER , suggesting that BC6OTHER functions as a regulator of BC6OTHER oscillations in the cellular autonomous clock. CPR:falsenewlineThe serum or BC6ENTC - induced oscillation in the expression of BC6OTHER in cells was abrogated by the downregulation or overexpression of BC6ENTG , suggesting that BC6OTHER functions as a regulator of BC6OTHER oscillations in the cellular autonomous clock. CPR:falsenewlineThe serum or BC6ENTC - induced oscillation in the expression of BC6OTHER in cells was abrogated by the downregulation or overexpression of BC6OTHER , suggesting that BC6ENTG functions as a regulator of BC6OTHER oscillations in the cellular autonomous clock. CPR:falsenewlineThe serum or BC6ENTC - induced oscillation in the expression of BC6OTHER in cells was abrogated by the downregulation or overexpression of BC6OTHER , suggesting that BC6OTHER functions as a regulator of BC6ENTG oscillations in the cellular autonomous clock. CPR:falsenewline